PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Misra, P; Owuor, ED; Li, WG; Yu, ST; Qi, C; Meyer, K; Zhu, YJ; Rao, MS; Kong, ANT; Reddy, JK				Misra, P; Owuor, ED; Li, WG; Yu, ST; Qi, C; Meyer, K; Zhu, YJ; Rao, MS; Kong, ANT; Reddy, JK			Phosphorylation of transcriptional coactivator peroxisome proliferator-activated receptor (PPAR)-binding protein (PBP) - Stimulation of transcriptional regulation by mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING-PROTEIN; NUCLEAR RECEPTORS; EMBRYONIC-DEVELOPMENT; TRAP220 COMPONENT; MOLECULAR-CLONING; GENE-EXPRESSION; COMPLEX; P300; CBP; INTERACTS	Peroxisome proliferator-activated receptor (PPAR)binding protein (PBP) is an important coactivator for PPARgamma and other transcription factors. PBP is an integral component of a multiprotein thyroid hormone receptor-associated protein (TRAP)/vitamin D-3 receptor-interacting protein (DRIP)/activator-recruited cofactor (ARC) complex required for transcriptional activity. To study the regulation of PBP by cellular signaling pathways, we identified the phosphorylation sites of PBP. Using a combination of in vitro and in vivo approaches and mutagenesis of PBP phosphorylation sites, we identified six phosphorylation sites on PBP: one exclusive protein kinase A (PKA) phosphorylation site at serine 656, two protein kinase C (PKC) sites at serine 796 and serine 1345, a common PKA/PKC site at serine 756, and two extracellular signal-regulated kinase 2 sites of the mitogen-activated protein kinase (MAPK) family at threonine 1017 and threonine 1444. Binding of PBP to PPARgamma1 or retinoid-X-receptor for 9-cis-retinoic acid (RXR) is independent of their phosphorylation states, implying no changes in protein-protein interaction after modification by phosphorylation. Overexpression of RafBXB, an activated upstream kinase of the MAPK signal transduction pathway, exerts a significant additive inductive effect on PBP coactivator function. This effect is significantly diminished by overexpression of Raf-BXB301, a dominant negative mutant of RafBXB. These results identify phosphorylation as a regulatory modification event of PBP and demonstrate that PBP phosphorylation by Raf/MEK/MAPK cascade exerts a positive effect on PBP coactivator function. The functional role of PKA and PKC phosphorylation sites in PBP remains to be elucidated.	Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; Rutgers State Univ, Dept Pharmaceut, Coll Pharm, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA; Dr Reddys Labs Ltd, Hyderabad 500050, Andhra Pradesh, India	Northwestern University; Feinberg School of Medicine; Rutgers State University New Brunswick; Dr. Reddy's Laboratories Ltd.	Reddy, JK (corresponding author), Northwestern Univ, Dept Pathol, Feinberg Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.	jkreddy@northwestern.edu	Kong, Ah-Ng Tony/AAX-2828-2020		NATIONAL CANCER INSTITUTE [R01CA084472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K08ES000356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023750, R37GM023750] Funding Source: NIH RePORTER; NCI NIH HHS [CA-73647, CA84472, CA-888898] Funding Source: Medline; NIEHS NIH HHS [K08 ES00356] Funding Source: Medline; NIGMS NIH HHS [GM23750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Crawford SE, 2002, J BIOL CHEM, V277, P3585, DOI 10.1074/jbc.M107995200; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Goodman RH, 2000, GENE DEV, V14, P1553; Gusterson R, 2002, J BIOL CHEM, V277, P2517, DOI 10.1074/jbc.M104626200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Jung DJ, 2002, J BIOL CHEM, V277, P1229, DOI 10.1074/jbc.M110417200; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Ko L, 2002, MOL CELL BIOL, V22, P357, DOI 10.1128/MCB.22.1.357-369.2002; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Kung AL, 2000, GENE DEV, V14, P272; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; LIN J, 1998, CELL, V92, P829; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Misra P, 2002, J BIOL CHEM, V277, P20011, DOI 10.1074/jbc.M201739200; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oike Y, 1999, BLOOD, V93, P2771; ONATE SA, 1995, SCIENCE, V270, P1354; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Qi C, 1999, P NATL ACAD SCI USA, V96, P1585, DOI 10.1073/pnas.96.4.1585; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; See RH, 2001, J BIOL CHEM, V276, P16310, DOI 10.1074/jbc.M008113200; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Surapureddi S, 2002, P NATL ACAD SCI USA, V99, P11836, DOI 10.1073/pnas.182426699; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545; Yu R, 2000, J BIOL CHEM, V275, P9612, DOI 10.1074/jbc.275.13.9612; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510; Zhu YJ, 2000, J BIOL CHEM, V275, P14779, DOI 10.1074/jbc.C000121200; ZHU YJ, 1993, J BIOL CHEM, V268, P26817; Zhu YJ, 1996, GENE EXPRESSION, V6, P185; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848; Zhu YJ, 2001, P NATL ACAD SCI USA, V98, P10380, DOI 10.1073/pnas.181347498	69	61	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48745	48754		10.1074/jbc.M208829200	http://dx.doi.org/10.1074/jbc.M208829200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12356758	hybrid			2022-12-27	WOS:000179789600101
J	Kobayashi, T; Tanaka, K; Inoue, K; Kakizuka, A				Kobayashi, T; Tanaka, K; Inoue, K; Kakizuka, A			Functional ATPase activity of p97/valosin-containing protein (VCP) is required for the quality control of endoplasmic reticulum in neuronally differentiated mammalian PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME SYSTEM; VALOSIN-CONTAINING PROTEIN; MACHADO-JOSEPH DISEASE; AAA-ATPASE; ALZHEIMERS-DISEASE; RESPIRATORY-CHAIN; MEMBRANE-FUSION; DEGRADATION; ER; PATHWAY	Abnormal protein accumulation and cell death with cytoplasmic vacuoles are hallmarks of several neurodegenerative disorders. We previously identified p97/valosin-containing protein (VCP), an AAA ATPase with two conserved ATPase domains (D1 and D2), as an interacting partner of the Machado-Joseph disease (MJD) protein with expanded polyglutamines that causes Machado-Joseph disease. To reveal its pathophysiological roles in neuronal cells, we focused on its ATPase activity. We constructed and characterized PC12 cells expressing wild-type p97/VCP and p97(K524A), a D2 domain mutant. The expression level, localization, and complex formation of both proteins were indistinguishable, but the ATPase activity of p97(K524A) was much lower than that of the wild type. p97(K524A) induced cytoplasmic vacuoles that stained with an endoplasmic reticulum (ER) marker, and accumulation of polyubiquitinated proteins in the nuclear and membrane but not cytoplasmic fractions was observed, together with the elevation of ER stress markers. These results show that p97/VCP is essential for degrading membrane-associated ubiquitinated proteins and that profound deficits in its ATPase activity severely affect ER quality control, leading to abnormal ER expansion and cell death. Excessive accumulation of misfolded proteins may inactivate p97/VCP in several neurodegenerative disorders, eventually leading to the neurodegenerations.	Kyoto Univ, Grad Sch Biostudies, Kyoto 6068501, Japan; Osaka Biosci Inst, Dept 4, Suita, Osaka 5650874, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan	Kyoto University; Japan Science & Technology Agency (JST)	Kakizuka, A (corresponding author), Kyoto Univ, Grad Sch Biostudies, Kyoto 6068501, Japan.		KOBAYASHI, TAEKO/GSJ-2693-2022	KOBAYASHI, TAEKO/0000-0002-5514-0866; Tanaka-Yamamoto, Keiko/0000-0002-1246-9784				Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; Dalal S, 2001, CELL, V104, P5, DOI 10.1016/S0092-8674(01)00186-6; Ghoshal N, 1999, AM J PATHOL, V155, P1163, DOI 10.1016/S0002-9440(10)65219-4; Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086; Higashiyama H, 2002, CELL DEATH DIFFER, V9, P264, DOI 10.1038/sj.cdd.4400955; Hirabayashi M, 2001, CELL DEATH DIFFER, V8, P977, DOI 10.1038/sj.cdd.4400907; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kakizuka A, 1997, CURR OPIN NEUROL, V10, P285, DOI 10.1097/00019052-199708000-00002; Kakizuka A, 1998, TRENDS GENET, V14, P396, DOI 10.1016/S0168-9525(98)01559-5; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Kobayashi T, 2001, MOL MICROBIOL, V39, P158, DOI 10.1046/j.1365-2958.2001.02229.x; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Lord JM, 2002, CURR BIOL, V12, pR182, DOI 10.1016/S0960-9822(02)00738-8; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rockel B, 2002, J MOL BIOL, V317, P673, DOI 10.1006/jmbi.2002.5448; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Skinner PJ, 2001, AM J PATHOL, V159, P905, DOI 10.1016/S0002-9440(10)61766-X; TOKUDA H, 1993, BIOCHEM BIOPH RES CO, V195, P1415, DOI 10.1006/bbrc.1993.2201; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Xiong XM, 1999, J BIOL CHEM, V274, P2616, DOI 10.1074/jbc.274.5.2616; Yasuda S, 1999, GENES CELLS, V4, P743, DOI 10.1046/j.1365-2443.1999.00294.x; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	42	126	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47358	47365		10.1074/jbc.M207783200	http://dx.doi.org/10.1074/jbc.M207783200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351637	hybrid			2022-12-27	WOS:000179663700068
J	Lepourcelet, M; Shivdasani, RA				Lepourcelet, M; Shivdasani, RA			Characterization of a novel mammalian groucho isoform and its role in transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCIN-LIKE-ENHANCER; AMINO-TERMINAL ENHANCER; EPITHELIAL STEM-CELL; BETA-CATENIN; COLORECTAL-CANCER; MEDIATED TRANSCRIPTION; DROSOPHILA ENHANCER; SIGNALING ACTIVITY; XENOPUS EMBRYOS; BINDING-PROTEIN	The Wnt/beta-catenin/Tcf pathway serves important functions in embryonic development and is constitutively activated in human colorectal cancer. The nuclear output of Wnt signaling is mediated by a complex between DNA-binding proteins of the TCF family and the transcriptional coactivator beta-catenin. Groucho proteins act to repress transcriptional activation by beta-cateninTcf complexes, probably by interacting directly with Tcf transcription factors. We have identified several splice forms of the mouse Groucho Grg1 gene expressed in the developing intestine. Prominent among these is a novel and abundant isoform, Grg1-S, which we characterize in this report. Grg1-S has highest homology with the TLE family of large Groucho proteins but features only the amino-terminal Q and glycine- and proline-rich domains typical of the Groucho/AES subfamily. Grg1-S is expressed in development and in several adult mouse tissues. Expression in the adult small intestine is highest at the base of the crypts of Lieberkuhn. Grg1-S acts to antagonize beta-catenin activity in Xenopus axis duplication and luciferase reporter assays in mammalian cells. Taken together, these findings suggest that Grg1-S may operate in conjunction with beta-catenin and Tcf factors to regulate vertebrate gut epithelial cell differentiation.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Shivdasani, RA (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.							ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Barker N, 2000, ADV CANCER RES, V77, P1; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Bonifacino J. S., 1998, CURRENT PROTOCOLS CE; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Chen GQ, 1998, MOL CELL BIOL, V18, P7259, DOI 10.1128/MCB.18.12.7259; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; Choudhury BK, 1997, GENE, V195, P41, DOI 10.1016/S0378-1119(97)00150-9; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; DEHNI G, 1995, MECH DEVELOP, V53, P369, DOI 10.1016/0925-4773(95)00452-1; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Grbavec D, 1998, EUR J BIOCHEM, V258, P339, DOI 10.1046/j.1432-1327.1998.2580339.x; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Hurlstone A, 2002, EMBO J, V21, P2303, DOI 10.1093/emboj/21.10.2303; Husain J, 1996, BIOCHEM J, V317, P523, DOI 10.1042/bj3170523; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Javed A, 2000, J CELL SCI, V113, P2221; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Larabell CA, 1997, J CELL BIOL, V136, P1123, DOI 10.1083/jcb.136.5.1123; Lee YJ, 1999, J BIOL CHEM, V274, P1566, DOI 10.1074/jbc.274.3.1566; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; MALLO M, 1995, DEV DYNAM, V204, P338, DOI 10.1002/aja.1002040311; McLarrent FW, 2001, J BIOL CHEM, V276, P1578, DOI 10.1074/jbc.M007629200; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Molenaar M, 2000, MECH DEVELOP, V91, P311, DOI 10.1016/S0925-4773(99)00259-2; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nuthall HN, 2002, MOL CELL BIOL, V22, P389, DOI 10.1128/MCB.22.2.389-399.2002; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Pinto M, 1996, J BIOL CHEM, V271, P33026, DOI 10.1074/jbc.271.51.33026; Polakis P, 1999, ADV EXP MED BIOL, V470, P23; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; Pukrop T, 2001, J BIOL CHEM, V276, P8968, DOI 10.1074/jbc.M007533200; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sakamoto I, 2000, J BIOL CHEM, V275, P32871, DOI 10.1074/jbc.M004089200; Sambrook J, 2001, MOL CLONING LAB MANU, V3; Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500; Shoichet SA, 2000, P NATL ACAD SCI USA, V97, P4076, DOI 10.1073/pnas.97.8.4076; Snider L, 2001, MOL CELL BIOL, V21, P1866, DOI 10.1128/MCB.21.5.1866-1873.2001; Sparks AB, 1998, CANCER RES, V58, P1130; Stappenbeck TS, 1998, CURR OPIN CELL BIOL, V10, P702, DOI 10.1016/S0955-0674(98)80110-5; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; Tago K, 2000, GENE DEV, V14, P1741; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang JCW, 2000, J BIOL CHEM, V275, P18418, DOI 10.1074/jbc.M910211199; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; Yao J, 2000, MECH DEVELOP, V93, P105, DOI 10.1016/S0925-4773(00)00278-1; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	67	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47732	47740		10.1074/jbc.M208154200	http://dx.doi.org/10.1074/jbc.M208154200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359720	hybrid			2022-12-27	WOS:000179663700116
J	Dormond, O; Bezzi, M; Mariotti, A; Ruegg, C				Dormond, O; Bezzi, M; Mariotti, A; Ruegg, C			Prostaglandin E-2 promotes integrin alpha(V)beta(3)-dependent endothelial cell adhesion, Rac-activation, and spreading through cAMP/PKA-dependent signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CANCER GROWTH; ANGIOGENESIS; MIGRATION; CYCLOOXYGENASE; INHIBITION; ALPHA-V-BETA-3; TRANSDUCTION; RECEPTORS; A(2)	We have recently reported that the inhibition of endothelial cell COX-2 by non-steroidal anti-inflammatory drugs suppresses alpha(V)beta(3)- (but not a(5)beta(1)-) dependent Rac activation, endothelial cell spreading, migration, and angiogenesis (Dormond, O., Foletti, A., Paroz, C., and Ruegg, C. (2001) Nat. MecL 7, 1041-1047). Here we investigated the role of the COX-2 metabolites PGE(2) and TXA2 in regulating human umbilical vein endothelial cell (HUVEC) adhesion and spreading. We report that PGE(2) accelerated alpha(V)beta(3)-mediated HUVEC adhesion and promoted Rac activation and cell spreading, whereas the TXA2 agonist U46619 retarded adhesion and inhibited spreading. We show that the cAMP level and the cAMP-regulated protein kinase A (PKA) activity are critical mediators of these PGE(2) effects. alpha(V)beta(3)-mediated adhesion induced a transient COX-2-dependent rise in cAMP levels, whereas the cell-permeable cAMP analogue 8-brcAMP accelerated adhesion, promoted Rac activation, and cell spreading in the presence of the COX-2 inhibitor NS-398. Pharmacological inhibition of PKA completely blocked alpha(V)beta(3)-mediated adhesion. A constitutively active Rac mutant (L61Rac) rescued alpha(V)beta(3)-dependent spreading in the presence of NS398 or U46691, but did not accelerate adhesion, whereas a dominant negative Rac mutant (N17Rac) suppressed spreading without affecting adhesion. alpha(5)beta(1)-mediated HUVEC adhesion, Rac activation, and spreading were not affected by PGE(2), U46691, 8-brcAAIEP, or the inhibition of PKA. In conclusion, these results demonstrate that PGE2 accelerates alpha(V)beta(3)-mediated endothelial cell adhesion through cAMP-dependent PKA activation and induces alpha(V)beta(3)-dependent spreading via cAMP- and PKA-dependent Rac activation and may contribute to the further understanding of the regulation of vascular integrins alpha(V)beta(3) by COX-2/PGE(2) during tumor angiogenesis and inflammation.	Univ Lausanne, Sch Med, CePO, CH-1011 Lausanne, Switzerland	University of Lausanne	Ruegg, C (corresponding author), Swiss Inst Expt Canc Res, Lab CePO, 155 Chemin Boveresses, CH-1066 Epalinges, Switzerland.	curzio.ruegg@isrec.unil.ch	Dormond, Olivier/B-5347-2017	Dormond, Olivier/0000-0002-6418-1782; Mariotti, Agnese/0000-0002-3704-7908				AUER KL, 1995, MOL BIOL CELL, V6, P1305, DOI 10.1091/mbc.6.10.1305; Bhattacharya S, 2001, AM J PHYSIOL-LUNG C, V280, pL1049, DOI 10.1152/ajplung.2001.280.5.L1049; Breyer MD, 2000, CURR OPIN NEPHROL HY, V9, P23, DOI 10.1097/00041552-200001000-00005; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; Daniel TO, 1999, CANCER RES, V59, P4574; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FORM DM, 1983, P SOC EXP BIOL MED, V172, P214; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Goldman AP, 1998, CARCINOGENESIS, V19, P2195, DOI 10.1093/carcin/19.12.2195; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; HALVORSON MJ, 1995, J IMMUNOL, V155, P4567; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; Jones MK, 1999, NAT MED, V5, P1418; Jones SL, 2002, J LEUKOCYTE BIOL, V71, P1042; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Maier GD, 1996, CLIN EXP METASTAS, V14, P314; Masferrer JL, 2000, CANCER RES, V60, P1306; Max R, 1997, INT J CANCER, V71, P320, DOI 10.1002/(SICI)1097-0215(19970502)71:3<320::AID-IJC2>3.3.CO;2-3; Meyer CJ, 2000, NAT CELL BIOL, V2, P666, DOI 10.1038/35023621; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Plopper George E., 2000, Molecular Cell Biology Research Communications, V4, P129, DOI 10.1006/mcbr.2001.0267; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Shiff SJ, 1999, J EXP MED, V190, P445, DOI 10.1084/jem.190.4.445; SHIMIZU Y, 1992, J EXP MED, V175, P577, DOI 10.1084/jem.175.2.577; Sipkins DA, 1998, NAT MED, V4, P623, DOI 10.1038/nm0598-623; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Whittard JD, 2001, J CELL SCI, V114, P3265; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	45	126	131	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45838	45846		10.1074/jbc.M209213200	http://dx.doi.org/10.1074/jbc.M209213200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237321	hybrid			2022-12-27	WOS:000179529300017
J	Gaudilliere, B; Shi, Y; Bonni, A				Gaudilliere, B; Shi, Y; Bonni, A			RNA interference reveals a requirement for myocyte enhancer factor 2A in activity-dependent neuronal survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM; GRANULE CELLS; MEF2 GENES; EXPRESSION; DIFFERENTIATION; APOPTOSIS; PATHWAY	RNA interference (RNAi) provides a powerful method of gene silencing in eukaryotic cells, including proliferating mammalian cells. However, the utility of RNAi as a method of gene knock-down in primary postmitotic mammalian neurons remained unknown. Here, we asked if RNAi might be utilized to allow the assessment of the biological function of a specific gene in the nervous system. We employed a U6 promoter-driven DNA template approach to induce hairpin RNA-triggered RNAi to characterize the role of the transcription factor myocyte enhancer factor 2A (MEF2A) in the neuronal activity-dependent survival of granule neurons of the developing rat cerebellum. We found that the expression of MEF2A hairpin RNAs leads to the efficient and specific inhibition of endogenous MEF2A protein expression in primary cerebellar granule neurons. We also found that RNAi of NMF2A reduces significantly MEF2 response element-mediated transcription in granule neurons and inhibits activity-dependent granule neuron survival. Taken together, our RNAi experiments have revealed that MEF2A plays a critical role in activity-dependent neuronal survival. In addition, our findings indicate that RNAi does operate in postmitotic mammalian neurons and thus offers a rapid genetic method of studying gene function in the development and function of the mammalian nervous system.	Harvard Univ, Sch Med, Dept Pathol, Program Biol & Biomed Sci, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Bonni, A (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Program Biol & Biomed Sci, Boston, MA 02115 USA.			Gaudilliere, Brice/0000-0002-3475-5706	NIGMS NIH HHS [GM 53874] Funding Source: Medline; NINDS NIH HHS [R01-NS41021-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041021] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Harborth J, 2001, J CELL SCI, V114, P4557; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Lee JK, 2000, DEV DYNAM, V217, P361, DOI 10.1002/(SICI)1097-0177(200004)217:4<361::AID-DVDY3>3.0.CO;2-8; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Li MT, 2001, J NEUROSCI, V21, P6544, DOI 10.1523/JNEUROSCI.21-17-06544.2001; Lin X, 1996, MOL BRAIN RES, V42, P307, DOI 10.1016/S0169-328X(96)00135-0; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Miller TM, 1996, J NEUROSCI, V16, P7487; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Miyata T, 1999, GENE DEV, V13, P1647, DOI 10.1101/gad.13.13.1647; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	27	85	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46442	46446		10.1074/jbc.M206653200	http://dx.doi.org/10.1074/jbc.M206653200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235147	hybrid			2022-12-27	WOS:000179529300096
J	Lim, JW; Kim, H; Kim, KH				Lim, JW; Kim, H; Kim, KH			Expression of Ku70 and Ku80 mediated by NF-kappa B and cyclooxygenase-2 is related to proliferation of human gastric cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; DNA END-BINDING; PROSTAGLANDIN E-2; CATALYTIC SUBUNIT; BCL-2 EXPRESSION; IL-8 PRODUCTION; EGF RECEPTOR; APOPTOSIS; AUTOANTIGEN	Cyclooxygenase-2 (COX-2) expression is mediated by constitutive NF-kappaB and regulates human gastric cancer cell growth and proliferation. Inactivating Ku70 or Ku80 suppresses cell growth and induces apoptosis. It has been hypothesized that Ku70 and Ku80 expression may be associated with NF-kappaB activation and COX-2 expression and is involved in cell proliferation. In this study, we found that inhibition of constitutive NF-kappaB (by transfecting a mutated IkappaBalpha gene) and of COX-2 (by treatment with indomethacin and NS-398) suppressed Ku70 and Ku80 expression in cells. Treatment with prostaglandin E-2 adenocarcinoma gastric (AGS) increased expression of these Ku proteins in cells with low constitutive NF-kappaB levels. Inhibition of the Ku DNA end-binding activity by transfection. with the C-terminal Ku80 expression gene suppressed cell proliferation. Ku70 or Ku80 overexpression by transfection with the Ku70 or Ru80 expression gene, respectively, enhanced proliferation of cells with low NF-kappaB levels. These results demonstrate that Ku70 and Ku80 expression is mediated by constitutively activated NF-kappaB and constitutively expressed COX-2 in gastric cancer cells and that the high Ku DNA end-binding activity contributes to cell proliferation. Ku70 and Ku80 expression may be related to gastric cell proliferation and carcinogenesis.	Yonsei Univ, Coll Med, Dept Pharmacol, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Inst Gastroenterol, Brain Korea Project Med Sci 21, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Kim, H (corresponding author), Yonsei Univ, Coll Med, Dept Pharmacol, Brain Korea Project Med Sci 21, Seoul 120752, South Korea.	kim626@yumc.yonsei.ac.kr		Kim, Hyeyoung/0000-0002-7019-917X				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Battu S, 1998, ANTICANCER RES, V18, P2397; Battu S, 1998, ANTICANCER RES, V18, P3579; BHUYAN BK, 1986, CANCER RES, V46, P1688; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bureau F, 2002, BLOOD, V99, P3683, DOI 10.1182/blood.V99.10.3683; Cary RB, 1998, NUCLEIC ACIDS RES, V26, P974, DOI 10.1093/nar/26.4.974; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Erickson BA, 1999, J SURG RES, V81, P101, DOI 10.1006/jsre.1998.5511; Factor V, 2001, HEPATOLOGY, V34, P32, DOI 10.1053/jhep.2001.25270; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; Gao HJ, 2000, WORLD J GASTROENTERO, V6, P848, DOI 10.3748/wjg.v6.i6.848; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Ghoshal K, 1998, P NATL ACAD SCI USA, V95, P10390, DOI 10.1073/pnas.95.18.10390; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gu YS, 2000, P NATL ACAD SCI USA, V97, P2668, DOI 10.1073/pnas.97.6.2668; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; Hida T, 1998, ANTICANCER RES, V18, P775; Higashi Y, 2000, INT J CANCER, V86, P667, DOI 10.1002/(SICI)1097-0215(20000601)86:5<667::AID-IJC10>3.3.CO;2-P; Jin SF, 1997, CANCER SURV, V29, P221; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Kim H, 2000, DIGEST DIS SCI, V45, P621, DOI 10.1023/A:1005474013988; Kim H, 1999, PHARMACOLOGY, V59, P201, DOI 10.1159/000028321; Kim SH, 2000, LEUKEMIA RES, V24, P917, DOI 10.1016/S0145-2126(00)00061-8; Kinoshita T, 1999, BBA-MOL CELL BIOL L, V1438, P120, DOI 10.1016/S1388-1981(99)00034-7; Klein A, 2000, LEUKEMIA, V14, P40, DOI 10.1038/sj.leu.2401636; KUMAR R, 1991, Current Opinion in Oncology, V3, P70, DOI 10.1097/00001622-199102000-00011; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li G, 2002, P NATL ACAD SCI USA, V99, P832, DOI 10.1073/pnas.022649699; Li JJ, 1997, CANCER RES, V57, P3569; Lim JW, 2001, LAB INVEST, V81, P349, DOI 10.1038/labinvest.3780243; Lipart C, 2002, J VIROL METHODS, V101, P1, DOI 10.1016/S0166-0934(01)00413-X; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Liu XH, 1998, CANCER RES, V58, P4245; MaleckaPanas E, 1997, HEPATO-GASTROENTEROL, V44, P435; Marangoni E, 2000, NUCLEIC ACIDS RES, V28, P4778, DOI 10.1093/nar/28.23.4778; Mendelsohn J, 1997, J NATL CANCER I, V89, P341, DOI 10.1093/jnci/89.5.341; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P375; Molina MA, 1999, CANCER RES, V59, P4356; Moorghen M, 1998, CELL PROLIFERAT, V31, P59, DOI 10.1046/j.1365-2184.1998.00111.x; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; Osipovich O, 1999, BIOCHEM BIOPH RES CO, V261, P802, DOI 10.1006/bbrc.1999.1118; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; Pucci S, 2001, ONCOGENE, V20, P739, DOI 10.1038/sj.onc.1204148; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Raz A, 2002, BIOCHEM PHARMACOL, V63, P343, DOI 10.1016/S0006-2952(01)00857-7; RESNICK MB, 1995, CANCER-AM CANCER SOC, V76, P187, DOI 10.1002/1097-0142(19950715)76:2<187::AID-CNCR2820760205>3.0.CO;2-C; Sadji Z, 2000, CELL SIGNAL, V12, P745, DOI 10.1016/S0898-6568(00)00126-1; Sasaki N, 2001, CLIN CANCER RES, V7, P4136; Sawaoka H, 1998, AM J PHYSIOL-GASTR L, V274, pG1061, DOI 10.1152/ajpgi.1998.274.6.G1061; SEIBERT K, 1995, AGENT ACTION SUPPL, V46, P41; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1998, CANCER RES, V58, P362; Shimada N, 1998, J GASTROEN HEPATOL, V13, P794, DOI 10.1111/j.1440-1746.1998.tb00735.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sovak MA, 1999, CELL GROWTH DIFFER, V10, P537; Sung JJY, 2000, AM J PATHOL, V157, P729, DOI 10.1016/S0002-9440(10)64586-5; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Tai DI, 2000, CANCER, V89, P2274, DOI 10.1002/1097-0142(20001201)89:11<2274::AID-CNCR16>3.0.CO;2-2; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA, P121; Taylor MT, 2000, CANCER RES, V60, P6607; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Tjandrawinata RR, 1997, BRIT J CANCER, V75, P1111, DOI 10.1038/bjc.1997.192; Tuteja R, 2000, CRIT REV BIOCHEM MOL, V35, P1, DOI 10.1080/10409230091169177; Um JH, 2001, ONCOGENE, V20, P6048, DOI 10.1038/sj.onc.1204732; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wu XT, 1996, MOL CELL BIOL, V16, P5186; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; YANG X, 1998, AM J PHYSIOL, V275, pC1058; Zhao YL, 2000, CARCINOGENESIS, V21, P2005, DOI 10.1093/carcin/21.11.2005	87	74	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46093	46100		10.1074/jbc.M206603200	http://dx.doi.org/10.1074/jbc.M206603200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324457	hybrid			2022-12-27	WOS:000179529300052
J	Cheng, HF; Harris, RC				Cheng, HF; Harris, RC			Cyclooxygenase-2 expression in cultured cortical thick ascending limb of Henle increases in response to decreased extracellular ionic content by both transcriptional and post-transcriptional mechanisms - Role of p38-mediated pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; SMOOTH-MUSCLE CELLS; MACULA DENSA; MESSENGER-RNA; GENE-EXPRESSION; SIGNALING PATHWAYS; NUCLEAR-FACTOR; P38 MAPK; DIFFERENTIAL REGULATION	We showed previously that decreased extracellular salt or chloride up-regulates the cortical thick ascending limb of Henle (cTALH) COX-2 expression via a p38-dependent pathway. The present studies determined that low salt medium increased COX-2 mRNA expression 3.9-fold control by 6 h in cultured cTALH, which was blocked by actinomycin D pretreatment, suggesting transcriptional regulation. Luciferase activity (normalized to beta-galactosidase activity) of the full-length (-3400) COX-2 promoter in cTALH increased from 1.8 +/- 0.3 in control media to 5.8 +/- 0.7 in low salt (n = 9;p < 0.01). Low chloride medium had similar effects as low salt has on COX-2 promoter activity. Deletion constructs -815, -512, and -410 were similarly stimulated, but -385 could not be stimulated significantly by low salt (1.8 +/- 0.3 versus 2.4 +/- 0.5, n = 10). This suggested involvement of an NF-kappaB cis-element located in this region, which was confirmed by utilizing a construct with a point mutation of this NF-kappaB-binding site that was not stimulated by low salt medium. Co-incubation of the specific p38 inhibitor, SB203580 or PD169316, inhibited a low salt-induced increase in luciferase activity of the intact COX-2 promoter (5.8 +/- 0.7 versus 1.1 +/- 0.2, n = = 8 and 1.4 +/- 0.4, n = 4 respectively, p < 0.01). Mobility shift assays indicated that the low salt medium stimulated NF-kappaB binding activity, and this stimulation was inhibited by p38 inhibitors. To test whether p38 also increased COX-2 expression by increasing mRNA stability, cTALH were incubated in low salt for 2 h, and actinomycin was then added with or without SB203580. p38 inhibition led to a decreased half-life of COX-2 mRNA (from 68 to 18 min, n = 4-7, p < 0.05). Therefore, these studies indicate that p38 stimulates COX-2 expression in cTALH and macula densa by transcriptional regulation predominantly via a NF-kappaB-dependent pathway and by post-transcriptional increases in mRNA stability.	Vanderbilt Univ, Sch Med, Div Nephrol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, George M OBrien Kidney & Urol Dis Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Harris, RC (corresponding author), Vanderbilt Univ, Sch Med, Div Nephrol, S3322, Nashville, TN 37232 USA.				NIDDK NIH HHS [DK 39261] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039261] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN ML, 1988, AM J PHYSIOL, V255, pF704, DOI 10.1152/ajprenal.1988.255.4.F704; ARAKAWA T, 1995, FEBS LETT, V363, P105, DOI 10.1016/0014-5793(95)00293-I; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Bartlett SR, 1999, J PHYSIOL-LONDON, V520, P399, DOI 10.1111/j.1469-7793.1999.00399.x; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; Cheng HF, 2001, AM J PHYSIOL-RENAL, V280, pF449, DOI 10.1152/ajprenal.2001.280.3.F449; Cheng HF, 1999, J CLIN INVEST, V103, P953, DOI 10.1172/JCI5505; Cheng HF, 2000, J CLIN INVEST, V106, P681, DOI 10.1172/JCI10318; Cheng HF, 2000, AM J PHYSIOL-RENAL, V279, pF122, DOI 10.1152/ajprenal.2000.279.1.F122; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goebeler M, 2001, BLOOD, V97, P46, DOI 10.1182/blood.V97.1.46; Greger R, 1997, NEPHROL DIAL TRANSPL, V12, P2215, DOI 10.1093/ndt/12.11.2215; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; Han SW, 1999, MOL CELL ENDOCRINOL, V147, P7, DOI 10.1016/S0303-7207(98)00240-8; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; Ingram AJ, 2000, AM J PHYSIOL-RENAL, V279, pF243, DOI 10.1152/ajprenal.2000.279.2.F243; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Jang BC, 2000, J BIOL CHEM, V275, P39507, DOI 10.1074/jbc.M003224200; Jensen BL, 1997, KIDNEY INT, V52, P1242, DOI 10.1038/ki.1997.449; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LaPointe MC, 1999, HYPERTENSION, V33, P276, DOI 10.1161/01.HYP.33.1.276; Laporte JD, 2000, AM J PHYSIOL-LUNG C, V279, pL932, DOI 10.1152/ajplung.2000.279.5.L932; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Leonard M, 1999, KIDNEY INT, V56, P1366, DOI 10.1046/j.1523-1755.1999.00664.x; Lim JW, 2001, LAB INVEST, V81, P349, DOI 10.1038/labinvest.3780243; LORENZ JN, 1991, AM J PHYSIOL, V260, pF486, DOI 10.1152/ajprenal.1991.260.4.F486; LORENZ JN, 1990, AM J PHYSIOL, V259, pF186, DOI 10.1152/ajprenal.1990.259.1.F186; Mann B, 2001, KIDNEY INT, V59, P62, DOI 10.1046/j.1523-1755.2001.00466.x; MASFERRER JL, 1990, J CLIN INVEST, V86, P1375, DOI 10.1172/JCI114850; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mestre JR, 2001, J BIOL CHEM, V276, P3977, DOI 10.1074/jbc.M005077200; Nakao S, 2000, MOL CELL BIOCHEM, V209, P113, DOI 10.1023/A:1007155525020; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; Newton R, 1997, FEBS LETT, V418, P135, DOI 10.1016/S0014-5793(97)01362-8; Nielsen S, 1998, AM J PHYSIOL-RENAL, V275, pF885, DOI 10.1152/ajprenal.1998.275.6.F885; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; PERSSON AE, 1991, KIDNEY INT S, V32, P39; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Sakai T, 2000, CAN J ANAESTH, V47, P1019, DOI 10.1007/BF03024876; SALOMONSSON M, 1991, KIDNEY INT S, V32, P51; SCHLATTER E, 1989, PFLUG ARCH EUR J PHY, V414, P286, DOI 10.1007/BF00584628; Schnermann J, 1998, AM J PHYSIOL-REG I, V274, pR263, DOI 10.1152/ajpregu.1998.274.2.R263; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Slice LW, 2000, BIOCHEM BIOPH RES CO, V276, P406, DOI 10.1006/bbrc.2000.3487; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Tai H, 1997, ENDOCRINOLOGY, V138, P2372, DOI 10.1210/en.138.6.2372; Varghese J, 2001, J IMMUNOL, V166, P6570, DOI 10.4049/jimmunol.166.11.6570; von Knethen A, 1999, J IMMUNOL, V163, P2858; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Wang JL, 2000, KIDNEY INT, V57, P2334, DOI 10.1046/j.1523-1755.2000.00093.x; Wang JL, 1999, HYPERTENSION, V34, P96, DOI 10.1161/01.HYP.34.1.96; Wolf K, 1999, HYPERTENSION, V34, P503, DOI 10.1161/01.HYP.34.3.503; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yang TX, 2000, J BIOL CHEM, V275, P37922, DOI 10.1074/jbc.M006218200; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhang X, 1997, BIOTECHNIQUES, V22, P848, DOI 10.2144/97225bm13	69	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45638	45643		10.1074/JBC.m206040200	http://dx.doi.org/10.1074/JBC.m206040200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237297	hybrid			2022-12-27	WOS:000179404800130
J	Crespo, PM; Zurita, AR; Daniotti, JL				Crespo, PM; Zurita, AR; Daniotti, JL			Effect of gangliosides on the distribution of a glycosylphosphatidylinositol-anchored protein in plasma membrane from Chinese hamster ovary-K1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR PHOSPHORYLATION; LIPID RAFTS; SIGNAL-TRANSDUCTION; GLYCOSPHINGOLIPID SYNTHESIS; GLUCOSYLCERAMIDE SYNTHASE; GM1 GANGLIOSIDE; TISSUE-CULTURE; GOLGI-COMPLEX; GD3 SYNTHASE; CHO-K1 CELLS	Glycosylphosphatidylinositol (GPI)-anchored proteins are clustered mainly in sphingolipid-cholesterol microdomains of the plasma membrane. The distribution of GPI-anchored fusion yellow fluorescent protein (GPI-YFP) in the plasma membrane of Chinese hamster ovary (CHO)-K1 cells with different glycolipid compositions was investigated. Cells depleted of glycosphingolipids by inhibiting glucosylceramide synthase activity or cell lines expressing different gangliosides caused by stable transfection of appropriate ganglioside glycosyltransferases or exposed to exogenous GM1 were transfected with GPI-YFP cDNA. The distribution of GPI-YFP fusion protein expressed at the plasma membrane was studied using the membrane-impermeable cross-linking agent bis(sulfosuccinimidyl)suberate. Results indicate that GPI-YFP forms clusters at the surface of cells expressing GM3, or cells depleted of glycolipids, or transfected cells expressing mainly GD3 and GT3, or GM1 and GDla, or mostly GM2, or highly expressing GM1. However, no significant changes in membrane microdomains of GPI-YFP were detected in the different glycolipid environments provided by the membranes of the cell lines under study. On the other hand, wild type CHO-K1 cells exposed to 100 muM GM1 before cross-linking with bis(sulfosuccinimidyl)suberate showed a dramatic reduction in the amount of GPI-YFP clusters. These findings clearly indicate that manipulating the glycolipid content of the cellular membrane, just by changing the ganglioside biosynthetic activity of the cell, did not significantly affect the association of GPI-YFP on the cell surface of CHO-K1 cells. The effect of exogenous GM1 gangliosides on GPI-YFP plasma membrane distribution might be a consequence of the ganglioside level reached in plasma membrane and/or the effect of particular ganglioside species (micelles) that lead to membrane architecture and/or dynamic modifications.	Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, Ctr Invest Quim Biol Cordoba, RA-5000 Cordoba, Argentina	National University of Cordoba	Daniotti, JL (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, Ctr Invest Quim Biol Cordoba, RA-5000 Cordoba, Argentina.							ABE A, 1995, J LIPID RES, V36, P611; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BUSCH G, 1989, EUR J CELL BIOL, V50, P257; Chatterjee S, 2001, CELL MOL LIFE SCI, V58, P1969, DOI 10.1007/PL00000831; Chatterjee S, 2001, EMBO J, V20, P1583, DOI 10.1093/emboj/20.7.1583; Daniotti JL, 2000, J NEUROCHEM, V74, P1711, DOI 10.1046/j.1471-4159.2000.0741711.x; Dietrich C, 2001, P NATL ACAD SCI USA, V98, P10642, DOI 10.1073/pnas.191168698; El-Husseini AE, 2001, J BIOL CHEM, V276, P44984, DOI 10.1074/jbc.M103049200; Ferrari G, 1998, ANN NY ACAD SCI, V845, P263, DOI 10.1111/j.1749-6632.1998.tb09679.x; FOLCH J, 1951, J BIOL CHEM, V191, P819; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Fritz VMR, 1997, BBA-GENE STRUCT EXPR, V1354, P153, DOI 10.1016/S0167-4781(97)00117-6; FRITZ VMR, 1995, J NEUROCHEM, V65, P1859; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Giraudo CG, 1999, BIOCHEM J, V342, P633, DOI 10.1042/0264-6021:3420633; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; Hakomori SI, 1998, ANN NY ACAD SCI, V845, P1, DOI 10.1111/j.1749-6632.1998.tb09657.x; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; JI L, 1995, GLYCOBIOLOGY, V5, P343, DOI 10.1093/glycob/5.3.343; Kasahara K, 2000, J BIOL CHEM, V275, P34701, DOI 10.1074/jbc.M003163200; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; LESTER RL, 1993, J BIOL CHEM, V268, P845; Li RX, 2000, J BIOL CHEM, V275, P34213, DOI 10.1074/jbc.M906368199; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Meuillet EJ, 1999, CANCER RES, V59, P234; Mitsuda T, 2002, J BIOL CHEM, V277, P11239, DOI 10.1074/jbc.M107756200; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; Rodriguez JA, 2001, J NEUROSCI, V21, P8387, DOI 10.1523/JNEUROSCI.21-21-08387.2001; Rosner H, 1998, ANN NY ACAD SCI, V845, P200, DOI 10.1111/j.1749-6632.1998.tb09672.x; SAQR HE, 1993, J NEUROCHEM, V61, P395; SCHNEIDER JS, 1995, NEUROLOGY, V45, P1149, DOI 10.1212/WNL.45.6.1149; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1999, MOL BIOL CELL, V10, P3187, DOI 10.1091/mbc.10.10.3187; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Sprong H, 2001, J CELL BIOL, V155, P369, DOI 10.1083/jcb.200106104; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; Tifft CJ, 2000, GLYCOBIOLOGY, V10, P1249, DOI 10.1093/glycob/10.12.1249; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vyas KA, 2001, BIOL CHEM, V382, P241, DOI 10.1515/BC.2001.031; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142; Zurita AR, 2001, BIOCHEM J, V355, P465, DOI 10.1042/0264-6021:3550465	50	35	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44731	44739		10.1074/jbc.M204604200	http://dx.doi.org/10.1074/jbc.M204604200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237294	hybrid			2022-12-27	WOS:000179404800019
J	Fujita, H; Katoh, H; Ishikawa, Y; Mori, K; Negishi, M				Fujita, H; Katoh, H; Ishikawa, Y; Mori, K; Negishi, M			Rapostlin is a novel effector of Rnd2 GTPase inducing neurite branching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; RHO-FAMILY GTPASES; PC12 CELLS; ACTIN CYTOSKELETON; IN-VIVO; GROWTH CONE; BINDING; NEURONS; IDENTIFICATION; MICROTUBULES	Rho family GTPases are central regulators of neuronal morphology. Recently, Rnd proteins, Rnd1, Rnd2, and Rnd3/RhoE, have been identified as new members of Rho family GTPases. Of these, Rnd2 is specifically expressed in neurons in brain; however, the signaling pathways of RnA2 are not known. Here we have performed a yeast two-hybrid screen using Rnd2 as a bait and identified a novel Rnd2-effector protein, expressed predominantly in brain. We named it Rapostlin (apostle of Rnd2). Rapostlin has two functional domains, Fer-CIP4 homology (FCH) domain at the amino terminus and SH3 (Src homology 3) domain at the carboxyl terminus. In in vitro binding assays, Rapostlin specifically binds to Rnd2 among the Rho family GTPases in a GTP-dependent manner, and the Rnd2-binding domain of Rapostlin is localized between FCH and SH3 domains. Rapostlin directly binds to microtubules, and the aminoterminal region containing the FCH domain of Rapostlin is essential for this interaction. In PC 12 cells, Rapostlin induces neurite branching in response to Rnd2, and at least the amino-terminal region of Rapostlin is necessary for this activity. Therefore, Rapostlin is the first effector of RnA2, regulating neurite branch formation.	Kyoto Univ, Mol Neurobiol Lab, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Negishi, M (corresponding author), Kyoto Univ, Mol Neurobiol Lab, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan.			Katoh, Hironori/0000-0002-8191-8117				Aoki J, 2000, BIOCHEM BIOPH RES CO, V278, P604, DOI 10.1006/bbrc.2000.3842; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Banzai Y, 2000, J BIOL CHEM, V275, P11987, DOI 10.1074/jbc.275.16.11987; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Foster R, 1996, MOL CELL BIOL, V16, P2689; Fuchs U, 2001, P NATL ACAD SCI USA, V98, P8756, DOI 10.1073/pnas.121433898; Fujita H, 2000, BIOCHEM J, V346, P617, DOI 10.1042/0264-6021:3460617; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; Katoh H, 2002, MOL CELL BIOL, V22, P2952, DOI 10.1128/MCB.22.9.2952-2964.2002; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Li Z, 2000, NAT NEUROSCI, V3, P217, DOI 10.1038/72920; Linder S, 2000, J CELL SCI, V113, P4165; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; MANSER E, 1995, METHOD ENZYMOL, V256, P130; Nakayama AY, 2000, J NEUROSCI, V20, P5329, DOI 10.1523/JNEUROSCI.20-14-05329.2000; Nishi M, 1999, MOL BRAIN RES, V67, P74, DOI 10.1016/S0169-328X(99)00039-X; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Ruchhoeft ML, 1999, J NEUROSCI, V19, P8454; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Szebenyi G, 1998, J NEUROSCI, V18, P7930; Tanabe K, 2000, J NEUROSCI, V20, P4138; Tanaka H, 2002, BIOCHEM J, V365, P349, DOI 10.1042/BJ20020062; Tian L, 2000, J BIOL CHEM, V275, P7854, DOI 10.1074/jbc.275.11.7854; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200	34	68	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45428	45434		10.1074/jbc.M208090200	http://dx.doi.org/10.1074/jbc.M208090200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244061	hybrid			2022-12-27	WOS:000179404800106
J	Javaherian, K; Park, SY; Pickl, WF; LaMontagne, KR; Sjin, RTT; Gillies, S; Lo, KM				Javaherian, K; Park, SY; Pickl, WF; LaMontagne, KR; Sjin, RTT; Gillies, S; Lo, KM			Laminin modulates morphogenic properties of the collagen XVIII endostatin domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOGENESIS INHIBITOR ENDOSTATIN; HEPARAN-SULFATE; CAENORHABDITIS-ELEGANS; NC1/ENDOSTATIN DOMAIN; INTEGRINS; EXPRESSION; RECEPTORS; COMPONENT; BINDING; CELLS	We have shown previously that the oligomeric endostatin domain of collagen XVIII (NC1) functioned as a motility-inducing factor regulating the extracellular matrix-dependent morphogenesis of endothelial cells. This motogenic activity gave rise to structures resembling filipodia and lamellipodia and was dependent on Rac, Cdc42, and mitogen-activated protein kinase. Here, we demonstrate that these properties of endostatin are primarily mediated by laminin in the basement membrane and heparan sulfates on the cell surface. The sites of interaction between laminin and oligomeric endostain include the N-terminal regions of all three laminin chains (amino acids 204-1243 of the alpha chain, 932-1161 of the beta chain, and 150-965 of the gamma chain). A monoclonal antibody that blocks the interactions between endostatin and laminin was utilized to inhibit the motogenic activity of endostatin. In parallel, we have engineered selective point mutations and produced recombinant forms that lack binding to heparan sulfates on the cell surface. Our data are consistent with a model of endostatin with two binding sites: one mainly to laminin in the basement membrane and the other to heparan sulfates on the cell surface. The two binding domains on endostatin appear to be separate with the possibility of some overlap between the two sites.	Harvard Univ, Sch Med, Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Lexigen Pharmaceut Corp, Lexington, MA 02421 USA; Univ Vienna, Sch Med, Inst Immunol, A-1090 Vienna, Austria	Harvard University; Boston Children's Hospital; Harvard Medical School; University of Vienna	Javaherian, K (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Dept Surg, Enders 470,320 Longwood Ave, Boston, MA 02115 USA.		Pickl, Winfried F/E-5682-2011	Pickl, Winfried F./0000-0003-0430-4952				Ackley BD, 2001, J CELL BIOL, V152, P1219, DOI 10.1083/jcb.152.6.1219; Belkin AM, 2000, MICROSC RES TECHNIQ, V51, P280, DOI 10.1002/1097-0029(20001101)51:3<280::AID-JEMT7>3.0.CO;2-O; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Chang Z, 1999, AM J PATHOL, V155, P71, DOI 10.1016/S0002-9440(10)65101-2; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; DAUGHERTY BL, 1991, NUCLEIC ACIDS RES, V19, P2471, DOI 10.1093/nar/19.9.2471; Dhanabal M, 1999, CANCER RES, V59, P189; Ding YH, 1998, P NATL ACAD SCI USA, V95, P10443, DOI 10.1073/pnas.95.18.10443; Ghosh S, 2000, MICROSC RES TECHNIQ, V51, P238, DOI 10.1002/1097-0029(20001101)51:3<238::AID-JEMT4>3.0.CO;2-3; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Halfter W, 1998, J BIOL CHEM, V273, P25404, DOI 10.1074/jbc.273.39.25404; Harlow E., 1988, ANTIBODIES LABORATOR, P310; Hohenester E, 1998, EMBO J, V17, P1656, DOI 10.1093/emboj/17.6.1656; Hopker VH, 1999, NATURE, V401, P69, DOI 10.1038/43441; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Kuo CJ, 2001, J CELL BIOL, V152, P1233, DOI 10.1083/jcb.152.6.1233; Lim YS, 1999, J NEUROSCI, V19, P7048, DOI 10.1523/JNEUROSCI.19-16-07048.1999; Lo KM, 1998, PROTEIN ENG, V11, P495, DOI 10.1093/protein/11.6.495; MacDonald NJ, 2001, J BIOL CHEM, V276, P25190, DOI 10.1074/jbc.M100743200; Miosge N, 1999, FASEB J, V13, P1743, DOI 10.1096/fasebj.13.13.1743; OREILLY MS, 1997, CELL, V88, P227; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Saarela J, 1998, AM J PATHOL, V153, P611, DOI 10.1016/S0002-9440(10)65603-9; Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; Sim B K, 1999, Angiogenesis, V3, P41, DOI 10.1023/A:1009058931769; TIMPL R, 1979, J BIOL CHEM, V254, P9933; Tunggal P, 2000, MICROSC RES TECHNIQ, V51, P214, DOI 10.1002/1097-0029(20001101)51:3<214::AID-JEMT2>3.0.CO;2-J	30	41	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45211	45218		10.1074/jbc.M206358200	http://dx.doi.org/10.1074/jbc.M206358200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237301	hybrid			2022-12-27	WOS:000179404800080
J	Lee, SF; Shah, S; Li, HQ; Yu, C; Han, WP; Yu, G				Lee, SF; Shah, S; Li, HQ; Yu, C; Han, WP; Yu, G			Mammalian APH-1 interacts with presenilin and nicastrin and is required for intramembrane proteolysis of amyloid-beta precursor protein and Notch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE ACTIVITY; ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; APP; ASPARTATES; CLEAVAGE; COMPLEX; RELEASE	Presenilin and nicastrin are essential components of the gamma-secretase complex that is required for the intramembrane proteolysis of an increasing number of membrane proteins including the amyloid-beta precursor protein (APP) and Notch. By using co-immunoprecipitation and nickel affinity pull-down approaches, we now show that mammalian APH-1 (mAPH-1), a conserved multipass membrane protein, physically associates with nicastrin and the heterodimers of the presenilin aminoand carboxyl-terminal fragments in human cell lines and in rat brain. Similar to the loss of presenilin or nicastrin, the inactivation of endogenous mAPH-1 using small interfering RNAs results in the decrease of presenilin levels, accumulation of gamma-secretase substrates (APP carboxyl-terminal fragments), and reduction of gamma-secretase products (amyloid-beta peptides and the intracellular domains of APP and Notch). These data indicate that mAPH-1 is probably a functional component of the gamma-secretase complex required for the intramembrane proteolysis of APP and Notch.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yu, G (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.							Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Goutte C, 2000, DEVELOPMENT, V127, P2481; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Karlstrom H, 2002, J BIOL CHEM, V277, P6763, DOI 10.1074/jbc.C100649200; Kehoe P, 1999, HUM MOL GENET, V8, P237, DOI 10.1093/hmg/8.2.237; Kopan R, 2002, NEURON, V33, P321, DOI 10.1016/S0896-6273(02)00585-8; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Levitan D, 2001, DEV BIOL, V240, P654, DOI 10.1006/dbio.2001.0486; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lopez-Schier H, 2002, DEV CELL, V2, P79, DOI 10.1016/S1534-5807(01)00109-5; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; YU G, 1994, J CELL SCI, V107, P1671; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	32	189	209	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45013	45019		10.1074/jbc.M208164200	http://dx.doi.org/10.1074/jbc.M208164200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12297508	hybrid			2022-12-27	WOS:000179404800055
J	Sasaki, H; Sato, H; Kuriyama-Matsumura, K; Sato, K; Maebara, K; Wang, HY; Tamba, M; Itoh, K; Yamamoto, M; Bannai, S				Sasaki, H; Sato, H; Kuriyama-Matsumura, K; Sato, K; Maebara, K; Wang, HY; Tamba, M; Itoh, K; Yamamoto, M; Bannai, S			Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; HUMAN-DIPLOID FIBROBLASTS; PLANAR AROMATIC-COMPOUNDS; YA-SUBUNIT GENE; INDUCIBLE EXPRESSION; BACTERIAL LIPOPOLYSACCHARIDE; OXIDATIVE STRESS; CYSTINE; GLUTATHIONE; NRF2	In mammalian cultured cells, the cystine/glutamate exchange transport mediated by system x(c)(-) is important to maintain intracellular GSH. levels. System x(c)(-) consists of two protein components, xCT and the heavy chain of 4F2 antigen. The activity of system x(c)(-) is induced by various stimuli, including electrophilic agents like diethyl maleate. In the present study, we have investigated the mechanism of the transcriptional regulation of xCT mRNA by diethyl maleate. The xCT gene consisted of twelve exons and sequence analysis identified four electrophile response element (EpRE)-like sequences between -230 and -1 in the W-flanking region, designated EpRE-1 to EpRE-4. To identify sequences mediating the constitutive and induced expression of xCT, a series of 5'-deletion mutants created from the 5'-flanking region were cloned into a luciferase reproter vector and transfected into BBR21 cells. The 5'-deletion analysis revealed that the sequence between -116 and -82 is essential for the basal expression and the sequence between -226 and -116 containing EpRE-1 is essential in response to diethyl maleate. Mutational analysis demonstrated that EpRE-1 is critically involved in the response to diethyl maleate. Other stress agents like arsenite, cadmium, and hydroquinone seemed to induce system xc- activity via the same sequence. Furthermore, the experiments using the mouse embryonic fibroblasts derived from the Nrf2-deficient mice revealed that the induction of xCT gene by electrophilic agents is mediated by Nrf2. EpRE occurs in a broad spectrum of genes for the proteins that are involved in the defense against xenobiotics and regulates their expression. The present results have demonstrated that xCT is a novel member of this protein family.	Univ Tsukuba, Inst Basic Med Sci, Dept Biochem, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan	University of Tsukuba; University of Tsukuba	Sato, H (corresponding author), Univ Tsukuba, Inst Basic Med Sci, Dept Biochem, Tsukuba, Ibaraki 3058575, Japan.		Itoh, Ken/B-9506-2013; Yamamoto, Masayuki/A-4873-2010	Itoh, Ken/0000-0002-5518-0729; Yamamoto, Masayuki/0000-0002-9073-9436				BANNAI S, 1986, J MEMBRANE BIOL, V89, P1, DOI 10.1007/BF01870891; BANNAI S, 1991, BIOCHIM BIOPHYS ACTA, V1092, P175, DOI 10.1016/0167-4889(91)90153-O; BANNAI S, 1980, J BIOL CHEM, V255, P2372; BANNAI S, 1982, J CELL PHYSIOL, V112, P265, DOI 10.1002/jcp.1041120216; Campagne MV, 2000, J NEUROSCI, V20, P5200, DOI 10.1523/JNEUROSCI.20-14-05200.2000; CHO Y, 1990, J NEUROCHEM, V55, P2091, DOI 10.1111/j.1471-4159.1990.tb05800.x; COTGREAVE IA, 1986, J BIOCHEM BIOPH METH, V13, P231, DOI 10.1016/0165-022X(86)90102-8; Erickson AM, 2002, J BIOL CHEM, V277, P30730, DOI 10.1074/jbc.M205225200; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kim YC, 2001, J BIOL CHEM, V276, P18399, DOI 10.1074/jbc.M100103200; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SAGARA J, 1993, J NEUROCHEM, V61, P1667, DOI 10.1111/j.1471-4159.1993.tb09801.x; SATO H, 1995, BIOCHEM J, V310, P547, DOI 10.1042/bj3100547; SATO H, 1987, J BIOL CHEM, V262, P13015; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Sato H, 2001, J BIOL CHEM, V276, P10407, DOI 10.1074/jbc.M007216200; Sato H, 2000, ANTIOXID REDOX SIGN, V2, P665, DOI 10.1089/ars.2000.2.4-665; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Verrey F, 2000, PFLUG ARCH EUR J PHY, V440, P503, DOI 10.1007/s004240050001; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WATANABE H, 1987, J EXP MED, V165, P628, DOI 10.1084/jem.165.3.628	29	368	375	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44765	44771		10.1074/jbc.M208704200	http://dx.doi.org/10.1074/jbc.M208704200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235164	hybrid			2022-12-27	WOS:000179404800024
J	Trotter, EW; Kao, CMF; Berenfeld, L; Botstein, D; Petsko, GA; Gray, JV				Trotter, EW; Kao, CMF; Berenfeld, L; Botstein, D; Petsko, GA; Gray, JV			Misfolded proteins are competent to mediate a subset of the responses to heat shock in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-AZETIDINE-2-CARBOXYLIC ACID RESIDUE; MAP KINASE PATHWAY; SIGNALING PATHWAY; STRESS-RESPONSE; YEAST; TRANSCRIPTION; CONFORMATION; DEGRADATION; EXPRESSION; REGULATOR	Cells may sense heat shock via the accumulation of thermally misfolded proteins. To explore this possibility, we determined the effect of protein misfolding on gene expression in the absence of temperature changes. The imino acid analog azetidine-2-carboxylic acid (AZC) is incorporated into protein competitively with proline and causes reduced thermal stability or misfolding. We found that adding AZC to yeast at sublethal concentrations sufficient to arrest proliferation selectively induced expression of heat shock factor-regulated genes to a maximum of 27-fold and that these inductions were dependent on heat shock factor. AZC treatment also selectively repressed expression of the ribosomal protein genes, another heat shock factor-dependent process, to a maximum of 20-fold. AZC treatment thus strongly and selectively activates heat shock factor. AZC treatment causes this activation by misfolding proteins. Induction of HSP42 by AZC treatment required protein synthesis; treatment with ethanol, which can also misfold proteins, activated heat shock factor, but treatment with canavanine, an arginine analog less potent than AZC at misfolding proteins, did not. However, misfolded proteins did not strongly induce the stress response element regulon. We conclude that misfolded proteins are competent to specifically trigger activation of heat shock factor in response to heat shock.	Univ Glasgow, Fac Biomed & Life Sci, Div Mol Genet, Glasgow G11 6NU, Lanark, Scotland; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA	University of Glasgow; Stanford University; Stanford University; Brandeis University	Gray, JV (corresponding author), Univ Glasgow, Fac Biomed & Life Sci, Div Mol Genet, Anderson Coll Complex,54-56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.		Petsko, Gregory/AAO-7962-2020		NATIONAL CANCER INSTITUTE [R01CA077097] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000983] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046406, R01GM046406] Funding Source: NIH RePORTER; NCI NIH HHS [CA77097] Funding Source: Medline; NHGRI NIH HHS [HG00983] Funding Source: Medline; NIGMS NIH HHS [GM46406] Funding Source: Medline; DRS NIH HHS [RS19987] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); DRS NIH HHS		Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Boy-Marcotte E, 1999, MOL MICROBIOL, V33, P274, DOI 10.1046/j.1365-2958.1999.01467.x; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; CRAIG EA, 1984, CELL, V38, P841, DOI 10.1016/0092-8674(84)90279-4; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FOWDEN L, 1967, ADV ENZYMOL RAMB, V29, P89; FOWDEN L, 1963, BIOCHIM BIOPHYS ACTA, V71, P459, DOI 10.1016/0006-3002(63)91104-1; GRANT CM, 1989, MOL MICROBIOL, V3, P213; Gray JV, 1997, EMBO J, V16, P4924, DOI 10.1093/emboj/16.16.4924; HALLADAY JT, 1995, MOL CELL BIOL, V15, P4890; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; LANE JM, 1971, BIOCHIM BIOPHYS ACTA, V236, P528, DOI 10.1016/0005-2795(71)90236-4; Lopez N, 1999, J BACTERIOL, V181, P3136, DOI 10.1128/JB.181.10.3136-3143.1999; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PIPER PW, 1995, FEMS MICROBIOL LETT, V134, P121, DOI 10.1016/0378-1097(95)00431-9; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Trotter EW, 2001, P NATL ACAD SCI USA, V98, P7313, DOI 10.1073/pnas.121172998; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; ZAGARI A, 1990, BIOPOLYMERS, V30, P951, DOI 10.1002/bip.360300909; ZAGARI A, 1994, BIOPOLYMERS, V34, P51, DOI 10.1002/bip.360340107	30	124	132	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44817	44825		10.1074/jbc.M204686200	http://dx.doi.org/10.1074/jbc.M204686200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12239211	hybrid			2022-12-27	WOS:000179404800031
J	Tseng, HM; Tomkinson, AE				Tseng, HM; Tomkinson, AE			A physical and functional interaction between yeast Pol4 and Dnl4-Lif1 links DNA synthesis and ligation in nonhomologous end joining	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; SACCHAROMYCES-CEREVISIAE; LIGASE-IV; HOMOLOGOUS RECOMBINATION; PROTEIN COMPLEX; DAMAGE RESPONSE; MAMMALIAN-CELLS; BETA-POLYMERASE; XRCC4 PROTEIN; MATING-TYPE	Genetic studies have implicated the Saccharomyces cerevisiae POL4 gene product in the repair of DNA double-strand breaks by nonhomologous end joining. Here we show that Pol4 preferentially catalyzes DNA synthesis on small gaps formed by the alignment of linear duplex DNA molecules with complementary ends, a DNA substrate specificity that is compatible with its predicted role in the repair of DNA double-strand breaks. Pol4 also interacts directly with the Dnl4 subunit of the Dnl4-Lif1 complex via its N-terminal BRCT domain. This interaction stimulates the DNA synthesis activity of Pol4 and, to a lesser extent, the DNA joining activity of Dnl4-Lif1. Notably, the joining of DNA substrates that require the combined action of Pol4 and Dnl4-Lif1 is much more efficient than the joining of similar DNA substrates that require only ligation. Thus, the physical and functional interactions between Pol4 and Dnl4-Lif1 provide a molecular mechanism for both the recruitment of Pol4 to in vivo DNA double-strand breaks and the coupling of the gap filling DNA synthesis and DNA joining reactions that complete the microhomology-mediated pathway of nonhomologous end joining.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Tomkinson, AE (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.				NCI NIH HHS [P01 CA81020, P30 CA54174] Funding Source: Medline; NIGMS NIH HHS [R01 GM47251] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA054174, P01CA081020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047251] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen L, 2001, MOL CELL, V8, P1105, DOI 10.1016/S1097-2765(01)00388-4; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; D'Amours D, 2001, GENE DEV, V15, P2238, DOI 10.1101/gad.208701; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; Frank-Vaillant M, 2001, GENE DEV, V15, P3005, DOI 10.1101/gad.206801; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; Gilfillan S, 1995, IMMUNOL REV, V148, P201, DOI 10.1111/j.1600-065X.1995.tb00099.x; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grenon M, 2001, NAT CELL BIOL, V3, P844, DOI 10.1038/ncb0901-844; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Herrmann G, 1998, EMBO J, V17, P4188, DOI 10.1093/emboj/17.14.4188; Kegel A, 2001, CURR BIOL, V11, P1611, DOI 10.1016/S0960-9822(01)00488-2; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; KRAMER KM, 1994, MOL CELL BIOL, V14, P1293, DOI 10.1128/MCB.14.2.1293; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; Marintchev A, 1999, NAT STRUCT BIOL, V6, P884; Milne GT, 1996, MOL CELL BIOL, V16, P4189; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Moreau S, 1999, MOL CELL BIOL, V19, P556; Ooi SL, 2001, SCIENCE, V294, P2552, DOI 10.1126/science.1065672; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Paull TT, 2000, P NATL ACAD SCI USA, V97, P6409, DOI 10.1073/pnas.110144297; PRASAD R, 1993, NUCLEIC ACIDS RES, V21, P5301, DOI 10.1093/nar/21.23.5301; Ramos W, 1998, NUCLEIC ACIDS RES, V26, P5676, DOI 10.1093/nar/26.24.5676; RON D, 1992, BIOTECHNIQUES, V13, P866; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; SHIMIZU K, 1993, J BIOL CHEM, V268, P27148; Siede W, 1996, GENETICS, V142, P91; SOBEL RW, 1996, NATURE, V379, P183; Sobol RW, 2001, PROG NUCLEIC ACID RE, V68, P57; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Teo SH, 2000, CURR BIOL, V10, P165, DOI 10.1016/S0960-9822(00)00317-1; Usui T, 2001, MOL CELL, V7, P1255, DOI 10.1016/S1097-2765(01)00270-2; Valencia M, 2001, NATURE, V414, P666, DOI 10.1038/414666a; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Wilson TE, 1999, J BIOL CHEM, V274, P23599, DOI 10.1074/jbc.274.33.23599; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303	56	89	92	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45630	45637		10.1074/jbc.M206861200	http://dx.doi.org/10.1074/jbc.M206861200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235149	hybrid			2022-12-27	WOS:000179404800129
J	Vander Heiden, MG; Choy, JS; VanderWeele, DJ; Brace, JL; Harris, MH; Bauer, DE; Prange, B; Kron, SJ; Thompson, CB; Rudin, CM				Vander Heiden, MG; Choy, JS; VanderWeele, DJ; Brace, JL; Harris, MH; Bauer, DE; Prange, B; Kron, SJ; Thompson, CB; Rudin, CM			Bcl-x(L) complements Saccharomyces cerevisiae genes that facilitate the switch from glycolytic to oxidative metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROAPOPTOTIC PROTEIN BAX; BCL-2 FAMILY-MEMBERS; REGULATES APOPTOSIS; YEAST; EXPRESSION; MITOCHONDRIA; DEATH; HETERODIMERIZATION; PROHIBITIN; CHAPERONE	All eukaryotic organisms have mechanisms to adapt to changing metabolic conditions. The mammalian cell survival gene Bcl-x(L) enables cells to adapt to changes in cellular metabolism. To identify genes whose function can be substituted by Bcl-x(L) in a unicellular eukaryote, a genetic screen was performed using the yeast Saccharomyces cerevisiae. S. cerevisiae grows by anaerobic glycolysis when glucose is available, switching to oxidative phosphorylation when carbohydrate in the media becomes limiting (diauxic shift). Given that Bcl-x(L) appears to facilitate the switch from glycolytic to oxidative metabolism in mammalian cells, a library of yeast mutants was tested for the ability to efficiently undergo diauxic shift in the presence and absence of Bcl-x(L). Several mutants were identified that have a defect in growth when switched from a fermentable to a nonfermentable carbon source that is corrected by the expression of Bcl-x(L). These genes include the mitochondrial chaperonin TCM62, as well as previously uncharacterized genes. One of these uncharacterized genes, SVF1, promotes cell survival in mammalian cells in response to multiple apoptotic stimuli. The finding that TCM62 and the analogous human prohibitin gene also inhibit mammalian cell death following growth factor withdrawal implicates mitochondrial chaperones as regulators of apoptosis. Further characterization of the genes identified in this screen may enhance our understanding of Bcl-x(L) function in mammalian cells, and of cell survival pathways in general.	Univ Chicago, Ctr Med, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Chicago; University of Chicago; University of Pennsylvania; Pennsylvania Medicine	Rudin, CM (corresponding author), Univ Chicago, Ctr Med, Dept Med, 5841 S Maryland Ave,MC2115, Chicago, IL 60637 USA.	crudin@medicine.bsd.uchicago.edu	Rudin, Charles/R-2530-2019	Rudin, Charles/0000-0001-5204-3465; VanderWeele, David/0000-0003-4576-5034; Choy, John/0000-0001-9196-3280; Brace, Jennifer/0000-0002-7734-2450	NATIONAL CANCER INSTITUTE [K23CA081138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281] Funding Source: NIH RePORTER; NCI NIH HHS [CA81138] Funding Source: Medline; NIGMS NIH HHS [5 T32 GM07281] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BlachlyDyson E, 1997, MOL CELL BIOL, V17, P5727, DOI 10.1128/MCB.17.10.5727; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Coates PJ, 1997, CURR BIOL, V7, P607, DOI 10.1016/S0960-9822(06)00261-2; DellOrco RT, 1996, EXP GERONTOL, V31, P245, DOI 10.1016/0531-5565(95)02009-8; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dibrov E, 1998, J BIOL CHEM, V273, P32042, DOI 10.1074/jbc.273.48.32042; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Harris MH, 2000, MOL CELL BIOL, V20, P3590, DOI 10.1128/MCB.20.10.3590-3596.2000; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Jurgensmeier JM, 1997, MOL BIOL CELL, V8, P325; Klanner C, 2000, FEBS LETT, V470, P365, DOI 10.1016/S0014-5793(00)01322-3; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Longo VD, 1997, J CELL BIOL, V137, P1581, DOI 10.1083/jcb.137.7.1581; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Zha HB, 1996, MOL CELL BIOL, V16, P6494	36	49	50	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44870	44876		10.1074/jbc.M204888200	http://dx.doi.org/10.1074/jbc.M204888200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244097	hybrid			2022-12-27	WOS:000179404800037
J	Foeger, N; Glaser, W; Skern, T				Foeger, N; Glaser, W; Skern, T			Recognition of eukaryotic initiation factor 4G isoforms by picornaviral proteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUTH-DISEASE-VIRUS; TRANSLATION INITIATION; BINDING-PROTEIN; 2A PROTEINASE; LEADER PROTEINASE; P220 CLEAVAGE; FACTOR-III; EIF4G; RHINOVIRUS; SITE	The leader proteinase (L-pro) of foot and mouth disease virus is a papain-like cysteine proteinase. After processing itself from the polyprotein, L-pro then cleaves the host protein eukaryotic initiation factor (eIf) 4GI, thus preventing protein synthesis from capped mRNA in the infected cell. We have investigated L-pro interaction with eIF4GI and its isoform, eIF4GIL L-pro, expressed as a catalytically inactive fusion protein with glutathione S-transferase, binds specifically to eIF4G isomers in rabbit reticulocyte lysates. Deletion and specific mutagenesis were used to map the binding domain on L-pro to residues 183-195 of the C-terminal extension and to residue Cys(133). These residues of the C-terminal extension and Cys(133) are adjacent in the crystal structure but lie about 25 A from the active site. The region on eIF4GI recognized by the L-pro C-terminal extension was mapped to residues 640-669 using eIF4GI fragments generated by proteolysis or by in vitro translation. The L-pro cleavage site at Gly(674)down arrowArg(675) was not necessary for binding. Similar experiments with human rhinovirus 2A proteinase (2A(pro)), a chymotrypsin-like cysteine proteinase that also cleaves eIF4G isoforms, revealed that 2A(pro) can also bind to eIF4GI fragments lacking its cleavage site. These experiments strongly suggest a novel interaction between picornaviral proteinases and eIF4G isoforms.	Univ Vienna, Div Biochem, Inst Med Biochem, Vienna Bio Ctr, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC)	Skern, T (corresponding author), Univ Vienna, Div Biochem, Inst Med Biochem, Vienna Bio Ctr, Dr Bohr Gasse 9-3, A-1030 Vienna, Austria.	timothy.skern@univie.ac.at	Skern, Tim/AAC-1732-2022; Foeger, Nicole/L-2620-2019	Skern, Tim/0000-0001-8865-5500; Foeger, Nicole/0000-0001-7775-7325				Belsham GJ, 2000, J VIROL, V74, P272, DOI 10.1128/JVI.74.1.272-280.2000; Belsham GJ, 2000, COLD SPRING HARBOR M, V39, P869; Belsham GJ, 1996, MICROBIOL REV, V60, P499, DOI 10.1128/MMBR.60.3.499-511.1996; BERNSTEIN HD, 1985, MOL CELL BIOL, V5, P2913, DOI 10.1128/MCB.5.11.2913; Bovee ML, 1998, VIROLOGY, V245, P241, DOI 10.1006/viro.1998.9172; Bovee ML, 1998, VIROLOGY, V245, P229, DOI 10.1006/viro.1998.9171; Brown CC, 1996, J VIROL, V70, P5638, DOI 10.1128/JVI.70.8.5638-5641.1996; Byrd MP, 2002, MOL CELL BIOL, V22, P4499, DOI 10.1128/MCB.22.13.4499-4511.2002; DEVANEY MA, 1988, J VIROL, V62, P4407, DOI 10.1128/JVI.62.11.4407-4409.1988; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Glaser W, 2000, FEBS LETT, V480, P151, DOI 10.1016/S0014-5793(00)01928-1; Glaser W, 2001, J BIOL CHEM, V276, P35473, DOI 10.1074/jbc.M104192200; Gradi A, 1998, P NATL ACAD SCI USA, V95, P11089, DOI 10.1073/pnas.95.19.11089; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Guarne A, 2000, J MOL BIOL, V302, P1227, DOI 10.1006/jmbi.2000.4115; Guarne A, 1998, EMBO J, V17, P7469, DOI 10.1093/emboj/17.24.7469; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hershey PEC, 1999, J BIOL CHEM, V274, P21297, DOI 10.1074/jbc.274.30.21297; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; Kanno T, 2001, VIRUS RES, V80, P101, DOI 10.1016/S0168-1702(01)00341-0; KIRCHWEGER R, 1994, J VIROL, V68, P5677, DOI 10.1128/JVI.68.9.5677-5684.1994; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; LLOYD RE, 1988, J VIROL, V62, P4216, DOI 10.1128/JVI.62.11.4216-4223.1988; LLOYD RE, 1986, VIROLOGY, V150, P299, DOI 10.1016/0042-6822(86)90291-6; MADER S, 1995, MOL CELL BIOL, V15, P4990; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; MEDINA M, 1993, VIROLOGY, V194, P355, DOI 10.1006/viro.1993.1267; Morley SJ, 1997, RNA, V3, P1085; Ohlmann T, 1997, EMBO J, V16, P844, DOI 10.1093/emboj/16.4.844; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Petersen JFW, 1999, EMBO J, V18, P5463, DOI 10.1093/emboj/18.20.5463; Piron M, 1998, EMBO J, V17, P5811, DOI 10.1093/emboj/17.19.5811; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Sakoda Y, 2001, J VIROL, V75, P10643, DOI 10.1128/JVI.75.22.10643-10650.2001; SANGAR DV, 1987, NUCLEIC ACIDS RES, V15, P3305, DOI 10.1093/nar/15.8.3305; Seipelt J, 2000, J BIOL CHEM, V275, P20084, DOI 10.1074/jbc.275.26.20084; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Svitkin YV, 1999, J VIROL, V73, P3467, DOI 10.1128/JVI.73.4.3467-3472.1999; THOMAS AAM, 1992, EUR J BIOCHEM, V207, P471, DOI 10.1111/j.1432-1033.1992.tb17073.x; van Rensburg H, 2002, GENE, V289, P19, DOI 10.1016/S0378-1119(02)00471-7; Ventoso I, 1998, FEBS LETT, V435, P79, DOI 10.1016/S0014-5793(98)01027-8; WYCKOFF EE, 1992, J VIROL, V66, P2943, DOI 10.1128/JVI.66.5.2943-2951.1992; YAN RQ, 1992, J BIOL CHEM, V267, P23226; YU SF, 1991, VIROLOGY, V182, P615, DOI 10.1016/0042-6822(91)90602-8; Zamora M, 2002, J VIROL, V76, P165, DOI 10.1128/JVI.76.1.165-177.2002; ZIEGLER E, 1995, J VIROL, V69, P3465, DOI 10.1128/JVI.69.6.3465-3474.1995	54	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44300	44309		10.1074/jbc.M208006200	http://dx.doi.org/10.1074/jbc.M208006200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228254	hybrid			2022-12-27	WOS:000179272000100
J	Jeong, YJ; Kim, DE; Patel, SS				Jeong, YJ; Kim, DE; Patel, SS			Kinetic pathway of dTTP hydrolysis by hexameric T7 helicase-printase in the absence of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CHANGE MECHANISM; SEQUENTIAL HYDROLYSIS; OLIGOMERIC STRUCTURE; INORGANIC-PHOSPHATE; ATP HYDROLYSIS; PROTEIN; F1-ATPASE; RELEASE; SITES; RHO	Bacteriophage T7 gp4A' protein is a hexameric helicase-primase protein that separates the strands of a duplex DNA in a reaction coupled to dTTP hydrolysis. Here we reexamine in more detail the kinetic mechanism of dTTP hydrolysis by a preassembled T7 helicase hexamer in the absence of DNA. Pre-steady state dTTP hydrolysis kinetics showed a distinct burst whose amplitude indicated that a preformed hexamer of T7 helicase hydrolyzes on an average one dTTP per hexamer. The presteady state chase-time experiments provided evidence for sequential hydrolysis of two dTTPs. The medium [O-18]P-i exchange experiments failed to detect dTTP synthesis, indicating that the less than six-site hydrolysis observed is not due to reversible dTTP hydrolysis on the helicase active site. The P-i-release rate was measured directly using a stopped-flow fluorescence assay, and it was found that the rate of dTTP hydrolysis on the helicase active site is eight times faster than the P-i-release rate, which in turn is three times faster than the dTDP release rate. Thus, the rate-limiting step in the pathway of helicase-catalyzed deoxythymidine triphosphatase (dTTPase) reaction is the release of dTDP. Chase-time dTTPase kinetics in the steady state phase provided evidence for two to three slowly hydrolyzing dTTPase sites on the hexamer. The results of this study are therefore consistent with those reported earlier (Hingorani, M. M., Washington, M. T., Moore, K. C., and Patel, S. S. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 5012-5017), and they support a model of dTTP hydrolysis by T7 helicase hexamer that is similar to the binding change mechanism of F-1-ATPase with dTTP hydrolysis occurring sequentially at the catalytic sites.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Patel, SS (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.		Kim, Dong-Eun/D-8304-2011	Kim, Dong-Eun/0000-0001-6545-8387	NIGMS NIH HHS [GM55310] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; Baird CL, 2001, J BIOL CHEM, V276, P27893, DOI 10.1074/jbc.M102544200; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; COHN M, 1978, P NATL ACAD SCI USA, V75, P200, DOI 10.1073/pnas.75.1.200; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Hackney D D, 1980, Methods Enzymol, V64, P60; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; HUTTON RL, 1979, J BIOL CHEM, V254, P9990; Kim DE, 1999, J BIOL CHEM, V274, P32667, DOI 10.1074/jbc.274.46.32667; Kim DE, 2002, J MOL BIOL, V321, P807, DOI 10.1016/S0022-2836(02)00733-7; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MARRIONE PE, 1995, BIOCHEMISTRY-US, V34, P9809, DOI 10.1021/bi00030a019; Morris PD, 1999, BIOCHEMISTRY-US, V38, P5164, DOI 10.1021/bi9822269; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1993, J BIOL CHEM, V268, P10668; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Picha KM, 1998, J BIOL CHEM, V273, P27315, DOI 10.1074/jbc.273.42.27315; PIPER JM, 1981, ANAL BIOCHEM, V117, P70, DOI 10.1016/0003-2697(81)90693-X; Rajendran S, 2000, J MOL BIOL, V303, P773, DOI 10.1006/jmbi.2000.4124; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Stitt BL, 1998, J BIOL CHEM, V273, P26477, DOI 10.1074/jbc.273.41.26477; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740	27	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43778	43784		10.1074/jbc.M208634200	http://dx.doi.org/10.1074/jbc.M208634200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226105	hybrid			2022-12-27	WOS:000179272000033
J	Mahajan, SS; Little, MM; Vazquez, R; Wilson, AC				Mahajan, SS; Little, MM; Vazquez, R; Wilson, AC			Interaction of HCF-1 with a cellular nuclear export factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; KAPPA-B-ALPHA; VP16 ACCESSORY PROTEIN; SUBCELLULAR-LOCALIZATION; VP16-INDUCED COMPLEX; ACTIVATION DOMAIN; TEGUMENT PROTEIN; BINDING PROTEIN; POTENTIAL ROLE; LEPTOMYCIN-B	HCF-1 is a cellular protein required by VP16 to activate the herpes simplex virus (HSV) immediate-early genes. VP16 is a component of the viral tegument and, after release into the cell, binds to HCF-1 and translocates to the nucleus to form a complex with the POU domain protein Oct-1 and a VP16-responsive DNA sequence. This VP16-induced complex boosts transcription of the viral immediate-early genes and initiates lytic replication. In uninfected cells, HCF-1 functions as a coactivator for the cellular transcription factors LZIP and GABP and also plays an essential role in cell proliferation. VP16 and LZIP share a tetrapeptide HCF-binding motif recognized by the beta-propeller domain of HCF-1. Here we describe a new cellular HCF-1 beta-propeller domain binding protein, termed HPIP, which contains a functional HCF-binding motif and a leucine-rich nuclear export sequence. We show that HPIP shuttles between the nucleus and cytoplasm in a CRM1-dependent manner and that overexpression of HPIP leads to accumulation of HCF-1 in the cytoplasm. These data suggest that HPIP regulates HCF-1 activity by modulating its subcellular localization. Furthermore, HPIP-mediated export may provide the pool of cytoplasmic HCF-1 required for import of virion-derived VP16 into the nucleus.	NYU, Med Ctr, Dept Microbiol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Wilson, AC (corresponding author), NYU, Med Ctr, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.		Wilson, Angus C/AAA-8153-2019	Wilson, Angus C/0000-0002-5016-4164	NIGMS NIH HHS [R01 GM061139, GM61139] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061139] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Donnelly M, 2001, J VIROL, V75, P2566, DOI 10.1128/JVI.75.6.2566-2574.2001; Elliott G, 2000, J VIROL, V74, P2131, DOI 10.1128/JVI.74.5.2131-2141.2000; Forgues M, 2001, J BIOL CHEM, V276, P22797, DOI 10.1074/jbc.M101259200; Fornerod M, 1997, CELL, V90, P1051; FRATTINI A, 1994, GENOMICS, V23, P30, DOI 10.1006/geno.1994.1455; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; GREAVES R, 1989, J VIROL, V63, P1641, DOI 10.1128/JVI.63.4.1641-1650.1989; GREAVES RF, 1990, J VIROL, V64, P2716, DOI 10.1128/JVI.64.6.2716-2724.1990; Hughes TA, 1999, J BIOL CHEM, V274, P16437, DOI 10.1074/jbc.274.23.16437; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kim FJ, 1996, MOL CELL BIOL, V16, P5147; Knopf CW, 2000, ACTA VIROL, V44, P289; Kristie TM, 1999, P NATL ACAD SCI USA, V96, P1229, DOI 10.1073/pnas.96.4.1229; KRISTIE TM, 1995, J BIOL CHEM, V270, P4387, DOI 10.1074/jbc.270.9.4387; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; La Boissiere S, 1999, EMBO J, V18, P480; LaBoissiere S, 1997, MOL CELL BIOL, V17, P7108, DOI 10.1128/MCB.17.12.7108; Lai JS, 1997, MOL CELL BIOL, V17, P3937, DOI 10.1128/MCB.17.7.3937; Lee SH, 2001, J BIOL CHEM, V276, P23599, DOI 10.1074/jbc.M011197200; Liu JL, 1997, J VIROL, V71, P3188, DOI 10.1128/JVI.71.4.3188-3196.1997; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Lu R, 2000, J VIROL, V74, P934, DOI 10.1128/JVI.74.2.934-943.2000; Lu R, 2000, NUCLEIC ACIDS RES, V28, P2446, DOI 10.1093/nar/28.12.2446; Lu R, 1998, J VIROL, V72, P6291, DOI 10.1128/JVI.72.8.6291-6297.1998; Luciano RL, 2000, P NATL ACAD SCI USA, V97, P10757, DOI 10.1073/pnas.190062797; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; MORIUCHI H, 1995, J VIROL, V69, P4693, DOI 10.1128/JVI.69.8.4693-4701.1995; Morrison EE, 1998, J GEN VIROL, V79, P2517, DOI 10.1099/0022-1317-79-10-2517; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; OHARE P, 1993, SEMIN VIROL, V4, P145, DOI 10.1006/smvy.1993.1010; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; ROIZMAN B, 1996, FIELDS VIROLOGY, V2, P2231; Simmen KA, 1997, J VIROL, V71, P3886, DOI 10.1128/JVI.71.5.3886-3894.1997; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VARAGONA MJ, 1994, PLANT J, V5, P207, DOI 10.1046/j.1365-313X.1994.05020207.x; Vogel JL, 2000, P NATL ACAD SCI USA, V97, P9425, DOI 10.1073/pnas.160266697; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Williams SC, 1997, GENE EXPRESSION, V6, P371; Wilson AC, 2000, MOL CELL BIOL, V20, P6721, DOI 10.1128/MCB.20.18.6721-6730.2000; WILSON AC, 1995, GENOMICS, V25, P462, DOI 10.1016/0888-7543(95)80046-O; WILSON AC, 1993, COLD SPRING HARB SYM, V58, P167, DOI 10.1101/SQB.1993.058.01.021; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001; Ye GJ, 2000, J VIROL, V74, P1355, DOI 10.1128/JVI.74.3.1355-1363.2000	59	20	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44292	44299		10.1074/jbc.M205440200	http://dx.doi.org/10.1074/jbc.M205440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12235138	hybrid, Green Accepted			2022-12-27	WOS:000179272000099
J	Petro, JB; Gerstein, RM; Lowe, J; Carter, RS; Shinners, N; Khan, WN				Petro, JB; Gerstein, RM; Lowe, J; Carter, RS; Shinners, N; Khan, WN			Transitional type 1 and 2 B lymphocyte subsets are differentially responsive to antigen receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; X-LINKED AGAMMAGLOBULINEMIA; HEAT-STABLE ANTIGEN(HI); CELL DEVELOPMENT; NEGATIVE SELECTION; PHOSPHOLIPASE C-GAMMA-2; REPERTOIRE SELECTION; IMMATURE; ACTIVATION; MICE	Mature B-lymphocytes develop sequentially from transitional type 1 (T1) and type 2 (T2) precursors in the spleen. To elucidate the mechanisms that regulate the developmental fate of these distinct B cell subsets, we investigated their biochemical and biological responses following stimulation through the B-cell antigen receptor (BCR). As compared with the T1 subset, T2 cells are more responsive to BCR engagement, as evidenced by their robust induction of activation markers, expression of the prosurvival protein Bcl-x(L), and enhanced proliferation. BCR stimulation of T2 cells leads to the appearance of B cells with mature phenotypic characteristics, whereas T1 cells die. All of these T2 responses are dependent on the BCR signal transducer Bruton's tyrosine kinase, which is dispensable for the T1 to T2 transition. Furthermore, the serine/threonine kinases ERK, p38 MAPK, and Akt are predominantly activated in T2 compared with T1 B cells following BCR cross-linking. We conclude that T1 and T2 B cells respond differentially to BCR engagement via the induction of stage-specific signaling pathways. In turn, these signaling pathways probably govern the development and selection processes that are critical for the formation of the mature B cell compartment.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA	Vanderbilt University; University of Massachusetts System; University of Massachusetts Worcester	Khan, WN (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068744, T32HL069765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050213, R01AI043534] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL69715-01, T32 HL69765-01, 1 P01 HL68744] Funding Source: Medline; NIAID NIH HHS [R01 AI43534, R01 AI50213-01] Funding Source: Medline; NIDDK NIH HHS [5 P30 DK32520] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allman D, 2001, J IMMUNOL, V167, P6834, DOI 10.4049/jimmunol.167.12.6834; ALLMAN DM, 1992, J IMMUNOL, V149, P2533; ALLMAN DM, 1993, J IMMUNOL, V151, P4431; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Anderson JS, 1996, P NATL ACAD SCI USA, V93, P10966, DOI 10.1073/pnas.93.20.10966; Batten M, 2000, J EXP MED, V192, P1453, DOI 10.1084/jem.192.10.1453; Benschop RJ, 2001, J IMMUNOL, V167, P4172, DOI 10.4049/jimmunol.167.8.4172; Brorson K, 1997, J IMMUNOL, V159, P135; Buhl AM, 2000, IMMUNOL REV, V176, P141; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; CARSETTI R, 1995, J EXP MED, V181, P2129, DOI 10.1084/jem.181.6.2129; Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X; Chung JB, 2001, J IMMUNOL, V166, P736, DOI 10.4049/jimmunol.166.2.736; COUTINHO A, 1993, IMMUNOL TODAY, V14, P38, DOI 10.1016/0167-5699(93)90323-D; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fleming HE, 2001, IMMUNITY, V15, P521, DOI 10.1016/S1074-7613(01)00216-3; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; Fruman DA, 2000, IMMUNITY, V13, P1, DOI 10.1016/S1074-7613(00)00002-9; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Glassford J, 2001, J BIOL CHEM, V276, P41040, DOI 10.1074/jbc.M105305200; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; Khan WN, 1997, INT IMMUNOL, V9, P395, DOI 10.1093/intimm/9.3.395; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; King LB, 2000, IMMUNOL REV, V176, P86; Kurosaki T, 2000, CURR OPIN IMMUNOL, V12, P276, DOI 10.1016/S0952-7915(00)00087-X; Kurosaki T, 2000, IMMUNITY, V12, P1, DOI 10.1016/S1074-7613(00)80153-3; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Levine MH, 2000, P NATL ACAD SCI USA, V97, P2743, DOI 10.1073/pnas.050552997; Lewis CM, 2001, CURR OPIN IMMUNOL, V13, P317, DOI 10.1016/S0952-7915(00)00221-1; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; Marshall AJ, 2000, IMMUNOL REV, V176, P30; Meffre E, 2000, NAT IMMUNOL, V1, P379, DOI 10.1038/80816; Melchers F, 2000, IMMUNOL REV, V175, P33, DOI 10.1111/j.1600-065X.2000.imr017510.x; Monroe JG, 2000, CURR TOP MICROBIOL, V245, P1; Monroe JG, 2000, CLIN IMMUNOL, V95, pS8, DOI 10.1006/clim.1999.4817; NORVELL A, 1995, J IMMUNOL, V154, P4404; Norvell A, 1996, J IMMUNOL, V156, P1328; Oliver AM, 1997, EUR J IMMUNOL, V27, P2366, DOI 10.1002/eji.1830270935; Petro JB, 2001, J BIOL CHEM, V276, P1715, DOI 10.1074/jbc.M009137200; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Rolink AG, 2001, CURR OPIN IMMUNOL, V13, P202, DOI 10.1016/S0952-7915(00)00205-3; Rolink AG, 1998, EUR J IMMUNOL, V28, P3738, DOI 10.1002/(SICI)1521-4141(199811)28:11<3738::AID-IMMU3738>3.0.CO;2-Q; Sakata N, 1999, EUR J IMMUNOL, V29, P2999, DOI 10.1002/(SICI)1521-4141(199909)29:09<2999::AID-IMMU2999>3.0.CO;2-L; Sandel PC, 1999, IMMUNITY, V10, P289, DOI 10.1016/S1074-7613(00)80029-1; Satterthwaite AB, 2000, IMMUNOL REV, V175, P120, DOI 10.1034/j.1600-065X.2000.017504.x; Scheick WJ, 2001, RELIG LIT, V33, P1; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; SIDERAS P, 1995, ADV IMMUNOL, V59, P135, DOI 10.1016/S0065-2776(08)60631-8; Solvason N, 1998, J EXP MED, V187, P1081, DOI 10.1084/jem.187.7.1081; Su TT, 2002, J IMMUNOL, V168, P2101, DOI 10.4049/jimmunol.168.5.2101; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; VIALE AC, 1993, INT IMMUNOL, V5, P599, DOI 10.1093/intimm/5.6.599; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Willerford DM, 1996, CURR OPIN GENET DEV, V6, P603, DOI 10.1016/S0959-437X(96)80090-6; Wu HJ, 2001, J IMMUNOL, V167, P1263, DOI 10.4049/jimmunol.167.3.1263; Xu SL, 2000, INT IMMUNOL, V12, P397, DOI 10.1093/intimm/12.3.397	65	90	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48009	48019		10.1074/jbc.M200305200	http://dx.doi.org/10.1074/jbc.M200305200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12356763	hybrid			2022-12-27	WOS:000179789600007
J	Cleverley, RM; Gierasch, LM				Cleverley, RM; Gierasch, LM			Mapping the signal sequence-binding site on SRP reveals a significant role for the NG domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE-RICH DOMAIN; RECOGNITION PARTICLE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; PROTEIN TRANSLOCATION; CONSERVED GTPASE; CROSS-LINKING; RNA; SUBUNIT; MEMBRANE	We present evidence that the signal recognition particle (SRP) recognizes signal sequences via the NG domain on the SRP54 protein subunit. Using a recently developed cross-linking method (Fancy, D. A., and Kodadek, T. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 6020-6024; Correction (1999) Proc. NatL Acad. Sci. U. S. A. 96,1317), we find that signal peptides cross-link to the Escherichia coli SRP protein Ffh (the homologue of the mammalian SRP54 subunit) via the NG domain. Within the NG domain, the cross-linking site maps to the ras-like C-terminal subdomain termed the G domain. This result stands in contrast to previous studies, which concluded based on nascent chain cross-linking that the signal sequence bound to the adjacent M domain. As independent evidence of a direct binding interaction between the NG domain and the signal sequence, we find that the NG domain of Ffh binds signal peptides as an isolated entity. Our results suggest that the NG domain forms a substantial part of the binding site for the signal sequence.	Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA; Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Gierasch, LM (corresponding author), Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA.	gierasch@biochem.umass.edu	Gierasch, Lila M/D-1494-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034962] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34962] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTHOFF S, 1994, NUCLEIC ACIDS RES, V22, P1933, DOI 10.1093/nar/22.11.1933; Batey RT, 2000, SCIENCE, V287, P1232, DOI 10.1126/science.287.5456.1232; Baud C, 2002, J BIOL CHEM, V277, P13724, DOI 10.1074/jbc.M200047200; Bernstein HD, 1998, CURR BIOL, V8, pR715, DOI 10.1016/S0960-9822(98)70456-7; Cleverley RM, 2001, J BIOL CHEM, V276, P19327, DOI 10.1074/jbc.M011130200; Fancy DA, 2000, CHEM BIOL, V7, P697, DOI 10.1016/S1074-5521(00)00020-X; Fancy DA, 1999, P NATL ACAD SCI USA, V96, P6020, DOI 10.1073/pnas.96.11.6020; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; Freymann DM, 1999, NAT STRUCT BIOL, V6, P793, DOI 10.1038/11572; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HIGH S, 1991, J CELL BIOL, V113, P229, DOI 10.1083/jcb.113.2.229; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Keenan RJ, 1998, CELL, V94, P181, DOI 10.1016/S0092-8674(00)81418-X; Lee HC, 2001, P NATL ACAD SCI USA, V98, P3471, DOI 10.1073/pnas.051484198; Lentzen G, 1996, RNA, V2, P244; Lo Conte L, 1999, J MOL BIOL, V285, P2177; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; Macao B, 1997, MOL MICROBIOL, V24, P523, DOI 10.1046/j.1365-2958.1997.3551729.x; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Montoya G, 2000, STRUCTURE, V8, P515, DOI 10.1016/S0969-2126(00)00131-3; Newitt JA, 1997, EUR J BIOCHEM, V245, P720, DOI 10.1111/j.1432-1033.1997.00720.x; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schmitz U, 1996, RNA, V2, P1213; Shepotinovskaya IV, 2002, BBA-PROTEIN STRUCT M, V1597, P107, DOI 10.1016/S0167-4838(02)00287-X; STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Weber PJA, 1997, J PEPT RES, V49, P375; Zheng N, 1997, MOL CELL, V1, P79, DOI 10.1016/S1097-2765(00)80009-X; ZOPF D, 1993, J CELL BIOL, V120, P1113, DOI 10.1083/jcb.120.5.1113; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	32	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46763	46768		10.1074/jbc.M207427200	http://dx.doi.org/10.1074/jbc.M207427200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244111	hybrid			2022-12-27	WOS:000179529300136
J	Idicula, AM; Blatch, GL; Cooper, TG; Dorrington, RA				Idicula, AM; Blatch, GL; Cooper, TG; Dorrington, RA			Binding and activation by the zinc cluster transcription factors of Saccharomyces cerevisiae - Redefining the UAS(GABA) and its interaction with Uga3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; REGULATORY ELEMENTS; GENE-EXPRESSION; PROTEIN-BINDING; IN-VITRO; GAL4; RECOGNITION; REPRESSION; INDUCTION; PERMEASE	Uga3p, a member of zinc binuclear cluster transcription factor family, is required for gamma-aminobutyric aciddependent transcription of the UGA genes in Saccharomyces cerevisiae. Members of this family bind to CGG triplets with the spacer region between the triplets being an important specificity determinant. A conserved 19-nucleotide activation element in certain UGA gene promoter regions contains a CCGN(4)CGG-everted repeat proposed to be the binding site of Uga3p, UAS(GABA). The function of conserved nucleotides flanking the everted repeat has not been rigorously investigated. The interaction of Uga3p with UAS(GABA) was characterized in terms of binding in vitro and transcriptional activation of lacZ reporter genes in vivo. Electromobility shift assays using mutant UAS(GABA) sequences and heterologously produced full-length Uga3p demonstrated that UAS(GABA) consists of two independent Uga3p binding sites. Simultaneous occupation of both Uga3p binding sites of UASGABA with high affinity is essential for GABA-dependent transcriptional activation in vivo. We present evidence that the two Uga3p molecules bound to UASGABA probably interact with each other and show that Uga3p((1-124)), previously used for binding studies, is not functionally equivalent to the full-length protein with respect to binding in vitro. We propose that the Uga3p binding site is an asymmetric site of 5'-SGCGGN-WTTT-3' (S = G or C, W = A, or T and n = no nucleotide or G). However, UAS(GABA), is a palindrome containing two asymmetric Uga3p binding sites.	Rhodes Univ, Dept Biochem Microbiol & Biotechnol, ZA-6140 Grahamstown, South Africa; Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA	Rhodes University; University of Tennessee System; University of Tennessee Health Science Center	Dorrington, RA (corresponding author), Rhodes Univ, Dept Biochem Microbiol & Biotechnol, POB 94, ZA-6140 Grahamstown, South Africa.	r.dorrington@ru.ac.za	Blatch, Gregory Lloyd/Q-5900-2019	Blatch, Gregory Lloyd/0000-0003-0778-8577; Cooper, Terrance G./0000-0002-7651-9963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM035642] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRE B, 1990, MOL GEN GENET, V220, P269; AXELROD JD, 1991, MOL CELL BIOL, V11, P564, DOI 10.1128/MCB.11.1.564; BRAM RJ, 1985, P NATL ACAD SCI USA, V82, P43, DOI 10.1073/pnas.82.1.43; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; Coffman JA, 1997, J BACTERIOL, V179, P5609, DOI 10.1128/jb.179.17.5609-5613.1997; COFFMAN JA, 1994, J BACTERIOL, V176, P7476, DOI 10.1128/JB.176.24.7476-7483.1994; CUNNINGHAM TS, 1994, J BACTERIOL, V176, P4718, DOI 10.1128/JB.176.15.4718-4725.1994; DAUGHERTY JR, 1993, J BACTERIOL, V175, P64, DOI 10.1128/JB.175.1.64-73.1993; DHAWALE SS, 1993, NUCLEIC ACIDS RES, V21, P5537, DOI 10.1093/nar/21.24.5537; DORRINGTON RA, 1993, NUCLEIC ACIDS RES, V21, P3777, DOI 10.1093/nar/21.16.3777; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; Hellauer K, 1996, MOL CELL BIOL, V16, P6096; IDICULA AM, 2002, THESIS RHODES U GRAH; KING DA, 1999, EUR J MORPHOL, V36, P86; KOVARI L, 1990, MOL CELL BIOL, V10, P5087, DOI 10.1128/MCB.10.10.5087; Lenouvel F, 1997, J BIOL CHEM, V272, P15521, DOI 10.1074/jbc.272.24.15521; Mamane Y, 1998, J BIOL CHEM, V273, P18556, DOI 10.1074/jbc.273.29.18556; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; MCKELVEY J, 1990, YEAST, V6, P263, DOI 10.1002/yea.320060311; Moretti MB, 2001, INT J BIOCHEM CELL B, V33, P1202, DOI 10.1016/S1357-2725(01)00085-1; Noel J, 1998, J BIOL CHEM, V273, P17463, DOI 10.1074/jbc.273.28.17463; PAN T, 1989, P NATL ACAD SCI USA, V86, P3145, DOI 10.1073/pnas.86.9.3145; PARK HD, 1992, NUCLEIC ACIDS RES, V20, P1909, DOI 10.1093/nar/20.8.1909; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROY A, 1990, MOL CELL BIOL, V10, P5257, DOI 10.1128/MCB.10.10.5257; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; SoussiBoudekou S, 1997, MOL MICROBIOL, V23, P1157, DOI 10.1046/j.1365-2958.1997.3021665.x; SZE JY, 1993, J BIOL CHEM, V268, P2505; TABOR S, 1990, CURRENT PROTOCOL MOL; TALIBI D, 1995, NUCLEIC ACIDS RES, V23, P550, DOI 10.1093/nar/23.4.550; VASHEE S, 1993, J BIOL CHEM, V268, P24699; VISSERS S, 1989, EUR J BIOCHEM, V181, P357, DOI 10.1111/j.1432-1033.1989.tb14732.x; Yu LH, 2000, PROTEIN SCI, V9, P2470, DOI 10.1110/ps.9.12.2470; ZHANG L, 1994, GENE DEV, V8, P2110, DOI 10.1101/gad.8.17.2110	35	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45977	45983		10.1074/jbc.M201789200	http://dx.doi.org/10.1074/jbc.M201789200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235130	hybrid, Green Accepted			2022-12-27	WOS:000179529300037
J	Iwamoto, S; Kumada, M; Kamesaki, T; Okuda, H; Kajii, E; Inagaki, T; Saikawa, D; Takeuchi, K; Ohkawara, S; Takahashi, R; Ueda, S; Inoue, S; Tahara, K; Hakamata, Y; Kobayashi, E				Iwamoto, S; Kumada, M; Kamesaki, T; Okuda, H; Kajii, E; Inagaki, T; Saikawa, D; Takeuchi, K; Ohkawara, S; Takahashi, R; Ueda, S; Inoue, S; Tahara, K; Hakamata, Y; Kobayashi, E			Rat encodes the paralogous gene equivalent of the human histo-blood group ABO gene - Association with antigen expression by overexpression of human ABO transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GALACTOSIDE 2-ALPHA-L-FUCOSYL-TRANSFERASE; CHEMICAL CARCINOGENESIS; DNA METHYLATION; LARGE-INTESTINE; HUMAN CANCER; GROUP-A; REGION; TRANSPLANTATION; HEPATOMA; LIVER	We cloned a rat ABO homologue and established human A- and B-transferase transgenic rats. A DNA fragment corresponding to exon 7 of the human ABO gene was amplified from Wistar rat genomic DNA and sequenced. Using the amplified fragments as a probe for Southern blotting, multiple hybridized bands appeared on both EcoRI- and BamHI-digested genomes of seven rat strains, which showed variations in the band numbers among the strains. Four cDNAs were cloned from a Wistar rat, three of which showed A-iransferase activity and one of which showed B-transferase activity. These activities were dependent on the equivalent residues at 266 and 268 of human ABO transferase. Wild Wistar rats expressed A-antigen in salivary gland, intestine, and urinary bladder tissue, but B-antigen was not stained in any organs studied, whereas a transcript from the ABO homologue with B-transferase activity was ubiquitous. Human A-transferase and B-transferase were transferred into Wistar rats. A-transgenic rats expressed A-antigen in ectopic tissue of the brain plexus, type II lung epithelium, pancreas, and epidermis. B-antigen in the B-transgenic rat was expressed in the same organs as A-transgenic rats. These results may shed light on the function and evolution of the ABO gene in primates.	Jichi Med Sch, Dept Legal Med & Human Genet, Minami Kawachi, Tochigi 32904, Japan; Jichi Med Sch, Dept Anat, Minami Kawachi, Tochigi 32904, Japan; YS New Technol Inst Inc, Minami Kawachi, Tochigi 32904, Japan; Jichi Med Sch, Ctr Mol Med, Minami Kawachi, Tochigi 3290498, Japan	Jichi Medical University; Jichi Medical University; Jichi Medical University	Iwamoto, S (corresponding author), Jichi Med Sch, Dept Legal Med & Human Genet, 3311-1 Minamikawachi Machi, Minami Kawachi, Tochigi 32904, Japan.	siwamoto@ms.jichi.ac.jp	Hakamata, Yoji/AAF-7759-2020; INAGAKI, Takeshi/N-2247-2016	INAGAKI, Takeshi/0000-0002-8720-2654; Hakamata, Yoji/0000-0002-0138-6692				ANGSTROM J, 1987, BIOCHIM BIOPHYS ACTA, V926, P79, DOI 10.1016/0304-4165(87)90184-X; BOUHOURS D, 1995, BBA-LIPID LIPID MET, V1255, P131, DOI 10.1016/0005-2760(94)00229-R; BOUHOURS JF, 1987, J BIOL CHEM, V262, P16370; BREIMER ME, 1979, BIOMED MASS SPECTROM, V6, P231, DOI 10.1002/bms.1200060603; COOPER DKC, 1990, J HEART TRANSPLANT, V9, P376; Hakamata Y, 2001, BIOCHEM BIOPH RES CO, V286, P779, DOI 10.1006/bbrc.2001.5452; Hakomori S, 1999, BBA-GEN SUBJECTS, V1473, P247, DOI 10.1016/S0304-4165(99)00183-X; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; Hallouin F, 1997, GLYCOCONJUGATE J, V14, P801, DOI 10.1023/A:1018581719944; HOLMES EH, 1982, J BIOL CHEM, V257, P7698; HOLMES EH, 1983, J BIOL CHEM, V258, P3706; Ichikawa D, 1997, CANCER RES, V57, P3092; ISHIKAWA N, 1993, IMMUNOLOGY, V78, P303; Iwamoto S, 1998, INT J HEMATOL, V68, P257; Iwamoto S, 1999, GLYCOCONJUGATE J, V16, P659, DOI 10.1023/A:1007085202379; Koda Y, 1997, J BIOL CHEM, V272, P7501, DOI 10.1074/jbc.272.11.7501; Kominato Y, 1999, J BIOL CHEM, V274, P37240, DOI 10.1074/jbc.274.52.37240; KOMINATO Y, 1992, BIOCHEM BIOPH RES CO, V189, P154, DOI 10.1016/0006-291X(92)91538-2; Mak KM, 2000, ANAT RECORD, V259, P395; MIYAO N, 1993, CANCER RES, V53, P4066; Okuda H, 2000, BIOCHEM BIOPH RES CO, V274, P670, DOI 10.1006/bbrc.2000.3206; Olson FJ, 2002, J BIOL CHEM, V277, P15044, DOI 10.1074/jbc.M112287200; PIAU JP, 1994, BIOCHEM J, V300, P623, DOI 10.1042/bj3000623; Saitou N, 1997, MOL BIOL EVOL, V14, P399, DOI 10.1093/oxfordjournals.molbev.a025776; Sherwood AL, 1998, ARCH BIOCHEM BIOPHYS, V355, P215, DOI 10.1006/abbi.1998.0728; Soejima M, 1999, EUR J BIOCHEM, V266, P274, DOI 10.1046/j.1432-1327.1999.00865.x; Szulman A E, 1980, Curr Top Dev Biol, V14, P127; Tanabe K, 1996, TRANSFUS SCI, V17, P455; Wagner FF, 2000, BLOOD, V95, P3662; Watkins W.M., 1995, GLYCOPROTEINS, P313; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; YAMAMOTO F, 1995, GLYCOBIOLOGY, V5, P51, DOI 10.1093/glycob/5.1.51; Yamamoto M, 2001, J BIOL CHEM, V276, P13701, DOI 10.1074/jbc.M010805200	33	17	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46463	46469		10.1074/jbc.M206439200	http://dx.doi.org/10.1074/jbc.M206439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237302	hybrid			2022-12-27	WOS:000179529300099
J	Miura, Y; Takahashi, T; Jung, SM; Moroi, M				Miura, Y; Takahashi, T; Jung, SM; Moroi, M			Analysis of the interaction of platelet collagen receptor glycoprotein VI (GPVI)with collagen - A dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN SUPERFAMILY; ALPHA(2)BETA(1) INTEGRIN; FC RECEPTOR; ACTIVATION; EXPRESSION; CONVULXIN; CLONING; VENOM; INVOLVEMENT; AGGREGATION	Glycoprotein VI (GPVI) is a platelet-specific glycoprotein that has been indicated to react with collagen and activate platelets. Its structure was recently identified by cDNA cloning (Clemetson, J. M., Polgar, J., Magnenat, E., Wells, T. N., and Clemetson, K. J. (1999) J. Biol. Chem. 274, 29019-29024). However, the mechanism of the interaction between collagen and GPVI has not been analyzed in detail because both collagen and GPVI are insoluble molecules. In this study, we expressed the extracellular domain of GPVI as soluble forms as follows: the monomeric form (GPVIex) and the dimeric form of GPVI fused with the human immunoglobulin Fc domain (GPVI-Fc(2)). Purified GPVIex strongly inhibited convulxin (Cvx)-induced platelet aggregation but only weakly inhibited that induced by collagen-related peptide. However, only GPVI-Fc(2), and not GPVIex, inhibited collagen-induced platelet aggregation. The dimeric form of GPVI exhibits high affinity for collagen, as concluded from measurements of GPVI bindling to immobilized collagen by both the enzyme-linked immunosorbent assay and surface plasmon resonance methods. GPVI-Fc(2) bound to the surface of immobilized collagen with a dissociation constant (K-D) of 5.76 x 10(-7) m,but the binding of GPVIex was too weak to allow estimation of this parameter. Cvx did not inhibit the binding of dimeric GPVI to collagen, indicating that the binding site of GPVI to collagen was different from that to Cvx. Taken together, our data indicate that the high affinity binding site for collagen is composed from two chains of GPVI. Furthermore, they suggest that the binding sites for Cvx are different from the collagen-binding sites and do not need to be formed by two GPVI molecules. Because dimeric GPVI is the only form that shows high affinity to fibrous collagen, our results indicate that GPVI would be present as a dimeric form on the platelet. Moreover, surface plasmon resonance indicated that there is no detectable interaction between soluble collagen and GPVI, supporting our previous observation that GPVI only reacts with fibrous collagen.	Kurume Univ, Dept Prot Biochem, Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Kurume Univ, Dept Cell Biol, Inst Life Sci, Kurume, Fukuoka 8390861, Japan	Kurume University; Kurume University	Moroi, M (corresponding author), Kurume Univ, Dept Prot Chem, Inst Life Sci, 2432-3 Aikawa MAchi, Kurume, Fukuoka 8390861, Japan.		Miura, Yoshiki/U-8875-2019	Miura, Yoshiki/0000-0002-7596-0482				CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen H, 2002, J BIOL CHEM, V277, P3011, DOI 10.1074/jbc.M109714200; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; COLLER BS, 1989, BLOOD, V74, P182; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; HANDA M, 1995, THROMB HAEMOSTASIS, V73, P521; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; Jung SM, 2000, J BIOL CHEM, V275, P8016, DOI 10.1074/jbc.275.11.8016; Jung SM, 1998, J BIOL CHEM, V273, P14827, DOI 10.1074/jbc.273.24.14827; Jung SM, 2001, EUR J BIOCHEM, V268, P3513, DOI 10.1046/j.1432-1327.2001.02252.x; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; Miura Y, 2000, THROMB RES, V98, P301, DOI 10.1016/S0049-3848(00)00182-1; Moroi M, 1997, THROMB HAEMOSTASIS, V78, P439; Moroi M, 1996, BLOOD, V88, P2081, DOI 10.1182/blood.V88.6.2081.bloodjournal8862081; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Nieswandt B, 2001, J EXP MED, V193, P459, DOI 10.1084/jem.193.4.459; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; RAGHAVAN M, 1995, P NATL ACAD SCI USA, V92, P11200, DOI 10.1073/pnas.92.24.11200; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUGIYAMA T, 1993, INT J HEMATOL, V58, P99; SUGIYAMA T, 1987, BLOOD, V69, P1712; Watson S, 2000, PLATELETS, V11, P252; Zheng YM, 2001, J BIOL CHEM, V276, P12999, DOI 10.1074/jbc.M009344200	25	128	134	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46197	46204		10.1074/jbc.M204029200	http://dx.doi.org/10.1074/jbc.M204029200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12356768	hybrid			2022-12-27	WOS:000179529300067
J	Bowen, C; Birrer, M; Gelmann, EP				Bowen, C; Birrer, M; Gelmann, EP			Retinoblastoma protein-mediated apoptosis after gamma-irradiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TYROSINE KINASE; RADIATION-INDUCED APOPTOSIS; N-TERMINAL KINASE; ETOPOSIDE-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR PROTEIN; CELL-CYCLE ARREST; LARGE T-ANTIGEN; C-ABL; GENE-PRODUCT; DNA-DAMAGE	Restoration of expression of the retinoblastoma gene to DU-145 prostate-cancer cells sensitizes them to apoptosis induced by y-irradiation. In contrast, RB expression-protected cells from UV-induced cell death. RB, a caspase substrate, remained intact during apoptosis in y-irradiated DU-145 cells because serine proteases, but not caspases, were activated. In DU-145 cells, RB-mediated apoptosis involved biphasic activation of ABL kinase. ABL kinase was activated within minutes of irradiation, but in the presence of RB expression ABL kinase activation was enhanced 48 It after irradiation, coincident with the onset of cell death. Apoptosis was inhibited by RB mutants with constitutive ABL binding, but ABL overexpression overcame the effect of the RB mutant constructs. Expression of kinase-dead ABL had a dominant-negative effect on RB-mediated cell death. Activation of JUN N-terminal kinase depended on the presence of RB and occurred within 8 h of irradiation. Mutant JUN proteins that lacked the N-terminal transactivation domain and serine substrates for JUN N-terminal kinase inhibited cell death in a dominant-negative manner. Irradiation of DU-145 cells caused activation of p38 MAPK independent of the expression of RB. Inhibitors of p38 MAPK blocked apoptosis after irradiation of RB-expressing cells. The data show that after y-irradiation, intact RB mediates transcriptional activation that leads to activation of JNK and late activation of ABL kinase. In addition, p38 MAPK activation occurred independent of RB. ABL kinase, JUN N-terminal kinase, and p38 MAPK activity were all required for RB-mediated DU-145 cell death after y-irradiation.	NCI, NIH, Rockville, MD 20850 USA; Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Med, Washington, DC 20007 USA; Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20007 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University; Georgetown University	Gelmann, EP (corresponding author), NCI, NIH, Ste 300,9610 Med Ctr Dr, Rockville, MD 20850 USA.				NCI NIH HHS [CA79912] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079912] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; An B, 1998, INT J MOL MED, V1, P131; An B, 1996, CANCER RES, V56, P438; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Berry DE, 1996, ONCOGENE, V12, P1809; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; Bowen C, 1998, CANCER RES, V58, P3275; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1994, ONCOGENE, V9, P791; Browne SJ, 1998, CELL DEATH DIFFER, V5, P206, DOI 10.1038/sj.cdd.4400331; CARROLL A G, 1992, Journal of Urology, V147, p216A; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Diederich L, 1998, CELL BIOL TOXICOL, V14, P133, DOI 10.1023/A:1007434005573; Fan GS, 1996, ONCOGENE, V12, P1909; Fattman CL, 2001, ONCOGENE, V20, P2918, DOI 10.1038/sj.onc.1204414; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Gong JG, 1999, NATURE, V399, P806; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; HAUPT Y, 1995, ONCOGENE, V10, P1563; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishii H, 1997, AM J HEMATOL, V55, P46, DOI 10.1002/(SICI)1096-8652(199705)55:1<46::AID-AJH9>3.0.CO;2-3; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Lauricella M, 2001, FEBS LETT, V499, P191, DOI 10.1016/S0014-5793(01)02553-4; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Martel C, 1996, CELL DEATH DIFFER, V3, P285; McConkey DJ, 1996, ONCOGENE, V13, P1693; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Napier JR, 1999, J ENDOCRINOL, V163, P63; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; Noguchi K, 2000, BIOCHEM BIOPH RES CO, V267, P221, DOI 10.1006/bbrc.1999.1952; Oh S, 2000, CANCER LETT, V148, P105, DOI 10.1016/S0304-3835(99)00319-5; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rosini P, 2000, BIOCHEM BIOPH RES CO, V278, P753, DOI 10.1006/bbrc.2000.3871; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shangary S, 2000, J BIOL CHEM, V275, P30163, DOI 10.1074/jbc.M004302200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shim J, 2000, J BIOL CHEM, V275, P14107, DOI 10.1074/jbc.275.19.14107; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; SLACK RS, 1995, J CELL BIOL, V129, P779, DOI 10.1083/jcb.129.3.779; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang JYJ, 2001, BIOCHEM SOC T, V29, P666, DOI 10.1042/0300-5127:0290666; Wang JYJ, 2001, ACTA ONCOL, V40, P689; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang GH, 2000, TOXICOL APPL PHARM, V164, P149, DOI 10.1006/taap.1999.8888; Yu JT, 2001, MOL CELL BIOL, V21, P3325, DOI 10.1128/MCB.21.10.3325-3335.2001; Yuan ZM, 1997, J BIOL CHEM, V272, P23485, DOI 10.1074/jbc.272.38.23485; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129	92	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44969	44979		10.1074/jbc.M202000200	http://dx.doi.org/10.1074/jbc.M202000200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12297496	hybrid			2022-12-27	WOS:000179404800050
J	Brandlin, I; Eiseler, T; Salowsky, R; Johannes, FJ				Brandlin, I; Eiseler, T; Salowsky, R; Johannes, FJ			Protein kinase C mu regulation of the JNK pathway is triggered via phosphoinositide-dependent kinase 1 and protein kinase C epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER DOMAIN; MOLECULAR-CLONING; PI 3-KINASE; IN-VITRO; KAPPA-B; PKC-MU; ACTIVATION; GOLGI; PHOSPHORYLATION; INTERACTS	The protein kinase C (PKC)-related enzyme PKCmu/PKD (protein kinase D) is activated by activation loop phosphorylation through PKCeta. Here we demonstrate that PKCmu is activated by the direct phosphorylation of PKC,E. PKCmu colocalizes with PKCepsilon in HEK293 and MCF7 cells as shown by confocal immunofluorescence analyses. PDK1, known as the upstream kinase for several PKC isozymes, associates intracellularly with PKCepsilon and PKCeta. PKCeta is phosphorylated by PDK1 in vitro, leading to kinase activation as similarly reported for PKCepsilon activation by PDK1. Coexpression of PDK1, PKCe and PKCmu in HEK293 cells results in PKCmu activation. In contrast, the coexpression of PDK1 and PKCeta with PKCmu does not activate PKCeta or consequently PKCmu. PDK1/PKCepsilon-triggered activation of PKCmu inhibits JNE a downstream effector of PKCmu, whereas upon transient expression of PDK1, PKCeta, and PKCmu, JNK is not affected. These data implicate PKCepsilon as the biologically important upstream kinase for PKCmu in HEK293 cells, regulating downstream effectors. Our results further indicate a PDK1/PKCeta/PKCmu controlled negative regulation of PKCeta kinase activity. In this study, we show that differentially activated kinase cascades involving PDK1 and novel PKC isotypes are responsible for the regulation of PKCmu activity and consequently inhibit the JNK pathway.	Fraunhofer Inst Interfacial Engn, D-70569 Stuttgart, Germany	Fraunhofer Gesellschaft	Johannes, FJ (corresponding author), Fraunhofer Inst Interfacial Engn, Nobelstr 12, D-70569 Stuttgart, Germany.	FJJ@IGB.FhG.de						Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; Cabodi S, 2000, MOL CELL, V6, P1121, DOI 10.1016/S1097-2765(00)00110-6; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Gschwendt M, 1997, J BIOL CHEM, V272, P20742, DOI 10.1074/jbc.272.33.20742; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Hausser A, 2002, J CELL BIOL, V156, P65, DOI 10.1083/jcb.200110047; Hausser A, 2001, FEBS LETT, V492, P39, DOI 10.1016/S0014-5793(01)02219-0; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; Hurd C, 2002, ONCOGENE, V21, P2154, DOI 10.1038/sj.onc.1205290; Hurd C, 2001, BIOCHEM BIOPH RES CO, V282, P404, DOI 10.1006/bbrc.2001.4591; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Jones DH, 2000, J BIOL CHEM, V275, P13962, DOI 10.1074/jbc.C901019199; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; Li RCX, 2000, AM J PHYSIOL-HEART C, V279, pH1679, DOI 10.1152/ajpheart.2000.279.4.H1679; Maeda Y, 2001, EMBO J, V20, P5982, DOI 10.1093/emboj/20.21.5982; MEDEMA JP, 1994, MOL CELL BIOL, V14, P7078, DOI 10.1128/MCB.14.11.7078; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Rennecke J, 1999, INT J CANCER, V80, P98, DOI 10.1002/(SICI)1097-0215(19990105)80:1<98::AID-IJC19>3.3.CO;2-4; Storz P, 2002, FRONT BIOSCI-LANDMRK, V7, pD886, DOI 10.2741/storz; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; Vertommen D, 2000, J BIOL CHEM, V275, P19567, DOI 10.1074/jbc.M001357200; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	39	52	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45451	45457		10.1074/jbc.M205299200	http://dx.doi.org/10.1074/jbc.M205299200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223477	hybrid			2022-12-27	WOS:000179404800109
J	Haeseleer, F; Jang, GF; Imanishi, Y; Driessen, CAGG; Matsumura, M; Nelson, PS; Palczewski, K				Haeseleer, F; Jang, GF; Imanishi, Y; Driessen, CAGG; Matsumura, M; Nelson, PS; Palczewski, K			Dual-substrate specificity short chain retinol dehydrogenases from the vertebrate retina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VISUAL CYCLE; 11-CIS-RETINOL DEHYDROGENASE; FUNDUS-ALBIPUNCTATUS; 9-CIS-RETINOIC ACID; CRYSTAL-STRUCTURES; OUTER SEGMENTS; GENE; PIGMENT; IDENTIFICATION; EXPRESSION	Retinoids are chromophores involved in vision, transcriptional regulation, and cellular differentiation. Members of the short chain alcohol dehydrogenase/reductase superfamily catalyze the transformation of retinol to retinal. Here, we describe the identification and properties of three enzymes from a novel subfamily of four retinol dehydrogenases (RDH11-14) that display dual-substrate specificity, uniquely metabolizing all-trans- and cis-retinols with C-15 pro-R specificity. RDH11-14 could be involved in the first step of all-trans- and 9-cis-retinoic acid production in many tissues. RDH11-14 fill the gap in our understanding of 11-cis-retinal and all-trans-retinal transformations in photoreceptor (RDH12) and retinal pigment epithelial cells (RDH11). The dual-substrate specificity of RDH11 explains the minor phenotype associated with mutations in 11-cis-retinol dehydrogenase (RDH5) causing fundus albipunctatus in humans and engineered mice lacking RDH5. Furthermore, photoreceptor RDH12 could be involved in the production of 11-cis-retinal from 11-cisretinol during regeneration of the cone visual pigments. These newly identified enzymes add new elements to important retinoid metabolic pathways that have not been explained by previous genetic and biochemical studies.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Catholic Univ Nijmegen, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Radboud University Nijmegen; Fred Hutchinson Cancer Center	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.		Imanishi, Yoshikazu/E-8178-2010	Imanishi, Yoshikazu/0000-0003-4696-4836	NATIONAL CANCER INSTITUTE [K08CA075173] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R29EY008061, R01EY008061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059125] Funding Source: NIH RePORTER; NCI NIH HHS [CA75173] Funding Source: Medline; NEI NIH HHS [R01 EY008061, EY08061] Funding Source: Medline; NIDDK NIH HHS [DK59125] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bennett MJ, 1996, BIOCHEMISTRY-US, V35, P10702, DOI 10.1021/bi9604688; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; BLISS AF, 1951, ARCH BIOCHEM BIOPHYS, V31, P197, DOI 10.1016/0003-9861(51)90206-8; Chen P, 2001, NAT GENET, V28, P256, DOI 10.1038/90089; Chen P, 2001, J BIOL CHEM, V276, P21098, DOI 10.1074/jbc.M010441200; Chou CF, 2002, J BIOL CHEM, V277, P25209, DOI 10.1074/jbc.M201947200; Cideciyan AV, 2000, VISUAL NEUROSCI, V17, P667, DOI 10.1017/S0952523800175029; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; Driessen CAGG, 1998, FEBS LETT, V428, P135, DOI 10.1016/S0014-5793(98)00473-6; DRIESSEN CAGG, 1995, INVEST OPHTH VIS SCI, V36, P1988; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; Grimm C, 2000, J BIOL CHEM, V275, P41333, DOI 10.1074/jbc.M007559200; Haeseleer F, 2001, INVEST OPHTH VIS SCI, V42, P3294; Haeseleer F, 2000, METHOD ENZYMOL, V316, P372; Imanishi Y, 2002, EUR J NEUROSCI, V15, P63, DOI 10.1046/j.0953-816x.2001.01835.x; Jang GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/jbc.M104949200; Jang GF, 2000, J BIOL CHEM, V275, P28128; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kedishvili NY, 2002, J BIOL CHEM, V277, P28909, DOI 10.1074/jbc.M202588200; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Lin BY, 2001, CANCER RES, V61, P1611; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MATSCHINSKY FM, 1968, J NEUROCHEM, V15, P643, DOI 10.1111/j.1471-4159.1968.tb08963.x; McBee JK, 2001, J BIOL CHEM, V276, P48483, DOI 10.1074/jbc.M105840200; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; MERCER EI, 1997, CONCISE ENCY BIOCH M; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; NAGAO A, 1994, FASEB J, V8, P968, DOI 10.1096/fasebj.8.12.8088462; Nakajima K, 1998, P NATL ACAD SCI USA, V95, P4876, DOI 10.1073/pnas.95.9.4876; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; Paik J, 2000, BIOCHEMISTRY-US, V39, P8073, DOI 10.1021/bi992152g; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; Romert A, 2000, EXP CELL RES, V256, P338, DOI 10.1006/excr.2000.4817; Romert A, 1998, P NATL ACAD SCI USA, V95, P4404, DOI 10.1073/pnas.95.8.4404; Saari JC, 2000, METHOD ENZYMOL, V316, P359; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707	44	154	169	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45537	45546		10.1074/jbc.M208882200	http://dx.doi.org/10.1074/jbc.M208882200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12226107	Green Accepted, Green Published, hybrid			2022-12-27	WOS:000179404800119
J	Ito, N; Yokomizo, T; Sasaki, T; Kurosu, H; Penninger, J; Kanaho, Y; Katada, T; Hanaoka, K; Shimizu, T				Ito, N; Yokomizo, T; Sasaki, T; Kurosu, H; Penninger, J; Kanaho, Y; Katada, T; Hanaoka, K; Shimizu, T			Requirement of phosphatidylinositol 3-kinase activation and calcium influx for leukotriene B-4-induced enzyme release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FC-EPSILON-RI; MAST-CELL DEGRANULATION; GTP-BINDING PROTEIN; RBL-2H3 CELLS; B-4 RECEPTOR; NEUTROPHIL MIGRATION; SIGNAL-TRANSDUCTION; TYROSINE KINASE; CA2+ INFLUX	Leukotriene B-4 (LTB4) is a potent lipid mediator involved in host defense and inflammatory responses. It causes chemotaxis, generation of reactive oxygen species, and degranulation. However, only little is known of the molecular mechanisms by which LTB4 induces these biological activities. To analyze the intracellular signaling pathways to mediate lysosomal enzyme release through the cloned LTB4 receptor (BLT1), we transfected BLT1 to rat basophilic leukemia cells (RBL-2H3). LTB4 dose-dependently released beta-hexosaminidase, and the release was mostly inhibited when the cells were pretreated with pertussis toxin, indicating that the degranulation is mediated by G(i) proteins. LTB4 activated phosphatidylinositol 3-kinase (PI3-K) through Gi, and inhibition of PI3-K by wortmannin or LY290042 inhibited degranulation. Granulocytes from PI3-Kgamma-deficient mice showed reduced LTB4-induced degranulation, suggesting that this isozyme of PI3-K is involved in the degranulation. LTB4 also caused calcium release from intracellular stores and calcium influx from the outside milieu through Gi, but only the calcium influx is critical for the lysosomal enzyme release. Calcium influx and PI3-K activation are both downstream events of Gi, since they were inhibited by pertussis toxin. These two events are in essence independent each other, because calcium. depletion did not affect PI3-K, and inhibition of PI3-K did not attenuate calcium influx significantly. Thus, our results have clearly shown that LTB4 binds BLT1 and activates G(i)-like protein, and both PI3-Kgamma activation and a sustained calcium elevation by calcium influx are necessary for enzyme release in these cells.	Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Dept Anesthesiol, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Tokyo 1130033, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1130033, Japan; Japan Sci & Technol Corp, PRESTO, Tokyo 1130033, Japan; Tokyo Metropolitan Inst Med Sci, Dept Pharmacol, Bunkyo Ku, Tokyo 1138613, Japan; Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria	University of Tokyo; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Tokyo Metropolitan Institute of Medical Science; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Yokomizo, T (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.		Penninger, Josef M/I-6860-2013; Yokomizo, Takehiko/P-5673-2016	Penninger, Josef M/0000-0002-8194-3777; Yokomizo, Takehiko/0000-0002-5219-1553; Sasaki, Takehiko/0000-0003-1837-3748				Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; Beaven MA, 1996, CURR OPIN IMMUNOL, V8, P766, DOI 10.1016/S0952-7915(96)80002-1; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Ching TT, 2001, J BIOL CHEM, V276, P14814, DOI 10.1074/jbc.M009851200; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; Gaudreau R, 1998, BIOCHEM J, V335, P15, DOI 10.1042/bj3350015; GRIFFITHS RJ, 1995, P NATL ACAD SCI USA, V92, P517, DOI 10.1073/pnas.92.2.517; Haribabu B, 1999, J BIOL CHEM, V274, P37087, DOI 10.1074/jbc.274.52.37087; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; HIDE I, 1993, J CELL BIOL, V123, P585, DOI 10.1083/jcb.123.3.585; HIDE M, 1991, MOL PHARMACOL, V40, P473; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Ishii I, 1997, J BIOL CHEM, V272, P7846, DOI 10.1074/jbc.272.12.7846; Iversen L, 1997, SKIN PHARMACOL, V10, P169, DOI 10.1159/000211501; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; KELLY KL, 1992, J BIOL CHEM, V267, P3423; Kim TD, 1997, J BIOL CHEM, V272, P31225, DOI 10.1074/jbc.272.50.31225; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; KUIJPERS TW, 1992, J IMMUNOL, V148, P72; Lee E, 1999, AM J RESP CRIT CARE, V160, P2079, DOI 10.1164/ajrccm.160.6.9903136; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; MURAKAMI M, 1995, J EXP MED, V182, P197, DOI 10.1084/jem.182.1.197; Noiri E, 2000, P NATL ACAD SCI USA, V97, P823, DOI 10.1073/pnas.97.2.823; Nusse O, 1998, EMBO J, V17, P1279, DOI 10.1093/emboj/17.5.1279; OKADA T, 1994, J BIOL CHEM, V269, P3563; OZAWA K, 1993, J BIOL CHEM, V268, P2280; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Penner R, 1993, Curr Opin Neurobiol, V3, P368, DOI 10.1016/0959-4388(93)90130-Q; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; SAITO H, 1987, J IMMUNOL, V138, P3927; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; SHARON P, 1984, GASTROENTEROLOGY, V86, P453; Smith AJ, 2001, J BIOL CHEM, V276, P17213, DOI 10.1074/jbc.M100417200; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; Turner CR, 1996, J CLIN INVEST, V97, P381, DOI 10.1172/JCI118426; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; YANO H, 1993, J BIOL CHEM, V268, P25846; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	47	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44898	44904		10.1074/jbc.M208051200	http://dx.doi.org/10.1074/jbc.M208051200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244116	hybrid			2022-12-27	WOS:000179404800040
J	Kikkawa, Y; Moulson, CL; Virtanen, I; Miner, JH				Kikkawa, Y; Moulson, CL; Virtanen, I; Miner, JH			Identification of the binding site for the Lutheran blood group glycoprotein on laminin alpha 5 through expression of chimeric laminin chains in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE GLYCOPROTEIN; BASEMENT-MEMBRANE; MOLECULAR-CLONING; B-CAM; ADHESION; ADULT; GENE; DOMAIN; KIDNEY; MICE	The Lutheran blood group glycoprotein (Lu), also known as basal cell adhesion molecule, is an Ig superfamily transmembrane receptor for laminin alpha5. Lu is expressed on the surface of a subset of muscle and epithelial cells in diverse tissues and is thought to be involved in both normal and disease processes, including sickle cell disease and cancer. Here we investigated the binding of Lu to laminin alpha5 in vivo and in vitro. We prepared a soluble recombinant Lu (sol-Lu) composed of the Lu extracellular domain and a His(6) tag. Sol-Lu bound specifically to laminin-10/11 (alpha5beta1/beta2gamma1) in enzyme-linked immunosorbent assays and bound to bona fide basement membranes containing laminin alpha5 in tissue sections. Sol-Lu did not bind to tissue sections of laminin alpha5 knockout embryos, despite the fact that the four other a chains were present. To identify the Lu-binding site on laminin alpha5, we prepared modified alpha5 cDNAs encoding chimeric laminins containing all or part of the laminin alpha1 G domain in place of the analogous alpha5 regions. These constructs were used to generate transgenic mice. Proteins derived from transgenes were detected in basement membranes and were assayed for their ability to bind Lu by examining the localization of endogenous Lu and the binding of sol-Lu applied to tissue sections. Our results demonstrate that the alpha5 LG3 module is essential for Lu binding to laminin a5.	Washington Univ, Sch Med, Div Renal, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ Helsinki, Inst Biomed Anat Biomed Helsinki, FIN-00014 Helsinki, Finland	Washington University (WUSTL); Washington University (WUSTL); University of Helsinki	Miner, JH (corresponding author), Washington Univ, Sch Med, Div Renal, Dept Internal Med, Box 8126,660 S Euclid, St Louis, MO 63110 USA.	minerj@pcg.wustl.edu	Kikkawa, Yamato/D-1503-2010		NIDDK NIH HHS [P50 DK045181] Funding Source: Medline; NIGMS NIH HHS [R01 GM060432] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK045181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060432] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aumailley M, 1998, J ANAT, V193, P1, DOI 10.1046/j.1469-7580.1998.19310001.x; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CAMPBELL IG, 1994, CANCER RES, V54, P5761; Champliaud MF, 2000, EXP CELL RES, V259, P326, DOI 10.1006/excr.2000.4980; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Durkin ME, 1997, FEBS LETT, V411, P296, DOI 10.1016/S0014-5793(97)00686-8; El Nemer W, 1998, J BIOL CHEM, V273, P16686; El Nemer W, 2001, J BIOL CHEM, V276, P23757, DOI 10.1074/jbc.M102978200; ELION EA, 1998, CURRENT PROTOCOLS MO, V1; ElNemer W, 1997, BLOOD, V89, P4608, DOI 10.1182/blood.V89.12.4608; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Ettner N, 1998, FEBS LETT, V430, P217, DOI 10.1016/S0014-5793(98)00601-2; GARINCHESA P, 1994, INT J ONCOL, V5, P1261; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Kikkawa Y, 1998, J BIOL CHEM, V273, P15854, DOI 10.1074/jbc.273.25.15854; Kikkawa Y, 2000, J CELL SCI, V113, P869; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; Lee SP, 1998, BLOOD, V92, P2951, DOI 10.1182/blood.V92.8.2951.420k30_2951_2958; Libby RT, 2000, J NEUROSCI, V20, P6517, DOI 10.1523/JNEUROSCI.20-17-06517.2000; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 2000, DEV BIOL, V217, P278, DOI 10.1006/dbio.1999.9546; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Moulson CL, 2001, DEV DYNAM, V222, P101, DOI 10.1002/dvdy.1169; Muller U, 1997, CELL, V88, P603, DOI 10.1016/S0092-8674(00)81903-0; Nguyen NM, 2002, DEV BIOL, V246, P231, DOI 10.1006/dbio.2002.0658; Parsons SF, 2001, BLOOD, V97, P312, DOI 10.1182/blood.V97.1.312; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Rahuel C, 1996, BLOOD, V88, P1865; Rahuel C, 1999, IMMUNOGENETICS, V50, P271, DOI 10.1007/s002510050602; Sasaki T, 2001, FEBS LETT, V505, P173, DOI 10.1016/S0014-5793(01)02812-5; Shimizu H, 1999, J BIOL CHEM, V274, P11995, DOI 10.1074/jbc.274.17.11995; Sorokin LM, 1997, DEV DYNAM, V210, P446, DOI 10.1002/(SICI)1097-0177(199712)210:4<446::AID-AJA8>3.0.CO;2-G; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; SUEMORI H, 1990, CELL DIFFER DEV, V29, P181, DOI 10.1016/0922-3371(90)90120-L; Talts JF, 1999, FEBS LETT, V458, P319, DOI 10.1016/S0014-5793(99)01180-1; Talts JF, 1998, FEBS LETT, V426, P71, DOI 10.1016/S0014-5793(98)00312-3; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Tsubota Y, 2000, BIOCHEM BIOPH RES CO, V278, P614, DOI 10.1006/bbrc.2000.3851; UDAI M, 1998, J CLIN INVEST, V101, P2550; Virtanen I, 2000, EXP CELL RES, V257, P298, DOI 10.1006/excr.2000.4883; Zen Q, 1999, J BIOL CHEM, V274, P728, DOI 10.1074/jbc.274.2.728	44	74	74	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44864	44869		10.1074/jbc.M208731200	http://dx.doi.org/10.1074/jbc.M208731200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244066	hybrid			2022-12-27	WOS:000179404800036
J	Schmidt, KH; Derry, KL; Kolodner, RD				Schmidt, KH; Derry, KL; Kolodner, RD			Saccharomyces cerevisiae RRM3, a 5 ' to 3 ' DNA helicase, physically interacts with proliferating cell nuclear antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FORK PROGRESSION; DNA-LIGASE-I; PCNA; PROTEINS; BINDING; REGION; INHERITANCE; CHROMATIN; FEN1	Proliferating cell nuclear antigen (PCNA) plays an essential role in eukaryotic DNA replication, and numerous DNA replication proteins have been found to interact with PCNA through a conserved eight-amino acid motif called the PIP-box. We have searched the genome of the yeast Saccharomyces cerevisiae for open reading frames that encode proteins with putative PIP-boxes and initiated testing of 135 novel candidates for their ability to interact with PCNA-conjugated agarose beads. The first new PCNA-binding protein identified in this manner is the 5' to 3' DNA helicase RRM3. Yeast two-hybrid tests show that N-terminal deletions of RRM3, which remove the PIP-box but leave the helicase motifs intact, abolish the interaction with PCNA. In addition, mutating the two phenylalanine residues in the PIP-box to alanine or aspartic acid reduces binding to PCNA, confirming that the PIP-box in RRM3 is responsible for interaction with PCNA. The results presented here suggest that the RRM3 helicase functions at the replication fork.	Univ Calif San Diego, Ludwig Inst Canc Res, Sch Med, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Kolodner, RD (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, Sch Med, Ctr Canc, CMME 3080,9500 Gilman Dr, La Jolla, CA 92093 USA.	rkolodner@ucsd.edu			NIGMS NIH HHS [GM27017] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amin NS, 1996, GENETICS, V144, P479; Bessler JB, 2001, TRENDS CELL BIOL, V11, P60, DOI 10.1016/S0962-8924(00)01877-8; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Ivessa AS, 2000, CELL, V100, P479, DOI 10.1016/S0092-8674(00)80683-2; Ivessa AS, 2002, GENE DEV, V16, P1383, DOI 10.1101/gad.982902; KEIL RL, 1993, GENETICS, V135, P711; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Koundrioukoff S, 2000, J BIOL CHEM, V275, P22882, DOI 10.1074/jbc.M001850200; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Krawitz DC, 2002, MOL CELL BIOL, V22, P614, DOI 10.1128/MCB.22.2.614-625.2002; LAHAYE A, 1991, EMBO J, V10, P997, DOI 10.1002/j.1460-2075.1991.tb08034.x; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; Moarefi I, 2000, J MOL BIOL, V296, P1215, DOI 10.1006/jmbi.1999.3511; Monson EK, 1997, P NATL ACAD SCI USA, V94, P13081, DOI 10.1073/pnas.94.24.13081; Myung K, 2001, NATURE, V411, P1073, DOI 10.1038/35082608; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Paunesku T, 2001, INT J RADIAT BIOL, V77, P1007, DOI 10.1080/09553000110069335; Scholes DT, 2001, GENETICS, V159, P1449; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1998, NUCLEIC ACIDS RES, V26, P3925, DOI 10.1093/nar/26.17.3925; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R	31	45	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45331	45337		10.1074/jbc.M207263200	http://dx.doi.org/10.1074/jbc.M207263200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12239216	hybrid			2022-12-27	WOS:000179404800095
J	Stolz, J; Munro, S				Stolz, J; Munro, S			The components of the Saccharomyces cerevisiae mannosyltransferase complex M-Pol I have distinct functions in mannan synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; YEAST GOLGI-APPARATUS; PROTEIN GLYCOSYLATION; OUTER CHAIN; CATALYTIC DOMAIN; CANDIDA-ALBICANS; HEPARAN-SULFATE; MUTANTS; SYNTHASE; PATHWAY	The yeast Saccharomyces cerevisiae processes N-linked glycans in the Golgi apparatus in two different ways. Whereas most of the proteins of internal membranes receive a simple core-type structure, a long branched polymer termed mannan is attached to the glycans of many of the proteins destined for the cell wall. The first step in mannan synthesis is the initiation and extension of an alpha-1,6-linked polymannose backbone. This requires the sequential action of two enzyme complexes, mannan polymerases (M-Pol) I and II. M-Pol I contains the proteins Mnn9p and Van1p, although the stoichiometry and individual contributions to enzyme action are unclear. We report here that the two proteins are each present as a single copy in the complex. Both proteins contain a DXD motif found in the active site of many glycosyltransferases, and mutations in this motif in Mnn9p or Van1p reveal that both proteins contribute to mannose polymerization. However, the effects of these mutations on both the in vivo and in vitro activity are distinct, suggesting that the two proteins may have different roles in the complex. Finally, we show that a simple glycoprotein based on hen egg lysozyme can be used as a substrate for modification by purified M-Pol I in vitro.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Munro, S (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	sean@mrc-lmb.cam.ac.uk		Munro, Sean/0000-0001-6160-5773				ALVARADO E, 1990, BIOCHEMISTRY-US, V29, P2471, DOI 10.1021/bi00462a006; BALLOU L, 1995, P NATL ACAD SCI USA, V92, P2790, DOI 10.1073/pnas.92.7.2790; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; BALLOU L, 1980, J BIOL CHEM, V255, P5986; CHAPMAN RE, 1994, EMBO J, V13, P4896, DOI 10.1002/j.1460-2075.1994.tb06817.x; Cullen PJ, 2000, GENETICS, V155, P1005; de Nobel H, 2000, TRENDS MICROBIOL, V8, P344, DOI 10.1016/S0966-842X(00)01805-9; Dean N, 1999, BBA-GEN SUBJECTS, V1426, P309, DOI 10.1016/S0304-4165(98)00132-9; DEAN N, 1995, P NATL ACAD SCI USA, V92, P1287, DOI 10.1073/pnas.92.5.1287; Dennis JW, 1999, BIOESSAYS, V21, P412, DOI 10.1002/(SICI)1521-1878(199905)21:5<412::AID-BIES8>3.0.CO;2-5; Drickamer K, 1998, TRENDS BIOCHEM SCI, V23, P321, DOI 10.1016/S0968-0004(98)01246-8; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Gibbons BJ, 2002, J MOL BIOL, V319, P463, DOI 10.1016/S0022-2836(02)00305-4; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Giraudo CG, 2001, P NATL ACAD SCI USA, V98, P1625, DOI 10.1073/pnas.031458398; GOPAL PK, 1987, P NATL ACAD SCI USA, V84, P8824, DOI 10.1073/pnas.84.24.8824; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; Hashimoto H, 1997, BIOCHEM BIOPH RES CO, V241, P682, DOI 10.1006/bbrc.1997.7888; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; Horie T, 2001, YEAST, V18, P1493, DOI 10.1002/yea.790; HORST M, 1991, J BIOL CHEM, V266, P13914; Hummel M, 1997, EUR J BIOCHEM, V245, P428, DOI 10.1111/j.1432-1033.1997.00428.x; Ikuta K, 1997, BIOCHEM J, V323, P297, DOI 10.1042/bj3230297; JACKSON P, 1994, METHOD ENZYMOL, V230, P250; Jing W, 2000, GLYCOBIOLOGY, V10, P883, DOI 10.1093/glycob/10.9.883; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; Jungmann J, 1999, J BIOL CHEM, V274, P6579, DOI 10.1074/jbc.274.10.6579; KANIKENNULAT C, 1990, MOL CELL BIOL, V10, P898, DOI 10.1128/MCB.10.3.898; Kobayashi S, 2000, BIOCHEM BIOPH RES CO, V268, P860, DOI 10.1006/bbrc.2000.2219; Kojima H, 1999, BIOSCI BIOTECH BIOCH, V63, P1970, DOI 10.1271/bbb.63.1970; LEWIS MS, 1991, J BIOL CHEM, V266, P8255; Li JG, 2001, GLYCOBIOLOGY, V11, P217, DOI 10.1093/glycob/11.3.217; Lussier M, 1999, BBA-GEN SUBJECTS, V1426, P323, DOI 10.1016/S0304-4165(98)00133-0; Marks DL, 2001, J BIOL CHEM, V276, P26492, DOI 10.1074/jbc.M102612200; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; Munro S, 2001, FEBS LETT, V498, P223, DOI 10.1016/S0014-5793(01)02488-7; Nacken V, 1996, GENE, V175, P253, DOI 10.1016/0378-1119(96)00171-0; NAKAMURA S, 1993, J BIOL CHEM, V268, P12706; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; Neiman AM, 1997, GENETICS, V145, P637; Osmond BC, 1999, P NATL ACAD SCI USA, V96, P11206, DOI 10.1073/pnas.96.20.11206; RAM AFJ, 1994, YEAST, V10, P1019, DOI 10.1002/yea.320100804; Rayner JC, 1998, J BIOL CHEM, V273, P26836, DOI 10.1074/jbc.273.41.26836; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Saxena IM, 2000, CURR OPIN PLANT BIOL, V3, P523, DOI 10.1016/S1369-5266(00)00125-4; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SHIBATA N, 1995, J BIOL CHEM, V270, P1113, DOI 10.1074/jbc.270.3.1113; Southard SB, 1999, J BACTERIOL, V181, P7439, DOI 10.1128/JB.181.24.7439-7448.1999; Tessier DC, 2000, GLYCOBIOLOGY, V10, P403, DOI 10.1093/glycob/10.4.403; TRIMBLE RB, 1986, J BIOL CHEM, V261, P9815; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Wei G, 2000, J BIOL CHEM, V275, P27733; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723	62	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44801	44808		10.1074/jbc.M208023200	http://dx.doi.org/10.1074/jbc.M208023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235155	hybrid			2022-12-27	WOS:000179404800029
J	Inoshita, S; Takeda, K; Hatai, T; Terada, Y; Sano, M; Hata, J; Umezawa, A; Ichijo, H				Inoshita, S; Takeda, K; Hatai, T; Terada, Y; Sano, M; Hata, J; Umezawa, A; Ichijo, H			Phosphorylation and inactivation of myelbid cell leukemia 1 by JNK in response to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HAMSTER OVARY CELLS; BCL-2 FAMILY; APOPTOSIS; MCL-1; PATHWAY; GENE; EXPRESSION; ASK1; MECHANISM	Oxidative stress induces JNK activation, which leads to apoptosis through mitochondria-dependent caspase activation. However, little is known about the mechanism by which JNK alters mitochondrial function. In this study, we investigated the role of phosphorylation of myeloid cell leukemia I (Mcl-1), an anti-apoptotic member of the Bcl-2 family, in oxidative stress-induced apoptosis. We found that JNK phosphorylated Ser-121 and Thr-163 of Mcl-1 in response to stimulation with H2O2 and that transfection of unphosphorylatable Mcl-1 resulted in an enhanced anti-apoptotic activity in response to stimulation with H2O2. JNK-dependent phosphorylation and thus inactivation of Mcl-1 may be one of the mechanisms through which oxidative stress induces cellular damage.	Tokyo Med & Dent Univ, Grad Sch, Lab Cell Signaling, Dept Hard Tissue Engn,Div Bio Matrix,Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Regulat & Internal Environm & Reprod, Div Syst Organ Regulat, Tokyo 1138549, Japan; Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1608582, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Keio University	Ichijo, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Cell Signaling, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.			Ichijo, Hidenori/0000-0002-5005-6438; Takeda, Kohsuke/0000-0002-8359-8399				Basu A, 1998, INT J ONCOL, V13, P659; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; GUIGLIANO D, 1996, DIABETES CARE, V19, P257; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Haldar S, 1998, CANCER RES, V58, P1609; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Muller I, 1997, BIOCHEM BIOPH RES CO, V230, P254, DOI 10.1006/bbrc.1996.5898; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SAITO I, 1985, J VIROL, V54, P711, DOI 10.1128/JVI.54.3.711-719.1985; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shigemasa K, 2002, JPN J CANCER RES, V93, P542, DOI 10.1111/j.1349-7006.2002.tb01289.x; Thomas A, 2000, ONCOGENE, V19, P5259, DOI 10.1038/sj.onc.1203895; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Umezawa A, 1996, CELL STRUCT FUNCT, V21, P143, DOI 10.1247/csf.21.143; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	37	189	194	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43730	43734		10.1074/jbc.M207951200	http://dx.doi.org/10.1074/jbc.M207951200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223490	hybrid			2022-12-27	WOS:000179272000026
J	Paulussen, A; Raes, A; Matthijs, G; Snyders, DJ; Cohen, N; Aerssens, J				Paulussen, A; Raes, A; Matthijs, G; Snyders, DJ; Cohen, N; Aerssens, J			A novel mutation (T65P) in the PAS domain of the human potassium channel HERG results in the long QT syndrome by trafficking deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFECTIVE PROTEIN TRAFFICKING; INHERITED CARDIAC-ARRHYTHMIA; HUMAN INWARD RECTIFIER; K+-CHANNEL; GENOMIC ORGANIZATION; MISSENSE MUTATIONS; SYNDROME GENES; ACTIVATION; MUTANT; MECHANISM	The congenital long QT syndrome is a cardiac disease characterized by an increased susceptibility to ventricular arrhythmias. The clinical hallmark is a prolongation of the QT interval, which reflects a delay in repolarization caused by mutations in cardiac ion channel genes. Mutations in the HERG (human ether-a-go-go-related gene KCNH2 can cause a reduction in I-Kr, one of the currents responsible for cardiac repolarization. We describe the identification and characterization of a novel missense mutation T65P in the PAS (Per-Arnt-Sim) domain of HERG, resulting in defective trafficking of the protein to the cell membrane. Defective folding of the mutant protein could be restored by decreased cell incubation temperature and pharmacologically by cisapride and E-4031. When trafficking was restored by growing cells at 27 degreesC, the kinetics of the mutated channel resembled that of wildtype channels although the rate of activation, deactivation, and recovery from inactivation were accelerated. No positive evidence for the formation of heterotetramers was obtained by co-expression of wild-type with mutant subunits at 37 degreesC. As a consequence the clinical symptoms may be explained rather by haploinsufficiency than by dominant negative effects. This study is the first to relate a PAS domain mutation in HERG to a trafficking deficiency at body temperature, apart from effects on channel deactivation.	Johnson & Johnson Pharmaceut Res & Dev, Dept Pharmacogenom, B-2340 Beerse, Belgium; Raritan, Raritan, NJ 08869 USA; Univ Maastricht, Dept Genet & Cell Biol, Inst Cardiovasc Res, NL-6200 MD Maastricht, Netherlands; Univ Antwerp, Dept Biomed Sci, Lab Mol Biophys Physiol & Pharmacol, Antwerp, Belgium; Univ Leuven, Dept Human Genet, Louvain, Belgium	Johnson & Johnson; Janssen Pharmaceuticals; Maastricht University; University of Antwerp; KU Leuven	Paulussen, A (corresponding author), Univ Maastricht, Dept Populat Genet, POB 616 16, NL-6200 MD Maastricht, Netherlands.	paulussen.aimee@advalvas.be	Snyders, Dirk/A-2713-2013	Snyders, Dirk/0000-0001-7142-6672; Aerssens, Jeroen/0000-0002-9254-4800; Matthijs, Gert/0000-0001-6710-1912	NHLBI NIH HHS [HL59689] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059689] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; Chen J, 1999, J BIOL CHEM, V274, P10113, DOI 10.1074/jbc.274.15.10113; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Ficker E, 2002, J BIOL CHEM, V277, P4989, DOI 10.1074/jbc.M107345200; Ficker E, 2000, J MOL CELL CARDIOL, V32, P2327, DOI 10.1006/jmcc.2000.1263; Ficker E, 2000, AM J PHYSIOL-HEART C, V279, pH1748, DOI 10.1152/ajpheart.2000.279.4.H1748; Furutani M, 1999, CIRCULATION, V99, P2290, DOI 10.1161/01.CIR.99.17.2290; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Huang FD, 2001, CIRCULATION, V104, P1071, DOI 10.1161/hc3501.093815; Jongbloed RJE, 1999, HUM MUTAT, V13, P301, DOI 10.1002/(SICI)1098-1004(1999)13:4<301::AID-HUMU7>3.3.CO;2-M; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Kupershmidt S, 1998, J BIOL CHEM, V273, P27231, DOI 10.1074/jbc.273.42.27231; Lees-Miller JP, 2000, CIRC RES, V86, P507, DOI 10.1161/01.RES.86.5.507; LeesMiller JP, 1997, CIRC RES, V81, P719; London B, 1997, CIRC RES, V81, P870; Nakajima T, 1999, CARDIOVASC RES, V44, P283, DOI 10.1016/S0008-6363(99)00195-9; Nakajima T, 2000, FEBS LETT, V481, P197, DOI 10.1016/S0014-5793(00)01988-8; Neyroud N, 1999, CIRC RES, V84, P290, DOI 10.1161/01.RES.84.3.290; Ottschytsch N, 2002, P NATL ACAD SCI USA, V99, P7986, DOI 10.1073/pnas.122617999; Paulussen A, 2000, Hum Mutat, V15, P483, DOI 10.1002/(SICI)1098-1004(200005)15:5<483::AID-HUMU18>3.0.CO;2-T; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Priori SG, 1999, CIRCULATION, V99, P518, DOI 10.1161/01.CIR.99.4.518; Rajamani S, 2002, CIRCULATION, V105, P2830, DOI 10.1161/01.CIR.0000019513.50928.74; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; Schonherr R, 1996, J PHYSIOL-LONDON, V493, P635, DOI 10.1113/jphysiol.1996.sp021410; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Splawski I, 1998, GENOMICS, V51, P86, DOI 10.1006/geno.1998.5361; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Terlau H, 1997, J PHYSIOL-LONDON, V502, P537, DOI 10.1111/j.1469-7793.1997.537bj.x; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	40	82	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48610	48616		10.1074/jbc.M206569200	http://dx.doi.org/10.1074/jbc.M206569200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12354768	hybrid			2022-12-27	WOS:000179789600084
J	Kim, H; Ralph, J; Lu, FC; Pilate, G; Leple, JC; Pollet, B; Lapierre, C				Kim, H; Ralph, J; Lu, FC; Pilate, G; Leple, JC; Pollet, B; Lapierre, C			Identification of the structure and origin of thioacidolysis marker compounds for cinnamyl alcohol dehydrogenase deficiency in angiosperms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC TOBACCO; DOWN-REGULATION; LIGNIN MODEL; CONIFERYL ALDEHYDE; ABNORMAL LIGNIN; SPRUCE LIGNIN; DFRC METHOD; PLANTS; BIOSYNTHESIS; LIGNIFICATION	Molecular marker compounds, derived from lignin by the thioacidolysis degradative method, for cinnamyl alcohol dehydrogenase (CAD) deficiency in angiosperms have been structurally identified as indene derivatives. They are shown to derive from hydroxycinnamyl aldehydes that have undergone 8-O-4-cross-coupling during lignification. As such, they are valuable markers for ascertaining plant responses to various levels of CAD down-regulation. Their derivation illustrates that hydroxycinnamyl aldehydes incorporate into angiosperm lignins by endwise coupling reactions in much the same way as normal monolignols do, suggesting that the hydroxycinnamyl aldehydes should be considered authentic lignin precursors.	USDA ARS, US Dairy Forage Res Ctr, Madison, WI 53706 USA; Univ Wisconsin, Dept Forestry, Madison, WI 53706 USA; INRA, Ameliorat Arbres Forestiers Stn, F-45160 Olivet, France; INRA, Inst Natl Agron Paris Grignon, Chim Biol Lab, F-78850 Grignon, France	United States Department of Agriculture (USDA); University of Wisconsin System; University of Wisconsin Madison; INRAE; AgroParisTech; INRAE	Ralph, J (corresponding author), USDA ARS, US Dairy Forage Res Ctr, 1925 Linden Dr W, Madison, WI 53706 USA.	jralph@facstaff.wisc.edu	LEPLE, Jean-Charles/H-4210-2012; Ralph, John/C-3161-2009; Lu, Fachuang/K-6487-2019; Pilate, Gilles/E-8784-2017; Lapierre, Catherine/AAD-9209-2020; Kim, Hoon/E-8245-2013; Pilate, Gilles/D-1666-2011; LEPLE, Jean-Charles/AAT-7414-2021; LEPLE, Jean charles/L-9604-2014	Ralph, John/0000-0002-6093-4521; Pilate, Gilles/0000-0003-4802-8849; Kim, Hoon/0000-0001-7425-7464; LEPLE, Jean-Charles/0000-0003-4125-0738; LEPLE, Jean charles/0000-0003-4125-0738; Lapierre, Catherine/0000-0002-6757-1524				ADLER E, 1948, ACTA CHEM SCAND, V2, P93, DOI 10.3891/acta.chem.scand.02-0093; Barcelo AR, 2001, PHYTOCHEMISTRY, V57, P1105, DOI 10.1016/S0031-9422(01)00050-4; Baucher M, 1998, CRIT REV PLANT SCI, V17, P125, DOI 10.1016/S0735-2689(98)00360-8; Baucher M, 1996, PLANT PHYSIOL, V112, P1479, DOI 10.1104/pp.112.4.1479; BECKER HD, 1980, J ORG CHEM, V45, P1596, DOI 10.1021/jo01297a010; BLAGBROUGH IS, 1982, TETRAHEDRON LETT, V23, P4843, DOI 10.1016/S0040-4039(00)85728-7; Boudet AM, 1998, TRENDS PLANT SCI, V3, P67, DOI 10.1016/S1360-1385(97)01176-X; CONNORS WJ, 1970, J ORG CHEM, V35, P1920, DOI 10.1021/jo00831a044; Dixon R, 1996, BIOTECHNOL BIOTEC EQ, V10, P45; Grima-Pettenati J, 1999, PLANT SCI, V145, P51, DOI 10.1016/S0168-9452(99)00051-5; HALPIN C, 1992, PLANT PHYSIOL, V98, P12, DOI 10.1104/pp.98.1.12; HALPIN C, 1994, PLANT J, V6, P339, DOI 10.1046/j.1365-313X.1994.06030339.x; Halpin C, 1998, PLANT J, V14, P545, DOI 10.1046/j.1365-313X.1998.00153.x; HIGUCHI T, 1994, J BIOTECHNOL, V37, P151, DOI 10.1016/0168-1656(94)90006-X; Ito T, 2002, J WOOD SCI, V48, P216, DOI 10.1007/BF00771370; Jung HG., 1990, MICROB PLANT OPPOR I, P173; Kim H, 2000, ORG LETT, V2, P2197, DOI 10.1021/ol005906o; LAPIERRE C, 1991, HOLZFORSCHUNG, V45, P61, DOI 10.1515/hfsg.1991.45.1.61; Lapierre C, 1999, PLANT PHYSIOL, V119, P153, DOI 10.1104/pp.119.1.153; Lapierre C, 2000, J AGR FOOD CHEM, V48, P2326, DOI 10.1021/jf991398p; LAPIERRE C, 1986, HOLZFORSCHUNG, V40, P113, DOI 10.1515/hfsg.1986.40.2.113; LAPIERRE C, 2001, 11 INT S WOOD PULP C, V2, P23; LAPIERRE C, 1993, FORAGE CELL WALL STR, V1, P133; Lu FC, 1997, J AGR FOOD CHEM, V45, P4655, DOI 10.1021/jf970539p; Lu FC, 1999, J AGR FOOD CHEM, V47, P1981, DOI 10.1021/jf981138s; LUNDQUIST K, 1983, ACTA CHEM SCAND B, V37, P734, DOI 10.3891/acta.chem.scand.37b-0734; NAKATSUBO F, 1975, HOLZFORSCHUNG, V29, P165, DOI 10.1515/hfsg.1975.29.5.165; PAVLIC AA, 1946, J AM CHEM SOC, V68, P1471, DOI 10.1021/ja01212a023; Pilate G, 2002, NAT BIOTECHNOL, V20, P607, DOI 10.1038/nbt0602-607; Provan GJ, 1997, J SCI FOOD AGR, V73, P133, DOI 10.1002/(SICI)1097-0010(199702)73:2&lt;133::AID-JSFA696&gt;3.0.CO;2-Q; QUIDEAU S, 1992, J AGR FOOD CHEM, V40, P1108, DOI 10.1021/jf00019a003; Ralph J, 1997, SCIENCE, V277, P235, DOI 10.1126/science.277.5323.235; Ralph J, 2001, PHYTOCHEMISTRY, V57, P993, DOI 10.1016/S0031-9422(01)00109-1; RALPH J, 1994, J CHEM SOC PERK T 1, P3485, DOI 10.1039/p19940003485; Ralph J, 1998, P NATL ACAD SCI USA, V95, P12803, DOI 10.1073/pnas.95.22.12803; RALPH J, 1983, J WOOD CHEM TECHNOL, V3, P161, DOI 10.1080/02773818308085158; Ralph J., 1999, PROGR LIGNOCELLULOSI, P55; Rolando C., 1992, METHODS LIGNIN CHEM, P334, DOI DOI 10.1007/978-3-642-74065-7_23; Sarkanen K.V., 1971, LIGNINS OCCURRENCE F; Savidge RA, 2001, PHYTOCHEMISTRY, V57, P1095, DOI 10.1016/S0031-9422(01)00142-X; Sederoff RR, 1999, CURR OPIN PLANT BIOL, V2, P145, DOI 10.1016/S1369-5266(99)80029-6; Stewart D, 1997, PLANTA, V201, P311, DOI 10.1007/s004250050072; Syrjanen K, 2000, J CHEM SOC PERK T 1, P183, DOI 10.1039/a907919j; TOLLIER MT, 1995, COLLOQ INRA, V69, P339; Tsai CJ, 1998, PLANT PHYSIOL, V117, P101, DOI 10.1104/pp.117.1.101; Vailhe MAB, 1998, J SCI FOOD AGR, V76, P505, DOI 10.1002/(SICI)1097-0010(199804)76:4&lt;505::AID-JSFA981&gt;3.0.CO;2-M; Whetten RW, 1998, ANNU REV PLANT PHYS, V49, P585, DOI 10.1146/annurev.arplant.49.1.585; Yahiaoui N, 1998, PLANTA, V204, P8, DOI 10.1007/s004250050224	48	69	71	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47412	47419		10.1074/jbc.M208860200	http://dx.doi.org/10.1074/jbc.M208860200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351655	Green Submitted, hybrid			2022-12-27	WOS:000179663700076
J	Koolpe, M; Dail, M; Pasquale, EB				Koolpe, M; Dail, M; Pasquale, EB			An ephrin mimetic peptide that selectively targets the EphA2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; PHAGE DISPLAY LIBRARY; TUMOR VASCULATURE; CRYSTAL-STRUCTURE; LIGAND-BINDING; GROWTH-FACTOR; EXPRESSION; OVEREXPRESSION; CANCER; MOUSE	Eph receptor tyrosine kinases represent promising disease targets because they are differentially expressed in pathologic versus normal tissues. The EphA2 receptor is up-regulated in transformed cells and tumor vasculature where it likely contributes to cancer pathogenesis. To exploit EpbA2 as a therapeutic target, we used phage display to identify two related peptides that bind selectively to EphA2 with high affinity (submicromolar K-D values). The peptides target the ligand-binding domain of EphA2 and compete with ephrin ligands for binding. Remarkably, one of the peptides has ephrin-like activity in that it stimulates EphA2 tyrosine phosphorylation and signaling. Furthermore, this peptide can deliver phage particles to endothelial and tumor cells expressing EphA2. In contrast, peptides corresponding to receptor-interacting portions of ephrin ligands bind weakly and promiscuously to many Eph receptors. Bioactive ephrin mimetic peptides could be used to selectively deliver agents to Eph receptor-expressing tissues and modify Eph signaling in therapies for cancer, pathological angiogenesis, and nerve regeneration.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Pasquale, EB (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA82713] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA082713] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES AC, 1994, ONCOGENE, V9, P1461; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Arap W, 2002, P NATL ACAD SCI USA, V99, P1527, DOI 10.1073/pnas.241655998; Carles-Kinch K, 2002, CANCER RES, V62, P2840; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; DANIEL TO, 1996, KIDNEY INT S, V57, P73; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Dohn M, 2001, ONCOGENE, V20, P6503, DOI 10.1038/sj.onc.1204816; DVORAK HF, 1988, AM J PATHOL, V133, P95; EASTY DJ, 1995, INT J CANCER, V60, P129, DOI 10.1002/ijc.2910600119; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Essler M, 2002, P NATL ACAD SCI USA, V99, P2252, DOI 10.1073/pnas.251687998; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; GANJU P, 1994, ONCOGENE, V9, P1613; Gerlag DM, 2001, ARTHRITIS RES, V3, P357, DOI 10.1186/ar327; Hess AR, 2001, CANCER RES, V61, P3250; Himanen JP, 1998, NATURE, V396, P486, DOI 10.1038/24904; Himanen JP, 2001, NATURE, V414, P933, DOI 10.1038/414933a; Hornberger MR, 1999, NEURON, V22, P731, DOI 10.1016/S0896-6273(00)80732-1; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; Labrador JP, 1997, EMBO J, V16, P3889, DOI 10.1093/emboj/16.13.3889; McBride JL, 1998, MECH DEVELOP, V77, P201, DOI 10.1016/S0925-4773(98)00142-7; Menzel P, 2001, DEV BIOL, V230, P74, DOI 10.1006/dbio.2000.0109; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miranda JD, 1999, EXP NEUROL, V156, P218, DOI 10.1006/exnr.1998.7012; Myers C, 2000, J CELL BIOL, V148, P343, DOI 10.1083/jcb.148.2.343; Nemoto T, 1997, PATHOBIOLOGY, V65, P195, DOI 10.1159/000164123; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; Olson TA, 1997, INT J CANCER, V73, P865; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; Rajotte D, 1999, J BIOL CHEM, V274, P11593, DOI 10.1074/jbc.274.17.11593; Rodger J, 2001, EUR J NEUROSCI, V14, P1929, DOI 10.1046/j.0953-816x.2001.01822.x; RUIZ JC, 1994, MECH DEVELOP, V46, P87; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; WRIGHT RM, 1995, BIO-TECHNOL, V13, P165, DOI 10.1038/nbt0295-165; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; YAYON A, 1993, P NATL ACAD SCI USA, V90, P10643, DOI 10.1073/pnas.90.22.10643; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zelinski DP, 2002, J CELL BIOCHEM, V85, P714, DOI 10.1002/jcb.10186; Zelinski DP, 2001, CANCER RES, V61, P2301	48	172	191	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46974	46979		10.1074/jbc.M208495200	http://dx.doi.org/10.1074/jbc.M208495200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351647	hybrid			2022-12-27	WOS:000179663700019
J	Montuori, N; Carriero, MV; Salzano, S; Rossi, G; Ragno, P				Montuori, N; Carriero, MV; Salzano, S; Rossi, G; Ragno, P			The cleavage of the urokinase receptor regulates its multiple functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR RECEPTOR; LIGAND-BINDING; CELL-MIGRATION; INTEGRINS; ADHESION; EXPRESSION; FORM; REQUIREMENT; CHEMOTAXIS; PLASMA	The urokinase-type plasminogen activator (uPA) is able to cleave its cell surface receptor (uPAR) anchored to the cell membrane through a glycophosphatidylinositol tail. The cleavage leads to the formation of cell surface truncated forms, devoid of the N-terminal domain 1 (D1) and unmasks or disrupts, depending on the cleavage site, a sequence in the D1-D2 linker region (residues 88-92), which in the soluble form is a potent chemoattractant for monocyte-like cells. To investigate the possible role(s) of the cleaved forms of cell surface glycophosphatidylinositol-anchored uPAR, uPAR-negative human embrional kidney 293 cells were transfected with the cDNA of intact uPAR (uPAR-293) or with cDNAs corresponding to the truncated forms of uPAR exposing (D2D3-293) or lacking (D2D3wc-293) the peptide 88-92 (P88-92). Cell adhesion assays and co-immunoprecipitation experiments indicated that the removal of D1, independently of the presence of P88-92, abolished the lateral interaction of uPAR with integrins and its capability to regulate integrin adhesive functions. The expression of intact uPAR induced also a moderate increase in 293 cell proliferation, which was accompanied by the activation of ERK. Also this effect was abolished by D1 removal, independently of the presence of P88-92. The expression of intact and truncated uPARs regulated cell directional migration toward uPA, the specific uPAR ligand, and toward fMLP, a bacterial chemotactic peptide. In fact, the uPA-dependent cell migration required the expression of intact uPAR, including D1, whereas the fMLP-dependent cell migration required the expression of a P88-92 containing uPAR and was independent of the presence of D1. Together these observations indicate that uPA-mediated uPAR cleavage and D1 removal, occurring on the cell surface of several cell types, can play a fundamental role in the regulation of multiple uPAR functions.	CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Natl Canc Inst, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); IRCCS Fondazione Pascale; University of Naples Federico II	Ragno, P (corresponding author), CNR, Ist Endocrinol & Oncol Sperimentale, Via Pansini 5, I-80131 Naples, Italy.	ragno@unina.it	Montuori, Nunzia/J-8542-2013; Carriero, Maria Vincenza/K-1240-2018	Carriero, Maria Vincenza/0000-0002-9768-2997; Montuori, Nunzia/0000-0001-8697-986X				Behrendt N, 1996, J BIOL CHEM, V271, P22885, DOI 10.1074/jbc.271.37.22885; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; Carriero MV, 1999, CANCER RES, V59, P5307; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; Degryse B, 2001, ONCOGENE, V20, P2032, DOI 10.1038/sj.onc.1204261; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; FIBBI G, 1988, EXP CELL RES, V179, P385, DOI 10.1016/0014-4827(88)90277-7; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; Holst-Hansen C, 1999, BRIT J CANCER, V81, P203, DOI 10.1038/sj.bjc.6690678; Hoyer-Hansen G, 1997, FEBS LETT, V420, P79, DOI 10.1016/S0014-5793(97)01491-9; Hoyer-Hansen G, 2001, BIOCHEM J, V358, P673, DOI 10.1042/0264-6021:3580673; HoyerHansen G, 1997, EUR J BIOCHEM, V243, P21, DOI 10.1111/j.1432-1033.1997.0021a.x; HOYERHANSEN G, 1992, J BIOL CHEM, V267, P18224; HOYERHANSEN G, 1993, BIOL VITRONECTIN THE; Irigoyen JP, 1999, CELL MOL LIFE SCI, V56, P104, DOI 10.1007/PL00000615; Koolwijk P, 2001, BLOOD, V97, P3123, DOI 10.1182/blood.V97.10.3123; Le YY, 2000, IMMUNOL REV, V177, P185, DOI 10.1034/j.1600-065X.2000.17704.x; Liang OD, 2001, J BIOL CHEM, V276, P28946, DOI 10.1074/jbc.M011437200; May AE, 1998, J EXP MED, V188, P1029, DOI 10.1084/jem.188.6.1029; MAZZIERI R, 1994, FIBRINOLYSIS, V8, P344, DOI 10.1016/0268-9499(94)90002-7; Montuori N, 1999, FEBS LETT, V460, P32, DOI 10.1016/S0014-5793(99)01314-9; Montuori N, 2000, FEBS LETT, V476, P166, DOI 10.1016/S0014-5793(00)01713-0; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Mustjoki S, 2000, CANCER RES, V60, P7126; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; Ragno P, 1998, CANCER RES, V58, P1315; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Rijneveld AW, 2002, J IMMUNOL, V168, P3507, DOI 10.4049/jimmunol.168.7.3507; RONNE E, 1995, BRIT J HAEMATOL, V89, P576, DOI 10.1111/j.1365-2141.1995.tb08366.x; Sidenius N, 2000, FEBS LETT, V470, P40, DOI 10.1016/S0014-5793(00)01282-5; Sier CFM, 1999, LAB INVEST, V79, P717; SOLBERG H, 1994, INT J CANCER, V58, P877, DOI 10.1002/ijc.2910580622; STOPPELLI MP, 2001, CELL INVASION, P128; Tarui T, 2001, J BIOL CHEM, V276, P3983, DOI 10.1074/jbc.M008220200; van der Pluijm G, 2001, AM J PATHOL, V159, P971, DOI 10.1016/S0002-9440(10)61773-7; Wahlberg K, 1998, CANCER RES, V58, P3294; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Xue W, 1997, CANCER RES, V57, P1682; XUE W, 1994, J IMMUNOL, V152, P4630; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; Zhou HM, 2000, EMBO J, V19, P4817, DOI 10.1093/emboj/19.17.4817	47	118	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46932	46939		10.1074/jbc.M207494200	http://dx.doi.org/10.1074/jbc.M207494200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12297505	hybrid			2022-12-27	WOS:000179663700014
J	Novak, JP; Xu, WF; Brender, T; Yao, L; Jones, C; West, J; Brandt, C; Jelinek, L; Madden, K; McKernan, PA; Foster, DC; Jaspers, S; Chandrasekher, YA				Novak, JP; Xu, WF; Brender, T; Yao, L; Jones, C; West, J; Brandt, C; Jelinek, L; Madden, K; McKernan, PA; Foster, DC; Jaspers, S; Chandrasekher, YA			Interleukins 19, 20, and 24 signal through two distinct receptor complexes - Differences in receptor-ligand interactions mediate unique biological functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-ASSOCIATED GENE; INTERFERON RECEPTOR; STAT FAMILY; MDA-7; EXPRESSION; PROTEINS; CYTOKINE; CLONING; PATHWAY; TRANSDUCTION	Cytokines that signal through Class II receptors form a distinct family that includes the interferons and interleukin 10 (IL-10). Recent identification of several IL-10 homologs has defined a cytokine subfamily that includes AK155, IL-19, IL-20, IL-22, and IL-24. Within this subfamily, IL-19, IL-20, and IL-24 exhibit substantial sharing of receptor complexes; all three are capable of signaling through IL-20RA/IL-20RB, and IL-20 and IL-24 both can also use IL-22R/IL-20RB. However, the biological effects of these three cytokines appear quite distinct: immune activity with IL-19, skin biology with IL-20, and tumor apoptosis with IL-24. To more fully elucidate their interactions with the receptor complexes, we have performed a series of in vitro assays. Reporter, proliferation, and direct STAT activation assays using cell lines expressing transfected receptors revealed differences between the receptor complexes. IL-19 and IL-24 also exhibited growth inhibition on a cell line endogenously expressing all three receptor subunits, an effect that was seen at cytokine levels two orders of magnitude above those required for STAT activation or proliferation. These results demonstrate that, although this subclass exhibits receptor complex redundancy, there are differences in ligand/receptor interactions and in signal transduction that may lead to specificity and a distinct biology for each cytokine.	Zymogenet Inc, Dept In Vitro Biol, Seattle, WA 98102 USA; Zymogenet Inc, Dept Cytokine & Receptor Biol, Seattle, WA 98102 USA; Zymogenet Inc, Dept Genet, Seattle, WA 98102 USA	Zymogenet Inc.; Zymogenet Inc.; Zymogenet Inc.	Chandrasekher, YA (corresponding author), Zymogenet Inc, Dept In Vitro Biol, 1201 Eastlake Ave E, Seattle, WA 98102 USA.							Aggarwal S, 2001, J INTERF CYTOK RES, V21, P1047, DOI 10.1089/107999001317205178; Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Ding GJF, 1998, J BIOL CHEM, V273, P28897, DOI 10.1074/jbc.273.44.28897; Donnelly RP, 1999, J INTERF CYTOK RES, V19, P563, DOI 10.1089/107999099313695; Dumoutier L, 2001, J IMMUNOL, V167, P3545, DOI 10.4049/jimmunol.167.7.3545; Dumoutier L, 2000, P NATL ACAD SCI USA, V97, P10144, DOI 10.1073/pnas.170291697; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; HAMILTON TC, 1983, CANCER RES, V43, P5379; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Knappe A, 2000, J VIROL, V74, P3881, DOI 10.1128/JVI.74.8.3881-3887.2000; Laskin DL, 2001, J LEUKOCYTE BIOL, V70, P163; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; MHASHILKAR M, 2000, P AM ASSOC CANC RES, V41, P752; Pataer A, 2002, CANCER RES, V62, P2239; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Semenzato G, 1996, CRIT REV CL LAB SCI, V33, P423, DOI 10.3109/10408369609084692; Soo C, 1999, J CELL BIOCHEM, V74, P1; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Subramaniam PS, 1995, P NATL ACAD SCI USA, V92, P12270, DOI 10.1073/pnas.92.26.12270; Wang M, 2002, J BIOL CHEM, V277, P7341, DOI 10.1074/jbc.M106043200; Wehinger J, 1996, FEBS LETT, V394, P365, DOI 10.1016/0014-5793(96)00990-8; Wolk K, 2002, J IMMUNOL, V168, P5397, DOI 10.4049/jimmunol.168.11.5397; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200	31	219	296	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47517	47523		10.1074/jbc.M205114200	http://dx.doi.org/10.1074/jbc.M205114200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351624	hybrid			2022-12-27	WOS:000179663700089
J	Temiakov, D; Anikin, M; McAllister, WT				Temiakov, D; Anikin, M; McAllister, WT			Characterization of T7 RNA polymerase transcription complexes assembled on nucleic acid scaffolds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION COMPLEXES; DNA HYBRID; KINETIC-ANALYSIS; INITIATION; PROMOTER; BACTERIOPHAGE-T7; PROCESSIVITY; MECHANISM; BINDING; BUBBLE	We have used synthetic oligomers of DNA and RNA to assemble nucleic acid scaffolds that, when mixed with T7 RNA polymerase, allow the formation of functional transcription complexes. Manipulation of the scaffold structure allows the contribution of each element in the scaffold to transcription activity to be independently determined. The minimal scaffold that allows efficient extension after challenge with 200 mM NaCl consists of an 8-nt RNA primer hybridized to a DNA template (T strand) that extends 5-10 nt downstream. Constructs in which the RNA-DNA hybrid is less than or greater than 8 bp are less salt-resistant, and the hybrid cannot be extended beyond 12-13 bp. Although the presence of a complementary nontemplate strand downstream of the primer does not affect salt resistance, the presence of DNA upstream decreases resistance. The addition of a 4-nt unpaired "tail" to the 5' end of the primer increases salt resistance, as does the presence of an impaired nontemplate strand in the region that contains the 8-bp hybrid (thereby generating an artificial transcription "bubble"). Scaffold complexes having these features remain active for over 1 week in the absence of salt and exhibit many of the properties of halted elongation complexes, including resistance to salt challenge, a similar trypsin cleavage pattern, and a similar pattern of RNA-RNA polymerase cross-linking.	SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, Morse Inst Mol Genet, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	McAllister, WT (corresponding author), SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, Morse Inst Mol Genet, 450 Clarkson Ave, Brooklyn, NY 11203 USA.	pogo51@aol.com			NIGMS NIH HHS [R01 GM038147, R01 GM038147-14, GM38147] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038147] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASU S, 1986, J MOL BIOL, V190, P425, DOI 10.1016/0022-2836(86)90013-6; Brieba LG, 2001, EMBO J, V20, P6826, DOI 10.1093/emboj/20.23.6826; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; DAUBE SS, 1994, BIOCHEMISTRY-US, V33, P340, DOI 10.1021/bi00167a044; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; Diaz GA, 1996, BIOCHEMISTRY-US, V35, P10837, DOI 10.1021/bi960488+; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Imburgio D, 2002, J MOL BIOL, V319, P37, DOI 10.1016/S0022-2836(02)00261-9; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; Jia YP, 1996, J BIOL CHEM, V271, P30451, DOI 10.1074/jbc.271.48.30451; Jiang ML, 2001, J MOL BIOL, V310, P509, DOI 10.1006/jmbi.2001.4793; Kireeva ML, 2000, J BIOL CHEM, V275, P6530, DOI 10.1074/jbc.275.9.6530; Kireeva ML, 2000, J MOL BIOL, V299, P325, DOI 10.1006/jmbi.2000.3755; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; LING ML, 1989, NUCLEIC ACIDS RES, V17, P1605, DOI 10.1093/nar/17.4.1605; Liu CH, 2002, J BIOL CHEM, V277, P2725, DOI 10.1074/jbc.M108856200; Liu CH, 2001, J MOL BIOL, V308, P465, DOI 10.1006/jmbi.2001.4601; Ma KY, 2002, J BIOL CHEM, V277, P43206, DOI 10.1074/jbc.M206658200; MARTIN CT, 1987, BIOCHEMISTRY-US, V26, P2690, DOI 10.1021/bi00384a006; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MASLAK M, 1993, BIOCHEMISTRY-US, V32, P4281, DOI 10.1021/bi00067a017; MCALLISTER WT, 1997, NUCL ACIDS MOL BIOL, V11, P15; Mentesana PE, 2000, J MOL BIOL, V302, P1049, DOI 10.1006/jmbi.2000.4114; MOOKHTIAR KA, 1991, BIOCHEMISTRY-US, V30, P6305, DOI 10.1021/bi00239a032; MULLER DK, 1988, BIOCHEMISTRY-US, V27, P5763, DOI 10.1021/bi00415a055; Place C, 1999, BIOCHEMISTRY-US, V38, P4948, DOI 10.1021/bi982689e; SASTRY SS, 1991, J MOL BIOL, V221, P1091, DOI 10.1016/0022-2836(91)90921-R; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; SOUSA R, 1992, J MOL BIOL, V224, P319, DOI 10.1016/0022-2836(92)90997-X; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; Temiakov D, 2000, PRACT APPROACH SER, P351; Temiakov D, 2000, P NATL ACAD SCI USA, V97, P14109, DOI 10.1073/pnas.250473197; TYAGARAJAN K, 1991, BIOCHEMISTRY-US, V30, P10920, DOI 10.1021/bi00109a016; Ujvari A, 1996, BIOCHEMISTRY-US, V35, P14574, DOI 10.1021/bi961165g; Ujvari A, 1997, J MOL BIOL, V273, P775, DOI 10.1006/jmbi.1997.1350; Villemain J, 1997, J MOL BIOL, V273, P958, DOI 10.1006/jmbi.1997.1358	40	38	41	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47035	47043		10.1074/jbc.M208923200	http://dx.doi.org/10.1074/jbc.M208923200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351656	hybrid			2022-12-27	WOS:000179663700028
J	Armstrong, S; Yates, SP; Merrill, AR				Armstrong, S; Yates, SP; Merrill, AR			Insight into the catalytic mechanism of Pseudomonas aeruginosa exotoxin A - Studies of toxin interaction with eukaryotic elongation factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION; FACTOR-II; DOMAIN-III; SACCHAROMYCES-CEREVISIAE; CONFORMATIONAL-CHANGES; ADENYLIC NUCLEOTIDES; TRYPTOPHAN RESIDUES; CRYSTAL-STRUCTURE; DIPHTHERIA-TOXIN; BINDING SITE	The molecular nature of the protein-protein interactions between the catalytic domain from Pseudomonas aeruginosa exotoxin A (PE24H) and its protein substrate, eukaryotic elongation factor-2 (eEF-2) were probed using a fluorescence resonance energy transfer method. Single cysteine mutant proteins of PE24H were prepared and site-specifically labeled with the donor fluorophore IAEDANS (5-(2-iodoacetylaminoethylamino)-1-napthalenesulfonic acid), whereas eEF-2 was labeled with the acceptor fluorophore fluorescein. The association was found to be independent of ionic strength and of the co-substrate, NAD(+) but dependent upon pH. The lack of requirement for NAD(+) to produce the toxin-eEF-2 complex demonstrates that the catalytic process is a random order mechanism, thereby disputing the current model. The previously observed pH dependence for catalytic function can be assigned to the toxin-eEF-2 binding event, as the pH dependence of binding observed in this study showed a strong correlation with enzymatic activity. The ability of the toxin to bind eEF-2 with bound GTP/GDP was assessed using nonhydrolyzable analogues. The results from the substrate binding and catalytic activity experiments indicate that PE24H is able to interact and bind with eEF-2 in all of its guanyl nucleotide-induced conformational states. Thus, the toxin ribosylates eEF-2 regardless of the nucleotide-charged state of eEF-2. These results represent the first detailed characterization of the molecular details and physiological conditions governing this protein-protein interaction.	Univ Guelph, Guelph Waterloo Ctr Grad Work Chem & Biochem, Dept Chem & Biochem, Guelph, ON N1G 2W1, Canada	University of Guelph; University of Waterloo; Guelph-Waterloo Centre for Graduate Work in Chemistry & Biochemistry	Merrill, AR (corresponding author), Univ Guelph, Guelph Waterloo Ctr Grad Work Chem & Biochem, Dept Chem & Biochem, Guelph, ON N1G 2W1, Canada.		Merrill, Rod/M-8313-2014; Armstrong, Souzan/R-9703-2019					ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; Armstrong S, 2001, ANAL BIOCHEM, V292, P26, DOI 10.1006/abio.2001.5052; Beattie BK, 1999, J BIOL CHEM, V274, P15646, DOI 10.1074/jbc.274.22.15646; Beattie BK, 1996, BIOCHEMISTRY-US, V35, P9042, DOI 10.1021/bi960396k; Beattie BK, 1996, BIOCHEMISTRY-US, V35, P15134, DOI 10.1021/bi961985t; CARROLL SF, 1988, MOL MICROBIOL, V2, P293, DOI 10.1111/j.1365-2958.1988.tb00031.x; Domenighini M, 1996, MOL MICROBIOL, V21, P667, DOI 10.1046/j.1365-2958.1996.321396.x; DUMONTMISCOPEIN A, 1995, BBA-GENE STRUCT EXPR, V1263, P221, DOI 10.1016/0167-4781(95)00104-O; Elzaim HS, 1998, INFECT IMMUN, V66, P2170, DOI 10.1128/IAI.66.5.2170-2179.1998; GIOVANE A, 1987, BIOCHEM J, V244, P337, DOI 10.1042/bj2440337; Gonzalo P, 2000, BIOCHEMISTRY-US, V39, P13558, DOI 10.1021/bi000896k; HAN XY, 1995, J BIOL CHEM, V270, P679, DOI 10.1074/jbc.270.2.679; IGLEWSKI WJ, 1994, MOL CELL BIOCHEM, V138, P131, DOI 10.1007/BF00928454; KESSLER SP, 1992, J BIOL CHEM, V267, P19107; LAVERGNE JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P231, DOI 10.1016/0167-4781(90)90061-6; Li M, 1996, P NATL ACAD SCI USA, V93, P6902, DOI 10.1073/pnas.93.14.6902; LI M, 1995, P NATL ACAD SCI USA, V92, P9308, DOI 10.1073/pnas.92.20.9308; LUKAC M, 1988, BIOCHEMISTRY-US, V27, P7629, DOI 10.1021/bi00420a009; MATTHEAKIS LC, 1992, MOL CELL BIOL, V12, P4026, DOI 10.1128/MCB.12.9.4026; Mohammadi F, 2001, BIOCHEMISTRY-US, V40, P10273, DOI 10.1021/bi011035u; NILSSON L, 1985, EUR J BIOCHEM, V148, P299, DOI 10.1111/j.1432-1033.1985.tb08839.x; NILSSON L, 1988, EUR J BIOCHEM, V171, P293, DOI 10.1111/j.1432-1033.1988.tb13789.x; NYGARD O, 1990, EUR J BIOCHEM, V191, P1, DOI 10.1111/j.1432-1033.1990.tb19087.x; OPPENHEIMER NJ, 1981, J BIOL CHEM, V256, P8579; PERENTESIS JP, 1992, J BIOL CHEM, V267, P1190; Prentice GA, 1999, ANAL BIOCHEM, V272, P216, DOI 10.1006/abio.1999.4188; SANYAL G, 1993, BIOCHEMISTRY-US, V32, P3488, DOI 10.1021/bi00064a037; SONTAG B, 1993, BIOCHEMISTRY-US, V32, P1976, DOI 10.1021/bi00059a014; STEER BA, 1995, BIOCHEMISTRY-US, V34, P7225, DOI 10.1021/bi00021a038; VASIL ML, 1986, J PEDIATR-US, V108, P800, DOI 10.1016/S0022-3476(86)80748-X; Wedekind JE, 2001, J MOL BIOL, V314, P823, DOI 10.1006/jmbi.2001.5195; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; Yates SP, 2001, J BIOL CHEM, V276, P35029, DOI 10.1074/jbc.M105002200	34	29	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46669	46675		10.1074/jbc.M206916200	http://dx.doi.org/10.1074/jbc.M206916200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270928	hybrid			2022-12-27	WOS:000179529300125
J	Choe, EY; Schoenberger, ES; Groopman, JE; Park, IW				Choe, EY; Schoenberger, ES; Groopman, JE; Park, IW			HIV Nef inhibits T cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 NEF; SH3 DOMAIN; ACTIVATION; PROTEIN; RECEPTOR; KINASE; CHEMOTAXIS; BINDING; DIFFERENTIATION; FACTOR-1-ALPHA	Nef is a viral regulatory protein of the human immunodeficiency virus (HIV) that has been shown to contribute to disease progression. Among its putative effects on T cell functions are the down-regulation of CD4 and major histocompatibility class I surface molecules. These effects occur in part via Nef interactions with intracellular signaling molecules. We sought to better characterize the effects of HIV Nef on T cell function by examining chemotaxis in response to stromal cell-derived factor-1alpha (SDF-1alpha) as well as CXCR4 signaling molecules. Here, we report the novel observation that HIV Nef inhibited chemotaxis in response to SDF-1alpha in both Jurkat T cells and primary peripheral CD4+ T lymphocytes. Our data indicate that HIV Nef altered critical downstream molecules in the CXCR4 pathway, including focal adhesion kinases. These findings suggest that HIV Nef may blunt the T cell response to chemokines. Because T lymphocyte migration is an integral component of host defense, HIV Nef may thereby contribute to the pathogenesis of AIDS.	Harvard Univ, Sch Med, Inst Med,Div Expt Med, Beth Israel Deaconess Med Ctr,BIDMC, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Groopman, JE (corresponding author), Harvard Univ, Sch Med, Inst Med,Div Expt Med, Beth Israel Deaconess Med Ctr,BIDMC, 4 Blackfan Circle,Rm 351, Boston, MA 02115 USA.	jgroopma@caregroup.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053745, R01HL061940] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53745, HL61940] Funding Source: Medline; NIDA NIH HHS [DA5008] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Baur AS, 1997, IMMUNITY, V6, P283, DOI 10.1016/S1074-7613(00)80331-3; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; Brown A, 1999, J VIROL, V73, P9899, DOI 10.1128/JVI.73.12.9899-9907.1999; Cherla RP, 2001, J IMMUNOL, V166, P3067, DOI 10.4049/jimmunol.166.5.3067; Collette Y, 1996, J IMMUNOL, V156, P360; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cullen BR, 1999, NAT MED, V5, P985, DOI 10.1038/12417; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; Denny MF, 2000, MOL CELL BIOL, V20, P1426, DOI 10.1128/MCB.20.4.1426-1435.2000; DU ZJ, 1995, CELL, V82, P665, DOI 10.1016/0092-8674(95)90038-1; Dutt P, 1998, J IMMUNOL, V161, P3652; Fackler OT, 2002, IMMUNITY, V16, P493, DOI 10.1016/S1074-7613(02)00307-2; FERNANDIS AZ, 2001, SCIENCES STKE; FOSTER R, 1998, J IMMUNOL, V160, P1522; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Graziani A, 1996, J BIOL CHEM, V271, P6590, DOI 10.1074/jbc.271.12.6590; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; Hannigan M, 2002, P NATL ACAD SCI USA, V99, P3603, DOI 10.1073/pnas.052010699; Hernandez-Lopez C, 2002, BLOOD, V99, P546, DOI 10.1182/blood.V99.2.546; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; Karn T, 1998, VIROLOGY, V246, P45, DOI 10.1006/viro.1998.9157; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Ottoson NC, 2001, J IMMUNOL, V167, P1857, DOI 10.4049/jimmunol.167.4.1857; Peacock JW, 1999, J IMMUNOL, V162, P215; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Renkema GH, 2000, FRONT BIOSCI-LANDMRK, V5, pD268, DOI 10.2741/Renkema; Renkema GH, 2001, J VIROL, V75, P2154, DOI 10.1128/JVI.75.5.2154-2160.2001; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Ross TM, 1999, CURR BIOL, V9, P613, DOI 10.1016/S0960-9822(99)80283-8; Schibeci SD, 2000, AIDS, V14, P1701, DOI 10.1097/00002030-200008180-00003; Schrager JA, 2002, J BIOL CHEM, V277, P6137, DOI 10.1074/jbc.M107322200; Schrager JA, 1999, P NATL ACAD SCI USA, V96, P8167, DOI 10.1073/pnas.96.14.8167; Simmons A, 2001, IMMUNITY, V14, P763, DOI 10.1016/S1074-7613(01)00158-3; Stephens L, 2002, CURR OPIN CELL BIOL, V14, P203, DOI 10.1016/S0955-0674(02)00311-3; Swigut T, 2000, J VIROL, V74, P5691, DOI 10.1128/JVI.74.12.5691-5701.2000; Swingler S, 1999, NAT MED, V5, P997, DOI 10.1038/12433; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Wang JK, 2000, P NATL ACAD SCI USA, V97, P394, DOI 10.1073/pnas.97.1.394; Weber KSC, 2001, MOL BIOL CELL, V12, P3074, DOI 10.1091/mbc.12.10.3074; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Woo CH, 2002, J BIOL CHEM, V277, P8572, DOI 10.1074/jbc.M104766200; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	50	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46079	46084		10.1074/jbc.M204698200	http://dx.doi.org/10.1074/jbc.M204698200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12354773	hybrid			2022-12-27	WOS:000179529300050
J	Hu, JX; Reyes-Cruz, G; Chen, WZ; Jacobson, KA; Spiegel, AM				Hu, JX; Reyes-Cruz, G; Chen, WZ; Jacobson, KA; Spiegel, AM			Identification of acidic residues in the extracellular loops of the seven-transmembrane domain of the human Ca2+ receptor critical for response to Ca2+ and a positive allosteric modulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; CELL-SURFACE EXPRESSION; CA2+-SENSING RECEPTOR; SIGNAL-TRANSDUCTION; ACTIVATING MUTATIONS; CHIMERIC RECEPTORS; ACID(B) RECEPTORS; TERMINAL DOMAIN; BINDING; ANTAGONIST	We investigated the role of the eight acidic residues in the extracellular loops (exo-loops) of the seven-transmembrane domain of the human Ca2+ receptor (hCaR) in receptor activation by Ca2+ and in response to a positive allosteric modulator, NPS R-568. Both in the context of the full-length receptor and of a truncated receptor lacking the extracellular domain (Rho-C-hCaR), we mutated each acidic residue to. alanine, singly and in combination, and tested the effect on expression of the receptor, on activation by Ca2+, and on NPS R-568 augmentation of sensitivity to Ca2+. Of the eight acidic residues, mutation of any of three in exo-loop 2, Asp(758), Glu(759), and Glu(767), increased the sensitivity of both the full-length hCaR and of Rho-C-hCaR to activation by Ca2+. Mutation of all five acidic residues in exo-loop 2, whether in the full-length receptor or in Rho-C-hCaR, impaired cell surface expression of the mutant receptor and thereby largely abolished response to Ca2+. Mutation of Glu(837) in exo-loop 3 to alanine did not alter Ca2+ sensitivity of the full-length receptor, but in both the latter context and in Rho-C-hCaR, alanine substitution of Glu(837) drastically reduced sensitivity to NPS R-568. Our data point to a key role of three specific acidic residues in exo-loop 2 in Wall activation and to Glu(837) at the junction between exo-loop 3 and transmembrane helix seven in response to NPS R-568. We speculate on the basis of these results that the three acidic residues we identified in exo-loop 2 help maintain an inactive conformation of the seven-transmembrane domain of the hCaR.	NIDCD, Mol Pathophysiol Sect, NIH, Bethesda, MD 20892 USA; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hu, JX (corresponding author), NIDCD, Mol Pathophysiol Sect, NIH, Bldg 10,Rm 8C-101,9000 Rockville Pike, Bethesda, MD 20892 USA.		Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	Intramural NIH HHS [Z99 DK999999, Z01 DK031126-01] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000061] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BORCH RF, 1971, J AM CHEM SOC, V93, P2897, DOI 10.1021/ja00741a013; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Brown EM, 2000, CELL BIOCHEM BIOPHYS, V33, P63, DOI 10.1385/CBB:33:1:63; D'Souza-Li L, 2002, J CLIN ENDOCR METAB, V87, P1309, DOI 10.1210/jc.87.3.1309; Diaz R, 1997, AM J PHYSIOL-REG I, V273, pR1008, DOI 10.1152/ajpregu.1997.273.3.R1008; Flanagan JA, 2002, GEN COMP ENDOCR, V127, P117, DOI 10.1016/S0016-6480(02)00035-7; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; Hauache OM, 2000, ENDOCRINOLOGY, V141, P4156, DOI 10.1210/en.141.11.4156; Hu JX, 2000, J BIOL CHEM, V275, P16382, DOI 10.1074/jbc.M000277200; Hu JX, 2002, J BONE MINER RES, V17, P1461, DOI 10.1359/jbmr.2002.17.8.1461; Knoflach F, 2001, P NATL ACAD SCI USA, V98, P13402, DOI 10.1073/pnas.231358298; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Litschig S, 1999, MOL PHARMACOL, V55, P453; Malitschek B, 1999, MOL PHARMACOL, V56, P448, DOI 10.1124/mol.56.2.448; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14643, DOI 10.1073/pnas.251554798; Naito T, 1998, P NATL ACAD SCI USA, V95, P5178, DOI 10.1073/pnas.95.9.5178; Nearing J, 2002, P NATL ACAD SCI USA, V99, P9231, DOI 10.1073/pnas.152294399; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; Ray K, 1998, J BIOL CHEM, V273, P34558, DOI 10.1074/jbc.273.51.34558; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; Ray K, 2002, J BIOL CHEM, V277, P18908, DOI 10.1074/jbc.M202113200; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; SAKAI K, 1993, B CHEM SOC JPN, V66, P3414, DOI 10.1246/bcsj.66.3414; Urwyler S, 2001, MOL PHARMACOL, V60, P963, DOI 10.1124/mol.60.5.963; Watanabe T, 1998, J CLIN ENDOCR METAB, V83, P2497, DOI 10.1210/jc.83.7.2497; Zhao XM, 1999, FEBS LETT, V448, P180, DOI 10.1016/S0014-5793(99)00368-3	31	71	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46622	46631		10.1074/jbc.M207100200	http://dx.doi.org/10.1074/jbc.M207100200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12297503	Green Accepted, hybrid			2022-12-27	WOS:000179529300119
J	Krasnoperov, V; Lu, Y; Buryanovsky, L; Neubert, TA; Ichtchenko, K; Petrenko, AG				Krasnoperov, V; Lu, Y; Buryanovsky, L; Neubert, TA; Ichtchenko, K; Petrenko, AG			Post-translational proteolytic processing of the calciumin-dependent receptor of alpha-latrotoxin (CIRL), a natural chimera of the cell adhesion protein and the G protein-coupled recent - Role of the G protein-coupled receptor proteolysis site (GPS) motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETIN FAMILY; MEMBER; 7-TRANSMEMBRANE; CLONING; CD97; SUPERFAMILY; HOMOLOGY; BINDING; DOMAIN	The calcium-independent receptor of a-latrotoxin (CIRL), a neuronal cell surface receptor implicated in the regulation of exocytosis, is a natural chimera of the cell adhesion protein and the G protein-coupled receptor (GPCR). In contrast with canonic GPCRs, CIRL consists of two heterologous non-covalently bound subunits, p120 and p85, due to endogenous proteolytic processing of the receptor precursor in the endoplasmic reticulum. Extracellularly oriented p120 contains hydrophilic cell adhesion domains, whereas p85 resembles a generic GPCR. We determined that the site of the CIRL cleavage is located within a juxtamembrane Cys- and Trp-rich domain of the N-terminal extracellular region of CIRL. Mutations in this domain make CIRL resistant to the cleavage and impair its trafficking. Therefore, we have named it GPS for G protein-coupled receptor proteolysis site. The GPS motif is found in homologous adhesion GPCRs and thus defines a novel receptor family. We postulate that the proteolytic processing and two-subunit structure is a common characteristic feature in the family of GPS-containing adhesion GPCRs.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst, New York, NY 10016 USA	New York University; New York University; New York University	Petrenko, AG (corresponding author), NYU, Ctr Med, Dept Pharmacol, 550 1St Ave,MSB-320A, New York, NY 10016 USA.			Ichtchenko, Konstantin/0000-0002-2198-1325; Petrenko, Alexander/0000-0002-6689-6546	NCRR NIH HHS [1 S10 RR14662-01] Funding Source: Medline; NIGMS NIH HHS [R01GM59699] Funding Source: Medline; NINDS NIH HHS [R01NS35098] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035098] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe J, 2002, J BIOL CHEM, V277, P23391, DOI 10.1074/jbc.M110877200; BAUD V, 1995, GENOMICS, V26, P334, DOI 10.1016/0888-7543(95)80218-B; Bittner MA, 1998, J NEUROSCI, V18, P2914; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Gray JX, 1996, J IMMUNOL, V157, P5438; HAMANN J, 1995, J IMMUNOL, V155, P1942; Hamann J, 1996, J EXP MED, V184, P1185, DOI 10.1084/jem.184.3.1185; Hayflick JS, 2000, J RECEPT SIGNAL TR R, V20, P119, DOI 10.3109/10799890009150640; Ichtchenko K, 1999, J BIOL CHEM, V274, P5491, DOI 10.1074/jbc.274.9.5491; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; McMillan DR, 2002, J BIOL CHEM, V277, P785, DOI 10.1074/jbc.M108929200; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Nechiporuk T, 2001, J BIOL CHEM, V276, P4150, DOI 10.1074/jbc.M004814200; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Osterhoff C, 1997, DNA CELL BIOL, V16, P379, DOI 10.1089/dna.1997.16.379; PETRENKO AG, 1993, J BIOL CHEM, V268, P1860; PETRENKO AG, 1990, EMBO J, V9, P2023, DOI 10.1002/j.1460-2075.1990.tb08331.x; PETRENKO AG, 1998, CELLULAR MOL MECH TO, P185; Ponting CP, 1999, CURR BIOL, V9, pR585, DOI 10.1016/S0960-9822(99)80379-0; Stacey M, 2002, J BIOL CHEM, V277, P29283, DOI 10.1074/jbc.M204306200; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	27	109	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46518	46526		10.1074/jbc.M206415200	http://dx.doi.org/10.1074/jbc.M206415200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270923	hybrid			2022-12-27	WOS:000179529300106
J	Pahan, K; Jana, M; Liu, XJ; Taylor, BS; Wood, C; Fischer, SM				Pahan, K; Jana, M; Liu, XJ; Taylor, BS; Wood, C; Fischer, SM			Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED RECEPTOR-ALPHA; RAT PRIMARY ASTROCYTES; GLIAL-CELLS; TRANSCRIPTION FACTOR; CYTOKINE INDUCTION; MICROGLIAL CELLS; GENE-EXPRESSION; MESSENGER-RNA; DLD-1 CELLS	Gernfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes. Similar to gemfibrozil, clofibrate, another fibrate drug, also inhibited the expression of iNOS. Inhibition of human iNOS promoter-driven luciferase activity by gernfibrozil in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS. Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS. Gemfibrozil induced peroxisome proliferator-responsive element (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha. However, DeltahPPAR-alpha was unable to abrogate gemfibrozil-mediated inhibition of iNOS suggesting that gemfibrozil inhibits iNOS independent of PPAR-alpha. The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of gemfibrozil on the activation of these transcription factors. The combination of interleukin (IL)-1beta and IFN-gamma induced the activation of NF-kappaB, AP-1, C/EBPbeta, and GAS but not that of ISRE, suggesting that IRF-1 may not be involved in cytokine-induced expression of WOS in human astrocytes. Interestingly, gernfibrozil strongly inhibited the activation of NF-kappaB, AP-1, and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells. These results suggest that gernfibrozil inhibits the induction of iNOS probably by inhibiting the activation of NF-kappaB, AP-1, and C/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.	Univ Nebraska, Med Ctr, Dept Oral Biol, Lincoln, NE 68583 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15261 USA; Univ Nebraska, Sch Biol Sci, Lincoln, NE 68588 USA; Univ Texas, MD Anderson Canc Inst, Smithville, TX 78957 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Nebraska System; University of Nebraska Lincoln; University of Texas System; UTMD Anderson Cancer Center	Pahan, K (corresponding author), Univ Nebraska, Med Ctr, Dept Oral Biol, 40th & Holdrege, Lincoln, NE 68583 USA.			Wood, Charles/0000-0002-4256-1530	NINDS NIH HHS [R01 NS039940, R01 NS039940-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039940] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; BLOOMFIELD RH, 2001, CIRCULATION, V103, P2828; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun L, 1999, FEBS LETT, V458, P359, DOI 10.1016/S0014-5793(99)01184-9; Bright JJ, 1999, J IMMUNOL, V162, P6255; Coccia EM, 2000, INT IMMUNOL, V12, P977, DOI 10.1093/intimm/12.7.977; Cullingford TE, 1998, J NEUROCHEM, V70, P1366; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Elia G, 1996, CANCER RES, V56, P210; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; Fujimura M, 1997, BRAIN RES, V759, P247, DOI 10.1016/S0006-8993(97)00264-3; Gonzalez FJ, 1998, J NATL CANCER I, V90, P1702, DOI 10.1093/jnci/90.22.1702; Hsu HC, 2001, J LAB CLIN MED, V137, P414, DOI 10.1067/mlc.2001.114991; ILLINGWORTH DR, 1989, ARTERIOSCLEROSIS, V9, P1121; Jana M, 2001, J BIOL CHEM, V276, P44527, DOI 10.1074/jbc.M106771200; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; Kristof AS, 2001, J BIOL CHEM, V276, P8445, DOI 10.1074/jbc.M009563200; Laubach VE, 1997, BBA-GENE STRUCT EXPR, V1351, P287, DOI 10.1016/S0167-4781(96)06909-6; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; Linn SC, 1997, AM J PHYSIOL-GASTR L, V272, pG1499, DOI 10.1152/ajpgi.1997.272.6.G1499; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; MCCARTHY M, 1995, J NEUROVIROL, V1, P275, DOI 10.3109/13550289509114024; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Pahan K, 2000, FEBS LETT, V472, P203, DOI 10.1016/S0014-5793(00)01465-4; Pahan K, 1998, J BIOL CHEM, V273, P12219, DOI 10.1074/jbc.273.20.12219; Pahan K, 2001, J BIOL CHEM, V276, P7899, DOI 10.1074/jbc.M008262200; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; RADI R, 1991, J BIOL CHEM, V266, P4244; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Roberts RA, 1998, CARCINOGENESIS, V19, P43, DOI 10.1093/carcin/19.1.43; Salzman AL, 2000, INT J MOL MED, V6, P209; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Saura M, 1999, J MOL BIOL, V289, P459, DOI 10.1006/jmbi.1999.2752; Spitsin SV, 1996, MOL MED, V2, P226, DOI 10.1007/BF03401619; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Taylor BS, 2000, SHOCK, V13, P413, DOI 10.1097/00024382-200006000-00001; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yeldandi AV, 2000, MUTAT RES-FUND MOL M, V448, P159, DOI 10.1016/S0027-5107(99)00234-1; Zhao ML, 1998, BRAIN RES, V813, P402, DOI 10.1016/S0006-8993(98)01023-3	53	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45984	45991		10.1074/jbc.M200250200	http://dx.doi.org/10.1074/jbc.M200250200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244038	Green Published, Green Accepted, hybrid			2022-12-27	WOS:000179529300038
J	Sherameti, I; Sopory, SK; Trebicka, A; Pfannschmidt, T; Oelmuller, R				Sherameti, I; Sopory, SK; Trebicka, A; Pfannschmidt, T; Oelmuller, R			Photosynthetic electron transport determines nitrate reductase gene expression and activity in higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-REGULATED EXPRESSION; NITRITE-REDUCTASE; POSTTRANSCRIPTIONAL REGULATION; CHLOROPLAST; TRANSCRIPTION; PHYTOCHROME; LEAVES; INDUCTION; PROMOTER; AMMONIUM	The influence of photosynthetic electron flow in chloroplasts on the expression and enzyme activity of the cytosolic nitrate reductase (NR) was studied. Using light sources that predominantly excite either photosystem I (PSI) or photosystem II (PSII), we modulated photosynthetic electron transport in tobacco, Arabidopsis, and Lemna sprouts. In all instances, oxidation of components of photosynthetic electron flow by PSI light correlated with an increase in NR activity and/or transcription. This is confirmed by experiments with electron transport inhibitors 3-(3',4'-dichlorophenyl)-1,1'-dimethyl urea and 2,5-dibromo-3-methyl-6-isopropyl-p-benzoquinone. In addition, a Lemna mutant deficient in the cytochrome b(6)/f complex failed to respond to the different light sources and exhibited a constitutively high level of NR activity. These data indicate that NR is activated by the oxidized state of an electron transport component located after the plastoquinone pool. Am involvement of the cytoplasmic photoreceptor phytochrome A in this light regulation could be excluded, since an Arabidopsis phytochrome A mutant exhibited a wild-type like response. The observation that NR activity in the cytoplasm and the expression of its gene in the nucleus is controlled by signals from photosynthetic electron flow adds a new facet to the intracellular crosstalk between chloroplasts and the nucleus.	Inst Allgemeine Bot, Lehrstuhl Pflanzenphysiol, D-07743 Jena, Germany		Oelmuller, R (corresponding author), Univ Jena, Dept Plant Physiol, Inst Gen Bot, Dornburger Str 159, D-07743 Jena, Germany.	b7oera@uni-jena.de	Pfannschmidt, Thomas/AAH-5916-2021					Allen JF, 2000, PHILOS T R SOC B, V355, P1351, DOI 10.1098/rstb.2000.0697; APPENROTH KJ, 1992, PLANTA, V188, P587, DOI 10.1007/BF00197053; Appenroth KJ, 1996, BIOL PLANTARUM, V38, P95, DOI 10.1007/BF02879642; Aslam M, 1997, PHYSIOL PLANTARUM, V101, P612, DOI 10.1111/j.1399-3054.1997.tb01045.x; Bachmann M, 1996, FEBS LETT, V387, P127, DOI 10.1016/0014-5793(96)00478-4; BECKER TW, 1992, PLANTA, V188, P39, DOI 10.1007/BF00198937; BORNER T, 1986, PLANTA, V169, P202, DOI 10.1007/BF00392315; BRUCE BD, 1991, PLANT CELL, V3, P203, DOI 10.1105/tpc.3.2.203; Bueno MS, 1996, ACTA PHYSIOL PLANT, V18, P335; CABOCHE M, 1990, TRENDS GENET, V6, P187, DOI 10.1016/0168-9525(90)90175-6; Campbell WH, 1999, ANNU REV PLANT PHYS, V50, P277, DOI 10.1146/annurev.arplant.50.1.277; Campbell WH, 1996, PLANT PHYSIOL, V111, P355, DOI 10.1104/pp.111.2.355; CHENG CL, 1992, P NATL ACAD SCI USA, V89, P1861, DOI 10.1073/pnas.89.5.1861; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAWFORD NM, 1986, P NATL ACAD SCI USA, V83, P8073, DOI 10.1073/pnas.83.21.8073; CRAWFORD NM, 1995, PLANT CELL, V7, P859, DOI 10.1105/tpc.7.7.859; DanielVedele F, 1996, CR ACAD SCI III-VIE, V319, P961; DEANEDRUMMOND CE, 1980, PLANT CELL ENVIRON, V3, P303, DOI 10.1111/1365-3040.ep11581851; DENG MD, 1991, PLANT PHYSIOL BIOCH, V29, P239; DENG MD, 1990, PLANTA, V180, P257, DOI 10.1007/BF00194005; Douglas P, 1997, BIOCHEM J, V325, P101, DOI 10.1042/bj3250101; Douglas P, 1995, FEBS LETT, V377, P113, DOI 10.1016/0014-5793(95)01300-8; Geiger M, 1998, PLANT CELL ENVIRON, V21, P253, DOI 10.1046/j.1365-3040.1998.00277.x; GENTY B, 1989, BIOCHIM BIOPHYS ACTA, V990, P87, DOI 10.1016/S0304-4165(89)80016-9; GOWRI G, 1989, PLANT PHYSIOL, V90, P792, DOI 10.1104/pp.90.3.792; Hachtel W, 2000, PLANT SOIL, V221, P33, DOI 10.1023/A:1004739621352; HUBER JL, 1994, PLANT PHYSIOL, V106, P1667, DOI 10.1104/pp.106.4.1667; HUBER SC, 1997, PHYS PLANT, V98, P833; Hwang CF, 1997, PLANT PHYSIOL, V113, P853, DOI 10.1104/pp.113.3.853; JEFFERSON RA, 1987, EMBO J, V6, P3901; Kaiser WM, 1999, PHYSIOL PLANTARUM, V105, P385, DOI 10.1034/j.1399-3054.1999.105225.x; KAISER WM, 1991, PLANT PHYSIOL, V91, P970; KOJIMA M, 1995, PHYSIOL PLANTARUM, V93, P139, DOI 10.1034/j.1399-3054.1995.930120.x; Larios B, 2001, PLANTA, V212, P305, DOI 10.1007/s004250000395; Lejay L, 1997, PLANT PHYSIOL, V115, P623, DOI 10.1104/pp.115.2.623; LI XZ, 1993, PLANT PHYSIOL, V102, P1251, DOI 10.1104/pp.102.4.1251; Lillo C, 1998, J PHOTOCH PHOTOBIO B, V44, P205, DOI 10.1016/S1011-1344(98)00144-4; Lillo C, 1996, PLANTA, V200, P181, DOI 10.1007/BF00208307; Lillo C, 2001, BIOL RHYTHM RES, V32, P489, DOI 10.1076/brhm.32.4.489.1332; Lillo C, 2001, PLANT BIOLOGY, V3, P455, DOI 10.1055/s-2001-17732; LIN Y, 1994, PLANT PHYSIOL, V106, P477, DOI 10.1104/pp.106.2.477; LONG DM, 1992, PHYSIOL PLANTARUM, V85, P561, DOI 10.1111/j.1399-3054.1992.tb04755.x; LUBBERSTEDT T, 1994, MOL GEN GENET, V242, P602, DOI 10.1007/BF00285284; MOHR H, 1992, BOT ACTA, V105, P81, DOI 10.1111/j.1438-8677.1992.tb00270.x; MOHR H, 1984, TECHNIQUES PHOTOMORP, P12; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NUSSAUME L, 1995, PLANT CELL, V7, P611, DOI 10.1105/tpc.7.5.611; OELMULLER R, 1989, PHOTOCHEM PHOTOBIOL, V49, P229, DOI 10.1111/j.1751-1097.1989.tb04101.x; Ogawa K, 2000, J PLANT PHYSIOL, V157, P299, DOI 10.1016/S0176-1617(00)80051-6; Oswald O, 2001, P NATL ACAD SCI USA, V98, P2047, DOI 10.1073/pnas.021449998; PATTANAYAK D, 1988, J PLANT BIOCHEM BIOT, V7, P73; Pfannschmidt T, 1999, IUBMB LIFE, V48, P271, DOI 10.1080/713803507; Pfannschmidt T, 1999, NATURE, V397, P625, DOI 10.1038/17624; Pfannschmidt T, 2001, J BIOL CHEM, V276, P36125, DOI 10.1074/jbc.M105701200; PILGRIM ML, 1993, PLANT MOL BIOL, V23, P349, DOI 10.1007/BF00029010; Provan F, 1999, J PLANT PHYSIOL, V154, P605, DOI 10.1016/S0176-1617(99)80233-8; Raghuram N, 1999, BIOCHEM MOL BIOL INT, V47, P239; SCHREIBER U, 1986, PHOTOSYNTH RES, V10, P51, DOI 10.1007/BF00024185; SCHUSTER C, 1989, PLANTA, V177, P74, DOI 10.1007/BF00392156; Sivasankar S, 1996, PLANT PHYSIOL BIOCH, V34, P609; Strater T, 2000, PLANT SCI, V150, P153, DOI 10.1016/S0168-9452(99)00182-X; VINCENTZ M, 1993, PLANT J, V3, P315, DOI 10.1046/j.1365-313X.1993.t01-16-00999.x; Wollman FA, 2001, EMBO J, V20, P3623, DOI 10.1093/emboj/20.14.3623; Yu XD, 1998, PLANT PHYSIOL, V116, P1091, DOI 10.1104/pp.116.3.1091	64	53	59	0	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46594	46600		10.1074/jbc.M202924200	http://dx.doi.org/10.1074/jbc.M202924200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244040	hybrid			2022-12-27	WOS:000179529300115
J	Duquette, M; Laneuville, O				Duquette, M; Laneuville, O			Translational regulation of prostaglandin endoperoxide H synthase-1 mRNA in megakaryocytic MEG-01 cells - Specific protein binding to a conserved 20-nucleotide cis element in the 3 '-untranslated region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; MESSENGER-RNA; EXPRESSION; LINE; ACID; CYCLOOXYGENASE-1; DIFFERENTIATION; DEGRADATION; INDUCTION; SEQUENCE	Prostaglandin endoperoxide H synthase-1 (PGHS-1) is an abundant enzyme in platelets, where it plays a key role in the cascade of prostanoid formation. In platelets, the primary site of PGHS-1 synthesis is in precursor megakaryocytic cells. We have previously shown that in megakaryocytic MEG-01 cells, TPA induces an increase of PGHS-1 mRNA within a few hours, whereas protein increase occurs after several days of treatment. We now report that the delayed increase in PGHS-1 protein is caused by translational regulation. De novo PGHS-1 synthesis, measured using [S-35]methionine pulse labeling followed by immunoprecipitation, was detected at day 4 after TPA treatment but not at day 1. To identify a potential element of PGHS-1 mRNA controlling translation, we compared the 3'-untranslated region from different species and identified a 20-nt segment perfectly conserved. The 20-nt segment was used as a probe in RNA gel mobility-shift assays using MEG-01 extracts from control cells or from TPA-treated cells. Four complexes were formed with extracts from control cells or cells treated with TPA for 1 day but were not observed with extracts from cells treated for 4 days. Of the 4 complexes, one was sequence-specific and binding involved uridylate residues and interactions with a 45-kDa protein and a protein doublet of 116 kDa. Binding of this 45/116-kDa complex to the 20-nt conserved cis element most likely regulates negatively PGHS-1 protein accumulation. We have provided evidence that the PGHS-1 gene is regulated at the translational level.	Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Laneuville, O (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	olaneuvi@uottawa.ca						Amara FM, 1996, BIOCHEM BIOPH RES CO, V228, P347, DOI 10.1006/bbrc.1996.1664; BRANNON TS, 1994, J CLIN INVEST, V93, P2230, DOI 10.1172/JCI117220; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Fraboulet S, 1998, ENDOCRINOLOGY, V139, P894, DOI 10.1210/en.139.3.894; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Kroll SL, 2001, J BIOL CHEM, V276, P49410, DOI 10.1074/jbc.M109577200; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; MATIJEVICALEKSIC N, 1995, BBA-MOL CELL RES, V1269, P167, DOI 10.1016/0167-4889(95)00116-A; Mroske C, 2000, EXP HEMATOL, V28, P411, DOI 10.1016/S0301-472X(00)00125-9; OGURA M, 1988, BLOOD, V72, P49; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; Plant MH, 1999, BIOCHEM J, V344, P677, DOI 10.1042/0264-6021:3440677; Schneider N, 2001, J NEUROCHEM, V77, P416, DOI 10.1046/j.1471-4159.2001.00264.x; Smith CJ, 1997, ADV EXP MED BIOL, V400, P99; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Taniura S, 2002, J BIOL CHEM, V277, P16823, DOI 10.1074/jbc.M200527200; Tholanikunnel BG, 1997, J BIOL CHEM, V272, P11471; Xu XM, 1997, J BIOL CHEM, V272, P6943, DOI 10.1074/jbc.272.11.6943; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931	24	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44631	44637		10.1074/jbc.M207007200	http://dx.doi.org/10.1074/jbc.M207007200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237309	hybrid			2022-12-27	WOS:000179404800007
J	Jonassen, T; Marbois, BN; Faull, KF; Clarke, CF; Larsen, PL				Jonassen, T; Marbois, BN; Faull, KF; Clarke, CF; Larsen, PL			Development and fertility in Caenorhabditis elegans clk-1 mutants depend upon transport of dietary coenzyme Q(8) to mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBICALLY FUNCTIONING EUKARYOTES; EMBRYONIC CELL LINEAGES; SACCHAROMYCES-CEREVISIAE; UBIQUINONE BIOSYNTHESIS; ELECTRON-TRANSPORT; LIFE-SPAN; GENE; YEAST; PROTEIN; CHAIN	The Caenorhabditis elegans clk-1 mutants lack coenzyme Q, and instead accumulate the biosynthetic intermediate demethoxy-Q(9) (DMQ(9)). clk-1 animals grow to reproductive adults, albeit slowly, if supplied with Q(8)-containing Escherichia coli. However, if Q is withdrawn from the diet, clk-1 animals either arrest development as young larvae or become sterile adults depending upon the stage at the time of the withdrawal. To understand this stage-dependent response to a Q-less diet, the quinone content was determined during development of wild-type animals. The quinone content varies in the different developmental stages in wild-type fed Q(8)-replete E. coli. The amounts peak at the second larval stage, which coincides with the stage of arrest of clk-1 larvae fed a Q-less diet from hatching. Levels of the endogenously synthesized DMQ(9) are high in the clk1(qmM30)-arrested larvae and sterile adults fed Q-less food. Comparison of quinones from animals fed a Q-replete or a Q-less diet establishes that the Q(8) present is assimilated from the E. coli. Furthermore, this E. colispecific Q(8) is present in mitochondria isolated from fertile clk-1(qm30) adults fed a Q-replete diet. These results suggest that the uptake and transport of dietary Q(8) to mitochondria prevent the arrest and sterility phenotypes of clk-1 mutants and that DMQ is not functionally equivalent to Q.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Larsen, PL (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.				NIGMS NIH HHS [GM 45952] Funding Source: Medline; PHS HHS [19777] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNER S, 1974, GENETICS, V77, P71; Crane FL, 2001, J AM COLL NUTR, V20, P591, DOI 10.1080/07315724.2001.10719063; Do TQ, 2001, J BIOL CHEM, V276, P18161, DOI 10.1074/jbc.M100952200; Dutton PL, 2000, COENZYME Q OXIDATION, P65, DOI [10.1201/9781420036701.sec1b, DOI 10.1201/9781420036701.SEC1B]; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; Finckh B, 1995, ANAL BIOCHEM, V232, P210, DOI 10.1006/abio.1995.0009; Foll RL, 1999, COMP BIOCHEM PHYS B, V124, P269, DOI 10.1016/S0305-0491(99)00130-3; Glasgow BJ, 1998, BIOCHEMISTRY-US, V37, P2215, DOI 10.1021/bi9720888; Hihi AK, 2002, J BIOL CHEM, V277, P2202, DOI 10.1074/jbc.M109034200; Hsu AY, 1996, BIOCHEMISTRY-US, V35, P9797, DOI 10.1021/bi9602932; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; Jonassen T., 2000, COENZYME Q MOL MECH, P185; KAGAN VE, 1996, HDB ANTIOXIDANTS, P157; KHAN FR, 1982, EXP PARASITOL, V54, P47, DOI 10.1016/0014-4894(82)90109-6; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Larsen PL, 2002, SCIENCE, V295, P120, DOI 10.1126/science.1064653; Lee PT, 1997, J BACTERIOL, V179, P1748, DOI 10.1128/jb.179.5.1748-1754.1997; LENAZ G, 1968, ARCH BIOCHEM BIOPHYS, V123, P539, DOI 10.1016/0003-9861(68)90175-6; Levavasseur F, 2001, J BIOL CHEM, V276, P46160, DOI 10.1074/jbc.M108980200; LIU ZC, 1991, NATURE, V350, P162, DOI 10.1038/350162a0; Lonnrot K, 1998, BIOCHEM MOL BIOL INT, V44, P727; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Matthews RT, 1998, P NATL ACAD SCI USA, V95, P8892, DOI 10.1073/pnas.95.15.8892; Miyadera H, 2001, J BIOL CHEM, V276, P7713, DOI 10.1074/jbc.C000889200; NAGY M, 1992, P NATL ACAD SCI USA, V89, P8966, DOI 10.1073/pnas.89.19.8966; Nakai D, 2001, BIOCHEM BIOPH RES CO, V289, P463, DOI 10.1006/bbrc.2001.5977; Poon WW, 1999, J BIOL CHEM, V274, P21665, DOI 10.1074/jbc.274.31.21665; Proft M, 1995, EMBO J, V14, P6116, DOI 10.1002/j.1460-2075.1995.tb00302.x; Rotig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9; Santos-Ocana C, 2002, J BIOL CHEM, V277, P10973, DOI 10.1074/jbc.M112222200; Santos-Ocana C, 1998, J BIOENERG BIOMEMBR, V30, P465, DOI 10.1023/A:1020542230308; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SUZUKI K, 1994, BIOSCI BIOTECH BIOCH, V58, P1814, DOI 10.1271/bbb.58.1814; Tielens AGM, 1998, BBA-BIOENERGETICS, V1365, P71, DOI 10.1016/S0005-2728(98)00045-0; Tsang WY, 2002, BIOCHEM BIOPH RES CO, V291, P8, DOI 10.1006/bbrc.2002.6394; Tsang WY, 2001, J BIOL CHEM, V276, P32240, DOI 10.1074/jbc.M103999200; Vande Weghe JG, 1999, J BIOL CHEM, V274, P13250, DOI 10.1074/jbc.274.19.13250; VanHellemond JJ, 1995, J BIOL CHEM, V270, P31065, DOI 10.1074/jbc.270.52.31065; VanHellemond JJ, 1996, MOL BIOCHEM PARASIT, V82, P217, DOI 10.1016/0166-6851(96)02738-7; WADSWORTH WG, 1989, DEV BIOL, V132, P167, DOI 10.1016/0012-1606(89)90214-5; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P75, DOI 10.1016/0005-2728(77)90070-6; WONG A, 1995, GENETICS, V139, P1247; Xia L, 2001, EUR J BIOCHEM, V268, P1486, DOI 10.1046/j.1432-1327.2001.02013.x; YOUNG IG, 1973, J BACTERIOL, V114, P42, DOI 10.1128/JB.114.1.42-52.1973	51	75	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45020	45027		10.1074/jbc.M204758200	http://dx.doi.org/10.1074/jbc.M204758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12324451	hybrid			2022-12-27	WOS:000179404800056
J	Lee, TH; Lwu, S; Kim, J; Pelletier, J				Lee, TH; Lwu, S; Kim, J; Pelletier, J			Inhibition of Wilms tumor 1 transactivation by bone marrow zinc finger 2, a novel transcriptional repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSOR GENE; DNA-BINDING; SUBNUCLEAR LOCALIZATION; MOLECULAR-CLONING; WT1 GENE; DIFFERENTIATION; PROTEIN; EXPRESSION; PRODUCT; DOMAINS	The Wilms tumor suppressor gene, wt1, encodes a zinc finger transcription factor that has been implicated in the regulation of a number of genes. Protein-protein interactions are known to modulate the transcription regulatory functions of Wilms tumor (WT1) and have also implicated WT1 in splicing. In this report, we identify a novel WT1-interacting protein, bone marrow zinc finger 2 (BMZF2), by affinity chromatography utilizing immobilized WT1 protein. BMZF2 is a potential transcription factor with 18 zinc fingers. The BMZF2 mRNA is mainly expressed in fetal tissues, and the protein is predominantly nuclear. Co-immunoprecipitation experiments are consistent with an in vivo association between WT1 and BMZF2. Glutathione S-transferase pulldown assays and far Western blots revealed that zinc fingers VI-X (amino acids 231-370) are required for interaction with the zinc finger region of WT1. Functionally, BMZF2 inhibits transcriptional activation by WT1. Moreover, a chimeric protein generated by fusion of BMZF2 to the GAL4 DNA-binding domain significantly decreases promoter activity of a reporter containing GAL4 DNA-binding sites, suggesting the presence of an active repressor domain within BMZF2. Our results suggest that BMZF2 interferes with the transactivation potential of WT1.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; Sogang Univ, Dept Life Sci, Mapo Gu, Seoul 121742, South Korea	McGill University; McGill University; Sogang University	Pelletier, J (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg,Rm 810,3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.		Lee, Tae Ho/AAT-1721-2020					Baird PN, 1997, EXP HEMATOL, V25, P312; Bardeesy N, 1998, NUCLEIC ACIDS RES, V26, P1784, DOI 10.1093/nar/26.7.1784; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Ellisen LW, 2001, EMBO J, V20, P1897, DOI 10.1093/emboj/20.8.1897; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Han ZG, 1999, J BIOL CHEM, V274, P35741, DOI 10.1074/jbc.274.50.35741; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Kim J, 1999, MOL CELL BIOL, V19, P2289; Laity JH, 2000, P NATL ACAD SCI USA, V97, P11932, DOI 10.1073/pnas.97.22.11932; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee JK, 2001, MET MATER-KOREA, V7, P187, DOI 10.1007/BF03026974; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Maheswaran S, 1998, GENE DEV, V12, P1108, DOI 10.1101/gad.12.8.1108; MATSUNAGA E, 1981, HUM GENET, V57, P231; Maurer U, 1997, EXP HEMATOL, V25, P945; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MESSEN HD, 1997, BLOOD, V89, P3486; MOFFETT P, 1995, P NATL ACAD SCI USA, V92, P11105, DOI 10.1073/pnas.92.24.11105; Moffett P, 1997, MOL CELL BIOL, V17, P4933, DOI 10.1128/MCB.17.9.4933; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PritchardJones K, 1997, LEUKEMIA LYMPHOMA, V27, P207, DOI 10.3109/10428199709059677; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Sambrook J., 2002, MOL CLONING LAB MANU; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; SEKIYA M, 1994, BLOOD, V83, P1867; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; Smith SI, 2000, CANCER RES, V60, P808; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1995, ONCOGENE, V10, P415; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; WU YJ, 1995, J BIOL CHEM, V270, P5944, DOI 10.1074/jbc.270.11.5944	44	26	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44826	44837		10.1074/jbc.M205667200	http://dx.doi.org/10.1074/jbc.M205667200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12239212	hybrid			2022-12-27	WOS:000179404800032
J	Piccininni, S; Varaklioti, A; Nardelli, M; Dave, B; Raney, KD; McCarthy, JEG				Piccininni, S; Varaklioti, A; Nardelli, M; Dave, B; Raney, KD; McCarthy, JEG			Modulation of the hepatitis C virus RNA-dependent RNA polymerase activity by the non-structural (NS) 3 helicase and the NS4B membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO INITIATION; CRYSTAL-STRUCTURE; VIRAL-RNA; REPLICATION; IDENTIFICATION; REQUIREMENTS; MECHANISM; TEMPLATE; COMPLEX; REGION	The hepatitis C virus (HCV) nonstructural protein 5B (NS5B) is believed to be the central catalytic enzyme responsible for HCV replication but there are many unanswered questions about how its activity is controlled. In this study we reveal that two other HCV proteins, NS3 (a protease/helicase) and NS4B (a hydrophobic protein of unknown function), physically and functionally interact with the NS5B polymerase. We describe a new procedure for generating highly pure NS4B, and use this protein in biochemical studies together with NS5B and NS3. To study the functional effects of the protein-protein interactions, we have developed an in vitro replication assay using the natural noncoding 3' regions of the respective positive ((+)-3'-untranslated region) and negative ((-)-3'-terminal region) RNA strands of the HCV genome. Our studies show that NS3 dramatically modulates template recognition by NS5B and changes the synthetic products generated by this enzyme. The use of an NTPase-deficient mutant form of NS3 demonstrates that the NTPase activity (and thus helicase activity) of this protein is specifically required for these effects. Moreover, NS4B is found to be a negative regulator of the NS3-NS5B replication complex. Overall, these results reveal that NS3, NS4B, and NS5B can interact to form a regulatory complex that could feature in the process of HCV replication.	Univ Manchester, Dept Biomol Sci, Posttranscript Control Grp, Manchester M60 1QD, Lancs, England; Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	University of Manchester; University of Arkansas System; University of Arkansas Medical Sciences	McCarthy, JEG (corresponding author), Univ Manchester, Dept Biomol Sci, Posttranscript Control Grp, POB 88, Manchester M60 1QD, Lancs, England.	J.McCarthy@umist.ac.uk	Dave, Bhuvanesh/ABF-8334-2020; Varaklioti, Agoritsa/AAP-7116-2020	Dave, Bhuvanesh/0000-0001-6741-1363; Varaklioti, Agoritsa/0000-0002-3897-819X	NIAID NIH HHS [AI47350] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047350] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Cho HS, 1998, J BIOL CHEM, V273, P15045, DOI 10.1074/jbc.273.24.15045; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Ferre-D'Amare AR, 1998, NATURE, V395, P567, DOI 10.1038/26912; Harlow E., 1988, ANTIBODIES LAB MANUA; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; Hugle T, 2001, VIROLOGY, V284, P70, DOI 10.1006/viro.2001.0873; Hwang SB, 1997, VIROLOGY, V227, P439, DOI 10.1006/viro.1996.8357; Ishido S, 1998, BIOCHEM BIOPH RES CO, V244, P35, DOI 10.1006/bbrc.1998.8202; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; Kato J, 2002, J MED VIROL, V66, P187, DOI 10.1002/jmv.2129; Khu YL, 2001, J VIROL, V75, P205, DOI 10.1128/JVI.75.1.205-214.2001; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Lavanchy D, 1999, J VIRAL HEPATITIS, V6, P35; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; Lin C, 1997, J VIROL, V71, P6465, DOI 10.1128/JVI.71.9.6465-6471.1997; Lohmann V, 1999, J BIOL CHEM, V274, P10807, DOI 10.1074/jbc.274.16.10807; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Macnaughton TB, 2002, J VIROL, V76, P3920, DOI 10.1128/JVI.76.8.3920-3927.2002; Matsumoto M, 1996, VIROLOGY, V218, P43, DOI 10.1006/viro.1996.0164; Moradpour D, 2002, J BIOL CHEM, V277, P593, DOI 10.1074/jbc.M108748200; Neddermann P, 1999, J VIROL, V73, P9984, DOI 10.1128/JVI.73.12.9984-9991.1999; Oh JW, 2000, J BIOL CHEM, V275, P17710, DOI 10.1074/jbc.M908781199; Oh JW, 1999, J VIROL, V73, P7694, DOI 10.1128/JVI.73.9.7694-7702.1999; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; Park C, 2002, J VIROL METHODS, V101, P211, DOI 10.1016/S0166-0934(01)00443-8; Qin WP, 2002, J BIOL CHEM, V277, P2132, DOI 10.1074/jbc.M106880200; Qin WP, 2001, HEPATOLOGY, V33, P728, DOI 10.1053/jhep.2001.22765; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Reigadas S, 2001, EUR J BIOCHEM, V268, P5857, DOI 10.1046/j.0014-2956.2001.02532.x; Rosenberg S, 2001, J MOL BIOL, V313, P451, DOI 10.1006/jmbi.2001.5055; Sarbah SA, 2000, J CLIN GASTROENTEROL, V30, P125, DOI 10.1097/00004836-200003000-00005; Schmidt-Mende J, 2001, J BIOL CHEM, V276, P44052, DOI 10.1074/jbc.M103358200; Shimotohno K, 2000, SEMIN CANCER BIOL, V10, P233, DOI 10.1006/scbi.2000.0322; Shirota Y, 2002, J BIOL CHEM, V277, P11149, DOI 10.1074/jbc.M111392200; Tackett AJ, 2001, NUCLEIC ACIDS RES, V29, P565, DOI 10.1093/nar/29.2.565; Tomei L, 2000, J GEN VIROL, V81, P759, DOI 10.1099/0022-1317-81-3-759; Wang QM, 2002, J VIROL, V76, P3865, DOI 10.1128/JVI.76.8.3865-3872.2002; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000	46	121	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45670	45679		10.1074/jbc.M204124200	http://dx.doi.org/10.1074/jbc.M204124200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235135	hybrid			2022-12-27	WOS:000179404800134
J	Honsho, M; Hiroshige, T; Fujiki, Y				Honsho, M; Hiroshige, T; Fujiki, Y			The membrane biogenesis peroxin Pex16p - Topogenesis and functional roles in peroxisomal membrane assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARY CELL MUTANTS; COMPLEMENTATION GROUP; ZELLWEGER-SYNDROME; TARGETING SIGNALS; CDNA CLONING; MUTATION ANALYSIS; PROTEIN; GENE; IMPORT; PEX3P	Previously we isolated human PEX16 encoding 336-amino acid-long peroxin Pex16p and showed that its dysfunction was responsible for Zellweger syndrome of complementation group D (group 9). Here we have determined the membrane topology of Pex16p by differential permeabilization method: both N- and C-terminal parts are exposed to the cytosol. In the search for Pex16p topogenic sequence, basic amino acids clustered sequence, RKELRKKLPVSLSQQK, at positions 66-81 and the first transmembrane segment locating far downstream, nearly by 40 amino acids, of this basic region were defined to be essential for integration into peroxisome membranes. Localization to peroxisomes of membrane proteins such as Pex14p, Pex13p, and PMP70 was interfered with in CHO-K1 cells by a higher level expression of the pex16 patient-derived dysfunctional but topogenically active Pex16pR176ter comprising resides 1-176 or of the C-terminal cytoplasmic part starting from residues at 244 to the C terminus. Furthermore, Pex16p C-terminal cytoplasmic part severely abrogated peroxisome restoration in pex mutants such as matrix protein import-defective pex12 and membrane assembly impaired pex3 by respective PEX12 and PEX3 expression, whereas the N-terminal cytosolic region did not affect restoration. These results imply that Pex16p functions in peroxisome membrane assembly, more likely upstream of Pex3p.	Kyushu Univ, Grad Sch, Fac Sci, Dept Biol, Fukuoka 8128581, Japan; Japan Sci & Technol Corp, SORST, Kawaguchi, Saitama 3320012, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Fujiki, Y (corresponding author), Kyushu Univ, Grad Sch, Fac Sci, Dept Biol, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	yfujiscb@mbox.nc.kyushu-u.ac.jp		Honsho, Masanori/0000-0001-6165-4516				Abe I, 1998, FEBS LETT, V431, P468, DOI 10.1016/S0014-5793(98)00815-1; Baerends RJS, 2000, J BIOL CHEM, V275, P9986, DOI 10.1074/jbc.275.14.9986; Brosius U, 2002, J BIOL CHEM, V277, P774, DOI 10.1074/jbc.M108155200; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; Eitzen GA, 1997, J CELL BIOL, V137, P1265, DOI 10.1083/jcb.137.6.1265; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; Fransen M, 2001, MOL CELL BIOL, V21, P4413, DOI 10.1128/MCB.21.13.4413-4424.2001; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Fujiki Y, 2000, FEBS LETT, V476, P42, DOI 10.1016/S0014-5793(00)01667-7; Fujiki Y, 1997, BBA-MOL BASIS DIS, V1361, P235, DOI 10.1016/S0925-4439(97)00051-3; Ghaedi K, 2000, AM J HUM GENET, V67, P976, DOI 10.1086/303086; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; Ghaedi K, 1999, EXP CELL RES, V248, P489, DOI 10.1006/excr.1999.4413; Gotte K, 1998, MOL CELL BIOL, V18, P616; Gould SJ, 2000, TRENDS GENET, V16, P340, DOI 10.1016/S0168-9525(00)02056-4; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; Honsho M, 1998, AM J HUM GENET, V63, P1622, DOI 10.1086/302161; Honsho M, 2001, J BIOL CHEM, V276, P9375, DOI 10.1074/jbc.M003304200; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; Kammerer S, 1998, FEBS LETT, V429, P53, DOI 10.1016/S0014-5793(98)00557-2; Kinoshita N, 1998, J BIOL CHEM, V273, P24122, DOI 10.1074/jbc.273.37.24122; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; MARSHALL PA, 1995, J CELL BIOL, V129, P345, DOI 10.1083/jcb.129.2.345; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Mukai S, 2002, J BIOL CHEM, V277, P9548, DOI 10.1074/jbc.M108635200; Muntau AC, 2000, AM J HUM GENET, V67, P967, DOI 10.1086/303071; Okumoto K, 2000, J BIOL CHEM, V275, P25700, DOI 10.1074/jbc.M003303200; Okumoto K, 1997, EXP CELL RES, V233, P11, DOI 10.1006/excr.1997.3552; Okumoto K, 1998, HUM MOL GENET, V7, P1399, DOI 10.1093/hmg/7.9.1399; Okumoto K, 1998, MOL CELL BIOL, V18, P4324, DOI 10.1128/MCB.18.7.4324; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; Otera H, 2001, J BIOL CHEM, V276, P2858, DOI 10.1074/jbc.M007730200; Otera H, 2002, MOL CELL BIOL, V22, P1639, DOI 10.1128/MCB.22.6.1639-1655.2002; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; SAKAI Y, 1995, J BACTERIOL, V177, P6773, DOI 10.1128/jb.177.23.6773-6781.1995; Schrader M, 1998, J BIOL CHEM, V273, P29607, DOI 10.1074/jbc.273.45.29607; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; Shimozawa N, 2000, HUM MOL GENET, V9, P1995, DOI 10.1093/hmg/9.13.1995; Shimozawa N, 2002, BIOCHEM BIOPH RES CO, V292, P109, DOI 10.1006/bbrc.2002.6642; Snyder WB, 1999, MOL BIOL CELL, V10, P1745, DOI 10.1091/mbc.10.6.1745; Soukupova M, 1999, EUR J CELL BIOL, V78, P357, DOI 10.1016/S0171-9335(99)80078-8; South ST, 2000, J CELL BIOL, V149, P1345, DOI 10.1083/jcb.149.7.1345; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Subramani S, 1997, NAT GENET, V15, P331, DOI 10.1038/ng0497-331; Titorenko VI, 1998, TRENDS BIOCHEM SCI, V23, P231, DOI 10.1016/S0968-0004(98)01226-2; Titorenko VI, 2001, NAT REV MOL CELL BIO, V2, P357, DOI 10.1038/35073063; Toyama R, 1999, HUM MOL GENET, V8, P1673, DOI 10.1093/hmg/8.9.1673; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; Voorn-Brouwer T, 2001, J CELL SCI, V114, P2199; Wang XD, 2001, J BIOL CHEM, V276, P10897, DOI 10.1074/jbc.M010883200; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973; Yamasaki M., 1998, BIOIMAGES, V6, P1	57	65	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44513	44524		10.1074/jbc.M206139200	http://dx.doi.org/10.1074/jbc.M206139200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223482	hybrid			2022-12-27	WOS:000179272000123
J	Rontein, D; Dieuaide-Noubhani, M; Dufourc, EJ; Raymond, P; Rolin, D				Rontein, D; Dieuaide-Noubhani, M; Dufourc, EJ; Raymond, P; Rolin, D			The metabolic architecture of plant cells - Stability of central metabolism and flexibility of anabolic pathways during the growth cycle of tomato cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC POTATO PLANTS; PHOSPHOENOLPYRUVATE CARBOXYLASE; CARBOHYDRATE-METABOLISM; SUSPENSION CULTURES; PENTOSE-PHOSPHATE; PYRUVATE-KINASE; ACID CYCLE; GLUCOSE; FLUXES; SUCROSE	The changes in the intermediary metabolism of plant cells were quantified according to growth conditions at three different stages of the growth cycle of tomato cell suspension. Eighteen fluxes of central metabolism were calculated from C-13 enrichments after near steady-state labeling by a metabolic model similar to that described in Dieuaide-Noubhani et aL (Dieuaide-Noubhani, M., Raffard, G., Canioni, P., Pradet, A., and Raymond, P. (1995) J. BioL Chem 270,13147-13159), and 10 net fluxes were obtained directly from end-product accumulation rates. The absolute flux values of central metabolic pathways gradually slowed down with the decrease of glucose influx into the cells. However, the relative fluxes of glycolysis, the pentose-P pathway, and the tricarboxylic acid cycle remained unchanged during the culture cycle at 70, 28, and 40% of glucose influx, respectively, and the futile cycle of sucrose remained high at about 6-fold the glucose influx, independently from carbon nutritional conditions. This natural resistance to flux alterations is referred to as metabolic stability. The numerous anabolic pathways, including starch synthesis, hexose accumulation, biosynthesis of wall polysaccharides, and amino and organic acid biosynthesis were comparatively low and variable. The phosphoenolpyruvate carboxylase flux decreased 5-fold in absolute terms and 2-fold in relation to the glucose influx rate during the culture cycle. We conclude that anabolic fluxes constitute the flexible part of plant cell metabolism that can fluctuate in relation to cell demands for growth.	INRA, UMR 619, Inst Biol Vegetale & Mol, F-33883 Villenave Dornon, France; Ecole Polytech, Inst Europeen Chim & Biol, F-33402 Talence, France	INRAE	Rolin, D (corresponding author), INRA, UMR 619, Inst Biol Vegetale & Mol, BP 81, F-33883 Villenave Dornon, France.	rolin@bordeaux.inra.fr	DUFOURC, Erick Joel/AAA-4992-2020	DUFOURC, Erick Joel/0000-0002-8221-9326; RONTEIN, Denis/0000-0002-3288-3800				ADAMS CA, 1982, PLANT CELL PHYSIOL, V23, P959; Botha FC, 1998, PHYSIOL PLANTARUM, V102, P429, DOI 10.1034/j.1399-3054.1998.1020311.x; Bouzier AK, 1998, J BIOL CHEM, V273, P27162, DOI 10.1074/jbc.273.42.27162; BROUQUISSE R, 1992, PLANTA, V188, P384, DOI 10.1007/BF00192806; BROUQUISSE R, 1991, PLANT PHYSIOL, V96, P619, DOI 10.1104/pp.96.2.619; BRYAN JK, 1992, BIOCH PLANTS COMP TR, V5, P403; COHEN SA, 1994, J CHROMATOGR A, V661, P25, DOI 10.1016/0021-9673(93)E0821-B; CORTEZ S, 2002, IN PRESS PLANT PHYSL; DANCER J, 1990, PLANTA, V182, P223, DOI 10.1007/BF00197115; DAVIES SEC, 1992, BIOCHEMISTRY-US, V31, P4729, DOI 10.1021/bi00134a028; DAVIS BM, 1982, J INT ASS MATH GEOL, V14, P189, DOI 10.1007/BF01083951; Dieuaide-Noubhani M, 1997, PLANT PHYSIOL, V115, P1505, DOI 10.1104/pp.115.4.1505; DIEUAIDENOUBHANI M, 1995, J BIOL CHEM, V270, P13147, DOI 10.1074/jbc.270.22.13147; Edwards S, 1998, PLANT PHYSIOL, V116, P1073, DOI 10.1104/pp.116.3.1073; Flugge UI, 1998, CURR OPIN PLANT BIOL, V1, P201, DOI 10.1016/S1369-5266(98)80105-2; GOTTLOBMCHUGH SG, 1992, PLANT PHYSIOL, V100, P820, DOI 10.1104/pp.100.2.820; HAJIREZAEI M, 1994, PLANTA, V192, P16; HATZFELD WD, 1990, PLANTA, V180, P198, DOI 10.1007/BF00193996; Herbers K, 1996, TRENDS BIOTECHNOL, V14, P198, DOI 10.1016/0167-7799(96)10027-5; HILL SA, 1994, PLANTA, V192, P52, DOI 10.1007/BF00198692; Ireland R.J., 1997, PLANT METABOLISM, P478; KANABUS J, 1986, PLANT PHYSIOL, V82, P363, DOI 10.1104/pp.82.2.363; KATZ J, 1967, BIOCHEMISTRY-US, V6, P2227, DOI 10.1021/bi00859a046; Krook J, 1998, J EXP BOT, V49, P1917, DOI 10.1093/jexbot/49.329.1917; Kunst A., 1984, METHOD ENZYMAT AN, VVI, P163; Lozovaya VV, 1996, PLANT PHYSIOL, V111, P921, DOI 10.1104/pp.111.3.921; Macnicol PK, 1998, PHYSIOL PLANTARUM, V103, P132, DOI 10.1034/j.1399-3054.1998.1030116.x; MACRAE E, 1992, PLANTA, V188, P314, DOI 10.1007/BF00192797; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; Martin F, 1998, PLANT PHYSIOL, V118, P627, DOI 10.1104/pp.118.2.627; Marx A, 1996, BIOTECHNOL BIOENG, V49, P111, DOI 10.1002/(SICI)1097-0290(19960120)49:2<111::AID-BIT1>3.0.CO;2-T; McNeil SD, 2000, PLANT PHYSIOL, V124, P153, DOI 10.1104/pp.124.1.153; MOELLERING H, 1966, ANAL BIOCHEM, V17, P369, DOI 10.1016/0003-2697(66)90172-2; MOING A, 1994, PLANT PHYSIOL, V106, P591, DOI 10.1104/pp.106.2.591; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nuccio ML, 1998, PLANT J, V16, P487, DOI 10.1046/j.1365-313x.1998.00316.x; Plaxton WC, 1996, ANNU REV PLANT PHYS, V47, P185, DOI 10.1146/annurev.arplant.47.1.185; RANCE M, 1983, J MAGN RESON, V52, P221, DOI 10.1016/0022-2364(83)90190-7; REES TA, 1994, PLANT CELL ENVIRON, V17, P587; Roscher A, 1998, J BIOL CHEM, V273, P25053, DOI 10.1074/jbc.273.39.25053; Roscher A, 2000, J BIOTECHNOL, V77, P81, DOI 10.1016/S0168-1656(99)00209-6; SALON C, 1988, J BIOL CHEM, V263, P12278; SCHAAFF I, 1989, YEAST, V5, P285, DOI 10.1002/yea.320050408; SMIRNOFF N, 1995, ENV PLANT B, P1; STEPHANOPOULOS G, 1991, SCIENCE, V252, P1675, DOI 10.1126/science.1904627; STITT M, 1995, ANNU REV PLANT PHYS, V46, P341, DOI 10.1146/annurev.pp.46.060195.002013; STITT M, 1978, PHYTOCHEMISTRY, V17, P1251, DOI 10.1016/S0031-9422(00)94566-7; Stitt Mark, 1994, Current Opinion in Biotechnology, V5, P137, DOI 10.1016/S0958-1669(05)80026-6; Weber A, 2000, PLANT CELL, V12, P787, DOI 10.1105/tpc.12.5.787; WENDLER R, 1991, PLANTA, V183, P31, DOI 10.1007/BF00197564; Zrenner R, 1996, PLANT J, V9, P671, DOI 10.1046/j.1365-313X.1996.9050671.x	51	157	166	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43948	43960		10.1074/jbc.M206366200	http://dx.doi.org/10.1074/jbc.M206366200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226084	hybrid, Green Published			2022-12-27	WOS:000179272000055
J	Scheinfeld, MH; Ghersi, E; Laky, K; Fowlkes, BJ; D'Adamio, L				Scheinfeld, MH; Ghersi, E; Laky, K; Fowlkes, BJ; D'Adamio, L			Processing of beta-amyloid precursor-like protein-1 and-2 by gamma-secretase regulates transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR DOMAIN; ALZHEIMERS-DISEASE; INTRAMEMBRANE CLEAVAGE; FE65 PROTEIN; FAMILY; NOTCH; APLP2; GENE; PRESENILIN-1; INHIBITORS	The familial Alzheimer's disease gene product beta-amyloid (Abeta) precursor protein (APP) is processed by the beta-and gamma-secretases to produce Abeta as well as AID (APP Intracellular Domain) which is derived from the extreme carboxyl terminus of APP. AID was originally shown to lower the cellular threshold to apoptosis and more recently has been shown to modulate gene expression such that it represses Notch-dependent gene expression while in combination with Fe65 it enhances gene activation. Here we report that the two other members of the APP family, beta-amyloid precursor-like protein-1 and -2 (APLP1 and APLP2), are also processed by the gamma-secretase in a Presenilin 1-dependent manner. Furthermore, the extreme carboxyl-terminal fragments produced by this processing (here termed APP-like Intracellular Domain or ALID1 and ALID2) are able to enhance Fe65-dependent gene activation, similar to what has been reported for AID. Considering that only APP and not the APLPs have been linked to familial Alzheimer's disease (AD), this data should help in understanding the physiologic roles of the APP family members and in differentiating these functions from the pathologic role of APP in Alzheimer's disease.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; NIAID, Cellular & Mol Immunol Lab, NIH, Bethesda, MD 20892 USA	Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	D'Adamio, L (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	ldadamio@aecom.yu.edu		Scheinfeld, Meir H/0000-0001-8880-4318; D'Adamio, Luciano/0000-0002-9820-4882; D'Adamio, Luciano/0000-0002-2204-9441	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM07288] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bayer TA, 1999, MOL PSYCHIATR, V4, P524, DOI 10.1038/sj.mp.4000552; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cappai R, 1999, FEBS LETT, V442, P95, DOI 10.1016/S0014-5793(98)01635-4; Cowan CM, 2001, J NEUROSCI, V21, P7099, DOI 10.1523/JNEUROSCI.21-18-07099.2001; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; D'Adamio L, 2002, RES PER ALZ, P101; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Galvan V, 2002, J NEUROCHEM, V82, P283, DOI 10.1046/j.1471-4159.2002.00970.x; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Heber S, 2000, J NEUROSCI, V20, P7951; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; KIM TW, 1995, MOL BRAIN RES, V32, P36, DOI 10.1016/0169-328X(95)00328-P; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lenkkeri U, 1998, HUM GENET, V102, P192, DOI 10.1007/s004390050676; LO ACY, 1995, J BIOL CHEM, V270, P12641, DOI 10.1074/jbc.270.21.12641; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; McNamara MJ, 1998, BRAIN RES, V804, P45, DOI 10.1016/S0006-8993(98)00653-2; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Paliga K, 1997, EUR J BIOCHEM, V250, P354, DOI 10.1111/j.1432-1033.1997.0354a.x; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Roncarati R, 2002, P NATL ACAD SCI USA, V99, P7102, DOI 10.1073/pnas.102192599; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Von Koch CS, 1997, NEUROBIOL AGING, V18, P661, DOI 10.1016/S0197-4580(97)00151-6; VONDERKAMMER H, 1994, GENOMICS, V20, P308, DOI 10.1006/geno.1994.1174; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xu KP, 2001, AM J PHYSIOL-CELL PH, V281, pC603, DOI 10.1152/ajpcell.2001.281.2.C603	41	132	137	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44195	44201		10.1074/jbc.M208110200	http://dx.doi.org/10.1074/jbc.M208110200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228233	hybrid			2022-12-27	WOS:000179272000086
J	Tanimoto, T; Jin, ZG; Berk, BC				Tanimoto, T; Jin, ZG; Berk, BC			Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SMOOTH-MUSCLE CELLS; ANGIOTENSIN-II; EGF RECEPTOR; SIGNAL-TRANSDUCTION; ACTIVATION; ANGIOGENESIS; SPHINGOSINE-1-PHOSPHATE; CONVERGENCE; CAVEOLIN-1	Sphingosine 1-phosphate (S1P) and vascular endothelial growth factor (VEGF) elicit numerous biological responses including cell survival, growth, migration, and differentiation in endothelial cells mediated by the endothelial differentiation gene, a family of G-protein-coupled receptors, and fetal liver kinase-1/kinase-insert domain-containing receptor (Flk-1/KDR), one of VEGF receptors, respectively. Recently, it was reported that SIP or VEGF treatment of endothelial cells leads to phosphorylation at Ser-1179 in bovine endothelial nitric oxide synthase (eNOS), and this phosphorylation is critical for eNOS activation. SIP stimulation of eNOS phosphorylation was shown to involve G(i) protein, phosphoinositide 3-kinase, and Akt. VEGF also activates eNOS through Flk-1/KDR, phosphoinositide 3-kinase, and Akt, which suggested that SIP and VEGF may share upstream signaling mediators. We now report that SIP treatment of bovine aortic endothelial cells acutely increases the tyrosine phosphorylation of Flk-1/KDR, similar to VEGF treatment. S1P-mediated phosphorylation of Flk-1/KDR, Akt, and eNOS were all inhibited by VEGF receptor tyrosine kinase inhibitors and by antisense Flk-1/KDR oligonucleotides. Our study suggests that SIP activation of eNOS involves Gi, calcium, and Src family kinase-dependent transactivation of Flk-1/KDR. These data are the first to establish a critical role of Flk-1/KDR in S1P-stimulated eNOS phosphorylation and activation.	Univ Rochester, Cardiovasc Res Ctr, Rochester, NY 14642 USA	University of Rochester	Berk, BC (corresponding author), Univ Rochester, Cardiovasc Res Ctr, 601 Elmwood Ave,Box 679, Rochester, NY 14642 USA.			Berk, Bradford/0000-0002-2767-4115	NHLBI NIH HHS [HV64839, HV49192] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790; Fulton D, 2001, J PHARMACOL EXP THER, V299, P818; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Igarashi J, 2001, J BIOL CHEM, V276, P36281, DOI 10.1074/jbc.M105628200; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Kim JH, 2000, IUBMB LIFE, V50, P119, DOI 10.1080/713803698; Kroll J, 1999, BIOCHEM BIOPH RES CO, V265, P636, DOI 10.1006/bbrc.1999.1729; Kwon YG, 2001, J BIOL CHEM, V276, P10627, DOI 10.1074/jbc.M011449200; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Peterson TE, 1999, CIRC RES, V85, P29; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Pyne S, 2000, PHARMACOL THERAPEUT, V88, P115, DOI 10.1016/S0163-7258(00)00084-X; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Rikitake Y, 2002, ARTERIOSCL THROM VAS, V22, P108, DOI 10.1161/hq0102.101843; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	41	179	184	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42997	43001		10.1074/jbc.M204764200	http://dx.doi.org/10.1074/jbc.M204764200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12226078	hybrid			2022-12-27	WOS:000179081200075
J	Lee, HJ; Lee, SJ				Lee, HJ; Lee, SJ			Characterization of cytoplasmic alpha-synuclein aggregates - Fibril formation is tightly linked to the inclusion-forming process in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; PROTEIN AGGREGATION; IN-VITRO; NEURODEGENERATIVE DISEASES; ALZHEIMERS-DISEASE; BODY FORMATION; PATHOGENESIS; OLIGOMERIZATION; FIBRILLIZATION; AGGRESOMES	The alpha-synuclein fibrillation process has been associated with the pathogenesis of several neurodegenerative diseases. Here, we have characterized the cytoplasmic alpha-synuclein aggregates using a fractionation procedure with which different aggregate species can be separated. Overexpression of alpha-synuclein in cells produce two distinct types of aggregates: large juxtanuclear inclusion bodies and small punctate aggregates scattered throughout the cytoplasm. Biochemical fractionation results in an inclusion-enriched fraction and two small aggregate fractions. Electron microscopy and thioflavin S reactivity of the fractions show that the juxtanuclear inclusion bodies are filled with amyloid-like alpha-synuclein fibrils, whereas both the small aggregate fractions contain non-fibrillar spherical aggregates with distinct size distributions. These aggregates appear sequentially, with the smallest population appearing the earliest and the fibrillar inclusions the latest. Based on the structural and kinetic properties, we suggest that the small spherical aggregates are the cellular equivalents of the protofibrils. The proteins that co-exist in the Lewy bodies, such as proteasome subunit, ubiquitin, and hsp70 chaperone, are present in the fibrillar inclusions but absent in the protofibrils, suggesting that these proteins may not be directly involved in the early aggregation stage. As predicted in the aggresome model, disruption of microtubules with nocodazole reduced the number of inclusions and increased the size of the protofibrils. Despite the increased size, the protofibrils remained non-fibrillar, suggesting that the deposition of the protofibrils in the juxtanuclear region is important in fibril formation. This study provides evidence that the cellular fibrillation also involves non-fibrillar intermediate species, and the microtubule-dependent inclusion-forming process is required for the protofibril-to-fibril conversion in cells.	Parkinsons Inst, Sunnyvale, CA 94089 USA		Lee, SJ (corresponding author), Parkinsons Inst, 1170 Morse Ave, Sunnyvale, CA 94089 USA.			Lee, Seung-Jae/0000-0002-5155-5335				Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bouley DM, 2001, INFECT IMMUN, V69, P7820, DOI 10.1128/IAI.69.12.7820-7831.2001; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Ding TT, 2002, BIOCHEMISTRY-US, V41, P10209, DOI 10.1021/bi020139h; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Gosavi N, 2002, J BIOL CHEM, V277, P48984, DOI 10.1074/jbc.M208194200; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lee HJ, 2002, J BIOL CHEM, V277, P5411, DOI 10.1074/jbc.M105326200; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Li J, 2001, BIOCHEMISTRY-US, V40, P11604, DOI 10.1021/bi010616g; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rajan RS, 2001, P NATL ACAD SCI USA, V98, P13060, DOI 10.1073/pnas.181479798; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2001, J BIOL CHEM, V276, P43495, DOI 10.1074/jbc.C100551200; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509	40	140	151	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48976	48983		10.1074/jbc.M208192200	http://dx.doi.org/10.1074/jbc.M208192200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12351642	hybrid			2022-12-27	WOS:000179789600130
J	Okada, T; Sonoda, E; Yamashita, YM; Koyoshi, S; Tateishi, S; Yamaizumi, M; Takata, M; Ogawa, O; Takeda, S				Okada, T; Sonoda, E; Yamashita, YM; Koyoshi, S; Tateishi, S; Yamaizumi, M; Takata, M; Ogawa, O; Takeda, S			Involvement of vertebrate Pol kappa in Rad18-independent postreplication repair of UV damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-KAPPA; ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; TRANSLESION SYNTHESIS; SACCHAROMYCES-CEREVISIAE; CHROMOSOMAL INTEGRITY; GENE ENCODES; RAD18 GENE; MUTAGENESIS; DINB1	DNA damage, which is left unrepaired by excision repair pathways, often blocks replication, leading to lesions such as breaks and gaps on the sister chromatids. These lesions may be processed by either homologous recombination (HR) repair or translesion DNA synthesis (TLS). Vertebrate Polkappa belongs to the DNA polymerase Y family, as do most TLS polymerases. However, the role for Polkappa in vertebrate cells is unclear because of the lack of reverse genetic studies. Here, we generated cells deficient in Polkappa (polkappa cells) from the chicken B lymphocyte line DT40. Although purified Polkappa is unable to bypass ultraviolet (UV) damage, polkappa cells exhibited increased UV sensitivity, and the phenotype was suppressed by expression of human and chicken polkappa, suggesting that Polkappa is involved in TLS of UV photoproduct. Defects in both Polkappa and Rad18, which regulates TLS in yeast, in DT40 showed an additive effect on UV sensitivity. Interestingly, the level of sister chromatid exchange, which reflects HR-mediated repair, was elevated in normally cycling polkappa cells. This implies functional redundancy between HR and Polkappa in maintaining chromosomal DNA. In conclusion, vertebrate Polkappa is involved in Rad18-independent TLS of UV damage and plays a role in maintaining genomic stability.	Kyoto Univ, Dept Radiat Genet, Sch Med, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto 6068507, Japan; Kumamoto Univ, Sch Med, Inst Mol Embryol & Genet, Kumamoto 8620976, Japan; Kawasaki Med Coll, Sch Med, Dept Immunol & Mol Genet, Kurashiki, Okayama 7010192, Japan	Kyoto University; Kyoto University; Kumamoto University; Kawasaki Medical School	Takeda, S (corresponding author), Kyoto Univ, Dept Radiat Genet, Sch Med, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	stakeda@rg.med.kyoto-u.ac.jp		Yamashita, Yukiko/0000-0001-5541-0216; Takeda, Shunichi/0000-0002-7924-7991; Takata, Minoru/0000-0002-4926-3675				BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Broomfield S, 2001, MUTAT RES-DNA REPAIR, V486, P167, DOI 10.1016/S0921-8777(01)00091-X; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Cejka P, 2001, GENETICS, V159, P953; Chiapperino D, 2002, J BIOL CHEM, V277, P11765, DOI 10.1074/jbc.M112139200; Cleaver JE, 1999, CANCER RES, V59, P1102; Cordonnier AM, 1999, MUTAT RES-DNA REPAIR, V435, P111, DOI 10.1016/S0921-8777(99)00047-6; Evans H J, 1977, Adv Hum Genet, V8, P347; FABRE F, 1989, MOL GEN GENET, V215, P425, DOI 10.1007/BF00427039; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P523; Fujimori A, 2001, EMBO J, V20, P5513, DOI 10.1093/emboj/20.19.5513; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Gerlach VL, 2001, J BIOL CHEM, V276, P92, DOI 10.1074/jbc.M004413200; Goodman MF, 2000, NAT REV MOL CELL BIO, V1, P101, DOI 10.1038/35040051; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Kulaeva OI, 1996, MUTAT RES-FUND MOL M, V357, P245, DOI 10.1016/0027-5107(96)00164-9; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; LAWRENCE CW, 1976, GENETICS, V82, P207; Levine RL, 2001, J BIOL CHEM, V276, P18717, DOI 10.1074/jbc.M102158200; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; O-Wang J, 2001, CANCER RES, V61, P5366; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; Ogi T, 2001, GENES CELLS, V6, P943, DOI 10.1046/j.1365-2443.2001.00478.x; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; OHMORI H, 1995, MUTAT RES LETT, V347, P1, DOI 10.1016/0165-7992(95)90024-1; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Sonoda E, 2001, DEV CELL, V1, P759, DOI 10.1016/S1534-5807(01)00088-0; Suzuki N, 2002, BIOCHEMISTRY-US, V41, P6100, DOI 10.1021/bi020049c; Suzuki N, 2001, BIOCHEMISTRY-US, V40, P15176, DOI 10.1021/bi010702g; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tateishi S, 2000, P NATL ACAD SCI USA, V97, P7927, DOI 10.1073/pnas.97.14.7927; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; van der Laan R, 2000, GENOMICS, V69, P86, DOI 10.1006/geno.2000.6220; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang ZG, 2001, MUTAT RES-DNA REPAIR, V486, P59, DOI 10.1016/S0921-8777(01)00089-1; Washington MT, 2002, P NATL ACAD SCI USA, V99, P1910, DOI 10.1073/pnas.032594399; Woodgate R, 2001, MUTAT RES-DNA REPAIR, V485, P83, DOI 10.1016/S0921-8777(00)00076-8; Xin H, 2000, NUCLEIC ACIDS RES, V28, P2847, DOI 10.1093/nar/28.14.2847; Yamashita YM, 2002, EMBO J, V21, P5558, DOI 10.1093/emboj/cdf534; Yuan FH, 2000, J BIOL CHEM, V275, P8233, DOI 10.1074/jbc.275.11.8233; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4147, DOI 10.1093/nar/28.21.4147	51	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48690	48695		10.1074/jbc.M207957200	http://dx.doi.org/10.1074/jbc.M207957200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12356753	Green Submitted, hybrid			2022-12-27	WOS:000179789600094
J	Pannequin, J; Barnham, KJ; Hollande, F; Shulkes, A; Norton, RS; Baldwin, GS				Pannequin, J; Barnham, KJ; Hollande, F; Shulkes, A; Norton, RS; Baldwin, GS			Ferric ions are essential for the biological activity of the hormone glycine-extended gastrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; INSULIN HEXAMER; GROWTH-FACTOR; METAL-IONS; CELL-LINE; RECEPTOR; CHOLECYSTOKININ; EXPRESSION; PROLIFERATION; PROGASTRIN	Amidated and nonamidated gastrins elicit different biological effects via distinct receptors in different tissues. Amidated gastrin 17 stimulates gastric acid secretion and the development of gastric carcinoids, whereas glycine-extended gastrin 17 stimulates proliferation of the colonic mucosa and the development of colorectal cancers. Because glycine-extended gastrin 17 binds two ferric ions with high affinity (Baldwin, G. S., Curtain, C. C., and Sawyer, W. H. (2001) Biochemistry 40, 1074110746), we have investigated the identity of the iron ligands and the role of ferric ions in biological activity. Here we report the solution structure of glycine-extended gastrin 17, determined by NMR spectroscopy. The spectral changes observed upon the addition of ferric ions revealed that Glu(7) acted as a ligand at the first ferric binding site, and that Glu(8) and Glu(9) acted as ligands at the second ferric ion binding site. Fluorescence quenching experiments confirmed that a GglyE7A mutant bound only one ferric ion. The inability of this mutant to stimulate proliferation or migration in the IMGE-5 cell line and the observation that the iron chelator desferrioxamine selectively blocked the effects of glycine-extended gastrin 17 indicated that binding of a ferric ion to Glu(7) was essential for biological activity. This is the first report of an essential role for a metal ion in the action of a hormone.	Univ Melbourne, Dept Surg, Heidelberg, Vic 3084, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia; Mental Hlth Res Inst, Parkville, Vic 3010, Australia; Fac Pharm Montpellier, EA MNRT 2995, Lab Signalisat Cellulaire & Tumorale, Montpellier, France; PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	University of Melbourne; University of Melbourne; Florey Institute of Neuroscience & Mental Health; Universite de Montpellier; Royal Melbourne Hospital; Walter & Eliza Hall Institute	Baldwin, GS (corresponding author), Univ Melbourne, Dept Surg, Austin Campus,A&RMC,Studley Rd, Heidelberg, Vic 3084, Australia.		Hollande, Frederic/E-3133-2013; Hollande, Frederic/GLS-4120-2022	Hollande, Frederic/0000-0002-7046-8392; Baldwin, Graham/0000-0002-0944-8747; pannequin, julie/0000-0002-9956-373X; Norton, Raymond/0000-0001-8893-0584				Aly A, 2001, INT J CANCER, V94, P307, DOI 10.1002/ijc.1483; BALDWIN GS, 1995, J GASTROEN HEPATOL, V10, P215, DOI 10.1111/j.1440-1746.1995.tb01083.x; Baldwin GS, 2001, BIOCHEMISTRY-US, V40, P10741, DOI 10.1021/bi010016h; Baldwin GS, 2001, J BIOL CHEM, V276, P7791, DOI 10.1074/jbc.M009985200; Barnham KJ, 1998, PROTEIN SCI, V7, P1738, DOI 10.1002/pro.5560070808; Barnham KJ, 1999, BBA-PROTEIN STRUCT M, V1435, P127, DOI 10.1016/S0167-4838(99)00214-9; De Hauwer C, 1998, J NEUROBIOL, V37, P373, DOI 10.1002/(SICI)1097-4695(19981115)37:3<373::AID-NEU3>3.0.CO;2-H; Dockray GJ, 1999, J PHYSIOL-LONDON, V518, P315, DOI 10.1111/j.1469-7793.1999.0315p.x; EMDIN SO, 1980, DIABETOLOGIA, V19, P174, DOI 10.1007/BF00275265; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Hollande F, 1997, GASTROENTEROLOGY, V113, P1576, DOI 10.1053/gast.1997.v113.pm9352860; Hollande F, 2001, AM J PHYSIOL-GASTR L, V280, pG910, DOI 10.1152/ajpgi.2001.280.5.G910; Hollande F, 2001, J BIOL CHEM, V276, P40402, DOI 10.1074/jbc.M105090200; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; ITO M, 1993, J BIOL CHEM, V268, P18300; Kadima W, 1999, BIOCHEMISTRY-US, V38, P13443, DOI 10.1021/bi9903188; KAISE M, 1995, J BIOL CHEM, V270, P11155, DOI 10.1074/jbc.270.19.11155; KARLIN KD, 1993, SCIENCE, V261, P701, DOI 10.1126/science.7688141; Kermorgant S, 2001, BIOCHEM BIOPH RES CO, V285, P136, DOI 10.1006/bbrc.2001.5132; Kicic A, 2001, CANCER, V92, P3093, DOI 10.1002/1097-0142(20011215)92:12<3093::AID-CNCR10107>3.0.CO;2-B; Koh TJ, 1999, J CLIN INVEST, V103, P1119, DOI 10.1172/JCI4910; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LONGANO SC, 1988, ARCH BIOCHEM BIOPHYS, V263, P410, DOI 10.1016/0003-9861(88)90653-4; MAMMI S, 1988, BIOCHEMISTRY-US, V27, P1374, DOI 10.1021/bi00404a043; Moore C, 1997, DNA SEQUENCE, V8, P39, DOI 10.3109/10425179709020883; Oiry C, 2000, EUR J PHARMACOL, V403, P17, DOI 10.1016/S0014-2999(00)00576-8; PALLAGHY PK, 1993, J MOL BIOL, V234, P405, DOI 10.1006/jmbi.1993.1595; PALUMBO M, 1980, FEBS LETT, V119, P158, DOI 10.1016/0014-5793(80)81020-9; PEGGION E, 1983, BIOPOLYMERS, V22, P2443, DOI 10.1002/bip.360221110; PEGGION E, 1984, BIOPOLYMERS, V23, P1225, DOI 10.1002/bip.360230707; Popescu VC, 2001, BIOCHEMISTRY-US, V40, P7984, DOI 10.1021/bi010198f; RahuelClermont S, 1997, BIOCHEMISTRY-US, V36, P5837, DOI 10.1021/bi963038q; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; SOLOFF MS, 1977, FED PROC, V36, P1861; TORDA AE, 1985, BIOCHEMISTRY-US, V24, P1720, DOI 10.1021/bi00328a023; TRACY HJ, 1964, NATURE, V204, P935, DOI 10.1038/204935a0; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; WILLIAMS JA, 1993, PHYSIOL REV, V73, P701, DOI 10.1152/physrev.1993.73.4.701; WINZOR DJ, 1995, QUANTITATIVE CHARACT, P28; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Wroblewski LE, 2002, BIOCHEM J, V365, P873, DOI 10.1042/BJ20020068	42	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48602	48609		10.1074/jbc.M208440200	http://dx.doi.org/10.1074/jbc.M208440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12270941	Green Published, hybrid			2022-12-27	WOS:000179789600083
J	Singer, AG; Ghomashchi, F; Le Calvez, C; Bollinger, J; Bezzine, S; Rouault, M; Sadilek, M; Nguyen, E; Lazdunski, M; Lambeau, G; Gelb, MH				Singer, AG; Ghomashchi, F; Le Calvez, C; Bollinger, J; Bezzine, S; Rouault, M; Sadilek, M; Nguyen, E; Lazdunski, M; Lambeau, G; Gelb, MH			Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; STRUCTURE-BASED DESIGN; ESCHERICHIA-COLI; VENOM PHOSPHOLIPASE-A2; RECOMBINANT EXPRESSION; COMPETITIVE INHIBITORS; MEMBRANE-BINDING; MAJOR PROTEIN; RAY STRUCTURE; CATALYSIS	Expression of the full set of human and mouse groups I, II, V, X, and XII secreted phospholipases A(2) (sPLA(2)s) in Escherichia coli and insect cells has provided pure recombinant enzymes for detailed comparative interfacial kinetic and binding studies. The set of mammalian sPLA2s display dramatically different sensitivity to dithiothreitol. The specific activity for the hydrolysis of vesicles of differing phospholipid composition by these enzymes varies by up to 4 orders of magnitude, and yet all enzymes display similar catalytic site specificity toward phospholipids with different polar head groups. Discrimination between sn-2 polyunsaturated versus saturated fatty acyl chains is <6-fold. These enzymes display apparent dissociation constants for activation by calcium in the 1-225 mu M range, depending on the phospholipid substrate. Analysis of the inhibition by a set of 12 active site-directed, competitive inhibitors reveals a large variation in the potency among the mammalian sPLA(2)s, with Me-Indoxam being the most generally potent sPLA(2) inhibitor. A dramatic correlation exists between the ability of the sPLA(2)s to hydrolyze phosphatidylcholine-rich vesicles efficiently in vitro and the ability to release arachidonic acid when added exogenously to mammalian cells; the group V and X sPLA(2)s are uniquely efficient in this regard.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lambeau, G (corresponding author), Univ Washington, Dept Chem & Biochem, Seattle, WA 98195 USA.	lambeau@ipme.cnrs.fr	Lambeau, Gerard/GRJ-5624-2022	Lambeau, Gerard/0000-0002-9239-518X; gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL36236] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANCIAN P, 1995, BIOCHEMISTRY-US, V34, P13146, DOI 10.1021/bi00040a028; [Anonymous], 1987, PHOSPHOLIPASES; Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; Beers SA, 2002, J BIOL CHEM, V277, P1788, DOI 10.1074/jbc.M109777200; Berg OG, 2001, CHEM REV, V101, P2613, DOI 10.1021/cr990139w; Berg OG, 2002, INTERFACIAL ENZYME K; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; BEZZINE S, 2002, J BIOL CHEM     0919, DOI DOI 10.1074/JBC9M2203137200; Bryant MD, 1999, BIOORG MED CHEM LETT, V9, P1097, DOI 10.1016/S0960-894X(99)00147-X; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; Chen YJ, 1998, BBA-LIPID LIPID MET, V1394, P57, DOI 10.1016/S0005-2760(98)00098-8; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DEGEUS P, 1987, NUCLEIC ACIDS RES, V15, P3743, DOI 10.1093/nar/15.9.3743; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; ELSBACH P, 1990, PROG CLIN BIOL RES, V349, P1; Enomoto A, 2000, J IMMUNOL, V165, P4007, DOI 10.4049/jimmunol.165.7.4007; Fenard D, 1999, J CLIN INVEST, V104, P611, DOI 10.1172/JCI6915; Gelb M H, 2000, Tanpakushitsu Kakusan Koso, V45, P1065; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P7318, DOI 10.1021/bi00243a037; GUTIERREZ JM, 1995, TOXICON, V33, P1405, DOI 10.1016/0041-0101(95)00085-Z; Han SK, 1998, BIOCHEM J, V331, P353, DOI 10.1042/bj3310353; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hanasaki K, 1999, ARCH BIOCHEM BIOPHYS, V372, P215, DOI 10.1006/abbi.1999.1511; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Hassani O, 1999, FEBS LETT, V443, P175, DOI 10.1016/S0014-5793(98)01710-4; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; Ho IC, 2001, J BIOL CHEM, V276, P18321, DOI 10.1074/jbc.M008837200; HOLLANDER T, 1993, CARBOHYD RES, V247, P291, DOI 10.1016/0008-6215(93)84261-4; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7330, DOI 10.1021/bi00243a038; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P10256, DOI 10.1021/bi00106a025; JAIN MK, 1987, BIOCHIM BIOPHYS ACTA, V905, P1, DOI 10.1016/0005-2736(87)90002-2; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; JAIN MK, 1995, PHYTOCHEMISTRY, V39, P537, DOI 10.1016/0031-9422(94)00960-2; KELLEY MJ, 1992, BIOCHIM BIOPHYS ACTA, V1118, P107, DOI 10.1016/0167-4838(92)90136-2; Kim KP, 2000, BIOCHEM J, V348, P643, DOI 10.1042/0264-6021:3480643; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; Koduri RS, 2002, J BIOL CHEM, V277, P5849, DOI 10.1074/jbc.M109699200; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LIN HK, 1993, J AM CHEM SOC, V115, P3932, DOI 10.1021/ja00063a012; Madsen LM, 1996, INFECT IMMUN, V64, P2425, DOI 10.1128/IAI.64.7.2425-2430.1996; MaoQiang M, 1996, J INVEST DERMATOL, V106, P57, DOI 10.1111/1523-1747.ep12327246; MARSHALL LA, 1995, J PHARMACOL EXP THER, V274, P1254; Mihelich ED, 1999, BBA-MOL CELL BIOL L, V1441, P223, DOI 10.1016/S1388-1981(99)00157-2; Murakami M, 2002, J BIOL CHEM, V277, P19145, DOI 10.1074/jbc.M112385200; Murakami M, 2002, BIOCHEM BIOPH RES CO, V292, P689, DOI 10.1006/bbrc.2002.6716; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; NOEL JP, 1989, J CELL BIOCHEM, V40, P309, DOI 10.1002/jcb.240400307; Ownby CL, 1999, TOXICON, V37, P411, DOI 10.1016/S0041-0101(98)00188-3; Pan YH, 2002, J BIOL CHEM, V277, P29086, DOI 10.1074/jbc.M202531200; POTE KG, 1993, BIOCHEMISTRY-US, V32, P5017, DOI 10.1021/bi00070a007; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; Richmond BL, 2001, GASTROENTEROLOGY, V120, P1193, DOI 10.1053/gast.2001.23254; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Schadow A, 2001, J INVEST DERMATOL, V116, P31, DOI 10.1046/j.1523-1747.2001.00179.x; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Snitko Y, 1999, BIOCHEMISTRY-US, V38, P7803, DOI 10.1021/bi990600e; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Suzuki N, 2000, J BIOL CHEM, V275, P5785, DOI 10.1074/jbc.275.8.5785; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 2000, BIOCHEM BIOPH RES CO, V279, P223, DOI 10.1006/bbrc.2000.3908; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; Verpy E, 1999, P NATL ACAD SCI USA, V96, P529, DOI 10.1073/pnas.96.2.529; VUILLARD L, 1995, ELECTROPHORESIS, V16, P295, DOI 10.1002/elps.1150160148; Wang YX, 1998, P NATL ACAD SCI USA, V95, P15345, DOI 10.1073/pnas.95.26.15345; YU BZ, 1993, BIOCHEMISTRY-US, V32, P6485, DOI 10.1021/bi00076a024	83	291	297	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48535	48549		10.1074/jbc.M205855200	http://dx.doi.org/10.1074/jbc.M205855200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12359733	hybrid			2022-12-27	WOS:000179789600075
J	Pan, Y; Cohen, I; Guillerault, F; Feve, B; Girard, J; Prip-Buus, C				Pan, Y; Cohen, I; Guillerault, F; Feve, B; Girard, J; Prip-Buus, C			The extreme C terminus of rat liver carnitine palmitoyltransferase I is not involved in malonyl-CoA sensitivity but in initial protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; INHIBITORY BINDING-SITES; FATTY-ACID OXIDATION; CATALYTIC ACTIVITY; SINGLE POLYPEPTIDE; CHIMERIC PROTEINS; HIGH-AFFINITY; CPT I; RESIDUES; EXPRESSION	We previously reported that the N-terminal domain (1-147 residues) of rat liver carnitine palmitoyltransferase I (L-CPTI) was essential for import into the outer mitochondrial membrane and for maintenance of a malonyl-CoA-sensitive conformation. Malonyl-CoA binding experiments using mitochondria of Saccharomyces cerevisiae strains expressing wild-type L-CPTI or previously constructed chimeric CPTs (Cohen, I., Kohl, C., McGarry, J.D., Girard, J., and Prip-Buus, C. (1998) J. Biol. Chem. 273, 29896-29904) indicated that the N-terminal domain was unable, independently of the C-terminal domain, to bind malonyl-CoA with a high affinity, suggesting that the modulation of malonyl-CoA sensitivity occurred through N/C intramolecular interactions. To assess the role of the C terminus in malonyl-CoA sensitivity, a series of C-terminal deletion mutants was generated. The kinetic properties of Delta772-773 and Delta767-773 deletion mutants were similar to those of L-CPTI, indicating that the last two highly conserved Lys residues in all known L-CPTI species were not functionally essential. By contrast, Delta743-773 deletion mutant was totally inactive and unfolded, as shown by its sensitivity to trypsin proteolysis. Because the C terminus of the native folded L-CPTI could be cleaved by trypsin without inducing protein unfolding, we concluded that the last 31 C-terminal residues constitute a secondary structural determinant essential for the initial protein folding of L-CPTI.	Univ Paris 05, Dept Endocrinol, INSERM, Cochin Inst,U567,CNRSUMR 8104, F-75014 Paris, France; CNRS, Enseignement Super Associec, UPR 7079, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	Prip-Buus, C (corresponding author), Univ Paris 05, Dept Endocrinol, INSERM, Cochin Inst,U567,CNRSUMR 8104, 24 Rue Faubourg St Jacques, F-75014 Paris, France.		PRIP-BUUS, Carina/P-9084-2017	Feve, Bruno/0000-0001-6577-9009; Prip-Buus, Carina/0000-0002-2153-7857				Anderson RC, 1998, CURR PHARM DESIGN, V4, P1; Battiste JL, 2002, BIOCHEMISTRY-US, V41, P2237, DOI 10.1021/bi011693e; Bergman RN, 2000, TRENDS ENDOCRIN MET, V11, P351, DOI 10.1016/S1043-2760(00)00323-4; BIRD MI, 1984, BIOCHEM J, V222, P639, DOI 10.1042/bj2220639; BROWN NF, 1994, J BIOL CHEM, V269, P26438; Cohen I, 1998, J BIOL CHEM, V273, P29896, DOI 10.1074/jbc.273.45.29896; Cohen I, 2001, J BIOL CHEM, V276, P5403, DOI 10.1074/jbc.M009555200; COOK GA, 1994, J BIOL CHEM, V269, P8803; Dai J, 2000, J BIOL CHEM, V275, P22020, DOI 10.1074/jbc.M002118200; ESSER V, 1993, J BIOL CHEM, V268, P5817; Fraser F, 1997, BIOCHEM J, V323, P711, DOI 10.1042/bj3230711; Fukao T, 2002, MOL GENET METAB, V75, P235, DOI 10.1006/mgme.2001.3288; Garcia C, 2000, BIOCHEMISTRY-US, V39, P11227, DOI 10.1021/bi0010266; HOROVITZ A, 1992, J MOL BIOL, V224, P733, DOI 10.1016/0022-2836(92)90557-Z; Jackson VN, 2000, J BIOL CHEM, V275, P38410, DOI 10.1074/jbc.M007722200; Jackson VN, 2000, J BIOL CHEM, V275, P19560, DOI 10.1074/jbc.M002177200; Jackson VN, 2001, BIOCHEMISTRY-US, V40, P14629, DOI 10.1021/bi011632g; KASHFI K, 1994, BBA-LIPID LIPID MET, V1212, P245, DOI 10.1016/0005-2760(94)90259-3; Kursula I, 2002, FEBS LETT, V518, P39, DOI 10.1016/S0014-5793(02)02639-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JM, 1992, SCIENCE, V256, P1815, DOI 10.1126/science.1615327; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; MCGARRY JD, 1994, J CELL BIOCHEM, V55, P29, DOI 10.1002/jcb.240550005; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MILLS SE, 1983, BIOCHEM J, V214, P83, DOI 10.1042/bj2140083; Morillas M, 2002, J BIOL CHEM, V277, P11473, DOI 10.1074/jbc.M111628200; Morillas M, 2001, J BIOL CHEM, V276, P45001, DOI 10.1074/jbc.M106920200; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Prip-Buus C, 1998, FEBS LETT, V429, P173, DOI 10.1016/S0014-5793(98)00584-5; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Shi JY, 2000, BIOCHEMISTRY-US, V39, P712, DOI 10.1021/bi9918700; Shi JY, 1999, J BIOL CHEM, V274, P9421, DOI 10.1074/jbc.274.14.9421; Shi JY, 1998, BIOCHEMISTRY-US, V37, P11033, DOI 10.1021/bi9803426; Swanson ST, 1998, BIOCHEM J, V335, P513, DOI 10.1042/bj3350513; Unger RH, 2001, FASEB J, V15, P312, DOI 10.1096/fj.00-0590; ZAMMIT VA, 1984, BIOCHEM J, V222, P335, DOI 10.1042/bj2220335; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505	39	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47184	47189		10.1074/jbc.M208055200	http://dx.doi.org/10.1074/jbc.M208055200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351641	hybrid			2022-12-27	WOS:000179663700045
J	Pasta, SY; Raman, B; Ramakrishna, T; Rao, CM				Pasta, SY; Raman, B; Ramakrishna, T; Rao, CM			Role of the C-terminal extensions of alpha-crystallins - Swapping the C-terminal extension of alpha A-crystallin to alpha B-crystallin results in enhanced chaperone activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; MOLTEN-GLOBULE STATE; DESMIN-RELATED MYOPATHY; MOLECULAR CHAPERONE; QUATERNARY STRUCTURE; MISSENSE MUTATION; THERMAL-STRESS; LENS; DOMAIN; IDENTIFICATION	Several small heat shock proteins contain a well conserved a-crystallin domain, flanked by an N-terminal domain and a C-terminal extension, both of which vary in length and sequence. The structural and functional role of the C-terminal extension of small heat shock proteins, particularly of alphaA- and alphaB-crystallins, is not well understood. We have swapped the C-terminal extensions between alphaA- and alphaB-crystallins and generated two novel chimeric proteins, alphaABc and alphaBAc. We have investigated the domain-swapped chimeras for structural and functional alterations. We have used thermal and non-thermal models of protein aggregation and found that the chimeric alphaB with the C-terminal extension of alphaA-crystallin, alphaBAc, exhibits dramatically enhanced chaperone-like activity. Interestingly, however, the chimeric alphaA with the C-terminal extension of alphaB-crystallin, alphaABc, has almost lost its activity. Pyrene solubilization and bis-1-anilino-8-naphthalenesulfonate binding studies show that alphaBAc exhibits more solvent-exposed hydrophobic pockets than alphaA, alphaB, or alphaABc. Significant tertiary structural changes are revealed by tryptophan fluorescence and near-UV CD studies upon swapping the C-terminal extensions. The far-UV CD spectrum of alphaBAc differs from that of alphaB-crystallin whereas that of alphaABc overlaps with that of alphaA-crystallin. Gel filtration chromatography shows alteration in the size of the proteins upon swapping the C-terminal extensions. Our study demonstrates that the unstructured C-terminal extensions play a crucial role in the structure and chaperone activity, in addition to generally believed electrostatic "solubilizer" function.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Rao, CM (corresponding author), Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.							Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; Andley UP, 2002, J BIOL CHEM, V277, P10178, DOI 10.1074/jbc.M109211200; Berengian AR, 1997, BIOCHEMISTRY-US, V36, P9951, DOI 10.1021/bi9712347; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BHAT SP, 1991, EUR J BIOCHEM, V202, P775, DOI 10.1111/j.1432-1033.1991.tb16432.x; Bloemendal H, 1981, MOL CELLULAR BIOL EY, P1; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; CARVER JA, 1992, FEBS LETT, V311, P143, DOI 10.1016/0014-5793(92)81386-Z; Carver JA, 1998, INT J BIOL MACROMOL, V22, P197, DOI 10.1016/S0141-8130(98)00017-8; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; Clark JI, 2000, CURR OPIN STRUC BIOL, V10, P52, DOI 10.1016/S0959-440X(99)00048-2; Das BK, 1997, BIOCHEM BIOPH RES CO, V236, P370, DOI 10.1006/bbrc.1997.6950; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; Datta SA, 1999, J BIOL CHEM, V274, P34773, DOI 10.1074/jbc.274.49.34773; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Derham BK, 1999, PROG RETIN EYE RES, V18, P463, DOI 10.1016/S1350-9462(98)00030-5; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Feil IK, 2001, J BIOL CHEM, V276, P12024, DOI 10.1074/jbc.M010856200; Fernando P, 2000, CELL STRESS CHAPERON, V5, P148, DOI 10.1379/1466-1268(2000)005<0148:FCOXSH>2.0.CO;2; Goenka S, 2001, BIOCHEM J, V359, P547, DOI 10.1042/0264-6021:3590547; Hess J F, 1998, Mol Vis, V4, P29; Hook DWA, 1997, EUR J BIOCHEM, V247, P380, DOI 10.1111/j.1432-1033.1997.00380.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; Kumar LVS, 2000, J BIOL CHEM, V275, P22009, DOI 10.1074/jbc.M003307200; Kumar LVS, 1999, J BIOL CHEM, V274, P24137, DOI 10.1074/jbc.274.34.24137; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; LI LK, 1973, EXP EYE RES, V15, P179, DOI 10.1016/0014-4835(73)90117-6; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; Marini I, 2000, J BIOL CHEM, V275, P32559, DOI 10.1074/jbc.M006133200; Martin JL, 1997, CIRCULATION, V96, P4343; Mornon JP, 1998, INT J BIOL MACROMOL, V22, P219, DOI 10.1016/S0141-8130(98)00019-1; Muchowski PJ, 1998, P NATL ACAD SCI USA, V95, P1004, DOI 10.1073/pnas.95.3.1004; Muchowski PJ, 1997, J BIOL CHEM, V272, P2578; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; QUAXJEUKEN Y, 1985, P NATL ACAD SCI USA, V82, P5819, DOI 10.1073/pnas.82.17.5819; Rajaraman K, 1996, J BIOL CHEM, V271, P27595, DOI 10.1074/jbc.271.44.27595; Rajaraman K, 1998, BIOCHEM BIOPH RES CO, V249, P917, DOI 10.1006/bbrc.1998.9242; Rajaraman K, 2001, FEBS LETT, V497, P118, DOI 10.1016/S0014-5793(01)02451-6; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; Rao CM, 1998, INT J BIOL MACROMOL, V22, P271; RAO PV, 1991, ARCH BIOCHEM BIOPHYS, V284, P181, DOI 10.1016/0003-9861(91)90281-M; Rawat U, 1998, J BIOL CHEM, V273, P9415, DOI 10.1074/jbc.273.16.9415; Reddy GB, 2000, J BIOL CHEM, V275, P4565, DOI 10.1074/jbc.275.7.4565; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; Sharma KK, 1998, J BIOL CHEM, V273, P15474, DOI 10.1074/jbc.273.25.15474; Sharma KK, 2000, J BIOL CHEM, V275, P3767, DOI 10.1074/jbc.275.6.3767; Sharma KK, 1997, BIOCHEM BIOPH RES CO, V239, P217, DOI 10.1006/bbrc.1997.7460; Smith JB, 1996, EXP EYE RES, V63, P125, DOI 10.1006/exer.1996.0100; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; Studer S, 2002, EUR J BIOCHEM, V269, P3578, DOI 10.1046/j.1432-1033.2002.03049.x; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; van Rijk AF, 2000, FEBS LETT, V480, P79, DOI 10.1016/S0014-5793(00)01908-6; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wang KY, 2000, EUR J BIOCHEM, V267, P4705, DOI 10.1046/j.1432-1327.2000.01521.x	66	45	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45821	45828		10.1074/jbc.M206499200	http://dx.doi.org/10.1074/jbc.M206499200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235146	hybrid			2022-12-27	WOS:000179529300015
J	Piluso, D; Bilan, P; Capone, JP				Piluso, D; Bilan, P; Capone, JP			Host cell factor-1 interacts with and antagonizes transactivation by the cell cycle regulatory factor Miz-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS VP16-INDUCED COMPLEX; PROTEIN INTERACTION MOTIF; COACTIVATOR C1 HCF; TRANSCRIPTIONAL ACTIVATION; GENE-REGULATION; DNA-BINDING; POZ DOMAIN; VP16; ASSOCIATION; FAMILY	Human host cell factor-1 (HCF-1) is essential for cell cycle progression and is required, in conjunction with the herpes simplex virus transactivator VP16, for induction of viral immediate-early gene expression. We show here that HCF-1 directly binds to the Myc-interacting protein Miz-1, a transcription factor that induces cell cycle arrest at G(1), in part by directly stimulating expression of the cyclin-dependent kinase inhibitor p15(INK4b). A domain encompassing amino acids 750-836, contained within a subregion of HCF-1 required for cell cycle progression, was sufficient to bind Miz-1. Conversely, HCF-1 interacted with two separate regions in Miz-1: the N-terminal POZ domain and a C-terminal domain (residues 637-803) previously shown to harbor determinants for interaction with c-Myc and the coactivator p300. The latter functioned as a potent transactivation domain when tethered to DNA, indicating that HCF-1 targets a transactivation function in Miz-1. HCF-1 or a Miz-1-binding fragment of HCF-1 repressed transactivation by Gal4-Miz-1 in transfection assays. Moreover, HCF-1 repressed Miz-1-mediated transactivation of a reporter gene linked to the p15(INK4b) promoter. Protein/protein interaction studies and transient transfection assays demonstrated that HCF-1 interferes with recruitment of p300 to Miz-1, similar to what has been reported with c-Myc. Our findings identify Miz-1 as a novel HCF-1-interacting partner and illustrate cross-talk between these two proteins that may be of consequence to their respective functions in gene regulation and their opposing effects on the cell cycle.	McMaster Univ, Fac Hlth Sci, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	McMaster University	Capone, JP (corresponding author), McMaster Univ, Fac Hlth Sci, Dept Biochem, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.							Ajuh PM, 2000, NUCLEIC ACIDS RES, V28, P678, DOI 10.1093/nar/28.3.678; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Amati B, 2001, NAT CELL BIOL, V3, pE112, DOI 10.1038/35074634; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bai C, 1997, METHOD ENZYMOL, V283, P141; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; Gunther M, 2000, MOL CELL BIOCHEM, V210, P131, DOI 10.1023/A:1007177623283; Herr W, 1998, COLD SPRING HARB SYM, V63, P599, DOI 10.1101/sqb.1998.63.599; Hughes TA, 1999, J BIOL CHEM, V274, P16437, DOI 10.1074/jbc.274.23.16437; Johnson KM, 1999, J VIROL, V73, P3930, DOI 10.1128/JVI.73.5.3930-3940.1999; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; Kristie TM, 1997, J BIOL CHEM, V272, P26749, DOI 10.1074/jbc.272.42.26749; KRISTIE TM, 1995, J BIOL CHEM, V270, P4387, DOI 10.1074/jbc.270.9.4387; La Boissiere S, 1999, EMBO J, V18, P480; Lee S, 2001, J VIROL, V75, P12402, DOI 10.1128/JVI.75.24.12402-12411.2001; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; LIU Y, 1999, J VIROL, V74, P99; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Lu R, 2000, NUCLEIC ACIDS RES, V28, P2446, DOI 10.1093/nar/28.12.2446; Lu R, 1998, J VIROL, V72, P6291, DOI 10.1128/JVI.72.8.6291-6297.1998; Luciano RL, 2000, P NATL ACAD SCI USA, V97, P10757, DOI 10.1073/pnas.190062797; Mahajan SS, 2000, MOL CELL BIOL, V20, P919, DOI 10.1128/MCB.20.3.919-928.2000; Meertens LM, 1998, EMBO J, V17, P6972, DOI 10.1093/emboj/17.23.6972; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; POPOVA B, 1995, VIROLOGY, V209, P19, DOI 10.1006/viro.1995.1227; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Scarr RB, 2000, MOL CELL BIOL, V20, P3568, DOI 10.1128/MCB.20.10.3568-3575.2000; Schneider A, 1997, CURR TOP MICROBIOL, V224, P137; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Vogel JL, 2000, P NATL ACAD SCI USA, V97, P9425, DOI 10.1073/pnas.160266697; Vogel JL, 2000, EMBO J, V19, P683, DOI 10.1093/emboj/19.4.683; Wilson AC, 2000, MOL CELL BIOL, V20, P6721, DOI 10.1128/MCB.20.18.6721-6730.2000; WILSON AC, 1993, COLD SPRING HARB SYM, V58, P167, DOI 10.1101/SQB.1993.058.01.021; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001; Zhou HJ, 2001, J BIOL CHEM, V276, P28933, DOI 10.1074/jbc.M103893200; Ziegelbauer J, 2001, MOL CELL, V8, P339, DOI 10.1016/S1097-2765(01)00313-6	46	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46799	46808		10.1074/jbc.M206226200	http://dx.doi.org/10.1074/jbc.M206226200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244100				2022-12-27	WOS:000179529300141
J	Tosetti, P; Turner, T; Lu, QA; Dunlap, K				Tosetti, P; Turner, T; Lu, QA; Dunlap, K			Unique isoform of G alpha-interacting protein (RGS-GAIP) selectively discriminates between two G(o)-mediated pathways that inhibit Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; HETEROTRIMERIC G-PROTEINS; SUBCELLULAR-LOCALIZATION; MEDIATED INHIBITION; DYNAMIC REGULATION; SIGNALING RGS; BETA-GAMMA; RECEPTOR; KINASE; K+	Regulators of G-protein signaling (RGS) proteins constitute a large family of GTPase-activating proteins for heterotrimeric G proteins. More than 20 RIGS genes have been identified in mammals. One of these, the Galpha-interacting protein (GAIP), preferentially interacts with members of the G(i)/G(o) subfamily of G proteins in mammalian cells, but its selectivity among members of this subfamily in vitro is limited. Here we report the cloning and functional characterization of a unique cDNA isoform of GAIP, derived from embryonic chicken dorsal root ganglion neurons. Chick GAIP is composed of 199 amino acids, organized into a conserved RGS domain (85% identical to human GAIP), and a unique, short N terminus (only 41% identical, 50% homologrous to known mammalian orthologues). Consistent with this unique primary structure, chick GAIP has physiological properties that distinguish it from mammalian GAIPs. We have explored the selectivity of chick GAIP in electro-physiologicalassays of two G(o)-mediated forms of Ca2+ channel inhibition produced by gamma-aminobutyric acid in chick dorsal root ganglion neurons, voltage-independent inhibition (mediated by G(o)alpha) and voltage-dependent inhibition (mediated by G(o)P(gamma)). Dialyzing recombinant chick GAIP in these cells selectively reduced voltage-independent inhibition without affecting voltage-dependent inhibition. Mammalian GAIP, tested under identical conditions in previous studies, demonstrated no selectivity between these two inhibitory processes; thus, our results suggest that the functional specificity of chick GAIP is likely to be determined by its unique N terminus.	Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA	Tufts University; Tufts Medical Center	Dunlap, K (corresponding author), Tufts Univ, Sch Med, Dept Neurosci, 136 Harrison Ave, Boston, MA 02111 USA.	kathleen.dunlap@tufts.edu		Turner, Timothy/0000-0001-9770-2647	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016483] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16483] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENVENISTE M, 1990, J PHYSIOL-LONDON, V428, P333, DOI 10.1113/jphysiol.1990.sp018215; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; BLUM S, 1990, DNA CELL BIOL, V9, P589, DOI 10.1089/dna.1990.9.589; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Diverse-Pierluissi M, 2000, J BIOL CHEM, V275, P28380, DOI 10.1074/jbc.M003571200; Diverse-Pierluissi MA, 1999, J BIOL CHEM, V274, P14490, DOI 10.1074/jbc.274.20.14490; DiversePierluissi M, 1996, NEURON, V16, P579, DOI 10.1016/S0896-6273(00)80077-X; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DiversePierluissi M, 1997, P NATL ACAD SCI USA, V94, P5417, DOI 10.1073/pnas.94.10.5417; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; DUNLAP K, 1981, BRIT J PHARMACOL, V74, P579, DOI 10.1111/j.1476-5381.1981.tb10467.x; Fischer T, 2000, P NATL ACAD SCI USA, V97, P4040, DOI 10.1073/pnas.97.8.4040; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; Fujita S, 2000, J PHYSIOL-LONDON, V526, P341, DOI 10.1111/j.1469-7793.2000.00341.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harder S, 2001, ENDOCRINOLOGY, V142, P1188, DOI 10.1210/en.142.3.1188; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Jeong SW, 2000, J NEUROSCI, V20, P4489, DOI 10.1523/JNEUROSCI.20-12-04489.2000; Jeong SW, 2001, J PHYSIOL-LONDON, V535, P335, DOI 10.1111/j.1469-7793.2001.00335.x; Kammermeier PJ, 1999, NEURON, V22, P819, DOI 10.1016/S0896-6273(00)80740-0; Keir MJ, 1999, MOL BRAIN RES, V71, P279, DOI 10.1016/S0169-328X(99)00199-0; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lu Q, 2001, J NEUROSCI, V21, P2949, DOI 10.1523/JNEUROSCI.21-09-02949.2001; Lu Q, 1999, J BIOL CHEM, V274, P34566, DOI 10.1074/jbc.274.49.34566; LUEBKE JI, 1994, PFLUG ARCH EUR J PHY, V428, P499, DOI 10.1007/BF00374571; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Melliti K, 2001, J PHYSIOL-LONDON, V532, P337, DOI 10.1111/j.1469-7793.2001.0337f.x; Melliti K, 1999, J GEN PHYSIOL, V113, P97, DOI 10.1085/jgp.113.1.97; Melliti K, 2000, J NEUROSCI, V20, P7167; Miles RR, 2000, ENDOCRINOLOGY, V141, P28, DOI 10.1210/en.141.1.28; Muller RT, 1997, MOL BIOL CELL, V8, P2039, DOI 10.1091/mbc.8.10.2039; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; OgierDenis E, 1997, J BIOL CHEM, V272, P24599, DOI 10.1074/jbc.272.39.24599; Park D, 1998, J NEUROSCI, V18, P6757; Reif K, 2000, J IMMUNOL, V164, P4720, DOI 10.4049/jimmunol.164.9.4720; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Saitoh O, 2001, J BIOL CHEM, V276, P5052, DOI 10.1074/jbc.M006917200; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Schiff ML, 2000, NATURE, V408, P723, DOI 10.1038/35047093; Shea LD, 2000, LIFE SCI, V68, P647, DOI 10.1016/S0024-3205(00)00977-2; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TOSETTI P, 1999, SOC NEUR ABSTR, V25; TURNER TJ, 1989, ANAL BIOCHEM, V178, P8, DOI 10.1016/0003-2697(89)90347-3; Woulfe DS, 1999, J BIOL CHEM, V274, P17718, DOI 10.1074/jbc.274.25.17718; Wylie F, 1999, AM J PHYSIOL-CELL PH, V276, pC497, DOI 10.1152/ajpcell.1999.276.2.C497; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zheng B, 1999, TRENDS BIOCHEM SCI, V24, P411, DOI 10.1016/S0968-0004(99)01474-7	63	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46001	46009		10.1074/jbc.M207874200	http://dx.doi.org/10.1074/jbc.M207874200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270936	hybrid			2022-12-27	WOS:000179529300040
J	van Rossenberg, SMW; Sliedregt-Bol, KM; Meeuwenoord, NJ; van Berkel, TJC; van Boom, JH; van der Marel, GA; Biessen, EAL				van Rossenberg, SMW; Sliedregt-Bol, KM; Meeuwenoord, NJ; van Berkel, TJC; van Boom, JH; van der Marel, GA; Biessen, EAL			Targeted lysosome disruptive elements for improvement of parenchymal liver cell-specific gene delivery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-INDUCED FUSION; ASIALOGLYCOPROTEIN RECEPTOR; MEMBRANE-FUSION; IN-VITRO; INTRACELLULAR DELIVERY; FUSOGENIC PEPTIDE; MAMMALIAN-CELLS; DNA COMPLEXES; EXPRESSION; HEPATOCYTES	The transfection ability of nonviral gene therapy vehicles is generally hampered by untimely lysosomal degradation of internalized DNA. In this study we describe the development of a targeted lysosome disruptive element to facilitate the escape of DNA from the lysosomal compartment, thus enhancing the transfection efficacy, in a cell-specific fashion. Two peptides (INF7 and JTS-1) were tested for their capacity to disrupt liposomes. In contrast to JTS-1, INF7 induced rapid cholesterol-independent leakage (EC50, 1.3 mum). INF7 was therefore selected for coupling to a high affinity ligand for the asialoglycoprotein receptor (ASGPr), K(GalNAc)(2) to improve its uptake by parenchymal liver cells. Although the parent peptide disrupted both cholesterol-rich and -poor liposomes, the conjugate, INF7-K(GalNAc)(2) only induced leakage of cholesterol-poor liposomes. Given that endosomal membranes of eukaryotic cells contain <5% cholesterol, this implies that the conjugate will display a higher selectivity toward endosomal membranes. Although both INF7 and INF7-K(GalNAc)(2) were found to increase the transfection efficiency on polyplex-mediated gene transfer to parenchymal liver cells by 30-fold, only INF7-K(GaINAc)(2) appeared to do so in an ASGPr-specific manner. In mice, INF7-K(GaINAc)(2) was specifically targeted to the liver, whereas INF7 was distributed evenly over various organs. In summary, we have prepared a nontoxic cell-specific lysosome disruptive element that improves gene delivery to parenchymal liver cells via the ASGPr. Its high cell specificity and preference to lyse intracellular membranes make this conjugate a promising lead in hepatocyte-specific drug/gene delivery protocols.	Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, Gorlaeus Labs, NL-2300 RA Leiden, Netherlands; Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC	van Rossenberg, SMW (corresponding author), Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, Gorlaeus Labs, PO Box 9502, NL-2300 RA Leiden, Netherlands.	rossenbe@lacdr.leidenuniv.nl	Van Berkel, Theo/ABD-7677-2021					Akhtar S, 2000, ADV DRUG DELIVER REV, V44, P3, DOI 10.1016/S0169-409X(00)00080-6; ALBERTS B, 1983, MOL BIOL CELL, P260; ARAR K, 1995, BIOCONJUGATE CHEM, V6, P573, DOI 10.1021/bc00035a011; Beck NB, 2000, GENE THER, V7, P1274, DOI 10.1038/sj.gt.3301246; Biessen EAL, 1999, BIOCHEM J, V340, P783, DOI 10.1042/0264-6021:3400783; Biessen EAL, 2002, BIOCONJUGATE CHEM, V13, P295, DOI 10.1021/bc015550g; Chowdhury NR, 1996, J BIOL CHEM, V271, P2341, DOI 10.1074/jbc.271.4.2341; COTTEN M, 1993, METHOD ENZYMOL, V217, P618; Decout A, 1998, BBA-BIOMEMBRANES, V1372, P102, DOI 10.1016/S0005-2736(98)00050-9; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Gottschalk S, 1996, GENE THER, V3, P448; Huang H, 1999, J PEPT RES, V53, P548, DOI 10.1034/j.1399-3011.1999.00059.x; Kickler A, 1997, BIOCONJUGATE CHEM, V8, P213, DOI 10.1021/bc970009z; Kobayashi T, 2001, SEMIN CELL DEV BIOL, V12, P173, DOI 10.1006/scdb.2000.0234; Lim DW, 2000, BIOCONJUGATE CHEM, V11, P688, DOI 10.1021/bc000014u; Martin I, 1999, BIOCHEMISTRY-US, V38, P9337, DOI 10.1021/bi9829534; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; McKenzie DL, 1999, J PEPT RES, V54, P311, DOI 10.1034/j.1399-3011.1999.00104.x; Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730; Niidome T, 2000, BIOMATERIALS, V21, P1811, DOI 10.1016/S0142-9612(00)00076-4; Nishikawa M, 2000, GENE THER, V7, P548, DOI 10.1038/sj.gt.3301140; PARENTE RA, 1990, BIOCHEMISTRY-US, V29, P8720, DOI 10.1021/bi00489a031; Pecheur EI, 2000, J BIOL CHEM, V275, P3936, DOI 10.1074/jbc.275.6.3936; Pecheur EI, 1999, J MEMBRANE BIOL, V167, P1, DOI 10.1007/s002329900466; Pecheur EI, 1999, BIOCHEMISTRY-US, V38, P364, DOI 10.1021/bi981389u; Pecheur EI, 1998, BIOCHEMISTRY-US, V37, P2361, DOI 10.1021/bi972697f; PLANK C, 1994, J BIOL CHEM, V269, P12918; Plourde R, 1996, BIOCONJUGATE CHEM, V7, P131, DOI 10.1021/bc950083m; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; Rensen PCN, 1997, MOL PHARMACOL, V52, P445, DOI 10.1124/mol.52.3.445; Rensen PCN, 2001, J BIOL CHEM, V276, P37577, DOI 10.1074/jbc.M101786200; Schoen P, 1999, GENE THER, V6, P823, DOI 10.1038/sj.gt.3300919; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Simoes S, 1999, GENE THER, V6, P1798, DOI 10.1038/sj.gt.3301015; Sliedregt LAJM, 1999, J MED CHEM, V42, P609, DOI 10.1021/jm981078h; Smith LC, 1998, ADV DRUG DELIVER REV, V30, P115, DOI 10.1016/S0169-409X(97)00111-7; Sugano M, 1996, J BIOL CHEM, V271, P19080, DOI 10.1074/jbc.271.32.19080; Terpstra V, 2000, ARTERIOSCL THROM VAS, V20, P1860, DOI 10.1161/01.ATV.20.8.1860; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Valentijn ARPM, 1997, TETRAHEDRON, V53, P759, DOI 10.1016/S0040-4020(96)01018-6; VAYSSE L, 2000, BIOCHIM BIOPHYS ACTA, V26, P369; Wadhwa MS, 1997, BIOCONJUGATE CHEM, V8, P81, DOI 10.1021/bc960079q; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934; WATABE A, 1999, BIOCH BIOPHYS ACTA B, V12, P1; Wolfert MA, 1998, GENE THER, V5, P409, DOI 10.1038/sj.gt.3300606; Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474; Zang Y, 2001, CELL DEATH DIFFER, V8, P477, DOI 10.1038/sj.cdd.4400843; Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91; Zhang X, 2001, BIOORG MED CHEM LETT, V11, P1269, DOI 10.1016/S0960-894X(01)00198-6	49	31	36	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45803	45810		10.1074/jbc.M203510200	http://dx.doi.org/10.1074/jbc.M203510200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237290	Green Published, hybrid			2022-12-27	WOS:000179529300013
J	Zhao, B; Bower, MJ; McDevitt, PJ; Zhao, HZ; Davis, ST; Johanson, KO; Green, SM; Concha, NO; Zhou, BBS				Zhao, B; Bower, MJ; McDevitt, PJ; Zhao, HZ; Davis, ST; Johanson, KO; Green, SM; Concha, NO; Zhou, BBS			Structural basis for Chk1 inhibition by UCN-01	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHECKPOINT KINASE CHK1; PROTEIN-KINASE; 7-HYDROXYSTAUROSPORINE UCN-01; CRYSTAL-STRUCTURE; CYTOTOXICITY	Chk1 is a serine-threonine kinase that plays an important role in the DNA damage response, including G(2)/M cell cycle control. UCN-01 (7-hydroxystaurosporine), currently in clinical trials, has recently been shown to be a potent Chk1 inhibitor that abrogates the G(2)/M checkpoint induced by DNA-damaging agents. To understand the structural basis of Chk1 inhibition by UCN-01, we determined the crystal structure of the Chk1 kinase domain in complex with UCN-01. Chk1 structures with staurosporine and its analog SB-218078 were also determined. All three compounds bind in the ATP-binding pocket of Chk1, producing only slight changes in the protein conformation. Selectivity of UCN-01 toward Chk1 over cyclin-dependent kinases can be explained by the presence of a hydroxyl group in the lactam moiety interacting with the ATP-binding pocket. Hydrophobic interactions and hydrogen-bonding interactions were observed in the structures between UCN-01 and the Chk1 kinase domain. The high structural complementarity of these interactions is consistent with the potency and selectivity of UCN-01.	GlaxoSmithKline, Dept Biol Struct, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Dept Phys & Struct Chem, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Dept Prot Biochem, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Dept Gene Express Sci, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Dept Oncol Res, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Dept High Through Put Biol, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Zhou, BBS (corresponding author), Incyte Genom Inc, Stine Haskell Res Ctr, 1090 Elkon Rd, Newark, DE 19714 USA.	binbing_s_zhou@yahoo.com	ID, IMCACAT/D-5867-2014					BRUNNETT B, 1993, SURVEYS MATH IND, V3, P1; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Busby EC, 2000, CANCER RES, V60, P2108; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Gray N, 1999, CURR MED CHEM, V6, P859; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hu H, 1996, DRUG DISCOV TODAY, V1, P438, DOI 10.1016/S1359-6446(96)80010-9; Jackson JR, 2000, CANCER RES, V60, P566; JANIN J, 1990, J BIOL CHEM, V265, P16027; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lawrie AM, 1997, NAT STRUCT BIOL, V4, P796, DOI 10.1038/nsb1097-796; Liu QH, 2000, GENE DEV, V14, P1448; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; Sausville EA, 2001, J CLIN ONCOL, V19, P2319, DOI 10.1200/JCO.2001.19.8.2319; Shao RG, 1997, CANCER RES, V57, P4029; Takai H, 2000, GENE DEV, V14, P1439; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	26	185	196	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46609	46615		10.1074/jbc.M201233200	http://dx.doi.org/10.1074/jbc.M201233200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244092	hybrid			2022-12-27	WOS:000179529300117
J	Zhu, MH; Janssen, E; Leung, K; Zhang, WU				Zhu, MH; Janssen, E; Leung, K; Zhang, WU			Molecular cloning of a novel gene encoding a membrane-associated adaptor protein (LAX) in lymphocyte signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; ANTIGEN RECEPTOR; TYROSINE KINASE; MEDIATED ACTIVATION; LINKER PROTEINS; SLP-76; PATHWAYS; TCR; TRANSDUCTION; INTEGRATION	Membrane-associated adaptors play an important role in coupling antigen receptor engagement to downstream signaling events, such as Ras-MAPK activation, Ca2+ flux, and nuclear factor of activated T cells (NFAT) activation. Here we identified a novel membrane-associated adaptor protein, LAX. LAX is mainly expressed in B cells, T cells, and other lymphoid-specific cell types. It shares no overall sequence homology with LAT and is not localized to lipid rafts. However, like LAT, LAX has tyrosine motifs for binding Grb2, Gads, and the p85 subunit of phosphatidylinositol 3-kinase. Upon stimulation via the B or T cell receptors, LAX is rapidly phosphorylated by Src and Syk family tyrosine kinases and interacts with Grb2, Gads, and p85. Overexpression of LAX in Jurkat cells specifically inhibits T cell receptor-mediated p38 MAPK activation and NFAT/AP-1 transcriptional activation. Our data suggested that LAX functions to negatively regulate signaling in lymlphocytes.	Duke Univ, Dept Immunol, Ctr Med, Durham, NC 27710 USA	Duke University	Zhang, WU (corresponding author), Duke Univ, Dept Immunol, Ctr Med, Rm 112,Jones Bldg,Box 3010, Durham, NC 27710 USA.			Janssen, Erin/0000-0002-0687-2550	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048674] Funding Source: NIH RePORTER; NIAID NIH HHS [1R01 AI48674-01, R01 AI048674] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Boerth NJ, 2000, J EXP MED, V192, P1047, DOI 10.1084/jem.192.7.1047; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ebinu JO, 2000, BLOOD, V95, P3199; Facchetti F, 1999, AM J PATHOL, V154, P1037, DOI 10.1016/S0002-9440(10)65356-4; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Kelly ME, 2000, CURR OPIN IMMUNOL, V12, P267, DOI 10.1016/S0952-7915(00)00086-8; Kurosaki T, 2000, CURR OPIN IMMUNOL, V12, P276, DOI 10.1016/S0952-7915(00)00087-X; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; Mulroy T, 2001, EUR J IMMUNOL, V31, P3056, DOI 10.1002/1521-4141(2001010)31:10<3056::AID-IMMU3056>3.0.CO;2-B; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Rincon M, 2000, FREE RADICAL BIO MED, V28, P1328, DOI 10.1016/S0891-5849(00)00219-7; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Tamir I, 1998, ONCOGENE, V17, P1353, DOI 10.1038/sj.onc.1202187; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Wong J, 2000, J BIOL CHEM, V275, P33116, DOI 10.1074/jbc.M004467200; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Zhang J, 1999, J IMMUNOL, V162, P3819; Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	33	60	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46151	46158		10.1074/jbc.M208946200	http://dx.doi.org/10.1074/jbc.M208946200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12359715	hybrid			2022-12-27	WOS:000179529300060
J	Kang, SJ; Cresswell, P				Kang, SJ; Cresswell, P			Calnexin, calreticulin, and ERp57 cooperate in disulfide bond formation in human CD1d heavy chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECOGNITION; CLASS-I MOLECULES; ENDOPLASMIC-RETICULUM; BIOCHEMICAL-CHARACTERIZATION; ALPHA-GALACTOSYLCERAMIDE; SURFACE EXPRESSION; SELF-GLYCOLIPIDS; LOADING COMPLEX; QUALITY-CONTROL; LYMPHOCYTES-T	Members of the CD1 family of membrane glycoproteins can present antigenic lipids to T lymphocytes. Like major histocompatibility complex class I molecules, they form a heterodimeric complex of a heavy chain and beta(2)-microglobulin (beta(2)m) in the endoplasmic reticulum (ER). Binding of lipid antigens, however, takes place in endosomal compartments, similar to class II molecules, and on the plasma membrane. Unlike major histocompatibility complex class I or CD1b molecules, which need beta(2)m to exit the ER, CD1d can be expressed on the cell surface as either a free heavy chain or associated with beta(2)m. These differences led us to investigate early events of CD1d biosynthesis and maturation and the role of ER chaperones in its assembly. Here we show that CD1d associates in the ER with both calnexin and calreticulin and with the thiol oxidoreductase ERp57 in a manner dependent on glucose trimming of its N-linked glycans. Complete disulfide bond formation in the CD1d heavy chain was substantially impaired if the chaperone interactions were blocked by the glucosidase inhibitors castanospermine or N-butyldeoxynojirimycin. The formation of at least one of the disulfide bonds in the CD1d heavy chain is coupled to its glucose trimming-dependent association with ERp57, calnexin, and calreticulin.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University	Cresswell, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, 333 Cedar St, New Haven, CT 06520 USA.		Kang, Suk-Jo/C-1796-2011		NIAID NIH HHS [AI23081] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023081, R01AI023081] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amano M, 1998, J IMMUNOL, V161, P1710; ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; Bai A, 2000, J IMMUNOL, V165, P7025, DOI 10.4049/jimmunol.165.12.7025; Bai A, 1998, IMMUNITY, V9, P413, DOI 10.1016/S1074-7613(00)80624-X; BALK SP, 1994, SCIENCE, V265, P259, DOI 10.1126/science.7517575; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BERGER AE, 1982, HYBRIDOMA, V1, P87, DOI 10.1089/hyb.1.1982.1.87; Briken V, 2002, EMBO J, V21, P825, DOI 10.1093/emboj/21.4.825; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Brossay L, 1998, J IMMUNOL, V160, P3681; Brossay L, 1998, J IMMUNOL, V161, P5124; BRUTKIEWICZ RR, 1995, J EXP MED, V182, P1913, DOI 10.1084/jem.182.6.1913; Burdin N, 1998, J IMMUNOL, V161, P3271; Cannon KS, 2001, EMBO J, V20, P2443, DOI 10.1093/emboj/20.10.2443; CARDELL S, 1995, J EXP MED, V182, P993, DOI 10.1084/jem.182.4.993; Chiu NM, 1999, J EXP MED, V190, P423, DOI 10.1084/jem.190.3.423; Chun T, 2001, J IMMUNOL, V167, P1507, DOI 10.4049/jimmunol.167.3.1507; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; De Silva AD, 2002, J IMMUNOL, V168, P723, DOI 10.4049/jimmunol.168.2.723; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; Denzin LK, 1996, J EXP MED, V184, P2153, DOI 10.1084/jem.184.6.2153; Dick TP, 2002, IMMUNITY, V16, P87, DOI 10.1016/S1074-7613(02)00263-7; Diedrich G, 2001, J IMMUNOL, V166, P1703, DOI 10.4049/jimmunol.166.3.1703; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; Exley M, 1997, J EXP MED, V186, P109, DOI 10.1084/jem.186.1.109; Exley M, 2000, IMMUNOLOGY, V100, P37, DOI 10.1046/j.1365-2567.2000.00001.x; Gao B, 2002, IMMUNITY, V16, P99, DOI 10.1016/S1074-7613(01)00260-6; Gumperz JE, 2000, IMMUNITY, V12, P211, DOI 10.1016/S1074-7613(00)80174-0; Hebert DN, 1997, J CELL BIOL, V139, P613, DOI 10.1083/jcb.139.3.613; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; Huttinger R, 1999, INT IMMUNOL, V11, P1615, DOI 10.1093/intimm/11.10.1615; Joyce S, 1998, SCIENCE, V279, P1541, DOI 10.1126/science.279.5356.1541; Kang SJ, 2002, EMBO J, V21, P1650, DOI 10.1093/emboj/21.7.1650; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Kim HS, 1999, J BIOL CHEM, V274, P9289, DOI 10.1074/jbc.274.14.9289; Lee N, 1998, J IMMUNOL, V160, P4951; Lybarger L, 2001, J IMMUNOL, V167, P2097, DOI 10.4049/jimmunol.167.4.2097; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Moody DB, 2000, NATURE, V404, P884, DOI 10.1038/35009119; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; Porcelli SA, 1999, ANNU REV IMMUNOL, V17, P297, DOI 10.1146/annurev.immunol.17.1.297; Rodionov DG, 1999, J IMMUNOL, V162, P1488; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Shamshiev A, 2000, IMMUNITY, V13, P255, DOI 10.1016/S1074-7613(00)00025-X; Shamshiev A, 2002, J EXP MED, V195, P1013, DOI 10.1084/jem.20011963; Shamshiev A, 1999, EUR J IMMUNOL, V29, P1667, DOI 10.1002/(SICI)1521-4141(199905)29:05<1667::AID-IMMU1667>3.0.CO;2-U; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; STAM NJ, 1986, J IMMUNOL, V137, P2299; SUGITA M, 1994, J EXP MED, V180, P2163, DOI 10.1084/jem.180.6.2163; Sugita M, 1997, J IMMUNOL, V159, P2358; Teitell M, 1997, J IMMUNOL, V158, P2143; Van der Wal FJ, 1998, EUR J BIOCHEM, V256, P51, DOI 10.1046/j.1432-1327.1998.2560051.x; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	58	89	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44838	44844		10.1074/jbc.M207831200	http://dx.doi.org/10.1074/jbc.M207831200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12239218	hybrid			2022-12-27	WOS:000179404800033
J	Shah, M; Patel, K; Fried, VA; Sehgal, PB				Shah, M; Patel, K; Fried, VA; Sehgal, PB			Interactions of STAT3 with caveolin-1 and heat shock protein 90 in plasma membrane raft and cytosolic complexes - Preservation of cytokine signaling during fever	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS PYROGEN; IFN-GAMMA; IN-VITRO; ACTIVATION; INTERLEUKIN-6; RECEPTOR; COMPONENTS; PATHWAYS; CELLS; LOCALIZATION	Interleukin-6 (IL-6) initiates STAT3 signaling in plasma membrane rafts with the subsequent transit of Tyr-phosphorylated STAT3 (PY-STAT3) through the cytoplasmic compartment to the nucleus in association with accessory proteins. We initially identified caveolin-1 (cav-1) as a candidate STAT3-associated accessory protein due to its co-localization with STAT3 and PY-STAT3 in flotation raft fractions, and heat shock protein 90 (HSP90) due to its inclusion in cytosolic STAT3-containing 200-400-kDa complexes. Subsequent immuno-magnetic bead pullout assays showed that STAT3, PY-STAT3, cav-1, and HSP90 interacted in plasma membrane and cytoplasmic complexes derived from uninduced and stimulated Hep3B cells. This was a general property of STAT3 in that these interactions were also observed in alveolar epithelial type II-like cells, lung fibroblasts, and pulmonary arterial endothelial cells. Exposure of Hep3B cells to the raft disrupter methyl-beta-cyclodextrin for 1-10 min followed by IL-6 stimulation for 15 min preferentially inhibited the appearance of PY-STAT3 in the cav-1-enriched sedimentable cytoplasmic fraction, suggesting that these complexes may represent a trafficking intermediate immediately downstream from the raft. Because IL-6 is known to function in the body in the context of fever, the possibility that HSP90 may help preserve IL-6-induced STAT3 signaling at elevated temperature was investigated. Geldanamycin, an HSP90 inhibitor, markedly inhibited IL-6-stimulated STAT3 signaling in Hep3B hepatocytes cultured overnight at 39.5 degreesC as evaluated by DNA-shift assays, trafficking of PY-STAT3 to the nucleus, cross-precipitation of HSP90 by anti-STAT3 polyclonal antibody, and reporter/luciferase construct experiments. Taken together, the data show that IL-6/raft/STAT3 signaling is a chaperoned pathway that involves cav-1 and HSP90 as accessory proteins and suggest a mechanism for the preservation of this signaling during fever.	New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA; New York Med Coll, Dept Med, Valhalla, NY 10595 USA	New York Medical College; New York Medical College	Sehgal, PB (corresponding author), New York Med Coll, Dept Cell Biol & Anat, Rm 201,Basic Sci Bldg, Valhalla, NY 10595 USA.				NCI NIH HHS [CA-82647] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082647] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1989, Ann N Y Acad Sci, V557, P1; Bild AH, 2002, EMBO J, V21, P3255, DOI 10.1093/emboj/cdf351; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DINARELLO CA, 1991, BRAIN RES, V562, P199, DOI 10.1016/0006-8993(91)90622-3; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; Guo GG, 2002, J INTERF CYTOK RES, V22, P555, DOI 10.1089/10799900252982034; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HELFGOTT DC, 1989, J IMMUNOL, V142, P948; Ju H, 2000, BIOCHEM J, V351, P257, DOI 10.1042/0264-6021:3510257; Kone BC, 2000, ACTA PHYSIOL SCAND, V168, P27; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; Lackmann M, 1998, GROWTH FACTORS, V16, P39, DOI 10.3109/08977199809017490; LEMAY LG, 1990, AM J PHYSIOL, V258, P798; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; MACKIEWICZ A, 1995, ANN NY ACAD SCI, V762, P1; Marmor MD, 2001, BLOOD, V98, P1489, DOI 10.1182/blood.V98.5.1489; Monier S, 1996, FEBS LETT, V388, P143, DOI 10.1016/0014-5793(96)00519-4; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Predescu SA, 2001, MOL BIOL CELL, V12, P1019, DOI 10.1091/mbc.12.4.1019; Rayanade RJ, 1997, J BIOL CHEM, V272, P4659, DOI 10.1074/jbc.272.8.4659; Rayanade RJ, 1998, J IMMUNOL, V161, P325; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROTHWELL NJ, 1991, CAN J PHYSIOL PHARM, V69, P1465, DOI 10.1139/y91-219; Sadir R, 2001, CYTOKINE, V14, P19, DOI 10.1006/cyto.2000.0854; Sehgal PB, 2000, CELL SIGNAL, V12, P525, DOI 10.1016/S0898-6568(00)00098-X; Sehgal PB, 2002, J BIOL CHEM, V277, P12067, DOI 10.1074/jbc.M200018200; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stephanou A, 1998, BIOCHEM J, V330, P189, DOI 10.1042/bj3300189; Stephanou A, 1999, GENE EXPRESSION, V7, P311; Subramaniam PS, 2002, J IMMUNOL, V169, P1959, DOI 10.4049/jimmunol.169.4.1959; Takaoka A, 2000, SCIENCE, V288, P2357, DOI 10.1126/science.288.5475.2357; Teixeira A, 1999, J NEUROCHEM, V72, P120, DOI 10.1046/j.1471-4159.1999.0720120.x; WANG L, 1995, J BIOL CHEM, V270, P23159, DOI 10.1074/jbc.270.39.23159; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Yeung YG, 1998, J BIOL CHEM, V273, P17128, DOI 10.1074/jbc.273.27.17128	39	94	94	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45662	45669		10.1074/jbc.M205935200	http://dx.doi.org/10.1074/jbc.M205935200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235142	hybrid			2022-12-27	WOS:000179404800133
J	Sinha, SK; Zachariah, S; Quinones, HI; Shindo, M; Chaudhary, PM				Sinha, SK; Zachariah, S; Quinones, HI; Shindo, M; Chaudhary, PM			Role of TRAF3 and -6 in the activation of the NF-kappa B and JNK pathways by X-linked ectodermal dysplasia receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; TNF RECEPTOR; MICE LACKING; ECTODYSPLASIN-A; HAIR-FOLLICLES; IKK-ALPHA; GENE; DROSOPHILA; KINASE; DEATH	X-linked ectodermal dysplasia receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that has been shown to be highly expressed in ectodermal derivatives during embryonic development and binds to ectodysplasin-A2 (EDA-A2). By using a subclone of 293F cells with stable expression of XEDAR, we report that XEDAR activates the NF-kappaB and JNK pathways in an EDA-A2-dependent fashion. Treatment with EDA-A2 leads to the recruitment of TRAF3 and -6 to the aggregated XEDAR complex, suggesting a central role of these adaptors in the proximal aspect of XEDAR signaling. Whereas TRAF3 and -6, IKK1/IKKalpha, IKK2/IKKbeta, and NEMO/IKKgamma are involved in XEDAR-induced NF-kappaB activation, XEDAR-induced JNK activation seems to be mediated via a pathway dependent on TRAF3, TRAF6, and ASK1. Deletion and point mutagenesis studies delineate two distinct regions in the cytoplasmic domain of XEDAR, which are involved in binding to TRAF3 and -6, respectively, and play a major role in the activation of the NF-kappaB and JNK pathways. Taken together, our results establish a major role of TRAF3 and -6 in XEDAR signaling and in the process of ectodermal differentiation.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Div Hematol Oncol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Chaudhary, Preet/E-1970-2018		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041940] Funding Source: NIH RePORTER; NIAMS NIH HHS [P30-AR41940-09] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baker SJ, 1996, ONCOGENE, V12, P1; Bayes M, 1998, HUM MOL GENET, V7, P1661, DOI 10.1093/hmg/7.11.1661; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Copley RR, 1999, J MOL MED-JMM, V77, P361, DOI 10.1007/s001090050362; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Eby MT, 2000, J BIOL CHEM, V275, P15336, DOI 10.1074/jbc.275.20.15336; Gamper C, 2001, HUM IMMUNOL, V62, P1167, DOI 10.1016/S0198-8859(01)00284-1; Headon DJ, 1999, NAT GENET, V22, P370, DOI 10.1038/11943; Headon DJ, 2001, NATURE, V414, P913, DOI 10.1038/414913a; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Kere J, 1996, NAT GENET, V13, P409, DOI 10.1038/ng0895-409; Knust E, 1996, CURR BIOL, V6, P379, DOI 10.1016/S0960-9822(02)00500-6; Kockel L, 1997, GENE DEV, V11, P1748, DOI 10.1101/gad.11.13.1748; Kojima T, 2000, J BIOL CHEM, V275, P20742, DOI 10.1074/jbc.M002691200; Kumar A, 2001, J BIOL CHEM, V276, P2668, DOI 10.1074/jbc.M008356200; Laurikkala J, 2002, DEVELOPMENT, V129, P2541; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Monreal AW, 1999, NAT GENET, V22, P366, DOI 10.1038/11937; Munoz F, 1997, AM J HUM GENET, V61, P94; Naito A, 2002, P NATL ACAD SCI USA, V99, P8766, DOI 10.1073/pnas.132636999; PINHEIRO M, 1994, AM J MED GENET, V53, P153, DOI 10.1002/ajmg.1320530207; Qian YC, 2002, P NATL ACAD SCI USA, V99, P9386, DOI 10.1073/pnas.142294499; Schmidt-Ullrich R, 2001, DEVELOPMENT, V128, P3843; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Seitz CS, 2000, J CLIN INVEST, V105, P253, DOI 10.1172/JCI7630; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Srivastava AK, 1997, P NATL ACAD SCI USA, V94, P13069, DOI 10.1073/pnas.94.24.13069; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; van Eyndhoven WG, 1999, MOL IMMUNOL, V36, P647, DOI 10.1016/S0161-5890(99)00079-6; Yan MH, 2002, CURR BIOL, V12, P409, DOI 10.1016/S0960-9822(02)00687-5; Yan MH, 2000, SCIENCE, V290, P523, DOI 10.1126/science.290.5491.523; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	43	57	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44953	44961		10.1074/jbc.M207923200	http://dx.doi.org/10.1074/jbc.M207923200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12270937	hybrid			2022-12-27	WOS:000179404800048
J	Grantcharova, E; Furkert, J; Reusch, HP; Krell, HW; Papsdorf, G; Beyermann, M; Schulein, R; Rosenthal, W; Oksche, A				Grantcharova, E; Furkert, J; Reusch, HP; Krell, HW; Papsdorf, G; Beyermann, M; Schulein, R; Rosenthal, W; Oksche, A			The extracellular N terminus of the endothelin B (ETB) receptor is cleaved by a metalloprotease in an agonist-dependent process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; ET(B) RECEPTORS; CIRCULATING ENDOTHELIN-1; DOWN-REGULATION; INSECT CELLS; L-SELECTIN; MEMBRANE; PROTEIN; LIGAND; ECTODOMAIN	The extracellular N terminus of the endothelin B (ETB) receptor is susceptible to limited proteolysis (cleavage at R64 down arrow S65), but the regulation and the functional consequences of the proteolysis remain elusive. We analyzed the ETB receptor or an ETB-GFP fusion protein stably or transiently expressed in HEK293 cells. After incubation of cells at 4 degreesC, only the full-length ETB receptor was detected at the cell surface. However, when cells were incubated at 37 degreesC, N-terminal cleavage was observed, provided endothelin 1 was present during the incubation. Cleavage was not inhibited by internalization inhibitors (sucrose, phenylarsine oxide). However, in cells incubated with both internalization inhibitors and metalloprotease inhibitors (batimastat, inhibitor of TNFalpha-convertase) or metal chelators (EDTA, phenanthroline), the cleavage was blocked, indicating that metalloproteases cleave the agonist-occupied ETB receptor at the cell surface. Functional analysis of a mutant ETB receptor lacking the first 64 amino acids ([Delta2-64]ETB receptor) revealed normal functional properties, but a 15-fold reduced cell surface expression. The results suggest a role of the N-terminal proteolysis in the regulation of cell surface expression of the ETB receptor. This is the first example of a multispanning membrane protein, which is cleaved by a metalloprotease, but retains its functional activity and overall structure.	Free Univ Berlin, Inst Klin Pharmakol & Toxikol, D-14195 Berlin, Germany; Roche Diagnost GmbH, Pharma Res Penzberg, D-82372 Penzberg, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany; Forsch Inst Mol Pharmakol, D-13125 Berlin, Germany	Free University of Berlin; Roche Holding; Free University of Berlin	Oksche, A (corresponding author), Thiellallee 67-73, D-14195 Berlin, Germany.		Oksche, Alexander/M-6678-2019	Oksche, Alexander/0000-0003-4592-1770				AKIYAMA N, 1992, PROTEIN EXPRES PURIF, V3, P427, DOI 10.1016/S1046-5928(05)80046-4; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BELDENT V, 1993, J BIOL CHEM, V268, P26428; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; Couet J, 1996, J BIOL CHEM, V271, P4545; Cramer H, 2001, EUR J BIOCHEM, V268, P5449, DOI 10.1046/j.0014-2956.2001.02486.x; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; Doi T, 1997, EUR J BIOCHEM, V248, P139, DOI 10.1111/j.1432-1033.1997.00139.x; Dupuis J, 1996, J APPL PHYSIOL, V81, P1510, DOI 10.1152/jappl.1996.81.4.1510; EGUCHI S, 1993, J CARDIOVASC PHARM, V22, pS161, DOI 10.1097/00005344-199322008-00043; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FUKURODA T, 1994, BIOCHEM BIOPH RES CO, V199, P1461, DOI 10.1006/bbrc.1994.1395; Gomis-Ruth FX, 1998, PROTEIN SCI, V7, P283; HAGIWARA H, 1991, J CARDIOVASC PHARM, V17, pS117, DOI 10.1097/00005344-199100177-00030; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Kochl R, 2002, J BIOL CHEM, V277, P16131, DOI 10.1074/jbc.M111674200; KOJRO E, 1995, J BIOL CHEM, V270, P6476, DOI 10.1074/jbc.270.12.6476; Krause G, 2000, MOL PHARMACOL, V57, P232; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Mizuguchi T, 1997, BRIT J PHARMACOL, V120, P1427, DOI 10.1038/sj.bjp.0701054; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLBERG J, 1995, J IMMUNOL, V155, P5198; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; Oksche A, 2000, MOL PHARMACOL, V57, P1104; Oksche A, 2002, MOL ENDOCRINOL, V16, P799, DOI 10.1210/me.16.4.799; Oksche A, 2000, J CARDIOVASC PHARM, V36, pS44; OPPONG SY, 1993, BIOCHEM J, V292, P597, DOI 10.1042/bj2920597; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; ROBINSON PJ, 1987, P NATL ACAD SCI USA, V84, P527, DOI 10.1073/pnas.84.2.527; SAITO Y, 1991, J BIOL CHEM, V266, P23433; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Satoh M, 1997, EUR J BIOCHEM, V249, P803, DOI 10.1111/j.1432-1033.1997.00803.x; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schmidlin Fabien, 2001, Current Opinion in Pharmacology, V1, P575, DOI 10.1016/S1471-4892(01)00099-6; SEO B, 1994, CIRCULATION, V89, P1203, DOI 10.1161/01.CIR.89.3.1203; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SMITH BJ, 1993, APPL BIOCHEM BIOTECH, V41, P189, DOI 10.1007/BF02916422; SOKOLOVSKY M, 1992, J BIOL CHEM, V267, P20551; TAKASUKA T, 1994, J BIOL CHEM, V269, P7509; TAKASUKA T, 1991, J CARDIOVASC PHARM, V17, pS109; TAKAYANAGI R, 1991, REGUL PEPTIDES, V32, P23, DOI 10.1016/0167-0115(91)90004-Z; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WAGGONER WG, 1992, LIFE SCI, V51, P1869, DOI 10.1016/0024-3205(92)90038-Q; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132	52	55	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43933	43941		10.1074/jbc.M208407200	http://dx.doi.org/10.1074/jbc.M208407200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226103	hybrid			2022-12-27	WOS:000179272000053
J	Jin, P; Weiger, TM; Levitan, IB				Jin, P; Weiger, TM; Levitan, IB			Reciprocal modulation between the alpha and beta 4 subunits of hSlo calcium-dependent potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNEL; LARGE-CONDUCTANCE; SURFACE EXPRESSION; LINKED GLYCOSYLATION; NERVE-TERMINALS; VOLTAGE; PROTEIN; PHOSPHORYLATION; INACTIVATION; CLONING	Large conductance Ca2+-dependent potassium (K-Ca or maxi K) channels are composed of a pore-forming alpha subunit and an auxiliary beta subunit. We have shown that the brain-specific beta4 subunit modulates the voltage dependence, activation kinetics, and toxin sensitivity of the hSlo channel (Weiger, T. M., Holmqvist, M. H., Levitan, I. B., Clark, F. T., Sprague, S., Huang, W. J., Ge, P., Wang, C., Lawson, D., Jurman, M. E., Glucksmann, M. A., Silos-Santiago, L, DiStefano, P. S., and Curtis, R. (2000) J. Neurosci. 20, 3563-3570). We investigated here the N-linked glycosylation of the beta4 subunit and its effect on the modulation of the hSlo a subunit. When expressed alone in HEK293 cells, the beta4 subunit runs as a single molecular weight band on an SDS gel. However, when coexpressed with the hSlo alpha subunit, the beta4 subunit appears as two different molecular weight bands. Enzymatic deglycosylation or mutation of the N-linked glycosylation residues in beta4 converts it to a single lower molecular weight band, even in the presence of the hSlo alpha subunit, suggesting that the beta4 subunit can be present as an immature, core glycosylated form and a mature, highly glycosylated form. Blockage of protein transport from the endoplasmic reticulum to the Golgi compartment with brefeldin A abolishes the mature, highly glycosylated beta4 band. Glycosylation of the beta4 subunit is not required for its binding to the hSlo channel a subunit. It also is not necessary for cell membrane targeting of the beta4 subunit, as demonstrated by surface biotinylation experiments. However, the double glycosylation site mutant beta4 (beta4 N53A/N90A) protects the channel less against toxin blockade, as compared with the hSlo, channel coexpressed with wild type beta4 subunit. Taken together, these data show that the pore-forming a subunit of the hSlo channel promotes N-linked glycosylation of its auxiliary beta4 subunit, and this in turn influences the modulation of the channel by the beta4 subunit.	Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA; Salzburg Univ, Inst Zool, Dept Mol Neurosci & Cell Physiol, A-5020 Salzburg, Austria	University of Pennsylvania; Salzburg University	Jin, P (corresponding author), Univ Penn, Sch Med, Dept Neurosci, 223 Stemmler Hall,3450 Hamilton Walk, Philadelphia, PA 19104 USA.		Weiger, Thomas M/D-8133-2017	Weiger, Thomas M/0000-0002-5231-930X				Behrens R, 2000, FEBS LETT, V474, P99, DOI 10.1016/S0014-5793(00)01584-2; Bennett E, 1997, J GEN PHYSIOL, V109, P327, DOI 10.1085/jgp.109.3.327; BIELEFELDT K, 1994, J PHYSIOL-LONDON, V475, P241, DOI 10.1113/jphysiol.1994.sp020065; Bravo-Zehnder M, 2000, P NATL ACAD SCI USA, V97, P13114, DOI 10.1073/pnas.240455697; Brenner R, 2000, J BIOL CHEM, V275, P6453, DOI 10.1074/jbc.275.9.6453; Bunemann M, 1999, J BIOL CHEM, V274, P33851, DOI 10.1074/jbc.274.48.33851; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; DUKSIN D, 1982, J BIOL CHEM, V257, P3105; Dworetzky SI, 1996, J NEUROSCI, V16, P4543; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; GHO M, 1992, J EXP BIOL, V170, P93; Hanwell D, 2002, J BIOL CHEM, V277, P9772, DOI 10.1074/jbc.M110904200; Holmes TC, 1997, J NEUROSCI, V17, P8964; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; Jiang Z, 1999, GENOMICS, V55, P57, DOI 10.1006/geno.1998.5627; Jin P, 2002, J BIOL CHEM, V277, P10014, DOI 10.1074/jbc.M107682200; Kennedy ME, 1999, J BIOL CHEM, V274, P2571, DOI 10.1074/jbc.274.4.2571; Khanna R, 2001, J BIOL CHEM, V276, P34028, DOI 10.1074/jbc.M105248200; Kwak YG, 1999, J BIOL CHEM, V274, P13928, DOI 10.1074/jbc.274.20.13928; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 2000, P NATL ACAD SCI USA, V97, P5562, DOI 10.1073/pnas.100118597; O'Riordan CR, 2000, GLYCOBIOLOGY, V10, P1225, DOI 10.1093/glycob/10.11.1225; Pabon A, 2000, J BIOL CHEM, V275, P30677, DOI 10.1074/jbc.M005338200; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; ROBITAILLE R, 1993, J PHYSIOLOGY-PARIS, V87, P15, DOI 10.1016/0928-4257(93)90020-T; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; Schopperle WM, 1998, NEURON, V20, P565, DOI 10.1016/S0896-6273(00)80995-2; Shi G, 1999, J MEMBRANE BIOL, V168, P265, DOI 10.1007/s002329900515; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; STROUS GJ, 1993, J BIOL CHEM, V268, P2341; TAI T, 1975, J BIOL CHEM, V250, P8569; Tyrrell L, 2001, J NEUROSCI, V21, P9629, DOI 10.1523/JNEUROSCI.21-24-09629.2001; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Wallner M, 1999, P NATL ACAD SCI USA, V96, P4137, DOI 10.1073/pnas.96.7.4137; Wang J, 1999, J Neurosci, V19, pRC4; Wanner SG, 1999, BIOCHEMISTRY-US, V38, P5392, DOI 10.1021/bi983040c; Weiger TM, 2000, J NEUROSCI, V20, P3563, DOI 10.1523/JNEUROSCI.20-10-03563.2000; Weiger TM, 2002, J COMP PHYSIOL A, V188, P79, DOI 10.1007/s00359-002-0281-2; Zhou Y, 1999, NEURON, V22, P809, DOI 10.1016/S0896-6273(00)80739-4; Zhu J, 2001, J BIOL CHEM, V276, P39419, DOI 10.1074/jbc.M107399200	41	29	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43724	43729		10.1074/jbc.M205795200	http://dx.doi.org/10.1074/jbc.M205795200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223479	hybrid			2022-12-27	WOS:000179272000025
J	Dell'Acqua, ML; Dodge, KL; Tavalin, SJ; Scott, JD				Dell'Acqua, ML; Dodge, KL; Tavalin, SJ; Scott, JD			Mapping the protein phosphatase-2B anchoring site on AKAP79 - Binding and inhibition of phosphatase activity are mediated by residues 315-360	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C INTERACTION; REGULATORY SUBUNIT; TARGETED INHIBITION; SIGNALING COMPLEX; ION CHANNELS; II-BETA; CALCINEURIN; RECEPTORS; EXPRESSION; NFAT	Compartmentalization of protein kinases and phosphatases with substrates is a means to increase the efficacy of signal transduction events. The A-kinase anchoring protein, AKAP79, is a multivalent anchoring protein that maintains the cAMP-dependent protein kinase, protein kinase C, and protein phosphatase-2B (PP2B/calcineurin) at the postsynaptic membrane of excitatory synapses where it is recruited into complexes with N-methyl-D-aspartic acid or alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-subtype glutamate receptors. We have used cellular targeting of AKAP79 truncation and deletion mutants as an assay to map the PP2B-binding site on AKAP79. We demonstrate that residues 315-360 are necessary and sufficient for AKAP79-PP2B anchoring in cells. Multiple determinants contained within this region bind directly to the A subunit of PP2B and inhibit phosphatase activity. Peptides spanning the 315-360 region of AKAP79 can antagonize PP2B anchoring in vitro and targeting in transfected cells. Electrophysiological experiments further emphasize this point by demonstrating that a peptide encompassing residues 330-357 of AKAP79 attenuates PP2B-dependent down-regulation of GluR1 receptor currents when perfused into HEK293 cells. We propose that the structural features of this AKAP79-PP2B-binding domain may share similarities with other proteins that serve to coordinate PP2B localization and activity.	Oregon Hlth Sci Univ, Vollum Inst, Howard Hughes Med Inst, Portland, OR 97201 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	Howard Hughes Medical Institute; Oregon Health & Science University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Scott, JD (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, Howard Hughes Med Inst, L474, Portland, OR 97201 USA.			Dell'Acqua, Mark/0000-0003-3798-3461	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048231, R01GM048231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040701] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48231, R01 GM048231, R37 GM048231] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1991, J BIOL CHEM, V266, P14188; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; De Windt LJ, 2001, P NATL ACAD SCI USA, V98, P3322, DOI 10.1073/pnas.031371998; Dell'Acqua ML, 1998, EMBO J, V17, P2246, DOI 10.1093/emboj/17.8.2246; Dodge KL, 1999, ENDOCRINOLOGY, V140, P5165, DOI 10.1210/en.140.11.5165; Faux MC, 1999, BIOCHEM J, V343, P443, DOI 10.1042/0264-6021:3430443; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; Feliciello A, 1997, CURR BIOL, V7, P1011, DOI 10.1016/S0960-9822(06)00424-6; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Fink MA, 2001, CIRC RES, V88, P291, DOI 10.1161/01.RES.88.3.291; Fraser IDC, 1999, NEURON, V23, P423, DOI 10.1016/S0896-6273(00)80795-3; Hausken ZE, 1996, J BIOL CHEM, V271, P29016, DOI 10.1074/jbc.271.46.29016; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jordan JD, 2000, CELL, V103, P193, DOI 10.1016/S0092-8674(00)00112-4; Kameyama K, 1998, NEURON, V21, P1163, DOI 10.1016/S0896-6273(00)80633-9; Kashishian A, 1998, J BIOL CHEM, V273, P27412, DOI 10.1074/jbc.273.42.27412; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Lai MM, 2000, J BIOL CHEM, V275, P34017, DOI 10.1074/jbc.C000429200; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; LUO S, 1998, IMMUNITY, V8, P703; Newlon MG, 2001, EMBO J, V20, P1651, DOI 10.1093/emboj/20.7.1651; Park S, 2000, P NATL ACAD SCI USA, V97, P7130, DOI 10.1073/pnas.97.13.7130; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Schillace RV, 2001, J BIOL CHEM, V276, P12128, DOI 10.1074/jbc.M010398200; Smith FD, 2002, CURR BIOL, V12, pR32, DOI 10.1016/S0960-9822(01)00646-7; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Swope SL, 1999, ADV SEC MESS PHOSPH, V33, P49; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; Tavalin SJ, 2002, J NEUROSCI, V22, P3044, DOI 10.1523/JNEUROSCI.22-08-03044.2002; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93	45	118	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48796	48802		10.1074/jbc.M207833200	http://dx.doi.org/10.1074/jbc.M207833200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12354762	Green Accepted, hybrid, Green Submitted			2022-12-27	WOS:000179789600107
J	Bompard, G; Puech, C; Prebois, C; Vignon, F; Freiss, G				Bompard, G; Puech, C; Prebois, C; Vignon, F; Freiss, G			Protein-tyrosine phosphatase PTPL1/FAP-1 triggers apoptosis in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-MEDIATED APOPTOSIS; GROWTH-FACTOR-I; RECEPTOR SUBSTRATE-1 EXPRESSION; PHOSPHATIDYLINOSITOL 3'-KINASE; SIGNALING PATHWAYS; ESTROGEN-RECEPTOR; SURVIVAL SIGNALS; INSULIN; DEATH; FAP-1	Studies in Jurkat leukemia cells have suggested that protein-tyrosine phosphatase PTPL1/FAP-1 rescues Fas-induced cell death. However, we have previously shown that this enzyme triggers 4-hydroxytamoxifen-induced growth inhibition in human breast cancer cells. The present study addresses the role of PTPL1/FAP-1 in antiestrogen-regulated apoptotic effect and insulin-like growth factor-I survival action in MCF7 cells and further identifies the impacted signaling pathway. By terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling and cytoplasmic nucleosome enzyme-linked immunosorbent assay, we demonstrated that 4-hydroxytamoxifen-induced apoptosis was totally lost in PTPL1/FAP-1 antisense transfectants in which enzyme expression was abrogated, revealing the crucial role of this phosphatase in the apoptotic process in human breast cancer cells. Time-dependent expression of PTPL1/FAP-1 in MCF7 cells completely abolished the survival action of insulin-like growth factor-1. This effect occurred through a highly significant reduction in phosphatidylinositol 3-kinase/Akt pathway activation (80% reduction in phosphatidylinositol 3-kinase activity, 55% inhibition of Akt activation) accompanied by a 65% decrease in insulin receptor substrate-1 growth factor-induced tyrosine phosphorylation. These results provide the first evidence that PTPL1/FAP-1 has a key role in the apoptotic process in human breast cancer cells independent of Fas but associated with an early inhibition of the insulin receptor substrate-1/phosphatidylinositol 3-kinase pathway. Our data therefore suggest new therapeutic routes and strengthen the importance of identifying endogenous regulators and substrates of this phosphatase in breast tumors.	INSERM, Unit 540, F-34090 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Vignon, F (corresponding author), INSERM, Unit 540, 60 Rue Navacelles, F-34090 Montpellier, France.	vignon@u540.montp.inserm.fr	Freiss, Gilles/T-2057-2019	Freiss, Gilles/0000-0002-1943-0735; Bompard, Guillaume/0000-0001-6729-4507				Ardini E, 2000, ONCOGENE, V19, P4979, DOI 10.1038/sj.onc.1203869; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; BARDON S, 1987, CANCER RES, V47, P1441; BASERGA R, 1999, IGF SYSTEM, P329; Boekelheide K, 1998, TOXICOL LETT, V103, P503, DOI 10.1016/S0378-4274(98)00242-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broome HE, 1998, CELL DEATH DIFFER, V5, P200, DOI 10.1038/sj.cdd.4400329; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cuppen E, 1997, J BIOL CHEM, V272, P30215, DOI 10.1074/jbc.272.48.30215; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Ellis PA, 1997, INT J CANCER, V72, P608, DOI 10.1002/(SICI)1097-0215(19970807)72:4<608::AID-IJC10>3.0.CO;2-7; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FREISS G, 1994, MOL ENDOCRINOL, V8, P1389, DOI 10.1210/me.8.10.1389; Freiss G, 1998, MOL ENDOCRINOL, V12, P568, DOI 10.1210/me.12.4.568; FREISS G, 1993, BREAST CANCER RES TR, V27, P57, DOI 10.1007/BF00683193; Gooch JL, 1999, CANCER LETT, V144, P31, DOI 10.1016/S0304-3835(99)00208-6; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Guvakova MA, 1997, CANCER RES, V57, P2606; HUOVINEN R, 1993, INT J CANCER, V55, P685, DOI 10.1002/ijc.2910550429; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Keane MM, 1996, CANCER RES, V56, P4791; Keane MM, 1996, CANCER RES, V56, P4236; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KYPRIANOU N, 1991, CANCER RES, V51, P162; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Li Y, 2000, INT J CANCER, V87, P473, DOI 10.1002/1097-0215(20000815)87:4<473::AID-IJC3>3.0.CO;2-1; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; Mori S, 1996, CANCER RES, V56, P1874; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Navarro M, 2001, ENDOCRINOLOGY, V142, P1073, DOI 10.1210/en.142.3.1073; Parrizas M, 1997, J BIOL CHEM, V272, P154; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Peto R, 2000, LANCET, V355, P1822, DOI 10.1016/S0140-6736(00)02277-7; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; Saras J, 1997, J BIOL CHEM, V272, P20979, DOI 10.1074/jbc.272.34.20979; SARAS J, 1994, J BIOL CHEM, V269, P24082; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Thangaraju M, 1999, J BIOL CHEM, V274, P29549, DOI 10.1074/jbc.274.41.29549; Tillman DM, 1998, CELL DEATH DIFFER, V5, P450, DOI 10.1038/sj.cdd.4400369; Ungefroren H, 1998, CANCER RES, V58, P1741; VIGNON F, 1987, BIOCHEM BIOPH RES CO, V146, P1502, DOI 10.1016/0006-291X(87)90819-9; Yamada Y, 1999, CANCER LETT, V147, P215, DOI 10.1016/S0304-3835(99)00313-4; Yanagisawa J, 1997, J BIOL CHEM, V272, P8539, DOI 10.1074/jbc.272.13.8539; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837	48	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47861	47869		10.1074/jbc.M208950200	http://dx.doi.org/10.1074/jbc.M208950200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354757	Green Published, hybrid			2022-12-27	WOS:000179663700132
J	Liu, T; Li, RL; Pan, T; Liu, DC; Petersen, RB; Wong, BS; Gambetti, P; Sy, MS				Liu, T; Li, RL; Pan, T; Liu, DC; Petersen, RB; Wong, BS; Gambetti, P; Sy, MS			Intercellular transfer of the cellular prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							37-KDA/67-KDA LAMININ RECEPTOR; PLASMA-MEMBRANE; KINASE-C; CULTURED-CELLS; SCRAPIE ISOFORM; IN-VIVO; SUPEROXIDE-DISMUTASE; BINDS COPPER; DOMAINS; CONVERSION	The cellular prion protein (PrPC) is a glycosylphosphatidylinositol (GPI)-anchored protein. We investigated whether PrPC can move from one cell to another cell in a cell model. Little PrPC transfer was detected when a PrPC expressing human neuroblastoma. cell line was cultured with the human erythroleukemia cells IA lacking PrPC. Efficient transfer of PrPC was detected with the presence of phorbol 12-myristate 13-acetate, an activator of protein kinase C. Maximum PrPC transfer was observed when both donor and recipient cells were activated. Furthermore, PrPC transfer required the GPI anchor and direct cell to cell contact. However, intercellular protein transfer is not limited to PrPC, another GPI-anchored protein, CD90, also transfers from the donor cells to acceptor cells after cellular activation. Therefore, this transfer process is GPI-anchor and cellular activation dependent. These findings suggest that the intercellular transfer of GPI-anchored proteins is a regulated process, and may have implications for the pathogenesis of prion disease.	Case Western Reserve Univ, Sch Med, BRB, Ctr Canc Res, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Inst Pathol, Div Neuropathol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Sy, MS (corresponding author), Case Western Reserve Univ, Sch Med, BRB, Ctr Canc Res, Rm 933,10900 Euclid Ave, Cleveland, OH 44106 USA.		Wong, Boon-Seng/G-2759-2012; Petersen, Robert/B-5075-2011	Wong, Boon-Seng/0000-0002-7118-8077; Petersen, Robert/0000-0002-3154-0072	NCI NIH HHS [P030CA43703] Funding Source: Medline; NIA NIH HHS [AG14359] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG014359] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson SM, 1996, P NATL ACAD SCI USA, V93, P5894, DOI 10.1073/pnas.93.12.5894; Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; CAUGHEY B, 1988, J GEN VIROL, V69, P711, DOI 10.1099/0022-1317-69-3-711; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; Chakraborty P, 2000, J BIOCHEM-TOKYO, V127, P185, DOI 10.1093/oxfordjournals.jbchem.a022593; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; DEARMOND SJ, 1995, AM J PATHOL, V146, P785; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; DICKINSON AG, 1978, NATURE, V272, P54, DOI 10.1038/272054a0; EKLUND CM, 1967, J INFECT DIS, V117, P15, DOI 10.1093/infdis/117.1.15; FRASER H, 1970, NATURE, V226, P462, DOI 10.1038/226462a0; Furlong ST, 1997, J INFECT DIS, V175, P661, DOI 10.1093/infdis/175.3.661; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Gambetti P, 2001, J ALZHEIMERS DIS, V3, P87, DOI 10.3233/JAD-2001-3113; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOESSLI DC, 1983, P NATL ACAD SCI-BIOL, V80, P439, DOI 10.1073/pnas.80.2.439; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; Horiuchi M, 2001, J BIOL CHEM, V276, P15489, DOI 10.1074/jbc.M100288200; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; Ilangumaran S, 1996, TRENDS CELL BIOL, V6, P163, DOI 10.1016/0962-8924(96)20012-1; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; KOOYMAN DL, 1995, SCIENCE, V269, P89, DOI 10.1126/science.7541557; Kramer ML, 2001, J BIOL CHEM, V276, P16711, DOI 10.1074/jbc.M006554200; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; Li RL, 2000, J MOL BIOL, V301, P567, DOI 10.1006/jmbi.2000.3986; Lin T, 2001, J IMMUNOL, V166, P3733; Liu T, 2001, BRAIN RES, V896, P118, DOI 10.1016/S0006-8993(01)02050-9; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Marsh R F, 1981, Adv Exp Med Biol, V134, P359; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MEDOF ME, 1985, P NATL ACAD SCI USA, V82, P2980, DOI 10.1073/pnas.82.9.2980; Melikyan GB, 1997, J CELL BIOL, V136, P995, DOI 10.1083/jcb.136.5.995; Miller JL, 1998, J LAB CLIN MED, V131, P215, DOI 10.1016/S0022-2143(98)90092-0; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Muniz M, 2000, EMBO J, V19, P10, DOI 10.1093/emboj/19.1.10; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Orito A, 2001, J NEUROSCI RES, V64, P235, DOI 10.1002/jnr.1071; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parizek P, 2001, J BIOL CHEM, V276, P44627, DOI 10.1074/jbc.M107458200; Parolini I, 1999, J BIOL CHEM, V274, P14176, DOI 10.1074/jbc.274.20.14176; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; Pitto M, 1999, BIOCHEM J, V344, P177, DOI 10.1042/0264-6021:3440177; Pomorski T, 2001, SEMIN CELL DEV BIOL, V12, P139, DOI 10.1006/scdb.2000.0231; PRUSINER SB, 1989, ANNU REV MICROBIOL, V43, P345, DOI 10.1146/annurev.mi.43.100189.002021; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; ROGERS RA, 1993, J CELL SCI, V106, P485; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STEVENS EM, 1979, J CLIN PSYCHIAT, V40, P445; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; TAYLOR DD, 1983, BIOCHEM BIOPH RES CO, V113, P470, DOI 10.1016/0006-291X(83)91749-7; Tykocinski ML, 1996, AM J PATHOL, V148, P1; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; VUORI K, 1993, J BIOL CHEM, V268, P21459; Wong BS, 2000, BIOCHEM BIOPH RES CO, V273, P136, DOI 10.1006/bbrc.2000.2911; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812	68	82	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47671	47678		10.1074/jbc.M207458200	http://dx.doi.org/10.1074/jbc.M207458200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359724	hybrid			2022-12-27	WOS:000179663700108
J	Matias, PM; Coelho, AV; Valente, FMA; Placido, D; LeGall, J; Xavier, AV; Pereira, IAC; Carrondo, MA				Matias, PM; Coelho, AV; Valente, FMA; Placido, D; LeGall, J; Xavier, AV; Pereira, IAC; Carrondo, MA			Sulfate respiration in Desulfovibrio vulgaris Hildenborough - Structure of the 16-heme cytochrome c HmcA at 2.5-angstrom resolution and a view of its role in transmembrane electron transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFURICANS ATCC 27774; MOLECULAR-WEIGHT CYTOCHROME; 3-DIMENSIONAL STRUCTURE; REDUCING BACTERIA; C(3); REFINEMENT; HYDROGEN; ANGSTROM; OPERON; GIGAS	The crystal structure of the high molecular mass cytochrome c HmcA from Desulfovibrio vulgaris Hildenborough is described. HmcA contains the unprecedented number of sixteen hemes c attached to a single polypeptide chain, is associated with a membrane-bound redox complex, and is involved in electron transfer from the periplasmic oxidation of hydrogen to the cytoplasmic reduction of sulfate. The structure of HmcA is organized into four tetraheme cytochrome c(3)-like domains, of which the first is incomplete and contains only three hemes, and the final two show great similarity to the nine-heme cytochrome c from Desulfovibrio desulfuricans. An isoleucine residue fills the vacant coordination space above the iron atom in the five-coordinated high-spin Heme 15. The characteristics of each of the tetraheme domains of HmcA, as well as its surface charge distribution, indicate this cytochrome has several similarities with the nine-heme cytochrome c and the Type II cytochrome c(3) molecules, in agreement with their similar genetic organization and mode of reactivity and further support an analogous physiological function for the three cytochromes. Based on the present structure, the possible electron transfer sites between HmcA and its redox partners (namely Type I cytochrome c, and other proteins of the Hmc complex), as well as its physiological role, are discussed.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2781901 Oeiras, Portugal; Univ Evora, Dept Chem, P-7001 Evora, Portugal; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	Universidade Nova de Lisboa; University of Evora; University System of Georgia; University of Georgia	Carrondo, MA (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Av Republ,EAN,Apartado 127, P-2781901 Oeiras, Portugal.	carrondo@itqb.unl.pt	Coelho, Ana V Varela/O-3977-2014; Pereira, Inês/C-2748-2009; Coelho, Ana V/H-8885-2012; Matias, Pedro M/B-7180-2008	Coelho, Ana V Varela/0000-0002-6143-4203; Pereira, Inês/0000-0003-3283-4520; Coelho, Ana V/0000-0002-6143-4203; Matias, Pedro M/0000-0001-6170-451X; Carrondo, Maria Armenia/0000-0002-1261-1162				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERKS BC, 1995, MOL MICROBIOL, V15, P319, DOI 10.1111/j.1365-2958.1995.tb02246.x; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRANDIS A, 1981, J GEN MICROBIOL, V126, P249; BRENT W, 1991, J BACTERIOL, V173, P220; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHEN L, 1994, FEBS LETT, V347, P295, DOI 10.1016/0014-5793(94)00563-X; Coutinho IB, 1996, J BIOL INORG CHEM, V1, P305, DOI 10.1007/s007750050058; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Czjzek M, 2001, ACTA CRYSTALLOGR D, V57, P670, DOI 10.1107/S0907444901003481; Dolla A, 2000, ARCH MICROBIOL, V174, P143, DOI 10.1007/s002030000183; Frazao C, 1999, J BIOL INORG CHEM, V4, P162, DOI 10.1007/s007750050299; Hamilton WA, 1998, BIODEGRADATION, V9, P201, DOI 10.1023/A:1008362304234; HIGUCHI Y, 1987, BIOCHIM BIOPHYS ACTA, V911, P341, DOI 10.1016/0167-4838(87)90075-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keon RG, 1996, ANAEROBE, V2, P231, DOI 10.1006/anae.1996.0032; Keon RG, 1997, ARCH MICROBIOL, V167, P376, DOI 10.1007/s002030050458; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOUBINOUX J, 2002, FEMS MICROBIOL ECOL, V1341, P1; Louro RO, 1998, BIOCHEMISTRY-US, V37, P15808, DOI 10.1021/bi981505t; Louro RO, 2001, J BIOL CHEM, V276, P44044, DOI 10.1074/jbc.M107136200; Magro V, 1997, BBA-PROTEIN STRUCT M, V1342, P149, DOI 10.1016/S0167-4838(97)00096-4; Matias PM, 2001, J BIOL INORG CHEM, V6, P63, DOI 10.1007/s007750000167; Matias PM, 1999, J BIOL INORG CHEM, V4, P478, DOI 10.1007/s007750050334; Matias PM, 1997, J BIOL INORG CHEM, V2, P507, DOI 10.1007/s007750050162; Matias PM, 1999, STRUCTURE, V7, P119, DOI 10.1016/S0969-2126(99)80019-7; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nicholls A., 1992, GRASP GRAPHICAL REPR; Norager S, 1999, J MOL BIOL, V290, P881, DOI 10.1006/jmbi.1999.2917; ODOM JM, 1981, FEMS MICROBIOL LETT, V12, P47; OGATA M, 1993, BIOCHIMIE, V75, P977, DOI 10.1016/0300-9084(93)90148-L; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Pereira IAC, 1998, J BIOL INORG CHEM, V3, P494, DOI 10.1007/s007750050259; Pereira IAC, 1997, J BIOL INORG CHEM, V2, P23, DOI 10.1007/s007750050102; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Pieulle L, 1996, BBA-BIOENERGETICS, V1273, P51, DOI 10.1016/0005-2728(95)00129-8; Postgate J, 1984, SULPHATE REDUCING BA, P56; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson DJ, 2000, MICROBIOL-SGM, V146, P551, DOI 10.1099/00221287-146-3-551; ROSSI M, 1993, J BACTERIOL, V175, P4699, DOI 10.1128/JB.175.15.4699-4711.1993; ROUSSEL A, 1990, 15 IUCR C BORD FRANC, P66; Saraiva LM, 1999, BIOCHEM BIOPH RES CO, V262, P629, DOI 10.1006/bbrc.1999.1238; SARAIVA LM, 2001, BIOCHIM BIOPHYS ACTA, P1; SCHOMAKER V, 1968, ACTA CRYSTALL B-STRU, VB 24, P63, DOI 10.1107/S0567740868001718; Simoes P, 1998, INORG CHIM ACTA, V273, P213, DOI 10.1016/S0020-1693(97)06018-0; Steger JL, 2002, APPL ENVIRON MICROB, V68, P1932, DOI 10.1128/AEM.68.4.1932-1937.2002; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tickle IJ, 1998, ACTA CRYSTALLOGR D, V54, P547, DOI 10.1107/S0907444997013875; TRAORE AS, 1981, J BACTERIOL, V154, P101; TSUJI K, 1980, ARCH MICROBIOL, V125, P35, DOI 10.1007/BF00403195; Umhau S, 2001, BIOCHEMISTRY-US, V40, P1308, DOI 10.1021/bi001479a; Valente FMA, 2001, CHEMBIOCHEM, V2, P895, DOI 10.1002/1439-7633(20011203)2:12<895::AID-CBIC895>3.0.CO;2-V; VERHAGEN MFJM, 1994, EUR J BIOCHEM, V225, P311, DOI 10.1111/j.1432-1033.1994.00311.x; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504	63	47	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47907	47916		10.1074/jbc.M207465200	http://dx.doi.org/10.1074/jbc.M207465200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356749	hybrid			2022-12-27	WOS:000179663700138
J	Witko-Sarsat, V; Canteloup, S; Durant, S; Desdouets, C; Chabernaud, R; Lemarchand, P; Descamps-Latscha, A				Witko-Sarsat, V; Canteloup, S; Durant, S; Desdouets, C; Chabernaud, R; Lemarchand, P; Descamps-Latscha, A			Cleavage of p21(waf1) by proteinase-3, a myeloid-specific serine protease, potentiates cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CDK-INHIBITORS; CATHEPSIN-G; EXPRESSION; P21; P21(CIP1/WAF1); AUTOANTIGEN; NEUTROPHILS; APOPTOSIS; GROWTH	In this study, we present evidence for the critical role of proteinase-3 (PR3) in the proliferation of myeloid cells via the proteolytic regulation of the cyclin-dependent kinase inhibitor p21(waf1). Expression of recombinant PR3 in rat (RBL) or human (IMCl) mast cell lines increased bromodeoxyuridine incorporation and CDK2 activity compared with RBL and HMC1 cells transfected with an enzymatically inactive PR3 mutant (PR3(S203A)) or with human neutrophil elastase. Western blot analysis of p21(waf1) showed an absence of detectable protein, despite normal levels of p21 mRNA. Ectopic overexpression of p21. restored normal levels of p21 in the RBL/PR3/p21 double transfectants and reverted the proliferative effect of PR3. Inhibition of the 26 S proteasome by lactacystin or of caspases by benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone did not inhibit p21 proteolysis. p21 cleavage correlated with PR3 expression in HMC1 cells infected with recombinant adenoviral vector Ad/PR3. During in vitro studies, purified p21 was cleaved by PR3, resulting in a 10-kDa p21 fragment. Employing double immunofluorescence confocal microscopy, subcellular fractionation, and coimmunoprecipitation, we found that PR3 and p21 colocalized in the cytosol. In human neutrophils treated with tumor necrosis factor-a, which induces PR3 re-expression, we observed that p21 disappeared and was reversed by Pefabloc, a serine proteinase inhibitor. The physiopathological implications of the cleavage of p21 by PR3 have to be determined.	Hop Necker Enfants Malad, INSERM, U507, F-75015 Paris, France; Fac Med Necker Enfants Malad, INSERM, U370, F-75015 Paris, France; Fac Med, INSERM, U533, F-44000 Nantes, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Witko-Sarsat, V (corresponding author), Hop Necker Enfants Malad, INSERM, U507, 161 Rue Sevres, F-75015 Paris, France.	witko-sarsat@necker.fr	Desdouets, Chantal/M-3430-2017; Witko-Sarsat, Veronique/L-9714-2017; lemarchand, patricia/C-3247-2011	Witko-Sarsat, Veronique/0000-0002-5296-9601; lemarchand, patricia/0000-0002-5330-2008				Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; BAGGIOLINI M, 1978, AGENTS ACTIONS, V8, P3, DOI 10.1007/BF01972395; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; CAMPANELLI D, 1990, J EXP MED, V172, P1709, DOI 10.1084/jem.172.6.1709; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Danel C, 1998, HUM GENE THER, V9, P1487, DOI 10.1089/hum.1998.9.10-1487; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Garwicz D, 1997, J LEUKOCYTE BIOL, V61, P113, DOI 10.1002/jlb.61.1.113; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Goldmann WH, 1999, EUR J BIOCHEM, V261, P155, DOI 10.1046/j.1432-1327.1999.00259.x; GULLBERG U, 1995, J BIOL CHEM, V270, P12912, DOI 10.1074/jbc.270.21.12912; GULLBERG U, 1994, J BIOL CHEM, V269, P25219; HARPER JW, 1993, CELL, V75, P805; HULTBERG B, 1976, BIOCHEM J, V155, P599, DOI 10.1042/bj1550599; JENNE DE, 1990, NATURE, V346, P520, DOI 10.1038/346520a0; JIANG HP, 1994, ONCOGENE, V9, P3397; Jin YH, 2000, J BIOL CHEM, V275, P30256, DOI 10.1074/jbc.M001902200; Just J, 1999, FEBS LETT, V457, P437, DOI 10.1016/S0014-5793(99)01098-4; Lutz PG, 2000, P NATL ACAD SCI USA, V97, P1601, DOI 10.1073/pnas.97.4.1601; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; McIntyre M, 1999, ONCOGENE, V18, P4577, DOI 10.1038/sj.onc.1202815; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Poon RYC, 1998, ONCOGENE, V16, P1333, DOI 10.1038/sj.onc.1201897; Rousseau D, 1999, ONCOGENE, V18, P3290, DOI 10.1038/sj.onc.1202681; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Specks U, 1996, FEBS LETT, V390, P265, DOI 10.1016/0014-5793(96)00669-2; Steinman RA, 1998, BLOOD, V91, P4531, DOI 10.1182/blood.V91.12.4531.412k10_4531_4542; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Taekema-Roelvink MEJ, 2000, J AM SOC NEPHROL, V11, P640, DOI 10.1681/ASN.V114640; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Witko-Sarsat V, 1999, AM J RESP CELL MOL, V20, P729, DOI 10.1165/ajrcmb.20.4.3371; Witko-Sarsat V, 1999, BLOOD, V94, P2487, DOI 10.1182/blood.V94.7.2487.419k07_2487_2496; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang JJ, 1996, AM J PATHOL, V149, P1617; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Zhou ZJ, 2000, J RHEUMATOL, V27, P2406	43	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47338	47347		10.1074/jbc.M202789200	http://dx.doi.org/10.1074/jbc.M202789200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354776	hybrid			2022-12-27	WOS:000179663700066
J	Chen, H; MacDonald, A; Coffino, P				Chen, H; MacDonald, A; Coffino, P			Structural elements of antizymes 1 and 2 are required for proteasomal degradation of ornithine decarboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULOCYTE LYSATE; ANGSTROM RESOLUTION; POLYAMINES; PROTEIN; CONSERVATION; PROTEOLYSIS	The antizymes constitute a conserved gene family with at least three mammalian orthologs. As described previously, in a degradation system utilizing rabbit reticulocyte lysate, antizyme 1 (AZ1) accelerates proteasomal ornithine decarboxylase (ODC) degradation, but antizyme 2 (AZ2) does not. To examine the relationship between antizyme structure and function, we further characterized the properties of AZ1 and AZ2 and protein chimeras composed of elements of the two. AZ1 binds to ODC with about a 3-fold higher potency than AZ2, but this cannot account for their distinct degradative activities. The dissimilar degradative capacity of AZ1 and AZ2 is also observed using purified proteasomes. A series of reciprocal AZ1/ AZ2 chimeras was used to determine the sequence elements needed to direct ODC degradation. An element contained within amino acids 130-145 of AZ1 is essential for this function. Constructs in which amino acids 130-145 were exchanged between the antizymes confirmed the critical nature of this region. Within this region amino acids 131 and 145 proved responsible for the functional difference between the two forms of AZ.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Coffino, P (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.	pcoffin@itsa.ucsf.edu		Coffino, Philip/0000-0003-0344-5083	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045335] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM-45335] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almrud JJ, 2000, J MOL BIOL, V295, P7, DOI 10.1006/jmbi.1999.3331; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Coffino P, 2000, MOL B INT U, V12, P254; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; ICHIBA T, 1994, BIOCHEM BIOPH RES CO, V200, P1721, DOI 10.1006/bbrc.1994.1651; Ivanov IP, 2000, P NATL ACAD SCI USA, V97, P4808, DOI 10.1073/pnas.070055897; Ivanov IP, 1998, GENOMICS, V52, P119, DOI 10.1006/geno.1998.5434; Ivanov IP, 2000, EMBO J, V19, P1907, DOI 10.1093/emboj/19.8.1907; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; MAMROUDKIDRON E, 1994, EUR J BIOCHEM, V226, P547, DOI 10.1111/j.1432-1033.1994.tb20079.x; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MURAKAMI Y, 1994, BIOCHEM J, V304, P183, DOI 10.1042/bj3040183; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Sambrook J., 2001, MOL CLONING LAB MANU, V3; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Zhu C, 1999, J BIOL CHEM, V274, P26425, DOI 10.1074/jbc.274.37.26425	23	32	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45957	45961		10.1074/jbc.M206799200	http://dx.doi.org/10.1074/jbc.M206799200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12359729	hybrid			2022-12-27	WOS:000179529300034
J	Ge, HF; Huang, L; Pourbahrami, T; Li, C				Ge, HF; Huang, L; Pourbahrami, T; Li, C			Generation of soluble leptin receptor by ectodomain shedding of membrane-spanning receptors in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND LEPTIN; OBESE GENE; SIGNAL-TRANSDUCTION; DIABETIC MICE; DB/DB MICE; OB-R; PROTEIN; IDENTIFICATION; TISSUES; CLONING	Leptin is an adipocyte-derived hormone with potent effects on food intake and body weight. Genetically obese rodents with mutations of leptin or leptin receptor develop morbid obesity and diabetes. The receptor for leptin, OB-R, is alternatively spliced to at least five transcripts, encoding receptors designated OB-Ra, -b, -c, -d, and -e. OB-Re does not encode a transmembrane domain and is secreted. In humans, transcripts corresponding to OB-Re have not been discovered. However, soluble leptin receptor does circulate in human plasma and represents the major leptin-binding activity. In this report, we attempted to determine whether the soluble leptin receptor may also be derived from membrane-spanning receptor isoforms by ectodomain shedding. Using stable cell lines expressing both OB-Ra, the most abundant leptin receptor isoform, and OB-Rb, the signaling form of the leptin receptor, we demonstrate that soluble leptin receptor protein can indeed be generated by proteolytic cleavage of these two receptor isoforms in vitro. Experiments using adenoviruses expressing dually tagged OB-Ra or Ob-Rb also demonstrate that soluble leptin receptor may be derived from ectodomain shedding of both receptor isoforms in vivo. Because our earlier and other studies have shown that the soluble receptors modulate the levels as well as activity of leptin, our findings suggest that regulated shedding of the ectodomain of membrane-spanning leptin receptors may represent a novel mechanism of modulating leptin's biological activity.	Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Li, C (corresponding author), Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dept Physiol, Dallas, TX 75390 USA.	Cai.Li@UTSouthwestern.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060137] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 60137] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chan JL, 2002, DIABETES, V51, P2105, DOI 10.2337/diabetes.51.7.2105; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1997, GENOMICS, V45, P264, DOI 10.1006/geno.1997.4962; Cohen SL, 1996, NATURE, V382, P589, DOI 10.1038/382589a0; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Gavrilova O, 1997, J BIOL CHEM, V272, P30546, DOI 10.1074/jbc.272.48.30546; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Huang L, 2000, Cell Res, V10, P81, DOI 10.1038/sj.cr.7290038; Huang L, 2001, J BIOL CHEM, V276, P6343, DOI 10.1074/jbc.M009795200; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Lahlou N, 2002, DIABETES, V51, P1980, DOI 10.2337/diabetes.51.6.1980; Laimer M, 2002, OBES RES, V10, P597, DOI 10.1038/oby.2002.81; Lammert A, 2001, BIOCHEM BIOPH RES CO, V283, P982, DOI 10.1006/bbrc.2001.4885; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Lewandowski K, 1999, J CLIN ENDOCR METAB, V84, P300, DOI 10.1210/jc.84.1.300; Li C, 1998, J BIOL CHEM, V273, P10078, DOI 10.1074/jbc.273.16.10078; Li C, 1999, P NATL ACAD SCI USA, V96, P9677, DOI 10.1073/pnas.96.17.9677; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Maamra M, 2001, ENDOCRINOLOGY, V142, P4389, DOI 10.1210/en.142.10.4389; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Monteleone P, 2002, MOL PSYCHIATR, V7, P641, DOI 10.1038/sj.mp.4001043; Ogier V, 2002, INT J OBESITY, V26, P496, DOI 10.1038/sj.ijo.0801951; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Sinha MK, 1996, J CLIN INVEST, V98, P1277, DOI 10.1172/JCI118913; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; van Dielen FMH, 2002, J CLIN ENDOCR METAB, V87, P1708, DOI 10.1210/jc.87.4.1708; Widjaja A, 2000, NEPHROL DIAL TRANSPL, V15, P846, DOI 10.1093/ndt/15.6.846; Wu ZD, 2002, J CLIN ENDOCR METAB, V87, P2931, DOI 10.1210/jc.87.6.2931; Yamaguchi M, 1998, BIOCHEM BIOPH RES CO, V252, P363, DOI 10.1006/bbrc.1998.9636; Zhang Y, 2000, ENDOCRINOLOGY, V141, P4342, DOI 10.1210/en.141.12.4342; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	43	138	149	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45898	45903		10.1074/jbc.M205825200	http://dx.doi.org/10.1074/jbc.M205825200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270921	hybrid			2022-12-27	WOS:000179529300026
J	Wada, S; Niimi, M; Niimi, K; Holmes, AR; Monk, BC; Cannon, RD; Uehara, Y				Wada, S; Niimi, M; Niimi, K; Holmes, AR; Monk, BC; Cannon, RD; Uehara, Y			Candida glabrata ATP-binding cassette transporters Cdr1p and Pdh1p expressed in a Saccharomyces cerevisiae strain deficient in membrane transporters show phosphorylation-dependent pumping properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOLE ANTIFUNGAL AGENTS; HUMAN P-GLYCOPROTEIN; PROTEIN-KINASE-C; YEAST ABC PROTEINS; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; FLUCONAZOLE RESISTANCE; PLEIOTROPIC DRUG; METAL RESISTANCE; PLASMA-MEMBRANE	The expression and drug efflux activity of the ATP binding cassette transporters Cdr1p and Pdh1p are thought to have contributed to the recent increase in the number of fungal infections caused by Candida glabrata. The function of these transporters and their pumping characteristics, however, remain ill defined. We have evaluated the function of Cdr1p and Pdh1p through their heterologous hyperexpression in a Saccharomyces cerevisiae strain deleted in seven major drug efflux transporters to minimize the background drug efflux activity. Although both Cdr1p- and Pdh1p-expressing strains CDR1-AD and PDH1-AD acquired multiple resistances to structurally unrelated compounds, CDR1-AD showed, in most cases, higher levels of resistance than PDH1-AD. CDR1-AD also showed greater rhodamine 6G efflux and resistance to pump inhibitors, although plasma membrane fractions had comparable NTPase activities. These results indicate that Cdr1p makes a larger contribution than Phd1p to the reduced susceptibility of C. glabrata to xenobiotics. Both pump proteins were phosphorylated in a glucose-dependent manner. Whereas the phosphorylation of Cdr1p affected its NTPase activity, the protein kinase A-mediated phosphorylation of Pdh1p, which was necessary for drug efflux, did not. This suggests that phosphorylation of Pdh1p may be required for efficient coupling of NTPase activity with drug efflux.	Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, Tokyo 1628640, Japan; Univ Otago, Dept Oral Sci & Orthodont, Dunedin 9001, New Zealand	National Institute of Infectious Diseases (NIID); University of Otago	Niimi, M (corresponding author), Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, 1-23-1 Toyamam, Tokyo 1628640, Japan.	niimi@nih.go.jp	Holmes, Ann R/G-6978-2017	Holmes, Ann R/0000-0001-9313-2114; Monk, Brian/0000-0003-2264-3480; Cannon, Richard/0000-0002-5398-2066				Albertson GD, 1996, ANTIMICROB AGENTS CH, V40, P2835, DOI 10.1128/AAC.40.12.2835; ARCECI RJ, 1992, BLOOD, V80, P1528; BALZI E, 1994, J BIOL CHEM, V269, P2206; BARNS SM, 1991, J BACTERIOL, V173, P2250, DOI 10.1128/JB.173.7.2250-2255.1991; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; Borges-Walmsley MI, 2001, TRENDS MICROBIOL, V9, P71, DOI 10.1016/S0966-842X(00)01920-X; Castilla R, 1998, CELL SIGNAL, V10, P713, DOI 10.1016/S0898-6568(98)00015-1; CHAMBERS TC, 1994, BIOCHEM J, V299, P309, DOI 10.1042/bj2990309; CHAMBERS TC, 1993, J BIOL CHEM, V268, P4592; CHAMBERS TC, 1992, MOL PHARMACOL, V41, P1008; Chen XJ, 2001, J BACTERIOL, V183, P3939, DOI 10.1128/JB.183.13.3939-3948.2001; Coleman DC, 1998, MED MYCOL, V36, P156; DANIEL T, 1998, METHOD ENZYMOL, V292, P130; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DECOTTIGNIES A, 1994, J BIOL CHEM, V269, P12797; Decottignies A, 1999, J BIOL CHEM, V274, P37139, DOI 10.1074/jbc.274.52.37139; DelSorbo G, 1997, MOL GEN GENET, V254, P417, DOI 10.1007/s004380050434; Diekema DJ, 2002, J CLIN MICROBIOL, V40, P1298, DOI 10.1128/JCM.40.4.1298-1302.2002; Egner R, 2000, MOL MICROBIOL, V35, P1255, DOI 10.1046/j.1365-2958.2000.01798.x; Egner R, 1998, MOL BIOL CELL, V9, P523, DOI 10.1091/mbc.9.2.523; Fidel PL, 1999, CLIN MICROBIOL REV, V12, P80, DOI 10.1128/CMR.12.1.80; FOXWELL BMJ, 1989, MOL PHARMACOL, V36, P543; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; GLASS DB, 1992, BIOCHEMISTRY-US, V31, P1728, DOI 10.1021/bi00121a021; Golin J, 2000, ANTIMICROB AGENTS CH, V44, P134, DOI 10.1128/AAC.44.1.134-138.2000; HAMADA H, 1988, CANCER RES, V48, P4926; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; Katiyar SK, 2001, MED MYCOL, V39, P109, DOI 10.1080/mmy.39.1.109.116; Kolaczkowski M, 1996, J BIOL CHEM, V271, P31543, DOI 10.1074/jbc.271.49.31543; Kralli A, 1996, J BIOL CHEM, V271, P17152, DOI 10.1074/jbc.271.29.17152; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Lupetti A, 2002, TRENDS MOL MED, V8, P76, DOI 10.1016/S1471-4914(02)02280-3; Miyazaki H, 1998, ANTIMICROB AGENTS CH, V42, P1695, DOI 10.1128/AAC.42.7.1695; MONK BC, 1991, J BACTERIOL, V173, P6826, DOI 10.1128/jb.173.21.6826-6836.1991; NAITO M, 1992, CANCER CHEMOTH PHARM, V29, P195, DOI 10.1007/BF00686252; Nakamura K, 2001, ANTIMICROB AGENTS CH, V45, P3366, DOI 10.1128/AAC.45.12.3366-3374.2001; Nikaido H, 1998, CURR OPIN MICROBIOL, V1, P516, DOI 10.1016/S1369-5274(98)80083-0; PARDO LA, 1989, BIOCHEM SOC T, V17, P1010, DOI 10.1042/bst0171010; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; Saier MH, 1998, FASEB J, V12, P265, DOI 10.1096/fasebj.12.3.265; Sanglard D, 1999, ANTIMICROB AGENTS CH, V43, P2753, DOI 10.1128/AAC.43.11.2753; SANGLARD D, 1995, ANTIMICROB AGENTS CH, V39, P2378, DOI 10.1128/AAC.39.11.2378; Sanglard D, 1997, MICROBIOL-UK, V143, P405, DOI 10.1099/00221287-143-2-405; Sanglard D, 2001, ANTIMICROB AGENTS CH, V45, P1174, DOI 10.1128/AAC.45.4.1174-1183.2001; SCHERER S, 1987, J CLIN MICROBIOL, V25, P675, DOI 10.1128/JCM.25.4.675-679.1987; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Standards N., 1997, M27A NAT COMM CLIN L; Szabo K, 1997, J BIOL CHEM, V272, P23165, DOI 10.1074/jbc.272.37.23165; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; Thornewell SJ, 1997, GENE, V201, P21, DOI 10.1016/S0378-1119(97)00421-6; TWENTYMAN PR, 1992, BIOCHEM PHARMACOL, V43, P109, DOI 10.1016/0006-2952(92)90668-9; Vanden Bossche H, 1998, MED MYCOL, V36, P119; WALSH DA, 1991, METHOD ENZYMOL, V201, P304; Wolfger H, 2001, RES MICROBIOL, V152, P375, DOI 10.1016/S0923-2508(01)01209-8; YUSA K, 1989, CANCER RES, V49, P5002	60	47	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46809	46821		10.1074/jbc.M207817200	http://dx.doi.org/10.1074/jbc.M207817200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244114	hybrid			2022-12-27	WOS:000179529300142
J	Gill, A; Gao, NG; Lehrman, MA				Gill, A; Gao, NG; Lehrman, MA			Rapid activation of glycogen phosphorylase by the endoplasmic reticulum unfolded protein response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED OLIGOSACCHARIDES; GLYCOSYLATION; PYROPHOSPHATE; TISSUES	Endoplasmic reticulum (ER) stress is associated with misfolding of ER proteins and triggers the unfolded protein response (UPR). The UPR, in turn, helps restore normal ER function. Since fastidious N-linked glycosylation. is critical for folding of most ER proteins, this study examined whether metabolic interconversions of precursors used for glycan assembly were controlled by the UPR. Thus, eight enzymes and factors with key roles in hexose phosphate metabolism were assayed in cytoplasmic extracts from primary dermal fibroblasts treated with UPR inducers. Stimulation of only one activity by the UPR was detected, AMP-independent glycogen phosphorylase (GP). GP activation required only 20 min of ER stress, with concurrent decreases in cellular glycogen and elevations of its metabolites Glc-1-P and Glc-6-P. Addition of phosphatase inhibitors to enzyme extracts from unstressed cells mimicked the effect of ER stress on GP activity, suggesting that phosphorylation of GP or a regulatory factor was involved. These data show that the UPR can modulate hexose metabolism in a manner beneficial for protein glycosylation. Since activation of GP appears to occur by a rapid posttranslational process, it may be part of a general strategy of ER damage control, preceding the well-known transcription-dependent processes of the UPR that are manifested hours after the occurrence of ER stress.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lehrman, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.	mlehrm@mednet.swmed.edu			NIGMS NIH HHS [GM38545] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM038545, R01GM038545] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anand M, 2001, MOL BIOL CELL, V12, P487, DOI 10.1091/mbc.12.2.487; Doerrler WT, 1999, P NATL ACAD SCI USA, V96, P13050, DOI 10.1073/pnas.96.23.13050; FURUYA E, 1981, J BIOL CHEM, V256, P7109; Gao NG, 2002, GLYCOBIOLOGY, V12, P353, DOI 10.1093/glycob/12.5.353; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; KEPPLER D, 1974, METHOD ENZYMAT AN, V6, P1127; Lehrman MA, 2001, J BIOL CHEM, V276, P8623, DOI 10.1074/jbc.R100002200; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Marquardt T, 2001, BIOL CHEM, V382, P161, DOI 10.1515/BC.2001.024; MARTYS JL, 1995, J BIOL CHEM, V270, P25976, DOI 10.1074/jbc.270.43.25976; McMahon RJ, 1996, AM J PHYSIOL-ENDOC M, V270, pE640, DOI 10.1152/ajpendo.1996.270.4.E640; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; ROBSON RL, 1974, BIOCHEM J, V144, P513, DOI 10.1042/bj1440513; Shang J, 2002, GLYCOBIOLOGY, V12, P307, DOI 10.1093/glycob/12.5.307; SPIRO MJ, 1984, DIABETOLOGIA, V26, P70; UYEDA K, 1981, J BIOL CHEM, V256, P8394; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VanSchaftingen E, 1995, FEBS LETT, V377, P318, DOI 10.1016/0014-5793(95)01357-1	22	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44747	44753		10.1074/jbc.M205001200	http://dx.doi.org/10.1074/jbc.M205001200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223475	hybrid			2022-12-27	WOS:000179404800021
J	Melendez, J; Welch, S; Schaefer, E; Moravec, CS; Avraham, S; Avraham, H; Sussman, MA				Melendez, J; Welch, S; Schaefer, E; Moravec, CS; Avraham, S; Avraham, H; Sussman, MA			Activation of pyk2/related focal adhesion tyrosine kinase and focal adhesion kinase in cardiac remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR; DILATED CARDIOMYOPATHY; SUBCELLULAR TRANSLOCATION; VENTRICULAR MYOCYTES; PRESSURE-OVERLOAD; PYK2 EXPRESSION; ANGIOTENSIN-II; C BETA; PAXILLIN	Cellular remodeling during progression of dilation involves focal adhesion contact reorganization. However, the signaling mechanisms and structural consequences leading to impaired cardiomyocyte adhesion are poorly defined. These events were studied in tropomodulin-overexpressing transgenic mice that develop dilated cardiomyopathy associated with chronic elevation of intracellular calcium. Analysis of tropomodulin-overexpressing transgenic hearts by immunoblot and confocal microscopy revealed activation and redistribution of signaling molecules known to regulate adhesion. Calcium-dependent pyk2/related focal adhesion tyrosine kinase (RAFTK) showed changes in expression and phosphorylation state, similar to changes observed for a related downstream target molecule of pyk2/RAFTK termed focal adhesion kinase. Paxillin, the target substrate molecule for focal adhesion kinase phosphorylation, was redistributed in tropomodulin-overexpressing transgenic hearts with enhanced paxillin phosphorylation and cleavage. Certain aspects of the in vivo signaling phenotype including increased paxillin phosphorylation could be recapitulated in vitro using neonatal rat cardiomyocytes infected with recombinant adenovirus to overexpress tropomodulin. In addition, increasing intracellular calcium levels with ionomycin induced pyk2/ RAFTK phosphorylation, and adenovirally mediated expression of wild-type pyk2/RAFTK resulted in increased phospho-pyk2/RAFTK levels and concomitant paxillin phosphorylation. Collectively, these results delineate a cardiomyocyte signaling pathway associated with dilation that has potential relevance for cardiac remodeling, focal adhesion reorganization, and loss of contractility.	Childrens Hosp Res Fdn, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; Biosource Int, Hopkinton, MA 01748 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Kaufman Ctr Heart Failure, Cleveland, OH 44195 USA; Beth Israel Hosp, Div Expt Med, Harvard Inst Med, Boston, MA 02215 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Cleveland Clinic Foundation; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Sussman, MA (corresponding author), Childrens Hosp Res Fdn, Div Mol Cardiovasc Biol, Rm 3033,3333 Burnet Ave, Cincinnati, OH 45229 USA.	sussman@heart.chmce.org	; Sussman, Mark/H-2284-2014	Avraham, Hava/0000-0002-7545-3640; Sussman, Mark/0000-0002-0104-4799; Melendez Rojel, Jaime/0000-0003-4711-864X	NHLBI NIH HHS [HL66035, HL58224, HL67245] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066035, R29HL058224, R01HL058224, R01HL067245] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Bayer AL, 2002, AM J PHYSIOL-HEART C, V283, pH695, DOI 10.1152/ajpheart.00021.2002; Bayer AL, 2001, J MOL CELL CARDIOL, V33, P1017, DOI 10.1006/jmcc.2001.1369; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BELTRAMI CA, 1995, J MOL CELL CARDIOL, V27, P291, DOI 10.1016/S0022-2828(08)80028-4; BEUCKELMANN DJ, 1992, CIRCULATION, V85, P1046, DOI 10.1161/01.CIR.85.3.1046; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Bowman JC, 1997, J CLIN INVEST, V100, P2189, DOI 10.1172/JCI119755; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; Chay KO, 2002, J BIOL CHEM, V277, P14521, DOI 10.1074/jbc.M111639200; CLERK A, 1994, J BIOL CHEM, V269, P32848; DANOWSKI BA, 1992, J CELL BIOL, V118, P1411, DOI 10.1083/jcb.118.6.1411; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Domingos PP, 2002, AM J PHYSIOL-HEART C, V282, pH556, DOI 10.1152/ajpheart.00534.2001; Du QS, 2001, J CELL SCI, V114, P2977; Eble DM, 2000, AM J PHYSIOL-HEART C, V278, pH1695, DOI 10.1152/ajpheart.2000.278.5.H1695; Franchini KG, 2000, CIRC RES, V87, P558, DOI 10.1161/01.RES.87.7.558; Francis GS, 1998, CURR OPIN CARDIOL, V13, P156; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Koziak K, 2001, BRIT J HAEMATOL, V114, P134, DOI 10.1046/j.1365-2141.2001.02894.x; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; Laser M, 2000, J BIOL CHEM, V275, P35624, DOI 10.1074/jbc.M006124200; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Mukhopadhyay D, 1998, CANCER RES, V58, P1278; Murasawa S, 1998, HYPERTENSION, V32, P668, DOI 10.1161/01.HYP.32.4.668; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Park SY, 2000, J BIOL CHEM, V275, P19768, DOI 10.1074/jbc.M909932199; Pham CG, 2000, AM J PHYSIOL-HEART C, V279, pH2916, DOI 10.1152/ajpheart.2000.279.6.H2916; Richard S, 1998, CARDIOVASC RES, V37, P300, DOI 10.1016/S0008-6363(97)00273-3; Rocic P, 2001, AM J PHYSIOL-CELL PH, V280, pC90, DOI 10.1152/ajpcell.2001.280.1.C90; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHAPER J, 1991, CIRCULATION, V83, P504, DOI 10.1161/01.CIR.83.2.504; Seko Y, 1999, BIOCHEM BIOPH RES CO, V262, P290, DOI 10.1006/bbrc.1999.1185; Seko Y, 1999, BIOCHEM BIOPH RES CO, V259, P8, DOI 10.1006/bbrc.1999.0720; SHARP WW, 1997, AM J PHYSIOL, V273, P546; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sussman MA, 1999, AM J PATHOL, V155, P2101, DOI 10.1016/S0002-9440(10)65528-9; Sussman MA, 1998, J CLIN INVEST, V101, P51, DOI 10.1172/JCI1167; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Sussman MA, 2000, J CLIN INVEST, V105, P875, DOI 10.1172/JCI8497; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Takahashi N, 1999, CIRC RES, V84, P1194, DOI 10.1161/01.RES.84.10.1194; Taylor JM, 2000, J BIOL CHEM, V275, P19250, DOI 10.1074/jbc.M909099199; TURNER CE, 1994, J CELL SCI, V107, P1583; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; Welch S, 2002, CIRC RES, V90, P641, DOI 10.1161/01.RES.0000013780.77774.75; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	61	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45203	45210		10.1074/jbc.M204886200	http://dx.doi.org/10.1074/jbc.M204886200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228222	hybrid			2022-12-27	WOS:000179404800079
J	Park, SG; Kang, YS; Ahn, YH; Lee, SH; Kim, KR; Kim, KW; Koh, GY; Ko, YG; Kim, S				Park, SG; Kang, YS; Ahn, YH; Lee, SH; Kim, KR; Kim, KW; Koh, GY; Ko, YG; Kim, S			Dose-dependent biphasic activity of tRNA synthetase-associating factor, p43, in angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ACTIVATING POLYPEPTIDE-II; PROTEIN-PROTEIN INTERACTIONS; HUMAN ENDOTHELIAL-CELLS; IN-VITRO; MULTISYNTHETASE COMPLEX; INDUCED APOPTOSIS; ATP SYNTHASE; CYTOKINE; JNK	Mammalian aminoacyl tRNA synthetases form a macromolecular protein complex with three non-enzymatic cofactors. Among these factors, p43 is also secreted to work as a cytokine on endothelial as well as immune cells. Here we investigated the activity of p43 in angiogenesis and determined the related mediators. It promoted the migration of endothelial cells at low dose but induced their apoptosis at high dose. p43 at low concentration activated extracellular signal-regulating kinase, which resulted in the induction and activation of matrix metalloproteinase 9. In contrast, p43 at high concentration activated Jun N-terminal kinase, which mediated apoptosis of endothelial cells. These results suggest that p43 is a novel cytokine playing a dose-dependent biphasic role in angiogenesis.	Seoul Natl Univ, Coll Pharm, Natl Creat Res Initiat Ctr ARS Network, Seoul 151742, South Korea; Seoul Natl Univ, Coll Pharm, Angiogenesis Res Lab, Seoul 151742, South Korea; Postech, Natl Creat Res Initiat Ctr Cardiac Regenerat, Pohang 790784, South Korea	Seoul National University (SNU); Seoul National University (SNU); Pohang University of Science & Technology (POSTECH)	Kim, S (corresponding author), Seoul Natl Univ, Coll Pharm, Ctr ARS Network, Kwanak Ku, San 56-1,Shillim Dong, Seoul 151746, South Korea.	sungkim@snu.ac.kr	Koh, Gou Young/C-1615-2011; Kim, Sunghoon/AAE-8314-2020	Ahn, Young Ha/0000-0002-6843-5444				Banerjee SK, 1997, MOL CELL BIOCHEM, V177, P97, DOI 10.1023/A:1006888020596; Berger AC, 2000, MICROVASC RES, V60, P70, DOI 10.1006/mvre.2000.2249; Chang SY, 2002, J BIOL CHEM, V277, P8388, DOI 10.1074/jbc.M108792200; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; FISHER C, 1994, DEV BIOL, V162, P499, DOI 10.1006/dbio.1994.1104; Genersch E, 2000, J CELL SCI, V113, P4319; Harding TC, 2001, J BIOL CHEM, V276, P4531, DOI 10.1074/jbc.C000815200; Ho FM, 2000, CIRCULATION, V101, P2618, DOI 10.1161/01.CIR.101.22.2618; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Khan KMF, 2002, J BIOL CHEM, V277, P2353, DOI 10.1074/jbc.M108989200; Kim JY, 2002, P NATL ACAD SCI USA, V99, P7912, DOI 10.1073/pnas.122110199; Kim T, 2000, J BIOL CHEM, V275, P21768, DOI 10.1074/jbc.M002404200; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; Ko YG, 2001, J BIOL CHEM, V276, P23028, DOI 10.1074/jbc.M101544200; Ko YG, 2001, J BIOL CHEM, V276, P39103, DOI 10.1074/jbc.M105928200; Kraling BM, 1999, J CELL SCI, V112, P1599; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; Moser TL, 2001, P NATL ACAD SCI USA, V98, P6656, DOI 10.1073/pnas.131067798; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Norcum MT, 2000, J BIOL CHEM, V275, P17921, DOI 10.1074/jbc.C000266200; Park H, 2002, J LEUKOCYTE BIOL, V71, P223; Park SG, 1999, J BIOL CHEM, V274, P16673, DOI 10.1074/jbc.274.24.16673; Pazouki S, 1996, BIOCHEM SOC T, V24, pS368, DOI 10.1042/bst024368s; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Puyraimond A, 1999, J CELL SCI, V112, P1283; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Quevillon S, 1997, J BIOL CHEM, V272, P32573, DOI 10.1074/jbc.272.51.32573; Rho SB, 1996, P NATL ACAD SCI USA, V93, P10128, DOI 10.1073/pnas.93.19.10128; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; Rho SB, 1998, J BIOL CHEM, V273, P11267, DOI 10.1074/jbc.273.18.11267; Robinson JC, 2000, J MOL BIOL, V304, P983, DOI 10.1006/jmbi.2000.4242; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; Schwarz MA, 1999, J EXP MED, V190, P341, DOI 10.1084/jem.190.3.341; Shalak V, 2001, J BIOL CHEM, V276, P23769, DOI 10.1074/jbc.M100489200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wakasugi K, 2002, P NATL ACAD SCI USA, V99, P173, DOI 10.1073/pnas.012602099; Wakasugi K, 1999, J BIOL CHEM, V274, P23155, DOI 10.1074/jbc.274.33.23155; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Yang DCH, 1996, CURR TOP CELL REGUL, V34, P101, DOI 10.1016/S0070-2137(96)80004-5	43	93	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45243	45248		10.1074/jbc.M207934200	http://dx.doi.org/10.1074/jbc.M207934200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237313	hybrid			2022-12-27	WOS:000179404800084
J	Selva, DM; Hogeveen, KN; Seguchi, K; Tekpetey, F; Hammond, GL				Selva, DM; Hogeveen, KN; Seguchi, K; Tekpetey, F; Hammond, GL			A human sex hormone-binding globulin isoform accumulates in the acrosome during spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; PROTEIN GENE; EXPRESSION; RNA; CONTAINS; HOMOLOGY; PROMOTER; SEQUENCE; SHBG	Human sex hormone-binding globulin (SHBG) binds estradiol and testosterone with high affinity. Plasma SHBG is produced by hepatocytes, but the human SHBG gene is also expressed in the testis. Little is known about SHBG gene expression in the human testis, but human SHBG transcripts accumulate in a spermatogenic stage-dependent manner in the testes of mice containing an 11-kb human SHBG transgene. We have now found that human SHBG transcripts containing an alternative exon 1 sequence are located specifically in the testicular germ cells of these transgenic mice, whereas murine SHBG transcripts are confined to Sertoli cells. In addition, we have detected immunoreactive human SHBG in the acrosome during all stages of spermiogenesis in mice containing an 11-kb human SHBG transgene. Western blots of germ cell extracts from these transgenic mice and from human sperm indicate that the immunoreactive human SHBG in the acrosome composes electrophoretic variants, which are 3-5 kDa smaller than the major electrophoretic isoforms of human SHBG in the blood. This apparent size difference is due in part to differences in glycosylation of plasma and acrosomal SHBG isoforms. The function of the human SHBG isoform in the acrosome is unknown, but it binds steroid ligands with high affinity. This is the first demonstration that human SHBG transcripts encode an SHBG isoform that remains within a cellular compartment.	Univ Western Ontario, Dept Obstet & Gynecol, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 4L6, Canada; Univ Western Ontario, Canadian Inst Hlth Res Grp Fetal & Neonatal Hlth, London, ON N6A 4L6, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Hammond, GL (corresponding author), London Reg Canc Ctr, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.	ghammond@uwo.ca	Selva, David Martínez/O-6444-2016	Hammond, Geoffrey/0000-0002-4639-7336				Avvakumov GV, 2000, J BIOL CHEM, V275, P25920, DOI 10.1074/jbc.M004484200; AVVAKUMOV GV, 1988, BIOCHEMISTRY-MOSCOW+, V53, P726; BERUBE D, 1990, CYTOGENET CELL GENET, V54, P65, DOI 10.1159/000132958; BOCCHINFUSO WP, 1992, ENDOCRINOLOGY, V131, P2331, DOI 10.1210/en.131.5.2331; GERSHAGEN S, 1989, NUCLEIC ACIDS RES, V17, P9245, DOI 10.1093/nar/17.22.9245; HALL SH, 1990, MOL ENDOCRINOL, V4, P349, DOI 10.1210/mend-4-2-349; HAMMOND GL, 1983, CLIN CHIM ACTA, V132, P101, DOI 10.1016/0009-8981(83)90237-1; HAMMOND GL, 1987, FEBS LETT, V215, P100, DOI 10.1016/0014-5793(87)80121-7; HAMMOND GL, 1989, MOL ENDOCRINOL, V3, P1869, DOI 10.1210/mend-3-11-1869; HAMMOND GL, 1993, STEROID HORMONE ACTI, P1; Hogeveen KN, 2002, J CLIN INVEST, V109, P973, DOI 10.1172/JCI200214060; Hogeveen KN, 2001, J BIOL CHEM, V276, P36383, DOI 10.1074/jbc.M104681200; Janne M, 1998, J BIOL CHEM, V273, P34105, DOI 10.1074/jbc.273.51.34105; Janne M, 1998, MOL ENDOCRINOL, V12, P123; Janne M, 1999, ENDOCRINOLOGY, V140, P4166, DOI 10.1210/en.140.9.4166; JOSEPH DR, 1994, VITAM HORM, V49, P197; JOSEPH DR, 1987, P NATL ACAD SCI USA, V84, P339, DOI 10.1073/pnas.84.2.339; Joseph DR, 1996, ENDOCRINOLOGY, V137, P1138, DOI 10.1210/en.137.3.1138; MARTINEZMENARGUEZ JA, 1992, HISTOCHEMISTRY, V97, P439, DOI 10.1007/BF00270391; Misao R, 1997, CANCER RES, V57, P5579; Misao R, 1998, FERTIL STERIL, V69, P324, DOI 10.1016/S0015-0282(97)00495-0; REVENTOS J, 1993, MOL CELL ENDOCRINOL, V96, P69, DOI 10.1016/0303-7207(93)90096-3; REVENTOS J, 1988, MOL ENDOCRINOL, V2, P125, DOI 10.1210/mend-2-2-125; RUSSELL LD, 1990, HISTOLOGICAL HISTOPA, P140; SANTIEMMA V, 1992, J STEROID BIOCHEM, V43, P423, DOI 10.1016/0960-0760(92)90080-3; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Selva DM, 2000, ENDOCRINOLOGY, V141, P1168, DOI 10.1210/en.141.3.1168; SULLIVAN PM, 1993, MOL ENDOCRINOL, V7, P702, DOI 10.1210/me.7.5.702; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; WANG YM, 1989, MOL CELL ENDOCRINOL, V63, P85, DOI 10.1016/0303-7207(89)90084-1; WANG YM, 1990, ENDOCRINOLOGY, V127, P3124, DOI 10.1210/endo-127-6-3124; Weiss M, 1997, BIOL REPROD, V57, P68, DOI 10.1095/biolreprod57.1.68; WESTPHAL U, 1986, MONOGRAPHS ENDOCRINO, P276	34	26	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45291	45298		10.1074/jbc.M205903200	http://dx.doi.org/10.1074/jbc.M205903200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235141	hybrid			2022-12-27	WOS:000179404800090
J	Hurbin, A; Dubrez, L; Coll, JL; Favrot, MC				Hurbin, A; Dubrez, L; Coll, JL; Favrot, MC			Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; EGF-RELATED PEPTIDES; EPITHELIAL-CELLS; TUMOR-CELLS; HUMAN COLON; IGF-I; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; SIGNALING NETWORK; CARCINOMA CELLS; HEPARIN-BINDING	Several abnormalities in the insulin-like growth factor-1 (IGF1) and erbB receptors pathways stimulate the growth and survival of lung cancer cells, but their mechanisms of action and cooperation are poorly understood. In this report, we have identified a new mechanism of apoptosis inhibition by amphiregulin through an IGF1-dependent survival pathway in non-small cell lung cancer (NSCLC) cells: amphiregulin activates the IGF1 receptor that in turn induces the secretion of amphiregulin and IGF1. In the absence of serum, the NSCLC cell line H358 resists apoptosis and secretes factors protecting the NSCLC cell line H322 from serum deprivation apoptosis. IGF1 receptor inhibitor AG1024 as well as epidermal growth factor receptor inhibitors AG556 and ZD1839 restore apoptosis in H322 cells cultured in H358-conditioned medium. Accordingly, the anti-apoptotic activity of H358-conditioned medium is completely abolished after incubation with anti-amphiregulin neutralizing antibody and only partially with anti-IGF1 neutralizing antibody. H358-conditioned medium and amphiregulin induce IGF1 receptor phosphorylation in H322 cells, which is prevented by anti-amphiregulin neutralizing antibody but not by AG556 or ZD1839. H358 cells secrete a high level of amphiregulin that, in combination with IGF1, prevents serum deprivation apoptosis. Finally, IGF1 receptor inhibitor blocks amphiregulin and IGF1 release by H358 cells.	Inst Albert Bonniot, INSERM, EMI 9924, Grp Rech Canc Poumon, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Favrot, MC (corresponding author), Inst Albert Bonniot, INSERM, EMI 9924, Grp Rech Canc Poumon, F-38706 La Tronche, France.	MCFavrot@chu-grenoble.fr	Coll, Jean-Luc/G-2520-2013; Dubrez, Laurence/I-4971-2016; Laurence, Dubrez/P-9472-2019; Hurbin, Amandine/M-2693-2013	Coll, Jean-Luc/0000-0002-2453-3552; Dubrez, Laurence/0000-0002-7030-2181; Laurence, Dubrez/0000-0002-7030-2181; Hurbin, Amandine/0000-0003-0535-1945				AKAGI M, 1995, CANCER, V75, P1460, DOI 10.1002/1097-0142(19950315)75:6+<1460::AID-CNCR2820751513>3.0.CO;2-L; Alemany R, 1996, CANCER GENE THER, V3, P296; Balana ME, 2001, ONCOGENE, V20, P34, DOI 10.1038/sj.onc.1204050; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; Blakesley VA, 1998, J BIOL CHEM, V273, P18411, DOI 10.1074/jbc.273.29.18411; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Casamassimi A, 2000, ANN ONCOL, V11, P319, DOI 10.1023/A:1008350811639; Chakravarti A, 2002, CANCER RES, V62, P200; Chen H, 1998, CELL GROWTH DIFFER, V9, P939; Cheng HL, 2000, MOL CELL ENDOCRINOL, V170, P211, DOI 10.1016/S0303-7207(00)00324-5; COLES HSR, 1993, DEVELOPMENT, V118, P777; DAmbrosio C, 1997, CANCER RES, V57, P3264; DAmbrosio C, 1996, CANCER RES, V56, P4013; Damstrup L, 1999, BRIT J CANCER, V80, P1012, DOI 10.1038/sj.bjc.6690456; De Luca A, 2000, ONCOGENE, V19, P5863, DOI 10.1038/sj.onc.1203979; De Luca A, 1999, INT J CANCER, V80, P589, DOI 10.1002/(SICI)1097-0215(19990209)80:4<589::AID-IJC17>3.0.CO;2-D; Dews M, 1997, RECEPT SIGNAL TRANS, V7, P231; Dubrez L, 2001, J BIOL CHEM, V276, P38980, DOI 10.1074/jbc.M102683200; Esposito DL, 1997, ENDOCRINOLOGY, V138, P2979, DOI 10.1210/en.138.7.2979; Fernandes AM, 1999, CANCER LETT, V142, P55, DOI 10.1016/S0304-3835(99)00166-4; Fontanini G, 1998, CLIN CANCER RES, V4, P241; Funatomi H, 1997, INT J CANCER, V72, P512, DOI 10.1002/(SICI)1097-0215(19970729)72:3<512::AID-IJC21>3.0.CO;2-C; Gagnon A, 2001, ENDOCRINOLOGY, V142, P205, DOI 10.1210/en.142.1.205; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; Hague A, 1997, BRIT J CANCER, V75, P960, DOI 10.1038/bjc.1997.167; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hongo A, 1996, ONCOGENE, V12, P1231; Ilio KY, 1995, J ANDROL, V16, P482; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; Jung YK, 1996, J BIOL CHEM, V271, P5112; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Ma L, 1999, ONCOGENE, V18, P6513, DOI 10.1038/sj.onc.1203042; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MOODY TW, 1993, LIFE SCI, V52, P1161, DOI 10.1016/0024-3205(93)90098-N; MUTA K, 1993, J CELL PHYSIOL, V156, P264, DOI 10.1002/jcp.1041560207; NORMANNO N, 1995, INT J CANCER, V62, P762, DOI 10.1002/ijc.2910620619; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Piepkorn M, 1998, J INVEST DERMATOL, V111, P715, DOI 10.1046/j.1523-1747.1998.00390.x; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; Putz T, 1999, CANCER RES, V59, P227; RAWSON CL, 1991, J CELL BIOL, V113, P671, DOI 10.1083/jcb.113.3.671; RESNICOFF M, 1995, CANCER RES, V55, P2463; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Rozengurt Enrique, 1999, Current Opinion in Oncology, V11, P116; RUSCH V, 1995, CANCER RES, V55, P1365; Rusch V, 1997, CLIN CANCER RES, V3, P515; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Sizemore N, 1999, GASTROENTEROLOGY, V117, P567, DOI 10.1016/S0016-5085(99)70449-X; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; TATEISHI M, 1990, CANCER RES, V50, P7077; VARDY DA, 1995, J CELL PHYSIOL, V163, P257, DOI 10.1002/jcp.1041630206; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; Wu XF, 2000, JNCI-J NATL CANCER I, V92, P737, DOI 10.1093/jnci/92.9.737; ZHU CZ, 1994, J CEREBR BLOOD F MET, V14, P237, DOI 10.1038/jcbfm.1994.30; Zushi S, 1997, INT J CANCER, V73, P917, DOI 10.1002/(SICI)1097-0215(19971210)73:6<917::AID-IJC26>3.0.CO;2-#	63	78	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49127	49133		10.1074/jbc.M207584200	http://dx.doi.org/10.1074/jbc.M207584200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12356750	hybrid, Green Submitted			2022-12-27	WOS:000180028900006
J	Rao, MK; Wayne, CM; Wilkinson, MF				Rao, MK; Wayne, CM; Wilkinson, MF			Pem homeobox gene regulatory sequences that direct androgen-dependent developmentally regulated gene expression in different subregions of the epididymis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATED GLYCOPROTEIN-2 CLUSTERIN; MESSENGER-RIBONUCLEIC-ACID; RAT EPIDIDYMIS; EXTRAEMBRYONIC TISSUES; TRANSGENE EXPRESSION; TESTICULAR FACTORS; VENTRAL PROSTATE; PROXIMAL REGION; SEMINAL-VESICLE; SERTOLI-CELLS	The epididymis is a useful model system to understand the mechanisms that govern region-specific gene expression, as many gene products display spatially restricted expression within this organ. However, surprisingly little is known about how this regulation is achieved. Here, we report regulatory sequences from the Pent homeobox gene that drive expression in different subregions of the mouse epididymis in vivo. We found that the 0.3-kb 5'-flanking sequence (region I) from the Pent proximal promoter (Pem Pp) was sufficient to confer androgen-dependent and developmentally regulated expression in the caput region of the epididymis. Expression was restricted to the normal regions of expression of Pent in the caput (segments 2-4), but there was also aberrant expression in the corpus region. This corpus misexpression was extinguished when 0.6 kb of Pem Pp 5'-flanking sequence was included in the transgene, indicating that one or more negative regulatory elements exist between 0.6 and 0.3 kb upstream of the Pent Pp start site (region II). When heterologous sequences were introduced upstream of the Pent Pp, expression was further restricted, mainly to caput segment 3, implying that the Pent Pp has segment-specific regulatory elements. To our knowledge, the regulatory regions we have identified are the shortest so far defined that dictate regionally localized expression in the epididymis in vivo. They may be useful for identifying the factors that regulate region-specific expression in the epididymis, for expressing and conditionally knocking out genes in different subregions of the epididymis, for treating male infertility, and for generating novel methods of male contraception.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Wilkinson, MF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Box 180,1515 Holcombe Blvd, Houston, TX 77030 USA.	mwilkins@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA078023] Funding Source: NIH RePORTER; NCI NIH HHS [CA78023] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN JR, 2002, EPIDIDYMIS MOL CLIN, P435; AYERLELIEVRE C, 1988, P NATL ACAD SCI USA, V85, P2628, DOI 10.1073/pnas.85.8.2628; Barbulescu K, 2001, MOL ENDOCRINOL, V15, P1803, DOI 10.1210/me.15.10.1803; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; BORSOOK D, 1992, MOL ENDOCRINOL, V6, P1502, DOI 10.1210/me.6.9.1502; CHAREST NJ, 1989, ENDOCRINOLOGY, V125, P942, DOI 10.1210/endo-125-2-942; Cheuk BLY, 2000, BIOL REPROD, V63, P775, DOI 10.1093/biolreprod/63.3.775; CORNWALL GA, 1995, J ANDROL, V16, P379; CORNWALL GA, 1992, MOL ENDOCRINOL, V6, P1653, DOI 10.1210/me.6.10.1653; Cyr DG, 2001, J ANDROL, V22, P124; CYR DG, 1992, ENDOCRINOLOGY, V130, P2160, DOI 10.1210/en.130.4.2160; DOUGLASS J, 1991, ANN NY ACAD SCI, V637, P384, DOI 10.1111/j.1749-6632.1991.tb27324.x; EWING LL, 1979, BIOL REPROD, V21, P765, DOI 10.1095/biolreprod21.4.765; Ezer N., 2002, EPIDIDYMIS MOL CLIN, P297, DOI [10.1007/978-1-4615-0679-9_17, DOI 10.1007/978-1-4615-0679-9_17]; GALLON C, 1989, J ANDROL, V10, P188; GARRETT JE, 1990, MOL ENDOCRINOL, V4, P108, DOI 10.1210/mend-4-1-108; GIROTTI M, 1992, BIOCHEM J, V281, P203, DOI 10.1042/bj2810203; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Han YJ, 2000, GENE, V241, P149, DOI 10.1016/S0378-1119(99)00453-9; HERMO L, 1992, ANAT RECORD, V233, P205, DOI 10.1002/ar.1092330205; HERMO L, 1994, ANAT RECORD, V240, P327, DOI 10.1002/ar.1092400306; Hermo L., 2002, EPIDIDYMIS MOL CLIN, P81, DOI [10.1007/978-1-4615-0679-9_5, DOI 10.1007/978-1-4615-0679-9_5]; HINTON BT, 1995, MICROSC RES TECHNIQ, V30, P67, DOI 10.1002/jemt.1070300106; JEANFAUCHER C, 1985, INT J ANDROL, V8, P44, DOI 10.1111/j.1365-2605.1985.tb00817.x; Jervis KM, 2001, BIOL REPROD, V65, P696, DOI 10.1095/biolreprod65.3.696; KANGASNIEMI M, 1995, ENDOCRINOLOGY, V136, P2881, DOI 10.1210/en.136.7.2881; Kuschert S, 2001, DEV BIOL, V229, P128, DOI 10.1006/dbio.2000.9971; Lahti PP, 2001, BIOL REPROD, V64, P1115, DOI 10.1095/biolreprod64.4.1115; Lan ZJ, 1998, BIOL REPROD, V58, P197, DOI 10.1095/biolreprod58.1.197; Lan ZJ, 1999, BIOL REPROD, V60, P664, DOI 10.1095/biolreprod60.3.664; Lareyre JJ, 1999, J BIOL CHEM, V274, P8282, DOI 10.1074/jbc.274.12.8282; Lareyre JJ, 1998, J REPROD FERTIL, P59; LAW GL, 1994, BIOL REPROD, V50, P669, DOI 10.1095/biolreprod50.3.669; Li YH, 1997, DEV BIOL, V188, P85, DOI 10.1006/dbio.1997.8640; LIN TP, 1994, DEV BIOL, V166, P170, DOI 10.1006/dbio.1994.1305; Lindsey JS, 1996, DEV BIOL, V179, P471, DOI 10.1006/dbio.1996.0276; Lindsey JS, 1996, BIOL REPROD, V55, P975, DOI 10.1095/biolreprod55.5.975; Maiti S, 1996, GENOMICS, V34, P304, DOI 10.1006/geno.1996.0291; Maiti S, 1996, J BIOL CHEM, V271, P17536, DOI 10.1074/jbc.271.29.17536; Maiti S, 2001, ENDOCRINOLOGY, V142, P1567, DOI 10.1210/en.142.4.1567; Pitman JL, 1998, DEV BIOL, V202, P196, DOI 10.1006/dbio.1998.8978; Rao M, 2002, EPIDIDYMIS MOL CLIN, P269, DOI 10.1007/978-1-4615-0679-9_15; RITZEN EM, 1971, ENDOCRINOLOGY, V89, P143; ROBAIRE B, 1995, BIOL REPROD, V52, P226, DOI 10.1095/biolreprod52.2.226; Rodriguez CM, 2001, REPRODUCTION, V122, P41, DOI 10.1530/reprod/122.1.41; Rodriguez CM, 2002, EPIDIDYMIS MOL CLIN, P251, DOI DOI 10.4049/JIMMUNOL.1402706; SENSIBAR JA, 1993, BIOL REPROD, V49, P233, DOI 10.1095/biolreprod49.2.233; Sutton HG, 1999, ENDOCRINOLOGY, V140, P2721, DOI 10.1210/en.140.6.2721; Sutton KA, 1998, J ANDROL, V19, P21; Sutton KA, 1997, GENOMICS, V45, P447, DOI 10.1006/geno.1997.4946; TINDALL DJ, 1975, MOL CELL ENDOCRINOL, V3, P83, DOI 10.1016/0303-7207(75)90056-8; Tramer F, 1998, BIOL REPROD, V59, P753, DOI 10.1095/biolreprod59.4.753; TULSIANI DRP, 1995, DEV BIOL, V167, P584, DOI 10.1006/dbio.1995.1050; Vernet P, 1997, MOL REPROD DEV, V47, P87, DOI 10.1002/(SICI)1098-2795(199705)47:1&lt;87::AID-MRD12&gt;3.0.CO;2-X; VIGER RS, 1992, ENDOCRINOLOGY, V131, P1534, DOI 10.1210/en.131.3.1534; WILKINSON M, 2000, ESSENTIAL MOL BIOL, P69	56	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48771	48778		10.1074/jbc.M209417200	http://dx.doi.org/10.1074/jbc.M209417200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12351657	hybrid			2022-12-27	WOS:000179789600104
J	Crane, MS; Ollosson, R; Moore, KP; Rossi, AG; Megson, IL				Crane, MS; Ollosson, R; Moore, KP; Rossi, AG; Megson, IL			Novel role for low molecular weight plasma thiols in nitric oxide-mediated control of platelet function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-NITROSO-GLUTATHIONE; RELAXING FACTOR; IN-VIVO; VASCULAR ENDOTHELIUM; AQUEOUS-SOLUTION; SERUM-ALBUMIN; HEMOGLOBIN; MECHANISM; CYSTEINE; KINETICS	Nitric oxide (NO) is a powerful antiplatelet agent, but its notoriously short biological half-life limits its potential to prevent the activation of circulating platelets. Here we used diethylamine diazeniumdiolate (DEA/NO) as an NO generator to determine whether the antiplatelet effects of NO are prolonged by the formation of a durable, plasma-borne S-nitrosothiol reservoir. Preincubation of both platelet rich plasma (PRP) and washed platelets (WP) with DEAINO (2 muM) for 1 min inhibited collagen-induced platelet aggregation by 82 +/- 5 and 91 +/- 2%, respectively. After 30 min preincubation with DEA/NO, NO was no longer detectable in either preparation, but aggregation remained markedly inhibited (72 +/- 7%) in PRP. In contrast, the inhibitory effect in MTP was almost completely lost at this time (5 +/- 3%) but was partially restored (39 +/- 10%) in WP containing human serum albumin (1%) and fully restored by co-incubation with albumin and the low molecular weight (LAW) thiols, glutathione, (5 muM), cysteinyl-glycine (10 muM), or cysteine (10 muM). This NO-mediated effect was not seen with LMW thiols in the absence of albumin and was associated with S-nitrosothiol formation. Our results demonstrate that LAW thiols play an important role in both the formation and activation of an S-nitrosoalbumin reservoir that significantly prolongs the duration of action of NO.	Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh EH8 9XD, Midlothian, Scotland; Univ Edinburgh, Ctr Inflammat Res, Edinburgh EH8 9XD, Midlothian, Scotland; UCL Royal Free & Univ Coll, Ctr Hepatol, London NW3 2PF, England	University of Edinburgh; University of Edinburgh; University of London; University College London	Megson, IL (corresponding author), Univ Edinburgh, Ctr Cardiovasc Sci, Hugh Robson Bldg, Edinburgh EH8 9XD, Midlothian, Scotland.	ian.megson@ed.ac.uk	Megson, Ian L/K-2195-2012	Megson, Ian L/0000-0001-8287-2459				Akaike T, 1997, J BIOCHEM-TOKYO, V122, P459; COCKS TM, 1985, J CELL PHYSIOL, V123, P310, DOI 10.1002/jcp.1041230304; Creager MA, 1997, HYPERTENSION, V29, P668, DOI 10.1161/01.HYP.29.2.668; Davies KM, 2001, J AM CHEM SOC, V123, P5473, DOI 10.1021/ja002899q; DEBELDER AJ, 1994, CARDIOVASC RES, V28, P691; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Espey MG, 2001, J BIOL CHEM, V276, P30085, DOI 10.1074/jbc.M101723200; FOLEY PL, 1993, ACTA NEUROCHIR, V123, P82, DOI 10.1007/BF01476290; Goldman RK, 1998, ANAL BIOCHEM, V259, P98, DOI 10.1006/abio.1998.2651; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; GRIFFITH TM, 1984, NATURE, V308, P645, DOI 10.1038/308645a0; HOFMANN H, 1995, BIOCHEMISTRY-US, V34, P13443, DOI 10.1021/bi00041a023; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Inoue K, 1999, J BIOL CHEM, V274, P27069, DOI 10.1074/jbc.274.38.27069; JOCELYN PC, 1972, BIOCH SH GROUP; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; Kugiyama K, 1998, CIRCULATION, V97, P2299, DOI 10.1161/01.CIR.97.23.2299; Lancaster JR, 1997, NITRIC OXIDE-BIOL CH, V1, P18, DOI 10.1006/niox.1996.0112; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LEWIS RS, 1994, CHEM RES TOXICOL, V7, P568, DOI 10.1021/tx00040a013; LIJANA RC, 1979, J LAB CLIN MED, V94, P266; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; MANSOOR MA, 1992, ANAL BIOCHEM, V200, P218, DOI 10.1016/0003-2697(92)90456-H; Marley R, 2001, FREE RADICAL BIO MED, V31, P688, DOI 10.1016/S0891-5849(01)00627-X; Marley R, 2000, FREE RADICAL RES, V32, P1, DOI 10.1080/10715760000300011; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; Mayer B, 1998, J BIOL CHEM, V273, P3264, DOI 10.1074/jbc.273.6.3264; McDonald L J, 1995, Adv Pharmacol, V34, P263; Morrison JA, 1999, CIRCULATION, V100, P2244, DOI 10.1161/01.CIR.100.22.2244; MULSCH A, 1991, FEBS LETT, V294, P252, DOI 10.1016/0014-5793(91)81441-A; O'Donnell VB, 2000, J BIOL CHEM, V275, P38239, DOI 10.1074/jbc.M001802200; Pigazzi A, 1999, J BIOL CHEM, V274, P14368, DOI 10.1074/jbc.274.20.14368; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639, DOI 10.1111/j.1476-5381.1987.tb11367.x; RADOMSKI MW, 1987, BIOCHEM BIOPH RES CO, V148, P1482, DOI 10.1016/S0006-291X(87)80299-1; Rafikova O, 2002, P NATL ACAD SCI USA, V99, P5913, DOI 10.1073/pnas.092048999; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; Schwarz UR, 2001, BIOCHEM PHARMACOL, V62, P1153, DOI 10.1016/S0006-2952(01)00760-2; SIMON DI, 1993, ARTERIOSCLER THROMB, V13, P791, DOI 10.1161/01.ATV.13.6.791; Sogo N, 2000, BIOCHEM BIOPH RES CO, V279, P412, DOI 10.1006/bbrc.2000.3976; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STANDEFER JC, 1977, CLIN CHEM, V23, P749; Tsikas D, 1999, J CHROMATOGR B, V726, P13, DOI 10.1016/S0378-4347(99)00058-4; Tsikas D, 1999, ANAL BIOCHEM, V272, P117, DOI 10.1006/abio.1999.4177; VEDERNIKOV YP, 1992, EUR J PHARMACOL, V211, P313, DOI 10.1016/0014-2999(92)90386-I; Vita JA, 1998, J CLIN INVEST, V101, P1408, DOI 10.1172/JCI1155; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007	50	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46858	46863		10.1074/jbc.M208608200	http://dx.doi.org/10.1074/jbc.M208608200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12297511	hybrid			2022-12-27	WOS:000179663700005
J	Miller, SK; Good, RT; Drew, DR; Delorenzi, M; Sanders, PR; Hodder, AN; Speed, TP; Cowman, AF; de Koning-Ward, TF; Crabb, BS				Miller, SK; Good, RT; Drew, DR; Delorenzi, M; Sanders, PR; Hodder, AN; Speed, TP; Cowman, AF; de Koning-Ward, TF; Crabb, BS			A subset of Plasmodium falciparum SERA genes are expressed and appear to play an important role in the erythrocytic cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-REPEAT ANTIGEN; BLOOD STAGE ANTIGEN; PROTECTIVE IMMUNITY; MALARIA PARASITES; AOTUS MONKEYS; PARASITOPHOROUS VACUOLE; ESCHERICHIA-COLI; TERMINAL DOMAIN; ANTIBODIES; PROTEIN	The Plasmodium falciparum serine repeat antigen (SERA) has shown considerable promise as a blood stage vaccine for the control of malaria. A related protein, SERPH, has also been described in P. falciparum. Whereas their biological role remains unknown, both proteins possess papain-like protease domains that may provide attractive targets for therapeutic intervention. Genomic sequencing has recently shown that SERA and SERPH are the fifth and sixth genes, respectively, in a cluster of eight SERA homologues present on chromosome 2. In this paper, the expression and functional relevance of these eight genes and of a ninth SERA homologue found on chromosome 9 were examined in blood stage parasites. Using reverse transcriptase-PCR and microarray approaches, we demonstrate that whereas mRNA to all nine SERA genes is synthesized late in the erythrocytic cycle, it is those genes in the central region of the chromosome 2 cluster that are substantially up-regulated at this time. Using antibodies specific to each SERA, it was apparent that SERA4 to -6, and possibly also SERA9, are synthesized in blood stage parasites. The reactivity of antibodies from malaria-immune individuals with the SERA recombinant proteins suggested that SERA2 and SERA3 are also expressed at least in some parasite populations. To examine whether SERA genes are essential to blood stage growth, each of the eight chromosome 2 SERA genes was targeted for disruption. Whereas genes at the periphery of the cluster were mostly dispensable (SERA2 and -3 and SERA7 and -8), those in the central region (SERA4 to -6) could not be disrupted. The inability to disrupt SERA4, -5, and -6 is consistent with their apparent dominant expression and implies an important role for these genes in maintenance of the erythrocytic cycle.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Crabb, BS (corresponding author), Walter & Eliza Hall Inst Med Res, PO Royal Melbourne Hosp, Melbourne, Vic 3050, Australia.		Crabb, Brendan/F-5287-2013; de Koning-Ward, Tania F/N-3572-2017; Speed, Terence P/B-8085-2009; Cowman, Alan F/C-7642-2013	de Koning-Ward, Tania F/0000-0001-5810-8063; Speed, Terence P/0000-0002-5403-7998; Cowman, Alan F/0000-0001-5145-9004				Anders RF, 2000, PARASITOL TODAY, V16, P444, DOI 10.1016/S0169-4758(00)01784-1; BARR PJ, 1991, MOL BIOCHEM PARASIT, V45, P159, DOI 10.1016/0166-6851(91)90038-8; BZIK DJ, 1988, MOL BIOCHEM PARASIT, V30, P279, DOI 10.1016/0166-6851(88)90097-7; COOPER JA, 1992, MOL BIOCHEM PARASIT, V51, P301, DOI 10.1016/0166-6851(92)90080-4; COPPEL RL, 1987, MOL BIOCHEM PARASIT, V25, P73, DOI 10.1016/0166-6851(87)90020-X; Cowman AF, 2000, FEBS LETT, V476, P84, DOI 10.1016/S0014-5793(00)01703-8; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; Crabb BS, 1997, CELL, V89, P287, DOI 10.1016/S0092-8674(00)80207-X; DEBRABANT A, 1989, MOL BIOCHEM PARASIT, V33, P151, DOI 10.1016/0166-6851(89)90029-7; DEBRABANT A, 1992, MOL BIOCHEM PARASIT, V53, P89, DOI 10.1016/0166-6851(92)90010-H; DELPLACE P, 1988, BIOL CELL, V64, P215, DOI 10.1016/0248-4900(88)90080-9; DELPLACE P, 1987, MOL BIOCHEM PARASIT, V23, P193, DOI 10.1016/0166-6851(87)90026-0; EAKIN AE, 1989, NATURE, V342, P132, DOI 10.1038/342132b0; Fernandez V, 1998, INFECT IMMUN, V66, P2969, DOI 10.1128/IAI.66.6.2969-2975.1998; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; FOX BA, 1994, MOL BIOCHEM PARASIT, V68, P133, DOI 10.1016/0166-6851(94)00162-6; Fox BA, 1997, EXP PARASITOL, V85, P121, DOI 10.1006/expr.1996.4118; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Gor DO, 1998, VACCINE, V16, P1193, DOI 10.1016/S0264-410X(98)80119-9; HIGGINS DG, 1989, NATURE, V340, P604, DOI 10.1038/340604a0; INSELBURG J, 1993, INFECT IMMUN, V61, P2048, DOI 10.1128/IAI.61.5.2048-2052.1993; INSELBURG J, 1993, INFECT IMMUN, V61, P2041, DOI 10.1128/IAI.61.5.2041-2047.1993; INSELBURG J, 1991, INFECT IMMUN, V59, P1247, DOI 10.1128/IAI.59.4.1247-1250.1991; Kiefer MC, 1996, MOL BIOCHEM PARASIT, V78, P55, DOI 10.1016/S0166-6851(96)02607-2; KNAPP B, 1989, MOL BIOCHEM PARASIT, V32, P73, DOI 10.1016/0166-6851(89)90131-X; KNAPP B, 1991, MOL BIOCHEM PARASIT, V44, P1, DOI 10.1016/0166-6851(91)90215-R; KNAPP B, 1991, BEHRING I MITT, V88, P147; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Li J, 2002, MOL BIOCHEM PARASIT, V120, P177, DOI 10.1016/S0166-6851(01)00452-2; LI WB, 1989, MOL BIOCHEM PARASIT, V33, P13, DOI 10.1016/0166-6851(89)90037-6; LYON JA, 1989, MOL BIOCHEM PARASIT, V36, P77, DOI 10.1016/0166-6851(89)90203-X; Marshall VM, 1998, MOL BIOCHEM PARASIT, V94, P13, DOI 10.1016/S0166-6851(98)00045-0; MOTTRAM JC, 1989, FEBS LETT, V258, P211, DOI 10.1016/0014-5793(89)81655-2; O'Donnell RA, 2001, J EXP MED, V193, P1403, DOI 10.1084/jem.193.12.1403; O'Donnell RA, 2000, NAT MED, V6, P91, DOI 10.1038/71595; Okech BA, 2001, AM J TROP MED HYG, V65, P912, DOI 10.4269/ajtmh.2001.65.912; Pang XL, 1999, INFECT IMMUN, V67, P1821; Pang XL, 1998, VACCINE, V16, P1299, DOI 10.1016/S0264-410X(98)00057-7; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sugiyama T, 1996, VACCINE, V14, P1069, DOI 10.1016/0264-410X(95)00238-V; Suzuki H, 1997, EXP ANIM TOKYO, V46, P17, DOI 10.1538/expanim.46.17; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	47	128	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47524	47532		10.1074/jbc.M206974200	http://dx.doi.org/10.1074/jbc.M206974200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12228245	Green Published, hybrid			2022-12-27	WOS:000179663700090
J	Sangkuhl, K; Schulz, A; Schultz, G; Schoneberg, T				Sangkuhl, K; Schulz, A; Schultz, G; Schoneberg, T			Structural requirements for mutational lutropin/choriogonadotropin receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE RECEPTOR; V2 VASOPRESSIN RECEPTORS; EXTRACELLULAR DOMAIN; THYROTROPIN RECEPTOR; LUTROPIN RECEPTOR; SIGNAL GENERATION; HINGE REGION; PROTEIN; RESIDUES; PORTION	Different activation mechanisms of glycoprotein hormone receptors, which are members of the G protein-coupled receptor superfamily, have been proposed. For example, the large ectodomain of glycoprotein hormone receptors may function as an inverse agonist keeping the transmembrane domain in an inactive conformation. To provide support for this hypothesis, we have generated different lutropin/choriogonadotropin receptor (LHR) constructs lacking the ectodomain. Although some ectodomain-deficient LHR constructs were targeted to the cell surface, cAMP levels remained unchanged under basal conditions and agonist application but could be increased by a mutation within the transmembrane domain 6 (D578H). Taking advantage of a constitutive activating mutation (S277N) located in the extracellular domain, we showed that the intact leucine-rich repeat-containing ectodomain is essential for constitutive activation of the LHR by mutation of the hinge region. Our findings support an activation scenario in which agonist binding or mutational alterations expose a structure within the ectodomain, which then activates the transmembrane core.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schoneberg, T (corresponding author), Free Univ Berlin, Inst Pharmakol, Thielallee 69-73, D-14195 Berlin, Germany.							Abell AN, 1997, J BIOL CHEM, V272, P14586, DOI 10.1074/jbc.272.23.14586; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; Biebermann H, 1998, FASEB J, V12, P1461, DOI 10.1096/fasebj.12.14.1461; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; Gruters A, 1998, J CLIN ENDOCR METAB, V83, P1431, DOI 10.1210/jc.83.5.1431; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; JI I, 1991, J BIOL CHEM, V266, P13076; Krause G, 2000, MOL PHARMACOL, V57, P232; Kundu GC, 1996, J BIOL CHEM, V271, P11063, DOI 10.1074/jbc.271.19.11063; Lin ZL, 1997, PROTEIN ENG, V10, P501, DOI 10.1093/protein/10.5.501; Ling K, 1999, P NATL ACAD SCI USA, V96, P7922, DOI 10.1073/pnas.96.14.7922; Liu G, 1999, NEW ENGL J MED, V341, P1731, DOI 10.1056/NEJM199912023412304; Nakabayashi K, 2000, J BIOL CHEM, V275, P30264, DOI 10.1074/jbc.M005568200; Nishi S, 2002, J BIOL CHEM, V277, P3958, DOI 10.1074/jbc.M109617200; Osuga Y, 1997, J BIOL CHEM, V272, P25006, DOI 10.1074/jbc.272.40.25006; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schoneberg T, 2002, REV PHYSIOL BIOCH P, V144, P143; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; Schoneberg T, 1997, J CLIN INVEST, V100, P1547, DOI 10.1172/JCI119678; Schulz A, 2000, J BIOL CHEM, V275, P37860, DOI 10.1074/jbc.M006709200; Schulz A, 1999, MOL ENDOCRINOL, V13, P181, DOI 10.1210/me.13.2.181; Zeng HW, 2001, J BIOL CHEM, V276, P3451, DOI 10.1074/jbc.M007488200; Zhang M, 2000, ENDOCRINOLOGY, V141, P3514, DOI 10.1210/en.141.9.3514; ZHANG ML, 1995, BIOCHEM BIOPH RES CO, V211, P205, DOI 10.1006/bbrc.1995.1797	26	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47748	47755		10.1074/jbc.M203491200	http://dx.doi.org/10.1074/jbc.M203491200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356766	hybrid			2022-12-27	WOS:000179663700118
J	Colombo, B; Longhi, R; Marinzi, C; Magni, F; Cattaneo, A; Yoo, SH; Curnis, F; Corti, A				Colombo, B; Longhi, R; Marinzi, C; Magni, F; Cattaneo, A; Yoo, SH; Curnis, F; Corti, A			Cleavage of chromogranin A N-terminal domain by plasmin provides a new mechanism for regulating cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL CHANGE; PROTEIN FAMILY; IN-VITRO; A GENE; VASOSTATINS; IDENTIFICATION; FRAGMENTS; ENDOCRINE; SECRETION; TUMORS	It has been proposed that chromogranin A (CgA), a protein secreted by many normal and neoplastic neuroendocrine cells, can play a role as a positive or a negative modulator of cell adhesion. The mechanisms that regulate these extracellular functions of CgA are unknown. We show here that plasmin can regulate the anti/pro-adhesive activity of CgA by proteolytic cleavage of the N-terminal domain. Limited proteolytic processing decreased its anti-adhesive activity and induced pro-adhesive effects in fibronectin or serum-dependent fibroblast adhesion assays. Cleavage of LyS77 -LyS78 dibasic site in CgA(1-115) was relatively rapid and associated with an increase of pro-adhesive effect. In contrast, antibodies against the region 53-90 enhanced the anti-adhesive activity of CgA and CgA(1-115). Structure-activity relationship studies showed that the conserved region 47-64 (RILSILRHQNLLKELQDL) is critical for both pro- and anti-adhesive activity. These findings suggest that CgA might work on one hand as a negative modulator of cell adhesion and on the other hand as a precursor of positive modulators, the latter requiring proteolytic processing for activation. Given the importance of plasminogen activation in tissue invasion and remodeling, the interplay between CgA and plasmin could provide a novel mechanism for regulating fibroblast adhesion and function in neuroendocrine tumors.	San Raffaele H Sci Inst, Dept Biol & Technol Res, I-20132 Milan, Italy; ICRM, CNR, I-20132 Milan, Italy; Inha Univ, Coll Med, Dept Biochem,Nam Gu, Natl Creat Res Initiat Ctr Secretory Granule Res, Inchon 402751, South Korea	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica del Riconoscimento Molecolare (ICRM-CNR); Inha University	Corti, A (corresponding author), San Raffaele H Sci Inst, Dept Biol & Technol Res, Via Olgettina 58, I-20132 Milan, Italy.		Corti, Angelo/F-7046-2012; Colombo, Barbara/AAN-5045-2020; Curnis, Flavio/AAK-3542-2020; Magni, Fulvio/A-7340-2014	Corti, Angelo/0000-0002-0893-6191; Colombo, Barbara/0000-0002-5887-5868; Curnis, Flavio/0000-0002-7231-9569; Magni, Fulvio/0000-0002-8663-0374; Subba, Rajkrishna/0000-0003-0051-0062				AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; BRANDT DW, 1994, P SOC EXP BIOL MED, V205, P316; Ceconi C, 2002, EUR HEART J, V23, P967, DOI 10.1053/euhj.2001.2977; Ciesielski-Treska J, 1998, J BIOL CHEM, V273, P14339, DOI 10.1074/jbc.273.23.14339; Colombo B, 2002, CANCER RES, V62, P941; CONESE M, 1995, BAILLIERE CLIN HAEM, V8, P365, DOI 10.1016/S0950-3536(05)80273-2; Corti A, 1997, EUR J BIOCHEM, V248, P692, DOI 10.1111/j.1432-1033.1997.00692.x; Corti A, 1996, EUR J BIOCHEM, V235, P275, DOI 10.1111/j.1432-1033.1996.00275.x; Corti A, 2000, ADV EXP MED BIOL, V482, P351; DEFTOS LJ, 1991, ENDOCR REV, V12, P181, DOI 10.1210/edrv-12-2-181; FERRER M, 1992, INT J PEPT PROT RES, V40, P194; Gasparri A, 1997, J BIOL CHEM, V272, P20835, DOI 10.1074/jbc.272.33.20835; Helle K. B., 2001, Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents, V1, P119, DOI 10.2174/1568013013359087; HELLE KB, 1993, J NEUROENDOCRINOL, V5, P413, DOI 10.1111/j.1365-2826.1993.tb00502.x; Helle KB, 2000, ADV EXP MED BIOL, V482, P225; Helle KB, 2000, ADV EXP MED BIOL, V482, P3; IACANGELO A, 1988, FEBS LETT, V227, P115, DOI 10.1016/0014-5793(88)80880-9; IGUCHI H, 1992, EUR J CANCER, V28A, P1458, DOI 10.1016/0959-8049(92)90543-B; Jiang QJ, 2001, J BIOL CHEM, V276, P25022, DOI 10.1074/jbc.M101545200; KONECKI DS, 1987, J BIOL CHEM, V262, P17026; KRAMER MD, 1994, INVAS METAST, V14, P210; LANKATBUTTGEREIT B, 1988, FEBS LETT, V236, P352, DOI 10.1016/0014-5793(88)80054-1; Laslop A, 2000, ADV EXP MED BIOL, V482, P155; LIANG F, 1995, ACTA PHYSIOL SCAND, V155, P23, DOI 10.1111/j.1748-1716.1995.tb09944.x; Lugardon K, 2000, J BIOL CHEM, V275, P10745, DOI 10.1074/jbc.275.15.10745; Lugardon K, 2001, J BIOL CHEM, V276, P35875, DOI 10.1074/jbc.M104670200; MAYER M, 1990, CLIN BIOCHEM, V23, P197, DOI 10.1016/0009-9120(90)90601-P; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; Nobels FRE, 1997, J CLIN ENDOCR METAB, V82, P2622, DOI 10.1210/jc.82.8.2622; OCONNOR DT, 1984, NEW ENGL J MED, V311, P764, DOI 10.1056/NEJM198409203111204; Parmer RJ, 2000, J CLIN INVEST, V106, P907, DOI 10.1172/JCI7394; Parmer RJ, 1997, J BIOL CHEM, V272, P1976, DOI 10.1074/jbc.272.3.1976; Ratti S, 2000, J BIOL CHEM, V275, P29257, DOI 10.1074/jbc.M003796200; ROSA P, 1994, J ENDOCRINOL INVEST, V17, P207, DOI 10.1007/BF03347721; RUSSELL J, 1994, ENDOCRINOLOGY, V135, P337, DOI 10.1210/en.135.1.337; SIMON JP, 1989, BIOCHEM J, V262, P1; SOBOL RE, 1989, NEW ENGL J MED, V320, P444, DOI 10.1056/NEJM198902163200707; Soriano JV, 1999, BIOCHEM BIOPH RES CO, V259, P563, DOI 10.1006/bbrc.1999.0826; STRIDSBERG M, 1995, J ENDOCRINOL, V144, P49, DOI 10.1677/joe.0.1440049; Turquier V, 1999, ENDOCRINOLOGY, V140, P4104, DOI 10.1210/en.140.9.4104; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WU HJ, 1991, J BIOL CHEM, V266, P13130; Wu TL, 1999, J CLIN LAB ANAL, V13, P312, DOI 10.1002/(SICI)1098-2825(1999)13:6<312::AID-JCLA11>3.0.CO;2-1; WUN TC, 1988, CRIT REV BIOTECHNOL, V8, P131, DOI 10.3109/07388558809150542; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8816, DOI 10.1021/bi00085a012; YOO SH, 1990, J BIOL CHEM, V265, P14414; YOO SH, 1993, FEBS LETT, V334, P373, DOI 10.1016/0014-5793(93)80715-7; YOO SH, 1991, J BIOL CHEM, V266, P7740; YOO SH, 1992, BIOCHEMISTRY-US, V31, P6134, DOI 10.1021/bi00141a025; ZIEGLER MG, 1990, KIDNEY INT, V37, P1357, DOI 10.1038/ki.1990.122	52	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45911	45919		10.1074/jbc.M202637200	http://dx.doi.org/10.1074/jbc.M202637200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12297497	hybrid			2022-12-27	WOS:000179529300028
J	Gallagher, ED; Xu, SC; Moomaw, C; Slaughter, CA; Cobb, MH				Gallagher, ED; Xu, SC; Moomaw, C; Slaughter, CA; Cobb, MH			Binding of JNK/SAPK to MEKK1 is regulated by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; ALPHA-PAK; PTP-SL; DOMAIN; ERK2; JNK; CASCADE; DOCKING; CDC42	We sought to characterize the role of upstream kinases in the regulation of the MAP3 kinase MEKK1 and the potential impact on signaling to MAP kinase cascades. We find that the MAP4 kinase PAK1 phosphorylates the amino terminus of MEKK1 on serine 67. We show that serine 67 lies in a D domain, which binds to the c-Jun-NH2-terminal kinase/stress-activated protein kinases (JNK/SAPK). Serine 67 is constitutively phosphorylated in resting 293 cells, but is dephosphorylated following exposure to stress stimuli such as anisomycin and UV irradiation. Phosphorylation of this site inhibits binding of JNK/SAPK to MEKK1. Thus, we propose a mechanism by which the MEKK1-dependent JNK/SAPK pathway is negatively regulated by PAK through phosphorylation of serine 67.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Cobb, Melanie/0000-0003-0833-5473	NIGMS NIH HHS [GM53032, GM56498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Christerson LB, 2002, J CELL PHYSIOL, V192, P200, DOI 10.1002/jcp.10125; Cobb M H, 1996, Adv Pharmacol, V36, P49, DOI 10.1016/S1054-3589(08)60576-1; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; Drewett V, 2000, J BIOL CHEM, V275, P1757, DOI 10.1074/jbc.275.3.1757; Elion EA, 2000, CURR OPIN MICROBIOL, V3, P573, DOI 10.1016/S1369-5274(00)00143-0; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; FROST JA, 1998, J BIOL CHEM, V273, P28253; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Karandikar M, 1999, CELL CALCIUM, V26, P219, DOI 10.1054/ceca.1999.0074; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Roig J, 1999, J BIOL CHEM, V274, P31119, DOI 10.1074/jbc.274.44.31119; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	46	38	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45785	45792		10.1074/jbc.M207702200	http://dx.doi.org/10.1074/jbc.M207702200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12228228	hybrid			2022-12-27	WOS:000179529300011
J	Parton, RG; Molero, JC; Floetenmeyer, M; Green, KM; James, DE				Parton, RG; Molero, JC; Floetenmeyer, M; Green, KM; James, DE			Characterization of a distinct plasma membrane macrodomain in differentiated adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE CELL-LINE; 3T3-L1 ADIPOCYTES; INTERMEDIATE-FILAMENT; INSULIN; CONVERSION; PATHWAY; GLUT4; TRANSLOCATION; LOCALIZATION; FIBROBLASTS	Caveolae are small invaginations of the cell surface that are abundant in mature adipocytes. A recent study (Kanzaki, M., and Pessin, J. E. (2002) J. Biol Chem 277, 25867-25869) described novel caveolin- and actin-containing structures associated with the adipocyte cell surface that contain specific signaling proteins. We have characterized these structures, here termed "caves," using light and electron microscopy and observe that they represent surface-connected wide invaginations of the basal plasma membrane that are sometimes many micrometers in diameter. Rather than simply a caveolar domain, these structures contain all elements of the plasma membrane including clathrin-coated pits, lipid raft markers, and non-raft markers. GLUT4 is recruited to caves in response to insulin stimulation. Caves can occupy a significant proportion of the plasma membrane area and are surrounded by cortical actin. Caveolae density in caves is similar to that on the bulk plasma membrane, but because these structures protrude much deeper into the plane of focus of the light microscope molecules such as caveolin and other plasma membrane proteins appear more concentrated in caves. We conclude that the adipocyte surface membrane contains numerous wide invaginations that do not represent novel caveolar structures but rather large surface caves.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Microscopy & Microanal, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland; University of Queensland	Parton, RG (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	R.Parton@imb.uq.edu.au	Parton, Robert G/C-5673-2009	Parton, Robert G/0000-0002-7494-5248; James, David/0000-0001-5946-5257; Floetenmeyer, Matthias/0000-0002-0133-1632				Arcangeletti C, 1997, J STRUCT BIOL, V119, P35, DOI 10.1006/jsbi.1997.3871; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Hill MM, 1997, ELECTROPHORESIS, V18, P2629, DOI 10.1002/elps.1150181419; Kanzaki M, 2002, J BIOL CHEM, V277, P25867, DOI 10.1074/jbc.C200292200; KURIHARCUCH W, 1977, J BIOL CHEM, V252, P2158; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rea S, 1998, J BIOL CHEM, V273, P18784, DOI 10.1074/jbc.273.30.18784; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, AM J PHYSIOL, V263, pE383, DOI 10.1152/ajpendo.1992.263.2.E383; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; RUSSELL TR, 1976, P NATL ACAD SCI USA, V73, P4516, DOI 10.1073/pnas.73.12.4516; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; SPIEGELMAN BM, 1993, J BIOL CHEM, V268, P6823; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; WILLIAMS IH, 1977, BIOCHEM BIOPH RES CO, V77, P175, DOI 10.1016/S0006-291X(77)80180-0	27	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46769	46778		10.1074/jbc.M205683200	http://dx.doi.org/10.1074/jbc.M205683200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12356772	hybrid, Green Submitted			2022-12-27	WOS:000179529300137
J	Sun, Y; Wilson, MP; Majerus, PW				Sun, Y; Wilson, MP; Majerus, PW			Inositol 1,3,4-trisphosphate 5/6-kinase associates with the COP9 signalosome by binding to CSN1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PROTEIN-KINASE; C-JUN; COMPLEX; ARABIDOPSIS; TRANSDUCTION; PHOTOMORPHOGENESIS; DEGRADATION; LIGASE; CELLS	The COP9 signalosome (CSN) is a complex of eight proteins first identified as a repressor of plant photomorphogenesis. A protein kinase activity associated with the COP9 signalosome has been reported but not identified; we present evidence for inositol 1,3,4-trisphosphate 5/6-kinase (5/6-kinase) as a protein kinase associated with the COP9 signalosome. We have shown that 5/6-kinase exists in a complex with the eight-component COP9 signalosome both when purified from bovine brain and when transfected into HEK 293 cells. 5/6-kinase phosphorylates the same substrates as those of the COP9 signalosome, including IkappaBalpha, p53, and c-Jun but fails to phosphorylate several other substrates, including c-Jun 1-79, which are not substrates for the COP9-associated kinase. Both the COP9 signalosome-associated kinase and 5/6-kinase are inhibited by curcumin. The association of 5/6-kinase with the COP9 signalosome is through an interaction with CSN1, which immunoprecipitates with 5/6-kinase. In addition, the inositol kinase activity of 5/6-kinase is inhibited when in a complex with CSN1. We propose that 5/6-kinase is the previously described COP9 signalosome-associated kinase.	Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA	Washington University (WUSTL)	Majerus, PW (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Hematol, 660 S Euclid Ave,Campus Box 8125, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672, R01HL016634] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL16634, R01-HL55672] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bech-Otschir D, 2002, J CELL SCI, V115, P467; Chamovitz DA, 2002, CURR BIOL, V12, pR232, DOI 10.1016/S0960-9822(02)00775-3; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; Field J, 2000, MOL BIOCHEM PARASIT, V108, P119, DOI 10.1016/S0166-6851(00)00197-3; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; Henke W, 1999, MOL BIOL REP, V26, P29, DOI 10.1023/A:1006991419464; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Kapelari B, 2000, J MOL BIOL, V300, P1169, DOI 10.1006/jmbi.2000.3912; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Ohh M, 2002, EMBO REP, V3, P177, DOI 10.1093/embo-reports/kvf028; Pollmann C, 2001, CANCER RES, V61, P8416; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Schwechheimer C, 2001, TRENDS CELL BIOL, V11, P420, DOI 10.1016/S0962-8924(01)02091-8; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Shears SB, 2001, CELL SIGNAL, V13, P151, DOI 10.1016/S0898-6568(01)00129-2; Spain BH, 1996, MOL CELL BIOL, V16, P6698; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Tsuge T, 2001, J MOL BIOL, V305, P1, DOI 10.1006/jmbi.2000.4288; Verbsky JW, 2002, J BIOL CHEM, V277, P31857, DOI 10.1074/jbc.M205682200; Wang XP, 2002, MOL BIOL CELL, V13, P646, DOI 10.1091/mbc.01-08-0427; WEI N, 1992, PLANT CELL, V4, P1507, DOI 10.1105/tpc.4.12.1507; Wei N, 1998, PHOTOCHEM PHOTOBIOL, V68, P237; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; Wilson MP, 2001, J BIOL CHEM, V276, P40998, DOI 10.1074/jbc.M106605200; Wilson MP, 1996, J BIOL CHEM, V271, P11904, DOI 10.1074/jbc.271.20.11904; Wilson MP, 1997, BIOCHEM BIOPH RES CO, V232, P678, DOI 10.1006/bbrc.1997.6355; Yang XN, 2000, BIOCHEM J, V351, P551, DOI 10.1042/0264-6021:3510551; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; York JD, 2001, ADV ENZYME REGUL, V41, P57, DOI 10.1016/S0065-2571(00)00025-X	32	80	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45759	45764		10.1074/jbc.M208709200	http://dx.doi.org/10.1074/jbc.M208709200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324474	hybrid			2022-12-27	WOS:000179529300007
J	van der Wel, H; Morris, HR; Panico, M; Paxton, T; Dell, A; Kaplan, L; West, CM				van der Wel, H; Morris, HR; Panico, M; Paxton, T; Dell, A; Kaplan, L; West, CM			Molecular cloning and expression of a UDP-N-acetylglucosamine (GlcNAc): hydroxyproline polypeptide GlcNAc-transferase that modifies Skp1 in the cytoplasm of Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-D-GALACTOSAMINE; RECOMBINANT PROTEINS; O-GLCNAC; SCF; GLYCOSYLATION; SEQUENCE; GLYCOSYLTRANSFERASES; GLYCOPROTEIN; DISCOIDEUM; PATTERNS	Skp1 is a ubiquitous eukaryotic protein found in several cytoplasmic and nuclear protein complexes, including the SCF-type E3 ubiquitin ligase. In Dictyostelium, Skp1 is hydroxylated at proline 143, which is then modified by a pentasaccharide chain. The enzyme activity that attaches the first sugar, GlcNAc, was previously shown to copurify with the GnT51 polypeptide whose gene has now been cloned using a proteomics approach based on a quadrupole/time-of-flight hybrid mass spectrometer. When expressed in Escherichia coli, recombinant GnT51 exhibits UDP-GlcNAc:hydroxyproline Skp1 GlcNAc-transferase activity. Based on amino acid sequence alignments, GnT51 defines a new family of microbial polypeptide glycosyltransferases that appear to be distantly related to the catalytic domain of mucintype LTDP-GalNAc:Ser/Thr polypeptide alpha-GalNAc-transferases expressed in the Golgi compartment of animal cells. This relationship is supported by the effects of site-directed mutagenesis of GnT51 amino acids associated with its predicted DXD-like motif, DAH. In contrast, GnT51 lacks the N-terminal signal anchor sequence present in the Golgi enzymes, consistent with the cytoplasmic localization of the Skp1 acceptor substrate and the biochemical properties of the enzyme. The first glycosylation step of Dictyostelium Skp1 is concluded to be mechanistically similar to that of animal mucin type O-linked glycosylation, except that it occurs in the cytoplasm rather than the Golgi compartment of the cell.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AY, England; M SCAN Res & Training Ctr, Ascot SL5 9PZ, Berks, England	State University System of Florida; University of Florida; Imperial College London	West, CM (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, 1600 SW Archer Rd, Gainesville, FL 32610 USA.	westcm@ufl.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037539] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM37539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Busch C, 2000, CURR OPIN STRUC BIOL, V10, P528, DOI 10.1016/S0959-440X(00)00126-3; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Chong SR, 1998, NUCLEIC ACIDS RES, V26, P5109, DOI 10.1093/nar/26.22.5109; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Farras R, 2001, EMBO J, V20, P2742, DOI 10.1093/emboj/20.11.2742; Galan JM, 2001, MOL CELL BIOL, V21, P3105, DOI 10.1128/MCB.21.9.3105-3117.2001; Glockner G, 2002, NATURE, V418, P79, DOI 10.1038/nature00847; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; Hassan H, 2000, J BIOL CHEM, V275, P38197, DOI 10.1074/jbc.M005783200; Jung E, 1998, EUR J BIOCHEM, V253, P517, DOI 10.1046/j.1432-1327.1998.2530517.x; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; Kaplan KB, 1997, CELL, V91, P491, DOI 10.1016/S0092-8674(00)80435-3; Kreppel L, 2002, NUCLEIC ACIDS RES, V30, P84, DOI 10.1093/nar/30.1.84; Morris HR, 1996, RAPID COMMUN MASS SP, V10, P889, DOI 10.1002/(SICI)1097-0231(19960610)10:8<889::AID-RCM615>3.0.CO;2-F; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; Nayak S, 2002, CURR BIOL, V12, P277, DOI 10.1016/S0960-9822(02)00682-6; Ohshima K, 1996, J BIOL CHEM, V271, P16784, DOI 10.1074/jbc.271.28.16784; Previato JO, 1998, J BIOL CHEM, V273, P14982, DOI 10.1074/jbc.273.24.14982; Roux Kenneth H., 1995, P53; Sassi S, 2001, GLYCOBIOLOGY, V11, P283, DOI 10.1093/glycob/11.4.283; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Teng-umnuay P, 1998, J BIOL CHEM, V273, P18242, DOI 10.1074/jbc.273.29.18242; Teng-umnuay P, 1999, J BIOL CHEM, V274, P36392, DOI 10.1074/jbc.274.51.36392; van der Wel H, 2002, J BIOL CHEM, V277, P46527, DOI 10.1074/jbc.M208824200; van der Wel H, 2001, J BIOL CHEM, V276, P33952, DOI 10.1074/jbc.M102555200; Vervoort EB, 2000, NUCLEIC ACIDS RES, V28, P2069, DOI 10.1093/nar/28.10.2069; Wang GF, 1999, CHIN J INORG CHEM, V15, P435; West CM, 2002, GLYCOBIOLOGY, V12, p17R, DOI 10.1093/glycob/12.2.17R; West CM, 1997, GENE, V200, P1, DOI 10.1016/S0378-1119(97)00194-7; Yamanaka A, 2002, CURR BIOL, V12, P267, DOI 10.1016/S0960-9822(02)00657-7; Yeh KC, 2002, J BACTERIOL, V184, P525, DOI 10.1128/JB.184.2.525-530.2002; Zachara NE, 1996, EUR J BIOCHEM, V238, P511, DOI 10.1111/j.1432-1033.1996.0511z.x; Zachara NE, 2002, CHEM REV, V102, P431, DOI 10.1021/cr000406u; Zhang Z, 1998, NUCLEIC ACIDS RES, V26, P3986, DOI 10.1093/nar/26.17.3986; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	38	30	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46328	46337		10.1074/jbc.M208024200	http://dx.doi.org/10.1074/jbc.M208024200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244115	hybrid			2022-12-27	WOS:000179529300083
J	Wang, J; Kirby, CE; Herbst, R				Wang, J; Kirby, CE; Herbst, R			The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRENYLATION-DEPENDENT ASSOCIATION; MICROTUBULE DYNAMICS; CELL-CYCLE; K-RAS; PROTEIN; KINASE; PHOSPHORYLATION; METHYLATION; ROLES; YEAST	PRL-1 is one of three closely related protein-tyrosine phosphatases, which are characterized by C-terminal farnesylation. Recent reports suggest that they are involved in the regulation of cell proliferation and transformation. However, their biological function has not yet been determined. Here we show that PRL-1 mRNA is overexpressed in a number of human tumor cell lines, including HeLa cells. Using immunofluorescence we studied the subcellular localization of endogenous PRL-1, and our results demonstrate that PRL-1 exhibits cell cycle-dependent localization; in non-mitotic HeLa cells, PRL-1 is localized to the endoplasmic reticulum in a farnesylation-dependent manner. In mitotic cells PRL-1 relocalizes to the centrosomes and the spindle apparatus, proximal to the centrosomes, in a farnesylation-independent manner. Conditional expression of a catalytic domain mutant in HeLa cells results in a delay in the progression of cells through mitosis but has no effect on other phases of the cell cycle. Further, expression of a farnesylation site PRL-1 mutant results in mitotic defects, characterized by chromosomal bridges in anaphase and lagging chromosomes, without affecting spindle checkpoint function. Together, these results suggest that PRL-1 function is regulated in a cell cycle-dependent manner and implicate PRL-1 in regulating progression through mitosis, possibly by modulating spindle dynamics.	DNAX Res Inst Molec & Cellular Biol Inc, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Herbst, R (corresponding author), DNAX Res Inst Molec & Cellular Biol Inc, 901 Calif Ave, Palo Alto, CA 94304 USA.	ronald.herbst@dnax.org						Andersen SSL, 1999, BIOESSAYS, V21, P53, DOI 10.1002/(SICI)1521-1878(199901)21:1<53::AID-BIES7>3.0.CO;2-L; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Ashar HR, 2000, J BIOL CHEM, V275, P30451, DOI 10.1074/jbc.M003469200; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; Chen Z, 2000, J BIOL CHEM, V275, P41251, DOI 10.1074/jbc.M006687200; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; Dixon JE, 1996, RECENT PROG HORM RES, V51, P405; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Frearson JA, 1997, BIOESSAYS, V19, P417, DOI 10.1002/bies.950190509; Fujii GH, 1999, ONCOGENE, V18, P1765, DOI 10.1038/sj.onc.1202492; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Peng Y, 1999, J BIOL CHEM, V274, P4513, DOI 10.1074/jbc.274.8.4513; Peng Y, 1998, J BIOL CHEM, V273, P17286, DOI 10.1074/jbc.273.27.17286; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Sorger PK, 1997, CURR OPIN CELL BIOL, V9, P807, DOI 10.1016/S0955-0674(97)80081-6; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537; van Huijsduijnen RH, 1998, GENE, V225, P1; Wang Q, 2002, CANCER LETT, V175, P63, DOI 10.1016/S0304-3835(01)00703-0; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zeng Q, 1998, BIOCHEM BIOPH RES CO, V244, P421, DOI 10.1006/bbrc.1998.8291; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	31	106	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46659	46668		10.1074/jbc.M206407200	http://dx.doi.org/10.1074/jbc.M206407200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235145	hybrid			2022-12-27	WOS:000179529300124
J	Torres, VI; Weiss, DS				Torres, VI; Weiss, DS			Identification of a tyrosine in the agonist binding site of the homomeric rho 1 gamma-aminobutyric acid (GABA) receptor that, when mutated, produces spontaneous opening	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; A-RECEPTOR; XENOPUS OOCYTES; ALPHA-SUBUNIT; NICOTINIC RECEPTORS; AMINO-ACID; M2 DOMAIN; CHANNEL; LIGAND; ACTIVATION	Mutagenesis of recombinant rho1 gamma-aminobutyric acid (GABA) receptors has previously identified five residues in the amino terminal extracellular domain that play an important role in GABA binding. Here, we present evidence that the tyrosine at position 102 of the rho1 receptor is also associated with the agonist binding site. Wildtype and mutant pl receptors were expressed in Xenopus laevis oocytes and examined using the two-electrode voltage clamp. When Tyr-102 was mutated to cysteine, serine, tryptophan, or glycine the EC50 increased 31-, 214-, 664-, and 8752-fold, respectively. An increase in the IC50 was also observed for the competitive antagonist 3-APMPA, but not for the non-competitive antagonist picrotoxin. Y102C was accessible to modification by methanethiosulfonate, and this modification was prevented by both GABA and 3-APMPA. An interesting characteristic of the Y102S mutant receptor was that, in the absence of GABA, there was an unusually high oocyte resting conductance that was blocked by both 3-APMPA and picrotoxin, indicating spontaneously opening GABA receptors. It appears that mutation of Tyr-102 perturbs the binding site and gates the pore. We conclude that Tyr-102 is a component of the GABA binding domain and speculate that Tyr-102 might be important for coupling agonist binding to channel opening.	Univ Alabama Birmingham, Sch Med, Dept Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Weiss, DS (corresponding author), Univ Alabama Birmingham, Sch Med, Dept Neurobiol, 1719 6th Ave S CIRC 410, Birmingham, AL 35294 USA.	dweiss@nrc.uab.edu	Torres, Viviana/AAC-3329-2019	Torres, Viviana/0000-0002-1220-7709	NINDS NIH HHS [NS36195, NS35291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036195, R01NS035291, R37NS035291] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; AMIN J, 1994, RECEPTOR CHANNEL, V2, P227; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Buhr A, 2001, J BIOL CHEM, V276, P7775, DOI 10.1074/jbc.M008907200; Chang YC, 2000, MOL PHARMACOL, V58, P1375, DOI 10.1124/mol.58.6.1375; Chang YC, 1998, MOL PHARMACOL, V53, P511, DOI 10.1124/mol.53.3.511; Chang YC, 1999, NAT NEUROSCI, V2, P219, DOI 10.1038/6313; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; Enz R, 1996, J NEUROSCI, V16, P4479; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; JACKSON MB, 1995, ANNU REV PHYSIOL, V57, P447; KAMMANN M, 1989, NUCLEIC ACIDS RES, V12, P4445; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KUSAMA T, 1993, BRIT J PHARMACOL, V109, P200, DOI 10.1111/j.1476-5381.1993.tb13554.x; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; Newell JG, 2000, J BIOL CHEM, V275, P14198, DOI 10.1074/jbc.275.19.14198; OHNO K, 1995, P NATL ACAD SCI USA, V92, P758, DOI 10.1073/pnas.92.3.758; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Pan ZH, 1997, P NATL ACAD SCI USA, V94, P6490, DOI 10.1073/pnas.94.12.6490; SHIMADA S, 1992, MOL PHARMACOL, V41, P683; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SMITH GB, 1994, J BIOL CHEM, V269, P20380; Thompson SA, 1999, BRIT J PHARMACOL, V127, P1349, DOI 10.1038/sj.bjp.0702687; Wegelius K, 1998, EUR J NEUROSCI, V10, P350, DOI 10.1046/j.1460-9568.1998.00023.x; WOODWARD RM, 1992, MOL PHARMACOL, V42, P165; Wotring VE, 1999, J PHYSIOL-LONDON, V521, P327, DOI 10.1111/j.1469-7793.1999.00327.x; Zhang DX, 2001, TRENDS PHARMACOL SCI, V22, P121, DOI 10.1016/S0165-6147(00)01625-4; ZHANG HG, 1994, J PHYSIOL-LONDON, V479, P65, DOI 10.1113/jphysiol.1994.sp020278; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088	39	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43741	43748		10.1074/jbc.M202007200	http://dx.doi.org/10.1074/jbc.M202007200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226075	hybrid			2022-12-27	WOS:000179272000028
J	Whetstine, JR; Witt, TL; Matherly, LH				Whetstine, JR; Witt, TL; Matherly, LH			The human reduced folate carrier gene is regulated by the AP2 and Sp1 transcription factor families and a functional 61-base pair polymorphism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLYLPOLYGLUTAMATE SYNTHETASE GENE; ACUTE LYMPHOBLASTIC-LEUKEMIA; GAMMA-GLUTAMATE SYNTHETASE; TISSUE-SPECIFIC PROMOTERS; MESSENGER-RNA; 5'-UNTRANSLATED REGION; RESPONSE ELEMENT; RECEPTOR GENE; FOLIC-ACID; CELL LINE	Recently, our laboratory reported an intricate regulation of the human reduced folate carrier (hRFC) gene, involving multiple promoters and noncoding exons. We localized promoter activity to a 452-bp GC-rich region upstream of noncoding exon A, including a 47-bp basal promoter with a CRE/AP-1-like consensus element that bound the bZip family of DNA-binding proteins (e.g. CREB-1 and c -Jun). We now report that three nearly identical tandem repeats (49-61 bp) in the hRFC-A upstream region are involved in regulating promoter activity. By in vitro binding assays, multiple transcription factors (e.g. AP2 and Sp1/Sp3) bound this region. When AP2 was cotransfected with the hRFC-A reporter construct into HT1080 cells, promoter activity increased 3-fold. In Drosophila SL2 cells, Sp1 transactivated promoter A and showed synergism with CREB-1. However, c-Jun was antagonistic to the effects of Sp1. A sequence variant in the hRFC-A repeated region was identified, involving an exact duplication of a 61-bp sequence. This variant had an allelic frequency of 78% in 72 genomic DNAs and resulted in a 63% increase in promoter activity. These results identify important regions in the hRFC-A promoter and critical roles for AP2 and Sp1, in combination with the bZip transcription factors. Moreover, they document a functionally novel polymorphism that increases promoter activity and may contribute to interpatient variations in hRFC expression and effects on tissue folate homeostasis and antitumor response to antifolates.	Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Expt & Clin Therapeut Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Pharmacol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Matherly, LH (corresponding author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Expt & Clin Therapeut Program, 110 E Warren Ave, Detroit, MI 48201 USA.				NCI NIH HHS [CA53535] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBLE FM, 1998, CURRENT PROTOCOLS MO; Butterworth CE, 1996, ANNU REV NUTR, V16, P73, DOI [10.1146/annurev.nutr.16.1.73, 10.1146/annurev.nu.16.070196.000445]; Chen L, 1996, J BIOL CHEM, V271, P13077, DOI 10.1074/jbc.271.22.13077; Chen SJ, 1998, GENE, V215, P101, DOI 10.1016/S0378-1119(98)00268-6; Choi SW, 2000, J NUTR, V130, P129, DOI 10.1093/jn/130.2.129; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dooley KA, 1999, J BIOL CHEM, V274, P5285, DOI 10.1074/jbc.274.9.5285; Elwood PC, 1997, BIOCHEMISTRY-US, V36, P1467, DOI 10.1021/bi962070h; Fiaschi T, 2000, FEBS LETT, V473, P42, DOI 10.1016/S0014-5793(00)01496-4; Fournier B, 2001, J BACTERIOL, V183, P2367, DOI 10.1128/JB.183.7.2367-2371.2001; Gao B, 1997, MOL PHARMACOL, V52, P1019, DOI 10.1124/mol.52.6.1019; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; Gong MK, 1997, BLOOD, V89, P2494, DOI 10.1182/blood.V89.7.2494; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Guo W, 1999, CLIN CANCER RES, V5, P621; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; Ito T, 2002, BIOCHEM BIOPH RES CO, V290, P1048, DOI 10.1006/bbrc.2001.6325; Jansen G, 1998, J BIOL CHEM, V273, P30189, DOI 10.1074/jbc.273.46.30189; Jansen G, 1999, ANTIFOLATE DRUGS CAN, P293; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kocarek TA, 2000, ARCH BIOCHEM BIOPHYS, V376, P180, DOI 10.1006/abbi.2000.1704; Matherly LH, 1996, LEUKEMIA LYMPHOMA, V21, P359, DOI 10.3109/10428199609093433; Matherly LH, 2001, PROG NUCLEIC ACID RE, V67, P131, DOI 10.1016/S0079-6603(01)67027-2; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; Pullarkat S. T., 2001, Pharmacogenomics Journal, V1, P65; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Roberts SJ, 1997, BIOCHEM J, V326, P439, DOI 10.1042/bj3260439; Roy K, 1996, J BIOL CHEM, V271, P23820, DOI 10.1074/jbc.271.39.23820; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; Serot JM, 2001, J NEURAL TRANSM, V108, P93, DOI 10.1007/s007020170100; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SIROTNAK FM, 1985, CANCER RES, V45, P3992; Stokstad ELR, 1990, FOLIC ACID METABOLIS, P1; Sumpio BE, 1997, AM J PHYSIOL-CELL PH, V273, pC1441, DOI 10.1152/ajpcell.1997.273.5.C1441; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Turner FB, 1999, CANCER RES, V59, P6074; Turner FB, 2000, J BIOL CHEM, V275, P35960, DOI 10.1074/jbc.M005228200; Ueland PM, 2001, TRENDS PHARMACOL SCI, V22, P195, DOI 10.1016/S0165-6147(00)01675-8; Whetstine Johnathan R., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P101; Whetstine JR, 2002, BIOCHEM J, V367, P629, DOI 10.1042/BJ20020512; Whetstine JR, 2001, CLIN CANCER RES, V7, P3416; Whetstine JR, 2001, J BIOL CHEM, V276, P6350, DOI 10.1074/jbc.M008074200; Williams FMR, 1998, SOMAT CELL MOLEC GEN, V24, P143, DOI 10.1023/B:SCAM.0000007117.50428.63; Wong SC, 1999, J BIOL CHEM, V274, P10388, DOI 10.1074/jbc.274.15.10388; Wong SC, 1997, BIOCHEM PHARMACOL, V53, P199, DOI 10.1016/S0006-2952(96)00710-1; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; Xu Y, 2002, BIOCHEM J, V362, P401, DOI 10.1042/0264-6021:3620401; Zhang L, 1998, CLIN CANCER RES, V4, P2169; Zhang L, 1998, BIOCHEM J, V332, P773, DOI 10.1042/bj3320773	59	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43873	43880		10.1074/jbc.M208296200	http://dx.doi.org/10.1074/jbc.M208296200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228234	hybrid			2022-12-27	WOS:000179272000046
J	Wu, ZL; O'Kane, TM; Scott, RW; Savage, MJ; Bozyczko-Coyne, D				Wu, ZL; O'Kane, TM; Scott, RW; Savage, MJ; Bozyczko-Coyne, D			Protein tyrosine phosphatases are up-regulated and participate in cell death induced by polyglutamine expansion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; DUAL-SPECIFICITY PHOSPHATASE; HUNTINGTONS-DISEASE; MOUSE MODEL; GLUTAMINE REPEATS; HEAT-SHOCK; GENE; TOXICITY; NUCLEAR; TRACT	Polyglutamine expansion is the cause of several neuro-degenerative diseases. An in vitro model of polyglutamine-induced neuronal cell death was developed using truncated mutant huntingtin (Htt) and PC12 cells. Cell death was specifically observed in cells expressing a truncated mutant huntingtin-green fluorescence protein (GFP) fusion protein with 118 glutamine repeats (Gln(118)), as demonstrated by the release of lactate dehydrogenase (LDH). To gain further insights into the mechanisms of polyglutamine expansion-induced cell death, the Affymetrix rat genome array U34A was used to investigate gene expression changes associated with polyglutamine-mediated protein aggregation and cell death. Among the up-regulated genes, the increase of four protein tyrosine phosphatases (PTPs) was further confirmed by real-time quantitative reverse transcription PCR Protein expression of mitogen activated protein (MAP) kinase phosphatase 1 (MKP1) was also increased as demonstrated by Western blot. Furthermore, phosphorylation of MAP kinase extracellular signal-regulated kinase 1/2 (ERK1/2) was substantially reduced in association with protein aggregation, and two general PTP inhibitors, sodium orthovanadate and bpV(pic), dramatically rescued the cells from polyglutamine-induced cell death. These results suggest that one or more of the PTPs are involved in the polyglutamine-induced cell death.	Cephalon Inc, W Chester, PA 19380 USA	Teva Pharmaceutical Industries; Cephalon Inc.	Wu, ZL (corresponding author), Cephalon Inc, 145 Brandywine Pkwy, W Chester, PA 19380 USA.							Bozyczko-Coyne D, 2001, J NEUROCHEM, V77, P849, DOI 10.1046/j.1471-4159.2001.00294.x; Cao LG, 1998, J BIOL CHEM, V273, P21077, DOI 10.1074/jbc.273.33.21077; Carter RJ, 1999, J NEUROSCI, V19, P3248; Cooper JK, 1998, HUM MOL GENET, V7, P783, DOI 10.1093/hmg/7.5.783; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Gafni J, 2002, J NEUROSCI, V22, P4842, DOI 10.1523/JNEUROSCI.22-12-04842.2002; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Iannicola C, 2000, J NEUROCHEM, V75, P830, DOI 10.1046/j.1471-4159.2000.0750830.x; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Lunkes A, 1998, HUM MOL GENET, V7, P1355, DOI 10.1093/hmg/7.9.1355; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Moulder KL, 1999, J NEUROSCI, V19, P705; Peters MF, 1999, MOL CELL NEUROSCI, V14, P121, DOI 10.1006/mcne.1999.0773; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Seta KA, 2001, J BIOL CHEM, V276, P44405, DOI 10.1074/jbc.M103346200; Song C, 2002, J BIOL CHEM, V277, P6703, DOI 10.1074/jbc.M110338200; Turmaine M, 2000, P NATL ACAD SCI USA, V97, P8093, DOI 10.1073/pnas.110078997; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Wyttenbach A, 2001, HUM MOL GENET, V10, P1829, DOI 10.1093/hmg/10.17.1829; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	29	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44208	44213		10.1074/jbc.M206890200	http://dx.doi.org/10.1074/jbc.M206890200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226089	hybrid			2022-12-27	WOS:000179272000088
J	Schwarzmann, N; Kunerth, S; Weber, K; Mayr, GW; Guse, AH				Schwarzmann, N; Kunerth, S; Weber, K; Mayr, GW; Guse, AH			Knock-down of the type 3 ryanodine receptor impairs sustained Ca2+ signaling via the T cell receptor/CD3 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; RELEASE; RNA; RESISTANT; INTERFERENCE; LYMPHOCYTES; ACTIVATION; MECHANISMS	In Jurkat T cells, the type 3 ryanodine receptor (RyR) was knocked-down by stable integration of plasmid expressing type 3 ryanodine receptor antisense RNA. Stable integration of the antisense plasmid in individual clones was demonstrated by PCR of genomic DNA, expression of antisense RNA by reverse transcriptase PCR, and efficiently reduced expression of type 3 ryanodine receptor protein by Western blot. Selected clones were successfully used to analyze T cell receptor/CD3 complex-mediated Ca2+ signaling. Reduced expression of the type 3 RyR resulted in (i) significantly decreased Ca2+ signaling in the sustained phase and (ii) in permeabilized cells in a significantly impaired response toward cyclic ADP-ribose but not to D-myo-inositol 1,4,5-trisphosphate. For the first time, the role of the type 3 RyR in sustained Ca2+ signaling was directly visualized by confocal Ca2+ imaging as a significant contribution to the number and the magnitude of subcellular Ca2+ signals. These data suggest that the type 3 ryanodine receptor is essential in the sustained Ca2+ response in T cells.	Univ Hamburg, Hosp Eppendorf, Ctr Theoret Med, Inst Cellular Signal Transduct, D-20246 Hamburg, Germany	University of Hamburg	Guse, AH (corresponding author), Univ Hamburg, Hosp Eppendorf, Ctr Theoret Med, Inst Cellular Signal Transduct, Martinistr 52, D-20246 Hamburg, Germany.	guse@uke.uni-hamburg.de						Berg I, 2000, J CELL BIOL, V150, P581, DOI 10.1083/jcb.150.3.581; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; Coussin F, 2000, J BIOL CHEM, V275, P9596, DOI 10.1074/jbc.275.13.9596; da Silva CP, 2000, BBA-MOL CELL RES, V1498, P122, DOI 10.1016/S0167-4889(00)00089-6; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fulceri R, 2001, BIOCHEM BIOPH RES CO, V288, P697, DOI 10.1006/bbrc.2001.5834; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; Guse AH, 1997, J BIOL CHEM, V272, P8546, DOI 10.1074/jbc.272.13.8546; Guse AH, 2002, BIOCHEMISTRY-US, V41, P6744, DOI 10.1021/bi020171b; Guse AH, 2001, J BIOL CHEM, V276, P34722, DOI 10.1074/jbc.M100715200; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; GUSE AH, 1991, J BIOL CHEM, V266, P24498; GUSE AH, 1995, J IMMUNOL, V155, P3353; Guse AH, 1996, J BIOL CHEM, V271, P23946, DOI 10.1074/jbc.271.39.23946; GUSE AH, 2002, CYCLIC ADP RIBOSE NA; Guse Andreas H., 2002, Current Molecular Medicine (Hilversum), V2, P273, DOI 10.2174/1566524024605707; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hohenegger M, 1999, BRIT J PHARMACOL, V128, P1235, DOI 10.1038/sj.bjp.0702935; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; Kiselyov K, 2001, BIOCHEM J, V360, P17, DOI 10.1042/0264-6021:3600017; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; Mironneau J, 2001, J BIOL CHEM, V276, P11257, DOI 10.1074/jbc.M005994200; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; Novotny J, 2001, METHOD ENZYMOL, V342, P193, DOI 10.1016/S0076-6879(01)42545-6; Ricard I, 1997, CELL SIGNAL, V9, P197, DOI 10.1016/S0898-6568(96)00141-6; Schottelndreier H, 2001, CELL SIGNAL, V13, P895, DOI 10.1016/S0898-6568(01)00225-X; Schweitzer K, 2001, ANAL BIOCHEM, V299, P218, DOI 10.1006/abio.2001.5419; Sethi JK, 1997, J BIOL CHEM, V272, P16358, DOI 10.1074/jbc.272.26.16358	34	55	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50636	50642		10.1074/jbc.M209061200	http://dx.doi.org/10.1074/jbc.M209061200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12354756	hybrid			2022-12-27	WOS:000180177700059
J	Kajava, AV				Kajava, AV			What curves alpha-solenoids? Evidence for an alpha-helical toroid structure of Rpn1 and Rpn2 proteins of the 26 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; LEUCINE-RICH REPEAT; SECONDARY STRUCTURE PREDICTION; F1F0 ATP SYNTHASE; CRYSTAL-STRUCTURE; ANKYRIN REPEAT; CROSS-LINKING; SUBUNIT-C; DOMAIN; MOTIF	The alpha-helical solenoid proteins adopt a variety of elongated curved structures. They have been examined to identify the interactions that determine their curvature. A sequence pattern characteristic for strongly curved alpha-helical solenoids has been constructed and was found to match protein sequences containing the proteasome/cyclosome repeats. Based on this, a structural model of the repeat-containing domains of the Rpn1/S2 and Rpn2/S1 proteins, which represent the largest subunits of the 26 S proteasome, has been proposed. The model has a novel architecture resembling an a-helical toroid. Molecular modeling shows that these toroids have a central pore that would allow passage of an unfolded protein substrate through it. This implies that the Rpn1 and Rpn2 toroids are aligned along the common axial pores of the ATPase hexamer and form an "antechamber'' of the 26 S proteasome. The proposed quaternary structure agrees with the available experimental data. It is suggested that the function of this antechamber is assistance to the ATPases in the unfolding of protein substrates prior to proteolysis. An evolutionary link between the PC repeat-containing proteins and tetratricopeptide repeat proteins is proposed.	NIH, Ctr Mol Modeling, Ctr Informat Technol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT)	Kajava, AV (corresponding author), CNRS, Ctr Rech Biochim Macromol, UPR 1086, 1919 Route Mende, F-34293 Montpellier 5, France.		Kajava, Andrey V/E-1107-2014	Kajava, Andrey V/0000-0002-2342-6886				ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Bateman A, 1998, PROTEIN SCI, V7, P1477, DOI 10.1002/pro.5560070625; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; Davy A, 2001, EMBO REP, V2, P821, DOI 10.1093/embo-reports/kve184; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Ferrell K, 2000, TRENDS BIOCHEM SCI, V25, P83, DOI 10.1016/S0968-0004(99)01529-7; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576; Gieffers C, 2001, MOL CELL, V7, P907, DOI 10.1016/S1097-2765(01)00234-9; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Gorbea C, 2000, J BIOL CHEM, V275, P875, DOI 10.1074/jbc.275.2.875; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Hartmann-Petersen R, 2001, ARCH BIOCHEM BIOPHYS, V386, P89, DOI 10.1006/abbi.2000.2178; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kajava AV, 2002, PROTEIN SCI, V11, P1082, DOI 10.1110/ps.4010102; Kajava AV, 2001, MOL MICROBIOL, V42, P279, DOI 10.1046/j.1365-2958.2001.02598.x; Kajava AV, 2001, J STRUCT BIOL, V134, P132, DOI 10.1006/jsbi.2000.4328; Kobe B, 2000, TRENDS BIOCHEM SCI, V25, P509, DOI 10.1016/S0968-0004(00)01667-4; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P195, DOI 10.1016/S0968-0004(97)01058-X; McLuskey K, 2001, BIOCHEMISTRY-US, V40, P8783, DOI 10.1021/bi010309a; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; Peters JW, 1996, NAT STRUCT BIOL, V3, P991, DOI 10.1038/nsb1296-991; Ponting CP, 2000, J MOL BIOL, V302, P1041, DOI 10.1006/jmbi.2000.4087; RAAG R, 1988, J MOL BIOL, V200, P553, DOI 10.1016/0022-2836(88)90542-6; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; Richmond C, 1997, J BIOL CHEM, V272, P13403, DOI 10.1074/jbc.272.20.13403; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Steegborn C, 2001, STRUCTURE, V9, P1051, DOI 10.1016/S0969-2126(01)00665-7; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; THUNNISSEN AMWH, 1994, NATURE, V367, P750, DOI 10.1038/367750a0; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Walz J, 1998, J STRUCT BIOL, V121, P19, DOI 10.1006/jsbi.1998.3958; Wang J, 2001, STRUCTURE, V9, P177, DOI 10.1016/S0969-2126(01)00570-6; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; Ybe JA, 1999, NATURE, V399, P371, DOI 10.1038/20708; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	66	64	64	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49791	49798		10.1074/jbc.M204982200	http://dx.doi.org/10.1074/jbc.M204982200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12270919	hybrid			2022-12-27	WOS:000180028900092
J	Holmes, ML; Bartle, N; Eisbacher, M; Chong, BH				Holmes, ML; Bartle, N; Eisbacher, M; Chong, BH			Cloning and analysis of the thrombopoietin-induced megakaryocyte-specific glycoprotein VI promoter and its regulation by GATA-1, Fli-1, and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; REPRESENTATIONAL DIFFERENCE ANALYSIS; COLLAGEN RECEPTOR; IIB GENE; BINDING-SITE; IX PROMOTER; EXPRESSION; PROTEIN; DIFFERENTIATION; MUTATION	The exposure of collagen fibers at sites of vascular injury results in the adherence of platelets and their subsequent activation. The platelet collagen receptor glycoprotein (GP)(1) VI plays a crucial role in platelet activation and thrombus formation and decreased levels or defective GPVI may lead to excessive bleeding. In addition, elevated levels of collagen receptors may predispose individuals to coronary heart disease or strokes. GPVI expression is restricted to platelets and their precursor cell, the megakaryocyte. In this study we investigate the regulation of GPVI expression and show that thrombopoietin induces its expression in the megakaryocytic cell line UT-7/TPO. A W-region flanking the transcription start point of the GPVI gene was cloned (-694 to +29) and we report that this putative GPVI promoter bestows megakaryocye-specific expression. Deletion analyses and site-directed mutagenesis identified Sp1(227), GATA(177), and Ets(48) sites as essential for GPVI expression. We show that transcription factors GATA-1, Fli-1, and Sp1 can bind to and activate this promoter. Finally, GPVI mRNA was detected only in megakaryocytic cell lines expressing both Fli-1 and GATA-1, and we show that overexpression of Fli-1 in a stable cell line (which expresses endogenous GATA-1 and Sp1) results in expression of the endogenous GPVI gene.	Univ New S Wales, Dept Med, St George Clin Sch, Sydney, NSW 2052, Australia; Univ New S Wales, Ctr Thrombosis & Vasc Res, St George Clin Sch, Sydney, NSW 2052, Australia	University of New South Wales Sydney; University of New South Wales Sydney	Chong, BH (corresponding author), Univ New S Wales, Dept Med, St George Clin Sch, Sydney, NSW 2052, Australia.	b.h.chong@unsw.edu.au	Chong, Beng/AAE-2617-2019; Chong, Beng/AAM-9010-2021	Holmes, Melissa/0000-0001-5894-6649				AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554; Bastian LS, 1999, BLOOD, V93, P2637, DOI 10.1182/blood.V93.8.2637.408k20_2637_2644; Berlanga O, 2000, BLOOD, V96, P2740; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; Doubeikovski A, 1997, J BIOL CHEM, V272, P24300, DOI 10.1074/jbc.272.39.24300; Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483; Eisbacher M, 2001, CELL GROWTH DIFFER, V12, P435; Emami KH, 1998, NUCLEIC ACIDS RES, V26, P839, DOI 10.1093/nar/26.3.839; Ezumi Y, 2000, BIOCHEM BIOPH RES CO, V277, P27, DOI 10.1006/bbrc.2000.3624; Furihata K, 2002, ARCH PATHOL LAB MED, V126, P305; Gaines P, 2000, J BIOL CHEM, V275, P34114, DOI 10.1074/jbc.M006017200; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; Holmes ML, 1999, MOL CELL BIOL, V19, P4182; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Jacquelin B, 2001, J BIOL CHEM, V276, P23518, DOI 10.1074/jbc.M102019200; Jacquelin B, 2001, BLOOD, V97, P1721, DOI 10.1182/blood.V97.6.1721; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; Komatsu N, 1996, BLOOD, V87, P4552, DOI 10.1182/blood.V87.11.4552.bloodjournal87114552; Lagrue-Lak-Hal AH, 2001, J BIOL CHEM, V276, P15316, DOI 10.1074/jbc.M009117200; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; Lepage A, 1999, BLOOD, V94, P3366, DOI 10.1182/blood.V94.10.3366.422k35_3366_3380; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Ludlow LB, 1996, J BIOL CHEM, V271, P22076, DOI 10.1074/jbc.271.36.22076; Mehaffey MG, 2001, BLOOD, V98, P2681, DOI 10.1182/blood.V98.9.2681; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; NAGATA Y, 1995, J BIOL CHEM, V270, P19673, DOI 10.1074/jbc.270.34.19673; Nichols KE, 2000, NAT GENET, V24, P266, DOI 10.1038/73480; Nieswandt B, 2001, J EXP MED, V193, P459, DOI 10.1084/jem.193.4.459; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Prandini MH, 1996, BLOOD, V88, P2062, DOI 10.1182/blood.V88.6.2062.bloodjournal8862062; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Shou YP, 1998, J BIOL CHEM, V273, P5716, DOI 10.1074/jbc.273.10.5716; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Takatoku M, 1997, J BIOL CHEM, V272, P7259, DOI 10.1074/jbc.272.11.7259; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; WEISS MJ, 1995, EXP HEMATOL, V23, P99; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	44	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48333	48341		10.1074/jbc.M206127200	http://dx.doi.org/10.1074/jbc.M206127200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12359731	hybrid			2022-12-27	WOS:000179789600049
J	Jung, JH; Yoon, T; Choi, EC; Lee, K				Jung, JH; Yoon, T; Choi, EC; Lee, K			Interaction of cofilin with triose-phosphate isomerase contributes glycolytic fuel for Na,K-ATPase via Rho-mediated signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-DEPOLYMERIZING FACTOR; LIM-KINASE; PHOSPHOINOSITIDE-BINDING; STRESS FIBERS; PHOSPHORYLATION; PROTEIN; DEPHOSPHORYLATION; ACTIVATION; PHOSPHOPROTEINS; IDENTIFICATION	We reported previously that cofilin, an actin-binding protein, interacts with Na,K-ATPase and enhances its activity (Lee, K., Jung, J., Kim, M., and Guidotti, G. (2001) Biochem. J. 353, 377-385). To understand the nature of this interaction and the role of cofilin in the regulation of Na,K-ATPase activity, we searched for cofilin-binding proteins in the rat skeletal muscle cDNA library using the yeast two-hybrid system. Several cDNA clones were isolated, some of which coded for triosephosphate isomerase, a glycolytic enzyme. The interaction of cofilin with triose-phosphate isomerase as well as Na,K-ATPase was confirmed by immunoprecipitation and confocal microscopy in HeLa cells. Cofilin was translocated to the plasma membrane along with triosephosphate isomerase by the Rho activator lysophosphatidic acid but not by the p160 Rho-associated kinase inhibitor Y-27632, suggesting that the phosphorylated form of cofilin bound to TPI interacts with Na,K-ATPase. Ouabain-sensitive Rb-86(+) uptake showed that Na,K-ATPase activity was increased by the overexpression of cofilin and lysophosphatidic acid treatment, but not by the overexpression of mutant cofilin S3A and Y-27632 treatment. Pretreatment with the glycolytic inhibitor iodoacetic acid caused a remarkable reduction of Na,K-ATPase activity, whereas pretreatment with the oxidative inhibitor carbonyl cyanide m-chlorophenylhydrazone caused no detectable changes, suggesting that the phosphorylated cofilin is involved in feeding glycolytic fuel for Na,K-ATPase activity. These findings provide a novel molecular mechanism for the regulation of Na,K-ATPase activity and for the nature of the functional coupling of cellular energy transduction.	Ewha Womans Univ, Coll Pharm, Ctr Cell Signaling Res, Seoul 120750, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea	Ewha Womans University; Ewha Womans University; Seoul National University (SNU)	Lee, K (corresponding author), Ewha Womans Univ, Coll Pharm, Ctr Cell Signaling Res, Daehyun Dong 11-1, Seoul 120750, South Korea.	klyoon@ewha.ac.kr						ABE H, 1989, J BIOCHEM-TOKYO, V106, P696, DOI 10.1093/oxfordjournals.jbchem.a122919; ABE H, 1993, EXP CELL RES, V206, P1, DOI 10.1006/excr.1993.1113; Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; BALABAN RS, 1984, BIOCHIM BIOPHYS ACTA, V804, P419, DOI 10.1016/0167-4889(84)90069-7; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; BAMBURG JR, 1987, J CELL BIOL, V105, P2817, DOI 10.1083/jcb.105.6.2817; BAORTO DM, 1992, J CELL BIOL, V117, P357, DOI 10.1083/jcb.117.2.357; CANTIELLO HF, 1995, AM J PHYSIOL-RENAL, V269, pF637, DOI 10.1152/ajprenal.1995.269.5.F637; CLARKE FM, 1975, BIOCHIM BIOPHYS ACTA, V381, P37, DOI 10.1016/0304-4165(75)90187-7; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Dizon J, 1998, AM J PHYSIOL-HEART C, V274, pH1082, DOI 10.1152/ajpheart.1998.274.4.H1082; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126; HARDIN CD, 1993, AM J PHYSIOL, V265, pH1326, DOI 10.1152/ajpheart.1993.265.4.H1326; Heyworth PG, 1997, HISTOCHEM CELL BIOL, V108, P221, DOI 10.1007/s004180050162; KANAMORI T, 1995, J BIOL CHEM, V270, P8061, DOI 10.1074/jbc.270.14.8061; Kim KS, 2001, INT J SOC WELF, V10, P2, DOI 10.1111/1468-2397.00148; Kusano K, 1999, MOL CELL BIOCHEM, V190, P133, DOI 10.1023/A:1006962210692; Lee K, 2001, BIOCHEM J, V353, P377, DOI 10.1042/0264-6021:3530377; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; Moriyama K, 2002, J CELL SCI, V115, P1591; NAGAOKA R, 1995, CELL MOTIL CYTOSKEL, V30, P1, DOI 10.1002/cm.970300102; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OHTA Y, 1989, J BIOL CHEM, V264, P16143; Okada K, 1996, EXP CELL RES, V227, P116, DOI 10.1006/excr.1996.0256; Okamoto K, 2001, AM J PHYSIOL-ENDOC M, V281, pE479, DOI 10.1152/ajpendo.2001.281.3.E479; PAUL RJ, 1983, AM J PHYSIOL, V244, pC399, DOI 10.1152/ajpcell.1983.244.5.C399; Pfannstiel J, 2001, J BIOL CHEM, V276, P49476, DOI 10.1074/jbc.M104760200; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAITO T, 1994, EXP CELL RES, V212, P49, DOI 10.1006/excr.1994.1117; SAMSTAG Y, 1994, P NATL ACAD SCI USA, V91, P4494, DOI 10.1073/pnas.91.10.4494; STEPHAN P, 1986, BIOCHIM BIOPHYS ACTA, V873, P127, DOI 10.1016/0167-4838(86)90198-6; Sugiyama S, 2001, MOL CELL BIOCHEM, V217, P153, DOI 10.1023/A:1007261322878; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Szaszi K, 2000, J BIOL CHEM, V275, P28599, DOI 10.1074/jbc.M001193200; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Takuma T, 1996, J BIOCHEM, V120, P35; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; WALSH JL, 1989, BIOCHIM BIOPHYS ACTA, V999, P64, DOI 10.1016/0167-4838(89)90031-9; WEISS J, 1985, J CLIN INVEST, V75, P436, DOI 10.1172/JCI111718; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YONEZAWA N, 1987, CELL STRUCT FUNCT, V12, P443, DOI 10.1247/csf.12.443	49	43	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48931	48937		10.1074/jbc.M208806200	http://dx.doi.org/10.1074/jbc.M208806200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12359716	hybrid			2022-12-27	WOS:000179789600124
J	Liu, L; Liang, XH; Uliel, S; Unger, R; Ullu, E; Michaeli, S				Liu, L; Liang, XH; Uliel, S; Unger, R; Ullu, E; Michaeli, S			RNA interference of signal peptide-binding protein SRP54 elicits deleterious effects and protein sorting defects in trypanosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNITION PARTICLE RECEPTOR; ENDOPLASMIC-RETICULUM MEMBRANE; DOUBLE-STRANDED-RNA; COLLOSOMA 7SL RNA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; LEPTOMONAS-COLLOSOMA; CRYSTAL-STRUCTURE; YARROWIA-LIPOLYTICA; MOLECULAR-CLONING	Trypanosomes are protozoan parasites that have a major impact on health. This family diverged very early from the eukaryotic lineage and possesses unique RNA processing mechanisms such as trans-splicing and RNA editing. The trypanosome signal recognition particle (SRP) has a unique composition compared with all known SRP complexes, because it contains two RNA molecules, the 7SL RNA and a tRNA-like molecule. RNA interference was utilized to elucidate the essentiality of the SRP pathway and its role in protein translocation in Trypanosoma brucei. The production of double stranded RNA specific for the signal peptide-binding protein SRP54 induced the degradation of the mRNA and a loss of the SRP54 protein. SRP54 depletion elicited inhibition in growth and cytokinesis, suggesting that the SRP pathway is essential. The translocation of four signal peptide-containing proteins was examined. Surprisingly, the proteins were translocated to the endoplasmic reticulum and properly processed. However, the surface EP procyclin, the lysosomal protein p67, and the flagellar pocket protein CRAM were mislocalized and accumulated in megavesicles, most likely because of a secondary effect on protein sorting. The translocation of these proteins to the endoplasmic reticulum under SRP54 depletion suggests that an alternative pathway for protein translocation exists in trypanosomes.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; Yale Univ, Sch Med, Dept Med & Cell Biol, New Haven, CT 06520 USA	Bar Ilan University; Yale University	Michaeli, S (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.		Michaeli, Shulamit/AAC-8255-2022	Liu, Li/0000-0002-3733-6961				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Al-Qahtani A, 1998, BIOCHEM J, V331, P521, DOI 10.1042/bj3310521; ALTHOFF SM, 1994, MOL CELL BIOL, V14, P7839, DOI 10.1128/MCB.14.12.7839; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aphasizhev R, 2002, CELL, V108, P637, DOI 10.1016/S0092-8674(02)00647-5; BANGS JD, 1993, J CELL SCI, V105, P1101; Bastin P, 2000, J CELL SCI, V113, P3321; Batey RT, 2000, SCIENCE, V287, P1232, DOI 10.1126/science.287.5456.1232; BEJA O, 1993, MOL BIOCHEM PARASIT, V57, P223, DOI 10.1016/0166-6851(93)90198-7; Ben-Shlomo H, 1997, NUCLEIC ACIDS RES, V25, P4977, DOI 10.1093/nar/25.24.4977; Ben-Shlomo H, 1999, J BIOL CHEM, V274, P25642, DOI 10.1074/jbc.274.36.25642; BROWN JD, 1994, EMBO J, V13, P4390, DOI 10.1002/j.1460-2075.1994.tb06759.x; Bui N, 1999, BIOL CHEM, V380, P135, DOI 10.1515/BC.1999.021; Butikofer P, 2002, MOL BIOCHEM PARASIT, V119, P87, DOI 10.1016/S0166-6851(01)00398-X; Butikofer P, 2001, FASEB J, V15, P545, DOI 10.1096/fj.00-0415hyp; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; Estevez AM, 1999, GENE, V240, P247, DOI 10.1016/S0378-1119(99)00437-0; Estevez AM, 2001, EMBO J, V20, P3831, DOI 10.1093/emboj/20.14.3831; Field H, 1999, J CELL SCI, V112, P147; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; Grosshans H, 2001, J CELL BIOL, V153, P745, DOI 10.1083/jcb.153.4.745; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HE F, 1990, CURR GENET, V17, P289, DOI 10.1007/BF00314874; HE XP, 1994, J CELL SCI, V107, P903; Hegde RS, 1999, TRENDS CELL BIOL, V9, P132, DOI 10.1016/S0962-8924(99)01504-4; Herskovits AA, 2001, EMBO REP, V2, P1040, DOI 10.1093/embo-reports/kve226; Jacobson MR, 1998, P NATL ACAD SCI USA, V95, P7981, DOI 10.1073/pnas.95.14.7981; Keenan RJ, 1998, CELL, V94, P181, DOI 10.1016/S0092-8674(00)81418-X; Kelley RJ, 1999, MOL BIOCHEM PARASIT, V98, P17, DOI 10.1016/S0166-6851(98)00155-8; Lee IH, 1997, YEAST, V13, P499, DOI 10.1002/(SICI)1097-0061(199705)13:6<499::AID-YEA100>3.0.CO;2-M; LEE MGS, 1990, MOL CELL BIOL, V10, P4506, DOI 10.1128/MCB.10.9.4506; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; MICHAELI S, 1990, J BIOL CHEM, V265, P10582; MICHAELI S, 1993, EXP PARASITOL, V76, P308, DOI 10.1006/expr.1993.1037; MICHAELI S, 1992, MOL BIOCHEM PARASIT, V51, P55, DOI 10.1016/0166-6851(92)90200-4; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; Moreira-Leite FF, 2001, SCIENCE, V294, P610, DOI 10.1126/science.1063775; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; Roditi I, 1999, MOL BIOCHEM PARASIT, V103, P99, DOI 10.1016/S0166-6851(99)00124-3; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Seluanov A, 1997, J BIOL CHEM, V272, P2053; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X	58	29	31	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47348	47357		10.1074/jbc.M207736200	http://dx.doi.org/10.1074/jbc.M207736200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12244113	hybrid			2022-12-27	WOS:000179663700067
J	Pu, LX; Amoscato, AA; Bier, ME; Lazo, JS				Pu, LX; Amoscato, AA; Bier, ME; Lazo, JS			Dual G(1) and G(2) phase inhibition by a novel, selective Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino)-quinoline-5,8-dione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; PROTEIN PHOSPHATASE; DEPENDENT KINASES; CDK2 ACTIVITY; ACTIVATION; PHOSPHORYLATION; TRANSITION; EXPRESSION; TARGET	The Cdc25 dual specificity phosphatases coordinate cell cycle progression, but potent and selective inhibitors have generally been unavailable. In the present study, we have examined one potential inhibitor, 7-chloro-6-(2-morpholin-4-ylethylamino)-quinoline-5,8-dione (NSC 663284), that was identified in the compound library of the National Cancer Institute. We found that NSC 663284 arrested synchronized cells at both G, and G(2)/M phase, and blocked dephosphorylation and activation of Cdk2 and Cdk1 in vivo, as predicted for a Cdc25 inhibitor. Using the natural Cdc25A substrate, Tyr(15)-phosphorylated Cdk2/cyclin A, we demonstrated that NSC 663284 blocked reactivation of Cdk2/cyclin A kinase by Cdc25A catalytic domain in vitro. In-gel trypsin digestion followed by capillary liquid chromatography-electrospray ionization mass spectrometry and tandem mass spectrometry revealed the direct binding of NSC 663284 to one of the two serine residues in the active site loop HCEFSSER of the Cdc25A catalytic domain. Cdc25 binding and inhibition could contribute to the antiproliferative activity of NSC 663284 and its ability to arrest cell cycle progression. Moreover, NSC 663284 should be a valuable reagent to probe the actions of Cdc25 phosphatases within cells and may also be useful structure for the design of more potent and selective antiproliferative agents.	Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA; Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University	Lazo, JS (corresponding author), Univ Pittsburgh, Dept Pharmacol, E-1340 Biomed Sci Tower, Pittsburgh, PA 15261 USA.		BIER, MARK E/F-5385-2015	BIER, MARK E/0000-0002-5220-9338; Amoscato, Andrew/0000-0002-1340-9150	NATIONAL CANCER INSTITUTE [U19CA052995, P01CA078039, U01CA052995] Funding Source: NIH RePORTER; NCI NIH HHS [CA 52995, CA 78039] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Dixon D, 1998, EXP CELL RES, V240, P236, DOI 10.1006/excr.1998.3940; Endicott JA, 1999, CURR OPIN STRUC BIOL, V9, P738, DOI 10.1016/S0959-440X(99)00038-X; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hagopian JC, 2001, J BIOL CHEM, V276, P275, DOI 10.1074/jbc.M007337200; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Lammer C, 1998, J CELL SCI, V111, P2445; Lazo JS, 2001, J MED CHEM, V44, P4042, DOI 10.1021/jm0102046; Nurse P, 1998, NAT MED, V4, P1103, DOI 10.1038/2594; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Tamura K, 2000, CANCER RES, V60, P1317; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0	23	76	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46877	46885		10.1074/jbc.M207902200	http://dx.doi.org/10.1074/jbc.M207902200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356752	hybrid			2022-12-27	WOS:000179663700008
J	Hellman, NE; Kono, S; Mancini, GM; Hoogeboom, AJ; de Jong, GJ; Gitlin, JD				Hellman, NE; Kono, S; Mancini, GM; Hoogeboom, AJ; de Jong, GJ; Gitlin, JD			Mechanisms of copper incorporation into human ceruloplasmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; APOCERULOPLASMIN; IDENTIFICATION; BIOSYNTHESIS; OXIDASE; CLUSTER; YEAST; GENE	Ceruloplasmin is a multicopper oxidase essential for normal iron homeostasis. To elucidate the mechanisms of copper incorporation into this protein, holocerulo-plasmin biosynthesis was examined by immunoblot analysis and Cu-64 metabolic labeling of Chinese hamster ovary cells transfected with cDNAs encoding wild-type or mutant ceruloplasmin. This analysis reveals that the incorporation of copper into newly synthesized apoceruloplasmin in vivo results in a detectable conformational change in the protein. Strikingly, despite the unique functional role of each copper site within ceruloplasmin, metabolic studies indicate that achieving this final conformation-driven state requires the occupation of all six copper-binding sites with no apparent hierarchy for copper incorporation at any given site. Consistent with these findings a missense mutation (G631R), resulting in aceruloplasminemia and predicted to alter the interactions at a single type I copper-binding site, results in the synthesis and secretion only of apoceruloplasmin. Analysis of copper incorporation into apoceruloplasmin in vitro reveals that this process is cooperative and that the failure of copper incorporation into copper-binding site mutants observed in vivo is intrinsic to the mutant proteins. These findings reveal a precise and sensitive mechanism for the formation of holoceruloplasmin under the limiting conditions of copper availability within the cell that may be generally applicable to the biosynthesis of cuproproteins within the secretory pathway.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands	Washington University (WUSTL); Erasmus University Rotterdam	Gitlin, JD (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, McDonnell Pediat Res Bldg,660 S Euclid Ave, St Louis, MO 63110 USA.	gitlin@kids.wustl.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061763] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 61763] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asante-Appiah E, 1998, J BIOL CHEM, V273, P35078, DOI 10.1074/jbc.273.52.35078; Bartnikas TB, 2001, NAT STRUCT BIOL, V8, P733, DOI 10.1038/nsb0901-733; Blackburn NJ, 2000, BIOCHEMISTRY-US, V39, P2316, DOI 10.1021/bi992334a; CALABRESE L, 1989, J BIOL CHEM, V264, P6183; CARRICO RJ, 1969, J BIOL CHEM, V244, P4141; Connett JM, 1996, P NATL ACAD SCI USA, V93, P6814, DOI 10.1073/pnas.93.13.6814; Culotta V.C., 2001, METABOLIC MOL BASES, P3105; Davis-Kaplan SR, 1998, P NATL ACAD SCI USA, V95, P13641, DOI 10.1073/pnas.95.23.13641; DeFilippis V, 1996, BBA-PROTEIN STRUCT M, V1297, P119, DOI 10.1016/S0167-4838(96)00139-2; GITLIN JD, 1992, BIOCHEM J, V282, P835, DOI 10.1042/bj2820835; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Hellman NE, 2002, ANNU REV NUTR, V22, P439, DOI 10.1146/annurev.nutr.22.012502.114457; Hellman NE, 2002, J BIOL CHEM, V277, P1375, DOI 10.1074/jbc.M109123200; HOLTZMAN NA, 1970, J BIOL CHEM, V245, P2354; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Machonkin TE, 1998, BIOCHEMISTRY-US, V37, P9570, DOI 10.1021/bi980434v; Narayanan VS, 2001, J NUTR, V131, P1427, DOI 10.1093/jn/131.5.1427; Petrescu SM, 1997, J BIOL CHEM, V272, P15796, DOI 10.1074/jbc.272.25.15796; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; SATO M, 1991, J BIOL CHEM, V266, P5128; Shimizu A, 1999, BIOCHEMISTRY-US, V38, P3034, DOI 10.1021/bi9819531; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; SUGAWARA T, 1991, BIOCHEMISTRY-US, V30, P2698, DOI 10.1021/bi00224a018; TERADA K, 1995, BBA-MOL BASIS DIS, V1270, P58, DOI 10.1016/0925-4439(94)00072-X; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	28	123	130	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46632	46638		10.1074/jbc.M206246200	http://dx.doi.org/10.1074/jbc.M206246200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351628	hybrid			2022-12-27	WOS:000179529300120
J	Lin, PS; Dubois, MF; Dahmus, ME				Lin, PS; Dubois, MF; Dahmus, ME			TFIIF-associating carboxyl-terminal domain phosphatase dephosphorylates phosphoserines 2 and 5 of RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; LARGEST SUBUNIT; PHOSPHORYLATION SITES; SUBSTRATE-SPECIFICITY; ELONGATION COMPLEXES; POSSIBLE INVOLVEMENT; CAPPING ENZYME; DISTINCT ROLES; MAP KINASES; IN-VITRO	The carboxyl-terminal domain (CTD) of the largest RNA polymerase (RNAP) II subunit undergoes reversible phosphorylation throughout the transcription cycle. The unphosphorylated form of RNAP II is referred to as IIA, whereas the hyperphosphorylated form is known as IIO. Phosphorylation. occurs predominantly at serine 2 and serine 5 within the CTD heptapeptide repeat and has functional implications for RNAP II with respect to initiation, elongation, and transcription-coupled RNA processing. In an effort to determine the role of the major CTD phosphatase (FCP1) in regulating events in transcription that appear to be influenced by serine 2 and serine 5 phosphorylation, the specificity of FCP1 was examined. FCP1 is capable of dephosphorylating heterogeneous RNAP IIO populations of HeLa nuclear extracts. The extent of dephosphorylation at specific positions was assessed by immunoreactivity with monoclonal antibodies specific for phosphoserine 2 or phosphoserine 5. As an alternative method to assess FCP1 specificity, RNAP IIO isozymes were prepared in vitro by the phosphorylation of purified calf thymus RNAP IIA with specific CTD kinases and used as substrates for FCP1. FCP1 dephosphorylates serine 2 and serine 5 with comparable efficiency. Accordingly, the specificity of FCP1 is sufficiently broad to dephosphorylate RNAP IIO at any point in the transcription cycle irrespective of the site of serine phosphorylation within the consensus repeat.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Ecole Normale Super, Genet Mol Lab, F-75230 Paris 05, France	University of California System; University of California Davis; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Dahmus, ME (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA.				NIGMS NIH HHS [GM-33300] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033300] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BREGMAN DB, 1994, J CELL SCI, V107, P387; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; CADENA DL, 1987, J BIOL CHEM, V262, P12468; Casse C, 1999, J BIOL CHEM, V274, P16097, DOI 10.1074/jbc.274.23.16097; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Dubois MF, 1997, NUCLEIC ACIDS RES, V25, P694, DOI 10.1093/nar/25.4.694; DUBOIS MF, 1994, EMBO J, V13, P4787, DOI 10.1002/j.1460-2075.1994.tb06804.x; DUBOIS MF, 1994, J CELL PHYSIOL, V158, P417, DOI 10.1002/jcp.1041580305; GERARD M, 1991, J BIOL CHEM, V266, P20940; Hausmann S, 2002, J BIOL CHEM, V277, P21213, DOI 10.1074/jbc.M202056200; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; KANG ME, 1993, J BIOL CHEM, V268, P25033; Kimura M, 2002, MOL CELL BIOL, V22, P1577, DOI 10.1128/MCB.22.5.1577-1588.2002; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; KONTERMANN RE, 1995, BIOL CHEM H-S, V376, P473, DOI 10.1515/bchm3.1995.376.8.473; KRAMER A, 1980, MOL GEN GENET, V180, P193, DOI 10.1007/BF00267369; Lavoie SB, 1999, BIOCHEM CELL BIOL, V77, P367, DOI 10.1139/bcb-77-4-367; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; Lehman AL, 2000, J BIOL CHEM, V275, P14923, DOI 10.1074/jbc.275.20.14923; Lin PS, 2002, PROG NUCLEIC ACID RE, V72, P333, DOI 10.1016/S0079-6603(02)72074-6; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Marshall NF, 2000, J BIOL CHEM, V275, P32430, DOI 10.1074/jbc.M005898200; Marshall NF, 1998, J BIOL CHEM, V273, P31726, DOI 10.1074/jbc.273.48.31726; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Palancade B, 2001, MOL CELL BIOL, V21, P6359, DOI 10.1128/MCB.21.19.6359-6368.2001; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; PAYNE JM, 1993, J BIOL CHEM, V268, P80; Ramanathan Y, 2001, J BIOL CHEM, V276, P10913, DOI 10.1074/jbc.M010975200; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; Rodriguez CR, 2000, MOL CELL BIOL, V20, P104, DOI 10.1128/MCB.20.1.104-112.2000; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; THIBODEAU A, 1991, EXP CELL RES, V195, P145, DOI 10.1016/0014-4827(91)90510-2; Trigon S, 1998, J BIOL CHEM, V273, P6769, DOI 10.1074/jbc.273.12.6769; VENETIANER A, 1995, EUR J BIOCHEM, V233, P83, DOI 10.1111/j.1432-1033.1995.083_1.x; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; WARREN SL, 1992, J CELL SCI, V103, P381; WEST ML, 1995, GENETICS, V140, P1223; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Yuryev A, 1996, GENETICS, V143, P661; ZHANG J, 1991, J BIOL CHEM, V266, P2290; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000	54	55	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45949	45956		10.1074/jbc.M208588200	http://dx.doi.org/10.1074/jbc.M208588200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351650	hybrid			2022-12-27	WOS:000179529300033
J	Taverner, T; Hall, NE; O'Hair, RAJ; Simpson, RJ				Taverner, T; Hall, NE; O'Hair, RAJ; Simpson, RJ			Characterization of an antagonist interleukin-6 dimer by stable isotope labeling, cross-linking, and mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT MURINE INTERLEUKIN-6; CRYSTAL-STRUCTURE; RECEPTOR COMPLEX; IL-6 RECEPTOR; BINDING; REAGENTS; DOMAIN; GP130; CELLS; IDENTIFICATION	The homodimeric form of a recombinant cytokine interleukin-6 (IL-6(D)) is known to antagonize IL-6 signaling. In this study, spatially proximal residues between IL-6 chains in IL-6, were identified using a method for specific recognition of intermolecular cross-linked peptides. Our strategy involved mixing 1:1 N-15-labeled and unlabeled (N-14) protein to form a mixture of isotopically labeled and unlabeled homodimers, which was chemically cross-linked. This cross-linked IL-6(D) was subjected to proteolysis by trypsin and the generated peptides were analyzed by electrospray ionization time-of-flight mass spectrometry (MS). Molecular ions from crosslinked peptides of intermolecular origin are labeled with [N-15/N-15] + [N-15/N-14] + [N-14/N-15] + [N-14/N-14] yielding readily identified triplet/quadruplet MS peaks. All other peptide species are labeled with [N-15] + [N-14] yielding doublet peaks. Intermolecular cross-linked peptides were identified by MS, and cross-linked residues were identified. This intermolecular cross-link detection method, which we have designated "mixed isotope cross-linking" MIX may have more general application to protein-protein interaction studies. The pattern of proximal residues found was consistent with IL-6(D) having a domain-swapped fold similar to IL-10 and interferon-gamma. This fold implies that IL-6(D)-mediated antagonism of IL-6 signaling is caused by obstruction of cooperative gp130 binding on IL-6(D), rather than direct blocking of gp-130-binding sites on IL-6(D).	Ludwig Inst Canc Res, Joint Proteom Lab, Parkville, Vic 3050, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Univ Melbourne, Sch Chem, Melbourne, Vic 3010, Australia	Ludwig Institute for Cancer Research; Walter & Eliza Hall Institute; University of Melbourne	Simpson, RJ (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, Joint Proteom Lab, POB 2008, Parkville, Vic 3050, Australia.	Richard.Simpson@ludwig.edu.au		Simpson, Richard/0000-0002-9834-0796; O'Hair, Richard/0000-0002-8044-0502; Hall, Nathan/0000-0001-8942-0498				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Apuy JL, 2001, BIOCHEMISTRY-US, V40, P15153, DOI 10.1021/bi0112199; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392; Bennett KL, 2000, PROTEIN SCI, V9, P1503, DOI 10.1110/ps.9.8.1503; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BIEMANN K, 1994, ACCOUNTS CHEM RES, V27, P370, DOI 10.1021/ar00047a008; Chen XH, 1999, ANAL BIOCHEM, V273, P192, DOI 10.1006/abio.1999.4243; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; Cole AR, 1999, J BIOL CHEM, V274, P7207, DOI 10.1074/jbc.274.11.7207; FONG YM, 1989, J IMMUNOL, V142, P2321; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; HANIU M, 1993, PROTEIN SCI, V2, P1441, DOI 10.1002/pro.5560020908; Henry CM, 2001, CHEM ENG NEWS, V79, P24, DOI 10.1021/cen-v079n029.p024; HIRANO T, 1988, EUR J IMMUNOL, V18, P1797, DOI 10.1002/eji.1830181122; JABLONS DM, 1989, J IMMUNOL, V142, P1542; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; Jones SA, 2001, FASEB J, V15, P43, DOI 10.1096/fj.99-1003rev; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuster B, 1998, CURR OPIN STRUC BIOL, V8, P393, DOI 10.1016/S0959-440X(98)80075-4; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Matthews JM, 1998, BIOCHEMISTRY-US, V37, P10671, DOI 10.1021/bi980127p; MAY LT, 1991, J BIOL CHEM, V266, P9950; Means GE, 1990, BIOCONJUGATE CHEM, V1, P2, DOI 10.1021/bc00001a001; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moreno A, 2001, BLOOD, V97, P242, DOI 10.1182/blood.V97.1.242; Moritz RL, 1999, GROWTH FACTORS, V16, P265, DOI 10.3109/08977199909069145; MORTON CJ, 1995, BBA-PROTEIN STRUCT M, V1249, P189, DOI 10.1016/0167-4838(95)00023-N; Muller DR, 2001, ANAL CHEM, V73, P1927, DOI 10.1021/ac001379a; NAKAJIMA K, 1989, J IMMUNOL, V142, P531; Nishimoto N, 2000, ANN RHEUM DIS, V59, P21, DOI 10.1136/ard.59.suppl_1.i21; NISHIMURA C, 1992, FEBS LETT, V311, P271, DOI 10.1016/0014-5793(92)81118-6; Onishi M, 1998, Int Rev Immunol, V16, P617, DOI 10.3109/08830189809043011; Pearson KM, 2002, RAPID COMMUN MASS SP, V16, P149, DOI 10.1002/rcm.554; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; Rappsilber J, 2000, ANAL CHEM, V72, P267, DOI 10.1021/ac991081o; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROSEJOHN S, 1991, J BIOL CHEM, V266, P3841; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAVINO R, 1993, P NATL ACAD SCI USA, V90, P4067, DOI 10.1073/pnas.90.9.4067; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; Sinz A, 2001, BIOCHEMISTRY-US, V40, P7903, DOI 10.1021/bi010259+; Somers W, 1997, EMBO J, V16, P989, DOI 10.1093/emboj/16.5.989; VANDAM M, 1993, J BIOL CHEM, V268, P15285; Wallon G, 2000, EMBO J, V19, P213, DOI 10.1093/emboj/19.2.213; WARD LD, 1994, J BIOL CHEM, V269, P23286; Ward LD, 1996, J BIOL CHEM, V271, P20138, DOI 10.1074/jbc.271.33.20138; WIJDENES J, 1991, MOL IMMUNOL, V28, P1183, DOI 10.1016/0161-5890(91)90004-4; Xu GY, 1997, J MOL BIOL, V268, P468, DOI 10.1006/jmbi.1997.0933; Yamada N, 2002, RAPID COMMUN MASS SP, V16, P293, DOI 10.1002/rcm.579; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; Young MM, 2000, P NATL ACAD SCI USA, V97, P5802, DOI 10.1073/pnas.090099097; ZDANOV A, 1995, STRUCTURE, V3, P591, DOI 10.1016/S0969-2126(01)00193-9; ZHANG JG, 1992, EUR J BIOCHEM, V207, P903, DOI 10.1111/j.1432-1033.1992.tb17123.x	59	93	97	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46487	46492		10.1074/jbc.M207370200	http://dx.doi.org/10.1074/jbc.M207370200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235153	hybrid			2022-12-27	WOS:000179529300102
J	Alexandrov, AI; Botchan, MR; Cozzarelli, NR				Alexandrov, AI; Botchan, MR; Cozzarelli, NR			Characterization of simian virus 40 T-antigen double hexamers bound to a replication fork - The active form of the helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; LARGE TUMOR-ANTIGEN; TERMINATION FACTOR-RHO; VIRAL ORIGIN; CRYSTAL-STRUCTURE; BINDING; PROTEIN; MECHANISM; COMPLEXES; RNA	Large T-antigen (T-ag) is a viral helicase required for the initiation and elongation of simian virus 40 DNA replication. The unwinding activity of the helicase is powered by ATP hydrolysis and is critically dependent on the oligomeric state of the protein. We confirmed that the double hexamer is the active form of the helicase on synthetic replication forks. In contrast, the single hexamer cannot unwind synthetic forks and remains bound to the DNA as ATP is hydrolyzed. This inability of the T-ag single hexamer to release the DNA fork is the likely explanation for its poor helicase activity. We characterized the interactions of T-ag single and double hexamers with synthetic forks and single-stranded (ss) DNA. We demonstrated that DNA forks promote the formation of T-ag double hexamer. The lengths of the duplex region and the 3' tail of the synthetic forks are the critical factors in assembly of the double hexamer, which is bound to a single fork. We found that the cooperativity of T-ag binding to ss oligonucleotides increased with DNA length, suggesting that multiple consecutive subunits in the hexamer engage the ssDNA.	Univ Calif Berkeley, Div Biochem & Mol Biol, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Cozzarelli, NR (corresponding author), Univ Calif Berkeley, Div Biochem & Mol Biol, Dept Mol & Cell Biol, 401 Barker Hall 3204, Berkeley, CA 94720 USA.				NCI NIH HHS [CA42414] Funding Source: Medline; NIGMS NIH HHS [GM31655] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031655] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barcena M, 1998, J MOL BIOL, V283, P809, DOI 10.1006/jmbi.1998.2128; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; Bullock PA, 1997, CRIT REV BIOCHEM MOL, V32, P503, DOI 10.3109/10409239709082001; COHEN GL, 1984, J VIROL, V51, P91, DOI 10.1128/JVI.51.1.91-96.1984; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; Donate LE, 2000, J MOL BIOL, V303, P383, DOI 10.1006/jmbi.2000.4132; Fouts ET, 1999, J BIOL CHEM, V274, P4447, DOI 10.1074/jbc.274.7.4447; GEISELMANN J, 1992, PROTEIN SCI, V1, P861, DOI 10.1002/pro.5560010704; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; Huang SG, 1998, BIOCHEMISTRY-US, V37, P15345, DOI 10.1021/bi9810959; Huang SG, 1998, BIOCHEMISTRY-US, V37, P15336, DOI 10.1021/bi981094g; Jezewska MJ, 1998, J BIOL CHEM, V273, P9058, DOI 10.1074/jbc.273.15.9058; Jezewska MJ, 2000, J BIOL CHEM, V275, P27865; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Lemon KP, 2000, MOL CELL, V6, P1321, DOI 10.1016/S1097-2765(00)00130-1; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; Niedenzu T, 2001, J MOL BIOL, V306, P479, DOI 10.1006/jmbi.2000.4398; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Pflumm MF, 2001, DEVELOPMENT, V128, P1697; Sambrook J., 2002, MOL CLONING LAB MANU; SENGUPTA DJ, 1992, SCIENCE, V256, P1656, DOI 10.1126/science.256.5064.1656; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SIMMONS DT, 1990, J VIROL, V64, P4858, DOI 10.1128/JVI.64.10.4858-4865.1990; Simmons DT, 2000, ADV VIRUS RES, V55, P75, DOI 10.1016/S0065-3527(00)55002-7; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Smelkova NV, 1998, J VIROL, V72, P8676, DOI 10.1128/JVI.72.11.8676-8681.1998; Smelkova NV, 1997, J VIROL, V71, P8766, DOI 10.1128/JVI.71.11.8766-8773.1997; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STAHL H, 1983, J VIROL, V47, P65, DOI 10.1128/JVI.47.1.65-76.1983; Stenger J E, 1992, Genet Eng (N Y), V14, P33; Valle M, 2000, MOL CELL BIOL, V20, P34, DOI 10.1128/MCB.20.1.34-41.2000; VanLoock MS, 2002, CURR BIOL, V12, P472, DOI 10.1016/S0960-9822(02)00696-6; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; VIRSHUP DM, 1992, MOL CELL BIOL, V12, P4883, DOI 10.1128/MCB.12.11.4883; Weber K, 1972, Methods Enzymol, V26, P3; Weisshart K, 1999, J VIROL, V73, P2201, DOI 10.1128/JVI.73.3.2201-2211.1999; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; WESSEL R, 1992, VIROLOGY, V189, P293, DOI 10.1016/0042-6822(92)90705-T; Wu CX, 1998, J VIROL, V72, P10256, DOI 10.1128/JVI.72.12.10256-10259.1998; Wu CX, 2001, J VIROL, V75, P2839, DOI 10.1128/JVI.75.6.2839-2847.2001	45	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44886	44897		10.1074/jbc.M207022200	http://dx.doi.org/10.1074/jbc.M207022200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244108	hybrid			2022-12-27	WOS:000179404800039
J	Eroglu, B; Powers-Lee, SG				Eroglu, B; Powers-Lee, SG			Unmasking a functional allosteric domain in an allosterically nonresponsive carbamoyl-phosphate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; COOH-TERMINAL DOMAIN; ESCHERICHIA-COLI; BINDING-SITE; REGULATORY DOMAIN; CRUCIAL RESIDUES; ACTIVATOR IMP; YEAST; ARGININE; SUBUNIT	Although carbamoyl-phosphate synthetases (CPSs) share sequence identity, multidomain structure, and reaction mechanism, they have varying physiological roles and allosteric effectors. Escherichia coli CPS (eCPS) provides CP for both arginine and pyrimidine nucleotide biosynthesis and is allosterically regulated by metabolites from both pathways, with inhibition by UMP and activation by IMP and ornithine. The arginine-specific CPS from Saccharomyces cerevisiae (sCPS), however, apparently responds to no allosteric effectors. We have designed and analyzed a chimeric CPS (chCPS, in which the C-terminal 136 residues of eCPS were replaced by the corresponding residues of sCPS) to define the structural basis for the allosteric nonresponsiveness of sCPS and thereby provide insight into the mechanism for allosteric selectivity and responsiveness in the other CPSs. Surprisingly, ornithine and UMP each had a significant effect on chCPS activity, and did so at concentrations that were similar to those effective for eCPS. We further found that sCPS bound both UMP and IMP and that chCPS bound IMP, although none of these interactions led to changes in enzymatic activity. These findings strongly suggest that the nonresponsive sCPS is not able to communicate occupancy of the allosteric site to the active site but does contain a latent allosteric interaction domain.	Northeastern Univ, Dept Biol, Boston, MA 02115 USA	Northeastern University	Powers-Lee, SG (corresponding author), Northeastern Univ, Dept Biol, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054423] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54423] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AITKEN DM, 1973, BIOCHIM BIOPHYS ACTA, V309, P50, DOI 10.1016/0005-2744(73)90316-1; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3164, DOI 10.1021/bi00874a013; ANDERSON PM, 1968, BIOCHEM BIOPH RES CO, V32, P928, DOI 10.1016/0006-291X(68)90116-2; ANDERSON PM, 1995, NITROGEN METABOLISM, P33; BOETTCHER B, 1982, J BIOL CHEM, V257, P3971; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braxton BL, 1996, BIOCHEMISTRY-US, V35, P11918, DOI 10.1021/bi961305m; Bueso J, 1999, BIOCHEMISTRY-US, V38, P3910, DOI 10.1021/bi982871f; BUESO J, 1994, BIOCHEM BIOPH RES CO, V203, P1083, DOI 10.1006/bbrc.1994.2293; Cervera J, 1996, BIOCHEMISTRY-US, V35, P7247, DOI 10.1021/bi952549u; CZERWINSKI RM, 1995, BIOCHEMISTRY-US, V34, P13920, DOI 10.1021/bi00042a025; Delannay S, 1999, J MOL BIOL, V286, P1217, DOI 10.1006/jmbi.1999.2561; Fresquet V, 2000, J MOL BIOL, V299, P979, DOI 10.1006/jmbi.2000.3794; GLANSDORFF N, 1965, GENETICS, V51, P167; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; GUTHOHRL.G, 1968, ANAL BIOCHEM, V26, P188, DOI 10.1016/0003-2697(68)90045-6; Hewagama A, 1998, BBA-PROTEIN STRUCT M, V1388, P489, DOI 10.1016/S0167-4838(98)00212-X; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; LILJELUND P, 1986, Molecular and General Genetics, V205, P74, DOI 10.1007/BF02428034; Lim AL, 1997, ARCH BIOCHEM BIOPHYS, V339, P344, DOI 10.1006/abbi.1997.9887; Lim AL, 1996, J BIOL CHEM, V271, P11400, DOI 10.1074/jbc.271.19.11400; LIU X, 1994, J BIOL CHEM, V269, P27747; LUSTY CJ, 1983, J BIOL CHEM, V258, P4466; MAREYA SM, 1994, BIOCHEMISTRY-US, V33, P2945, DOI 10.1021/bi00176a026; McCudden CR, 1996, J BIOL CHEM, V271, P18285, DOI 10.1074/jbc.271.30.18285; MEISTER A, 1978, ADV ENZYME REGUL, V16, P289; MESSENGUY F, 1983, EMBO J, V2, P1249, DOI 10.1002/j.1460-2075.1983.tb01577.x; Mora P, 1999, FEBS LETT, V446, P133, DOI 10.1016/S0014-5793(99)00197-0; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; PAULUS H, 1983, CURR TOP CELL REGUL, V22, P177; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PIERARD A, 1966, SCIENCE, V154, P1572, DOI 10.1126/science.154.3756.1572; PIERARD A, 1978, J BACTERIOL, V106, P145; Pierrat OA, 2002, ARCH BIOCHEM BIOPHYS, V400, P34, DOI 10.1006/abbi.2002.2767; Pierrat OA, 2002, ARCH BIOCHEM BIOPHYS, V400, P26, DOI 10.1006/abbi.2002.2768; PRESCOTT LM, 1969, ANAL BIOCHEM, V32, P408, DOI 10.1016/S0003-2697(69)80008-4; PRICE CW, 1978, J GEN MICROBIOL, V106, P145, DOI 10.1099/00221287-106-1-145; Rochera L, 2002, FEBS LETT, V514, P323, DOI 10.1016/S0014-5793(02)02392-X; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; Rose MD., 1990, METHODS YEAST GENETI; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; Saeed-Kothe A, 2002, J BIOL CHEM, V277, P7231, DOI 10.1074/jbc.M110926200; Sambrook J., 1989, MOL CLONING; STEWART PM, 1980, J BIOL CHEM, V255, P5270; TATIBANA M, 1972, J BIOCHEM, V72, P549, DOI 10.1093/oxfordjournals.jbchem.a129934; Thoden JB, 1999, J BIOL CHEM, V274, P22502, DOI 10.1074/jbc.274.32.22502; Thoden JB, 1999, ACTA CRYSTALLOGR D, V55, P8, DOI 10.1107/S0907444998006234; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; Tuchman M, 1997, APPL ENVIRON MICROB, V63, P33, DOI 10.1128/AEM.63.1.33-38.1997; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; XU W, 1988, BIOCHEMISTRY-US, V27, P5507, DOI 10.1021/bi00415a018	52	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45466	45472		10.1074/jbc.M208185200	http://dx.doi.org/10.1074/jbc.M208185200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244118	hybrid			2022-12-27	WOS:000179404800111
J	Feng, W; Tu, JC; Yang, TZ; Vernon, PS; Allen, PD; Worley, PF; Pessah, IN				Feng, W; Tu, JC; Yang, TZ; Vernon, PS; Allen, PD; Worley, PF; Pessah, IN			Homer regulates gain of ryanodine receptor type 1 channel complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; CALCIUM-RELEASE UNITS; SARCOPLASMIC-RETICULUM; CA2+ RELEASE; SKELETAL; PROTEIN; ACTIVATION; FAMILY; MODULATION; PSD-ZIP45	Homer proteins form an adapter system that regulates coupling of group 1 metabotropic glutamate receptors with intracellular inositol trisphosphate receptors and is modified by neuronal activity. Here, we demonstrate that Homer proteins also physically associate with ryanodine receptors type 1 (RyR1) and regulate gating responses to Ca2+, depolarization, and caffeine. In contrast to the prevailing notion of Homer function, Homerlc (long form) and Homer1-EVH1 (short form) evoke similar changes in RyR activity. The EVH1 domain mediates these actions of Homer and is selectively blocked by a peptide that mimics the Homer ligand. 1135 dyspedic myotubes expressing RyR1 with a point mutation of a putative Homer-binding domain exhibit significantly reduced (similar to33%) amplitude in their responses to K+ depolarization compared with cells expressing wild type protein. These results reveal that in addition to its known role as an adapter protein, Homer is a direct modulator of Ca2+ release gain. Homer is the first example of an "adapter" that also modifies signaling properties of its target protein. The present work reveals a novel mechanism by which Homer directly modulates the function of its target protein RyR1 and excitation-contraction coupling in skeletal myotubes. This form of regulation may be important in other cell types that express Homer and RyR1.	Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Brigham & Womens Hosp, Dept Anesthesia Preoperat & Pain Med, Boston, MA 02115 USA	University of California System; University of California Davis; Johns Hopkins University; Harvard University; Brigham & Women's Hospital	Pessah, IN (corresponding author), Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, 1 Shields Ave, Davis, CA 95616 USA.	inpessah@ucdavis.edu	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X	NIAMS NIH HHS [AR17605] Funding Source: Medline; NIDA NIH HHS [DA10309] Funding Source: Medline; NIEHS NIH HHS [ES10173, ES11269] Funding Source: Medline; NIMH NIH HHS [MH01153] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011269, R03ES010173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K20MH001153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA010309, R01DA010309] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Alkon DL, 1998, TRENDS NEUROSCI, V21, P529, DOI 10.1016/S0166-2236(98)01277-6; Ango F, 2001, NATURE, V411, P962, DOI 10.1038/35082096; Beneken J, 2000, NEURON, V26, P143, DOI 10.1016/S0896-6273(00)81145-9; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Fajloun Z, 2000, FEBS LETT, V469, P179, DOI 10.1016/S0014-5793(00)01239-4; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; Fessenden JD, 2000, BIOPHYS J, V79, P2509, DOI 10.1016/S0006-3495(00)76492-7; Franzini-Armstrong C, 1998, ANN NY ACAD SCI, V853, P20, DOI 10.1111/j.1749-6632.1998.tb08253.x; Futatsugi A, 1999, NEURON, V24, P701, DOI 10.1016/S0896-6273(00)81123-X; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Gonzalez A, 2000, P NATL ACAD SCI USA, V97, P4380, DOI 10.1073/pnas.070056497; IVANENKO A, 1993, J NEUROPHYSIOL, V70, P710, DOI 10.1152/jn.1993.70.2.710; KANO M, 1995, J PHYSIOL-LONDON, V487, P1; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Korkotian E, 1999, P NATL ACAD SCI USA, V96, P12068, DOI 10.1073/pnas.96.21.12068; Kurebayashi N, 2001, J PHYSIOL-LONDON, V533, P185, DOI 10.1111/j.1469-7793.2001.0185b.x; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; LLANO I, 1994, NEURON, V12, P663, DOI 10.1016/0896-6273(94)90221-6; Marengo JJ, 1998, BIOPHYS J, V74, P1263, DOI 10.1016/S0006-3495(98)77840-3; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Moore RA, 1998, J CELL BIOL, V140, P843, DOI 10.1083/jcb.140.4.843; Murayama T, 1999, J BIOL CHEM, V274, P17297, DOI 10.1074/jbc.274.24.17297; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; O'Brien JJ, 2002, BIOPHYS J, V82, P2428, DOI 10.1016/S0006-3495(02)75586-0; Okabe S, 2001, J NEUROSCI, V21, P9561, DOI 10.1523/JNEUROSCI.21-24-09561.2001; PALADE P, 1987, J BIOL CHEM, V262, P6135; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; Protasi F, 2000, BIOPHYS J, V79, P2494, DOI 10.1016/S0006-3495(00)76491-5; Protasi F, 1998, J CELL BIOL, V140, P831, DOI 10.1083/jcb.140.4.831; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; Sandona D, 2000, BIOCHEM BIOPH RES CO, V279, P348, DOI 10.1006/bbrc.2000.3948; Serge A, 2002, J NEUROSCI, V22, P3910, DOI 10.1523/JNEUROSCI.22-10-03910.2002; Soloviev MM, 2000, EUR J BIOCHEM, V267, P634, DOI 10.1046/j.1432-1327.2000.01078.x; Sun J, 1998, FEBS LETT, V437, P304, DOI 10.1016/S0014-5793(98)01256-3; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098; Sun MK, 2000, P NATL ACAD SCI USA, V97, P12300, DOI 10.1073/pnas.210396697; Tadokoro S, 1999, P NATL ACAD SCI USA, V96, P13801, DOI 10.1073/pnas.96.24.13801; Thomas U, 2002, J NEUROCHEM, V81, P407, DOI 10.1046/j.1471-4159.2002.00869.x; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Usachev YM, 1997, J NEUROSCI, V17, P7404; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Wang Y, 2000, AM J PHYSIOL-CELL PH, V278, pC619, DOI 10.1152/ajpcell.2000.278.3.C619; Ward CW, 2002, BIOPHYS J, V82, p284A; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8	52	121	124	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44722	44730		10.1074/jbc.M207675200	http://dx.doi.org/10.1074/jbc.M207675200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223488	hybrid			2022-12-27	WOS:000179404800018
J	Hou, SY; Wu, SY; Chiang, CM				Hou, SY; Wu, SY; Chiang, CM			Transcriptional activity among high and low risk human papillomavirus E2 proteins correlates with E2 DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ONCOGENIC HUMAN PAPILLOMAVIRUSES; E1 REPLICATION PROTEIN; TRANSACTIVATION DOMAIN; IN-VITRO; FUNCTIONAL INTERACTION; EPISOMAL MAINTENANCE; VIRAL TRANSCRIPTION; ACTIVATION DOMAINS; COMPLEX-FORMATION	The full-length E2 protein, encoded by human papillomaviruses (HPVs), is a sequence-specific transcription factor found in all HPVs, including cancer-causing high risk HPV types 16 and 18 and wart-inducing low risk HPV types 6 and 11. To investigate whether E2 proteins encoded by high risk HPVs may function differentially from E2 proteins encoded by low risk HPVs and animal papillomaviruses, we conducted comparative DNA-binding and transcription studies using electrophoretic mobility shift assays and cell-free transcription systems reconstituted with purified general transcription factors, cofactor, RNA polymerase II, and with E2 proteins encoded by HPV-16, HPV-18, HPV-11, and bovine papillomavirus type 1 (BPV-1). We found that although different types of E2 proteins all exhibited transactivation and repression activities, depending on the sequence context of the E2-binding sites, HPV-16 E2 shows stronger transcription activity and greater DNA-binding affinity than those displayed by the other E2 proteins. Surprisingly, HPV-18 E2 behaves more similarly to BPV-1 E2 than HPV-16 E2 in its functional properties. Our studies thus categorize HPV-18 E2 and BPV-1 E2 in the same protein family, a finding consistent with the available E2 structural data that separate the closely related HPV-16 and HPV-18 E2 proteins but classify together the more divergent BPV-1 and HPV-18 E2 proteins.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University	Chiang, CM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, 10900 Euclid Ave,W-409, Cleveland, OH 44106 USA.				NCI NIH HHS [CA81017] Funding Source: Medline; NIGMS NIH HHS [GM59643] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081017] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059643] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abroi A, 1996, J VIROL, V70, P6169, DOI 10.1128/JVI.70.9.6169-6179.1996; Antson AA, 2000, NATURE, V403, P805, DOI 10.1038/35001638; Bellanger S, 2001, J VIROL, V75, P7244, DOI 10.1128/JVI.75.16.7244-7251.2001; Benson JD, 1997, J VIROL, V71, P8041, DOI 10.1128/JVI.71.10.8041-8047.1997; BERNARD BA, 1989, J VIROL, V63, P4317, DOI 10.1128/JVI.63.10.4317-4324.1989; Boeckle S, 2002, VIROLOGY, V293, P103, DOI 10.1006/viro.2001.1231; Boner W, 2002, J BIOL CHEM, V277, P22297, DOI 10.1074/jbc.M202163200; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; CHIANG CM, 1991, J VIROL, V65, P3317, DOI 10.1128/JVI.65.6.3317-3329.1991; CHONG T, 1991, J VIROL, V65, P5933, DOI 10.1128/JVI.65.11.5933-5943.1991; Dell C, 2001, CELL MOL LIFE SCI, V58, P1923, DOI 10.1007/PL00000827; DEMERET C, 1994, J VIROL, V68, P7075, DOI 10.1128/JVI.68.11.7075-7082.1994; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DONG G, 1994, J VIROL, V68, P1115, DOI 10.1128/JVI.68.2.1115-1127.1994; DOSTATNI N, 1991, GENE DEV, V5, P1657, DOI 10.1101/gad.5.9.1657; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; Enzenauer C, 1998, INTERVIROLOGY, V41, P80, DOI 10.1159/000024918; Ferran MC, 1998, J VIROL, V72, P796, DOI 10.1128/JVI.72.1.796-801.1998; Ferreiro DU, 2000, BIOCHEMISTRY-US, V39, P14692, DOI 10.1021/bi001694r; Francis DA, 2000, J VIROL, V74, P2679, DOI 10.1128/JVI.74.6.2679-2686.2000; Frattini MG, 1997, EMBO J, V16, P318, DOI 10.1093/emboj/16.2.318; FRATTINI MG, 1994, P NATL ACAD SCI USA, V91, P12398, DOI 10.1073/pnas.91.26.12398; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Goodwin EC, 1998, J VIROL, V72, P3925, DOI 10.1128/JVI.72.5.3925-3934.1998; Hartley KA, 2002, J VIROL, V76, P5014, DOI 10.1128/JVI.76.10.5014-5023.2002; Hegde RS, 2002, ANNU REV BIOPH BIOM, V31, P343, DOI 10.1146/annurev.biophys.31.100901.142129; Hines CS, 1998, J MOL BIOL, V276, P809, DOI 10.1006/jmbi.1997.1578; Hou SY, 2000, MOL CELL BIOL, V20, P113, DOI 10.1128/MCB.20.1.113-125.2000; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; Ilves I, 1999, J VIROL, V73, P4404, DOI 10.1128/JVI.73.5.4404-4412.1999; JACKSON ME, 1995, J VIROL, V69, P6038, DOI 10.1128/JVI.69.10.6038-6046.1995; Kim SS, 2000, J BIOL CHEM, V275, P31245, DOI 10.1074/jbc.M004541200; Kovelman R, 1996, J VIROL, V70, P7549, DOI 10.1128/JVI.70.11.7549-7560.1996; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; Lee D, 2002, J BIOL CHEM, V277, P6483, DOI 10.1074/jbc.M105085200; Lefebvre O, 1997, J MOL BIOL, V266, P465, DOI 10.1006/jmbi.1996.0807; Lehman CW, 1998, P NATL ACAD SCI USA, V95, P4338, DOI 10.1073/pnas.95.8.4338; Lewis H, 1999, J MOL BIOL, V294, P885, DOI 10.1006/jmbi.1999.3314; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munoz N, 2000, J CLIN VIROL, V19, P1, DOI 10.1016/S1386-6532(00)00125-6; Nelson DL, 2000, LEHNINGER PRINCIPLES, p[243, 203]; O'Connor M, 1995, HUMAN PAPILLOMAVIRUS, pIII21; Peng YC, 2000, J VIROL, V74, P5872, DOI 10.1128/JVI.74.13.5872-5879.2000; Pepinsky RB, 1997, J VIROL, V71, P828, DOI 10.1128/JVI.71.1.828-831.1997; Piirsoo M, 1996, EMBO J, V15, P1; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; SANDLER AB, 1993, J VIROL, V67, P5079, DOI 10.1128/JVI.67.9.5079-5087.1993; SARVER N, 1982, P NATL ACAD SCI-BIOL, V79, P7147, DOI 10.1073/pnas.79.23.7147; Skiadopoulos MH, 1998, J VIROL, V72, P2079, DOI 10.1128/JVI.72.3.2079-2088.1998; STEGER G, 1995, EMBO J, V14, P329, DOI 10.1002/j.1460-2075.1995.tb07007.x; STENLUND A, 1990, GENE DEV, V4, P123, DOI 10.1101/gad.4.1.123; Stubenrauch F, 1996, J VIROL, V70, P119, DOI 10.1128/JVI.70.1.119-126.1996; Stubenrauch F, 2001, J VIROL, V75, P4139, DOI 10.1128/JVI.75.9.4139-4149.2001; Stubenrauch F, 2000, J VIROL, V74, P1178, DOI 10.1128/JVI.74.3.1178-1186.2000; TAN SH, 1994, J VIROL, V68, P6411, DOI 10.1128/JVI.68.10.6411-6420.1994; THIERRY F, 1991, NEW BIOL, V3, P90; USHIKAI M, 1994, J VIROL, V68, P6655, DOI 10.1128/JVI.68.10.6655-6666.1994; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; Voitenleitner C, 2002, J VIROL, V76, P3440, DOI 10.1128/JVI.76.7.3440-3451.2002; Wang JC, 1998, BBA-GENE STRUCT EXPR, V1397, P141, DOI 10.1016/S0167-4781(98)00012-8; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Wu SY, 1998, J BIOL CHEM, V273, P12492, DOI 10.1074/jbc.273.20.12492; Wu SY, 1999, J BIOL CHEM, V274, P23480, DOI 10.1074/jbc.274.33.23480; Wu SY, 2001, J BIOL CHEM, V276, P34235, DOI 10.1074/jbc.M102463200; Wu SY, 1998, EMBO J, V17, P4478, DOI 10.1093/emboj/17.15.4478; Yao JM, 1998, J VIROL, V72, P1013, DOI 10.1128/JVI.72.2.1013-1019.1998; Zou NX, 2000, J VIROL, V74, P3761, DOI 10.1128/JVI.74.8.3761-3770.2000; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	75	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45619	45629		10.1074/jbc.M206829200	http://dx.doi.org/10.1074/jbc.M206829200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12239214	hybrid			2022-12-27	WOS:000179404800128
J	Li, FS; Macfarlan, T; Pittman, RN; Chakravarti, D				Li, FS; Macfarlan, T; Pittman, RN; Chakravarti, D			Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUNTINGTONS-DISEASE; EXPANDED POLYGLUTAMINE; REPRESSES TRANSCRIPTION; MEDIATED TRANSCRIPTION; NUCLEAR MATRIX; AFFECTED BRAIN; GENE-PRODUCT; MOUSE MODEL; CELL-DEATH; INTERACTS	The mechanisms of pathology for the family of polyglutamine disease proteins are unknown; however, recently it was shown that several of these proteins inhibit transcription suggesting that transcriptional repression may be a potential mechanism for pathology. In the present study we use cell transfections, in vitro binding, co-immunoprecipitations, and reporter assays to show that the polyglutamine disease protein, ataxin-3, interacts with the major histone acetyltransferases cAMP-response-element binding protein (CREB)-binding protein, p300, and p300/CREB-binding protein-associated factor and inhibits transcription by these coactivators. Importantly, endogenous ataxin-3 is co-immunoprecipitated with each of these coactivators in non-transfected cells. The C-teriminal polyglutamine-containing domain of ataxin-3 inhibits coactivator-dependent transcription and is required for binding coactivators. The N-terminal domain of ataxin-3 inhibits histone acetylation by p300 in vitro and inhibits transcription in vivo. Histone binding and blocking access of coactivators to acetylation sites on histones appears to be the mechanism of inhibition. Together, our data provide a novel mechanism of transcriptional regulation by ataxin-3 that involves targeting histones, coactivators, and an independent mode of direct repression of transcription, and suggests that its physiological function and possibly pathological effects are linked to its interactions with these proteins.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Pittman, RN (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.		Macfarlan, Todd/S-3750-2017	Macfarlan, Todd/0000-0003-2495-9809; Chakravarti, Debabrata/0000-0001-8446-8599	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042625] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK057079, DK57079] Funding Source: Medline; NINDS NIH HHS [NS42625] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bevivino AE, 2001, P NATL ACAD SCI USA, V98, P11955, DOI 10.1073/pnas.211305198; Boutell JM, 1999, HUM MOL GENET, V8, P1647, DOI 10.1093/hmg/8.9.1647; Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299; Chai YH, 2001, J BIOL CHEM, V276, P44889, DOI 10.1074/jbc.M106575200; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Dyer RB, 2001, NAT GENET, V29, P270, DOI 10.1038/ng745; Evert BO, 2001, J NEUROSCI, V21, P5389, DOI 10.1523/JNEUROSCI.21-15-05389.2001; Glass CK, 2000, GENE DEV, V14, P121; Goodman RH, 2000, GENE DEV, V14, P1553; Hughes RE, 2001, P NATL ACAD SCI USA, V98, P13201, DOI 10.1073/pnas.191498198; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; La Spada AR, 2001, NEURON, V31, P913, DOI 10.1016/S0896-6273(01)00422-6; Lin X, 2000, NAT NEUROSCI, V3, P157, DOI 10.1038/72101; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Nakatani Y, 2001, GENES CELLS, V6, P79, DOI 10.1046/j.1365-2443.2001.00411.x; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Paulson HL, 1999, AM J HUM GENET, V64, P339, DOI 10.1086/302269; Perez MK, 1999, HUM MOL GENET, V8, P2377, DOI 10.1093/hmg/8.13.2377; Perez MK, 1998, J CELL BIOL, V143, P1457, DOI 10.1083/jcb.143.6.1457; Ross CA, 1999, PHILOS T ROY SOC B, V354, P1005, DOI 10.1098/rstb.1999.0452; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Schmidt T, 1998, BRAIN PATHOL, V8, P669, DOI 10.1111/j.1750-3639.1998.tb00193.x; Seo SB, 2002, J BIOL CHEM, V277, P14005, DOI 10.1074/jbc.M112455200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; WANG SL, 1993, P NATL ACAD SCI USA, V90, P10385, DOI 10.1073/pnas.90.21.10385; Wood JD, 2000, J CELL BIOL, V150, P939, DOI 10.1083/jcb.150.5.939; Wyttenbach A, 2001, HUM MOL GENET, V10, P1829, DOI 10.1093/hmg/10.17.1829; Zhang QH, 2000, MOL CELL BIOL, V20, P4970, DOI 10.1128/MCB.20.14.4970-4978.2000; Zhang S, 2002, CELL, V108, P45, DOI 10.1016/S0092-8674(01)00630-4; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	38	170	179	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45004	45012		10.1074/jbc.M205259200	http://dx.doi.org/10.1074/jbc.M205259200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12297501	hybrid			2022-12-27	WOS:000179404800054
J	Obrero, M; Yu, DV; Shapiro, DJ				Obrero, M; Yu, DV; Shapiro, DJ			Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; ACTIVATED PROTEIN-KINASES; CYTOCHROME-C; INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; MAP KINASES; CATHEPSIN-D; IN-VITRO; NECROSIS; P38	The therapeutic efficacy of tamoxifen (TAM) in cancer therapy is thought to arise primarily from its ability to compete with estrogens for binding to the estrogen receptor (ER). We show that TAM and its active metabolite, 4-hydroxytamoxifen (OHT), can actively induce programmed cell death through distinct ER-dependent and ER-independent pathways. The ER-independent pathway is activated by 10-20 muM TAM and OHT and by 10-20 mum 17beta-estradiol and raloxifene, and occurs in ER-negative cells. The ER dependence of a second pathway, caused by submicromolar concentrations of TAM and OHT, was demonstrated by the ability of the ER ligands 17beta-estradiol, raloxifene, and ICI 182,780 to effectively block the cell death-inducing effects of TAM and OHT. Because the p38-specific inhibitor SB203580 blocks OHT-ER-induced cell death, stress kinase pathways are likely involved. ER-independent cell death triggers classic caspase-dependent apoptosis. However, although OHT-ER triggers some hallmarks of apoptosis, including Bax translocation and cytochrome c release, the absence of poly(ADP-ribose) polymerase cleavage or DNA laddering indicates that the death pathway involved is caspase-independent. The OHT-ER-dependent cell death pathway appears to diverge from classical apoptosis at the level of caspase 9 activation. The ability to promote ER-dependent programmed cell death represents a novel activity of TAM and OHT.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Shapiro, DJ (corresponding author), Univ Illinois, Dept Biochem, Urbana, IL 61801 USA.				NCI NIH HHS [CA90374] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090374] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bonetti B, 1997, ANN NEUROL, V42, P74, DOI 10.1002/ana.410420113; Chen HM, 1996, J CELL BIOCHEM, V61, P9, DOI 10.1002/(SICI)1097-4644(19960401)61:1<9::AID-JCB2>3.3.CO;2-2; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; COLLETTA AA, 1990, BRIT J CANCER, V62, P405, DOI 10.1038/bjc.1990.307; DAUVOIS S, 1993, J CELL SCI, V106, P1377; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dietze EC, 2001, J BIOL CHEM, V276, P5384, DOI 10.1074/jbc.M007915200; DUBIK D, 1992, ONCOGENE, V7, P1587; Eguchi Y, 1997, CANCER RES, V57, P1835; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gundimeda U, 1996, J BIOL CHEM, V271, P13504, DOI 10.1074/jbc.271.23.13504; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jiang XJ, 2000, J BIOL CHEM, V275, P31199, DOI 10.1074/jbc.C000405200; Kang Y, 1996, J NATL CANCER I, V88, P279, DOI 10.1093/jnci/88.5.279; KATZENELLENBOGEN BS, 1984, CANCER RES, V44, P112; Kim JA, 1999, CANCER LETT, V147, P115, DOI 10.1016/S0304-3835(99)00284-0; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Leng Y, 2000, EUR J PHARMACOL, V409, P123, DOI 10.1016/S0014-2999(00)00826-8; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mandlekar S, 2000, CANCER RES, V60, P6601; Mandlekar S, 2000, CANCER RES, V60, P5995; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Mao CJ, 2000, ENDOCRINOLOGY, V141, P2361, DOI 10.1210/en.141.7.2361; Mateo V, 1999, NAT MED, V5, P1277, DOI 10.1038/15233; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; NICOTERA P, 1986, J BIOL CHEM, V261, P4628; OBRIAN CA, 1986, J NATL CANCER I, V76, P1243; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Ortiz MA, 2001, CANCER RES, V61, P8504; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Park WC, 2002, TRENDS MOL MED, V8, P82, DOI 10.1016/S1471-4914(02)02282-7; Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002; ROCHEFORT H, 1990, CANCER CELL-MON REV, V2, P383; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shiraishi J, 2001, AM J PHYSIOL-HEART C, V281, pH1637, DOI 10.1152/ajpheart.2001.281.4.H1637; Sohn S, 1998, NEUROSCI LETT, V240, P147, DOI 10.1016/S0304-3940(97)00936-1; SPYRATOS F, 1989, LANCET, V2, P1115; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Wijayaratne AL, 1999, ENDOCRINOLOGY, V140, P5828, DOI 10.1210/en.140.12.5828; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhang CC, 2000, J BIOL CHEM, V275, P479, DOI 10.1074/jbc.275.1.479; Zhang CC, 1999, MOL ENDOCRINOL, V13, P632, DOI 10.1210/me.13.4.632; Zhang W, 2000, CANCER RES, V60, P5395; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	60	94	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45695	45703		10.1074/jbc.M208092200	http://dx.doi.org/10.1074/jbc.M208092200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244117	hybrid			2022-12-27	WOS:000179404800137
J	Parrot, I; Huang, PC; Khosla, C				Parrot, I; Huang, PC; Khosla, C			Circular dichroism and nuclear magnetic resonance spectroscopic analysis of immunogenic gluten peptides and their analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CELIAC-DISEASE; POLYPROLINE-II; CHEMICAL-SHIFT; ALPHA-GLIADIN; CONFORMATION; RECOGNITION; TRANSGLUTAMINASE; EPITOPE	Celiac Sprue, or gluten-sensitive enteropathy, is an inheritable human disease of the small intestine that is triggered by the dietary intake of gluten. Recently, several Pro- and Gln-rich peptide sequences (most notably PQPQLPY and analogs) have been identified from gluten with potent immunogenic activity toward CD4(+) T cells from small intestinal biopsies of Celiac Sprue patients. These peptides have three unusual properties. First, they are relatively stable toward further proteolysis by gastric, pancreatic, and intestinal enzymes. Second, they are recognized and deamidated by human tissue transglutaminase (tTGase) with high selectivity. Third, tTGase-catalyzed deamidation enhances their affinity for HLA-DQ2, the disease-specific class II major histocompatibility complex heterodimer. In an attempt to seek a mechanistic explanation for these properties, we undertook secondary structural studies on PQPQLPY and its analogs. Circular dichroism studies on a series of monomeric and dimeric analogs revealed a strong polyproline II helical propensity in a subset of them. Two-dimensional nuclear magnetic resonance spectroscopic analysis confirmed a polyproline II conformation of PQPQLPY, and was also used to elucidate the secondary structure of the most helical variant, (D-P)QPQLPY. Remarkably, a strong correlation was observed between polyproline II content of naturally occurring gluten peptides and the specificity of human tTGase toward these substrates. Analogs with up to two D-amino acid residues retained both polyproline II helical content and transglutaminase affinity. Since the Michaelis constant (K-m) is the principal determinant of tTGase specificity for naturally occurring gluten peptides and their analogs, our results suggest that the tTGase binding site may have a preference for polyproline II helical substrates. If so, these insights could be exploited for the design of selective small molecule inhibitors of this pharmacologically important enzyme.	Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Khosla, C (corresponding author), Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA.	ck@chemeng.stanford.edu	parrot, isabelle/AAS-5546-2020	Khosla, Chaitan/0000-0001-6529-495X				Alfonso P, 1998, FEBS LETT, V427, P36, DOI 10.1016/S0014-5793(98)00388-3; Anderson RP, 2000, NAT MED, V6, P337, DOI 10.1038/73200; Arentz-Hansen H, 2000, J EXP MED, V191, P603, DOI 10.1084/jem.191.4.603; Dalcol I, 1996, J ORG CHEM, V61, P6775, DOI 10.1021/jo960987g; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; Fiebig KM, 1996, J PHYS CHEM-US, V100, P2661, DOI 10.1021/jp952747v; Fleckenstein B, 2002, J BIOL CHEM, V277, P34109, DOI 10.1074/jbc.M204521200; FRAZER AC, 1959, LANCET, V2, P252; GILBERT SM, 2000, BIOCHIM BIOPHYS ACTA, P135; Hausch F, 2002, AM J PHYSIOL-GASTR L, V283, pG996, DOI 10.1152/ajpgi.00136.2002; HELBECQUE N, 1982, INT J PEPT PROT RES, V19, P94; HINCK AP, 1993, BIOCHEMISTRY-US, V32, P11810, DOI 10.1021/bi00095a009; Jardetzky TS, 1996, P NATL ACAD SCI USA, V93, P734, DOI 10.1073/pnas.93.2.734; KARPLUS M, 1959, J CHEM PHYS, V30, P11, DOI 10.1063/1.1729860; Kelly MA, 2001, BIOCHEMISTRY-US, V40, P14376, DOI 10.1021/bi011043a; Kim SY, 2002, NEUROCHEM INT, V40, P85, DOI 10.1016/S0197-0186(01)00064-X; Lee KH, 2001, NAT IMMUNOL, V2, P501, DOI 10.1038/88694; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; PADI A, 1984, J MOL BIOL, V180, P741; Papadopoulos GK, 2001, J CLIN INVEST, V108, P1261; Piper JL, 2002, BIOCHEMISTRY-US, V41, P386, DOI 10.1021/bi011715x; RABANAL F, 1993, BIOPOLYMERS, V33, P1019, DOI 10.1002/bip.360330704; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; RONISH EW, 1974, BIOPOLYMERS, V13, P1635, DOI 10.1002/bip.1974.360130810; Sharman GJ, 1998, J AM CHEM SOC, V120, P5291, DOI 10.1021/ja9705405; SILIGARDI G, 1995, BIOPOLYMERS, V37, P281, DOI 10.1002/bip.360370406; Sollid LM, 2000, ANNU REV IMMUNOL, V18, P53, DOI 10.1146/annurev.immunol.18.1.53; SOLLID LM, 1989, J EXP MED, V169, P345, DOI 10.1084/jem.169.1.345; Stapley BJ, 1999, PROTEIN SCI, V8, P587; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; TATHAM AS, 1990, BIOCHEM J, V270, P313, DOI 10.1042/bj2700313; TIFFANY ML, 1968, BIOPOLYMERS, V6, P1767, DOI 10.1002/bip.1968.360061212; Uray K, 2000, ARCH BIOCHEM BIOPHYS, V378, P25, DOI 10.1006/abbi.2000.1801; Vader LW, 2002, J EXP MED, V195, P643, DOI 10.1084/jem.20012028; Wieser H, 1996, ACTA PAEDIATR, V85, P3, DOI 10.1111/j.1651-2227.1996.tb14239.x; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Woody R. W., 1992, ADV BIOPHYS CHEM, V2, P37; Wuthrich K, 1986, NMR PROTEINS NUCL AC	42	30	42	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45572	45578		10.1074/jbc.M207606200	http://dx.doi.org/10.1074/jbc.M207606200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12324465	hybrid			2022-12-27	WOS:000179404800123
J	Biroccio, A; Benassi, B; Filomeni, G; Amodei, S; Marchini, S; Chiorino, G; Rotilio, G; Zupi, G; Ciriolo, MR				Biroccio, A; Benassi, B; Filomeni, G; Amodei, S; Marchini, S; Chiorino, G; Rotilio, G; Zupi, G; Ciriolo, MR			Glutathione influences c-Myc-induced apoptosis in M14 human melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTISENSE OLIGODEOXYNUCLEOTIDES ENHANCE; MEDIATED APOPTOSIS; DOWN-REGULATION; S-TRANSFERASE; GSH EXTRUSION; CYCLE ARREST; IN-VITRO; EXPRESSION; CISPLATIN; DEATH	The objective of this article is to dissect the mechanisms by which the down-regulation of c-Myc induces programmed cell death in melanoma cells. In stable and doxycycline-inducible M14 melanoma cells, down-regulation of c-Myc induced apoptosis subsequent to a decrease in the intracellular reduced glutathione content and a concomitant accumulation of its oxidized form. This redox alteration was associated with a decrease of the enzyme activities of gamma-glutamyl-cysteine synthetase and NADPH-dependent GSSG reductase, as well as a consequent glutathione release in the extracellular medium. Cytochrome c was released into the cytosol at very early stages of apoptosis induction, long before detectable production of reactive oxygen species and activation of caspase-9 and -3. Macroarray analysis revealed that down-regulation of c-Myc produced striking changes in gene expression in the section related to metabolism, where the expression of gamma-glutamyl-cysteine synthetase and GSSG reductase was found to be significantly reduced. The addition of N-acetyl-L-cysteine or glutathione ethyl ester inhibited the apoptotic process, thus confirming the key role of glutathione in programmed cell death induced by c-Myc.	Regina Elena Inst Canc Res, Expt Chemotherapy Lab, I-00158 Rome, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; G Dannunzio Univ, Dept Biomed Sci, I-66013 Chieti, Italy; Mario Negri Inst Pharmacol Res, Dept Oncol, I-20154 Milan, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Rome Tor Vergata; G d'Annunzio University of Chieti-Pescara; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Biroccio, A (corresponding author), Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Via Messi Doro 156, I-00158 Rome, Italy.		Biroccio, Annamaria/B-2861-2018; Marchini, sergio/J-3968-2018; Chiorino, Giovanna/K-5037-2016; Ciriolo, Maria Rosa/K-6572-2016	Biroccio, Annamaria/0000-0003-3198-3532; Marchini, sergio/0000-0003-1783-7651; Chiorino, Giovanna/0000-0002-9502-6400; Filomeni, Giuseppe/0000-0002-2719-1412; Ciriolo, Maria Rosa/0000-0002-7863-9029				ASKEW DS, 1991, ONCOGENE, V6, P1915; Backway KL, 1997, CANCER RES, V57, P2446; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Biroccio A, 2002, ONCOGENE, V21, P3011, DOI 10.1038/sj.onc.1205415; Biroccio A, 2001, MOL PHARMACOL, V60, P174, DOI 10.1124/mol.60.1.174; Chiba T, 1996, EUR J IMMUNOL, V26, P1164, DOI 10.1002/eji.1830260530; Citro G, 1998, CANCER RES, V58, P283; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; Desbarats L, 1996, EXPERIENTIA, V52, P1123, DOI 10.1007/BF01952111; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Franklin CC, 2002, AM J PATHOL, V160, P1887, DOI 10.1016/S0002-9440(10)61135-2; FREEDMAN JH, 1989, J BIOL CHEM, V264, P5598; Fruehauf JP, 1997, PIGM CELL RES, V10, P236, DOI 10.1111/j.1600-0749.1997.tb00490.x; Fruehauf JP, 1998, CHEM-BIOL INTERACT, V112, P277, DOI 10.1016/S0009-2797(97)00167-1; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Ghibelli L, 1999, FASEB J, V13, P2031, DOI 10.1096/fasebj.13.14.2031; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; KIMURA S, 1995, CANCER RES, V55, P1379; Leonetti C, 1999, CLIN CANCER RES, V5, P2588; Leonetti C, 1996, JNCI-J NATL CANCER I, V88, P419, DOI 10.1093/jnci/88.7.419; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Macho A, 1997, J IMMUNOL, V158, P4612; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; Nesbit CE, 1998, BLOOD, V92, P1003; PENA A, 1993, J BIOL CHEM, V268, P27277; Pierce RH, 2000, AM J PATHOL, V157, P221, DOI 10.1016/S0002-9440(10)64533-6; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; SEELIG GF, 1985, METHOD ENZYMOL, V113, P379; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SKORSKI T, 1995, J EXP MED, V182, P1645, DOI 10.1084/jem.182.6.1645; Um HD, 1996, J IMMUNOL, V156, P3469; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; VanWardenburg RCAM, 1997, INT J CANCER, V73, P544, DOI 10.1002/(SICI)1097-0215(19971114)73:4<544::AID-IJC15>3.3.CO;2-C; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wonsey DR, 2002, P NATL ACAD SCI USA, V99, P6649, DOI 10.1073/pnas.102523299	44	40	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43763	43770		10.1074/jbc.M207684200	http://dx.doi.org/10.1074/jbc.M207684200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226097	hybrid, Green Published			2022-12-27	WOS:000179272000031
J	Cichy, J; Bals, R; Potempa, J; Mani, A; Pure, E				Cichy, J; Bals, R; Potempa, J; Mani, A; Pure, E			Proteinase-mediated release of epithelial cell-associated CD44 - Extracellular CD44 complexes with components of cellular matrices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE-HOMING RECEPTOR; SOLUBLE CD44; PERICELLULAR MATRICES; CHONDROITIN SULFATE; HYALURONAN-BINDING; SPLICE VARIANTS; EXPRESSION; ISOFORMS; PATHOGENESIS; ACTIVATION	CD44 is a receptor for the matrix glycosaminoglycan hyaluronan. Proteoglycan forms of CD44 also exhibit affinity for fibronectin and collagen as well as chemokines and growth factors. CD44 plays a role in autoimmunity, inflammation, and tumor progression. Soluble CD44 (sCD44) is found in plasma, and the levels of sCD44 correlate with immune function and some malignancies. The mechanisms by which sCD44 is generated and its function are unknown. We demonstrate here that normal bronchial epithelial cells spontaneously release sCD44. Exposure to phagocyte- and bacterium-derived proteinases markedly increased the release of sCD44 from epithelial cells. The spontaneously released sCD44 was incorporated into high molecular mass complexes derived from the matrix that also contained chondroitin sulfate, fibronectin, hyaluronan, and collagens I and IV. Enzymatic digestion with proteinases liberated sCD44 from the high molecular mass complex. Consistent with the homology of CD44 to proteoglycan core and link proteins, these data suggest that CD44 spontaneously released from normal bronchial epithelial cells can accumulate as an integral component of the matrix, where it may play a role in the organization of matrices and in anchoring growth factors and chemokines to the matrix. Increases in plasma CD44 during immune activation and tumor progression therefore may be a manifestation of the matrix remodeling that occurs in the face of the enhanced proteolytic activity associated with infection, inflammation, and tumor metastasis, leading to alterations in cell-matrix interactions.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Jagiellonian Univ, Inst Mol Biol & Biotechnol, PL-31120 Krakow, Poland; Univ Munich, Med Klin & Poliklin 1, D-81377 Munich, Germany; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Ludwig Inst Canc Res, New York, NY 10158 USA	The Wistar Institute; Jagiellonian University; University of Munich; University System of Georgia; University of Georgia; Ludwig Institute for Cancer Research	Pure, E (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	pure@wistar.upenn.edu		Cichy, Joanna/0000-0002-0552-8344	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045813, R21AI045813] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26148] Funding Source: Medline; NIAID NIH HHS [AI45813] Funding Source: Medline; PHS HHS [6P05A14721] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTOLAZZI A, 1995, J CELL SCI, V108, P1723; Blass SL, 2001, J IMMUNOL, V166, P5726, DOI 10.4049/jimmunol.166.9.5726; Cichy J, 2000, J BIOL CHEM, V275, P18061, DOI 10.1074/jbc.M907962199; Cuff CA, 2001, J CLIN INVEST, V108, P1031, DOI 10.1172/JCI12455; DEBELDER AN, 1975, CARBOHYD RES, V44, P251, DOI 10.1016/S0008-6215(00)84168-3; DROLL A, 1995, J BIOL CHEM, V270, P11567, DOI 10.1074/jbc.270.19.11567; Ehnis T, 1996, EXP CELL RES, V229, P388, DOI 10.1006/excr.1996.0384; Estess P, 1998, J CLIN INVEST, V102, P1173, DOI 10.1172/JCI4235; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GREEN SJ, 1988, J CELL SCI, V90, P145; Greenfield B, 1999, J BIOL CHEM, V274, P2511, DOI 10.1074/jbc.274.4.2511; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; Katoh S, 1999, ALLERGY, V54, P1286, DOI 10.1034/j.1398-9995.1999.00277.x; KATOH S, 1994, J IMMUNOL, V153, P3440; Kessler E., 1998, HDB PROTEOLYTIC ENZY, P1058; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; Knudson W, 1996, EXP CELL RES, V228, P216, DOI 10.1006/excr.1996.0320; KNUDSON W, 1993, P NATL ACAD SCI USA, V90, P4003, DOI 10.1073/pnas.90.9.4003; Konig H, 1996, EMBO J, V15, P4030, DOI 10.1002/j.1460-2075.1996.tb00776.x; Lackie PM, 1997, AM J RESP CELL MOL, V16, P14, DOI 10.1165/ajrcmb.16.1.8998074; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; Nandi A, 2000, J BIOL CHEM, V275, P14939, DOI 10.1074/jbc.275.20.14939; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; POTEMPA J, 1998, HDB PROTEINASES, P1540; SALVESEN GS, 1998, HDB PROTEOLYTIC ENZY, P60; SCHLOSSMAN SF, 1995, WHITE CELL DIFFERENT; Schrager HM, 1998, J CLIN INVEST, V101, P1708, DOI 10.1172/JCI2121; SCREATON GR, 1993, J BIOL CHEM, V268, P12235; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; STOCKLEY RA, 1994, AM J RESP CRIT CARE, V150, pS109, DOI 10.1164/ajrccm/150.6_Pt_2.S109; SUTER S, 1994, AM J RESP CRIT CARE, V150, pS118, DOI 10.1164/ajrccm/150.6_Pt_2.S118; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; VANWEERING DHJ, 1993, PCR METH APPL, V3, P100; Wolff EA, 1999, J BIOL CHEM, V274, P2518, DOI 10.1074/jbc.274.4.2518; Yu Q, 1996, J BIOL CHEM, V271, P20603, DOI 10.1074/jbc.271.34.20603; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35	41	33	37	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44440	44447		10.1074/jbc.M207437200	http://dx.doi.org/10.1074/jbc.M207437200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226094	hybrid			2022-12-27	WOS:000179272000115
J	Jorge, B; Zarich, N; Oliva, JL; Azanedo, M; Martinez, N; de la Cruz, X; Rojas, JM				Jorge, B; Zarich, N; Oliva, JL; Azanedo, M; Martinez, N; de la Cruz, X; Rojas, JM			RETRACTED: hSos1 contains a new amino-terminal regulatory motif with specific binding affinity for its pleckstrin homology domain (Retracted article. See vol. 293, pg. 11650, 2018)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							GUANINE-NUCLEOTIDE EXCHANGE; SON-OF-SEVENLESS; GRB2-BINDING DOMAIN; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; PROTEIN-KINASE; N-TERMINUS; PH DOMAIN; RAS; DBL	The protein hSos1 is a Ras guanine nucleotide exchange factor. In the present study, we investigated the function of the amino-terminal region of the hSos1 protein, corresponding to the first 600 residues, which includes the DbI and pleckstrin homology (DH and PH) domains. We demonstrated, using a series of truncated mutants, that this region is absolutely necessary for hSos1 activity. Our results suggest that the first 200 residues (upstream of DH domain), which we called the HF motif on the basis of their homology with histone H2A, may exert negative control over the functional activity of the whole hSos1 protein. In vitro binding analysis showed that the HF motif is able to interact specifically with the PH domain of hSos1. The amino-terminal region of hSos1 may be associated in vivo with an expressed HF motif. These findings document the existence of the HF motif located upstream of the DH domain in the hSos1 protein. This motif may be responsible for the negative control of hSos1, probably by intramolecular binding with the PH domain.	Inst Salud Carlos III, Unidad Biol Celular, Ctr Nacl Microbiol, Km 2,Carretera Majadahonda Pozuela, Madrid 28220, Spain; Univ Barcelona, Dept Bioquim & Biol Mol, Fac Quim, E-08028 Barcelona, Spain; ICREA, E-08028 Barcelona, Spain	Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM); University of Barcelona; ICREA	Rojas, JM (corresponding author), Inst Salud Carlos III, Unidad Biol Celular, Ctr Nacl Microbiol, Km 2,Carretera Majadahonda Pozuela, Madrid 28220, Spain.	jmrojas@isciii.es	Rojas, José M/D-3718-2018	Rojas, José M/0000-0002-5383-3482; Zarich, Natasha/0000-0003-1058-6191; De la Cruz Montserrat, Fco. Xavier/0000-0002-9738-8472	ICREA Funding Source: Custom	ICREA(ICREA)		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; Byrne JL, 1996, ONCOGENE, V13, P2055; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; deMora JF, 1996, J BIOL CHEM, V271, P18272, DOI 10.1074/jbc.271.30.18272; Hall BE, 2001, J BIOL CHEM, V276, P27629, DOI 10.1074/jbc.M101727200; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rojas JM, 1996, ONCOGENE, V12, P2291; Rojas JM, 1999, ONCOGENE, V18, P1651, DOI 10.1038/sj.onc.1202483; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Zarich N, 2000, ONCOGENE, V19, P5872, DOI 10.1038/sj.onc.1203955	32	23	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44171	44179		10.1074/jbc.M204423200	http://dx.doi.org/10.1074/jbc.M204423200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223473	hybrid, Green Published			2022-12-27	WOS:000179272000083
J	Karsdal, MA; Larsen, L; Engsig, MT; Lou, H; Ferreras, M; Lochter, A; Delaisse, JM; Foged, NT				Karsdal, MA; Larsen, L; Engsig, MT; Lou, H; Ferreras, M; Lochter, A; Delaisse, JM; Foged, NT			Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GELATINASE-A MMP-2; TGF-BETA; BONE-FORMATION; IN-VITRO; COLLAGEN LATTICES; MC3T3-E1 CELLS; MT1-MMP MMP-14; EXPRESSION; MINERALIZATION; FIBROBLASTS	Upon termination of bone matrix synthesis, osteoblasts either undergo apoptosis or differentiate into osteocytes or bone lining cells. In this study, we investigated the role of matrix metalloproteinases (MMPs) and growth factors in the differentiation of osteoblasts into osteocytes and in osteoblast apoptosis. The mouse osteoblast cell line MC3T3-El and primary mouse calvarial osteoblasts were either grown on two-dimensional (2-D) collagen-coated surfaces, where they morphologically resemble flattened, cuboidal bone lining cells, or embedded in three-dimensional (3-D) collagen gels, where they resemble dendritic osteocytes constituting a network of cells. When MC3T3-El osteoblasts were grown in a 3-D matrix in the presence of an MMP inhibitor (GM6001), the cell number was dose-dependently reduced by approximately 50%, whereas no effect was observed on a 2-D substratum. In contrast, the murine mature osteocyte cell line, MLO-Y4, was unaffected by GM6001 under all culture conditions. According to TUNEL assay, the osteoblast apoptosis was increased 2.5-fold by 10 muM GM6001. To investigate the mechanism by which MMPs mediate the survival of osteoblasts, we examined the effect of GM6001 on MC3T3-E1 osteoblasts in the presence of extracellular matrix components and growth factors, including tenascin, fibronectin, laminin, collagenase-cleaved collagen, gelatin, parathyroid hormone, basic fibroblast growth factor, vascular epidermal growth factor, insulin-like growth factor, interleukin-1, and latent and active transforming growth factor-beta (TGF-beta). Only active TGF-beta, but not latent TGF-beta or other agents tested, restored cell number and apoptosis to control levels. Furthermore, we found that the membrane type MMP, MT1-MMP, which is produced by osteoblasts, could activate latent TGF-beta and that antibodies neutralizing endogenous TGF-beta led to a similar decrease in cell number as GM6001. Whereas inhibitors of other protease families did not induce osteoblast apoptosis, an inhibitor of the p44/42 mitogen-activated protein kinase showed the same but non-synergetic effect as GM6001. These findings suggest that MMP-activated TGF-beta maintains osteoblast survival during trans-differentiation into osteocytes by a p44/42-dependent pathway.	Nord Biosci AS, Ctr Clin & Basic Res, DK-2730 Herlev, Denmark	Center Clinical & Basic Research; Nordic Bioscience	Karsdal, MA (corresponding author), Nord Biosci AS, Ctr Clin & Basic Res, DK-2730 Herlev, Denmark.		Foged, Niels T/AHA-2122-2022	Delaisse, Jean-Marie/0000-0001-7370-1500; Karsdal, Morten/0000-0001-5026-8740				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; BELLOWS CG, 1981, J CELL SCI, V50, P299; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Bonewald LF, 1999, J BONE MINER METAB, V17, P61, DOI 10.1007/s007740050066; Borton AJ, 2001, J BONE MINER RES, V16, P1754, DOI 10.1359/jbmr.2001.16.10.1754; BOUVIER M, 1990, ARCH ORAL BIOL, V35, P301, DOI 10.1016/0003-9969(90)90047-E; BOUVIER M, 1990, DIFFERENTIATION, V45, P128, DOI 10.1111/j.1432-0436.1990.tb00466.x; CASSERBETTE M, 1990, CALCIFIED TISSUE INT, V46, P46, DOI 10.1007/BF02555824; Chaudhary LR, 2001, J CELL BIOCHEM, V81, P304, DOI 10.1002/1097-4644(20010501)81:2<304::AID-JCB1045>3.3.CO;2-L; Cheng BX, 2001, ENDOCRINOLOGY, V142, P3464, DOI 10.1210/en.142.8.3464; Choi JY, 1996, J CELL BIOCHEM, V61, P609, DOI 10.1002/(SICI)1097-4644(19960616)61:4<609::AID-JCB15>3.3.CO;2-Q; CLARK RAF, 1995, J CELL SCI, V108, P1251; Cooper LF, 2000, J CELL PHYSIOL, V185, P401, DOI 10.1002/1097-4652(200012)185:3<401::AID-JCP10>3.0.CO;2-C; D'Angelo M, 2001, J BONE MINER RES, V16, P2339, DOI 10.1359/jbmr.2001.16.12.2339; D'Angelo M, 2001, J BIOL CHEM, V276, P11347, DOI 10.1074/jbc.M009725200; Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879; Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; Ferrera D, 2002, BONE, V30, P718, DOI 10.1016/S8756-3282(02)00691-9; Festuccia C, 2000, INT J CANCER, V85, P407, DOI 10.1002/(SICI)1097-0215(20000201)85:3<407::AID-IJC18>3.0.CO;2-8; Filanti C, 2000, J BONE MINER RES, V15, P2154, DOI 10.1359/jbmr.2000.15.11.2154; Filvaroff E, 1999, DEVELOPMENT, V126, P4267; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Hayashi K, 1999, J CELL BIOL, V145, P727, DOI 10.1083/jcb.145.4.727; Hock JM, 2001, J BONE MINER RES, V16, P975, DOI 10.1359/jbmr.2001.16.6.975; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Karsdal MA, 2001, J BIOL CHEM, V276, P39350, DOI 10.1074/jbc.M008738200; Kim MK, 2001, YONSEI MED J, V42, P338, DOI 10.3349/ymj.2001.42.3.338; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P85; Li S, 1999, J ORTHOP RES, V17, P891, DOI 10.1002/jor.1100170614; Lin HC, 2001, INVEST OPHTH VIS SCI, V42, P2517; Maeda S, 2002, CALCIFIED TISSUE INT, V70, P54, DOI 10.1007/s002230010032; Maeda S, 2001, J BONE MINER RES, V16, P1281, DOI 10.1359/jbmr.2001.16.7.1281; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; MAUCH C, 1988, EXP CELL RES, V178, P493, DOI 10.1016/0014-4827(88)90417-X; MCGUIRE PG, 1989, J CELL BIOCHEM, V40, P215, DOI 10.1002/jcb.240400210; Morimura N, 2001, J BIOL CHEM, V276, P42172, DOI 10.1074/jbc.M103216200; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; Mu DZ, 2002, J CELL BIOL, V157, P493, DOI 10.1083/jcb.200109100; PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303; Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800; Sato A, 1999, ADV SPACE RES, V24, P807, DOI 10.1016/S0273-1177(99)00076-9; SPRAGUE SM, 1994, KIDNEY INT, V46, P1199, DOI 10.1038/ki.1994.385; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Takamine Y, 2002, CLIN ORTHOP RELAT R, P240; Uchida M, 2000, J CELL PHYSIOL, V185, P207, DOI 10.1002/1097-4652(200011)185:2<207::AID-JCP5>3.0.CO;2-J; Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002-9343(99)00420-9; Yu Q, 2000, GENE DEV, V14, P163; Zhao WG, 2000, J CLIN INVEST, V106, P941, DOI 10.1172/JCI10158	58	192	201	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44061	44067		10.1074/jbc.M207205200	http://dx.doi.org/10.1074/jbc.M207205200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226090	hybrid			2022-12-27	WOS:000179272000069
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATPASE ACTIVITY; PREDICTED TRANSMEMBRANE DOMAIN; CYSTEINE-SCANNING MUTAGENESIS; DRUG-BINDING; FUNCTIONAL CONSEQUENCES; CROSS-LINKING; SUBSTRATE-SPECIFICITY; MUTATIONS; MUTANTS; IDENTIFICATION	The human multidrug resistance P-glycoprotein (P-gp) pumps a wide variety of structurally diverse compounds out of the cell. It is an ATP-binding cassette transporter with two nucleotide-binding domains and twos transmembrane (TM) domains. One class of compounds transported by P-gp is the rhodamine dyes. A P-gp deletion mutant (residues 1-379 plus 681-1025) With only the TM domains retained the ability to bind rhodamine. Therefore, to identify the residues involved in rhodamine binding, 252 mutants containing a cysteine in the predicted TM segments were generated and reacted with a thiol-reactive analog of rhodamine, methanethiosulfonate (MTS)-rhodamine. The activities of 28 mutants (in TMs 2-12) were inhibited by at least 50% after reaction with MTS-rhodamine. The activities of five mutants, 1340C(TM6), A841C(TM9), L975C(TM12), V981C(TM12), and V982C(TM12), however, were significantly protected from inhibition by MTS-rhodamine by pretreatment with rhodamine B, indicating that residues in TMs 6, 9, and 12 contribute to the binding of rhodamine dyes. These results, together with those from previous labeling studies with other thiol-reactive compounds, dibromobimane, MTS-verapamil, and MTS-cross-linker substrates, indicate that common residues are involved in the binding of structurally different drug substrates and that P-gp has a common drug-binding site. The results support the "substrate-induced fit" hypothesis for drug binding.	Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Loo, TW (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NCI NIH HHS [R01 CA80900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; Ayesh S, 1996, BBA-MOL BASIS DIS, V1316, P8, DOI 10.1016/0925-4439(96)00008-7; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; Bruice T.W., 1982, J PROTEIN CHEM, V1, P47, DOI DOI 10.1007/BF01025550; CARDO CC, 1989, P NATL ACAD SCI USA, V86, P695; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Demeule M, 1998, BIOCHEMISTRY-US, V37, P18110, DOI 10.1021/bi981992c; Demmer A, 1997, J BIOL CHEM, V272, P20913, DOI 10.1074/jbc.272.33.20913; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; Ecker GF, 2002, MOL PHARMACOL, V61, P637, DOI 10.1124/mol.61.3.637; Eytan GD, 1997, EUR J BIOCHEM, V248, P104, DOI 10.1111/j.1432-1033.1997.00104.x; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hrycyna CA, 2001, SEMIN CELL DEV BIOL, V12, P247, DOI 10.1006/scdb.2000.0250; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kenyon G L, 1977, Methods Enzymol, V47, P407; Krishna R, 2000, EUR J PHARM SCI, V11, P265, DOI 10.1016/S0928-0987(00)00114-7; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 1999, BIOCHEM CELL BIOL, V77, P11, DOI 10.1139/bcb-77-1-11; Loo TW, 1999, FASEB J, V13, P1724, DOI 10.1096/fasebj.13.13.1724; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7243; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; LOO TW, 1994, J BIOL CHEM, V269, P28683; Loo TW, 2000, JNCI-J NATL CANCER I, V92, P898, DOI 10.1093/jnci/92.11.898; Loo TW, 1998, METHOD ENZYMOL, V292, P480; Muller M, 1996, J BIOL CHEM, V271, P1877; Pascaud C, 1998, BIOCHEM J, V333, P351, DOI 10.1042/bj3330351; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Senior AE, 1998, ARCH BIOCHEM BIOPHYS, V357, P121, DOI 10.1006/abbi.1998.0778; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Shapiro AB, 1999, EUR J BIOCHEM, V259, P841, DOI 10.1046/j.1432-1327.1999.00098.x; Song JM, 2001, MOL PHARMACOL, V60, P254, DOI 10.1124/mol.60.2.254; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735	59	169	173	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44332	44338		10.1074/jbc.M208433200	http://dx.doi.org/10.1074/jbc.M208433200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223492	hybrid			2022-12-27	WOS:000179272000104
J	Mori, H; Shimizu, Y; Ito, K				Mori, H; Shimizu, Y; Ito, K			Superactive SecY variants that fulfill the essential translocation function with a reduced cellular quantity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN-TRANSLOCATION; PREPROTEIN TRANSLOCATION; CYTOPLASMIC MEMBRANE; SYNTHETIC LETHALITY; DOMAINS; EXPORT; PRLA; INSERTION; MUTATIONS	The fifth and the sixth cytoplasmic regions (C5 and C6) of SecY are important for the SecA-driven preprotein translocation reaction. A cold-sensitive mutation, secY205 (Tyr-429 --> Asp), in C6 impairs the ATP- and precursor-dependent SecA insertion into the membrane. We now identified second site mutations that suppressed the defect. Cis-placement of these mutations proved to suppress mutations at another essential residue (Arg-357) of SecY as well. Thus, they tolerate the otherwise defective SecY alterations in the same molecule. Two alterations (Ile-195 to Ser in TM5 region and Ile-408 to Leu in TM10 region) were found to make the translocation channel more active, because it enabled cells to survive with reduced content of the SecYE complex. These mutations only very weakly suppressed a signal sequence defect of the lambda receptor protein. The mutant SecYEG translocase exhibited higher than normal activity in vitro, being accompanied by striking independence of the proton motive force as well as by stabilization of a bound and active SecA species against urea treatment. These results have been interpreted in terms of balance shifts between channel closing and channel opening alterations in the SecYEG translocase.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Ito, K (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.			Mori, Hiroyuki/0000-0002-0429-1269				AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; BABA T, 1990, J BACTERIOL, V172, P7005, DOI 10.1128/jb.172.12.7005-7010.1990; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; Duong F, 1999, EMBO J, V18, P3263, DOI 10.1093/emboj/18.12.3263; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1998, J BIOL CHEM, V273, P21675, DOI 10.1074/jbc.273.34.21675; Eichler J, 1997, P NATL ACAD SCI USA, V94, P5574, DOI 10.1073/pnas.94.11.5574; FLOWER AM, 1995, EMBO J, V14, P884, DOI 10.1002/j.1460-2075.1995.tb07070.x; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; Matsumoto G, 1997, EMBO J, V16, P6384, DOI 10.1093/emboj/16.21.6384; Matsumoto G, 1998, P NATL ACAD SCI USA, V95, P13567, DOI 10.1073/pnas.95.23.13567; Matsuo E, 1998, J BIOL CHEM, V273, P18835, DOI 10.1074/jbc.273.30.18835; MAYER TH, 1996, J MOL BIOL, V285, P1789; Miller J. H., 1972, EXPT MOL GENETICS, P431; Mori H, 1998, J BIOCHEM, V124, P122, DOI 10.1093/oxfordjournals.jbchem.a022070; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Mori H, 2001, P NATL ACAD SCI USA, V98, P5128, DOI 10.1073/pnas.081617398; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; OSBORNE RS, 1993, EMBO J, V12, P3391, DOI 10.1002/j.1460-2075.1993.tb06013.x; Price A, 1996, J BIOL CHEM, V271, P31580, DOI 10.1074/jbc.271.49.31580; RIGGS PD, 1988, GENETICS, V118, P571; SAKO T, 1988, J BACTERIOL, V170, P5389, DOI 10.1128/jb.170.11.5389-5391.1988; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; SCHATZ PJ, 1989, GENE DEV, V3, P1035, DOI 10.1101/gad.3.7.1035; SHIMOIKE T, 1995, J BIOL CHEM, V270, P5519, DOI 10.1074/jbc.270.10.5519; SILHAVY TJ, 1984, EXPT GENE FUSIONS, pR11; Suzuki H, 1998, MOL MICROBIOL, V29, P331, DOI 10.1046/j.1365-2958.1998.00937.x; TAURA T, 1993, J BACTERIOL, V175, P7771, DOI 10.1128/JB.175.24.7771-7775.1993; TAURA T, 1994, MOL GEN GENET, V243, P261, DOI 10.1007/BF00301061; TAURA T, 1997, BIOCHIMIE, V79, P512; Uchida K, 1995, J BIOL CHEM, V270, P30862, DOI 10.1074/jbc.270.52.30862; UEGUCHI C, 1989, MOL GEN GENET, V217, P1, DOI 10.1007/BF00330934; van der Wolk JPW, 1998, EMBO J, V17, P3631, DOI 10.1093/emboj/17.13.3631; Veenendaal AKJ, 2001, J BIOL CHEM, V276, P32559, DOI 10.1074/jbc.M103912200; Yoshihisa T, 1996, J BIOL CHEM, V271, P9429, DOI 10.1074/jbc.271.16.9429	41	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48550	48557		10.1074/jbc.M204436200	http://dx.doi.org/10.1074/jbc.M204436200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12351621	hybrid			2022-12-27	WOS:000179789600076
J	Walker, SA; Kupzig, S; Lockyer, PJ; Bilu, S; Zharhary, D; Cullen, PJ				Walker, SA; Kupzig, S; Lockyer, PJ; Bilu, S; Zharhary, D; Cullen, PJ			Analyzing the role of the putative inositol 1,3,4,5-tetrakisphosphate receptor GAP1(IP4BP) in intracellular Ca2+ homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; INS(1,3,4,5)P-4 RECEPTOR; GAP1 FAMILY; RAS; CELLS; TRISPHOSPHATE; BINDING; IDENTIFICATION; MOBILIZATION; PHOSPHATES	Inositol 1,3,4,5-tetrakisphosphate (IP4) has been linked to a potential role in the regulation of intracellular free Ca2+ concentration ([Ca2+](i)) following cellular stimulation with agonists that activate phosphoinositide-specific phospholipase C. However, despite many studies, the function of IP4 remains unclear and indeed there is still some debate over whether it has a function at all. Here we have used various molecular approaches to address whether manipulation of the potential IP4 receptor, GAP1(IP4BP), affects [Ca2+](i) following cellular stimulation. Using single cell imaging, we show that the overexpression of a constitutively active and a potential dominant negative form of GAP1(IP4BP) appear to have no effect on Ca2+ mobilization or Ca2+ entry following stimulation of HeLa cells with histamine. In addition, through the use of small interfering RNA duplexes, we have examined the effect of suppressing endogenous GAP1(IP4BP) production on [Ca2+](i). In HeLa cells in which the endogenous level of GAP1(IP4BP) has been suppressed by similar to95%, we failed to observe any effect on Ca2+ mobilization or Ca2+ entry following histamine stimulation. Thus, using various approaches to manipulate the function of endogenous GAP1(IP4BP) in intact HeLa cells, we have been unable to observe any detectable effect of GAP1(IP4BP) on [Ca2+](i).	Univ Bristol, Sch Med Sci, Dept Biochem, Integrated Signalling Labs, Bristol BS8 1TD, Avon, England; Sigma Aldrich Israel Ltd, Rehovot, Israel	University of Bristol; Merck KGaA; MilliporeSigma	Cullen, PJ (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Integrated Signalling Labs, Bristol BS8 1TD, Avon, England.	Pete.Cullen@bris.ac.uk		Walker, Simon/0000-0001-9185-4922; Cullen, Peter/0000-0002-9070-8349				Allen M, 1998, GENE, V218, P17, DOI 10.1016/S0378-1119(98)00394-1; BABA H, 1995, J NEUROSCI RES, V41, P846, DOI 10.1002/jnr.490410615; BATTY IR, 1985, BIOCHEM J, V232, P211, DOI 10.1042/bj2320211; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; Bootman MD, 1996, BIOCHEM J, V314, P347, DOI 10.1042/bj3140347; Bottomley JR, 1998, BIOCHEM BIOPH RES CO, V250, P143, DOI 10.1006/bbrc.1998.9179; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHANGYA L, 1989, FEBS LETT, V251, P43, DOI 10.1016/0014-5793(89)81425-5; Corbett KD, 2001, TRENDS BIOCHEM SCI, V26, P710, DOI 10.1016/S0968-0004(01)01974-0; Cozier GE, 2000, J BIOL CHEM, V275, P28261; CULLEN PJ, 1990, BIOCHEM J, V271, P549, DOI 10.1042/bj2710549; CULLEN PJ, 1995, BIOCHEM J, V305, P139, DOI 10.1042/bj3050139; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Cullen PJ, 1998, BBA-MOL CELL BIOL L, V1436, P35, DOI 10.1016/S0005-2760(98)00149-0; Cullen PJ, 1997, BIOCHEM SOC T, V25, P991, DOI 10.1042/bst0250991; CULLEN PJ, 1995, FEBS LETT, V358, P240, DOI 10.1016/0014-5793(94)01435-4; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Harborth J, 2001, J CELL SCI, V114, P4557; Irvine R, 2001, CURR BIOL, V11, pR172, DOI 10.1016/S0960-9822(01)00086-0; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; Irvine RF, 1999, CHEM PHYS LIPIDS, V98, P49, DOI 10.1016/S0009-3084(99)00017-1; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Li SW, 1996, GENOMICS, V35, P625, DOI 10.1006/geno.1996.0412; Lockyer PJ, 1997, CURR BIOL, V7, P1007, DOI 10.1016/S0960-9822(06)00423-4; Lockyer PJ, 1999, CURR BIOL, V9, P265, DOI 10.1016/S0960-9822(99)80116-X; Lockyer PJ, 2001, CURR BIOL, V11, P981, DOI 10.1016/S0960-9822(01)00261-5; Loomis-Husselbee JW, 1998, BIOCHEM J, V331, P947, DOI 10.1042/bj3310947; LoomisHusselbee JW, 1996, BIOCHEM J, V314, P811, DOI 10.1042/bj3140811; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; Lu XH, 1999, J GEN PHYSIOL, V113, P81, DOI 10.1085/jgp.113.1.81; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; Minagawa T, 2001, BIOCHEM BIOPH RES CO, V288, P87, DOI 10.1006/bbrc.2001.5740; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SMITH PM, 1992, BIOCHEM J, V283, P27, DOI 10.1042/bj2830027; Smith PM, 2000, BIOCHEM J, V347, P77, DOI 10.1042/0264-6021:3470077; Szinyei C, 1999, J PHYSIOL-LONDON, V516, P855, DOI 10.1111/j.1469-7793.1999.0855u.x; Tsubokawa H, 1996, J PHYSIOL-LONDON, V497, P67, DOI 10.1113/jphysiol.1996.sp021750; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557	44	12	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48779	48785		10.1074/jbc.M204839200	http://dx.doi.org/10.1074/jbc.M204839200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12356770	hybrid			2022-12-27	WOS:000179789600105
J	Lee, SJ; Gralla, JD				Lee, SJ; Gralla, JD			Promoter use by sigma(38) (rpoS) RNA polymerase - Amino acid clusters for DNA binding and isomerizatton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; GLOBAL REGULATORS; CRYSTAL-STRUCTURE; RECOGNITION; TRANSCRIPTION; REGION; SELECTIVITY; GENE; IDENTIFICATION	sigma(38) is a non-essential but highly homologous member of the sigma(70) family of transcription factors. In vitro mutagenesis and in vivo screening were used to identify 22 critical amino acids in the promoter interaction domain of Escherichia coli sigma(38). Electrophoretic mobility shift assay studies showed that residues involved in duplex DNA binding largely segregated into distinct regions that coincided with those of sigma(70). However, the majority of these amino acids were in non-conserved positions. Analysis indicates that this region of the two sigmas probably has a common overall organization but differs in how its amino acids are used to form functional open complexes. Placement of the mutations on the known sigma(70) holoenzyme structure shows two clusters; one appears to be used for duplex DNA recognition and the other for the subsequent isomerization events. Permanganate assays for DNA melting support this view.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gralla, JD (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, POB 951569, Los Angeles, CA 90095 USA.	gralla@chem.ucla.edu			NIGMS NIH HHS [GM35754] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035754] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azam TA, 1999, J BACTERIOL, V181, P6361, DOI 10.1128/JB.181.20.6361-6370.1999; BALKE VL, 1987, J BACTERIOL, V169, P4499, DOI 10.1128/jb.169.10.4499-4506.1987; Barne KA, 1997, EMBO J, V16, P4034, DOI 10.1093/emboj/16.13.4034; Becker G, 1999, P NATL ACAD SCI USA, V96, P6439, DOI 10.1073/pnas.96.11.6439; Becker G, 2001, MOL MICROBIOL, V39, P1153, DOI 10.1046/j.1365-2958.2001.02313.x; Bouvier J, 1998, MOL MICROBIOL, V28, P971, DOI 10.1046/j.1365-2958.1998.00855.x; Colland F, 2000, EMBO J, V19, P3028, DOI 10.1093/emboj/19.12.3028; DANIELS D, 1990, P NATL ACAD SCI USA, V87, P8075, DOI 10.1073/pnas.87.20.8075; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; DING QQ, 1995, MOL MICROBIOL, V16, P649, DOI 10.1111/j.1365-2958.1995.tb02427.x; Fenton MS, 2001, P NATL ACAD SCI USA, V98, P9020, DOI 10.1073/pnas.161085798; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; Gaal T, 2001, MOL MICROBIOL, V42, P939, DOI 10.1046/j.1365-2958.2001.02703.x; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; Guo YL, 1997, J BACTERIOL, V179, P1239, DOI 10.1128/jb.179.4.1239-1245.1997; Hengge-Aronis R, 1999, CURR OPIN MICROBIOL, V2, P148, DOI 10.1016/S1369-5274(99)80026-5; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; Kusano S, 1996, J BIOL CHEM, V271, P1998, DOI 10.1074/jbc.271.4.1998; Kusano S, 1997, J BACTERIOL, V179, P3649, DOI 10.1128/jb.179.11.3649-3654.1997; Lee SJ, 2001, J BIOL CHEM, V276, P30064, DOI 10.1074/jbc.M102886200; LOMOVSKAYA OL, 1994, J BACTERIOL, V176, P3928, DOI 10.1128/JB.176.13.3928-3935.1994; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Ohnuma M, 2000, J BACTERIOL, V182, P4628, DOI 10.1128/JB.182.16.4628-4631.2000; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; Schellhorn HE, 1998, J BACTERIOL, V180, P6283; Sharp MM, 1999, GENE DEV, V13, P3015, DOI 10.1101/gad.13.22.3015; Tomsic M, 2001, J BIOL CHEM, V276, P31891, DOI 10.1074/jbc.M105027200; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; WALDBURGER C, 1994, J MOL BIOL, V235, P1489, DOI 10.1006/jmbi.1994.1103; XU JM, 1995, J BACTERIOL, V177, P3166, DOI 10.1128/jb.177.11.3166-3175.1995; XU JM, 1995, J BACTERIOL, V177, P5222, DOI 10.1128/jb.177.18.5222-5231.1995	34	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47420	47427		10.1074/jbc.M208363200	http://dx.doi.org/10.1074/jbc.M208363200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351645	hybrid			2022-12-27	WOS:000179663700077
J	Mohrmann, L; Kal, AJ; Verrijzer, CP				Mohrmann, L; Kal, AJ; Verrijzer, CP			Characterization of the extended Myb-like DNA-binding domain of trithorax group protein zeste	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCOMB-GROUP GENE; C-MYB; TRANSCRIPTION FACTORS; CRYSTAL-STRUCTURE; DROSOPHILA-MELANOGASTER; ULTRABITHORAX PROMOTER; TELOMERIC DNA; COMPLEX; RECOGNITION; TRANSVECTION	Zeste is a Drosophila sequence-specific DNA-binding protein that performs a variety of functions during chromatin-directed gene regulation. Its DNA-binding domain (DBD) was previously identified, but no similarities to established DNA-binding structures are known. Here we present sequence comparisons suggesting that the Zeste-DBD is a novel variant of the tri-helical Myb-DBD. Using band shift assays, we mapped the Zeste-DBD to 76 residues, corresponding to a single Myb repeat of only 50 residues. All residues involved in formation of the hydrophobic core of the Myb domain are conserved in Zeste, suggesting it forms an extended Myb domain. Mutagenesis studies determined (T/C/g)GAGTG(A/G/c) as the consensus Zeste recognition sequence. Reconstituted transcription experiments established that deviations from this optimal consensus compromise transcriptional activation by Zeste. In addition, flanking DNA is critical because Zeste-DBD binding requires a DNA sequence of minimally 16 base pairs, which is much longer than the consensus site. The DNA flanking the consensus is contacted by Zeste through sequence-independent backbone contacts. Interestingly, hydroxyl radical footprinting revealed that the Zeste-DNA backbone contacts all map to one face of the DNA. We compare the DNA-binding properties of Zeste with those of classical tri-helical DBDs harboring a helix-turn-helix motif and suggest a model for Zeste-DNA recognition.	Leiden Univ, Med Ctr, Ctr Biomed Genet, Dept Mol & Cell Biol, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Verrijzer, CP (corresponding author), Leiden Univ, Med Ctr, Ctr Biomed Genet, Dept Mol & Cell Biol, POB 9503, NL-2300 RA Leiden, Netherlands.							Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; BENSON M, 1988, EMBO J, V7, P3907, DOI 10.1002/j.1460-2075.1988.tb03277.x; BENSON M, 1987, EMBO J, V6, P1387, DOI 10.1002/j.1460-2075.1987.tb02379.x; BIGGIN MD, 1988, CELL, V53, P713, DOI 10.1016/0092-8674(88)90089-X; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; CHEN JD, 1993, EMBO J, V12, P2075, DOI 10.1002/j.1460-2075.1993.tb05856.x; CHEN JD, 1992, MOL CELL BIOL, V12, P598, DOI 10.1128/MCB.12.2.598; CHEN JD, 1993, EMBO J, V12, P2061, DOI 10.1002/j.1460-2075.1993.tb05855.x; Dorsett D, 1999, CURR OPIN GENET DEV, V9, P505, DOI 10.1016/S0959-437X(99)00002-7; EBNETH A, 1994, BIOCHEMISTRY-US, V33, P14586, DOI 10.1021/bi00252a026; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Hanaoka S, 2001, J MOL BIOL, V312, P167, DOI 10.1006/jmbi.2001.4924; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; JUDD BH, 1995, GENETICS, V141, P245; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; Kal AJ, 2000, GENE DEV, V14, P1058; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; Konig P, 1998, NUCLEIC ACIDS RES, V26, P1731, DOI 10.1093/nar/26.7.1731; LANEY JD, 1992, GENE DEV, V6, P1531, DOI 10.1101/gad.6.8.1531; LEWIS EB, 1954, AM NAT, V88, P225, DOI 10.1086/281833; Lyko F, 1999, BIOESSAYS, V21, P824; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; MANSUKHANI A, 1988, MOL CELL BIOL, V8, P615, DOI 10.1128/MCB.8.2.615; Nishikawa T, 1998, STRUCT FOLD DES, V6, P1057, DOI 10.1016/S0969-2126(98)00106-3; Nishikawa T, 2001, STRUCTURE, V9, P1237, DOI 10.1016/S0969-2126(01)00688-8; Oda M, 1997, PROTEIN ENG, V10, P1407, DOI 10.1093/protein/10.12.1407; OGATA K, 1995, NAT STRUCT BIOL, V2, P309, DOI 10.1038/nsb0495-309; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PARO R, 1995, TRENDS GENET, V11, P295, DOI 10.1016/S0168-9525(00)89081-2; PELEGRI F, 1994, GENETICS, V136, P1341; PHILLIPS MD, 1990, GENETICS, V125, P91; Pinson B, 2001, NUCLEIC ACIDS RES, V29, P527, DOI 10.1093/nar/29.2.527; PIRROTTA V, 1988, GENE DEV, V2, P1839, DOI 10.1101/gad.2.12b.1839; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Pirrotta V, 1999, BBA-REV CANCER, V1424, pM1; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; Rosen C, 1998, GENETICS, V148, P1865; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Saurin AJ, 2001, NATURE, V412, P655, DOI 10.1038/35088096; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; Wolberger C, 1996, CURR OPIN STRUC BIOL, V6, P62, DOI 10.1016/S0959-440X(96)80096-0	51	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47385	47392		10.1074/jbc.M202341200	http://dx.doi.org/10.1074/jbc.M202341200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354778	hybrid			2022-12-27	WOS:000179663700072
J	Yang, RB; Ng, CKD; Wasserman, SM; Colman, SD; Shenoy, S; Mehraban, F; Komuves, LG; Tomlinson, JE; Topper, JN				Yang, RB; Ng, CKD; Wasserman, SM; Colman, SD; Shenoy, S; Mehraban, F; Komuves, LG; Tomlinson, JE; Topper, JN			Identification of a novel family of cell-surface proteins expressed in human vascular endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TUMOR NECROSIS FACTOR; PDGF-BETA-RECEPTOR; FACTOR-LIKE DOMAIN; IN-VIVO; GENE-EXPRESSION; HUMAN THROMBOMODULIN; PHAGE DISPLAY; TISSUE FACTOR; SHEAR-STRESS	Vascular endothelial cells (EC) play a key role in a variety of pathophysiologic processes, such as angiogenesis, inflammation, cancer metastasis, and vascular diseases. As part of a strategy to identify all genes expressed in human EC, a full-length cDNA encoding a potential secreted protein harboring 10 epidermal growth factor (EGF)-like domains and one CUB domain at the carboxyl terminus (termed, SCUBE1 for Signal peptide-CUB-EGF-like domain containing protein 1) was identified. SCUBE1 shares homology with several protein families, including members of the fibrillin and Notch families, and the anticoagulant proteins, thrombomodulin and protein C. SCUBE1 mRNA is found in several highly vascularized tissues such as liver, kidney, lung, spleen, and brain and is selectively expressed in EC by in situ hybridization. SCUBE1 is a secreted glycoprotein that can form oligomers and manifests a stable association with the cell surface. A second gene encoding a homologue (designated SCUBE2) was also identified and is expressed in EC as well as other cell types. SCUBE2 is also a cell-surface protein and can form a heteromeric complex with SCUBE1. Both SCUBE1 and SCUBE2 are rapidly down-regulated in EC after interleukin-1beta and tumor necrosis factor-a treatment in vitro and after lipopolysaccharide injection in vivo. Thus, SCUBE1 and SCUBE2 define an emerging family of human secreted proteins that are expressed in vascular endothelium and may play important roles in development, inflammation, and thrombosis.	Millennium Pharmaceut Inc, Dept Cardiovasc Res, San Francisco, CA 94080 USA; CuraGen Corp, Dept Collaborat Res, New Haven, CT 06511 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Topper, JN (corresponding author), Millennium Pharmaceut Inc, Dept Cardiovasc Res, San Francisco, CA 94080 USA.		Yang, Ruey-Bing/O-1494-2018	Yang, Ruey-Bing/0000-0003-3017-3714				Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Boehme MWJ, 1996, IMMUNOLOGY, V87, P134; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Cines DB, 1998, BLOOD, V91, P3527; Clark TG, 1999, DEVELOPMENT, V126, P2631; DAVIES DR, 1995, FASEB J, V9, P50, DOI 10.1096/fasebj.9.1.7821759; DAVIS C G, 1990, New Biologist, V2, P410; DELGADILLOREYNOSO MG, 1989, J MOL EVOL, V29, P314, DOI 10.1007/BF02103619; DiChiara MR, 2000, J EXP MED, V192, P695, DOI 10.1084/jem.192.5.695; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Duke-Cohan JS, 2000, ADV EXP MED BIOL, V477, P173; Duke-Cohan JS, 1998, P NATL ACAD SCI USA, V95, P11336, DOI 10.1073/pnas.95.19.11336; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; FINELLI AL, 1994, DEVELOPMENT, V120, P861; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; Gleizes PE, 1997, STEM CELLS, V15, P190, DOI 10.1002/stem.150190; Grimmond S, 2000, GENOMICS, V70, P74, DOI 10.1006/geno.2000.6370; Grimmond S, 2001, MECH DEVELOP, V102, P209, DOI 10.1016/S0925-4773(00)00586-4; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; JOHNSON RC, 1993, J CELL BIOL, V121, P1423, DOI 10.1083/jcb.121.6.1423; KAPIOTIS S, 1991, BLOOD, V78, P410; Komuves LG, 2000, J INVEST DERMATOL, V115, P353, DOI 10.1046/j.1523-1747.2000.00073.x; Komuves LG, 2000, J HISTOCHEM CYTOCHEM, V48, P821, DOI 10.1177/002215540004800610; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P4855, DOI 10.1021/bi00365a020; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MOORE KL, 1989, BLOOD, V73, P159; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Persson E, 1998, BLOOD COAGUL FIBRIN, V9, pS79; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; RAPAPORT SI, 1992, ARTERIOSCLER THROMB, V12, P1111, DOI 10.1161/01.ATV.12.10.1111; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; Saharinen J, 1998, J BIOL CHEM, V273, P18459, DOI 10.1074/jbc.273.29.18459; Shimkets RA, 1999, NAT BIOTECHNOL, V17, P798, DOI 10.1038/11743; SMITH CW, 1993, SEMIN HEMATOL, V30, P45; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; Starnes T, 2001, J IMMUNOL, V167, P4137, DOI 10.4049/jimmunol.167.8.4137; Stelnicki EJ, 1998, J INVEST DERMATOL, V110, P110, DOI 10.1046/j.1523-1747.1998.00092.x; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; THOMPSON EA, 1986, J CLIN INVEST, V78, P13, DOI 10.1172/JCI112541; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Topper JN, 1999, MOL MED TODAY, V5, P40, DOI 10.1016/S1357-4310(98)01372-0; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; YANG RB, 2002, PHYSIOLOGIST, V45, P76; YU SQ, 1994, BIOCHEMISTRY-US, V33, P823, DOI 10.1021/bi00169a025; ZUSHI M, 1991, J BIOL CHEM, V266, P19886	58	115	124	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46364	46373		10.1074/jbc.M207410200	http://dx.doi.org/10.1074/jbc.M207410200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270931	hybrid			2022-12-27	WOS:000179529300087
J	Yeh, SH; Lin, CH; Lee, CF; Gean, PW				Yeh, SH; Lin, CH; Lee, CF; Gean, PW			A requirement of nuclear factor-kappa B activation in fear-potentiated startle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; TRANSCRIPTION FACTOR; PROTEIN-SYNTHESIS; LATE-PHASE; EXPRESSION; KINASE; ALPHA; HIPPOCAMPAL; MEMORY; FAMILY	Previous studies have shown that biochemical changes that occur in the amygdala during fear conditioning in vivo are similar to those occur during long term potentiation (LTP) in vitro. Electrophoretic mobility shift assay of nuclear extracts from startle-potentiated rats showed a selective increase in the amygdala of nuclear factor-kappaB (NF-kappaB) DNA binding activity. Supershift experiments further indicated that p65 and p50 subunits but not c-Rel were involved in DNA binding. The protein levels of IkappaB-alpha were reduced by treatments that reliably induced LTP in this area of the brain. This was accompanied by a decrease of NF-kappaB in the cytoplasm concomitant with an increase in the nucleus. Quantitative analysis of IkappaB kinase activity demonstrated that fear training led to an increase in kinase activity, and this effect was inhibited by thalidomide. Paralleled behavioral tests revealed that thalidomide inhibited fear-potentiated startle. Intra-amygdala administration of kappaB decoy DNA prior to training impaired fear-potentiated startle as well as LTP induction. Similarly, NF-kappaB inhibitors blocked IkappaB-alpha degradation and startle response. These results provide the first evidence of a requirement of NF-kappaB activation in the amygdala for consolidation of fear memory.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan	National Cheng Kung University	Gean, PW (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan.	powu@mail.ncku.edu.tw	Yeh, Shiu-Hwa/D-2088-2010					Albensi BC, 2000, SYNAPSE, V35, P151; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bailey DJ, 1999, BEHAV NEUROSCI, V113, P276, DOI 10.1037/0735-7044.113.2.276; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barco A, 2002, CELL, V108, P689, DOI 10.1016/S0092-8674(02)00657-8; Blondeau N, 2001, J NEUROSCI, V21, P4668, DOI 10.1523/JNEUROSCI.21-13-04668.2001; CASSELLA JV, 1986, PHYSIOL BEHAV, V36, P377, DOI 10.1016/0031-9384(86)90032-6; Castagne V, 2001, NEUROSCIENCE, V108, P517, DOI 10.1016/S0306-4522(01)00430-4; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Denk A, 2000, CYTOKINE GROWTH F R, V11, P303, DOI 10.1016/S1359-6101(00)00009-5; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Frey U, 1998, TRENDS NEUROSCI, V21, P181, DOI 10.1016/S0166-2236(97)01189-2; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Hall J, 2001, EUR J NEUROSCI, V13, P1453, DOI 10.1046/j.0953-816x.2001.01531.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Huang YY, 1998, NEURON, V21, P169, DOI 10.1016/S0896-6273(00)80524-3; Huang YY, 2000, J NEUROSCI, V20, P6317, DOI 10.1523/JNEUROSCI.20-17-06317.2000; Impey S, 1998, NAT NEUROSCI, V1, P595, DOI 10.1038/2830; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Josselyn SA, 2001, J NEUROSCI, V21, P2404, DOI 10.1523/JNEUROSCI.21-07-02404.2001; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Keifer JA, 2001, J BIOL CHEM, V276, P22382, DOI 10.1074/jbc.M100938200; Lin CH, 2001, NEURON, V31, P841, DOI 10.1016/S0896-6273(01)00433-0; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; McKernan MG, 1997, NATURE, V390, P607, DOI 10.1038/37605; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Ozes ON, 1999, NATURE, V401, P82; Paxinos G, 1986, RAT BRAIN STEREOTAXI, P27; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Pitkanen A, 1997, TRENDS NEUROSCI, V20, P517, DOI 10.1016/S0166-2236(97)01125-9; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Roshak AK, 1996, J BIOL CHEM, V271, P31496, DOI 10.1074/jbc.271.49.31496; Schafe GE, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-18-j0003.2000; Schafe GE, 2000, J NEUROSCI, V20, P8177; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Stephens TD, 2000, TERATOLOGY, V61, P189, DOI 10.1002/(SICI)1096-9926(200003)61:3<189::AID-TERA6>3.0.CO;2-W; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; ToliverKinsky T, 1997, J NEUROSCI RES, V48, P580, DOI 10.1002/(SICI)1097-4547(19970615)48:6<580::AID-JNR11>3.0.CO;2-Z; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999	48	80	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46720	46729		10.1074/jbc.M206258200	http://dx.doi.org/10.1074/jbc.M206258200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351629	hybrid			2022-12-27	WOS:000179529300131
J	Courbard, JR; Fiore, F; Adelaide, J; Borg, JP; Birnbaum, D; Ollendorff, V				Courbard, JR; Fiore, F; Adelaide, J; Borg, JP; Birnbaum, D; Ollendorff, V			Interaction between two ubiquitin-protein isopeptide ligases of different classes, CBLC and AIP4/ITCH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-CBL; TYROSINE; GENE; ELEGANS; DOMAIN; REGULATOR; CLONING; SLI-1	In metazoans, CBL proteins are RING finger type ubiquitin-protein isopeptide (E3) ligases involved in the down-regulation of epidermal growth factor tyrosine kinase receptors (EGFR). Among the three CBL proteins described in humans, CBLC (CBL3) remains poorly studied. By screening in parallel a human and a Caenorhabditis elegans library using the two-hybrid procedure in yeast, we found a novel interaction between Hsa-CBLC and Hsa-AIP4 or its C. elegans counterpart Cel-WWP1. Hsa-AIP4 and Cel-WWP1 are also ubiquitin E3 ligases. They contain a HECT (homologous to E6-AP C terminus) catalytic domain and four WW domains known to bind proline-rich regions. We confirmed the interaction between Hsa-CBLC and Hsa-AIP4 by a combination of glutathione S-transferase pull-down, co-immunoprecipitation, and colocalization experiments. We show that these two E3 ligases are involved in EGFR signaling because both become phosphorylated on tyrosine following epidermal growth factor stimulation. In addition, we observed that CBLC increases the ubiquitination of EGFR, and that coexpressing the WW domains of AIP4 exerts a dominant negative effect on EGFR ubiquitination. Finally, coexpressing CBLC and AIP4 induces a down-regulation of EGFR signaling. In conclusion, our data demonstrate that two E3 ligases of different classes can interact and cooperate to down-regulate EGFR signaling.	INSERM, Dept Mol Oncol, U119, F-13009 Marseille, France; Inst J Paoli I Calmettes, Ipsogen SA, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC)	Birnbaum, D (corresponding author), INSERM, Dept Mol Oncol, U119, 27 Bd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	ADELAIDE, José JA/O-4390-2017; Borg, Jean-Paul/AAX-8096-2020	ADELAIDE, José JA/0000-0003-4364-9857; Borg, Jean-Paul/0000-0001-8418-3382; Ollendorff, Vincent/0000-0001-9751-2202; Birnbaum, Daniel/0000-0001-7920-9883; FIORE, FREDERIC/0000-0001-7955-6594				Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Baumann CA, 2001, J BIOL CHEM, V276, P6065, DOI 10.1074/jbc.C000856200; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Fiore F, 2001, BIOCHEM BIOPH RES CO, V280, P182, DOI 10.1006/bbrc.2000.4116; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; Huang K, 2000, GENE, V252, P137, DOI 10.1016/S0378-1119(00)00216-X; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; Jehn BM, 2002, J BIOL CHEM, V277, P8033, DOI 10.1074/jbc.M108552200; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JONGEWARD GD, 1995, GENETICS, V139, P1553; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Kim M, 1999, GENE, V239, P145, DOI 10.1016/S0378-1119(99)00356-X; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; Lai EC, 2002, CURR BIOL, V12, pR74, DOI 10.1016/S0960-9822(01)00679-0; LANGDON W, 1989, P NATL ACAD SCI USA, V91, P9665; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Murillas R, 2002, J BIOL CHEM, V277, P2897, DOI 10.1074/jbc.M110047200; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Ollendorff V, 1998, INT J ONCOL, V13, P1159; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Popovici C, 2001, FEBS LETT, V491, P237, DOI 10.1016/S0014-5793(01)02187-1; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Smit L, 1996, ONCOGENE, V13, P381; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Yoon CH, 2000, MOL BIOL CELL, V11, P4019, DOI 10.1091/mbc.11.11.4019; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	50	69	73	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45267	45275		10.1074/jbc.M206460200	http://dx.doi.org/10.1074/jbc.M206460200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12226085	hybrid, Green Published			2022-12-27	WOS:000179404800087
J	Rachek, LI; Grishko, VI; Musiyenko, SI; Kelley, MR; LeDoux, SP; Wilson, GL				Rachek, LI; Grishko, VI; Musiyenko, SI; Kelley, MR; LeDoux, SP; Wilson, GL			Conditional targeting of the DNA repair enzyme hOGG1 into mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; MAMMALIAN-CELLS; GENE-EXPRESSION; ALZHEIMER-DISEASE; OXIDATIVE DAMAGE; RINR-38 CELLS; GLYCOSYLASE; SITES; MICE; ENDONUCLEASE	Oxidative damage to mitochondrial DNA (mtDNA) has been suggested to be a key factor in the etiologies of many diseases and in the normal process of aging. Although the presence of a repair system to remove this damage has been demonstrated, the mechanisms involved in this repair have not been well defined. In an effort to better understand the physiological role of recombinant 8-oxoguanine DNA glycosylase/apuriniclyase (OGG1) in mtDNA repair, we constructed an expression vector containing the gene for OGG1 downstream of the mitochondrial localization sequence from manganese-superoxide dismutase. This gene construct was placed under the control of a tetracycline-regulated promoter. Transfected cells that conditionally expressed OGG1 in the absence of the tetracycline analogue doxycycline and targeted this recombinant protein to mitochondria were generated. Western blots of mitochondrial extracts from vector- and OGG1-transfected clones with and without doxycycline revealed that removal of doxycycline for 4 days caused an approximate 8-fold increase in the amount of OGG1 protein in mitochondria. Enzyme activity assays and DNA repair studies showed that the doxycycline-dependent recombinant OGG1 is functional. Functional studies revealed that cells containing recombinant OGG1 were more proficient at repairing oxidative damage in their mtDNA, and this increased repair led to increased cellular survival following oxidative stress.	Univ S Alabama, Coll Med, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA; Indiana Univ, Sch Med, Wells Ctr Pediat Res, Dept Pediat, Indianapolis, IN 46202 USA	University of South Alabama; Indiana University System; Indiana University-Purdue University Indianapolis	Wilson, GL (corresponding author), Univ S Alabama, Coll Med, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA.			Kelley, Mark/0000-0002-6120-9532	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019602] Funding Source: NIH RePORTER; NIA NIH HHS [AG19602] Funding Source: Medline; NIEHS NIH HHS [ES05865, ES03456] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aburatani H, 1997, CANCER RES, V57, P2151; Bandmann O, 1997, J NEUROL, V244, P262, DOI 10.1007/s004150050082; Bogenhagen DF, 1999, AM J HUM GENET, V64, P1276, DOI 10.1086/302392; Bohr VA, 2002, GENE, V286, P127, DOI 10.1016/S0378-1119(01)00813-7; CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525; Croteau DL, 1999, MUTAT RES-DNA REPAIR, V434, P137, DOI 10.1016/S0921-8777(99)00025-7; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; Dobson AW, 2000, J BIOL CHEM, V275, P37518, DOI 10.1074/jbc.M000831200; Dobson AW, 2002, AM J PHYSIOL-LUNG C, V283, pL205, DOI 10.1152/ajplung.00443.2001; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FREI B, 1986, BIOCHEMISTRY-US, V25, P4438, DOI 10.1021/bi00363a040; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hazra TK, 2002, J BIOL CHEM, V277, P30417, DOI 10.1074/jbc.C200355200; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; Hudson EK, 1998, FREE RADICAL RES, V29, P573, DOI 10.1080/10715769800300611; HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; Ozawa T, 1997, PHYSIOL REV, V77, P425, DOI 10.1152/physrev.1997.77.2.425; Paul R, 2001, MUTAT RES-DNA REPAIR, V486, P11, DOI 10.1016/S0921-8777(01)00069-6; PETTEPHER CC, 1991, J BIOL CHEM, V266, P3113; Pinz KG, 1998, MOL CELL BIOL, V18, P1257, DOI 10.1128/MCB.18.3.1257; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Sawyer DE, 1999, MUTAT RES-DNA REPAIR, V434, P161, DOI 10.1016/S0921-8777(99)00027-0; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; Stebbins MJ, 2001, P NATL ACAD SCI USA, V98, P10775, DOI 10.1073/pnas.121186498; Stierum RH, 1999, NUCLEIC ACIDS RES, V27, P3712, DOI 10.1093/nar/27.18.3712; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; Tamura T, 1996, BIOCHEM BIOPH RES CO, V222, P659, DOI 10.1006/bbrc.1996.0800; TOMKINSON AE, 1988, J BIOL CHEM, V263, P12532; Vialettes B, 1997, DIABETES METAB, V23, P52; Wallace DC, 2000, AM HEART J, V139, pS70, DOI 10.1067/mhj.2000.103934; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WEINMANN P, 1994, PLANT J, V5, P559, DOI 10.1046/j.1365-313X.1994.5040559.x; Wooten GF, 1997, ANN NEUROL, V41, P265, DOI 10.1002/ana.410410218; Zharkov DO, 2000, J BIOL CHEM, V275, P28607, DOI 10.1074/jbc.M002441200	43	82	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44932	44937		10.1074/jbc.M208770200	http://dx.doi.org/10.1074/jbc.M208770200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244119	hybrid, Green Submitted			2022-12-27	WOS:000179404800045
J	Pang, TX; Wakabayashi, S; Shigekawa, M				Pang, TX; Wakabayashi, S; Shigekawa, M			Expression of calcineurin B homologous protein 2 protects serum deprivation-induced cell death by serum-independent activation of Na+/H+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES NA-H; INTRACELLULAR PH; GROWTH-FACTOR; CA2+-BINDING PROTEIN; CYTOPLASMIC DOMAIN; NHE1; APOPTOSIS; KINASE; ANTIPORTER; ISOFORM-1	The calcineurin B homologous protein (designated CHP1) has been shown to be a common essential cofactor for the plasma membrane Na+/H+ exchangers (NHEs) (Pang, T., Su, YL, Wakabayashi, S., and Shigekawa, M. (2001) J. BioL Chem. 276,17367-17372). In this study, we characterized the function of another isoform of CHP (designated CHP2) that has a 61% amino acid identity with CHP1. CHP2, like CHP1, conferred the ability to NHEs 1-3 to express a high exchange activity by binding to the juxtamembrane region of the cytoplasmic domain of the exchanger, but it interacts more strongly (similar to5-fold) with NHE1 than does CHP1. Although CHP1 is expressed ubiquitously at relatively high levels, CHP2 expression was extremely low in most human tissues but was higher in tumor cells. We produced stable cell clones overexpressing either CHP1 or CHP2 in which one of them is predominantly bound to NHE1. Serum (10%) induced a significant cytoplasmic alkalinization (0.1-0.2 pH unit) in cells co-expressing CHP1 and NHE1 but not in cells co-expressing CHP2 and NHE1. In the latter, pH(i) was high (7.4-7.5) even in the absence of serum, suggesting that NHE1 was already activated. Surprisingly, most (>80%) of CHP2/NHE1 cells unlike CHP1/NHE1 cells were viable even after long serum starvation (>7 days). Thus, the expression of CHP2 appears to protect cells from serum deprivation-induced death by increasing pHi. These properties of CHP2/NHE1 cells are similar to those of malignantly transformed cells. We propose that serum-independent activation of NHE1 by bound CHP2 is one of the key mechanisms for the maintenance of high pHi and the resistance to serum deprivation-induced cell death in malignantly transformed cells.	Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Suita, Osaka 5658565, Japan	National Cerebral & Cardiovascular Center - Japan	Wakabayashi, S (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Fujishiro Dai 5-7-1, Suita, Osaka 5658565, Japan.							Aharonovitz O, 2000, J CELL BIOL, V150, P213, DOI 10.1083/jcb.150.1.213; Barroso MR, 1996, J BIOL CHEM, V271, P10183, DOI 10.1074/jbc.271.17.10183; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Bianchini L, 1997, J BIOL CHEM, V272, P271; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Ikeda T, 1997, J BIOCHEM-TOKYO, V121, P295; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; Kluza J, 2000, CANCER RES, V60, P4077; Lehoux S, 2001, J BIOL CHEM, V276, P15794, DOI 10.1074/jbc.M100410200; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; Lin X, 1999, J BIOL CHEM, V274, P36125, DOI 10.1074/jbc.274.51.36125; MALY K, 1989, J BIOL CHEM, V264, P11839; Marches R, 2001, P NATL ACAD SCI USA, V98, P3434, DOI 10.1073/pnas.061028998; Matsumoto M, 2001, J BIOCHEM, V130, P217, DOI 10.1093/oxfordjournals.jbchem.a002975; McLean LA, 2000, AM J PHYSIOL-CELL PH, V278, pC676, DOI 10.1152/ajpcell.2000.278.4.C676; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Pang TX, 2001, J BIOL CHEM, V276, P17367, DOI 10.1074/jbc.M100296200; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; RAO GN, 1991, J BIOL CHEM, V266, P13485; Reshkin SJ, 2000, J BIOL CHEM, V275, P5361, DOI 10.1074/jbc.275.8.5361; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; Rich IN, 2000, BLOOD, V95, P1427, DOI 10.1182/blood.V95.4.1427.004k48_1427_1434; Sailer BL, 1998, CANCER RES, V58, P413; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; Takasu T, 1998, CANCER RES, V58, P2504; Thangaraju M, 1999, CANCER RES, V59, P1649; Thangaraju M, 1999, J BIOL CHEM, V274, P29549, DOI 10.1074/jbc.274.41.29549; Timm S, 1999, MOL BIOL CELL, V10, P3473, DOI 10.1091/mbc.10.10.3473; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1995, J BIOL CHEM, V270, P26460, DOI 10.1074/jbc.270.44.26460; Wang HY, 1997, J BIOL CHEM, V272, P26545, DOI 10.1074/jbc.272.42.26545; Yan WH, 2001, J BIOL CHEM, V276, P31349, DOI 10.1074/jbc.M102679200	42	68	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43771	43777		10.1074/jbc.M208313200	http://dx.doi.org/10.1074/jbc.M208313200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226101	hybrid			2022-12-27	WOS:000179272000032
J	Paris, R; Morales, A; Coll, O; Sanchez-Reyes, A; Garcia-Ruiz, C; Fernandez-Checa, JC				Paris, R; Morales, A; Coll, O; Sanchez-Reyes, A; Garcia-Ruiz, C; Fernandez-Checa, JC			Ganglioside GD3 sensitizes human hepatoma cells to cancer therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MITOCHONDRIAL PERMEABILITY TRANSITION; MULTIDRUG-RESISTANCE; IONIZING-RADIATION; INDUCED APOPTOSIS; INHIBITION; CERAMIDE; EXPRESSION; ACTIVATION; CHEMORESISTANCE	Ganglioside GD3 (GD3) has emerged as a modulator of cell death pathways due to its ability to interact with mitochondria and disable survival pathways. Because NF-kappaB activation contributes to cancer therapy resistance, this study was undertaken to test whether GD3 modulates the response of human hepatoblastoma HepG2 cells to radio- and chemotherapy. NF-kappaB was activated in HepG2 cells shortly after therapeutic doses of ionizing radiation or daunorubicin treatment that translated into up-regulation of kappaB-dependent genes. These effects were accompanied by minimal killing of HepG2 cells by either ionizing radiation or daunorubicin. However, GD3 pretreatment blocked the nuclear translocation of active kappaB members, without effect on Akt phosphorylation, induced by either treatment. The suppression of kappaB-dependent gene induction by GD3 was accompanied by enhanced apoptotic cell death caused by these therapies. Furthermore, the combination of GD3 plus ionizing radiation stimulated the formation of reactive species followed by the mitochondrial release of cytochrome c and Smac/Diablo and caspase 3 activation. Pretreatment with cyclosporin A before radiotherapy protected HepG2 cells from the therapeutic combination of GD3 plus ionizing radiation. These findings underscore a key role of mitochondria in the response of tumor cells to cancer therapy and highlight the potential relevance of GD3 to overcome resistance to cancer therapy by combining its dual action as a mitochondria-interacting and NF-kappaB-inactivating agent.	Hosp Clin Barcelona, Liver Unit, Inst Malalties Digest, Barcelona 08036, Spain; Hosp Clin Barcelona, Serv Radioterapia, Inst Invest Biomed Augusts Pi Suner, Barcelona 08036, Spain; CSIC, Dept Expt Pathol, Inst Invest Biomed, Barcelona 08036, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB)	Fernandez-Checa, JC (corresponding author), Hosp Clin Barcelona, Liver Unit, Inst Malalties Digest, Barcelona 08036, Spain.	checa229@yahoo.com	Morales, Albert/E-2988-2013; Coll, Olga/H-6129-2015; Garcia-Ruiz, Carmen/L-8211-2014; Fernández-Checa, José Carlos/L-8342-2014	Morales, Albert/0000-0001-8702-2269; Coll, Olga/0000-0002-7946-1250; Garcia-Ruiz, Carmen/0000-0002-2652-6102; Fernández-Checa, José Carlos/0000-0003-3422-2990	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA011999] Funding Source: NIH RePORTER; NIAAA NIH HHS [P50 AA 11999] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Colell A, 2002, FEBS LETT, V526, P15, DOI 10.1016/S0014-5793(02)03106-X; Colell Anna, 2001, FASEB Journal, V15, P1068; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; Cusack JC, 1999, DRUG RESIST UPDATE, V2, P271, DOI 10.1054/drup.1999.0094; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Degli Esposti M, 1998, FEBS LETT, V430, P338, DOI 10.1016/S0014-5793(98)00688-7; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; di Bartolomeo S, 2001, BIOCHEM BIOPH RES CO, V288, P269, DOI 10.1006/bbrc.2001.5748; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2002, J BIOL CHEM, V277, P36443, DOI 10.1074/jbc.M206021200; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Giammarioli AM, 2001, FEBS LETT, V506, P45, DOI 10.1016/S0014-5793(01)02776-4; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P143, DOI 10.1023/A:1026524820177; Hatano E, 2001, GASTROENTEROLOGY, V120, P1251, DOI 10.1053/gast.2001.23239; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Leach JK, 2001, CANCER RES, V61, P3894; Lemasters JJ, 1999, AM J PHYSIOL-GASTR L, V276, pG1, DOI 10.1152/ajpgi.1999.276.1.G1; Morales A, 1998, INT J RADIAT ONCOL, V42, P191, DOI 10.1016/S0360-3016(98)00185-0; Morales A, 1998, FEBS LETT, V427, P15, DOI 10.1016/S0014-5793(98)00381-0; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Riboni L, 1997, PROG LIPID RES, V36, P153, DOI 10.1016/S0163-7827(97)00008-8; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Roman J, 2000, J BIOL CHEM, V275, P14684, DOI 10.1074/jbc.275.19.14684; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Shimada M, 1996, HEPATO-GASTROENTEROL, V43, P1159; SPITALNIK PF, 1989, ARCH BIOCHEM BIOPHYS, V273, P578, DOI 10.1016/0003-9861(89)90518-3; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Uzzo RG, 1999, J CLIN INVEST, V104, P769, DOI 10.1172/JCI6775; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Veldman RJ, 2002, FASEB J, V16, P1111, DOI 10.1096/fj.01-0863fje; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XD, 2001, GENE DEV, V15, P2922; Watanabe R, 2002, CANCER RES, V62, P3850	52	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49870	49876		10.1074/jbc.M208303200	http://dx.doi.org/10.1074/jbc.M208303200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12351644	hybrid			2022-12-27	WOS:000180028900101
J	Blystone, SD				Blystone, SD			Kinetic regulation of beta(3) integrin tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN	Tyrosine phosphorylation of beta(3) integrins is a permissive stage in the activation of alpha(IIb)beta(3) and alpha(v)beta(3) in platelets and leukocytes, respectively. In this study we demonstrated direct phosphorylation of beta(3) integrins as a result of interaction with soluble monomeric ligand, and we characterized the differential kinetics of beta(3) phosphorylation as a consequence of alpha subunit pairing. We found that beta(3) phosphorylation is initiated by RGD peptide binding in a dose-dependent and saturable fashion with alpha(IIb)beta(3) becoming phosphorylated and dephosphorylated more rapidly than alpha(v)beta(3). Site mapping of phosphate incorporation reveals significant phosphorylation at Tyr-747 in both beta(3) integrin species with incorporation at Tyr-759 found at significant levels only in alpha(IIb)beta(3). Mutation of cytoplasmic beta(3) tyrosine residues in a transfection model prevents cell adhesion via these integrins. These data demonstrate that recognition of ligand is sufficient to induce beta(3) tyrosine phosphorylation and suggests that this event is regulated by the alpha subunit pairing of beta(3).	SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Blystone, SD (corresponding author), SUNY Upstate Med Univ, Dept Cell & Dev Biol, 750 E Adams St, Syracuse, NY 13210 USA.	blystons@mail.upstate.edu						Blystone SD, 1996, J BIOL CHEM, V271, P31458, DOI 10.1074/jbc.271.49.31458; Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; Boettiger D, 2001, MOL BIOL CELL, V12, P1227, DOI 10.1091/mbc.12.5.1227; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; Liu SC, 2000, J CELL SCI, V113, P3563; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777	9	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46886	46890		10.1074/jbc.M209506200	http://dx.doi.org/10.1074/jbc.M209506200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359711	hybrid			2022-12-27	WOS:000179663700009
J	Funk, JD; Nedialkov, YA; Xu, DP; Burton, ZF				Funk, JD; Nedialkov, YA; Xu, DP; Burton, ZF			A key role for the alpha 1 helix of human RAP74 in the initiation and elongation of RNA chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIF; PROTEIN SECONDARY STRUCTURE; POLYMERASE-II; PREINITIATION COMPLEX; NEURAL NETWORKS; FACTOR TFIIF; SUBUNIT; RAP30; CDNA; PREDICTION	RNA polymerase II-associating protein 74 (RAP74) is the large subunit of transcription factor IIF (TFIIF), which is essential for accurate initiation and stimulates elongation by RNA polymerase II. Mutations within or adjacent to the alpha1 helix of the RAP74 subunit have been shown to decrease both initiation and elongation stimulation activities without strongly affecting the interactions of RAP74 with the RAP30 subunit or the interaction between TFIIF and RNA polymerase II. In this manuscript, mutations within the alpha1 helix are compared with mutations made throughout the neighboring conserved N-terminal domain of RAP74. Changes within the N-terminal domain include disruptions of specific contacts with the alpha1 helix, which were revealed in the recently published x-ray crystal structure (Gaiser, F., Tan, S., and Richmond, T. J. (2000) J. Mol. Biol. 302, 1119-1127). Contacts between the 134-135 loop and the alpha1 helix are shown to be largely unimportant for alpha1 helix function. Other mutations throughout the N-terminal domain are consistent with the establishment of the dimer interface with the RAP30 subunit. The RAP74-RAP30 interface is important for TFIIF function, but no particular RAP74 amino acids within this region have been identified that are required for TFIIF activities. The molecular target of the alpha1 helix remains unknown, but our studies refocus attention on this important functional motif of TFIIF.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Burton, ZF (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.							ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; Gaiser F, 2000, J MOL BIOL, V302, P1119, DOI 10.1006/jmbi.2000.4110; GONG DW, 1993, NUCL ACIDS RES; Groft CM, 1998, P NATL ACAD SCI USA, V95, P9117, DOI 10.1073/pnas.95.16.9117; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; Kamada K, 2001, P NATL ACAD SCI USA, V98, P3115, DOI 10.1073/pnas.051631098; KEPHART DD, 1993, NUCLEIC ACIDS RES, V21, P1319, DOI 10.1093/nar/21.5.1319; Lei L, 1999, MOL CELL BIOL, V19, P8372; Lei L, 1998, MOL CELL BIOL, V18, P2130, DOI 10.1128/MCB.18.4.2130; NIU W, 1994, J MOL BIOL, V243, P595, DOI 10.1016/0022-2836(94)90034-5; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; Ren DL, 1999, MOL CELL BIOL, V19, P7377; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Samkurashvili I, 1996, J BIOL CHEM, V271, P23495, DOI 10.1074/jbc.271.38.23495; SUN ZW, 1995, P NATL ACAD SCI USA, V92, P3127, DOI 10.1073/pnas.92.8.3127; TAN SY, 1994, J BIOL CHEM, V269, P25684; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; WANG BQ, 1994, PROTEIN EXPRES PURIF, V5, P476, DOI 10.1006/prep.1994.1067; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027	25	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46998	47003		10.1074/jbc.M206249200	http://dx.doi.org/10.1074/jbc.M206249200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354769	hybrid			2022-12-27	WOS:000179663700023
J	Wang, XQ; Sun, P; Paller, AS				Wang, XQ; Sun, P; Paller, AS			Ganglioside induces caveolin-1 redistribution and interaction with the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOMA B16 CELLS; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; MEDIATED MODULATION; SIGNAL-TRANSDUCTION; MEMBRANE-PROTEIN; LIPID RAFTS; BINDING; LOCALIZATION; KINASE	Although caveolin-1 is thought to facilitate the interaction of receptors and signaling components, its role in epidermal growth factor receptor (EGFR) signaling remains poorly understood. Ganglioside GM3 inhibits EGFR autophosphorylation and may thus affect the interaction of caveolin-1 and the EGFR. We report here that endogenous overexpression of GM3 leads to the clustering of GM3 on the cell membrane of the keratinocyte-derived SCC12 cell line and promotes co-immunoprecipitation of caveolin-1 and GM3 with the EGFR. Overexpression of GM3 does not affect EGFR distribution but shifts caveolin-1 to the detergent-soluble, EGFR-containing region; consistently, caveolin-1 is retained in the detergent-insoluble membrane when ganglioside is depleted. GM3 overexpression inhibits EGFR tyrosine phosphorylation and receptor dimerization and concurrently increases both the content and tyrosine phosphorylation of EGFR-associated caveolin-1, providing evidence that tyrosine phosphorylation of caveolin-1 inhibits EGFR signaling. Consistently, depletion of ganglioside both increases EGFR phosphorylation and prevents the EGF-induced tyrosine phosphorylation of caveolin-1. GM3 also induces delayed serine phosphorylation of EGFR-unassociated caveolin-1, suggesting a role for serine phosphorylation of caveolin-1 in regulating EGFR signaling. These studies suggest that GM3 modulates the caveolin-1/EGFR association and is critical for the EGF-induced tyrosine phosphorylation of caveolin-1 that is associated with its inhibition of EGFR activation.	Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Dept Pediat, Chicago, IL 60614 USA; Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Dept Dermatol, Chicago, IL 60614 USA	Northwestern University; Northwestern University	Paller, AS (corresponding author), Childrens Mem Hosp, Div Dermatol, 107,2300 Childrens Plaza, Chicago, IL 60614 USA.	apaller@northwestern.edu		Paller, Amy/0000-0001-6187-6549	NIAMS NIH HHS [R01 AR44619] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044619] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE A, 1995, J LIPID RES, V36, P611; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Badizadegan K, 2000, AM J PHYSIOL-GASTR L, V278, pG895, DOI 10.1152/ajpgi.2000.278.6.G895; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chigorno V, 2000, EUR J BIOCHEM, V267, P4187, DOI 10.1046/j.1432-1327.2000.01454.x; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Dolo V, 2000, BBA-MOL CELL BIOL L, V1486, P265, DOI 10.1016/S1388-1981(00)00063-9; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gniadecki R, 2002, J INVEST DERMATOL, V118, P582, DOI 10.1046/j.1523-1747.2002.01716.x; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; Hayashi K, 2001, CANCER RES, V61, P2361; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; Iwabuchi K, 2000, J BIOL CHEM, V275, P15174, DOI 10.1074/jbc.275.20.15174; Kazui A, 2000, BIOCHEM BIOPH RES CO, V273, P159, DOI 10.1006/bbrc.2000.2903; Kim YN, 2000, J BIOL CHEM, V275, P7481, DOI 10.1074/jbc.275.11.7481; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Mitsuda T, 2002, J BIOL CHEM, V277, P11239, DOI 10.1074/jbc.M107756200; PALLER AS, 1995, J INVEST DERMATOL, V105, P237, DOI 10.1111/1523-1747.ep12317572; PALLER AS, 1995, EXP CELL RES, V217, P118, DOI 10.1006/excr.1995.1070; PALLER AS, 1993, J INVEST DERMATOL, V100, P841, DOI 10.1111/1523-1747.ep12476755; PALLER AS, 1992, J INVEST DERMATOL, V98, P226, DOI 10.1111/1523-1747.ep12555896; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Pitto M, 2000, GLYCOCONJUGATE J, V17, P215, DOI 10.1023/A:1026593307882; Razani B, 2001, BIOCHEM SOC T, V29, P494, DOI 10.1042/BST0290494; Ringerike T, 2002, J CELL SCI, V115, P1331; Schlegel A, 2001, J BIOL CHEM, V276, P4398, DOI 10.1074/jbc.M005448200; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sowa G, 2001, P NATL ACAD SCI USA, V98, P14072, DOI 10.1073/pnas.241409998; Sun P, 2002, J INVEST DERMATOL, V119, P107, DOI 10.1046/j.1523-1747.2002.01802.x; VANBROCKLYN J, 1993, J NEUROCHEM, V61, P371; Wada T, 1999, BIOCHEM BIOPH RES CO, V261, P21, DOI 10.1006/bbrc.1999.0973; Wang XQ, 2001, J INVEST DERMATOL, V116, P69, DOI 10.1046/j.1523-1747.2001.00222.x; Wang XQ, 2001, GLYCOBIOLOGY, V11, P515, DOI 10.1093/glycob/11.7.515; Wang XQ, 2001, J BIOL CHEM, V276, P44504, DOI 10.1074/jbc.M106563200; Wang XQ, 2001, J BIOL CHEM, V276, P8436, DOI 10.1074/jbc.M006097200; Wang Y, 2002, J BIOL CHEM, V277, P26252, DOI 10.1074/jbc.M110515200; Waugh MG, 1999, BIOCHEM J, V337, P591, DOI 10.1042/0264-6021:3370591; ZENG GC, 1995, P NATL ACAD SCI USA, V92, P8670, DOI 10.1073/pnas.92.19.8670; Zhang W, 2000, J BIOL CHEM, V275, P20717, DOI 10.1074/jbc.M909895199; ZHOU QG, 1994, J BIOL CHEM, V269, P1959	51	64	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47028	47034		10.1074/jbc.M208257200	http://dx.doi.org/10.1074/jbc.M208257200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354760	hybrid			2022-12-27	WOS:000179663700027
J	Wu, TR; Hong, YK; Wang, XD; Ling, MY; Dragoi, AM; Chung, AS; Campbell, AG; Han, ZY; Feng, GS; Chin, YE				Wu, TR; Hong, YK; Wang, XD; Ling, MY; Dragoi, AM; Chung, AS; Campbell, AG; Han, ZY; Feng, GS; Chin, YE			SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED JAK/STAT PATHWAY; SH2 DOMAIN; SIGNAL-TRANSDUCTION; NEGATIVE REGULATOR; INTERFERON-ALPHA; GENE-EXPRESSION; JAK2 KINASE; PROTEIN; ACTIVATION; PHOSPHORYLATION	Signal transducer and activator of transcription (STAT) proteins are both tyrosine- and serine-phosphorylated, mediating signal transduction and gene regulation. Following gene regulation, STAT activity in the nucleus is then terminated by a nuclear protein phosphatase(s), which remains unidentified. Using novel antibody arrays to screen the Stat1-specific protein phosphatase(s), we identified a SHP-2-Stat1 interaction in the A431 cell nucleus. SHP-2 and Stat1 nuclear localization and their association in response to either epidermal growth factor or interferon-gamma (IFN-gamma) were confirmed by immunofluorescent staining and affinity precipitation assays. The SHP-2 C-terminal region containing protein-tyrosine phosphatase activity interacted with the C-terminal SH2 transcriptional activation domain of Stat1. In SHP-2-/-mouse fibroblast cells, Stat1 phosphorylation at both the tyrosine residue Tyr(701) and the serine residue Ser(727) by IFNgamma was enhanced and prolonged. Consistently, purified GST-SHP-2 dephosphorylated Stat1 at both tyrosine and serine residues when immunoprecipitated phospho-Stat1 or a peptide corresponding to the sequence surrounding Tyr(p)(701) or Ser(p)(717) of Stat1 was used as the substrate. Overexpression of SHP-2 in 293T cells inhibited IFNgamma-dependent Stat1 phosphorylation and suppressed Stat1-dependent induction of luciferase activity. Our findings demonstrate that SHP-2 is a dual-specificity protein phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues and plays an important role in modulating STAT function in gene regulation.	Brown Univ, Sch Med, Dept Pathol & Lab Med, Providence, RI 02912 USA; Brown Univ, Sch Med, Dept Mol Microbiol & Immunol, Providence, RI 02912 USA; Burnham Inst, La Jolla, CA 92037 USA	Brown University; Brown University; Sanford Burnham Prebys Medical Discovery Institute	Chin, YE (corresponding author), Brown Univ, Sch Med, Dept Pathol & Lab Med, Providence, RI 02912 USA.		Hong, Kate/ABH-6993-2020	Hong, Kate/0000-0001-5810-8266; Campbell, Andrew G./0000-0003-4579-349X	NCI NIH HHS [R01 CA82549] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082549] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GUAN KL, 1991, J BIOL CHEM, V266, P17992; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; HOEVE J, 2002, MOL CELL BIOL, P5662; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; MARRERO MB, 1998, AM J PHYSIOL, V275, P1216; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Shuai K, 1996, MOL CELL BIOL, V16, P4932; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; Wang YJ, 2000, MOL CELL BIOL, V20, P4505, DOI 10.1128/MCB.20.13.4505-4512.2000; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	43	120	126	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47572	47580		10.1074/jbc.M207536200	http://dx.doi.org/10.1074/jbc.M207536200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12270932	hybrid			2022-12-27	WOS:000179663700096
J	Im, H; Woo, MS; Hwang, KY; Yu, MH				Im, H; Woo, MS; Hwang, KY; Yu, MH			Interactions causing the kinetic trap in serpin protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; CENTER LOOP INSERTION; HUMAN ALPHA(1)-ANTITRYPSIN; INFLUENZA HEMAGGLUTININ; REACTIVE CENTER; CONFORMATIONAL CHANGE; STRUCTURAL BASIS; NATIVE STRAIN; HINGE REGION; DISEASE	Conformational transition is fundamental to the mechanism of functional regulation in proteins, and serpins (serine protease inhibitors) can provide insight into this process. Serpins are metastable in their native forms, and they ordinarily undergo conformational transition to a stable state only when they form a tight complex with target proteases. The metastable native form is thus considered to be a kinetically trapped folding intermediate. We sought to understand the nature of the serpin kinetic trap as a step toward discovering how conformational transition is regulated. We found that mutations of the B/C beta-barrel of native alpha(1)-antitrypsin, a prototypical serpin, allowed conversion of the molecule into a more stable state. A 2.2 Angstrom resolution crystal structure of the stable form (PDB code, 1IZ2) showed that the reactive site loop is inserted into an A beta-sheet, as in the latent plasminogen activator inhibitor-1. Mutational analyses suggest strongly that interactions not found in the final stable form cause the kinetic trap in serpin protein folding.	Korea Inst Sci & Technol, Natl Creat Res Iniat, Prot Strain Res Ctr, Sungbuk Gu, Seoul 136791, South Korea; CrystalGenom Inc, Daeduk BioCommunity, Yuseong Gu, Taejon 305390, South Korea	Korea Institute of Science & Technology (KIST)	Yu, MH (corresponding author), Korea Inst Sci & Technol, Natl Creat Res Iniat, Prot Strain Res Ctr, Sungbuk Gu, 39-1 Hawolgok Dong, Seoul 136791, South Korea.							ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; AERTGEERTS K, 1995, NAT STRUCT BIOL, V2, P891, DOI 10.1038/nsb1095-891; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER D, 1994, STRUCTURE, V2, P907, DOI 10.1016/S0969-2126(94)00091-3; Baldwin RL, 1996, FOLD DES, V1, pR1, DOI 10.1016/S1359-0278(96)00003-X; BIETH J, 1974, BIOCHEM MED METAB B, V11, P350, DOI 10.1016/0006-2944(74)90134-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Capaldi AP, 2001, NAT STRUCT BIOL, V8, P68; Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306; Carrell RW, 2001, THROMB HAEMOSTASIS, V86, P14; Dinner AR, 1998, NAT STRUCT BIOL, V5, P236, DOI 10.1038/nsb0398-236; DOBSON CM, 1994, TRENDS BIOCHEM SCI, V19, P31, DOI 10.1016/0968-0004(94)90171-6; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 1997, BIOCHEMISTRY-US, V36, P5432, DOI 10.1021/bi9702142; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Im H, 1999, J BIOL CHEM, V274, P11072, DOI 10.1074/jbc.274.16.11072; Im H, 2000, PROTEIN SCI, V9, P1497, DOI 10.1110/ps.9.8.1497; KIEFHABER T, 1995, P NATL ACAD SCI USA, V92, P9029, DOI 10.1073/pnas.92.20.9029; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; Kim SJ, 2001, J MOL BIOL, V306, P109, DOI 10.1006/jmbi.2000.4357; KWON KS, 1994, J BIOL CHEM, V269, P9627; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; Lee C, 2001, PROTEIN SCI, V10, P1446, DOI 10.1110/ps.840101; Lee C, 2001, BIOCHEM BIOPH RES CO, V287, P636, DOI 10.1006/bbrc.2001.5638; Lee C, 2000, P NATL ACAD SCI USA, V97, P7727, DOI 10.1073/pnas.97.14.7727; Lee KN, 1998, J BIOL CHEM, V273, P2509, DOI 10.1074/jbc.273.5.2509; Lee KN, 1996, NAT STRUCT BIOL, V3, P497, DOI 10.1038/nsb0696-497; Lukacs CM, 1996, NAT STRUCT BIOL, V3, P888, DOI 10.1038/nsb1096-888; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ozkan SB, 2001, NAT STRUCT BIOL, V8, P765, DOI 10.1038/nsb0901-765; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; Ryu SE, 1996, STRUCTURE, V4, P1181, DOI 10.1016/S0969-2126(96)00126-8; Seo EJ, 2000, J BIOL CHEM, V275, P16904, DOI 10.1074/jbc.M001006200; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Tew DJ, 2001, J MOL BIOL, V313, P1161, DOI 10.1006/jmbi.2001.5104; TUCKER HM, 1995, NAT STRUCT BIOL, V2, P442, DOI 10.1038/nsb0695-442; Wang ZL, 1996, BIOCHEMISTRY-US, V35, P16443, DOI 10.1021/bi961214p; WEISSMAN JS, 1991, SCIENCE, V253, P1357; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303	53	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46347	46354		10.1074/jbc.M207682200	http://dx.doi.org/10.1074/jbc.M207682200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244055	hybrid			2022-12-27	WOS:000179529300085
J	Kuettner, EB; Hilgenfeld, R; Weiss, MS				Kuettner, EB; Hilgenfeld, R; Weiss, MS			The active principle of garlic at atomic resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLIUM-SATIVUM; ALLIINASE; CRYSTALLIZATION; MOLSCRIPT; PROGRAM	Despite the fact that many cultures around the world value and utilize garlic as a fundamental component of their cuisine as well as of their medicine cabinets, relatively little is known about the plant's protein configuration that is responsible for the specific properties of garlic. Here, we report the three-dimensional structure of the garlic enzyme alliinase at 1.5 Angstrom resolution. Alliinase constitutes the major protein component in garlic bulbs, and it is able to cleave carbon-sulfur bonds. The active enzyme is a pyridoxal-5'-phosphate-dependent homodimeric glycoprotein and belongs to the class I family of pyridoxal-5'-phosphate-dependent enzymes. In addition, it contains a novel epidermal growth factor-like domain that makes it unique among all pyridoxal5'-phosphate-dependent enzymes.	Inst Mol Biotechnol, Dept Struct Biol & Crystallog, D-07745 Jena, Germany		Weiss, MS (corresponding author), DESY, European Mol Biol Lab, Hamburg Outstn, Notkestr 85, D-22603 Hamburg, Germany.	msweiss@embl-hamburg.de	Hilgenfeld, Rolf/C-9675-2011; Weiss, Manfred S/B-6857-2013	Weiss, Manfred S/0000-0002-2362-7047				Agarwal KC, 1996, MED RES REV, V16, P111, DOI 10.1002/(SICI)1098-1128(199601)16:1&lt;111::AID-MED4&gt;3.0.CO;2-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Birolo L, 1999, BIOCHEMISTRY-US, V38, P905, DOI 10.1021/bi981467d; BLOCK E, 1992, ANGEW CHEM INT EDIT, V31, P1135, DOI 10.1002/anie.199211351; Brandl M, 2001, J MOL BIOL, V307, P357, DOI 10.1006/jmbi.2000.4473; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; Capitani G, 1999, J MOL BIOL, V294, P745, DOI 10.1006/jmbi.1999.3255; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; Denesyuk AI, 2002, J MOL BIOL, V316, P155, DOI 10.1006/jmbi.2001.5310; ELLMORE GS, 1994, AM J BOT, V81, P89, DOI 10.2307/2445567; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krest I, 1999, PHARMAZIE, V54, P289; Kuettner EB, 2002, ARCH BIOCHEM BIOPHYS, V402, P192, DOI 10.1016/S0003-9861(02)00088-7; Louie GV, 1997, MOL CELL, V1, P67, DOI 10.1016/S1097-2765(00)80008-8; Matsui I, 2000, J BIOL CHEM, V275, P4871, DOI 10.1074/jbc.275.7.4871; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Schneider G, 2000, STRUCT FOLD DES, V8, pR1, DOI 10.1016/S0969-2126(00)00085-X; Shimon LJW, 2002, ACTA CRYSTALLOGR D, V58, P1335, DOI 10.1107/S0907444902010466; Siegel G, 1999, Wien Med Wochenschr, V149, P217; STOLL A, 1947, EXPERIENTIA, V3, P114; Tchernychev B, 2000, IMMUNOL LETT, V71, P43, DOI 10.1016/S0165-2478(99)00162-5; TSAI Y, 1985, PLANTA MED, V51, P460, DOI 10.1055/s-2007-969553; VANDAMME EJM, 1992, EUR J BIOCHEM, V209, P751	29	54	58	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46402	46407		10.1074/jbc.M208669200	http://dx.doi.org/10.1074/jbc.M208669200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235163	hybrid			2022-12-27	WOS:000179529300091
J	Sirangelo, I; Malmo, C; Casillo, M; Mezzogiorno, A; Papa, M; Irace, G				Sirangelo, I; Malmo, C; Casillo, M; Mezzogiorno, A; Papa, M; Irace, G			Tryptophanyl substitutions in apomyoglobin determine protein aggregation and amyloid-like fibril formation at physiological pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL-CHARACTERIZATION; THERMODYNAMIC STABILITY; FAMILIAL AMYLOIDOSIS; MYOGLOBIN; INTERMEDIATE; MODEL; FIBRILLOGENESIS; CONFORMATIONS; MICROSCOPY; DISEASES	Myoglobin is an a-helical globular protein that contains two highly conserved tryptophan residues located at positions 7 and 14 in the N-terminal region of the protein. Replacement of both indole residues with phenylalanine residues, i.e. W7F/W14F, results in the expression of an unstable, not correctly folded protein that does not bind the prosthetic group. Here we report data (Congo red and thioflavine T binding assay, birefringence, and electron microscopy) showing that the double Trp/Phe replacements render apomyoglobin molecules highly susceptible to aggregation and amyloid-like fibril formation under physiological conditions in which most of the wild-type protein is in the native state. In refolding experiments, like the wild-type protein, the W7F/W14F apomyoglobin mutant formed a soluble, partially folded helical state between pH 2.0 and pH 4.0. A pH increase from 4.0 to 7.0 restored the native structure only in the case of the wild-type protein and determined aggregation of W7F/W14F. The circular dichroism spectrum recorded immediately after neutralization showed that the polypeptide consists mainly of P-structures. In conclusion, under physiological pH conditions, some mutations that affect folding may cause protein aggregation and the formation of amyloid-like fibrils.	Univ Naples 2, Dipartimento Biochim & Biofis, I-80138 Naples, Italy; Univ Naples 2, Dipartimento Med Pubbl Anat, I-80138 Naples, Italy	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	Irace, G (corresponding author), Univ Naples 2, Dipartimento Biochim & Biofis, Via L De Crecchio 7, I-80138 Naples, Italy.	gaetano.irace@unina2.it	Papa, Michele/A-7228-2017; Papa, Michele/AAB-1759-2021	Papa, Michele/0000-0003-4834-7970; Papa, Michele/0000-0002-6609-7453; Sirangelo, Ivana/0000-0002-6408-4990				Babu KR, 2000, BIOCHEMISTRY-US, V39, P14702, DOI 10.1021/bi001265t; BISMUTO E, 1992, ARCH BIOCHEM BIOPHYS, V298, P624, DOI 10.1016/0003-9861(92)90458-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen CD, 2001, EMBO J, V20, P6277, DOI 10.1093/emboj/20.22.6277; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Damaschun G, 2000, PROTEINS, V39, P204, DOI 10.1002/(SICI)1097-0134(20000515)39:3<204::AID-PROT20>3.0.CO;2-8; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Eliezer D, 1998, NAT STRUCT BIOL, V5, P148; Eliezer D, 1996, J MOL BIOL, V263, P531, DOI 10.1006/jmbi.1996.0596; EVANS SV, 1988, J BIOL CHEM, V263, P4263; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Gilmanshin R, 1997, PROTEIN SCI, V6, P2134; GOTO Y, 1990, J MOL BIOL, V214, P803, DOI 10.1016/0022-2836(90)90334-I; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; HUGHSON FM, 1989, BIOCHEMISTRY-US, V28, P4415, DOI 10.1021/bi00436a044; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; Inouye H, 2000, J STRUCT BIOL, V130, P123, DOI 10.1006/jsbi.2000.4258; Jamin M, 1998, J MOL BIOL, V276, P491, DOI 10.1006/jmbi.1997.1543; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; Jimenez JL, 1999, EMBO J, V18, P815, DOI 10.1093/emboj/18.4.815; Kay MS, 1996, NAT STRUCT BIOL, V3, P439, DOI 10.1038/nsb0596-439; Kazmirski SL, 2002, NAT STRUCT BIOL, V9, P112, DOI 10.1038/nsb745; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Lim A, 2000, J STRUCT BIOL, V130, P363, DOI 10.1006/jsbi.2000.4272; MISSMAHL HP, 1968, AMYLOIDOSIS, P22; NAIKI H, 1991, LAB INVEST, V65, P104; Pappu RV, 1998, PROTEIN SCI, V7, P480; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Samuel D, 2001, J BIOL CHEM, V276, P4134, DOI 10.1074/jbc.M005921200; SIRANGELO I, 1994, FEBS LETT, V338, P11, DOI 10.1016/0014-5793(94)80107-X; Sirangelo I, 2000, EUR J BIOCHEM, V267, P3937, DOI 10.1046/j.1432-1327.2000.01401.x; Sirangelo I, 1998, BBA-PROTEIN STRUCT M, V1385, P69, DOI 10.1016/S0167-4838(98)00038-7; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; TAN SY, 1994, HISTOPATHOLOGY, V25, P403, DOI 10.1111/j.1365-2559.1994.tb00001.x; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; TIRADORIVES J, 1993, BIOCHEMISTRY-US, V32, P4175, DOI 10.1021/bi00067a004; Tjernberg LO, 1999, J BIOL CHEM, V274, P12619, DOI 10.1074/jbc.274.18.12619; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; West MW, 1999, P NATL ACAD SCI USA, V96, P11211, DOI 10.1073/pnas.96.20.11211; Westermark P, 1999, AMYLOID, V6, P151, DOI 10.3109/13506129909007319; YANG JT, 1986, METHOD ENZYMOL, V130, P208	50	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45887	45891		10.1074/jbc.M207659200	http://dx.doi.org/10.1074/jbc.M207659200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244112	hybrid			2022-12-27	WOS:000179529300024
J	Cooper, CD; Lampe, PD				Cooper, CD; Lampe, PD			Casein kinase 1 regulates connexin-43 gap junction assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INTERCELLULAR COMMUNICATION; INTRACELLULAR TRAFFICKING; TYROSINE PHOSPHORYLATION; CARDIAC MYOCYTES; CELLS; INHIBITION; TURNOVER; SITES; LOCALIZATION	Phosphorylation of members of the connexin family of gap junction proteins has been correlated with gap junction assembly, but the mechanisms involved remain unclear. We have examined the role of casein kinase 1 (CKI) in connexin-43 (Cx43) gap junction assembly. Cellular co-immunoprecipitation experiments and in vitro CK1 phosphorylation reactions indicate that CK1 interacted with and phosphorylated Cx43, initially on serine(s) 325, 328, or 330. P-32(i)-Metabolically labeled cells treated with CKI-7, a specific CK1 inhibitor, showed a reduction in Cx43 phosphorylation on site(s) that can be phosphorylated by CK1 in vitro. To examine CK1 function, normal rat kidney cells were treated with CKI-7, and Cx43 content was analyzed by Triton X-100 extraction, cell-surface biotinylation, and immunofluorescence. Western blot analysis indicated a slight increase in total Cx43, whereas gap junctional (Triton-insoluble) Cx43 decreased, and non-junctional plasma membrane Cx43 increased (as detected by cell surface biotinylation). Immunofluorescence experiments in the presence of CK1 inhibitor showed increases in Cx43 plasma membrane localization but not necessarily accumulation at cell-cell interfaces. Decreased gap junctional and phosphorylated Cx43 was also detected when cells were treated with IC261, a CKI inhibitor specific for 6 or E isoforms. These data suggest CK1delta could regulate Cx43 gap junction assembly by directly phosphorylating Cx43.	Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lampe, PD (corresponding author), Univ Washington, Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,DE-320, Seattle, WA 98109 USA.	plampe@fhcrc.org			NIGMS NIH HHS [GM55632, R01 GM055632] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055632] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beardslee MA, 1998, CIRC RES, V83, P629, DOI 10.1161/01.RES.83.6.629; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Behrend L, 2000, EUR J CELL BIOL, V79, P240, DOI 10.1078/S0171-9335(04)70027-8; CARTER AN, 1997, CURRENT PROTOCOLS MO, V2; Chen CY, 2000, SEX TRANSM DIS, V27, P21, DOI 10.1097/00007435-200001000-00005; Cheng HL, 1999, EUR J BIOCHEM, V263, P276, DOI 10.1046/j.1432-1327.1999.00502.x; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; Cooper CD, 2000, METHODS, V20, P196, DOI 10.1006/meth.1999.0937; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; Decottignies A, 1999, J BIOL CHEM, V274, P37139, DOI 10.1074/jbc.274.52.37139; DESOUSA PA, 1993, DEVELOPMENT, V117, P1355; FILSON AJ, 1990, CELL GROWTH DIFFER, V1, P661; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; Grietzen KF, 1999, J BIOL CHEM, V274, P32063, DOI 10.1074/jbc.274.45.32063; Gross SD, 1997, J CELL SCI, V110, P3083; Jordan K, 1999, MOL BIOL CELL, V10, P2033, DOI 10.1091/mbc.10.6.2033; Kanemitsu MY, 1998, CELL GROWTH DIFFER, V9, P13; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; LAIRD DW, 1991, BIOCHEM J, V273, P67, DOI 10.1042/bj2730067; LAIRD DW, 1995, J CELL BIOL, V131, P1193, DOI 10.1083/jcb.131.5.1193; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Lampe PD, 1998, GAP JUNCTIONS, P249; Lampe PD, 1998, J CELL SCI, V111, P833; LAMPE PD, 1994, J CELL BIOL, V127, P1895, DOI 10.1083/jcb.127.6.1895; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; McKay RM, 2001, DEV BIOL, V235, P378, DOI 10.1006/dbio.2001.0307; Murakami A, 1999, J BIOL CHEM, V274, P3804, DOI 10.1074/jbc.274.6.3804; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1990, J MEMBRANE BIOL, V116, P163, DOI 10.1007/BF01868674; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Robinson LC, 1999, MOL BIOL CELL, V10, P1077, DOI 10.1091/mbc.10.4.1077; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; TenBroek EM, 2001, J CELL BIOL, V155, P1307, DOI 10.1083/jcb.200102017; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Warn-Cramer BJ, 1998, J BIOL CHEM, V273, P9188, DOI 10.1074/jbc.273.15.9188; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Yasojima K, 2000, BRAIN RES, V865, P116, DOI 10.1016/S0006-8993(00)02200-9; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	48	159	164	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44962	44968		10.1074/jbc.M209427200	http://dx.doi.org/10.1074/jbc.M209427200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12270943	hybrid			2022-12-27	WOS:000179404800049
J	Li, SS; Smerdon, MJ				Li, SS; Smerdon, MJ			Nucleosome structure and repair of N-methylpurines in the GAL1-10 genes of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; CHROMATIN STRUCTURE; REGULATORY PROTEIN; METHYLATION DAMAGE; NUCLEOTIDE LEVEL; CONTROL REGION; HUMAN-CELLS; DNA-DAMAGE; YEAST	Nucleosome structure and repair of N-methylpurines were analyzed at nucleotide resolution in the divergent GAL1-10 genes of intact yeast cells, encompassing their common upstream-activating sequence. In glucose cultures where genes are repressed, nucleosomes with fixed positions exist in regions adjacent to the upstream-activating sequence, and the variability of nucleosome positioning sharply increases with increasing distance from this sequence. Galactose induction causes nucleosome disruption throughout the region analyzed, with those nucleosomes close to the upstream-activating sequence being most striking. In glucose cultures, a strong correlation between N-methylpurine repair and nucleosome positioning was seen in nucleosomes with fixed positions, where slow and fast repair occurred in nucleosome core and linker DNA, respectively. Galactose induction enhanced N-methylpurine repair in both strands of nucleosome core DNA, being most dramatic in the clearly disrupted, fixed nucleosomes. Furthermore, N-methylpurines are repaired primarily by the Mag1-initiated base excision repair pathway, and nucleotide excision repair contributes little to repair of these lesions. Finally, N-methylpurine repair is significantly affected by nearest-neighbor nucleotides, where fast and slow repair occurred in sites between pyrimidines and purines, respectively. These results indicate that nucleosome positioning and DNA sequence significantly modulate Mag1-initiated base excision repair in intact yeast cells.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA	Washington State University	Smerdon, MJ (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.		Li, Shisheng/H-9126-2012		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004106] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04106] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bash R, 2001, PROG NUCLEIC ACID RE, V65, P197; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P3608, DOI 10.1073/pnas.75.8.3608; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; Grunberger D., 1983, MOL BIOL MUTAGENS CA, P55; Hanawalt PC, 2001, MUTAT RES-DNA REPAIR, V485, P3, DOI 10.1016/S0921-8777(00)00071-9; KUO MT, 1978, NATURE, V271, P83, DOI 10.1038/271083a0; Li SS, 1996, CARCINOGENESIS, V17, P1549, DOI 10.1093/carcin/17.8.1549; Li SS, 2000, METHODS, V22, P170, DOI 10.1006/meth.2000.1058; Li SS, 1999, J BIOL CHEM, V274, P12201, DOI 10.1074/jbc.274.18.12201; LOHR D, 1987, J BIOL CHEM, V262, P15589; LOHR D, 1984, NUCLEIC ACIDS RES, V12, P8457, DOI 10.1093/nar/12.22.8457; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MCGHEE JD, 1979, P NATL ACAD SCI USA, V76, P2133, DOI 10.1073/pnas.76.5.2133; Memisoglu A, 2000, J BACTERIOL, V182, P2104, DOI 10.1128/JB.182.8.2104-2112.2000; Miao F, 2000, J BIOL CHEM, V275, P28433, DOI 10.1074/jbc.M001064200; MOORE CW, 1988, CANCER RES, V48, P6837; PIEPER RO, 1998, DNA DAMAGE REPAIR, V2, P199; POSNICK LM, 1999, MUTAT RES, V257, P127; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; RYAN AJ, 1986, CARCINOGENESIS, V7, P1497, DOI 10.1093/carcin/7.9.1497; Sambrook J., 2002, MOL CLONING LAB MANU; SCICCHITANO DA, 1989, P NATL ACAD SCI USA, V86, P3050, DOI 10.1073/pnas.86.9.3050; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SIDIK K, 1990, CANCER RES, V50, P1613; SLATER ML, 1973, J BACTERIOL, V113, P263, DOI 10.1128/JB.113.1.263-270.1973; Smith SA, 2000, NUCLEIC ACIDS RES, V28, P3294, DOI 10.1093/nar/28.17.3294; SOLOMON LR, 1989, BIOCHEMISTRY-US, V28, P9932, DOI 10.1021/bi00452a009; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; THOMAS L, 1982, BIOCHEMISTRY-US, V21, P1162, DOI 10.1021/bi00535a009; vanHolde K.E, 1989, CHROMATIN, P289; WOLFFE AP, 1999, CHROMATIN STRUCTURE, P7; Xiao W, 1998, CURR GENET, V33, P92, DOI 10.1007/s002940050313; Xiao W, 2001, MUTAT RES-DNA REPAIR, V487, P137, DOI 10.1016/S0921-8777(01)00113-6; Ye N, 1998, J MOL BIOL, V284, P269, DOI 10.1006/jmbi.1998.2138; Zheng WJ, 1997, J BIOL CHEM, V272, P30350, DOI 10.1074/jbc.272.48.30350	38	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44651	44659		10.1074/jbc.M206623200	http://dx.doi.org/10.1074/jbc.M206623200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244104	hybrid			2022-12-27	WOS:000179404800009
J	Liu, F; Virshup, DM; Nairn, AC; Greengard, P				Liu, F; Virshup, DM; Nairn, AC; Greengard, P			Mechanism of regulation of casein kinase I activity by group I metabotropic glutamate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ALZHEIMERS-DISEASE; STRIATAL NEURONS; PHOSPHORYLATION; DOPAMINE; DARPP-32; EPSILON; PHOSPHOPROTEIN; CLONING; FAMILY	Previously, we reported that (S)-3,5-dihydroxypenyl-glycine (DHPG), an agonist for group I metabotropic glutamate receptors (mGluRs), stimulates CK1 and Cdk5 kinase activities in neostriatal neurons, leading to enhanced phosphorylation, respectively, of Ser-137 and Thr-75 of DARPP-32 (dopamine and cAMP-regulated phosphoprotein, (32) under bar kDa). We have now investigated the signaling pathway that leads from mGluRs to casein kinase 1 (CK1) activation. In mouse neostriatal slices, the effect of DHPG on phosphorylation of Ser-137 or Thr-75 of DARPP-32 was blocked by the phospholipase Cbeta inhibitor U73122, the Ca2+ chelator 1,2-bis(2-amino-phenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA/AM), and the calcineurin inhibitor cyclosporin A. In neuroblastoma N2a cells, the effect of DHPG on the activity of transfected RA-tagged CK1epsilon was blocked by BAPTA/AM and cyclosporin A. In neostriatal slices, the effect of DHPG on Cdk5 activity was also abolished by BAPTA/AM and cyclosporin A, presumably through blocking activation of CK1. Metabolic labeling studies and phosphopeptide mapping revealed that a set of C-terminal sites in HA-CK1epsilon were transiently dephosphorylated in N2a cells upon treatment with DHPG, and this was blocked by cyclosporin A. A mutant CK1epsilon with a nonphosphorylatable C-terminal domain was not activated by DHPG. Together, these studies suggest that DHPG activates CK1epsilon via Ca2+-dependent stimulation of calcineurin and subsequent dephosphorylation of inhibitory C-terminal autophosphorylation sites.	Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Univ Utah, Dept Pediat, Div Hematol Oncol, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Yale Univ, Dept Psychiat, New Haven, CT 06520 USA	Rockefeller University; Utah System of Higher Education; University of Utah; Yale University	Nairn, AC (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, 1230 York Ave, New York, NY 10021 USA.	nairn@mail.rockefeller.edu	Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X; Nairn, Angus/0000-0002-7075-0195	NATIONAL CANCER INSTITUTE [P01CA073992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060387] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA073992-06A10004] Funding Source: Medline; NIGMS NIH HHS [R01 GM060387-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Budd DC, 2000, J BIOL CHEM, V275, P19667, DOI 10.1074/jbc.M000492200; Cartmell J, 1998, BRAIN RES, V791, P191, DOI 10.1016/S0006-8993(98)00094-8; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; DESDOUITS F, 1995, P NATL ACAD SCI USA, V92, P2682, DOI 10.1073/pnas.92.7.2682; DESDOUITS F, 1995, J BIOL CHEM, V270, P8772, DOI 10.1074/jbc.270.15.8772; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Eide EJ, 2001, CHRONOBIOL INT, V18, P389, DOI 10.1081/CBI-100103963; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Ghoshal N, 1999, AM J PATHOL, V155, P1163, DOI 10.1016/S0002-9440(10)65219-4; GOTO S, 1986, BRAIN RES, V397, P161, DOI 10.1016/0006-8993(86)91381-8; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Grietzen KF, 1999, J BIOL CHEM, V274, P32063, DOI 10.1074/jbc.274.45.32063; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; Hermans E, 2001, BIOCHEM J, V359, P465, DOI 10.1042/0264-6021:3590465; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Kuret J, 1997, J NEUROCHEM, V69, P2506; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu F, 2001, P NATL ACAD SCI USA, V98, P11062, DOI 10.1073/pnas.191353898; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Nishi A, 1997, J NEUROSCI, V17, P8147; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Paolillo M, 1998, EUR J NEUROSCI, V10, P1937, DOI 10.1046/j.1460-9568.1998.00203.x; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Rivers A, 1998, J BIOL CHEM, V273, P15980, DOI 10.1074/jbc.273.26.15980; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Sallese M, 2000, BBA-MOL CELL RES, V1498, P112, DOI 10.1016/S0167-4889(00)00088-4; Schwab C, 2000, NEUROBIOL AGING, V21, P503, DOI 10.1016/S0197-4580(00)00110-X; Takano A, 2000, FEBS LETT, V477, P106, DOI 10.1016/S0014-5793(00)01755-5; Tobin AB, 1997, J BIOL CHEM, V272, P20844, DOI 10.1074/jbc.272.33.20844; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X	39	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45393	45399		10.1074/jbc.M204499200	http://dx.doi.org/10.1074/jbc.M204499200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223474	hybrid, Green Accepted			2022-12-27	WOS:000179404800102
J	Zeng, MS; Kumar, A; Meng, GY; Gao, QS; Dimri, G; Wazer, D; Band, H; Band, V				Zeng, MS; Kumar, A; Meng, GY; Gao, QS; Dimri, G; Wazer, D; Band, H; Band, V			Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; ACUTE PROMYELOCYTIC LEUKEMIA; P53 ACTIVITY; PROTEIN; TYPE-16; COMPLEX; DIFFERENTIATION; CANCER; GENE; ACTIVATION	The expression of human papillomavirus (HPV) E6 oncoprotein is causally linked to high-risk HPV-associated human cancers. We have recently isolated hADA3, the human homologue of yeast transcriptional co-activator yADA3, as a novel E6 target. Human ADA3 binds to the high-risk (cancer-associated) but not the low-risk HPV E6 proteins and to immortalization-competent but not to immortalization-defective HPV16 E6 mutants, suggesting a role for the perturbation of hADA3 function in E6-mediated oncogenesis. We demonstrate here that hADA3 directly binds to the retinoic X receptor (RXR)alpha in vitro and in vivo. Using chromatin immuno-precipitation, we show that hADA3 is part of activator complexes bound to the native RXR response elements within the promoter of the cyclin-dependent kinase inhibitor gene p21. We show that hADA3 enhances the RYRalpha-mediated sequence-specific transactivation of retinoid target genes, cellular retinoic acid-binding protein II and p21. Significantly, we demonstrate that E6 inhibits the RYRalpha-mediated transactivation. of target genes, implying that perturbation of RXR-mediated transactivation by E6 could contribute to HPV oncogenesis.	Tufts Univ New England Med Ctr, Dept Radiat Oncol, Div Radiat & Canc Biol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA	Tufts Medical Center; Tufts University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Band, V (corresponding author), Tufts Univ New England Med Ctr, Dept Radiat Oncol, Div Radiat & Canc Biol, Box 824,750 Washington St, Boston, MA 02111 USA.		Dimri, Goberdhan/AAO-4210-2021	zeng, musheng/0000-0003-3509-5591	NCI NIH HHS [CA81076, CA70195, CA87986, CA75075, CA76118] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087986, R01CA081076, R01CA075075, R01CA070195, R01CA076118] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; Benecke A, 2002, NUCLEIC ACIDS RES, V30, P2508, DOI 10.1093/nar/30.11.2508; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Christova R, 2002, NAT CELL BIOL, V4, P79, DOI 10.1038/ncb733; Degenhardt YY, 2001, J VIROL, V75, P151, DOI 10.1128/JVI.75.1.151-160.2001; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; Emerson BM, 2002, CELL, V109, P267, DOI 10.1016/S0092-8674(02)00740-7; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537; Henriksson A, 1997, MOL CELL BIOL, V17, P3065, DOI 10.1128/MCB.17.6.3065; HILL DL, 1992, ANNU REV NUTR, V12, P161, DOI 10.1146/annurev.nu.12.070192.001113; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Kumar A, 2002, MOL CELL BIOL, V22, P5801, DOI 10.1128/MCB.22.16.5801-5812.2002; Kung AL, 2000, GENE DEV, V14, P272; Kurie Jonathan M., 1999, Current Opinion in Oncology, V11, P497, DOI 10.1097/00001622-199911000-00011; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LOTAN R, 1994, CANCER RES, V54, pS1987; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; MUNGER K, 1989, J VIROL, V63, P4417; ODWYER PJ, 1987, J SURG RES, V43, P550, DOI 10.1016/0022-4804(87)90130-2; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998; Peng YC, 2001, MOL CELL BIOL, V21, P5913, DOI 10.1128/MCB.21.17.5913-5924.2001; Ratsch SB, 2001, RADIAT RES, V155, P143, DOI 10.1667/0033-7587(2001)155[0143:MGCARF]2.0.CO;2; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; SAMBROOK J, 1989, MOL CLONING LABORATO, V7, P43; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; vom Baur E, 1998, GENE DEV, V12, P1278, DOI 10.1101/gad.12.9.1278; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Wang T, 2001, EMBO J, V20, P6404, DOI 10.1093/emboj/20.22.6404; WAZER DE, 1994, MOL CELL BIOL, V14, P2468, DOI 10.1128/MCB.14.4.2468; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; Yamada O, 1998, LEUKEMIA RES, V22, P711, DOI 10.1016/S0145-2126(98)00065-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang DM, 2000, J CELL PHYSIOL, V185, P1, DOI 10.1002/1097-4652(200010)185:1<1::AID-JCP1>3.0.CO;2-O; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; zur Hausen H, 1999, EUR J CANCER, V35, P1878, DOI 10.1016/S0959-8049(99)00291-9	49	55	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45611	45618		10.1074/jbc.M208447200	http://dx.doi.org/10.1074/jbc.M208447200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235159	hybrid			2022-12-27	WOS:000179404800127
J	Kolodziejczak, M; Kolaczkowska, A; Szczesny, B; Urantowka, A; Knorpp, C; Kieleczawa, J; Janska, H				Kolodziejczak, M; Kolaczkowska, A; Szczesny, B; Urantowka, A; Knorpp, C; Kieleczawa, J; Janska, H			A higher plant mitochondrial homologue of the yeast m-AAA protease - Molecular cloning, localization, and putative function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; INNER MEMBRANE; SACCHAROMYCES-CEREVISIAE; FTSH PROTEASE; PROTEINS; CHLOROPLAST; DEGRADATION; MUTATIONS; METALLOPROTEASE; ARABIDOPSIS	Mitochondrial AAA metalloproteases play a fundamental role in mitochondrial biogenesis and function. They have been identified in yeast and animals but not yet in plants. This work describes the isolation and sequence analysis of the full-length cDNA from the pea (Pisum sativum) with significant homology to the yeast matrix AAA (m-AAA) protease. The product of this clone was imported into isolated pea mitochondria where it was processed to its mature form (PsFtsH). We have shown that the central region of PsFtsH containing the chaperone domain is exposed to the matrix space. Furthermore, we have demonstrated that the pea protease can complement respiration deficiency in the yta10 and/or yta12 null yeast mutants, indicating that the plant protein can compensate for the loss of at least some of the important m-AAA functions in yeast. Based on biochemical experiments using isolated pea mitochondria, we propose that PsFtsH-like m-AAA is involved in the accumulation of the subunit 9 of the ATP synthase in the mitochondrial membrane.	Wroclaw B Beirut Univ, Inst Biochem & Mol Biol, PL-50137 Wroclaw, Poland; Swedish Univ Agr Sci, Dept Plant Biol, S-75007 Uppsala, Sweden; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	University of Wroclaw; Swedish University of Agricultural Sciences; United States Department of Energy (DOE); Brookhaven National Laboratory	Janska, H (corresponding author), Wroclaw B Beirut Univ, Inst Biochem & Mol Biol, Tamka 2, PL-50137 Wroclaw, Poland.		Szczesny, Bartosz/D-1026-2012	Janska, Hanna/0000-0002-6542-343X; Urantowka, Adam/0000-0003-1144-0549				Adam Z, 2001, BIOCHEM SOC T, V29, P427, DOI 10.1042/BST0290427; Adam Z, 2001, PLANT PHYSIOL, V125, P1912, DOI 10.1104/pp.125.4.1912; Arlt H, 1998, EMBO J, V17, P4837, DOI 10.1093/emboj/17.16.4837; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; Chen M, 2000, PLANT J, V22, P303, DOI 10.1046/j.1365-313x.2000.00738.x; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gietz R.D., 1994, MOL GENETICS YEAST P, P121; HAKANSSON G, 1988, THEOR APPL GENET, V76, P431, DOI 10.1007/BF00265345; Juhola MK, 2000, FEBS LETT, V481, P91, DOI 10.1016/S0014-5793(00)01989-X; Kaser M, 2000, SEMIN CELL DEV BIOL, V11, P181, DOI 10.1006/scdb.2000.0166; Klanner C, 2001, MOL BIOL CELL, V12, P2858, DOI 10.1091/mbc.12.9.2858; KNORPP C, 1995, BIOCHEM J, V310, P527, DOI 10.1042/bj3100527; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Leonhard K, 1999, NATURE, V398, P348, DOI 10.1038/18704; Lindahl M, 1996, J BIOL CHEM, V271, P29329, DOI 10.1074/jbc.271.46.29329; MICHON T, 1988, EUR J BIOCHEM, V172, P621, DOI 10.1111/j.1432-1033.1988.tb13934.x; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; PAUL MF, 1995, FEBS LETT, V373, P66, DOI 10.1016/0014-5793(95)00979-J; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schumann W, 1999, FEMS MICROBIOL REV, V23, P1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Steglich G, 1999, MOL CELL BIOL, V19, P3435; SZCZEPANIAK A, 1990, J BIOL CHEM, V265, P17720; VERHEUL FEAM, 1981, EUR J BIOCHEM, V119, P401, DOI 10.1111/j.1432-1033.1981.tb05622.x; WHELAN J, 1991, PLANT MOL BIOL, V16, P283, DOI 10.1007/BF00020559; Young L, 2001, SCIENCE, V291, P2135, DOI 10.1126/science.1056957; Zhang LX, 1999, J BIOL CHEM, V274, P16062, DOI 10.1074/jbc.274.23.16062	31	24	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43792	43798		10.1074/jbc.M203831200	http://dx.doi.org/10.1074/jbc.M203831200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228240	hybrid			2022-12-27	WOS:000179272000035
J	Roos-Mattjus, P; Vroman, BT; Burtelow, MA; Rauen, M; Eapen, AK; Karnitz, LM				Roos-Mattjus, P; Vroman, BT; Burtelow, MA; Rauen, M; Eapen, AK; Karnitz, LM			Genotoxin-induced Rad9-Hus1-Rad1 (9-1-1) chromatin association is an early checkpoint signaling event	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; PROTEIN-KINASE; RADIOSENSITIZING AGENT; SLIDING CLAMP; HUMAN RAD9; ATM; CAFFEINE; COMPLEX; REPLICATION; PHOSPHORYLATION	Rad17, Rad1, Hus1, and Rad9 are key participants in checkpoint signaling pathways that block cell cycle progression in response to genotoxins. Biochemical and molecular modeling data predict that Rad9, Hus1, and Rad1 form a heterotrimeric complex, dubbed 9-1-1, which is loaded onto chromatin by a complex of Rad17 and the four small replication factor C (RFC) subunits (Rad17-RFC) in response to DNA damage. It is unclear what checkpoint proteins or checkpoint signaling events regulate the association of the 9-1-1 complex with DNA. Here we show that genotoxin-induced chromatin binding of 9-1-1 does not require the Rad9-inducible phosphorylation site (Ser-272). Although we found that Rad9 undergoes an additional phosphatidylinositol 3-kinase-related kinase (PIKK)-dependent posttranslational modification, we also show that genotoxin-triggered 9-1-1 chromatin binding does not depend on the catalytic activity of the PIKKs ataxia telangiectasia-mutated (ATM), ataxia telangiectasia and Rad3-related (ATR), or DNA-PK. Additionally, 9-1-1 chromatin binding does not require DNA replication, suggesting that the complex can be loaded onto DNA in response to DNA structures other than stalled DNA replication forks. Collectively, these studies demonstrate that 9-1-1 chromatin binding is a proximal event in the checkpoint signaling cascade.	Mayo Clin & Mayo Fdn, Div Dev Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Radiat Oncol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Karnitz, LM (corresponding author), Mayo Clin & Mayo Fdn, Div Dev Oncol Res, Guggenheim 13,200 1st St SW, Rochester, MN 55905 USA.			Roos-Mattjus, Pia/0000-0002-7187-2012	NCI NIH HHS [R01-CA84321] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084321] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Eapen AK, 2001, MOL CELL BIOL, V21, P6113, DOI 10.1128/MCB.21.18.6113-6121.2001; Griffith JD, 2002, J BIOL CHEM, V277, P15233, DOI 10.1074/jbc.C200129200; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Kaur R, 2001, MOL BIOL CELL, V12, P3744, DOI 10.1091/mbc.12.12.3744; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; Oakley GG, 2001, MOL BIOL CELL, V12, P1199, DOI 10.1091/mbc.12.5.1199; Rhind N, 2000, J CELL SCI, V113, P3889; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; St Onge RP, 2001, J BIOL CHEM, V276, P41898, DOI 10.1074/jbc.M105152200; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	30	71	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43809	43812		10.1074/jbc.M207272200	http://dx.doi.org/10.1074/jbc.M207272200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228248	hybrid			2022-12-27	WOS:000179272000037
J	Loo, TW; Bartlett, MC; Clarke, DM				Loo, TW; Bartlett, MC; Clarke, DM			The "LSGGQ" motif in each nucleotide-binding domain of human P-glycoprotein is adjacent to the opposing Walker A sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATPASE ACTIVITY; DISULFIDE CROSS-LINKING; TRANSMEMBRANE SEGMENTS; CRYSTAL-STRUCTURE; ABC TRANSPORTER; DRUG-BINDING; SITES; CYSTEINE; RESIDUES; MUTANTS	The human multidrug resistance P-glycoprotein (P-gp, ABCB1), a member of the ATP-binding cassette (ABC) family of transport proteins, actively transports many cytotoxic compounds out of the cell. ABC transporters have two nucleotide-binding domains (NBD) and two transmembrane domains. The presence of the conserved "signature" sequence (LSGGQ) in each NBD is a unique feature in these transporters. The function of the signature sequences is unknown. In this study, we tested whether the signature sequences ((531)LSGGQ(535) in NBD1; (1176)LSGGQ(1180) in NBD2) in P-gp are in close proximity to the opposing Walker A consensus nucleotide-binding sequences ((1070)GSSGCGKS(1077) in NBD2; (427)GNS- GCGKS(434) in NBD1). Pairs of cysteines were introduced into a Cys-less P-gp at the signature and "Walker A" sites and the mutant P-gps were subjected to oxidative cross-linking. At 4 degreesC, when thermal motion is low, P-gp mutants (L531C(Signature)/C1074(Walker A) and C431(Walker A)/L1176C (Signature) were cross-linked. Cross-linking inhibited the drug-stimulated ATPase activities of these two mutants. Their activities were restored, however, after addition of the reducing agent, dithiothreitol. Vanadate trapping of nucleotide at the ATP-binding sites prevented cross-linking of the mutants. These results indicate that the signature sequences are adjacent to the opposing Walker A site. They likely participate in forming the ATP-binding sites and are displaced upon ATP hydrolysis. The resulting conformational change may be the signal responsible for coupling ATP hydrolysis to drug transport by inducing conformational changes in the transmembrane segments.	Univ Toronto, Dept Med, Canadian Inst Hlth Res, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Canadian Inst Hlth Res, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada	Institute for Work & Health; University of Toronto; Institute for Work & Health; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth Res, Grp Membrane Biol, 100 Coll St, Toronto, ON M5S 1A8, Canada.	david.clarke@utoronto.ca	Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER; NCI NIH HHS [CA80900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; Loo TW, 2000, JNCI-J NATL CANCER I, V92, P898, DOI 10.1093/jnci/92.11.898; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Urbatsch IL, 2000, J BIOL CHEM, V275, P25031, DOI 10.1074/jbc.M003962200; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Urbatsch IL, 2001, J BIOL CHEM, V276, P26980, DOI 10.1074/jbc.M010829200; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	35	136	138	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41303	41306		10.1074/jbc.C200484200	http://dx.doi.org/10.1074/jbc.C200484200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12226074	hybrid			2022-12-27	WOS:000178985300003
J	Hektor, HJ; Kloosterman, H; Dijkhuizen, L				Hektor, HJ; Kloosterman, H; Dijkhuizen, L			Identification of a magnesium-dependent NAD(P)(H)-binding domain in the nicotinoprotein methanol dehydrogenase from Bacillus methanolicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-FRUCTOSE OXIDOREDUCTASE; ELECTRON-MICROSCOPIC ANALYSIS; ALCOHOL-DEHYDROGENASE; ZYMOMONAS-MOBILIS; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; CLOSTRIDIUM-ACETOBUTYLICUM; MOLECULAR CHARACTERIZATION; GENE-CLUSTER; THERMOTOLERANT BACILLUS	The Bacillus methanolicus methanol dehydrogenase (MDH) is a decameric nicotinoprotein alcohol dehydrogenase (family III) with one Zn2+ ion, one or two Mg2+ ions, and a tightly bound cofactor NAD(H) per subunit. The Mg2+ ions are essential for binding of cofactor NAD(H) in MDH. A B. methanolicus activator protein strongly stimulates the relatively low coenzyme NAD(+)-dependent MDH activity, involving hydrolytic removal of the NMN(H) moiety of cofactor NAD(H) (Kloosterman, H., Vrijbloed, J. W., and Dijkhuizen, L. (2002) J. Biol. Chem. 277, 34785-34792). Members of family III of NAD(P)-dependent alcohol dehydrogenases contain three unique, conserved sequence motifs (domains A, B, and C). Domain C is thought to be involved in metal binding, whereas the functions of domains A and B are still unknown. This paper provides evidence that domain A constitutes (part of) a new magnesium-dependent NAD(P)(H)-binding domain. Site-directed mutants D100N and K103R lacked (most of the) bound cofactor NAD(H) and had lost all coenzyme NAD(+)-dependent MDH activity. Also mutants G95A and S97G were both impaired in cofactor NAD(H) binding but retained coenzyme NAD(+)-dependent MDH activity. Mutant G95A displayed a rather low MDH activity, whereas mutant S97G was insensitive to activator protein but displayed "fully activated" MDH reaction rates. The various roles of these amino acid residues in coenzyme and/or cofactor NAD(H) binding in MDH are discussed.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Dijkhuizen, L (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.		Dijkhuizen, Lubbert/E-9454-2014; Dijkhuizen, Lubbert/K-3539-2019	Dijkhuizen, Lubbert/0000-0003-2312-7162				Arfman N, 1997, EUR J BIOCHEM, V244, P426, DOI 10.1111/j.1432-1033.1997.00426.x; ARFMAN N, 1991, J BIOL CHEM, V266, P3955; ARFMAN N, 1989, ARCH MICROBIOL, V152, P280, DOI 10.1007/BF00409664; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; BYSTRYKH LV, 1993, J BACTERIOL, V175, P1814, DOI 10.1128/JB.175.6.1814-1822.1993; CABISCOL E, 1994, J BIOL CHEM, V269, P6592; CHEN YM, 1989, J BACTERIOL, V171, P6097, DOI 10.1128/jb.171.11.6097-6105.1989; CONWAY T, 1987, J BACTERIOL, V169, P2591, DOI 10.1128/jb.169.6.2591-2597.1987; Cue D, 1997, APPL ENVIRON MICROB, V63, P1406, DOI 10.1128/AEM.63.4.1406-1420.1997; DANIEL R, 1995, J BACTERIOL, V177, P2151, DOI 10.1128/jb.177.8.2151-2156.1995; DAUBARAS DL, 1995, APPL ENVIRON MICROB, V61, P1279, DOI 10.1128/AEM.61.4.1279-1289.1995; DEHOOP M, 1991, PROTEIN ENG, V4, P821, DOI 10.1093/protein/4.7.821; DEVRIES GE, 1992, J BACTERIOL, V174, P5346, DOI 10.1128/JB.174.16.5346-5353.1992; Dixon M., 1979, ENZYMES, Vthird; FRICK DN, 1994, J BIOL CHEM, V269, P1794; GOODLOVE PE, 1989, GENE, V85, P209, DOI 10.1016/0378-1119(89)90483-6; HENSGENS CMH, 1993, J BACTERIOL, V175, P2859, DOI 10.1128/JB.175.10.2859-2863.1993; HENSGENS CMH, 1995, ARCH MICROBIOL, V164, P265, DOI 10.1007/BF02529960; JORNVALL H, 1987, EUR J BIOCHEM, V167, P195, DOI 10.1111/j.1432-1033.1987.tb13323.x; KANAGASUNDARAM V, 1992, J BACTERIOL, V174, P1439, DOI 10.1128/jb.174.5.1439-1447.1992; Kingston RL, 1996, STRUCTURE, V4, P1413, DOI 10.1016/S0969-2126(96)00149-9; Kloosterman H, 2002, J BIOL CHEM, V277, P34785, DOI 10.1074/jbc.M205617200; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Li DH, 1997, J BACTERIOL, V179, P4433, DOI 10.1128/jb.179.13.4433-4437.1997; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; NAGY I, 1995, ARCH MICROBIOL, V163, P439, DOI 10.1007/BF00272133; NAIR RV, 1994, J BACTERIOL, V176, P871, DOI 10.1128/jb.176.3.871-885.1994; PERKINS EJ, 1990, J BACTERIOL, V172, P2351, DOI 10.1128/jb.172.5.2351-2359.1990; REID MF, 1994, CRIT REV MICROBIOL, V20, P13, DOI 10.3109/10408419409113545; Ruzheinikov SN, 2001, STRUCTURE, V9, P789, DOI 10.1016/S0969-2126(01)00645-1; Sambrook J., 2002, MOL CLONING LAB MANU; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576; Sohling B, 1996, J BACTERIOL, V178, P871; STOJILJKOVIC I, 1995, J BACTERIOL, V177, P1357, DOI 10.1128/jb.177.5.1357-1366.1995; Tamarit J, 1997, J BACTERIOL, V179, P1102, DOI 10.1128/jb.179.4.1102-1104.1997; VALENTIN HE, 1995, EUR J BIOCHEM, V227, P43, DOI 10.1111/j.1432-1033.1995.tb20358.x; VANDERMEER JR, 1991, J BACTERIOL, V173, P2425, DOI 10.1128/jb.173.8.2425-2434.1991; VONCK J, 1991, J BIOL CHEM, V266, P3949; WALTER KA, 1992, J BACTERIOL, V174, P7149, DOI 10.1128/jb.174.22.7149-7158.1992; Wiegert T, 1997, J BIOL CHEM, V272, P13126, DOI 10.1074/jbc.272.20.13126; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILLIAMSON VM, 1987, MOL GEN GENET, V209, P374, DOI 10.1007/BF00329668; Wong JT, 1975, KINETICS ENZYME MECH; YANG WG, 1994, MOL BIOCHEM PARASIT, V64, P253, DOI 10.1016/0166-6851(93)00020-A; YOUNGLESON JS, 1989, GENE, V78, P355, DOI 10.1016/0378-1119(89)90238-2	51	32	39	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46966	46973		10.1074/jbc.M207547200	http://dx.doi.org/10.1074/jbc.M207547200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351635	hybrid, Green Published			2022-12-27	WOS:000179663700018
J	Lavine, N; Ethier, N; Oak, JN; Pei, L; Liu, F; Trieu, P; Rebois, RV; Bouvier, M; Hebert, TE; Van Tol, HHM				Lavine, N; Ethier, N; Oak, JN; Pei, L; Liu, F; Trieu, P; Rebois, RV; Bouvier, M; Hebert, TE; Van Tol, HHM			G protein-coupled receptors form stable complexes with inwardly rectifying potassium channels and adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; BETA-GAMMA-SUBUNITS; BETA(2)-ADRENERGIC RECEPTOR; SIGNALING COMPLEXES; XENOPUS OOCYTES; K+ CHANNELS; KINASE; TRAFFICKING; ACTIVATION; MEMBRANES	A large number of studies have demonstrated co-purification or co-immunoprecipitation of receptors with G proteins. We have begun to look for the presence of effector molecules in these receptor complexes. Co-expression of different channel and receptor permutations in COS-7 and HEK 293 cells in combination with co-immunoprecipitation experiments established that the dopamine D-2 and D-4, and beta(2)-adrenergic receptors (beta(2)-AR) form stable complexes with Kir3 channels. The D-4/ Kir3 and D-2 receptor/Kir3 interaction does not occur when the channel and receptor are expressed separately and mixed prior to immunoprecipitation, indicating that the interaction is not an artifact of the experimental protocol and reflects a biosynthetic event. The observed complexes are stable in that they are not disrupted by receptor activation or modulation of G protein a subunit function. However, using a peptide that binds Gbetagamma (betaARKct), we show that Gbetagamma is critical for dopamine receptor-Kir3 complex formation, but not for maintenance of the complex. We also provide evidence that Kir3 channels and another effector, adenylyl cyclase, are stably associated with the beta(2)-adrenergic receptor and can be co-immunoprecipitated by anti-receptor antibodies. Using bioluminescence resonance energy transfer, we have shown that in living cells under physiological conditions, beta(2)AR interacts directly with Kir3.1/3.4 and Kir3.1/3.2c heterotetramers as well as with adenylyl cyclase. All of these interactions are stable in the presence of receptor agonists, suggesting that these signaling complexes persist during signal transduction. In addition, we provide evidence that the receptor-effector complexes are also found in vivo. The observation that several G protein-coupled receptors form stable complexes with their effectors suggests that this arrangement might be a general feature of G protein-coupled signal transduction.	Univ Toronto, Ctr Addict & Mental Hlth, Mol Neurobiol Lab, Dept Pharmacol, Toronto, ON M5T 1R8, Canada; Univ Toronto, Inst Med Sci, Dept Psychiat, Toronto, ON M5T 1R8, Canada; Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; NINDS, NIH, Bethesda, MD 20892 USA; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Universite de Montreal	Van Tol, HHM (corresponding author), Univ Toronto, Ctr Addict & Mental Hlth, Mol Neurobiol Lab, Dept Pharmacol, 250 Coll St, Toronto, ON M5T 1R8, Canada.	hubert.van.tol@utoronto.ca	Lavine, Natalie/AAC-9623-2021; Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100; Lavine, Natalie Elisabeth/0000-0003-4897-0092	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002784] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BARSINAI A, 1992, EUR J BIOCHEM, V207, P703, DOI 10.1111/j.1432-1033.1992.tb17098.x; Basi NS, 1996, CELL SIGNAL, V8, P209, DOI 10.1016/0898-6568(95)02056-X; Bray D, 1998, ANNU REV BIOPH BIOM, V27, P59, DOI 10.1146/annurev.biophys.27.1.59; Chan KW, 1997, J BIOL CHEM, V272, P6548, DOI 10.1074/jbc.272.10.6548; Chidiac P, 1998, BIOCHEM PHARMACOL, V55, P549, DOI 10.1016/S0006-2952(97)00361-4; Cong M, 2001, J BIOL CHEM, V276, P15192, DOI 10.1074/jbc.M009130200; Davare MA, 1999, J BIOL CHEM, V274, P30280, DOI 10.1074/jbc.274.42.30280; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Dunigan CD, 2000, METH MOL B, V136, P329; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; Ganpat MM, 2000, CELL SIGNAL, V12, P113, DOI 10.1016/S0898-6568(99)00078-9; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; Helms JB, 1998, J BIOL CHEM, V273, P15203, DOI 10.1074/jbc.273.24.15203; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Husi H, 2001, J NEUROCHEM, V77, P281, DOI 10.1046/j.1471-4159.2001.t01-1-00248.x; Inanobe A, 1999, J NEUROSCI, V19, P1006; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Kennedy ME, 1999, J BIOL CHEM, V274, P2571, DOI 10.1074/jbc.274.4.2571; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P28777, DOI 10.1074/jbc.270.48.28777; Lachance M, 1999, CELL SIGNAL, V11, P523, DOI 10.1016/S0898-6568(99)00024-8; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; NAIR LA, 1995, CIRC RES, V76, P832, DOI 10.1161/01.RES.76.5.832; Oak JN, 2001, MOL PHARMACOL, V60, P92, DOI 10.1124/mol.60.1.92; Oldenhof J, 1998, BIOCHEMISTRY-US, V37, P15726, DOI 10.1021/bi981634+; Rebois RV, 1997, CELL SIGNAL, V9, P141, DOI 10.1016/S0898-6568(96)00133-7; REBOIS RV, 2002, IN PRESS RECEPTORS C; Rehm A, 1997, J CELL BIOL, V137, P305, DOI 10.1083/jcb.137.2.305; Robillard L, 2000, CELL SIGNAL, V12, P673, DOI 10.1016/S0898-6568(00)00118-2; Schoots O, 1999, CELL SIGNAL, V11, P871, DOI 10.1016/S0898-6568(99)00059-5; Stow JL, 1998, BBA-MOL CELL RES, V1404, P161, DOI 10.1016/S0167-4889(98)00055-X; Wellner-Kienitz MC, 2001, J BIOL CHEM, V276, P37347, DOI 10.1074/jbc.M106234200; Werner P, 1996, MOL PHARMACOL, V49, P656; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Yamaguchi T, 2000, FEBS LETT, V470, P25, DOI 10.1016/S0014-5793(00)01284-9; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	41	150	154	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46010	46019		10.1074/jbc.M205035200	http://dx.doi.org/10.1074/jbc.M205035200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12297500	hybrid			2022-12-27	WOS:000179529300041
J	Li, QX; Wang, J; Armant, DR; Bagchi, MK; Bagchi, IC				Li, QX; Wang, J; Armant, DR; Bagchi, MK; Bagchi, IC			Calcitonin down-regulates E-cadherin expression in rodent uterine epithelium during implantation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE EXPRESSION; CELL-ADHESION; JUNCTIONAL COMPLEX; RECEPTOR; RECEPTIVITY; BLASTOCYST; PREGNANCY; UTERUS; ESTABLISHMENT; ENDOMETRIUM	Previous studies indicated that calcitonin (CT), a peptide hormone involved in calcium homeostasis, is transiently expressed in the receptive rat and human endometrial epithelia within the window of implantation. Attenuation of uterine CT expression using antisense methods severely impaired implantation in the rat. The molecular pathway of CT in the pregnant uterus, however, remains unknown. In the present study, we investigated the cellular events following the binding of CT to its membrane receptors in human endometrial epithelial cell line Ishikawa. We observed that CT treatment triggers a transient rise in intracellular calcium in these cells. Most interestingly, CT treatment also led to the disappearance of E-cadherin, a critical cell adhesion molecule, from cell-cell contact sites. Blockade of intracellular calcium release by BAPTA-AM (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl) prevented the CT-induced disappearance of E-cadherin. Our studies further revealed that CT treatment markedly down-regulates the level of E-cadherin mRNA in Ishikawa cells. We also examined whether CT influences the expression of E-cadherin mRNA in intact rat uterine tissue during implantation. In pregnant rats, high levels of E-cadherin mRNA were expressed during the first 3 days of gestation when the CT mRNA in uterine epithelial cells is undetectable. Concomitant with a transient burst of CT expression during days 4-5 of pregnancy, the level of E-cadherin mRNA declined sharply. Furthermore, administration of exogenous CT to animals on day 2 of pregnancy led to a premature suppression of E-cadherin mRNA level on day 3, indicating a direct link between elevated levels of uterine CT and the down-regulation of E-cadherin expression in the surface epithelium. Collectively, our results are consistent with the hypothesis that CT-induced reduction in E-cadherin expression may remodel the adherens junctions between epithelial cells, and this change in epithelial cell phenotype might be a critical event during the implantation of the blastocyst.	Univ Illinois, Dept Vet Biosci, Urbana, IL 61802 USA; Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61802 USA; Wayne State Univ, Sch Med, Dept Obstet & Gynecol, CS Mott Ctr Human Growth & Dev, Detroit, MI 48201 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Wayne State University	Bagchi, IC (corresponding author), Univ Illinois, Dept Vet Biosci, 3641 VMBSB,2001 S Lincoln, Urbana, IL 61802 USA.	ibagchi@uiuc.edu		Armant, D. Randall/0000-0001-5904-9325	NICHD NIH HHS [U54-HD-13541, R01 HD-39291, R01 HD-34527] Funding Source: Medline; NIDDK NIH HHS [R01-DK-50257] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD013541, R01HD039291, R01HD034527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050257] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carson DD, 2000, DEV BIOL, V223, P217, DOI 10.1006/dbio.2000.9767; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; Chen Y, 1998, J BIOL CHEM, V273, P19809, DOI 10.1074/jbc.273.31.19809; CHIBA T, 1989, AM J PHYSIOL, V256, pE331, DOI 10.1152/ajpendo.1989.256.2.E331; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; DENKER HW, 1993, J EXP ZOOL, V266, P541, DOI 10.1002/jez.1402660606; DING YQ, 1994, ENDOCRINOLOGY, V135, P2265, DOI 10.1210/en.135.5.2265; FORCE T, 1992, AM J PHYSIOL, V262, pF1110, DOI 10.1152/ajprenal.1992.262.6.F1110; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Geisert R D, 1990, J Reprod Fertil Suppl, V40, P293; GEISERT RD, 1982, BIOL REPROD, V27, P925, DOI 10.1095/biolreprod27.4.925; GEISERT RD, 1982, BIOL REPROD, V27, P957, DOI 10.1095/biolreprod27.4.957; GLASSER SR, 1993, MICROSC RES TECHNIQ, V25, P106, DOI 10.1002/jemt.1070250204; GLASSER SR, 1990, TROPH RES, V4, P377; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HEERSCHE JN, 1974, ENDOCRINOLOGY, V94, P241, DOI 10.1210/endo-94-1-241; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Illingworth IM, 2000, BIOL REPROD, V63, P1764, DOI 10.1095/biolreprod63.6.1764; KOIDA M, 1982, JPN J PHARMACOL, V32, P981, DOI 10.1254/jjp.32.981; KUESTNER RE, 1994, MOL PHARMACOL, V46, P246; Kumar S, 1998, J CLIN ENDOCR METAB, V83, P4443, DOI 10.1210/jc.83.12.4443; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; Parr MB., 1989, BIOL UTERUS, P233; Psychoyos A, 1976, J Reprod Fertil Suppl, P17; PSYCHOYOS A, 1986, ANN NY ACAD SCI, V476, P36, DOI 10.1111/j.1749-6632.1986.tb20920.x; PSYCHOYOS A, 1973, HDB PHYSL, P187; RIZZO AJ, 1981, ENDOCRINOLOGY, V108, P1672, DOI 10.1210/endo-108-5-1672; SCHLAFKE S, 1975, BIOL REPROD, V12, P41, DOI 10.1095/biolreprod12.1.41; Sharkey A, 1998, REV REPROD, V3, P52, DOI 10.1530/revreprod/3.1.52; Thie M, 1996, EUR J CELL BIOL, V70, P221; THIE M, 1995, EUR J CELL BIOL, V66, P180; TWERY MJ, 1988, EUR J PHARMACOL, V155, P285, DOI 10.1016/0014-2999(88)90515-8; Wang J, 1998, DEVELOPMENT, V125, P4293; YAMAGUCHI M, 1985, ACTA ENDOCRINOL-COP, V110, P239, DOI 10.1530/acta.0.1100239; YOSHINAGA K, 1988, ANN NY ACAD SCI, V541, P424, DOI 10.1111/j.1749-6632.1988.tb22279.x; Zhu LJ, 1998, ENDOCRINOLOGY, V139, P3923, DOI 10.1210/en.139.9.3923; Zhu LJ, 1998, ENDOCRINOLOGY, V139, P330, DOI 10.1210/en.139.1.330	40	61	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46447	46455		10.1074/jbc.M203555200	http://dx.doi.org/10.1074/jbc.M203555200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237291	hybrid			2022-12-27	WOS:000179529300097
J	Okamoto, Y; de Avalos, SV; Hannun, YA				Okamoto, Y; de Avalos, SV; Hannun, YA			Structural requirements for selective binding of ISC1 to anionic phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MONOCLONAL-ANTIBODY; PHOSPHATIDIC-ACID; MEMBRANE-BINDING; AMINO-ACIDS; L-SERINE; IDENTIFICATION; DOMAIN; MOTIF; ACTIVATION	Yeast ISC1 (Yer019w) encodes inositolphosphosphingolipid-phospholipase C and is activated by phosphatidylserine (PS) and cardiolipin (CL) (Sawai, H., Okamoto, Y., Lubert, C., Mao, C., Bielawska, A., Domae, M., and Hannun, Y. A. (2000) J. Biol. Chem. 275, 39793-39798). In this study, the structural requirements for anionic phospholipid-selective binding of ISC1 were determined using site-directed and deletion mutants. FLAG-tagged Isc1p was activated by PS, CL, and phosphatidylglycerol (PG) in a dose-dependent manner. Using lipid-protein overlay assays, Isc1p interacted specifically and directly with PS/CI/PG. Lipid-protein binding studies of a series of deletion mutants demonstrated that the second transmembrane domain (TMII) and the C terminus were required for PS binding. Moreover, the TMII and the C terminus domain were sufficient to impart PS binding to a heterologous protein, green fluorescence protein. In addition, mutations of positively charged amino acid residues at the C terminus of ISC1 reduced the activating effects of PS, suggesting involvement of these amino acids in interaction with PS/CI/PG and in the activation of the enzyme. Finally, when separate fragments containing the N terminus-TMI and TMII-C terminus were expressed heterologously, enzyme activity was reconstituted, demonstrating that the interaction of the N terminus and the C terminus is required for activity of Isc1p. These results raise the hypothesis that in the presence of PS/CL/PG, the catalytic domain in the N terminus of Isc1p is "pulled" to the membrane to interact with substrate. These studies provide unique insights into the properties of ISC1 and define a novel mechanism for activation of enzymes by lipids cofactors.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.		OKAMOTO, Yasuo/J-8438-2015		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL RM, 1991, J BIOL CHEM, V266, P4661; BURKLAND AG, 2000, BIOCHIM BIOPHYS ACTA, V1483, P199; CALDERON C, 1994, J EXP MED, V180, P945, DOI 10.1084/jem.180.3.945; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; COMFURIUS P, 1994, BIOCHEMISTRY-US, V33, P10319, DOI 10.1021/bi00200a012; Dalton KA, 1998, BIOCHEM J, V329, P637; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; FOLCH J, 1957, J BIOL CHEM, V226, P497; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GILBERT GE, 1993, BIOCHEMISTRY-US, V32, P9577, DOI 10.1021/bi00088a009; IGARASHI K, 1995, J BIOL CHEM, V270, P29075, DOI 10.1074/jbc.270.49.29075; Improta-Brears T, 1999, MOL CELL BIOCHEM, V198, P171, DOI 10.1023/A:1006981411691; Johnson JE, 1997, J BIOL CHEM, V272, P30787, DOI 10.1074/jbc.272.49.30787; Jones JA, 2002, J BIOL CHEM, V277, P15530, DOI 10.1074/jbc.M111555200; Makise M, 2001, J BIOL CHEM, V276, P7450, DOI 10.1074/jbc.M009643200; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Sawai H, 2000, J BIOL CHEM, V275, P39793, DOI 10.1074/jbc.M007721200; STEKHOVEN FMAHS, 1994, BBA-BIOMEMBRANES, V1194, P155; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Watanabe Y, 1998, ARCH BIOCHEM BIOPHYS, V358, P68, DOI 10.1006/abbi.1998.0820	25	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46470	46477		10.1074/jbc.M207779200	http://dx.doi.org/10.1074/jbc.M207779200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244059	hybrid			2022-12-27	WOS:000179529300100
J	Li, HW; Park, SM; Kilburn, B; Jelinek, MA; Henschen-Edman, A; Aswad, DW; Stallcup, MR; Laird-Offringa, IA				Li, HW; Park, SM; Kilburn, B; Jelinek, MA; Henschen-Edman, A; Aswad, DW; Stallcup, MR; Laird-Offringa, IA			Lipopolysaccharide-induced methylation of HuR, an mRNA-stabilizing protein, by CARM1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEINS; ARGININE N-METHYLTRANSFERASE; FACTOR MESSENGER-RNAS; IN-VIVO; 3'-UNTRANSLATED REGION; SUBCELLULAR-LOCALIZATION; GENE-EXPRESSION; RICH ELEMENTS; ELAV PROTEIN; COACTIVATOR	The RNA-binding protein HuR stabilizes labile mRNAs carrying AU-rich instability elements. This mRNA stabilization can be induced by hypoxia, lipopolysaccharide, and UV light. The mechanism by which these stimuli activate HuR is unclear and might be related to post-translational modification of this protein. Here we show that HuR can be methylated on arginine. However, HuR is not a substrate for PRMT1, the most prominent protein-arginine methyltransferase in mammalian cells, which methylates a number of heterogeneous nuclear ribonucleoproteins. Instead, HuR is specifically methylated by coactivator-associated arginine methyltransferase I (CARM1), a protein-arginine methyltransferase previously shown to serve as a transcriptional coactivator. By analyzing methylation of specific HuR arginine-to-lysine mutants and by sequencing radioactively methylated HuR peptides, Arg(217) was identified as the major HuR methylation site. Arg(217) is located in the hinge region between the second and third of the three HuR RNA recognition motif domains. Antibodies against a methylated HuR peptide were used to demonstrate in vivo methylation of HuR. HuR methylation increased in cells that overexpressed CARM1. Importantly, lipopolysaccharide stimulation of macrophages, which leads to HuR-mediated stabilization of tumor necrosis factor a mRNA in these cells, caused increased methylation of endogenous HuR. Thus, CARM1, which plays a role in transcriptional activation through histone H3 methylation, may also play a role in post-transcriptional gene regulation by methylating HuR.	Univ So Calif, Keck Sch Med, Norris Canc Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of Southern California; University of Southern California; University of Southern California; University of California System; University of California Irvine	Laird-Offringa, IA (corresponding author), Univ So Calif, Keck Sch Med, Norris Canc Ctr, Los Angeles, CA 90089 USA.		Offringa, Ite/R-4101-2019		NCI NIH HHS [R29CA78407] Funding Source: Medline; NIDDK NIH HHS [DK55274] Funding Source: Medline; NINDS NIH HHS [NS17269] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078407] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055274, R37DK055274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017269] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Atasoy U, 1998, J CELL SCI, V111, P3145; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Di Marco S, 2001, NUCLEIC ACIDS RES, V29, P863, DOI 10.1093/nar/29.4.863; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/s1355838201016089; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; LAIRDOFFRINGA IA, 1995, P NATL ACAD SCI USA, V92, P11859, DOI 10.1073/pnas.92.25.11859; Lau JS, 2000, J CELL BIOCHEM, V79, P395, DOI 10.1002/1097-4644(20001201)79:3<395::AID-JCB50>3.0.CO;2-M; Lee J, 2002, EMBO REP, V3, P268, DOI 10.1093/embo-reports/kvf052; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; LIU Q, 1995, MOL CELL BIOL, V15, P2800; Ma H, 1999, MOL CELL BIOL, V19, P6164; Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Manna SK, 2000, J IMMUNOL, V165, P4927, DOI 10.4049/jimmunol.165.9.4927; Maurer F, 1999, NUCLEIC ACIDS RES, V27, P1664, DOI 10.1093/nar/27.7.1664; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Mears WE, 1996, J VIROL, V70, P7445, DOI 10.1128/JVI.70.11.7445-7453.1996; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Moore MJ, 2001, SCIENCE, V294, P1841, DOI 10.1126/science.1067676; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Nabors LB, 2001, CANCER RES, V61, P2154; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Nichols RC, 2000, EXP CELL RES, V256, P522, DOI 10.1006/excr.2000.4827; Okano HJ, 1997, J NEUROSCI, V17, P3024; Park SM, 2000, MOL CELL BIOL, V20, P4765, DOI 10.1128/MCB.20.13.4765-4772.2000; Pawlak MR, 2000, MOL CELL BIOL, V20, P4859, DOI 10.1128/MCB.20.13.4859-4869.2000; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; RAJPUROHIT R, 1994, BIOCHEM J, V304, P903, DOI 10.1042/bj3040903; Rho J, 2001, J VIROL, V75, P8031, DOI 10.1128/JVI.75.17.8031-8044.2001; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Stallcup MR, 2001, ONCOGENE, V20, P3014, DOI 10.1038/sj.onc.1204325; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Valentini SR, 1999, RNA, V5, P272, DOI 10.1017/S1355838299981633; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961	67	193	199	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44623	44630		10.1074/jbc.M206187200	http://dx.doi.org/10.1074/jbc.M206187200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237300	hybrid			2022-12-27	WOS:000179404800006
J	Zugaza, JL; Lopez-Lago, MA; Caloca, MJ; Dosil, M; Movilla, N; Bustelo, XR				Zugaza, JL; Lopez-Lago, MA; Caloca, MJ; Dosil, M; Movilla, N; Bustelo, XR			Structural determinants for the biological activity of Vav proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; DBL HOMOLOGY DOMAIN; T-CELL; PLECKSTRIN HOMOLOGY; SIGNAL-TRANSDUCTION; RHO-FAMILY; ACTIVATION; RECOGNITION; RESPONSES; SELECTION	We have used an extensive mutagenesis approach to study the specific role of the eight structural domains of Vav during both the activation and signaling steps of this Rac1 exchange factor. Our results indicate that several Vav domains (Dbl homology, pleckstrin homology, and zinc finger) are essential for all the biological activities tested, whereas others are required for discrete, cell type-specific biological effects. Interestingly, we have found that Vav domains have no unique functions. Thus, the calponin homology domain mediates the inhibition of Vav both in vitro and in vivo but, at the same time, exerts effector functions in lymphocytes upon receptor activation. The Vav SH2 and SH3 regions play regulatory roles in the activation of Vav in fibroblasts, mediating both its phosphorylation and translocation to the plasma membrane. In contrast, the Vav SH2 and SH3 regions act as scaffolding platforms in T-cells, ensuring the proper phosphorylation of Vav and the subsequent engagement of downstream effectors. We also provide evidence indicating that the zinc finger region exerts at least three different functional roles in Vav, aiding in the down-regulation of its basal activity, the engagement of substrates, and the induction of ancillary pathways required for cell transformation. Finally, the results obtained are consistent with a new regulatory model for Vav, in which the calponin homology region inhibits the basal activity of Vav through interactions with the zinc finger region.	Univ Salamanca, CSIC, Ctr Invest Canc, E-37007 Salamanca, Spain; Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Campus Unamuno, E-37007 Salamanca, Spain.	xbustelo@usal.es	Bustelo, Xose R./AAD-2081-2022; Caloca, María-José/K-9357-2014; Bustelo, Xose R./A-9526-2010; Dosil, Mercedes/A-9536-2016	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Dosil, Mercedes/0000-0001-8119-8263; ZUGAZA GURRUCHAGA, JOSE LUIS/0000-0003-2287-6671; Caloca, Maria-Jose/0000-0002-1003-2685	NCI NIH HHS [CA7373501] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; Bustelo XR, 2002, FRONT BIOSCI, V7, pD24, DOI 10.2741/bustelo; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Daub M, 1998, MOL CELL BIOL, V18, P6698, DOI 10.1128/MCB.18.11.6698; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Groysman M, 2000, FEBS LETT, V467, P75, DOI 10.1016/S0014-5793(00)01121-2; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Inabe K, 2002, J EXP MED, V195, P189, DOI 10.1084/jem.20011571; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kong YY, 1998, J EXP MED, V188, P2099, DOI 10.1084/jem.188.11.2099; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Nishida M, 2001, EMBO J, V20, P2995, DOI 10.1093/emboj/20.12.2995; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; van der Eb A J, 1980, Methods Enzymol, V65, P826; Wery-Zennaro S, 2000, ONCOGENE, V19, P1596, DOI 10.1038/sj.onc.1203458; Wu J, 1997, J EXP MED, V185, P1877, DOI 10.1084/jem.185.10.1877; WU J, 1995, MOL CELL BIOL, V15, P4337; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	40	99	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45377	45392		10.1074/jbc.M208039200	http://dx.doi.org/10.1074/jbc.M208039200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228230	hybrid			2022-12-27	WOS:000179404800101
J	Franca-Koh, J; Yeo, M; Fraser, E; Young, N; Dale, TC				Franca-Koh, J; Yeo, M; Fraser, E; Young, N; Dale, TC			The regulation of glycogen synthase kinase-3 nuclear export by Frat/GBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-BETA; FRAT1; PHOSPHORYLATION; ONCOGENESIS; SIGNALS; GSK-3	Previous studies have shown that nuclear levels of glycogen synthase kinase-3 (GSK-3) are dynamically regulated and may affect access of GSK-3 to its substrates. In this study we show that the GSK-3-binding protein Frat/GBP regulates the nuclear export of GSK-3. We show that Frat/GBP contains a nuclear export sequence that promotes its own nuclear export and that of associated GSK-3. Treating cells with leptomycin B increased nuclear levels of endogenous GSK-3 suggesting that an endogenous process targets GSK-3 for nuclear export. To investigate this further, we used two approaches to disrupt the interaction between GSK-3 and endogenous Frat. First we isolated mutants of GSK-3 that selectively interfered with Frat binding and found that these mutants were poorly exported. Second we expressed a peptide that competes with Frat for GSK-3 binding and found that it caused endogenous GSK-3 to accumulate in the nucleus. Together these data suggest that Frat may be the endogenous factor that targets GSK-3 for nuclear export. The dynamic expression patterns of Frat mRNAs together with the role of Frat in mediating GSK-3 nuclear export have important implications for the control of the substrate access of GSK-3 in several signaling pathways.	Inst Canc Res, Chester Beatty Labs, Sect Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Dale, TC (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Cell & Mol Biol, London SW3 6JB, England.		Dale, Trevor C/D-3749-2009; Fraser, Elizabeth/M-7049-2015	Dale, Trevor C/0000-0002-4880-9963; Fraser, Elizabeth/0000-0001-8420-3208				Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Crowder RJ, 2000, J BIOL CHEM, V275, P34266, DOI 10.1074/jbc.M006160200; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Ginger RS, 2000, EMBO J, V19, P5483, DOI 10.1093/emboj/19.20.5483; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; Jonkers J, 1999, MECH DEVELOP, V88, P183, DOI 10.1016/S0925-4773(99)00187-2; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; WOODGETT JR, 2001, SCI STKE; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8	22	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43844	43848		10.1074/jbc.M207265200	http://dx.doi.org/10.1074/jbc.M207265200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223487	hybrid			2022-12-27	WOS:000179272000042
J	Potrykus, K; Wegrzyn, G; Hernandez, VJ				Potrykus, K; Wegrzyn, G; Hernandez, VJ			Multiple mechanisms of transcription inhibition by ppGpp at the lambda rho(R) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; OPEN COMPLEX-FORMATION; ESCHERICHIA-COLI; GUANOSINE TETRAPHOSPHATE; STRINGENT CONTROL; SPOT; ELONGATION; DEGRADATION; INITIATION; REQUIRES	General stress conditions in bacterial cells cause a global cellular response called the stringent response. The first event in this control is production of large amounts of a regulatory nucleotide, guanosine-3',5'-(bis)pyrophospahte (ppGpp). It was proposed recently that ppGpp acts by decreasing stability of open complexes at promoters that make short-lived open complexes, e.g. the rRNA promoters. However, here we report that the bacteriophage lambdap(R) promoter, which forms long-lived open complexes, is inhibited by ppGpp in vitro as observed in vivo. We performed a systematic investigation of the ppGpp-specific inhibition of transcription initiation at lambdap(R) and found that ppGpp does decrease stability of open complexes at lambdap(R), but only slightly. Likewise the equilbrium binding constant and rate of open complex formation by RNA polymerase at lambdap(R) are only slightly affected by ppGpp. The major effect of ppGpp-mediated inhibition is to decrease the rate of promoter escape. We conclude that ppGpp-mediated inhibition of transcription initiation is not restricted to promoters that make short-lived open complexes. Rather we conclude that the initial catalytic step of transcript formation is affected by ppGpp, specifically formation of the first phosphodiester bond is inhibited by ppGpp at) lambdap(R).	SUNY Buffalo, Dept Microbiol, Buffalo, NY 14214 USA; Univ Gdansk, Dept Mol Biol, PL-80822 Gdansk, Poland; Polish Acad Sci, Inst Oceanol, PL-81347 Gdynia, Poland	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Fahrenheit Universities; University of Gdansk; Polish Academy of Sciences; Institute of Oceanology of the Polish Academy of Sciences	Hernandez, VJ (corresponding author), SUNY Buffalo, Dept Microbiol, Buffalo, NY 14214 USA.		Wegrzyn, Grzegorz/AAL-1179-2020; Wegrzyn, Grzegorz/ABD-6699-2020	Wegrzyn, Grzegorz/0000-0003-4042-7466; Potrykus, Katarzyna/0000-0002-4902-3348	FIC NIH HHS [TW01244] Funding Source: Medline; NIGMS NIH HHS [GM57189] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057189] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barker MM, 2001, J MOL BIOL, V305, P689, DOI 10.1006/jmbi.2000.4328; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; Chatterji D, 1998, GENES CELLS, V3, P279, DOI 10.1046/j.1365-2443.1998.00190.x; Gentry DR, 1996, MOL MICROBIOL, V19, P1373, DOI 10.1111/j.1365-2958.1996.tb02480.x; GILADI H, 1992, J MOL BIOL, V227, P985, DOI 10.1016/0022-2836(92)90514-K; GOODRICH JA, 1992, J MOL BIOL, V224, P15, DOI 10.1016/0022-2836(92)90573-3; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; HERNANDEZ VJ, 1991, J BIOL CHEM, V266, P5991; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; McKane M, 2000, J MOL BIOL, V299, P337, DOI 10.1006/jmbi.2000.3757; Murray KD, 1996, J MOL BIOL, V259, P41; OHLSEN KL, 1992, MOL MICROBIOL, V6, P2243, DOI 10.1111/j.1365-2958.1992.tb01400.x; Petersen C, 2000, J BIOL CHEM, V275, P3931, DOI 10.1074/jbc.275.6.3931; REDDY PS, 1995, MOL MICROBIOL, V15, P255, DOI 10.1111/j.1365-2958.1995.tb02240.x; Slominska M, 1999, VIROLOGY, V262, P431, DOI 10.1006/viro.1999.9907; SZALEWSKAPALASZ A, 1994, EMBO J, V13, P5779, DOI 10.1002/j.1460-2075.1994.tb06916.x; TAYLOR K, 1998, MOL MICROBIOL, P81; Toulokhonov II, 2001, J BIOL CHEM, V276, P1220, DOI 10.1074/jbc.M007184200; TRAVERS AA, 1984, NUCLEIC ACIDS RES, V12, P2605, DOI 10.1093/nar/12.6.2605; VOGEL U, 1995, J BIOL CHEM, V270, P18335, DOI 10.1074/jbc.270.31.18335; VOGEL U, 1994, J BIOL CHEM, V269, P16236; WRGRZYN G, 2001, RECENT RES DEV VIROL, V3, P375; Wrobel B, 1998, MOL GEN GENET, V257, P490, DOI 10.1007/s004380050674; XIAO H, 1991, J BIOL CHEM, V266, P5980	25	23	23	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43785	43791		10.1074/jbc.M208768200	http://dx.doi.org/10.1074/jbc.M208768200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226106	hybrid			2022-12-27	WOS:000179272000034
J	Scholze, P; Freissmuth, M; Sitte, HH				Scholze, P; Freissmuth, M; Sitte, HH			Mutations within an intramembrane leucine heptad repeat disrupt oligomer formation of the rat GABA transporter 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+CL COTRANSPORT FUNCTION; OOCYTE MEMBRANE PATCHES; GAMMA-AMINOBUTYRIC-ACID; PROTEIN-KINASE-C; SEROTONIN TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; TRANSMEMBRANE HELIX; POINT MUTATION; RECEPTOR; CELLS	Na+/Cl--dependent neurotransmitter transporters form constitutive oligomers, the significance of which is not known. In soluble proteins, leucine heptad repeats drive dimerization; the rat gamma-aminobutyric acid transporter GAT-1 (rGAT) contains a motif reminiscent of a leucine heptad repeat in the second transmembrane helix (TM2). We substituted leucine residues in TM2 of rGAT by alanine and tested the ability of the resulting mutants to form oligomers by three methods of Forster resonance energy transfer (FRET) microscopy. Replacement of one leucine (L97A) resulted in considerable loss of energy transfer, replacing two or more ablated it completely. Furthermore, intracellular trapping increased with the number of leucine substitutions. Only rGAT-L97A reached the cell surface to a sufficient amount such that, in intact cells, it was indistinguishable from wild type rGAT with respect to substrate transport, binding of inhibitors, and regulation by protein kinase C. However, in membrane vesicles prepared from transfected cells, all mutants were still functional. In addition, FRET was readily detected during maturation of wild type rGAT, when the bulk of the protein resided in the endoplasmic reticulum. Hence, our findings strongly argue for a role of oligomer formation during biosynthesis and subsequent delivery of the multimer from the endoplasmic reticulum to the plasma membrane.	Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria	University of Vienna	Sitte, HH (corresponding author), Univ Vienna, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.		Sitte, Harald/N-2681-2013; Sitte, Harald/O-7025-2019	Sitte, Harald/0000-0002-1339-7444; Sitte, Harald/0000-0002-1339-7444; Scholze, Petra/0000-0003-4984-6034; Freissmuth, Michael/0000-0001-9398-1765				ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; ASANO T, 1992, J BIOL CHEM, V267, P19636; AXELROD J, 1961, SCIENCE, V133, P383, DOI 10.1126/science.133.3450.383; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Beckman ML, 1998, J NEUROSCI, V18, P6103; Beckman ML, 1998, J MEMBRANE BIOL, V164, P1; BECKMAN ML, 1999, J NEUROSCI RC, V9, P1; BENDAHAN A, 1993, FEBS LETT, V318, P41, DOI 10.1016/0014-5793(93)81323-R; Cammack JN, 1996, P NATL ACAD SCI USA, V93, P723, DOI 10.1073/pnas.93.2.723; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Cornea RL, 2000, J BIOL CHEM, V275, P41487, DOI 10.1074/jbc.M008195200; DeFelice LJ, 1996, BIOPHYS J, V70, P579, DOI 10.1016/S0006-3495(96)79604-2; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; Fleming KG, 2001, P NATL ACAD SCI USA, V98, P14340, DOI 10.1073/pnas.251367498; Forster T., 1948, ANN PHYS, V437, P57; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Garcia J, 1997, BIOPHYS J, V72, P2515, DOI 10.1016/S0006-3495(97)78896-9; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Hilgemann DW, 1999, J GEN PHYSIOL, V114, P459, DOI 10.1085/jgp.114.3.459; Iversen L, 2000, MOL PSYCHIATR, V5, P357, DOI 10.1038/sj.mp.4000728; Jentsch TJ, 2002, NATURE, V415, P276, DOI 10.1038/415276a; Jess U, 1996, FEBS LETT, V394, P44, DOI 10.1016/0014-5793(96)00916-7; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; LEVI G, 1993, TRENDS NEUROSCI, V16, P415, DOI 10.1016/0166-2236(93)90010-J; Lu CC, 1999, J GEN PHYSIOL, V114, P429, DOI 10.1085/jgp.114.3.429; Lu CC, 1999, J GEN PHYSIOL, V114, P445, DOI 10.1085/jgp.114.3.445; MABJEESH NJ, 1992, J BIOL CHEM, V267, P2563; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Perego C, 1997, J BIOL CHEM, V272, P6584, DOI 10.1074/jbc.272.10.6584; Quick MW, 2002, P NATL ACAD SCI USA, V99, P5686, DOI 10.1073/pnas.082712899; Risso S, 1996, J PHYSIOL-LONDON, V490, P691, DOI 10.1113/jphysiol.1996.sp021178; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; SATO K, 1995, FEBS LETT, V375, P99, DOI 10.1016/0014-5793(95)01191-G; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Scholze P, 2002, J BIOL CHEM, V277, P21505, DOI 10.1074/jbc.M112265200; Sitte HH, 2002, BRIT J PHARMACOL, V135, P93, DOI 10.1038/sj.bjp.0704446; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; Su HP, 2000, J BIOL CHEM, V275, P9542, DOI 10.1074/jbc.275.13.9542; Veenhoff LM, 2002, TRENDS BIOCHEM SCI, V27, P242, DOI 10.1016/S0968-0004(02)02077-7; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Wilson MC, 2002, J BIOL CHEM, V277, P3666, DOI 10.1074/jbc.M109658200; Zahniser NR, 2001, PHARMACOL THERAPEUT, V92, P21, DOI 10.1016/S0163-7258(01)00158-9; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	50	94	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43682	43690		10.1074/jbc.M205602200	http://dx.doi.org/10.1074/jbc.M205602200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223478	hybrid			2022-12-27	WOS:000179272000020
J	Van Komen, S; Petukhova, G; Sigurdsson, S; Sung, P				Van Komen, S; Petukhova, G; Sigurdsson, S; Sung, P			Functional cross-talk among Rad51, Rad54, and replication protein A in heteroduplex DNA joint formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; YEAST RAD51; RECOMBINATION FACTORS; RECA PROTEIN; BINDING; EXCHANGE; REPAIR; MECHANISMS; CATALYSIS	Saccharomyces cerevisiae Rad51, Rad54, and replication protein A (RPA) proteins work in concert to make heteroduplex DNA joints during homologous recombination. With plasmid length DNA substrates, maximal DNA joint formation is observed with amounts of Rad51. substantially below what is needed to saturate the initiating single-stranded DNA template, and, relative to Rad51, Rad54 is needed in only catalytic quantities. RPA is still indispensable for optimal reaction efficiency, but its role in this instance is to sequester free single-stranded DNA, which otherwise inhibits Rad51 and Rad54 functions. We also demonstrate that Rad54 helps overcome various reaction constraints in DNA joint formation. These results thus shed light on the function of Rad54 in the Rad51-mediated homologous DNA pairing reaction and also reveal a novel role of RPA in the presynaptic stage of this reaction.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Sung, P (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	sung@uthscsa.edu	Sigurdsson, Stefan/L-9820-2015	Sigurdsson, Stefan/0000-0002-5284-0058	NIEHS NIH HHS [R01ES07061] Funding Source: Medline; NIGMS NIH HHS [R01GM57814] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057814] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beernink HTH, 1999, TRENDS BIOCHEM SCI, V24, P385, DOI 10.1016/S0968-0004(99)01451-6; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Cromie GA, 2001, MOL CELL, V8, P1163, DOI 10.1016/S1097-2765(01)00419-1; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Mazin AV, 1998, EMBO J, V17, P1161, DOI 10.1093/emboj/17.4.1161; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nakagawa T, 2001, J BIOL CHEM, V276, P31487, DOI 10.1074/jbc.M104003200; Namsaraev E, 1997, MOL CELL BIOL, V17, P5359, DOI 10.1128/MCB.17.9.5359; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Petukhova G, 2000, GENE DEV, V14, P2206, DOI 10.1101/gad.826100; Petukhova G, 1999, J BIOL CHEM, V274, P33839, DOI 10.1074/jbc.274.48.33839; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Zaitseva EM, 1999, J BIOL CHEM, V274, P2907, DOI 10.1074/jbc.274.5.2907	29	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43578	43587		10.1074/jbc.M205864200	http://dx.doi.org/10.1074/jbc.M205864200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226081	hybrid			2022-12-27	WOS:000179272000007
J	Bruhat, A; Averous, J; Carraro, V; Zhong, C; Reimold, AM; Kilberg, MS; Fafournoux, P				Bruhat, A; Averous, J; Carraro, V; Zhong, C; Reimold, AM; Kilberg, MS; Fafournoux, P			Differences in the molecular mechanisms involved in the transcriptional activation of the CHOP and asparagine synthetase genes in response to amino acid deprivation or activation of the unfolded protein response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT/ENHANCER-BINDING PROTEIN; ENDOPLASMIC-RETICULUM; EXPRESSION; STRESS; GADD153; ELEMENTS; PROMOTER; C/EBP; IDENTIFICATION; CHOP/GADD153	A promoter element called the amino acid response element (AARE), which is essential for the induction of CHOP (a CCAAT/enhancer-binding protein-related gene) transcription by amino acid depletion, has been previously characterized. Conversely, the human asparagine synthetase (AS) promoter contains two cis-acting elements termed nutrient-sensing response elements (NSRE-1 and NSRE-2) that are required to activate the gene by either amino acid deprivation or the endoplasmic reticulum stress response. The results reported here document the comparison between CHOP and AS transcriptional control elements used by the amino acid pathway. We first establish that the AS NSRE-1 sequence shares nucleotide sequence and functional similarities with the CHOP AARE. However, we demonstrate that the CHOP AARE can function independently, whereas AS NSRE-1 is functionally weak by itself and instead requires the presence of NSRE-2. Furthermore, AS NSRE-2 can confer endoplasmic reticulum stress responsiveness to the CHOP AARE. Using activating transcription factor-2-deficient mouse embryonic fibroblasts, we also show that lack of this transcription factor does not abolish the amino acid inducibility of AS transcription, but this transcription factor is necessary to obtain the full AS response to amino acid starvation. Collectively, these results document that there are significant differences in the molecular mechanisms involved in the transcriptional activation of CHOP and AS by amino acid limitation.	INRA, Unite Nutr & Metab Prot, F-63122 St Genes Champanelle, France; Univ Florida, Coll Med, Ctr Mammalian Genet, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Texas, SW Med Ctr, Div Rheumat Dis, Dallas, TX 75390 USA	INRAE; State University System of Florida; University of Florida; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bruhat, A (corresponding author), INRA, Unite Nutr & Metab Prot, F-63122 St Genes Champanelle, France.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052064] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-52064] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Bruhat A, 2000, MOL CELL BIOL, V20, P7192, DOI 10.1128/MCB.20.19.7192-7204.2000; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; HUTSON RG, 1994, BIOCHEM J, V304, P745, DOI 10.1042/bj3040745; Jousse C, 2000, J NUTR, V130, P1555, DOI 10.1093/jn/130.6.1555; Jousse C, 1999, FEBS LETT, V448, P211, DOI 10.1016/S0014-5793(99)00373-7; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Laine RO, 1996, PROG NUCLEIC ACID RE, V53, P219, DOI 10.1016/S0079-6603(08)60146-4; Leung-Pineda V, 2002, J BIOL CHEM, V277, P16585, DOI 10.1074/jbc.M110972200; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LUETHY JD, 1992, CANCER RES, V52, P5; Maekawa T, 1999, J BIOL CHEM, V274, P17813, DOI 10.1074/jbc.274.25.17813; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Roesler WJ, 2001, ANNU REV NUTR, V21, P141, DOI 10.1146/annurev.nutr.21.1.141; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sambrook J., 2002, MOL CLONING LAB MANU; Schmitt-Ney M, 2000, J BIOL CHEM, V275, P40839, DOI 10.1074/jbc.M007440200; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Sok J, 1999, MOL CELL BIOL, V19, P495; SYLVESTER SL, 1994, J BIOL CHEM, V269, P20119; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	41	63	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48107	48114		10.1074/jbc.M206149200	http://dx.doi.org/10.1074/jbc.M206149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12351626	hybrid, Green Published			2022-12-27	WOS:000179789600019
J	Pei, ZF; Reske, G; Huang, QH; Hammock, BD; Qi, YP; Chejanovsky, N				Pei, ZF; Reske, G; Huang, QH; Hammock, BD; Qi, YP; Chejanovsky, N			Characterization of the apoptosis suppressor protein P49 from the Spodoptera littoralis nucleopolyhedrovirus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; REACTIVE-SITE LOOP; BACULOVIRUS P35; CRYSTAL-STRUCTURE; INHIBITING GENE; CASPASES; SEQUENCE; FAMILY; PROTEASES; CLEAVAGE	Two antiapoptotic types of genes, iap and p35, were found in baculoviruses. P35 is a 35-kDa protein that can suppress apoptosis induced by virus infection or by diverse stimuli in vertebrates or invertebrates. iap homologues were identified in insects and mammals. Recently, we have identified sl-p49, a novel apoptosis suppressor gene and the first homologue of p35, in the genome of the Spodoptera littoralis nucleopolyhedrovirus. Here we show that sl-p49 encodes a 49-kDa protein, confirmed its primary structure that displays 48.8% identity to P35, and performed computer-assisted modeling of P49 based on the structure of P35. We demonstrated that P49 is able to inhibit insect and human effector caspases, which requires P49 cleavage at Asp(94). Finally we identified domains important for P49's antiapoptotic function that include a reactive site loop (RSL) protruding from a beta-barrel domain. RSL begins at an amphipathic alpha1 helix, traverses the beta-sheet central region, exposing Asp(94) at the apex, and rejoins the beta-barrel. Our model predicted seven alpha-helical motifs, three of them unique to P49. alpha-Helical motifs alpha(1), alpha2, and alpha4, were required for P49 function. The high structural homology between P49 and P35 suggests that these molecules bear a scaffold common to baculovirus "apoptotic suppressor" proteins. P49 may serve as a novel tool to analyze the contribution of different components of the caspase chain in the apoptotic response in organisms not related phylogenetically.	Agr Res Org, Inst Plant Protect, Dept Entomol, Volcani Ctr, IL-50250 Bet Dagan, Israel; Wuhan Univ, Inst Virol, Wuhan 430072, Peoples R China; Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA	VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; Chinese Academy of Sciences; Wuhan Institute of Virology, CAS; Wuhan University; University of California System; University of California Davis	Chejanovsky, N (corresponding author), Agr Res Org, Inst Plant Protect, Dept Entomol, Volcani Ctr, POB 6, IL-50250 Bet Dagan, Israel.	ninar@volcani.agri.gov.il		Chejanovsky, Nor/0000-0002-6455-6521				Afonso CL, 2001, J VIROL, V75, P11157, DOI 10.1128/JVI.75.22.11157-11165.2001; Ahmad M, 1997, J BIOL CHEM, V272, P1421, DOI 10.1074/jbc.272.3.1421; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CARTIER JL, 1994, J VIROL, V68, P7728, DOI 10.1128/JVI.68.12.7728-7737.1994; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; CHEJANOVSKY N, 1995, VIROLOGY, V209, P519, DOI 10.1006/viro.1995.1284; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Clem RJ, 2001, CELL DEATH DIFFER, V8, P137, DOI 10.1038/sj.cdd.4400821; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Dai XJ, 1999, J GEN VIROL, V80, P1841, DOI 10.1099/0022-1317-80-7-1841; dela Cruz WP, 2001, J BIOL CHEM, V276, P32933, DOI 10.1074/jbc.M103930200; Du QS, 1999, J VIROL, V73, P1278, DOI 10.1128/JVI.73.2.1278-1285.1999; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Fisher AJ, 1999, EMBO J, V18, P2031, DOI 10.1093/emboj/18.8.2031; Gershburg E, 1997, J VIROL, V71, P7593, DOI 10.1128/JVI.71.10.7593-7599.1997; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HINK WF, 1970, NATURE, V226, P466, DOI 10.1038/226466b0; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KAMITA SG, 1993, J VIROL, V67, P455, DOI 10.1128/JVI.67.1.455-463.1993; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Miller LK, 1998, SEMIN VIROL, V8, P445, DOI 10.1006/smvy.1998.0149; Pang Y, 2001, VIROLOGY, V287, P391, DOI 10.1006/viro.2001.1056; Papworth C.B., 1996, STRATEGIES, V9, P3, DOI DOI 10.1080/08924562.1996.11000299; PEISCH MC, 1995, BIOTECHNOLOGY, V13, P658; Qi Y, 2001, ARCH VIROL, V146, P2149, DOI 10.1007/s007050170026; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stennicke HR, 1999, METHODS, V17, P313, DOI 10.1006/meth.1999.0745; SUMMERS MD, 1978, TEX AGR EXP STN B, V1555; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Xu GZ, 2001, NATURE, V410, P494, DOI 10.1038/35068604; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w; Zoog SJ, 1999, J BIOL CHEM, V274, P25995, DOI 10.1074/jbc.274.37.25995	38	55	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48677	48684		10.1074/jbc.M208810200	http://dx.doi.org/10.1074/jbc.M208810200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12324475	hybrid			2022-12-27	WOS:000179789600092
J	Aoki, S; Li, J; Itagaki, S; Okech, BA; Egwang, TG; Matsuoka, H; Palacpac, NMQ; Mitamura, T; Horii, T				Aoki, S; Li, J; Itagaki, S; Okech, BA; Egwang, TG; Matsuoka, H; Palacpac, NMQ; Mitamura, T; Horii, T			Serine repeat antigen (SERA5) is predominantly expressed among the SERA multigene family of Plasmodium falciparum, and the acquired antibody titers correlate with serum inhibition of the parasite growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD STAGE ANTIGEN; PROTECTIVE IMMUNITY; AOTUS MONKEYS; ESCHERICHIA-COLI; TERMINAL DOMAIN; MALARIA; PROTEIN; SEQUENCE; GENES; LOCALIZATION	The Plasmodium falciparum serine repeat antigen (SERA) is one of the blood stage malaria vaccine candidates. The malaria genome project has revealed that SERA is a member of the SERA multigene family consisting of eight SERA homologues clustered on chromosome 2 and one SERA homologue on chromosome 9. Northern blotting and real time quantitative reverse transcription-PCR with five independent parasite strains, including three allelic representative forms of the SERA gene, have shown that all of the SERA homologues are transcribed most actively at trophozoite and schizont stages and that SERA5 (SERA/SERP) is transcribed predominantly among the family. Polyclonal antibodies were raised against recombinant proteins representing the N-terminal portions of four significantly transcribed SERA homologues (SERA3 to -6) in the center of the cluster on chromosome 2. Using these antibodies, indirect immunofluorescence microscopy detected the expression of SERA3 to -6, with similar localization, in all trophozoite- and schizont-infected erythrocytes. We have examined 40 sera from Ugandan adults for their antibody reactivity and found that enzyme-linked immunosorbent assay titer against SERA5 N-terminal domain, but not against other SERA proteins, is positively correlated with the inhibition of in vitro parasite growth by individual sera. Our data confirm the usefulness of the N-terminal domain of SERA5 as a promising malaria candidate vaccine.	Osaka Univ, Microbial Dis Res Inst, Dept Mol Protozool, Suita, Osaka 5650871, Japan; Med Biotech Labs, Div Med Parasitol & Trop Med, Kampala, Uganda; Jichi Med Sch, Dept Med Zool, Minami Kawachi, Tochigi 3290498, Japan	Osaka University; Jichi Medical University	Horii, T (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Mol Protozool, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Horii, Toshihiro/0000-0002-3000-2045; Matsuoka, Hiroyuki/0000-0001-8839-0012; Palacpac, Nirianne Marie/0000-0003-4098-3972				Baca AM, 2000, INT J PARASITOL, V30, P113, DOI 10.1016/S0020-7519(00)00019-9; BZIK DJ, 1988, MOL BIOCHEM PARASIT, V30, P279, DOI 10.1016/0166-6851(88)90097-7; DEBRABANT A, 1992, MOL BIOCHEM PARASIT, V53, P89, DOI 10.1016/0166-6851(92)90010-H; DELPLACE P, 1985, MOL BIOCHEM PARASIT, V17, P239, DOI 10.1016/0166-6851(85)90021-0; DELPLACE P, 1987, MOL BIOCHEM PARASIT, V23, P193, DOI 10.1016/0166-6851(87)90026-0; EAKIN AE, 1989, NATURE, V342, P132, DOI 10.1038/342132b0; FOX BA, 1994, MOL BIOCHEM PARASIT, V68, P133, DOI 10.1016/0166-6851(94)00162-6; Fox BA, 1997, EXP PARASITOL, V85, P121, DOI 10.1006/expr.1996.4118; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Hanada K, 2000, BIOCHEM J, V346, P671, DOI 10.1042/0264-6021:3460671; Hanada K, 2002, J EXP MED, V195, P23, DOI 10.1084/jem.20010724; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HIGGINS DG, 1989, NATURE, V340, P604, DOI 10.1038/340604a0; HORII T, 1988, MOL BIOCHEM PARASIT, V30, P9, DOI 10.1016/0166-6851(88)90127-2; INSELBURG J, 1983, J PARASITOL, V69, P592, DOI 10.2307/3281375; INSELBURG J, 1993, INFECT IMMUN, V61, P2048, DOI 10.1128/IAI.61.5.2048-2052.1993; INSELBURG J, 1993, INFECT IMMUN, V61, P2041, DOI 10.1128/IAI.61.5.2041-2047.1993; INSELBURG J, 1991, INFECT IMMUN, V59, P1247, DOI 10.1128/IAI.59.4.1247-1250.1991; KNAPP B, 1989, MOL BIOCHEM PARASIT, V32, P73, DOI 10.1016/0166-6851(89)90131-X; KNAPP B, 1991, MOL BIOCHEM PARASIT, V44, P1, DOI 10.1016/0166-6851(91)90215-R; Kubata BK, 1998, J EXP MED, V188, P1197, DOI 10.1084/jem.188.6.1197; Li J, 2002, MOL BIOCHEM PARASIT, V120, P177, DOI 10.1016/S0166-6851(01)00452-2; LI J, 2002, PARASITOL INT, V53, P89; Liu Qing, 2000, Southeast Asian Journal of Tropical Medicine and Public Health, V31, P808; MAEDA S, 1985, NATURE, V315, P592, DOI 10.1038/315592a0; Miller SK, 2002, J BIOL CHEM, V277, P47524, DOI 10.1074/jbc.M206974200; Mitamura T, 2000, PARASITOL INT, V49, P219, DOI 10.1016/S1383-5769(00)00048-9; Morimatsu K, 1997, MOL BIOCHEM PARASIT, V86, P249, DOI 10.1016/S0166-6851(97)00038-8; MOTTRAM JC, 1989, NATURE, V342, P132, DOI 10.1038/342132c0; O'Donnell RA, 2001, J EXP MED, V193, P1403, DOI 10.1084/jem.193.12.1403; Okech BA, 2001, AM J TROP MED HYG, V65, P912, DOI 10.4269/ajtmh.2001.65.912; Pang XL, 1999, INFECT IMMUN, V67, P1821; Pang XL, 1998, VACCINE, V16, P1299, DOI 10.1016/S0264-410X(98)00057-7; Sugiyama T, 1996, VACCINE, V14, P1069, DOI 10.1016/0264-410X(95)00238-V; Suzuki H, 1997, EXP ANIM TOKYO, V46, P17, DOI 10.1538/expanim.46.17; TANABE K, 1987, J MOL BIOL, V195, P273, DOI 10.1016/0022-2836(87)90649-8; TOSTA CE, 1980, EXP PARASITOL, V50, P7, DOI 10.1016/0014-4894(80)90003-X; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0	40	75	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47533	47540		10.1074/jbc.M207145200	http://dx.doi.org/10.1074/jbc.M207145200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12244052	hybrid			2022-12-27	WOS:000179663700091
J	Hulsmeyer, M; Hillig, RC; Volz, A; Ruhl, M; Schroder, W; Saenger, W; Ziegler, A; Uchanska-Ziegler, B				Hulsmeyer, M; Hillig, RC; Volz, A; Ruhl, M; Schroder, W; Saenger, W; Ziegler, A; Uchanska-Ziegler, B			HLA-B27 subtypes differentially associated with disease exhibit subtle structural alterations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANKYLOSING-SPONDYLITIS; HLA-B-ASTERISK-2709 SUBTYPE; BINDING PEPTIDES; CUTTING EDGE; SUSCEPTIBILITY; POLYMORPHISM; PROGRAM; ANTIGEN; SPECIFICITY; COMPLEXES	The reasons for the association of the human major histocompatibility complex protein HIA-B27 with spondyloarthropathies are unknown. To uncover the underlying molecular causes, we determined the crystal structures of the disease-associated B*2705 and the nonassociated B*2709 subtypes complexed with the same nonapeptide (GRFAAALAK). Both differ in only one residue (Asp(116) and His(116), respectively) in the F-pocket that accommodates the peptide C terminus. Several different effects of the Asp(116)-->His replacement are observed. The bulkier His(116) induces a movement of peptide C-terminal pLys(9), allowing the formation of a novel salt bridge to Asp(77), whereas the salt bridge between pLys(9) and Asp(116) is converted into a hydrogen bond with His(116). His(116) but not Asp(116) adopts two alternative conformations, one of which leads to breakage of hydrogen bonds. Water molecules near residue 116 differ with regard to number, position, and contacts made. Furthermore, F-pocket atoms exhibit higher B-factors in B*2709 than in B*2705, indicating an increased flexibility of the entire region in the former subtype. These changes induce subtle peptide conformational alterations that may be responsible for the immunobiological differences between these HLA-B27 subtypes.	Free Univ Berlin, Inst Kristallog, D-14195 Berlin, Germany; Humboldt Univ, Univ Klinikum Charite, Inst Immungenet, D-14050 Berlin, Germany	Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Saenger, W (corresponding author), Free Univ Berlin, Inst Kristallog, Takustr 6, D-14195 Berlin, Germany.	saenger@chemie.fu-berlin.de; barbara.uchanska-ziegler@charite.de						Allen RL, 1999, IMMUNOGENETICS, V50, P220, DOI 10.1007/s002510050596; Allen RL, 2001, J IMMUNOL, V167, P5543, DOI 10.4049/jimmunol.167.10.5543; Allen RL, 1999, J IMMUNOL, V162, P5045; Armas JB, 1999, TISSUE ANTIGENS, V53, P237, DOI 10.1034/j.1399-0039.1999.530303.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker BM, 2001, J EXP MED, V193, P551, DOI 10.1084/jem.193.5.551; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; Boyle LH, 2001, J IMMUNOL, V167, P2619, DOI 10.4049/jimmunol.167.5.2619; BREWERTON DA, 1973, LANCET, V1, P904; Brown Matthew, 1997, Current Opinion in Rheumatology, V9, P308; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brusic V, 1998, NUCLEIC ACIDS RES, V26, P368, DOI 10.1093/nar/26.1.368; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Ciatto C, 2001, J MOL BIOL, V312, P1059, DOI 10.1006/jmbi.2001.5016; Colbert RA, 2000, MOL MED TODAY, V6, P224, DOI 10.1016/S1357-4310(00)01699-3; DAMATO M, 1995, EUR J IMMUNOL, V25, P3199, DOI 10.1002/eji.1830251133; Dangoria NS, 2002, J BIOL CHEM, V277, P23459, DOI 10.1074/jbc.M110336200; de Castro JAL, 1998, CURR OPIN IMMUNOL, V10, P59, DOI 10.1016/S0952-7915(98)80033-2; Dedier S, 2000, J BIOL CHEM, V275, P27055; Edwards JCW, 2000, IMMUNOL TODAY, V21, P256, DOI 10.1016/S0167-5699(00)01625-X; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Ferrara GB, 2001, BLOOD, V98, P3150, DOI 10.1182/blood.V98.10.3150; Fiorillo MT, 1997, EUR J IMMUNOL, V27, P368, DOI 10.1002/eji.1830270205; Fiorillo MT, 2000, J CLIN INVEST, V106, P47, DOI 10.1172/JCI9295; Fiorillo MT, 1998, EUR J IMMUNOL, V28, P2508, DOI 10.1002/(SICI)1521-4141(199808)28:08<2508::AID-IMMU2508>3.0.CO;2-1; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Garcia F, 1997, TISSUE ANTIGENS, V49, P580, DOI 10.1111/j.1399-0039.1997.tb02805.x; Garcia-Peydro M, 1999, J IMMUNOL, V163, P2299; GonzalezRoces S, 1997, TISSUE ANTIGENS, V49, P116, DOI 10.1111/j.1399-0039.1997.tb02724.x; Hillig RC, 2001, J MOL BIOL, V310, P1167, DOI 10.1006/jmbi.2001.4816; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Khan MA, 2000, CURR OPIN RHEUMATOL, V12, P235, DOI 10.1097/00002281-200007000-00001; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krebs S, 1999, PROTEIN SCI, V8, P1393, DOI 10.1110/ps.8.7.1393; Kubo H, 1998, IMMUNOGENETICS, V47, P256, DOI 10.1007/s002510050355; LATRON F, 1992, SCIENCE, V257, P964, DOI 10.1126/science.1380181; Lopez-Larrea C, 1998, MOL MED TODAY, V4, P540, DOI 10.1016/S1357-4310(98)01375-6; Luque I, 1996, EUR J IMMUNOL, V26, P1974, DOI 10.1002/eji.1830260845; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Martinez-Borra J, 2000, HUM IMMUNOL, V61, P131, DOI 10.1016/S0198-8859(99)00145-7; MCLACHLAN AD, 1982, ACTA CRYSTALLOGR A, V38, P871, DOI 10.1107/S0567739482001806; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Nasution AR, 1997, J RHEUMATOL, V24, P1111; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Olivieri I, 2002, ARTHRITIS RHEUM-US, V46, P553, DOI 10.1002/art.10127; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Ramos M, 2002, J BIOL CHEM, V277, P28749, DOI 10.1074/jbc.M204155200; Rehm A, 2000, HUM IMMUNOL, V61, P408, DOI 10.1016/S0198-8859(99)00176-7; SCHLOSSTEIN L, 1973, NEW ENGL J MED, V288, P704, DOI 10.1056/NEJM197304052881403; SCHOMBURG D, 1988, J MOL GRAPHICS, V6, P161, DOI 10.1016/0263-7855(88)80069-9; URBAN RG, 1994, P NATL ACAD SCI USA, V91, P1534, DOI 10.1073/pnas.91.4.1534; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	57	76	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47844	47853		10.1074/jbc.M206392200	http://dx.doi.org/10.1074/jbc.M206392200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12244049	hybrid			2022-12-27	WOS:000179663700130
J	Modur, V; Nagarajan, R; Evers, BM; Milbrandt, J				Modur, V; Nagarajan, R; Evers, BM; Milbrandt, J			FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression - Implications for PTEN mutation in prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTORS; CELL-SURVIVAL; PTEN/MMAC1 MUTATIONS; GERMLINE MUTATIONS; MMAC1/PTEN GENE; INACTIVATION; DEATH; SUPPRESSION; ACTIVATION; FREQUENT	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA	Washington University (WUSTL); University of Texas System; University of Texas Medical Branch Galveston	Milbrandt, J (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.			Milbrandt, Jeffrey/0000-0002-5477-7689	NATIONAL CANCER INSTITUTE [T32CA009547] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009547-15] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cairns P, 1997, CANCER RES, V57, P4997; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cao GW, 2001, CANCER GENE THER, V8, P497, DOI 10.1038/sj.cgt.7700333; Cheney IW, 1998, CANCER RES, V58, P2331; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Davies MA, 1999, CANCER RES, V59, P2551; Davies MA, 1998, CANCER RES, V58, P5285; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Guldberg P, 1997, CANCER RES, V57, P3660; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Kawamura N, 1999, JPN J CANCER RES, V90, P413, DOI 10.1111/j.1349-7006.1999.tb00763.x; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liu WG, 1997, CANCER RES, V57, P5254; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; McMenamin ME, 1999, CANCER RES, V59, P4291; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Rasheed BKA, 1997, CANCER RES, V57, P4187; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Ririe KM, 1997, ANAL BIOCHEM, V245, P154, DOI 10.1006/abio.1996.9916; SCHNEEBERGER C, 1995, PCR METH APPL, V4, P234; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Svaren J, 1998, EMBO J, V17, P6010, DOI 10.1093/emboj/17.20.6010; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; Wang QD, 2000, BIOCHEM BIOPH RES CO, V276, P466, DOI 10.1006/bbrc.2000.3512; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01; Yuan XJ, 2002, ONCOGENE, V21, P319, DOI 10.1038/sj/onc/1205054	49	309	320	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47928	47937		10.1074/jbc.M207509200	http://dx.doi.org/10.1074/jbc.M207509200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351634	hybrid			2022-12-27	WOS:000179663700140
J	Comin-Anduix, B; Boros, LG; Marin, S; Boren, J; Callol-Massot, C; Centelles, JJ; Torres, JL; Agell, N; Bassilian, S; Cascante, M				Comin-Anduix, B; Boros, LG; Marin, S; Boren, J; Callol-Massot, C; Centelles, JJ; Torres, JL; Agell, N; Bassilian, S; Cascante, M			Fermented wheat germ extract inhibits glycolysis/pentose cycle enzymes and induces apoptosis through poly(ADP-ribose) polymerase activation in Jurkat T-cell leukemia tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL COLON CARCINOGENESIS; FATTY-ACID SYNTHESIS; ADENOCARCINOMA CELLS; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; PROTEINS; RELEASE; RIBOSE; GROWTH; CANCER; DEATH	The fermented extract of wheat germ, trade name Avemar, is a complex mixture of biologically active molecules with potent anti-metastatic activities in various human malignancies. Here we report the effect of Avemar on Jurkat leukemia cell viability, proliferation, cell cycle distribution, apoptosis, and the activity of key glycolytic/pentose cycle enzymes that control carbon flow for nucleic acid synthesis. The cytotoxic IC50 concentration of Avemar for Jurkat tumor cells is 0.2 mg/ml, and increasing doses of the crude powder inhibit Jurkat cell proliferation in a dose-dependent fashion. At concentrations higher than 0.2 mg/ml, Avemar inhibits cell growth by more than 50% (72 h of incubation), which is preceded by the appearance of a sub-G(1) peak on flow histograms at 48 h. Laser scanning cytometry of propidium iodide and annexin V-stained cells indicated that the growth-inhibiting effect of Avemar was consistent with a strong induction of apoptosis. Inhibition by benzyloxycarbonyl-Val-Ala-Asp fluoromethyl ketone of apoptosis but increased proteolysis of poly(ADP-ribose) indicate caspases mediate the cellular effects of Avemar. Activities of glucose-6-phosphate dehydrogenase and transketolase were inhibited in a dose-dependent fashion, which correlated with decreased C-13 incorporation and pentose cycle substrate flow into RNA ribose. This decrease in pentose cycle enzyme activities and carbon flow toward nucleic acid precursor synthesis provide the mechanistic understanding of the cell growth-controlling and apoptosis-inducing effects of fermented wheat germ. Avemar exhibits about a 50-fold higher IC50 (10.02 mg/ml) for peripheral blood lymphocytes to induce a biological response, which provides the broad therapeutic window for this supplemental cancer treatment modality with no toxic effects.	Univ Barcelona, Dept Biochem & Mol Biol, IDIBAPS, CeRQT PCB, E-08028 Barcelona, Spain; Univ Calif Los Angeles, Sch Med, Harbor UCLA Res & Educ Inst, Torrance, CA 90502 USA; CSIC, Dept Peptide & Prot Chem, Inst Chem & Environm Res, IIQAB, ES-08034 Barcelona, Spain; Univ Barcelona, Dept Cell Biol, IDIBAPS, Fac Med, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Consejo Superior de Investigaciones Cientificas (CSIC); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Cascante, M (corresponding author), Univ Barcelona, Dept Biochem & Mol Biol, IDIBAPS, CeRQT PCB, Barcelona Sci Pk,1 Marti & Franques, E-08028 Barcelona, Spain.		CASCANTE, MARTA/AAG-4355-2022; CASCANTE, MARTA/AFK-5991-2022; Torres, Josep Lluís/N-7256-2013; Boren, Joan/A-8515-2012; Centelles, Josep J./K-2972-2014; Marin, Silvia/C-5492-2017; Agell, Neus/E-9640-2016	CASCANTE, MARTA/0000-0002-2062-4633; CASCANTE, MARTA/0000-0002-2062-4633; Torres, Josep Lluís/0000-0002-5072-8265; Centelles, Josep J./0000-0002-6289-9678; Marin, Silvia/0000-0003-0693-2207; Agell, Neus/0000-0002-1205-6074	NATIONAL CANCER INSTITUTE [P01CA042710] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA42710] Funding Source: Medline; NCRR NIH HHS [M01-RR00425] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Boren J, 2001, J BIOL CHEM, V276, P37747; Boros LG, 2002, NEW ENGL J MED, V347, P67, DOI 10.1056/NEJM200207043470116; Boros LG, 2002, DRUG DISCOV TODAY, V7, P364, DOI 10.1016/S1359-6446(02)02179-7; Boros LG, 2001, PANCREAS, V23, P141, DOI 10.1097/00006676-200108000-00004; Boros LG, 1997, CANCER RES, V57, P4242; BOYUM A, 1968, SCAND J CLIN LAB S21, V97, P51; Cascante M, 2002, NAT BIOTECHNOL, V20, P243, DOI 10.1038/nbt0302-243; Castano E, 1999, BRIT J CANCER, V81, P294, DOI 10.1038/sj.bjc.6990690; Comin-Anduix B, 2001, MOL PHARMACOL, V60, P1235; de la HABA G., 1955, JOUR BIOL CHEM, V214, P409; DEMIDOV L, 2002, 18 UICC INT CANC C O; Fajka-Boja R, 2002, INT J ONCOL, V20, P563; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; Haridas V, 2001, P NATL ACAD SCI USA, V98, P5821, DOI 10.1073/pnas.101619098; Hidvegi M, 1998, ANTICANCER RES, V18, P2353; Hidvegi M, 1999, IMMUNOPHARMACOLOGY, V41, P183, DOI 10.1016/S0162-3109(99)00002-8; Inayat-Hussain SH, 2001, TOXICOL APPL PHARM, V175, P95, DOI 10.1006/taap.2001.9221; Jakab F, 2000, HEPATO-GASTROENTEROL, V47, P393; JAKAB F, 2001, HEPATAGASTROENTER S1, V48; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee WNP, 1998, AM J PHYSIOL-ENDOC M, V274, pE843, DOI 10.1152/ajpendo.1998.274.5.E843; MOMMSEN TP, 1980, CAN J ZOOL, V58, P1785, DOI 10.1139/z80-246; Orosz F, 1999, BRIT J CANCER, V79, P1356, DOI 10.1038/sj.bjc.6690218; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Pique M, 2000, FEBS LETT, V480, P193, DOI 10.1016/S0014-5793(00)01922-0; Reddy BS, 2000, CANCER RES, V60, P4792; SUTTLE S, 2000, RADIAT RES, V153, P781; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; Tian WN, 1999, AM J PHYSIOL-CELL PH, V276, pC1121, DOI 10.1152/ajpcell.1999.276.5.C1121; TIAN WN, 1994, J BIOL CHEM, V269, P14798; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Zalatnai A, 2001, CARCINOGENESIS, V22, P1649, DOI 10.1093/carcin/22.10.1649	32	79	81	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46408	46414		10.1074/jbc.M206150200	http://dx.doi.org/10.1074/jbc.M206150200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351627	hybrid, Green Published, Green Submitted			2022-12-27	WOS:000179529300092
J	Kim, JE; Jeong, HW; Nam, JO; Lee, BH; Choi, JY; Park, RW; Park, JY; Kim, IS				Kim, JE; Jeong, HW; Nam, JO; Lee, BH; Choi, JY; Park, RW; Park, JY; Kim, IS			Identification of motifs in the fasciclin domains of the transforming growth factor-beta-induced matrix protein beta ig-h3 that interact with the alpha v65 integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; IN-VITRO; GENE; ALPHA(V)BETA(3); FIBROBLASTS; BINDING; CHONDROCYTES; OSTEOPONTIN; SUPPRESSES; ACTIVATION	betaig-h3 is a TGF-beta-induced matrix protein known to mediate the adhesion of several cell types. In this study, we found that all four of the fas-1 domains in betaig-h3 mediate MRC-5 fibroblast adhesion and that this was specifically inhibited by a function-blocking monoclonal antibody specific for the alphavbeta5 integrin. Using deletion mutants of the fourth fas-1 domain revealed the MRC-5 cell adhesion motif (denoted the YH motif) is located in amino acids 548-614. Experiments with substitution mutants showed that tyrosine 571, histidine 572, and their flanking leucine and isoleucine amino acids, which are all highly conserved in many fas-1 domains, are essential for mediating MRC-5 cell adhesion. A synthetic 18-amino acid peptide encompassing these conserved amino acids could effectively block MRC-5 cell adhesion to betaig-h3. Using HEK293 cells stably trans-fected with the beta5 integrin cDNA, we confirmed that the alphavbeta5 integrin is a functional receptor for the YH motif. In conclusion, we have identified a new alphavbeta5 integrin-interacting motif that is highly conserved in the fas-1 domains of many proteins. This suggests that fas-1 domain-containing proteins may perform their biological functions by interacting with integrins.	Kyungpook Natl Univ, Sch Med, Dept Biochem,Cell & Matrix Biol Natl Res Lab, Jung Gu, Taegu 700422, South Korea; Dongguk Univ, Dept Biochem, Sch Med, Kyungju 780714, South Korea	Kyungpook National University; Dongguk University	Kim, IS (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Biochem,Cell & Matrix Biol Natl Res Lab, Jung Gu, 101 Dongindong, Taegu 700422, South Korea.	iskim@knu.ac.kr	김, 인산/I-8988-2014					Bayless KJ, 2000, AM J PATHOL, V156, P1673, DOI 10.1016/S0002-9440(10)65038-9; BOSSY B, 1990, BIOCHEMISTRY-US, V29, P10191, DOI 10.1021/bi00496a006; Datta A, 2002, J BIOL CHEM, V277, P3943, DOI 10.1074/jbc.M109536200; Dieudonne SC, 2000, J CELL BIOCHEM, V76, P231, DOI 10.1002/(SICI)1097-4644(20000201)76:2<231::AID-JCB7>3.0.CO;2-X; Gimeno MJ, 2001, HISTOL HISTOPATHOL, V16, P821, DOI 10.14670/HH-16.821; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Kawamoto T, 1998, BBA-GENE STRUCT EXPR, V1395, P288, DOI 10.1016/S0167-4781(97)00172-3; Kim IS, 1996, MOL CELL BIOL, V16, P4003; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Kim JE, 2000, J BIOL CHEM, V275, P30907, DOI 10.1074/jbc.M002752200; Kim JE, 2002, INVEST OPHTH VIS SCI, V43, P656; Kumar CC, 2001, CANCER RES, V61, P2232; LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523-1747.ep12607024; OBrien ER, 1996, ARTERIOSCL THROM VAS, V16, P576, DOI 10.1161/01.ATV.16.4.576; Ohno S, 1999, BBA-MOL CELL RES, V1451, P196, DOI 10.1016/S0167-4889(99)00093-2; Politz O, 2002, BIOCHEM J, V362, P155, DOI 10.1042/0264-6021:3620155; Rawe IM, 1997, INVEST OPHTH VIS SCI, V38, P893; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; SMITH JW, 1990, J BIOL CHEM, V265, P11008; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	24	161	167	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46159	46165		10.1074/jbc.M207055200	http://dx.doi.org/10.1074/jbc.M207055200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270930	hybrid			2022-12-27	WOS:000179529300061
J	Zhang, RL; Brennan, ML; Shen, ZZ; MacPherson, JC; Schmitt, D; Molenda, CE; Hazen, SL				Zhang, RL; Brennan, ML; Shen, ZZ; MacPherson, JC; Schmitt, D; Molenda, CE; Hazen, SL			Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MASS-SPECTROMETRIC QUANTIFICATION; DITYROSINE CROSS-LINKING; NITRIC-OXIDE; ARACHIDONIC-ACID; OXIDATIVE STRESS; HYDROXYEICOSATETRAENOIC ACIDS; PHOSPHOLIPID OXIDATION; NITROGEN-DIOXIDE; NITRATION	Initiation of lipid peroxidation and the formation of bioactive eicosanoids are pivotal processes in inflammation and atherosclerosis. Currently, lipoxygenases, cyclooxygenases, and cytochrome P450 monooxygenases are considered the primary enzymatic participants in these events. Myeloperoxidase (MPO), a heme protein secreted by activated leukocytes, generates reactive intermediates that promote lipid peroxidation in vitro. For example, MPO catalyzes oxidation of tyrosine and nitrite to form tyrosyl radical and nitrogen dioxide ('NO2), respectively, reactive intermediates capable of initiating oxidation of lipids in plasma. Neither the ability of MPO to initiate lipid peroxidation in vivo nor its role in generating bioactive eicosanoids during inflammation has been reported. Using a model of inflammation (peritonitis) with MPO knockout mice (MPO-/-), we examined the role for MPO in the formation of bioactive lipid oxidation products and promoting oxidant stress in vivo. Electrospray ionization tandem mass spectrometry was used to simultaneously quantify individual molecular species of hydroxy- and hydroperoxy-eicosatetraenoic acids (H(P)ETEs), F-2-isoprostanes, hydroxy- and hydroperoxy-octadecadienoic acids (H(P)ODEs), and their precursors, arachidonic acid and linoleic acid. Peritonitis-triggered formation of F-2-isoprostanes, a marker of oxidant stress in vivo, was reduced by 85% in the MPO-/- mice. Similarly, formation of all molecular species of H(P)ETEs and H(P)ODEs monitored were significantly reduced (by at least 50%) in the MPO-/- group during inflammation. Parallel analyses of peritoneal lavage proteins for protein dityrosine and nitrotyrosine, molecular markers for oxidative modification by tyrosyl radical and 'NO2, respectively, revealed marked reductions in the content of nitrotyrosine, but not dityrosine, in MPO-/- samples. Thus, MPO serves as a major enzymatic catalyst of lipid peroxidation at sites of inflammation. Moreover, MPO-dependent formation of 'NO-derived oxidants, and not tyrosyl radical, appears to serve as a preferred pathway for initiating lipid peroxidation and promoting oxidant stress in vivo.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University	Hazen, SL (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.	hazens@ccf.org	Hazen, Stanley L/ABD-5845-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062526, R01HL061878, R01HL070621] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61878, HL70621, HL62526] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524; Abu-Soud HM, 2000, J BIOL CHEM, V275, P5425, DOI 10.1074/jbc.275.8.5425; Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P11866, DOI 10.1021/bi011206v; Abu-Soud Husam M., 2000, Nitric Oxide, V4, P179; Baldus S, 2001, J CLIN INVEST, V108, P1759; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Bhattacharjee S, 2001, ARCH BIOCHEM BIOPHYS, V395, P69, DOI 10.1006/abbi.2001.2557; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Carr AC, 2001, J BIOL CHEM, V276, P1822, DOI 10.1074/jbc.M009082200; Cathcart MK, 2000, FREE RADICAL BIO MED, V28, P1726, DOI 10.1016/S0891-5849(00)00230-6; Chisolm GM, 1999, J BIOL CHEM, V274, P25959, DOI 10.1074/jbc.274.37.25959; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; Dworski R, 2001, CLIN EXP ALLERGY, V31, P387, DOI 10.1046/j.1365-2222.2001.01055.x; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; Exner M, 2001, FEBS LETT, V490, P28, DOI 10.1016/S0014-5793(01)02131-7; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gaut JP, 2002, J CLIN INVEST, V109, P1311, DOI 10.1172/JCI200215021; Goss SPA, 1999, FREE RADICAL RES, V31, P597, DOI 10.1080/10715769900301171; Hazen SL, 1999, METHOD ENZYMOL, V300, P88; Hazen SL, 1999, CIRC RES, V85, P950; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Heinecke JW, 2002, TOXICOLOGY, V177, P11, DOI 10.1016/S0300-483X(02)00192-0; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HENDERSON WR, 1983, J BIOL CHEM, V258, P3522; Hogg N, 1998, FREE RADICAL RES, V28, P593, DOI 10.3109/10715769809065815; Jacob JS, 1996, J BIOL CHEM, V271, P19950, DOI 10.1074/jbc.271.33.19950; KUEHL FA, 1980, SCIENCE, V210, P978, DOI 10.1126/science.6254151; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Mallat Z, 1999, J CLIN INVEST, V103, P421, DOI 10.1172/JCI3985; Marathe GK, 2000, FREE RADICAL BIO MED, V28, P1762, DOI 10.1016/S0891-5849(00)00234-3; Mukhopadhyay CK, 1998, BIOCHEMISTRY-US, V37, P14222, DOI 10.1021/bi981137t; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Noguchi N, 2000, J BIOCHEM-TOKYO, V127, P971, DOI 10.1093/oxfordjournals.jbchem.a022713; O'Donnell VB, 1999, CHEM RES TOXICOL, V12, P83, DOI 10.1021/tx980207u; Pennathur S, 1999, J BIOL CHEM, V274, P34621, DOI 10.1074/jbc.274.49.34621; Podrez EA, 2000, FREE RADICAL BIO MED, V28, P1717, DOI 10.1016/S0891-5849(00)00229-X; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Pratico D, 1998, P NATL ACAD SCI USA, V95, P3449, DOI 10.1073/pnas.95.7.3449; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; PRYOR WA, 1983, SCIENCE, V220, P425, DOI 10.1126/science.6301009; ROBERTS LJ, 1994, ANN NY ACAD SCI, V744, P237, DOI 10.1111/j.1749-6632.1994.tb52741.x; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; SANTANAM N, 1995, J CLIN INVEST, V95, P2594, DOI 10.1172/JCI117961; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; Schmitt D, 1999, BIOCHEMISTRY-US, V38, P16904, DOI 10.1021/bi991623w; SEVANIAN A, 1982, J TOXICOL ENV HEALTH, V10, P743, DOI 10.1080/15287398209530292; Shigenaga MK, 1997, P NATL ACAD SCI USA, V94, P3211, DOI 10.1073/pnas.94.7.3211; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; SPECTOR AA, 1988, PROG LIPID RES, V27, P271, DOI 10.1016/0163-7827(88)90009-4; Subbanagounder G, 2000, FREE RADICAL BIO MED, V28, P1751, DOI 10.1016/S0891-5849(00)00233-1; van Dalen CJ, 2000, J BIOL CHEM, V275, P11638, DOI 10.1074/jbc.275.16.11638; van der Vliet A, 1999, AM J RESP CRIT CARE, V160, P1; Wink DA, 1995, TOXICOL LETT, V82-3, P221, DOI 10.1016/0378-4274(95)03557-5; Yla-Herttuala S, 1999, ANN NY ACAD SCI, V874, P134, DOI 10.1111/j.1749-6632.1999.tb09231.x; Zhang RL, 2002, BLOOD, V99, P1802, DOI 10.1182/blood.V99.5.1802.h8001802_1802_1810	64	330	366	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46116	46122		10.1074/jbc.M209124200	http://dx.doi.org/10.1074/jbc.M209124200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12359714	hybrid			2022-12-27	WOS:000179529300055
J	Kiat, LS; Hui, KM; Gopalan, G				Kiat, LS; Hui, KM; Gopalan, G			Aurora-a kinase interacting protein (AIP), a novel negative regulator of human aurora-A kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE-DEPENDENT EXPRESSION; ANAPHASE-PROMOTING COMPLEX; POLO-LIKE KINASES; CELL-CYCLE; CHROMOSOME SEGREGATION; MICROTUBULE DYNAMICS; BREAST-CANCER; YEAST; SPINDLE; FAMILY	Aurora kinases have evolved as a new family of mitotic centrosome- and microtubule-associated kinases that regulate the structure and function of centrosomes and spindle. One of its members, Aurora-A, is a potential oncogene. Overexpression of Aurora-A is also implicated in defective centrosome duplication and segregation, leading to aneuploidy and tumorigenesis in various cancer cell types. However, the regulatory pathways for mammalian Aurora-A are not well understood. Exploiting the lethal phenotype associated with the overexpression of Aurora-A in yeast, we performed a dosage suppressor screen in yeast and report here the identification of a novel negative regulator of Aurora-A, named AIP (Aurora-A kinase Interacting Protein). AIP is a ubiquitously expressed nuclear protein that interacts specifically with human Aurora-A in vivo. Ectopic expression of AIP with Aurora-A in NIH 3T3 and COS cells results in the down-regulation of ectopically expressed Aurora-A protein levels, and this down-regulation is demonstrated to be the result of destabilization of Aurora-A through a proteasome-dependent protein degradation pathway. A noninteracting deletion mutant of AIP does not down-regulate Aurora-A protein, suggesting that the interaction is important for the protein degradation. AIP could therefore be a potential useful target gene for anti-tumor drugs.	Natl Canc Ctr, Gene Struct & Express Lab, Div Cellular & Mol Res, Singapore 169610, Singapore	National Cancer Centre Singapore (NCCS)	Gopalan, G (corresponding author), Natl Canc Ctr, Gene Struct & Express Lab, Div Cellular & Mol Res, Level 6,11 Hosp Dr, Singapore 169610, Singapore.	cmrgop@nccs.com.sg	Hui, Kam/C-6186-2011	Hui, Kam/0000-0003-1820-1399				Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Andersen SSL, 1999, BIOESSAYS, V21, P53, DOI 10.1002/(SICI)1521-1878(199901)21:1<53::AID-BIES7>3.0.CO;2-L; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; CENTONZE VE, 1990, J CELL SCI, V95, P405; CHAN CSM, 1993, GENETICS, V135, P677; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Courjal F, 1996, BRIT J CANCER, V74, P1984, DOI 10.1038/bjc.1996.664; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; De Angelis PM, 1999, BRIT J CANCER, V80, P526; Donaldson MM, 2001, J CELL SCI, V114, P2357; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Geiser JR, 1997, MOL BIOL CELL, V8, P1035, DOI 10.1091/mbc.8.6.1035; Giet R, 1999, J CELL SCI, V112, P3591; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hilioti Z, 2001, CURR BIOL, V11, P1347, DOI 10.1016/S0960-9822(01)00399-2; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Inoue T, 2001, J BIOL CHEM, V276, P45255, DOI 10.1074/jbc.M107477200; Isaacs JS, 2001, J BIOL CHEM, V276, P18497, DOI 10.1074/jbc.M100638200; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kimura M, 1999, J BIOL CHEM, V274, P7334, DOI 10.1074/jbc.274.11.7334; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 1996, EXP CELL RES, V229, P174, DOI 10.1006/excr.1996.0356; Nigg EA, 2001, E SCHERING RES FDN W, V34, P19; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Niwa H, 1996, GENE, V169, P197, DOI 10.1016/0378-1119(95)00809-8; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Sassoon I, 1999, GENE DEV, V13, P545, DOI 10.1101/gad.13.5.545; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Shindo M, 1998, BIOCHEM BIOPH RES CO, V244, P285, DOI 10.1006/bbrc.1998.8250; Straight AF, 1997, CURR BIOL, V7, pR613, DOI 10.1016/S0960-9822(06)00315-0; TANNER MM, 1994, CANCER RES, V54, P4257; Tatsuka M, 1998, CANCER RES, V58, P4811; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TUNG HYL, 1995, MOL CELL BIOL, V15, P6064; VANDRE DD, 1989, J CELL SCI, V94, P245; VANDRE DD, 1986, EUR J CELL BIOL, V41, P72; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	57	31	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45558	45565		10.1074/jbc.M206820200	http://dx.doi.org/10.1074/jbc.M206820200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244051	hybrid			2022-12-27	WOS:000179404800121
J	Lantto, J; Ohlin, M				Lantto, J; Ohlin, M			Functional consequences of insertions and deletions in the complementarity-determining regions of human antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOMATIC HYPERMUTATION; ANTIGEN INTERACTIONS; STRUCTURAL REPERTOIRE; FRAMEWORK RESIDUE-71; HYPERVARIABLE LOOPS; RECEPTOR REVISION; IMMUNE-RESPONSE; B-LYMPHOCYTES; BINDING-SITE; HEAVY	Insertions and deletions of nucleotides in the genes encoding the variable domains of antibodies are natural components of the hypermutation process, which may expand the available repertoire of hypervariable loop lengths and conformations. Although insertion of amino acids has also been utilized in antibody engineering, little is known about the functional consequences of such modifications. To investigate this further, we have introduced single-codon insertions and deletions as well as more complex modifications in the complementarity-determining regions of human antibody fragments with different specificities. Our results demonstrate that single amino acid insertions and deletions are generally well tolerated and permit production of stably folded proteins, often with retained antigen recognition, despite the fact that the thus modified loops carry amino acids that are disallowed at key residue positions in canonical loops of the corresponding length or are of a length not associated with a known canonical structure. We have thus shown that single-codon insertions and deletions can efficiently be utilized to expand structure and sequence space of the antigen-binding site beyond what is encoded by the germline gene repertoire.	Lund Univ, Dept Immunotechnol, S-22007 Lund, Sweden	Lund University	Ohlin, M (corresponding author), Lund Univ, Dept Immunotechnol, POB 7031, S-22007 Lund, Sweden.		Ohlin, Mats/A-7307-2010	Ohlin, Mats/0000-0002-5105-1938; Lantto, Johan/0000-0002-8650-7157				AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; Brezinschek HP, 1997, J CLIN INVEST, V99, P2488, DOI 10.1172/JCI119433; CHOTHIA C, 1992, J MOL BIOL, V227, P799, DOI 10.1016/0022-2836(92)90224-8; de Wildt RMT, 1999, J MOL BIOL, V285, P895, DOI 10.1006/jmbi.1998.2396; de Wildt RMT, 1999, J MOL BIOL, V294, P701, DOI 10.1006/jmbi.1999.3289; Ellmark P, 2002, MOL IMMUNOL, V39, P349, DOI 10.1016/S0161-5890(02)00109-8; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; HELMS LR, 1995, PROTEIN SCI, V4, P2073, DOI 10.1002/pro.5560041012; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Itoh K, 2000, J EXP MED, V192, P1151, DOI 10.1084/jem.192.8.1151; Jirholt P, 2001, PROTEIN ENG, V14, P67, DOI 10.1093/protein/14.1.67; Jirholt P, 1998, GENE, V215, P471, DOI 10.1016/S0378-1119(98)00317-5; Lamminmaki U, 1999, J MOL BIOL, V291, P589, DOI 10.1006/jmbi.1999.2981; Lantto J, 2002, J GEN VIROL, V83, P2001, DOI 10.1099/0022-1317-83-8-2001; Lantto J, 2002, EUR J IMMUNOL, V32, P1659, DOI 10.1002/1521-4141(200206)32:6<1659::AID-IMMU1659>3.0.CO;2-9; Lantto J, 2002, J MOL EVOL, V54, P346, DOI 10.1007/s00239-001-0049-2; LANTTO J, 2002, IN PRESS VIROLOGY; Lantto Johan, 2002, Methods Mol Biol, V178, P303; Lefranc MP, 2001, NUCLEIC ACIDS RES, V29, P207, DOI 10.1093/nar/29.1.207; MacCallum RM, 1996, J MOL BIOL, V262, P732, DOI 10.1006/jmbi.1996.0548; Martin ACR, 1996, J MOL BIOL, V263, P800, DOI 10.1006/jmbi.1996.0617; McGrew JT, 1997, GENE, V187, P193, DOI 10.1016/S0378-1119(96)00747-0; McMahon MJ, 2000, J IMMUNOL METHODS, V241, P1, DOI 10.1016/S0022-1759(00)00196-4; Nemazee D, 2000, J EXP MED, V191, P1813, DOI 10.1084/jem.191.11.1813; Noppe SM, 1999, BRIT J HAEMATOL, V107, P625, DOI 10.1046/j.1365-2141.1999.01732.x; OHLIN M, 1993, J VIROL, V67, P703, DOI 10.1128/JVI.67.2.703-710.1993; Ohlin M, 1996, MOL IMMUNOL, V33, P47, DOI 10.1016/0161-5890(95)00123-9; Ohlin M, 1998, MOL IMMUNOL, V35, P233, DOI 10.1016/S0161-5890(98)00030-3; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Parhami-Seren B, 2002, J IMMUNOL METHODS, V259, P43, DOI 10.1016/S0022-1759(01)00488-4; Soderlind E, 2000, NAT BIOTECHNOL, V18, P852, DOI 10.1038/78458; TOMLINSON IM, 1995, EMBO J, V14, P4628, DOI 10.1002/j.1460-2075.1995.tb00142.x; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TRAMONTANO A, 1990, J MOL BIOL, V215, P175, DOI 10.1016/S0022-2836(05)80102-0; VARGASMADRAZO E, 1995, J MOL BIOL, V254, P497, DOI 10.1006/jmbi.1995.0633; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; Whitelegg NRJ, 2000, PROTEIN ENG, V13, P819, DOI 10.1093/protein/13.12.819; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C; Wilson PC, 2000, J EXP MED, V191, P1881, DOI 10.1084/jem.191.11.1881; Wilson PC, 1998, J EXP MED, V187, P59, DOI 10.1084/jem.187.1.59; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; XIANG J, 1995, J MOL BIOL, V253, P385, DOI 10.1006/jmbi.1995.0560	44	16	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45108	45114		10.1074/jbc.M208401200	http://dx.doi.org/10.1074/jbc.M208401200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237318	hybrid			2022-12-27	WOS:000179404800067
J	Morris, MT; Coppin, A; Tomavo, S; Carruthers, VB				Morris, MT; Coppin, A; Tomavo, S; Carruthers, VB			Functional analysis of Toxoplasma gondii protease inhibitor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITOPHOROUS VACUOLE MEMBRANE; PROTEINASE-INHIBITORS; MOLECULAR CHARACTERIZATION; POLYACRYLAMIDE-GELS; MYXOMA VIRUS; TRYPSIN; COMPLEX; SECRETION; MECHANISM; SERPIN	We have characterized a Kazal family serine protease inhibitor, Toxoplasma gondii protease inhibitor 1 (TgPI-1), in the obligate intracellular parasite Toxoplasma gondii. TgPI-1 contains four inhibitor domains predicted to inhibit trypsin, chymotrypsin, and elastase. Antibodies against recombinant TgPI-1 detect two polypeptides, of 43 and 41 kDa, designated TgPI-1(43) and TgPI-1(41), in tachyzoites, bradyzoites, and sporozoites. TgPI-1(43) and TgPI-1(41) are secreted constitutively from dense granules into the excreted/secreted antigen fraction as well as the parasitophorous vacuole that T. gondii occupies during intracellular replication. Recombinant TgPI-1 inhibits trypsin, chymotrypsin, pancreatic elastase, and neutrophil elastase. Immunoprecipitation studies with anti-rTgPI-1 antibodies reveal that recombinant TgPI-1 forms a complex with trypsin that is dependent on interactions with the active site of the pro- tease. TgPI-1 is the first anti-trypsin/chymotrypsin inhibitor to be identified in bradyzoites and sporozoites, stages of the parasite that would be exposed to proteolytic enzymes in the digestive tract of the host.	Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Univ Sci & Technol Lille, CNRS, Chim Biol Lab, UMR 8576, F-59655 Villeneuve Dascq, France	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Carruthers, VB (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, 615 N Wolfe St, Baltimore, MD 21205 USA.	vcarruth@jhsph.edu		Carruthers, Vern/0000-0001-6859-8895	NIAID NIH HHS [AI074417-06, R01 AI046675] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI074417, R01AI046675, R56AI074417] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Black MW, 2000, MICROBIOL MOL BIOL R, V64, P607, DOI 10.1128/MMBR.64.3.607-623.2000; Bliss SK, 2001, INFECT IMMUN, V69, P4898, DOI 10.1128/IAI.69.8.4898-4905.2001; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Brydges SD, 2000, MOL BIOCHEM PARASIT, V111, P51, DOI 10.1016/S0166-6851(00)00296-6; Carruthers VB, 2000, J BIOL CHEM, V275, P14346, DOI 10.1074/jbc.275.19.14346; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; CARTER AO, 1986, CAN MED ASSOC J, V135, P618; CESBRONDELAUW MF, 1993, RES IMMUNOL, V144, P41, DOI 10.1016/S0923-2494(05)80096-3; CORNELISSEN AWCA, 1981, PARASITOLOGY, V83, P103, DOI 10.1017/S0031182000050071; Del Rio L, 2001, J IMMUNOL, V167, P6503, DOI 10.4049/jimmunol.167.11.6503; Dzierszinski F, 1999, J BIOL CHEM, V274, P24888, DOI 10.1074/jbc.274.35.24888; KAZAL LA, 1948, J AM CHEM SOC, V70, P3034, DOI 10.1021/ja01189a060; KHAN IA, 2001, AM ASSN IMMUNOLOGIST, V1, P1930; Labruyere E, 1999, MOL BIOCHEM PARASIT, V102, P311, DOI 10.1016/S0166-6851(99)00092-4; Laskowski Jr. M., 2000, PROTEIN PROTEIN RECO, P228; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LASKOWSKI M, 1968, ANN NY ACAD SCI, V146, P374, DOI 10.1111/j.1749-6632.1968.tb20295.x; LAURA R, 1980, BIOCHEMISTRY-US, V19, P4859, DOI 10.1021/bi00562a024; LECORDIER L, 1993, MOL BIOCHEM PARASIT, V59, P143, DOI 10.1016/0166-6851(93)90015-P; Lingelbach K, 1998, J CELL SCI, V111, P1467; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; LUTHY JA, 1973, J BIOL CHEM, V248, P1760; MACEN JL, 1993, VIROLOGY, V195, P348, DOI 10.1006/viro.1993.1385; Mercier C, 1998, J CELL SCI, V111, P2171; Milstone AM, 2000, J BIOL CHEM, V275, P29391, DOI 10.1074/jbc.M002715200; Nash P, 1998, J BIOL CHEM, V273, P20982, DOI 10.1074/jbc.273.33.20982; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Onnerfjord P, 1999, RAPID COMMUN MASS SP, V13, P315; OSSORIO PN, 1994, J BIOL CHEM, V269, P15350; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Pszenny V, 2000, MOL BIOCHEM PARASIT, V107, P241, DOI 10.1016/S0166-6851(00)00202-4; Roberts RM, 1995, CRIT REV EUKAR GENE, V5, P385, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.80; SHARMA SP, 1981, AM J VET RES, V42, P128; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIBLEY LD, 1995, J CELL SCI, V108, P1669; SILVERMAN JA, 1997, HOST RESPONSE INTRAC, P315; Speer CA, 1995, MOL BIOCHEM PARASIT, V75, P75, DOI 10.1016/0166-6851(95)02515-4; Stubbs MT, 1997, J BIOL CHEM, V272, P19931, DOI 10.1074/jbc.272.32.19931; Turner PC, 2001, ASM NEWS, V67, P201; VANDELOCHT A, 1995, EMBO J, V14, P5149, DOI 10.1002/j.1460-2075.1995.tb00199.x; Wan KL, 1997, MOL BIOCHEM PARASIT, V84, P203, DOI 10.1016/S0166-6851(96)02796-X	42	58	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45259	45266		10.1074/jbc.M205517200	http://dx.doi.org/10.1074/jbc.M205517200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228242	hybrid			2022-12-27	WOS:000179404800086
J	Kiakos, K; Howard, TT; Lee, M; Hartley, JA; McHugh, PJ				Kiakos, K; Howard, TT; Lee, M; Hartley, JA; McHugh, PJ			Saccharomyces cerevisiae RAD5 influences the excision repair of DNA minor groove adducts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING-ENZYME; SIMPLE REPETITIVE SEQUENCES; THYMINE-THYMINE DIMER; UV-DAMAGED DNA; POSTREPLICATION REPAIR; POLYUBIQUITIN CHAINS; POLYMERASE-DELTA; ERROR-PRONE; YEAST RAD6; PROTEIN	Nucleotide excision repair (NER) is the primary pathway for the removal of DNA adducts that distort the double helix. In the yeast Saccharomyces cerevisiae the RAD6 epistasis group defines a more poorly characterized set of DNA damage response pathways, believed to be distinct from NER. Here we show that the elimination of the DNA minor groove adducts formed by an important class of anticancer antibiotic (CC-1065 family) requires NER factors in S. cerevisiae. We also demonstrate that the elimination of this class of minor groove adduct from the active MFA2 gene depends upon functional Rad18 and Rad6. This is most clear for the repair of adducts on the transcribed strand, where an absolute requirement for Rad6 and Rad18 was seen. Further experiments revealed that a specific RAD6-RAD18-controlled subpathway, the RAD5 branch, mediates these events. Cells disrupted for rad5 are highly sensitive to this minor groove binding agent, and rad5 cells exhibit an in vivo adduct elimination defect indistinguishable from that seen in rad6 and rad18 cells as well as in NER-defective cells. Our results indicate that the RAD5 subpathway may interact with NER factors during the repair of certain DNA adducts.	UCL, Royal Free & Univ Coll, Sch Med,Dept Oncol, Canc Res UK Drug DNA Interact Res Grp, London W1W 7BS, England; Furman Univ, Dept Chem, Greenville, SC 29613 USA	Cancer Research UK; University of London; University College London; UCL Medical School	McHugh, PJ (corresponding author), Univ Oxford, Canc Res UK Mol Oncol Labs, Weatherall Inst Mol Med, John Radcliffe Hosp, Oxford OX3 9DS, England.	peter.mchugh@cancer.org.uk	Hartley, John/GRY-6691-2022	McHugh, Peter/0000-0002-8679-4627				Ahne F, 1997, NUCLEIC ACIDS RES, V25, P743, DOI 10.1093/nar/25.4.743; Bailly V, 1997, MOL CELL BIOL, V17, P4536, DOI 10.1128/MCB.17.8.4536; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Balajee AS, 2000, GENE, V250, P15, DOI 10.1016/S0378-1119(00)00172-4; BANKMANN M, 1992, NATURE, V355, P555, DOI 10.1038/355555a0; Bessho T, 1997, MOL CELL BIOL, V17, P6822, DOI 10.1128/MCB.17.12.6822; Brooks N, 2000, CHEM BIOL, V7, P659, DOI 10.1016/S1074-5521(00)00010-7; Broomfield S, 1998, P NATL ACAD SCI USA, V95, P5678, DOI 10.1073/pnas.95.10.5678; Broomfield S, 2001, MUTAT RES-DNA REPAIR, V486, P167, DOI 10.1016/S0921-8777(01)00091-X; Cejka P, 2001, GENETICS, V159, P953; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Grimaldi K A, 1997, Methods Mol Biol, V90, P157; Gunz D, 1996, J BIOL CHEM, V271, P25089, DOI 10.1074/jbc.271.41.25089; HANAWALT PC, 1989, GENOME, V2, P605; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Howard TT, 2002, BIOORGAN MED CHEM, V10, P2941, DOI 10.1016/S0968-0896(02)00157-8; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; Huang ME, 2000, CURR GENET, V38, P178, DOI 10.1007/s002940000149; HURLEY LH, 1984, SCIENCE, V226, P843, DOI 10.1126/science.6494915; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; JOHNSON RE, 1994, J BIOL CHEM, V269, P28259; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Kuraoka I, 2000, J BIOL CHEM, V275, P26632, DOI 10.1074/jbc.C000337200; Li SS, 1999, J BIOL CHEM, V274, P12201, DOI 10.1074/jbc.274.18.12201; MCCREADY S, 1994, MUTAT RES-DNA REPAIR, V315, P261, DOI 10.1016/0921-8777(94)90037-X; McDonald JP, 1997, GENETICS, V147, P1557; McHugh PJ, 1999, NUCLEIC ACIDS RES, V27, P3259, DOI 10.1093/nar/27.16.3259; Mu D, 2000, MOL CELL BIOL, V20, P2446, DOI 10.1128/MCB.20.7.2446-2454.2000; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; PICOLOGLOU S, 1990, MOL CELL BIOL, V10, P1017, DOI 10.1128/MCB.10.3.1017; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; REYNOLDS VL, 1986, J ANTIBIOT, V39, P319, DOI 10.7164/antibiotics.39.319; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SELBY CP, 1988, BIOCHEMISTRY-US, V27, P7184, DOI 10.1021/bi00419a004; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Torres-Ramos CA, 2002, MOL CELL BIOL, V22, P2419, DOI 10.1128/MCB.22.7.2419-2426.2002; TorresRamos CA, 1997, J BIOL CHEM, V272, P25445, DOI 10.1074/jbc.272.41.25445; TorresRamos CA, 1996, P NATL ACAD SCI USA, V93, P9676, DOI 10.1073/pnas.93.18.9676; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; Ulrich HD, 2001, NUCLEIC ACIDS RES, V29, P3487, DOI 10.1093/nar/29.17.3487; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Xiao W, 2000, GENETICS, V155, P1633; Xiao W, 1999, MUTAT RES-DNA REPAIR, V435, P1, DOI 10.1016/S0921-8777(99)00034-8; Xiao W, 1996, CURR GENET, V30, P461, DOI 10.1007/s002940050157	51	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44576	44581		10.1074/jbc.M208169200	http://dx.doi.org/10.1074/jbc.M208169200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226100	hybrid			2022-12-27	WOS:000179272000130
J	Sevcik, J; Urbanikova, L; Leland, PA; Raines, RT				Sevcik, J; Urbanikova, L; Leland, PA; Raines, RT			X-ray structure of two crystalline forms of a Streptomycete ribonuclease with cytotoxic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE SEMINAL RIBONUCLEASE; ELECTRON-DENSITY MAPS; CONFORMATIONAL STABILITY; EXOCELLULAR RIBONUCLEASE; BIOLOGICAL-ACTIVITIES; CATALYTIC ACTIVITY; PROTEIN STABILITY; ALPHA-SARCIN; RNASE SA; AUREOFACIENS	Ribonuclease (RNase) Sa3 is secreted by the Gram-positive bacterium Streptomyces aureofaciens. The enzyme catalyzes the cleavage of RNA on the 3' side of guanosine residues. Here, x-ray diffraction analysis was used to determine the three-dimensional structure of two distinct crystalline forms of RNase Sa3 to a resolution of 2.0 and 1.7 Angstrom. These two structures are similar to each other as well as to that of a homolog, RNase Sa. All of the key active-site residues of RNase Sa (Asn(42), Glu(44), Glu(57), Arg(72), and His(88)) are located in the putative active site of RNase Sa3. Also herein, RNase Sa3 is shown to be toxic to human erythroleukemia cells in culture. Like onconase, which is an amphibian ribonuclease in Phase III clinical trials as a cancer chemotherapeutic, RNase Sa3 is not inhibited by the cytosolic ribonuclease inhibitor protein. Thus, a prokaryotic ribonuclease can be toxic to mammalian cells.	Slovak Acad Sci, Inst Mol Biol, Bratislava 84251, Slovakia; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA	Slovak Academy of Sciences; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Sevcik, J (corresponding author), Slovak Acad Sci, Inst Mol Biol, Dubravska Cesta 21, Bratislava 84251, Slovakia.		Raines, Ronald T./A-5009-2013	Raines, Ronald T./0000-0001-7164-1719; Urbanikova, Lubica/0000-0002-5592-8346	NCI NIH HHS [CA73808] Funding Source: Medline; NIGMS NIH HHS [T32 GM07215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073808] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACOVA M, 1971, BIOCHIM BIOPHYS ACTA, V235, P335, DOI 10.1016/0005-2744(71)90212-9; Bretscher LE, 2000, J BIOL CHEM, V275, P9893, DOI 10.1074/jbc.275.14.9893; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CAFARO V, 1995, FEBS LETT, V359, P31, DOI 10.1016/0014-5793(94)01450-F; CHO SW, 1989, ANAL BIOCHEM, V176, P175, DOI 10.1016/0003-2697(89)90289-3; Cruickshank D.W.J, 1996, P CCP4 STUD WEEK, P11; EGAMI F, 1964, PROG NUCLEIC ACID RE, V3, P59, DOI 10.1016/S0079-6603(08)60739-4; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Futami J, 2001, BIOCHEMISTRY-US, V40, P7518, DOI 10.1021/bi010248g; Haigis MC, 2002, J BIOL CHEM, V277, P11576, DOI 10.1074/jbc.M112227200; HARTLEY RW, 1980, J MOL EVOL, V15, P355, DOI 10.1007/BF01733142; HARTLEY RW, 1996, PROTEIN PEPTIDE LETT, V4, P225; Hebert EJ, 1997, PROTEIN EXPRES PURIF, V11, P162, DOI 10.1006/prep.1997.0776; Hebert EJ, 1998, BIOCHEMISTRY-US, V37, P16192, DOI 10.1021/bi9815243; Hlinkova V, 2001, ACTA CRYSTALLOGR D, V57, P737, DOI 10.1107/S0907444901003456; Hofsteenge J., 1997, RIBONUCLEASES STRUCT, P621, DOI [10.1016/b978-012588945-2/50020-0, DOI 10.1016/B978-012588945-2/50020-0]; HOMEROVA D, 1992, GENE, V119, P147, DOI 10.1016/0378-1119(92)90082-Z; Ilinskaya O, 2001, TOXICOLOGY, V156, P101, DOI 10.1016/S0300-483X(00)00335-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kao R, 1999, J BIOL CHEM, V274, P12576, DOI 10.1074/jbc.274.18.12576; KIM JS, 1995, J BIOL CHEM, V270, P10525, DOI 10.1074/jbc.270.18.10525; KIM JS, 1995, BIOCHEM J, V308, P547, DOI 10.1042/bj3080547; Klink TA, 2000, J BIOL CHEM, V275, P17463, DOI 10.1074/jbc.M001132200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leland PA, 1998, P NATL ACAD SCI USA, V95, P10407, DOI 10.1073/pnas.95.18.10407; Leland PA, 2001, J BIOL CHEM, V276, P43095, DOI 10.1074/jbc.M106636200; Leland PA, 2001, CHEM BIOL, V8, P405, DOI 10.1016/S1074-5521(01)00030-8; Leland PA, 2000, FEBS LETT, V477, P203, DOI 10.1016/S0014-5793(00)01804-4; Madan T, 1997, MOL CELL BIOCHEM, V175, P21, DOI 10.1023/A:1006822906343; Matousek J, 2001, COMP BIOCHEM PHYS C, V129, P175, DOI 10.1016/S1532-0456(01)90202-9; Matousek J, 1997, COMP BIOCHEM PHYS B, V118, P881, DOI 10.1016/S0305-0491(97)00278-2; Mikulski SM, 2002, J CLIN ONCOL, V20, P274, DOI 10.1200/JCO.20.1.274; Murshudov G.N., 1997, CCP4 NEWSLETTER, V33, P31; MURTHY BS, 1992, BIOCHEM J, V281, P343, DOI 10.1042/bj2810343; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; NAZAROV V, 1991, THESIS I MOL BIOL; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pace CN, 2000, PROTEIN SCI, V9, P1395; Pace CN, 2001, J MOL BIOL, V312, P393, DOI 10.1006/jmbi.2001.4956; Perez-Canadillas JM, 2000, J MOL BIOL, V299, P1061, DOI 10.1006/jmbi.2000.3813; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; RAPPUOLI R, 1997, GUIDEBOOK PROTEIN TO; SCHINDLER DG, 1977, NUCLEIC ACIDS RES, V4, P1097, DOI 10.1093/nar/4.4.1097; SEVCIK J, 1993, ACTA CRYSTALLOGR D, V49, P257, DOI 10.1107/S0907444992007261; SEVCIK J, 1991, ACTA CRYSTALLOGR B, V47, P240, DOI 10.1107/S0108768190009569; Sevcik J, 1996, ACTA CRYSTALLOGR D, V52, P327, DOI 10.1107/S0907444995007669; SEVCIK J, 1993, EUR J BIOCHEM, V216, P301, DOI 10.1111/j.1432-1033.1993.tb18145.x; Sevcik J, 1998, ACTA CRYSTALLOGR D, V54, P954, DOI 10.1107/S0907444998004429; SEVCIK J, 1990, TRENDS BIOCHEM SCI, V15, P158, DOI 10.1016/0968-0004(90)90217-Y; Shapiro R, 2001, METHOD ENZYMOL, V341, P611, DOI 10.1016/S0076-6879(01)41180-3; Shaw KL, 2001, PROTEIN SCI, V10, P1206, DOI 10.1110/ps.440101; SHLYAPNIKOV SV, 1986, FEBS LETT, V209, P335; Urbanikova L, 1998, ACTA CRYSTALLOGR D, V54, P403, DOI 10.1107/S0907444997010688; Wilson AJC, 1942, NATURE, V150, P151, DOI 10.1038/150152a0; Wool I.G., 1997, RIBONUCLEASES STRUCT, P131; WU YN, 1993, J BIOL CHEM, V268, P10686; Yang XJ, 1996, STRUCTURE, V4, P837, DOI 10.1016/S0969-2126(96)00090-1; Youle R. J., 1997, RIBONUCLEASES STRUCT, P491; ZELINKOVA E, 1971, BIOCHIM BIOPHYS ACTA, V235, P343, DOI 10.1016/0005-2744(71)90213-0	63	42	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47325	47330		10.1074/jbc.M208425200	http://dx.doi.org/10.1074/jbc.M208425200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12228255	hybrid			2022-12-27	WOS:000179663700064
J	Srimathi, T; Kumar, TKS; Chi, YH; Chiu, IM; Yu, C				Srimathi, T; Kumar, TKS; Chi, YH; Chiu, IM; Yu, C			Characterization of the structure and dynamics of a near-native equilibrium intermediate in the unfolding pathway of an all beta-barrel protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; MOLTEN GLOBULE STATE; BACKBONE DYNAMICS; SUCROSE OCTASULFATE; HYDROGEN-EXCHANGE; ALPHA-LACTALBUMIN; CRYSTAL-STRUCTURE; BINDING; N-15; DENATURATION	The structure and dynamics of equilibrium intermediate in the unfolding pathway of the human acidic fibroblast growth factor (hFGF-1) are investigated using a variety of biophysical techniques including multidimensional NMR spectroscopy. Guanidinium hydrochloride (GdnHCl)-induced unfolding of hFGF-1 proceeds with the accumulation of a stable intermediate state. The transition from the intermediate state to the unfolded state(s) is cooperative without the accumulation of additional intermediate(s). The intermediate state induced maximally in 0.96 M GdnHCl is found to be obligatory in the folding/unfolding pathway of hFGF-1. Most of the native tertiary structure interactions are preserved in the intermediate state. H-1-N-15 chemical shift perturbation data suggest that the residues in the C-terminal segment including those located in the P-strands M X, and XI undergo the most discernible structural change(s) in the intermediate state in 0.96 M GdnHCl. hFGF-1 in the intermediate state (0.96 M GdnHCl) does not bind to its ligand, sucrose octasulfate. Limited proteolytic digestion experiments and hydrogen-deuterium exchange monitored by N-15 heteronuclear single quantum coherence (HSQC) spectra show that the conformational flexibility of the protein in the intermediate state is significantly higher than in the native conformation. N-15 spin relaxation experiments show that many residues located in beta-strands IX, X, and XI exhibit conformational motions in the micro- to millisecond time scale. Analysis of N-15 relaxation data in conjunction with the amide proton exchange kinetics suggests that residues in the beta-strands II, VIII, and XII possibly constitute the stability core of the protein in the near-native intermediate state.	Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA	National Tsing Hua University; University System of Ohio; Ohio State University	Yu, C (corresponding author), Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan.	cyu@mx.nthu.edu.tw	Chi, Ya-Hui/ABE-8550-2020; KUMAR, P. SURESH/AAT-8951-2020; Kumar, Dr Suresh/HHZ-2615-2022; Chiu, Ing-Ming/B-1534-2008; Kumar, Suresh Thallapuranam/R-5606-2016; Chi, Ya-Hui/B-1080-2010	Chi, Ya-Hui/0000-0002-9216-0938; KUMAR, P. SURESH/0000-0003-3222-2604; Kumar, Dr Suresh/0000-0002-2539-6553; Kumar, Suresh Thallapuranam/0000-0001-7262-1373; 				ALEXANDRESCU AT, 1994, J MOL BIOL, V242, P527, DOI 10.1006/jmbi.1994.1598; ALEXANDRESCU AT, 1993, BIOCHEMISTRY-US, V32, P1707, DOI 10.1021/bi00058a003; Arai M, 2000, ADV PROTEIN CHEM, V53, P209; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; Bilsel O, 2000, ADV PROTEIN CHEM, V53, P153; Blaber M, 1996, BIOCHEMISTRY-US, V35, P2086, DOI 10.1021/bi9521755; Blaber SI, 1999, BIOPHYS J, V77, P470, DOI 10.1016/S0006-3495(99)76904-3; Brandts J. F., 1969, STRUCTURE STABILITY, V2, P213; Burton RE, 1998, BIOCHEMISTRY-US, V37, P5337, DOI 10.1021/bi980245c; Bychkova VE, 1996, BIOCHEMISTRY-US, V35, P6058, DOI 10.1021/bi9522460; Bychkova VE, 1998, FOLD DES, V3, P285, DOI 10.1016/S1359-0278(98)00039-X; Cavagnero S, 2001, BIOCHEMISTRY-US, V40, P14459, DOI 10.1021/bi011500n; Chamberlain AK, 1998, BIOCHEMISTRY-US, V37, P1736, DOI 10.1021/bi972692i; Chi YH, 2001, BIOCHEMISTRY-US, V40, P7746, DOI 10.1021/bi002364+; Chi YH, 2000, J BIOL CHEM, V275, P39444, DOI 10.1074/jbc.M007205200; CLARKE J, 1995, CURR OPIN STRUC BIOL, V8, P112; DABORA JM, 1991, J BIOL CHEM, V266, P23637; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; Dobson CM, 2001, BIOCHEM SOC SYMP, V68, P1; DOBSON CM, 1994, CURR BIOL, V4, P636, DOI 10.1016/S0960-9822(00)00141-X; Dyson HJ, 1998, NAT STRUCT BIOL, V5, P499, DOI 10.1038/739; ENGLANDER WW, 1993, Q REV BIOPHYS, V16, P521; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fersht AR, 2002, CELL, V108, P573, DOI 10.1016/S0092-8674(02)00620-7; Jackson SE, 1998, FOLD DES, V3, pR81, DOI 10.1016/S1359-0278(98)00033-9; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; Li RH, 1999, PROTEIN SCI, V8, P1571, DOI 10.1110/ps.8.8.1571; LIU ZP, 1994, BIOCHEMISTRY-US, V33, P134, DOI 10.1021/bi00167a017; MACH H, 1995, BIOCHEMISTRY-US, V34, P9913, DOI 10.1021/bi00031a013; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; Mosavi LK, 2002, J MOL BIOL, V320, P165, DOI 10.1016/S0022-2836(02)00441-2; NATH U, 1995, BIOCHEMISTRY-US, V34, P1702, DOI 10.1021/bi00005a027; Ogura K, 1999, J BIOMOL NMR, V13, P11, DOI 10.1023/A:1008330622467; OREKHOV VY, 1995, J BIOMOL NMR, V6, P113, DOI 10.1007/BF00211774; PACE CN, 1979, ADV PROTEIN CHEM, V33, P167; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PALMER AG, 1999, APPL NMR STUDY STRUC, P171; PinedaLucena A, 1996, J MOL BIOL, V264, P162, DOI 10.1006/jmbi.1996.0631; Press W., 1992, NUMERICAL RECIPES FO; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Ren JH, 1999, SCIENCE, V284, P955, DOI 10.1126/science.284.5416.955; Samuel D, 2001, J BIOL CHEM, V276, P4134, DOI 10.1074/jbc.M005921200; Samuel D, 2000, J BIOL CHEM, V275, P34968, DOI 10.1074/jbc.M005147200; Sanz JM, 1997, EUR J BIOCHEM, V246, P328, DOI 10.1111/j.1432-1033.1997.00328.x; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schulman BA, 1997, NAT STRUCT BIOL, V4, P630, DOI 10.1038/nsb0897-630; Schwartz MP, 1999, J BIOL CHEM, V274, P12759, DOI 10.1074/jbc.274.18.12759; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; Soulages JL, 1998, BIOPHYS J, V75, P484, DOI 10.1016/S0006-3495(98)77537-X; Van Mierlo CPM, 2000, PROTEIN SCI, V9, P145; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VANMIERLO CPM, 1993, J MOL BIOL, V229, P1125, DOI 10.1006/jmbi.1993.1108; VOLKIN DB, 1993, BIOCHIM BIOPHYS ACTA, V1203, P18, DOI 10.1016/0167-4838(93)90031-L; WANG L, 1998, PROTEIN SCI, V7, P2360; WIEDLOCHA A, 1992, EMBO J, V11, P4835, DOI 10.1002/j.1460-2075.1992.tb05589.x; Wijesinha-Bettoni R, 2001, J MOL BIOL, V312, P261, DOI 10.1006/jmbi.2001.4927; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Wong KB, 1996, J MOL BIOL, V259, P805, DOI 10.1006/jmbi.1996.0359; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	64	16	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47507	47516		10.1074/jbc.M203407200	http://dx.doi.org/10.1074/jbc.M203407200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12226076	hybrid			2022-12-27	WOS:000179663700088
J	Chang, TL; Naqvi, A; Anand, SP; Kramer, MG; Munshi, R; Khan, SA				Chang, TL; Naqvi, A; Anand, SP; Kramer, MG; Munshi, R; Khan, SA			Biochemical characterization of the Staphylococcus aureus PcrA helicase and its role in plasmid rolling circle replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; INITIATOR PROTEIN; ESCHERICHIA-COLI; BACTERIAL PLASMIDS; CRYSTAL-STRUCTURES; PT181; ORIGIN; MECHANISM; COMPLEXES; SITE	Previous genetic studies have suggested that a putative chromosome-encoded helicase, PcrA, is required for the rolling circle replication of plasmid pT181 in Staphylococcus aureus. We have overexpressed and purified the staphylococcal PcrA protein and studied its biochemical properties in vitro. Purified PcrA helicase supported the in vitro replication of plasmid pT181. It had ATPase activity that was stimulated in the presence of single-stranded DNA. Unlike many replicative helicases, PcrA was highly active as a 5' --> 3' helicase and had a weaker 3' --> 5' helicase activity. The RepC initiator protein encoded by pT181 nicks at the origin of replication and becomes covalently attached to the 5' end of the DNA. The 3' OH end at the nick then serves as a primer for displacement synthesis. PcrA helicase showed an origin-specific unwinding activity with supercoiled plasmid pT181 DNA that had been nicked at the origin by Rep,C. We also provide direct evidence for a protein-protein interaction between PcrA and RepC proteins. Our results are consistent with a model in which the PcrA helicase is targeted to the pT181 origin through a protein-protein interaction with RepC and facilitates the movement of the replisome by initiating unwinding from the RepC-generated nick.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Khan, SA (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E 1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.							Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; Bird LE, 2000, BIOCHEMISTRY-US, V39, P171, DOI 10.1021/bi9918801; Bruand C, 2000, MOL MICROBIOL, V35, P204, DOI 10.1046/j.1365-2958.2000.01700.x; Chang TL, 2000, J BIOL CHEM, V275, P13529, DOI 10.1074/jbc.275.18.13529; Cheng W, 2001, J MOL BIOL, V310, P327, DOI 10.1006/jmbi.2001.4758; del Solar G, 1998, MICROBIOL MOL BIOL R, V62, P434, DOI 10.1128/MMBR.62.2.434-464.1998; DEMPSEY LA, 1992, P NATL ACAD SCI USA, V89, P3083, DOI 10.1073/pnas.89.7.3083; Dillingham MS, 1999, NUCLEIC ACIDS RES, V27, P3310, DOI 10.1093/nar/27.16.3310; Dillingham MS, 2001, P NATL ACAD SCI USA, V98, P8381, DOI 10.1073/pnas.131009598; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; IORDANESCU S, 1991, J MOL BIOL, V221, P1183, DOI 10.1016/0022-2836(91)90927-X; IORDANESCU S, 1993, J BACTERIOL, V175, P3916, DOI 10.1128/JB.175.12.3916-3917.1993; IORDANESCU S, 1993, MOL GEN GENET, V241, P185, DOI 10.1007/BF00280216; IORDANESCU S, 1989, J BACTERIOL, V171, P4501, DOI 10.1128/JB.171.8.4501-4503.1989; Jiang Y, 2002, MOL MICROBIOL, V44, P971, DOI 10.1046/j.1365-2958.2002.02921.x; Jin RZ, 1997, EMBO J, V16, P4456, DOI 10.1093/emboj/16.14.4456; Khan SA, 1997, MICROBIOL MOL BIOL R, V61, P442, DOI 10.1128/.61.4.442-455.1997; KOEPSEL RR, 1985, J BIOL CHEM, V260, P8571; KOEPSEL RR, 1985, P NATL ACAD SCI USA, V82, P6845, DOI 10.1073/pnas.82.20.6845; KOEPSEL RR, 1986, P NATL ACAD SCI USA, V83, P5484, DOI 10.1073/pnas.83.15.5484; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Kramer MG, 1999, MOL MICROBIOL, V33, P466, DOI 10.1046/j.1365-2958.1999.01471.x; Kramer MG, 1998, P NATL ACAD SCI USA, V95, P10505, DOI 10.1073/pnas.95.18.10505; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; NOIROT P, 1990, P NATL ACAD SCI USA, V87, P8560, DOI 10.1073/pnas.87.21.8560; Petit MA, 1998, MOL MICROBIOL, V29, P261, DOI 10.1046/j.1365-2958.1998.00927.x; Sambrook J., 2002, MOL CLONING LAB MANU; Soultanas P, 2000, CURR OPIN STRUC BIOL, V10, P124, DOI 10.1016/S0959-440X(99)00059-7; Soultanas P, 1999, NUCLEIC ACIDS RES, V27, P1421, DOI 10.1093/nar/27.6.1421; Soultanas P, 2000, EMBO J, V19, P3799, DOI 10.1093/emboj/19.14.3799; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; THOMAS CD, 1995, J MOL BIOL, V254, P381, DOI 10.1006/jmbi.1995.0625; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Zhao AC, 1997, MOL MICROBIOL, V24, P535, DOI 10.1046/j.1365-2958.1997.3641730.x	35	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45880	45886		10.1074/jbc.M207383200	http://dx.doi.org/10.1074/jbc.M207383200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244110	hybrid			2022-12-27	WOS:000179529300023
J	D'Amico, S; Gerday, C; Feller, G				D'Amico, S; Gerday, C; Feller, G			Dual effects of an extra disulfide bond on the activity and stability of a cold-adapted alpha-amylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTEROMONAS-HALOPLANCTIS; TEMPERATURE ADAPTATION; PSYCHROPHILIC ENZYMES; ANGSTROM RESOLUTION; GLOBULAR-PROTEINS; INHIBITOR; MUTANTS; BARNASE; FLEXIBILITY; ACTIVATION	Chloride-dependent alpha-amylases constitute a well conserved family of enzymes thereby allowing investigation of the characteristics of each member to understand, for example, relevant properties required for environmental adaptation. In this context, we have constructed a double mutant (Q58C/A99C) of the cold-active and heat-labile alpha-amylase from the Antarctic bacterium Pseudoalteromonas haloplanktis, defined on the basis of its strong similarity with the mesophilic enzyme from pig pancreas. This mutant was characterized to understand the role of an extra disulfide bond specific to warm-blooded animals and located near the entrance of the catalytic cleft. We show that the catalytic parameters of the mutant are drastically modified and similar to those of the mesophilic enzyme. Calorimetric studies demonstrated that the mutant is globally stabilized (DeltaDeltaG = 1.87 kcal/mol at 20 degreesC) when compared with the wild-type enzyme, although the melting point (T-m) was not increased. Moreover, fluorescence quenching experiments indicate a more compact structure for the mutated a-amylase. However, the strain imposed on the active site architecture induces a 2-fold higher thermal inactivation rate at 45 degreesC as well as the appearance of a less stable calorimetric domain. It is concluded that stabilization by the extra disulfide bond arises from an enthalpy-entropy compensation effect favoring the enthalpic contribution.	Univ Liege, Biochem Lab, Inst Chem B6, B-4000 Liege, Belgium	University of Liege	Feller, G (corresponding author), Univ Liege, Biochem Lab, Inst Chem B6, B-4000 Liege, Belgium.	sdamico@ulg.ac.be						Aghajari N, 1998, STRUCTURE, V6, P1503, DOI 10.1016/S0969-2126(98)00149-X; Aghajari N, 1998, PROTEIN SCI, V7, P564, DOI 10.1002/pro.5560070304; BETZ SF, 1993, PROTEIN SCI, V2, P1551, DOI 10.1002/pro.5560021002; CLARKE J, 1995, J MOL BIOL, V253, P493, DOI 10.1006/jmbi.1995.0568; CLARKE J, 1995, J MOL BIOL, V253, P505, DOI 10.1006/jmbi.1995.0569; D'Amico S, 2000, GENE, V253, P95, DOI 10.1016/S0378-1119(00)00229-8; D'Amico S, 2002, PHILOS T R SOC B, V357, P917, DOI 10.1098/rstb.2002.1105; D'Amico S, 2001, J BIOL CHEM, V276, P25791, DOI 10.1074/jbc.M102741200; DOIG AJ, 1991, J MOL BIOL, V217, P389, DOI 10.1016/0022-2836(91)90551-G; Feller G, 1999, BIOCHEMISTRY-US, V38, P4613, DOI 10.1021/bi982650+; Feller G, 1996, J BIOL CHEM, V271, P23836, DOI 10.1074/jbc.271.39.23836; Feller G, 1998, APPL ENVIRON MICROB, V64, P1163; Johnson CM, 1997, J MOL BIOL, V268, P198, DOI 10.1006/jmbi.1997.0928; Kumar S, 2002, BIOCHEMISTRY-US, V41, P5359, DOI 10.1021/bi012154c; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE; LARSON SB, 1994, J MOL BIOL, V235, P1560, DOI 10.1006/jmbi.1994.1107; Lonhienne T, 2000, BBA-PROTEIN STRUCT M, V1543, P1, DOI 10.1016/S0167-4838(00)00210-7; Lonhienne T, 2001, BBA-PROTEIN STRUCT M, V1545, P349, DOI 10.1016/S0167-4838(00)00296-X; LOW PS, 1973, P NATL ACAD SCI USA, V70, P430, DOI 10.1073/pnas.70.2.430; MATOUSCHEK A, 1994, PROTEIN ENG, V7, P1089, DOI 10.1093/protein/7.9.1089; PACE CN, 1988, J BIOL CHEM, V263, P11820; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; Privalov Peter L., 1992, P83; QIAN MX, 1993, J MOL BIOL, V231, P785, DOI 10.1006/jmbi.1993.1326; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; VOGL T, 1995, J MOL BIOL, V254, P481, DOI 10.1006/jmbi.1995.0632; Wintrode PL, 2001, ADV PROTEIN CHEM, V55, P161, DOI 10.1016/S0065-3233(01)55004-4; Zavodszky M, 2001, PROTEIN SCI, V10, P149, DOI 10.1110/ps.26801; Zavodszky P, 1998, P NATL ACAD SCI USA, V95, P7406, DOI 10.1073/pnas.95.13.7406; Zecchinon L, 2001, EXTREMOPHILES, V5, P313, DOI 10.1007/s007920100207	31	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46110	46115		10.1074/jbc.M207253200	http://dx.doi.org/10.1074/jbc.M207253200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324460	Green Published, hybrid			2022-12-27	WOS:000179529300054
J	Hamm, J; Alessi, DR; Biondi, RM				Hamm, J; Alessi, DR; Biondi, RM			Bi-functional, substrate mimicking RNA inhibits MSK1-mediated cAMP-response element-binding protein phosphorylation and reveals magnesium ion-dependent conformational changes of the kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO SELECTION; EXPORT SIGNAL; NUCLEIC-ACIDS; CREB; CELLS; ACTIVATION; EXPRESSION; POLYMERASE; RIBOZYMES; EVOLUTION	The design of specific inhibitors for protein kinases is an important step toward elucidation of intracellular signal transduction pathways and to guide drug discovery programs. We devised a model approach to generate specific, competitive kinase inhibitors by isolating substrate mimics containing two independent binding sites with an anti-idiotype strategy from combinatorial RNA libraries. As a general test for the ability to generate highly specific kinase inhibitors, we selected the transcription factor cAMP-response element-binding protein (CREB) that is phosphorylated on the same serine residue by the protein kinase MSK1 as well as by RSK1. The sequences and structures of these kinases are very similar, about 60% of their amino acids are identical. Nevertheless, we can demonstrate that the selected RNA inhibitors inhibit specifically CREB phosphorylation by MSK1 but do not affect CREB phosphorylation by RSK1. The inhibitors interact preferentially with the inactive form of MSK1. Furthermore, we demonstrate that RNA ligands can be conformation-specific probes, and this feature allowed us to describe magnesium ion-dependent conformational changes of MSK1 upon activation.	Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland; MSI, WTB Complex, Div Signal Transduct Therapy, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Hamm, J (corresponding author), Univ Turin, Dipartimento Genet Biol & Biochim, Sez Biol, Centro Ric Med Sperimentale, Via Santena 5bis, I-10126 Turin, Italy.	jorg.hamm@unito.it		Alessi, Dario/0000-0002-2140-9185; Biondi, Ricardo/0000-0002-8873-7167				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Barcellini-Couget S, 1998, ANTISENSE NUCLEIC A, V8, P379, DOI 10.1089/oli.1.1998.8.379; Bertrand E, 1997, RNA, V3, P75; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DOUDNA JA, 1995, P NATL ACAD SCI USA, V92, P2355, DOI 10.1073/pnas.92.6.2355; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Famulok M, 2001, CHEM BIOL, V8, P931, DOI 10.1016/S1074-5521(01)00070-9; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Gwizdek C, 2001, J BIOL CHEM, V276, P25910, DOI 10.1074/jbc.M100493200; HAMM J, 1990, METHOD ENZYMOL, V181, P273; Hamm J, 1996, NUCLEIC ACIDS RES, V24, P2220, DOI 10.1093/nar/24.12.2220; Hamm J, 1997, P NATL ACAD SCI USA, V94, P12839, DOI 10.1073/pnas.94.24.12839; Hamm J, 2000, CHEM BIOL, V7, P345, DOI 10.1016/S1074-5521(00)00112-5; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Johnson DA, 2001, CHEM REV, V101, P2243, DOI 10.1021/cr000226k; JOYCE GF, 1994, CURR OPIN STRUC BIOL, V4, P331, DOI 10.1016/S0959-440X(94)90100-7; Keane JD, 1996, CHEM BIOL, V3, P505, DOI 10.1016/S1074-5521(96)90139-8; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SMITH D, 1995, CHEM BIOL, V2, P741, DOI 10.1016/1074-5521(95)90102-7; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; White RR, 2000, J CLIN INVEST, V106, P929, DOI 10.1172/JCI11325; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611	32	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45793	45802		10.1074/jbc.M205072200	http://dx.doi.org/10.1074/jbc.M205072200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235136	hybrid			2022-12-27	WOS:000179529300012
J	Moncion, A; Truong, NT; Garrone, A; Beaune, P; Barouki, R; de Waziers, I				Moncion, A; Truong, NT; Garrone, A; Beaune, P; Barouki, R; de Waziers, I			Identification of a 16-nucleotide sequence that mediates post-transcriptional regulation of rat CYP2E1 by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-PROTEIN INTERACTIONS; HISTONE MESSENGER-RNA; DOWN-REGULATION; GROWTH-HORMONE; GENE PROMOTER; CODING REGION; CYTOCHROME-P450; EXPRESSION; BINDING; STABILITY	Insulin directly down-regulates the gene expression of the rat CYP2E1 by altering its mRNA stability (De Waziers, I., Garlatti, M., Bouguet, J., Beaune, P. H., and Barouki, R. (1995) Mol. Pharmacol 47, 474-479). Because the regulation of CYP mRNA stability was poorly understood, the molecular mechanisms involved in this regulation in the rat hepatoma H4IIEC3 cell line were studied. By using RNase T1 protection methods, the formation of a major CYP2E1 RNA-protein complex was observed. By competition experiments, the binding site of this complex was located on a 16-nucleotide sequence in the 5'-proximal region of the CYP2E1-coding sequence. Insulin did not modify the binding pattern of proteins to this sequence. and transfections of expression vectors or antisense oligonucleotides were undertaken to demonstrate the actual functionality of the 16-mer sequence. The insertion of this sequence in a luciferase gene was sufficient to render the chimeric mRNA sensitive to insulin. Furthermore, transfection of H4IIEC3 cells with antisense oligonucleotide complementary to this sequence blocked the insulin effect on the CYP2E1 mRNA expression, i.e. its rapid degradation. All these results demonstrate that this 16-nucleotide sequence is implicated in the CYP2E1 post-transcriptional regulation by insulin.	INSERM, Fac Med, Mol Toxicol Lab, U490, F-75270 Paris 06, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	de Waziers, I (corresponding author), INSERM, Fac Med, Mol Toxicol Lab, U490, 45 Rue St Peres, F-75270 Paris 06, France.	Isabelle.Waziers@biomedicale.univ-paris5.fr	De Waziers, Isabelle/N-5453-2018	Beaune, Philippe/0000-0002-6569-9014; de Waziers, Isabelle/0000-0002-7859-3315				AGGERBECK M, 1993, BIOCHEMISTRY-US, V32, P9065, DOI 10.1021/bi00086a011; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Coon MJ, 1996, FASEB J, V10, P428, DOI 10.1096/fasebj.10.4.8647341; CORCOS L, 1988, FEBS LETT, V233, P37, DOI 10.1016/0014-5793(88)81351-6; DANDEKAR T, 1995, TRENDS GENET, V11, P45, DOI 10.1016/S0168-9525(00)88996-9; Day DA, 1998, J ENDOCRINOL, V157, P361, DOI 10.1677/joe.0.1570361; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; DEWAZIERS I, 1992, PHARMACOGENETICS, V2, P12, DOI 10.1097/00008571-199202000-00003; DEWAZIERS I, 1995, MOL PHARMACOL, V47, P474; Dogra SC, 1998, CLIN EXP PHARMACOL P, V25, P1, DOI 10.1111/j.1440-1681.1998.tb02135.x; DONG ZG, 1988, ARCH BIOCHEM BIOPHYS, V263, P29, DOI 10.1016/0003-9861(88)90610-8; EKSTROM G, 1986, BIOCHEM J, V233, P755, DOI 10.1042/bj2330755; Geneste O, 1996, BIOCHEM J, V313, P1029, DOI 10.1042/bj3131029; GONZALEZ FJ, 1994, DRUG METAB REV, V26, P165, DOI 10.3109/03602539409029789; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P391, DOI 10.1021/tx00022a001; Hall Robert K., 1999, Journal of Basic and Clinical Physiology and Pharmacology, V10, P119; Hannon-Fletcher MPA, 2001, FOOD CHEM TOXICOL, V39, P125, DOI 10.1016/S0278-6915(00)00119-8; Honkakoski P, 2000, BIOCHEM J, V347, P321, DOI 10.1042/0264-6021:3470321; Jammi NV, 2001, NUCLEIC ACIDS RES, V29, P3020; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOOP DR, 1986, ALCOHOL CLIN EXP RES, V10, pS44, DOI 10.1111/j.1530-0277.1986.tb05179.x; Lieber CS, 1997, PHYSIOL REV, V77, P517, DOI 10.1152/physrev.1997.77.2.517; Lucas D, 1998, FUNDAM CLIN PHARM, V12, P553, DOI 10.1111/j.1472-8206.1998.tb00985.x; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; Morel Y, 1998, J BIOL CHEM, V273, P26969, DOI 10.1074/jbc.273.41.26969; Novak RF, 2000, ARCH PHARM RES, V23, P267, DOI 10.1007/BF02975435; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ostrowski J, 2001, P NATL ACAD SCI USA, V98, P9044, DOI 10.1073/pnas.161284098; PANDEY NB, 1987, MOL CELL BIOL, V7, P4557, DOI 10.1128/MCB.7.12.4557; PAVEPREUX M, 1990, J BIOL CHEM, V265, P4444; Peng HM, 1998, MOL PHARMACOL, V54, P740; PETER R, 1990, CHEM RES TOXICOL, V3, P566, DOI 10.1021/tx00018a012; RaffalliMathieu F, 1997, EUR J BIOCHEM, V245, P17, DOI 10.1111/j.1432-1033.1997.00017.x; SHIMOJO N, 1993, BIOCHEM PHARMACOL, V46, P621, DOI 10.1016/0006-2952(93)90547-A; Sidhu JS, 2001, MOL PHARMACOL, V59, P1138, DOI 10.1124/mol.59.5.1138; SONG BJ, 1987, MOL ENDOCRINOL, V1, P542, DOI 10.1210/mend-1-8-542; Staton JM, 2000, J MOL ENDOCRINOL, V25, P17, DOI 10.1677/jme.0.0250017; Thulke-Gross M, 1998, BIOCHEM J, V331, P473, DOI 10.1042/bj3310473; THUMMEL KE, 1990, MOL PHARMACOL, V37, P119; Tilloy-Ellul A, 1999, BIOCHEM J, V339, P695, DOI 10.1042/0264-6021:3390695; Troy CM, 1996, J NEUROSCI, V16, P253; WATKINS JB, 1988, TOXICOL APPL PHARM, V93, P329, DOI 10.1016/0041-008X(88)90133-0; WELLINGTON CL, 1993, MOL CELL BIOL, V13, P5034, DOI 10.1128/MCB.13.8.5034; WILLIAMS AS, 1995, NUCLEIC ACIDS RES, V23, P654, DOI 10.1093/nar/23.4.654; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Woodcroft KJ, 2002, HEPATOLOGY, V35, P263, DOI 10.1053/jhep.2002.30691; Woodcroft KJ, 1997, CHEM-BIOL INTERACT, V107, P75, DOI 10.1016/S0009-2797(97)00075-6; Woodcroft KJ, 1999, J PHARMACOL EXP THER, V289, P1121; YAMAZOE Y, 1989, ARCH BIOCHEM BIOPHYS, V268, P567, DOI 10.1016/0003-9861(89)90324-X; YANG CS, 1990, DRUG METAB REV, V22, P147, DOI 10.3109/03602539009041082; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224	54	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45904	45910		10.1074/jbc.M207841200	http://dx.doi.org/10.1074/jbc.M207841200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270935	hybrid			2022-12-27	WOS:000179529300027
J	Smith, L; Smith, JRB				Smith, L; Smith, JRB			Lack of constitutive activity of the free kinase domain of protein kinase C zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PHOSPHOINOSITIDE-DEPENDENT KINASE; INDUCED APOPTOSIS; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; RAT ADIPOCYTES; PKC-ZETA; ACTIVATION; PHOSPHORYLATION; ISOFORMS; TRANSLOCATION	Following the induction of apoptosis in mammalian cells, protein kinase C zeta (PKC zeta) is processed between the regulatory and catalytic domains by caspases, which increases its kinase activity. The catalytic domain fragments of PKC isoforms are considered to be constitutively active, because they lack the autoinhibitory amino-terminal regulatory domain, which includes a pseudosubstrate segment that plugs the active site. Phosphorylation of the activation loop at Thr(410) is known to be sufficient to activate the kinase function of full-length PKC zeta, apparently by inducing a conformational change, which displaces the amino-terminal pseudosubstrate segment from the active site. Amino acid substitutions for Thr(410) of the catalytic domain of PKzeta (CAT zeta) essentially abolished the kinase function of ectopically expressed CAT zeta in mammalian cells. Similarly, substitution of Ala for a Phe of the docking motif for phosphoinositide-dependent kinase-1 prevented activation loop phosphorylation and abolished the kinase activity of CAT zeta. Treatment of purified CAT zeta with the catalytic subunit of protein phosphatase 1 decreased activation loop phosphorylation and kinase activity. Recombinant CAT zeta from bacteria lacked detectable kinase activity. Phosphoinositide-dependent kinase-1 phosphorylated the activation loop and activated recombinant CAT zeta from bacteria. Treatment of HeLa cells with fetal bovine serum markedly increased the phosphothreonine 410 content of CAT zeta and stimulated its kinase activity. These findings indicate that the catalytic domain of PKC zeta is intrinsically inactive and dependent on the transphosphorylation of the activation loop.	Univ Alabama, Sch Med, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Smith, JRB (corresponding author), Univ Alabama, Sch Med, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060383] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60383] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Bandyopadhyay G, 1999, BIOCHEM J, V337, P461, DOI 10.1042/0264-6021:3370461; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; Carlin S, 1999, AM J PHYSIOL-LUNG C, V276, pL506, DOI 10.1152/ajplung.1999.276.3.L506; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; CEPKO C, 1995, METHOD ENZYMOL, V254, P387; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; Gao TY, 2001, J BIOL CHEM, V276, P19588, DOI 10.1074/jbc.M101357200; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; Hrabetova S, 2001, MOL BRAIN RES, V95, P146, DOI 10.1016/S0169-328X(01)00185-1; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; Mutter R, 2000, BIOORGAN MED CHEM, V8, P1841, DOI 10.1016/S0968-0896(00)00150-4; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ORR JW, 1994, J BIOL CHEM, V269, P8383; Smith L, 2000, J BIOL CHEM, V275, P40620, DOI 10.1074/jbc.M908517199; Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200	49	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45866	45873		10.1074/jbc.M206420200	http://dx.doi.org/10.1074/jbc.M206420200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244101	hybrid			2022-12-27	WOS:000179529300021
J	Sullivan, WP; Owen, BAL; Toft, DO				Sullivan, WP; Owen, BAL; Toft, DO			The influence of ATP and p23 on the conformation of hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; CO-CHAPERONE P23; PROGESTERONE-RECEPTOR; TERMINAL DOMAIN; GLUCOCORTICOID RECEPTOR; SIGNAL-TRANSDUCTION; IN-VIVO; BINDING; HEAT-SHOCK-PROTEIN-90; HYDROLYSIS	The chaperoning activity of the heat shock protein hsp90 is directed, in part, by the binding and hydrolysis of ATP and also by association with co-chaperone proteins. One co-chaperone, p23, binds to hsp90 only when hsp90 is in a conformation induced by the binding of ATP. Once formed, the p23-hsp90 complex is very stable upon the removal of ATP and dissipates at 30degrees with a half-life of about 45 min. This was shown to be due to the high stability of the ATP-induced state of hsp,90, not to the rate of p23 dissociation. Further stabilization of this ATP-induced state is achieved by including molybdate or by use of the ATP analogue ATPgammaS. This conformational state of hsp90 is correlated with the tight binding of ADP resulting from hydrolysis of bound ATP. Both p23 and molybdate enhance and stabilize the nucleotide-bound state of hsp90, and this state is maximized by the presence of both agents. These results can be explained in a model where the binding of ATP induces a conformational transition in hsp90 that traps the nucleotide and is committed to ATP hydrolysis. p23 specifically recognizes this state and may also facilitate subsequent steps in the chaperoning cycle.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Mayo Grad Sch, Rochester, MN 55905 USA	Mayo Clinic	Toft, DO (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Mayo Grad Sch, 200 1st St SW, Rochester, MN 55905 USA.		Owen, Barbara/AAD-2322-2021		NIDDK NIH HHS [DK 46249, DK 59284] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046249, R01DK059284] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Freeman BC, 2000, GENE DEV, V14, P422; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 2001, TRENDS BIOCHEM SCI, V26, P285, DOI 10.1016/S0968-0004(01)01834-5; Garnier C, 2002, J BIOL CHEM, V277, P12208, DOI 10.1074/jbc.M111874200; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Hartson SD, 1999, BIOCHEMISTRY-US, V38, P3837, DOI 10.1021/bi983027s; Hernandez MP, 2002, J BIOL CHEM, V277, P11873, DOI 10.1074/jbc.M111445200; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; HOUSLEY PR, 1990, BIOCHEMISTRY-US, V29, P3578, DOI 10.1021/bi00466a022; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; McLaughlin SH, 2002, J MOL BIOL, V315, P787, DOI 10.1006/jmbi.2001.5245; Morishima Y, 2001, BIOCHEMISTRY-US, V40, P1109, DOI 10.1021/bi002399+; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; NISHIGORI H, 1980, BIOCHEMISTRY-US, V19, P77, DOI 10.1021/bi00542a012; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Owen BAL, 2002, J BIOL CHEM, V277, P7086, DOI 10.1074/jbc.M111450200; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Prapapanich V, 1998, MOL CELL BIOL, V18, P944, DOI 10.1128/MCB.18.2.944; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; Soti C, 2002, J BIOL CHEM, V277, P7066, DOI 10.1074/jbc.M105568200; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Weaver AJ, 2000, J BIOL CHEM, V275, P23045, DOI 10.1074/jbc.M003410200; Weikl T, 2000, J MOL BIOL, V303, P583, DOI 10.1006/jmbi.2000.4157; Weikl T, 1999, J MOL BIOL, V293, P685, DOI 10.1006/jmbi.1999.3172; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	39	83	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45942	45948		10.1074/jbc.M207754200	http://dx.doi.org/10.1074/jbc.M207754200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324468	hybrid			2022-12-27	WOS:000179529300032
J	Todeschin, AR; Girard, MF; Wieruszeski, JM; Nunes, MP; DosReis, GA; Mendonca-Previato, L; Previato, JO				Todeschin, AR; Girard, MF; Wieruszeski, JM; Nunes, MP; DosReis, GA; Mendonca-Previato, L; Previato, JO			trans-sialidase from Trypanosoma cruzi binds host T-lymphocytes in a lectin manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER DIFFERENCE NMR; NEURAMINIDASE ACTIVITIES; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURE; MAMMALIAN-CELLS; CHAGAS-DISEASE; CD43; RECEPTOR; ADHESION; ACTIVATION	Trypanosoma cruzi, the protozoan parasite responsible for Chagas' disease, expresses on its surface an uncommon membrane-bound sialidase, known as trans-sialidase. trans-Sialidase is the product of a multigene family encoding both active and inactive proteins. We report here that an inactive mutant of trans-sialidase physically interacts with CD4(+) T cells. Using a combination of flow cytometry and immunoprecipitation techniques, we identified the sialomucin CD43 as a counter-receptor for trans-sialidase on CD4(+) T cells. Using biochemical, immunological, and spectroscopic approaches, we demonstrated that the inactive trans-sialidase is a sialic acid-binding protein displaying the same specificity required by active trans-sialidase. Taken together, these results suggest that inactive members of the trans-sialidase family can physically interact with sialic acid-containing molecules on host cells and could play a role in host cell/T. cruzi interaction.	Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Biofis Carlos Chagas Filho, Ilha Fdn, BR-21944970 Rio De Janeiro, Brazil; Univ Estado Rio De Janeiro, Inst Biol, Dept Bioquim, BR-20551013 Rio De Janeiro, Brazil; Inst Pasteur, Lab RMN Synth, F-59019 Lille, France	Universidade Federal do Rio de Janeiro; Universidade do Estado do Rio de Janeiro; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Mendonca-Previato, L (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Biofis Carlos Chagas Filho, Ilha Fdn, Bloco G,Cidade Univ, BR-21944970 Rio De Janeiro, Brazil.			DosReis, George/0000-0002-8924-4727; Girard, Murielle/0000-0003-1222-0329; Previato, Jose Osvaldo/0000-0002-9233-9954; Mendonca Previato, Lucia/0000-0003-3927-3244				ABRAMSON JS, 1995, BLOOD, V85, P1615, DOI 10.1182/blood.V85.6.1615.bloodjournal8561615; Baum LG, 1996, J BIOL CHEM, V271, P10793, DOI 10.1074/jbc.271.18.10793; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8625, DOI 10.1074/jbc.275.12.8625; BURLEIGH BA, 1995, ANNU REV MICROBIOL, V49, P175, DOI 10.1146/annurev.mi.49.100195.001135; Buschiazzo A, 2000, EMBO J, V19, P16, DOI 10.1093/emboj/19.1.16; Buschiazzo A, 1996, CELL MOL BIOL, V42, P703; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; CHUENKOVA M, 1995, J EXP MED, V181, P1693, DOI 10.1084/jem.181.5.1693; Costa F, 1998, VACCINE, V16, P768, DOI 10.1016/S0264-410X(97)00277-6; CREMONA ML, 1995, GENE, V160, P123, DOI 10.1016/0378-1119(95)00175-6; Cremona ML, 1999, GLYCOBIOLOGY, V9, P581, DOI 10.1093/glycob/9.6.581; CRENNELL S, 1994, STRUCTURE, V2, P535, DOI 10.1016/S0969-2126(00)00053-8; CRENNELL SJ, 1993, P NATL ACAD SCI USA, V90, P9852, DOI 10.1073/pnas.90.21.9852; Diercks T, 2001, CURR OPIN CHEM BIOL, V5, P285, DOI 10.1016/S1367-5931(00)00204-0; DosReis GA, 1997, PARASITOL TODAY, V13, P335, DOI 10.1016/S0169-4758(97)01073-9; Frasch ACC, 2000, PARASITOL TODAY, V16, P282, DOI 10.1016/S0169-4758(00)01698-7; Fratazzi C, 2000, J EXP MED, V192, P183, DOI 10.1084/jem.192.2.183; GARSKELL A, 1995, STRUCTURE, V15, P1197; HARLOW E, 1988, ANTIBODIES LABORATOR, P340; Hunter CA, 1997, J IMMUNOL, V158, P3311; Iorio RM, 2001, J VIROL, V75, P1918, DOI 10.1128/JVI.75.4.1918-1927.2001; JONES AT, 1994, J IMMUNOL, V153, P3426; LOPES MF, 1995, J IMMUNOL, V154, P744; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; Maaheimo H, 2000, BIOCHEMISTRY-US, V39, P12778, DOI 10.1021/bi000780o; MANJUNATH N, 1995, NATURE, V377, P535, DOI 10.1038/377535a0; Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; Moller H, 2002, EUR J BIOCHEM, V269, P1444, DOI 10.1046/j.1432-1033.2002.02787.x; Ostberg JR, 1998, IMMUNOL TODAY, V19, P546, DOI 10.1016/S0167-5699(98)01343-7; Paris G, 2001, GLYCOBIOLOGY, V11, P305, DOI 10.1093/glycob/11.4.305; PARODI AJ, 1992, EMBO J, V11, P1705, DOI 10.1002/j.1460-2075.1992.tb05221.x; POLLEVICK GD, 1991, MOL BIOCHEM PARASIT, V47, P247, DOI 10.1016/0166-6851(91)90185-9; PREVIATO JO, 1985, MOL BIOCHEM PARASIT, V16, P85, DOI 10.1016/0166-6851(85)90051-9; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; REUTER G, 1994, METHOD ENZYMOL, V230, P168; ROGGENTIN P, 1989, GLYCOCONJUGATE J, V6, P349, DOI 10.1007/BF01047853; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; ROTHWELL SW, 1994, J IMMUNOL, V152, P2358; Sabri S, 2000, J CELL SCI, V113, P1589; SAWADA R, 1994, J BIOL CHEM, V269, P1425; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; Stockl J, 1996, J EXP MED, V184, P1769, DOI 10.1084/jem.184.5.1769; Todeschini AR, 2002, J IMMUNOL, V168, P5192, DOI 10.4049/jimmunol.168.10.5192; Todeschini AR, 2000, GLYCOBIOLOGY, V10, P213, DOI 10.1093/glycob/10.2.213; UEMURA H, 1992, EMBO J, V11, P3837, DOI 10.1002/j.1460-2075.1992.tb05476.x; van den Berg TK, 2001, J IMMUNOL, V166, P3637, DOI 10.4049/jimmunol.166.6.3637; VANDEKERCKHOVE F, 1992, GLYCOBIOLOGY, V2, P541, DOI 10.1093/glycob/2.6.541; Vogtherr M, 2000, J AM CHEM SOC, V122, P6093, DOI 10.1021/ja0001916	49	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45962	45968		10.1074/jbc.M203185200	http://dx.doi.org/10.1074/jbc.M203185200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237289	hybrid			2022-12-27	WOS:000179529300035
J	MacDonald, PE; Sewing, S; Wang, JL; Joseph, JW; Smukler, SR; Sakellaropoulos, G; Wang, J; Saleh, MC; Chan, CB; Tsushima, RG; Salapatek, AMF; Wheeler, MB				MacDonald, PE; Sewing, S; Wang, JL; Joseph, JW; Smukler, SR; Sakellaropoulos, G; Wang, J; Saleh, MC; Chan, CB; Tsushima, RG; Salapatek, AMF; Wheeler, MB			Inhibition of Kv2.1 voltage-dependent K+ channels in pancreatic beta-cells enhances glucose-dependent insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; TRANSIENT OUTWARD CURRENT; B-CELLS; EXTERNAL TETRAETHYLAMMONIUM; ION CHANNELS; ISLET CELLS; TEDISAMIL; QUININE; BLOCK; DEPOLARIZATION	Voltage-dependent (Kv) outward K+ currents repolarize beta-cell action potentials during a glucose stimulus to limit Ca2+ entry and insulin secretion. Dominant-negative "knockout" of Kv2 family channels enhances glucose-stimulated insulin secretion. Here we show that a putative Kv2.1 antagonist (C-1) stimulates insulin secretion from MIN6 insulinoma cells in a glucose- and dose-dependent manner while blocking voltage-dependent outward K+ currents. C-1-blocked recombinant Kv2.1-mediated currents more specifically than currents mediated by Kv1, -3, and -4 family channels (Kv1.4, 3.1, 4.2). Additionally, C-1 had little effect on currents recorded from MIN6 cells expressing a dominant-negative Kv2.1 a-subunit. The insulinotropic effect of acute Kv2.1 inhibition resulted from enhanced membrane depolarization and augmented intracellular Ca2+ responses to glucose. Immunohistochemical staining of mouse pancreas sections showed that expression of Kv2.1 correlated highly with insulin-containing beta-cells, consistent with the ability of C-1 to block voltage-dependent outward K+ currents in isolated mouse beta-cells. Antagonism of Kv2.1 in an ex vivo perfused mouse pancreas model enhanced first- and second-phase insulin secretion, whereas glucagon secretion was unaffected. The present study demonstrates that Kv2.1 is an important component of beta-cell stimulus-secretion coupling, and a compound that enhances, but does not initiate, beta-cell electrical activity by acting on Kv2.1 would be a useful antidiabetic agent.	Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Lilly Res Labs, D-22419 Hamburg, Germany; Univ Prince Edward Isl, Atlantic Vet Coll, Charlottetown, PE C1A 4P3, Canada	University of Toronto; University of Toronto; Eli Lilly; Lilly Deutschland GmbH; University of Prince Edward Island	Wheeler, MB (corresponding author), Univ Toronto, Dept Physiol, 1 Kings Coll Circle,Rm 3352, Toronto, ON M5S 1A8, Canada.	michael.wheeler@utoronto.ca	MacDonald, Patrick/A-4154-2008; Chan, Catherine/C-1162-2011	Chan, Catherine/0000-0003-3882-0592; Wheeler, Michael B./0000-0002-7480-7267; MacDonald, Patrick/0000-0002-5439-6288				Ashcroft FM, 1999, DIABETOLOGIA, V42, P903, DOI 10.1007/s001250051247; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ATWATER I, 1979, J PHYSIOL-LONDON, V288, P561; ATWATER I, 1983, CELL CALCIUM, V4, P451, DOI 10.1016/0143-4160(83)90021-0; Berger F, 1998, N-S ARCH PHARMACOL, V357, P291, DOI 10.1007/PL00005170; BOKVIST K, 1990, J PHYSIOL-LONDON, V423, P311, DOI 10.1113/jphysiol.1990.sp018024; BOKVIST K, 1990, J PHYSIOL-LONDON, V423, P327, DOI 10.1113/jphysiol.1990.sp018025; BOYD AE, 1992, J CELL BIOCHEM, V48, P234, DOI 10.1002/jcb.240480303; Chan CB, 1999, DIABETES, V48, P1482, DOI 10.2337/diabetes.48.7.1482; CONLEY EC, 1999, ION CHANNEL FACTSBOO, V4, P374; CONLEY EC, 1999, ION CHANNEL FACTS BO, V4, P617; DagogoJack S, 1997, ARCH INTERN MED, V157, P1802, DOI 10.1001/archinte.157.16.1802; Doggrell SA, 2001, EXPERT OPIN INV DRUG, V10, P129, DOI 10.1517/13543784.10.1.129; Dukes ID, 1996, DIABETES, V45, P845, DOI 10.2337/diabetes.45.7.845; Dunne MJ, 1999, TRENDS ENDOCRIN MET, V10, P146, DOI 10.1016/S1043-2760(98)00135-0; Eberhardson M, 1996, BBA-BIOMEMBRANES, V1283, P67, DOI 10.1016/0005-2736(96)00075-2; FATHERAZI S, 1991, J MEMBRANE BIOL, V120, P105, DOI 10.1007/BF01872393; FINDLAY I, 1985, FEBS LETT, V185, P4, DOI 10.1016/0014-5793(85)80729-8; FINDLAY I, 1985, J MEMBRANE BIOL, V83, P169, DOI 10.1007/BF01868748; Gopel S, 1999, J PHYSIOL-LONDON, V521, P717, DOI 10.1111/j.1469-7793.1999.00717.x; Gopel SO, 2000, J PHYSIOL-LONDON, V528, P497, DOI 10.1111/j.1469-7793.2000.00497.x; GRODSKY GM, 1963, AM J PHYSIOL, V205, P638, DOI 10.1152/ajplegacy.1963.205.4.638; Hayward RA, 1997, JAMA-J AM MED ASSOC, V278, P1663, DOI 10.1001/jama.278.20.1663; HENQUIN JC, 1977, BIOCHEM BIOPH RES CO, V77, P551, DOI 10.1016/S0006-291X(77)80014-4; HENQUIN JC, 1990, PFLUG ARCH EUR J PHY, V416, P568, DOI 10.1007/BF00382691; HENQUIN JC, 1979, BIOCHIM BIOPHYS ACTA, V587, P579, DOI 10.1016/0304-4165(79)90010-2; Himmel HM, 1999, AM J PHYSIOL-HEART C, V277, pH107, DOI 10.1152/ajpheart.1999.277.1.H107; HWANG PM, 1993, J NEUROSCI, V13, P1569; Kozak JA, 1998, J PHYSIOL-LONDON, V509, P355, DOI 10.1111/j.1469-7793.1998.355bn.x; LEBRUN P, 1983, FEBS LETT, V161, P41, DOI 10.1016/0014-5793(83)80726-1; Leung YM, 2002, BIOCHEM BIOPH RES CO, V292, P980, DOI 10.1006/bbrc.2002.6712; LIGHT DB, 1987, J MEMBRANE BIOL, V95, P63, DOI 10.1007/BF01869631; MacDonald PE, 2001, MOL ENDOCRINOL, V15, P1423, DOI 10.1210/me.15.8.1423; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; McLarnon JG, 1997, EUR J PHARMACOL, V339, P279, DOI 10.1016/S0014-2999(97)01394-0; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; OLEARY ME, 1994, J GEN PHYSIOL, V104, P507, DOI 10.1085/jgp.104.3.507; Pederson RA, 1998, DIABETES, V47, P1046, DOI 10.2337/diabetes.47.7.1046; Philipson LH, 1999, HORM METAB RES, V31, P455, DOI 10.1055/s-2007-978774; PHILIPSON LH, 1994, J BIOL CHEM, V269, P27787; Roe MW, 1996, J BIOL CHEM, V271, P32241, DOI 10.1074/jbc.271.50.32241; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; RORSMAN P, 1986, J PHYSIOL-LONDON, V374, P531, DOI 10.1113/jphysiol.1986.sp016096; Schon U, 1998, J MED CHEM, V41, P318, DOI 10.1021/jm970120q; Silvestre RA, 2001, AM J PHYSIOL-ENDOC M, V280, pE443, DOI 10.1152/ajpendo.2001.280.3.E443; SMITH PA, 1989, PFLUG ARCH EUR J PHY, V413, P441, DOI 10.1007/BF00584497; Su JP, 2001, PFLUG ARCH EUR J PHY, V442, P49, DOI 10.1007/s004240000508; Swartz KJ, 1997, NEURON, V18, P665, DOI 10.1016/S0896-6273(00)80306-2; Wettwer E, 1998, BRIT J PHARMACOL, V125, P659, DOI 10.1038/sj.bjp.0702110	49	143	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44938	44945		10.1074/jbc.M205532200	http://dx.doi.org/10.1074/jbc.M205532200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12270920	hybrid			2022-12-27	WOS:000179404800046
J	Tzagarakis-Foster, C; Geleziunas, R; Lomri, A; An, JP; Leitman, DC				Tzagarakis-Foster, C; Geleziunas, R; Lomri, A; An, JP; Leitman, DC			Estradiol represses human T-cell leukemia virus type 1 tax activation of tumor necrosis factor-a gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FACTOR-ALPHA GENE; HORMONE REPLACEMENT THERAPY; ESTROGEN-RECEPTOR; BINDING-PROTEIN; BONE-RESORPTION; INTERLEUKIN-6 PROMOTER; TRANSGENIC MICE; DNA-BINDING; I CARRIERS	Adult T-cell leukemia is caused by human T-cell leukemia virus type I (HTLV-I). The HTLV-I Tax protein is essential for clinical manifestations because it activates viral and cellular gene transcription. Tax enhances production of tumor necrosis factor-alpha (TNF-alpha), which may lead to bone and joint destruction. Because estrogens might prevent osteoporosis by repressing TNF-alpha gene transcription, we investigated whether estrogens inhibit the transcriptional effects of Tax on the TNF-alpha promoter. Tax activated the -1044, -163, and -125 TNF-a promoters by 9-25-fold but not the -82 promoter, demonstrating that Tax activation requires the -125 to -82 region, known as the TNF response element (TNF-RE). Three copies of the TNF-RE upstream of the minimal thymidine kinase promoter conferred a similar magnitude of activation by Tax. We demonstrated that c-Jun, NFkappaB, p50, and p65 interact with and activate the TNF-RE by using mutational analysis of the TNF-RE, Tax mutants that selectively activate NFkappaB or the cAMP-response element binding proteinlactivating transcription factor pathway, and gel shift assays with nuclear extracts. Estradiol markedly repressed Tax-activated transcription of the TNF-a gene with estrogen receptor (ER) alpha or beta. Nuclear extracts from U2OS cells stably transfected with ERalpha demonstrated that ERs interact with the TNF-RE. Our studies provide evidence that ERs repress Tax-activated TNF-alpha transcription by interacting with a c-Jun and NFkappaB platform on the TNF-RE. Estrogens may ameliorate bone and inflammatory joint diseases in patients infected with HTLV-1 by repressing transcription of the TNF-alpha gene.	Univ Calif San Francisco, Ctr Reprod Sci, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; Merck Res Labs, W Point, PA 19486 USA	University of California System; University of California San Francisco; Merck & Company	Leitman, DC (corresponding author), Univ Calif San Francisco, Ctr Reprod Sci, Dept Obstet Gynecol & Reprod Sci, HSE 1619 POB 0556, San Francisco, CA 94143 USA.			Lomri, Abderrahim/0000-0001-9847-026X				ALBRECHT H, 1992, J VIROL, V66, P6191, DOI 10.1128/JVI.66.10.6191-6193.1992; Ammann P, 1997, J CLIN INVEST, V99, P1699, DOI 10.1172/JCI119333; An JP, 1999, P NATL ACAD SCI USA, V96, P15161, DOI 10.1073/pnas.96.26.15161; An JP, 2001, J BIOL CHEM, V276, P17808, DOI 10.1074/jbc.M100953200; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; Bruce-Keller AJ, 2000, ENDOCRINOLOGY, V141, P3646, DOI 10.1210/en.141.10.3646; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; CENTRELLA M, 1988, ENDOCRINOLOGY, V123, P1442, DOI 10.1210/endo-123-3-1442; Coscoy L, 1998, VIROLOGY, V248, P332, DOI 10.1006/viro.1998.9298; Cowan EP, 1997, J VIROL, V71, P6982, DOI 10.1128/JVI.71.9.6982-6989.1997; Dennison EM, 1998, BRIT J RHEUMATOL, V37, P1198; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Galien R, 1996, MOL ENDOCRINOL, V10, P713, DOI 10.1210/me.10.6.713; GESSAIN A, 1985, LANCET, V2, P407; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; Goldring M B, 2000, Curr Rheumatol Rep, V2, P459, DOI 10.1007/s11926-000-0021-y; Hausmann S, 1999, J IMMUNOL, V162, P5389; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; Hisada M, 2001, INT J CANCER, V91, P497, DOI 10.1002/1097-0215(20010215)91:4&lt;497::AID-IJC1044&gt;3.0.CO;2-A; Hisada M, 1998, INT J CANCER, V77, P188, DOI 10.1002/(SICI)1097-0215(19980717)77:2&lt;188::AID-IJC3&gt;3.0.CO;2-M; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; IWAKURA Y, 1995, J IMMUNOL, V155, P1588; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Johnson JM, 2001, INT J EXP PATHOL, V82, P135, DOI 10.1046/j.1365-2613.2001.00191.x; JOHNSON RA, 1989, ENDOCRINOLOGY, V124, P1424, DOI 10.1210/endo-124-3-1424; Johnson SR, 1998, MED CLIN N AM, V82, P297, DOI 10.1016/S0025-7125(05)70608-8; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; Kenny AM, 2000, RHEUM DIS CLIN N AM, V26, P569, DOI 10.1016/S0889-857X(05)70157-5; Kimble RB, 1997, J BONE MINER RES, V12, P935, DOI 10.1359/jbmr.1997.12.6.935; KIYOKAWA T, 1987, CANCER, V59, P1187, DOI 10.1002/1097-0142(19870315)59:6<1187::AID-CNCR2820590626>3.0.CO;2-8; LEITMAN DC, 1992, MOL CELL BIOL, V12, P1352, DOI 10.1128/MCB.12.3.1352; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; Lenzmeier BA, 1999, J MOL BIOL, V291, P731, DOI 10.1006/jmbi.1999.2969; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Lomri A, 1999, CALCIFIED TISSUE INT, V64, P394, DOI 10.1007/PL00005821; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MORI N, 1994, BLOOD, V84, P2904; Ozden S, 1996, J ACQ IMMUN DEF SYND, V13, pS154, DOI 10.1097/00042560-199600001-00024; Pacifici R, 1996, J BONE MINER RES, V11, P1043; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Riggs BL, 2000, J CLIN INVEST, V106, P1203, DOI 10.1172/JCI11468; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RUDDLE NH, 1993, VIROLOGY, V197, P196, DOI 10.1006/viro.1993.1580; Shimamoto Y, 1996, INT J HEMATOL, V64, P111; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; STEIN B, 1995, MOL CELL BIOL, V15, P4971; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; SUZUKI T, 1993, ONCOGENE, V8, P2391; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; TERADA K, 1994, LANCET, V344, P1116, DOI 10.1016/S0140-6736(94)90630-0; Teyssier C, 2001, J BIOL CHEM, V276, P36361, DOI 10.1074/jbc.M101806200; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; TSCHACHLER E, 1993, BLOOD, V81, P95; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; Watanabe T, 1997, INT J HEMATOL, V66, P257; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	71	30	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44772	44777		10.1074/jbc.M205355200	http://dx.doi.org/10.1074/jbc.M205355200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237295	hybrid			2022-12-27	WOS:000179404800025
J	Shin, EY; Shin, KS; Lee, CS; Woo, KN; Quan, SH; Soung, NK; Kim, YG; Cha, CI; Kim, SR; Park, D; Bokoch, GM; Kim, EG				Shin, EY; Shin, KS; Lee, CS; Woo, KN; Quan, SH; Soung, NK; Kim, YG; Cha, CI; Kim, SR; Park, D; Bokoch, GM; Kim, EG			Phosphorylation of p85 beta PIX, a Rac/Cdc42-specific guanine nucleotide exchange factor, via the Ras/ERK/PAK2 pathway is required for basic fibroblast growth factor-induced neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P21-ACTIVATED KINASE PAK1; ADAPTER PROTEIN NCK; PC12 CELL-DIFFERENTIATION; THREONINE PHOSPHORYLATION; LYSOPHOSPHATIDIC ACID; REGULATORY REGION; FOCAL ADHESION; NEURONAL CELLS; RHO GTPASES; SH3 DOMAIN	Guanine nucleotide exchange factors (GEFs) have been implicated in growth factor-induced neuronal differentiation through the activation of small GTPases. Although phosphorylation of these GEFs is considered an activation mechanism, little is known about the upstream of PAK-interacting exchange factor (PIX), a member of the Dbl family of GEFs. We report here that phosphorylation of p85 betaPIX/Cool/p85SPR is mediated via the Ras/ERK/PAK2 pathway. To understand the role of p85 betaPIX in basic fibroblast growth factor (bFGF)induced neurite outgrowth, we established PC12 cell lines that overexpress the fibroblast growth factor receptor-1 in a tetracycline-inducible manner. Treatment with bFGF induces the phosphorylation of p85 PPIX, as determined by metabolic labeling and mobility shift upon gel electrophoresis. Interestingly, phosphorylation of p85 betaPIX is inhibited by PD98059, a specific MEK inhibitor, suggesting the involvement of the ERK cascade. PAK2, a major PAK isoforin in PC12 cells as well as a binding partner of p85 betaPIX, also functions upstream of p85 betaPIX phosphorylation. Surprisingly, PAK2 directly binds to ERK, and its activation is dependent on ERK. p85 betaPIX specifically localizes to the lamellipodia at neuronal growth cones in response to bFGF. A mutant form of p85 betaPIX (S525A/T526A), in which the major phosphorylation sites are replaced by alanine, shows significant defect in targeting. Moreover, expression of the mutant p85 betaPIX efficiently blocks PC 12 cell neurite outgrowth. Our study defines a novel signaling pathway for bFGF-induced neurite outgrowth that involves activation of the PAK2-p85 betaPIX complex via the ERK cascade and subsequent translocation of this complex.	Chungbuk Natl Univ, Coll Med, Dept Biochem, Med Res Inst,Heungduk Ku, Cheongju 361763, South Korea; Chungbuk Natl Univ, Coll Med, Dept Neurosurg, Cheongju 361763, South Korea; Daewoong Pharmaceut Co, R&D Ctr, Biotechnol Res Team, Yongin 449814, South Korea; Seoul Natl Univ, Coll Med, Dept Anat, Seoul 110799, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; The Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; The Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Chungbuk National University; Chungbuk National University; Samsung; Seoul National University (SNU); Seoul National University (SNU); Scripps Research Institute; Scripps Research Institute	Kim, EG (corresponding author), Chungbuk Natl Univ, Coll Med, Dept Biochem, Med Res Inst,Heungduk Ku, San 48, Cheongju 361763, South Korea.		Cha, Choong Ik/J-5680-2012		NIGMS NIH HHS [GM39434] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Albertinazzi C, 1998, J CELL BIOL, V142, P815, DOI 10.1083/jcb.142.3.815; AltunGultekin ZF, 1996, J NEUROSCI RES, V44, P308, DOI 10.1002/(SICI)1097-4547(19960515)44:4<308::AID-JNR2>3.0.CO;2-G; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Chen XQ, 1999, J BIOL CHEM, V274, P19901, DOI 10.1074/jbc.274.28.19901; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; Di Cesare A, 2000, NAT CELL BIOL, V2, P521, DOI 10.1038/35019561; Feng QY, 2002, J BIOL CHEM, V277, P5644, DOI 10.1074/jbc.M107704200; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Goi T, 1999, MOL CELL BIOL, V19, P1731; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; KIM EG, 1993, AM J PHYSIOL, V264, pF66, DOI 10.1152/ajprenal.1993.264.1.F66; Kim MD, 2002, J NEUROSCI, V22, P1794, DOI 10.1523/JNEUROSCI.22-05-01794.2002; Kim S, 2000, BIOCHEM BIOPH RES CO, V272, P721, DOI 10.1006/bbrc.2000.2845; Kim S, 2001, J BIOL CHEM, V276, P10581, DOI 10.1074/jbc.C000806200; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Kita Y, 1998, J CELL SCI, V111, P907; Koh CG, 2001, J CELL SCI, V114, P4239; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Kuhn TB, 1998, J NEUROBIOL, V37, P524, DOI 10.1002/(SICI)1097-4695(199812)37:4<524::AID-NEU3>3.0.CO;2-H; Lamoureux P, 1997, J CELL SCI, V110, P635; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matafora V, 2001, J CELL SCI, V114, P4509; Meakin SO, 1998, J NEUROCHEM, V71, P1875; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Nunn MF, 1996, J VIROL, V70, P6157, DOI 10.1128/JVI.70.9.6157-6161.1996; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Oh WK, 1997, BIOCHEM BIOPH RES CO, V235, P794, DOI 10.1006/bbrc.1997.6875; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Posern G, 2000, J CELL PHYSIOL, V183, P416, DOI 10.1002/(SICI)1097-4652(200006)183:3<416::AID-JCP15>3.0.CO;2-R; Renkema GH, 1999, CURR BIOL, V9, P1407, DOI 10.1016/S0960-9822(00)80086-X; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Rockow S, 1996, ONCOGENE, V12, P2351; Roig J, 2000, P NATL ACAD SCI USA, V97, P14346, DOI 10.1073/pnas.97.26.14346; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Tanabe K, 2000, J NEUROSCI, V20, P4138; Tang JP, 1997, ONCOGENE, V15, P1823, DOI 10.1038/sj.onc.1201351; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Yoshii S, 1999, ONCOGENE, V18, P5680, DOI 10.1038/sj.onc.1202936; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	70	110	111	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44417	44430		10.1074/jbc.M203754200	http://dx.doi.org/10.1074/jbc.M203754200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226077	hybrid			2022-12-27	WOS:000179272000113
J	Gao, ZG; Hwang, D; Bataille, F; Lefevre, M; York, D; Quon, M; Ye, JP				Gao, ZG; Hwang, D; Bataille, F; Lefevre, M; York, D; Quon, M; Ye, JP			Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; TNF-ALPHA; OKADAIC ACID; PHOSPHATIDYLINOSITOL 3-KINASE; SKELETAL-MUSCLE; IKK-BETA; RESISTANCE; PATHWAY; IRS-1	Insulin resistance contributes importantly to the pathophysiology of type 2 diabetes mellitus. One mechanism mediating insulin resistance may involve the phosphorylation of serine residues in insulin receptor substrate-1 (IRS-1), leading to impairment in the ability of IRS-1 to activate downstream phosphatidylinositol 3-kinase-dependent pathways. Insulin-resistant states and serine phosphorylation of IRS-1 are associated with the activation of the inhibitor kappaB kinase (IKK) complex. However, the precise molecular mechanisms by which IKK may contribute to the development of insulin resistance are not well understood. In this study, using phosphospecific antibodies against rat IRS-1 phosphorylated at Ser(307) (equivalent to Ser(312) in human IRS-1), we observed serine phosphorylation of IRS-1 in response to TNF-alpha or calyculin A treatment that paralleled surrogate markers for IKK activation. The phosphorylation of human IRS-1 at Ser(312) in response to tumor necrosis factor-alpha was significantly reduced in cells pretreated with the IKK inhibitor 15 deoxy-prostaglandin J(2) as well as in cells derived from IKK knock-out mice. We observed interactions between endogenous IRS-1 and IKK in intact cells using a co-immunoprecipitation approach. Moreover, this interaction between IRS-1 and IKK in the basal state was reduced upon IKK activation and increased serine phosphorylation of IRS-1. Data from in vitro kinase assays using recombinant IRS-1 as a substrate were consistent with the ability of IRS-1 to function as a direct substrate for IKK with multiple serine phosphorylation sites in addition to Ser(312). Taken together, our data suggest that IRS-1 is a novel direct substrate for IKK and that phosphorylation of IRS-1 at Ser(312) (and other sites) by IKK may contribute to the insulin resistance mediated by activation of inflammatory pathways.	Louisiana State Univ, Pennington Biomed Res Ctr, Gene Regulat Lab, Baton Rouge, LA 70808 USA; NIH, Diabet Unit, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Ye, JP (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, Gene Regulat Lab, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.		Quon, Michael/B-1970-2008; Lefevre, Michael/B-5030-2014; Ye, Jianping/N-1998-2017	Lefevre, Michael/0000-0002-2046-3593; Ye, Jianping/0000-0003-3875-365X; QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [ZIAAT000002, Z01AT000002] Funding Source: NIH RePORTER	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Cam MC, 2000, CAN J PHYSIOL PHARM, V78, P829, DOI 10.1139/cjpp-78-10-829; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Engelman JA, 2000, MOL ENDOCRINOL, V14, P1557, DOI 10.1210/me.14.10.1557; Ghanim H, 2001, J CLIN ENDOCR METAB, V86, P1306, DOI 10.1210/jc.86.3.1306; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; JULLIEN D, 1993, J BIOL CHEM, V268, P15246; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; Ouchi N, 2000, CIRCULATION, V102, P1296, DOI 10.1161/01.CIR.102.11.1296; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Su TT, 2002, NAT IMMUNOL, V3, P780, DOI 10.1038/ni823; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TANTI JF, 1991, J BIOL CHEM, V266, P2099; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; White MF, 1998, CURR TOP MICROBIOL, V228, P179; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Ye JP, 1999, MOL CELL BIOCHEM, V198, P193, DOI 10.1023/A:1006969008056; Ye JP, 1996, MOL CELL BIOL, V16, P4744; Ye JP, 2001, J BIOL CHEM, V276, P5360, DOI 10.1074/jbc.M008814200; Young VM, 1998, METABOLISM, V47, P566, DOI 10.1016/S0026-0495(98)90241-4; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	62	554	582	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48115	48121		10.1074/jbc.M209459200	http://dx.doi.org/10.1074/jbc.M209459200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12351658	hybrid			2022-12-27	WOS:000179789600020
J	Guigal, N; Rodriguez, M; Cooper, RN; Dromaint, S; Di Santo, JP; Mouly, V; Boutin, JA; Galizzi, JP				Guigal, N; Rodriguez, M; Cooper, RN; Dromaint, S; Di Santo, JP; Mouly, V; Boutin, JA; Galizzi, JP			Uncoupling protein-3 (UCP3) mRNA expression in reconstituted human muscle after myoblast transplantation in RAG2(-/-)/(gamma)c/C5(-) immunodeficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; SKELETAL-MUSCLE; GENE-EXPRESSION; THYROID-HORMONE; ADIPOSE-TISSUE; UP-REGULATION; MYOTUBES; CLONING; OBESITY; REGION	Uncoupling protein-3 (UCP3), which is expressed abundantly in skeletal muscle, is one of the carrier proteins dissipating the transmitochondrial electrochemical gradient as heat and has therefore been implicated in the regulation of energy metabolism. Myoblasts or differentiated muscle cells in vitro expressed little if any UCP3, compared with the levels detected in biopsies of skeletal muscle. In the present report, we sought to investigate UCP3 mRNA expression in human muscle generated by myoblast transplantation in the skeletal muscle of an immunodeficient mouse model. Time course experiments demonstrated that 7-8 weeks following transplantation fully differentiated human muscle fibers were formed. The presence of differentiated human muscle fibers was assessed by quantitative PCR measurement of the human a-actin mRNA together with immunohistochemical staining using specific antibodies for spectrin and the slow adult myosin heavy chain. Interestingly, we found that the expression of UCP3 mRNA was dependant on human muscle differentiation and that the UCP3 mRNA level was comparable with that found in human muscle biopsies. Moreover, the human UCP3 (hUCP3) promoter seems to be fully functional, since triiodothyronine treatment of the mice not only stimulated the mouse UCP3 (mUCP3) mRNA expression but also strongly stimulated the hUCP3 mRNA expression in human fibers formed after myoblast transplantation. To our knowledge, this is the first time that primary myoblasts could be induced to express the UCP3 gene at a level comparable of that found in human muscle fibers.	Inst Rech Servier, Div Pharmacol Mol & Cellulaire, F-78290 Croissy Sur Seine, France; Univ Paris 06, CNRS, UMR 7000, F-75634 Paris 13, France; Inst Pasteur, Unite Cytokines & Dev Lymphoide, F-75724 Paris 15, France	Servier; Institut de Recherches Internationales Servier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Boutin, JA (corresponding author), Inst Rech Servier, Div Pharmacol Mol & Cellulaire, 125 Chemin Ronde, F-78290 Croissy Sur Seine, France.		Di Santo, James P/M-4298-2014; Boutin, Jean Albert/W-9103-2019	Di Santo, James P/0000-0002-7146-1862; Boutin, Jean Albert/0000-0003-0068-7204; Mouly, Vincent/0000-0003-3809-4033				Acin A, 1999, BIOCHEM BIOPH RES CO, V258, P278, DOI 10.1006/bbrc.1999.0530; Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Bouillaud F, 1999, INT J OBESITY, V23, pS19, DOI 10.1038/sj.ijo.0800938; Brun S, 1999, FEBS LETT, V453, P205, DOI 10.1016/S0014-5793(99)00722-X; Brun S, 1999, DIABETES, V48, P1217, DOI 10.2337/diabetes.48.6.1217; Cadenas S, 2002, J BIOL CHEM, V277, P2773, DOI 10.1074/jbc.M109736200; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Cooper RN, 2001, HUM GENE THER, V12, P823, DOI 10.1089/104303401750148784; Decary S, 1996, HUM GENE THER, V7, P1347, DOI 10.1089/hum.1996.7.11-1347; Edom-Vovard F, 1999, J CELL SCI, V112, P191; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Harper JA, 2002, BIOCHEM J, V361, P49, DOI 10.1042/0264-6021:3610049; Hwang CS, 1999, BIOCHEM BIOPH RES CO, V258, P464, DOI 10.1006/bbrc.1999.0662; Irintchev A, 1997, J PHYSIOL-LONDON, V500, P775, DOI 10.1113/jphysiol.1997.sp022057; KAUFMAN SJ, 1988, P NATL ACAD SCI USA, V85, P9606, DOI 10.1073/pnas.85.24.9606; Khalfallah Y, 2000, DIABETES, V49, P25, DOI 10.2337/diabetes.49.1.25; Matsuda J, 1997, FEBS LETT, V418, P200, DOI 10.1016/S0014-5793(97)01381-1; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; Nagase I, 1999, FEBS LETT, V461, P319, DOI 10.1016/S0014-5793(99)01477-5; Otabe S, 2000, DIABETOLOGIA, V43, P245, DOI 10.1007/s001250050037; Otabe S, 1999, DIABETES, V48, P206; Solanes G, 1997, J BIOL CHEM, V272, P25433, DOI 10.1074/jbc.272.41.25433; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X	28	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47407	47411		10.1074/jbc.M208048200	http://dx.doi.org/10.1074/jbc.M208048200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351640	hybrid			2022-12-27	WOS:000179663700075
J	Hotokezaka, H; Sakai, E; Kanaoka, K; Saito, K; Matsuo, K; Kitaura, H; Yoshida, N; Nakayama, K				Hotokezaka, H; Sakai, E; Kanaoka, K; Saito, K; Matsuo, K; Kitaura, H; Yoshida, N; Nakayama, K			U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; FACTOR RECEPTOR FAMILY; NERVE GROWTH-FACTOR; CATHEPSIN-K; PC12 CELLS; CYCLIN D1; NEURONAL DIFFERENTIATION; SUSTAINED ACTIVATION; CYSTEINE PROTEINASE	Osteoclasts are multinucleated cells that differentiate from hematopoietic cells and possess characteristics responsible for bone resorption. To study the involvement of mitogen-activated protein kinases (MAPKs) in osteoclastogenesis of the murine monocytic cell line RAW264.7, which can differentiate into osteoclast-like cells in the presence of the receptor activator of nuclear factor kappa B ligand (RANKL), we treated the cells with specific inhibitors of p38 MAPK, PD169316 and SB203580, and specific inhibitors of MAPK extracellular signaling-regulated kinase (ERK) kinase (MEK), U0126 and PD98059. Each inhibitor blocked differentiation into osteoclast-like cells when the cells were plated at the standard cell density (2000-4000 cells per well (96-well)). However, the effect of MEK inhibitors on osteoclastogenesis varied according to the initial cell density during culture, because cell growth was clearly inhibited by them. When the cells were plated at more than 8000 cells per well, marked enhancement and acceleration of the differentiation were observed. In addition, immunoblot analysis revealed that phosphorylation of ERK was increased by treatment with the p38 inhibitors, whereas the MEK inhibitors increased phosphorylation of p38, which implies a seesaw-like balance between ERK and p38 phosphorylation. We suggest that osteoclastogenesis is regulated under a balance between ERK and p38 pathways and that the MEK/ERK pathway negatively regulates osteoclastogenesis while the p38 pathway does so positively. This is the first report that an inhibitor of signal transduction enhanced osteoclastogenesis.	Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Orthodont & Biomed Engn, Nagasaki 8528588, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Oral Mol Pharmacol, Nagasaki 8528588, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Pediat Dent, Nagasaki 8528588, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Microbial & Oral Infect, Nagasaki 8528588, Japan	Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University	Hotokezaka, H (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Orthodont & Biomed Engn, Sakamoto 1-7-1, Nagasaki 8528588, Japan.	hotoke@net.nagasaki-u.ac.jp	Saito, Kan/AAG-3507-2020; Saito, Kan/AFS-5564-2022; Kitaura, Hideki/U-7277-2019	Saito, Kan/0000-0002-2151-6204; Saito, Kan/0000-0002-2151-6204; sakai, eiko/0000-0002-6776-6540				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Assoian RK, 2002, NAT CELL BIOL, V4, pE187, DOI 10.1038/ncb0802-e187; Asthagiri AR, 2001, BIOTECHNOL PROGR, V17, P227, DOI 10.1021/bp010009k; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Huang M, 2002, J BIOL CHEM, V277, P28364, DOI 10.1074/jbc.C200321200; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; Kaji H, 1997, J BONE MINER RES, V12, P734, DOI 10.1359/jbmr.1997.12.5.734; Kamiya T, 1998, J BIOCHEM-TOKYO, V123, P752; Kim HH, 1999, FEBS LETT, V443, P297, DOI 10.1016/S0014-5793(98)01731-1; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756-3282(01)00657-3; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788; New LG, 2001, J CELL BIOCHEM, V83, P585, DOI 10.1002/jcb.1253; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; Rohde T, 1996, EUR J APPL PHYSIOL, V74, P428; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Seghatoleslami MR, 2002, J CELL BIOCHEM, V84, P237, DOI 10.1002/jcb.10019; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	46	258	269	0	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47366	47372		10.1074/jbc.M208284200	http://dx.doi.org/10.1074/jbc.M208284200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12237315	hybrid			2022-12-27	WOS:000179663700069
J	Jarad, G; Wang, BC; Khan, S; DeVore, J; Miao, H; Wu, K; Nishimura, SL; Wible, BA; Konieczkowski, M; Sedor, JR; Schelling, JR				Jarad, G; Wang, BC; Khan, S; DeVore, J; Miao, H; Wu, K; Nishimura, SL; Wible, BA; Konieczkowski, M; Sedor, JR; Schelling, JR			Fas activation induces renal tubular epithelial cell beta(8) integrin expression and function in the absence of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-2 MESSENGER-RNA; CONFER IMMUNE PRIVILEGE; DOWN-REGULATION; LIGAND; CD95; ALPHA-V-BETA-8; VITRONECTIN; MECHANISM; ADHESION; FIBROSIS	Cell fate following Fas (CD95) ligand or agonistic anti-Fas antibody stimulation is determined by multiple factors, including Fas expression level, microdomain localization, and modulating cytokines. Highly expressed Fas clusters and activates a canonical apoptosis signaling pathway. In less susceptible cells, Fas transduces apoptosis-independent signals, which are not well defined, but have been linked to inflammation, angiogenesis, and fibrosis. To identify apoptosis-independent Fas pathways, cultured renal tubular epithelial cells were stimulated with agonistic anti-Fas antibodies under conditions that did not cause cell death. Analysis of filter cDNA microarrays revealed beta(8) integrin subunit mRNA induction in Fas-stimulated cells. beta(8) integrin mRNA expression increased within 3-6 h of Fas ligation due to enhanced mRNA stabilization, and mRNA increases were sustained for 48-72 h. Expression of plasma membrane beta(8) integrin, as well as its heterodimer partner alpha(v), was increased by Fas activation with a similar kinetic pattern. Fas-induced alpha(v)beta(8), expression correlated with increased migration to vitronectin, the ligand for alpha(v)beta(8). Results from studies with function-blocking antibodies against other alpha(v)beta integrins or suppression of beta(8) integrin expression by RNA interference demonstrated that induced beta(8) integrin expression mediated Fas-stimulated migration. We conclude that alpha(v)beta(8) integrin induction defines an unexpected role for Fas in cell migration, rather than as a cell death receptor.	Case Western Reserve Univ, Sch Med, Rammelkamp Ctr Educ & Res, Dept Med, Cleveland, OH 44109 USA; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44109 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44109 USA; Univ Calif San Francisco, Sch Med, Dept Pathol, Div Pulm, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Lung Biol, San Francisco, CA 94143 USA	Case Western Reserve University; MetroHealth System; Case Western Reserve University; Case Western Reserve University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Schelling, JR (corresponding author), Case Western Reserve Univ, Sch Med, Rammelkamp Ctr Educ & Res, Dept Med, MetroHlth Med Ctr Campus,2500 Metrohlth Dr,G531, Cleveland, OH 44109 USA.				NATIONAL CANCER INSTITUTE [R01CA096533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK054178, R01DK038558, R21DK057933] Funding Source: NIH RePORTER; NCI NIH HHS [CA96533] Funding Source: Medline; NIDDK NIH HHS [DK38558, DK54178, DK57933] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; Aznavoorian S, 1996, J BIOL CHEM, V271, P3247, DOI 10.1074/jbc.271.6.3247; Biancone L, 1997, J EXP MED, V186, P147, DOI 10.1084/jem.186.1.147; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boonstra JG, 1997, J AM SOC NEPHROL, V8, P1517; Cambier S, 2000, CANCER RES, V60, P7084; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen CY, 2000, GENE DEV, V14, P1236; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chervonsky AV, 1997, CELL, V89, P17, DOI 10.1016/S0092-8674(00)80178-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Hohlbaum AM, 2002, CLIN IMMUNOL, V103, P1, DOI 10.1006/clim.2001.5165; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; KATAGIRI Y, 1995, J BIOL CHEM, V270, P1785, DOI 10.1074/jbc.270.4.1785; Khan S, 2001, KIDNEY INT, V60, P65, DOI 10.1046/j.1523-1755.2001.00771.x; Khan S, 1999, LAB INVEST, V79, P1089; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Milner R, 1997, DEV BIOL, V185, P215, DOI 10.1006/dbio.1997.8547; Milner R, 1999, J CELL SCI, V112, P4271; MOYLE M, 1991, J BIOL CHEM, V266, P19650; Mu DZ, 2002, J CELL BIOL, V157, P493, DOI 10.1083/jcb.200109100; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NISHIMURA SL, 1994, J BIOL CHEM, V269, P28708; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OrtizArduan A, 1996, AM J PHYSIOL-RENAL, V271, pF1193; Parlato S, 2000, EMBO J, V19, P5123, DOI 10.1093/emboj/19.19.5123; Peruzzi L, 1996, KIDNEY INT, V50, P1310, DOI 10.1038/ki.1996.443; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; Racusen LC, 1997, J LAB CLIN MED, V129, P318, DOI 10.1016/S0022-2143(97)90180-3; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Retta SF, 2001, MOL BIOL CELL, V12, P3126, DOI 10.1091/mbc.12.10.3126; RoyChaudhury P, 1997, KIDNEY INT, V52, P103, DOI 10.1038/ki.1997.309; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Schelling JR, 1999, KIDNEY INT, V56, P1313, DOI 10.1046/j.1523-1755.1999.00684.x; SCHELLING JR, 1994, KIDNEY INT, V46, P675, DOI 10.1038/ki.1994.320; Schelling JR, 1998, LAB INVEST, V78, P813; Schelling JR, 1996, AM J PHYSIOL-RENAL, V270, pF682, DOI 10.1152/ajprenal.1996.270.4.F682; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Seiffert D, 1997, HISTOL HISTOPATHOL, V12, P787; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; VENSTROM K, 1995, MOL BIOL CELL, V6, P419, DOI 10.1091/mbc.6.4.419; YAMAMOTO T, 1994, KIDNEY INT, V45, P916, DOI 10.1038/ki.1994.122; Yang JW, 2001, AM J PATHOL, V159, P1465, DOI 10.1016/S0002-9440(10)62533-3; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Zeisberg M, 2001, AM J PATHOL, V159, P1313, DOI 10.1016/S0002-9440(10)62518-7	55	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47826	47833		10.1074/jbc.M204901200	http://dx.doi.org/10.1074/jbc.M204901200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12324452	hybrid			2022-12-27	WOS:000179663700128
J	Jin, YJ; Blue, EK; Dixon, S; Shao, ZL; Gallagher, PJ				Jin, YJ; Blue, EK; Dixon, S; Shao, ZL; Gallagher, PJ			A death-associated protein kinase (DAPK)-interacting protein, DIP-1, is an E3 ubiquitin ligase that promotes tumor necrosis factor-induced apoptosis and regulates the cellular levels of DAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME PATHWAY; IDENTIFICATION; DOMAINS; DEGRADATION; SMART; RING; MEDIATORS; INHIBITOR; CASPASE-3; FAMILY	Death-associated protein kinase (DAPK) is a multidomain Ser/Thr protein kinase with an important role in apoptosis regulation. In these studies we have identified a DAPK-interacting protein called DIP-1, which is a novel multi-RING finger protein. The RING finger motifs of DIP-1 have E3 ligase activity that can auto-ubiquitinate DIP-1 in vitro. In vivo, DIP-1 is detected as a polyubiquitinated protein, suggesting that the intracellular levels of DIP-1 are regulated by the ubiquitin-proteasome system. Transient expression of DIP-1 in HeLa cells antagonizes the anti-apoptotic function of DAPK to promote a caspase-dependent apoptosis. These studies also demonstrate that DAPK is an in vitro and in vivo target for ubiquitination by DIP-1, thereby providing a mechanism by which DAPK activities can be regulated through proteasomal degradation.	Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Gallagher, PJ (corresponding author), Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	pgallag@iupui.edu		Blue, Emily/0000-0001-8290-4473	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054118] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL054118, R01 HL054118-04, R01HL54118] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Ciechanover A, 2002, HEPATOLOGY, V35, P3, DOI 10.1053/jhep.2002.30316; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Ciechanover A, 2000, J CELL BIOCHEM, P40; Cohen O, 2001, CELL DEATH DIFFER, V8, P6, DOI 10.1038/sj.cdd.4400794; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; ESSER C, 1995, CYTOMETRY, V21, P382, DOI 10.1002/cyto.990210411; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Gallagher PJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1078, DOI 10.1152/ajpcell.2000.279.4.C1078; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang HK, 2000, J BIOL CHEM, V275, P26661; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; ISAKSSON A, 1996, BIOCHIM BIOPHYS ACTA, V1288, P21; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Jin YJ, 2001, J BIOL CHEM, V276, P39667, DOI 10.1074/jbc.M101886200; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kogel D, 2001, BIOESSAYS, V23, P352, DOI 10.1002/bies.1050; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Palaga T, 2002, NAT CELL BIOL, V4, pE149, DOI 10.1038/ncb0602-e149; Ponting CP, 1999, NUCLEIC ACIDS RES, V27, P229, DOI 10.1093/nar/27.1.229; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Schwartz AL, 1999, ANNU REV MED, V50, P57; Shohat G, 2001, J BIOL CHEM, V276, P47460, DOI 10.1074/jbc.M105133200; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Wojcik C, 2002, J CELL MOL MED, V6, P25, DOI 10.1111/j.1582-4934.2002.tb00309.x; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046	36	87	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46980	46986		10.1074/jbc.M208585200	http://dx.doi.org/10.1074/jbc.M208585200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351649	hybrid, Green Accepted			2022-12-27	WOS:000179663700020
J	Rakhit, R; Cunningham, P; Furtos-Matei, A; Dahan, S; Qi, XF; Crow, JP; Cashman, NR; Kondejewski, LH; Chakrabartty, A				Rakhit, R; Cunningham, P; Furtos-Matei, A; Dahan, S; Qi, XF; Crow, JP; Cashman, NR; Kondejewski, LH; Chakrabartty, A			Oxidation-induced misfolding and agagaregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASTROCYTIC HYALINE INCLUSIONS; ALS-LINKED SOD1; COPPER CHAPERONE; CU,ZN-SUPEROXIDE DISMUTASE; MOTOR-NEURONS; GENE MUTATION; MUTANT; DISEASE; AGGREGATION; PROTEIN	The presence of intracellular aggregates that contain Cu/Zn superoxide dismutase (SOD1) in spinal cord motor neurons is a pathological hallmark of amyotrophic lateral sclerosis (ALS). Although SOD1 is abundant in all cells, its half-life in motor neurons far exceeds that in any other cell type. On the basis of the premise that the long half-life of the protein increases the potential for oxidative damage, we investigated the effects of oxidation on misfolding/aggregation of SOD1 and ALS-associated SOD1 mutants. Zinc-deficient wild-type SOD1 and SOD1 mutants were extremely prone to form visible aggregates upon oxidation as compared with wild-type holo-protein. Oxidation of select histidine residues that bind metals in the active site mediates SOD1 aggregation. Our results provide a plausible model to explain the accumulation of SOD1 aggregates in motor neurons affected in ALS.	Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ontario Canc Inst, Dept Biochem, Toronto, ON M5G 2M9, Canada; Caprion Pharmaceut Inc, St Laurent, PQ H4S 2C8, Canada; Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pharmacol Toxicol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M5S 3H2, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Chakrabartty, A (corresponding author), Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada.	chakrab@uhnres.utoronto.ca		Chakrabartty, Avi/0000-0001-7002-8381				BANCI L, 1991, EUR J BIOCHEM, V196, P123, DOI 10.1111/j.1432-1033.1991.tb15794.x; Borchelt DR, 1998, NEUROBIOL DIS, V5, P27, DOI 10.1006/nbdi.1998.0178; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Crow JP, 1997, J NEUROCHEM, V69, P1936; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; Hart PJ, 1998, PROTEIN SCI, V7, P545; HUDSON AJ, 1981, BRAIN, V104, P217, DOI 10.1093/brain/104.2.217; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Kato S, 1999, ACTA NEUROPATHOL, V97, P260, DOI 10.1007/s004010050983; Kato S, 1996, J NEUROPATH EXP NEUR, V55, P1089, DOI 10.1097/00005072-199655100-00009; Kato S, 2001, NEUROPATHOLOGY, V21, P67, DOI 10.1046/j.1440-1789.2001.00359.x; Kato S, 1997, AM J PATHOL, V151, P611; Khossravi M, 2000, BIOCHEMISTRY-US, V39, P5876, DOI 10.1021/bi9924720; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KLAPPER I, 1986, Proteins Structure Function and Genetics, V1, P47, DOI 10.1002/prot.340010109; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Koide T, 1998, NEUROSCI LETT, V257, P29, DOI 10.1016/S0304-3940(98)00800-3; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LI SH, 1995, BIOCHEMISTRY-US, V34, P5762, DOI 10.1021/bi00017a008; Liochev SI, 2002, J BIOL CHEM, V277, P34674, DOI 10.1074/jbc.M204726200; Liochev SI, 2002, ARCH BIOCHEM BIOPHYS, V402, P166, DOI 10.1016/S0003-9861(02)00074-7; Lyons TJ, 1996, P NATL ACAD SCI USA, V93, P12240, DOI 10.1073/pnas.93.22.12240; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; OKAMOTO K, 1991, NEUROSCI LETT, V129, P233, DOI 10.1016/0304-3940(91)90469-A; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; Requena JR, 2001, P NATL ACAD SCI USA, V98, P7170, DOI 10.1073/pnas.121190898; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; SMITT PAES, 1993, CLIN NEUROPATHOL, V12, P88; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; Stadtman ER, 1997, CHEM RES TOXICOL, V10, P485, DOI 10.1021/tx960133r; Subramaniam JR, 2002, NAT NEUROSCI, V5, P301, DOI 10.1038/nn823; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709	43	262	279	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47551	47556		10.1074/jbc.M207356200	http://dx.doi.org/10.1074/jbc.M207356200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356748	hybrid			2022-12-27	WOS:000179663700093
J	Sfakianos, MK; Wilson, L; Sakalian, M; Falany, CN; Barnes, S				Sfakianos, MK; Wilson, L; Sakalian, M; Falany, CN; Barnes, S			Conserved residues in the putative catalytic triad of human bile acid coenzyme A : amino acid N-acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA THIOESTERASES; RAT-LIVER; PEROXISOME PROLIFERATORS; MOLECULAR-CLONING; ESCHERICHIA-COLI; CHOLYL-COA; LONG-CHAIN; PURIFICATION; CONJUGATION; EXPRESSION	Human bile acid-CoA:amino acid N-acyltransferase (hBAT), an enzyme catalyzing the conjugation of bile acids with the amino acids glycine or taurine has significant sequence homology with dienelactone hydrolases and other alpha/beta hydrolases. These enzymes have a conserved catalytic triad that maps onto the mammalian BATs at residues Cys-235, Asp-328, and His-362 of the human sequence, albeit that the hydrolases contain a serine instead of a cysteine. In the present study, the function of the putative catalytic triad of hBAT was examined by chemical modification with the cysteine alkylating reagent N-ethylmaleimide (NEM) and by site-directed mutagenesis of the triad residues followed by enzymology studies of mutant and wild-type hBATs. Treatment with NEM caused inactivation of wild-type hBAT. However, preincubation of wild-type hBAT with the substrate cholyl-CoA before NEM treatment prevented loss of N-acyltransferase activity. Substitution of His-362 or Asp-328 with alanine results in inactivation of hBAT. Although substitution of Cys-235 with serine generated an hBAT mutant with lower N-acyltransferase activity, it substantially increased the bile acid-CoA thioesterase activity compared with wild type. In summary, data from this study support the existence of an essential catalytic triad within hBAT consisting of Cys-235, His-362, and Asp-328 with Cys-235 serving as the probable nucleophile and thus the site of covalent attachment of the bile acid molecule.	Univ Alabama, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Univ Alabama, Comprehens Canc Ctr Mass Spectrometry Shared Faci, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Barnes, S (corresponding author), Univ Alabama, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA.				NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR006487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043230] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046390] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA13148] Funding Source: Medline; NCRR NIH HHS [S10RR06487] Funding Source: Medline; NIAID NIH HHS [AI43230, R01 AI043230-02] Funding Source: Medline; NIDDK NIH HHS [DK-46390] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Beckett D, 1999, PROTEIN SCI, V8, P921, DOI 10.1110/ps.8.4.921; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CZUBA B, 1981, BIOCHEM J, V195, P263, DOI 10.1042/bj1950263; FALANY CN, 1994, J BIOL CHEM, V269, P19375; Falany CN, 1997, J LIPID RES, V38, P1139; FURUTANI M, 1995, BIOCHEM J, V311, P203, DOI 10.1042/bj3110203; Huhtinen K, 2002, J BIOL CHEM, V277, P3424, DOI 10.1074/jbc.M109040200; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; JOHNSON MR, 1991, J BIOL CHEM, V266, P10227; JOHNSON MR, 1989, ANAL BIOCHEM, V182, P360, DOI 10.1016/0003-2697(89)90608-8; KILLENBERG PG, 1978, J BIOL CHEM, V253, P1005; KIMURA M, 1983, H-S Z PHYSIOL CHEM, V364, P637, DOI 10.1515/bchm2.1983.364.1.637; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; Lindquist PJG, 1998, EUR J BIOCHEM, V251, P631, DOI 10.1046/j.1432-1327.1998.2510631.x; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PAZIRANDEH M, 1991, J BIOL CHEM, V266, P20946; Schroeder A, 1998, AM J PHYSIOL-GASTR L, V274, pG370, DOI 10.1152/ajpgi.1998.274.2.G370; SHAH PP, 1968, STEROIDS, V12, P571, DOI 10.1016/S0039-128X(68)80034-0; Solaas K, 2000, J LIPID RES, V41, P1154; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; SVENSSON LT, 1995, EUR J BIOCHEM, V230, P813; SWEENY DJ, 1987, P NATL ACAD SCI USA, V84, P5439, DOI 10.1073/pnas.84.15.5439; VESSEY DA, 1983, BIOCHEM J, V214, P923, DOI 10.1042/bj2140923; VESSEY DA, 1979, J BIOL CHEM, V254, P2059; WITKOWSKI A, 1994, J BIOL CHEM, V269, P379; WITKOWSKI A, 1991, J BIOL CHEM, V266, P18514; WITKOWSKI A, 1992, J BIOL CHEM, V267, P18488; ZOUBOULISVAFIADIS I, 1982, AM J PHYSIOL, V243, pG208, DOI 10.1152/ajpgi.1982.243.3.G208	29	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47270	47275		10.1074/jbc.M207463200	http://dx.doi.org/10.1074/jbc.M207463200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12239217	hybrid			2022-12-27	WOS:000179663700056
J	Chen, ZY; Shie, JL; Tseng, CC				Chen, ZY; Shie, JL; Tseng, CC			Gut-enriched Kruppel-like factor represses ornithine decarboxylase gene expression and functions as checkpoint regulator in colonic cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR WT1; ZINC-FINGER PROTEIN; CHROMATIN IMMUNOPRECIPITATION; TRANSCRIPTIONAL TARGET; PROMOTER ACTIVITY; CARCINOMA CELLS; C-MYC; GROWTH; INDUCTION; TRANSFORMATION	Gut-enriched Kruppel-like factor (GKLF, KLF4) is an epithelial-specific transcription factor that expresses in the gastrointestinal tract and mediates growth arrest of colonic epithelium. The molecular mechanisms governing its growth inhibitory effect have not been fully elucidated. In the present study, we showed that induction of GKLF mRNA and protein expression by interferon-gamma treatment was associated with reduction of ornithine decarboxylase (ODC) gene expression and enzyme activity in colon cancer HT-29 cells. Overexpression of GKLF in HT-29 cells significantly reduced ODC mRNA and protein levels as well as enzyme activity and resulted in growth arrest, indicating that ODC might be a downstream target of GYCLF. This conclusion was further supported by data showing that GKLF mRNA and protein concentrations were the highest at the G(1)/S boundary of the cell cycle, where ODC mRNA and protein levels were the lowest and that overexpression of GKLF resulted in cell arrested at the G, phase. Reporter gene transfection studies and electrophoretic mobility gel shift assays demonstrated that GYCLF repressed ODC promoter activity and that these effects appeared to be mediated through interaction with a GC box in the proximal portion of the promoter. Transfection studies using reporter constructs and chromatin immunoprecipitation assays also demonstrated that GKLF inhibited transactivation of the ODC gene by interfering with the binding of Sp1 to the ODC promoter. These results indicate that GKLF may function as a G(1)/S checkpoint regulator and exert its growth arrest effect through down-regulation of ODC gene expression. Furthermore, GKLF is a transcriptional repressor of the ODC gene, and these effects are mediated by interaction with the GC-rich region on the promoter.	Vet Affairs Boston Healthcare Syst, Gastroenterol Sect, Boston, MA 02118 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Tseng, CC (corresponding author), Boston Univ, Sch Med, Gastroenterol Sect, EBRC X-513,650 Albany St, Boston, MA 02118 USA.				NCI NIH HHS [CA-82593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSEN MS, 1992, J BIOL CHEM, V267, P18866; ABRAHAMSEN MS, 1992, J BIOL CHEM, V10, P5525; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; Chen ZY, 2000, FEBS LETT, V477, P67, DOI 10.1016/S0014-5793(00)01764-6; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; HIETALA OA, 1990, CANCER RES, V50, P2088; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; JAGGI R, 1998, J STEROID BIOCHEM, V29, P457; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; KOZA RA, 1992, BIOCHEM J, V281, P87, DOI 10.1042/bj2810087; KUMAR AP, 1995, J BIOL CHEM, V270, P4341, DOI 10.1074/jbc.270.39.22980; Law GL, 1998, J BIOL CHEM, V273, P19955, DOI 10.1074/jbc.273.32.19955; Li RS, 1999, EXP CELL RES, V247, P257, DOI 10.1006/excr.1998.4361; LI RS, 1994, J BIOL CHEM, V269, P7941; LUC GD, 1984, NEW ENGL J MED, V311, P80; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; Moshier JA, 1996, NUCLEIC ACIDS RES, V24, P1149, DOI 10.1093/nar/24.6.1149; MOSHIER JA, 1993, CANCER RES, V53, P2618; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PARK J, 1995, MOL CELL BIOL, V15, P2374; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PENA A, 1993, J BIOL CHEM, V268, P27277; PORTER CW, 1987, CANCER, V60, P1275, DOI 10.1002/1097-0142(19870915)60:6<1275::AID-CNCR2820600619>3.0.CO;2-I; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; TAKANO S, 1981, CANCER RES, V41, P624; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657	32	61	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46831	46839		10.1074/jbc.M204816200	http://dx.doi.org/10.1074/jbc.M204816200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12297499	hybrid			2022-12-27	WOS:000179529300144
J	Giese, KC; Vierling, E				Giese, KC; Vierling, E			Changes in oligomerization are essential for the chaperone activity of a small heat shock protein in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ALPHA-CRYSTALLIN; CYANOBACTERIUM SYNECHOCOCCUS; MOLECULAR CHAPERONE; DENATURED PROTEINS; PHOTOSYSTEM-II; THERMOTOLERANCE; EXPRESSION; STRESS; CLPB	The ability of small heat shock proteins (sHSPs) to prevent thermal aggregation of other proteins may require disassembly and reassembly of sHSP oligomers. We investigated the role of changes in sHSP oligomerization by studying a mutant with reduced oligomeric stability. In HSP16.6, the single sHSP in the cyanobacterium. Synechocystis sp. PCC 6803, the mutation L66A causes oligomer instability and reduced chaperone activity in vitro. Because thermotolerance of Synechocystis depends on HSP16.6, a phenotype that is enhanced in a DeltaClpB1 strain, the effect of mutations can also be assayed in vivo. L66A causes severe defects in thermotolerance, suggesting that oligomeric stability of sHSPs is required for cellular function. This hypothesis was supported by a selection for intragenic suppressors of L66A, which identified mutations that stabilize oligomers of both L66A and wild-type HSP16.6. Analysis of both over- and under-oligoinerizing mutants suggests that sHSPs must disassemble before they can release substrates. Furthermore, the suppressor mutations not only restore in vivo activity to L66A, they also ameliorate chaperone defects in vitro, and thus provide the first direct evidence for a chaperone function of an sHSP in cellular thermotolerance.	Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA	University of Arizona	Vierling, E (corresponding author), Univ Arizona, Dept Biochem & Mol Biophys, 1007 E Lowell St, Tucson, AZ 85721 USA.	vierling@email.arizona.edu		Vierling, Elizabeth/0000-0002-0066-4881	NIGMS NIH HHS [R01 GM42762, F32 GM18966] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018966, R01GM042762] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLOS J, 1994, PROTEIN EXPRES PURIF, V5, P133, DOI 10.1006/prep.1994.1020; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; ELHAI J, 1988, GENE, V68, P119, DOI 10.1016/0378-1119(88)90605-1; Eriksson MJ, 1996, J BACTERIOL, V178, P4839, DOI 10.1128/jb.178.16.4839-4846.1996; Eriksson MJ, 2001, J BACTERIOL, V183, P7392, DOI 10.1128/JB.183.24.7392-7396.2001; Feil IK, 2001, J BIOL CHEM, V276, P12024, DOI 10.1074/jbc.M010856200; GHOSH S, 1988, ANAL BIOCHEM, V169, P227, DOI 10.1016/0003-2697(88)90278-3; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Kaneko T, 1996, DNA Res, V3, P109; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kuczynska-Wisnik D, 2002, MICROBIOL-SGM, V148, P1757, DOI 10.1099/00221287-148-6-1757; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; Lee GJ, 2000, PLANT PHYSIOL, V122, P189, DOI 10.1104/pp.122.1.189; Lee GJ, 1998, METHOD ENZYMOL, V290, P350, DOI 10.1016/S0076-6879(98)90031-3; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Lee S, 2000, CURR MICROBIOL, V40, P283, DOI 10.1007/s002849910056; Leung DW, 1989, TECHNIQUE, V1, P11; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PETKO L, 1986, CELL, V45, P885, DOI 10.1016/0092-8674(86)90563-5; PLESOFSKYVIG N, 1995, P NATL ACAD SCI USA, V92, P5032, DOI 10.1073/pnas.92.11.5032; RADZICKA A, 1988, BIOCHEMISTRY-US, V27, P1664, DOI 10.1021/bi00405a042; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Soto A, 1999, PLANT PHYSIOL, V120, P521, DOI 10.1104/pp.120.2.521; Thomas JG, 1998, J BACTERIOL, V180, P5165, DOI 10.1128/JB.180.19.5165-5172.1998; Torok Z, 2001, P NATL ACAD SCI USA, V98, P3098, DOI 10.1073/pnas.051619498; van Boekel MAM, 1999, BBA-PROTEIN STRUCT M, V1434, P114, DOI 10.1016/S0167-4838(99)00178-8; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; Vermaas WFJ, 1998, METHOD ENZYMOL, V297, P293; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	38	125	126	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46310	46318		10.1074/jbc.M208926200	http://dx.doi.org/10.1074/jbc.M208926200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12297515	Green Published, hybrid			2022-12-27	WOS:000179529300081
J	Hara, M; Ma, TH; Verkman, AS				Hara, M; Ma, TH; Verkman, AS			Selectively reduced glycerol in skin of aquaporin-3-deficient mice may account for impaired skin hydration, elasticity, and barrier recovery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOLOGIC STRATUM-CORNEUM; UVB-INDUCED ALTERATIONS; IN-VIVO; MECHANICAL-PROPERTIES; WATER-CONTENT; BOUND-WATER; PERMEABILITY; EPIDERMIS; INVIVO; TUMORS	Deletion of the epidermal water/glycerol transporter aquaporin-3 (AQP3) in mice reduced superficial skin conductance by similar to2-fold (Ma, T., Hara, M., Sougrat, R., Verbavatz, J. M., and Verkman, A. S. (2002) J. Biol. Chem. 277, 17147-17153), suggesting defective stratum corneum. (SC) hydration. Here, we demonstrate significant impairment of skin hydration, elasticity, barrier recovery, and wound healing in AQP3 null mice in a hairless (SKH1) genetic background and investigate the cause of the functional defects by analysis of SC morphology and composition. Utilizing a novel (H2O)-H-3 distribution method, SC water content was reduced by similar to50% in AQP3 null mice. Skin elasticity measured by cutometry was significantly reduced in AQP3 null mice with similar to50% reductions in elasticity parameters Uf, Ue, and Ur. Although basal skin barrier function was not impaired, AQP3 deletion produced an similar to2-fold delay in recovery of barrier function as measured by transepidermal water loss after tape stripping. Another biosynthetic skin function, wound healing, was also similar to2-fold delayed by AQP3 deletion. By electron microscopy AQP3 deletion did not affect the structure of the unperturbed SC. The SC content of ions (Na+, K+, Ca2+, Mg2+) and small solutes (urea, lactic acid, glucose) was not affected by AQP3 deletion nor was the absolute amount or profile of lipids and free amino acids. However, AQP3 deletion produced significant reductions in glycerol content in SC and epidermis (in nmol/mug protein: 5.5 +/- 0.4 versus 2.3 +/- 0.7 in SC; 0.037 +/- 0.007 versus 0.022 +/- 0.005 in epidermis) but not in dermis or blood. These results establish hydration, mechanical, and biosynthetic defects in skin of AQP3-deficient mice. The selective reduction in epidermal and SC glycerol content in AQP3 null mice may account for these defects, providing the first functional evidence for physiologically important glycerol transport by an aquaporin.	Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Physiol, San Francisco, CA 94143 USA; Kanebo Ltd, Basic Res Lab, Odawara, Kanagawa, Japan	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, 1246 Hlth Sci Tower,Box 0521, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu		Ma, Tonghui/0000-0001-9338-1030	NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198, P50HL060288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER; NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL60288] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ablett S, 1996, MAGN RESON IMAGING, V14, P357, DOI 10.1016/0730-725X(95)02105-3; AGACHE PG, 1980, ARCH DERMATOL RES, V269, P221, DOI 10.1007/BF00406415; BLANK IH, 1965, J INVEST DERMATOL, V45, P249, DOI 10.1038/jid.1965.125; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Caspers PJ, 2001, J INVEST DERMATOL, V116, P434, DOI 10.1046/j.1523-1747.2001.01258.x; DENDA M, 1992, ARCH DERMATOL RES, V284, P363, DOI 10.1007/BF00372041; Dobrev H, 2000, SKIN RES TECHNOL, V6, P239, DOI 10.1034/j.1600-0846.2000.006004239.x; Elias PM, 2001, SKIN PHARMACOL APPL, V14, P28, DOI 10.1159/000056387; FRIGERI A, 1995, J CELL SCI, V108, P2993; Fujimura T, 2000, J DERMATOL SCI, V24, P105, DOI 10.1016/S0923-1811(00)00090-6; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; HARA M, 1993, ACTA DERM-VENEREOL, V73, P283; Haratake A, 1997, J INVEST DERMATOL, V108, P319, DOI 10.1111/1523-1747.ep12286474; HASHIMOTOKUMASAKA K, 1993, ACTA DERM-VENEREOL, V73, P335; Holleran WM, 1997, PHOTODERMATOL PHOTO, V13, P117, DOI 10.1111/j.1600-0781.1997.tb00214.x; HORII I, 1989, BRIT J DERMATOL, V121, P587, DOI 10.1111/j.1365-2133.1989.tb08190.x; IMOKAWA G, 1991, J INVEST DERMATOL, V96, P845, DOI 10.1111/1523-1747.ep12474562; JACOBSON TM, 1990, J INVEST DERMATOL, V95, P296, DOI 10.1111/1523-1747.ep12484970; Ma TH, 2002, J BIOL CHEM, V277, P17147, DOI 10.1074/jbc.M200925200; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; Marchell NL, 1998, J INVEST DERMATOL, V110, P383, DOI 10.1046/j.1523-1747.1998.00145.x; Nishimori Y, 2001, J INVEST DERMATOL, V117, P1458; POTTS RO, 1985, ARCH DERMATOL RES, V277, P489, DOI 10.1007/BF00510068; PROKSCH E, 1993, BRIT J DERMATOL, V128, P473, DOI 10.1111/j.1365-2133.1993.tb00222.x; Sakai S, 2000, SKIN RES TECHNOL, V6, P128, DOI 10.1034/j.1600-0846.2000.006003128.x; SCHEUPLEIN RJ, 1971, PHYSIOL REV, V51, P702, DOI 10.1152/physrev.1971.51.4.702; Sougrat R, 2002, J INVEST DERMATOL, V118, P678, DOI 10.1046/j.1523-1747.2002.01710.x; TAGAMI H, 1994, ACTA DERM-VENEREOL, P29; TAGAMI H, 1985, ARCH DERMATOL, V121, P642, DOI 10.1001/archderm.121.5.642; Tagami H, 2001, J INVEST DERM SYMP P, V6, P87, DOI 10.1046/j.0022-202x.2001.00016.x; TAKEMA Y, 1994, BRIT J DERMATOL, V131, P641, DOI 10.1111/j.1365-2133.1994.tb04975.x; TAKENOUCHI M, 1986, J INVEST DERMATOL, V87, P574, DOI 10.1111/1523-1747.ep12455817; Taljebini M, 1996, SKIN PHARMACOL, V9, P111; THUNE P, 1989, ACTA DERM-VENEREOL, P133; TRIEBSKORN A, 1983, DERMATOLOGICA, V167, P64, DOI 10.1159/000249750; Tsukahara K, 2001, BRIT J DERMATOL, V144, P452, DOI 10.1046/j.1365-2133.2001.04067.x; WATANABE M, 1991, ARCH DERMATOL, V127, P1689, DOI 10.1001/archderm.127.11.1689	37	177	195	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46616	46621		10.1074/jbc.M209003200	http://dx.doi.org/10.1074/jbc.M209003200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270942	hybrid			2022-12-27	WOS:000179529300118
J	Kitagawa, Y; Inoue, K; Sasaki, S; Hayashi, Y; Matsuo, Y; Lieber, MR; Mizoguchi, H; Yokota, J; Kohno, T				Kitagawa, Y; Inoue, K; Sasaki, S; Hayashi, Y; Matsuo, Y; Lieber, MR; Mizoguchi, H; Yokota, J; Kohno, T			Prevalent involvement of illegitimate V(D)J recombination in chromosome 9p21 deletions in lymphoid leukemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINES; METHYLTHIOADENOSINE PHOSPHORYLASE; GENOMIC INSTABILITY; GENE; TRANSLOCATIONS; SIGNALS; CANCER; MALIGNANCIES; BREAKPOINTS; NEOPLASIA	To understand molecular pathways underlying 9p21 deletions, which lead to inactivation of the p16/CDKN2A, p14/ARF, and/or p15/CDKN2B genes, in lymphoid leukemia, 30 breakpoints were cloned from 15 lymphoid leukemia cell lines. Seventeen (57%) breakpoints were mapped at five breakpoint cluster sites, BCS-LL1 to LL5, each of <15 bp. Two breakpoint cluster sites were located within the ARF and CDMN2B loci, respectively, whereas the remaining three were located >100 kb distal to the CDKN2A, ARF, and CDMN2B loci. The sequences of breakpoint junctions indicated that deletions in the 11 (73%) cell lines were mediated by illegitimate V(D)J recombination targeted at the five BCS-LL and six other sites, which contain sequences similar to recombination signal sequences for V(D)J recombination. An extrachromosomal V(D)J recombination assay indicated that BCS-LLS, at which the largest number of breakpoints (ie. five breakpoints) was clustered, has a V(D)J recombination potential 150-fold less than the consensus recombination signal sequence. Three other BCS-LLs tested also showed V(D)J recombination potential, although it was lower than that of BCS-LL3. These results indicated that illegitimate V(D)J recombination, which was targeted at several ectopic recombination signal sequences widely distributed in 9p21, caused a large fraction of 9p21 deletions in lymphoid leukemia.	Natl Inst Canc Res, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Tokyo Womens Med Univ, Dept Hematol, Tokyo 1628666, Japan; Univ Tokyo, Dept Pediat, Grad Sch Med, Tokyo 1038655, Japan; Fujisaki Cell Ctr, Hayashibara Biochem Labs, Okayama 7028006, Japan; Univ So Calif, Norris Comprehens Canc Ctr, Sch Med, Los Angeles, CA 90089 USA	National Cancer Center - Japan; Tokyo Women's Medical University; University of Tokyo; Hayashibara Biochemical Laboratories, Inc.; University of Southern California	Yokota, J (corresponding author), Natl Inst Canc Res, Div Biol, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.			Lieber, Michael/0000-0003-3700-6345; Lieber, Michael/0000-0001-8809-0909				AKAMATSU Y, 1994, J IMMUNOL, V153, P4520; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; Cayuela JM, 1997, BLOOD, V90, P3720, DOI 10.1182/blood.V90.9.3720; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; Cherry SR, 1999, P NATL ACAD SCI USA, V96, P10788, DOI 10.1073/pnas.96.19.10788; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; Davila M, 2001, ADV CANCER RES, V81, P61, DOI 10.1016/S0065-230X(01)81002-2; Drexler HG, 2000, LEUKEMIA RES, V24, P881, DOI 10.1016/S0145-2126(00)00070-9; Drexler HG, 1998, LEUKEMIA LYMPHOMA, V31, P305, DOI 10.3109/10428199809059223; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Furukawa Y, 2000, BRIT J HAEMATOL, V110, P663, DOI 10.1046/j.1365-2141.2000.02253.x; GAUSS GH, 1993, MOL CELL BIOL, V13, P3900, DOI 10.1128/MCB.13.7.3900; Gauss GH, 1996, MOL CELL BIOL, V16, P258; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; Gauss GH, 1998, EUR J IMMUNOL, V28, P351, DOI 10.1002/(SICI)1521-4141(199801)28:01<351::AID-IMMU351>3.0.CO;2-#; Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X; Hamada K, 2000, GENE CHROMOSOME CANC, V27, P308, DOI 10.1002/(SICI)1098-2264(200003)27:3<308::AID-GCC12>3.3.CO;2-N; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; Kirsch I R, 1997, Semin Immunol, V9, P207, DOI 10.1006/smim.1997.0071; Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403; Kohno T, 1996, DNA Res, V3, P421, DOI 10.1093/dnares/3.6.421; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Kwon J, 2000, MOL CELL, V6, P1037, DOI 10.1016/S1097-2765(00)00102-7; Lewis SM, 1997, MOL CELL BIOL, V17, P3125, DOI 10.1128/MCB.17.6.3125; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Lieber MR, 1998, AM J PATHOL, V153, P1323, DOI 10.1016/S0002-9440(10)65716-1; Marculescu R, 2002, J EXP MED, V195, P85, DOI 10.1084/jem.20011578; Nishioka M, 2000, ONCOGENE, V19, P6251, DOI 10.1038/sj.onc.1204031; Nobori T, 1996, P NATL ACAD SCI USA, V93, P6203, DOI 10.1073/pnas.93.12.6203; OCHMAN H, 1988, GENETICS, V120, P621; OHNISHI H, 1995, BLOOD, V86, P1269, DOI 10.1182/blood.V86.4.1269.bloodjournal8641269; POMYKALA HM, 1994, MOL CELL BIOL, V14, P7604, DOI 10.1128/MCB.14.11.7604; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raghavan SC, 2001, J BIOL CHEM, V276, P29126, DOI 10.1074/jbc.M103797200; Sherr CJ, 2000, CANCER RES, V60, P3689; Vanasse GJ, 1999, BLOOD, V94, P3997, DOI 10.1182/blood.V94.12.3997.424k44_3997_4010; Yu J, 1997, CLIN CANCER RES, V3, P433	39	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46289	46297		10.1074/jbc.M208353200	http://dx.doi.org/10.1074/jbc.M208353200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12228235	hybrid			2022-12-27	WOS:000179529300078
J	Sakamoto, H; Mashima, T; Yamamoto, K; Tsuruo, T				Sakamoto, H; Mashima, T; Yamamoto, K; Tsuruo, T			Modulation of heat-shock protein 27 (Hsp27) anti-apoptotic activity by methylglyoxal modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCT; ALPHA-B-CRYSTALLIN; GLYOXALASE-I; CELL-DEATH; PROTECTIVE ACTIVITY; PROSTATE-CANCER; SERUM-ALBUMIN; CROSS-LINKING; CYTOCHROME-C; PHOSPHORYLATION	Methylglyoxal (MG) is one of the side-products in glycolysis, and it reacts with proteins under physiological conditions. Here, we identified heat-shock protein 27 (Hsp27) as a major MG-modified protein in cells. MG modification of Hsp27 selectively occurs at Arg-188 to form argpyrimidine, and mutation in the residue represses the formation of a large oligomer. This modification process is essential to its repressing activity for cytochrome c-mediated caspase activation. Inhibition of MG modification of Hsp27 causes sensitization of the cells to anti-tumor drug-induced apoptosis. Thus, MG is a novel modulator of cell survival by directly incorporating with the specific protein residue.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Tokyo 1130032, Japan	University of Tokyo; Japanese Foundation for Cancer Research; University of Tokyo	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.							Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; Chaplen FWR, 1998, P NATL ACAD SCI USA, V95, P5533, DOI 10.1073/pnas.95.10.5533; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; CHAUDHARY AK, 1994, SCIENCE, V265, P1580, DOI 10.1126/science.8079172; Cornford PA, 2000, CANCER RES, V60, P7099; Davidson SD, 1999, J UROLOGY, V161, P690, DOI 10.1016/S0022-5347(01)61996-7; Du J, 2000, J CELL BIOCHEM, V77, P333, DOI 10.1002/(SICI)1097-4644(20000501)77:2<333::AID-JCB15>3.0.CO;2-Q; EGYUD LG, 1968, SCIENCE, V160, P1140, DOI 10.1126/science.160.3832.1140; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1998, CANCER RES, V58, P5495; Garrido C, 1997, CANCER RES, V57, P2661; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200; Kang YB, 1996, LEUKEMIA RES, V20, P397, DOI 10.1016/0145-2126(95)00162-X; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim R, 1998, P NATL ACAD SCI USA, V95, P9129, DOI 10.1073/pnas.95.16.9129; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Koschinsky T, 1997, P NATL ACAD SCI USA, V94, P6474, DOI 10.1073/pnas.94.12.6474; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; LO TWC, 1994, J BIOL CHEM, V269, P32299; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Miyata T, 1998, J AM SOC NEPHROL, V9, P2349; Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338; Nakamura S, 1997, DIABETES, V46, P895, DOI 10.2337/diabetes.46.5.895; Okado A, 1996, BIOCHEM BIOPH RES CO, V225, P219, DOI 10.1006/bbrc.1996.1157; Oya T, 1999, J BIOL CHEM, V274, P18492, DOI 10.1074/jbc.274.26.18492; PAPOULIS A, 1995, BIOCHEMISTRY-US, V34, P648, DOI 10.1021/bi00002a032; RANGANATHAN S, 1995, BIOCHEM J, V309, P127, DOI 10.1042/bj3090127; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sakamoto H, 2001, CLIN CANCER RES, V7, P2513; Shamsi FA, 1998, J BIOL CHEM, V273, P6928, DOI 10.1074/jbc.273.12.6928; Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885; Shipanova IN, 1997, ARCH BIOCHEM BIOPHYS, V344, P29, DOI 10.1006/abbi.1997.0195; THORNALLEY PJ, 1995, CRIT REV ONCOL HEMAT, V20, P99, DOI 10.1016/1040-8428(94)00149-N; Vargas-Roig LM, 1998, INT J CANCER, V79, P468, DOI 10.1002/(SICI)1097-0215(19981023)79:5<468::AID-IJC4>3.0.CO;2-Z; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WESTWOOD ME, 1994, J BIOL CHEM, V269, P32293; Wilker SC, 2001, ANAL BIOCHEM, V290, P353, DOI 10.1006/abio.2001.4992; Zhao HR, 1997, J BIOL CHEM, V272, P14465, DOI 10.1074/jbc.272.22.14465	43	115	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45770	45775		10.1074/jbc.M207485200	http://dx.doi.org/10.1074/jbc.M207485200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12226095	hybrid			2022-12-27	WOS:000179529300009
J	Jono, H; Shuto, T; Xu, HD; Kai, H; Lim, DJ; Gum, JR; Kim, YS; Yamaoka, S; Feng, XH; Li, JD				Jono, H; Shuto, T; Xu, HD; Kai, H; Lim, DJ; Gum, JR; Kim, YS; Yamaoka, S; Feng, XH; Li, JD			Transforming growth factor-beta-Smad signaling pathway cooperates with NF-kappa B to mediate nontypeable Haemophilus influenzae-induced MUC2 mucin transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; EPITHELIAL-CELLS; GENE-EXPRESSION; ACTIVATION; PATHOGENESIS; REQUIRES; DISEASE; ALPHA; SPECIFICITY; SEQUENCES	Transforming growth factor-beta (TGF-beta) and related factors are multifunctional cytokines that regulate diverse cellular processes, including proliferation, differentiation, apoptosis, and immune response. The involvement of TGF-beta receptor-mediated signaling in bacteria-induced up-regulation of mucin, a primary innate defensive response for mammalian airways, however, still remains unknown. Here, we report that the bacterium nontypeable Haemophilus influenzae (NTHi), an important human respiratory pathogen, utilizes the TGF-beta-Smad signaling pathway together with the TLR2-MyD88-TAK1-NIK-IKKbeta/gamma-IkappaBalpha pathway to mediate NF-kappaB-dependent MUC2 mucin transcription. The NTHi- induced TGF-beta receptor Type II phosphorylation occurred at as early as 5 min. Pretreatment of NTHi with TGF-beta neutralization antibody reduced up-regulation of MUC2 transcription. Moreover, functional cooperation of NF-kappaB p65/p50 with Smad3/4 appears to positively mediate NF-kappaB-dependent MUC2 transcription. These data are the first to demonstrate the involvement of TGF-beta receptor-mediated signaling in bacteria-induced up-regulation of mucin transcription, bring insights into the novel role of TGF-beta signaling in bacterial pathogenesis, and may lead to new therapeutic intervention of NTHi infections.	Univ So Calif, Gonda Dept Cell & Mol Biol, House Ear Inst, Los Angeles, CA 90057 USA; Kumamoto Univ, Dept Mol Med, Kumamoto 8620973, Japan; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Vet Affairs Med Ctr, Gastrointestinal Res Lab, San Francisco, CA 94121 USA; Tokyo Med & Dent Univ, Dept Mol Virol, Tokyo 1138519, Japan; Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	House Research Institute; University of Southern California; Kumamoto University; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Tokyo Medical & Dental University (TMDU); Baylor College of Medicine; Baylor College of Medicine	Li, JD (corresponding author), Univ So Calif, Gonda Dept Cell & Mol Biol, House Ear Inst, 2100 W 3rd St, Los Angeles, CA 90057 USA.			Li, Jian-Dong/0000-0002-5593-050X	NATIONAL CANCER INSTITUTE [R01CA024321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004562] Funding Source: NIH RePORTER; NCI NIH HHS [CA24321] Funding Source: Medline; NIDCD NIH HHS [R01-DC04562] Funding Source: Medline; NIGMS NIH HHS [GM63773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; Beauparlant P, 1996, J VIROL, V70, P5777, DOI 10.1128/JVI.70.9.5777-5785.1996; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; CARRIE S, 1992, ACTA OTO-LARYNGOL, V112, P504, DOI 10.3109/00016489209137432; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Foxwell AR, 1998, MICROBIOL MOL BIOL R, V62, P294, DOI 10.1128/MMBR.62.2.294-308.1998; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Hill CS, 2001, CURR OPIN GENET DEV, V11, P533, DOI 10.1016/S0959-437X(00)00229-X; Horng T, 2001, P NATL ACAD SCI USA, V98, P12654, DOI 10.1073/pnas.231471798; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim WD, 1997, EUR RESPIR J, V10, P1914, DOI 10.1183/09031936.97.10081914; KIM YS, 1995, GASTROENTEROLOGY, V109, P999, DOI 10.1016/0016-5085(95)90412-3; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Kon A, 1999, ONCOGENE, V18, P1837, DOI 10.1038/sj.onc.1202495; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Lawler S, 1997, J BIOL CHEM, V272, P14850, DOI 10.1074/jbc.272.23.14850; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Li JD, 1997, P NATL ACAD SCI USA, V94, P967, DOI 10.1073/pnas.94.3.967; Li JM, 1998, MOL CELL BIOL, V18, P110, DOI 10.1128/MCB.18.1.110; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MING M, 1995, CELL, V82, P287, DOI 10.1016/0092-8674(95)90316-X; Murphy T F, 2000, Semin Respir Infect, V15, P41; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Rao VK, 1999, FEMS MICROBIOL REV, V23, P99, DOI 10.1016/S0168-6445(98)00039-4; Roberts AB, 2002, CYTOKINE GROWTH F R, V13, P3, DOI 10.1016/S1359-6101(01)00027-2; Rose MC, 2001, AM J RESP CELL MOL, V25, P533, DOI 10.1165/ajrcmb.25.5.f218; Sethi S, 2000, NEW ENGL J MED, V343, P1969; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shuto T, 2002, J BIOL CHEM, V277, P17263, DOI 10.1074/jbc.M112190200; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Wang BN, 2002, J BIOL CHEM, V277, P949, DOI 10.1074/jbc.M107484200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; 1995, AM J RSP CRIT CARE M, V152, pS78	43	87	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45547	45557		10.1074/jbc.M206883200	http://dx.doi.org/10.1074/jbc.M206883200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237307	hybrid			2022-12-27	WOS:000179404800120
J	Lammich, S; Okochi, M; Takeda, M; Kaether, C; Capell, A; Zimmer, AK; Edbauer, D; Walter, J; Steiner, H; Haass, C				Lammich, S; Okochi, M; Takeda, M; Kaether, C; Capell, A; Zimmer, AK; Edbauer, D; Walter, J; Steiner, H; Haass, C			Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an A beta-like peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; NUCLEAR TRANSLOCATION; THYMOCYTE DEVELOPMENT; SIGNAL-TRANSDUCTION; GAMMA; NOTCH; CLEAVAGE; INHIBITORS; PROTEASES	Alzheimer's disease (AD)-associated gamma-secretase is a presenilin (PS)-dependent proteolytic activity involved in the intramembraneous cleavage of the beta-amyloid precursor protein, Notch, LDL receptor-related protein, E-cadherin, and ErbB-4. This cut produces the corresponding intracellular domains (ICD), which are required for nuclear signaling of Notch and probably ErbB-4, the beta-amyloid precursor protein, E-cadherin, and the LDL receptor-related protein as well. We have now investigated CD44, a cell surface adhesion molecule, which also undergoes an intramembraneous cleavage to liberate its ICD. We demonstrate that this cleavage requires a PS-dependent gamma-secretase activity. A loss-of-function PS1 mutation, a PS1/PS2 knockout, as well as two independent and highly specific gamma-secretase inhibitors, abolish this cleavage. Surprisingly, small peptides similar to the amyloid beta-peptide (Abeta) are generated by an additional cut in the middle of the transmembrane region of CD44. Like Abeta, these CD44 beta-peptides are generated in a PS-dependent manner. These findings therefore suggest a dual intramembraneous cleavage mechanism mediated by PS proteins. The dual cleavage mechanism is required for nuclear signaling as well as removal of remaining transmembrane domains, a general function of PS in membrane protein metabolism.	Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany; Osaka Univ, Grad Sch Med, Dept Post Genom & Dis, Div Psychiat & Behav Preteom, Osaka 5650871, Japan	University of Munich; Osaka University	Haass, C (corresponding author), Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, Schillerstr 44, D-80336 Munich, Germany.		Wang, Caihong/T-5837-2019; Walter, Jochen/B-3677-2014; Edbauer, Dieter/M-9906-2019	Wang, Caihong/0000-0002-6808-3709; Edbauer, Dieter/0000-0002-7186-4653; Okochi, Masayasu/0000-0002-2318-7651; Walter, Jochen/0000-0002-4678-2912				Berezovska O, 2000, J NEUROCHEM, V75, P583, DOI 10.1046/j.1471-4159.2000.0750583.x; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2002, J BIOL CHEM, V277, P13389, DOI 10.1074/jbc.M111571200; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Geling A, 2002, EMBO REP, V3, P688, DOI 10.1093/embo-reports/kvf124; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; LaPointe CF, 2000, J BIOL CHEM, V275, P1502, DOI 10.1074/jbc.275.2.1502; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lee JR, 2001, CELL, V107, P161, DOI 10.1016/S0092-8674(01)00526-8; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Martys-Zage JL, 2000, J MOL NEUROSCI, V15, P189, DOI 10.1385/JMN:15:3:189; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mizutani T, 2001, P NATL ACAD SCI USA, V98, P9026, DOI 10.1073/pnas.161269998; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Saxena MT, 2001, J BIOL CHEM, V276, P40268, DOI 10.1074/jbc.M107234200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Steinhilb ML, 2001, J BIOL CHEM, V276, P4476, DOI 10.1074/jbc.M008793200; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Urban S, 2001, CELL, V107, P173, DOI 10.1016/S0092-8674(01)00525-6; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang JM, 2002, J BIOL CHEM, V277, P15069, DOI 10.1074/jbc.M105375200; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	62	241	252	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44754	44759		10.1074/jbc.M206872200	http://dx.doi.org/10.1074/jbc.M206872200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223485	hybrid			2022-12-27	WOS:000179404800022
J	Coppolino, MG; Dierckman, R; Loijens, J; Collins, RF; Pouladi, M; Jongstra-Bilen, J; Schreiber, AD; Trimble, WS; Anderson, R; Grinstein, S				Coppolino, MG; Dierckman, R; Loijens, J; Collins, RF; Pouladi, M; Jongstra-Bilen, J; Schreiber, AD; Trimble, WS; Anderson, R; Grinstein, S			Inhibition of phosphatidylinositol-4-phosphate 5-kinase I alpha impairs localized actin remodeling and suppresses phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED PHAGOCYTOSIS; PHOSPHATE KINASES; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; PLASMA-MEMBRANE; BINDING; PROTEIN; REQUIREMENTS; SEQUENCE; TALIN	Actin polymerization drives the extension of pseudopods required for phagocytosis. Phosphatidylinositol 4,5-bisphosphate (PIP2) is thought to play a central role in this process, because it interacts with several actin-regulatory proteins and undergoes acute and localized changes at sites of phagocytosis. We therefore studied whether phosphatidylinositol-4-phosphate 5-kinase (PIPK), the enzyme responsible for the generation of PIP2 from phosphatidylinositol 4-phosphate, is involved in the control of phagocytosis. PIPKIalpha was found to accumulate transiently on forming phagosomes. To test the functional involvement of PIPKIalpha in particle engulfment, we generated a double mutant (D309N/R427Q) that lacks kinase activity. When ectopically expressed in cultured cells, this mutant is targeted to the plasma membrane and accumulates at the phagosomal cup during particle engulfment. Expression of PIP5KIalpha D309N/R427Q impaired phagocytosis in RAW264.7 macrophages and in engineered phagocytes generated by transfection of Fc receptors in Chinese hamster ovary cells. Inhibition of phagocytosis could not be attributed to defects in particle binding or receptor clustering, which was monitored using green fluorescent protein-tagged Fcy receptors. Instead, expression of the inactive kinase diminished the accumulation of PIP2 and of F-actin in the phagosomal cup. These data suggest that PIPKIalpha activity is involved in the actin remodeling that is a prerequisite for efficient phagocytosis. PIPKIalpha appears to contribute to the transient changes in PIP2 levels that are associated with, and likely required for, the recruitment and regulation of actin-modulating proteins.	Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada; Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Wisconsin System; University of Wisconsin Madison; University of Pennsylvania	Grinstein, S (corresponding author), Hosp Sick Children, Cell Biol Programme, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	sga@sickkids.ca	Pouladi, Mahmoud A/B-8743-2016	Pouladi, Mahmoud A/0000-0002-9030-0976; Anderson, Richard/0000-0001-6265-8359				Allen LAH, 1996, CURR OPIN IMMUNOL, V8, P36, DOI 10.1016/S0952-7915(96)80102-6; Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Bajno L, 2000, J CELL BIOL, V149, P697, DOI 10.1083/jcb.149.3.697; Booth JW, 2002, EMBO J, V21, P251, DOI 10.1093/emboj/21.3.251; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; BROOKSBANK CEL, 1993, BIOCHEM J, V291, P77, DOI 10.1042/bj2910077; BROWN EJ, 1995, BIOESSAYS, V17, P109, DOI 10.1002/bies.950170206; Burden LM, 1999, BIOCHEMISTRY-US, V38, P15141, DOI 10.1021/bi991571a; Chaudhary A, 1998, CHEM BIOL, V5, P273, DOI 10.1016/S1074-5521(98)90620-2; Cox D, 1996, J BIOL CHEM, V271, P16597, DOI 10.1074/jbc.271.28.16597; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Cox D, 2001, SEMIN IMMUNOL, V13, P339, DOI 10.1006/smim.2001.0330; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; GREENBERG S, 1990, J EXP MED, V172, P1853, DOI 10.1084/jem.172.6.1853; GRIFFIN FM, 1975, J EXP MED, V142, P1263, DOI 10.1084/jem.142.5.1263; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; INDIK ZK, 1995, IMMUNOL LETT, V44, P133, DOI 10.1016/0165-2478(94)00204-5; Kiefer F, 1998, MOL CELL BIOL, V18, P4209, DOI 10.1128/MCB.18.7.4209; Kunz J, 2002, J BIOL CHEM, V277, P5611, DOI 10.1074/jbc.M110775200; Kunz J, 2000, MOL CELL, V5, P1, DOI 10.1016/S1097-2765(00)80398-6; Kwiatkowska K, 1999, BIOESSAYS, V21, P422, DOI 10.1002/(SICI)1521-1878(199905)21:5<422::AID-BIES9>3.0.CO;2-#; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; May RC, 2000, NAT CELL BIOL, V2, P246, DOI 10.1038/35008673; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; Sechi AS, 2000, J CELL SCI, V113, P3685; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TEMPEL M, 1995, BIOPHYS J, V69, P228, DOI 10.1016/S0006-3495(95)79894-0; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YU FX, 1992, J BIOL CHEM, V267, P14616; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	45	116	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43849	43857		10.1074/jbc.M209046200	http://dx.doi.org/10.1074/jbc.M209046200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223494	hybrid			2022-12-27	WOS:000179272000043
J	Taylor, AL; Hewett, SJ				Taylor, AL; Hewett, SJ			Potassium-evoked glutamate release liberates arachidonic acid from cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCITOTOXIC CELL-DEATH; FREE FATTY-ACIDS; PHOSPHOLIPASE A(2); PRIMARY CULTURES; D-ASPARTATE; SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; BRAIN SYNAPTOSOMES; CEREBRAL-ISCHEMIA; NMDA RECEPTORS	Brain cells in situ contain low concentrations of free polyunsaturated fatty acids such as arachidonic acid (AA) that are released following pathological insults. As a large rise in extracellular [K+] accompanies cerebral ischemia, we explored whether this was a stimulus for cellular AA release employing a murine mixed cortical cell culture preparation radiolabeled with AA. Elevating the [K+], from 5 to 52 mm induced a time-dependent increase in [H-3]AA release, which reached a plateau after 15 min. Removal of [Ca2+](o) or addition of CdCl2 (100 muM) diminished the net high K+-induced AA release, as did treatment of the cultures with tetanus toxin (300 ng/ml) to block endogenous neurotransmitter release. Pharmacological antagonism of both ionotropic and metabotropic glutamate receptors completely prevented high K+-evoked AA release, indicating that glutamate was the neurotransmitter in question. Addition of exogenous glutamate mimicked precisely the characteristics of AA release that followed increases in [K+](o). Finally, glutamate and AA were released solely from neurons as tetanus toxin did not cleave astrocytic synaptobrevin-2, nor was AA released from pure astrocyte cultures using the same stimuli that were effective in mixed cultures. Taken in toto, our data are consistent with the following scenario: high [K+](o) depolarizes neurons, causing an influx of Ca2+ via voltage-gated Ca2+ channels. This Ca2+ influx stimulates the release of glutamate into the synaptic cleft, where it activates postsynaptic glutamate receptors. Events likely converge on the activation of a phospholipase A(2) family member and possibly the enzymes diacylglycerol and monoacylglycerol lipases to yield free AA.	Univ Connecticut, Ctr Hlth, Dept Neurosci, Sch Med, Farmington, CT 06030 USA	University of Connecticut	Hewett, SJ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, Sch Med, MC-3401,263 Farmington Ave, Farmington, CT 06030 USA.	shewett@neuron.uchc.edu		Hewett, Sandra/0000-0002-2987-3791	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS036812, R01NS036812] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS036812, NS36812] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen JW, 2001, EXP NEUROL, V169, P449, DOI 10.1006/exnr.2001.7672; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BAZAN NG, 1989, ANN NY ACAD SCI, V559, P1; BAZAN NG, 1970, LIFE SCI, V9, P501, DOI 10.1016/0024-3205(70)90205-5; BRADFORD PG, 1983, J NEUROCHEM, V41, P1684, DOI 10.1111/j.1471-4159.1983.tb00881.x; Briand S I, 1998, Methods Mol Biol, V105, P161; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; CHAN PH, 1985, PROG BRAIN RES, V63, P227; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Clements MP, 1996, J NEUROCHEM, V67, P1317; COLE DJ, 1993, J PHARMACOL EXP THER, V266, P1713; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Cummings BS, 2000, J PHARMACOL EXP THER, V294, P793; DORMAN RV, 1986, BRAIN RES BULL, V17, P243, DOI 10.1016/0361-9230(86)90121-8; DUGAN LL, 1994, ANN NEUROL, V35, pS17, DOI 10.1002/ana.410350707; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; DUMUIS A, 1993, MOL PHARMACOL, V43, P976; EATON SA, 1993, EUR J PHARM-MOLEC PH, V244, P195, DOI 10.1016/0922-4106(93)90028-8; Egan R W, 1980, Adv Prostaglandin Thromboxane Res, V6, P153; FAROOQUI AA, 1993, BRAIN RES, V604, P180, DOI 10.1016/0006-8993(93)90366-U; Gido G, 1997, STROKE, V28, P206, DOI 10.1161/01.STR.28.1.206; GORDINIER AL, 2001, SOC NEUROSCI ABS, V27; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; HILLERED L, 1988, J NEUROSCI RES, V19, P94, DOI 10.1002/jnr.490190113; JANE DE, 1993, NEUROPHARMACOLOGY, V32, P725, DOI 10.1016/0028-3908(93)90088-K; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; LAZAREWICZ JW, 1990, J NEUROCHEM, V55, P1875, DOI 10.1111/j.1471-4159.1990.tb05771.x; LAZAREWICZ JW, 1983, NEUROCHEM INT, V5, P471, DOI 10.1016/0197-0186(83)90077-3; LEFER AM, 1986, BIOCHEM PHARMACOL, V35, P123, DOI 10.1016/0006-2952(86)90502-2; Liu XH, 1998, CANCER RES, V58, P4245; MANZONI OJ, 1994, EUR J NEUROSCI, V6, P1050, DOI 10.1111/j.1460-9568.1994.tb00599.x; MATSUBARA C, 1983, ANAL BIOCHEM, V130, P128, DOI 10.1016/0003-2697(83)90659-0; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; MOORE SA, 1991, J NEUROCHEM, V56, P518, DOI 10.1111/j.1471-4159.1991.tb08180.x; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Nogawa S, 1997, J NEUROSCI, V17, P2746; Parpura V, 1995, FEBS LETT, V377, P489, DOI 10.1016/0014-5793(95)01401-2; PATEL PM, 1993, BRAIN RES, V614, P315, DOI 10.1016/0006-8993(93)91050-3; PetersGolden M, 1996, BIOCHEM J, V318, P797, DOI 10.1042/bj3180797; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; RABASSEDA X, 1987, FEBS LETT, V213, P337, DOI 10.1016/0014-5793(87)81518-1; RUBIN RP, 1970, PHARMACOL REV, V22, P389; SANFELIU C, 1990, BRAIN RES, V526, P241, DOI 10.1016/0006-8993(90)91228-9; SASAKI T, 1988, STROKE, V19, P1399, DOI 10.1161/01.STR.19.11.1399; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; STELLA N, 1995, J NEUROSCI, V15, P3307; STELLA N, 1994, J NEUROSCI, V14, P568; TAKEUCHI Y, 1991, ARCH BIOCHEM BIOPHYS, V289, P33, DOI 10.1016/0003-9861(91)90438-O; TAPIAARANCIBIA L, 1992, EUR J PHARM-MOLEC PH, V225, P253, DOI 10.1016/0922-4106(92)90027-S; Trackey JL, 2001, J NEUROCHEM, V79, P445, DOI 10.1046/j.1471-4159.2001.00584.x; Uliasz TF, 2000, J NEUROSCI METH, V100, P157, DOI 10.1016/S0165-0270(00)00248-X; VAZQUEZ E, 1994, NEUROSCI LETT, V174, P9, DOI 10.1016/0304-3940(94)90106-6; Vesce S, 1999, CELL MOL LIFE SCI, V56, P991, DOI 10.1007/s000180050488; Vidwans AS, 2001, BIOCHEMISTRY-US, V40, P11533, DOI 10.1021/bi0108960; VOLTERRA A, 1994, MOL PHARMACOL, V46, P986; WATKINS J, 1994, TRENDS PHARMACOL SCI, V15, P333, DOI 10.1016/0165-6147(94)90028-0; WIELOCH T, 1982, PATHOL BIOL, V30, P269; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; YU ACH, 1986, J NEUROCHEM, V47, P1181	63	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43881	43887		10.1074/jbc.M205872200	http://dx.doi.org/10.1074/jbc.M205872200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12235140	hybrid			2022-12-27	WOS:000179272000047
J	Chen, W; White, MA; Cobb, MH				Chen, W; White, MA; Cobb, MH			Stimulus-specific requirements for MAP3 kinases in activating the JNK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; SIGNAL-TRANSDUCTION PATHWAY; BINDING PROTEINS RAC1; CELL SHEET MOVEMENT; DROSOPHILA MORPHOGENESIS; TRANSCRIPTIONAL ACTIVITY; MOLECULAR-CLONING; FAMILY; CASCADE; PHOSPHORYLATES	Mitogen-activated protein kinases (MAPKs) are activated by numerous ligands typically through a protein kinase cascade minimally composed of the MAPK in series with a MAPK kinase (MAP2K) and a MAP3K. This arrangement is thought to confer specificity and appropriate kinetic properties on the activation of MAPKs in response to physiological stimuli. Surprisingly, more than a dozen MAP3Ks have been identified that activate the c-Jun N-terminal kinases (JNKs) when overexpressed, but there is no clear understanding of which kinases actually mediate JNK activation by ligands. Here, we use double-stranded RNA-mediated interference of gene expression to reveal the explicit participation of discrete MAP3Ks in controlling JNK activity by multiple stimuli. Maximal activation of JNK by lipopolysaccharide requires the AL4LP3K TAK1. On the other hand, sorbitol requires expression of four MAP3Ks to cause maximal JNK activation. Thus, we demonstrate that specific stimuli use different mechanisms to recruit distinct MAP3Ks to regulate the JNK pathway.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Neurosci & Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Cobb, Melanie/0000-0003-0833-5473	NCI NIH HHS [CA 71443] Funding Source: Medline; NIGMS NIH HHS [GM 53032, GM 56498] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056498] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON NG, 1991, J BIOL CHEM, V266, P10131; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Chen Z, 2001, J BIOL CHEM, V276, P16070, DOI 10.1074/jbc.M100681200; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Foltz IN, 1998, J BIOL CHEM, V273, P9344, DOI 10.1074/jbc.273.15.9344; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARDEN N, 1995, DEVELOPMENT, V121, P903; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hou XS, 1997, GENE DEV, V11, P1728, DOI 10.1101/gad.11.13.1728; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Inoue H, 2001, EMBO J, V20, P5421, DOI 10.1093/emboj/20.19.5421; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Mihaly J, 2001, MECH DEVELOP, V102, P67, DOI 10.1016/S0925-4773(01)00285-4; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; Noselli S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9; Plowman GD, 1999, P NATL ACAD SCI USA, V96, P13603, DOI 10.1073/pnas.96.24.13603; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; Sajan MP, 2002, BIOCHEM J, V362, P665, DOI 10.1042/0264-6021:3620665; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Stronach B, 2002, GENE DEV, V16, P377, DOI 10.1101/gad.953002; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Takatsu Y, 2000, MOL CELL BIOL, V20, P3015, DOI 10.1128/MCB.20.9.3015-3026.2000; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAN AL, 1997, GENE DEV, V11, P2295; Wallner EI, 2001, RENAL FAILURE, V23, P311, DOI 10.1081/JDI-100104715; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Wang XHSN, 1998, BIOCHEM BIOPH RES CO, V253, P33, DOI 10.1006/bbrc.1998.9749; WORBY CA, 2001, SCI STKE, pL1; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Young PR, 1998, CYTOKINE GROWTH F R, V9, P239, DOI 10.1016/S1359-6101(98)00011-2; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876	65	70	74	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49105	49110		10.1074/jbc.M204934200	http://dx.doi.org/10.1074/jbc.M204934200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12351623	hybrid			2022-12-27	WOS:000180028900003
J	Pearson, GW; Cobb, MH				Pearson, GW; Cobb, MH			Cell condition-dependent regulation of ERK5 by cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; MAP KINASE; SIGNALING PATHWAY; TYROSINE KINASES; SKELETAL-MUSCLE; CYCLIC-AMP; PC12 CELLS; S6 KINASE; RECEPTOR	ERK5 activity is increased by agents known to activate receptor tyrosine kinases, G-protein coupled receptors, and stress response pathways. We now find a role for cAMP in the regulation of ERK5. ERK5 is activated by forskolin, isoproterenol, and epinephrine in NIH3T3 cells and C2C12 myoblasts. ERK1/2 are also activated by cAMP in NIH3T3 cells, but not in C2C12 myoblasts, demonstrating differential regulation of ERK5 and ERK1/2 by cAMP. We examined the effect of cell context on activation of ERK5 and discovered ERK5 activity is inhibited, rather than activated, by cAMP in confluent, serum-deprived NIH3T3 cells and C2C12 myoblasts. Our results suggest that regulation of MAP kinase pathways by cAMP is not only dictated by cell type, but also by cell context.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK34128] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABELL CW, 1973, J CELL BIOL, V59, P549, DOI 10.1083/jcb.59.3.549; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Brandon EP, 1997, CURR OPIN NEUROBIOL, V7, P397, DOI 10.1016/S0959-4388(97)80069-4; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Calleja V, 1997, ENDOCRINOLOGY, V138, P1111, DOI 10.1210/en.138.3.1111; Cao WH, 2001, J BIOL CHEM, V276, P27077, DOI 10.1074/jbc.M101049200; Cavanaugh JE, 2001, J NEUROSCI, V21, P434, DOI 10.1523/JNEUROSCI.21-02-00434.2001; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; ChoChung YS, 1995, CRIT REV ONCOL HEMAT, V21, P33, DOI 10.1016/1040-8428(94)00166-9; Ciardiello F, 1998, CLIN CANCER RES, V4, P821; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; De Potter IY, 2001, EXP CELL RES, V271, P315, DOI 10.1006/excr.2001.5390; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Dinev D, 2001, EMBO REP, V2, P829, DOI 10.1093/embo-reports/kve177; Dong F, 2001, J BIOL CHEM, V276, P10811, DOI 10.1074/jbc.M008748200; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200; GILMAN AG, 1995, BIOSCIENCE REP, V15, P65, DOI 10.1007/BF01200143; Hayashi M, 2001, J BIOL CHEM, V276, P8631, DOI 10.1074/jbc.C000838200; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li XA, 2001, J SURG RES, V100, P197, DOI 10.1006/jsre.2001.6238; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Napoli R, 1998, DIABETES, V47, P1549, DOI 10.2337/diabetes.47.10.1549; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PETRITSCH C, 1995, J BIOL CHEM, V270, P26619, DOI 10.1074/jbc.270.44.26619; Pomerance M, 2000, J BIOL CHEM, V275, P40539, DOI 10.1074/jbc.M002097200; Ramakrishna G, 2000, EXP LUNG RES, V26, P659, DOI 10.1080/01902140150216747; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Sanada S, 2001, CIRCULATION, V104, P705, DOI 10.1161/hc3201.092216; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Tokuda H, 2001, J ENDOCRINOL, V170, P629, DOI 10.1677/joe.0.1700629; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yan C, 1999, J BIOL CHEM, V274, P143, DOI 10.1074/jbc.274.1.143; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6; Zhen XC, 1998, MOL PHARMACOL, V54, P453, DOI 10.1124/mol.54.3.453; Zheng M, 2000, J BIOL CHEM, V275, P40635, DOI 10.1074/jbc.M006325200	49	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48094	48098		10.1074/jbc.M208535200	http://dx.doi.org/10.1074/jbc.M208535200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12297510	hybrid			2022-12-27	WOS:000179789600017
J	Whitehead, SE; Jones, KW; Zhang, X; Cheng, XD; Terns, RM; Terns, MP				Whitehead, SE; Jones, KW; Zhang, X; Cheng, XD; Terns, RM; Terns, MP			Determinants of the interaction of the spinal muscular atrophy disease protein SMN with the dimethylarginine-modified box EUACA small nucleolar ribonucleoprotein GAR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; SPLICEOSOMAL-U-SNRNP; ARGININE METHYLATION; RIBOSOMAL-RNA; IN-VITRO; COILED BODIES; SUBCELLULAR-LOCALIZATION; GENE-PRODUCT; PSEUDOURIDINE SYNTHASE; H/ACA SNORNPS	Deletion or mutation of the SMN1 (survival of motor neurons) gene causes the common, fatal neuromuscular disease spinal muscular atrophy. The SMN protein is important in small nuclear ribonucleoprotein (snRNP) assembly and interacts with snRNP proteins via arginine/glycine-rich domains. Recently, SMN was also found to interact with core protein components of the two major families of small nucleolar RNPs, fibrillarin and GAR1, suggesting that SMN may also function in the assembly of small nucleolar RNPs. Here we present results that indicate that the interaction of SMN with GAR1 is mediated by the Tudor domain of SMN. Single point mutations within the Tudor domain, including a spinal muscular atrophy patient mutation, impair the interaction of SMN with GAR1. Furthermore, we find that either of the two arginine/glycine-rich domains of GAR1 can provide for interaction with SMN, but removal of both results in loss of the interaction. Finally, we have found that unlike the interaction of SMN with the Sm snRNP proteins, interaction with GAR1 and fibrillarin is not enhanced by arginine dimethylation. Our results argue against post-translational arginine dimethylation as a general requirement for SMN recognition of proteins bearing arginine/glycine-rich domains.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Georgia, Dept Genet, Athens, GA 30602 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Emory University	Terns, MP (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.	mterns@bmb.uga.edu	Terns, Michael/N-6435-2016		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061355, R01GM054682] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61355, GM54682] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagni C, 1998, J BIOL CHEM, V273, P10868, DOI 10.1074/jbc.273.18.10868; BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; Bechade C, 1999, EUR J NEUROSCI, V11, P293, DOI 10.1046/j.1460-9568.1999.00428.x; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; Carvalho T, 1999, J CELL BIOL, V147, P715, DOI 10.1083/jcb.147.4.715; Cavaille J, 2000, P NATL ACAD SCI USA, V97, P14311, DOI 10.1073/pnas.250426397; CHRISTENSEN ME, 1988, BIOCHEM BIOPH RES CO, V155, P1278, DOI 10.1016/S0006-291X(88)81279-8; de los Santos T, 2000, AM J HUM GENET, V67, P1067, DOI 10.1086/303106; Dez C, 2001, NUCLEIC ACIDS RES, V29, P598, DOI 10.1093/nar/29.3.598; Dragon F, 2000, MOL CELL BIOL, V20, P3037, DOI 10.1128/MCB.20.9.3037-3048.2000; Filipowicz W, 1999, ACTA BIOCHIM POL, V46, P377, DOI 10.18388/abp.1999_4171; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Francis JW, 1998, P NATL ACAD SCI USA, V95, P6492, DOI 10.1073/pnas.95.11.6492; Frankel A, 1999, BIOCHEM BIOPH RES CO, V259, P391, DOI 10.1006/bbrc.1999.0779; Friesen MJ, 2000, J BIOL CHEM, V275, P26370, DOI 10.1074/jbc.M003299200; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Gall JG, 2000, ANNU REV CELL DEV BI, V16, P273, DOI 10.1146/annurev.cellbio.16.1.273; Ganot P, 1997, GENE DEV, V11, P941, DOI 10.1101/gad.11.7.941; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; Green DM, 2002, J BIOL CHEM, V277, P7752, DOI 10.1074/jbc.M110053200; Hebert MD, 2001, GENE DEV, V15, P2720, DOI 10.1101/gad.908401; Henras A, 1998, EMBO J, V17, P7078, DOI 10.1093/emboj/17.23.7078; Henras A, 2001, NUCLEIC ACIDS RES, V29, P2733, DOI 10.1093/nar/29.13.2733; Henry MF, 1996, MOL CELL BIOL, V16, P3668; Jones KW, 2001, J BIOL CHEM, V276, P38645, DOI 10.1074/jbc.M106161200; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Le TT, 2000, NEUROGENETICS, V3, P7, DOI 10.1007/s100480000090; Lefebvre S, 1998, HUM MOL GENET, V7, P1531, DOI 10.1093/hmg/7.10.1531; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; LIU Q, 1995, MOL CELL BIOL, V15, P2800; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Lukowiak AA, 2001, RNA, V7, P1833; Matera AG, 1998, AM J HUM GENET, V63, P317, DOI 10.1086/301992; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Meguro M, 2001, HUM MOL GENET, V10, P383, DOI 10.1093/hmg/10.4.383; Meister G, 2000, HUM MOL GENET, V9, P1977, DOI 10.1093/hmg/9.13.1977; Meister G, 2001, CURR BIOL, V11, P1990, DOI 10.1016/S0960-9822(01)00592-9; Meister G, 2001, NAT CELL BIOL, V3, P945, DOI 10.1038/ncb1101-945; Mishra RK, 1997, P NATL ACAD SCI USA, V94, P4972, DOI 10.1073/pnas.94.10.4972; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Mourelatos Z, 2001, EMBO J, V20, P5443, DOI 10.1093/emboj/20.19.5443; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Narayanan A, 1999, MOL BIOL CELL, V10, P2131, DOI 10.1091/mbc.10.7.2131; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; Pagliardini S, 2000, HUM MOL GENET, V9, P47, DOI 10.1093/hmg/9.1.47; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; Pellizzoni L, 2001, CURR BIOL, V11, P1079, DOI 10.1016/S0960-9822(01)00316-5; Pogacic V, 2000, MOL CELL BIOL, V20, P9028, DOI 10.1128/MCB.20.23.9028-9040.2000; Ponting CP, 1997, TRENDS BIOCHEM SCI, V22, P51, DOI 10.1016/S0968-0004(96)30049-2; RAJPUROHIT R, 1994, BIOCHEM J, V304, P903, DOI 10.1042/bj3040903; Rossoll W, 2002, HUM MOL GENET, V11, P93, DOI 10.1093/hmg/11.1.93; Samarsky DA, 1998, EMBO J, V17, P3747, DOI 10.1093/emboj/17.13.3747; Selenko P, 2001, NAT STRUCT BIOL, V8, P27; Sendtner M, 2001, CURR OPIN NEUROL, V14, P629, DOI 10.1097/00019052-200110000-00012; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Snaar S, 2000, J CELL BIOL, V151, P653, DOI 10.1083/jcb.151.3.653; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Terns MP, 2002, GENE EXPRESSION, V10, P17; Terns MP, 2001, CURR BIOL, V11, pR862, DOI 10.1016/S0960-9822(01)00517-6; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; Valentini SR, 1999, RNA, V5, P272, DOI 10.1017/S1355838299981633; Verheggen C, 2001, EMBO J, V20, P5480, DOI 10.1093/emboj/20.19.5480; Watkins NJ, 1998, RNA, V4, P1549, DOI 10.1017/S1355838298980761; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Young PJ, 2000, HUM MOL GENET, V9, P2869, DOI 10.1093/hmg/9.19.2869; Young PJ, 2001, EXP CELL RES, V265, P252, DOI 10.1006/excr.2001.5186; Young PJ, 2000, EXP CELL RES, V256, P365, DOI 10.1006/excr.2000.4858	83	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48087	48093		10.1074/jbc.M204551200	http://dx.doi.org/10.1074/jbc.M204551200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12244096	hybrid			2022-12-27	WOS:000179789600016
J	Dorsam, RT; Kim, S; Jin, JG; Kunapuli, SP				Dorsam, RT; Kim, S; Jin, JG; Kunapuli, SP			Coordinated signaling through both G(12/13) and G(i) pathways is sufficient to activate GPIIb/IIIa in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBIT ADENYLYL CYCLASE; SHAPE CHANGE; G-PROTEINS; INTEGRIN ALPHA(IIB)BETA(3); ANTITHROMBOTIC DRUGS; THROMBOXANE A(2); MOLECULAR-BASIS; ADP RECEPTORS; KINASE; THROMBIN	Activation of GPIIb/IIIa is known to require agonist-induced inside-out signaling through G(q), G(i), and G(z). Although activated by several platelet agonists, including thrombin and thromboxane A(2), the contribution of the G(12/13) signaling pathway to GPIIb/IIIa activation has not been investigated. In this study, we used selective stimulation of G protein pathways to investigate the contribution of G(12/13) activation to platelet fibrinogen receptor activation. YFLLRNP is a PAR-1-specific partial agonist that, at low concentrations (60 muM), selectively activates the G(12/13) signaling cascade resulting in platelet shape change without stimulating the G(q) or G(i) signaling pathways. YFLLRNP-mediated shape change was completely inhibited by the p160(ROCK) inhibitor, Y-27632. At this low concentration, YFLLRNP-mediated G(12/13) signaling caused platelet aggregation and enhanced PAC-1 binding when combined with selective G(i) or G(z) signaling, via selective stimulation of the P2Y(12) receptor or alpha(2A)-adrenergic receptor, respectively. Similar data were obtained when using low dose U46619 (10 nM), a thromboxane A(2) mimetic, to activate G(12/13) in the presence of G(i) signaling. These results suggest that selective activation of G(12/13) causes platelet GPIIb/IIIa activation when combined with G(i) signaling. Unlike either G(12/13) or G(i) activation alone, co-activation of both G(12/13) and G(i) resulted in a small increase in intracellular calcium. Chelation of intracellular calcium with dimethyl BAPTA dramatically blocked G(12/13) and G(i)-mediated platelet aggregation. No significant effect on aggregation was seen when using selective inhibitors for p160(ROCK), PKC, or MEKK1. PI 3-kinase inhibition lead to near abolishment of platelet aggregation induced by co-stimulation of G(q) and G(i) pathways, but not by G(12/13) and G(i) pathways. These data demonstrate that co-stimulation of G(12/13) and G(i) pathways is sufficient to activate GPIIb/IIIa in human platelets in a mechanism that involves intracellular calcium, and that PI 3-kinase is an important signaling molecule downstream of G(q) but not downstream of G(12/13) pathway.	Temple Univ, Sch Med, Dept Physiol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Kunapuli, SP (corresponding author), Temple Univ, Sch Med, Dept Physiol, Rm 224,OMS,3420 Broad St, Philadelphia, PA 19140 USA.	kunapuli@nimbus.temple.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060683, T32HL007777, P01HL064943] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64943, T32 HL07777, HL60683] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banfic H, 1998, J BIOL CHEM, V273, P13, DOI 10.1074/jbc.273.1.13; Bauer M, 1999, BLOOD, V94, P1665, DOI 10.1182/blood.V94.5.1665.417k33_1665_1672; Bauer M, 2001, THROMB HAEMOSTASIS, V85, P331, DOI 10.1055/s-0037-1615689; BRASS LF, 1988, J BIOL CHEM, V263, P5348; Brass LF, 1997, THROMB HAEMOSTASIS, V78, P581; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Dangelmaier C, 2001, THROMB HAEMOSTASIS, V85, P341, DOI 10.1055/s-0037-1615690; Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024; Foster CJ, 2001, J CLIN INVEST, V107, P1591, DOI 10.1172/JCI12242; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hirsch E, 2001, FASEB J, V15, P2019, DOI 10.1096/fj.00-0810fje; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Jin JG, 1998, J BIOL CHEM, V273, P2030, DOI 10.1074/jbc.273.4.2030; Kim S, 2002, BLOOD, V99, P3629, DOI 10.1182/blood.V99.10.3629; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; KUNAPULI SP, 1994, BIOCHEM J, V298, P263, DOI 10.1042/bj2980263; LANZA F, 1988, AM J PHYSIOL, V255, pH1276, DOI 10.1152/ajpheart.1988.255.6.H1276; Li ZY, 2001, J BIOL CHEM, V276, P42226, DOI 10.1074/jbc.M106129200; McNicol A, 1998, BIOCHEM PHARMACOL, V55, P1759, DOI 10.1016/S0006-2952(97)00632-1; MILLIGAN G, 1992, FEBS LETT, V297, P186, DOI 10.1016/0014-5793(92)80357-M; Mills DCB, 1996, THROMB HAEMOSTASIS, V76, P835; NIESWANDT B, 2002, J BIOL CHEM; Offermanns S, 2000, BIOL CHEM, V381, P389, DOI 10.1515/BC.2000.051; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Ohkubo S, 1996, BRIT J PHARMACOL, V117, P1095, DOI 10.1111/j.1476-5381.1996.tb16702.x; Pasquet JM, 2002, THROMB HAEMOSTASIS, V88, P115; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; Paul BZS, 1999, J BIOL CHEM, V274, P28293, DOI 10.1074/jbc.274.40.28293; QUINTON TM, 2002, IN PRESS BIOCH J; RASMUSSEN UB, 1993, J BIOL CHEM, V268, P14322; RAYCHOWDHURY MK, 1995, J BIOL CHEM, V270, P7011, DOI 10.1074/jbc.270.12.7011; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; Rosado JA, 2001, J BIOL CHEM, V276, P15659, DOI 10.1074/jbc.M009218200; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMPSON AWM, 1986, FEBS LETT, V201, P301, DOI 10.1016/0014-5793(86)80628-7; STEEN VM, 1993, THROMB HAEMOSTASIS, V70, P506; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597	46	103	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47588	47595		10.1074/jbc.M208778200	http://dx.doi.org/10.1074/jbc.M208778200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12297512	hybrid			2022-12-27	WOS:000179663700098
J	Moore, KJ; El Khoury, J; Medeiros, LA; Terada, K; Geula, C; Luster, AD; Freeman, MW				Moore, KJ; El Khoury, J; Medeiros, LA; Terada, K; Geula, C; Luster, AD; Freeman, MW			A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE SCAVENGER RECEPTORS; NITRIC-OXIDE SYNTHASE; ALZHEIMERS-DISEASE; PPAR-GAMMA; TNF-ALPHA; MICROGLIA; CD36; ATHEROSCLEROSIS; NEUROTOXICITY; PATHWAYS	beta-Amyloid accumulation is associated with pathologic changes in the brain in Alzheimer's disease and has recently been identified in plaques of another chronic inflammatory disorder, atherosclerosis. The class B scavenger receptor, CD36, mediates binding of fibrillar beta-amyloid to cells of the monocyte/macrophage lineage, including brain macrophages (microglia). In this study, we demonstrate that in microglia and other tissue macrophages, beta-amyloid initiates a CD36-dependent signaling cascade involving the Src kinase family members, Lyn and Fyn, and the mitogen-activated protein kinase, p44/42. Interruption of this signaling cascade, through targeted disruption of Src kinases downstream of CD36, inhibits macrophage inflammatory responses to beta-amyloid, including reactive oxygen and chemokine production, and results in decreased recruitment of microglia to sites of amyloid deposition in vivo. The finding that engagement of CD36 by beta-amyloid initiates a Src kinase-dependent production of inflammatory mediators in cells of the macrophage lineage reveals a novel receptor-mediated pro-inflammatory signaling pathway of potential therapeutic importance.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lipid Metab Unit, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med,Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Neurosurg Serv, Boston, MA 02114 USA; Beth Israel Deaconess Med Ctr, Div Aging, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center	Freeman, MW (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lipid Metab Unit, 55 Fruit St,GRJ 1328, Boston, MA 02114 USA.		Luster, Andrew/ABE-6504-2020; Moore, Kathryn/ABE-6416-2020	Luster, Andrew/0000-0001-9679-7912; Moore, Kathryn/0000-0003-2505-2547	NHLBI NIH HHS [R01 HL45098] Funding Source: Medline; NIA NIH HHS [R01AG20255-01] Funding Source: Medline; NIDDK NIH HHS [P01 DK50305] Funding Source: Medline; NINDS NIH HHS [NS41330-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS041330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020255] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000; Combs CK, 2001, J NEUROSCI, V21, P1179; Combs CK, 1999, J NEUROSCI, V19, P928; Coraci IS, 2002, AM J PATHOL, V160, P101, DOI 10.1016/S0002-9440(10)64354-4; De Meyer GRY, 2002, CIRC RES, V90, P1197, DOI 10.1161/01.RES.0000020017.84398.61; El Khoury J, 1998, NEUROBIOL AGING, V19, pS81, DOI 10.1016/S0197-4580(98)00036-0; ElKhoury J, 1996, NATURE, V382, P716; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Frautschy SA, 1998, AM J PATHOL, V152, P307; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Klein AM, 1999, ANN NY ACAD SCI, V893, P314, DOI 10.1111/j.1749-6632.1999.tb07845.x; McDonald DR, 1997, J NEUROSCI, V17, P2284; McDonald DR, 1998, J NEUROSCI, V18, P4451; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sakaguchi H, 1998, LAB INVEST, V78, P423; Smits HA, 2001, J NEUROIMMUNOL, V115, P144, DOI 10.1016/S0165-5728(01)00254-5; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Tedgui A, 2002, CIRC RES, V90, P1145, DOI 10.1161/01.RES.0000023048.87638.92; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Weldon DT, 1998, J NEUROSCI, V18, P2161; WOOD JG, 1991, NEUROSCI LETT, V121, P12, DOI 10.1016/0304-3940(91)90637-9	30	280	293	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47373	47379		10.1074/jbc.M208788200	http://dx.doi.org/10.1074/jbc.M208788200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12239221	hybrid			2022-12-27	WOS:000179663700070
J	Nappi, VM; Schaefer, JA; Petti, LM				Nappi, VM; Schaefer, JA; Petti, LM			Molecular examination of the transmembrane requirements of the platelet-derived growth factor beta receptor for a productive interaction with the bovine papillomavirus E5 oncoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAME; TRANSFORMING PROTEIN; ALPHA-HELICES; AMINO-ACIDS; CELLULAR-TRANSFORMATION; MUTATIONAL ANALYSIS; TYROSINE KINASE; C127 CELLS; DOMAIN; ACTIVATION	The small transmembrane E5 protein of bovine papillomavirus (BPV) transforms cells by forming a stable complex with and activating the platelet-derived growth factor beta receptor (PDGFbetaR). The E5/PDGFbetaR interaction is thought to involve specific physical contacts between the transmembrane domains of the two proteins. Lys(499) at the extracellular juxtamembrane position and Thr(513) within the transmembrane domain of the PDGFbetaR are required for the interaction and are predicted to contact analogously positioned residues in the E5 protein. Here, mutagenic analysis of the transmembrane region of the PDGFbetaR was performed to further characterize the nature of the E5/PDGFbetaR interaction. We show that the receptor transmembrane domain with minimal extracellular and intracellular sequence: is sufficient for the interaction. In addition, we provide evidence that the polar nature of Thr(513) as well; as its positioning along the transmembrane a-helix is Important for the interaction. We also identify the receptor transmembrane amino acids Ile(506) and Leu(520) as additional requirements for the interaction. Because Lys(499), Thr(513), Ile(506), and Leu(520) all align along the same face of the predicted PDGFbetaR transmembrane alpha-helix, our data support the model that the PDGFbetaR contacts the E5 protein via multiple amino acids along a single alpha-helical interface.	Albany Med Coll, Albany, NY 12208 USA	Albany Medical College	Petti, LM (corresponding author), Albany Med Coll, Albany, NY 12208 USA.				NATIONAL CANCER INSTITUTE [R29CA073682] Funding Source: NIH RePORTER; NCI NIH HHS [CA73682] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adduci AJ, 1999, J BIOL CHEM, V274, P10249, DOI 10.1074/jbc.274.15.10249; Bell CA, 2000, MOL BIOL CELL, V11, P3589, DOI 10.1091/mbc.11.10.3589; BERGMAN P, 1988, ONCOGENE, V2, P453; BURKHARDT A, 1987, EMBO J, V6, P2381, DOI 10.1002/j.1460-2075.1987.tb02515.x; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COHEN BD, 1993, MOL CELL BIOL, V13, P6462, DOI 10.1128/MCB.13.10.6462; COHEN BD, 1993, J VIROL, V67, P5303, DOI 10.1128/JVI.67.9.5303-5311.1993; Cornea RL, 2000, J BIOL CHEM, V275, P41487, DOI 10.1074/jbc.M008195200; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; DVORETZKY I, 1980, VIROLOGY, V103, P369, DOI 10.1016/0042-6822(80)90195-6; GOLDSTEIN DJ, 1990, EMBO J, V9, P137, DOI 10.1002/j.1460-2075.1990.tb08089.x; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HORWITZ BH, 1988, MOL CELL BIOL, V8, P4071, DOI 10.1128/MCB.8.10.4071; Klein O, 1999, J VIROL, V73, P3264, DOI 10.1128/JVI.73.4.3264-3272.1999; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; KULKE R, 1992, J VIROL, V66, P505, DOI 10.1128/JVI.66.1.505-511.1992; Lai CC, 1998, P NATL ACAD SCI USA, V95, P15241, DOI 10.1073/pnas.95.26.15241; LANCASTER WD, 1982, MICROBIOL REV, V46, P191, DOI 10.1128/MMBR.46.2.191-207.1982; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LI SC, 1993, J BIOL CHEM, V268, P22975; Liu LP, 1998, J BIOL CHEM, V273, P23645, DOI 10.1074/jbc.273.37.23645; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; Mattoon D, 2001, ONCOGENE, V20, P3824, DOI 10.1038/sj.onc.1204523; MEYER AN, 1994, P NATL ACAD SCI USA, V91, P4634, DOI 10.1073/pnas.91.11.4634; Nappi VM, 2002, J VIROL, V76, P7976, DOI 10.1128/JVI.76.16.7976-7986.2002; NILSON LA, 1995, J VIROL, V69, P5869, DOI 10.1128/JVI.69.9.5869-5874.1995; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Petrache HI, 2000, J MOL BIOL, V302, P727, DOI 10.1006/jmbi.2000.4072; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; Petti LM, 2000, CELL GROWTH DIFFER, V11, P395; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SEVERINSSON L, 1989, EUR J BIOCHEM, V182, P679, DOI 10.1111/j.1432-1033.1989.tb14879.x; Sharpe S, 2000, BIOCHEMISTRY-US, V39, P6572, DOI 10.1021/bi000038o; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; STAEBLER A, 1995, J VIROL, V69, P6507, DOI 10.1128/JVI.69.10.6507-6517.1995; TREUTLEIN HR, 1992, BIOCHEMISTRY-US, V31, P12726, DOI 10.1021/bi00166a003; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	54	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47149	47159		10.1074/jbc.M209582200	http://dx.doi.org/10.1074/jbc.M209582200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351659	hybrid			2022-12-27	WOS:000179663700041
J	Park, JH; Na, HJ; Kwon, YG; Ha, KS; Lee, SJ; Kim, CK; Lee, KS; Yoneyama, T; Hatakeyama, K; Kim, PKM; Billiar, TR; Kim, YM				Park, JH; Na, HJ; Kwon, YG; Ha, KS; Lee, SJ; Kim, CK; Lee, KS; Yoneyama, T; Hatakeyama, K; Kim, PKM; Billiar, TR; Kim, YM			Nitric oxide (NO) pretreatment increases cytokine-induced NO production in cultured rat hepatocytes by suppressing GTP cyclohydrolase I feedback inhibitory protein level and promoting inducible NO synthase dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-INDUCED APOPTOSIS; CELL-LINE; SMOOTH-MUSCLE; L-ARGININE; TETRAHYDROBIOPTERIN; EXPRESSION; BIOSYNTHESIS; ASSOCIATION; SUBUNITS; NECROSIS	Nitric oxide (NO) regulates the biological activity of many enzymes and other functional proteins as well as gene expression. In this study, we tested whether pretreatment with NO regulates NO production in response to cytokines in cultured rat hepatocytes. Hepatocytes were recovered in fresh medium for 24 h following pretreatment with the NO donor S-nitroso-N-acetyl-D,L-penicillamine (SNAP) and stimulated to express the inducible NO synthase (iNOS) with interleukin-1beta and interferon-gamma or transfected with the human iNOS gene. NO pretreatment resulted in a significant increase in NO production without changing iNOS expression for both conditions. This effect, which did not occur in macrophages and smooth muscle cells, was inhibited when NO was scavenged using red blood cells. Pretreatment with oxidized SNAP, 8-Br-cGMP, N-2(-), or NO3- did not increase the cytokine-induced NO production. SNAP pretreatment increased cytosolic iNOS activity measured only in the absence of exogenous tetrahydrobiopterin (BH4). SNAP pretreatment suppressed the level of GTP cyclohydrolase I (GTPCHI) feedback regulatory protein (GFRP) and increased GTPCHI activity without changing GTPCHI protein level. SNAP pretreatment also increased total cellular levels of biopterin and active iNOS dimer. These results suggest that SNAP pretreatment increased NO production from iNOS by elevating cellular BH4 levels and promoting iNOS subunit dimerization through the suppression of GFRP levels and subsequent activation of GTPCHI.	Kangweon Natl Univ, Dept Mol & Cellular Biochem, Sch Med, Chunchon 200701, South Korea; Kangweon Natl Univ, Vasc Syst Res Ctr, Sch Med, Chunchon 200701, South Korea; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA	Kangwon National University; Kangwon National University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kim, YM (corresponding author), Kangweon Natl Univ, Dept Mol & Cellular Biochem, Sch Med, Chunchon 200701, South Korea.		Ha, Kwon-Soo/AAU-4417-2020; Yoneyama, Tohru/ABG-2670-2020	Kim, Chunki/0000-0003-2410-9118; Lee, Seon-Jin/0000-0001-7214-7536; Ha, Kwon-Soo/0000-0002-4219-1787	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM044100, R01GM044100, R37GM044100] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44100] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BILLIAR TR, 1989, J EXP MED, V169, P1467, DOI 10.1084/jem.169.4.1467; BILLIAR TR, 1992, AM J PHYSIOL, V262, pC1077, DOI 10.1152/ajpcell.1992.262.4.C1077; BURG AW, 1968, J BIOL CHEM, V243, P2349; Cavicchi M, 2000, GUT, V47, P771, DOI 10.1136/gut.47.6.771; DISILVIO M, 1993, ADV EXP MED BIOL, V338, P305; DUCH DS, 1984, LIFE SCI, V35, P1895, DOI 10.1016/0024-3205(84)90541-1; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; Geller DA, 2000, BIOCHEM BIOPH RES CO, V276, P633, DOI 10.1006/bbrc.2000.3537; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GELLER DA, 1995, J IMMUNOL, V155, P4890; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; KAUFMAN S, 1993, ANNU REV NUTR, V13, P261, DOI 10.1146/annurev.nu.13.070193.001401; KIM YM, 1993, FEBS LETT, V332, P255, DOI 10.1016/0014-5793(93)80644-A; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 1996, INFECT IMMUN, V64, P3074, DOI 10.1128/IAI.64.8.3074-3080.1996; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kim YM, 1998, MOL MED, V4, P179, DOI 10.1007/BF03401915; Kim YM, 2000, J BIOL CHEM, V275, P10954, DOI 10.1074/jbc.275.15.10954; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; REIF DW, 1993, NEUROREPORT, V4, P566, DOI 10.1097/00001756-199305000-00026; Saavedra JE, 1997, J MED CHEM, V40, P1947, DOI 10.1021/jm9701031; SAKAI N, 1993, MOL PHARMACOL, V43, P6; SCOTTBURDEN T, 1993, BIOCHEM BIOPH RES CO, V196, P1261, DOI 10.1006/bbrc.1993.2388; Shears LL, 1998, J AM COLL SURGEONS, V187, P295, DOI 10.1016/S1072-7515(98)00163-X; SHEFFLER LA, 1995, J IMMUNOL, V155, P886; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Taylor BS, 1997, ARCH SURG-CHICAGO, V132, P1177; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yoneyama T, 1997, J BIOL CHEM, V272, P9690	41	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47073	47079		10.1074/jbc.M207053200	http://dx.doi.org/10.1074/jbc.M207053200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359727	hybrid			2022-12-27	WOS:000179663700032
J	Saharinen, P; Silvennoinen, O				Saharinen, P; Silvennoinen, O			The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; INTERFERON-ALPHA/BETA RECEPTOR; MICE LACKING JAK3; JANUS KINASES; LYMPHOID DEVELOPMENT; CATALYTIC ACTIVITY; STAT PATHWAYS; SH2 DOMAIN; BINDING; PHOSPHORYLATION	Janus (Jak) tyrosine kinases contain a tyrosine kinase (JH1) domain adjacent to a catalytically inactive pseudokinase domain (JH2). The JH2 domain has been implicated in regulation of Jak activity, but its function remains poorly understood. Here, we found that the JH2 domain negatively regulates the activity of Jak2 and Jak3. Deletion of JH2 resulted in increased tyrosine phosphorylation of the Jak2- and Jak3-JH2 deletion mutants as well as of coexpressed STAT5. In cytokine receptor signaling, the deletion of the Jak2- and Jak3-JH2 domains resulted in interferon-gamma and interleukin-2-independent STAT activation, respectively. However, cytokine stimulations did not further induce the JH2 deletion mutant-mediated STAT activation. The deletion of the Jak2 JH2 domain also abolished interferon-gamma-inducible kinase activation, although it did not affect the reciprocal Jak1-Jak2 interaction in 293T cells. Chimeric constructs, where the JH2 domains were swapped between Jak2 and Jak3, retained low basal activity and cytokine inducible signaling, indicating functional conservation between the two JH2 domains. However, the basal activity of Jak2 was significantly lower than that of Jak3, suggesting differences in the regulation of Jak2 and Jak3 activity. In conclusion, we found that the JH2 domain has a conserved function in Jak2 and Jak3. The JH2 domain is required for two distinct functions in cytokine signaling: (i) inhibition of the basal activity of Jak2 and Jak3, and (ii) cytokine-inducible activation of signaling. The Jak-JH2 deletion mutants are catalytically active, activate STAT5, and interact with another Jak kinase, but the JH2 domain is required to connect these signaling events to receptor activation. Thus, we propose that the JH2 domain contributes to both the uninduced and ligand-induced Jak-receptor complex, where it acts as a cytokine-inducible switch to regulate signal transduction.	Univ Helsinki, Dept Virol, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki, Programme Dev & Reprod Biol, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Dept Clin Microbiol, FIN-33101 Tampere, Finland	University of Helsinki; University of Helsinki; Tampere University; Tampere University; Tampere University Hospital	Silvennoinen, O (corresponding author), Univ Helsinki, Dept Virol, Haartman Inst, Haartmaninkatu 8,POB 63, FIN-00014 Helsinki, Finland.		Saharinen, Pipsa I/C-9601-2016	Saharinen, Pipsa I/0000-0003-2652-0584				Al-Lazikani B, 2001, P NATL ACAD SCI USA, V98, P14796, DOI 10.1073/pnas.011577898; Cacalano NA, 1999, EMBO J, V18, P1549, DOI 10.1093/emboj/18.6.1549; Candotti F, 1997, BLOOD, V90, P3996, DOI 10.1182/blood.V90.10.3996; Chen M, 2000, MOL CELL BIOL, V20, P947, DOI 10.1128/MCB.20.3.947-956.2000; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Greiser JS, 2002, J BIOL CHEM, V277, P26959, DOI 10.1074/jbc.M204113200; Haan C, 2002, BIOCHEM J, V361, P105, DOI 10.1042/0264-6021:3610105; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Kampa D, 2000, BIOCHEM BIOPH RES CO, V278, P175, DOI 10.1006/bbrc.2000.3757; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Liu KD, 1997, CURR BIOL, V7, P817, DOI 10.1016/S0960-9822(06)00369-1; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Oakes SA, 1996, IMMUNITY, V5, P605, DOI 10.1016/S1074-7613(00)80274-5; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Richter MF, 1998, J BIOL CHEM, V273, P24723, DOI 10.1074/jbc.273.38.24723; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Saharinen P, 1997, BLOOD, V90, P4341; Saito K, 2001, J BIOL CHEM, V276, P16201, DOI 10.1074/jbc.M100873200; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Simoncic PD, 2002, CURR BIOL, V12, P446, DOI 10.1016/S0960-9822(02)00697-8; SLIVA D, 1994, J BIOL CHEM, V269, P26208; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yeh TC, 2000, P NATL ACAD SCI USA, V97, P8991, DOI 10.1073/pnas.160130297; Zhou YJ, 1997, P NATL ACAD SCI USA, V94, P13850, DOI 10.1073/pnas.94.25.13850; Zhou YJ, 2001, MOL CELL, V8, P959, DOI 10.1016/S1097-2765(01)00398-7; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	50	226	237	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47954	47963		10.1074/jbc.M205156200	http://dx.doi.org/10.1074/jbc.M205156200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351625	hybrid			2022-12-27	WOS:000179663700143
J	Tominaga, T; Meng, WX; Togashi, K; Urano, H; Tominaga, M				Tominaga, T; Meng, WX; Togashi, K; Urano, H; Tominaga, M			The Rho GTPase effector protein, mDia, inhibits the DNA binding ability of the transcription factor Pax6 and changes the pattern of neurite extension in cerebellar granule cells through its binding to Pax6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBER FORMATION; KINASE; SRC; ACTIVATION; CYTOSKELETON; RETRACTION; DOWNSTREAM; OUTGROWTH; MUTATIONS; MIGRATION	mDia, one of the target proteins of the GTPase Rho, is known to be involved in cytoskeletal reorganization and cytokinesis. Here, we report that mDia enters the nucleus and binds to the transcription factor, Pax6. In cultured non-neuronal cells, overexpression of mDia with Pax6 causes redistribution of some Pax6 molecules from the nucleus to the cytosol and decreases Pax6 transcriptional activity. Because Pax6 functions in the early central nervous system morphogenesis, we also examined the effects of mDia on endogenous Pax6 localization and neurite extension in cerebellar granule cells. Here too, Pax6 was partially mislocalized to the cytosol, and its expression level was decreased by mDia overexpression. In addition, mDia overexpression in these cells led to increased neurite branching and length. These results strongly suggest that mDia influences Pax6-induced transcriptional activity and axonal pathfinding in a way opposite from ROCK (Rho kinase) and that it may act via Pax6 to modulate early neuronal development.	Mie Univ, Sch Med, Dept Physiol, Tsu, Mie 5148507, Japan; Fdn Advancement Int Sci, Tsukuba, Ibaraki 3050062, Japan	Mie University	Tominaga, T (corresponding author), Mie Univ, Sch Med, Dept Physiol, Tsu, Mie 5148507, Japan.	ttomoko@doc.medic.mie-u.ac.jp						Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Ashery-Padan R, 2001, CURR OPIN CELL BIOL, V13, P706, DOI 10.1016/S0955-0674(00)00274-X; Bione S, 1998, AM J HUM GENET, V62, P533, DOI 10.1086/301761; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; Chan DC, 1996, J BIOL CHEM, V271, P23472, DOI 10.1074/jbc.271.38.23472; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Engelkamp D, 1999, DEVELOPMENT, V126, P3585; Heins N, 2002, NAT NEUROSCI, V5, P308, DOI 10.1038/nn828; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; INGRAHAM CA, 1989, MOL CHEM NEUROPATHOL, V10, P1, DOI 10.1007/BF02969481; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Osumi N, 1997, DEVELOPMENT, V124, P2961; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Satoh S, 2001, J BIOL CHEM, V276, P39290, DOI 10.1074/jbc.M107026200; Singh S, 1998, J BIOL CHEM, V273, P21531, DOI 10.1074/jbc.273.34.21531; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Takahashi M, 2002, DEVELOPMENT, V129, P1327; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; WynshawBoris A, 1997, MOL MED, V3, P372, DOI 10.1007/BF03401684; Yamasaki T, 2001, DEVELOPMENT, V128, P3133	34	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47686	47691		10.1074/jbc.M207539200	http://dx.doi.org/10.1074/jbc.M207539200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12324464	hybrid			2022-12-27	WOS:000179663700110
J	Navdaev, A; Clemetson, KJ				Navdaev, A; Clemetson, KJ			Glycoprotein Ib cross-linking/ligation on echicetin-coated surfaces or echicetin-IgM kappa in stirred suspension activates platelets by cytoskeleton modulated calcium release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTIN; PHOSPHOINOSITIDE 3-KINASE; BINDING; IX; ALPHA; RECEPTOR; IB/V/IX; IIB/IIIA; ADHESION; COLLAGEN	Cross-linking platelet GPIb with the snake C-type lectin echicetin provides a specific technique for activation via this receptor. This allows GPlb-dependent mechanisms to be studied without the necessity for shear stress-induced binding of von Willebrand factor or primary alpha(IIb)beta(3) involvement. We already showed that platelets are activated, including tyrosine phosphorylation, by echicetin-IgM(k)-induced GPIb cross-linking. We now investigate the mechanism further and demonstrate that platelets, without modulator reagents, spread directly on an echicetin-coated surface, by a GPIb-specific mechanism, causing exocytosis of a-granule markers (P-selectin) and activation of alpha(IIb)beta(3). This spreading requires actin polymerization and release of internal calcium stores but is not dependent on external calcium nor on src family tyrosine kinases. Cross-linking of GPIb complex molecules on platelets, either in suspension or via specific surface attachment, is sufficient to induce platelet activation.	Univ Bern, Theodor Kocher Inst, CH-3012 Bern, Switzerland	University of Bern	Clemetson, KJ (corresponding author), Univ Bern, Theodor Kocher Inst, Freiestr 1, CH-3012 Bern, Switzerland.	clemetson@tki.unibe.ch						CARROLL RC, 1982, BLOOD, V59, P466; CARTEAUX JP, 1993, J THORAC CARDIOV SUR, V106, P834; Christodoulides N, 2001, THROMB RES, V102, P133, DOI 10.1016/S0049-3848(01)00243-2; Dong JF, 1997, BIOCHEMISTRY-US, V36, P12421, DOI 10.1021/bi970636b; Dopheide SM, 2002, BLOOD, V99, P159, DOI 10.1182/blood.V99.1.159; Englund GD, 2001, J BIOL CHEM, V276, P16952, DOI 10.1074/jbc.M008048200; Feng SJ, 2000, BLOOD, V95, P551, DOI 10.1182/blood.V95.2.551; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Gante J, 1995, LETT PEPT SCI, V2, P135, DOI 10.1007/BF00119139; Kasirer-Friede A, 2002, J BIOL CHEM, V277, P11949, DOI 10.1074/jbc.M108727200; Kehrel B, 1998, BLOOD, V91, P491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKHOF H, 1995, BLOOD, V86, P1035, DOI 10.1182/blood.V86.3.1035.bloodjournal8631035; Li ZY, 2001, J BIOL CHEM, V276, P42226, DOI 10.1074/jbc.M106129200; Mazzucato M, 2002, BLOOD, V100, P2793, DOI 10.1182/blood-2002-02-0514; Mistry N, 2000, BLOOD, V96, P3480; Munday AD, 2000, BLOOD, V96, P577; MUSZBEK L, 1989, J BIOL CHEM, V264, P9716; Navdaev A, 2001, BLOOD, V97, P2333, DOI 10.1182/blood.V97.8.2333; Nesbitt WS, 2002, J BIOL CHEM, V277, P2965, DOI 10.1074/jbc.M110070200; PENG ML, 1992, THROMB HAEMOSTASIS, V67, P702; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Williamson D, 2002, J BIOL CHEM, V277, P2151, DOI 10.1074/jbc.M109384200; Yap CL, 2002, BLOOD, V99, P151, DOI 10.1182/blood.V99.1.151	24	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45928	45934		10.1074/jbc.M206129200	http://dx.doi.org/10.1074/jbc.M206129200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324454	hybrid			2022-12-27	WOS:000179529300030
J	Radcliffe, CM; Diedrich, G; Harvey, DJ; Dwek, RA; Cresswell, P; Rudd, PM				Radcliffe, CM; Diedrich, G; Harvey, DJ; Dwek, RA; Cresswell, P; Rudd, PM			Identification of specific glycoforms of major histocompatibility complex class I heavy chains suggests that class I peptide loading is an adaptation of the quality control pathway involving calreticulin and ERp57	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; N-LINKED OLIGOSACCHARIDES; MOLECULAR CHAPERONE; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; CALNEXIN; GLYCOPROTEINS; TAP; PROTEIN; TAPASIN	Glycosylation analysis was used to probe the sequence of events accompanying the binding of antigenic peptides to the major histocompatibility complex class I heavy chains. Free heavy chains were isolated from the beta(2)-microglobulin-negative cell line Daudi and from the B-lymphoblastoid cell line Raji. Heavy chains were also isolated from Raji cells in multimolecular complexes (peptide loading complexes) containing the transporter associated with antigen processing, tapasin and ERp57 with and without the lectin-like folding chaperone, calreticulin. Calreticulin is a soluble protein that recognizes primarily the terminal glucose of Glc(1)Man(7-9)GlcNAC(2) glycans. This paper shows that monoglucosylated glycoforms of heavy chain, which exist transiently in the endoplasmic reticulum in the initial stages of the glycosylation processing pathway, are present in the peptide loading complex. The data are consistent with a model in which the release of peptide-loaded major histocompatibility complex class I molecules from calreticulin, induced by deglucosylation of the heavy chain N-linked glycan, signals the dissociation of the complex. This is consistent with the hypothesis that the class I loading process is an adaptation of the quality control mechanism involving calreticulin and ERp57.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England; Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA	University of Oxford; Howard Hughes Medical Institute; Yale University	Rudd, PM (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.		Harvey, David/A-5579-2013	Harvey, David/0000-0003-0544-771X				BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; Barber LD, 1996, J IMMUNOL, V156, P3275; Bergeron JJM, 1998, ADV EXP MED BIOL, V435, P105; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; Dick TP, 2002, IMMUNITY, V16, P87, DOI 10.1016/S1074-7613(02)00263-7; Diedrich G, 2001, J IMMUNOL, V166, P1703, DOI 10.4049/jimmunol.166.3.1703; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Farmery MR, 2000, J BIOL CHEM, V275, P14933, DOI 10.1074/jbc.275.20.14933; Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351; Harris MR, 1998, J IMMUNOL, V160, P5404; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hughes EA, 1998, CURR BIOL, V8, P709, DOI 10.1016/S0960-9822(98)70278-7; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; KARLSSON GB, 1993, J BIOL CHEM, V268, P570; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; Morrice NA, 1998, CURR BIOL, V8, P713, DOI 10.1016/S0960-9822(98)70279-9; NOSSNER E, 1995, J EXP MED, V181, P327, DOI 10.1084/jem.181.1.327; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Patil AR, 2000, J BIOL CHEM, V275, P24348, DOI 10.1074/jbc.M003102200; Paz P, 1999, IMMUNITY, V11, P241, DOI 10.1016/S1074-7613(00)80099-0; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; Suh WK, 1996, J EXP MED, V184, P337, DOI 10.1084/jem.184.2.337; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697	38	54	57	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46415	46423		10.1074/jbc.M202466200	http://dx.doi.org/10.1074/jbc.M202466200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235131	hybrid			2022-12-27	WOS:000179529300093
J	Rueda, D; Navarro, B; Martinez-Serrano, A; Guzman, M; Galve-Roperh, I				Rueda, D; Navarro, B; Martinez-Serrano, A; Guzman, M; Galve-Roperh, I			The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ERK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; FACTOR RECEPTOR; CANNABINOID RECEPTOR; MAP KINASE; NEUROGENESIS; CERAMIDE; BRAIN; RAP1; IDENTIFICATION	Endocannabinoids are neuromodulators that act as retrograde synaptic messengers inhibiting the release of different neurotransmitters in cerebral areas such as hippocampus, cortex, and striatum. However, little is known about other roles of the endocannabinoid system in brain. In the present work we provide substantial evidence that the endocannabinoid anandamide (AEA) regulates neuronal differentiation both in culture and in vivo. Thus AEA, through the CB1 receptor, inhibited cortical neuron progenitor differentiation to mature neuronal phenotype. In addition, human neural stem cell differentiation and nerve growth factor-induced PC12 cell differentiation were also inhibited by cannabinoid challenge. AEA decreased PC12 neuronal-like generation via CB1-mediated inhibition of sustained extracellular signal-regulated kinase (ERK) activation, which is responsible for nerve growth factor action. AEA thus inhibited TrkA-induced Rap1/B-Raf/ERK activation. Finally, immunohistochemical analyses by confocal microscopy revealed that adult neurogenesis in dentate gyrus was significantly decreased by the AEA analogue methanandamide and increased by the CB, antagonist SR141716. These data indicate that endocannabinoids inhibit neuronal progenitor cell differentiation through attenuation of the ERK pathway and suggest that they constitute a new physiological system involved in the regulation of neurogenesis.	Univ Complutense Madrid, Dept Biochem & Mol Biol 1, Sch Biol, E-28040 Madrid, Spain; Univ Autonoma Madrid, Mol Biol Ctr Severo Ochoa, Madrid 28049, Spain	Complutense University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Galve-Roperh, I (corresponding author), Univ Complutense Madrid, Dept Biochem & Mol Biol 1, Sch Biol, E-28040 Madrid, Spain.	igr@bbml.ucm.es	Galve-Roperh, Ismael/AAG-2369-2020; Navarro-Galve, Beatriz/A-4880-2009; Martínez-Serrano, Alberto/J-8146-2014; Navarro Galve, Beatriz/K-8755-2014; Rueda, Daniel/I-1176-2015	Navarro Galve, Beatriz/0000-0002-2021-9937; Rueda, Daniel/0000-0002-5377-8890; Guzman, Manuel/0000-0001-7475-118X; Martinez Serrano, Alberto/0000-0003-3927-6699				Blazquez C, 2000, FASEB J, V14, P2315, DOI 10.1096/fj.00-0122com; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DELPULGAR MTG, 2001, BIOCHEM J, V347, P369; Derkinderen P, 1999, NEUROREPORT, V10, pR24; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; Duman RS, 2001, J PHARMACOL EXP THER, V299, P401; Fernandez-Ruiz J, 2000, TRENDS NEUROSCI, V23, P14, DOI 10.1016/S0166-2236(99)01491-5; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Giuffrida A, 1999, NAT NEUROSCI, V2, P358, DOI 10.1038/7268; Gould E, 2002, J NEUROSCI, V22, P619, DOI 10.1523/JNEUROSCI.22-03-00619.2002; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Guzman M, 2001, TRENDS PHARMACOL SCI, V22, P19, DOI 10.1016/S0165-6147(00)01586-8; Hampson RE, 2000, J NEUROSCI, V20, P8932; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Katona I, 1999, J NEUROSCI, V19, P4544; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; LANGGUT W, 1995, FEBS LETT, V372, P173, DOI 10.1016/0014-5793(95)00971-B; MartinezSerrano A, 1996, J NEUROSCI, V16, P4604; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; Porter AC, 2001, PHARMACOL THERAPEUT, V90, P45, DOI 10.1016/S0163-7258(01)00130-9; Rubio FJ, 2000, MOL CELL NEUROSCI, V16, P1, DOI 10.1006/mcne.2000.0854; Rueda D, 2000, MOL PHARMACOL, V58, P814, DOI 10.1124/mol.58.4.814; Sachinidis A, 2002, FASEB J, V16, P893, DOI 10.1096/fj.01-0799fje; Schlicker E, 2001, TRENDS PHARMACOL SCI, V22, P565, DOI 10.1016/S0165-6147(00)01805-8; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Villa A, 2000, EXP NEUROL, V161, P67, DOI 10.1006/exnr.1999.7237; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wilson RI, 2002, SCIENCE, V296, P678, DOI 10.1126/science.1063545; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	41	178	190	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46645	46650		10.1074/jbc.M206590200	http://dx.doi.org/10.1074/jbc.M206590200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237305	hybrid			2022-12-27	WOS:000179529300122
J	Zeng, HY; Zhao, DZ; Mukhopadhyay, D				Zeng, HY; Zhao, DZ; Mukhopadhyay, D			KDR stimulates endothelial cell migration through heterotrimeric G protein Gq/11-mediated activation of a small GTPase RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; MICROVASCULAR HYPERPERMEABILITY; VASCULAR ENDOTHELIUM; SIGNALING PATHWAYS; TYROSINE KINASE; FACTOR VEGF; PROLIFERATION; EXPRESSION; ANGIOGENESIS; ADHESION	Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) functions by activating two receptor tyrosine kinases, Flt-1 (VEGFR-1) and KDR (VEGFR-2), both of which are selectively expressed on the primary vascular endothelium. KDR is responsible for VPF/VEGF-stimulated endothelial cell (EC) proliferation and migration, whereas Flt-1 down-modulates KDR-mediated EC proliferation. Flt-1 mediates down-regulation of EC proliferation through pertussis toxin-sensitive G proteins, betagamma subunits, small GTPase CDC42, and partly by Rac-1. However, the molecular mechanism by which KDR mediates EC migration is not clear yet. Here we show for the first time that activation of RhoA and Rac1 is fully and partially required for KDR-mediated human umbilical vein endothelial cell (HUVEC) migration, respectively, and that CDC42, however, is not involved. Furthermore, overexpression of the RhoA dominant negative mutant RhoA-19N does not affect VPF/VEGF-stimulated KDR phosphorylation, intracellular Ca2+ mobilization, and mitogen-activated protein kinase phosphorylation. Utilizing the receptor chimeras (EGDR and EGLT) in which the extracellular domain of the epidermal growth factor receptor (EGFR) was fused to the transmembrane domain and the intracellular domains of KDR and Flt-1, respectively, we demonstrate that RhoA activation is mediated by EGDR, not by EGLT, and that EGDR mediates activation of Rac1, not CDC42. Furthermore, the EGDR-mediated RhoA and Rac1 activation is regulated by G proteins Gq/11, Gbetagamma, and phospholipase C independent of phosphatidylinositol 3-kinase and intracellular Ca2+ mobilization. Interestingly, the RhoA activation can be partially inhibited by overexpression of Rac1-17N, but overexpression of RhoA-19N has no effect on Rac1 activation. Finally, Gq/11 and Gbetagamma subunits are also required for VPF/VEGF-stimulated HUVEC migration. Taken together, our results indicate that KDR stimulates endothelial cell migration through a heterotrimeric G protein Gq/11 and Gbetagamma-mediated RhoA pathway.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Gastroenterol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Mukhopadhyay, D (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave,RN270H, Boston, MA 02215 USA.	dmukhopa@caregroup.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA078383, R29CA078383] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070567] Funding Source: NIH RePORTER; NCI NIH HHS [CA78383] Funding Source: Medline; NHLBI NIH HHS [HL70567] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; DVORAK HF, 1995, AM J PATHOL, V146, P1029; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Imamura T, 1999, MOL CELL BIOL, V19, P6765; Keummerle JF, 2001, J BIOL CHEM, V276, P7187, DOI 10.1074/jbc.M011145200; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Liu F, 2001, AM J RESP CELL MOL, V24, P711, DOI 10.1165/ajrcmb.24.6.4323; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Matozaki T, 2000, CELL SIGNAL, V12, P515, DOI 10.1016/S0898-6568(00)00102-9; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rousseau S, 2000, TRENDS CARDIOVAS MED, V10, P321, DOI 10.1016/S1050-1738(01)00072-X; Sanchez-Blazquez P, 1998, J PHARMACOL EXP THER, V285, P820; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Thodeti CK, 2002, BIOCHEM J, V365, P157, DOI 10.1042/BJ20020248; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Zeng HY, 2002, J BIOL CHEM, V277, P4003, DOI 10.1074/jbc.M110842200; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200; Zhao DZ, 2001, J BIOL CHEM, V276, P44464, DOI 10.1074/jbc.M104942200	46	94	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46791	46798		10.1074/jbc.M206133200	http://dx.doi.org/10.1074/jbc.M206133200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244099	hybrid			2022-12-27	WOS:000179529300140
J	Shaw, S; Bencherif, M; Marrero, MB				Shaw, S; Bencherif, M; Marrero, MB			Janus kinase 2, an early target of alpha 7 nicotinic acetylcholine receptor-mediated neuroprotection against A beta-(1-42) amyloid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; IN-VITRO; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIVATION; SUBTYPES; AGONIST; CELLS; JAK2	The molecular mechanisms of alpha7 nicotinic acetylcholine receptor (nAChR)-mediated neuroprotection remain unclear. In this study we provide evidence that nicotine stimulation of alpha7 nAChR transduces signals to phosphatidylinositol 3-kinase and Akt via Janus kinase 2 (JAK2) in a cascade, which results in neuroprotection. Exposure to beta-amyloid results in the activation of the apoptotic enzyme caspase-3 and cleavage of the DNA-repairing enzyme poly-(ADP-ribose) polymerase. This cascade is inhibited by nicotine through JAK2 activation, and these effects are blocked by preincubation with the JAK2-specific inhibitor AG-490. We also found that pretreatment of cells with angiotensin II blocks the nicotine-induced activation of JAK2 via the AT(2) receptor and completely prevents alpha7 nAChR-mediated neuroprotective effects further suggesting a pivotal role for JAK2. These findings identify novel mechanisms of receptor interactions relevant to neuronal viability and suggest novel therapeutic strategies to optimize neuroprotection.	Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; Targacept Inc, Winston Salem, NC 27101 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Marrero, MB (corresponding author), Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA.	mmarrero@mail.mcg.edu						BARNES NM, 1991, EUR J PHARMACOL, V200, P289, DOI 10.1016/0014-2999(91)90584-D; Bencherif M, 1996, J PHARMACOL EXP THER, V279, P1413; Court J, 2001, BIOL PSYCHIAT, V49, P175, DOI 10.1016/S0006-3223(00)01116-1; DEFIEBRE CM, 1995, MOL PHARMACOL, V47, P164; Dicou E, 2001, NEUROREPORT, V12, P3947, DOI 10.1097/00001756-200112210-00019; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; DonnellyRoberts DL, 1996, BRAIN RES, V719, P36, DOI 10.1016/0006-8993(96)00063-7; Horiuchi M, 1998, ENDOCR RES, V24, P307, DOI 10.3109/07435809809032610; Horiuchi M, 1999, CIRC RES, V84, P876; Kem WR, 2000, BEHAV BRAIN RES, V113, P169, DOI 10.1016/S0166-4328(00)00211-4; Kihara T, 2001, J BIOL CHEM, V276, P13541, DOI 10.1074/jbc.M008035200; Kumano K, 2000, BIOCHEM BIOPH RES CO, V270, P209, DOI 10.1006/bbrc.2000.2403; Kunioku H, 2001, NEUROSCI LETT, V309, P13, DOI 10.1016/S0304-3940(01)02012-2; Liu QS, 2001, P NATL ACAD SCI USA, V98, P4734, DOI 10.1073/pnas.081553598; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Narain Y, 2000, J MED GENET, V37, P695, DOI 10.1136/jmg.37.9.695; Negoro S, 2000, CARDIOVASC RES, V47, P797, DOI 10.1016/S0008-6363(00)00138-3; Newhouse PA, 2001, BIOL PSYCHIAT, V49, P268, DOI 10.1016/S0006-3223(00)01069-6; Ryan RE, 2001, BRIT J PHARMACOL, V132, P1650, DOI 10.1038/sj.bjp.0703989; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; Seo JH, 2001, BIOL PSYCHIAT, V49, P240, DOI 10.1016/S0006-3223(00)01124-0; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626	23	159	168	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44920	44924		10.1074/jbc.M204610200	http://dx.doi.org/10.1074/jbc.M204610200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244045	hybrid			2022-12-27	WOS:000179404800043
J	Sugishima, M; Sakamoto, H; Higashimoto, Y; Omata, Y; Hayashi, S; Noguchi, M; Fukuyama, K				Sugishima, M; Sakamoto, H; Higashimoto, Y; Omata, Y; Hayashi, S; Noguchi, M; Fukuyama, K			Crystal structure of rat heme oxygenase-1 in complex with heme bound to azide - Implication for regiospecific hydroxylation of heme at the alpha-meso carbon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; REDUCING EQUIVALENT; RESONANCE RAMAN; PORPHYRIN RING; CATALYTIC SITE; SOLUBLE FORM; HYDROXYHEME; VERDOHEME; DIFFRACTION; ACTIVATION	Heme oxygenase (HO) catalyzes physiological heme degradation consisting of three sequential oxidation steps that use dioxygen molecules and reducing equivalents. We determined the crystal structure of rat HO-1 in complex with heme and azide (HO-heme-N-3(-)) at 1.9-Angstrom resolution. The azide, whose terminal nitrogen atom is coordinated to the ferric heme iron, is situated nearly parallel to the heme plane, and its other end is directed toward the a-meso position of the heme. Based on resonance Raman spectroscopic analysis of HO-heme bound to dioxygen, this parallel coordination mode suggests that the azide is an analog of dioxygen. The azide is surrounded by residues of the distal F-helix with only the direction to the alpha-meso carbon being open. This indicates that regiospecific oxygenation of the heme is primarily caused by the steric constraint between the dioxygen bound to heme and the F-helix. The azide interacts with Asp-140, Arg-136, and Thr-135 through a hydrogen bond network involving five water molecules on the distal side of the heme. This network, also present in HO-heme, may function in dioxygen activation in the first hydroxylation step. From the orientation of azide in HO-heme-N-3(-), the dioxygen or hydroperoxide bound to HO-heme, the active oxygen species of the first reaction, is inferred to have a similar orientation suitable for a direct attack on the alpha-meso carbon.	Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan; Kurume Univ, Sch Med, Dept Med Biochem, Kurume, Fukuoka 8300011, Japan	Osaka University; Kurume University	Fukuyama, K (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan.		Sugishima, Masakazu/M-2773-2019; Sakamoto, Hiroshi/A-3181-2011; Sugishima, Masakazu/B-1049-2010	Sugishima, Masakazu/0000-0002-0840-4929; Sugishima, Masakazu/0000-0002-0840-4929; Higashimoto, Yuichiro/0000-0003-1382-8598				BEALE SI, 1994, CIBA F SYMP, V180, P156; BLUMBERG WE, 1971, ADV CHEM, V100, P271; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cary SPL, 2001, J CLIN INVEST, V107, P1071, DOI 10.1172/JCI12823; Davydov R, 2002, J AM CHEM SOC, V124, P1798, DOI 10.1021/ja0122391; Davydov RM, 1999, J AM CHEM SOC, V121, P10656, DOI 10.1021/ja992425v; Fujii H, 2001, J AM CHEM SOC, V123, P6475, DOI 10.1021/ja010490a; Hawkins BK, 1996, BBA-PROTEIN STRUCT M, V1295, P165, DOI 10.1016/0167-4838(96)00031-3; HERNANDEZ G, 1994, BIOCHEMISTRY-US, V33, P6631, DOI 10.1021/bi00187a033; Hidaka Toshihiro, 1996, Kurume Medical Journal, V43, P313; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; Lightning LK, 2001, J BIOL CHEM, V276, P10612, DOI 10.1074/jbc.M010349200; Liu Y, 1997, J BIOL CHEM, V272, P6909, DOI 10.1074/jbc.272.11.6909; Matera KM, 1996, J BIOL CHEM, V271, P6618, DOI 10.1074/jbc.271.12.6618; Maurus R, 1998, BIOCHEM J, V332, P67, DOI 10.1042/bj3320067; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Migita CT, 1999, BBA-PROTEIN STRUCT M, V1432, P203; Omata Y, 1998, ACTA CRYSTALLOGR D, V54, P1017, DOI 10.1107/S0907444998003448; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pond AE, 1999, BIOCHEMISTRY-US, V38, P7601, DOI 10.1021/bi9825448; Prabhakar NR, 1999, RESP PHYSIOL, V115, P161, DOI 10.1016/S0034-5687(99)00019-5; Prabhakar NR, 1998, RESP PHYSIOL, V114, P57, DOI 10.1016/S0034-5687(98)00072-3; Sakamoto H, 1999, J BIOL CHEM, V274, P18196, DOI 10.1074/jbc.274.26.18196; Schmitt MP, 1997, J BACTERIOL, V179, P838, DOI 10.1128/jb.179.3.838-845.1997; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; WILKS A, 1994, J BIOL CHEM, V269, P29553; WILKS A, 1993, J BIOL CHEM, V268, P22357; YOSHIDA T, 1981, J BIOCHEM-TOKYO, V90, P125, DOI 10.1093/oxfordjournals.jbchem.a133441; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHIDA T, 1982, J BIOL CHEM, V257, P9345; YOSHINAGA T, 1990, BIOCHEM J, V270, P659, DOI 10.1042/bj2700659	43	66	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45086	45090		10.1074/jbc.M207267200	http://dx.doi.org/10.1074/jbc.M207267200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235152	hybrid			2022-12-27	WOS:000179404800064
J	Tupling, AR; Asahi, M; MacLennan, DH				Tupling, AR; Asahi, M; MacLennan, DH			Sarcolipin overexpression in rat slow twitch muscle inhibits sarcoplasmic reticulum Ca2+ uptake and impairs contractile function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; SKELETAL-MUSCLE; MYOCARDIAL-CONTRACTILITY; PHOSPHOLAMBAN GENE; BRODY-DISEASE; CA2+-ATPASE; PHOSPHORYLATION; SERCA1; SITE; STIMULATION	Sarcolipin (SLN) is an inhibitor of sarco(endo)plasmic reticulum Ca2+-ATPases (SERCAs) in vitro, but its function in vivo has not been defined. NF-SLN cDNA (SLN tagged N-terminally with a FLAG epitope) was introduced into rat soleus muscle in one hindlimb by plasmid injection and electrotransfer. Western blotting showed expression and co-immunoprecipitation showed physical interaction between NF-SLN and SERCA2a. Contractile properties and SERCA2a function were assessed and compared with vector-injected contralateral soleus muscles. NF-SLN reduced both peak twitch force (P-t) (123.9 +/- 12.5 versus 69.8 +/- 8.9 millinewtons) and tetanic force (P-o) (562.3 +/- 51.0 versus 300.7 +/- 56.9 millinewtons) and reduced both twitch and tetanic rates of contraction (+dF/dt) and relaxation (-dF/dt) significantly. Repetitive stimulation (750-ms trains at 50 Hz once every 2 s for 3 min) showed that NF-SLN increased susceptibility to fatigue. These changes in contractile function were observed in the absence of endogenous phospholamban, and NF-SLN had no effect on either SERCA2a or SERCA1a expression levels. NF-SLN also decreased maximal Ca2+ transport activity at pCa 5 by 31% with no significant change in apparent Ca2+ affinity (6.36 +/- 0.07 versus 6.39 +/- 0.08 pCa units). These results show that NF-SLN expression impairs muscle contractile function by inhibiting SERCA function and diminishing sarcoplasmic reticulum Ca2+ stores.	Univ Toronto, Charles H Best Inst, Banting & Best Dept Res, Toronto, ON M5G 1L6, Canada	University of Toronto	MacLennan, DH (corresponding author), Univ Toronto, Charles H Best Inst, Banting & Best Dept Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.			Tupling, A. Russell/0000-0002-3895-6767				ALLEN DG, 1995, EXP PHYSIOL, V80, P497, DOI 10.1113/expphysiol.1995.sp003864; Asahi M, 1999, J BIOL CHEM, V274, P32855, DOI 10.1074/jbc.274.46.32855; Asahi M, 2002, J BIOL CHEM, V277, P26725, DOI 10.1074/jbc.C200269200; BRODY IA, 1969, NEW ENGL J MED, V281, P187, DOI 10.1056/NEJM196907242810403; Carvalho AJ, 1997, PLAST RECONSTR SURG, V99, P163, DOI 10.1097/00006534-199701000-00025; CHIN ER, 1995, CAN J PHYSIOL PHARM, V73, P1154, DOI 10.1139/y95-165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu GX, 1996, CIRC RES, V79, P1064, DOI 10.1161/01.RES.79.6.1064; DAMIANI E, 2000, BIOCHIM BIOPHYS ACTA, V1464, P1; Davia K, 1999, PHYSIOL GENOMICS, V1, P41, DOI 10.1152/physiolgenomics.1999.1.2.41; de Groof AJC, 2002, J BIOL CHEM, V277, P5275, DOI 10.1074/jbc.M108157200; Dux L, 1993, Rev Physiol Biochem Pharmacol, V122, P69, DOI 10.1007/BFb0035274; FUJII J, 1988, FEBS LETT, V227, P51, DOI 10.1016/0014-5793(88)81412-1; Gayan-Ramirez G, 2000, J PHYSIOL-LONDON, V524, P387, DOI 10.1111/j.1469-7793.2000.t01-2-00387.x; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; Kimura Y, 1996, J BIOL CHEM, V271, P21726, DOI 10.1074/jbc.271.36.21726; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Li S, 2001, GENE THER, V8, P400, DOI 10.1038/sj.gt.3301418; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MACLENNAN DH, 1972, COLD SPRING HARB SYM, V37, P469; Maruyama H, 2001, GENE THER, V8, P461, DOI 10.1038/sj.gt.3301412; Mayer EJ, 2000, BIOCHEM BIOPH RES CO, V267, P40, DOI 10.1006/bbrc.1999.1920; Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; Odermatt A, 1997, GENOMICS, V45, P541, DOI 10.1006/geno.1997.4967; Odermatt A, 1996, NAT GENET, V14, P191, DOI 10.1038/ng1096-191; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; Odermatt A, 1996, J BIOL CHEM, V271, P14206, DOI 10.1074/jbc.271.24.14206; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; Slack JP, 1997, J BIOL CHEM, V272, P18862, DOI 10.1074/jbc.272.30.18862; Vilquin JT, 2001, GENE THER, V8, P1097, DOI 10.1038/sj.gt.3301484; WAWRZYNOW A, 1992, ARCH BIOCHEM BIOPHYS, V298, P620, DOI 10.1016/0003-9861(92)90457-8; WESTERBLAD H, 1993, J PHYSIOL-LONDON, V468, P729, DOI 10.1113/jphysiol.1993.sp019797; WU KD, 1993, AM J PHYSIOL, V264, P333; Zador E, 1996, BIOCHEM J, V320, P107, DOI 10.1042/bj3200107; Zubrzycka-Gaarn E, 1984, Prog Clin Biol Res, V168, P19; Zvaritch E, 2000, J BIOL CHEM, V275, P14985, DOI 10.1074/jbc.275.20.14985	40	77	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44740	44746		10.1074/jbc.M206171200	http://dx.doi.org/10.1074/jbc.M206171200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237298	hybrid			2022-12-27	WOS:000179404800020
J	Wiethoff, CM; Gill, ML; Koe, GS; Koe, JG; Middaugh, CR				Wiethoff, CM; Gill, ML; Koe, GS; Koe, JG; Middaugh, CR			The structural organization of cationic lipid-DNA complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; GENE DELIVERY; LIPOSOME COMPLEXES; PLASMID DNA; PHYSICOCHEMICAL CHARACTERIZATION; CRYOELECTRON MICROSCOPY; IN-VITRO; MEMBRANE; FLUORESCENCE; RECEPTOR	The interaction of cationic liposomes with supercoiled plasmid DNA results in a major rearrangement of each component to form compact multilamellar structures comprised of alternating layers of two-dimensional arrays of DNA sandwiched between lipid bilayers. Fluorescence resonance energy transfer was used to estimate the distance of closest approach of DNA to the lipid bilayers in these complexes. The effect of several compositional variables on this distance, including the ratio of cationic lipid to DNA, and the charge density, intrinsic curvature, and fluidity of the lipid bilayer were examined. Additionally, the effect of ionic strength was studied. For complexes prepared at or above a 3:1 charge ratio (+/-), the observed distance of closest approach was found to be in agreement with the intercalation of DNA between lipid bilayers. As the charge ratio was decreased, a monotonic increase in the distance was observed with a maximum observed at 0.5:1. Correlations between differences in the proximity of DNA to the lipid bilayer and the hydrodynamic size of the complexes were also found. A model based on these observations and previous reports suggests the formation of discrete populations of complexes below a charge ratio of 0.5:1 and above 3:1. The structure of the negatively charged complexes is consistent with DNA extending from the surface of the particles, whereas those possessing excess positive charge were multilamellar aggregates with the DNA effectively condensed between lipid bilayers. Complexes between these two states consist of weighted fractions of these two species.	Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA; Valentis Inc, Burlingame, CA 94010 USA	University of Kansas	Middaugh, CR (corresponding author), Univ Kansas, Dept Pharmaceut Chem, 2095 Constant Ave, Lawrence, KS 66047 USA.	middaugh@ku.edu		Gill, Michelle/0000-0002-2861-355X				ARAKI T, 1987, HISTOCHEMISTRY, V87, P331, DOI 10.1007/BF00492587; BAIRD B, 1985, BIOCHEMISTRY-US, V24, P6252, DOI 10.1021/bi00343a032; BAIRD B, 1989, INT ARCH ALLER A IMM, V88, P23, DOI 10.1159/000234742; Bandyopadhyay S, 1999, J PHYS CHEM B, V103, P10075, DOI 10.1021/jp9927496; Battersby BJ, 1998, BBA-BIOMEMBRANES, V1372, P379, DOI 10.1016/S0005-2736(98)00062-5; Bhattacharya S, 1998, BIOCHEMISTRY-US, V37, P7764, DOI 10.1021/bi971772j; Birchall JC, 1999, INT J PHARM, V183, P195, DOI 10.1016/S0378-5173(99)00117-9; Chadwick SL, 1997, GENE THER, V4, P937, DOI 10.1038/sj.gt.3300481; Choosakoonkriang S, 2001, J BIOL CHEM, V276, P8037, DOI 10.1074/jbc.M010592200; Crook K, 1996, GENE THER, V3, P834; Crook K, 1998, GENE THER, V5, P137, DOI 10.1038/sj.gt.3300554; DEWEY TG, 1980, BIOPHYS J, V32, P1023, DOI 10.1016/S0006-3495(80)85033-8; Eastman SJ, 1997, BBA-BIOMEMBRANES, V1325, P41, DOI 10.1016/S0005-2736(96)00242-8; Even-Chen S, 2000, BBA-BIOMEMBRANES, V1509, P176, DOI 10.1016/S0005-2736(00)00292-3; FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9; Ferrari ME, 1998, HUM GENE THER, V9, P341, DOI 10.1089/hum.1998.9.3-341; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; HAAS E, 1978, BIOCHEMISTRY-US, V17, P5064, DOI 10.1021/bi00616a032; Harries D, 1998, BIOPHYS J, V75, P159, DOI 10.1016/S0006-3495(98)77503-4; Hirsch-Lemer D, 1998, BBA-BIOMEMBRANES, V1370, P17, DOI 10.1016/S0005-2736(97)00239-3; Hirsch-Lerner D, 1999, BBA-BIOMEMBRANES, V1461, P47, DOI 10.1016/S0005-2736(99)00145-5; Huebner S, 1999, BIOPHYS J, V76, P3158, DOI 10.1016/S0006-3495(99)77467-9; JOHNSON ID, 1991, ANAL BIOCHEM, V198, P228, DOI 10.1016/0003-2697(91)90418-S; Kennedy MT, 2000, BIOPHYS J, V78, P1620, DOI 10.1016/S0006-3495(00)76714-2; Koltover I, 1999, BIOPHYS J, V77, P915, DOI 10.1016/S0006-3495(99)76942-0; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; Lasic DD, 1997, J AM CHEM SOC, V119, P832, DOI 10.1021/ja962713g; Lobo BA, 2002, J PHARM SCI, V91, P454, DOI 10.1002/jps.10025; Lobo BA, 2001, ARCH BIOCHEM BIOPHYS, V386, P95, DOI 10.1006/abbi.2000.2196; MacDonald RC, 1999, BIOPHYS J, V77, P2612, DOI 10.1016/S0006-3495(99)77095-5; Marsh D., 1990, CRC HDB LIPID BILAYE; McLachlan G, 1996, GENE THER, V3, P1113; Monk KWC, 1997, BIOPHYS J, V73, P2534, DOI 10.1016/S0006-3495(97)78282-1; Nishikawa M, 2001, HUM GENE THER, V12, P861, DOI 10.1089/104303401750195836; OKUYAMA K, 1988, B CHEM SOC JPN, V61, P1485, DOI 10.1246/bcsj.61.1485; PODGORNIK R, 1994, BIOPHYS J, V66, P962, DOI 10.1016/S0006-3495(94)80877-X; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; Schmutz M, 1999, P NATL ACAD SCI USA, V96, P12293, DOI 10.1073/pnas.96.22.12293; SHAHROKH Z, 1991, J BIOL CHEM, V266, P12082; SHAKLAI N, 1977, BIOCHEMISTRY-US, V16, P5585, DOI 10.1021/bi00644a031; Simberg D, 2001, J BIOL CHEM, V276, P47453, DOI 10.1074/jbc.M105588200; Smisterova J, 2001, J BIOL CHEM, V276, P47615, DOI 10.1074/jbc.M106199200; SOLODIN I, 1995, BIOCHEMISTRY-US, V34, P13537, DOI 10.1021/bi00041a033; Song YK, 1997, HUM GENE THER, V8, P1585, DOI 10.1089/hum.1997.8.13-1585; Tarahovsky YS, 2002, BIOPHYS J, V82, P264, DOI 10.1016/S0006-3495(02)75392-7; VALENZUELA CF, 1994, BIOPHYS J, V66, P674, DOI 10.1016/S0006-3495(94)80841-0; Waddill W, 1997, AM J ROENTGENOL, V169, P63, DOI 10.2214/ajr.169.1.9207502; Wiethoff CM, 2001, J BIOL CHEM, V276, P32806, DOI 10.1074/jbc.M007940200; WOLBER PK, 1979, BIOPHYS J, V28, P197, DOI 10.1016/S0006-3495(79)85171-1; Xu YH, 1999, BIOPHYS J, V77, P341, DOI 10.1016/S0006-3495(99)76894-3; YGUERABIDE J, 1994, BIOPHYS J, V66, P683, DOI 10.1016/S0006-3495(94)80842-2; Zuidam NJ, 1997, BBA-BIOMEMBRANES, V1329, P211, DOI 10.1016/S0005-2736(97)00110-7	52	50	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44980	44987		10.1074/jbc.M207758200	http://dx.doi.org/10.1074/jbc.M207758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12297507	hybrid			2022-12-27	WOS:000179404800051
J	Komissarov, AA; Declerck, PJ; Shore, JD				Komissarov, AA; Declerck, PJ; Shore, JD			Mechanisms of conversion of plasminogen activator inhibitor 1 from a suicide inhibitor to a substrate by monoclonal antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; SERPIN-PROTEASE COMPLEXES; INTERACTION SITES; TISSUE-TYPE; NEUTRALIZING ANTIBODIES; FLUORESCENT-PROBE; ENDOTHELIAL-CELLS; UROKINASE-TYPE; IDENTIFICATION; EPITOPE	We have delineated two different reaction mechanisms of monoclonal antibodies (mAbs), MA-8H9D4 and either MA-55F4C12 or MA-33H1F7, that convert plasminogen activator inhibitor 1 (PAI-1) to a substrate for tissue (tPA)- and urokinase plasminogen activators. MA-8H9D4 almost completely (98-99%) shifts the reaction to the substrate pathway by preventing disordering of the proteinase active site. MA-8H9D4 does not affect the rate-limiting constants (k(lim)) for the insertion of the reactive center loop cleaved by tPA (3.5 s(-1)) but decreases klim for urokinase plasminogen activator from 25 to 4.0 s(-1). MA-8H9D4 does not cause deacylation of preformed PAI-1/proteinase complexes and probably acts prior to the formation of the final inhibitory complex, interfering with displacement of the acylated serine from the proteinase active site. MA-55F4Cl2 and MA-33H1F7 (50-80% substrate reaction) do not interfere with initial PAI-1/proteinase complex formation but retard the inhibitory pathway by decreasing k(lim) (>10-fold for tPA). Interaction of two mAbs with the same molecule of PAI-1 has been directly demonstrated for pairs MA-8H9D4/MA-55F4C12 and MA-8H9D4/MA-33H1F7 but not for MA-55F4C12/MA-33H1F7. The strong functional additivity observed for MA-8H9D4 and MA-55F4C12 demonstrates that these mAbs interact independently and affect different steps of the PAI-1 reaction mechanism.	Henry Ford Hlth Syst, Div Biochem Res, Detroit, MI 48202 USA; Katholieke Univ Leuven, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium	Henry Ford Health System; Henry Ford Hospital; KU Leuven	Shore, JD (corresponding author), Henry Ford Hlth Syst, Div Biochem Res, Detroit, MI 48202 USA.		Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105	NHLBI NIH HHS [HL 54930] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AERTGEERTS K, 1995, PROTEINS, V23, P118, DOI 10.1002/prot.340230114; Bijnens AP, 2000, J BIOL CHEM, V275, P6375, DOI 10.1074/jbc.275.9.6375; Bijnens AP, 2001, THROMB HAEMOSTASIS, V85, P866; Bijnens AP, 2001, J BIOL CHEM, V276, P44912, DOI 10.1074/jbc.M103077200; Bjorquist P, 1997, BBA-PROTEIN STRUCT M, V1341, P87, DOI 10.1016/S0167-4838(97)00065-4; Bjorquist P, 1998, BIOCHEMISTRY-US, V37, P1227, DOI 10.1021/bi971554q; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; ChaillanHuntington CE, 1997, BIOCHEMISTRY-US, V36, P9562, DOI 10.1021/bi970651g; Charlton PA, 1996, THROMB HAEMOSTASIS, V75, P808; Debrock S, 1997, BBA-PROTEIN STRUCT M, V1337, P257, DOI 10.1016/S0167-4838(96)00173-2; Debrock S, 1998, THROMB HAEMOSTASIS, V79, P597; Egelund R, 1998, BIOCHEMISTRY-US, V37, P6375, DOI 10.1021/bi973043+; EVANS SA, 1982, J BIOL CHEM, V257, P3014; Folkes A, 2002, BIOORG MED CHEM LETT, V12, P1063, DOI 10.1016/S0960-894X(02)00078-1; Folkes A, 2001, BIOORG MED CHEM LETT, V11, P2589, DOI 10.1016/S0960-894X(01)00508-X; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; KEIJER J, 1991, BLOOD, V78, P401; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; Kvassman JO, 1998, BIOCHEMISTRY-US, V37, P15491, DOI 10.1021/bi9814787; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Nar H, 2000, J MOL BIOL, V297, P683, DOI 10.1006/jmbi.2000.3604; Ngo TH, 1997, FEBS LETT, V416, P373, DOI 10.1016/S0014-5793(97)01242-8; OLSON ST, 1982, J BIOL CHEM, V257, P4891; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; Petersen HH, 2001, EUR J BIOCHEM, V268, P4430, DOI 10.1046/j.1432-1327.2001.02365.x; Rajpal A, 1998, PROTEIN SCI, V7, P1868, DOI 10.1002/pro.5560070903; RANDO RR, 1974, SCIENCE, V185, P320, DOI 10.1126/science.185.4148.320; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Stout TJ, 2000, BIOCHEMISTRY-US, V39, P8460, DOI 10.1021/bi000290w; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; vanMeijer M, 1996, J BIOL CHEM, V271, P7423, DOI 10.1074/jbc.271.13.7423; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; vanZonneveld AJ, 1995, GENE, V167, P49, DOI 10.1016/0378-1119(95)00614-1; VAUGHAN DE, 1993, BIOCHIM BIOPHYS ACTA, V1202, P221, DOI 10.1016/0167-4838(93)90008-F; Verhamme I, 1999, J BIOL CHEM, V274, P17511, DOI 10.1074/jbc.274.25.17511; Walsh C, 1978, Methods Enzymol, V53, P437; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WIMAN B, 1995, THROMB HAEMOSTASIS, V74, P71; Wind T, 2001, EUR J BIOCHEM, V268, P1095, DOI 10.1046/j.1432-1327.2001.2680041095.x	52	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43858	43865		10.1074/jbc.M204110200	http://dx.doi.org/10.1074/jbc.M204110200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223472	hybrid			2022-12-27	WOS:000179272000044
J	Romano, M; Marcucci, R; Buratti, E; Ayala, YM; Sebastio, G; Baralle, FE				Romano, M; Marcucci, R; Buratti, E; Ayala, YM; Sebastio, G; Baralle, FE			Regulation of 3 ' splice site selection in the 844ins68 polymorphism of the cystathionine beta-synthase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; HNRNP-H; INTRON; ENHANCER; BINDING; EXON; HYPERHOMOCYSTEINEMIA; THROMBOSIS; MUTATIONS; VARIANT	844ins68 is a frequent polymorphism of the cystathionine beta-synthase gene (CBS) that consists of a 68-bp insertion duplicating the 3' splice site of intron 7 and the 5'-end of exon 8. The presence of two identical 3' splice sites spaced by 68 bp should lead to either a selection of the proximal site or to at least two alternatively spliced CBS mRNA variants. Instead, an accurate selection of the distal 3' splice site is observed in the 844ins68 carriers. The duplication has generated a gene re-arrangement at the 3' splice site where two GGGG runs have been brought close to each other. Using a minigene system, we have investigated the effect this peculiar configuration might have on the selection of the 3' splice site of intron 7 in the CBS gene. Minimal disruption of the G runs resulted in a dramatic shift toward the proximal 3' splice site selection with inclusion of the 68-bp insertion and a consequent change of the reading frame. The insertional event created this peculiar configuration of two G repeats close to each other that subsequently acquired the ability to strongly bind heterogeneous nuclear ribonucleoprotein (hnRNP) H1, a specific trans-acting factor. The interaction of hnRNP H1 with G runs within the 844ins68 context might interfere with the recruitment of splicing factors to the proximal 3' splice site thus favoring the selection of the distal 3' splice site. Our results therefore suggest the possibility that the insertion was an evolutionary event that allowed the rescue of the wild-type sequence, so preserving protein function.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Univ Trieste, Dept Physiol & Pathol, I-34127 Trieste, Italy; Univ Naples Federico II, Dept Pediat, I-80131 Naples, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB); University of Trieste; University of Naples Federico II	Baralle, FE (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.		Romano, Maurizio/G-9431-2012; Buratti, Emanuele/K-4691-2016	Romano, Maurizio/0000-0002-4820-2897; Buratti, Emanuele/0000-0002-1356-9074	Telethon [E.1038] Funding Source: Medline	Telethon(Fondazione Telethon)		Caputi M, 2002, EMBO J, V21, P845, DOI 10.1093/emboj/21.4.845; Caputi M, 2001, J BIOL CHEM, V276, P43850, DOI 10.1074/jbc.M102861200; Carlo T, 1996, RNA, V2, P342; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Chou MY, 1999, MOL CELL BIOL, V19, P69; de Franchis R, 2000, THROMB HAEMOSTASIS, V84, P576, DOI 10.1055/s-0037-1614070; Franco R, 1998, HAEMATOLOGICA, V83, P1006; Franco RF, 1998, HUM HERED, V48, P338, DOI 10.1159/000022826; Gaustadnes M, 2000, THROMB HAEMOSTASIS, V83, P554, DOI 10.1055/s-0037-1613862; Haut DD, 1998, J VIROL, V72, P1834, DOI 10.1128/JVI.72.3.1834-1843.1998; Kluijtmans LAJ, 1997, BIOCHEM MOL MED, V62, P23, DOI 10.1006/bmme.1997.2623; MATUNIS MJ, 1994, NUCLEIC ACIDS RES, V22, P1059, DOI 10.1093/nar/22.6.1059; Mazzarella R, 1998, GENOME RES, V8, P1007, DOI 10.1101/gr.8.10.1007; McCarthy EMS, 1998, HUM MOL GENET, V7, P1491, DOI 10.1093/hmg/7.9.1491; McCullough AJ, 1997, MOL CELL BIOL, V17, P4562, DOI 10.1128/MCB.17.8.4562; McCullough AJ, 2000, MOL CELL BIOL, V20, P9225, DOI 10.1128/MCB.20.24.9225-9235.2000; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; NUSSINOV R, 1989, J BIOMOL STRUCT DYN, V6, P985, DOI 10.1080/07391102.1989.10506526; Orendac M, 1999, J INHERIT METAB DIS, V22, P674, DOI 10.1023/A:1005554702861; SEBASTIO G, 1995, AM J HUM GENET, V56, P1324; SIRANDPUGNET P, 1995, NUCLEIC ACIDS RES, V23, P3501, DOI 10.1093/nar/23.17.3501; Sperandeo MP, 1996, AM J HUM GENET, V59, P1391; Tsai MY, 2000, ATHEROSCLEROSIS, V149, P131, DOI 10.1016/S0021-9150(99)00297-X; Tsai MY, 1996, AM J HUM GENET, V59, P1262	24	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43821	43829		10.1074/jbc.M208107200	http://dx.doi.org/10.1074/jbc.M208107200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228232	hybrid			2022-12-27	WOS:000179272000039
J	Hansen, SB; Radic, Z; Talley, TT; Molles, BE; Deerinck, T; Tsigelny, I; Taylor, P				Hansen, SB; Radic, Z; Talley, TT; Molles, BE; Deerinck, T; Tsigelny, I; Taylor, P			Tryptophan fluorescence reveals conformational changes in the acetylcholine binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC RECEPTOR; CHOLINERGIC RECEPTOR; TORPEDO-CALIFORNICA; KINETICS; MUSCLE; AGONIST; DOMAIN; SITE; DISSOCIATION; CHANNELS	The recent characterization of an acetylcholine binding protein (AChBP) from the fresh water snail, Lymnaea stagnalis, shows it to be a structural homolog of the extracellular domain of the nicotinic acetylcholine receptor (nAChR). To ascertain whether the AChBP exhibits the recognition properties and functional states of the nAChR, we have expressed the protein in milligram quantities from a synthetic cDNA transfected into human embryonic kidney (HEK) cells. The protein secreted into the medium shows a pentameric rosette structure with ligand stoichiometry approximating five sites per pentamer. Surprisingly, binding of acetylcholine, selective agonists, and antagonists ranging from small alkaloids to larger peptides results in substantial quenching of the intrinsic tryptophan fluorescence. Using stopped-flow techniques, we demonstrate rapid rates of association and dissociation of agonists and slow rates for the alpha-neurotoxins. Since agonist binding occurs in millisecond time frames, and the a-neurotoxins may induce a distinct conformational. state for the AChBP-toxin complex, the snail protein shows many of the properties expected for receptor recognition of interacting ligands. Thus, the marked tryptophan quenching not only documents the importance of aromatic residues in ligand recognition, but establishes that the AChBP will be a useful functional as well as structural surrogate of the nicotinic receptor.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Natl Ctr Microscopy & Imaging Res, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr,BSB 3027, La Jolla, CA 92093 USA.	pwtaylor@ucsd.edu	Talley, Todd/B-3630-2010	Talley, Todd/0000-0002-1077-1947	NIGMS NIH HHS [R37-GM 18360, T32-GM 07752, T32 GM007752, R37 GM018360] Funding Source: Medline; NINDS NIH HHS [F32 NS043063] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752, R37GM018360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS043063] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beene DL, 2002, BIOCHEMISTRY-US, V41, P10262, DOI 10.1021/bi020266d; Bouzat C, 2000, J GEN PHYSIOL, V115, P663, DOI 10.1085/jgp.115.5.663; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; BROCKES JP, 1975, BIOCHEMISTRY-US, V14, P2092, DOI 10.1021/bi00681a008; COLQUHOUN D, 1985, J PHYSIOL-LONDON, V369, P501, DOI 10.1113/jphysiol.1985.sp015912; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Figl A, 1996, J GEN PHYSIOL, V107, P369, DOI 10.1085/jgp.107.3.369; FLANAGAN SD, 1976, J BIOL CHEM, V251, P858; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; Grosman C, 2001, P NATL ACAD SCI USA, V98, P14102, DOI 10.1073/pnas.251402498; ITAKURA K, 1977, SCIENCE, V198, P1056, DOI 10.1126/science.412251; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; LACKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P185; Lockless SW, 1999, SCIENCE, V286, P295, DOI 10.1126/science.286.5438.295; Mandell JG, 2001, PROTEIN ENG, V14, P105, DOI 10.1093/protein/14.2.105; Prince RJ, 1998, BIOPHYS J, V75, P1817, DOI 10.1016/S0006-3495(98)77623-4; Radic Z, 2001, J BIOL CHEM, V276, P4622, DOI 10.1074/jbc.M006855200; Salamone FN, 1999, J PHYSIOL-LONDON, V516, P315, DOI 10.1111/j.1469-7793.1999.0315v.x; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 2000, HANDB EXP PHARM, V144, P79; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; WANG GK, 1980, J BIOL CHEM, V255, P1156; Wang HL, 1997, J GEN PHYSIOL, V109, P757, DOI 10.1085/jgp.109.6.757; WEILAND G, 1977, J BIOL CHEM, V252, P7648; Wenningmann I, 2001, MOL PHARMACOL, V60, P790; Xie Y, 2001, J BIOL CHEM, V276, P2417, DOI 10.1074/jbc.M009085200; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088	28	87	92	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41299	41302		10.1074/jbc.C200462200	http://dx.doi.org/10.1074/jbc.C200462200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12235129	Green Accepted, hybrid			2022-12-27	WOS:000178985300002
J	Chakraborty, A; Das, I; Datta, R; Sen, B; Bhattacharyya, D; Mandal, C; Datta, AK				Chakraborty, A; Das, I; Datta, R; Sen, B; Bhattacharyya, D; Mandal, C; Datta, AK			A single-domain cyclophilin from Leishmania donovani reactivates soluble aggregates of adenosine kinase by isomerase-independent chaperone function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-PROLYL ISOMERASE; ACTIVITY IN-VITRO; ESCHERICHIA-COLI; BINDING-PROTEIN; HEAT-SHOCK; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; CYCLOSPORINE-A; HIV-1 VIRIONS; HOMOLOG	Disaggregation and reactivation of aggregated proteins by chaperones is well established. However, little is known regarding such kind of function of single-domain small cyclophilins (CyPs). Here we demonstrate that, with increasing concentrations, fully active adenosine kinase (AdK) of Leishmania donovani tends to form soluble aggregates, resulting in inactivation. Using this inactive enzyme as the substrate, it is shown that a CyP from L. donovani (LdCyP) alone can cause complete disaggregation, leading to reactivation of the enzyme. The reactivating ability of LdCyP remains unaffected even in the presence of cyclosporin A and macromolecular crowding agents. The reactivation occurs noncatalytically and is reversible. A truncated LdCyP, devoid of 88 amino acids from the N terminus, is found to be required in near stoichiometric proportion to reactivate AdK, suggesting essentiality of the C-terminal region. Gel filtration and light-scattering experiments together with protein cross-linking studies revealed that both full-length LdCyP and the truncated form directly interact with AdK and convert oligomeric forms of the enzyme to monomeric state. Homology modeling studies suggest that the exposed hydrophobic residues of LdCyP, by interacting with solvent-accessible hydrophobic surface of AdK, pull apart its aggregated inactive oligomers to functional monomers. Clearly, the results are consistent with the interpretation that the higher efficiency of the truncated LdCyP is most likely due to increased exposure of the hydrophobic residues on its surface. These observations, besides establishing L. donovani AdK as one of the model enzymes to study aggregation-disaggregation of proteins, raise the possibility that single-domain small CyPs, under physiological conditions, may regulate the activity of aggregation-prone proteins by ensuring their disaggregation.	Indian Inst Chem Biol, Div Infect Dis, Leishmania Grp, Kolkata 700032, India; Indian Inst Chem Biol, Div Drug Design Dev & Mol Modelling, Kolkata 700032, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Datta, AK (corresponding author), Indian Inst Chem Biol, Div Infect Dis, Leishmania Grp, 4 Raja SC Mullick Rd, Kolkata 700032, India.	alokdatta@iicb.res.in						ARGAMAN M, 1994, MOL BIOCHEM PARASIT, V64, P95, DOI 10.1016/0166-6851(94)90138-4; Bagui TK, 1996, BIOCHEM J, V316, P439, DOI 10.1042/bj3160439; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Bhattacharyya AM, 2001, J BIOL CHEM, V276, P28739, DOI 10.1074/jbc.M102500200; BHAUMIK D, 1989, J BIOL CHEM, V264, P4356; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; DATTA AK, 1987, J BIOL CHEM, V262, P5515; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; Duina AA, 1998, J BIOL CHEM, V273, P10819, DOI 10.1074/jbc.273.18.10819; Dutta M, 2001, J BIOL CHEM, V276, P19294, DOI 10.1074/jbc.M009379200; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; Ellis RJ, 1997, CURR BIOL, V7, pR531, DOI 10.1016/S0960-9822(06)00273-9; Elowitz MB, 1999, J BACTERIOL, V181, P197, DOI 10.1128/JB.181.1.197-203.1999; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Fischer G, 1999, MOL CHAPERONES FOLDI, P461; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; FRESKGARD PO, 1992, SCIENCE, V258, P466, DOI 10.1126/science.1357751; Furutani M, 2000, BIOCHEMISTRY-US, V39, P453, DOI 10.1021/bi9911076; GHOSH M, 1994, BIOCHEM J, V298, P295, DOI 10.1042/bj2980295; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING SE, 1997, PROTEIN STRUCTURE PR, P219; ITSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3389; Jaenicke R, 1999, MOL CHAPERONES FOLDI, P407; Jaschke A, 1998, J MOL BIOL, V277, P763, DOI 10.1006/jmbi.1998.1644; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li J, 2001, J BIOL CHEM, V276, P34396, DOI 10.1074/jbc.M103392200; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Mandal C, 1996, NAT BIOTECHNOL, V14, P323, DOI 10.1038/nbt0396-323; MANDAL C, 1998, MODELYN ANALYN; Martin J, 1997, P NATL ACAD SCI USA, V94, P1107, DOI 10.1073/pnas.94.4.1107; Mathews II, 1998, BIOCHEMISTRY-US, V37, P15607, DOI 10.1021/bi9815445; McGwire BS, 2002, J BIOL CHEM, V277, P8802, DOI 10.1074/jbc.M109072200; NADEAU K, 1993, J BIOL CHEM, V268, P1479; Ow WB, 2001, PROTEIN SCI, V10, P2346, DOI 10.1110/ps.23301; Pak M, 1997, P NATL ACAD SCI USA, V94, P4901, DOI 10.1073/pnas.94.10.4901; Patzelt H, 2001, P NATL ACAD SCI USA, V98, P14244, DOI 10.1073/pnas.261432298; Pirkl F, 2001, J BIOL CHEM, V276, P37034, DOI 10.1074/jbc.M102595200; Pittz E P, 1973, Methods Enzymol, V27, P209; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; Ramm K, 2000, J BIOL CHEM, V275, P17106, DOI 10.1074/jbc.M910234199; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; RINFRET A, 1994, BIOCHEMISTRY-US, V33, P1668, DOI 10.1021/bi00173a008; Rivera VM, 2000, SCIENCE, V287, P826, DOI 10.1126/science.287.5454.826; ROTONDA J, 1993, J BIOL CHEM, V268, P7607; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Schumacher MA, 2000, J MOL BIOL, V298, P875, DOI 10.1006/jmbi.2000.3753; Sinha KM, 1999, BIOCHEM J, V339, P667, DOI 10.1042/0264-6021:3390667; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; SYKES K, 1993, P NATL ACAD SCI USA, V90, P5853, DOI 10.1073/pnas.90.12.5853; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van den Berg B, 1999, EMBO J, V18, P6927, DOI 10.1093/emboj/18.24.6927; von Ahsen O, 2000, J MOL BIOL, V297, P809, DOI 10.1006/jmbi.2000.3574; ZILBERSTEIN D, 1994, ANNU REV MICROBIOL, V48, P449, DOI 10.1146/annurev.mi.48.100194.002313; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	67	39	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47451	47460		10.1074/jbc.M204827200	http://dx.doi.org/10.1074/jbc.M204827200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12244046	hybrid			2022-12-27	WOS:000179663700081
J	Helfand, MS; Hujer, AM; Sonnichsen, FD; Bonomo, RA				Helfand, MS; Hujer, AM; Sonnichsen, FD; Bonomo, RA			Unexpected advanced generation cephalosporinase activity of the M69F variant of SHV beta-lactamase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; INHIBITOR-RESISTANT MUTANTS; ESCHERICHIA-COLI; CLAVULANIC ACID; INACTIVATION; TAZOBACTAM; MUTATIONS; TEM-1; ARGININE-244; MUTAGENESIS	Infections with bacteria that contain hydrolytic beta-lactamase enzymes are becoming a serious problem in the United States. Mutations at Met-69, an amino acid proximal to the active site Ser-70 in the TEM-1 and SHV-1 beta-lactamases, have emerged as a puzzling cause of bacterial resistance to inhibitors of beta-lactamases. Site-saturation mutagenesis of the 69 position in SHV beta-lactamase was performed to determine how mutations of this non-catalytic residue play a role in increasing 50% inhibitory concentrations (IC50 concentrations) for clinically important beta-lactamase enzyme inhibitors. Two distinct phenotypes are evident in the variant beta-lactamases studied: significantly increased minimum inhibitory concentrations (mug/ml) and IC50 concentrations to clavulanic acid for the Met69Ile, Leu, and Val substitutions, and unanticipated increased minimum inhibitory concentrations and hydrolytic activity toward ceftazidime, an advanced generation cephalosporin antibiotic, for the Met69Lys, Tyr- and Phe-substituted enzymes. Molecular modeling studies emphasize the conserved structure of these substitutions despite great variation in substrate specificity. This study demonstrates the key role of Met-69 in defining substrate specificity of SHV beta-lactamases and alerts us to new phenotypes that may emerge clinically.	Case Western Reserve Univ, Sch Med, Louis Stokes Cleveland Vet Affairs Med Ctr, Infect Dis Sect,Res Serv, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Div Infect Dis, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; University Hospitals of Cleveland; Case Western Reserve University	Bonomo, RA (corresponding author), Case Western Reserve Univ, Sch Med, Louis Stokes Cleveland Vet Affairs Med Ctr, Infect Dis Sect,Res Serv, 10701 East Blvd, Cleveland, OH 44106 USA.		Sönnichsen, Frank D/D-8408-2011	Sönnichsen, Frank D/0000-0002-4539-3755				AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; Bevington P. R., 1969, DATA REDUCTION ERROR, P56; BLAZQUEZ J, 1993, ANTIMICROB AGENTS CH, V37, P2059, DOI 10.1128/AAC.37.10.2059; BONOMO RA, 1995, BBA-PROTEIN STRUCT M, V1247, P121, DOI 10.1016/0167-4838(94)00188-M; BRENNER DG, 1984, BIOCHEMISTRY-US, V23, P5833, DOI 10.1021/bi00319a024; Brown RPA, 1996, BIOCHEMISTRY-US, V35, P12421, DOI 10.1021/bi961044g; BUSH K, LAHEY CLIN RESISTANT; Chaibi EB, 1998, BBA-PROTEIN STRUCT M, V1382, P38, DOI 10.1016/S0167-4838(97)00127-1; CHARNAS RL, 1981, BIOCHEMISTRY-US, V20, P3214, DOI 10.1021/bi00514a035; DELAIRE M, 1992, J BIOL CHEM, V267, P20600; Farzaneh S, 1996, ANTIMICROB AGENTS CH, V40, P2434, DOI 10.1128/AAC.40.10.2434; FERSHT A, 1984, ENZYME STRUCTURE MEC, P274; Huang WZ, 1997, P NATL ACAD SCI USA, V94, P8801, DOI 10.1073/pnas.94.16.8801; Hujer AM, 2002, J CLIN MICROBIOL, V40, P1947, DOI 10.1128/JCM.40.6.1947-1957.2002; Hujer AM, 2001, BBA-PROTEIN STRUCT M, V1547, P37, DOI 10.1016/S0167-4838(01)00164-9; HUJER AM, 2002, IN PRESS ANTIMICROB, V46; IMTIAZ U, 1993, J AM CHEM SOC, V115, P4435, DOI 10.1021/ja00064a003; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; Kuzin AP, 1999, BIOCHEMISTRY-US, V38, P5720, DOI 10.1021/bi990136d; Kuzin AP, 2001, BIOCHEMISTRY-US, V40, P1861, DOI 10.1021/bi0022745; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Meroueh SO, 2002, J AM CHEM SOC, V124, P9422, DOI 10.1021/ja026547q; Minasov G, 2002, J AM CHEM SOC, V124, P5333, DOI 10.1021/ja0259640; Page MGF, 2000, DRUG RESIST UPDATE, V3, P109, DOI 10.1054/drup.2000.0137; Powers RA, 2001, BIOCHEMISTRY-US, V40, P9207, DOI 10.1021/bi0109358; Wang XJ, 2002, J BIOL CHEM, V277, P32149, DOI 10.1074/jbc.M204212200; Yang Y, 2000, J BIOL CHEM, V275, P26674	27	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47719	47723		10.1074/jbc.M207271200	http://dx.doi.org/10.1074/jbc.M207271200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354765	hybrid			2022-12-27	WOS:000179663700114
J	Andrews, AL; Holloway, JW; Puddicombe, SM; Holgate, ST; Davies, DE				Andrews, AL; Holloway, JW; Puddicombe, SM; Holgate, ST; Davies, DE			Kinetic analysis of the interleukin-13 receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-13 RECEPTOR; FUNCTIONAL COMPONENT; SIGNAL-TRANSDUCTION; ALLERGIC-ASTHMA; ALPHA-2 CHAIN; B-CELLS; CLONING; BINDING; INTERNALIZATION; IDENTIFICATION	Interleukin (IL)-13 is a key cytokine associated with the asthmatic phenotype. It signals via its cognate receptor, a complex of IL-13 receptor alpha1 chain (IL-13Ralpha1) with IL-4Ralpha; however, a second protein, IL-13Ralpha2, also binds IL-13. To determine the binding contributions of the individual components of the IL-13 receptor to IL-13, we have employed surface plasmon resonance and equilibrium binding assays to investigate the ligand binding characteristics of shIL-13Ralpha1, shIL-13Ralpha2, and IL-4Ralpha. shIL-13Ralpha1 bound IL-13 with moderate affinity (K-D = 37.8 +/- 1.8 nm, n = 10), whereas no binding was observed for hIL-4Ralpha. In contrast, shIL-13Ralpha2 produced a high affinity interaction with IL-13 (K-D = 2.49 +/- 0.94 nm n = 10). IL-13Ra2 exhibited the binding characteristics of a negative regulator with a fast association rate and an exceptional slow dissociation rate. Although IL-13 interacted weakly with IL-4Ralpha on its own (K-D > 50 mum), the presence of hIL-4Ra significantly increased the affinity of shIL-13Ralpha1 for IL-13 but had no effect on the binding affinity of IL-13Ralpha2. Detailed kinetic analyses of the binding properties of the heteromeric complexes suggested a sequential mechanism for the binding of IL-13 to its signaling receptor, in which IL-13 first binds to IL-13Ralpha1 and this then recruits IL-4Ralpha to stabilize a high affinity interaction.	Univ Southampton, Southampton Gen Hosp, Sch Med, Infect Inflammat & Repair Div, Southampton SO16 6YD, Hants, England	University of Southampton	Davies, DE (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Med, Infect Inflammat & Repair Div, 97 Tremona Rd, Southampton SO16 6YD, Hants, England.	donnad@soton.ac.uk	Davies, Donna E/H-2993-2012; Holloway, John W/B-5424-2009	Holloway, John W/0000-0001-9998-0464; Davies, Donna/0000-0002-5117-2991				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; BOCHNER BS, 1995, J IMMUNOL, V154, P799; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chomarat P, 1998, Int Rev Immunol, V17, P1, DOI 10.3109/08830189809084486; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; de Vries JE, 1999, J ALLERGY CLIN IMMUN, V103, pS492, DOI 10.1016/S0091-6749(99)70166-1; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673; Kawakami K, 2001, J BIOL CHEM, V276, P25114, DOI 10.1074/jbc.M100936200; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; Murata T, 1998, BLOOD, V91, P3884; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhang JG, 1997, J BIOL CHEM, V272, P9474; ZHOU M, 1993, BIOCHEMISTRY-US, V32, P8193, DOI 10.1021/bi00083a020; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	26	69	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46073	46078		10.1074/jbc.M209560200	http://dx.doi.org/10.1074/jbc.M209560200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12354755	hybrid			2022-12-27	WOS:000179529300049
J	Rosen, K; Shi, W; Calabretta, B; Filmus, J				Rosen, K; Shi, W; Calabretta, B; Filmus, J			Cell detachment triggers p38 mitogen-activated protein kinase-dependent overexpression of Fas ligand - A novel mechanism of anoikis of intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-X-L; MAMMARY-GLAND INVOLUTION; JUN NH2-TERMINAL KINASE; INDUCED APOPTOSIS; DOWN-REGULATION; EXTRACELLULAR-MATRIX; CD95 FAS/APO-1; IN-VITRO; KI-RAS; DEATH	Many cell types undergo apoptosis when they are detached from the extracellular matrix (ECM). This phenomenon has been termed anoikis. Most epithelial cells, which are normally attached to a type of ECM called basement membrane, are particularly sensitive to anoikis. Conversely, carcinoma cells tend to be resistant to anoikis, and this resistance plays a critical role in tumor invasion and metastasis. We reported previously that detachment-induced down-regulation of the antiapoptotic molecule Bel-X, makes a significant contribution to anoikis of intestinal epithelial cells. Here we demonstrate that exogenous Bcl-X-L, no matter how highly expressed in these cells, can significantly attenuate anoikis but cannot completely prevent it, suggesting that at least another pro-apoptotic event is activated by the loss of cell-ECM contacts. Indeed, in this study we identified a novel mechanism of anoikis in intestinal epithelial cells that involves detachment-induced overexpression of Fas ligand. We also demonstrated that this elevation in Fas ligand expression requires a detachment-induced increase of p38 mitogen-activated protein kinase activity. We conclude that the activation of at least two different pro-apoptotic events is required for anoikis of intestinal epithelial cells.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M4N 3M5, Canada; Jefferson Med Coll, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Jefferson University	Filmus, J (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, 2075 Bayview Ave,S211, Toronto, ON M4N 3M5, Canada.			Rosen, Kirill/0000-0002-4317-9907				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cinatl J, 2000, J IMMUNOL, V165, P4405, DOI 10.4049/jimmunol.165.8.4405; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Dai CH, 1998, BLOOD, V91, P1235, DOI 10.1182/blood.V91.4.1235; Dermitzaki E, 2002, J BIOL CHEM, V277, P12280, DOI 10.1074/jbc.M111236200; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Frankel A, 2001, CANCER RES, V61, P4837; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Grossmann J, 1998, AM J PHYSIOL-GASTR L, V274, pG1117, DOI 10.1152/ajpgi.1998.274.6.G1117; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Ikeda H, 1998, GUT, V42, P530, DOI 10.1136/gut.42.4.530; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Krestow JK, 1999, BIOCHEM BIOPH RES CO, V260, P48, DOI 10.1006/bbrc.1999.0863; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li L, 2002, J BIOL CHEM, V277, P5977, DOI 10.1074/jbc.M111131200; Li SC, 2002, J BIOL CHEM, V277, P26912, DOI 10.1074/jbc.M200726200; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MEREDITH JE, 1997, TRENDS CELL BIOL, V7, P147; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Nagata S, 1999, NAT CELL BIOL, V1, pE143, DOI 10.1038/14094; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Ruemmele FM, 2002, BIOCHEM BIOPH RES CO, V290, P1308, DOI 10.1006/bbrc.2002.6348; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; SCAFFIDI CSCAF, 2001, J BIOL CHEM, V274, P22532; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Sevignani C, 1998, J CLIN INVEST, V101, P1572, DOI 10.1172/JCI919; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; STRANGE R, 1992, DEVELOPMENT, V115, P49; Strater J, 1996, GASTROENTEROLOGY, V110, P1776, DOI 10.1053/gast.1996.v110.pm8964403; SUX XM, 2002, J BIOL CHEM, V277, P11345; Tinhofer I, 1998, BLOOD, V91, P4273, DOI 10.1182/blood.V91.11.4273.411k25_4273_4281; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 2001, TRENDS BIOCHEM SCI, V26, P452, DOI 10.1016/S0968-0004(01)01895-3; Wang J, 2000, J CELL SCI, V113, P753; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wiesen J, 2000, MOL REPROD DEV, V56, P534, DOI 10.1002/1098-2795(200008)56:4&lt;534::AID-MRD12&gt;3.0.CO;2-O; Zhang J, 2000, J EXP MED, V191, P1017, DOI 10.1084/jem.191.6.1017	63	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46123	46130		10.1074/jbc.M207883200	http://dx.doi.org/10.1074/jbc.M207883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12356751	hybrid			2022-12-27	WOS:000179529300056
J	Tojo, M; Matsuzaki, K; Minami, T; Honda, Y; Yasuda, H; Chiba, T; Saya, H; Fujii-Kuriyama, Y; Nakao, M				Tojo, M; Matsuzaki, K; Minami, T; Honda, Y; Yasuda, H; Chiba, T; Saya, H; Fujii-Kuriyama, Y; Nakao, M			The aryl hydrocarbon receptor nuclear transporter is modulated by the SUMO-1 conjugation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; HYPOXIA-INDUCIBLE FACTOR-1; COVALENT MODIFICATION; DNA-BINDING; INTRACELLULAR-LOCALIZATION; ANDROGEN RECEPTOR; MODIFIER-1 SUMO-1; DIOXIN RECEPTOR; TRANSCRIPTION; ACTIVATION	The aryl hydrocarbon receptor nuclear transporter (ARNT) is a member of the basic helix-loop-helix/PAS (Per-ARNT-Sim) family of transcription factors, which are important for cell regulation in response to environmental conditions. ARNT is an indispensable partner of the aryl hydrocarbon receptor (AHR) or hypoxia-inducible factor-1alpha. This protein is also able to form homodimers such as ARNT/ARNT. However, the molecular mechanism that regulates the transcriptional activity of ARNT remains to be elucidated. Here, we report that ARNT is modified by SUMO-1 chiefly at Lys(245) within the PAS domain of this protein, both in vivo and in vitro. Substitution of the target lysine with alanine enhanced the transcriptional potential of ARNT per se. Furthermore, green fluorescent protein-fused ARNT tended to form nuclear foci in similar to20% of the transfected cells, and the foci partly colocalized with PML nuclear bodies. PML, one of the well known substrates for sumoylation, was found to augment the transcriptional activities of ARNT. ARNT bound AHR or PML, whereas the sumoylated form of ARNT associated with AHR, but not with PML, resulting in a reduced effect of PML on transactivation by ARNT. Our data suggest that the sumoylation of ARNT modulates its transcriptional role through affecting the ability of ARNT to interact with cooperative molecules such as PML. This exemplifies a crucial role of protein sumoylation in modulating protein-protein interactions.	Kumamoto Univ, Dept Regenerat Med, Inst Mol Embryol & Genet, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Sakyo Ku, Hachioji, Tokyo 6068507, Japan; Tohoku Univ, Grad Sch Sci, Dept Chem, Aoba Ku, Sendai, Miyagi 9808578, Japan	Kumamoto University; Kumamoto University; Kyoto University; Tokyo University of Pharmacy & Life Sciences; Tohoku University	Nakao, M (corresponding author), Kumamoto Univ, Dept Regenerat Med, Inst Mol Embryol & Genet, 2-2-1 Honjo, Kumamoto 8600811, Japan.	mnakao@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013					Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Chakrabarti SR, 1999, P NATL ACAD SCI USA, V96, P7467, DOI 10.1073/pnas.96.13.7467; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Duprez E, 1999, J CELL SCI, V112, P381; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Gonzalez FJ, 1998, DRUG METAB DISPOS, V26, P1194; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; HATTA M, 2001, SCI STKE; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Huffman JL, 2001, J BIOL CHEM, V276, P40537, DOI 10.1074/jbc.M105675200; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Ko HSP, 1996, MOL CELL BIOL, V16, P430; Kobayashi A, 1996, J BIOL CHEM, V271, P12310, DOI 10.1074/jbc.271.21.12310; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kurtzman AL, 2001, P NATL ACAD SCI USA, V98, P5602, DOI 10.1073/pnas.101129698; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Ma Q, 2000, J BIOL CHEM, V275, P8432, DOI 10.1074/jbc.275.12.8432; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pongratz I, 1998, MOL CELL BIOL, V18, P4079, DOI 10.1128/MCB.18.7.4079; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Rowlands JC, 1997, CRIT REV TOXICOL, V27, P109, DOI 10.3109/10408449709021615; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Salomon-Nguyen F, 2000, P NATL ACAD SCI USA, V97, P6757, DOI 10.1073/pnas.120162297; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; Sogawa K, 1998, P NATL ACAD SCI USA, V95, P7368, DOI 10.1073/pnas.95.13.7368; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Wang F, 1999, BIOCHEMISTRY-US, V38, P11490, DOI 10.1021/bi982578f; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wilson VG, 2001, EXP CELL RES, V271, P57, DOI 10.1006/excr.2001.5366; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	63	56	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46576	46585		10.1074/jbc.M205987200	http://dx.doi.org/10.1074/jbc.M205987200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12354770	hybrid			2022-12-27	WOS:000179529300113
J	Xiong, YM; Haas, TA; Zhang, L				Xiong, YM; Haas, TA; Zhang, L			Identification of functional segments within the beta I-2-domain of integrin alpha(M)beta(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL INHIBITORY FACTOR; I-DOMAIN; LIGAND-BINDING; CRYSTAL-STRUCTURE; CD18 SUBUNIT; A-DOMAIN; RECOGNITION; CD11B/CD18; RECEPTOR; SITE	The alpha(M)beta(2) integrin plays an important role in leukocyte biology through its interactions with a diverse set of ligands. Efficient ligand binding requires the involvement of both the alpha(M) and beta(2) subunits. Past ligand binding studies have focused mainly on the alpha(M) subunit, with the beta(2) subunit being largely unexplored. Therefore, in this study we conducted homolog-scanning mutagenesis on the 1-domain (residues 125-385) within the beta(2) subunit. We identified four noncontiguous sequences (Arg(144)-Lys(148), Gln(199)-Ala(203), Leu(225)-Leu(230), and Gly(305)-His(309)) that are critical for fibrinogen and C3bi binding to alpha(M)beta(2). modeling revealed that these four sequences reside within a narrow region on the surface of the beta(2)I-domain, in close proximity to three potential cation-binding sites. Among these sequences, Gln(199)-Ala(203), Leu(225)-Leu(230), and Gly(305-)His(309) are important for the binding of both ligands, whereas Arg(144)-Lys(148) is more critical for fibrinogen than for C3bi binding. These sequences within the beta(2)I-domain are directly involved in ligand binding, since 1) switching these segments to their corresponding beta(1) sequences destroyed ligand binding; 2) loss of function was not due to a nonspecific gross conformational change, since the defective alpha(M)beta(2) mutants reacted well with a panel of conformation-dependent mAbs; 3) mutation of these functional sequences did not effect Ca2+ binding; and 4) synthetic peptides corresponding to sequences Gln(199)-Ala(203) and Gly(305)-His(309) blocked ligand binding to alpha(M)beta(2), and the peptides interacted directly with fibrinogen and C3bi. Given the similarity among all integrin beta subunits, our results may help us to understand the underlying mechanism of integrin-ligand interactions in general.	Amer Red Cross, Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA; Cleveland Clin Fdn, Dept Mol Cardiol, Cleveland, OH 44195 USA	American Red Cross; Cleveland Clinic Foundation	Zhang, L (corresponding author), Amer Red Cross, Holland Lab, Dept Vasc Biol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.				NHLBI NIH HHS [R01 HL61589-01, P01 HL054710, R01 HL061589] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710, R01HL061589] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alonso JL, 2002, CURR BIOL, V12, pR340, DOI 10.1016/S0960-9822(02)00852-7; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BAJT ML, 1992, J BIOL CHEM, V267, P3789; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Forsyth CB, 1998, J IMMUNOL, V161, P6198; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOYLE M, 1994, J BIOL CHEM, V269, P10008; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; ROSS GD, 1985, J IMMUNOL, V134, P3307; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Ugarova TP, 1998, J BIOL CHEM, V273, P22519, DOI 10.1074/jbc.273.35.22519; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Xiong YM, 2001, J BIOL CHEM, V276, P19340, DOI 10.1074/jbc.M008903200; Zhang L, 1999, BIOCHEMISTRY-US, V38, P8064, DOI 10.1021/bi990141h; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211	26	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46639	46644		10.1074/jbc.M207971200	http://dx.doi.org/10.1074/jbc.M207971200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324470	hybrid			2022-12-27	WOS:000179529300121
J	Biswas, TK; Getz, GS				Biswas, TK; Getz, GS			Import of yeast mitochondrial transcription factor (Mtf1p) via a nonconventional pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL TARGETING SIGNAL; OUTER-MEMBRANE PROTEIN; RNA-POLYMERASE; SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; SPECIFICITY FACTOR; ADENYLATE KINASE; GENE-EXPRESSION; OXIDASE SUBUNIT; INNER MEMBRANE	The yeast mitochondrial (mt) transcription factor Mtf1p is imported into the mitochondria from the cytoplasm without a conventional mt-targeting presequence. To understand its import the mt translocation. of wild type and mutant Mtf1p constructs was investigated in vitro under various assay conditions. We report here that Mtf1p, unlike most mt matrix proteins hitherto studied, is translocated into the mitochondria independent of membrane potential, ATP hydrolysis, and membrane receptor. This unusual import of Mtf1p was also observed on ice (3 degreesC). Sub-mitochondrial fractionation demonstrated that Mtf1p was translocated in vitro to one or more of the same mt sites as the endogenous protein that includes the matrix. To identify the mt-targeting sequence of Mtf1p, various N-terminal, C-terminal, or internally deleted Mtf1p derivatives were generated. The full-length and C-terminal deletions but not the N-terminal truncated Mtf1p were imported into mitochondria, indicating the importance of its N-terminal sequence for mt targeting. However, the internal deletion of Mtf1p revealed that the first 150-amino acid N-terminal sequence alone was not sufficient for mt targeting of Mtf1p, suggesting that an extended rather than a short N-terminal sequence is required for import. We favor a model in which Mtf1p adopts an import-competent conformation during translation. Consistent with this model are three findings: most of the protein sequence appears to be required for optimal import, urea denaturation eliminates its import competence, and the import-competent form of the protein is more resistant to tryptic hydrolysis than is the denatured protein. This represents a novel mechanism for mitochondrial protein import.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Biswas, TK (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.							ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; ARAKAWA H, 1987, EMBO J, V6, P1361, DOI 10.1002/j.1460-2075.1987.tb02376.x; Artigues A, 2002, J BIOL CHEM, V277, P25047, DOI 10.1074/jbc.M203474200; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; Bandlow W, 1998, BIOCHEM J, V329, P359, DOI 10.1042/bj3290359; Bauer MF, 2001, J INHERIT METAB DIS, V24, P166, DOI 10.1023/A:1010314900814; BISWAS TK, 1987, J BIOL CHEM, V262, P13690; Biswas TK, 1998, GENE, V212, P305, DOI 10.1016/S0378-1119(98)00133-4; BOHNI PC, 1983, J BIOL CHEM, V258, P4937; Brunner M., 1994, SIGNAL PEPTIDASES, P73; CHRISTIANSON T, 1983, J BIOL CHEM, V258, P4025; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; CYR DM, 1991, J BIOL CHEM, V266, P21700; DAUM G, 1982, J BIOL CHEM, V257, P3028; DeLabre ML, 1999, FEBS LETT, V449, P201, DOI 10.1016/S0014-5793(99)00415-9; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Diekert K, 1999, P NATL ACAD SCI USA, V96, P11752, DOI 10.1073/pnas.96.21.11752; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; Glick BS, 1995, METHOD ENZYMOL, V260, P224, DOI 10.1016/0076-6879(95)60140-6; GRIVELL LA, 1995, CRIT REV BIOCHEM MOL, V30, P121, DOI 10.3109/10409239509085141; Hajek P, 1997, MOL CELL BIOL, V17, P7169, DOI 10.1128/MCB.17.12.7169; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; HOLLENBE.CP, 1970, BIOCHIM BIOPHYS ACTA, V209, P1, DOI 10.1016/0005-2787(70)90655-6; HURT EC, 1985, EMBO J, V4, P3509, DOI 10.1002/j.1460-2075.1985.tb04110.x; Isenman L, 1995, BBA-REV BIOMEMBRANES, V1241, P341, DOI 10.1016/0304-4157(95)00009-7; JANG SH, 1991, J BIOL CHEM, V266, P22671; Jiang N, 2001, J BIOL CHEM, V276, P29218, DOI 10.1074/jbc.M103686200; Kurz M, 1999, MOL BIOL CELL, V10, P2461, DOI 10.1091/mbc.10.7.2461; LAIN B, 1994, J BIOL CHEM, V269, P15588; LAW RHP, 1990, BIOCHIM BIOPHYS ACTA, V1027, P141, DOI 10.1016/0005-2736(90)90077-2; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; LISOWSKY T, 1988, MOL GEN GENET, V214, P218, DOI 10.1007/BF00337714; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; Matouschek A, 2000, EMBO REP, V1, P404, DOI 10.1093/embo-reports/kvd093; MILLER BR, 1991, J CELL BIOL, V112, P833, DOI 10.1083/jcb.112.5.833; Muckel E, 1996, J BIOL CHEM, V271, P23846, DOI 10.1074/jbc.271.39.23846; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NYE SH, 1990, MOL CELL BIOL, V10, P5763, DOI 10.1128/MCB.10.11.5763; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; PFANNER N, 1990, J BIOL CHEM, V265, P16324; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; PFANNER N, 1997, CURR BIOL, V7, P100; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Rodriguez-Cousino N, 1998, J BIOL CHEM, V273, P11527, DOI 10.1074/jbc.273.19.11527; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; SANYAL A, 1995, J BIOL CHEM, V270, P11970, DOI 10.1074/jbc.270.20.11970; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; SCHINKEL AH, 1987, J BIOL CHEM, V262, P12785; SCHRICKER R, 1992, MOL GEN GENET, V233, P363, DOI 10.1007/BF00265432; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; TICHO BS, 1988, J BIOL CHEM, V263, P10096; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; von Heijne G, 1990, CURR OPIN CELL BIOL, V2, P604, DOI 10.1016/0955-0674(90)90100-S; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; WINKLEY CS, 1985, J BIOL CHEM, V260, P4214; ZARA V, 1992, J BIOL CHEM, V267, P12077	67	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45704	45714		10.1074/jbc.M202565200	http://dx.doi.org/10.1074/jbc.M202565200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12270918	hybrid			2022-12-27	WOS:000179404800138
J	Hu, Y; Ippolito, JE; Garabedian, EM; Humphrey, PA; Gordon, JI				Hu, Y; Ippolito, JE; Garabedian, EM; Humphrey, PA; Gordon, JI			Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRADER-WILLI-SYNDROME; BHLH TRANSCRIPTION FACTORS; CHROMOGRANIN-A; DETERMINATION GENES; BINDING PROTEIN; NECDIN GENE; DIFFERENTIATION; GROWTH; EXPRESSION; DECARBOXYLASE	The features and functions of prostatic neuroendocrine (NE) cells remain ill-defined. Neuroendocrine differentiation (NED) in adenocarcinoma of the human prostate (Cap) is associated with more aggressive disease, but the underlying mediators are poorly understood. We examined these issues in transgenic mice that utilize regulatory elements from the cryptdin-2 gene (Defcr2) to express simian virus 40 large T antigen (TAg) in prostatic NE cells. CR2-TAg mice develop prostatic intraepithelial neoplasia at 8 weeks of age, I week after the onset of TAg expression. An invasive phase follows 2-4 weeks later, with lymph node, liver, lung, brain, and bone metastases appearing within 16 weeks. DNA microarray studies revealed 122 mRNAs that were increased greater than or equal to2-fold in duplicate assays of 16-week-old CR2-TAg versus normal prostates. Thirty two transcripts encode proteins associated with neurons and endocrine cells (e.g. basic helix loop helix, SRY-related high mobility group box and sine-oculis homeobox transcription factors, Hu RNA-binding proteins, neuronatin, Racgap1, collapsin response mediator protein-1, synaptotagmin-1, proprotein convertase, and secretogranins). Follow-up studies of candidate mediators and biomarkers of differentiation/growth in the microarray data set involved real time quantitative reverse transcriptase-PCR assays of laser capture microdissected NE cells from CR2-TAg prostates plus liver metastases, and immunohistochemical comparisons of transgenic mouse prostates and 35 human Cap samples. Our findings include (a) expression of the bHLH mouse achaete-scute homolog (mASH1) in normal and CR2-TAg NE cells and foci of NED in human CaP, (b) glutamic, acid decarboxylase and its product (gamma-aminobutyric acid) in neoplastic NE cells juxtaposed next to cohorts of normal gamma-aminobutyric acid receptor expressing secretory cells (a potential route for paracrine interactions between these two epithelial lineages), and (c) aromatic L-amino-acid decarboxylase, but not its dopamine/serotonin products, in CR2-TAg NE cells and NED. These results underscore the value of CR2-TAg mice for characterizing normal NE cell biology and tumorigenesis.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA.	jgordon@molecool.wustl.edu		Hu, Yan Helen/0000-0003-3269-4505	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059129] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59129] Funding Source: Medline; NIGMS NIH HHS [GM08492] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alaiya AA, 1997, INT J CANCER, V73, P678, DOI 10.1002/(SICI)1097-0215(19971127)73:5<678::AID-IJC11>3.0.CO;2-2; Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Bae SK, 2000, DEVELOPMENT, V127, P2933; BALL DW, 1993, P NATL ACAD SCI USA, V90, P5648, DOI 10.1073/pnas.90.12.5648; BENEDUM UM, 1987, EMBO J, V6, P1203, DOI 10.1002/j.1460-2075.1987.tb02355.x; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; BOHRER MH, 1993, VERH DEUT G, V77, P107; BONKHOFF H, 1994, HUM PATHOL, V25, P42, DOI 10.1016/0046-8177(94)90169-4; Borges M, 1997, NATURE, V386, P852, DOI 10.1038/386852a0; BORMANN J, 1988, TRENDS NEUROSCI, V11, P112, DOI 10.1016/0166-2236(88)90156-7; BOSTWICK DG, 1993, HUM PATHOL, V24, P298, DOI 10.1016/0046-8177(93)90041-E; Cardoso C, 1998, HUM MOL GENET, V7, P679, DOI 10.1093/hmg/7.4.679; Casarosa S, 1999, DEVELOPMENT, V126, P525; Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355; Cheung M, 2000, MOL BRAIN RES, V79, P180, DOI 10.1016/S0169-328X(00)00109-1; Cho SH, 1999, SYNAPSE, V34, P135, DOI 10.1002/(SICI)1098-2396(199911)34:2<135::AID-SYN6>3.0.CO;2-H; COHEN RJ, 1990, BRIT J UROL, V66, P405, DOI 10.1111/j.1464-410X.1990.tb14963.x; Collignon J, 1996, DEVELOPMENT, V122, P509; CUELLO AC, 1982, LANCET, V1, P771; DALMAU J, 1992, MEDICINE, V71, P59, DOI 10.1097/00005792-199203000-00001; Darlington DN, 1997, J ENDOCRINOL, V155, P329, DOI 10.1677/joe.0.1550329; delaPompa J, 1997, DEVELOPMENT, V124, P1139; Dema A, 1996, Rom J Morphol Embryol, V42, P83; DISANTAGNESE PA, 1992, HUM PATHOL, V23, P287; DISANTAGNESE PA, 1984, HUM PATHOL, V15, P1034; DOPAZO A, 1993, J MOL NEUROSCI, V4, P225, DOI 10.1007/BF02821554; El Gedaily A, 2001, PROSTATE, V46, P184; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Fode C, 2000, GENE DEV, V14, P67; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; FRIEDRICH B, 1995, PROSTATE, V27, P102, DOI 10.1002/pros.2990270207; Garabedian EM, 1998, P NATL ACAD SCI USA, V95, P15382, DOI 10.1073/pnas.95.26.15382; Gilbert JA, 2000, CLIN CANCER RES, V6, P4365; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Gotter AL, 2000, NAT NEUROSCI, V3, P755, DOI 10.1038/77653; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Gure AO, 2000, P NATL ACAD SCI USA, V97, P4198, DOI 10.1073/pnas.97.8.4198; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; Hooper LV, 2002, METHOD MICROBIOL, V31, P559, DOI 10.1016/S0580-9517(02)31030-4; Huang HP, 2000, MOL CELL BIOL, V20, P3292, DOI 10.1128/MCB.20.9.3292-3307.2000; Ito T, 2000, DEVELOPMENT, V127, P3913; Jay P, 1997, NAT GENET, V17, P357, DOI 10.1038/ng1197-357; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; Jongsma J, 2002, PROSTATE, V50, P203, DOI 10.1002/pros.10049; Kageyama R, 1997, INT J BIOCHEM CELL B, V29, P1389, DOI 10.1016/S1357-2725(97)89968-2; Kikyo N, 1997, DEV BIOL, V190, P66, DOI 10.1006/dbio.1997.8681; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; LAMPRECHT F, 1972, BRAIN RES, V41, P503, DOI 10.1016/0006-8993(72)90525-2; Lanigan TM, 1998, J NEUROBIOL, V34, P126, DOI 10.1002/(SICI)1097-4695(19980205)34:2<126::AID-NEU3>3.0.CO;2-4; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; MacDonald HR, 1997, HUM MOL GENET, V6, P1873, DOI 10.1093/hmg/6.11.1873; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Maillard M, 2001, J CLIN PATHOL-MOL PA, V54, P275, DOI 10.1136/mp.54.4.275; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; MARTINERIE C, 1992, ONCOGENE, V7, P2529; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; Masumori N, 2001, CANCER RES, V61, P2239; Millevoi S, 2001, EUR J BIOCHEM, V268, P781, DOI 10.1046/j.1432-1327.2001.01934.x; NAGATSU T, 1985, BIOCHEM MED METAB B, V34, P52, DOI 10.1016/0006-2944(85)90061-4; Nakada Y, 1998, GENE, V213, P65, DOI 10.1016/S0378-1119(98)00206-6; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Newey SE, 2001, MOL CELL NEUROSCI, V17, P127, DOI 10.1006/mcne.2000.0918; Ng J, 2002, NATURE, V416, P442, DOI 10.1038/416442a; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; OCONNOR DT, 1986, NEW ENGL J MED, V314, P1145, DOI 10.1056/NEJM198605013141803; Ohto H, 1998, INT J DEV BIOL, V42, P141; OMALLEY KL, 1995, J NEUROCHEM, V65, P2409; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Raynal JF, 1998, MOL BRAIN RES, V56, P227, DOI 10.1016/S0169-328X(98)00048-5; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Seidah NG, 1999, ANN NY ACAD SCI, V885, P57; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; Speights VO, 1997, BRIT J UROL, V80, P281, DOI 10.1046/j.1464-410X.1997.00359.x; Stappenbeck TS, 2002, METHOD ENZYMOL, V356, P167; Thambisetty MR, 2001, J NEURO-OPHTHALMOL, V21, P164, DOI 10.1097/00041327-200109000-00002; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; TILLAKARATNE NJK, 1995, COMP BIOCHEM PHYS A, V112, P247, DOI 10.1016/0300-9629(95)00099-2; Tomita K, 1996, GENES CELLS, V1, P765, DOI 10.1111/j.1365-2443.1996.tb00016.x; Toure A, 1998, J BIOL CHEM, V273, P6019, DOI 10.1074/jbc.273.11.6019; VANDENBERG C, 1995, CLIN CANCER RES, V1, P11; Vos MD, 1996, J CELL BIOCHEM, P257; Wang HY, 2002, J BIOL CHEM, V277, P17564, DOI 10.1074/jbc.M111037200; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; Yamamoto N, 2001, J BIOL CHEM, V276, P45031, DOI 10.1074/jbc.M105245200	89	81	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44462	44474		10.1074/jbc.M205784200	http://dx.doi.org/10.1074/jbc.M205784200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228243	hybrid			2022-12-27	WOS:000179272000118
J	Cheetham, GMT; Knegtel, RMA; Coll, JT; Renwick, SB; Swenson, L; Weber, P; Lippke, JA; Austen, DA				Cheetham, GMT; Knegtel, RMA; Coll, JT; Renwick, SB; Swenson, L; Weber, P; Lippke, JA; Austen, DA			Crystal structure of aurora-2, an oncogenic serine/threonine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROTEIN-KINASE; CHROMOSOME SEGREGATION; CATALYTIC SUBUNIT; COMPLEX; FAMILY; PHOSPHORYLATION; SPINDLE; DOMAIN; EXPRESSION; INHIBITORS	Aurora-2 is a key member of a closely related subgroup of serine/threonine kinases that plays important roles in the completion of essential mitotic events. Aurora-2 is oncogenic and amplified in various human cancers and could be an important therapeutic target for inhibitory molecules that would disrupt the cell cycle and block proliferation. We report the first crystal structure of Aurora-2 kinase in complex with adenosine. Analysis of residues in the active site suggests differences with structurally and biologically related protein kinases. The activation loop, which contains residues specific to the Aurora family of kinases, has a unique conformation. These results provide valuable insight into the design of selective and highly potent ATP-competitive inhibitors of the Aurora kinases.	Vertex Pharmaceut Europe Ltd, Abingdon OX14 4RY, Oxon, England; Vertex Pharmaceut Inc, Cambridge, MA 02139 USA	Vertex Pharmaceuticals; Vertex Pharmaceuticals	Cheetham, GMT (corresponding author), Vertex Pharmaceut Europe Ltd, 88 Milton Pk, Abingdon OX14 4RY, Oxon, England.	cheetham@vpharm.com						Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bicher A, 1997, GYNECOL ONCOL, V66, P36, DOI 10.1006/gyno.1997.4709; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; BRUNGER AT, 1991, ACTA CRYSTALLOGR A, V47, P195, DOI 10.1107/S0108767390011795; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, CURR OPIN STRUC BIOL, V8, P606, DOI 10.1016/S0959-440X(98)80152-8; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Fox T, 1998, PROTEIN SCI, V7, P2249, DOI 10.1002/pro.5560071102; Garcia-Echeverria C, 2000, MED RES REV, V20, P28, DOI 10.1002/(SICI)1098-1128(200001)20:1<28::AID-MED2>3.3.CO;2-U; Giet R, 1999, J CELL SCI, V112, P3591; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Goepfert TM, 2000, CURR TOP DEV BIOL, V49, P331; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hoglund M, 1998, GENE CHROMOSOME CANC, V21, P8; Kaitna S, 2000, CURR BIOL, V10, P1172, DOI 10.1016/S0960-9822(00)00721-1; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Lamers MBAC, 1999, J MOL BIOL, V285, P713, DOI 10.1006/jmbi.1998.2369; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Narayana N, 1997, BIOCHEMISTRY-US, V36, P4438, DOI 10.1021/bi961947+; Nigg EA, 1996, EXP CELL RES, V229, P174, DOI 10.1006/excr.1996.0356; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sondhi D, 1999, BIOCHEMISTRY-US, V38, P11147, DOI 10.1021/bi990827+; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tereshko V, 2001, NAT STRUCT BIOL, V8, P899, DOI 10.1038/nsb1001-899; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5	39	147	163	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42419	42422		10.1074/jbc.C200426200	http://dx.doi.org/10.1074/jbc.C200426200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12237287	hybrid			2022-12-27	WOS:000179081200001
J	Srivastava, M; Frolova, E; Rottinghaus, B; Boe, SP; Grinberg, A; Lee, E; Love, PE; Pfeifer, K				Srivastava, M; Frolova, E; Rottinghaus, B; Boe, SP; Grinberg, A; Lee, E; Love, PE; Pfeifer, K			Imprint control element-mediated secondary methylation imprints at the Igf2/H19 locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BECKWITH-WIEDEMANN-SYNDROME; MOUSE H19 GENE; DNA METHYLATION; MONOALLELIC EXPRESSION; H19/IGF2 LOCUS; DELETION; REGION; MECHANISMS; UPSTREAM; ALLELE	Understanding the molecular basis of monoallelic expression as observed at imprinted loci is helpful in understanding the mechanisms underlying epigenetic regulation. Genomic imprinting begins during gametogenesis with the establishment of epigenetic marks on the chromosomes such that paternal and maternal chromosomes are rendered distinct. During embryonic development, the primary imprint can lead to generation of secondary epigenetic modifications (secondary imprints) of the chromosomes. Eventually, either the primary imprints or the secondary imprints interfere with transcription, leading to parent-of-origin-dependent silencing of one of the two alleles. Here we investigated several aspects pertaining to the generation and functional necessity of secondary methylation imprints at the Igf2/H19 locus. At the H19 locus, these secondary imprints are, in fact, the signals mediating paternal chromosome-specific silencing of that gene. We first demonstrated that the H19 secondary methylation imprints are entirely stable through multiple cell divisions, even in the absence of the primary imprint. Second, we generated mouse mutations to determine which DNA sequences are important in mediating establishment and maintenance of the silent state of the paternal H19 allele. Finally, we analyzed the dependence of the methylation of Igf2DMR1 region on the primary methylation imprint about 90 kilobases away.	NICHD, Lab Mammalian Genes & Dev, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Srivastava, M (corresponding author), Natl Inst Immunol, Aruna Asaf Ali Rd, New Delhi 110067, India.	madhus@nii.res.in	Srivastava, Madhulika/M-8941-2019	Srivastava, Madhulika/0000-0002-0997-013X; Pfeifer, Karl/0000-0002-0254-682X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001804, ZIAHD001803] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001804, Z01HD001803] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; Constancia M, 2000, NAT GENET, V26, P203, DOI 10.1038/79930; Cranston MJ, 2001, GENOMICS, V73, P98, DOI 10.1006/geno.2001.6514; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; Eden S, 2001, EMBO J, V20, P3518, DOI 10.1093/emboj/20.13.3518; FEIL R, 1994, DEVELOPMENT, V120, P2933; Feng CG, 2002, INT IMMUNOL, V14, P535, DOI 10.1093/intimm/dxf020; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; Forejt J, 1999, EXP CELL RES, V252, P416, DOI 10.1006/excr.1999.4627; Forne T, 1997, P NATL ACAD SCI USA, V94, P10243, DOI 10.1073/pnas.94.19.10243; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; Kaffer CR, 2000, GENE DEV, V14, P1908; Kaffer CR, 2001, MOL CELL BIOL, V21, P8189, DOI 10.1128/MCB.21.23.8189-8196.2001; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; LaSalle JM, 1996, SCIENCE, V272, P725, DOI 10.1126/science.272.5262.725; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LOVE PE, 1994, J EXP MED, V179, P1485, DOI 10.1084/jem.179.5.1485; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; Milligan L, 2000, ONCOGENE, V19, P5810, DOI 10.1038/sj.onc.1203965; OHLSSON R, 1994, DEVELOPMENT, V120, P361; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; Parish CR, 1999, IMMUNOL CELL BIOL, V77, P499, DOI 10.1046/j.1440-1711.1999.00877.x; Paulsen M, 2000, HUM MOL GENET, V9, P1829, DOI 10.1093/hmg/9.12.1829; Paulsen M, 1998, HUM MOL GENET, V7, P1149, DOI 10.1093/hmg/7.7.1149; Pfeifer K, 1996, P NATL ACAD SCI USA, V93, P13876, DOI 10.1073/pnas.93.24.13876; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Reik W, 1996, Int J Dev Biol, VSuppl 1, p53S; Ripoche MA, 1997, GENE DEV, V11, P1596, DOI 10.1101/gad.11.12.1596; Rougier N, 1998, GENE DEV, V12, P2108, DOI 10.1101/gad.12.14.2108; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; Srivastava M, 2000, GENE DEV, V14, P1186; Sun FL, 1997, NATURE, V389, P809, DOI 10.1038/39797; Szabo PE, 1995, GENE DEV, V9, P3097, DOI 10.1101/gad.9.24.3097; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; Warnecke PM, 1998, GENOMICS, V51, P182, DOI 10.1006/geno.1998.5371; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702	44	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5977	5983		10.1074/jbc.M208437200	http://dx.doi.org/10.1074/jbc.M208437200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12270940	hybrid			2022-12-27	WOS:000181129400062
J	Liao, H; Bucala, R; Mitchell, RA				Liao, H; Bucala, R; Mitchell, RA			Adhesion-dependent signaling by macrophage migration inhibitory factor (MIF)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INTEGRIN-MEDIATED ACTIVATION; CYCLIN D1 EXPRESSION; MODULATE AP-1 ACTIVITY; CELL-PROLIFERATION; REGULATORY ROLE; FACTOR GENE; MAP KINASE; G1 PHASE; C-SRC	Proper stimulation of cell cycle progression and DNA synthesis requires cooperating signals from integrin and growth factor receptors. We previously found that the proinflammatory peptide, macrophage migration inhibitory factor (MIF), functions as an autocrine mediator of growth factor-dependent ERK MAP kinase activation and cell cycle progression. We now report that MIF secretion is induced by cell adhesion to fibronectin in quiescent mouse fibroblasts. Adhesion-mediated release of MIF subsequently promotes integrin-dependent activation of MAP kinase, cyclin D1 expression, and DNA synthesis. Secretion of MIF requires protein kinase C activity, and recombinant MIF reconstitutes the activation of MAP kinases in the presence of protein kinase C inhibition. Finally, we show that cells deficient in MIF have significantly higher retinoblastoma tumor suppressor and lower E2F transcriptional activities. These results suggest that MIF is an important autocrine mediator of adhesion-dependent signaling events and may provide mechanistic insight into how MIF regulates proliferative and oncogenic processes.	Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA; N Shore Long Isl Jewish Hlth Syst, Manhasset, NY 11030 USA; Yale Univ, Sch Med, New Haven, CT 06520 USA	University of Louisville; Northwell Health; Yale University	Mitchell, RA (corresponding author), Univ Louisville, James Graham Brown Canc Ctr, 529 S Jackson St, Louisville, KY 40292 USA.				NIAMS NIH HHS [1R01-AR049610] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049610] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Albanell J, 2001, CANCER RES, V61, P6500; Arteaga CL, 2001, CURR OPIN ONCOL, V13, P491, DOI 10.1097/00001622-200111000-00012; Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Berman A E, 2000, Membr Cell Biol, V13, P207; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Busche S, 2001, ENDOCRINOLOGY, V142, P4623, DOI 10.1210/en.142.11.4623; Calandra T, 1998, P NATL ACAD SCI USA, V95, P11383, DOI 10.1073/pnas.95.19.11383; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; Honma N, 2000, IMMUNOLOGY, V100, P84, DOI 10.1046/j.1365-2567.2000.00011.x; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Inoue H, 1996, VIROLOGY, V225, P223, DOI 10.1006/viro.1996.0591; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Kurzrock R, 2001, BIOMED PHARMACOTHER, V55, P543, DOI 10.1016/S0753-3322(01)00140-8; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lin TH, 1997, J BIOL CHEM, V272, P8849; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Ogawa H, 2000, CYTOKINE, V12, P309, DOI 10.1006/cyto.1999.0562; Petrenko O, 1999, IMMUNITY, V10, P691, DOI 10.1016/S1074-7613(00)80068-0; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Rossi AG, 1998, J CLIN INVEST, V101, P2869, DOI 10.1172/JCI1524; Sah JF, 2002, J BIOL CHEM, V277, P9728, DOI 10.1074/jbc.M110897200; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Watarai H, 2000, P NATL ACAD SCI USA, V97, P13251, DOI 10.1073/pnas.230445397; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	45	55	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					76	81		10.1074/jbc.M208820200	http://dx.doi.org/10.1074/jbc.M208820200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12297513	hybrid			2022-12-27	WOS:000180255700010
J	Capitani, G; McCarthy, DL; Gut, H; Grutter, MG; Kirsch, JF				Capitani, G; McCarthy, DL; Gut, H; Grutter, MG; Kirsch, JF			Apple 1-aminocyclopropane-1-carboxylate synthase in complex with the inhibitor L-aminoethoxyvinylglycine - Evidence for a ketimine intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MUTANT FORMS; WILD-TYPE; ENZYME; BIOSYNTHESIS; ETHYLENE	The 1.6-Angstrom crystal structure of the covalent ketimine complex of apple 1-aminocyclopropane-1-carboxylate (ACC) synthase with the potent inhibitor L-aminoethoxyvinylglycine (AVG) is described. ACC synthase catalyzes the committed step in the biosynthesis of ethylene, a plant hormone that is responsible for the initiation of fruit ripening and for regulating many other developmental processes. AVG is widely used in plant physiology studies to inhibit the activity of ACC synthase. The structural assignment is supported by the fact that the complex absorbs maximally at 341 nm. These results are not in accord with the recently reported crystal structure of the tomato ACC synthase AVG complex, which claims that the inhibitor only associates noncovalently. The rate constant for the association of AVG with apple ACC synthase was determined by stopped-flow spectrophotometry (2.1 X 10(5) M-1 s(-1)) and by the rate of loss of enzyme activity (1.1 X 10(5) M-1 s(-1)). The dissociation rate constant determined by activity recovery is 2.4 x 10(-6) s(-1). Thus, the calculated K-d value is 10-20 pM.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of Zurich; University of California System; University of California Berkeley	Capitani, G (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035393] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35393] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Capitani G, 1999, J MOL BIOL, V294, P745, DOI 10.1006/jmbi.1999.3255; Clausen T, 1997, BIOCHEMISTRY-US, V36, P12633, DOI 10.1021/bi970630m; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Feng L, 2000, BIOCHEMISTRY-US, V39, P2436, DOI 10.1021/bi9922704; Goldberg JM, 1996, BIOCHEMISTRY-US, V35, P5280, DOI 10.1021/bi952138d; Hayward S, 1997, PROTEINS, V27, P425, DOI 10.1002/(SICI)1097-0134(199703)27:3<425::AID-PROT10>3.0.CO;2-N; HOOFT RW, 1997, NATURE, V381, P272; Huai Q, 2001, J BIOL CHEM, V276, P38210; ICEKSON I, 1983, BIOCHEM BIOPH RES CO, V113, P586, DOI 10.1016/0006-291X(83)91766-7; JONES SA, 1995, J AM SOC NEPHROL, V5, P1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Krupka HI, 2000, EMBO J, V19, P3168, DOI 10.1093/emboj/19.13.3168; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li YS, 1997, BIOCHEMISTRY-US, V36, P15477, DOI 10.1021/bi971625l; McCarthy DL, 2001, BIOCHEMISTRY-US, V40, P12276, DOI 10.1021/bi011050z; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WHITE MF, 1994, P NATL ACAD SCI USA, V91, P12428, DOI 10.1073/pnas.91.26.12428; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103	22	43	47	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49735	49742		10.1074/jbc.M208427200	http://dx.doi.org/10.1074/jbc.M208427200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12228256	hybrid			2022-12-27	WOS:000180028900084
J	Martinez, R; Gomes, FCA				Martinez, R; Gomes, FCA			Neuritogenesis induced by thyroid hormone-treated astrocytes is mediated by epidermal growth factor/mitogen-activated protein kinase-phosphatidylinositol 3-kinase pathways and involves modulation of extracellular matrix proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR; REGULATES FIBRONECTIN; GENE-EXPRESSION; CROSS-TALK; BRAIN; NEURONS; LAMININ; CEREBELLUM; TRANSACTIVATION; HYPOTHYROIDISM	Thyroid hormone (T3) plays a crucial role in several steps of cerebellar ontogenesis. By using a neuron-astrocyte coculture model, we have investigated the effects of T3-treated astrocytes on cerebellar neuronal differentiation in vitro. Neurons plated onto T3-astrocytes presented a 40-60% increase on the total neurite length and an increment in the number of neurites. Treatment of astrocytes with epidermal growth factor (EGF) yielded similar results, suggesting that this growth factor might mediate T3-induced neuritogenesis. EGF and T3 treatment increased fibronectin and laminin expression by astrocytes, suggesting that astrocyte neurite permissiveness induced by these treatments is mostly due to modulation of extracellular matrix (ECM) components. Such increase in ECM protein expression as well as astrocyte permissiveness to neurite outgrowth was reversed by the specific EGF receptor tyrosine kinase inhibitor, tyrphostin. Moreover studies using selective inhibitors of several transduction-signaling cascades indicated that modulation of ECM proteins by EGF is mainly through a synergistic activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways. In this work, we provide evidence of a novel role of EGF as an intermediary factor of T3 action on cerebellar ontogenesis. By modulating the content of ECM proteins, EGF increases neurite outgrowth. Our data reveal an important role of astrocytes as mediators of T3-induced cerebellar development and partially elucidate the role of EGF and mitogen-activated protein kinase/phosphatidylinositol 3-kinase pathways on this process.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Anat, Ctr Ciencias Saude, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	Gomes, FCA (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Anat, Ctr Ciencias Saude, Bloco F,Iiha Fundao, BR-21941590 Rio De Janeiro, Brazil.	fgomes@anato.uf.rj.br	Gomes, Flavia/AAX-6354-2021; Gomes, Flavia/C-5383-2013	Gomes, Flavia/0000-0003-2966-0638				Alvarez-Dolado M, 1999, J NEUROSCI, V19, P6979, DOI 10.1523/JNEUROSCI.19-16-06979.1999; Alvarez-Dolado M, 1998, NEUROSCIENCE, V84, P309, DOI 10.1016/S0306-4522(97)00511-3; Anderson GW, 1997, MOL CELL ENDOCRINOL, V131, P79, DOI 10.1016/S0303-7207(97)00095-6; Anderson GW, 2001, FRONT NEUROENDOCRIN, V22, P1, DOI 10.1006/frne.2000.0208; BECK KD, 1993, NEUROSCIENCE, V52, P855, DOI 10.1016/0306-4522(93)90534-M; BERNAL J, 1995, EUR J ENDOCRINOL, V133, P390, DOI 10.1530/eje.0.1330390; BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; Calloni GW, 2001, DEV BRAIN RES, V126, P121, DOI 10.1016/S0165-3806(00)00142-5; Carballada R, 2001, DEVELOPMENT, V128, P35; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Cayrou C, 2002, ENDOCRINOLOGY, V143, P2242, DOI 10.1210/en.143.6.2242; Danielsen AJ, 2002, GROWTH FACTORS, V20, P1, DOI 10.1080/08977190290022185; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Farwell AP, 1999, ENDOCRINOLOGY, V140, P5014, DOI 10.1210/en.140.11.5014; Farwell AP, 1999, ENDOCRINOLOGY, V140, P4221, DOI 10.1210/en.140.9.4221; FIGUEIREDO BC, 1993, MOL BRAIN RES, V17, P258, DOI 10.1016/0169-328X(93)90010-M; Forrest D, 2002, CURR OPIN NEUROBIOL, V12, P49, DOI 10.1016/S0959-4388(02)00289-1; Freire E, 2002, J CELL SCI, V115, P4867, DOI 10.1242/jcs.00173; Fricker-Gates RA, 2000, EXP NEUROL, V165, P237, DOI 10.1006/exnr.2000.7482; Garcia-Segura LM, 1999, J NEUROBIOL, V40, P574, DOI 10.1002/(SICI)1097-4695(19990915)40:4<574::AID-NEU12>3.0.CO;2-8; GARCIAABREU J, 1995, NEUROREPORT, V6, P761, DOI 10.1097/00001756-199503270-00014; Gomes F C, 2001, Prog Brain Res, V132, P41; Gomes FCA, 1999, GLIA, V26, P97; Gomes FCA, 2001, BRAZ J MED BIOL RES, V34, P611, DOI 10.1590/S0100-879X2001000500008; Gomes FCA, 1999, GLIA, V25, P247, DOI 10.1002/(SICI)1098-1136(19990201)25:3<247::AID-GLIA5>3.0.CO;2-2; Kaiura TL, 1999, J SURG RES, V84, P212, DOI 10.1006/jsre.1999.5646; Kim J, 2002, J BIOL CHEM, V277, P32116, DOI 10.1074/jbc.M204895200; Koibuchi N, 1999, ENDOCRINOLOGY, V140, P3955, DOI 10.1210/en.140.9.3955; Komuro H, 2001, J NEUROSCI, V21, P527, DOI 10.1523/JNEUROSCI.21-02-00527.2001; Kornblum HI, 1997, J COMP NEUROL, V380, P243, DOI 10.1002/(SICI)1096-9861(19970407)380:2<243::AID-CNE7>3.0.CO;2-3; Lima FRS, 1998, INT J DEV NEUROSCI, V16, P19, DOI 10.1016/S0736-5748(98)00002-1; Lima FRS, 2001, J NEUROSCI, V21, P2028, DOI 10.1523/JNEUROSCI.21-06-02028.2001; Lindholm D, 1997, PERSPECT DEV NEUROBI, V5, P83; Matsubara H, 2000, MOL CELL BIOCHEM, V212, P187, DOI 10.1023/A:1007189828584; Menet V, 2001, J NEUROSCI, V21, P6147; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; Moriguchi Y, 1999, CIRC RES, V84, P1073, DOI 10.1161/01.RES.84.9.1073; Morte B, 2002, P NATL ACAD SCI USA, V99, P3985, DOI 10.1073/pnas.062413299; Neveu I, 1996, J CELL BIOL, V133, P631, DOI 10.1083/jcb.133.3.631; NICHOLSO.JL, 1972, BRAIN RES, V44, P13, DOI 10.1016/0006-8993(72)90362-9; Ono Y, 2002, CANCER LETT, V175, P197, DOI 10.1016/S0304-3835(01)00682-6; Palu E, 2002, J NEUROSCI RES, V69, P243, DOI 10.1002/jnr.10292; Potter GB, 2001, J NEUROSCI, V21, P4373, DOI 10.1523/JNEUROSCI.21-12-04373.2001; Rescan C, 2001, MOL BIOL CELL, V12, P725, DOI 10.1091/mbc.12.3.725; SEROOGY KB, 1995, BRAIN RES, V670, P157, DOI 10.1016/0006-8993(94)01300-7; TRENTIN AG, 1995, NEUROREPORT, V6, P293, DOI 10.1097/00001756-199501000-00017; Trentin AG, 2001, AM J PHYSIOL-ENDOC M, V281, pE1088, DOI 10.1152/ajpendo.2001.281.5.E1088; Yamada M, 1997, PROG NEUROBIOL, V51, P19, DOI 10.1016/S0301-0082(96)00046-9; Yart A, 2002, BBA-MOL CELL BIOL L, V1582, P107, DOI 10.1016/S1388-1981(02)00144-0; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Yu CF, 2002, J BIOL CHEM, V277, P19382, DOI 10.1074/jbc.M200732200	52	87	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49311	49318		10.1074/jbc.M209284200	http://dx.doi.org/10.1074/jbc.M209284200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12356760	hybrid			2022-12-27	WOS:000180028900027
J	Kasparkova, J; Zehnulova, J; Farrell, N; Brabec, V				Kasparkova, J; Zehnulova, J; Farrell, N; Brabec, V			DNA interstrand cross-links of the novel antitumor trinuclear platinum complex BBR3464 - Conformation, recognition by high mobility group domain proteins, and nucleotide excision	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CISPLATIN-DAMAGED DNA; DIETHYL PYROCARBONATE; CHEMICAL-REACTIVITY; BBR 3464; PHASE-I; REPAIR; BINDING; HMG1; TRANS-DIAMMINEDICHLOROPLATINUM(II); CIS-DIAMMINEDICHLOROPLATINUM(II)	The novel phase II antitumor polynuclear platinum drug BBR3464 ([(trans-PtCl(NH3)(2))(2)(mu-trans-Pt(NH3)(2)(NH2(CH2)(6)NH2)(2))](NO3)(4)) forms intra- and interstrand cross-links (CLs) on DNA (which is the pharmacological target of platinum drugs). We examined first in our recent work how various intrastrand CLs of BBR3464 affect the conformation of DNA and its recognition by cellular components (Zehnulova, J., Kasparkova, J., Farrell, N., and Brabec, V. (2001) J. Biol. Chem. 276, 22191-22199). In the present work, we have extended the studies on the DNA interstrand CLs of this drug. The results have revealed that the interstrand CLs are preferentially formed between guanine residues separated by 2 base pairs in both the 3' --> 3' and 5' --> 5' directions. The major 1,4-interstrand CLs distort DNA, inducing a directional bending of the helix axis and local unwinding of the duplex. Although such distortions represent a potential structural motif for recognition by high mobility group proteins, these proteins do not recognize 1,4-interstrand CLs of BBR3464. On the other hand, in contrast to intrastrand adducts of BBR3464, 1,4-interstrand CLs are not removed from DNA by nucleotide excision repair. It has been suggested that interstrand CLs of BBR3464 could persist considerably longer in cells compared with intrastrand adducts, which would potentiate the toxicity of the interstrand lesions to tumors sensitive to this polynuclear drug.	Virginia Commonwealth Univ, Dept Chem, Richmond, VA 23284 USA; Acad Sci Czech Republ, Inst Biophys, CZ-61265 Brno, Czech Republic	Virginia Commonwealth University; Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences	Farrell, N (corresponding author), Virginia Commonwealth Univ, Dept Chem, Box 2006, Richmond, VA 23284 USA.	nafrrell@mail1.vcu.edu	Brabec, Viktor/H-1946-2014	Brabec, Viktor/0000-0002-8233-1393				BAILLY C, 1994, BIOCHEM J, V300, P165, DOI 10.1042/bj3000165; BAILLY C, 1997, DRUG DNA INTERACTION, P51; BELLON SF, 1990, BIOPHYS CHEM, V35, P179, DOI 10.1016/0301-4622(90)80007-T; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BRABEC V, 1993, P NATL ACAD SCI USA, V90, P5345, DOI 10.1073/pnas.90.11.5345; BRABEC V, 1993, BIOCHEMISTRY-US, V32, P11676, DOI 10.1021/bi00094a025; Brabec V, 2000, CANC DRUG DISC DEV, V7, P37; Brabec V, 2000, J BIOL INORG CHEM, V5, P364, DOI 10.1007/PL00010665; Brabec V, 1999, BIOCHEMISTRY-US, V38, P6781, DOI 10.1021/bi990124s; BRABEC V, 1992, BIOCHEMISTRY-US, V31, P12397, DOI 10.1021/bi00164a014; Brabec V, 2002, PROG NUCLEIC ACID RE, V71, P1, DOI 10.1016/S0079-6603(02)71040-4; Buschta-Hedayat N, 1999, P NATL ACAD SCI USA, V96, P6090, DOI 10.1073/pnas.96.11.6090; CALVERT AH, 2001, EUR C CLIN ONC OCT 2; Calvert PM, 1999, CLIN CANCER RES, V5, p3796S; Cohen SM, 2000, BIOCHEMISTRY-US, V39, P11771, DOI 10.1021/bi001352l; COMESS KM, 1990, BIOCHEMISTRY-US, V29, P2102, DOI 10.1021/bi00460a020; Coste F, 1999, NUCLEIC ACIDS RES, V27, P1837, DOI 10.1093/nar/27.8.1837; DALBIES R, 1994, P NATL ACAD SCI USA, V91, P8147, DOI 10.1073/pnas.91.17.8147; Farrell N, 2000, CANC DRUG DISC DEV, V7, P321; FARRELL N, 1999, CISPLATIN CHEM BIOCH, P479; He Q, 2000, P NATL ACAD SCI USA, V97, P5768, DOI 10.1073/pnas.100108697; He Q, 2000, BIOCHEMISTRY-US, V39, P14426, DOI 10.1021/bi001700j; Hermanson-Miller IL, 2002, BIOCHEMISTRY-US, V41, P2402, DOI 10.1021/bi0112863; HERR W, 1985, P NATL ACAD SCI USA, V82, P8009, DOI 10.1073/pnas.82.23.8009; HUANG HF, 1995, SCIENCE, V270, P1842, DOI 10.1126/science.270.5243.1842; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; JONES SL, 1994, INT J CANCER, V59, P388, DOI 10.1002/ijc.2910590317; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P1, DOI 10.1016/s0027-5107(01)00142-7; KASPARKOVA J, 1995, BIOCHEMISTRY-US, V34, P12379, DOI 10.1021/bi00038a035; Kasparkova J, 1996, BIOCHEMISTRY-US, V35, P16705, DOI 10.1021/bi961160j; Kasparkova J, 1999, BIOCHEMISTRY-US, V38, P10997, DOI 10.1021/bi990245s; Kasparkova J, 2000, J BIOL CHEM, V275, P15789, DOI 10.1074/jbc.M000777200; Koberle B, 1999, CURR BIOL, V9, P273, DOI 10.1016/S0960-9822(99)80118-3; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; LEMAIRE MA, 1991, P NATL ACAD SCI USA, V88, P1982, DOI 10.1073/pnas.88.5.1982; LENG M, 1990, BIOPHYS CHEM, V35, P155, DOI 10.1016/0301-4622(90)80005-R; Li MJ, 1999, INT J ONCOL, V15, P1177; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MALINGE JM, 1994, NUCLEIC ACIDS RES, V22, P3834, DOI 10.1093/nar/22.19.3834; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; Manzotti C, 2000, CLIN CANCER RES, V6, P2626; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; MCCARTHY JG, 1991, NUCLEIC ACIDS RES, V19, P3421, DOI 10.1093/nar/19.12.3421; MCCARTHY JG, 1990, BIOCHEMISTRY-US, V29, P6071, DOI 10.1021/bi00477a027; Missura M, 2001, EMBO J, V20, P3554, DOI 10.1093/emboj/20.13.3554; Moggs JG, 1997, NUCLEIC ACIDS RES, V25, P480, DOI 10.1093/nar/25.3.480; Naegeli H., 1997, MECH DNA DAMAGE RECO; Nielsen P E, 1990, J Mol Recognit, V3, P1, DOI 10.1002/jmr.300030102; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Patrick SM, 1999, J BIOL CHEM, V274, P14972, DOI 10.1074/jbc.274.21.14972; Perego P, 1999, J INORG BIOCHEM, V77, P59, DOI 10.1016/S0162-0134(99)00142-7; QU Y, 2002, IN PRESS J BIOL INOR; Reardon JT, 1999, CANCER RES, V59, P3968; REARDON JT, 1998, ADV DNA DAMAGE REPAI, P377; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; RICE JA, 1988, P NATL ACAD SCI USA, V85, P4158, DOI 10.1073/pnas.85.12.4158; Roberts JD, 1999, J INORG BIOCHEM, V77, P51, DOI 10.1016/S0162-0134(99)00147-6; Ross SA, 1996, NUCLEIC ACIDS RES, V24, P5062, DOI 10.1093/nar/24.24.5062; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCAGLIOTTI G, 2001, EUR C CLIN ONC OCT 2; Sessa C, 2000, ANN ONCOL, V11, P977, DOI 10.1023/A:1008302309734; Stros M, 1998, J BIOL CHEM, V273, P10355; Stros M, 2001, BIOCHEMISTRY-US, V40, P4769, DOI 10.1021/bi002741i; Vrana O, 1996, NUCLEIC ACIDS RES, V24, P3918, DOI 10.1093/nar/24.20.3918; Wakasugi M, 1999, J BIOL CHEM, V274, P18759, DOI 10.1074/jbc.274.26.18759; WANG JC, 1979, P NATL ACAD SCI USA, V76, P200, DOI 10.1073/pnas.76.1.200; WEMER MH, 1995, CELL, V81, P705; Wood RD, 2000, COLD SPRING HARB SYM, V65, P173, DOI 10.1101/sqb.2000.65.173; Zamble DB, 1996, BIOCHEMISTRY-US, V35, P10004, DOI 10.1021/bi960453+; ZAMBLE DB, 1999, CISPLATIN CHEM BIOCH, P73; Zehnulova J, 2001, J BIOL CHEM, V276, P22191, DOI 10.1074/jbc.M103118200; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0; Zlatanova J, 1998, FASEB J, V12, P791, DOI 10.1096/fasebj.12.10.791	76	153	153	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48076	48086		10.1074/jbc.M208016200	http://dx.doi.org/10.1074/jbc.M208016200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12226099	hybrid			2022-12-27	WOS:000179789600015
J	Imasato, A; Desbois-Mouthon, C; Han, JH; Kai, H; Cato, ACB; Akira, S; Li, JD				Imasato, A; Desbois-Mouthon, C; Han, JH; Kai, H; Cato, ACB; Akira, S; Li, JD			Inhibition of p38 MAPK by glucocorticoids via induction of MAPK phosphatase-1 enhances nontypeable Haemophilus influenzae-induced expression of toll-like receptor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; SIGNAL-TRANSDUCTION; IMMUNE FUNCTION; GENE-REGULATION; KINASE PATHWAY; ACTIVATION; TRANSCRIPTION; MECHANISMS; PROTEINS; INNATE	Despite the importance of glucocorticoids in suppressing immune and inflammatory responses, their role in enhancing host immune and defense response against invading bacteria is poorly understood. We have demonstrated recently that glucocorticoids synergistically enhance nontypeable Haemophilus influenzae (NTHi)-induced expression of Toll-like receptor 2 (TLR2), an important TLR family member that has been shown to play a critical role in host immune and defense response. However, the molecular mechanisms underlying the glucocorticoid-mediated enhancement of TLR2 induction still remain unknown. Here we show that glucocorticoids synergistically enhance NTHi-induced TLR2 expression via specific up-regulation of the MAPK phosphatase-1 (MKP-1) that, in turn, leads to dephosphorylation and inactivation of p38 MAPK, the negative regulator for TLR2 expression. Moreover, increased expression of TLR2 in epithelial cells greatly enhances the NTHi-induced expression of several key cytokines, including tumor necrosis factor-a and interleukins 1beta and 8, thereby contributing significantly to host immune and defense response. These studies may bring new insights into the novel role of glucocorticoids in orchestrating and optimizing host immune and defense responses during bacterial infections and enhance our understanding of the signaling mechanisms underlying the glucocorticoid-mediated attenuation of MAPKs.	Univ So Calif, House Ear Inst, Gonda Dept Cell & Mol Biol, Los Angeles, CA 90057 USA; Univ So Calif, Dept Otolaryngol, Los Angeles, CA 90057 USA; Univ Paris 06, INSERM, U402, F-75571 Paris, France; The Scripps Res Inst, Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Kumamoto Univ, Dept Mol Med, Kumamoto 8620973, Japan; Forschungszentrum Karlsruhe, Inst Toxicol & Genet, D-76021 Karlsruhe, Germany; Osaka Univ, Microbial Dis Res Inst, Dept Host Def,Japan Sci & Technol Corp, Core Res Evolutional Sci & Technol, Suita, Osaka 5650871, Japan	House Research Institute; University of Southern California; University of Southern California; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Scripps Research Institute; Kumamoto University; Helmholtz Association; Karlsruhe Institute of Technology; Japan Science & Technology Agency (JST); Osaka University	Li, JD (corresponding author), Univ So Calif, House Ear Inst, Gonda Dept Cell & Mol Biol, 2100 W 3rd St, Los Angeles, CA 90057 USA.	jdli@hei.org	Han, J/G-4671-2010; Akira, Shizuo/C-3134-2009; Desbois-Mouthon, Christele/M-7076-2017; Cato, Andrew C. B./H-2071-2013	Desbois-Mouthon, Christele/0000-0002-0772-1711; Cato, Andrew C. B./0000-0001-8508-3834; Li, Jian-Dong/0000-0002-5593-050X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004562] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41637] Funding Source: Medline; NIDCD NIH HHS [DC04562] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; Butler CC, 2001, ARCH PEDIAT ADOL MED, V155, P641, DOI 10.1001/archpedi.155.6.641; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Haehnel V, 2002, J IMMUNOL, V168, P5629, DOI 10.4049/jimmunol.168.11.5629; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Krutzik SR, 2001, CURR OPIN IMMUNOL, V13, P104, DOI 10.1016/S0952-7915(00)00189-8; Kusuhara M, 1998, CIRC RES, V83, P824, DOI 10.1161/01.RES.83.8.824; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; Means TK, 2000, LIFE SCI, V68, P241, DOI 10.1016/S0024-3205(00)00939-5; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Niewoehner DE, 1999, NEW ENGL J MED, V340, P1941, DOI 10.1056/NEJM199906243402502; O'Neill LAJ, 2000, IMMUNOL TODAY, V21, P206, DOI 10.1016/S0167-5699(00)01611-X; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Quagliarello VJ, 1997, NEW ENGL J MED, V336, P708, DOI 10.1056/NEJM199703063361007; Shuto T, 2002, J BIOL CHEM, V277, P17263, DOI 10.1074/jbc.M112190200; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Tanaka K, 1998, J CELL PHYSIOL, V176, P235, DOI 10.1002/(SICI)1097-4652(199808)176:2<235::AID-JCP2>3.0.CO;2-P; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Wang BN, 2002, J BIOL CHEM, V277, P949, DOI 10.1074/jbc.M107484200; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Webster JC, 1999, TRENDS ENDOCRIN MET, V10, P396, DOI 10.1016/S1043-2760(99)00186-1; Wilckens T, 1997, IMMUNOL TODAY, V18, P418, DOI 10.1016/S0167-5699(97)01111-0; WILCKENS T, 1995, TRENDS PHARMACOL SCI, V16, P193, DOI 10.1016/S0165-6147(00)89021-5	36	114	120	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47444	47450		10.1074/jbc.M208140200	http://dx.doi.org/10.1074/jbc.M208140200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356755	hybrid			2022-12-27	WOS:000179663700080
J	Latz, E; Visintin, A; Lien, E; Fitzgerald, KA; Monks, BG; Kurt-Jones, EA; Golenbock, DT; Espevik, T				Latz, E; Visintin, A; Lien, E; Fitzgerald, KA; Monks, BG; Kurt-Jones, EA; Golenbock, DT; Espevik, T			Lipopolysaccharide rapidly traffics to and from the golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL LIPOPOLYSACCHARIDE; IMMUNE-RESPONSE; INNATE IMMUNITY; CUTTING EDGE; CELL-SURFACE; LPS GENE; PROTEIN; MD-2; INTERNALIZATION; SEPSIS	Mammalian responses to LPS require the expression of Toll-like receptor 4 (TLR4), CD14, and MD-2. We expressed fluorescent TLR4 in cell lines and found that TLR4 densely localized to the surface and the Golgi. Similar distributions were observed in human monocytes. Confocal imaging revealed rapid recycling of TLR4-CD14-MD-2 complexes between the Golgi and the plasma membrane. Fluorescent LPS followed these trafficking pathways in CD14-positive cells. The TLR4-adapter protein, MyD88, translocated to the cell surface upon LPS exposure, and cross-linking of surface TLR4 with antibody induced signaling. Golgi-associated TLR4 expression was disrupted by brefeldin A, yet LPS signaling was preserved. We conclude that LPS signaling may be initiated by surface aggregation of TLR4 and is not dependent upon LPS trafficking to the Golgi.	Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, N-7489 Trondheim, Norway; Univ Massachusetts, Sch Med, Div Infect Dis, Worcester, MA 01605 USA	Norwegian University of Science & Technology (NTNU); University of Massachusetts System; University of Massachusetts Worcester	Espevik, T (corresponding author), Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, N-7489 Trondheim, Norway.		Monks, Brian/B-8362-2015; Latz, Eicke/H-3951-2014; Fitzgerald, Katherine/ABE-6317-2020	Monks, Brian/0000-0003-4008-3093; Latz, Eicke/0000-0003-1488-5666; Fitzgerald, Kate/0000-0003-3175-609X	NIDDK NIH HHS [DK50305] Funding Source: Medline; NIGMS NIH HHS [GM63244, GM54060] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM054060, R01GM063244, R01GM054060] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BRUNBUISSON C, 1995, JAMA-J AM MED ASSOC, V274, P968, DOI 10.1001/jama.274.12.968; CDC, 1990, JAMA-J AM MED ASSOC, V263, P937; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Cowan DB, 2001, CIRC RES, V88, P491, DOI 10.1161/01.RES.88.5.491; Du X, 2000, EUR CYTOKINE NETW, V11, P362; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788; Hoshino K, 1999, J IMMUNOL, V162, P3749; Ingalls RR, 1997, J IMMUNOL, V159, P433; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Lippincott-Schwartz J, 2001, HISTOCHEM CELL BIOL, V116, P97; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Muzio M, 2000, J LEUKOCYTE BIOL, V67, P450, DOI 10.1002/jlb.67.4.450; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; OBRIEN AD, 1980, J IMMUNOL, V124, P20; Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Poussin C, 1998, J BIOL CHEM, V273, P20285, DOI 10.1074/jbc.273.32.20285; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sands KE, 1997, JAMA-J AM MED ASSOC, V278, P234, DOI 10.1001/jama.278.3.234; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Thieblemont N, 1998, IMMUNITY, V8, P771, DOI 10.1016/S1074-7613(00)80582-8; Thieblemont N, 1999, J EXP MED, V190, P523, DOI 10.1084/jem.190.4.523; Triantafilou M, 2002, J CELL SCI, V115, P2603; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Vasselon T, 1999, J EXP MED, V190, P509, DOI 10.1084/jem.190.4.509; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Visintin A, 2001, P NATL ACAD SCI USA, V98, P12156, DOI 10.1073/pnas.211445098; Ward TH, 2001, J CELL BIOL, V155, P557, DOI 10.1083/jcb.200107045; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200	42	358	375	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47834	47843		10.1074/jbc.M207873200	http://dx.doi.org/10.1074/jbc.M207873200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12324469	hybrid			2022-12-27	WOS:000179663700129
J	Tewari, R; Spaccapelo, R; Bistoni, F; Holder, AA; Crisanti, A				Tewari, R; Spaccapelo, R; Bistoni, F; Holder, AA; Crisanti, A			Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; MALARIA PARASITES; PROTECTIVE ANTIGEN; SALIVARY-GLANDS; THROMBOSPONDIN; BINDING; TRAP; INVASION; BERGHEI; HEPATOCYTES	The circumsporozoite protein of Plasmodium falciparum contains two conserved motifs (regions I and II) that have been proposed to interact with mosquito and vertebrate host molecules in the process of sporozoite invasion of salivary glands and hepatocytes, respectively. To study the function of this protein we have replaced the endogenous circumsporozoite protein gene of Plasmodium berghei with that of P. falciparum and with versions lacking either region I or region II. We show here that P. falciparum circumsporozoite protein functions in rodent parasite and that P. berghei sporozoites carrying the P. falciparum CS gene develop normally, are motile, invade mosquito salivary glands, and infect the vertebrate host. Region I-deficient sporozoites showed no impairment of motility or infectivity in either vector or vertebrate host. Disruption of region II abolished sporozoite motility and dramatically impaired their ability to invade mosquito salivary glands and infect the vertebrate host. These data shed new light on the role of the CS protein in sporozoite motility and infectivity.	Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England; Univ Perugia, Dept Expt Med, I-06100 Perugia, Italy; Natl Inst Med Res, Div Parasitol, London NW7 1AA, England	Imperial College London; University of Perugia; MRC National Institute for Medical Research	Crisanti, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England.	acrs@ic.ac.uk	Holder, Anthony A/A-7554-2013; Tewari, Rita/M-5698-2014	Holder, Anthony A/0000-0002-8490-6058; Spaccapelo, Roberta/0000-0003-2100-6172; Crisanti, Andrea/0000-0002-2406-4426; Tewari, Rita/0000-0003-3943-1847	MRC [MC_U117532067] Funding Source: UKRI; Medical Research Council [MC_U117532067] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adams JC, 2000, DEV DYNAM, V218, P280; Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; AIKAWA M, 1981, J IMMUNOL, V126, P2494; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; Gantt SM, 1997, J BIOL CHEM, V272, P19205, DOI 10.1074/jbc.272.31.19205; Gobron S, 1996, J CELL SCI, V109, P1053; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; HOLDER AA, 1988, PARASITOLOGY, V97, P373, DOI 10.1017/S0031182000058790; Kuno K, 1997, GENOMICS, V46, P466, DOI 10.1006/geno.1997.5064; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; McCutchan TF, 1996, P NATL ACAD SCI USA, V93, P11889, DOI 10.1073/pnas.93.21.11889; Menard R, 1997, NATURE, V385, P336, DOI 10.1038/385336a0; Morrissette NS, 2002, MICROBIOL MOL BIOL R, V66, P21, DOI 10.1128/MMBR.66.1.21-38.2002; Nunes A, 1999, MOL CELL BIOL, V19, P2895; Nussenzweig RS, 1997, NEW ENGL J MED, V336, P128, DOI 10.1056/NEJM199701093360210; NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283, DOI 10.1016/S0065-2776(08)60695-1; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; Pinzon-Ortiz C, 2001, J BIOL CHEM, V276, P26784, DOI 10.1074/jbc.M104038200; Rathore D, 2002, J BIOL CHEM, V277, P7092, DOI 10.1074/jbc.M106862200; Rathore D, 2001, BIOCHEMISTRY-US, V40, P11518, DOI 10.1021/bi0105476; ROBSON KJH, 1995, EMBO J, V14, P3883, DOI 10.1002/j.1460-2075.1995.tb00060.x; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; Rostand KS, 1997, INFECT IMMUN, V65, P1; Sidjanski SP, 1997, MOL BIOCHEM PARASIT, V90, P33, DOI 10.1016/S0166-6851(97)00124-2; SINNIS P, 1994, J EXP MED, V180, P297, DOI 10.1084/jem.180.1.297; Sinnis P, 1997, TRENDS MICROBIOL, V5, P52, DOI 10.1016/S0966-842X(97)84657-4; Spaccapelo R, 1997, LANCET, V350, P335, DOI 10.1016/S0140-6736(97)24031-6; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; VANDERBERG JP, 1975, J PARASITOL, V61, P43, DOI 10.2307/3279102; Waters AP, 1997, METHODS, V13, P134, DOI 10.1006/meth.1997.0506; Wengelnik K, 1999, EMBO J, V18, P5195, DOI 10.1093/emboj/18.19.5195; Ying P, 1997, EXP PARASITOL, V85, P168, DOI 10.1006/expr.1996.4134; YOSHIDA N, 1981, J EXP MED, V154, P1225, DOI 10.1084/jem.154.4.1225; YOSHIDA N, 1980, SCIENCE, V207, P71, DOI 10.1126/science.6985745	36	92	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47613	47618		10.1074/jbc.M208453200	http://dx.doi.org/10.1074/jbc.M208453200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12244064	hybrid			2022-12-27	WOS:000179663700101
J	Hormaeche, I; Alkorta, I; Moro, F; Valpuesta, JM; Goni, FM; de la Cruz, F				Hormaeche, I; Alkorta, I; Moro, F; Valpuesta, JM; Goni, FM; de la Cruz, F			Purification and properties of TrwB, a hexameric, ATP-binding integral membrane protein essential for R388 plasmid conjugation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE P-GLYCOPROTEIN; IV SECRETION SYSTEM; NUCLEOTIDE-BINDING; ESCHERICHIA-COLI; BACTERIAL CONJUGATION; DNA TRANSFER; ADENOSINE 5'-TRIPHOSPHATE; COUPLING PROTEIN; BETA-SUBUNIT; SITE	TrwB is an integral membrane protein linking the relaxosome to the DNA transport apparatus in plasmid R388 conjugation. Native TrwB has been purified in monomeric and hexameric forms, in the presence of dodecylmaltoside from overexpressing bacterial cells. A truncated protein (TrwBDeltaN70) that lacked the transmembrane domain could be purified only in the monomeric form. Electron microscopy images revealed the hexameric structure and were in fact superimposable to the previously published atomic structure for TrwBDeltaN70. In addition, the electron micrographs showed an appendix, similar to25 Angstrom wide, corresponding to the transmembrane region of TrwB. TrwB was located in the bacterial inner membrane in agreement with its proposed coupling role. Purified TrwB hexamers and monomers bound tightly the fluorescent ATP analogue TNP-ATP. A mutant in the Walker A motif, TrwB-K136T, was equally purified and found to bind TNP-ATP with a similar affinity to that of the wild type. However, the TNP-ATP affinity of TrwBDeltaN70 was significantly reduced in comparison with the TrwB hexamers. Competition experiments in which ATP was used to displace TNP-ATP gave an estimate of ATP binding by TrwB (K-d(ATP) = 0.48 mm for hexamers). The transmembrane domain appears to be involved in TrwB protein hexamerization and also influences its nucleotide binding properties.	Univ Basque Country, Unidad Biofis, Ctr Mixto, CSIC, E-48080 Bilbao, Spain; Univ Basque Country, Euskal Herriko Unibertsitatea, Dept Bioquim, E-48080 Bilbao, Spain; Univ Autonoma Madrid, Ctr Nacl Biotecnol, CSIC, E-28049 Madrid, Spain; Univ Cantabria, Dept Biol Mol, Unidad Asociada, Ctr Invest Biol,CSIC, Santander 39011, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Universidad de Cantabria	Goni, FM (corresponding author), Univ Basque Country, Unidad Biofis, Ctr Mixto, CSIC, Apdo 644, E-48080 Bilbao, Spain.	gbpgourf@lg.ehu.es	Alkorta, Itziar/N-4374-2014; Goni, Felix M/M-5425-2015; Valpuesta, Jose M/AAA-6002-2019; Valpuesta, José M/T-1977-2017; Alkorta, Itziar/Y-6267-2019; Moro Pérez, Fernando/P-3891-2015; de la Cruz, Fernando/L-2812-2014	Alkorta, Itziar/0000-0002-1976-8904; Goni, Felix M/0000-0001-6270-9216; Valpuesta, José M/0000-0001-7468-8053; Moro Pérez, Fernando/0000-0002-3568-3388; de la Cruz, Fernando/0000-0003-4758-6857; ALCORTA CALVO, MIREN ITZIAR/0000-0001-6978-389X				Avila P, 1996, J MOL BIOL, V261, P135, DOI 10.1006/jmbi.1996.0447; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BAUBICHONCORTAY H, 1994, J BIOL CHEM, V269, P22983; BOLLAND S, 1990, J BACTERIOL, V172, P5795, DOI 10.1128/jb.172.10.5795-5802.1990; Cabezon E, 1997, MOL GEN GENET, V254, P400, DOI 10.1007/s004380050432; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cho YK, 2001, J BIOL CHEM, V276, P12573, DOI 10.1074/jbc.M011478200; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; Conseil G, 1998, P NATL ACAD SCI USA, V95, P9831, DOI 10.1073/pnas.95.17.9831; DATTA N, 1972, J GEN MICROBIOL, V72, P349, DOI 10.1099/00221287-72-2-349; DELACRUZ F, 1982, J BACTERIOL, V151, P223; DIVITA G, 1993, J BIOL CHEM, V268, P13178; DUPONT Y, 1982, BIOCHEM BIOPH RES CO, V106, P1272, DOI 10.1016/0006-291X(82)91250-5; GARBOCZI DN, 1988, J BIOL CHEM, V263, P812; Gomis-Ruth FX, 2002, J BIOL CHEM, V277, P7556, DOI 10.1074/jbc.M110462200; Gomis-Ruth FX, 2001, NATURE, V409, P637, DOI 10.1038/35054586; GRANDOSO G, 1994, EUR J BIOCHEM, V226, P403, DOI 10.1111/j.1432-1033.1994.tb20065.x; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; LANKA E, 1995, ANNU REV BIOCHEM, V64, P141, DOI 10.1146/annurev.bi.64.070195.001041; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; LLOSA M, 1994, J MOL BIOL, V235, P448, DOI 10.1006/jmbi.1994.1005; Llosa M, 2002, MOL MICROBIOL, V45, P1, DOI 10.1046/j.1365-2958.2002.03014.x; LLOSA M, 1995, J MOL BIOL, V246, P54, DOI 10.1006/jmbi.1994.0065; LLOSA M, 1994, J BACTERIOL, V176, P3210, DOI 10.1128/jb.176.11.3210-3217.1994; Lu NT, 2000, ARCH BIOCHEM BIOPHYS, V375, P7, DOI 10.1006/abbi.1999.1656; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Marco S, 1996, ULTRAMICROSCOPY, V66, P5, DOI 10.1016/S0304-3991(96)00083-6; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Mitterauer T, 1999, BIOCHEM J, V342, P33, DOI 10.1042/0264-6021:3420033; Moncalian G, 1999, J BIOL CHEM, V274, P36117, DOI 10.1074/jbc.274.51.36117; Moncalian G, 1997, J MOL BIOL, V270, P188, DOI 10.1006/jmbi.1997.1082; Moncalian G, 1999, MOL MICROBIOL, V31, P1643, DOI 10.1046/j.1365-2958.1999.01288.x; Osborn M J, 1974, Methods Enzymol, V31, P642; PANICKER MM, 1992, J BIOL CHEM, V267, P12761; Pansegrau W, 1996, PROG NUCLEIC ACID RE, V54, P197, DOI 10.1016/S0079-6603(08)60364-5; SANDLER JR, 1980, GENE, V8, P279; Santini JM, 1998, J BACTERIOL, V180, P4093, DOI 10.1128/JB.180.16.4093-4101.1998; Schroder G, 2002, J BACTERIOL, V184, P2767, DOI 10.1128/JB.184.10.2767-2779.2002; STEWART GSAB, 1986, PLASMID, V15, P172, DOI 10.1016/0147-619X(86)90035-1; Stewart RC, 1998, BIOCHEMISTRY-US, V37, P12269, DOI 10.1021/bi980970n; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOMAS PJ, 1992, J BIOL CHEM, V267, P20331; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATANABE T, 1982, J BIOL CHEM, V257, P1510; Zechner E. L., 2000, HORIZONTAL GENE POOL, P87	49	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46456	46462		10.1074/jbc.M207250200	http://dx.doi.org/10.1074/jbc.M207250200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244053	hybrid			2022-12-27	WOS:000179529300098
J	Liu, Z; Zhang, J; Li, P; Chen, SRW; Wagenknecht, T				Liu, Z; Zhang, J; Li, P; Chen, SRW; Wagenknecht, T			Three-dimensional reconstruction of the recombinant type 2 ryanodine receptor and localization of its divergent region 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; GREEN FLUORESCENT PROTEIN; POLYMORPHIC VENTRICULAR-TACHYCARDIA; MUSCLE SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; CRYOELECTRON MICROSCOPY; 3-DIMENSIONAL RECONSTRUCTION; MOLECULAR-IDENTIFICATION; FK506-BINDING PROTEIN; ELECTRON-MICROSCOPY	Isoform 2 of the ryanodine receptor (RyR2) is the major calcium release channel in cardiac muscle. In the present study, two kinds of RyR2 cDNA were constructed, one encoding the wild type mouse RyR2 (RyR2(wt)) and the other encoding modified RyR2, into which was inserted a cDNA encoding green fluorescent protein (GFP). GFP was inserted into the divergent region 1 (DR1) of RyR2, after the Asp-4365 (RyR2(D4365-GFP)). HEK293 cells expressing both RyR2(wt) and RYR2D(4365-GFP) cDNAs showed caffeine- and ryanodine-sensitive calcium release, demonstrating that both wild type and modified RyR2s form functional calcium release channels. Cells expressing the fusion protein, RYR2(D4365-GFP), were readily identified by their fluorescence due to the presence of GFP, indicating that the inserted GFP folded properly. Both expressed RyR2s were purified from cell lysates in a single step by affinity chromatography using a GST-FKBP12.6 as the affinity ligand. Cryoelectron microscopy of purified RyR2s showed structurally intact receptors, and three-dimensional reconstructions were obtained by single particle image processing. The three-dimensional reconstruction of RyR2(wt) appeared very similar to that of the native RyR2 purified from dog heart. The location of the inserted GFP, and consequently of DR1, was mapped on the three-dimensidnal structure of RyR2 to one of the subunit's characteristic domains, domain 3, also known as the "handle" domain. This study describes the first internal fusion of a protein into a ryanodine receptor, and it demonstrates the potential of this technology for localizing functional and structural domains on the three-dimensional structure of RyR.	Wadsworth Ctr, New York State Dept Hlth, Albany, NY 12201 USA; Univ Calgary, Dept Physiol & Biophys Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; University of Calgary; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Liu, Z (corresponding author), Wadsworth Ctr, New York State Dept Hlth, Albany, NY 12201 USA.	liuz@wadsworth.org		Liu, Zheng/0000-0001-6952-3406	NIAMS NIH HHS [AR40615] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040615] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ataka K, 2002, BIOPHYS J, V82, P509, DOI 10.1016/S0006-3495(02)75415-5; Balshaw DM, 2002, J MEMBRANE BIOL, V185, P1, DOI 10.1007/s00232-001-0111-4; Benacquista BL, 2000, BIOPHYS J, V78, P1349, DOI 10.1016/S0006-3495(00)76689-6; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; Chen SRW, 2002, BIOPHYS J, V82, P2436, DOI 10.1016/S0006-3495(02)75587-2; Chen SRW, 1998, J BIOL CHEM, V273, P14675, DOI 10.1074/jbc.273.24.14675; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; Doi N, 1999, FEBS LETT, V457, P1, DOI 10.1016/S0014-5793(99)00991-6; Du GG, 1998, J BIOL CHEM, V273, P33259, DOI 10.1074/jbc.273.50.33259; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Frank J., 1996, 3 DIMENSIONAL ELECT, P54; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; Hodel AE, 2002, MOL CELL, V10, P347, DOI 10.1016/S1097-2765(02)00589-0; INUI M, 1987, J BIOL CHEM, V262, P1740; Jeyakumar LH, 1998, J BIOL CHEM, V273, P16011, DOI 10.1074/jbc.273.26.16011; Kratz PA, 1999, P NATL ACAD SCI USA, V96, P1915, DOI 10.1073/pnas.96.5.1915; Laitinen PJ, 2001, CIRCULATION, V103, P485, DOI 10.1161/01.CIR.103.4.485; Li P, 2001, J GEN PHYSIOL, V118, P33, DOI 10.1085/jgp.118.1.33; Liu Z, 2001, P NATL ACAD SCI USA, V98, P6104, DOI 10.1073/pnas.111382798; Mackrill JJ, 1999, BIOCHEM J, V337, P345, DOI 10.1042/0264-6021:3370345; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; Manjunatha B, 1997, J GEN PHYSIOL, V110, P749, DOI 10.1085/jgp.110.6.749; Marks AR, 2001, J MOL CELL CARDIOL, V33, P615, DOI 10.1006/jmcc.2000.1343; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; MICHALAK M, 1988, BIOCHIM BIOPHYS ACTA, V939, P587, DOI 10.1016/0005-2736(88)90106-X; Moore RA, 1998, J CELL BIOL, V140, P843, DOI 10.1083/jcb.140.4.843; Murayama T, 1999, J BIOL CHEM, V274, P17297, DOI 10.1074/jbc.274.24.17297; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; Niwa H, 1996, P NATL ACAD SCI USA, V93, P13617, DOI 10.1073/pnas.93.24.13617; OTSU K, 1990, J BIOL CHEM, V265, P13472; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; Priori SG, 2002, CIRCULATION, V106, P69, DOI 10.1161/01.CIR.0000020013.73106.D8; Priori SG, 2001, CIRCULATION, V103, P196; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; Samso M, 2002, J BIOL CHEM, V277, P1349, DOI 10.1074/jbc.M109196200; Sharma MR, 1998, J BIOL CHEM, V273, P18429, DOI 10.1074/jbc.273.29.18429; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Tiso N, 2001, HUM MOL GENET, V10, P189, DOI 10.1093/hmg/10.3.189; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Wagenknecht T, 1997, J BIOL CHEM, V272, P32463, DOI 10.1074/jbc.272.51.32463; WAGENKNECHT T, 1988, J MOL BIOL, V203, P753, DOI 10.1016/0022-2836(88)90207-0; Wagenknecht T, 1996, BIOPHYS J, V70, P1709, DOI 10.1016/S0006-3495(96)79733-3; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Williams AJ, 2001, Q REV BIOPHYS, V34, P61, DOI 10.1017/S0033583501003675; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	51	54	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46712	46719		10.1074/jbc.M208124200	http://dx.doi.org/10.1074/jbc.M208124200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324472	hybrid			2022-12-27	WOS:000179529300130
J	Lu, HG; Shah, P; Ennis, D; Shinder, G; Sap, J; Le-Tien, H; Fantus, IG				Lu, HG; Shah, P; Ennis, D; Shinder, G; Sap, J; Le-Tien, H; Fantus, IG			The differentiation of skeletal muscle cells involves a protein-tyrosine phosphatase-alpha-mediated C-Src signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PTP-ALPHA; DOWN-REGULATION; NEURONAL DIFFERENTIATION; INSULIN-RECEPTOR; FAMILY KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION FACTOR; C2C12 MYOBLASTS; QUAIL MYOTUBES	Protein-tyrosine phosphatase-alpha (PTPalpha) plays an important role in various cellular signaling events, including proliferation and differentiation. In this study, we established L6 cell lines either underexpressing or overexpressing PTPalpha by stable transfection of cells with antisense PTPalpha or with full-length wild-type human or mouse or double catalytic site Cys --> Ala mutant (DM8) PTPalpha cDNA. Expression of PTPalpha in these cell lines was determined by immunoblotting and immunofluorescence. Cells harboring antisense PTPalpha exhibited a significantly reduced growth rate and thymidine incorporation when compared with the wild-type L6 cells. In contrast, cells overexpressing PTPalpha showed more rapid (2-fold) proliferation. Myoblasts with diminished PTPalpha failed to undergo fusion and did not form myotubes in reduced serum whereas overexpression of PTPalpha promoted myogenesis 2 days earlier than wild-type L6 cells. Overexpression of phosphatase-inactive mutant PTPalpha recapitulated the phenotype of the antisense cells. The different myogenic activities of these cell lines were correlated with the expression of myogenin and creatine kinase activity. Consistent with previous reports, PTPalpha positively regulated the activity of the protein-tyrosine kinase Src. Treatment of L6 cells with PP2 or SU6656, specific inhibitors of Src family kinases, and transient transfection of dominant-inhibitory Src inhibited the formation of myotubes and expression of myogenin. Moreover, enhanced expression of PTPalpha and activation of Src was detected during myogenesis. Together, these data indicate that PTPalpha is involved in the regulation of L6 myoblast growth and skeletal muscle cell differentiation via an Src-mediated signaling pathway.	Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Dept Physiol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Univ Hlth Network, Toronto, ON M5G 1X5, Canada; Univ Toronto, Banting & Best Diabet Ctr, Toronto, ON M5G 1X5, Canada; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; New York University; New York University	Fantus, IG (corresponding author), Mt Sinai Hosp, Dept Med, 600 Univ Ave,Rm 780, Toronto, ON M5G 1X5, Canada.	fantus@mshri.on.ca						ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; Arnott CH, 1999, J BIOL CHEM, V274, P26105, DOI 10.1074/jbc.274.37.26105; BJELFMAN C, 1990, MOL CELL BIOL, V10, P361, DOI 10.1128/MCB.10.1.361; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Buist A, 2000, J BIOL CHEM, V275, P20754, DOI 10.1074/jbc.M001626200; CASTELLANI L, 1995, J CELL BIOL, V130, P871, DOI 10.1083/jcb.130.4.871; Chun YK, 2000, BIOCHEM BIOPH RES CO, V276, P502, DOI 10.1006/bbrc.2000.3486; Conejo R, 2001, J CELL PHYSIOL, V186, P82, DOI 10.1002/1097-4652(200101)186:1<82::AID-JCP1001>3.0.CO;2-R; Cong LN, 1999, BIOCHEM BIOPH RES CO, V255, P200, DOI 10.1006/bbrc.1999.0183; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; DAUM G, 1994, J BIOL CHEM, V269, P10524; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DING W, 1994, BIOCHEM BIOPH RES CO, V202, P902, DOI 10.1006/bbrc.1994.2015; FAIVRESARRAILH C, 1992, J NEUROSCI, V12, P257; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; Galbiati F, 1999, J BIOL CHEM, V274, P30315, DOI 10.1074/jbc.274.42.30315; Galliano MF, 2000, J BIOL CHEM, V275, P13933, DOI 10.1074/jbc.275.18.13933; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Inoue D, 1998, J BIOL CHEM, V273, P4180, DOI 10.1074/jbc.273.7.4180; Jacob KK, 1998, J BIOL CHEM, V273, P4800, DOI 10.1074/jbc.273.8.4800; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; Kang Q, 2000, BIOCHEM J, V352, P883, DOI 10.1042/0264-6021:3520883; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; Lammers R, 1998, BIOCHEM BIOPH RES CO, V242, P32, DOI 10.1006/bbrc.1997.7906; Lammers R, 1997, FEBS LETT, V404, P37, DOI 10.1016/S0014-5793(97)00080-X; Lee KH, 1997, BIOCHEM J, V324, P237, DOI 10.1042/bj3240237; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; McLean GW, 2000, J BIOL CHEM, V275, P23333, DOI 10.1074/jbc.M909322199; Mohamed AS, 1999, J BIOL CHEM, V274, P20529, DOI 10.1074/jbc.274.29.20529; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SCHMIDT JW, 1992, J CELL BIOL, V116, P1019, DOI 10.1083/jcb.116.4.1019; SCHNEIDER MD, 1988, NOL NEUROBIOL, V2, P1; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SU J, 1994, J BIOL CHEM, V269, P18731; TABITI K, 1995, CANCER LETT, V93, P239, DOI 10.1016/0304-3835(95)03816-F; Tamir Y, 2000, J BIOL CHEM, V275, P34424, DOI 10.1074/jbc.M005815200; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TSIANI E, 1995, ENDOCRINOLOGY, V136, P2505, DOI 10.1210/en.136.6.2505; vanInzen WG, 1996, DEV BRAIN RES, V91, P304, DOI 10.1016/0165-3806(95)00186-7; Walchli S, 2000, J BIOL CHEM, V275, P9792, DOI 10.1074/jbc.275.13.9792; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YOON HY, 1994, ONCOGENE, V9, P801; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; ZHENG XM, 1994, J BIOL CHEM, V269, P23302; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZISCH AH, 1995, MOL CELL NEUROSCI, V6, P263, DOI 10.1006/mcne.1995.1021	66	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46687	46695		10.1074/jbc.M209643200	http://dx.doi.org/10.1074/jbc.M209643200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351660	hybrid			2022-12-27	WOS:000179529300127
J	Kim, JS; Krasieva, TB; LaMorte, V; Taylor, AMR; Yokomori, K				Kim, JS; Krasieva, TB; LaMorte, V; Taylor, AMR; Yokomori, K			Specific recruitment of human cohesin to laser-induced DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAK; SISTER-CHROMATID COHESION; HUMAN CONDENSIN COMPLEX; CHROMOSOME CONDENSATION; ATAXIA-TELANGIECTASIA; MRE11 COMPLEX; REPAIR; PROTEIN; CELL; DISRUPTION	Cohesin is a conserved multiprotein complex that plays an essential role in sister chromatid cohesion. During interphase, cohesin is required for the establishment of cohesion following DNA replication. Because cohesin mutants resulted in increased sensitivity to DNA damage, a role for cohesin in DNA repair was also suggested. However, it was unclear whether this was due to general perturbation of cohesion or whether cohesin has a specialized role at the damage site. We therefore used a laser microbeam to create DNA damage at discrete sites in the cell nucleus and observed specific in vivo assembly of proteins at these sites by immunofluorescent detection. We observed that human cohesin is recruited to the damage site immediately after damage induction. Analysis of mutant cells revealed that cohesin recruitment to the damage site is dependent on the DNA double-strand break repair factor Mre11/Rad50 but not ATM or Nbs1. Consistently, Mre11/Rad50 and cohesin interact with each other in an interphase-specific manner. This interaction peaks in S/G(2) phase, during which cohesin is recruited to the DNA damage. Our results demonstrate the S/G(2)-specific and Mre11/Rad50-dependent recruitment of human cohesin to DNA damage, suggesting a specialized subfunction for cohesin in cell cycle-specific DNA double strand break repair.	Univ Calif Irvine, Dept Biol Chem, Coll Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Surg, Laser Microbeam & Med Program, Beckman Laser Inst, Irvine, CA 92612 USA; Univ Birmingham, Canc Res Campaign, Inst Canc Studies, Sch Med, Birmingham B15 2TT, W Midlands, England	University of California System; University of California Irvine; University of California System; University of California Irvine; University of Birmingham	Yokomori, K (corresponding author), Univ Calif Irvine, Dept Biol Chem, Coll Med, 240D Med Sci 1, Irvine, CA 92697 USA.				NCI NIH HHS [CA-62203] Funding Source: Medline; NCRR NIH HHS [RR01192] Funding Source: Medline; NIGMS NIH HHS [GM59150] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA062203] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001192] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059150] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aono N, 2002, NATURE, V417, P197, DOI 10.1038/417197a; Berns MW, 1998, METHOD CELL BIOL, V55, P71; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Gregson HC, 2001, J BIOL CHEM, V276, P47575, DOI 10.1074/jbc.M103364200; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Krasieva TB, 1998, P SOC PHOTO-OPT INS, V3260, P38, DOI 10.1117/12.307113; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Losada A, 2001, CURR BIOL, V11, P268, DOI 10.1016/S0960-9822(01)00066-5; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; LYDERSEN BK, 1980, CELL, V22, P489, DOI 10.1016/0092-8674(80)90359-1; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Schmiesing JA, 2000, MOL CELL BIOL, V20, P6996, DOI 10.1128/MCB.20.18.6996-7006.2000; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Sjogren C, 2001, CURR BIOL, V11, P991, DOI 10.1016/S0960-9822(01)00271-8; Sonoda E, 2001, DEV CELL, V1, P759, DOI 10.1016/S1534-5807(01)00088-0; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Venugopalan V, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.078103; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	37	195	198	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45149	45153		10.1074/jbc.M209123200	http://dx.doi.org/10.1074/jbc.M209123200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228239	hybrid			2022-12-27	WOS:000179404800072
J	Lerch-Gaggl, A; Haque, J; Li, JX; Ning, G; Traktman, P; Duncan, SA				Lerch-Gaggl, A; Haque, J; Li, JX; Ning, G; Traktman, P; Duncan, SA			Pescadillo is essential for nucleolar assembly, ribosome biogenesis, and mammalian cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN B23; CHROMOSOME PERIPHERY; LIVER-REGENERATION; HEPATOCYTE ENTRY; MOUSE EMBRYOS; RNA; MITOSIS; LOCALIZATION; ASSOCIATION; IDENTIFICATION	Mutation of the zebrafish pescadillo gene blocks expansion of a number of tissues in the developing embryo, suggesting roles for its gene product in controlling cell proliferation. We report that levels of the pescadillo protein increase in rodent hepatocytes as they enter the cell cycle. Pescadillo protein localizes to distinct substructures of the interphase nucleus including nucleoli, the site of ribosome biogenesis. During mitosis pescadillo closely associates with the periphery of metaphase chromosomes and by late anaphase is associated with nucleolus-derived foci and prenucleolar bodies. Blastomeres in mouse embryos lacking pescadillo arrest at morula stages of development, the nucleoli fail to differentiate and accumulation of ribosomes is inhibited. We propose that in mammalian cells pescadillo is essential for ribosome biogenesis and nucleologenesis and that disruption to its function results in cell cycle arrest.	Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Duncan, SA (corresponding author), Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA.	duncans@mcw.edu		Traktman, Paula/0000-0002-6517-0225; Duncan, Stephen/0000-0002-2507-7827	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055743, R01DK060064] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55743, DK60064] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CC, 2002, RNA, V8, P150, DOI 10.1017/S1355838202010026; Allende ML, 1996, GENE DEV, V10, P3141, DOI 10.1101/gad.10.24.3141; Anderson MT, 2001, CALC VAR PARTIAL DIF, V12, P1, DOI 10.1007/s005260000043; BARAN V, 1995, MOL REPROD DEV, V40, P305, DOI 10.1002/mrd.1080400306; Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; BOND VC, 1993, MOL CELL BIOL, V13, P3221, DOI 10.1128/MCB.13.6.3221; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; DELATORRE C, 1975, NATURE, V256, P503, DOI 10.1038/256503a0; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; Dundr M, 2000, J CELL BIOL, V150, P433, DOI 10.1083/jcb.150.3.433; Dundr M, 1998, MOL BIOL CELL, V9, P2407, DOI 10.1091/mbc.9.9.2407; Dundr M, 1997, CHROMOSOMA, V105, P407, DOI 10.1007/s004120050202; FANG GW, 1995, J CELL BIOL, V130, P243, DOI 10.1083/jcb.130.2.243; Gaiano N, 1996, P NATL ACAD SCI USA, V93, P7777, DOI 10.1073/pnas.93.15.7777; Ganot P, 1999, MOL CELL BIOL, V19, P6906; GAUTIER T, 1992, EXP CELL RES, V200, P5, DOI 10.1016/S0014-4827(05)80065-5; GAUTIER T, 1994, BIOL CELL, V82, P81, DOI 10.1016/S0248-4900(94)80010-3; GEUSKENS M, 1984, CELL DIFFER DEV, V14, P125, DOI 10.1016/0045-6039(84)90037-X; Haque J, 2000, GENOMICS, V70, P201, DOI 10.1006/geno.2000.6375; HERNANDEZVERDUN D, 1994, BIOESSAYS, V16, P179, DOI 10.1002/bies.950160308; HERRERA JE, 1995, NUCLEIC ACIDS RES, V23, P3974, DOI 10.1093/nar/23.19.3974; Higgins GM, 1931, ARCH PATHOL, V12, P186; HILLMAN N, 1969, AM J ANAT, V126, P151, DOI 10.1002/aja.1001260203; Hyttel P, 2000, BIOL REPROD, V63, P1848, DOI 10.1095/biolreprod63.6.1848; Jacobson MR, 1998, P NATL ACAD SCI USA, V95, P7981, DOI 10.1073/pnas.95.14.7981; KINOSHITA Y, 2000, J BIOL CHEM; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; KOPECNY V, 1989, Molecular Reproduction and Development, V1, P79; Laurincik J, 2000, BIOL REPROD, V62, P1024, DOI 10.1095/biolreprod62.4.1024; Leary DJ, 2001, FEBS LETT, V509, P145, DOI 10.1016/S0014-5793(01)03143-X; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Oeffinger M, 2002, RNA, V8, P626, DOI 10.1017/S1355838202020022; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Pestov DG, 1998, ONCOGENE, V17, P3187, DOI 10.1038/sj.onc.1202260; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; PIKO L, 1982, DEV BIOL, V89, P362, DOI 10.1016/0012-1606(82)90325-6; Pinol-Roma S, 1999, MOL BIOL CELL, V10, P77, DOI 10.1091/mbc.10.1.77; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; STEER CJ, 1995, FASEB J, V9, P1396, DOI 10.1096/fasebj.9.14.7589980; Strezoska Z, 2002, J BIOL CHEM, V277, P29617, DOI 10.1074/jbc.M204381200; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Sund NJ, 2000, MOL CELL BIOL, V20, P5175, DOI 10.1128/MCB.20.14.5175-5183.2000; Szebeni A, 1999, PROTEIN SCI, V8, P905; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Weglarz TC, 2000, P NATL ACAD SCI USA, V97, P12595, DOI 10.1073/pnas.220430497; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Ye HG, 1999, MOL CELL BIOL, V19, P8570	52	90	101	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45347	45355		10.1074/jbc.M208338200	http://dx.doi.org/10.1074/jbc.M208338200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237316	hybrid			2022-12-27	WOS:000179404800097
J	Fukamachi, K; Matsuoka, Y; Ohno, H; Hamaguchi, T; Tsuda, H				Fukamachi, K; Matsuoka, Y; Ohno, H; Hamaguchi, T; Tsuda, H			Neuronal leucine-rich repeat protein-3 amplifies MAPK activation by epidermal growth factor through a carboxyl-terminal region containing endocytosis motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE NERVOUS-SYSTEM; SIGNAL-TRANSDUCTION; SORTING SIGNALS; FACTOR RECEPTOR; MOLECULAR-CLONING; CLATHRIN; INTERNALIZATION; RAS; EXPRESSION; COMPLEXES	Neuronal leucine-rich repeat protein-3 (NLRR-3) belongs to the LRR superfamily. Expression of rat NLRR-3 gene isolated from c-Ha-ras transgenic rat tumor is regulated mainly through the Ras-MAPK signaling pathway. NLRR-3 was found to enhance phosphorylation of MAPK when COS-7 cells were transfected with NLRR-3 and stimulated with a low concentration (0.01 ng/ml) of epidermal growth factor (EGF), but the amplification of MAPK phosphorylation by NLRR-3 was no longer observed when the carboxyl-terminal 30 amino acid stretch containing clathrin-mediated endocytosis motifs was deleted. A green fluorescent protein-tagged NLRR-3 localized at the plasma membrane was efficiently internalized in COS-7 cells, but internalization of a carboxyl-terminal-deleted version (NLRRDeltaC) was less efficient. The presence of clathrin-adaptor protein complexes containing NLRR-3 in brain lysate was confirmed by immunoprecipitation and glutathione S-transferase pull-down experiments, and affinity column chromatography revealed that the carboxyl-terminal region of NILRR-3 interacts with beta-adaptin. We propose that NLRR-3 potentiates Ras-MAPK signaling by facilitating internalization of EGF in clathrin-coated vesicles.	Natl Canc Ctr, Res Inst, Expt Pathol & Chemotherapy Div, Chuo Ku, Tokyo 1040045, Japan; Kanazawa Univ, Canc Res Inst, Div Mol Membrane Biol, Kanazawa, Ishikawa 9200934, Japan; RIKEN, Res Ctr Allergy & Immunol, Yokohama, Kanagawa 2300045, Japan	National Cancer Center - Japan; Kanazawa University; RIKEN	Matsuoka, Y (corresponding author), Natl Canc Ctr, Res Inst, Expt Pathol & Chemotherapy Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.		Ohno, Hiroshi/L-7899-2014	Ohno, Hiroshi/0000-0001-8776-9661				Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bormann P, 1999, MOL CELL NEUROSCI, V13, P167, DOI 10.1006/mcne.1999.0742; CHANG CP, 1993, J BIOL CHEM, V268, P19312; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Fukamachi K, 2001, BIOCHEM BIOPH RES CO, V287, P257, DOI 10.1006/bbrc.2001.5579; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; Haugh JM, 1998, J THEOR BIOL, V195, P187, DOI 10.1006/jtbi.1998.0791; Haugh JM, 1999, J BIOL CHEM, V274, P8958, DOI 10.1074/jbc.274.13.8958; Hayata T, 1998, GENE, V221, P159, DOI 10.1016/S0378-1119(98)00414-4; Howe CL, 2001, NEURON, V32, P801, DOI 10.1016/S0896-6273(01)00526-8; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; Matsuoka Y, 1998, J CELL BIOL, V142, P485, DOI 10.1083/jcb.142.2.485; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Sato Y, 2001, J BIOL CHEM, V276, P11956, DOI 10.1074/jbc.M008551200; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; Sorkina T, 1999, J CELL SCI, V112, P317; Taguchi A, 1996, MOL BRAIN RES, V35, P31, DOI 10.1016/0169-328X(95)00178-U; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; Taniguchi H, 1996, MOL BRAIN RES, V36, P45, DOI 10.1016/0169-328X(95)00243-L; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279	31	38	42	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43549	43552		10.1074/jbc.C200502200	http://dx.doi.org/10.1074/jbc.C200502200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12297494	hybrid			2022-12-27	WOS:000179272000002
J	Dawson, JF; Sablin, EP; Spudich, JA; Fletterick, RJ				Dawson, JF; Sablin, EP; Spudich, JA; Fletterick, RJ			Structure of an F-actin trimer disrupted by gelsolin and implications for the mechanism of severing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-BINDING PROTEIN; CRYSTAL-STRUCTURE; FILAMENT DYNAMICS; PLASMA GELSOLIN; RATE CONSTANTS; COMPLEX; POLYMERIZATION; IDENTIFICATION; PROFILIN; DOMAIN	Stable oligomers of filamentous actin were obtained by cross-linking F-actin with 1,4-N,N'-phenylenedimaleimide and depolymerization with excess segment-1 of gelsolin. Segment-l-bound and cross-linked actin oligomers containing either two or three actin subunits were purified and shown to nucleate actin assembly. Kinetic assembly data from mixtures of monomeric actin and the actin oligomers fit a nucleation model where cross-linked actin dimer or trimer reacts with an actin monomer to produce a competent nucleus for filament assembly. We report the three-dimensional structure of the segment-l-actin hexamer containing three actin subunits, each with a tightly bound ATP. Comparative analysis of this structure with twelve other actin structures provides an atomic level explanation for the preferential binding of ATP by the segment-l-complexed actin. Although the structure of segment-l-bound actin trimer is topologically similar to the helical model of F-actin (1), it has a distorted symmetry compared with that of the helical model. This distortion results from intercalation of segment-1 between actin protomers that increase the rise per subunit and rotate each of the actin subunits relative to their positions in F-actin. We also show that segment-1 of gelsolin is able to sever actin filaments, although the severing activity of segment-1 is significantly lower than full-length gelsolin.	Univ Calif San Francisco, Dept Biochem Biophys, San Francisco, CA 94143 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	University of California System; University of California San Francisco; Stanford University	Fletterick, RJ (corresponding author), Univ Calif San Francisco, Dept Biochem Biophys, San Francisco, CA 94143 USA.	flett@msg.ucsf.edu			NIGMS NIH HHS [R01 GM033289] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033289] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bubb MR, 2002, J BIOL CHEM, V277, P20999, DOI 10.1074/jbc.M201371200; Burtnick L D, 2001, Results Probl Cell Differ, V32, P201; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; Chik JK, 1996, J MOL BIOL, V263, P607, DOI 10.1006/jmbi.1996.0602; COUE M, 1986, J BIOL CHEM, V261, P1588; De La Cruz EM, 2001, SCIENCE, V293, P616, DOI 10.1126/science.1063558; EGELMAN EH, 1983, J MOL BIOL, V166, P605, DOI 10.1016/S0022-2836(83)80286-1; EGELMAN EH, 1982, NATURE, V298, P131, DOI 10.1038/298131a0; ELZINGA M, 1984, P NATL ACAD SCI-BIOL, V81, P6599, DOI 10.1073/pnas.81.21.6599; FRENCH BA, 1990, GENE, V88, P173, DOI 10.1016/0378-1119(90)90029-Q; Galkin VE, 2002, CURR BIOL, V12, P570, DOI 10.1016/S0960-9822(02)00742-X; Galkin VE, 2001, J CELL BIOL, V153, P75, DOI 10.1083/jcb.153.1.75; GILBERT HR, 1983, BIOCHEM BIOPH RES CO, V111, P404, DOI 10.1016/0006-291X(83)90320-0; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; Head JF, 2002, BIOCHEMISTRY-US, V41, P9015, DOI 10.1021/bi026054y; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kinosian HJ, 1996, BIOCHEMISTRY-US, V35, P16550, DOI 10.1021/bi961891j; KNIGHT P, 1975, BIOCHEM J, V175, P1023; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; KWIATKOWSKI DJ, 1985, J BIOL CHEM, V260, P5232; LAL AA, 1984, J BIOL CHEM, V259, P8794; McGough A, 1998, BIOPHYS J, V74, P764, DOI 10.1016/S0006-3495(98)74001-9; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MILLONIG R, 1988, J CELL BIOL, V106, P785, DOI 10.1083/jcb.106.3.785; MOCKRIN SC, 1981, J BIOL CHEM, V256, P8228; OOSAWA F, 1975, THERMODYNAMICS POLYM, P47; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; Otterbein LR, 2002, P NATL ACAD SCI USA, V99, P8003, DOI 10.1073/pnas.122126299; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page R, 1998, J MOL BIOL, V280, P463, DOI 10.1006/jmbi.1998.1879; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POPE B, 1995, BIOCHEMISTRY-US, V34, P1583, DOI 10.1021/bi00005a014; Robinson RC, 1999, SCIENCE, V286, P1939, DOI 10.1126/science.286.5446.1939; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Sablin EP, 2002, P NATL ACAD SCI USA, V99, P10945, DOI 10.1073/pnas.152329899; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SCHUTT CE, 1992, P NATL ACAD SCI USA, V89, P319, DOI 10.1073/pnas.89.1.319; SCHUTT CE, 1995, BIOPHYS J, V68, pS12; SCHUTT CE, 1989, J MOL BIOL, V209, P735, DOI 10.1016/0022-2836(89)90603-7; SCHUTT CE, 1993, FEBS LETT, V325, P59, DOI 10.1016/0014-5793(93)81413-T; Selden LA, 1998, BIOPHYS J, V75, P3092, DOI 10.1016/S0006-3495(98)77750-1; Sept D, 2001, BIOPHYS J, V81, P667, DOI 10.1016/S0006-3495(01)75731-1; SHETERLINE P, 1998, PROTEIN PROFILE ACTI, P13; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; WAY M, 1992, J CELL BIOL, V119, P835, DOI 10.1083/jcb.119.4.835; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805; Zigmond SH, 2000, METHOD ENZYMOL, V325, P237	53	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1229	1238		10.1074/jbc.M209160200	http://dx.doi.org/10.1074/jbc.M209160200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12356759	hybrid			2022-12-27	WOS:000180321900070
J	Ceulemans, H; Vulsteke, V; De Maeyer, M; Tatchell, K; Stalmans, W; Bollen, M				Ceulemans, H; Vulsteke, V; De Maeyer, M; Tatchell, K; Stalmans, W; Bollen, M			Binding of the concave surface of the Sds22 superhelix to the alpha 4/alpha 5/alpha 6-triangle of protein phosphatase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; CRYSTAL-STRUCTURE; CATALYTIC SUBUNIT; 3-DIMENSIONAL STRUCTURE; STRUCTURAL BASIS; YEAST; TYPE-1; REGULATOR; RECOGNITION; COMPLEX	Functional studies of the protein phosphatase-1 (PP1) regulator Sds22 suggest that it is indirectly and/or directly involved in one of the most ancient functions of PP1, i.e. reversing phosphorylation by the Aurora-related protein kinases. We predict that the conserved portion of Sds22 folds into a curved superhelix and demonstrate that mutation to alanine of any of eight residues (Asp(148), Phe(170), Glu(192), Phe(214), Asp(280), Glu(300), Trp(302), or Tyr(327)) at the concave surface of this superhelix thwarts the interaction with PP1. Furthermore we show that all mammalian isoforms of PP1 have the potential to bind Sds22. Interaction studies with truncated versions of PP1 and with chimeric proteins comprising fragments of PP1 and the yeast PP1-like protein phosphatase Ppz1 suggest that the site(s) required for the binding of Sds22 reside between residues 43 and 173 of PP1gamma(1). Within this region, a major interaction site was mapped to a triangular region delineated by the alpha4-, alpha5-, and alpha6-helices. Our data also show that well known regulatory binding sites of PP1, such as the RVXF-binding channel, the beta12/beta13-loop, and the acidic groove, are not essential for the interaction with Sds22.	Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochim, B-3000 Louvain, Belgium; Catholic Univ Louvain, Fac WEtenschappen, Biomolec Modelling Lab, B-3000 Louvain, Belgium; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	KU Leuven; Universite Catholique Louvain; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Ceulemans, H (corresponding author), Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochim, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Hugo.Ceulemans@med.kuleuven.ac.be	Tatchell, Kelly/A-9643-2009	Ceulemans, Hugo/0000-0002-7059-4399				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ansai T, 1996, J BIOL CHEM, V271, P24401, DOI 10.1074/jbc.271.40.24401; Baker SH, 1997, GENETICS, V145, P615; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Ceulemans H, 2002, BIOESSAYS, V24, P371, DOI 10.1002/bies.10069; Ceulemans H, 1999, FEBS LETT, V456, P349, DOI 10.1016/S0014-5793(99)00965-5; Chun YS, 2000, BIOCHEM BIOPH RES CO, V273, P972, DOI 10.1006/bbrc.2000.3045; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; De Maeyer M, 2000, METH MOL B, V143, P265; Dinischiotu A, 1997, FEBS LETT, V402, P141, DOI 10.1016/S0014-5793(96)01514-1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; Evdokimov AG, 2001, J MOL BIOL, V312, P807, DOI 10.1006/jmbi.2001.4973; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; HARPER JW, 1993, CELL, V75, P805; HISAMOTO N, 1995, MOL CELL BIOL, V15, P3767; Ho DN, 2002, P NATL ACAD SCI USA, V99, P1888, DOI 10.1073/pnas.042698599; Hong G, 2000, ARCH BIOCHEM BIOPHYS, V376, P288, DOI 10.1006/abbi.2000.1715; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Kajava AV, 2002, PROTEIN SCI, V11, P1082, DOI 10.1110/ps.4010102; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Li L, 1998, J PHYSIOL-LONDON, V508, P871, DOI 10.1111/j.1469-7793.1998.871bp.x; Lin Q, 1999, MOL PHYLOGENET EVOL, V12, P57, DOI 10.1006/mpev.1998.0560; MACKELVIE SH, 1995, MOL CELL BIOL, V15, P3777; Moorhead G, 1998, FEBS LETT, V438, P141, DOI 10.1016/S0014-5793(98)01276-9; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; Papageorgiou AC, 1997, EMBO J, V16, P5162, DOI 10.1093/emboj/16.17.5162; Peggie MW, 2002, J CELL SCI, V115, P195; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; RENOUF S, 1995, FEBS LETT, V375, P75, DOI 10.1016/0014-5793(95)01180-M; Schubert WD, 2001, J MOL BIOL, V312, P783, DOI 10.1006/jmbi.2001.4989; STONE EM, 1993, CURR BIOL, V3, P13, DOI 10.1016/0960-9822(93)90140-J; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P27716, DOI 10.1074/jbc.M203365200; Venturi GM, 2000, GENETICS, V155, P69; Wu XL, 2001, BIOCHEMISTRY-US, V40, P7410, DOI 10.1021/bi002796k; Zhang H, 2000, STRUCTURE, V8, P241, DOI 10.1016/S0969-2126(00)00102-7	43	63	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47331	47337		10.1074/jbc.M206838200	http://dx.doi.org/10.1074/jbc.M206838200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12226088	hybrid			2022-12-27	WOS:000179663700065
J	Chintala, SK; Zhang, X; Austin, JS; Fini, ME				Chintala, SK; Zhang, X; Austin, JS; Fini, ME			Deficiency in matrix metalloproteinase gelatinase B (MMP-9) protects against retinal ganglion cell death after optic nerve ligation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESSURE-INDUCED ISCHEMIA; EXCITATORY AMINO-ACIDS; NEURONAL DEGENERATION; GENE KNOCKOUT; BRAIN; EXPRESSION; ADULT; LAMININ; MATRIX-METALLOPROTEINASE-9; APOPTOSIS	Loss of retinal ganglion cells is the final end point in blinding diseases of the optic nerve such as glaucoma. To enable the use of mouse genetics to investigate mechanisms underlying ganglion cell loss, we adapted an experimental model of optic nerve ligation to the mouse and further characterized post-surgical outcome. We made the novel finding that apoptosis of retinal ganglion cells correlates with specific degradation of laminin from the underlying inner limiting membrane and an increase in gelatinolytic metalloproteinase activity. These changes co-localize with a specific increase in levels of the matrix metalloproteinase, gelatinase B (GelB; MMP-9). Using a transgenic mouse line harboring a reporter gene driven by the GelB promoter, we further show that increased GelB is controlled by activation of the GelB promoter. These findings led us to hypothesize that GelB activity plays a role in ganglion cell death and degradation of laminin. Applying the genetic approach, we demonstrate that GelB-deficient mice are protected against these pathological changes. This is the first report demonstrating a causal connection between GelB activity and pathological changes to the inner retina after optic nerve ligation.	Oakland Univ, Eye Res Inst, Rochester, MI 48309 USA; Univ Miami, Sch Med, Bascom Palmer Eye Inst, Miami, FL 33101 USA; Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA; Tufts Ctr Vis Res, Boston, MA 02111 USA	Oakland University; Bascom Palmer Eye Institute; University of Miami; Tufts University	Chintala, SK (corresponding author), Oakland Univ, Eye Res Inst, 409 Dodge Hall, Rochester, MI 48309 USA.	Chintala@oakland.edu			NEI NIH HHS [EY13643, EY13078, R01 EY013643, R01 EY013643-02, EY12651] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013643, R01EY012651, P30EY013078] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Asahi M, 2001, NEUROREPORT, V12, P3003, DOI 10.1097/00001756-200109170-00050; BARNETT NL, 1995, BRAIN RES, V677, P337, DOI 10.1016/0006-8993(95)00193-T; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; BIRKEDALHANSEN H, 1982, BIOCHEM BIOPH RES CO, V107, P1173, DOI 10.1016/S0006-291X(82)80120-4; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BLOCK F, 1992, NEUROSCI LETT, V144, P124, DOI 10.1016/0304-3940(92)90731-L; BUCHI ER, 1992, JPN J OPHTHALMOL, V36, P62; CANETESOLER R, 1995, DEV BRAIN RES, V88, P37; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Clark AW, 1997, NEUROSCI LETT, V238, P53, DOI 10.1016/S0304-3940(97)00859-8; COHEN J, 1987, DEV BIOL, V122, P407, DOI 10.1016/0012-1606(87)90305-8; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; COYLE JT, 1978, J COMP NEUROL, V180, P301, DOI 10.1002/cne.901800208; DONG LJ, 1991, DIFFERENTIATION, V48, P157, DOI 10.1111/j.1432-0436.1991.tb00254.x; EPSTEIN DL, 1987, ARCH OPHTHALMOL-CHIC, V105, P1187, DOI 10.1001/archopht.1987.01060090045023; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GARCIAVALENZUELA E, 1995, EXP EYE RES, V61, P33, DOI 10.1016/S0014-4835(95)80056-5; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Grant G A, 1992, Matrix Suppl, V1, P217; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Halfter W, 2000, DEV BIOL, V220, P111, DOI 10.1006/dbio.2000.9649; HAYREH SS, 1980, BRIT J OPHTHALMOL, V64, P896, DOI 10.1136/bjo.64.12.896; Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005; HUGHES WF, 1991, EXP EYE RES, V53, P573, DOI 10.1016/0014-4835(91)90215-Z; Johnson EC, 2000, INVEST OPHTH VIS SCI, V41, P431; Lafuente MP, 2001, INVEST OPHTH VIS SCI, V42, P2074; Li Y, 1999, INVEST OPHTH VIS SCI, V40, P1004; Libby RT, 1997, J COMP NEUROL, V389, P655, DOI 10.1002/(SICI)1096-9861(19971229)389:4<655::AID-CNE8>3.0.CO;2-#; LIESI P, 1989, EXP NEUROL, V105, P86, DOI 10.1016/0014-4886(89)90175-1; Lijnen HR, 1998, ARTERIOSCL THROM VAS, V18, P1035, DOI 10.1161/01.ATV.18.7.1035; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; MATSUBARA M, 1991, DEV BIOL, V147, P425, DOI 10.1016/0012-1606(91)90300-R; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Mohan R, 1998, J BIOL CHEM, V273, P25903, DOI 10.1074/jbc.273.40.25903; Mohan R, 2002, J BIOL CHEM, V277, P2065, DOI 10.1074/jbc.M107611200; MOSINGER JL, 1989, EXP NEUROL, V105, P110, DOI 10.1016/0014-4886(89)90178-7; Murphy G, 1992, Matrix Suppl, V1, P224; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nickells RW, 1996, OPHTHALMIC GENET, V17, P145, DOI 10.3109/13816819609057889; Nickells RW, 1999, SURV OPHTHALMOL, V43, pS151, DOI 10.1016/S0039-6257(99)00029-6; Oh LYS, 1999, J NEUROSCI, V19, P8464; OSBORNE NN, 1994, NEUROSCIENCE, V59, P1071, DOI 10.1016/0306-4522(94)90306-9; OSBORNE NN, 1995, INVEST OPHTH VIS SCI, V36, P1692; Osborne NN, 1999, SURV OPHTHALMOL, V43, pS102, DOI 10.1016/S0039-6257(99)00044-2; Otori Y, 1997, SURV OPHTHALMOL, V42, pS96, DOI 10.1016/S0039-6257(97)80032-X; Planas AM, 2001, NEUROBIOL DIS, V8, P834, DOI 10.1006/nbdi.2001.0435; QUIGLEY HA, 1995, AUST NZ J OPHTHALMOL, V23, P85, DOI 10.1111/j.1442-9071.1995.tb00135.x; QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; Rosenberg GA, 1996, NEUROLOGY, V46, P1626, DOI 10.1212/WNL.46.6.1626; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; SARTHY PV, 1990, J CELL BIOL, V110, P2099, DOI 10.1083/jcb.110.6.2099; Sawada A, 1999, EXP EYE RES, V69, P525, DOI 10.1006/exer.1999.0732; SellesNavarro I, 1996, INVEST OPHTH VIS SCI, V37, P2002; SILIPRANDI R, 1992, VISUAL NEUROSCI, V8, P567, DOI 10.1017/S0952523800005666; Sivak JM, 2000, DEV BIOL, V222, P41, DOI 10.1006/dbio.2000.9694; STEFANSSON E, 1988, INVEST OPHTH VIS SCI, V29, P1050; Strickland S, 1996, COLD SPRING HARB SYM, V61, P739; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; Tsirka SE, 1997, J NEUROSCI, V17, P543; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Woessner JF, 1998, BIOL EXTRAC, P1; YAMAMOTO T, 1988, J NEUROL SCI, V84, P1, DOI 10.1016/0022-510X(88)90169-4; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307; Yu Q, 2000, GENE DEV, V14, P163	74	117	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47461	47468		10.1074/jbc.M204824200	http://dx.doi.org/10.1074/jbc.M204824200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354772	hybrid			2022-12-27	WOS:000179663700082
J	Fan, B; Rosen, BP				Fan, B; Rosen, BP			Biochemical characterization of CopA, the Escherichia coli Cu(I)-translocating P-type ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER-TRANSPORTING ATPASE; N-TERMINAL DOMAIN; WILSON-DISEASE; HELICOBACTER-PYLORI; ENTEROCOCCUS-HIRAE; MEMBRANE TOPOLOGY; BINDING DOMAIN; MENKES DISEASE; PURIFICATION; GENE	Escherichia coli CopA is a copper ion-translocating P-type ATPase that confers copper resistance. CopA formed a phosphorylated intermediate with [gamma(-32)P]ATP. Phosphorylation was inhibited by vanadate and sensitive to KOH and hydroxylamine, consistent with acylphosphate formation on conserved Asp-523. Phosphorylation required a monovalent cation, either Cu(I) or Ag(I). Divalent cations Cu(II), Zn(II), or Co(II) could not substitute, signifying that the substrate of this copper-translocating P-type ATPase is Cu(I) and not Cu(II). CopA purified from dodecylmaltoside-solubilized membranes similarly exhibited Cu(I)/Ag(I)-stimulated ATPase activity, with a K-m for ATP of 0.5 mM. CopA has two N-terminal Cys(X)(2)Cys sequences, Gly-Leu-Ser-Cys(14)-Gly-His-Cys(17), and Gly-Met-Ser-Cys(110)-Ala-Ser-Cys(113), and a Cys(479)-Pro-Cys(481) motif in membrane-spanning segment six. The requirement of these cysteine residues was investigated by the effect of mutations and deletions. Mutants with substitutions of the N-terminal cysteines or deletion of the first Cys-(X)(2)-Cys motif formed acylphosphate intermediates. From the copper dependence of phosphoenzyme formation, the mutants appear to have 2-3 fold higher affinity for Cu(I) than wild type CopA. In contrast, substitutions in Cys(479) or Cys(481) resulted in loss of copper resistance, transport and phosphoenzyme formation. These results imply that the cysteine residues of the Cys-Pro-Cys motif (but not the N-terminal cysteine residues) are required for CopA function.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Rosen, BP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	brosen@med.wayne.edu	Johnson, Michael D. L./B-4352-2012	Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052216] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52216] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; Camakaris J, 1999, BIOCHEM BIOPH RES CO, V261, P225, DOI 10.1006/bbrc.1999.1073; DEY S, 1994, ARCH BIOCHEM BIOPHYS, V311, P418, DOI 10.1006/abbi.1994.1256; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; DiDonato M, 2000, BIOCHEMISTRY-US, V39, P1890, DOI 10.1021/bi992222j; FAIRBANKS G, 1972, Journal of Supramolecular Structure, V1, P66, DOI 10.1002/jss.400010110; Fan B, 2001, BIOCHEM BIOPH RES CO, V286, P414, DOI 10.1006/bbrc.2001.5367; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Gatti D, 2000, J BIOL CHEM, V275, P34009, DOI 10.1074/jbc.R000012200; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Gupta A, 1999, NAT MED, V5, P183, DOI 10.1038/5545; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; Mandal AK, 2002, J BIOL CHEM, V277, P7201, DOI 10.1074/jbc.M109964200; Melchers K, 1999, RES MICROBIOL, V150, P507, DOI 10.1016/S0923-2508(99)00106-0; Melchers K, 1996, J BIOL CHEM, V271, P446, DOI 10.1074/jbc.271.1.446; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; Rutherford JC, 1999, J BIOL CHEM, V274, P25827, DOI 10.1074/jbc.274.36.25827; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Tsai KJ, 2002, J BIOENERG BIOMEMBR, V34, P147, DOI 10.1023/A:1016085301323; Tsivkovskii R, 2002, J BIOL CHEM, V277, P976, DOI 10.1074/jbc.M109368200; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Wunderli-Ye H, 2001, BIOCHEM BIOPH RES CO, V280, P713, DOI 10.1006/bbrc.2000.4176	33	103	108	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46987	46992		10.1074/jbc.M208490200	http://dx.doi.org/10.1074/jbc.M208490200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351646	hybrid			2022-12-27	WOS:000179663700021
J	Koprivnjak, T; Peschel, A; Gelb, MH; Liang, NS; Weiss, JP				Koprivnjak, T; Peschel, A; Gelb, MH; Liang, NS; Weiss, JP			Role of charge properties of bacterial envelope in bactericidal action of human group IIA phospholipase A(2) against Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANYL-LIPOTEICHOIC ACID; MAJOR PHYSIOLOGICAL-ROLE; WALL TEICHOIC-ACID; D-ALANINE; ESCHERICHIA-COLI; ANTIBACTERIAL PROPERTIES; INTERFACIAL ENZYMOLOGY; INFLAMMATORY FLUID; BACILLUS-SUBTILIS; HUMAN DEFENSINS	Mammalian Group IIA phospholipases A(2) (PLA(2)) potently kill Staphylococcus aureus. Highly cationic properties of these PLA(2) are important for Ca2+-independent binding and cell wall penetration, prerequisites for Ca2+- dependent degradation of membrane phospholipids and bacterial killing. To further delineate charge properties of the bacterial envelope important in Group IIA PLA(2) action against S. aureus, we examined the effects of mutations that prevent specific modifications of cell wall (dltA) and cell membrane (mprF) polyanions. In comparison to the parent strain, isogenic dltA(-) bacteria are similar to30-100x more sensitive to PLA(2), whereas mprF(-) bacteria are <3-fold more sensitive. Differences in PLA(2) sensitivity of intact bacteria reflect differences in cell wall, not cell membrane, properties since protoplasts from all three strains are equally sensitive to PLA(2). A diminished positive charge in PLA(2) reduces PLA(2) binding and antibacterial activity. In contrast, diminished cell wall negative charge by substitution of (lipo)teichoic acids with D-alanine reduces antibacterial activity of bound PLA(2), but not initial PLA(2) binding. Therefore, the potent antistaphylococcal activity of Group IIA PLA(2) depends on cationic properties of the enzyme that promote binding to the cell wall, and polyanionic properties of cell wall (lipo)teichoic acids that promote attack of membrane phospholipids by bound PLA(2).	Univ Iowa, Iowa City Vet Affairs Med Ctr, Dept Internal Med, Iowa City, IA 52246 USA; Univ Iowa, Iowa City Vet Affairs Med Ctr, Dept Microbiol, Iowa City, IA 52246 USA; Univ Iowa, Iowa City Vet Affairs Med Ctr, Inflammat Program, Iowa City, IA 52246 USA; Univ Tubingen, D-72076 Tubingen, Germany; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Guangxi Canc Hosp Inst, Dept Pharm, Nanning, Guangxi, Peoples R China	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; Eberhard Karls University of Tubingen; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Weiss, JP (corresponding author), Univ Iowa, Iowa City Vet Affairs Med Ctr, Dept Internal Med, 200 Hawkins Dr, Iowa City, IA 52246 USA.	jerrold-weiss@uiowa.edu	Koprivnjak, Tomaz/A-9663-2009	gelb, michael/0000-0001-7000-5219; Weiss, Jerrold/0000-0003-1476-4485	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL036235, R37HL036235, R01HL036235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018571] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36235] Funding Source: Medline; NIAID NIH HHS [AI-18571] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abachin E, 2002, MOL MICROBIOL, V43, P1, DOI 10.1046/j.1365-2958.2002.02723.x; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; Beers SA, 2002, J BIOL CHEM, V277, P1788, DOI 10.1074/jbc.M109777200; Berg OG, 2001, CHEM REV, V101, P2613, DOI 10.1021/cr990139w; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boyd DA, 2000, J BACTERIOL, V182, P6055, DOI 10.1128/JB.182.21.6055-6065.2000; Buckland AG, 2000, BBA-MOL CELL BIOL L, V1488, P71, DOI 10.1016/S1388-1981(00)00111-6; Buckland AG, 2000, BBA-MOL CELL BIOL L, V1484, P195, DOI 10.1016/S1388-1981(00)00018-4; Clemans DL, 1999, INFECT IMMUN, V67, P2464, DOI 10.1128/IAI.67.5.2464-2474.1999; Dunman PM, 2001, J BACTERIOL, V183, P7341, DOI 10.1128/JB.183.24.7341-7353.2001; FISCHER W, 1994, MED MICROBIOL IMMUN, V183, P61, DOI 10.1007/BF00277157; Foreman-Wykert AK, 1999, J CLIN INVEST, V103, P715, DOI 10.1172/JCI5468; Foreman-Wykert AK, 2000, INFECT IMMUN, V68, P1259, DOI 10.1128/IAI.68.3.1259-1264.2000; FORST S, 1987, BIOCHIM BIOPHYS ACTA, V920, P221, DOI 10.1016/0005-2760(87)90098-1; Ganz T, 2001, J EXP MED, V193, pF31, DOI 10.1084/jem.193.9.F31; Gelb MH, 2000, BBA-MOL CELL BIOL L, V1488, P20, DOI 10.1016/S1388-1981(00)00106-2; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; Gross M, 2001, INFECT IMMUN, V69, P3423, DOI 10.1128/IAI.69.5.3423-3426.2001; HEPTINSTALL S, 1970, NATURE, V225, P519, DOI 10.1038/225519a0; Hyyrylainen HL, 2000, J BIOL CHEM, V275, P26696; INADA M, 1991, EUR J BIOCHEM, V197, P323, DOI 10.1111/j.1432-1033.1991.tb15914.x; IORDANESCU S, 1976, J GEN MICROBIOL, V96, P277, DOI 10.1099/00221287-96-2-277; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; Koduri RS, 2002, J BIOL CHEM, V277, P5849, DOI 10.1074/jbc.M109699200; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; Laine VJO, 1999, J IMMUNOL, V162, P7402; Laine VJO, 2000, INFECT IMMUN, V68, P87, DOI 10.1128/IAI.68.1.87-92.2000; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; NEVALAINEN TJ, 1994, INVEST OPHTH VIS SCI, V35, P417; PEREGO M, 1995, J BIOL CHEM, V270, P15598, DOI 10.1074/jbc.270.26.15598; Peschel A, 2000, ANTIMICROB AGENTS CH, V44, P2845, DOI 10.1128/AAC.44.10.2845-2847.2000; Peschel A, 2002, TRENDS MICROBIOL, V10, P179, DOI 10.1016/S0966-842X(02)02333-8; Peschel A, 1999, J BIOL CHEM, V274, P8405, DOI 10.1074/jbc.274.13.8405; Peschel A, 2001, J EXP MED, V193, P1067, DOI 10.1084/jem.193.9.1067; Poyart C, 2001, J BACTERIOL, V183, P6324, DOI 10.1128/JB.183.21.6324-6334.2001; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; ROSE RK, 1995, BBA-GEN SUBJECTS, V1245, P94; SELSTED ME, 1985, INFECT IMMUN, V49, P202, DOI 10.1128/IAI.49.1.202-206.1985; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; TAKAYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P1505, DOI 10.1016/0006-291X(91)91064-J; Wecke J, 1997, MICROBIOL-UK, V143, P2953, DOI 10.1099/00221287-143-9-2953; Wecke J, 1996, MICROB DRUG RESIST, V2, P123, DOI 10.1089/mdr.1996.2.123; Weinrauch Y, 1996, J CLIN INVEST, V97, P250, DOI 10.1172/JCI118399; Weinrauch Y, 1998, J CLIN INVEST, V102, P633, DOI 10.1172/JCI3121; Weiss J, 2000, GRAM-POSITIVE PATHOGENS, P431; WEISS J, 1994, J BIOL CHEM, V269, P26331; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; Yang L, 2000, BIOPHYS J, V79, P2002, DOI 10.1016/S0006-3495(00)76448-4; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	50	106	113	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47636	47644		10.1074/jbc.M205104200	http://dx.doi.org/10.1074/jbc.M205104200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359734	Green Submitted, hybrid			2022-12-27	WOS:000179663700104
J	Whittaker, J; Sorensen, H; Gadsboll, VL; Hinrichsen, J				Whittaker, J; Sorensen, H; Gadsboll, VL; Hinrichsen, J			Comparison of the functional insulin binding epitopes of the A and B isoforms of the insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANINE-SCANNING MUTAGENESIS; GROWTH-FACTOR RECEPTOR; LIGAND-BINDING; ALPHA-SUBUNIT; STRUCTURAL BASIS; TYROSINE KINASE; CELLS; DOMAIN; SITE; IDENTIFICATION	The human insulin receptor is expressed as two isoforms that are generated by alternate splicing of its mRNA, the B isoform has 12 additional amino acids (718-729) encoded by exon 11 of the gene. The isoforms have been reported to have different ligand binding properties. To further characterize their insulin binding properties, we have performed structure-directed alanine-scanning mutagenesis of a major insulin binding site of the receptor, formed from the receptor L1 domain (amino acids 1-470) and amino acids 705-715 at the C terminus of the a subunit. Alanine mutants of each isoform were transiently expressed as recombinant secreted extracellular domain in 293 cells, and their insulin binding properties were evaluated by competitive binding assays. Mutation of Arg(86) and Phe(96) of each isoform resulted in receptors that were not secreted. The Kds of unmutated receptors were almost identical for both isoforms. Several new mutations compromising insulin binding were identified. In L1, mutation of Leu(37) decreased affinity 20- to 40-fold and mutations of Val(94), Glu(97), Glu(120), and Lys(121) 3 to 10-fold for each isoform. A number of mutations produced differential effects on the two isoforms. Mutation of Asn(15) in the L1 domain and Phe(714) at the C terminus of the a subunit inactivated the A isoform but only reduced the affinity of the B isoform 40- to 60-fold. At the C terminus of the a subunit, mutations of Asp(707), Val(713), and Val(715) produced 7- to 16-fold reductions in affinity of the A isoform but were without effect on the B isoform. In contrast, alanine mutations of Tyr(708) and Asn(711) inactivated the B isoform but only reduced the affinities of the A isoform 11- and 6-fold, respectively. In conclusion, alanine-scanning mutagenesis of the insulin receptor A and B isoforms has identified several new side chains contributing to insulin binding and indicates that the energetic contributions of certain side chains differ in each isoform, suggesting that different molecular mechanisms are used to obtain the same affinity.	Hagedorn Res Inst, Receptor Biol Lab, DK-2820 Gentofte, Denmark	Novo Nordisk; Hagedorn Research Institute	Whittaker, J (corresponding author), Case Western Reserve Univ, Dept Nutr, Dent Bldg,2123 Abington Rd,Rm 201, Cleveland, OH 44106 USA.							BRISSENDEN JE, 1984, NATURE, V310, P781, DOI 10.1038/310781a0; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GRONSKOV K, 1993, BIOCHEM BIOPH RES CO, V192, P905, DOI 10.1006/bbrc.1993.1501; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harlow E., 1988, ANTIBODIES LAB MANUA; KELLERER M, 1992, BIOCHEMISTRY-US, V31, P4588, DOI 10.1021/bi00134a008; KOSAKI A, 1995, J BIOL CHEM, V270, P20816, DOI 10.1074/jbc.270.35.20816; Kristensen C, 1997, J BIOL CHEM, V272, P12978, DOI 10.1074/jbc.272.20.12978; Kristensen C, 2002, J BIOL CHEM, V277, P18340, DOI 10.1074/jbc.M112249200; Kristensen C, 1998, J BIOL CHEM, V273, P17780, DOI 10.1074/jbc.273.28.17780; Kristensen C, 1999, J BIOL CHEM, V274, P37351, DOI 10.1074/jbc.274.52.37351; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; KUROSE T, 1994, J BIOL CHEM, V269, P29190; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; LONGO N, 1993, P NATL ACAD SCI USA, V90, P60, DOI 10.1073/pnas.90.1.60; Molina L, 2000, FEBS LETT, V467, P226, DOI 10.1016/S0014-5793(00)01161-3; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; Ottensmeyer FP, 2000, BIOCHEMISTRY-US, V39, P12103, DOI 10.1021/bi0015921; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; Sambrook J., 2001, MOL CLONING LAB MANU; Savkur RS, 2001, NAT GENET, V29, P40, DOI 10.1038/ng704; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SEINO S, 1989, BIOCHEM BIOPH RES CO, V159, P312, DOI 10.1016/0006-291X(89)92439-X; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; Sundberg EJ, 2000, STRUCTURE, V8, pR137, DOI 10.1016/S0969-2126(00)00167-2; WARD CW, 1995, PROTEINS, V22, P141, DOI 10.1002/prot.340220207; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; Whittaker J, 2001, J BIOL CHEM, V276, P43980, DOI 10.1074/jbc.M102863200; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; YAMAGUCHI Y, 1991, ENDOCRINOLOGY, V129, P2058, DOI 10.1210/endo-129-4-2058; YAMAGUCHI Y, 1993, ENDOCRINOLOGY, V132, P1132, DOI 10.1210/en.132.3.1132	40	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47380	47384		10.1074/jbc.M208371200	http://dx.doi.org/10.1074/jbc.M208371200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12270939	hybrid			2022-12-27	WOS:000179663700071
J	Al Mamun, AM; Marians, KJ; Humayun, MZ				Al Mamun, AM; Marians, KJ; Humayun, MZ			DNA polymerase III from Escherichia coli cells expressing mutA mistranslator tRNA is error-prone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA GENE; MISMATCH REPAIR; BETA-SUBUNIT; DINB GENE; POL-IV; TRANSLESION REPLICATION; RECOMBINATION FUNCTIONS; MUTATIONAL SPECIFICITY; UNTARGETED MUTAGENESIS; BASE SUBSTITUTION	Translational stress-induced mutagenesis (TSM) refers to the elevated mutagenesis observed in Escherichia coli cells in which mistranslation has been increased as a result of mutations in tRNA genes (such as mutA) or by exposure to streptomycin. TSM does not require lexA-regulated SOS functions but is suppressed in cells defective for homologous recombination genes. Crude cell-free extracts from TSM-induced E. coli strains express an error-prone DNA polymerase. To determine whether DNA polymerase III is involved in the TSM phenotype, we first asked if the phenotype is expressed in cells defective for all four of the non-replicative DNA polymerases, namely polymerase I, II, IV, and V. By using a colony papillation assay based on the reversion of a lacZ mutant, we show that the TSM phenotype is expressed in such cells. Second, we asked if pol III from TSM-induced cells is error-prone. By purifying DNA polymerase III* from TSM-induced and control cells, and by testing its fidelity on templates bearing 3N(4)-ethenocytosine (a mutagenic DNA lesion), as well as on undamaged DNA templates, we show here that polymerase III* purified from mutA cells is error-prone as compared with that from control cells. These findings suggest that DNA polymerase III is modified in TSM-induced cells.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, Newark, NJ 07101 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Memorial Sloan Kettering Cancer Center	Humayun, MZ (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, 225 Warren St, Newark, NJ 07101 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R37GM034557, R01GM058253] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34557, R37 GM034557, GM58253] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al Mamun AAM, 2000, MOL MICROBIOL, V38, P368, DOI 10.1046/j.1365-2958.2000.02136.x; Al Mamun AAM, 1999, MOL MICROBIOL, V33, P732, DOI 10.1046/j.1365-2958.1999.01520.x; AlMamun AM, 1996, J BACTERIOL, V178, P3722, DOI 10.1128/jb.178.13.3722-3726.1996; Balashov S, 2002, J MOL BIOL, V315, P513, DOI 10.1006/jmbi.2001.5273; Becherel OJ, 2001, P NATL ACAD SCI USA, V98, P8566, DOI 10.1073/pnas.141113398; BONNER CA, 1990, P NATL ACAD SCI USA, V87, P7663, DOI 10.1073/pnas.87.19.7663; BROSIUS J, 1989, DNA-J MOLEC CELL BIO, V8, P759, DOI 10.1089/dna.1989.8.759; BROTCORNELANNOYE A, 1986, P NATL ACAD SCI USA, V83, P3904, DOI 10.1073/pnas.83.11.3904; CAMPBELL JL, 1974, J BACTERIOL, V119, P494, DOI 10.1128/JB.119.2.494-499.1974; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHEN H, 1990, DNA CELL BIOL, V9, P631, DOI 10.1089/dna.1990.9.631; COOPER DL, 1993, J BIOL CHEM, V268, P11823; Cull MG, 1995, METHOD ENZYMOL, V262, P22; CUPPLES CG, 1990, GENETICS, V125, P275; DELUCIA P, 1969, NATURE, V224, P1164, DOI 10.1038/2241164a0; Drake JW, 1998, GENETICS, V148, P1667; FAY PJ, 1982, J BIOL CHEM, V257, P5692; Fijalkowska IJ, 1997, J BACTERIOL, V179, P7435, DOI 10.1128/jb.179.23.7435-7445.1997; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P407; GEIDER K, 1974, J BIOL CHEM, V249, P3999; HILL CW, 1975, CELL, V6, P419, DOI 10.1016/0092-8674(75)90031-8; Humayun MZ, 1998, MOL MICROBIOL, V30, P905, DOI 10.1046/j.1365-2958.1998.01120.x; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; Kim SR, 2001, MOL GENET GENOMICS, V266, P207; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KORNBERG A, 1991, DNA REPLICATION, P165; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; LIVNEH Z, 1986, P NATL ACAD SCI USA, V83, P4599, DOI 10.1073/pnas.83.13.4599; MAKI H, 1988, J BIOL CHEM, V263, P6570; Maor-Shoshani A, 2000, P NATL ACAD SCI USA, V97, P565, DOI 10.1073/pnas.97.2.565; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MICHAELS ML, 1990, P NATL ACAD SCI USA, V87, P9211, DOI 10.1073/pnas.87.23.9211; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; Mo JY, 1996, J BIOL CHEM, V271, P18947, DOI 10.1074/jbc.271.31.18947; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Murphy HS, 1997, J BACTERIOL, V179, P7507, DOI 10.1128/jb.179.23.7507-7514.1997; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; PALEJWALA VA, 1995, J BACTERIOL, V177, P6041, DOI 10.1128/jb.177.21.6041-6048.1995; PALEJWALA VA, 1994, J BIOL CHEM, V269, P27433; PALEJWALA VA, 1991, BIOCHEMISTRY-US, V30, P8736, DOI 10.1021/bi00100a004; Pham P, 2001, NATURE, V409, P366, DOI 10.1038/35053116; Pham P, 2001, P NATL ACAD SCI USA, V98, P8350, DOI 10.1073/pnas.111007198; Pham PT, 1998, J BIOL CHEM, V273, P23575, DOI 10.1074/jbc.273.36.23575; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; Rahman MS, 1999, J BACTERIOL, V181, P1515, DOI 10.1128/JB.181.5.1515-1523.1999; Rahman MS, 1996, MOL MICROBIOL, V22, P747; Rangarajan S, 1999, P NATL ACAD SCI USA, V96, P9224, DOI 10.1073/pnas.96.16.9224; Ren L, 1999, MOL MICROBIOL, V32, P607, DOI 10.1046/j.1365-2958.1999.01378.x; Ren L, 2000, J BACTERIOL, V182, P1427, DOI 10.1128/JB.182.5.1427-1431.2000; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; SCHAAPER RM, 1985, GENE, V39, P181, DOI 10.1016/0378-1119(85)90312-9; SCHAAPER RM, 1986, J MOL BIOL, V189, P273, DOI 10.1016/0022-2836(86)90509-7; SCHAAPER RM, 1989, EMBO J, V8, P3511, DOI 10.1002/j.1460-2075.1989.tb08516.x; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; SIMHA D, 1991, BIOCHEMISTRY-US, V30, P8727, DOI 10.1021/bi00100a003; SINGER M, 1989, MICROBIOL REV, V53, P1; Slupska MM, 1996, P NATL ACAD SCI USA, V93, P4380, DOI 10.1073/pnas.93.9.4380; Strauss BS, 2000, J BACTERIOL, V182, P6742, DOI 10.1128/JB.182.23.6742-6750.2000; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tomer G, 1999, BIOCHEMISTRY-US, V38, P5948, DOI 10.1021/bi982599+; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; WICKNER W, 1973, P NATL ACAD SCI USA, V70, P1764, DOI 10.1073/pnas.70.6.1764; WICKNER W, 1974, J BIOL CHEM, V249, P6244; WOODGATE R, 1992, MUTAT RES, V281, P221, DOI 10.1016/0165-7992(92)90012-7; Zhao JY, 2001, J BACTERIOL, V183, P1796, DOI 10.1128/JB.183.5.1796-1800.2001	73	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46319	46327		10.1074/jbc.M206856200	http://dx.doi.org/10.1074/jbc.M206856200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324458	hybrid			2022-12-27	WOS:000179529300082
J	Banerjee, A				Banerjee, A			Coordination of posttranslational modifications of bovine brain alpha-tubulin - Polyglycylation of Delta 2 tubulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-TUBULIN; MONOCLONAL-ANTIBODY; RAT-BRAIN; COLCHICINE BINDING; SINGLE-UNIT; C-TERMINUS; IN-VITRO; ISOTYPES; TYROSINE; EXPRESSION	Microtubules participate in a large number of intracellular events including cell division, intracellular transport and secretion, axonal transport, and maintenance of cell morphology. They are composed of tubulin, a heterodimeric protein, consisting of two similar polypeptides alpha and beta. In mammalian cells, both alpha- and beta-tubutin occur as seven to eight different genetic variants, which also undergo numerous posttranslational modifications that include tyrosination-detyrosination and deglutamylation, phosphorylation, acetylation, polyglutamylation, and polyglycylation. Tyrosination-detyrosination is one of the major posttranslational modifications in which the C-terminal tyrosine residue in a-tubulin is added or removed reversibly. Although this modification does not alter the assembly activity of tubulin in vitro, these two forms of tubulin have been found to be distributed differently in vivo and are also correlated with microtubule stability (Gunderson, G. G., Kalnoski, M. H., and Bulinski, J. C. (1984) Cell 38, 779789). Thus, the question arises as to whether these two forms of tubulin differ in any other modifications. In an effort to answer this question, the tyrosinated and the nontyrosinated forms of the alpha1/2 isoform have been purified from brain tubulin by immunoaffinity chromatography. matrix-assisted laser desorption/ionization-time of flight mass spectrometric analysis of the C-terminal peptide revealed that the tyrosinated form is polyglutamylated with one to four Glu residues, while the Delta2 tubulin is polyglycylated with one to three Gly residues. These results indicate that posttranslational modifications of tubulin are correlated with each other and that polyglutamylation and polyglycylation of tubulin may have important roles in regulating microtubule assembly, stability, and function in vivo.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Banerjee, A (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	asokb@worldnet.att.net			NCI NIH HHS [R29 CA 59711] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA059711] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; ARGARANA CE, 1978, MOL CELL BIOCHEM, V19, P17; Avila J, 1990, MICROTUBULE PROTEINS, V1st; BANERJEE A, 1992, J BIOL CHEM, V267, P5625; Banerjee A, 1998, BIOCHEM BIOPH RES CO, V245, P349, DOI 10.1006/bbrc.1998.8426; BANERJEE A, 1988, J BIOL CHEM, V263, P3029; BANERJEE A, 1992, J BIOL CHEM, V267, P13335; BANERJEE A, 1994, J BIOL CHEM, V269, P10324; Banerjee A, 1999, BIOCHEMISTRY-US, V38, P5438, DOI 10.1021/bi981572n; Banerjee A, 1997, EUR J BIOCHEM, V246, P420, DOI 10.1111/j.1432-1033.1997.00420.x; Banerjee A, 1997, BIOCHEM BIOPH RES CO, V231, P698, DOI 10.1006/bbrc.1997.6170; BANERJEE A, 1991, J BIOL CHEM, V266, P1689; BARRA HS, 1973, J NEUROCHEM, V21, P1241, DOI 10.1111/j.1471-4159.1973.tb07578.x; BARRA HS, 1974, BIOCHEM BIOPH RES CO, V60, P1384, DOI 10.1016/0006-291X(74)90351-9; BARRA HS, 1973, J NEUROCHEM, V20, P97, DOI 10.1111/j.1471-4159.1973.tb12108.x; Bonnet C, 2001, J BIOL CHEM, V276, P12839, DOI 10.1074/jbc.M011380200; BOUCHER D, 1994, BIOCHEMISTRY-US, V33, P12471, DOI 10.1021/bi00207a014; Derry WB, 1997, BIOCHEMISTRY-US, V36, P3554, DOI 10.1021/bi962724m; Dustin P., 1978, MICROTUBULES; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; ERSFELD K, 1993, J CELL BIOL, V120, P725, DOI 10.1083/jcb.120.3.725; Geyp M, 1996, CANCER GENET CYTOGEN, V87, P117, DOI 10.1016/0165-4608(95)00235-9; GUNDERSEN GG, 1984, CELL, V38, P779, DOI 10.1016/0092-8674(84)90273-3; Hyams J.S., 1979, MICROTUBULES; JOYCE CM, 1992, J MOL BIOL, V227, P97, DOI 10.1016/0022-2836(92)90684-C; Khan IA, 1996, BIOCHEMISTRY-US, V35, P3704, DOI 10.1021/bi951247p; KREIS TE, 1987, EMBO J, V6, P2597, DOI 10.1002/j.1460-2075.1987.tb02550.x; Larcher JC, 1996, J BIOL CHEM, V271, P22117, DOI 10.1074/jbc.271.36.22117; LEWIS SA, 1987, CELL, V49, P539, DOI 10.1016/0092-8674(87)90456-9; LEWIS SA, 1988, J CELL BIOL, V106, P2023, DOI 10.1083/jcb.106.6.2023; LHERNAULT SW, 1983, J CELL BIOL, V97, P258, DOI 10.1083/jcb.97.1.258; LHERNAULT SW, 1985, BIOCHEMISTRY-US, V24, P473, DOI 10.1021/bi00323a034; LOPATA MA, 1987, J CELL BIOL, V105, P1707, DOI 10.1083/jcb.105.4.1707; LUDUENA R F, 1992, Current Opinion in Cell Biology, V4, P53, DOI 10.1016/0955-0674(92)90058-K; Luduena RF, 1998, INT REV CYTOL, V178, P207; LUDUENA RF, 1993, MOL BIOL CELL, V4, P445, DOI 10.1091/mbc.4.5.445; MARY J, 1994, FEBS LETT, V353, P89, DOI 10.1016/0014-5793(94)01018-8; MONTEIRO MJ, 1988, J MOL BIOL, V199, P439, DOI 10.1016/0022-2836(88)90616-X; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; OLMSTED JB, 1973, ANNU REV BIOCHEM, V42, P507, DOI 10.1146/annurev.bi.42.070173.002451; PANDA D, 1994, P NATL ACAD SCI USA, V91, P11358, DOI 10.1073/pnas.91.24.11358; PATURLELAFANECHERE L, 1991, BIOCHEMISTRY-US, V30, P10523, DOI 10.1021/bi00107a022; PRATT LF, 1988, EMBO J, V7, P931, DOI 10.1002/j.1460-2075.1988.tb02898.x; Raff EC, 1997, SCIENCE, V275, P70, DOI 10.1126/science.275.5296.70; RAYBIN D, 1977, J CELL BIOL, V73, P492, DOI 10.1083/jcb.73.2.492; RAYBIN D, 1977, BIOCHEMISTRY-US, V16, P2189, DOI 10.1021/bi00629a023; RAYBIN D, 1975, BIOCHEM BIOPH RES CO, V65, P1088, DOI 10.1016/S0006-291X(75)80497-9; Redeker V, 1998, BIOCHEMISTRY-US, V37, P14838, DOI 10.1021/bi981335k; REDEKER V, 1994, SCIENCE, V266, P1688, DOI 10.1126/science.7992051; RODRIGUEZ JA, 1978, BIOCHEM BIOPH RES CO, V83, P579, DOI 10.1016/0006-291X(78)91029-X; RUDIGER M, 1995, FEBS LETT, V364, P147, DOI 10.1016/0014-5793(95)00373-H; RUDIGER M, 1994, EUR J BIOCHEM, V220, P309, DOI 10.1111/j.1432-1033.1994.tb18627.x; Schwarz PM, 1998, BIOCHEMISTRY-US, V37, P4687, DOI 10.1021/bi972763d; SHARMA J, 1994, J PROTEIN CHEM, V13, P165, DOI 10.1007/BF01891975; Stanchi F, 2000, BIOCHEM BIOPH RES CO, V270, P1111, DOI 10.1006/bbrc.2000.2571; SULLIVAN KF, 1986, MOL CELL BIOL, V6, P4409, DOI 10.1128/MCB.6.12.4409; SULLIVAN KF, 1986, J BIOL CHEM, V261, P3317; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; Thazhath R, 2002, NAT CELL BIOL, V4, P256, DOI 10.1038/ncb764; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; Vinh J, 1999, BIOCHEMISTRY-US, V38, P3133, DOI 10.1021/bi982304s; WANG D, 1986, J CELL BIOL, V103, P1903, DOI 10.1083/jcb.103.5.1903	63	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46140	46144		10.1074/jbc.M208065200	http://dx.doi.org/10.1074/jbc.M208065200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12356754	hybrid			2022-12-27	WOS:000179529300058
J	Guo, FS; Esser, L; Singh, SK; Maurizi, MR; Xia, D				Guo, FS; Esser, L; Singh, SK; Maurizi, MR; Xia, D			Crystal structure of the heterodimeric complex of the adaptor, ClpS, with the N-domain of the AAA(+) chaperone, ClpA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SUBSTRATE-RECOGNITION; RIBOSOMAL-PROTEIN; HSP100 CHAPERONE; DEGRADATION; PROTEOLYSIS; REGULATOR; PROTEASES; IDENTIFICATION; TRANSLOCATION	Substrate selectivity and proteolytic activity for the E. coli ATP-dependent protease, ClpAP, is modulated by an adaptor protein, ClpS. ClpS binds to ClpA, the regulatory component of the ClpAP complex. We report the crystal structure of ClpS in complex with the isolated N-terminal domain of CIpA in two different crystal forms at 2.3- and 3.3-Angstrom resolution. The ClpS structure forms an alpha/beta-sandwich and is topologically analogous to the C-terminal domain of the ribosomal protein L7/L12. ClpS contacts two surfaces on the N-terminal domain in both crystal forms; the more extensive interface was shown to be favored in solution by protease protection experiments. The N-terminal 20 residues of ClpS are not visible in the crystal structures; the removal of the first 17 residues produces ClpSDeltaN, which binds to the CIpA N-domain but no longer inhibits CIpA activity. A zinc binding site involving two His and one Glu residue was identified crystallographically in the N-terminal domain of ClpA. In a model of ClpS bound to hexameric ClpA, ClpS is oriented with its N terminus directed toward the distal surface of ClpA, suggesting that the N-terminal region of ClpS may affect productive substrate interactions at the apical surface or substrate entry into the CIpA translocation channel.	NCI, Ctr Canc Res, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Xia, D (corresponding author), NCI, Ctr Canc Res, Cell Biol Lab, NIH, 37 Convent Dr,MSC 4255,Bldg 37,Rm 1B22, Bethesda, MD 20892 USA.	dixia@helix.nih.gov						Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAN AWE, 1993, PROTEIN SCI, V2, P1574, DOI 10.1002/pro.5560021004; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLMES MA, 1981, BIOCHEMISTRY-US, V20, P6912, DOI 10.1021/bi00527a026; Hoskins JR, 2000, J BIOL CHEM, V275, P35361, DOI 10.1074/jbc.M006288200; Ishikawa T, 2001, P NATL ACAD SCI USA, V98, P4328, DOI 10.1073/pnas.081543698; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISCHA K, 1971, NATURE-NEW BIOL, V233, P62, DOI 10.1038/newbio233062a0; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEIJONMARCK M, 1987, J MOL BIOL, V195, P555, DOI 10.1016/0022-2836(87)90183-5; Levchenko I, 2000, SCIENCE, V289, P2354, DOI 10.1126/science.289.5488.2354; Littlefield O, 2001, PROTEINS, V45, P219, DOI 10.1002/prot.1142; Lo JH, 2001, PROTEIN SCI, V10, P551, DOI 10.1110/ps.41401; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; MOLLER W, 1983, J MOL BIOL, V163, P553, DOI 10.1016/0022-2836(83)90112-2; Neuwald AF, 1999, GENOME RES, V9, P27; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Ortega J, 2002, EMBO J, V21, P4938, DOI 10.1093/emboj/cdf483; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Pratt LA, 1996, P NATL ACAD SCI USA, V93, P2488, DOI 10.1073/pnas.93.6.2488; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Sheldrick GM, 1998, DIRECT METHODS SOLVI; Singh SK, 2001, J BIOL CHEM, V276, P29420, DOI 10.1074/jbc.M103489200; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; Taylor AB, 2001, STRUCTURE, V9, P615, DOI 10.1016/S0969-2126(01)00621-9; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; Turgay K, 1998, EMBO J, V17, P6730; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Wahl MC, 2000, EMBO J, V19, P174, DOI 10.1093/emboj/19.2.174; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Zhou YN, 2001, GENE DEV, V15, P627, DOI 10.1101/gad.864401	49	88	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46753	46762		10.1074/jbc.M208104200	http://dx.doi.org/10.1074/jbc.M208104200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235156	hybrid			2022-12-27	WOS:000179529300135
J	Henn, A; Shi, SP; Zarivach, R; Ben-Zeev, EA; Sagi, I				Henn, A; Shi, SP; Zarivach, R; Ben-Zeev, EA; Sagi, I			The RNA helicase DbpA exhibits a markedly different conformation in the ADP-bound state when compared with the ATP- or RNA-bound states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAD-BOX PROTEIN; 23S RIBOSOMAL-RNA; CRYSTAL-STRUCTURE; UNWINDING RNA; DNA HELICASE; NUCLEOTIDE; FAMILY; COMPLEXES; SEQUENCE; EIF4A	The motor enzymes that belong to the family of RNA helicases catalyze the strand separation of duplex RNA via ATP hydrolysis. Among these enzymes, Escherichia coli DbpA is a unique RNA helicase because it possesses ATPase-specific activity toward the peptidyl transferase center in 23 S ribosomal RNA. For this reason, it has been the subject of numerous biochemical and structure-function studies. The ATP-stimulated unwinding activity of DbpA toward specific and nonspecific RNA duplexes has been demonstrated. However, the underlying molecular and structural basis, which facilitates its helicase activities, is presently not known. We combined time-dependent limited proteolysis digestion, fluorescence spectroscopy, and three-dimensional structural homology modeling techniques to study the structural conformations of DbpA with respect to its binding to stoichiometric ratios of RNA and cofactors. We show that the conformational state of DbpA is markedly different in the ADP-bound state than in any other state (ATP- or RNA-bound). These results, together with structural homology studies, suggest that a hinge region located in the core domain of DbpA mediates such conformational changes.	Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Sagi, I (corresponding author), Weizmann Inst Sci, Dept Biol Struct, POB 26, IL-76100 Rehovot, Israel.		ZARIVACH, RAZ/F-1671-2012; Henn, Arnon/O-1896-2019	ZARIVACH, RAZ/0000-0001-6543-0296; Henn, Arnon/0000-0001-6360-7211				Aubourg S, 1999, NUCLEIC ACIDS RES, V27, P628, DOI 10.1093/nar/27.2.628; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; Brion P, 1997, ANNU REV BIOPH BIOM, V26, P113, DOI 10.1146/annurev.biophys.26.1.113; Caruthers JM, 2000, P NATL ACAD SCI USA, V97, P13080, DOI 10.1073/pnas.97.24.13080; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Conn GL, 1998, CURR OPIN STRUC BIOL, V8, P278, DOI 10.1016/S0959-440X(98)80059-6; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; Diges CM, 2001, EMBO J, V20, P5503, DOI 10.1093/emboj/20.19.5503; FULLERPACE FV, 1993, EMBO J, V12, P3619, DOI 10.1002/j.1460-2075.1993.tb06035.x; GORBALENYA AE, 1988, NATURE, V333, P22, DOI 10.1038/333022a0; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Henn A, 2001, P NATL ACAD SCI USA, V98, P5007, DOI 10.1073/pnas.071372498; Jankowsky E, 2000, NATURE, V403, P447, DOI 10.1038/35000239; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Kossen K, 1999, NUCLEIC ACIDS RES, V27, P3811, DOI 10.1093/nar/27.19.3811; Linder P, 2001, TRENDS BIOCHEM SCI, V26, P339, DOI 10.1016/S0968-0004(01)01870-9; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2180, DOI 10.1021/bi972430g; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2194, DOI 10.1021/bi9724319; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; Marians KJ, 1997, STRUCTURE, V5, P1129, DOI 10.1016/S0969-2126(97)00263-3; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NICOL SM, 1995, P NATL ACAD SCI USA, V92, P11681, DOI 10.1073/pnas.92.25.11681; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Polach KJ, 2002, BIOCHEMISTRY-US, V41, P3693, DOI 10.1021/bi012062n; Pugh GE, 1999, J MOL BIOL, V292, P771, DOI 10.1006/jmbi.1999.3112; RAY BK, 1985, J BIOL CHEM, V260, P7651; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; Story RM, 2001, P NATL ACAD SCI USA, V98, P1465, DOI 10.1073/pnas.98.4.1465; Tanaka H, 2002, NATURE, V415, P192, DOI 10.1038/415192a; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; Tsu CA, 1998, BIOCHEMISTRY-US, V37, P16989, DOI 10.1021/bi981837y; Tsu CA, 2001, RNA, V7, P702, DOI 10.1017/S1355838201010135; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3	36	20	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46559	46565		10.1074/jbc.M207438200	http://dx.doi.org/10.1074/jbc.M207438200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324462	hybrid			2022-12-27	WOS:000179529300111
J	Jenne, N; Frey, K; Brugger, B; Wieland, FT				Jenne, N; Frey, K; Brugger, B; Wieland, FT			Oligomeric state and stoichiometry of p24 proteins in the early secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPI-COATED VESICLES; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEINS; GOLGI-APPARATUS; FAMILY MEMBERS; CYTOPLASMIC DOMAIN; CARGO RECEPTORS; TRANSPORT; COMPLEX; LOCALIZATION	The p24 proteins belong to a highly conserved family of membrane proteins that cycle in the early secretory pathway. They bind to the coat proteins of COPI and COPII vesicles, and are proposed to be involved in vesicle biogenesis, cargo uptake, and quality control, but their precise function is still under debate. Most p24 proteins form hetero-oligomers, essential for their correct localization and stability. Functional insights regarding the mechanisms of their steady state localization and the role of interaction with coat proteins has been hampered by a lack of data on their concentration and state of oligomerization within the endoplasmic reticulum, the intermediate compartment, and Golgi complex. We have determined for all mammalian p24 family members the size of the oligomers formed and their stoichiometric relation in each of these individual organelles. In contrast to earlier reports, we show that individual members exist as dimers and monomers and that the ratio between these two forms depends on both the organelle investigated and the p24 protein. We find unequal quantities, with p23 and p27 building up concentration gradients, ruling out a simple 1:1 stoichiometry. In addition, we show differential cycling of individual p24 members. These data point to a complex and dynamic system of altering dimerizations of the family members.	Univ Heidelberg, Zentrum Biochem, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Wieland, FT (corresponding author), Univ Heidelberg, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.							Barr FA, 2001, J CELL BIOL, V155, P885, DOI 10.1083/jcb.200108102; Belden WJ, 2001, J BIOL CHEM, V276, P43040, DOI 10.1074/jbc.M108113200; Belden WJ, 1996, J BIOL CHEM, V271, P26939, DOI 10.1074/jbc.271.43.26939; Blum R, 1999, J CELL SCI, V112, P537; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; BREW K, 1975, J BIOL CHEM, V250, P1434; Brugger B, 2000, J CELL BIOL, V151, P507, DOI 10.1083/jcb.151.3.507; Denzel A, 2000, CURR BIOL, V10, P55, DOI 10.1016/S0960-9822(99)00266-3; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; Emery G, 1999, PROTOPLASMA, V207, P24, DOI 10.1007/BF01294710; Emery G, 2000, J CELL SCI, V113, P2507; Fullekrug J, 1999, MOL BIOL CELL, V10, P1939, DOI 10.1091/mbc.10.6.1939; Gommel D, 1999, FEBS LETT, V447, P179, DOI 10.1016/S0014-5793(99)00246-X; Gommel DU, 2001, EMBO J, V20, P6751, DOI 10.1093/emboj/20.23.6751; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; HARLOWE E, 1988, ANTIBODIES LAB MANUA; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Majoul I, 2001, DEV CELL, V1, P139, DOI 10.1016/S1534-5807(01)00004-1; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; Nickel W, 1997, P NATL ACAD SCI USA, V94, P11393, DOI 10.1073/pnas.94.21.11393; Nickel W, 1998, J CELL SCI, V111, P3081; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; Orci L, 2000, P NATL ACAD SCI USA, V97, P10400, DOI 10.1073/pnas.190292497; Reinhard C, 1999, P NATL ACAD SCI USA, V96, P1224, DOI 10.1073/pnas.96.4.1224; Rojo M, 2000, J CELL SCI, V113, P1043; Rojo M, 1997, J CELL BIOL, V139, P1119, DOI 10.1083/jcb.139.5.1119; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; TABAS I, 1979, J BIOL CHEM, V254, P1655; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; WARNOCK DE, 1993, J BIOL CHEM, V268, P10145; Weidler M, 2000, BIOCHEM BIOPH RES CO, V271, P401, DOI 10.1006/bbrc.2000.2511; Wen CH, 1999, J CELL BIOL, V145, P1165, DOI 10.1083/jcb.145.6.1165	39	95	101	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46504	46511		10.1074/jbc.M206989200	http://dx.doi.org/10.1074/jbc.M206989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237308	hybrid			2022-12-27	WOS:000179529300104
J	Krug, AW; Schuster, C; Gassner, B; Freudinger, R; Mildenberger, S; Troppmair, J; Gekle, M				Krug, AW; Schuster, C; Gassner, B; Freudinger, R; Mildenberger, S; Troppmair, J; Gekle, M			Human epidermal growth factor receptor-1 expression renders chinese hamster ovary cells sensitive to alternative aldosterone signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ACTIVATED PROTEIN-KINASE; NA+/H+-EXCHANGE; RAPID ACTIVATION; EGF-RECEPTOR; STEROID-HORMONES; ANGIOTENSIN-II; MDCK CELLS; STIMULATION; REQUIRES	The epidermal growth factor (EGF) regulates cell proliferation, differentiation, and ion transport using ERK1/2 as a downstream effector. Furthermore, the EGF receptor (EGFR) is involved in signaling by G-protein-coupled receptors, growth hormone, and cytokines via transactivation. It has been suggested that steroids interact with peptide hormones. Previously, we have shown that aldosterone modulates EGF responses in Madin-Darby canine kidney cells (Gekle, M., Freudinger, R., Mildenberger, S., and Silbernagl, S. (2002) Am. J. Physiol. 282, F669-F679). Here, we tested the hypothesis that human EGFR-1 can confer alternative aldosterone responsiveness with respect to ERK1/2 phosphorylation to Chinese hamster ovary cells, which do not express EGFR. Wild-type Chinese hamster ovary cells did not respond to EGF or aldosterone. After transfection of human EGFR-1, the cells responded to EGF, but not to aldosterone. However, when submaximal concentrations of EGF were used, nanomolar concentrations of aldosterone potentiated the action of EGF within minutes, resulting in a leftward shift of the EGF dose-response curve. This was not the case in mocktransfected cells. The EGFR kinase inhibitor tyrphostin AG1478 or the MEK1/2 inhibitor U0126 completely prevented the effect. Furthermore, aldosterone enhanced Tyr phosphorylation of c-Src and EGFR, and an inhibitor of cytosolic tyrosine kinases (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyriociaine) prevented the action of aldosterone. Our data show that aldosterone uses the EGF-EGFR-MEK1/2-ERR1/2 signaling cascade to elicit its alternative effects. In the presence of EGF, aldosterone leads to EGFR transactivation via cytosolic tyrosine kinases of the Src family.	Univ Wurzburg, Inst Physiol, D-97070 Wurzburg, Germany; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97070 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Gekle, M (corresponding author), Univ Wurzburg, Inst Physiol, Rontgenring 9, D-97070 Wurzburg, Germany.			Troppmair, Jakob/0000-0002-0611-3837				Alzamora R, 2000, HYPERTENSION, V35, P1099, DOI 10.1161/01.HYP.35.5.1099; Bokemeyer D, 2000, KIDNEY INT, V58, P549, DOI 10.1046/j.1523-1755.2000.t01-1-00201.x; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CHRIST M, 1993, J CLIN ENDOCR METAB, V77, P1452, DOI 10.1210/jc.77.6.1452; COOPER GJ, 1994, J PHYSIOL-LONDON, V479, P423, DOI 10.1113/jphysiol.1994.sp020306; Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272; Danto SI, 1998, AM J PHYSIOL-CELL PH, V275, pC82, DOI 10.1152/ajpcell.1998.275.1.C82; Doolan CM, 1996, J BIOL CHEM, V271, P8763, DOI 10.1074/jbc.271.15.8763; ELNAHAS AM, 1992, KIDNEY INT, V41, pS15; Gekle M, 2002, AM J PHYSIOL-RENAL, V282, pF669, DOI 10.1152/ajprenal.00159.2001; Gekle M, 2001, PFLUG ARCH EUR J PHY, V441, P781, DOI 10.1007/s004240000507; Gekle M, 2002, STEROIDS, V67, P499, DOI 10.1016/S0039-128X(01)00183-0; Gekle M, 1996, P NATL ACAD SCI USA, V93, P10500, DOI 10.1073/pnas.93.19.10500; Grazzini E, 1998, NATURE, V392, P509, DOI 10.1038/33176; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Ishida M, 1998, CIRC RES, V82, P7; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; Manegold JC, 1999, CELL MOL BIOL, V45, P805; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Neugarten J, 1999, AM J PHYSIOL-RENAL, V277, pF875, DOI 10.1152/ajprenal.1999.277.6.F875; OBERLEITHNER H, 1989, J MEMBRANE BIOL, V111, P49, DOI 10.1007/BF01869208; OBERLEITHNER H, 1987, P NATL ACAD SCI USA, V84, P1464, DOI 10.1073/pnas.84.5.1464; Ookawara S, 1999, MINER ELECTROL METAB, V25, P191, DOI 10.1159/000057444; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; Schramek H, 1997, J PHARMACOL EXP THER, V283, P1460; SCHWAB A, 1995, GENOMIC NONGENOMIC E, P51; Shi W, 2000, J CELL BIOL, V148, P591, DOI 10.1083/jcb.148.3.591; Stockand JD, 1999, J BIOL CHEM, V274, P35449, DOI 10.1074/jbc.274.50.35449; Urbach V, 1996, J PHYSIOL-LONDON, V491, P111, DOI 10.1113/jphysiol.1996.sp021200; Versteeg HH, 2000, BIOCHEM J, V350, P717, DOI 10.1042/0264-6021:3500717; VILELLA S, 1992, PFLUG ARCH EUR J PHY, V422, P9, DOI 10.1007/BF00381507; WARDEN DH, 1993, AM J PHYSIOL, V264, P670; WEHLING M, 1995, CIRC RES, V76, P973, DOI 10.1161/01.RES.76.6.973; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; WEHLING M, 1992, AM J PHYSIOL, V263, P974; Winter DC, 1999, J MEMBRANE BIOL, V170, P17	40	79	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45892	45897		10.1074/jbc.M208851200	http://dx.doi.org/10.1074/jbc.M208851200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244120	hybrid			2022-12-27	WOS:000179529300025
J	Prusty, D; Park, BH; Davis, KE; Farmer, SR				Prusty, D; Park, BH; Davis, KE; Farmer, SR			Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor gamma (PPAR gamma) and C/EBP alpha gene expression during the differentiation of 3T3-L1 preadipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-MEDIATED PHOSPHORYLATION; MITOTIC CLONAL EXPANSION; GROWTH FACTOR-I; PROTEIN-KINASE; ADIPOCYTE DIFFERENTIATION; DNA-BINDING; CELL-CYCLE; INSULIN; CASCADE; INHIBITION	We demonstrate that exposure of post-confluent 3T3-L1 preadipocytes to insulin, isobutylmethylxanthine (MIX), dexamethasone (DEX), and fetal bovine serum induces a rapid but transient activation of MEK1 as indicated by extensive phosphorylation of ERK1 and ERK2 during the initial 2 h of adipogenesis. Inhibition of this activity by treating the cells with a MEK1-specific inhibitor (U0126 or PD98059) prior to the induction of differentiation significantly attenuated the expression of peroxisome proliferator-activated receptor (PPAR) gamma, CCAAT/enhancer-binding protein (C/EBP) alpha, perilipin, and adipocyte-specific fatty acid-binding protein (aP2). Treating the preadipocytes with troglitazone, a potent PPAR-gamma ligand, could circumvent the inhibition of adipogenic gene expression by U0126. Fibroblast growth factor-2 (FGF-2), in the presence of dexamethasone, isobutylmethylxanthine, and insulin, induces a prolonged activation of the MEK/ERK signaling pathway, which lasts for at least 12 h post-induction, and this activity is less sensitive to the MEK inhibitors. Consequently, preadipocytes treated with U0126 in the presence of fibroblast growth factor-2 (FGF-2) express normal post-induction levels of MEK activity, and, in so doing, are capable of undergoing adipogenesis. We further show that activation of MEK1 significantly enhances the transactivation of the C/EBPalpha minimal promoter during the early phase of the differentiation process. Our results suggest that activation of the MEK/ERK signaling pathway during the initial 12 h of adipogenesis enhances the activity of factors that regulate both C/EBPalpha and PPARgamma expression.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Farmer, SR (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	farmer@biochem.bumc.bu.edu		Farmer, Stephen/0000-0003-2483-2795	NIDDK NIH HHS [DK58825, DK51586] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK051586, R01DK051586, R01DK058825, R56DK058825] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Aubert J, 1999, J BIOL CHEM, V274, P24965, DOI 10.1074/jbc.274.35.24965; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; Boney CM, 2000, MOL ENDOCRINOL, V14, P805, DOI 10.1210/me.14.6.805; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Camp HS, 1997, J BIOL CHEM, V272, P10811; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chan GK, 2001, ENDOCRINOLOGY, V142, P4900, DOI 10.1210/en.142.11.4900; Chupreta S, 2000, AM J PHYSIOL-CELL PH, V278, pC697, DOI 10.1152/ajpcell.2000.278.4.C697; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; GULLER S, 1988, ENDOCRINOLOGY, V122, P2084, DOI 10.1210/endo-122-5-2084; Hansen JB, 2002, J BIOL CHEM, V277, P26335, DOI 10.1074/jbc.M203870200; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3467, DOI 10.1073/pnas.95.7.3467; Kim SW, 2001, J BIOL CHEM, V276, P10199, DOI 10.1074/jbc.M010640200; Klemm DJ, 2001, J BIOL CHEM, V276, P28430, DOI 10.1074/jbc.M103382200; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Machinal-Quelin F, 2002, AM J PHYSIOL-CELL PH, V282, pC853, DOI 10.1152/ajpcell.00331.2001; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Milasincic DJ, 1996, MOL CELL BIOL, V16, P5964; Morrison RF, 1999, J CELL BIOCHEM, P59; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; MOUSTAID N, 1990, J CELL BIOCHEM, V42, P243, DOI 10.1002/jcb.240420407; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Patel YM, 2000, J BIOL CHEM, V275, P17653, DOI 10.1074/jbc.M910445199; Qiu ZL, 2001, J BIOL CHEM, V276, P11988, DOI 10.1074/jbc.M011729200; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; Rosen ED, 2000, GENE DEV, V14, P1293; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; SCOTT RE, 1982, P NATL ACAD SCI-BIOL, V79, P845, DOI 10.1073/pnas.79.3.845; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shimba S, 2001, J CELL SCI, V114, P2809; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771	43	404	426	3	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46226	46232		10.1074/jbc.M207776200	http://dx.doi.org/10.1074/jbc.M207776200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270934	hybrid			2022-12-27	WOS:000179529300070
J	Ullan, RV; Casqueiro, J; Banuelos, O; Fernandez, FJ; Gutierrez, S; Martin, JF				Ullan, RV; Casqueiro, J; Banuelos, O; Fernandez, FJ; Gutierrez, S; Martin, JF			A novel epimerization system in fungal secondary metabolism involved in the conversion of isopenicillin N into penicillin N in Acremonium chrysogenum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEACETYLCEPHALOSPORIN-C ACETYLTRANSFERASE; CEPHALOSPORIN BIOSYNTHETIC GENES; METHYLACYL-COA RACEMASE; CELL-FREE CONVERSION; DEACETOXYCEPHALOSPORIN-C; CEFG GENE; EPIMERASE ACTIVITY; MOLECULAR-CLONING; CHIRAL INVERSION; BETA-OXIDATION	The epimerization step that converts isopenicillin N into penicillin N during cephalosporin biosynthesis has remained uncharacterized despite its industrial relevance. A transcriptional analysis of a 9-kb region located downstream of the pcbC gene revealed the presence of two transcripts that correspond to the genes named cefD1 and cefD2 encoding proteins with high similarity to long chain acyl-CoA synthetases and acyl-CoA racemases from Mus musculus, Homo sapiens, and Rattus norvegicus. Both genes are expressed in opposite orientations from a bidirectional promoter region. Targeted inactivation of cefD1 and cefD2 was achieved by the two-marker gene replacement procedure. Disrupted strains lacked isopenicillin N epimerase activity, were blocked in cephalosporin C production, and accumulated isopenicillin N. Complementation in trans of the disrupted nonproducer mutant with both genes restored epimerase activity and cephalosporin biosynthesis. However, when cefD1 or cefD2 were introduced separately into the double-disrupted mutant, no epimerase activity was detected, indicating that the concerted action of both proteins encoded by cetD1 and cetD2 is required for epimerization of isopenicillin N into penicillin N. This epimerization system occurs in eukaryotic cells and is entirely different from the known epimerization systems involved in the biosynthesis of bacterial beta-lactam antibiotics.	Univ Leon, Area Microbiol, Fac Ciencias Biol & Ambientales, E-24071 Leon, Spain; Inst Biotecnol Leon, Leon 24006, Spain	Universidad de Leon	Martin, JF (corresponding author), Univ Leon, Area Microbiol, Fac Ciencias Biol & Ambientales, E-24071 Leon, Spain.	degjmm@unileon.es	Gutiérrez, Santiago/H-6456-2015; Fernandez, Francisco/L-3320-2015	Gutiérrez, Santiago/0000-0001-6659-1390; Fernandez, Francisco/0000-0003-4676-1828; Casqueiro, Javier/0000-0001-9046-2708; Banuelos, Oscar/0000-0002-7418-5955				ACKMAN RG, 1967, LIPIDS, V2, P357, DOI 10.1007/BF02531848; AHARONOWITZ Y, 1992, ANNU REV MICROBIOL, V46, P461, DOI 10.1146/annurev.mi.46.100192.002333; BALDWIN JE, 1981, BIOCHEM J, V194, P649, DOI 10.1042/bj1940649; CALDWELL J, 1988, BIOCHEM PHARMACOL, V37, P105, DOI 10.1016/0006-2952(88)90762-9; Cheng YQ, 2000, J BIOL CHEM, V275, P4906, DOI 10.1074/jbc.275.7.4906; COQUE JJR, 1993, MOL GEN GENET, V236, P453, DOI 10.1007/BF00277148; Demain AL, 1983, ANTIBIOTICS CONTAINI, P189; FINGERHUT R, 1993, J INHERIT METAB DIS, V16, P591, DOI 10.1007/BF00711690; Gutierrez S, 1999, MICROBIOL-SGM, V145, P317, DOI 10.1099/13500872-145-2-317; Gutierrez S, 1999, ANTON LEEUW INT J G, V75, P81, DOI 10.1023/A:1001861025070; GUTIERREZ S, 1992, J BACTERIOL, V174, P3056; GUTIERREZ S, 1991, J BACTERIOL, V173, P2354; Gutierrez S, 1997, APPL MICROBIOL BIOT, V48, P606, DOI 10.1007/s002530051103; GUTIERREZ S, 1991, MOL GEN GENET, V225, P56; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JAYATILAKE GS, 1981, BIOCHEM J, V194, P645, DOI 10.1042/bj1940645; JENSEN SE, 1983, CAN J MICROBIOL, V29, P1526, DOI 10.1139/m83-234; Kleinkauf H, 1996, EUR J BIOCHEM, V236, P335, DOI 10.1111/j.1432-1033.1996.00335.x; KNIHINICKI RD, 1991, BIOCHEM PHARMACOL, V42, P1905, DOI 10.1016/0006-2952(91)90588-V; KONOMI T, 1979, BIOCHEM J, V184, P427, DOI 10.1042/bj1840427; Kosalkova K, 2001, J IND MICROBIOL BIOT, V27, P252, DOI 10.1038/sj.jim.7000192; KOVACEVIC S, 1990, J BACTERIOL, V172, P3952, DOI 10.1128/jb.172.7.3952-3958.1990; LAIZ L, 1990, J GEN MICROBIOL, V136, P663, DOI 10.1099/00221287-136-4-663; Liras P, 1999, ANTON LEEUW INT J G, V75, P109, DOI 10.1023/A:1001804925843; Liu YY, 2000, CLIN CANCER RES, V6, p4502S; LUBBE C, 1986, APPL MICROBIOL BIOT, V23, P367; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Martin J F, 1989, Adv Biochem Eng Biotechnol, V39, P153; Martin JF, 2000, J ANTIBIOT, V53, P1008, DOI 10.7164/antibiotics.53.1008; Martin JF, 1998, APPL MICROBIOL BIOT, V50, P1, DOI 10.1007/s002530051249; Martin JF, 2000, J BACTERIOL, V182, P2355, DOI 10.1128/JB.182.9.2355-2362.2000; Martin JF, 1990, MOL IND MYCOLOGY, P149; MARTIN JF, 1997, FUNGAL BIOTECHNOLOGY, P91; MARTIN JF, 2000, ENCY MICROBIOLOGY, P213; NEUSS N, 1982, J ANTIBIOT, V35, P580, DOI 10.7164/antibiotics.35.580; PUNT PJ, 1990, GENE, V93, P101, DOI 10.1016/0378-1119(90)90142-E; Reichel C, 1997, MOL PHARMACOL, V51, P576, DOI 10.1124/mol.51.4.576; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAMSON SM, 1985, NATURE, V318, P191, DOI 10.1038/318191a0; SAMSON SM, 1987, P NATL ACAD SCI USA, V84, P5705, DOI 10.1073/pnas.84.16.5705; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADA Y, 1980, ANTIMICROB AGENTS CH, V27, P380; SCHMITZ W, 1994, EUR J BIOCHEM, V222, P313, DOI 10.1111/j.1432-1033.1994.tb18870.x; Schmitz W, 1997, EUR J BIOCHEM, V244, P434, DOI 10.1111/j.1432-1033.1997.00434.x; Schmitz W, 1997, BIOCHEM J, V326, P883, DOI 10.1042/bj3260883; SCHMITZ W, 1995, EUR J BIOCHEM, V231, P815, DOI 10.1111/j.1432-1033.1995.0815d.x; SHEN YQ, 1986, BIO-TECHNOL, V4, P61, DOI 10.1038/nbt0186-61; SHIEH WR, 1993, J BIOL CHEM, V268, P3487; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1111/j.1574-6968.1995.tb07328.x; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; Ullan RV, 2002, MOL GENET GENOMICS, V267, P673, DOI 10.1007/s00438-002-0702-5; USUI S, 1989, BIOCHIM BIOPHYS ACTA, V999, P78, DOI 10.1016/0167-4838(89)90033-2; VanVeldhoven PP, 1996, FEBS LETT, V388, P80, DOI 10.1016/0014-5793(96)00508-X; Velasco J, 1999, BIOCHEM J, V337, P379, DOI 10.1042/0264-6021:3370379; VELASCO J, 1994, J BACTERIOL, V176, P985, DOI 10.1128/JB.176.4.985-991.1994; Velasco J, 2001, APPL MICROBIOL BIOT, V57, P350	57	52	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46216	46225		10.1074/jbc.M207482200	http://dx.doi.org/10.1074/jbc.M207482200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12228250	hybrid			2022-12-27	WOS:000179529300069
J	Allen, DL; Leinwand, LA				Allen, DL; Leinwand, LA			Intracellular calcium and myosin isoform transitions - Calcineurin and calcium-calmodulin kinase pathways regulate preferential activation of the iia myosin heavy chain promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; SKELETAL-MUSCLE FIBERS; GENE-EXPRESSION; SLOW MYOSIN; DEPENDENT PATHWAY; SARCOPLASMIC-RETICULUM; ELECTRICAL-ACTIVITY; ADULT FAST; C-JUN; TRANSCRIPTION	Intracellular calcium levels can have profound effects on muscle biology via alterations in gene expression. In particular, intracellular calcium levels increase during muscle activation and are thought to underlie fast-to-slow shifts in muscle gene expression. In the present work, we determined that increased intracellular calcium has a significant effect on the activity of the adult fast myosin heavy chain (MyHC) promoters in the order of MyHC IIa much greater than IId/x > IIb. We have identified the pathways by which the calcium signal mediates increased activation of the MyHC IIa promoter. Inhibition of calcineurin or calcium-calmodulin kinase greatly attenuates ionophore-induced activation of the MyHC IIa promoter, whereas protein kinase C inhibitors have no effect. Inhibition and overexpression studies with members of the mitogen-activated protein kinase family reveal roles for MEK1/MEK2 and MEKK1, but not p38 or phosphatidylinositol 3-kinase. Downstream mediators of these effects are the activities of the MEF-2 and NFAT transcription factors, whose binding sites in the MyHC IIa promoter are required for calcium-induced activation of the MyHC IIa promoter.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Allen, DL (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Campus Box 347, Boulder, CO 80309 USA.			LEINWAND, LESLIE/0000-0003-1470-4810	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029090] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM29090] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen DL, 2001, J BIOL CHEM, V276, P43524, DOI 10.1074/jbc.M108017200; Altiok N, 2001, FEBS LETT, V487, P333, DOI 10.1016/S0014-5793(00)02311-5; Bernal-Mizrachi E, 2000, J BIOL CHEM, V275, P25681, DOI 10.1074/jbc.M003424200; Bigard X, 2000, J BIOL CHEM, V275, P19653, DOI 10.1074/jbc.M000430200; Boppart MD, 2000, J PHYSIOL-LONDON, V526, P663, DOI 10.1111/j.1469-7793.2000.00663.x; Buonanno A, 1999, CURR OPIN NEUROBIOL, V9, P110, DOI 10.1016/S0959-4388(99)80014-2; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DiMario JX, 1999, DEV DYNAM, V216, P177; Dunn SE, 2001, J BIOL CHEM, V276, P45243, DOI 10.1074/jbc.M105445200; Fluck M, 2000, BIOCHEM BIOPH RES CO, V270, P488, DOI 10.1006/bbrc.2000.2457; Fluck M, 1999, J APPL PHYSIOL, V86, P1793, DOI 10.1152/jappl.1999.86.6.1793; Freyssenet D, 1999, J BIOL CHEM, V274, P9305, DOI 10.1074/jbc.274.14.9305; Friday BB, 2001, J CELL SCI, V114, P303; Gordon SE, 2001, J APPL PHYSIOL, V90, P1174, DOI 10.1152/jappl.2001.90.3.1174; Halseth AE, 2000, J APPL PHYSIOL, V88, P669, DOI 10.1152/jappl.2000.88.2.669; Johnson CM, 1997, J NEUROSCI, V17, P6189; Kubis HP, 1997, P NATL ACAD SCI USA, V94, P4205, DOI 10.1073/pnas.94.8.4205; Lakich MM, 1998, J BIOL CHEM, V273, P15217, DOI 10.1074/jbc.273.24.15217; Marshall P, 2001, J BIOL CHEM, V276, P20719, DOI 10.1074/jbc.M102100200; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Meissner JD, 2001, J PHYSIOL-LONDON, V533, P215, DOI 10.1111/j.1469-7793.2001.0215b.x; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Murgia M, 2000, NAT CELL BIOL, V2, P142, DOI 10.1038/35004013; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; NEUFER PD, 1993, AM J PHYSIOL, V265, pC1597; Pette D, 1997, Int Rev Cytol, V170, P143, DOI 10.1016/S0074-7696(08)61622-8; PETTE D, 1984, MED SCI SPORT EXER, V16, P517; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; Serrano AL, 2001, P NATL ACAD SCI USA, V98, P13108, DOI 10.1073/pnas.231148598; Shin KS, 1997, J BIOL CHEM, V272, P21227, DOI 10.1074/jbc.272.34.21227; Swoap SJ, 2000, AM J PHYSIOL-CELL PH, V279, pC915, DOI 10.1152/ajpcell.2000.279.4.C915; Thelen MHM, 1997, BIOCHEM J, V321, P845, DOI 10.1042/bj3210845; Torgan CE, 2001, MOL BIOL CELL, V12, P1499, DOI 10.1091/mbc.12.5.1499; Vali S, 2000, J CELL PHYSIOL, V185, P184, DOI 10.1002/1097-4652(200011)185:2<184::AID-JCP3>3.0.CO;2-T; Wei L, 2000, AM J PHYSIOL-HEART C, V278, pH1736, DOI 10.1152/ajpheart.2000.278.6.H1736; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yu M, 2001, J PHYSIOL-LONDON, V536, P273, DOI 10.1111/j.1469-7793.2001.00273.x; Zhao M, 1999, MOL CELL BIOL, V19, P21	46	81	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45323	45330		10.1074/jbc.M208302200	http://dx.doi.org/10.1074/jbc.M208302200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235157	hybrid			2022-12-27	WOS:000179404800094
J	Hilario, P; Yan, SX; Hingerty, BE; Broyde, S; Basu, AK				Hilario, P; Yan, SX; Hingerty, BE; Broyde, S; Basu, AK			Comparative mutagenesis of the C8-guanine adducts of 1-nitropyrene and 1,6-and 1,8-dinitropyrene in a CpG repeat sequence - A slipped frameshift intermediate model for dinucleotide deletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; COMPARATIVE TUMORIGENICITY; REPETITIVE SEQUENCES; DNA-REPLICATION; MISMATCH REPAIR; MUTAGENICITY; N-(DEOXYGUANOSIN-8-YL)-1-AMINOPYRENE; POLYMERASE; OLIGODEOXYNUCLEOTIDES; MECHANISMS	In the Ames Salmonella typhimurium reversion assay 1,6- and 1,8-dinitropyrenes (1,6- and 1,8-DNPs) are much more potent mutagens than 1-nitropyrene (1-NP). Genetic experiments established that certain differences in the metabolism of the DNPs, which in turn result in increased DNA adduction, play a role. It remained unclear, however, if the DNP adducts, N-(guanin-8-yl)-1-amino-6 (8)-nitropyrene (Gua-C8-1,6-ANP and Gua-C8-1,8-ANP), which contain a nitro group on the pyrene ring covalently linked to the guanine C8, are more mutagenic than the major 1-NP adduct, N-(guanin-8-yl)-1-aminopyrene (Gua-C8-AP). In order to address this, we have compared the mutation frequency of the three guanine C8 adducts, Gua-C8-AP, Gua-C8-1,6-ANP, and GuaC8-1,8-ANP in a CGCG*CG sequence. Single-stranded M13mp7L2 vectors containing these adducts and a control were constructed and replicated in Escherichia coli. A remarkable difference in the induced CpG deletion frequency between these adducts was noted. In repair-competent cells the 1-NP adduct induced 1.7% CpG deletions without SOS, whereas the 1,6- and 1,8-DNP adducts induced 6.8 and 10.0% two-base deletions, respectively. With SOS, CpG deletions increased up to 1.9, 11.1, and 15.1% by 1-NP, 1,6-, and 1,8-DNP adducts, respectively. This result unequivocally established that DNP adducts are more mutagenic than the 1-NP adduct in the repetitive CpG sequence. In each case the mutation frequency was significantly increased in a mutS strain, which is impaired in methyl-directed mismatch repair, and a dnaQ strain, which carries a defect in proofreading activity of the DNA polymerase III. Modeling studies showed that the nitro group on the pyrene ring at the 8-position can provide additional stabilization to the two-nucleotide extrahelical loop in the promutagenic slipped frameshift intermediate through its added hydrogen-bonding capability. This could account for the increase in CpG deletions in the M13 vector with the nitro-containing adducts compared with the Gua-C8-AP adduct itself.	Univ Connecticut, Dept Chem, Storrs, CT 06269 USA; NYU, Dept Chem, New York, NY 10003 USA; NYU, Dept Biol, New York, NY 10003 USA; Oak Ridge Natl Lab, Div Life Sci Res, Oak Ridge, TN 37830 USA	University of Connecticut; New York University; New York University; United States Department of Energy (DOE); Oak Ridge National Laboratory	Basu, AK (corresponding author), Univ Connecticut, Dept Chem, U-60, Storrs, CT 06269 USA.			Yan, Frank/0000-0002-9121-9694	NCI NIH HHS [CA28038, CA75449] Funding Source: Medline; NIEHS NIH HHS [1 K02 ES00318, K02 ES000318, ES09127, R01 ES009127] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028038, R01CA075449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K02ES000318, R01ES009127, R56ES009127] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bacolod MD, 2000, CHEM RES TOXICOL, V13, P523, DOI 10.1021/tx000023r; Bacolod MD, 2001, MUTAGENESIS, V16, P461, DOI 10.1093/mutage/16.6.461; BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BELL DA, 1991, MUTAT RES, V252, P35, DOI 10.1016/0165-1161(91)90249-8; BONNER CA, 1992, J BIOL CHEM, V267, P11431; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ELBAYOUMY K, 1988, CANCER RES, V48, P4256; ELBAYOUMY K, 1995, CARCINOGENESIS, V16, P431, DOI 10.1093/carcin/16.2.431; ELBAYOUMY K, 1984, CARCINOGENESIS, V5, P1449, DOI 10.1093/carcin/5.11.1449; FIFER EK, 1986, CARCINOGENESIS, V7, P65, DOI 10.1093/carcin/7.1.65; FIFER EK, 1986, MUTAGENESIS, V1, P433, DOI 10.1093/mutage/1.6.433; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; GARCIA A, 1993, P NATL ACAD SCI USA, V90, P5989, DOI 10.1073/pnas.90.13.5989; HINGERTY BE, 1989, BIOPOLYMERS, V28, P1195, DOI 10.1002/bip.360280703; HIROSE M, 1984, CANCER RES, V44, P1158; *IARC, 1989, IARC MON EV CARC RIS, V39, P1; LAMBERT IB, 1992, P NATL ACAD SCI USA, V89, P1310, DOI 10.1073/pnas.89.4.1310; Lenne-Samuel N, 2000, MOL MICROBIOL, V38, P299, DOI 10.1046/j.1365-2958.2000.02116.x; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; MALIA SA, 1995, BIOCHEMISTRY-US, V34, P96, DOI 10.1021/bi00001a012; Malia SA, 1996, BIOCHEMISTRY-US, V35, P4568, DOI 10.1021/bi9525132; Maniatis T., 1989, MOL CLONING LABORATO, P21; Mao B, 1996, BIOCHEMISTRY-US, V35, P12659, DOI 10.1021/bi961078o; Marx A, 2002, CHEMBIOCHEM, V3, P405, DOI 10.1002/1439-7633(20020503)3:5<405::AID-CBIC405>3.0.CO;2-4; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; NAPOLITANO RL, 1994, BIOCHEMISTRY-US, V33, P1311, DOI 10.1021/bi00172a004; Nolan SJ, 1996, CARCINOGENESIS, V17, P133, DOI 10.1093/carcin/17.1.133; OHANDLEY SF, 1993, BIOCHEMISTRY-US, V32, P2481, DOI 10.1021/bi00061a005; PITTS JN, 1978, SCIENCE, V202, P515, DOI 10.1126/science.705341; Purohit V, 2000, CHEM RES TOXICOL, V13, P673, DOI 10.1021/tx000002x; Purohit V, 2000, ORG LETT, V2, P1871, DOI 10.1021/ol000090c; ROSENKRANZ HS, 1983, MUTAT RES, V114, P217, DOI 10.1016/0165-1110(83)90034-9; ROSENKRANZ HS, 1980, SCIENCE, V209, P1039, DOI 10.1126/science.6996095; Roy D, 1998, CHEM RES TOXICOL, V11, P1301, DOI 10.1021/tx980106w; SCHAAPER RM, 1990, CARCINOGENESIS, V11, P1087, DOI 10.1093/carcin/11.7.1087; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; Schlegel HB., 2009, GAUSSIAN 09 REVISION; STREISINGER G, 1985, GENETICS, V109, P633; VYAS RR, 1993, TETRAHEDRON LETT, V34, P2247, DOI 10.1016/S0040-4039(00)77585-X; Wagner J, 2002, DNA REPAIR, V1, P159, DOI 10.1016/S1568-7864(01)00012-X; Wang LH, 2002, BIOPHYS J, V83, P382, DOI 10.1016/S0006-3495(02)75177-1	41	17	17	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45068	45074		10.1074/jbc.M208103200	http://dx.doi.org/10.1074/jbc.M208103200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12239219	hybrid			2022-12-27	WOS:000179404800062
J	Saito, S; Frank, GD; Mifune, M; Ohba, M; Utsunomiya, H; Motley, ED; Inagami, T; Eguchi, S				Saito, S; Frank, GD; Mifune, M; Ohba, M; Utsunomiya, H; Motley, ED; Inagami, T; Eguchi, S			Ligand-independent trans-activation of the platelet-derived growth factor receptor by reactive oxygen species requires protein kinase C-delta and C-Src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SIGNAL-REGULATED KINASE; FACTOR-BETA-RECEPTOR; ANGIOTENSIN-II; TYROSINE KINASE; COUPLED RECEPTORS; PHOSPHORYLATION; TRANSACTIVATION; EGF; ATHEROSCLEROSIS	Reactive oxygen species are involved in the mitogenic signal transduction cascades initiated by several growth factors and play a critical role in mediating cardiovascular diseases. Interestingly, H2O2 induces tyrosine phosphorylation and trans-activation of the platelet-derived growth factor receptor and the epidermal growth factor receptor in many cell lines including vascular smooth muscle cells. To investigate the molecular mechanism by which reactive oxygen species contribute to vascular diseases, we have examined a signal transduction cascade involved in H2O2-induced platelet-derived growth factor receptor activation in vascular smooth muscle cells. We found that H2O2 induced a ligand-independent phosphorylation of the platelet-derived growth factor-beta receptor at Tyr(1012), a phospholipase C-gamma binding site, involving the requirement of protein kinase C-delta and c-Src that is distinct from a ligand-dependent autophosphorylation. Also, H2O2 induced the association of protein kinase C-delta with the platelet-derived growth factor-beta receptor and c-Src in vascular smooth muscle cells. These findings will provide new mechanistic insights by which enhanced reactive oxygen species production in vascular smooth muscle cells induces unique alleys of signal transduction distinct from those induced by endogenous ligands leading to an abnormal vascular remodeling process.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Showa Univ, Inst Mol Oncol, Tokyo 1428555, Japan; Wakayama Med Univ, Dept Pathol, Wakayama 6410012, Japan; Meharry Med Coll, Dept Anat & Physiol, Nashville, TN 37208 USA	Vanderbilt University; Showa University; Wakayama Medical University; Meharry Medical College	Eguchi, S (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007323, R01HL058205, R37HL058205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, P30DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NHLBI NIH HHS [HL-07323, HL58205] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; Benes C, 2001, AM J PHYSIOL-CELL PH, V280, pC1498, DOI 10.1152/ajpcell.2001.280.6.C1498; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dowler S, 2000, BIOCHEM J, V349, P605, DOI 10.1042/0264-6021:3490605; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Escargueil-Blanc I, 2001, CIRCULATION, V104, P1814, DOI 10.1161/hc4001.097179; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Frank GD, 2000, ENDOCRINOLOGY, V141, P3120, DOI 10.1210/en.141.9.3120; Frank GD, 2002, MOL ENDOCRINOL, V16, P367, DOI 10.1210/me.16.2.367; Frank GD, 2001, BIOCHEM BIOPH RES CO, V280, P1116, DOI 10.1006/bbrc.2001.4251; Frank GD, 2000, BIOCHEM BIOPH RES CO, V270, P761, DOI 10.1006/bbrc.2000.2505; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Heldin CH, 1997, FEBS LETT, V410, P17, DOI 10.1016/S0014-5793(97)00318-9; Heldin CH, 2002, ARCH BIOCHEM BIOPHYS, V398, P284, DOI 10.1006/abbi.2001.2707; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; Motley ED, 2002, HYPERTENSION, V39, P508, DOI 10.1161/hy02t2.102907; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Pawson T, 1997, NATURE, V385, P582, DOI 10.1038/385582b0; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rao GN, 1996, ONCOGENE, V13, P713; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sanna PP, 2000, P NATL ACAD SCI USA, V97, P8653, DOI 10.1073/pnas.140219097; Schwartz SM, 1997, J CLIN INVEST, V100, pS87; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699	41	86	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44695	44700		10.1074/jbc.M208332200	http://dx.doi.org/10.1074/jbc.M208332200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12226102	hybrid			2022-12-27	WOS:000179404800014
J	Szeltner, Z; Rea, D; Juhasz, T; Renner, V; Mucsi, Z; Orosz, G; Fulop, V; Polgar, L				Szeltner, Z; Rea, D; Juhasz, T; Renner, V; Mucsi, Z; Orosz, G; Fulop, V; Polgar, L			Substrate-dependent competency of the catalytic triad of prolyl oligopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEPTIDASE INHIBITORS; SERINE PROTEASES; ENZYME; SITE; MECHANISM; HISTIDINE; ACID; IDENTIFICATION; INACTIVATION; CONSTANT	Prolyl oligopeptidase, a serine peptidase unrelated to trypsin and subtilisin, is implicated in memory disorders and is an important target of drug design. The catalytic competence of the Asp 641 residue of the catalytic triad (Ser(554), Asp(641), His(680)) was studied using the D641N and D641A variants of the enzyme. Both variants displayed 3 orders of magnitude reduction in k(cat)/K-m for benzyloxycarbonyl-Gly-Pro-2-naphthylamide. Using an octapeptide substrate, the decrease was 6 orders of magnitude, whereas with Z-Gly-Pro-4-nitrophenyl ester there was virtually no change in k(cat)/K-m. This indicates that the contribution of Asp641 is very much dependent on the substrate-leaving group, which was not the case for the classic serine peptidase, trypsin. The rate constant for benzyloxycarbonyl-Gly-Pro-thiobenzylester conformed to this series as demonstrated by a method designed for monitoring the hydrolysis of thiolesters in the presence of thiol groups. Alkylation of His(680) with Z-Gly-Pro-CH2Cl was concluded with similar rate constants for wild-type and D641A variant. However, kinetic measurements with Z-Gly-Pro-OH, a product-like inhibitor, indicated that the His(680) is not accessible in the enzyme variants. Crystal structure determination of these mutants revealed subtle perturbations related to the catalytic activity. Many of these observations show differences in the catalysis between trypsin and prolyl oligopeptidase.	Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, H-1518 Budapest 112, Hungary; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Eotvos Lorand Univ, Dept Organ Chem, H-1117 Budapest 112, Hungary	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; University of Warwick; Eotvos Lorand University	Polgar, L (corresponding author), Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, POB 7, H-1518 Budapest 112, Hungary.	polgar@enzim.hu	Fulop, Vilmos/AAZ-7720-2021; Mucsi, Zoltan/J-9404-2019					ATACK JR, 1991, EUR J PHARMACOL, V205, P157, DOI 10.1016/0014-2999(91)90814-7; BACHOVCHIN WW, 1981, P NATL ACAD SCI-BIOL, V78, P7323, DOI 10.1073/pnas.78.12.7323; BACHOVCHIN WW, 1978, J AM CHEM SOC, V100, P8041, DOI 10.1021/ja00494a001; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; Cornish-Bowden A, 1995, FUNDAMENTALS ENZYME, p[44, 108, 139]; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; Cunningham DF, 1997, BBA-PROTEIN STRUCT M, V1343, P160, DOI 10.1016/S0167-4838(97)00134-9; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FERSHT AR, 1973, J MOL BIOL, V74, P137, DOI 10.1016/0022-2836(73)90103-4; Fulop V, 2000, EMBO REP, V1, P277, DOI 10.1093/embo-reports/kvd048; Fulop V, 2001, J BIOL CHEM, V276, P1262, DOI 10.1074/jbc.M007003200; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORDAN F, 1981, BIOCHEMISTRY-US, V20, P6366, DOI 10.1021/bi00525a013; KETTNER C, 1981, METHOD ENZYMOL, V80, P826; Kirschke H, 1999, PROTEOLYTIC ENZYMES, P11; KOSSIAKOFF AA, 1981, BIOCHEMISTRY-US, V20, P6462, DOI 10.1021/bi00525a027; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leatherbarrow R.J., 2001, GRAFIT VERSION 5; MAES M, 1994, BIOL PSYCHIAT, V35, P545, DOI 10.1016/0006-3223(94)90101-5; MENTLEIN R, 1988, FEBS LETT, V234, P251, DOI 10.1016/0014-5793(88)80092-9; MIURA N, 1995, NEUROSCI LETT, V196, P128, DOI 10.1016/0304-3940(95)11821-D; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Polg?r L., 1987, NEW COMPREHENSIVE BI, V16, P159; POLGAR L, 1969, P NATL ACAD SCI USA, V64, P1335, DOI 10.1073/pnas.64.4.1335; POLGAR L, 1993, FEBS LETT, V322, P227, DOI 10.1016/0014-5793(93)81575-K; POLGAR L, 1995, BIOCHEM J, V312, P267, DOI 10.1042/bj3120267; POLGAR L, 1992, BIOCHEM J, V283, P647, DOI 10.1042/bj2830647; Polgar L, 2002, CELL MOL LIFE SCI, V59, P349, DOI 10.1007/s00018-002-8427-5; POLGAR L, 1994, METHOD ENZYMOL, V244, P188; POLGAR L, 1972, ACTA BIOCHIMICA B A, V7, P29; POLGAR L, 1989, MECHANISMS PROTEASE, P87; Portevin B, 1996, J MED CHEM, V39, P2379, DOI 10.1021/jm950858c; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; SEGEL IH, 1975, ENZYME KINETICS, P72; SHAW E, 1981, METHOD ENZYMOL, V80, P820; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; St?cker, 1999, PROTEOLYTIC ENZYMES, P148, DOI 10.1007/978-3-642-59816-6; STONE SR, 1991, BIOCHEM J, V276, P837, DOI 10.1042/bj2760837; Szeltner Z, 2000, J BIOL CHEM, V275, P15000, DOI 10.1074/jbc.M000942200; Szeltner Z, 2000, PROTEIN SCI, V9, P353; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; TSOU CL, 1988, ADV ENZYMOL RAMB, V61, P381; WARSHEL A, 1978, P NATL ACAD SCI USA, V75, P5250, DOI 10.1073/pnas.75.11.5250; WELCHES WR, 1993, LIFE SCI, V52, P1461, DOI 10.1016/0024-3205(93)90108-F; WILK S, 1983, LIFE SCI, V33, P2149, DOI 10.1016/0024-3205(83)90285-0; Williams RSB, 1999, EMBO J, V18, P2734, DOI 10.1093/emboj/18.10.2734; YOSHIMOTO T, 1977, BIOCHEMISTRY-US, V16, P660	53	29	30	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44597	44605		10.1074/jbc.M207386200	http://dx.doi.org/10.1074/jbc.M207386200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228249	hybrid			2022-12-27	WOS:000179404800003
J	Hashiguchi, M; Saito, T; Hisanaga, S; Hashiguchi, T				Hashiguchi, M; Saito, T; Hisanaga, S; Hashiguchi, T			Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser(202)/Thr(205) of human tau	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; CDC2-LIKE PROTEIN-KINASE; RECOMBINANT-TAU; P25; CALPAIN; CLEAVAGE; BINDING; EPITOPE; BRAIN; SITE	Hyperphosphorylated tau is a major component of neurofibrillary tangles, one of the hallmarks of Alzheimer's disease. CDK5 is a kinase that phosphorylates the tau protein, and its endogenous activator, p35, regulates its activity. Recently, calpain was found to digest p35 to its truncated product, p25. Several lines of evidence suggest that p25-CDK5 has much more powerful kinase activity and that it may cause abnormal hyperphosphorylation of tau. In this study, we have examined the kinetic characteristics of in vitro phosphorylation of the longest isoform of human tau by CDK5 and its activators using recombinant proteins. Although the kinase activity of CDK5 in phosphorylating tau was significantly higher in the presence of p25, the affinity of CDK5 for tau was not different. Phosphopeptide mapping revealed enhanced phosphorylation of Ser(202)/Thr(205) residues by p25-CDK5 (amino acid residues of tau are numbered according to the longest isoform of human tau). These results suggest that cleavage of p35 to p25 greatly enhances the kinase activity of CDK5 and increases the phosphorylation of Ser(202)/Thr(205). Considering the fact that phosphorylation of Ser(202)/Thr(205) antagonizes the tau-mediated nucleation of tubulin, p25-CDK5 may play a pivotal role in neuronal cell death in Alzheimer's disease.	Tokyo Med Univ, Dept Physiol, Shinjuku Ku, Tokyo 1608402, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Dept Sci Biol, Hachioji, Tokyo 1920397, Japan	Tokyo Medical University; Tokyo Metropolitan University	Hashiguchi, M (corresponding author), Tokyo Med Univ, Dept Physiol, Shinjuku Ku, 6-1-1 Shinjuku, Tokyo 1608402, Japan.	Mhashigu@aol.com						Alvarez A, 1999, FEBS LETT, V459, P421, DOI 10.1016/S0014-5793(99)01279-X; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; GOEDERT M, 1995, NEUROSCI LETT, V189, P167, DOI 10.1016/0304-3940(95)11484-E; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; Jicha GA, 1999, J NEUROCHEM, V72, P214, DOI 10.1046/j.1471-4159.1999.0720214.x; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; LUC B, 2000, BRAIN RES REV, V33, P95; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1518, DOI 10.1046/j.1432-1327.2001.02024.x; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Paudel HK, 1997, J BIOL CHEM, V272, P28328, DOI 10.1074/jbc.272.45.28328; Paudel HK, 1997, J BIOL CHEM, V272, P1777; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; PREUSS U, 1995, MOL BIOL CELL, V6, P1397, DOI 10.1091/mbc.6.10.1397; Sengupta A, 1997, MOL CELL BIOCHEM, V167, P99, DOI 10.1023/A:1006883924775; Sharma P, 1999, J BIOL CHEM, V274, P9600, DOI 10.1074/jbc.274.14.9600; Sironi JJ, 1998, FEBS LETT, V436, P471, DOI 10.1016/S0014-5793(98)01185-5; Smith DS, 2001, CELL GROWTH DIFFER, V12, P277; Sobue K, 2000, J BIOL CHEM, V275, P16673, DOI 10.1074/jbc.M000784200; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; Taniguchi S, 2001, FEBS LETT, V489, P46, DOI 10.1016/S0014-5793(00)02431-5; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x	24	119	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44525	44530		10.1074/jbc.M207426200	http://dx.doi.org/10.1074/jbc.M207426200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226093	hybrid			2022-12-27	WOS:000179272000124
J	Rui, LY; Yuan, MS; Frantz, D; Shoelson, S; White, MF				Rui, LY; Yuan, MS; Frantz, D; Shoelson, S; White, MF			SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR SUBSTRATE-1; PHOSPHATIDYLINOSITOL 3-KINASE; BOX MOTIF; IFN-GAMMA; RESISTANCE; SUPPRESSORS; MICE; PROTEINS; LIVER; GENE	Inflammation associates with peripheral insulin resistance, which dysregulates nutrient homeostasis and leads to diabetes. Inflammation induces the expression of SOCS proteins. We show that SOCS1 or SOCS3 targeted IRS1 and IRS2, two critical signaling molecules for insulin action, for ubiquitin-mediated degradation. SOCS1 or SOCS3 bound both recombinant and endogenous IRS1 and IRS2 and promoted their ubiquitination and subsequent degradation in multiple cell types. Mutations in the conserved SOCS box of SOCS1 abrogated its interaction with the elongin BC ubiquitin-ligase complex without affecting its binding to IRS1 or IRS2. The SOCS1 mutants also failed to promote the ubiquitination and degradation of either IRS1 or IRS2. Adenoviral-mediated expression of SOCS1 in mouse liver dramatically reduced hepatic IRS1 and IRS2 protein levels and caused glucose intolerance; by contrast, expression of the SOCS1 mutants had no effect. Thus, SOCS-mediated degradation of IRS proteins, presumably via the elongin BC ubiquitin-ligase, might be a general mechanism of inflammation-induced insulin resistance, providing a target for therapy.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Howard Hughes Med Inst, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute	White, MF (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Howard Hughes Med Inst, 1 Joslin Pl, Boston, MA 02215 USA.	whitemor@joslab.harvard.edu						Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Burks DJ, 2000, NATURE, V407, P377, DOI 10.1038/35030105; Campbell JS, 2001, J CLIN INVEST, V107, P1285, DOI 10.1172/JCI11867; Chan JCN, 2002, INT J OBESITY, V26, P994, DOI 10.1038/sj.ijo.0802017; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; Colson A, 2000, ENDOCRINOLOGY, V141, P3687, DOI 10.1210/en.141.10.3687; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Emanuelli B, 2001, J BIOL CHEM, V276, P47944, DOI 10.1074/jbc.M104602200; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hostamisligil GS, 1999, EXP CLIN ENDOCR DIAB, V107, P119, DOI 10.1055/s-0029-1212086; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kawazoe Y, 2001, J EXP MED, V193, P263, DOI 10.1084/jem.193.2.263; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Konstantopoulos N, 2000, DIABETES, V49, pA14; Krebs DL, 2000, J CELL SCI, V113, P2813; Krebs DL, 2002, MOL CELL BIOL, V22, P4567, DOI 10.1128/MCB.22.13.4567-4578.2002; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Kushner JA, 2002, J CLIN INVEST, V109, P1193, DOI 10.1172/JCI200214439; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Mooney RA, 2001, J BIOL CHEM, V276, P25889, DOI 10.1074/jbc.M010579200; Naka T, 2001, IMMUNITY, V14, P535, DOI 10.1016/S1074-7613(01)00132-7; Ogle CK, 2000, SHOCK, V14, P392, DOI 10.1097/00024382-200014030-00026; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; Saito H, 2000, J IMMUNOL, V164, P5833, DOI 10.4049/jimmunol.164.11.5833; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Waite KJ, 2001, J BIOL CHEM, V276, P7062, DOI 10.1074/jbc.M007894200; WHITE MF, 2001, ENDOCRINOLOGY; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Withers DJ, 2000, ENDOCRINOLOGY, V141, P1917, DOI 10.1210/en.141.6.1917; Withers DJ, 1999, CURR OPIN ENDOCRINOL, V6, P141; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	45	666	701	1	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42394	42398		10.1074/jbc.C200444200	http://dx.doi.org/10.1074/jbc.C200444200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12228220	hybrid			2022-12-27	WOS:000178985300137
J	Borgius, LJ; Steffensen, KR; Gustafsson, JA; Treuter, E				Borgius, LJ; Steffensen, KR; Gustafsson, JA; Treuter, E			Glucocorticoid signaling is perturbed by the atypical orphan receptor and corepressor SHP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; DNA-BINDING DOMAIN; NUCLEAR RECEPTORS; COACTIVATOR PGC-1; TRANSCRIPTIONAL COACTIVATOR; HEPATIC GLUCONEOGENESIS; ESTROGEN-RECEPTORS; STEROID-RECEPTORS; HORMONE-RECEPTOR; LIVING CELLS	SHP (NROB2) is an atypical orphan nuclear receptor that lacks a DNA-binding domain but contains a putative ligand-binding domain. Previous studies have revealed that SHP interacts with a variety of nuclear receptors and inhibits their transcriptional activity, thereby acting as a corepressor. In this report we identify the glucocorticoid receptor (GR) as a novel downstream target receptor for SHP inhibition. SHP potently inhibits dexamethasone-induced transcriptional GR activity in mammalian cells, and the inhibition involves a functional second NR-box within SHP. Interestingly, this motif shows a high homology with the N-R-box in the glucocorticoid and cAMP-inducible GR coactivator PGC-1, indicating similar binding specificity and shared target receptors. We show that SHP antagonizes PGG-1 coactivation and, in addition, we identify the PGC-1-regulated phospho(enol)pyruvate carboxykinase (PEPCK) promoter as a novel target promoter for SHP inhibition. This implies a physiologically relevant role for SHP in modulating hepatic glucocorticoid action. Furthermore, when coexpressing green fluorescent protein-tagged GR together with SHP, an intranuclear redistribution of GR was observed. As inhibition-deficient SHP mutants were unable to induce this redistribution, intranuclear tethering of target receptors may represent yet another, previously uncovered, aspect of SHP inhibition.	Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden	Karolinska Institutet	Borgius, LJ (corresponding author), Karolinska Inst, Ludwig Inst Canc Res, Box 240, S-17177 Stockholm, Sweden.	lotta.borgius@licr.ki.se		Treuter, Eckardt/0000-0002-4147-8989; Steffensen, Knut/0000-0001-6093-2801				Almlof T, 1997, MOL CELL BIOL, V17, P934, DOI 10.1128/MCB.17.2.934; Baumann CT, 2001, MOL ENDOCRINOL, V15, P485, DOI 10.1210/me.15.4.485; Bavner A, 2002, EMBO REP, V3, P478, DOI 10.1093/embo-reports/kvf087; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Delaunay F, 1997, J CLIN INVEST, V100, P2094, DOI 10.1172/JCI119743; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Glass CK, 2000, GENE DEV, V14, P121; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Hager GL, 2000, J STEROID BIOCHEM, V74, P249, DOI 10.1016/S0960-0760(00)00100-X; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Hu X, 2001, MOL CELL BIOL, V21, P1747, DOI 10.1128/MCB.21.5.1747-1758.2001; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; Lalli E, 2000, MOL CELL BIOL, V20, P4910, DOI 10.1128/MCB.20.13.4910-4921.2000; Lee HK, 1998, J BIOL CHEM, V273, P14398, DOI 10.1074/jbc.273.23.14398; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Ling ZC, 1998, DIABETOLOGIA, V41, P634, DOI 10.1007/s001250050961; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Maglich JM, 2001, GENOME BIOL, V2; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Masuda N, 1997, BBA-GENE STRUCT EXPR, V1350, P27, DOI 10.1016/S0167-4781(96)00196-0; MCMAHON M, 1988, DIABETES METAB REV, V4, P17, DOI 10.1002/dmr.5610040105; Nishigori H, 2001, P NATL ACAD SCI USA, V98, P575, DOI 10.1073/pnas.98.2.575; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Sugiyama T, 2000, J BIOL CHEM, V275, P3446, DOI 10.1074/jbc.275.5.3446; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Wu XY, 2001, J BIOL CHEM, V276, P24177, DOI 10.1074/jbc.M100412200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang JS, 1999, MOL CELL BIOL, V19, P6448; Zhang M, 2001, J BIOL CHEM, V276, P41690, DOI 10.1074/jbc.M105117200; Zilliacus J, 2001, MOL ENDOCRINOL, V15, P501, DOI 10.1210/mend.15.4.0624	43	106	109	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49761	49766		10.1074/jbc.M205641200	http://dx.doi.org/10.1074/jbc.M205641200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12324453	hybrid			2022-12-27	WOS:000180028900088
J	Nillni, EA; Xie, WH; Mulcahy, L; Sanchez, VC; Wetsel, WC				Nillni, EA; Xie, WH; Mulcahy, L; Sanchez, VC; Wetsel, WC			Deficiencies in pro-thyrotropin-releasing hormone processing and abnormalities in thermoregulation in Cpe(fat/fat) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE-E MUTATION; CENTRAL-NERVOUS-SYSTEM; OBESE FAT/FAT MICE; METALLOCARBOXYPEPTIDASE-D; PROHORMONE CONVERTASES; CPE(FAT)/CPE(FAT) MICE; FAT MUTATION; PARAVENTRICULAR NUCLEUS; TISSUE DISTRIBUTION; RAT HYPOTHALAMUS	Cpe(fat/fat) mice are obese, diabetic, and infertile. They have a mutation in carboxypeptidase E (CPE), an enzyme that converts prohormone intermediates to bioactive peptides. The Cpe(fat) mutation leads to rapid degradation of the enzyme. To test whether pro-thyrotropin-releasing hormone (TRH) conversion to TRH involves CPE, processing was examined in the Cpe(fat/fat) mouse. Hypothalamic TRH is depressed by at least 75% compared with wild-type controls. Concentrations of pro-TRH forms are increased in homozygotes. TRH-[Gly(4)-Lys(5)-Arg(6)] and TRH-[Gly(4)-Lys(5)] represent approximately 45% of the total TRH-like immunoreactivity in Cpe(fat/fat) mice; they constitute similar to1% in controls. Levels of TRH-[Gly(4)] were depressed in homozygotes. Because the hypothalamus contains some TRH, another carboxypeptidase must be responsible for processing. Immunocytochemical studies indicate that TRH neurons contain CPE- and carboxypeptidase D-like immunoreactivity. Recombinant CPE or carboxypeptidase D can convert synthetic TRH-[Gly(4)-Lys(5)] and TRH-[Gly(4) -Lys(5)-Arg(6)] to TRH-[Gly(4)]. When Cpe(fat/fat) mice are exposed to cold, they cannot maintain their body temperatures, and this loss is associated with hypothalamic TRH depletion and reduction in thyroid hormone. These findings demonstrate that the Cpe(fat) mutation can affect not only carboxypeptidase activity but also endoproteolysis. Because Cpe(fat/fat) mice cannot sustain a cold challenge, and because alterations in the hypothalamic-pituitary-thyroid axis can affect metabolism, deficits in pro-TRH processing may contribute to the obese and diabetic phenotype in these mice.	Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Mouse Blvd & Neuroendocrine Anal Core Facil, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Endocrinol, Mouse Blvd & Neuroendocrine Anal Core Facil, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Mouse Blvd & Neuroendocrine Anal Core Facil, Durham, NC 27710 USA; Brown Univ, Rhode Isl Hosp, Dept Med, Div Endocrinol, Providence, RI 02903 USA	Duke University; Duke University; Duke University; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Wetsel, WC (corresponding author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Mouse Blvd & Neuroendocrine Anal Core Facil, Durham, NC 27710 USA.	wetse001@mc.duke.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK058148, R01DK058148] Funding Source: NIH RePORTER; NICHD NIH HHS [HD3615] Funding Source: Medline; NIDDK NIH HHS [DK58148] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Arancibia S, 1996, NEUROENDOCRINOLOGY, V64, P257, DOI 10.1159/000127126; ARANCIBIA S, 1983, NEUROENDOCRINOLOGY, V37, P225, DOI 10.1159/000123547; Berman Y, 2001, J BIOL CHEM, V276, P1466, DOI 10.1074/jbc.M008499200; Cain BM, 1997, ENDOCRINOLOGY, V138, P4034, DOI 10.1210/en.138.9.4034; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; delaCruz IP, 1996, J BIOL CHEM, V271, P22736, DOI 10.1074/jbc.271.37.22736; DONDERS SHJ, 1985, J CLIN ENDOCR METAB, V61, P56, DOI 10.1210/jcem-61-1-56; Dong W, 1999, NEUROSCIENCE, V89, P1301, DOI 10.1016/S0306-4522(98)00381-9; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; Fricker LD, 1996, J BIOL CHEM, V271, P30619, DOI 10.1074/jbc.271.48.30619; Fricker LD, 2000, J NEUROSCI, V20, P639, DOI 10.1523/JNEUROSCI.20-02-00639.2000; Fricker LD, 1999, TRENDS BIOCHEM SCI, V24, P390, DOI 10.1016/S0968-0004(99)01448-6; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1982, P NATL ACAD SCI-BIOL, V79, P3886, DOI 10.1073/pnas.79.12.3886; FRICKER LD, 1994, NEUROPROTOCOLS, V5, P151; FRIEDMAN TC, 1995, ENDOCRINOLOGY, V136, P4462, DOI 10.1210/en.136.10.4462; HANSEN LF, 2000, BIOCHEM BIOPH RES CO, V267, P638; JACKSON IMD, 1974, ENDOCRINOLOGY, V95, P854, DOI 10.1210/endo-95-3-854; Jutras I, 1997, J BIOL CHEM, V272, P15184, DOI 10.1074/jbc.272.24.15184; Lacourse KA, 1998, FEBS LETT, V436, P61, DOI 10.1016/S0014-5793(98)01099-0; LECHAN RM, 1982, ENDOCRINOLOGY, V111, P55, DOI 10.1210/endo-111-1-55; Leiter EH, 1999, ENDOCRINE, V10, P57, DOI 10.1385/ENDO:10:1:57; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maddatu T, 1997, MAMM GENOME, V8, P857, DOI 10.1007/s003359900594; MANDEL G, 1987, TRENDS NEUROSCI, V10, P101, DOI 10.1016/0166-2236(87)90050-6; McGivern RF, 1997, J NEUROSCI, V17, P4886; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1271, DOI 10.1210/en.132.3.1271; Nillni EA, 2000, J BIOL CHEM, V275, P36124, DOI 10.1074/jbc.M003549200; Nillni EA, 1999, ENDOCR REV, V20, P599, DOI 10.1210/er.20.5.599; Nillni EA, 2001, ENDOCRINOLOGY, V142, P896, DOI 10.1210/en.142.2.896; Novikova EG, 1999, J BIOL CHEM, V274, P28887, DOI 10.1074/jbc.274.41.28887; Perloff MD, 1998, PEPTIDES, V19, P1115, DOI 10.1016/S0196-9781(98)00010-2; REDEI E, 1995, ENDOCRINOLOGY, V136, P3557, DOI 10.1210/en.136.8.3557; Reichlin S., 1998, WILLIAMS TXB ENDOCRI, P165; RONDEEL JMM, 1991, NEUROENDOCRINOLOGY, V54, P477, DOI 10.1159/000125940; ROUSSEL JP, 1991, NEUROENDOCRINOLOGY, V54, P559, DOI 10.1159/000125960; Rovere C, 1996, ENDOCRINOLOGY, V137, P2954, DOI 10.1210/en.137.7.2954; SATOH T, 1992, MOL BRAIN RES, V14, P131, DOI 10.1016/0169-328X(92)90020-C; Schaner P, 1997, J BIOL CHEM, V272, P19958, DOI 10.1074/jbc.272.32.19958; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Shen FS, 1997, P NATL ACAD SCI USA, V94, P5314, DOI 10.1073/pnas.94.10.5314; Song LX, 1996, J BIOL CHEM, V271, P28884, DOI 10.1074/jbc.271.46.28884; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; TACHE Y, 1989, ANN NY ACAD SCI, V553, P269; Udupi V, 1997, ENDOCRINOLOGY, V138, P1959, DOI 10.1210/en.138.5.1959; Varlamov O, 1999, J BIOL CHEM, V274, P14759, DOI 10.1074/jbc.274.21.14759; Varlamov O, 1996, J BIOL CHEM, V271, P13981, DOI 10.1074/jbc.271.24.13981; WETSEL WC, 1988, MOL ENDOCRINOL, V2, P22, DOI 10.1210/mend-2-1-22; Yamada M, 1997, P NATL ACAD SCI USA, V94, P10862, DOI 10.1073/pnas.94.20.10862; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919; ZOELLER RT, 1990, ENDOCRINOLOGY, V127, P2955, DOI 10.1210/endo-127-6-2955	53	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48587	48595		10.1074/jbc.M206702200	http://dx.doi.org/10.1074/jbc.M206702200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12270926	hybrid			2022-12-27	WOS:000179789600081
J	Barker-Carlson, K; Lawrence, DA; Schwartz, BS				Barker-Carlson, K; Lawrence, DA; Schwartz, BS			Acyl-enzyme complexes between tissue-type plasminogen activator and neuroserpin are short-lived in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERPIN-PROTEASE COMPLEX; REACTIVE-CENTER LOOP; HUMAN-PLASMA; INHIBITOR; RECEPTOR; NEURONS; DEGENERATION; PURIFICATION; LIPOPROTEIN; UROKINASE	The serine protease tissue-type plasminogen activator (t-PA) initiates the fibrinolytic protease cascade and plays a significant role in motor learning, memory, and neuronal cell death induced by excitotoxin and ischemia. In the fibrinolytic system, the serpin PAI-1 negatively regulates the enzymatic activity of both single-chain and two-chain t-PA (sct-PA and tct-PA). In the central nervous system, neuroserpin (NSP) is a serpin thought to regulate t-PA enzymatic activity. We report that although both set-PA and tct-PA rapidly form acyl-enzyme complexes with NSP in vitro, the interactions are short-lived, rapidly progressing to complete cleavage of NSP and regeneration of fully active enzyme. All NSP molecules appear to transit through the detectable acyl-enzyme intermediate and progress to completion of cleavage; no subpopulation that functions as a pure substrate was detected. Likewise, all molecules were reactive, with no evidence of a latent subpopulation. The interactions between NSP and t-PA were distinct from those between plasmin and NSP, wherein the same peptide bond was cleaved but there was no evidence of a detectable plasmin-NSP acyl-enzyme complex. The interactions between t-PA and NSP contrast with the formation of long-lived, physiologically irreversible acylenzyme complexes between t-PA and PAI-1, suggesting that the physiologic effect of t-PA-NSP interactions may be more complex than previously thought.	Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Wisconsin, Med Scientist Training Program, Madison, WI 53706 USA; Amer Red Cross, Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Med, Urbana, IL 61801 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; American Red Cross; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Schwartz, BS (corresponding author), 190 Med Sci Bldg,MC-714,506 S Mathews, Urbana, IL 61801 USA.			Carlson, Karen-Sue/0000-0003-0418-652X; Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055374, R01HL043506, R01HL055747] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43506, HL55374, HL55747] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akassoglou K, 2000, J CELL BIOL, V149, P1157, DOI 10.1083/jcb.149.5.1157; BOOSE JA, 1987, J BIOCH, V28, P635; Calabresi P, 2000, EUR J NEUROSCI, V12, P1002, DOI 10.1046/j.1460-9568.2000.00991.x; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Cinelli P, 2001, MOL CELL NEUROSCI, V18, P443, DOI 10.1006/mcne.2001.1028; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; GALLAGHER S, 1997, CURRENT PROTOCOLS MO, V2; GAUSSEM P, 1993, J BIOL CHEM, V268, P12150; Gils A, 1998, THROMB HAEMOSTASIS, V80, P286, DOI 10.1055/s-0037-1615189; Hastings GA, 1997, J BIOL CHEM, V272, P33062, DOI 10.1074/jbc.272.52.33062; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Kjoller L, 1996, EUR J BIOCHEM, V241, P38, DOI 10.1111/j.1432-1033.1996.0038t.x; Krueger SR, 1997, J NEUROSCI, V17, P8984; KRUITHOF EKO, 1984, BLOOD, V64, P907; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; MUSSONI L, 1984, THROMB RES, V34, P241, DOI 10.1016/0049-3848(84)90008-2; Osterwalder T, 1998, J BIOL CHEM, V273, P2312, DOI 10.1074/jbc.273.4.2312; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; PITTMAN RN, 1989, J NEUROSCI, V9, P4269; Plotnick MI, 2002, BIOCHEMISTRY-US, V41, P334, DOI 10.1021/bi015650+; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RANBY M, 1982, THROMB RES, V27, P175, DOI 10.1016/0049-3848(82)90197-9; SCHAGGER H, 1988, ANAL BIOCHEM, V173, P201, DOI 10.1016/0003-2697(88)90179-0; Schwartz BS, 1999, J BIOL CHEM, V274, P15278, DOI 10.1074/jbc.274.21.15278; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; Tachias K, 1997, J BIOL CHEM, V272, P28; Takao M, 2000, J NEUROPATH EXP NEUR, V59, P1070, DOI 10.1093/jnen/59.12.1070; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; Ye S, 2001, NAT STRUCT BIOL, V8, P979, DOI 10.1038/nsb1101-979; Yepes M, 2002, J CLIN INVEST, V109, P1571, DOI 10.1172/JCI200214308; Yepes M, 2000, BLOOD, V96, P569; Zhang JC, 1998, J BIOL CHEM, V273, P32273, DOI 10.1074/jbc.273.48.32273; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200	37	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46852	46857		10.1074/jbc.M207740200	http://dx.doi.org/10.1074/jbc.M207740200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12228252	hybrid			2022-12-27	WOS:000179663700004
J	Glodowski, DR; Petersen, JM; Dahlberg, JE				Glodowski, DR; Petersen, JM; Dahlberg, JE			Complex nuclear localization signals in the matrix protein of vesicular stomatitis virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOCYTOPLASMIC TRANSPORT; UBIQUITIN LIGASE; GENE-EXPRESSION; PORE COMPLEX; EXPORT; IMPORT; INHIBITION; INTERACTS; SEQUENCE; DOMAIN	The matrix (M) protein of vesicular stomatitis virus (VSV) functions from within the nucleus to inhibit bidirectional nucleocytoplasmic transport. Here, we show that M protein can be imported into the nucleus by an active transport mechanism, even though it is small enough (similar to27 kDa) to diffuse through nuclear pore complexes. We map two distinct nuclear localization signal (NLS)-containing regions of M protein, each of which is capable of directing the nuclear localization of a heterologous protein. One of these regions, comprising amino acids 47-229, is also sufficient to inhibit nucleocytoplasmic transport. Two amino acids that are conserved among the matrix proteins of vesiculoviruses are important for nuclear localization, but are not essential for the inhibitory activity of M protein. Thus, different regions of M protein function for nuclear localization and for inhibitory activity.	Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Dahlberg, JE (corresponding author), Univ Wisconsin, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.	dahlberg@facstaff.wisc.edu			NIGMS NIH HHS [GM-30220] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030220, R01GM030220] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baake M, 2001, J CELL BIOCHEM, V81, P333, DOI 10.1002/1097-4644(20010501)81:2<333::AID-JCB1048>3.3.CO;2-4; BLACK BL, 1992, J VIROL, V66, P4058, DOI 10.1128/JVI.66.7.4058-4064.1992; CLINTON GM, 1981, VIROLOGY, V108, P510, DOI 10.1016/0042-6822(81)90459-1; Dahlberg JE, 1998, CURR OPIN CELL BIOL, V10, P400, DOI 10.1016/S0955-0674(98)80017-3; Desforges M, 2001, VIRUS RES, V76, P87, DOI 10.1016/S0168-1702(01)00251-9; Enninga J, 2002, SCIENCE, V295, P1523, DOI 10.1126/science.1067861; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Gaudier M, 2002, EMBO J, V21, P2886, DOI 10.1093/emboj/cdf284; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Grimm C, 1997, EMBO J, V16, P793, DOI 10.1093/emboj/16.4.793; Hamilton MH, 2001, J BIOL CHEM, V276, P26324, DOI 10.1074/jbc.M101205200; Harty RN, 2000, P NATL ACAD SCI USA, V97, P13871, DOI 10.1073/pnas.250277297; Harty RN, 1999, J VIROL, V73, P2921, DOI 10.1128/JVI.73.4.2921-2929.1999; Her LS, 1997, SCIENCE, V276, P1845, DOI 10.1126/science.276.5320.1845; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; KAPTUR PE, 1992, J VIROL, V66, P5384, DOI 10.1128/JVI.66.9.5384-5392.1992; LYLES DS, 1988, J VIROL, V62, P4387, DOI 10.1128/JVI.62.11.4387-4392.1988; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MORRISON TG, 1978, J VIROL, V26, P115, DOI 10.1128/JVI.26.1.115-125.1978; PAIK SY, 1995, J VIROL, V69, P3529, DOI 10.1128/JVI.69.6.3529-3537.1995; PAL R, 1985, J VIROL, V55, P298, DOI 10.1128/JVI.55.2.298-306.1985; Pasquinelli AE, 1995, RNA, V1, P957; Petersen JM, 2000, MOL CELL BIOL, V20, P8590, DOI 10.1128/MCB.20.22.8590-8601.2000; Petersen JM, 2001, P NATL ACAD SCI USA, V98, P8590, DOI 10.1073/pnas.151240998; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Schwamborn K, 1998, EXP CELL RES, V244, P206, DOI 10.1006/excr.1998.4177; Segref A, 2001, RNA, V7, P351, DOI 10.1017/S1355838201002278; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063; TERNS MP, 1994, SCIENCE, V264, P959, DOI 10.1126/science.8178154; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; von Kobbe C, 2000, MOL CELL, V6, P1243, DOI 10.1016/S1097-2765(00)00120-9; Wagner R.R., 1987, RHABDOVIRUSES, P9, DOI DOI 10.1007/978-1-4684-7032-1_2	37	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46864	46870		10.1074/jbc.M208576200	http://dx.doi.org/10.1074/jbc.M208576200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351648	hybrid			2022-12-27	WOS:000179663700006
J	Han, SY; Kim, SH; Heasley, LE				Han, SY; Kim, SH; Heasley, LE			Differential gene kegulation by specific gain-of-function JNK1 proteins expressed in swiss 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVITY; SIGNAL-TRANSDUCTION; KINASE PATHWAY; JUN; BETA; STRESS; PHOSPHORYLATION; INFLAMMATION; ENHANCEOSOME; REQUIREMENT	The c-Jun N-terminal kinases (JNKs) are encoded by three genes that yield 10 isoforms through alternative mRNA splicing. The roles of each JNK isoform in the many putative biological responses where the JNK pathway is activated are still unclear. To examine the cellular responses mediated by different JNK isoforms, gain-of-function JNK1 polypeptides were generated by fusing the upstream mitogen-activated protein kinase kinase, MKK7, with p46JN-K1alpha or p46JNK1beta. The MKK7-JNK fusion proteins, which exhibited constitutive activity in 293T cells, were stably expressed in Swiss 3T3 fibroblasts using retrovirus-mediated gene transfer. Swiss 3T3 cells expressing either of the MKK7-JNK polypeptides were equally sensitized to induction of cell death following serum withdrawal. To search for other cellular responses that may be selectively regulated by the JNK1 isoforms, the gene expression profiles of Swiss 3T3 cells expressing MKK7-JNK1alpha or MKK7-JNK1beta were compared with empty vector-transfected control cells. Affymetrix Genechips identified 46 genes for which expression was increased in MKK7-JNK-expressing cells relative to vector control cells. Twenty genes including those for c-Jun, MKP-7, interluekin-1 receptor family member ST2L/ST2, and c-Jun-binding protein were induced similarly by MKK7-JNK1alpha and MKK7-JNK1beta proteins, whereas 13 genes were selectively increased by MKK7-JNK1alpha and 13 genes were selectively increased by MKK7/JNK1beta. The set of genes selectively induced by MKK7-JNK1beta included a number of known interferon-stimulated genes (ISG12, ISG15, IGTP, and GTPI). Consistent with these gene expression changes, Swiss 3T3 cells expressing MKK7-JNK1beta exhibited increased resistance to vesicular stomatitis virus-induced cell death. These findings reveal evidence for JNK isoform-selective gene regulation and support a role for distinct JNK isoforms in specific cellular responses.	Univ Colorado, Hlth Sci Ctr, Div Renal Med, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Heasley, LE (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Renal Med, Dept Med, C-281,4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061718] Funding Source: NIH RePORTER; NCI NIH HHS [CA58157] Funding Source: Medline; NIDDK NIH HHS [DK19928] Funding Source: Medline; NIGMS NIH HHS [GM61718] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barr RK, 2001, INT J BIOCHEM CELL B, V33, P1047, DOI 10.1016/S1357-2725(01)00093-0; Beekman A, 1998, CANCER RES, V58, P910; Brownlees J, 2000, J CELL SCI, V113, P401; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; de los Pinos E, 2001, BIOCHEM J, V353, P267, DOI 10.1042/0264-6021:3530267; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Halonen SK, 2001, INFECT IMMUN, V69, P5573, DOI 10.1128/IAI.69.9.5573-5576.2001; He T, 2002, J BIOL CHEM, V277, P10767, DOI 10.1074/jbc.M111436200; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ivanov VN, 2002, J BIOL CHEM, V277, P4932, DOI 10.1074/jbc.M108233200; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kim T, 2000, J BIOL CHEM, V275, P16910, DOI 10.1074/jbc.M000524200; Kim TK, 2000, CANCER RES, V60, P1153; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pessah M, 2001, P NATL ACAD SCI USA, V98, P6198, DOI 10.1073/pnas.101579798; Sato M, 2001, CYTOKINE GROWTH F R, V12, P133, DOI 10.1016/S1359-6101(00)00032-0; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Taniguchi T, 2002, CURR OPIN IMMUNOL, V14, P111, DOI 10.1016/S0952-7915(01)00305-3; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Turkson J, 1999, MOL CELL BIOL, V19, P7519; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wolter S, 2002, J BIOL CHEM, V277, P3576, DOI 10.1074/jbc.M105800200; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	30	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47167	47174		10.1074/jbc.M204270200	http://dx.doi.org/10.1074/jbc.M204270200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354774	hybrid			2022-12-27	WOS:000179663700043
J	Vallejo, AN; Bryl, E; Klarskov, K; Naylor, S; Weyand, CM; Goronzy, JJ				Vallejo, AN; Bryl, E; Klarskov, K; Naylor, S; Weyand, CM; Goronzy, JJ			Molecular basis for the loss of CD28 expression in senescent T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; DNA-BINDING PROTEIN; TRANSCRIPTION FACTOR; RHEUMATOID-ARTHRITIS; REPLICATIVE SENESCENCE; CD28-DEFICIENT MICE; INITIATOR ELEMENTS; GENE; REPERTOIRE; PROMOTERS	CD28(null) T cells are the most consistent biological indicator of the aging immune system in humans and are predictors of immunoincompetence in the elderly. The loss of CD28 is the result of an inoperative transcriptional initiator (INR), which consists of two nonoverlapping alpha and beta motifs that have distinct protein binding profiles but function as a unit. In CD28(null) T cells, there is a coordinate loss of alpha-/beta-bound complexes, hence the alphabeta-INR is inactive. In the present work therefore, studies were conducted to identify the components of such complexes that may account for the trans-activation of the alphabeta-INR. By affinity chromatography and tandem mass spectrometry, two proteins, namely, nucleolin and the A isoform of heterogeneous nuclear ribonucleoprotein-D0 (hnRNP-D0A), were identified to be among the key components of the site a complex. In DNA binding assays, specific antibodies indicated their antigenic presence in alpha-bound complexes. Transcription assays showed that they are both required in the trans-activation of alphabeta-INR-driven DNA templates. Because CD28 is T cell-restricted, and nucleolin and hnRN-P-D0A are ubiquitous proteins, these results support the notion that cell-specific functions can be regulated by commonly expressed proteins. The present data also provide evidence for INR-regulated transcription that is independent of the known components of the basal transcription complex.	Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Biomed Mass Spect & Funct Proteon Facil, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Vallejo, AN (corresponding author), Mayo Clin & Mayo Fdn, Dept Med, Guggenheim 401,200 1st St SW, Rochester, MN 55905 USA.		Weyand, Cornelia/AAH-3343-2021	Bryl, Ewa/0000-0002-1410-4287; Goronzy, Jorg/0000-0001-7670-1856	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041974, R03AR045830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015043] Funding Source: NIH RePORTER; NIAMS NIH HHS [R03 AR045830-03, R03-AR45830, R01-AR41974] Funding Source: Medline; NIA NIH HHS [R01-AG15043] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; Bryl E, 2001, J IMMUNOL, V167, P3231, DOI 10.4049/jimmunol.167.6.3231; Chambers CA, 1999, CURR OPIN CELL BIOL, V11, P203, DOI 10.1016/S0955-0674(99)80027-1; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; Dempsey LA, 1998, GENOMICS, V49, P378, DOI 10.1006/geno.1998.5237; Dempsey LA, 1998, J BIOL CHEM, V273, P29224, DOI 10.1074/jbc.273.44.29224; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; EFFROS RB, 1994, EXP GERONTOL, V29, P601, DOI 10.1016/0531-5565(94)90073-6; Effros RB, 1997, IMMUNOL TODAY, V18, P450, DOI 10.1016/S0167-5699(97)01079-7; Ferguson SE, 1996, J IMMUNOL, V156, P4576; Garraway IP, 1996, P NATL ACAD SCI USA, V93, P4336, DOI 10.1073/pnas.93.9.4336; Ginisty H, 1999, J CELL SCI, V112, P761; Goronzy JJ, 2001, J VIROL, V75, P12182, DOI 10.1128/JVI.75.24.12182-12187.2001; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Kaufmann J, 1998, MOL CELL BIOL, V18, P233, DOI 10.1128/MCB.18.1.233; Kraus RJ, 1996, NUCLEIC ACIDS RES, V24, P1531, DOI 10.1093/nar/24.8.1531; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; LEE KP, 1990, J IMMUNOL, V145, P344; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Lin CJ, 2001, J IMMUNOL, V166, P6134, DOI 10.4049/jimmunol.166.10.6134; Liuzzo G, 1999, CIRCULATION, V100, P2135, DOI 10.1161/01.CIR.100.21.2135; Maizels N, 1999, AM J HUM GENET, V64, P1270, DOI 10.1086/302393; Martens PB, 1997, ARTHRITIS RHEUM, V40, P1106, DOI 10.1002/art.1780400615; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Mittrucker HW, 1996, J EXP MED, V183, P2481, DOI 10.1084/jem.183.6.2481; Monteiro J, 1996, J IMMUNOL, V156, P3587; Moosig F, 1998, CLIN EXP IMMUNOL, V114, P113; Namekawa T, 1998, ARTHRITIS RHEUM, V41, P2108; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; Poland GA, 2001, VACCINE, V19, P2692, DOI 10.1016/S0264-410X(00)00505-3; POSNETT DN, 1994, J EXP MED, V179, P609, DOI 10.1084/jem.179.2.609; Powell JD, 1998, IMMUNOL REV, V165, P287, DOI 10.1111/j.1600-065X.1998.tb01246.x; Schmidt D, 1996, MOL MED, V2, P608, DOI 10.1007/BF03401644; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Tolnay M, 1997, J IMMUNOL, V159, P5492; Tolnay M, 2000, BIOCHEM J, V348, P151, DOI 10.1042/0264-6021:3480151; Tolnay M, 1999, BIOCHEM J, V338, P417, DOI 10.1042/0264-6021:3380417; Tuteja R, 1998, CRIT REV BIOCHEM MOL, V33, P407, DOI 10.1080/10409239891204260; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; Valdez BC, 1995, MOL IMMUNOL, V32, P1207, DOI 10.1016/0161-5890(95)00093-3; Vallejo AN, 1998, J BIOL CHEM, V273, P8119, DOI 10.1074/jbc.273.14.8119; Vallejo AN, 1999, J IMMUNOL, V162, P6572; Vallejo AN, 2001, J BIOL CHEM, V276, P2565, DOI 10.1074/jbc.M005503200; VALLEJO AN, 1994, PCR METH APPL, V4, P123; Wagner UG, 1998, P NATL ACAD SCI USA, V95, P14447, DOI 10.1073/pnas.95.24.14447; Weyand CM, 1998, MECH AGEING DEV, V102, P131, DOI 10.1016/S0047-6374(97)00161-9	51	68	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46940	46949		10.1074/jbc.M207352200	http://dx.doi.org/10.1074/jbc.M207352200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12324461	hybrid			2022-12-27	WOS:000179663700015
J	Joyce, JG; Hurni, WM; Bogusky, MJ; Garsky, VM; Liang, XP; Citron, MP; Danzeisen, RC; Miller, MD; Shiver, JW; Keller, PM				Joyce, JG; Hurni, WM; Bogusky, MJ; Garsky, VM; Liang, XP; Citron, MP; Danzeisen, RC; Miller, MD; Shiver, JW; Keller, PM			Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro - Implications for vaccine design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL FUSION MECHANISM; ENVELOPE GLYCOPROTEIN; MEMBRANE-FUSION; COILED-COIL; GP41 CORE; ATOMIC-STRUCTURE; ROTATING-FRAME; EPITOPE; ENTRY	The synthetic peptide DP178, derived from the carboxyl-terminal heptad repeat region of human immunodeficiency virus type 1 GP41 protein is a potent inhibitor of viral-mediated fusion and contains the sequence ELDKWA, which constitutes the recognition epitope for the broadly neutralizing human monoclonal antibody 2F5. Efforts at eliciting a 2F5-like immune response by immunization with peptides or fusion proteins containing this sequence have not met with success, possibly because of incorrect structural presentation of the epitope. Although the structure of the carboxyl-terminal heptad repeat on the virion is not known, several recent reports have suggested a propensity for a-helical conformation. We have examined DP178 in the context of a model for optimized a-helices and show that the native sequence conforms poorly to the model. Solution conformation of DP178 was studied by circular dichroism and NMR spectroscopy and found to be predominantly random, consistent with previous reports. NMR mapping was used to show that the low percentage of a-helix present was localized to residues Glu(662) through Asn(671), a region encompassing the 2F5 epitope. Using NH2-terminal extensions derived from either GP41 or the yeast GCN4 leucine zipper dimerization domain, we designed peptide analogs in which the average helicity is significantly increased compared with DP178 and show that these peptides exhibit both a modest increase in affinity for 2F5 using a novel competitive solution-based binding assay and an increased ability to inhibit viral entry in a single-cycle infectivity model. Selected peptides were conjugated to carrier protein and used for guinea pig immunizations. High peptide-specific titers were achieved using these immunogens, but the resulting sera were incapable of viral neutralization. We discuss these findings in terms of structural and immunological considerations as to the utility of a 2F5-like response.	Merck Res Labs, Dept Virus & Cell Biol, W Point, PA 19486 USA; Merck Res Labs, Dept Med Chem, W Point, PA 19486 USA; Merck Res Labs, Dept Biol Chem, W Point, PA 19486 USA	Merck & Company; Merck & Company; Merck & Company	Joyce, JG (corresponding author), Merck Res Labs, Dept Virus & Cell Biol, W Point, PA 19486 USA.							Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Coeffier E, 2000, VACCINE, V19, P684, DOI 10.1016/S0264-410X(00)00267-X; CONLEY AJ, 1994, P NATL ACAD SCI USA, V91, P3348, DOI 10.1073/pnas.91.8.3348; Contreras LM, 2001, BIOCHEMISTRY-US, V40, P3196, DOI 10.1021/bi002613u; Dong XN, 2001, IMMUNOL LETT, V75, P215, DOI 10.1016/S0165-2478(00)00302-3; Earl PL, 2001, J VIROL, V75, P645, DOI 10.1128/JVI.75.2.645-653.2001; Eckhart L, 1996, J GEN VIROL, V77, P2001, DOI 10.1099/0022-1317-77-9-2001; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Follis KE, 2002, J VIROL, V76, P7356, DOI 10.1128/JVI.76.14.7356-7362.2002; Gorny MK, 2000, J VIROL, V74, P6186, DOI 10.1128/JVI.74.13.6186-6192.2000; GRIESINGER C, 1987, J MAGN RESON, V75, P261, DOI 10.1016/0022-2364(87)90035-7; Houston ME, 1996, J MOL BIOL, V262, P270, DOI 10.1006/jmbi.1996.0512; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jiang S, 1998, J VIROL, V72, P10213, DOI 10.1128/JVI.72.12.10213-10217.1998; Judice JK, 1997, P NATL ACAD SCI USA, V94, P13426, DOI 10.1073/pnas.94.25.13426; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kliger Y, 2000, J MOL BIOL, V301, P905, DOI 10.1006/jmbi.2000.4004; Kliger Y, 2000, J MOL BIOL, V295, P163, DOI 10.1006/jmbi.1999.3368; Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; LEVITT MH, 1982, J MAGN RESON, V47, P328, DOI 10.1016/0022-2364(82)90124-X; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; Mant CT, 1997, J CHROMATOGR A, V791, P85, DOI 10.1016/S0021-9673(97)00767-X; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; Moulard M, 2000, BBA-REV BIOMEMBRANES, V1469, P121, DOI 10.1016/S0304-4157(00)00014-9; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; PAI E, 2000, Patent No. 0061618; Phelan JC, 1997, J AM CHEM SOC, V119, P455, DOI 10.1021/ja9611654; Purtscher M, 1996, AIDS, V10, P587, DOI 10.1097/00002030-199606000-00003; Rabenstein MD, 1996, BIOCHEMISTRY-US, V35, P13922, DOI 10.1021/bi961743t; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Salzwedel K, 1999, J VIROL, V73, P2469, DOI 10.1128/JVI.73.3.2469-2480.1999; Sattentau QJ, 1996, CURR OPIN IMMUNOL, V8, P540, DOI 10.1016/S0952-7915(96)80044-6; SATTENTAU QJ, 1995, VIROLOGY, V206, P713, DOI 10.1016/S0042-6822(95)80094-8; Schibli DJ, 2001, BIOCHEMISTRY-US, V40, P9570, DOI 10.1021/bi010640u; Shu W, 2000, BIOCHEMISTRY-US, V39, P1634, DOI 10.1021/bi9921687; Shu W, 2000, J BIOL CHEM, V275, P1839, DOI 10.1074/jbc.275.3.1839; Shu W, 1999, BIOCHEMISTRY-US, V38, P5378, DOI 10.1021/bi990199w; SHULER KR, 1992, J IMMUNOL METHODS, V156, P137, DOI 10.1016/0022-1759(92)90020-T; Singh M, 1999, J MOL BIOL, V290, P1031, DOI 10.1006/jmbi.1999.2796; Sodroski JG, 1999, CELL, V99, P243, DOI 10.1016/S0092-8674(00)81655-4; SOLTYSIK S, 1995, VACCINE, V13, P1403, DOI 10.1016/0264-410X(95)00077-E; Suarez T, 2000, J VIROL, V74, P8038, DOI 10.1128/JVI.74.17.8038-8047.2000; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; URRY DW, 1971, BIOCHIM BIOPHYS ACTA, V241, P600, DOI 10.1016/0005-2736(71)90058-7; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yang XZ, 2002, J VIROL, V76, P4634, DOI 10.1128/JVI.76.9.4634-4642.2002	60	108	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45811	45820		10.1074/jbc.M205862200	http://dx.doi.org/10.1074/jbc.M205862200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237296	hybrid			2022-12-27	WOS:000179529300014
J	Takashima, S; Tsuji, S; Tsujimoto, M				Takashima, S; Tsuji, S; Tsujimoto, M			Characterization of the second type of human beta-galactoside alpha 2,6-sialyltransferase (ST6Gal II), which sialylates Gal beta 1,4GlcNAc structures on oligosaccharides preferentially	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY-REGULATED MEMBER; MOUSE SIALYLTRANSFERASE GENES; N-LINKED OLIGOSACCHARIDES; B-CELL ACTIVATION; MOLECULAR-CLONING; GALNAC ALPHA-2,6-SIALYLTRANSFERASE; TRANSCRIPTIONAL REGULATION; GENOMIC ORGANIZATION; EXPRESSION; FAMILY	A novel member of the human beta-galactoside alpha2,6-sialyltransferase (ST6Gal) family, designated ST6Gal II, was identified by BLAST analysis of expressed sequence tags and genomic sequences. The sequence of ST6Gal II encoded a protein of 529 amino acids, and it showed 48.9% amino acid sequence identity with human ST6Gal I. Recombinant ST6Gal II exhibited a2,6-sialyltransferase activity toward oligosaccharides that have the Galbeta1,4GlcNAc sequence at the nonreducing end of their carbohydrate groups, but it exhibited relatively low and no activities toward some glycoproteins and glycolipids, respectively. It is concluded that ST6Gal H is an oligosaccharide-specific enzyme compared with ST6Gal I, which exhibits broad substrate specificities, and is mainly involved in the synthesis of sialyloligosaccharides. The expression of the ST6Gal II gene was significantly detected by reverse transcription PCR in small intestine, colon, and fetal brain, whereas the ST6Gal I gene was ubiquitously expressed, and its expression levels were much higher than those of the ST6GaI II gene. The ST6GaI I gene was also expressed in all tumors examined, but no expression was observed for the ST6Gal II gene in these tumors. The ST6Gal II gene is located on chromosome 2 (2q11.2-q12.1), and it spans over 85 kb of human genomic DNA consisting of at least eight exons and shares a similar genomic structure with the ST6GaI I gene. In this paper, we have shown that ST6Gal 1, which has been known as the sole member of the ST6Gal family, also has the counterpart enzyme (ST6GaI II) like other sialyltransferases.	RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, Wako, Saitama 3510198, Japan; Ochanomizu Univ, Fac Sci, Dept Chem, Bunkyo Ku, Tokyo 1128610, Japan	RIKEN; Ochanomizu University	Tsujimoto, M (corresponding author), RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.							Dall'Olio Fabio, 2000, Glycoconjugate Journal, V17, P669, DOI 10.1023/A:1011077000164; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747; Geremia RA, 1997, GLYCOBIOLOGY, V7, pR5; HAMAMOTO T, 2001, HDB GLYCOSYLTRANSFER, P295; Harduin-Lepers A, 2001, BIOCHIMIE, V83, P727, DOI 10.1016/S0300-9084(01)01301-3; HARDUINLEPERS A, 2001, RRD CANCER 1, V3, P111; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; Ikehara Y, 1999, GLYCOBIOLOGY, V9, P1213, DOI 10.1093/glycob/9.11.1213; Ikehara Y, 1999, FEBS LETT, V463, P92, DOI 10.1016/S0014-5793(99)01605-1; KARLSSON KA, 1995, CURR OPIN STRUC BIOL, V5, P622, DOI 10.1016/0959-440X(95)80054-9; Kim KW, 2001, GENE, V273, P163, DOI 10.1016/S0378-1119(01)00595-9; Kitagawa H, 1996, J BIOL CHEM, V271, P931, DOI 10.1074/jbc.271.2.931; Kitazume-Kawaguchi S, 2001, J BIOL CHEM, V276, P15696, DOI 10.1074/jbc.M010371200; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kono M, 1996, J BIOL CHEM, V271, P29366, DOI 10.1074/jbc.271.46.29366; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; Kurosawa N, 2000, J BIOCHEM-TOKYO, V127, P845, DOI 10.1093/oxfordjournals.jbchem.a022678; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee YC, 1999, J BIOL CHEM, V274, P11958, DOI 10.1074/jbc.274.17.11958; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; Nakano Taku, 2001, Acta Paediatrica Taiwanica, V42, P11; Okajima T, 2000, J BIOL CHEM, V275, P6717, DOI 10.1074/jbc.275.10.6717; Okajima T, 1999, J BIOL CHEM, V274, P11479, DOI 10.1074/jbc.274.17.11479; Okajima T, 1999, J BIOL CHEM, V274, P30557, DOI 10.1074/jbc.274.43.30557; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1994, J BIOL CHEM, V269, P10628; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SGROI D, 1993, J BIOL CHEM, V268, P7011; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; Takashima S, 2002, J BIOL CHEM, V277, P24030, DOI 10.1074/jbc.M112367200; Takashima S, 1999, BIOCHEM BIOPH RES CO, V260, P23, DOI 10.1006/bbrc.1999.0794; Takashima S, 2000, J BIOCHEM-TOKYO, V128, P1033, DOI 10.1093/oxfordjournals.jbchem.a022831; Taniguchi A, 2001, BIOCHEM BIOPH RES CO, V287, P1148, DOI 10.1006/bbrc.2001.5709; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; Tsuji S., 1999, SIALOBIOLOGY OTHER N, P145; WANG XC, 1993, J BIOL CHEM, V268, P4355; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628	47	86	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45719	45728		10.1074/jbc.M206808200	http://dx.doi.org/10.1074/jbc.M206808200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235148	hybrid			2022-12-27	WOS:000179529300002
J	Wei, YJ; Sun, HQ; Yamamoto, M; Wlodarski, P; Kunii, K; Martinez, M; Barylko, B; Albanesi, JP; Yin, HL				Wei, YJ; Sun, HQ; Yamamoto, M; Wlodarski, P; Kunii, K; Martinez, M; Barylko, B; Albanesi, JP; Yin, HL			Type II phosphatidylinositol 4-kinase beta is a cytosolic and peripheral membrane protein that is recruited to the plasma membrane and activated by Rac-GTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-PHOSPHATE 5-KINASE; 4,5-BISPHOSPHATE; CELLS; FAMILY; YEAST; CYTOSKELETON; KINASES; RHO	Phosphoinositides have a pivotal role as precursors to important second messengers and as bona fide signaling and scaffold targeting molecules. Phosphatidylinositol 4-kinases (PtdIns 4-kinases or PI4Ks) are at the apex of the phosphoinsitide cascade. Sequence analysis revealed that mammalian cells contain two type 11 PtdIns 4-kinase isoforms, now termed PI4KIIalpha and PI4KIIbeta. PI4KIIalpha was cloned first. It is tightly membrane-associated and behaves as an integral membrane protein. In this study, we cloned PI4KIIbeta and compared the two isoforms by monitoring the distribution of endogenous and overexpressed proteins, their modes of association with membranes, their response to growth factor stimulation or Rac-GTP activation, and their kinetic properties. We find that the two kinases have different properties. PI4KIIbeta is primarily cytosolic, and it associates peripherally with plasma membranes, endoplasmic reticulum., and the Golgi. In contrast, PI4KIIalpha is primarily Golgi-associated. Platelet-derived growth factor promotes PI4KIIbeta recruitment to membrane ruffles. This effect is potentially mediated through Rac; overexpression of the constitutively active RacV12 induces membrane ruffling, increases PI4KIIbeta translocation to the plasma membrane, and stimulates its activity. The dominant-negative RacN17 blocks plasma membrane association and inhibits activity. RacV12 does not boost the catalytic activity of PI4KIIalpha further, probably because it is constitutively membrane-bound and already activated. Membrane recruitment is an important mechanism for PI4KIIbeta activation, because microsome-bound PI4KIIbeta is 16 times more active than cytosolic PI4KIIbeta. Membrane-associated PI4KIIbeta is as active as membrane-associated PI4KIIalpha and has essentially identical kinetic properties. We conclude that PI4KIIalpha and PI4KIIbeta may have partially overlapping, but not identical, functions. PI4KIIbeta is activated strongly by membrane association to stimulate phosphatidylinositol 4,5-bisphosphate synthesis at the plasma membrane. These findings provide new insight into how phosphoinositide cascades are propagated in cells.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yin, HL (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Wlodarski, Pawel/0000-0002-0683-1791	NIGMS NIH HHS [GM55562, GM5112] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Balla A, 2002, J BIOL CHEM, V277, P20041, DOI 10.1074/jbc.M111807200; Balla T, 2001, CURR PHARM DESIGN, V7, P475, DOI 10.2174/1381612013397906; Barylko B, 2001, J BIOL CHEM, V276, P7705, DOI 10.1074/jbc.C000861200; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Chatah NEH, 2001, J BIOL CHEM, V276, P34059, DOI 10.1074/jbc.M104917200; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; Foti M, 2001, MOL BIOL CELL, V12, P2396, DOI 10.1091/mbc.12.8.2396; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Holz RW, 2000, J BIOL CHEM, V275, P17878, DOI 10.1074/jbc.M000925200; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Jones DH, 2000, J BIOL CHEM, V275, P13962, DOI 10.1074/jbc.C901019199; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Micheva KD, 2001, J CELL BIOL, V154, P355, DOI 10.1083/jcb.200102098; Minogue S, 2001, J BIOL CHEM, V276, P16635, DOI 10.1074/jbc.M100982200; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Thorner Jeremy W., 2001, Nature Cell Biology, V3, pE196, DOI 10.1038/35087142; Watson RT, 2000, J BIOL CHEM, V275, P1261, DOI 10.1074/jbc.275.2.1261; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; YIN HL, 2003, IN PRESS ANN REV PHY; YU FX, 1994, CELL MOTIL CYTOSKEL, V27, P13, DOI 10.1002/cm.970270103; Zhao XH, 2001, J BIOL CHEM, V276, P40183, DOI 10.1074/jbc.M104048200	31	96	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46586	46593		10.1074/jbc.M206860200	http://dx.doi.org/10.1074/jbc.M206860200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324459	hybrid			2022-12-27	WOS:000179529300114
J	Zaganas, I; Spanaki, C; Karpusas, M; Plaitakis, A				Zaganas, I; Spanaki, C; Karpusas, M; Plaitakis, A			Substitution of Ser for Arg-443 in the regulatory domain of human housekeeping (GLUB1) glutamate dehydrogenase virtually abolishes basal activity and markedly alters the activation of the enzyme by ADP and L-leucine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLUM; METABOLISM; MECHANISMS; BRAIN; GENE	Human glutamate dehydrogenase (GDH) exists in GLUD1 (housekeeping) and in GLUD2-specified (brain-specific) isoforms, which differ markedly in their basal activity and allosteric regulation. To determine the structural basis of these functional differences, we mutagenized the GLUD1 GDH at four residues that differ from those of the GLUD2 isoenzyme. Functional analyses revealed that substitution of Ser for Arg-443 (but not substitution of Thr for Ser-331, Leu for Met-370, or Leu for Met-415) virtually abolished basal activity and totally abrogated the activation of the enzyme by L-leucine (1-10 mm) in the absence of other effectors. However, when ADP (0.025-0.1 mm) was present in the reaction mixture, L-leucine (0.3-6.0 mm) activated the mutant enzyme up to >2,000%. The R443S mutant was much less sensitive to ADP (SC50 = 383.9 +/- 14.6 mum) than the GLUD1 GDH (SC50 = 31.7 +/- 4.2 mum; p < 0.001); however, at 1 mm ADP the V-max for the mutant (136.67 mumol min(-1) mg(-1)) was comparable with that of the GLUD1 GDH (152.95 mumol min(-1) mg(-1)). Varying the composition and the pH of the reaction buffer differentially affected the mutant and the wild-type GDH. Arg-443 lies in the "antenna" structure, in a helix that undergoes major conformational changes during catalysis and is involved in intersubunit communication. Its replacement by Ser is sufficient to impair both the catalytic and the allosteric function of human GDH..	Univ Crete, Sch Hlth Sci, Med Sect, Dept Neurol, Iraklion 71500, Crete, Greece; Univ Crete, Sch Hlth Sci, Med Sect, Dept Basic Sci, Iraklion 71500, Crete, Greece	University of Crete; University of Crete	Plaitakis, A (corresponding author), Univ Crete, Sch Hlth Sci, Med Sect, Dept Neurol, Iraklion 71500, Crete, Greece.		Karpusas, Michael/AAP-5547-2021; Zaganas, Ioannis/AAE-5441-2020	Zaganas, Ioannis/0000-0002-0774-5772				AOKI C, 1987, J NEUROSCI RES, V18, P305, DOI 10.1002/jnr.490180207; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BRYLA J, 1994, METABOLISM, V43, P1187, DOI 10.1016/0026-0495(94)90064-7; CARLSON M, 1977, METHOD ENZYMOL, V277, P493; COLON AD, 1986, J NEUROCHEM, V46, P1811; Cornish-Bowden A, 2012, FUNDAMENTALS ENZYME, V3rd, DOI [10.1016/B978-0-408-10617-7.50013-4/, DOI 10.1016/B978-0-408-10617-7.50013-4]; CORNISHBOWDEN A, 1995, ANAL ENZYME KINETIC, P133; DIETER H, 1981, EUR J BIOCHEM, V115, P217; Fang J, 2002, BIOCHEM J, V363, P81, DOI 10.1042/0264-6021:3630081; FRIEDEN C, 1963, J BIOL CHEM, V238, P146; FRIEDEN C, 1959, J BIOL CHEM, V234, P815; GYLFE E, 1976, ACTA DIABETOL LAT, V13, P20, DOI 10.1007/BF02591577; HUDSON RC, 1993, COMP BIOCHEM PHYS B, V106, P767, DOI 10.1016/0305-0491(93)90031-Y; HUSSAIN MM, 1989, J BIOL CHEM, V264, P20730; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAVROTHALASSITIS G, 1988, P NATL ACAD SCI USA, V85, P3494, DOI 10.1073/pnas.85.10.3494; Nissim I, 1999, AM J PHYSIOL-RENAL, V277, pF493, DOI 10.1152/ajprenal.1999.277.4.F493; Peterson PE, 1999, STRUCTURE, V7, P769, DOI 10.1016/S0969-2126(99)80101-4; Plaitakis A, 2000, J NEUROCHEM, V75, P1862, DOI 10.1046/j.1471-4159.2000.0751862.x; Plaitakis A, 2001, J NEUROSCI RES, V66, P899, DOI 10.1002/jnr.10054; Poitry S, 2000, J NEUROSCI, V20, P1809; ROTHE F, 1994, NEUROSCIENCE, V62, P1134; SENER A, 1980, NATURE, V288, P187, DOI 10.1038/288187a0; Shashidharan P, 1997, J NEUROCHEM, V68, P1804; SHASHIDHARAN P, 1994, J BIOL CHEM, V269, P16971; Smith E.L., 1975, ENZYMES, P293, DOI DOI 10.1016/S1874-6047(08)60213-9; SMITH EL, 1979, P AM PHILOS SOC, V123, P73; Smith TJ, 2002, J MOL BIOL, V318, P765, DOI 10.1016/S0022-2836(02)00161-4; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; STILLMAN TJ, 1993, J MOL BIOL, V234, P1134; WRZESZCZYNSKI KO, 1994, BIOCHEMISTRY-US, V33, P11544, DOI 10.1021/bi00204a017; Zaganas I, 2002, J BIOL CHEM, V277, P26422, DOI 10.1074/jbc.M200022200; Zaganas I, 2001, J NEUROSCI RES, V66, P909, DOI 10.1002/jnr.10058	34	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46552	46558		10.1074/jbc.M208596200	http://dx.doi.org/10.1074/jbc.M208596200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324473	hybrid			2022-12-27	WOS:000179529300110
J	Battaini, G; Monzani, E; Casella, L; Lonardi, E; Tepper, AWJW; Canters, GW; Bubacco, L				Battaini, G; Monzani, E; Casella, L; Lonardi, E; Tepper, AWJW; Canters, GW; Bubacco, L			Tyrosinase-catalyzed oxidation of fluorophenols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-ANTIBIOTICUS TYROSINASE; CRYSTAL-STRUCTURE; KOJIC ACID; MUSHROOM TYROSINASE; ACTIVE-SITE; INHIBITION; HEMOCYANIN; MECHANISM; BINDING; NMR	The activity of the type 3 copper enzyme tyrosinase toward 2-, 3-, and 4-fluorophenol was studied by kinetic methods and H-1 and F-19 NMR spectroscopy. Whereas 3- and 4-fluorophenol react with tyrosinase to give products that undergo a rapid polymerization process, 2-fluorophenol is not reactive and actually acts as a competitive inhibitor in the enzymatic oxidation of 3,4-dihydroxyphenylalanine (L-dopa). The tyrosinase-mediated polymerization of 3- and 4-fluorophenols has been studied in detail. It proceeds through a phenolic coupling pathway in which the common reactive fluoro-quinone, produced stereospecifically by tyrosinase, eliminates an inorganic fluorine ion. The enzymatic reaction studied as a function of substrate concentration shows a prominent lag that is completely depleted in the presence Of L-dopa. The kinetic parameters of the reactions can be correlated to the electronic and steric effects of the fluorine substituent position. Whereas the fluorine electron withdrawing effect appears to control the binding of the substrates (K-m for 3- and 4-fluorophenols and K-1 for 2-fluorophenol), the k(cat) parameters do not follow the expected trend, indicating that in the transition state some additional steric effect rules the reactivity.	Univ Pavia, Dipartimento Chim Gen, I-27100 Pavia, Italy; Leiden Univ, Gorlaeus Labs, Leiden Inst Chem, NL-2333 CC Leiden, Netherlands; Univ Padua, Dipartimento Biol, I-3012 Padua, Italy	University of Pavia; Leiden University; Leiden University - Excl LUMC; University of Padua	Casella, L (corresponding author), Univ Pavia, Dipartimento Chim Gen, Via Taramelli 12, I-27100 Pavia, Italy.		Hu, Ruogu/B-2203-2008; Bubacco, Luigi/B-5602-2012	Bubacco, Luigi/0000-0001-7927-9208; MONZANI, ENRICO/0000-0002-8791-6446				Boersma MG, 2001, J IND MICROBIOL BIOT, V26, P22, DOI 10.1038/sj.jim.7000027; Bubacco L, 1999, FEBS LETT, V442, P215, DOI 10.1016/S0014-5793(98)01662-7; Bubacco L, 2000, J MOL CATAL B-ENZYM, V8, P27, DOI 10.1016/S1381-1177(99)00064-8; CABANES J, 1994, J PHARM PHARMACOL, V46, P982, DOI 10.1111/j.2042-7158.1994.tb03253.x; CHEN JS, 1991, J AGR FOOD CHEM, V39, P1897, DOI 10.1021/jf00011a001; CHEN JS, 1991, J AGR FOOD CHEM, V39, P1396, DOI 10.1021/jf00008a008; Clementi V, 1998, ACCOUNTS CHEM RES, V31, P351, DOI 10.1021/ar960159+; Cooksey CJ, 1997, J BIOL CHEM, V272, P26226, DOI 10.1074/jbc.272.42.26226; Cuff ME, 1998, J MOL BIOL, V278, P855, DOI 10.1006/jmbi.1998.1647; Decker H, 2000, ANGEW CHEM INT EDIT, V39, P1591, DOI 10.1002/(SICI)1521-3773(20000502)39:9<1591::AID-ANIE1591>3.0.CO;2-H; Decker H, 2000, TRENDS BIOCHEM SCI, V25, P392, DOI 10.1016/S0968-0004(00)01602-9; DUCKWORTH HW, 1970, J BIOL CHEM, V245, P1613; Espin JC, 1998, BIOCHEM J, V331, P547, DOI 10.1042/bj3310547; HAZES B, 1993, PROTEIN SCI, V2, P597; JACKMAN MP, 1991, BIOCHEM J, V274, P707, DOI 10.1042/bj2740707; KABALPURWALA K, 1966, J AM CHEM SOC, V88, P3224; Key BD, 1997, ENVIRON SCI TECHNOL, V31, P2445, DOI 10.1021/es961007c; Leffler JE., 1989, RATES EQUILIBRIA ORG; MENON S, 1990, ARCH BIOCHEM BIOPHYS, V280, P27, DOI 10.1016/0003-9861(90)90513-X; Olivares C, 2002, BIOCHEMISTRY-US, V41, P679, DOI 10.1021/bi011535n; Park JW, 1999, ENVIRON SCI TECHNOL, V33, P2028, DOI 10.1021/es9810787; Park JW, 2000, ARCH ENVIRON CON TOX, V38, P405, DOI 10.1007/s002449910054; PETER MG, 1989, ANGEW CHEM INT EDIT, V28, P555, DOI 10.1002/anie.198905551; Rodriguez-Lopez JN, 2001, BBA-PROTEIN STRUCT M, V1548, P238, DOI 10.1016/S0167-4838(01)00237-0; SANCHEZFERRER A, 1995, BBA-PROTEIN STRUCT M, V1247, P1; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; Tepper AWJW, 2002, J BIOL CHEM, V277, P30436, DOI 10.1074/jbc.M202461200; VanGelder CWG, 1997, PHYTOCHEMISTRY, V45, P1309, DOI 10.1016/S0031-9422(97)00186-6; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; WILCOX DE, 1985, J AM CHEM SOC, V107, P4015, DOI 10.1021/ja00299a043; [No title captured]	32	65	66	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44606	44612		10.1074/jbc.M207829200	http://dx.doi.org/10.1074/jbc.M207829200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235154	hybrid			2022-12-27	WOS:000179404800004
J	Han, SJ; Ko, HM; Choi, JH; Seo, KH; Lee, HS; Choi, EK; Choi, IW; Lee, HK; Im, SY				Han, SJ; Ko, HM; Choi, JH; Seo, KH; Lee, HS; Choi, EK; Choi, IW; Lee, HK; Im, SY			Molecular mechanisms for lipopolysaccharide-induced biphasic activation of nuclear factor-kappa B (NF-kappa B)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR ANTAGONIST; PHOSPHOLIPASE A(2); FACTOR-ALPHA; INNATE IMMUNITY; REL PROTEINS; CELL LINE; INTERLEUKIN-1; EXPRESSION; TNF	The nuclear factor-kappaB (NF-kappaB) is an important transcription factor necessary for initiating and sustaining inflammatory and immune reactions. The inducers of NF-kappaB are well characterized, but the molecular mechanisms underlying multiple in vivo NF-kappaB activation processes are poorly understood. The injection of lipopolysaccharide resulted in a biphasic activation of NF-kappaB during the 18-h observation period in various organs of mice. The early and late phases of NF-kappaB activation occurred at 0.5-2 h and 8-12 h, respectively. Platelet-activating factor, which is released in response to lipopolysaccharide injection, was responsible for the activation of the early phase of NF-kappaB The early NF-kappaB activity led to the induction of proinflammatory cytokines, tumor necrosis factor (TNF), and interleukin (IL)-1beta, which are known to be efficient inducers of NF-kappaB. Using the TNF knockout and IL-1 receptor knockout mice, we found that TNF and IL-1beta had a role in the second phase activation of NF-kappaB. These cytokines did promote the synthesis of platelet-activating factor, which in turn induced the secondary activation of NF-kappaB. These observations describe a novel autoregulatory molecular mechanism for the biphasic activation of NF-kappaB.	Chonnam Natl Univ, Dept Sci Biol, Coll Nat Sci, Inst Basic Sci, Kwangju 500757, South Korea; Chonnam Natl Univ, Sch Med, Dept Immunol, Chonju 561182, South Korea; Chonnam Natl Univ, Sch Med, Inst Med Sci, Chonju 561182, South Korea	Chonnam National University; Chonnam National University; Chonnam National University	Im, SY (corresponding author), Chonnam Natl Univ, Dept Sci Biol, Coll Nat Sci, Inst Basic Sci, Kwangju 500757, South Korea.							Aggarwal BB, 2000, ANN RHEUM DIS, V59, P6; BAUERLE PA, 1988, CELL, V53, P211; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Choi JH, 2001, J IMMUNOL, V166, P5139, DOI 10.4049/jimmunol.166.8.5139; Choi JH, 2000, INFLAMMATION, V24, P385, DOI 10.1023/A:1007068010645; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GODFREY RW, 1988, PROSTAGLANDINS, V35, P107, DOI 10.1016/0090-6980(88)90278-X; GOMEZCAMBRONERO J, 1985, BIOCHIM BIOPHYS ACTA, V845, P511, DOI 10.1016/0167-4889(85)90218-6; Gukovsky I, 1998, AM J PHYSIOL-GASTR L, V275, pG1402, DOI 10.1152/ajpgi.1998.275.6.G1402; Han SJ, 1999, EUR J IMMUNOL, V29, P1334, DOI 10.1002/(SICI)1521-4141(199904)29:04<1334::AID-IMMU1334>3.0.CO;2-0; Hauf N, 1997, P NATL ACAD SCI USA, V94, P9394, DOI 10.1073/pnas.94.17.9394; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; Im SY, 1997, EUR J IMMUNOL, V27, P2800, DOI 10.1002/eji.1830271109; Im SY, 1996, CANCER RES, V56, P2662; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KONIECZKOWSKI M, 1993, J CLIN INVEST, V92, P2524, DOI 10.1172/JCI116861; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Liu SJ, 1998, AM J PHYSIOL-HEART C, V275, pH1462, DOI 10.1152/ajpheart.1998.275.4.H1462; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; NOURSHARGH S, 1995, BLOOD, V85, P2553, DOI 10.1182/blood.V85.9.2553.bloodjournal8592553; O'Neill L, 2000, BIOCHEM SOC T, V28, P557, DOI 10.1042/bst0280557; POUBELLE PE, 1991, IMMUNOLOGY, V72, P181; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; SMITH CS, 1994, CELL IMMUNOL, V155, P292, DOI 10.1006/cimm.1994.1123; Sporn LA, 1997, INFECT IMMUN, V65, P2786, DOI 10.1128/IAI.65.7.2786-2791.1997; Suputtamongkol Y, 2000, ANTIMICROB AGENTS CH, V44, P693, DOI 10.1128/AAC.44.3.693-696.2000; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Thommesen L, 1998, J IMMUNOL, V161, P3421; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TOUQUI L, 1985, BIOCHIM BIOPHYS ACTA, V833, P111, DOI 10.1016/0005-2760(85)90258-9; van Puijenbroek AAFL, 1999, CYTOKINE, V11, P104, DOI 10.1006/cyto.1998.0404; Vincent JL, 2000, CRIT CARE MED, V28, P638, DOI 10.1097/00003246-200003000-00006; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Xing MZ, 1997, J CLIN INVEST, V99, P805, DOI 10.1172/JCI119227; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; YUROCHKO AD, 1995, J VIROL, V69, P5391, DOI 10.1128/JVI.69.9.5391-5400.1995	50	74	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44715	44721		10.1074/jbc.M202524200	http://dx.doi.org/10.1074/jbc.M202524200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235132	hybrid			2022-12-27	WOS:000179404800017
J	Momose, F; Naito, T; Yano, K; Sugimoto, S; Morikawa, Y; Nagata, K				Momose, F; Naito, T; Yano, K; Sugimoto, S; Morikawa, Y; Nagata, K			Identification of Hsp90 as a stimulatory host factor involved in influenza virus RNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; HEAT-SHOCK-PROTEIN; MESSENGER-RNA; SENDAI VIRUS; MOLECULAR CHAPERONES; POLYMERASE ACTIVITY; PHOSPHOPROTEIN P; IN-VITRO; TRANSCRIPTION; REPLICATION	Efficient transcription and replication of the influenza virus genome are dependent upon host-derived factors. Using an in vitro RNA synthesis system, we have purified and identified Hsp90 as one of the host factors that stimulate viral RNA polymerase activity. Hsp90 interacted with the PB2 subunit of the viral RNA polymerase through the amino-terminal chaperone domain and the middle region containing a highly acidic domain. The acidic middle region was also responsible for its stimulatory activity. We found that a portion of Hsp90 is re-localized to the cell nucleus after viral infection. A PB2 fragment containing a Hsp90 binding domain inhibited viral gene expression in a dominant-negative manner. These results suggest that Hsp90 is a host factor for the influenza virus RNA polymerase.	Univ Tsukuba, Inst Basic Med Sci, Dept Infect Biol, Tsukuba, Ibaraki 3058575, Japan; Kitasato Univ, Kitasato Inst Life Sci, Minato Ku, Tokyo 1088641, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 1948533, Japan; Tokyo Inst Technol, Yokohama, Kanagawa 2268501, Japan	University of Tsukuba; Kitasato University; Kyowa Kirin Ltd; Tokyo Institute of Technology	Nagata, K (corresponding author), Univ Tsukuba, Inst Basic Med Sci, Dept Infect Biol, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.		Naito, Toshio/AAR-5071-2021					BRAAM J, 1983, CELL, V34, P609; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; CHATTOPADHYAY D, 1987, P NATL ACAD SCI USA, V84, P8932, DOI 10.1073/pnas.84.24.8932; CHATTOPADHYAY D, 1988, P NATL ACAD SCI USA, V85, P7977, DOI 10.1073/pnas.85.21.7977; CURRAN J, 1994, VIROLOGY, V202, P875, DOI 10.1006/viro.1994.1409; DAS T, 1993, CELL MOL BIOL RES, V39, P93; DE BP, 1991, J VIROL, V65, P3268, DOI 10.1128/JVI.65.6.3268-3275.1991; Galarza JM, 1996, J VIROL, V70, P2360, DOI 10.1128/JVI.70.4.2360-2368.1996; HARTY RN, 1995, J GEN VIROL, V76, P2863, DOI 10.1099/0022-1317-76-11-2863; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; HUANG YT, 1993, VIROLOGY, V193, P862, DOI 10.1006/viro.1993.1195; Hung JJ, 2002, J VIROL, V76, P1379, DOI 10.1128/JVI.76.3.1379-1390.2002; ISHIHAMA A, 1988, CRC CR REV BIOCH MOL, V23, P27, DOI 10.3109/10409238809103119; KIMURA N, 1992, J GEN VIROL, V73, P1321, DOI 10.1099/0022-1317-73-6-1321; KRUG RM, 1975, J VIROL, V16, P790, DOI 10.1128/JVI.16.4.790-796.1975; Lai MMC, 1998, VIROLOGY, V244, P1, DOI 10.1006/viro.1998.9098; Li ML, 2001, EMBO J, V20, P2078, DOI 10.1093/emboj/20.8.2078; LUO GX, 1991, J VIROL, V65, P2861, DOI 10.1128/JVI.65.6.2861-2867.1991; Meng X, 1996, J CELL SCI, V109, P1677; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; Momose F, 2001, J VIROL, V75, P1899, DOI 10.1128/JVI.75.4.1899-1908.2001; Momose F, 1996, BIOCHIMIE, V78, P1103, DOI 10.1016/S0300-9084(97)86736-3; MOYER SA, 1986, P NATL ACAD SCI USA, V83, P5405, DOI 10.1073/pnas.83.15.5405; MOYER SA, 1990, J GEN VIROL, V71, P775, DOI 10.1099/0022-1317-71-4-775; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; NAGATA K, 1999, RRD VIROLOGY III, V1, P559; NAKAGAWA Y, 1995, J VIROL, V69, P728, DOI 10.1128/JVI.69.2.728-733.1995; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; Nemoto T, 1998, BIOCHEM J, V330, P989, DOI 10.1042/bj3300989; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohtsu Y, 2002, MICROBIOL IMMUNOL, V46, P167, DOI 10.1111/j.1348-0421.2002.tb02682.x; OHTSU Y, MICROBIOL IMMUNOL, V46, P16702; Okuwaki M, 2001, J MOL BIOL, V311, P41, DOI 10.1006/jmbi.2001.4812; Okuwaki M, 1998, J BIOL CHEM, V273, P34511, DOI 10.1074/jbc.273.51.34511; PLOTCH SJ, 1981, CELL, V23, P847, DOI 10.1016/0092-8674(81)90449-9; Poon LLM, 1999, J VIROL, V73, P3473, DOI 10.1128/JVI.73.4.3473-3476.1999; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; SHIMIZU K, 1994, NUCLEIC ACIDS RES, V22, P5047, DOI 10.1093/nar/22.23.5047; SPRIGGS MK, 1986, J GEN VIROL, V67, P2705, DOI 10.1099/0022-1317-67-12-2705; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Takagi T, 1996, ARCH VIROL, V141, P1623, DOI 10.1007/BF01718287; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; YAMANAKA K, 1990, J BIOL CHEM, V265, P11151	48	185	194	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45306	45314		10.1074/jbc.M206822200	http://dx.doi.org/10.1074/jbc.M206822200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12226087	hybrid			2022-12-27	WOS:000179404800092
J	Park, B; Nguyen, NT; Dutt, P; Merdek, KD; Bashar, M; Sterpetti, P; Tosolini, A; Testa, JR; Toksoz, D				Park, B; Nguyen, NT; Dutt, P; Merdek, KD; Bashar, M; Sterpetti, P; Tosolini, A; Testa, JR; Toksoz, D			Association of Lbc Rho guanine nucleotide exchange factor with alpha-catenin-related protein, alpha-catulin/CTNNAL1, supports serum response factor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CADHERIN-ASSOCIATED PROTEIN; CELL-CELL ADHESION; DBL FAMILY; CHROMOSOMAL LOCALIZATION; JUNCTIONAL COMPLEX; GENE CTNNA1; KINASE-A; BINDING; IDENTIFICATION; VINCULIN	The Rho GTPase signaling pathway is required for actin cytoskeletal organization and serum response factor-dependent gene transcription. Lbc is a Rho-specific guanine nucleotide exchange factor that contains a modulatory C-terminal region. To elucidate Lbc regulatory mechanism(s), a yeast two-hybrid screen for proteins that interact with the Lbc C-terminal region was carried out, resulting in multiple isolation of cDNAs encoding the same 734-amino acid Lbc interacting protein. The Lbc interacting protein has homology with the alpha-catenin cell adhesion component and is identical to the alpha-catenin-like alpha-catulin protein of unknown function. The human alpha-catulin gene (CTNNAL1) maps to 9q31-32. Here we identify the predicted endogenous alpha-catulin product, document alpha-catulin and Lbc co-expression in multiple human cell lines, and show alpha-catulin and Lbc subcellular co-fractionation and intracellular localization. The required regions for Lbc and alpha-catulin interaction were mapped, and complex formation between Lbc and alpha-catulin in mammalian cells was detected. Functionally, alpha-catulin co-expression leads to increased Lbc-induced serum response factor activation in vivo as measured by a transcriptional reporter assay. Furthermore, alpha-catulin co-expression enhances Lbc-induced GTP-Rho formation in vivo. These results support the concept that the recently identified alpha-catulin protein may modulate Rho pathway signaling in vivo by providing a scaffold for the Lbc Rho guanine nucleotide exchange factor.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA	Tufts University; Fox Chase Cancer Center	Toksoz, D (corresponding author), Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA.	dtokso01@granite.tufts.edu			NCI NIH HHS [CA62029, CA06927] Funding Source: Medline; NIDDK NIH HHS [1 P30 DK39428] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA062029, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; AUSUBEL FM, 1988, CURRENT PROTOCOLS MO, P1631; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BELL DW, 1995, CYTOGENET CELL GENET, V70, P263, DOI 10.1159/000134048; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CLAVERIE JM, 1993, GENOMICS, V15, P13, DOI 10.1006/geno.1993.1004; Diviani D, 2001, J BIOL CHEM, V276, P44247, DOI 10.1074/jbc.M106629200; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; Giannini AL, 2000, EXP CELL RES, V255, P207, DOI 10.1006/excr.1999.4785; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Janssens B, 1999, BBA-GENE STRUCT EXPR, V1447, P341, DOI 10.1016/S0167-4781(99)00170-0; Johns DG, 2000, J BIOMED SCI, V7, P431, DOI 10.1007/BF02253359; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Klussmann E, 2001, FEBS LETT, V507, P264, DOI 10.1016/S0014-5793(01)02995-7; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; MCPHERSON JD, 1994, GENOMICS, V19, P188, DOI 10.1006/geno.1994.1042; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Nern A, 1999, J CELL BIOL, V144, P1187, DOI 10.1083/jcb.144.6.1187; PIERCEALL WE, 1995, ONCOGENE, V11, P1319; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reuther GW, 2001, J BIOL CHEM, V276, P27145, DOI 10.1074/jbc.M103565200; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Rubino D, 1998, ONCOGENE, V16, P2513, DOI 10.1038/sj.onc.1201783; Sagi SA, 2001, J BIOL CHEM, V276, P15445, DOI 10.1074/jbc.M008961200; Sehgal RNM, 1997, J CELL BIOL, V139, P1033, DOI 10.1083/jcb.139.4.1033; Sterpetti P, 1999, MOL CELL BIOL, V19, P1334; Takahashi K, 1998, ONCOGENE, V16, P3279, DOI 10.1038/sj.onc.1201874; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TOKSOZ D, 1994, ONCOGENE, V9, P621; Toksoz D, 2002, HISTOL HISTOPATHOL, V17, P915, DOI 10.14670/HH-17.915; VAN AL, 1997, GENE DEV, V11, P2295; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Vermeulen SJ, 1999, ONCOGENE, V18, P905, DOI 10.1038/sj.onc.1202348; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Zhai JB, 2001, J BIOL CHEM, V276, P41318, DOI 10.1074/jbc.M107709200; Zhang JS, 1998, GENOMICS, V54, P149, DOI 10.1006/geno.1998.5458; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	64	50	52	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45361	45370		10.1074/jbc.M202447200	http://dx.doi.org/10.1074/jbc.M202447200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12270917	hybrid			2022-12-27	WOS:000179404800099
J	Werten, S; Mitschler, A; Romier, C; Gangloff, YG; Thuault, S; Davidson, I; Moras, D				Werten, S; Mitschler, A; Romier, C; Gangloff, YG; Thuault, S; Davidson, I; Moras, D			Crystal structure of a subcomplex of human transcription factor TFIID formed by TATA binding protein-associated factors hTAF4 (hTAF(II)135) and hTAF12 (hTAF(II)20)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-FOLD; DNA-BINDING; CORE; COMPLEX; TAFS; DROSOPHILA; REQUIREMENT; TAF(II)250; SIMILARITY; PROGRAM	The crystal structure is presented of a complex formed by the interacting domains from two subunits of the general transcription factor TFIID, the human TATA binding protein-associated factors hTAF4 (hTAF(II)135) and hTAF12 (hTAF(II)20). In agreement with predictions, hTAF12 forms a histone fold that is very similar to that of histone H2B, yet unexpected differences are observed between the structures of the hTAF12 interaction domain of hTAF4 and histone H2A. Most importantly, the hTAF4 fragment forms only the first two helices of a classical histone fold, which are followed by a 26-residue disordered region. This indicates that either full-length TAF4 contains an unusually long connecting loop between its second and third helix, and this helix is not required for stable interaction with TAF12, or that TAF4 represents a novel class of partial histone fold motifs. Structural models and structure-based sequence alignments support a role for TAF4b and hSTAF42/yADA1 as alternative partners for TAF12 and are consistent with the formation of nucleosome-like histone-fold octamers through interaction of TAF12 with a TAF6-TAF9 tetramer, yet argue against involvement of TAF12-containing histone-fold pairs in DNA binding.	Univ Louis Pasteur Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Moras, D (corresponding author), Univ Louis Pasteur Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, BP 163, F-67404 Illkirch Graffenstaden, France.	moras@igbmc.u-strasbg.fr	Werten, Sebastiaan/AAU-9011-2021; GANGLOFF, Yann-Gaël/I-2161-2014	Werten, Sebastiaan/0000-0003-2244-9688; GANGLOFF, Yann-Gaël/0000-0001-9031-1184; Davidson, Irwin/0000-0001-5533-1171; Romier, Christophe/0000-0002-3680-935X; THUAULT, Sylvie/0000-0003-0133-3803				Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; FLOCCO MW, 1995, J MOL BIOL, V254, P96, DOI 10.1006/jmbi.1995.0602; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; Fribourg S, 2001, J MOL BIOL, V306, P363, DOI 10.1006/jmbi.2000.4376; Gangloff YG, 2000, MOL CELL BIOL, V20, P340, DOI 10.1128/MCB.20.1.340-351.2000; Gangloff YG, 2001, TRENDS BIOCHEM SCI, V26, P250, DOI 10.1016/S0968-0004(00)01741-2; Gangloff YG, 2001, MOL CELL BIOL, V21, P1841, DOI 10.1128/MCB.21.5.1841-1853.2001; Hiller MA, 2001, GENE DEV, V15, P1021, DOI 10.1101/gad.869101; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Leurent C, 2002, EMBO J, V21, P3424, DOI 10.1093/emboj/cdf342; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; Luger K, 1998, CURR OPIN STRUC BIOL, V8, P33, DOI 10.1016/S0959-440X(98)80007-9; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Otwinowski Z, 1993, P CCP4 STUD WEEK DAT, P55; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Saurin AJ, 2001, NATURE, V412, P655, DOI 10.1038/35088096; Selleck W, 2001, NAT STRUCT BIOL, V8, P695, DOI 10.1038/90408; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thuault S, 2002, J BIOL CHEM, V277, P45510, DOI 10.1074/jbc.M206556200; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Wassarman DA, 2001, J CELL SCI, V114, P2895; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0	45	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45502	45509		10.1074/jbc.M206587200	http://dx.doi.org/10.1074/jbc.M206587200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237304	Green Published, hybrid			2022-12-27	WOS:000179404800115
J	Schoorlemmer, J; Goldfarb, M				Schoorlemmer, J; Goldfarb, M			Fibroblast growth factor homologous factors and the islet brain-2 scaffold protein regulate activation of a stress-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETING CELLS; SIGNAL-TRANSDUCTION; ACTIN REORGANIZATION; INDUCED APOPTOSIS; NERVOUS-SYSTEM; JNK ACTIVATION; MAP KINASES; FACTOR FGF; FAMILY; P38-DELTA	Fibroblast growth factor homologous factors (FHFs) form native intracellular complexes with the mitogen-activated protein kinase (MAPK) scaffold protein islet-brain 2 (IB2) in adult brain. FHF binding to IB2 facilitates recruitment of the MAPK p38delta (SAPK4), while failing to stimulate binding of JNK, the preferred kinase of the related scaffold IB1 (JIP-1). We now report further biochemical evidence supporting FHFs as regulators of IB2 scaffold activity. Mixed lineage kinase 3 (MLK3) and IB2 synergistically activate p38delta but not the MAPKs JNK-1 and p38alpha. Binding of p38delta to IB2 is mediated by the carboxyl-terminal half of the scaffold (IB2(Delta1-436)). FHF2 also binds weakly to IB2(Delta1-436) and can thereby increase p388 interaction with IB2(Delta1-436). FHF-induced recruitment of p388 to IB2 is accompanied by increased levels of activated p385, and synergistic activation of p38delta by MLK3 and IB2 is further enhanced by FHF2. Consistent with a role for FHFs as signaling molecules, FHF2 isolated from rat brain is serine/threonine-phosphorylated, and FHF can serve as a substrate for p38delta in vitro. These results support the existence of a signaling module in which IB2 scaffolds a MLK3/MKK/p38delta kinase cascade. FHFs aid in recruitment of p38 to IB2 and may serve as kinase substrates.	Mt Sinai Sch Med, Dept Mol Cell & Dev Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Goldfarb, M (corresponding author), Mt Sinai Sch Med, Dept Mol Cell & Dev Biol, Box 1020,1 Gustave Levy Pl, New York, NY 10029 USA.		Schoorlemmer, Jon/R-6814-2019	Schoorlemmer, Jon/0000-0001-6933-0567	NINDS NIH HHS [R01 NS039906-01, R01 NS039906] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039906] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Byrd DT, 2001, NEURON, V32, P787, DOI 10.1016/S0896-6273(01)00532-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DICKENS M, 1997, SCIENCE, V277, P696; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; Goedert M, 1997, FEBS LETT, V409, P57, DOI 10.1016/S0014-5793(97)00483-3; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Goldstein LSB, 2001, SCIENCE, V291, P2102, DOI 10.1126/science.1059766; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Hartung H, 1997, MECH DEVELOP, V64, P31, DOI 10.1016/S0925-4773(97)00042-7; Hollenbeck PJ, 2001, J CELL BIOL, V152, pF25, DOI 10.1083/jcb.152.5.F25; Hu MCT, 1999, J BIOL CHEM, V274, P7095, DOI 10.1074/jbc.274.11.7095; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; Matsuda S, 2001, J NEUROSCI, V21, P6597; Munoz-Sanjuan I, 2000, J BIOL CHEM, V275, P2589, DOI 10.1074/jbc.275.4.2589; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Negri S, 2000, GENOMICS, V64, P324, DOI 10.1006/geno.2000.6129; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Parker CG, 1998, BIOCHEM BIOPH RES CO, V249, P791, DOI 10.1006/bbrc.1998.9250; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; Schoorlemmer J, 2001, CURR BIOL, V11, P793, DOI 10.1016/S0960-9822(01)00232-9; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; Taru H, 2002, J BIOL CHEM, V277, P20070, DOI 10.1074/jbc.M108372200; Tawadros T, 2002, J CELL SCI, V115, P385; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Verdier AS, 1997, GENOMICS, V40, P151, DOI 10.1006/geno.1996.4492; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Wang Q, 2000, MECH DEVELOP, V90, P283, DOI 10.1016/S0925-4773(99)00241-5; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103	47	74	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49111	49119		10.1074/jbc.M205520200	http://dx.doi.org/10.1074/jbc.M205520200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12244047	Green Accepted, hybrid			2022-12-27	WOS:000180028900004
J	Crowley, PB; Diaz-Quintana, A; Molina-Heredia, FP; Nieto, P; Sutter, M; Haehnel, W; De la Rosa, MA; Ubbink, M				Crowley, PB; Diaz-Quintana, A; Molina-Heredia, FP; Nieto, P; Sutter, M; Haehnel, W; De la Rosa, MA; Ubbink, M			The interactions of cyanobacterial cytochrome c(6) and cytochrome f, characterized by NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST-ELECTRON TRANSFER; PHOTOSYSTEM-I; ESCHERICHIA-COLI; PCC 7119; PLASTOCYANIN; RESIDUES; IDENTIFICATION; PROTEINS; COMPLEX; SITE	During oxygenic photosynthesis, cytochrome c(6) shuttles electrons between the membrane-bound complexes cytochrome bf and photosystem I. Complex formation between Phormidium laminosum cytochrome f and cytochrome c(6) from both Anabaena sp. PCC 7119 and Synechococcus elongatus has been investigated by nuclear magnetic resonance spectroscopy. Chemical-shift perturbation analysis reveals a binding site on Anabaena cytochrome c(6), which consists of a predominantly hydrophobic patch surrounding the heme substituent, methyl 5. This region of the protein was implicated previously in the formation of the reactive complex with photosytem I. In contrast to the results obtained for Anabaena cytochrome c(6), there is no evidence for specific complex formation with the acidic cytochrome c(6) from Synechococcus. This remarkable variability between analogous cytochromes c(6) supports the idea that different organisms utilize distinct mechanisms of photosynthetic intermolecular electron transfer.	Leiden Univ, Gorlaeus Labs, Leiden Inst Chem, NL-2300 RA Leiden, Netherlands; Univ Seville, Ctr Invest Cient Isla Cartuja, Seville 41092, Spain; CSIC, Seville 41092, Spain; Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany	Leiden University; Leiden University - Excl LUMC; University of Sevilla; Consejo Superior de Investigaciones Cientificas (CSIC); University of Freiburg	Ubbink, M (corresponding author), Leiden Univ, Gorlaeus Labs, Leiden Inst Chem, POB 9502, NL-2300 RA Leiden, Netherlands.	m.ubbink@chem.leidenuniv.nl	De la Rosa, Miguel/B-2545-2014; Nieto, Pedro M/B-7869-2008; Ubbink, Marcellus/E-2158-2011; Molina-Heredia, Fernando P./F-7877-2015; Crowley, Peter B./A-7822-2013; Díaz-Quintana, Antonio/A-1946-2011	De la Rosa, Miguel/0000-0003-1187-5737; Nieto, Pedro M/0000-0002-4074-9011; Ubbink, Marcellus/0000-0002-2615-6914; Molina-Heredia, Fernando P./0000-0002-3637-0519; Díaz-Quintana, Antonio/0000-0001-8973-8009; Crowley, Peter/0000-0002-5365-0096				Andersson P, 1998, J BIOMOL NMR, V11, P279, DOI 10.1023/A:1008227631084; Arslan E, 1998, BIOCHEM BIOPH RES CO, V251, P744, DOI 10.1006/bbrc.1998.9549; Banci L, 1998, BIOCHEMISTRY-US, V37, P4831, DOI 10.1021/bi972765y; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Beissinger M, 1998, EMBO J, V17, P27, DOI 10.1093/emboj/17.1.27; Bergkvist A, 2001, PROTEIN SCI, V10, P2623, DOI 10.1110/ps.ps.27101; Crowley PB, 2002, CHEMBIOCHEM, V3, P526, DOI 10.1002/1439-7633(20020603)3:6<526::AID-CBIC526>3.0.CO;2-N; Crowley PB, 2001, J AM CHEM SOC, V123, P10444, DOI 10.1021/ja0112700; Fragata M, 2002, BIOPHYS J, V82, p333A; FRAZAO C, 1995, STRUCTURE, V3, P1159, DOI 10.1016/S0969-2126(01)00252-0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gupta R, 2002, NATURE, V417, P567, DOI 10.1038/417567a; Hervas M, 1996, BIOCHEMISTRY-US, V35, P2693, DOI 10.1021/bi951876z; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; Hippler M, 1998, P NATL ACAD SCI USA, V95, P7339, DOI 10.1073/pnas.95.13.7339; Illerhaus J, 2000, J BIOL CHEM, V275, P17590, DOI 10.1074/jbc.275.23.17590; Kannt A, 1996, BBA-BIOENERGETICS, V1277, P115, DOI 10.1016/S0005-2728(96)00090-4; Kerfeld CA, 1998, ANNU REV PLANT PHYS, V49, P397, DOI 10.1146/annurev.arplant.49.1.397; KERFELD CA, 1995, J MOL BIOL, V250, P627, DOI 10.1006/jmbi.1995.0404; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; MARINUS MG, 1973, J BACTERIOL, V114, P1143, DOI 10.1128/JB.114.3.1143-1150.1973; Medina M, 1997, J BIOL INORG CHEM, V2, P225, DOI 10.1007/s007750050128; Molina-Heredia FP, 1998, BIOCHEM BIOPH RES CO, V243, P302, DOI 10.1006/bbrc.1997.7953; Molina-Heredia FP, 1999, J BIOL CHEM, V274, P33565, DOI 10.1074/jbc.274.47.33565; Molina-Heredia FP, 2001, J BIOL CHEM, V276, P601, DOI 10.1074/jbc.M007081200; Navarro JA, 1997, J BIOL INORG CHEM, V2, P11, DOI 10.1007/s007750050101; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Palma PN, 2000, PROTEINS, V39, P372, DOI 10.1002/(SICI)1097-0134(20000601)39:4<372::AID-PROT100>3.0.CO;2-Q; PARK KS, 1988, ARCH BIOCHEM BIOPHYS, V267, P195, DOI 10.1016/0003-9861(88)90023-9; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sawaya MR, 2001, BIOCHEMISTRY-US, V40, P9215, DOI 10.1021/bi002679p; Schlarb BG, 1999, GENE, V234, P275, DOI 10.1016/S0378-1119(99)00198-5; Schnackenberg J, 1999, J MOL BIOL, V290, P1019, DOI 10.1006/jmbi.1999.2944; Soriano GM, 1996, BIOCHEMISTRY-US, V35, P14590, DOI 10.1021/bi9616211; Soriano GM, 1998, BIOCHEMISTRY-US, V37, P15120, DOI 10.1021/bi9807714; Sutter M, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P563; Ubbink M, 1998, STRUCTURE, V6, P323, DOI 10.1016/S0969-2126(98)00035-5; Ullmann GM, 1997, BIOCHEMISTRY-US, V36, P16187, DOI 10.1021/bi971241v; Wastl J, 2002, TRENDS PLANT SCI, V7, P244, DOI 10.1016/S1360-1385(02)02280-X; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; Worrall JAR, 2002, BIOCHEMISTRY-US, V41, P11721, DOI 10.1021/bi026296y; Yamada S, 2000, ACTA CRYSTALLOGR D, V56, P1577, DOI 10.1107/S090744490001461X; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	43	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48685	48689		10.1074/jbc.M203983200	http://dx.doi.org/10.1074/jbc.M203983200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12356767	Green Published, hybrid			2022-12-27	WOS:000179789600093
J	Gosavi, N; Lee, HJ; Lee, JS; Patel, S; Lee, SJ				Gosavi, N; Lee, HJ; Lee, JS; Patel, S; Lee, SJ			Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; AMYOTROPHIC-LATERAL-SCLEROSIS; PARKINSONS-DISEASE; PROTEIN AGGREGATION; TRANSGENIC MICE; IN-VITRO; DEATH; MUTANT; PATHOGENESIS; APPARATUS	Amyloid-like fibrillar aggregates of intracellular proteins are common pathological features of human neurodegenerative diseases. However, the nature of pathogenic aggregates and the biological consequences of their formation remain elusive. Here, we describe (i) a model cellular system in which prefibrillar alpha-synuclein aggregates and fibrillar inclusions are naturally formed in the cytoplasm with distinctive kinetics and (ii) a tight correlation between the presence of prefibrillar aggregates and the Golgi fragmentation. Consistent with the structural abnormality of Golgi apparatus, trafficking and maturation of dopamine transporter through the biosynthetic pathway were impaired in the presence of alpha-synuclein aggregates. Reduction in cell viability was also observed in the prefibrillar aggregate-forming condition and before the inclusion formation. The fibrillar inclusions, on the other hand, showed no correlation with Golgi fragmentation and were preceded by these events. Furthermore, at the early stage of inclusion formation, active lysosomes and mitochondria were enriched in the juxtanuclear area and co-aggregate into a compact inclusion body, suggesting that the fibrillar inclusions might be the consequence of an attempt of the cell to remove abnormal protein aggregates and damaged organelles. These results support the hypothesis that prefibrillar a-synuclein aggregates are the pathogenic species and suggest that Golgi fragmentation and subsequent trafficking impairment are the specific consequence of alpha-synuclein aggregation.	Parkinsons Inst, Sunnyvale, CA 94089 USA		Lee, SJ (corresponding author), Parkinsons Inst, 1170 Morse Ave, Sunnyvale, CA 94089 USA.			Lee, Seung-Jae/0000-0002-5155-5335				Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bouley DM, 2001, INFECT IMMUN, V69, P7820, DOI 10.1128/IAI.69.12.7820-7831.2001; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; Faber PW, 1999, P NATL ACAD SCI USA, V96, P179, DOI 10.1073/pnas.96.1.179; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Gonatas NK, 1998, HISTOCHEM CELL BIOL, V109, P591, DOI 10.1007/s004180050257; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; Iwata A, 2001, J BIOL CHEM, V276, P45320, DOI 10.1074/jbc.M103736200; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; Lee HJ, 2002, J BIOL CHEM, V277, P5411, DOI 10.1074/jbc.M105326200; Lee HJ, 2002, J BIOL CHEM, V277, P48976, DOI 10.1074/jbc.M208192200; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Melikian HE, 1999, J NEUROSCI, V19, P7699; Mourelatos Z, 1996, P NATL ACAD SCI USA, V93, P5472, DOI 10.1073/pnas.93.11.5472; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Saha AR, 2000, EUR J NEUROSCI, V12, P3073, DOI 10.1046/j.1460-9568.2000.00210.x; Sakurai A, 2000, ACTA NEUROPATHOL, V100, P270, DOI 10.1007/s004010000182; Sakurai A, 2002, ACTA NEUROPATHOL, V103, P550, DOI 10.1007/s00401-001-0500-x; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Wigley WC, 1999, J CELL BIOL, V145, P481; Yang W, 1998, MOL BIOL CELL, V9, P191, DOI 10.1091/mbc.9.1.191; Zhou WB, 2002, BRAIN RES, V926, P42, DOI 10.1016/S0006-8993(01)03292-9	43	230	238	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48984	48992		10.1074/jbc.M208194200	http://dx.doi.org/10.1074/jbc.M208194200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12351643	hybrid			2022-12-27	WOS:000179789600131
J	D'Addario, M; Arora, PD; Ellen, RP; McCulloch, CAG				D'Addario, M; Arora, PD; Ellen, RP; McCulloch, CAG			Interaction of p38 and Sp1 in a mechanical force-induced, beta(1), integrin-mediated transcriptional circuit that regulates the actin-binding protein filamin-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION; MAP KINASE; P21(WAF1/CIP1) GENE; CHAIN GENE; C-JUN; PHOSPHORYLATION; ACTIVATION; EXPRESSION; DNA	Connective tissue cells in mechanically active environments survive applied physical forces by modifying actin cytoskeletal structures that stabilize cell membranes. In fibroblasts, tensile forces induce the expression of filamin-A, a mechanoprotective actin-binding protein, but the mechanisms and protein interactions by which force activates filamin-A transcription are not defined. We found that in fibroblasts, application of tensile forces through collagen-coated magnetite beads to cell surface beta(1) integrins induced filamin-A expression. This induction required actin filaments and selective activation of the p38 mitogen-activated protein kinase. Force promoted the redistribution of p38 to the integrin/bead locus and the nucleus as well as enhanced binding of the transcription factor Sp1 to proximal, regulatory domains of the filamin-A promoter. Force application increased association of Sp1 with p38 and phosphorylation of Sp1. Transcriptional activation of filamin-A in force-treated fibroblasts was subsequently mediated by Sp1-binding sites on the filamin-A promoter. These results provide evidence for a mechanically coupled transcriptional circuit that originates at the magnetite bead/integrin locus, activates p38, tethers p38 to actin filaments, promotes binding of p38 to Sp1 in the nucleus, and induces filamin-A expression.	Univ Toronto, Canadian Inst Hlth Res Grp Matrix Dynam, Toronto, ON M5S 3E2, Canada; Univ Toronto, Fac Dent, Inst Dent Res, Toronto, ON M5S 3E2, Canada	University of Toronto; University of Toronto	McCulloch, CAG (corresponding author), Univ Toronto, Canadian Inst Hlth Res Grp Matrix Dynam, Rm 244,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	christopher.mcculloch@utoronto.ca						Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; Arora PD, 1996, J BIOL CHEM, V271, P20516, DOI 10.1074/jbc.271.34.20516; BRENTCARTER A, 1999, J BIOL CHEM, V274, P30858; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; D'Addario M, 1999, FASEB J, V13, P2203, DOI 10.1096/fasebj.13.15.2203; D'Addario M, 2001, J BIOL CHEM, V276, P31969, DOI 10.1074/jbc.M102715200; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; de Borja PF, 2001, EMBO J, V20, P5737; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Glogauer M, 1997, J CELL SCI, V110, P11; Glogauer M, 1998, J BIOL CHEM, V273, P1689, DOI 10.1074/jbc.273.3.1689; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Hui MZ, 1997, J CELL PHYSIOL, V172, P323, DOI 10.1002/(SICI)1097-4652(199709)172:3<323::AID-JCP6>3.0.CO;2-Q; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kainulainen T, 2002, J BIOL CHEM, V277, P21998, DOI 10.1074/jbc.M200715200; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kaytor EN, 2001, J BIOL CHEM, V276, P36896, DOI 10.1074/jbc.M104035200; Khachigian LM, 1999, CIRC RES, V84, P1258, DOI 10.1161/01.RES.84.11.1258; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Laniel MA, 2001, J BIOL CHEM, V276, P20766, DOI 10.1074/jbc.M010360200; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Liang FQ, 1999, J CLIN INVEST, V104, P1603, DOI 10.1172/JCI7362; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Melnikova IN, 2001, J BIOL CHEM, V276, P19040, DOI 10.1074/jbc.M010735200; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; PENDER N, 1991, J CELL SCI, V100, P187; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; Rafty LA, 2001, NUCLEIC ACIDS RES, V29, P1027, DOI 10.1093/nar/29.5.1027; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Saito T, 2001, J BIOL CHEM, V276, P38010; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Wang J, 2000, AM J PHYSIOL-HEART C, V279, pH2776, DOI 10.1152/ajpheart.2000.279.6.H2776; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; Yang TTC, 2002, MOL CELL BIOL, V22, P3892, DOI 10.1128/MCB.22.11.3892-3904.2002; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876	56	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47541	47550		10.1074/jbc.M207681200	http://dx.doi.org/10.1074/jbc.M207681200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12324467	hybrid			2022-12-27	WOS:000179663700092
J	Da Poian, AT; Johnson, JE; Silva, JL				Da Poian, AT; Johnson, JE; Silva, JL			Protein-RNA interactions and virus stability as probed by the dynamics of tryptophan side chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COWPEA MOSAIC-VIRUS; VARIABLE-FREQUENCY PHASE; PRESSURE STABILITY; HYDROSTATIC-PRESSURE; ICOSAHEDRAL VIRUSES; COLD DENATURATION; DNA RECOGNITION; MODULATION DATA; ARC REPRESSOR; RESOLUTION	The correlation between dynamics and stability of icosahedral viruses was studied by steady-state and time-resolved fluorescence approaches. We compared the environment and dynamics of tryptophan side chains of empty capsids and ribonucleoprotein particles of two icosahedral viruses from the comovirus group: cowpea mosaic virus (CPMV) and bean pod mottle virus (BPMV). We found a great difference between tryptophan fluorescence emission spectra of the ribonucleoprotein particles and the empty capsids of BPMV. For CPMV, time-resolved fluorescence revealed differences in the tryptophan environments of the capsid protein. The excited-state lifetimes of tryptophan residues were significantly modified by the presence of RNA in the capsid. More than half of the emission of the tryptophans in the ribonucleoprotein particles of CPMV originates from a single exponential decay that can be explained by a similar, nonpolar environment in the local structure of most of the tryptophans, even though they are physically located in different regions of the x-ray structure. CPMV particles without RNA lost this discrete component of emission. Anisotropy decay measurements demonstrated that tryptophans rotate faster in empty particles when compared with the ribonucleoprotein particles. The increased structural breathing facilitates the denaturation of the empty particles. Our studies bring new insights into the intricate interactions between protein and RNA where part of the missing structural information on the nucleic acid molecule is compensated for by the dynamics.	Univ Fed Rio de Janeiro, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Ctr Nacl Ressonancia Magnet Nucl Macromol, BR-21941590 Rio De Janeiro, Brazil; The Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Scripps Research Institute	Silva, JL (corresponding author), Univ Fed Rio de Janeiro, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil.	jerson@bioqmed.ufrj.br	Da Poian, Andrea T./V-1699-2019; Silva, Jerson/J-8984-2014; SILVA, JERSON Lima/GRF-1442-2022	Silva, Jerson/0000-0001-9523-9441; SILVA, JERSON Lima/0000-0001-9523-9441; Da Poian, Andrea/0000-0002-3969-704X				ALCALA JR, 1985, ANAL INSTRUM, V14, P225; Antson AA, 2000, CURR OPIN STRUC BIOL, V10, P87, DOI 10.1016/S0959-440X(99)00054-8; Balny C, 2002, BBA-PROTEIN STRUCT M, V1595, P3, DOI 10.1016/S0167-4838(01)00331-4; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Beechem JM., 2002, TOPICS FLUORESCENCE, P241, DOI DOI 10.1007/0-306-47058-6_5; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; BURLEY SK, 1986, J AM CHEM SOC, V108, P7995, DOI 10.1021/ja00285a019; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; CHEN ZG, 1990, NEW ASPECTS OF POSITIVE-STRAND RNA VIRUSES, P218; COOPER A, 1976, P NATL ACAD SCI USA, V73, P2740, DOI 10.1073/pnas.73.8.2740; DAPOIAN AT, 1994, BIOCHEMISTRY-US, V33, P8339, DOI 10.1021/bi00193a022; DAPOIAN AT, 1995, BIOCHEMISTRY-US, V34, P2672, DOI 10.1021/bi00008a034; DAPOIAN AT, 1993, J MOL BIOL, V231, P999, DOI 10.1006/jmbi.1993.1347; De Guzman RN, 1998, BIOPOLYMERS, V48, P181, DOI 10.1002/(SICI)1097-0282(1998)48:2<181::AID-BIP7>3.0.CO;2-L; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; EGGEN R, 1988, RNA GENETICS, P49; Ervin J, 2002, BIOPHYS J, V83, P473, DOI 10.1016/S0006-3495(02)75183-7; FOGUEL D, 1994, P NATL ACAD SCI USA, V91, P8244, DOI 10.1073/pnas.91.17.8244; FOGUEL D, 1995, BIOCHEMISTRY-US, V34, P1120, DOI 10.1021/bi00004a003; Gaspar LP, 1997, J MOL BIOL, V273, P456, DOI 10.1006/jmbi.1997.1299; GRATTON E, 1984, BIOPHYS J, V46, P479, DOI 10.1016/S0006-3495(84)84044-8; GRATTON E, 1986, BIOCHEM SOC T, V14, P835, DOI 10.1042/bst0140835; Hummer G, 1998, P NATL ACAD SCI USA, V95, P1552, DOI 10.1073/pnas.95.4.1552; Johnson JE, 1997, J MOL BIOL, V269, P665, DOI 10.1006/jmbi.1997.1068; Johnson JE, 1996, P NATL ACAD SCI USA, V93, P27, DOI 10.1073/pnas.93.1.27; LAKOWICZ JR, 1984, BIOPHYS J, V46, P463, DOI 10.1016/S0006-3495(84)84043-6; Lee AL, 2001, NATURE, V411, P501, DOI 10.1038/35078119; LI TS, 1990, BIOCHEMISTRY-US, V29, P5018, DOI 10.1021/bi00473a004; LOMONOSSOFF GP, 1983, EMBO J, V2, P2253, DOI 10.1002/j.1460-2075.1983.tb01731.x; LOMONOSSOFF GP, 1991, PROG BIOPHYS MOL BIO, V55, P107, DOI 10.1016/0079-6107(91)90003-B; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; Mohana-Borges R, 2000, J BIOL CHEM, V275, P4708, DOI 10.1074/jbc.275.7.4708; OLIVEIRA AC, 1994, J MOL BIOL, V240, P184, DOI 10.1006/jmbi.1994.1433; Oliveira AC, 1999, BIOPHYS J, V76, P1270, DOI 10.1016/S0006-3495(99)77290-5; Oliveira AC, 2000, J BIOL CHEM, V275, P16037, DOI 10.1074/jbc.M910145199; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Panda M, 2001, J BIOL CHEM, V276, P6253, DOI 10.1074/jbc.M009530200; Reddy VS, 1998, BIOPHYS J, V74, P546, DOI 10.1016/S0006-3495(98)77813-0; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; Royer C A, 1995, Methods Mol Biol, V40, P65; SCHMIDT T, 1983, VIROLOGY, V127, P65, DOI 10.1016/0042-6822(83)90371-9; SEHNKE PC, 1988, J CRYST GROWTH, V90, P222, DOI 10.1016/0022-0248(88)90319-3; SEMANCIK JS, 1965, VIROLOGY, V27, P476, DOI 10.1016/0042-6822(65)90172-8; SILER DJ, 1976, VIROLOGY, V71, P560, DOI 10.1016/0042-6822(76)90381-0; Silva JL, 1996, CURR OPIN STRUC BIOL, V6, P166, DOI 10.1016/S0959-440X(96)80071-6; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; Silva JL, 2001, TRENDS BIOCHEM SCI, V26, P612, DOI 10.1016/S0968-0004(01)01949-1; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; STAUFFACHER CV, 1987, NATO ASI SER, P293; Tsang SK, 2000, J MOL BIOL, V296, P335, DOI 10.1006/jmbi.1999.3483; Tuma R, 1999, BIOCHEMISTRY-US, V38, P15025, DOI 10.1021/bi991473p; VANKAMMEN A, 1970, VIROLOGY, V34, P312; VANWEZENBEEK P, 1983, EMBO J, V2, P941, DOI 10.1002/j.1460-2075.1983.tb01525.x; WEBER G, 1993, J PHYS CHEM-US, V97, P7108, DOI 10.1021/j100129a031; WHITE JM, 1980, VIROLOGY, V101, P319, DOI 10.1016/0042-6822(80)90513-9	57	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47596	47602		10.1074/jbc.M209174200	http://dx.doi.org/10.1074/jbc.M209174200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359712	hybrid			2022-12-27	WOS:000179663700099
J	Huang, MC; Laskowska, A; Vestweber, D; Wild, MK				Huang, MC; Laskowska, A; Vestweber, D; Wild, MK			The alpha(1,3)-fucosyltransferase Fuc-TIV, but not Fuc-TVII, generates sialyl Lewis X-like epitopes preferentially on glycolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIN GLYCOPROTEIN LIGAND-1; ELAM-1-DEPENDENT CELL-ADHESION; NORMAL HUMAN-LEUKOCYTES; LEUKEMIA HL-60 CELLS; P-SELECTIN; FUCOSYL-TRANSFERASE; MYELOID CELLS; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; IN-VIVO	Fuc-TIV and Fuc-TVII are the two alpha(1, 3)-fucosyltransferases in myeloid cells responsible for the biosynthesis of sialyl Lewis X (sLe(x)), the minimal ligand structure for the selectins. We have compared the ability of Fuc-TIV and Fuc-TVII to generate sLe(x)-like epitopes in transfected Chinese hamster ovary (CHO)-Pro(-)5 cells expressing the P-selectin glycoprotein ligand-1 and the core-2 branching enzyme C2GnT. We found that mouse Fuc-TIV and Fuc-TVII can generate similar levels of cell surface sLe(x). Surprisingly however, Fuc-TIV-generated sLe(x) was resistant to proteinase K and trypsin treatment and could be removed from cells by delipidation with chloroform/methanol, whereas 80-90% of Fuc-TVII-generated sLe(x) was protease-sensitive, and most of it resistant to delipidation. Despite similar levels of sLe(x) on the cell surface, Fuc-TVII transfectants adhered to immobilized E-selectin-IgG under static and flow conditions better than Fuc-TIV transfectants. Binding was mainly protease sensitive, indicating that glycoproteins were more efficient ligands than glycolipids. In summary, we conclude that the two fucosyltransferases differ in their in vivo specificity for acceptor substrates with Fuc-TVII generating sLe(x) preferentially on glycoproteins, whereas most of the Fuc-TIV-generated sLe(x) is found on glycolipids. Interestingly, the non-catalytic portion of Fuc-TIV in a Fuc-TIV/VII chimeric enzyme mediated the specificity for glycolipid substrates.	Univ Munster, Ctr Mol Biol Inflammat, Inst Cell Biol, D-48149 Munster, Germany	University of Munster	Wild, MK (corresponding author), Univ Munster, Ctr Mol Biol Inflammat, Inst Cell Biol, Von Esmarch Str 56, D-48149 Munster, Germany.			Vestweber, Dietmar/0000-0002-3517-732X; HUANG, MIN-CHUAN/0000-0002-0704-3447				ALON R, 1995, J IMMUNOL, V154, P5356; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Borges E, 1997, J EXP MED, V185, P573, DOI 10.1084/jem.185.3.573; Borges E, 1997, BLOOD, V90, P1934, DOI 10.1182/blood.V90.5.1934; Borges E, 1997, J BIOL CHEM, V272, P28786, DOI 10.1074/jbc.272.45.28786; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; DUIJVESTIJN AM, 1988, AM J PATHOL, V130, P147; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; Gotsch U, 1997, J CELL SCI, V110, P583; Grabenhorst E, 1998, J BIOL CHEM, V273, P30985, DOI 10.1074/jbc.273.47.30985; Grabenhorst E, 1999, J BIOL CHEM, V274, P36107, DOI 10.1074/jbc.274.51.36107; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; Handa K, 1997, BIOCHEMISTRY-US, V36, P12412, DOI 10.1021/bi971181t; HANISCH FG, 1988, CARBOHYD RES, V178, P23, DOI 10.1016/0008-6215(88)80099-5; Hirata T, 2000, J EXP MED, V192, P1669, DOI 10.1084/jem.192.11.1669; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; Homeister JW, 2001, IMMUNITY, V15, P115, DOI 10.1016/S1074-7613(01)00166-2; Huang MC, 2000, J BIOL CHEM, V275, P31353, DOI 10.1074/jbc.M005449200; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LOWE JB, 1991, J BIOL CHEM, V266, P17467; Lowe JB, 1997, KIDNEY INT, V51, P1418, DOI 10.1038/ki.1997.194; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MACHER BA, 1988, J BIOL CHEM, V263, P10186; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; Mitsuoka C, 1997, BIOCHEM BIOPH RES CO, V230, P546, DOI 10.1006/bbrc.1996.6012; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; Niemela R, 1998, J BIOL CHEM, V273, P4021, DOI 10.1074/jbc.273.7.4021; OHMORI K, 1993, BLOOD, V82, P2797; Osanai T, 1996, BIOCHEM BIOPH RES CO, V218, P610, DOI 10.1006/bbrc.1996.0108; Pendl GG, 2002, BLOOD, V99, P946, DOI 10.1182/blood.V99.3.946; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; STROUD MR, 1995, BIOCHEM BIOPH RES CO, V209, P777, DOI 10.1006/bbrc.1995.1568; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P758, DOI 10.1021/bi951600r; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Wagers AJ, 1997, J IMMUNOL, V159, P1917; Wagers AJ, 1998, J EXP MED, V188, P2225, DOI 10.1084/jem.188.12.2225; Weninger W, 2000, IMMUNITY, V12, P665, DOI 10.1016/S1074-7613(00)80217-4; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Yang J, 1996, BLOOD, V87, P4176, DOI 10.1182/blood.V87.10.4176.bloodjournal87104176; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769; Zollner O, 1996, J BIOL CHEM, V271, P33002, DOI 10.1074/jbc.271.51.33002	56	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47786	47795		10.1074/jbc.M208283200	http://dx.doi.org/10.1074/jbc.M208283200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359718	hybrid			2022-12-27	WOS:000179663700123
J	Adachi, R; Takeuchi, K; Suzuki, K				Adachi, R; Takeuchi, K; Suzuki, K			Antisense oligonucleotide to cofilin enhances respiratory burst and phagocytosis in opsonized zymosan-stimulated mouse macrophage J774.1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIM-KINASE 1; ACTIN-BINDING; NADPH OXIDASE; HL-60 CELLS; RAPID DEPHOSPHORYLATION; TRIGGERED ACTIVATION; POSSIBLE INVOLVEMENT; ADF/COFILIN FAMILY; PHOSPHORYLATION; PROTEIN	Phagocytes play a central role in the host defense system, and the relationship between the mechanism of their activation and cytoskeletal reorganization has been studied. We have previously reported a possible involvement of cofilin, an actin-binding protein, in phagocyte functions through its phosphorylation/dephosphorylation. and translocation to the plasma membrane regions. In this work, we have obtained a new line of evidence showing an important role of cofilin in phagocyte functions using the mouse macrophage cell line J774.1 and an antisense oligonucleotide to cofilin. Upon stimulation with opsonized zymosan (OZ), cofilin was phosphorylated, and it accumulated around phagocytic vesicles. As the antisense oligonucleotide to cofilin, a 20-mer S-oligo corresponding to the sequence including the AUG translational initiation site was found to be effective. In the cells treated with the antisense oligonucleotide, the amount of cofilin was less than 30% of that in the control cells, and the level of F-actin was two or three times higher than that in the control cells before and throughout the cell activation. In the antisense oligonucleotide-treated cells, OZ-triggered superoxide production was three times faster than that in the control cells. Furthermore, phagocytosis of OZ was enhanced by the antisense. These results show that cofilin plays an essential role in the control of phagocyte function through regulation of actin filament dynamics.	Natl Inst Hlth Sci, Setagaya Ku, Tokyo 1588501, Japan; Nagoya Univ, Div Biol Sci, Grad Sch Sci, Chigusa Ku, Nagoya, Aichi 4648602, Japan	National Institute of Health Sciences - Japan; Nagoya University	Suzuki, K (corresponding author), Natl Inst Hlth Sci, Setagaya Ku, Tokyo 1588501, Japan.	ksuzuki@nihs.go.jp	Takeuchi, Kosei/AAV-3577-2021	Takeuchi, Kosei/0000-0001-6397-2243				Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; Adachi R, 2000, INT J IMMUNOPHARMACO, V22, P855, DOI 10.1016/S0192-0561(00)00045-X; Aizawa H, 2001, NAT NEUROSCI, V4, P367, DOI 10.1038/86011; Aizawa H, 1996, J CELL BIOL, V132, P335, DOI 10.1083/jcb.132.3.335; AIZAWA H, 1995, J BIOL CHEM, V270, P10923, DOI 10.1074/jbc.270.18.10923; Aizawa H, 2001, GENES CELLS, V6, P913, DOI 10.1046/j.1365-2443.2001.00470.x; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bierne H, 2001, J CELL BIOL, V155, P101, DOI 10.1083/jcb.200104037; Djafarzadeh S, 1997, EXP CELL RES, V236, P427, DOI 10.1006/excr.1997.3731; DOWNEY GP, 1992, J CELL BIOL, V116, P695, DOI 10.1083/jcb.116.3.695; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; Granfeldt D, 2001, INFLAMMATION, V25, P165, DOI 10.1023/A:1011084330283; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; Grogan A, 1997, J CELL SCI, V110, P3071; Heyworth PG, 1997, HISTOCHEM CELL BIOL, V108, P221, DOI 10.1007/s004180050162; Ichetovkin I, 2000, CELL MOTIL CYTOSKEL, V45, P293, DOI 10.1002/(SICI)1097-0169(200004)45:4<293::AID-CM5>3.0.CO;2-1; IIDA K, 1993, GENE, V124, P115; Iida K, 1999, GENES CELLS, V4, P21, DOI 10.1046/j.1365-2443.1999.00235.x; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; Lee KH, 2000, EUR J IMMUNOL, V30, P892, DOI 10.1002/1521-4141(200003)30:3<892::AID-IMMU892>3.0.CO;2-U; Maciver SK, 2002, GENOME BIOL, V3; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Matsui S, 2002, J BIOL CHEM, V277, P544, DOI 10.1074/jbc.M110153200; Matsusaki H, 2000, BIOMACROMOLECULES, V1, P17, DOI 10.1021/bm9900040; May RC, 2001, J CELL SCI, V114, P1061; McGough Amy, 2001, Results and Problems in Cell Differentiation, V32, P135; Minamide LS, 2000, NAT CELL BIOL, V2, P628, DOI 10.1038/35023579; MORIYAMA K, 1990, NUCLEIC ACIDS RES, V18, P3053, DOI 10.1093/nar/18.10.3053; Nagaishi K, 1999, J BIOCHEM-TOKYO, V125, P891, DOI 10.1093/oxfordjournals.jbchem.a022365; Nagaishi K, 1999, J CELL PHYSIOL, V180, P345, DOI 10.1002/(SICI)1097-4652(199909)180:3<345::AID-JCP5>3.0.CO;2-J; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; Nishita M, 2002, MOL CELL BIOL, V22, P774, DOI 10.1128/MCB.22.3.774-783.2002; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Ojala PJ, 2001, BIOCHEMISTRY-US, V40, P15562, DOI 10.1021/bi0117697; Okada K, 1999, J CELL SCI, V112, P1553; Okada K, 1996, EXP CELL RES, V227, P116, DOI 10.1006/excr.1996.0256; OKADA K, 2002, J BIOL CHEM, V277; Samstag Y, 1996, J IMMUNOL, V156, P4167; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; SUZUKI K, 1995, BBA-MOL CELL RES, V1266, P261, DOI 10.1016/0167-4889(95)00029-R; SUZUKI K, 1995, J BIOL CHEM, V270, P19551, DOI 10.1074/jbc.270.33.19551; Tamura M, 2000, BIOCHEM J, V349, P369, DOI 10.1042/0264-6021:3490369; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; YONEZAWA N, 1987, CELL STRUCT FUNCT, V12, P443, DOI 10.1247/csf.12.443	49	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45566	45571		10.1074/jbc.M207419200	http://dx.doi.org/10.1074/jbc.M207419200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12297504	hybrid			2022-12-27	WOS:000179404800122
J	Holmes, WF; Soprano, DR; Soprano, KJ				Holmes, WF; Soprano, DR; Soprano, KJ			Elucidation of molecular events mediating induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian carcinoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MITOCHONDRIAL CYTOCHROME-C; CARBOXYLIC-ACID CD437; CANCER-CELLS; SELECTIVE RETINOIDS; POSSIBLE MECHANISM; GROWTH-INHIBITION; ORPHAN RECEPTOR; LEUKEMIA-CELLS; RAR-GAMMA	Retinoids have great promise in the area of cancer therapy and chemoprevention. Although some tumor cells are sensitive to the growth inhibitory effect of all-trans-retinoic acid (ATRA), many ovarian tumor cells are not. 6-((1-Admantyl)-4-hydroxyphenyl)-2-naphthalenecarboxylic acid (CD437) is a conformationally restricted synthetic retinoid that induces growth arrest and apoptosis in both ATRA-sensitive and ATRA-resistant ovarian tumor cell lines. To better understand the mechanism by which CD437 induces apoptosis in ovarian tumor cell lines, we prepared a cell line, CA-CD437R, from the ATRA-sensitive ovarian cell line, CA-OV-3, which was resistant to CD437. We found that the CD437-resistant cell line was also resistant to the induction of apoptosis by tumor necrosis factor-a but not resistant to the induction of apoptosis by another synthetic retinoid, fenretinide N-(4-hydroxyphenyl)retinamide. We also show that this cell line remains ATRA-sensitive and exhibits no deficiencies in RAR function. Analysis of this CD437-resistant cell line suggests that the pathway for induction of apoptosis by CD437 is similar to the pathway utilized by tumor necrosis factor-a and different from the pathway induced by the synthetic retinoid, fenretinide N-(4-hydroxyphenyl)retinamide. The CA-CD437R cell line is a valuable tool, permitting us to further elucidate the molecular events that mediate apoptosis induced by CD437 and other synthetic retinoids. Results of experiments utilizing this cell line suggest that the alteration responsible for resistance of CA-CD437R cells to CD437 induced event maps after the activation of p38 and TR3 expression, prior to mitochondrial depolarization, subsequent release of cytochrome c and activation of caspase-9 and caspase-3.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Soprano, KJ (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.	sopranok@astro.temple.edu			NATIONAL CANCER INSTITUTE [R01CA064945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013139] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64945] Funding Source: Medline; NIAID NIH HHS [AI 07101] Funding Source: Medline; NIDCR NIH HHS [DE 13139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adachi H, 1998, CELL DEATH DIFFER, V5, P973, DOI 10.1038/sj.cdd.4400445; Appierto V, 2001, BRIT J CANCER, V84, P1528, DOI 10.1054/bjoc.2001.1826; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; AVDI NJ, 2000, J BIOL CHEM, V25, P25; Chao WR, 1997, CANCER LETT, V115, P1, DOI 10.1016/S0304-3835(97)04598-9; Chen XL, 1998, J VIROL, V72, P6902, DOI 10.1128/JVI.72.8.6902-6906.1998; Chun HS, 2001, NEUROSCI LETT, V316, P5, DOI 10.1016/S0304-3940(01)02341-2; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Dawson MI, 2001, CANCER RES, V61, P4723; DE LUCA LM, 1991, FASEB J, V5, P2924; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; Gudas Lorraine J., 1994, P443; Hail N, 2001, CANCER RES, V61, P6698; Hail N, 2000, CANCER EPIDEM BIOMAR, V9, P1293; Han JH, 2000, TRENDS CARDIOVAS MED, V10, P19, DOI 10.1016/S1050-1738(00)00039-6; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; He JL, 2000, J PHARMACOL EXP THER, V295, P896; Holmes WF, 2000, J CELL PHYSIOL, V185, P61, DOI 10.1002/1097-4652(200010)185:1<61::AID-JCP5>3.0.CO;2-0; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Kang HJ, 2000, EXP CELL RES, V256, P545, DOI 10.1006/excr.2000.4832; Kang HJ, 2000, BIOL PHARM BULL, V23, P815; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kitareewan S, 1999, ONCOGENE, V18, P5747, DOI 10.1038/sj.onc.1202981; Kumar A, 2001, CANCER RES, V61, P7552; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Liu GZ, 1998, INT J CANCER, V78, P248, DOI 10.1002/(SICI)1097-0215(19981005)78:2&lt;248::AID-IJC20&gt;3.0.CO;2-5; Liu RY, 2000, J BIOL CHEM, V275, P21086, DOI 10.1074/jbc.M001281200; Liu S, 2002, WORLD J GASTROENTERO, V8, P446, DOI 10.3748/wjg.v8.i3.446; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; Marchetti P, 1999, CANCER RES, V59, P6257; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; Mologni L, 1999, BLOOD, V93, P1045, DOI 10.1182/blood.V93.3.1045.403k22_1045_1061; Moon Richard C., 1994, P573; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Newman SJ, 2000, BRAIN RES, V857, P131, DOI 10.1016/S0006-8993(99)02417-8; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; Pergolizzi R, 1999, INT J CANCER, V81, P829; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Ponzanelli I, 2000, BLOOD, V95, P2672; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; Sabichi AL, 1998, J NATL CANCER I, V90, P597, DOI 10.1093/jnci/90.8.597; Salgame P, 1997, NUCLEIC ACIDS RES, V25, P680, DOI 10.1093/nar/25.3.680; Schadendorf D, 1996, J CELL BIOL, V135, P1889, DOI 10.1083/jcb.135.6.1889; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHAO ZM, 1995, ONCOGENE, V11, P493; Spanjaard RA, 1997, J BIOL CHEM, V272, P18990, DOI 10.1074/jbc.272.30.18990; Sun SY, 1999, CANCER RES, V59, P2829; Sun SY, 1999, CANCER RES, V59, P2493; Sun SY, 1997, CANCER RES, V57, P4931; Sun SY, 2000, CANCER RES, V60, P7149; Supino R, 1996, INT J CANCER, V65, P491, DOI 10.1002/(SICI)1097-0215(19960208)65:4<491::AID-IJC17>3.0.CO;2-D; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Szondy Z, 1997, MOL PHARMACOL, V51, P972, DOI 10.1124/mol.51.6.972; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; Wei YH, 1996, ANN NY ACAD SCI, V786, P24, DOI 10.1111/j.1749-6632.1996.tb39049.x; Widschwendter M, 1997, INT J CANCER, V71, P497; Wu SJ, 1998, J CELL BIOCHEM, V68, P378, DOI 10.1002/(SICI)1097-4644(19980301)68:3<378::AID-JCB8>3.0.CO;2-R; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Zhang DM, 2001, ONCOGENE, V20, P7935, DOI 10.1038/sj.onc.1204971; Zhang XK, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090087; Zhang YX, 1999, EXP CELL RES, V247, P233, DOI 10.1006/excr.1998.4350; Zhao M, 2000, ACTA BIOCH BIOPH SIN, V32, P258; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200	70	50	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45408	45419		10.1074/jbc.M204600200	http://dx.doi.org/10.1074/jbc.M204600200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237293	hybrid			2022-12-27	WOS:000179404800104
J	Okuda, T; Okamura, M; Kaitsuka, C; Haga, T; Gurwitz, D				Okuda, T; Okamura, M; Kaitsuka, C; Haga, T; Gurwitz, D			Single nucleotide polymorphism of the human high affinity choline transporter alters transport rate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR ACETYLCHOLINE TRANSPORTER; ALZHEIMERS-DISEASE; MOLECULAR-CLONING; BRAIN SYNAPTOSOMES; COTRANSPORTER; EXPRESSION; SYSTEMS; RELEASE	High affinity choline uptake plays a critical role in the regulation of acetylcholine synthesis in cholinergic neurons. Recently, we succeeded in molecular cloning of the high affinity choline transporter (CHT1), which is specifically expressed in cholinergic neurons. Here we demonstrate the presence of functionally relevant, nonsynonymous single nucleotide polymorphism in the human CHT1 gene by comprehensive sequence analysis of the exons and the intron/exon boundaries including the transcription start site. The deduced amino acid change for the polymorphism is isoleucine to valine at amino acid 89 (I89V) located within the third transmembrane domain of the protein. The allele frequency of I89V was 6% for Ashkenazi Jews. Functional assessment of the I89V transporter in mammalian cell lines revealed a 40-50% decrease in V-max for choline uptake rate compared with the wild type, whereas there was no alteration in the apparent affinities for choline, sodium, chloride, and the specific inhibitor hemicholinum-3. There also was no change in the specific hemicholinum-3 binding activity. The decreased choline uptake was not associated with the surface expression level of the protein as assessed by biotinylation assay. These results suggest an impaired substrate translocation in the I89V transporter. The Caenorhabditis elegans ortholog of CHT1 has a valine residue at the corresponding position and a single replacement from valine to isoleucine caused a decrease in the choline uptake rate by 40%, suggesting that this hydrophobic residue is generally critical in the choline transport rate in CHT1. This polymorphism in the allelic CHT1 gene may represent a predisposing factor for cholinergic dysfunction.	Gakushuin Univ, Fac Sci, Inst Biomol Sci, Toshima Ku, Tokyo 1718588, Japan; Japan Sci & Technol Corp, CREST, Toshima Ku, Tokyo 1718588, Japan; Univ Tokyo, Fac Med, Dept Neurochem, Bunkyo Ku, Tokyo 1130033, Japan; Tel Aviv Univ, Sackler Fac Med, Natl Lab Genet Israeli Populat, IL-69978 Tel Aviv, Israel	Gakushuin University; Japan Science & Technology Agency (JST); University of Tokyo; Tel Aviv University; Sackler Faculty of Medicine	Haga, T (corresponding author), Gakushuin Univ, Fac Sci, Inst Biomol Sci, Toshima Ku, 1-5-1 Mejiro, Tokyo 1718588, Japan.		Gurwitz, David/E-7642-2013	Gurwitz, David/0000-0002-9363-1869				Apparsundaram S, 2000, BIOCHEM BIOPH RES CO, V276, P862, DOI 10.1006/bbrc.2000.3561; Apparsundaram S, 2001, BIOCHEM SOC T, V29, P711, DOI 10.1042/0300-5127:0290711; Bissette G, 1996, ANN NY ACAD SCI, V777, P197, DOI 10.1111/j.1749-6632.1996.tb34419.x; Calabresi P, 2000, TRENDS NEUROSCI, V23, P120, DOI 10.1016/S0166-2236(99)01501-5; Collins A, 1999, P NATL ACAD SCI USA, V96, P15173, DOI 10.1073/pnas.96.26.15173; Eiden LE, 1998, J NEUROCHEM, V70, P2227; Francis PT, 1999, J NEUROL NEUROSUR PS, V66, P137, DOI 10.1136/jnnp.66.2.137; Fujiwara H, 1997, NAT GENET, V16, P124, DOI 10.1038/ng0697-124; Guermonprez L, 2002, J NEUROCHEM, V82, P874, DOI 10.1046/j.1471-4159.2002.01044.x; HAGA T, 1971, J NEUROCHEM, V18, P781, DOI 10.1111/j.1471-4159.1971.tb12008.x; HAGA T, 1973, BIOCHIM BIOPHYS ACTA, V291, P564, DOI 10.1016/0005-2736(73)90508-7; HAPPE HK, 1993, J NEUROCHEM, V60, P1191, DOI 10.1111/j.1471-4159.1993.tb03277.x; Hyde TM, 2001, J CHEM NEUROANAT, V22, P53, DOI 10.1016/S0891-0618(01)00101-6; Isacson O, 2002, TRENDS NEUROSCI, V25, P79, DOI 10.1016/S0166-2236(02)02037-4; Kobayashi Y, 2002, NEUROSCI LETT, V317, P25, DOI 10.1016/S0304-3940(01)02413-2; KUHAR MJ, 1978, J NEUROCHEM, V31, P251, DOI 10.1111/j.1471-4159.1978.tb12456.x; KUHAR MJ, 1978, J NEUROCHEM, V30, P15, DOI 10.1111/j.1471-4159.1978.tb07029.x; Lips KS, 2002, CELL TISSUE RES, V307, P275, DOI 10.1007/s00441-002-0520-4; MARUYAMA K, 1994, GENE, V138, P171; Misawa H, 2001, NEUROSCIENCE, V105, P87, DOI 10.1016/S0306-4522(01)00147-6; Ohno K, 2001, P NATL ACAD SCI USA, V98, P2017, DOI 10.1073/pnas.98.4.2017; Okuda T, 2000, FEBS LETT, V484, P92, DOI 10.1016/S0014-5793(00)02134-7; Okuda T, 2000, NAT NEUROSCI, V3, P120, DOI 10.1038/72059; PARSONS SM, 1993, INT REV NEUROBIOL, V35, P279, DOI 10.1016/S0074-7742(08)60572-3; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; SIMON JR, 1975, NATURE, V255, P162, DOI 10.1038/255162a0; SLOTKIN TA, 1994, J CLIN INVEST, V94, P696, DOI 10.1172/JCI117387; Song HJ, 1997, NEURON, V18, P815, DOI 10.1016/S0896-6273(00)80320-7; TUCEK S, 1985, J NEUROCHEM, V44, P11, DOI 10.1111/j.1471-4159.1985.tb07106.x; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; Varoqui H, 1996, J BIOL CHEM, V271, P27229, DOI 10.1074/jbc.271.44.27229; Wang HP, 1999, J BIOL CHEM, V274, P14875, DOI 10.1074/jbc.274.21.14875; Wang YL, 2001, GENE, V268, P123, DOI 10.1016/S0378-1119(01)00421-8; Wright EM, 1998, AM J PHYSIOL-GASTR L, V275, pG879, DOI 10.1152/ajpgi.1998.275.5.G879; YAMAMURA HI, 1972, SCIENCE, V178, P626, DOI 10.1126/science.178.4061.626	36	62	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45315	45322		10.1074/jbc.M207742200	http://dx.doi.org/10.1074/jbc.M207742200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237312	hybrid			2022-12-27	WOS:000179404800093
J	Sato, C; Matsuda, T; Katajima, K				Sato, C; Matsuda, T; Katajima, K			Neuronal differentiation-dependent expression of the disialic acid epitope on CD166 and its involvement in neurite formation in neuro2A cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE; OLIGOSIALIC ACIDS; POLYSIALIC ACID; DM-GRASP; CLONING; GENE; ALPHA-2,8-SIALYLTRANSFERASE; GLYCOPROTEINS; MEMBRANE; RESIDUES	We previously demonstrated that alpha2,8-linked disialic acid (diSia) residues occur in several glycoproteins of mammalian brains (Sato, C., Fukuoka, H., Ohta, K., Matsuda, T., Koshino, R., Kobayashi, K., Troy, F. A., II, and Kitajima, K. (2000) J. Biol. Chem. 275,15422-15431). The role of the diSia epitope on these glycoproteins is not known, whereas the importance of the diSia epitope on glycolipids is well documented in neurite formation. In this study, we demonstrated that the diSia epitope (Neu5Acalpha2 --> 8Neu5Acalpha2 --> 3Gal) on glycoproteins, but not on glycolipids, is involved in neurite formation in a mouse neuroblastoma cell line, Neuro2A, based on the following lines of evidence. First, the amount of diSia epitope on glycoproteins increased during retinoic acid-induced neurite formation. Second, retinoic acid treatment primarily increased the diSia epitope on a 100-kDa glycoprotein. We identified this protein as CD166 (SC1) , an immunoglobulin superfamily cell adhesion molecule involved in neurite extension. Third, a monoclonal antibody against the diSia epitope specifically inhibited neurite formation. We also demonstrated that alpha2,8-sialyltransferase III mRNA expression increased 1.7-fold after the induction of neurite formation, suggesting that alpha2,8-sialyltransferase III is responsible for formation of the diSia epitope on CD166.	Nagoya Univ, Biosci Ctr, Dept Anim Sci, Div Organogenesis, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Grad Sch Bioagr SCi, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan	Nagoya University; Nagoya University	Katajima, K (corresponding author), Nagoya Univ, Biosci Ctr, Dept Anim Sci, Div Organogenesis, Nagoya, Aichi 4648601, Japan.		Naganawa, Shinji/I-1572-2012; SATO, Chihiro/B-7396-2014	Naganawa, Shinji/0000-0002-0214-613X; 				Angata T, 2002, J BIOL CHEM, V277, P24466, DOI 10.1074/jbc.M202833200; BOWEN MA, 2002, LEUKOCYTE TYPING, V7, P894; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRUES JL, 2000, MOL CELLULAR GLYCOBI, P116; BURRNS FR, 1991, NEURON, V7, P209; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; DEBERNARDO AP, 1995, DEV BIOL, V169, P65, DOI 10.1006/dbio.1995.1127; DeBernardo AP, 1996, J CELL BIOL, V133, P657, DOI 10.1083/jcb.133.3.657; DOCTOR BP, 1987, ANAL BIOCHEM, V166, P399, DOI 10.1016/0003-2697(87)90590-2; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; ECKHART M, 1995, NATURE, V373, P213; FOLCH J, 1951, J BIOL CHEM, V191, P819; HARA S, 1986, J CHROMATOGR, V377, P111, DOI 10.1016/S0378-4347(00)80766-5; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; Hasegawa T, 2000, J BIOL CHEM, V275, P8007, DOI 10.1074/jbc.275.11.8007; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; INOUE Y, 1992, POLYSIALIC ACIDS, P171; Kawai H, 2001, J BIOL CHEM, V276, P6885, DOI 10.1074/jbc.C000847200; KOHNO M, 1996, J BIOL CHEM, V271, P29366; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; LEEDEN RW, 1984, J NEUROSCI RES, V12, P147; Liu H, 1997, GLYCOBIOLOGY, V7, P1067, DOI 10.1093/glycob/7.8.1067; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; Nadanaka S, 2001, J BIOL CHEM, V276, P33657, DOI 10.1074/jbc.M011100200; NAKAMURA M, 1987, CHEM PHARM BULL, V35, P687; Nohara K, 1998, J BIOCHEM, V124, P194, DOI 10.1093/oxfordjournals.jbchem.a022079; Ohta K, 2000, GLYCOCONJUGATE J, V17, P205, DOI 10.1023/A:1026589223811; POURQUIE O, 1992, J NEUROSCI, V12, P1548; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; RIBONI L, 1995, J BIOL CHEM, V270, P26868, DOI 10.1074/jbc.270.45.26868; Rosenberg A, 1996, BIOL SIALIC ACIDS, P197; Sato C, 1999, TRENDS GLYCOSCI GLYC, V11, P371, DOI 10.4052/tigg.11.371; Sato C, 2001, J BIOL CHEM, V276, P28849, DOI 10.1074/jbc.M104148200; SATO C, 1995, J BIOL CHEM, V270, P18923, DOI 10.1074/jbc.270.32.18923; Sato C, 1998, ANAL BIOCHEM, V261, P191, DOI 10.1006/abio.1998.2718; Sato C, 1998, J BIOL CHEM, V273, P2575, DOI 10.1074/jbc.273.5.2575; Sato C, 2000, J BIOL CHEM, V275, P15422, DOI 10.1074/jbc.275.20.15422; Sato C, 1999, ANAL BIOCHEM, V266, P102, DOI 10.1006/abio.1998.2921; Seki T, 1998, J NEUROSCI, V18, P3757; Sekine-Aizawa Y, 1998, EUR J NEUROSCI, V10, P2810, DOI 10.1111/j.1460-9568.1998.00288.x; Sharon N., 1997, GLYCOSCIENCES STATUS, P133; Takashima S, 1999, BIOCHEM BIOPH RES CO, V260, P23, DOI 10.1006/bbrc.1999.0794; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; TROY FA, 1996, BIOL SIALIC ACIDS, P95; TSUJI S, 1988, J NEUROCHEM, V50, P414, DOI 10.1111/j.1471-4159.1988.tb02928.x; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628; Yoshida Y, 1996, GLYCOBIOLOGY, V6, P573, DOI 10.1093/glycob/6.6.573; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	50	51	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45299	45305		10.1074/jbc.M206046200	http://dx.doi.org/10.1074/jbc.M206046200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235144	hybrid			2022-12-27	WOS:000179404800091
J	Shimomura, Y; Aoki, N; Schweizer, J; Langbein, L; Rogers, MA; Winter, H; Ito, M				Shimomura, Y; Aoki, N; Schweizer, J; Langbein, L; Rogers, MA; Winter, H; Ito, M			Polymorphisms in the human high sulfur hair keratin-associated protein 1, KAP1, gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH PROTEINS; INVOLUCRIN GENE; CODING REGION; EXPRESSION; FOLLICLE; LORICRIN; WOOL; ORGANIZATION; SEQUENCE; MUTATIONS	Hair fiber differentiation and maturation involves the close interaction between hair keratins and their associated proteins, KAPs. Recently, a cluster of seven human KAP multigen families has been identified on chromosome 17q12-21 among which were four hKAP1 genes (hKAP1.1B, hKAP1.3, hKAP1.4, and hYAP1.5). In addition, there were previous as well as recent reports on four additional hKAP1 genes (hKAP1.1A, hKAP1.2, hKAP1. 6, and hKAP1. 7) with unknown chromosomal location. In this study, we have analyzed these eight hKAP1 genes in unrelated Japanese and Caucasian individuals and discovered that hKAP1.1A, hKAP1.6, and hKAP1. 7 represent size polymorphisms of the hKAP1.1B gene. In addition, we show that hKAP1.2 as well as three hitherto unknown genes (hKAP1.8A, hKAP1.8B, and hKAP1.9) are size polymorphisms of the hKAP1.3 gene. In contrast, no polymorphic alleles were found for the hKAP1.4 and hKAP1.5 genes. We provide evidence that the polymorphic hKAP1.1B and hKAP1.3 alleles arose mainly by intragenic deletion and/or duplication events of distinct pentapeptide repeats typical for hKAP1 genes. We also demonstrate the occurrence of both frequent and rare population-specific hKAP1.1B and hKAP1.3 alleles, which were obviously generated after the divergence of the Caucasian and Japanese lineage. In addition, by means of a pan-hKAP1 antibody, we confirm the previous hKAP1 family mRNA localization data in the middle to upper cortex of the human anagen hair follicle.	Niigata Univ, Sch Med, Dept Dermatol, Niigata 9518510, Japan; German Canc Res Ctr, Div Cell Biol, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Tumor Cell Regulat, D-69120 Heidelberg, Germany	Niigata University; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Shimomura, Y (corresponding author), Niigata Univ, Sch Med, Dept Dermatol, Asahimachi Dori, Niigata 9518510, Japan.	yshimo@med.niigata-u.ac.jp	Rogers, Michael A./J-9803-2012	Rogers, Michael A./0000-0002-3728-2107				Aoki N, 1997, J BIOL CHEM, V272, P30512, DOI 10.1074/jbc.272.48.30512; Aoki N, 1998, J INVEST DERMATOL, V111, P804, DOI 10.1046/j.1523-1747.1998.00387.x; Armstrong DKB, 1998, J INVEST DERMATOL, V111, P702, DOI 10.1046/j.1523-1747.1998.00343.x; Cole SE, 1998, GENOMICS, V54, P437, DOI 10.1006/geno.1998.5590; DJIAN P, 1995, AM J HUM GENET, V56, P1367; ELLEMAN TC, 1972, J BIOL CHEM, V247, P3900; FRATINI A, 1993, J BIOL CHEM, V268, P4511; FRATINI A, 1994, J INVEST DERMATOL, V102, P178, DOI 10.1111/1523-1747.ep12371759; FRENKEL MJ, 1989, GENOMICS, V4, P182, DOI 10.1016/0888-7543(89)90298-X; HUH N, 1994, J INVEST DERMATOL, V102, P716, DOI 10.1111/1523-1747.ep12375385; JENKINS BJ, 1994, J INVEST DERMATOL, V103, P310, DOI 10.1111/1523-1747.ep12394770; Korge BP, 1999, J INVEST DERMATOL, V113, P607, DOI 10.1046/j.1523-1747.1999.00722.x; Korge BP, 1997, J INVEST DERMATOL, V109, P604, DOI 10.1111/1523-1747.ep12337534; KUCZEK ES, 1987, EUR J BIOCHEM, V166, P79, DOI 10.1111/j.1432-1033.1987.tb13486.x; Kuhn F, 1999, MECH DEVELOP, V86, P193, DOI 10.1016/S0925-4773(99)00115-X; Langbein L, 1999, J BIOL CHEM, V274, P19874, DOI 10.1074/jbc.274.28.19874; Langbein L, 2001, J BIOL CHEM, V276, P35123, DOI 10.1074/jbc.M103305200; Li VW, 1996, DERMATOL CLIN, V14, P745, DOI 10.1016/S0733-8635(05)70401-0; MACKINNON PJ, 1990, J CELL BIOL, V111, P2587, DOI 10.1083/jcb.111.6.2587; Maestrini E, 1996, NAT GENET, V13, P70, DOI 10.1038/ng0596-70; MCNAB AR, 1989, J INVEST DERMATOL, V92, P263, DOI 10.1111/1523-1747.ep12276832; Mercier M, 1998, J INVEST DERMATOL, V111, P169, DOI 10.1046/j.1523-1747.1998.00234.x; Mitsui S, 1998, GENE, V208, P123, DOI 10.1016/S0378-1119(97)00607-0; Perez C, 1999, GENE, V227, P137, DOI 10.1016/S0378-1119(98)00616-7; Powell B C, 1997, EXS, V78, P59; POWELL BC, 1991, ANN NY ACAD SCI, V642, P1; POWELL BC, 1983, NUCLEIC ACIDS RES, V11, P5327, DOI 10.1093/nar/11.16.5327; POWELL BC, 1995, DIFFERENTIATION, V58, P227, DOI 10.1046/j.1432-0436.1995.5830227.x; ROGERS GE, 1993, J INVEST DERMATOL, V101, pS50, DOI 10.1111/1523-1747.ep12362626; ROGERS GR, 1994, ANIM GENET, V25, P407, DOI 10.1111/j.1365-2052.1994.tb00531.x; Rogers MA, 2001, J BIOL CHEM, V276, P19440, DOI 10.1074/jbc.M100657200; Shimomura Y, 2002, J INVEST DERMATOL, V118, P226, DOI 10.1046/j.0022-202x.2001.01653.x; SHIMOMURA Y, 2002, IN PRESS J INVEST DE; SIMON M, 1991, GENOMICS, V9, P576, DOI 10.1016/0888-7543(91)90349-J; SIMON M, 1989, AM J HUM GENET, V45, P910; SWART LS, 1973, BIOCHEM J, V133, P641, DOI 10.1042/bj1330641; SWART LS, 1976, P 5 INT WOOL TEXT RE, P254; Takaishi M, 1998, J INVEST DERMATOL, V111, P128, DOI 10.1046/j.1523-1747.1998.00241.x; URQUHART A, 1993, AM J HUM GENET, V53, P279; Winter H, 1997, NAT GENET, V16, P372, DOI 10.1038/ng0897-372; YONEDA K, 1992, J BIOL CHEM, V267, P18060; ZHUMABAEVA BD, 1992, MOL BIOL+, V26, P550; Zimmermann R, 1983, Dermatol Monatsschr, V169, P638	43	39	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45493	45501		10.1074/jbc.M206398200	http://dx.doi.org/10.1074/jbc.M206398200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228244	hybrid			2022-12-27	WOS:000179404800114
J	Sparla, F; Pupillo, P; Trost, P				Sparla, F; Pupillo, P; Trost, P			The C-terminal extension of glyceraldehyde-3-phosphate dehydrogenase subunit B acts as an autoinhibitory domain regulated by thioredoxins and nicotinamide adenine dinucleotide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATION-REDUCTION PROPERTIES; CHLOROPLAST ENZYMES; 3-PHOSPHATE DEHYDROGENASE; MULTIENZYME COMPLEXES; SPINACH-CHLOROPLASTS; REDOX REGULATION; ACTIVATION; NADP; LIGHT; PEA	The regulatory isoform. of glyceraidehyde-3-phosphate dehydrogenase (GAPDH) is a light-activated enzyme constituted by subunits GapA and GapB. The NADPH-dependent activity of regulatory GAPDH from spinach chloroplasts was affected by the redox potential (E-m,E-7.9, -353 +/- 11 mV) through the action of thioredoxin f The redox dependence of recombinant GapB (E-m,E-7.9, -347 +/- 9 mV) was similar to native GAPDH, whereas GapA was essentially redox-insensitive. GapB mutants having one or two C-terminal cysteines mutated into serines (C358S, C349S, C349S/C358S) were less redoxsensitive than GapB. Different mutants with other cysteines substituted by serines (C18S, C274S, C285S) still showed strong redox regulation. Fully active GapB was a tetramer of B-subunits, and, when incubated with NAD, it associated to a high molecular weight oligomer showing low NADPH-dependent activity. The C-terminal GapB mutants (C358S, C349S, C349S/C358S) were active tetramers unable to aggregate to higher oligomers in the presence of NAD, whereas other mutants (C18S, C274S, C285S) again behaved like GapB. We conclude that a regulatory disulfide, between Cys349 and Cys-358 of the C-terminal extension of GapB, does form in the presence of oxidized thioredoxin. This covalent modification is required for the NAD-dependent association into higher oligomers and inhibition of the NADPH-activity. By leading to GAPDH autoinhibition, thioredoxin and NAD may thus concur to the dark inactivation of the enzyme in vivo.	Univ Bologna, Dept Biol, Lab Plant Physiol, I-40126 Bologna, Italy	University of Bologna	Trost, P (corresponding author), Univ Bologna, Dept Biol, Lab Plant Physiol, Via Irnerio 42, I-40126 Bologna, Italy.		Trost, Paolo/F-2425-2011	Trost, Paolo/0000-0002-6347-8701; Sparla, Francesca/0000-0002-2103-4870				Baalmann E, 1996, PLANT MOL BIOL, V32, P505, DOI 10.1007/BF00019102; BAALMANN E, 1994, BOT ACTA, V107, P313, DOI 10.1111/j.1438-8677.1994.tb00801.x; Baalmann E, 1995, ARCH BIOCHEM BIOPHYS, V324, P201, DOI 10.1006/abbi.1995.0031; BIESECKER G, 1977, NATURE, V266, P328, DOI 10.1038/266328a0; BRINKMANN H, 1989, PLANT MOL BIOL, V13, P81, DOI 10.1007/BF00027337; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; CERFF R, 1979, EUR J BIOCHEM, V94, P243, DOI 10.1111/j.1432-1033.1979.tb12891.x; Chiadmi M, 1999, EMBO J, V18, P6809, DOI 10.1093/emboj/18.23.6809; Fermani S, 2001, J MOL BIOL, V314, P527, DOI 10.1006/jmbi.2001.5172; FERRI G, 1990, BIOCHIM BIOPHYS ACTA, V1041, P36, DOI 10.1016/0167-4838(90)90119-Z; GERHARDT R, 1987, PLANT PHYSIOL, V83, P399, DOI 10.1104/pp.83.2.399; HARRIS JI, 1976, ENZYMES, V13, P1; HEINEKE D, 1991, PLANT PHYSIOL, V95, P1131, DOI 10.1104/pp.95.4.1131; Hirasawa M, 2000, BIOCHEMISTRY-US, V39, P3344, DOI 10.1021/bi9916731; HUTCHISON RS, 1995, METHOD ENZYMOL, V252, P220; Hutchison RS, 2000, BIOCHEMISTRY-US, V39, P6679, DOI 10.1021/bi0001978; Jacquot JP, 1997, FEBS LETT, V401, P143, DOI 10.1016/S0014-5793(96)01459-7; Knaff DB, 2000, PHYSIOL PLANTARUM, V110, P309, DOI 10.1034/j.1399-3054.2000.1100304.x; Lebreton S, 1999, J BIOL CHEM, V274, P20879, DOI 10.1074/jbc.274.30.20879; LEES WJ, 1993, J ORG CHEM, V58, P642, DOI 10.1021/jo00055a016; Li AD, 1997, PLANT PHYSIOL, V115, P1201, DOI 10.1104/pp.115.3.1201; MULLER B, 1969, EUR J BIOCHEM, V9, P101, DOI 10.1111/j.1432-1033.1969.tb00581.x; PUPILLO P, 1979, ARCH BIOCHEM BIOPHYS, V194, P581, DOI 10.1016/0003-9861(79)90653-2; PUPILLO P, 1975, EUR J BIOCHEM, V51, P475, DOI 10.1111/j.1432-1033.1975.tb03947.x; Qi JF, 2001, J BIOL CHEM, V276, P35247, DOI 10.1074/jbc.M103855200; Reichert A, 2000, PHYSIOL PLANTARUM, V110, P330, DOI 10.1034/j.1399-3054.2000.1100307.x; RodriguezSuarez RJ, 1997, BIOCHEM BIOPH RES CO, V232, P388, DOI 10.1006/bbrc.1997.6242; Ruelland E, 1999, TRENDS PLANT SCI, V4, P136, DOI 10.1016/S1360-1385(99)01391-6; SCAGLIARINI S, 1993, PLANTA, V190, P313, DOI 10.1007/BF00196959; Scagliarini S, 1998, J EXP BOT, V49, P1307, DOI 10.1093/jexbot/49.325.1307; Schurmann P, 2000, ANNU REV PLANT PHYS, V51, P371, DOI 10.1146/annurev.arplant.51.1.371; SEGEL IH, 1975, ENZYME KINETICS, P607; SUSS KH, 1993, P NATL ACAD SCI USA, V90, P5514, DOI 10.1073/pnas.90.12.5514; TROST P, 1993, PLANTA, V190, P320, DOI 10.1007/BF00196960; WARAASWAPATI O, 1980, PLANT PHYSIOL, V66, P34, DOI 10.1104/pp.66.1.34; Wedel N, 1998, P NATL ACAD SCI USA, V95, P9699, DOI 10.1073/pnas.95.16.9699; WERDAN K, 1975, BIOCHIM BIOPHYS ACTA, V396, P276, DOI 10.1016/0005-2728(75)90041-9; WOLOSIUK R, 1990, ARCH BIOCHEM BIOPHYS, V246, P1; WOLOSIUK RA, 1976, J BIOL CHEM, V251, P6456; WOLOSIUK RA, 1978, PLANT PHYSIOL, V61, P669, DOI 10.1104/pp.61.4.669; WOLOSIUK RA, 1977, NATURE, V266, P565, DOI 10.1038/266565a0; ZAPPONI MC, 1993, BIOL CHEM H-S, V374, P395, DOI 10.1515/bchm3.1993.374.1-6.395; ZIEGLER H, 1965, PLANTA, V65, P369, DOI 10.1007/BF00385415	43	85	88	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44946	44952		10.1074/jbc.M206873200	http://dx.doi.org/10.1074/jbc.M206873200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12270927	hybrid			2022-12-27	WOS:000179404800047
J	St-Pierre, J; Buckingham, JA; Roebuck, SJ; Brand, MD				St-Pierre, J; Buckingham, JA; Roebuck, SJ; Brand, MD			Topology of superoxide production from different sites in the mitochondrial electron transport chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL PRODUCTION; HEART-MITOCHONDRIA; HYDROGEN-PEROXIDE; COMPLEX-I; UBIQUINONE OXIDOREDUCTASE; TRANSFER FLAVOPROTEIN; RESPIRATORY-CHAIN; GENERATION; OXYGEN; RAT	We measured production of reactive oxygen species by intact mitochondria from rat skeletal muscle, heart, and liver under various experimental conditions. By using different substrates and inhibitors, we determined the sites of production (which complexes in the electron transport chain produced superoxide). By measuring hydrogen peroxide production in the absence and presence of exogenous superoxide dismutase, we established the topology of superoxide production (on which side of the mitochondrial inner membrane superoxide was produced). Mitochondria did not release measurable amounts of superoxide or hydrogen peroxide when respiring on complex I or complex II substrates. Mitochondria from skeletal muscle or heart generated significant amounts of superoxide from complex I when respiring on palmitoyl carnitine. They produced superoxide at considerable rates in the presence of various inhibitors of the electron transport chain. Complex I (and perhaps the fatty acid oxidation electron transfer flavoprotein and its oxidoreductase) released superoxide on the matrix side of the inner membrane, whereas center o of complex III released superoxide on the cytoplasmic side. These results do not support the idea that mitochondria produce considerable amounts of reactive oxygen species under physiological conditions. Our upper estimate of the proportion of electron flow giving rise to hydrogen peroxide with palmitoyl carnitine as substrate (0.15%) is more than an order of magnitude lower than commonly cited values. We observed no difference in the rate of hydrogen peroxide production between rat and pigeon heart mitochondria respiring on complex I substrates. However, when complex I was fully reduced using rotenone, rat mitochondria released significantly more hydrogen peroxide than pigeon mitochondria. This difference was solely due to an elevated concentration of complex I in rat compared with pigeon heart mitochondria.	MRC Dunn Human Nutr Unit, Cambridge CB2 2XY, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	St-Pierre, J (corresponding author), Dana Farber Canc Inst, SM 958, Boston, MA 02115 USA.	julie_stpierre@dfci.harvard.edu	St-Pierre, Julie/AGB-3651-2022; Brand, Martin D/A-9423-2012	St-Pierre, Julie/0000-0002-2815-7099; Brand, Martin D/0000-0003-4418-6153				Barja G, 1998, J BIOENERG BIOMEMBR, V30, P235, DOI 10.1023/A:1020592719405; Barja G, 1999, J BIOENERG BIOMEMBR, V31, P347, DOI 10.1023/A:1005427919188; BARJA G, 1994, FREE RADICAL RES, V21, P317, DOI 10.3109/10715769409056584; Barja G, 1999, METHODS AGING RES, P533; BECKMANN JD, 1985, BIOCHEMISTRY-US, V24, P3913, DOI 10.1021/bi00336a016; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1972, BIOCHEM J, P617; BURCH HB, 1957, METHOD ENZYMOL, V3, P960, DOI 10.1016/S0076-6879(57)03485-0; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Forman HJ, 1997, FASEB J, V11, P374, DOI 10.1096/fasebj.11.5.9141504; Genova ML, 2001, FEBS LETT, V505, P364, DOI 10.1016/S0014-5793(01)02850-2; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Herrero A, 1997, J BIOENERG BIOMEMBR, V29, P241, DOI 10.1023/A:1022458010266; Herrero A, 1998, MECH AGEING DEV, V103, P133, DOI 10.1016/S0047-6374(98)00035-9; Herrero A, 1997, MECH AGEING DEV, V98, P95, DOI 10.1016/S0047-6374(97)00076-6; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; KU HH, 1993, MECH AGEING DEV, V72, P67, DOI 10.1016/0047-6374(93)90132-B; Kwong LK, 2000, ARCH BIOCHEM BIOPHYS, V373, P16, DOI 10.1006/abbi.1999.1495; Kwong LK, 1998, ARCH BIOCHEM BIOPHYS, V350, P118, DOI 10.1006/abbi.1997.0489; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427; RAMSAY RR, 1987, BIOCHEM J, V241, P883, DOI 10.1042/bj2410883; ROLFE DFS, 1994, BBA-BIOENERGETICS, V1188, P405, DOI 10.1016/0005-2728(94)90062-0; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; SOHAL RS, 1990, MECH AGEING DEV, V53, P209, DOI 10.1016/0047-6374(90)90039-I; SOHAL RS, 1989, MECH AGEING DEV, V49, P129, DOI 10.1016/0047-6374(89)90096-1; Staniek K, 1999, BBA-BIOENERGETICS, V1413, P70, DOI 10.1016/S0005-2728(99)00083-3; Staniek K, 2000, BBA-BIOENERGETICS, V1460, P268, DOI 10.1016/S0005-2728(00)00152-3; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	37	1156	1210	5	87	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44784	44790		10.1074/jbc.M207217200	http://dx.doi.org/10.1074/jbc.M207217200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237311	hybrid			2022-12-27	WOS:000179404800027
J	Verma, A; Mohindru, M; Deb, DK; Sassano, A; Kambhampati, S; Ravandi, F; Minucci, S; Kalvakolanu, DV; Platanias, LC				Verma, A; Mohindru, M; Deb, DK; Sassano, A; Kambhampati, S; Ravandi, F; Minucci, S; Kalvakolanu, DV; Platanias, LC			Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; MAP KINASE; INTERFERON-ALPHA; BCR-ABL; SIGNAL-TRANSDUCTION; GROWTH-INHIBITION; CELL-LINES; TRANSCRIPTIONAL ACTIVATION; SERINE PHOSPHORYLATION	Arsenic trioxide induces differentiation and apoptosis of malignant cells in vitro and in vivo, but the mechanisms by which such effects occur have not been elucidated. In the present study we provide evidence that arsenic trioxide induces activation of the small G-protein Rac1 and the alpha and beta isoforms of the p38 mitogen-activated protein (MAP) kinase in several leukemia cell lines. Such activation of Rac1 and p38-isoforms results in downstream engagement of the MAP kinase-activated protein kinase-2 and is enhanced by pre-treatment of cells with ascorbic acid. Interestingly, pharmacological inhibition of p38 potentiates arsenic-dependent apoptosis and suppression of growth of leukemia cell lines, suggesting that this signaling cascade negatively regulates induction of antileukemic responses by arsenic trioxide. Consistent with this, overexpression of a dominant-negative p38 mutant (p38betaAGF) enhances the antiproliferative effects of arsenic trioxide on target cells. To further define the relevance of activation of the Rac1/p38 MAP kinase pathway in the induction of arsenic-dependent antileukemic effects, studies were performed using bone marrows from patients with chronic myelogenous leukemia. Arsenic trioxide suppressed the growth of leukemic myeloid (CFU-GM) progenitors from such patients, whereas concomitant pharmacological inhibition of the p38 pathway enhanced its growth-suppressive effects. Altogether, these data provide evidence for a novel function of the p38 MAP kinase pathway, acting as a negative regulator of arsenic trioxide-induced apoptosis and inhibition of malignant cell growth.	Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Hematol Oncol Sect, Chicago, IL 60611 USA; Univ Illinois, Dept Med, Hematol Oncol Sect, Chicago, IL 60607 USA; W Side Vet Affairs Hosp, Chicago, IL 60607 USA; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; IRCCS European Institute of Oncology (IEO); University System of Maryland; University of Maryland Baltimore	Platanias, LC (corresponding author), Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, 303 E Chicago Ave,Olson Pavil 8250, Chicago, IL 60611 USA.	l-platanias@northwestern.edu	Minucci, Saverio/J-9669-2012		NATIONAL CANCER INSTITUTE [R01CA094079, R01CA077816, R01CA078282, R01CA071401] Funding Source: NIH RePORTER; NCI NIH HHS [CA78282, CA94079, CA77816, CA71401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Akao Y, 1999, FEBS LETT, V455, P59, DOI 10.1016/S0014-5793(99)00841-8; Alsayed Y, 2001, J BIOL CHEM, V276, P4012, DOI 10.1074/jbc.M007431200; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Chen Z, 2002, SEMIN HEMATOL, V39, P22, DOI 10.1053/shem.2002.33611; Chen Z, 2001, SEMIN HEMATOL, V38, P26, DOI 10.1053/shem.2001.20863; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Davison K, 2002, SEMIN HEMATOL, V39, P3, DOI 10.1053/shem.2002.33610; Du YH, 2001, CANCER CHEMOTH PHARM, V47, P481, DOI 10.1007/s002800100278; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fanelli M, 1999, BLOOD, V93, P1477, DOI 10.1182/blood.V93.5.1477.405a33_1477_1481; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Gartenhaus RB, 2002, CLIN CANCER RES, V8, P566; GOEBERT M, 1997, EMBO J, V16, P3563; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Grad JM, 2001, BLOOD, V98, P805, DOI 10.1182/blood.V98.3.805; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; KRUMER JL, 1997, J BIOL CHEM, V272, P20490; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Maeda H, 2001, CANCER RES, V61, P5432; Mahieux R, 2001, BLOOD, V98, P3762, DOI 10.1182/blood.V98.13.3762; Mayer IA, 2001, J BIOL CHEM, V276, P28570, DOI 10.1074/jbc.M011685200; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; O'Dwyer M, 2002, ONCOLOGIST, V7, P30, DOI 10.1634/theoncologist.7-suppl_1-30; O'Dwyer ME, 2002, SEMIN HEMATOL, V39, P18, DOI 10.1053/shem.2002.33612; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Park WH, 2000, CANCER RES, V60, P3065; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; Platanias LC, 1999, EXP HEMATOL, V27, P1315, DOI 10.1016/S0301-472X(99)00060-0; Puccetti E, 2000, CANCER RES, V60, P3409; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Salojin KV, 1999, J IMMUNOL, V163, P844; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Tallman MS, 2002, BLOOD, V99, P759, DOI 10.1182/blood.V99.3.759; Tallman MS, 2001, BLOOD REV, V15, P133, DOI 10.1054/blre.2001.0160; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; Verma A, 2002, J BIOL CHEM, V277, P7726, DOI 10.1074/jbc.M106640200; Verma A, 2002, J IMMUNOL, V168, P5984, DOI 10.4049/jimmunol.168.12.5984; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; Wang ZY, 2001, CANCER CHEMOTH PHARM, V48, pS72, DOI 10.1007/s002800100309; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	67	94	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44988	44995		10.1074/jbc.M207176200	http://dx.doi.org/10.1074/jbc.M207176200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12239215	hybrid			2022-12-27	WOS:000179404800052
J	Yang, PK; Rotondo, G; Porras, T; Legrain, P; Chanfreau, G				Yang, PK; Rotondo, G; Porras, T; Legrain, P; Chanfreau, G			The Shq1p center dot Naf1p complex is required for box H/ACA small nucleolar ribonucleoprotein particle biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; RIBOSE METHYLATION; PRERIBOSOMAL RNA; YEAST; PSEUDOURIDINE; NHP2P; CBF5P; RNPS; ELEMENTS; SNORNPS	Small nucleolar ribonucleoprotein particles (snoRNPs) are essential cofactors in ribosomal RNA metabolism. Although snoRNP composition has been thoroughly characterized, the biogenesis process of these particles is poorly understood. We have identified two proteins from the yeast Saccharomyces cerevisiae, Yil104c/Shq1p and Ynl124w/Naf1p, which are essential and required for the stability of box H/ACA snoRNPs. Depletion of either Shq1p or Naf1p leads to a dramatic and specific decrease in box H/ACA snoRNA levels in vivo. A severe concomitant defect in ribosomal RNA processing is observed, consistent with the depletion of this family of snoRNAs. Shq1p and Naf1p show nuclear localization and interact with Nhp2p and Cbf5p, two core proteins of mature box H/ACA snoRNPs. Shq1p and Naf1p form a complex, but they are not strongly associated with box H/ACA snoRNPs. We propose that Shq1p and Naf1p are involved in the early biogenesis steps of box H/ACA snoRNP assembly.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Inst Pasteur, GIM Biotechnol, F-75724 Paris 15, France	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Chanfreau, G (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Box 951569, Los Angeles, CA 90095 USA.	guillom@chem.ucla.edu	Chanfreau, Guillaume/S-7421-2019	Rotondo, Giuseppe/0000-0001-7811-1753	NIGMS NIH HHS [GM61518] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061518] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; Billy E, 2000, EMBO J, V19, P2115, DOI 10.1093/emboj/19.9.2115; Cavaille J, 1996, NATURE, V383, P732, DOI 10.1038/383732a0; Chanfreau G, 1997, GENE DEV, V11, P2741, DOI 10.1101/gad.11.20.2741; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; Dez C, 2002, MOL CELL BIOL, V22, P7053, DOI 10.1128/MCB.22.20.7053-7065.2002; Dez C, 2001, NUCLEIC ACIDS RES, V29, P598, DOI 10.1093/nar/29.3.598; Dragon F, 2000, MOL CELL BIOL, V20, P3037, DOI 10.1128/MCB.20.9.3037-3048.2000; FATICA A, 2002, IN PRESS RNA; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; Ganot P, 1997, GENE DEV, V11, P941, DOI 10.1101/gad.11.7.941; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; Goldsmith M, 1998, AM J PHYS ANTHROPOL, V106, P103, DOI 10.1002/(SICI)1096-8644(199805)106:1<103::AID-AJPA8>3.0.CO;2-T; Henras A, 1998, EMBO J, V17, P7078, DOI 10.1093/emboj/17.23.7078; Henras A, 2001, NUCLEIC ACIDS RES, V29, P2733, DOI 10.1093/nar/29.13.2733; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; King TH, 2001, MOL CELL BIOL, V21, P7731, DOI 10.1128/MCB.21.22.7731-7746.2001; Kiss T, 2001, EMBO J, V20, P3617, DOI 10.1093/emboj/20.14.3617; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Lafontaine DLJ, 2000, MOL CELL BIOL, V20, P2650, DOI 10.1128/MCB.20.8.2650-2659.2000; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; Pogacic V, 2000, MOL CELL BIOL, V20, P9028, DOI 10.1128/MCB.20.23.9028-9040.2000; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Steinmetz EJ, 2001, NATURE, V413, P327, DOI 10.1038/35095090; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; Tremblay A, 2002, MOL CELL BIOL, V22, P4792, DOI 10.1128/MCB.22.13.4792-4802.2002; Watkins NJ, 2000, CELL, V103, P457, DOI 10.1016/S0092-8674(00)00137-9; Watkins NJ, 1998, RNA, V4, P1549, DOI 10.1017/S1355838298980761	37	54	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45235	45242		10.1074/jbc.M207669200	http://dx.doi.org/10.1074/jbc.M207669200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228251	hybrid			2022-12-27	WOS:000179404800083
J	Notkins, AL				Notkins, AL			Immunologic and genetic factors in type 1 diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PROTEIN-TYROSINE-PHOSPHATASE; BETA-CELL; TRANSMEMBRANE PROTEIN; T-CELLS; AUTOANTIGEN; IA-2; AUTOANTIBODIES; IDENTIFICATION; MECHANISMS; MELLITUS		NIDCR, Expt Med Sect, Oral Infect & Immun Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Notkins, AL (corresponding author), NIDCR, Expt Med Sect, Oral Infect & Immun Branch, NIH, Bldg 30,Rm 121,30 Convent Dr,MSC 4322, Bethesda, MD 20892 USA.	anotkins@mail.nih.gov						Atkinson MA, 1999, NAT MED, V5, P601, DOI 10.1038/9442; Atkinson MA, 2001, LANCET, V358, P221, DOI 10.1016/S0140-6736(01)05415-0; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; Field LL, 2002, DIABETOLOGIA, V45, P21, DOI 10.1007/s125-002-8241-7; Horwitz MS, 2002, J CLIN INVEST, V109, P79, DOI 10.1172/JCI11198; Jun HS, 1997, J VIROL, V71, P9782, DOI 10.1128/JVI.71.12.9782-9785.1997; Jun HS, 2001, DIABETOLOGIA, V44, P271, DOI 10.1007/s001250051614; Kay TWH, 2000, TRENDS ENDOCRIN MET, V11, P11, DOI 10.1016/S1043-2760(99)00210-6; Klein J, 2000, NEW ENGL J MED, V343, P702, DOI 10.1056/NEJM200009073431006; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kukreja A, 2002, J CLIN INVEST, V109, P131, DOI 10.1172/JCI13605; Lan MS, 1996, P NATL ACAD SCI USA, V93, P6367, DOI 10.1073/pnas.93.13.6367; Lee HC, 2000, NATURE, V408, P483, DOI 10.1038/35044106; Leslie D, 2001, J CLIN INVEST, V108, P1417, DOI 10.1172/JCI14452; Lu J, 1996, P NATL ACAD SCI USA, V93, P2307, DOI 10.1073/pnas.93.6.2307; Mathis D, 2001, NATURE, V414, P792, DOI 10.1038/414792a; Notkins AL, 2001, J CLIN INVEST, V108, P1247, DOI 10.1172/JCI200114257; Oldstone MBA, 1998, FASEB J, V12, P1255, DOI 10.1096/fasebj.12.13.1255; Piccirillo CA, 2001, J IMMUNOL, V167, P1137, DOI 10.4049/jimmunol.167.3.1137; Rossini AA, 2001, TRANSPLANTATION, V72, pS43; Saeki K, 2002, DIABETES, V51, P1842, DOI 10.2337/diabetes.51.6.1842; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sevilla N, 2000, J VIROL, V74, P3284, DOI 10.1128/JVI.74.7.3284-3292.2000; She JX, 1996, IMMUNOL TODAY, V17, P323, DOI 10.1016/0167-5699(96)10014-1; Solimena M, 1996, EMBO J, V15, P2102, DOI 10.1002/j.1460-2075.1996.tb00564.x; Todd JA, 1999, BIOESSAYS, V21, P164, DOI 10.1002/(SICI)1521-1878(199902)21:2<164::AID-BIES10>3.3.CO;2-W; Turner R, 1997, LANCET, V350, P1288, DOI 10.1016/S0140-6736(97)03062-6	28	95	103	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43545	43548		10.1074/jbc.R200012200	http://dx.doi.org/10.1074/jbc.R200012200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12270944	hybrid			2022-12-27	WOS:000179272000001
J	Quentien, MH; Manfroid, I; Moncet, D; Gunz, G; Muller, M; Grino, M; Enjalbert, A; Pellegrini, I				Quentien, MH; Manfroid, I; Moncet, D; Gunz, G; Muller, M; Grino, M; Enjalbert, A; Pellegrini, I			Pitx factors are involved in basal and hormone-regulated activity of the human prolactin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; PROOPIOMELANOCORTIN GENE; PITUITARY DEVELOPMENT; HOMEODOMAIN FACTOR; RIEGER-SYNDROME; TRANSCRIPTION; PTX1; BINDING; DOMAIN; EXPRESSION	The pituitary-specific POU homeodomain factor Pit-1 likely interacts with other factors for cell-specific expression of prolactin. Here we identify the paired-like homeobox transcription factors Pitx1 and Pitx2 as factors functionally activating the proximal human prolactin promoter (hPRL-164luc). Using in vitro binding assays and a series of site-specific mutations of the proximal hPRL promoter, we mapped the 131 and B2 bicoid sites involved in Pitx-mediated transactivation of the hPRL-164luc construct. In somatolactotroph GH4C1 cells, basal proximal hPRL promoter activity was inhibited by a Pitx2 dominant-negative form in a dose-dependent manner, whereas binding disruptive mutations in the Pitx sites significantly reduced basal activity of the promoter. We also show that synergistic activation of hPRL-164luc by Pitx2 and Pit-1 requires the integrity of the B2 Pitx binding site, and at least one of the P1 and P2 Pit-1 response elements. In addition, mutation in the B2 Pitx site results in attenuation of the promoter's responsiveness to forskolin, thyrotropin-releasing hormone, and epidermal growth factor. Conversely, Pitx1 or Pitx2 overexpression in GH4C1 cells leads to an enhancement of the drugs stimulatory effects. Altogether, these results suggest that full responsiveness to several signaling pathways regulating the hPRL promoter requires the B2 Pitx binding site and that Pitx factors may be part of the proteic complex involved in these regulations. Finally, in situ hybridization analysis showing coexpression of the PRL and Pitx2 genes in rat and human lactotroph cells corroborates the physiological relevance of these results.	Univ Mediterranee, CNRS, UMR 6544, Lab ICNE,Inst Fed Jean Roche,Fac Med N, F-13916 Marseille 20, France; Univ Liege, Inst Chim, Lab Biol Mol & Genie Genet, B-4000 Sart Tilman Par Liege, Belgium; INSERM, U501, Lab IFNE, F-13258 Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Liege; Institut National de la Sante et de la Recherche Medicale (Inserm)	Pellegrini, I (corresponding author), Univ Mediterranee, CNRS, UMR 6544, Lab ICNE,Inst Fed Jean Roche,Fac Med N, Bd P Dramard, F-13916 Marseille 20, France.		Grino, Michel/O-5361-2017; Grino, Michel/M-7548-2017; Grino, Michel/GYD-8559-2022					Amendt BA, 1999, MOL CELL BIOL, V19, P7001; Andersen B, 2001, ENDOCR REV, V22, P2, DOI 10.1210/er.22.1.2; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BERWAER M, 1993, MOL CELL ENDOCRINOL, V92, P1, DOI 10.1016/0303-7207(93)90068-U; Bradford AP, 2000, J BIOL CHEM, V275, P3100, DOI 10.1074/jbc.275.5.3100; Caccavelli L, 1998, MOL ENDOCRINOL, V12, P1215, DOI 10.1210/me.12.8.1215; CARRILLO AJ, 1985, ENDOCRINOLOGY, V116, P202, DOI 10.1210/endo-116-1-202; Dasen JS, 1999, CELL, V97, P587, DOI 10.1016/S0092-8674(00)80770-9; Gage PJ, 1999, MAMM GENOME, V10, P197, DOI 10.1007/s003359900970; Gage PJ, 1999, DEVELOPMENT, V126, P4643; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; Gordon DF, 1997, J BIOL CHEM, V272, P24339, DOI 10.1074/jbc.272.39.24339; Grino M, 1998, J HISTOCHEM CYTOCHEM, V46, P753, DOI 10.1177/002215549804600608; Kitamura K, 1999, DEVELOPMENT, V126, P5749; Lamolet B, 2001, CELL, V104, P849, DOI 10.1016/S0092-8674(01)00282-3; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Lanctot C, 1999, ENDOCRINOLOGY, V140, P1416, DOI 10.1210/en.140.3.1416; LANTOT C, 1999, DEVELOPMENT, V126, P1805; LEMAIGRE FP, 1989, DNA-J MOLEC CELL BIO, V8, P149, DOI 10.1089/dna.1.1989.8.149; LI S, 1990, NATURE, V347, P529; Lin CR, 1999, NATURE, V401, P279, DOI 10.1038/45803; Logan M, 1999, SCIENCE, V283, P1736, DOI 10.1126/science.283.5408.1736; Lu MF, 1999, NATURE, V401, P276, DOI 10.1038/45797; Manfroid I, 2001, MOL ENDOCRINOL, V15, P625, DOI 10.1210/me.15.4.625; MAURER RA, 1980, J BIOL CHEM, V255, P8092; MURDOCH GH, 1985, J BIOL CHEM, V260, P1852; PEERS B, 1990, MOL CELL BIOL, V10, P4690, DOI 10.1128/MCB.10.9.4690; PEERS B, 1991, J BIOL CHEM, V266, P18127; PEERS B, 1992, EUR J BIOCHEM, V210, P53, DOI 10.1111/j.1432-1033.1992.tb17389.x; Pellegrini-Bouiller I, 1999, J CLIN ENDOCR METAB, V84, P2212, DOI 10.1210/jc.84.6.2212; Pernasetti F, 1997, MOL ENDOCRINOL, V11, P986, DOI 10.1210/me.11.7.986; Poulin G, 1997, MOL CELL BIOL, V17, P6673, DOI 10.1128/MCB.17.11.6673; Quentien MH, 2002, ENDOCRINOLOGY, V143, P2839, DOI 10.1210/en.143.8.2839; Quirk CC, 2001, MOL ENDOCRINOL, V15, P734, DOI 10.1210/me.15.5.734; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Suh H, 2002, DEVELOPMENT, V129, P329; Szeto DP, 1999, GENE DEV, V13, P484, DOI 10.1101/gad.13.4.484; Tremblay JJ, 2000, NEUROENDOCRINOLOGY, V71, P277, DOI 10.1159/000054547; Tremblay JJ, 1999, EMBO J, V18, P3431, DOI 10.1093/emboj/18.12.3431; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; Tremblay JJ, 1998, MOL ENDOCRINOL, V12, P428, DOI 10.1210/me.12.3.428; Van de Weerdt C, 2000, NEUROENDOCRINOLOGY, V71, P124, DOI 10.1159/000054528; Wilson DS, 1996, P NATL ACAD SCI USA, V93, P6886, DOI 10.1073/pnas.93.14.6886; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yost HJ, 1999, CURR OPIN GENET DEV, V9, P422	46	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44408	44416		10.1074/jbc.M207824200	http://dx.doi.org/10.1074/jbc.M207824200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223489	Green Submitted, hybrid			2022-12-27	WOS:000179272000112
J	Steinle, JJ; Meininger, CJ; Forough, R; Wu, G; Wu, MH; Granger, HJ				Steinle, JJ; Meininger, CJ; Forough, R; Wu, G; Wu, MH; Granger, HJ			Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIOVASCULAR DEVELOPMENT; LIGANDS; ACTIVATION; EPHRIN-B2; INVASION; GROWTH; VEINS	The goals of this study were 2-fold: 1) to determine whether stimulation of Eph B4 receptors promotes microvascular endothelial cell migration and/or proliferation, and 2) to elucidate signaling pathways involved in these responses. The human endothelial cells used possessed abundant Eph B4 receptors with no endogenous ephrin B2 expression. Stimulation of these receptors with ephrin B2/Fc chimera resulted in dose- and time-dependent phosphorylation of Akt. These responses were inhibited by LY294002 and MIL-9, blockers of phosphatidylinositol 3-kinase (PI3K) and Akt, respectively. Eph B4 receptor activation increased proliferation by 38%, which was prevented by prior blockade with LY294002, ML-9, and inhibitors of protein kinase G (KT5823) and MIEK (PD98059). Nitrite levels increased over 170% after Eph B4 stimulation, indicating increased nitric oxide production. Signaling of endothelial cell proliferation appears to be mediated by a PI3K/Akt/endothelial nitric-oxide synthase/protein kinase G/mitogen-activated protein kinase cascade. Stimulation with ephrin B2 also increased migration by 63% versus controls. This effect was inhibited by blockade with PP2 (Src inhibitor), LY294002 or ML-9 but was unaffected by the PKG and MEK blockers. Eph B4 receptor stimulation increased activation of both matrix metalloproteinase-2 and -9. The results from these studies indicate that Eph B4 stimulates migration and proliferation and may play a role in angiogenesis.	Texas A&M Univ Syst, Hlth Sci Ctr, Cardiovasc Res Inst, Temple, TX 76504 USA; Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Physiol, Coll Med, Temple, TX 76504 USA; Texas A&M Univ, Dept Anim Sci, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station	Steinle, JJ (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Cardiovasc Res Inst, 702 SW HK Dodgen Loop,Med Res Bldg,Rm 202A, Temple, TX 76504 USA.		Wu, Mack/I-6536-2012; Meininger, Cynthia/D-2846-2014	Steinle, Jena/0000-0002-7539-2892; Meininger, Cynthia/0000-0002-1314-5044	PHS HHS [446221] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams RH, 2000, TRENDS CARDIOVAS MED, V10, P183, DOI 10.1016/S1050-1738(00)00046-3; Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; DANIEL TO, 1996, KIDNEY INT S, V57, P73; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Frisen J, 1999, EMBO J, V18, P5159, DOI 10.1093/emboj/18.19.5159; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Helbling PM, 2000, DEVELOPMENT, V127, P269; Hood J, 1998, J BIOL CHEM, V273, P23504, DOI 10.1074/jbc.273.36.23504; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Kalo MS, 1999, CELL TISSUE RES, V298, P1, DOI 10.1007/PL00008807; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Li H, 2000, J CHROMATOGR B, V746, P199, DOI 10.1016/S0378-4347(00)00328-5; Park BK, 2001, CANCER RES, V61, P7647; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Zisch AH, 1997, CELL TISSUE RES, V290, P217, DOI 10.1007/s004410050926	16	144	160	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43830	43835		10.1074/jbc.M207221200	http://dx.doi.org/10.1074/jbc.M207221200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12235151	hybrid			2022-12-27	WOS:000179272000040
J	Wilson, HL; McFie, PJ; Roesler, WJ				Wilson, HL; McFie, PJ; Roesler, WJ			Different transcription factor binding arrays modulate the cAMP responsivity of the phosphoenolpyruvate carboxykinase gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-RECEPTOR-GAMMA; DEPENDENT PROTEIN-KINASE; GTP GENE; C/EBP-ALPHA; HEPATOMA-CELLS; HORMONAL-REGULATION; THYROID-HORMONE; ELEMENT; LIVER; EXPRESSION	The cAMP responsiveness of the phosphoenolpyruvate carboxykinase (PEPCK) gene promoter is mediated by a cAMP response unit, which includes three CCAAT/enhancer-binding protein (C/EBPs) sites, and a cAMP response element (CRE). Because both the CRE-binding protein and several C/EBP isoforms can to bind to the CRE with similar affinity, a variety of transcription factor bindings arrays in the cAMP response unit are possible that may affect the protein kinase A (PKA) responsivity of the promoter. To explore this issue, we have designed PEPCK promoter variants that have the native cis-elements within the cAMP response unit replaced with one or more LexA- and/or GAL4-binding sites. We also engineered the corresponding C/EBP and CRE-binding protein chimeras, which have their basic region leucine zipper domains replaced with LexA or GAL4 DNA-binding domains. Using this approach, we have reconstituted the PKA responsiveness of permissive PEPCK promoters in hepatoma cells and have characterized the PKA responsivity of the promoter under defined transcription factor occupancy patterns. Furthermore, analysis of deletion mutants of C/EBPalpha indicated that the domains that mediate its constitutive and PKA-inducible activities vary depending on which cis-element it occupies on the PEPCK promoter. These results suggest that promoter context may influence which domains within a transcription factor are employed to mediate transactivation.	Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan	Roesler, WJ (corresponding author), Univ Saskatchewan, Dept Biochem, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.		Wilson, Heather/B-4575-2011	Wilson, Heather/0000-0002-1261-0901				CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Crosson SM, 2000, J BIOL CHEM, V275, P5804, DOI 10.1074/jbc.275.8.5804; DAVIES GF, 1995, ARCH BIOCHEM BIOPHYS, V323, P477, DOI 10.1006/abbi.1995.0070; Davies GF, 2001, BIOCHEM PHARMACOL, V62, P1071, DOI 10.1016/S0006-2952(01)00764-X; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Jacob KK, 2001, J BIOL CHEM, V276, P24931, DOI 10.1074/jbc.M102826200; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; LIU JS, 1991, J BIOL CHEM, V266, P19095; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; PARK EA, 1995, BIOCHEM J, V309, P913, DOI 10.1042/bj3090913; Park EA, 1999, J BIOL CHEM, V274, P211, DOI 10.1074/jbc.274.1.211; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PATEL YM, 1994, J BIOL CHEM, V269, P5619; QUINN PG, 1993, J BIOL CHEM, V268, P16999; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; Roesler WJ, 1998, MOL CELL BIOCHEM, V178, P1, DOI 10.1023/A:1006886421795; Roesler WJ, 2000, MOL CELL ENDOCRINOL, V162, P1, DOI 10.1016/S0303-7207(00)00198-2; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; Roesler WJ, 1998, J BIOL CHEM, V273, P14950, DOI 10.1074/jbc.273.24.14950; ROESLER WJ, 1994, J BIOL CHEM, V269, P14276; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; Roesler WJ, 2001, ANNU REV NUTR, V21, P141, DOI 10.1146/annurev.nutr.21.1.141; Waite KJ, 2001, J BIOL CHEM, V276, P7062, DOI 10.1074/jbc.M007894200; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wilson HL, 2002, MOL CELL ENDOCRINOL, V188, P15, DOI 10.1016/S0303-7207(01)00754-7; Wilson HL, 2001, MOL CELL ENDOCRINOL, V181, P27, DOI 10.1016/S0303-7207(01)00540-8; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880	36	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43895	43902		10.1074/jbc.M203169200	http://dx.doi.org/10.1074/jbc.M203169200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12237288	hybrid			2022-12-27	WOS:000179272000049
J	Glantschnig, H; Rodan, GA; Reszka, AA				Glantschnig, H; Rodan, GA; Reszka, AA			Mapping of MST1 kinase sites of phosphorylation - Activation and autophosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STE20-LIKE PROTEIN-KINASE; CASPASE-MEDIATED ACTIVATION; GAMMA-PAK; INDUCED APOPTOSIS; CLEAVAGE; CLONING; CELLS; LOOP; ABSENCE; MST/KRS	MST1 is a member of the Sterile-20 family of cytoskeletal, stress, and apoptotic kinases. MST1 is activated by phosphorylation at previously unidentified sites. This study examines the role of phosphorylation at several sites and effects on kinase activation. We define Thr(183) in subdomain VIII as a primary site of phosphoactivation. Thr(187) is also critical for kinase activity. Phosphorylation of MST1 in subdomain VIII was catalyzed by active MST1 via intermolecular autophosphorylation, enhanced by homodimerization. Active MST1 (wild-type or T183E), but not inactive Thr(183)/Thr(187) mutants, was also highly autophosphorylated at the newly identified Thr(177) and Thr(387) residues. Cells expressing active MST1 were mostly detached, whereas with inactive MST1, adhesion was normal. Active MKK4, JNK, caspase-3, and caspase-9 were detected in the detached cells. These cells also contained all autophosphorylated and essentially all caspase-cleaved MST1. Similar phenotypes were elicited by a caspase-insensitive D326N mutant, suggesting that kinase activity, but not cleavage of MST1, is required. Interestingly, an S327E mutant mimicking Ser(327) autophosphorylation was also caspase-insensitive, but only when expressed in caspase-3-deficient cells. Together, these data suggest a model whereby MST1 activation is induced by existing, active MST kinase, which phosphorylates Thr(183) and possibly Thr(187). Dimerization promotes greater phosphorylation. This leads to induction of the JNK signaling pathway, caspase activation, and apoptosis. Further activation of MST1 by caspase cleavage is best promoted by caspase-3, although this appears to be unnecessary for signaling and morphological responses.	Merck Res Labs, Dept Bone Biol & Osteoporosis, W Point, PA 19486 USA	Merck & Company	Reszka, AA (corresponding author), Merck Res Labs, Dept Bone Biol & Osteoporosis, WP26A-1000 Sumneytown Pike, W Point, PA 19486 USA.							Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Fujita E, 2001, CELL DEATH DIFFER, V8, P335, DOI 10.1038/sj.cdd.4400824; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Graves JD, 2001, J BIOL CHEM, V276, P14909, DOI 10.1074/jbc.M010905200; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Jakobi R, 2000, EUR J BIOCHEM, V267, P4414, DOI 10.1046/j.1432-1327.2000.01488.x; Kakeya H, 1999, ANN NY ACAD SCI, V886, P273, DOI 10.1111/j.1749-6632.1999.tb09434.x; Lee KK, 2002, J BIOL CHEM, V277, P12351, DOI 10.1074/jbc.M108138200; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Lian JP, 2001, J IMMUNOL, V166, P6349, DOI 10.4049/jimmunol.166.10.6349; Liang Y, 2001, ONCOGENE, V20, P6570, DOI 10.1038/sj.onc.1204815; Messmer UK, 2001, BRIT J PHARMACOL, V133, P467, DOI 10.1038/sj.bjp.0704093; Qian ZJ, 2001, J BIOL CHEM, V276, P22439, DOI 10.1074/jbc.M009323200; Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967; Reszka AA, 2001, MOL PHARMACOL, V59, P193, DOI 10.1124/mol.59.2.193; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Ura S, 2001, GENES CELLS, V6, P519, DOI 10.1046/j.1365-2443.2001.00439.x; Ura S, 2001, P NATL ACAD SCI USA, V98, P10148, DOI 10.1073/pnas.181161698; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Watabe M, 1999, ONCOGENE, V18, P5211, DOI 10.1038/sj.onc.1202901; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5	31	140	145	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42987	42996		10.1074/jbc.M208538200	http://dx.doi.org/10.1074/jbc.M208538200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12223493	hybrid			2022-12-27	WOS:000179081200074
J	de Jong, AS; Wessels, E; Dijkman, HBPM; Galama, JMD; Melchers, WJG; Willems, PHGM; van Kuppeveld, FJM				de Jong, AS; Wessels, E; Dijkman, HBPM; Galama, JMD; Melchers, WJG; Willems, PHGM; van Kuppeveld, FJM			Determinants for membrane association and permeabilization of the coxsackievirus 2B protein and the identification of the Golgi complex as the target organelle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; VIRUS PROTEIN; POLIOVIRUS INFECTION; REPLICATION COMPLEX; AMPHIPATHIC HELIX; KIN RECOGNITION; RNA-SYNTHESIS; PLUS-STRAND; RETENTION; APPARATUS	The 2B protein of enterovirus is responsible for the alterations in the permeability of secretory membranes and the plasma membrane in infected cells. The structural requirements for the membrane association and the subcellular localization of this essential virus protein, however, have not been defined. Here, we provide evidence that the 2B protein is an integral membrane protein in vivo that is predominantly localized at the Golgi complex upon individual expression. Addition of organelle-specific targeting signals to the 213 protein revealed that the Golgi localization is an absolute prerequisite for the ability of the protein to modify plasma membrane permeability. Expression of deletion mutants and heterologous proteins containing specific domains of the 2B protein demonstrated that each of the two hydrophobic regions could mediate membrane binding individually. However, the presence of both hydrophobic regions was required for the correct membrane association, efficient Golgi targeting, and the membrane-permeabilizing activity of the 2B protein, suggesting that the two hydrophobic regions are cooperatively involved in the formation of a membrane-integral complex. The formation of membrane-integral pores by the 213 protein in the Golgi complex and the possible mechanism by which a Golgi-localized virus protein modifies plasma membrane permeability are discussed.	Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Dept Pathol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	van Kuppeveld, FJM (corresponding author), Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Med Microbiol, POB 9100, NL-6500 HB Nijmegen, Netherlands.	f.vankuppeveld@ncmls.kun.nl	Dijkman, Henry/L-4274-2015; Melchers, Willem/C-8819-2015; Willems, P.H.G.M./L-4759-2015; Jong, A.S./L-4416-2015	Melchers, Willem/0000-0002-5446-2230; Willems, P.H.G.M./0000-0002-0915-1599; van Kuppeveld, Frank/0000-0001-5800-749X				Aldabe R, 1997, J VIROL, V71, P6214, DOI 10.1128/JVI.71.8.6214-6217.1997; ALDABE R, 1995, BIOCHEM BIOPH RES CO, V206, P64, DOI 10.1006/bbrc.1995.1010; Aldabe R, 1996, J BIOL CHEM, V271, P23134, DOI 10.1074/jbc.271.38.23134; Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; BARCO A, 1995, EMBO J, V14, P3349, DOI 10.1002/j.1460-2075.1995.tb07341.x; BIENZ K, 1987, VIROLOGY, V160, P220, DOI 10.1016/0042-6822(87)90063-8; BIENZ K, 1994, ARCH VIROL, P147; Bolten R, 1998, J VIROL, V72, P8578, DOI 10.1128/JVI.72.11.8578-8585.1998; Breton C, 2001, BIOCHIMIE, V83, P713, DOI 10.1016/S0300-9084(01)01298-6; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; CARRASCO L, 1995, ADV VIRUS RES, V45, P61, DOI 10.1016/S0065-3527(08)60058-5; CHO MW, 1994, VIROLOGY, V202, P129, DOI 10.1006/viro.1994.1329; Cuconati A, 1998, J VIROL, V72, P1297, DOI 10.1128/JVI.72.2.1297-1307.1998; de Jong AS, 2002, J GEN VIROL, V83, P783, DOI 10.1099/0022-1317-83-4-783; Deitz SB, 2000, P NATL ACAD SCI USA, V97, P13790, DOI 10.1073/pnas.250483097; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Dodd DA, 2001, J VIROL, V75, P8158, DOI 10.1128/JVI.75.17.8158-8165.2001; Doedens JR, 1997, J VIROL, V71, P9054, DOI 10.1128/JVI.71.12.9054-9064.1997; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Hauri HP, 2000, J CELL SCI, V113, P587; KLUMP WM, 1990, J VIROL, V64, P1573, DOI 10.1128/JVI.64.4.1573-1583.1990; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; Nilsson T, 1996, J CELL SCI, V109, P1975; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; Opat AS, 2001, BIOCHIMIE, V83, P763, DOI 10.1016/S0300-9084(01)01312-8; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Rust RC, 2001, J VIROL, V75, P9808, DOI 10.1128/JVI.75.20.9808-9818.2001; Sandoval IV, 1997, J VIROL, V71, P4679, DOI 10.1128/JVI.71.6.4679-4693.1997; Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000; van Kuppeveld FJM, 2002, J VIROL, V76, P9446, DOI 10.1128/JVI.76.18.9446-9456.2002; VanKuppeveld FJM, 1997, VIROLOGY, V227, P111, DOI 10.1006/viro.1996.8320; vanKuppeveld FJM, 1997, EMBO J, V16, P3519, DOI 10.1093/emboj/16.12.3519; VANKUPPEVELD FJM, 1995, J VIROL, V69, P7782, DOI 10.1128/JVI.69.12.7782-7790.1995; vanKuppeveld FJM, 1996, J VIROL, V70, P3876, DOI 10.1128/JVI.70.6.3876-3886.1996; Watson RT, 2001, AM J PHYSIOL-CELL PH, V281, pC215, DOI 10.1152/ajpcell.2001.281.1.C215	45	79	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1012	1021		10.1074/jbc.M207745200	http://dx.doi.org/10.1074/jbc.M207745200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12244057	Green Published, hybrid			2022-12-27	WOS:000180321900043
J	Aoki, J; Taira, A; Takanezawa, Y; Kishi, Y; Hama, K; Kishimoto, T; Mizuno, K; Saku, K; Taguchi, R; Arai, H				Aoki, J; Taira, A; Takanezawa, Y; Kishi, Y; Hama, K; Kishimoto, T; Mizuno, K; Saku, K; Taguchi, R; Arai, H			Serum lysophosphatidic acid is produced through diverse phospholipase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-FACTOR-ACETYLHYDROLASE; SMOOTH-MUSCLE CELLS; SECRETORY PHOSPHOLIPASE; LYSOPHOSPHOLIPASE-D; RAT PLATELETS; RECEPTOR; FAMILY; PLASMA; IDENTIFICATION; PROLIFERATION	Lysophosphatidic acid (LPA) is a lipid mediator with multiple biological activities that accounts for many biological properties of serum. LPA is thought to be produced during serum formation based on the fact that the LPA level is much higher in serum than in plasma. In this study, to better understand the pathways of LPA synthesis in serum, we evaluated the roles of platelets, plasma, and phospholipases by measuring LPA using a novel enzyme-linked fluorometric assay. First, examination of platelet-depleted rats showed that half of the LPA in serum is produced via a platelet-dependent pathway. However, the amount of LPA released from isolated platelets after they are activated by thrombin or calcium ionophore accounted for only a small part of serum LPA. Most of the platelet-derived LPA was produced in a two-step process: lysophospholipids such as lysophosphatidylcholine (LPC), lysophosphatidylethanolamine, and lysophosphatidylserine, were released from activated rat platelets by the actions of two phospholipase, group HA secretory phospholipase A, (sPLA(2)-IIA) and phosphatidylserine-specific phospholipase A(1) (PS-PLA(1)), which were abundantly expressed in the cells. Then these lysophospholipids were converted to LPA by the action of plasma lysophospholipase D (lysoPLD). Second, accumulation of LPA in incubated plasma was strongly accelerated by the addition of recombinant lysoPLD with a concomitant decrease in LPC accumulation, indicating that the enzyme produces LPA by hydrolyzing LPC produced during the incubation. In addition, incubation of plasma isolated from human subjects who were deficient in lecithin-cholesterol acyltransferase (LCAT) did not result in increases of either LPC or LPA. The present study demonstrates multiple pathways for LPA production in serum and the involvement of several phospholipases, including PS-PIA, sPLA(2)-IIA LCAT, and lysoPLD.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Nesco Co, Azwell Inc, R&D Div, Diagnost Res & Dev Dept, Osaka 5670806, Japan; Fukuoka Univ, Dept Cardiol, Jonan Ku, Fukuoka 81480, Japan; Nagoya City Univ, Fac Pharmaceut Sci, Mizuho Ku, Nagoya, Aichi 4670027, Japan	University of Tokyo; Fukuoka University; Nagoya City University	Aoki, J (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Saku, Keijiro/HGB-6168-2022	Aoki, Junken/0000-0001-9435-1896; Takanezawa, Yasukazu/0000-0002-9220-5825				An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Aoki J, 2002, BBA-MOL CELL BIOL L, V1582, P26, DOI 10.1016/S1388-1981(02)00134-8; Baker DL, 2000, ANN NY ACAD SCI, V905, P267; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Bandoh K, 2000, FEBS LETT, V478, P159, DOI 10.1016/S0014-5793(00)01827-5; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chun Jerold, 1999, Cell Biochemistry and Biophysics, V30, P213, DOI 10.1007/BF02738068; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Croset M, 2000, BIOCHEM J, V345, P61, DOI 10.1042/0264-6021:3450061; DOBIASOVA M, 1986, PHYSIOL BOHEMOSLOV, V35, P464; Eder AM, 2000, CLIN CANCER RES, V6, P2482; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Gaits F, 1997, FEBS LETT, V410, P54, DOI 10.1016/S0014-5793(97)00411-0; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; Glomset J.A., 1995, METABOLIC MOL BASES, Vseventh, P1933; Hayashi K, 2001, CIRC RES, V89, P251, DOI 10.1161/hh1501.094265; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Hooks SB, 2001, J BIOL CHEM, V276, P4611, DOI 10.1074/jbc.M007782200; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P625, DOI 10.1093/jb/101.3.625; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P53, DOI 10.1093/oxfordjournals.jbchem.a121907; Hosono H, 2001, J BIOL CHEM, V276, P29664, DOI 10.1074/jbc.M104597200; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JALINK K, 1995, BIOCHEM J, V307, P609, DOI 10.1042/bj3070609; Jonas A, 2000, BBA-MOL CELL BIOL L, V1529, P245, DOI 10.1016/S1388-1981(00)00153-0; KOMADA M, 1989, J BIOCHEM-TOKYO, V106, P545, DOI 10.1093/oxfordjournals.jbchem.a122890; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; Le Balle F, 1999, ADV ENZYME REGUL, V39, P275, DOI 10.1016/S0065-2571(98)00024-7; Manning TJ, 2000, CELL MOTIL CYTOSKEL, V45, P185, DOI 10.1002/(SICI)1097-0169(200003)45:3<185::AID-CM2>3.0.CO;2-G; MAUCO G, 1978, BIOCHIMIE, V60, P653, DOI 10.1016/S0300-9084(78)80784-6; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4; Pilquil C, 2001, PROSTAG OTH LIPID M, V64, P83, DOI 10.1016/S0090-6980(01)00101-0; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Santamarina-Fojo S, 2001, METABOLIC MOL BASES, P2817; Sato T, 1997, J BIOL CHEM, V272, P2192; SATOH K, 1991, J CLIN INVEST, V87, P476, DOI 10.1172/JCI115020; SEKAS G, 1985, J LAB CLIN MED, V105, P190; Shen ZZ, 1998, GYNECOL ONCOL, V71, P364, DOI 10.1006/gyno.1998.5193; Sonoda H, 2002, J BIOL CHEM, V277, P34254, DOI 10.1074/jbc.M201659200; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Stracke ML, 1997, ADV ENZYME REGUL, V37, P135, DOI 10.1016/S0065-2571(96)00017-9; Sturm A, 1999, GASTROENTEROLOGY, V117, P368, DOI 10.1053/gast.1999.0029900368; TAMAOKU K, 1982, CHEM PHARM BULL, V30, P2492; TIGYI G, 1992, J BIOL CHEM, V267, P21360; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; Tokumura A, 1998, LIPIDS, V33, P1009, DOI 10.1007/s11745-998-0299-2; TOKUMURA A, 1994, AM J PHYSIOL, V267, pC204, DOI 10.1152/ajpcell.1994.267.1.C204; TOKUMURA A, 1995, PROG LIPID RES, V34, P151, DOI 10.1016/0163-7827(95)00001-G; TOKUMURA A, 1986, BIOCHIM BIOPHYS ACTA, V875, P31; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Xiao YJ, 2000, ANN NY ACAD SCI, V905, P242; YOKOYAMA K, 1995, J BIOCHEM-TOKYO, V117, P1280, DOI 10.1093/oxfordjournals.jbchem.a124856	55	333	340	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48737	48744		10.1074/jbc.M206812200	http://dx.doi.org/10.1074/jbc.M206812200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12354767	hybrid			2022-12-27	WOS:000179789600100
J	Hirzmann, J; Hintz, M; Kasper, M; Shresta, TR; Taubert, A; Conraths, FJ; Geyer, R; Stirm, S; Zahner, H; Hobom, G				Hirzmann, J; Hintz, M; Kasper, M; Shresta, TR; Taubert, A; Conraths, FJ; Geyer, R; Stirm, S; Zahner, H; Hobom, G			Cloning and expression analysis of two mucin-like genes encoding microfilarial sheath surface proteins of the parasitic nematodes Brugia and Litomosoides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARINII-MICROFILARIAE; PAHANGI MICROFILARIAE; HUMAN FILARIASIS; MESSENGER-RNA; CELLS; COMPONENTS; MALAYI; DIMETHYLAMINOETHANOL; UNRESPONSIVENESS; IDENTIFICATION	In several filarial genera the first stage larvae (microfilariae) are enclosed by an eggshell-derived sheath that provides a major interface between the parasite and the host immune system. Analysis of the polypeptide constituents of the microfilarial sheath from the cotton rat filaria Litomosoides sigmodontis identified two abundant surface glycoproteins: Shp3a and Shp3. The corresponding genes and the orthologues of the human parasite Brugia malayi and the rodent filaria Brugia pahangi were cloned and sequenced. They encode secreted, mucin-like proteins with N-terminal Ser/Thr-rich repeats and a C-terminal anchor domain rich in aromatic amino acids. About 75% of the protein molecular masses result from post-translational modifications. The Ser/Thr-rich motifs are supposed to serve as targets for dimethylaminoethanol-phosphate substitutions. These modifications were detected only on the sheaths of the late developmental stage of stretched microfilariae, corresponding with the expression of the proteins in the epithelium of the distal part of the uterus and the specific transcription of shp3 and shp3a in the anterior female worm segment. Genomic analysis of all three species demonstrated a conserved linkage of the two genes. Their transcripts undergo cis- and trans-splicing. The transcription start sites of the primary transcripts were determined for the L. sigmodontis genes. The core promoter regions are remarkably conserved between the paralogue genes Ls-shp3a and Ls-shp3 and their orthologues in Brugia, implicating conserved regulatory elements.	Inst Parasitol, D-35392 Giessen, Germany; Inst Biochem, D-35392 Giessen, Germany; Inst Microbiol & Mol Biol, D-35392 Giessen, Germany		Hirzmann, J (corresponding author), Inst Parasitol, Rudolf Buchheim Str 2, D-35392 Giessen, Germany.			Conraths, Franz/0000-0002-7400-9409				BARDEHLE G, 1992, PARASITOL RES, V78, P501, DOI 10.1007/BF00931571; BARDEHLE G, 1992, ACTA TROP, V50, P237, DOI 10.1016/0001-706X(92)90080-H; CHANDRASHEKAR R, 1984, J HELMINTHOL, V58, P69, DOI 10.1017/S0022149X00028078; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRIST H, 1992, GENE, V121, P219, DOI 10.1016/0378-1119(92)90125-9; CONRATHS FJ, 1993, MOL BIOCHEM PARASIT, V60, P111, DOI 10.1016/0166-6851(93)90034-U; DEVANEY E, 1985, TROPENMED PARASITOL, V36, P25; DINOIA JM, 1995, J BIOL CHEM, V270, P24146, DOI 10.1074/jbc.270.41.24146; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUHRMAN A, 1983, ACTA TROP, V40, P5; Gems D, 1996, P NATL ACAD SCI USA, V93, P1665, DOI 10.1073/pnas.93.4.1665; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; Hintz M, 1996, MOL BIOCHEM PARASIT, V76, P325, DOI 10.1016/0166-6851(95)02541-3; Hintz M, 1998, PARASITOLOGY, V117, P265, DOI 10.1017/S0031182098002996; HINTZ M, 1994, MOL BIOCHEM PARASIT, V67, P69, DOI 10.1016/0166-6851(94)90097-3; HIRZMANN J, 1995, MOL BIOCHEM PARASIT, V70, P95, DOI 10.1016/0166-6851(95)00011-O; HIRZMANN J, 1993, NUCLEIC ACIDS RES, V21, P3597, DOI 10.1093/nar/21.15.3597; HORSTMANN RD, 1992, INFECT IMMUN, V60, P721, DOI 10.1128/IAI.60.3.721-727.1992; Ilg T, 1996, J BIOL CHEM, V271, P21583, DOI 10.1074/jbc.271.35.21583; KLONISCH T, 1991, PARASITOL RES, V77, P448, DOI 10.1007/BF00931643; LAMMLER G, 1968, Zeitschrift fuer Parasitenkunde, V30, P281; LARSEN NI, 1995, NUCLEIC ACIDS RES, V23, P1223, DOI 10.1093/nar/23.7.1223; MAIZELS RM, 1991, PARASITOL TODAY, V7, P271, DOI 10.1016/0169-4758(91)90093-4; MALETTE B, 1995, MOL REPROD DEV, V41, P384, DOI 10.1002/mrd.1080410315; MENRATH M, 1995, PARASITOLOGY, V111, P477, DOI 10.1017/S0031182000065987; Michael E, 1997, PARASITOL TODAY, V13, P472, DOI 10.1016/S0169-4758(97)01151-4; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NILSEN TW, 1995, MOL BIOCHEM PARASIT, V73, P1, DOI 10.1016/0166-6851(94)00107-X; OTTESEN EA, 1977, IMMUNOLOGY, V33, P413; PIESSENS WF, 1980, J CLIN INVEST, V65, P172, DOI 10.1172/JCI109648; SANGER I, 1981, ACTA TROP, V38, P277; SAYERS G, 1984, PARASITOLOGY, V89, P425, DOI 10.1017/S0031182000056675; SCHARES G, 1994, PARASITOLOGY, V109, P73, DOI 10.1017/S0031182000077787; SCHRAERMEYER U, 1987, Z PARASITENKD, V73, P550; SCHRAERMEYER U, 1987, Z PARASITENKD, V73, P557; SELKIRK ME, 1991, J BIOL CHEM, V266, P11002; SIMPSON MG, 1972, PARASITOLOGY, V64, P61, DOI 10.1017/S0031182000044656; WIESE M, 1995, EMBO J, V14, P1067, DOI 10.1002/j.1460-2075.1995.tb07089.x; ZAHNER H, 1995, PARASITOL TODAY, V11, P116, DOI 10.1016/0169-4758(95)80173-1	39	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47603	47612		10.1074/jbc.M205770200	http://dx.doi.org/10.1074/jbc.M205770200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356773	hybrid			2022-12-27	WOS:000179663700100
J	Li, K; Zhao, SQ; Karur, V; Wojchowski, DM				Li, K; Zhao, SQ; Karur, V; Wojchowski, DM			DYRK3 activation, engagement of protein kinase A/cAMP response element-binding protein, and modulation of progenitor cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; SACCHAROMYCES-CEREVISIAE; MAP KINASE; PHOSPHORYLATION; FAMILY; GENE; EXPRESSION; MINIBRAIN; SPECIFICITY; INHIBITION	DYRKs are a new family of (d) under bar ual-specificity (t) under bar yrosine-(r) under bar egulated (k) under bar inases with emerging roles in cell growth and development. Recently, we discovered that DYRK3 is expressed primarily in erythroid progenitor cells and modulates late erythropoiesis. We now describe 1) roles for the DYRK3 YTY signature motif in kinase activation, 2) the coupling of DYRK3 to cAMP response element (CRE)-binding protein (CREB), and 3) effects of DYRK3 on hematopoietic progenitor cell survival. Regarding the DYRK3 kinase domain, intactness of Tyr(333) (but not Tyr(331)) within subdomain loop VII-VIII was critical for activation. Tyr(331) plus Tyr(333) acidification (Tyr mutated to Glu) was constitutively activating, but kinase activity was not affected substantially by unique N- or C-terminal domains. In transfected 293 and HeLa cells, DYRK3 was discovered to efficiently stimulate CRE-luciferase expression, to activate a CREB-Ga14 fusion protein, and to promote CREB phosphorylation at Ser(133). Interestingly, this CREB/CRE response was also supported (50% of wild-type activity) by a kinase-inactive DYRK3 mutant as well as a DYRK3 C-terminal region and was blocked by protein kinase A inhibitors, suggesting functional interactions between protein kinase A and DYRK3. Finally, DYRK3 expression in cytokine-dependent hematopoietic FDCW2 cells was observed to inhibit programmed cell death. Thus, primary new insight into DYRK3 kinase signaling routes, subdomain activities, and possible biofunctions is provided.	Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Immunobiol Program, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Wojchowski, DM (corresponding author), Penn State Univ, Dept Vet Sci, 115 Henning Bldg, University Pk, PA 16802 USA.	dmw@psu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040242] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK40242] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altafaj X, 2001, HUM MOL GENET, V10, P1915, DOI 10.1093/hmg/10.18.1915; Becker W, 1999, PROG NUCLEIC ACID RE, V62, P1; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; Campbell LE, 2002, FEBS LETT, V510, P31, DOI 10.1016/S0014-5793(01)03221-5; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Casteel D, 1998, BLOOD, V91, P3193, DOI 10.1182/blood.V91.9.3193.3193_3193_3201; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; ES SV, 2001, J BIOL CHEM, V276, P30761; Feliciello A, 1997, CURR BIOL, V7, P1011, DOI 10.1016/S0960-9822(06)00424-6; GARRETT S, 1989, GENE DEV, V3, P1336, DOI 10.1101/gad.3.9.1336; GARRETT S, 1991, MOL CELL BIOL, V11, P4045, DOI 10.1128/MCB.11.8.4045; Geiger JN, 2001, BLOOD, V97, P901, DOI 10.1182/blood.V97.4.901; Griffioen G, 2001, MOL CELL BIOL, V21, P511, DOI 10.1128/MCB.21.2.511-523.2001; Guimera J, 1999, GENOMICS, V57, P407, DOI 10.1006/geno.1999.5775; Henriksson M, 2001, APOPTOSIS, V6, P133, DOI 10.1023/A:1009644716727; Himpel S, 2001, BIOCHEM J, V359, P497, DOI 10.1042/0264-6021:3590497; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Lord KA, 2000, BLOOD, V95, P2838, DOI 10.1182/blood.V95.9.2838.009k29_2838_2846; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Matsuo R, 2001, J IMMUNOL METHODS, V247, P141, DOI 10.1016/S0022-1759(00)00313-6; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Miyata Y, 1999, BIOCHEM BIOPH RES CO, V266, P291, DOI 10.1006/bbrc.1999.1705; Pircher TJ, 2001, J BIOL CHEM, V276, P8995, DOI 10.1074/jbc.M007473200; SCHAAP P, 1993, J BIOL CHEM, V268, P6323; Seshasayee D, 1998, MOL CELL BIOL, V18, P3278, DOI 10.1128/MCB.18.6.3278; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shindoh N, 1996, BIOCHEM BIOPH RES CO, V225, P92, DOI 10.1006/bbrc.1996.1135; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; Souza GM, 1998, DEVELOPMENT, V125, P2291; Souza GM, 1999, DEVELOPMENT, V126, P3263; Tasken K, 1997, ADV SEC MESS PHOSPH, V31, P191; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; Varone CL, 1999, ARCH BIOCHEM BIOPHYS, V372, P261, DOI 10.1006/abbi.1999.1470; Woods YL, 2001, BIOCHEM J, V355, P609, DOI 10.1042/bj3550609; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200	44	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47052	47060		10.1074/jbc.M205374200	http://dx.doi.org/10.1074/jbc.M205374200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356771	hybrid			2022-12-27	WOS:000179663700030
J	Tsujii-Hayashi, Y; Kitahara, M; Yamagaki, T; Kojima-Aikawa, K; Matsumoto, I				Tsujii-Hayashi, Y; Kitahara, M; Yamagaki, T; Kojima-Aikawa, K; Matsumoto, I			A potential endogenous ligand of annexin IV in the exocrine pancreas - Carbohydrate structure of GP-2, a glycosylphosphatidylinositol-anchored glycoprotein of zymogen granule membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAMM-HORSFALL GLYCOPROTEIN; BINDING PROTEIN P33/41; LINKED OLIGOSACCHARIDES; MAJOR GLYCOPROTEIN; SECRETORY GRANULES; MAACKIA-AMURENSIS; CELLS; KIDNEY; UROMODULIN; EXPRESSION	We demonstrated previously that annexins IV, V, and VI, proteins of the calcium/phospholipid-binding annexin family, have glycosaminoglycan binding properties (Ishitsuka, R., Kojima, K., Utsumi, H., Ogawa, H., and Matsumoto, I. (1998) J. Biol. Chem. 273, 9935-9941). In this study, we investigated the endogenous ligands of annexin IV in the exocrine pancreas. Immunohistochemical study of bovine pancreas showed that annexin IV localized in the apical cytoplasmic region of pancreatic acinar cells where zymogen granules are concentrated. Because it is the major component of the zymogen granule membrane, the glycosylphosphatidylinositol-anchored glycoprotein GP-2 was suggested to play a role in apical sorting and secretion of zymogens. We isolated GP-2 from porcine pancreas extract and determined the structure of its N-linked oligosaccharides by two-dimensional mapping. The major carbohydrate structures of porcine GP-2 were trisialo-triantermary and tetrasialo-tetra-antennary complex-type oligosaccharides. Dot-blot assay showed that annexin IV interacts with GP-2 in the presence of calcium and that it recognizes the terminal sialic acid residues linked through alpha2-3 linkages to the carbohydrate of GP-2. Lectin blot assay showed that Maackia amurensis mitogen, a plant lectin specific for the trisaccharide sequence Siaalpha2-3Galbeta1-4GlcNAc of N-linked oligosaccharides, has strong affinity for GP-2. Thus, M. amurensis mitogen was used as a specific probe for GP-2 in the histochemical staining of the bovine pancreas. GP-2 was found to localize exclusively in the same apical cytoplasmic region of pancreatic acinar cells as annexin IV does. These results suggest that GP-2 is an endogenous ligand of annexin IV in the exocrine pancreas.	Ochanomizu Univ, Fac Sci, Dept Chem, Bunkyo Ku, Tokyo 1128610, Japan; Univ Tokyo, Sch Sci, Dept Chem, Bunkyo Ku, Tokyo 1130033, Japan	Ochanomizu University; University of Tokyo	Kojima-Aikawa, K (corresponding author), Ochanomizu Univ, Fac Sci, Dept Chem, Bunkyo Ku, 2-1-1 Otsuka, Tokyo 1128610, Japan.							ADAIR WL, 1974, J BIOL CHEM, V249, P4696; BACHMANN S, 1985, HISTOCHEMISTRY, V83, P531, DOI 10.1007/BF00492456; BEANZIGER JU, 1979, J BIOL CHEM, V254, P2400; BERMAN E, 1981, J BIOL CHEM, V256, P3853; BERMAN E, 1986, FEBS LETT, V204, P257, DOI 10.1016/0014-5793(86)80823-7; CODDEVILLE B, 1992, CARBOHYD RES, V236, P145, DOI 10.1016/0008-6215(92)85013-P; DULAWA J, 1988, EUR J CLIN INVEST, V18, P87, DOI 10.1111/j.1365-2362.1988.tb01171.x; EDWARDS HC, 1995, MOL CELL BIOCHEM, V149, P293, DOI 10.1007/BF01076591; FREEDMAN SD, 1993, J CLIN INVEST, V92, P83, DOI 10.1172/JCI116602; Fritz B.A., 1996, AM J PHYSIOL, V270, P176; FUKUOKA SI, 1992, P NATL ACAD SCI USA, V89, P1189, DOI 10.1073/pnas.89.4.1189; FUKUOKA SI, 1991, P NATL ACAD SCI USA, V88, P2898, DOI 10.1073/pnas.88.7.2898; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HAVINGA JR, 1985, EUR J CELL BIOL, V39, P70; HAVINGA JR, 1983, EUR J BIOCHEM, V133, P449, DOI 10.1111/j.1432-1033.1983.tb07484.x; HOOPS TC, 1991, J BIOL CHEM, V266, P4257; Ishitsuka R, 1998, J BIOL CHEM, V273, P9935, DOI 10.1074/jbc.273.16.9935; KNIBBS RN, 1991, J BIOL CHEM, V266, P83; Kojima K, 1996, J BIOL CHEM, V271, P7679, DOI 10.1074/jbc.271.13.7679; KOJIMA K, 1992, J BIOL CHEM, V267, P20536; KOJIMA K, 1994, FEBS LETT, V342, P313, DOI 10.1016/0014-5793(94)80523-7; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; KOPELMAN H, 1988, GASTROENTEROLOGY, V95, P349, DOI 10.1016/0016-5085(88)90490-8; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEL D, 1988, BIOCHEM BIOPH RES CO, V154, P818, DOI 10.1016/0006-291X(88)90213-6; LEWIS DS, 1977, FEBS LETT, V76, P115, DOI 10.1016/0014-5793(77)80133-6; LYNN KL, 1982, CLIN SCI, V62, P21, DOI 10.1042/cs0620021; MACDONAL.RJ, 1972, BIOCHEM BIOPH RES CO, V49, P377, DOI 10.1016/0006-291X(72)90421-4; Mohiti J, 1997, EXP CELL RES, V234, P98, DOI 10.1006/excr.1997.3584; OGAWA H, 1990, ANAL BIOCHEM, V190, P165, DOI 10.1016/0003-2697(90)90175-9; PEPINKY RB, 1996, NATURE, V321, P81; RADKE K, 1980, CELL, V21, P821, DOI 10.1016/0092-8674(80)90445-6; Raynal P, 1996, FEBS LETT, V392, P263, DOI 10.1016/0014-5793(96)00827-7; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; RINDLER MJ, 1990, J BIOL CHEM, V265, P20784; RINDLER MJ, 1990, EUR J CELL BIOL, V53, P154; SANDERS PW, 1990, J CLIN INVEST, V85, P570, DOI 10.1172/JCI114474; Satoh A, 1996, J BIOCHEM-TOKYO, V119, P346; SAWYER ST, 1985, J BIOL CHEM, V260, P8233; Scheele GA, 1996, PANCREAS, V12, P1, DOI 10.1097/00006676-199601000-00001; SCHEELE GA, 1994, PANCREAS, V9, P139, DOI 10.1097/00006676-199403000-00001; SHERBLOM AP, 1988, J BIOL CHEM, V263, P5418; SHIBUYA N, 1989, J BIOCHEM-TOKYO, V106, P1098, DOI 10.1093/oxfordjournals.jbchem.a122972; SIKRI KL, 1979, BIOCHEM J, V181, P525, DOI 10.1042/bj1810525; SLOMIANY A, 1981, BIOCHEM BIOPH RES CO, V100, P778, DOI 10.1016/S0006-291X(81)80242-2; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; TAMM I, 1950, P SOC EXP BIOL MED, V74, P108, DOI 10.3181/00379727-74-17825; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; TRESSLER RJ, 1994, EXP CELL RES, V215, P395, DOI 10.1006/excr.1994.1358; WANG WC, 1988, J BIOL CHEM, V263, P4576; WEN Y, 1999, BIOCHEM BIOPH RES CO, V187, P1579; WIGGINS RC, 1987, CLIN CHIM ACTA, V162, P329, DOI 10.1016/0009-8981(87)90052-0; Wong SME, 1996, GENE, V171, P311, DOI 10.1016/0378-1119(96)00065-0; YEATMAN TJ, 1993, CLIN EXP METASTAS, V11, P37, DOI 10.1007/BF00880064	56	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47493	47499		10.1074/jbc.M206572200	http://dx.doi.org/10.1074/jbc.M206572200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12324456	hybrid			2022-12-27	WOS:000179663700086
J	Nangle, LA; Lagardt, VD; Dodring, V; Schimmel, P				Nangle, LA; Lagardt, VD; Dodring, V; Schimmel, P			Genetic code ambiguity - Cell viability related to severity of editing defects in mutant tRNA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASE; RIBONUCLEIC-ACID SYNTHETASE; PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; AMINO-ACIDS; CLONING VECTORS; VALINE; SIEVE; ISOLEUCINE; DOMAIN	The rules of the genetic code are established in reactions that aminoacylate tRNAs with specific amino acids. Ambiguity in the code is prevented by editing activities whereby incorrect aminoacylations are cleared by specialized hydrolytic reactions of aminoacyl tRNA synthetases. Whereas editing reactions have long been known, their significance for cell viability is still poorly understood. Here we investigated in vitro and in vivo four different mutations in the center for editing that diminish the proofreading activity of valyl-tRNA synthetase (ValRS). The four mutant enzymes were shown to differ quantitatively in the severity of the defect in their ability to clear mischarged tRNA in vitro. Strikingly, in the presence of excess concentrations of a-aminobutyrate, one of the amino acids that is misactivated by ValRS, growth of bacterial strains bearing these mutant alleles is arrested. The concentration of misactivated amino acid required for growth arrest correlates in. versely in a rank order with the degree of the editing defect seen in vitro. Thus, cell viability depends directly on the suppression of genetic code ambiguity by these specific editing reactions and is finely tuned to any perturbation of these reactions.	Scripps Res Inst, Dept Mol Biol & Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Evol SA, F-91000 Evry, France	Scripps Research Institute; Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Dept Mol Biol & Chem, La Jolla, CA 92037 USA.				NIGMS NIH HHS [GM23562] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN AN, 1966, J BIOL CHEM, V241, P839; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; Bishop AC, 2002, P NATL ACAD SCI USA, V99, P585, DOI 10.1073/pnas.012611299; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; de Pouplana LR, 2001, TRENDS BIOCHEM SCI, V26, P591, DOI 10.1016/S0968-0004(01)01932-6; Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9; Doring V, 2001, SCIENCE, V292, P501, DOI 10.1126/science.1057718; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; Felden B, 1998, BIOCHEM BIOPH RES CO, V243, P426, DOI 10.1006/bbrc.1997.7753; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P354; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Fukai S, 2000, CELL, V103, P793, DOI 10.1016/S0092-8674(00)00182-3; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hale SP, 1997, SCIENCE, V276, P1250, DOI 10.1126/science.276.5316.1250; Hale SP, 1997, TETRAHEDRON, V53, P11985, DOI 10.1016/S0040-4020(97)00711-4; Hendrickson TL, 2002, MOL CELL, V9, P353, DOI 10.1016/S1097-2765(02)00449-5; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; LOFTFIELD RB, 1972, BIOCHEM J, V128, P1353, DOI 10.1042/bj1281353; Miller JH, 1972, EXPT MOL GENETICS, P201; Mursinna RS, 2001, BIOCHEMISTRY-US, V40, P5376, DOI 10.1021/bi002915w; Nomanbhoy TK, 1999, MOL CELL, V4, P519, DOI 10.1016/S1097-2765(00)80203-8; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; Qiu H, 2001, EMBO J, V20, P1425, DOI 10.1093/emboj/20.6.1425; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; Schimmel P, 2001, COLD SPRING HARB SYM, V66, P161, DOI 10.1101/sqb.2001.66.161; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; SCHREIER AA, 1972, BIOCHEMISTRY-US, V11, P1582, DOI 10.1021/bi00759a006; Sissler M, 1999, P NATL ACAD SCI USA, V96, P8985, DOI 10.1073/pnas.96.16.8985; Sissler M, 1998, RNA, V4, P647, DOI 10.1017/S1355838298980037; YARUS M, 1972, P NATL ACAD SCI USA, V69, P1915, DOI 10.1073/pnas.69.7.1915; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417	38	63	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45729	45733		10.1074/jbc.M208093200	http://dx.doi.org/10.1074/jbc.M208093200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244062	hybrid			2022-12-27	WOS:000179529300003
J	Marrakchi, H; Choi, KH; Rock, CO				Marrakchi, H; Choi, KH; Rock, CO			A new mechanism for anaerobic unsaturated fatty acid formation in Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; HYDROXYDECANOYL THIOESTER DEHYDRASE; PHENYLACETYL-COA CATABOLON; SYNTHASE III FABH; ESCHERICHIA-COLI; ENZYMATIC SYNTHESIS; THERMAL REGULATION; LIPID-COMPOSITION; ACTIVE-SITE; BIOSYNTHESIS	The anaerobic pathway for unsaturated fatty acid synthesis was established in the 1960s in Escherichia coli. The double bond is introduced into the growing acyl chain by FabA, an enzyme capable of both the dehydration of beta-hydroxydecanoyl-acyl carrier protein (ACP) to trans-2-decenoyl-ACP, and the isomerization of trans-2 to cis-3-decenoyl-ACP. However, there are a number of anaerobic bacteria whose genomes do not contain a fabA homolog, although these organisms nonetheless produce unsaturated fatty acids. We cloned and biochemically characterized a new enzyme in type II fatty acid synthesis from Streptococcus pneumoniae that carries out the isomerization of trans-2-decenoyl-ACP to cis-3-decenoyl-ACP, but is not capable of catalyzing the dehydration of beta-hydroxy intermediates. This tetrameric enzyme, designated FabM, has no similarity to FabA, but rather is a member of the hydratase/isomerase superfamily. Thus, the branch point in the biosynthesis of unsaturated fatty acids in S. pneumoniae occurs following the formation of trans-2-decenoyl-ACP, in contrast to E. coli where the branch point takes place after the formation of beta-hydroxydecanoyl-ACP.	St Jude Childrens Res Hosp, Prot Sci Div, Dept Infect Dis, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Biosci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Prot Sci Div, Dept Infect Dis, 332 N Lauderdale, Memphis, TN 38105 USA.	charles.rock@stjude.org	Marrakchi, Hedia/AAF-2657-2020		NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alekshun MN, 2001, NAT STRUCT BIOL, V8, P710, DOI 10.1038/90429; Alekshun MN, 2000, MOL MICROBIOL, V35, P1394, DOI 10.1046/j.1365-2958.2000.01802.x; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BLOCH K, 1969, ACCOUNTS CHEM RES, V2, P193, DOI 10.1021/ar50019a001; BLOCH K, 1987, ANNU REV BIOCHEM, V56, P1; BLOOMFIELD DK, 1960, J BIOL CHEM, V235, P337; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCK DJH, 1967, J BIOL CHEM, V242, P4432; Campbell JW, 2001, J BACTERIOL, V183, P5982, DOI 10.1128/JB.183.20.5982-5990.2001; Choi KH, 2000, J BIOL CHEM, V275, P28201; Choi KH, 2000, J BACTERIOL, V182, P365, DOI 10.1128/JB.182.2.365-370.2000; Clark D P, 1981, Methods Enzymol, V72, P693; CLARK DP, 1983, BIOCHEMISTRY-US, V22, P5897, DOI 10.1021/bi00294a032; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; DAGNOLO G, 1975, J BIOL CHEM, V250, P5289; DEMENDOZA D, 1983, TRENDS BIOCHEM SCI, V8, P49, DOI 10.1016/0968-0004(83)90388-2; DEMENDOZA D, 1983, J BIOL CHEM, V258, P2098; ENDO K, 1970, J BIOL CHEM, V245, P4293; FERRIGE AG, 1992, RAPID COMMUN MASS SP, V6, P707, DOI 10.1002/rcm.1290061115; GARWIN JL, 1980, J BACTERIOL, V141, P1457, DOI 10.1128/JB.141.3.1457-1459.1980; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; GELMANN EP, 1972, J BACTERIOL, V112, P381, DOI 10.1128/JB.112.1.381-387.1972; Heath RJ, 2000, NATURE, V406, P145, DOI 10.1038/35018162; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; Heath RJ, 1999, J BIOL CHEM, V274, P11110, DOI 10.1074/jbc.274.16.11110; HELMKAMP GM, 1969, J BIOL CHEM, V244, P6014; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; KASS LR, 1967, P NATL ACAD SCI USA, V58, P1168, DOI 10.1073/pnas.58.3.1168; Luengo JM, 2001, MOL MICROBIOL, V39, P1434, DOI 10.1046/j.1365-2958.2001.02344.x; MOHAN S, 1994, J BIOL CHEM, V269, P32896; Olivera ER, 1998, P NATL ACAD SCI USA, V95, P6419, DOI 10.1073/pnas.95.11.6419; Patton SM, 2000, BIOCHEMISTRY-US, V39, P7595, DOI 10.1021/bi0005714; Price AC, 2001, BIOCHEMISTRY-US, V40, P12772, DOI 10.1021/bi010737g; RANDO RR, 1968, J BIOL CHEM, V243, P5627; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Rock CO, 1996, J BACTERIOL, V178, P5382, DOI 10.1128/jb.178.18.5382-5387.1996; Schujman GE, 2001, J BACTERIOL, V183, P3032, DOI 10.1128/JB.183.10.3032-3040.2001; SCHWAB JM, 1985, ANAL BIOCHEM, V150, P121, DOI 10.1016/0003-2697(85)90449-X; SEUBERT W, 1953, J AM CHEM SOC, V75, P2787, DOI 10.1021/ja01107a529; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; TROMBE MC, 1979, BIOCHIM BIOPHYS ACTA, V574, P290, DOI 10.1016/0005-2760(79)90010-9; ULRICH AK, 1983, J BACTERIOL, V154, P221, DOI 10.1128/JB.154.1.221-230.1983; Xiang H, 1999, BIOCHEMISTRY-US, V38, P7638, DOI 10.1021/bi9901432; YANG SY, 1988, J BACTERIOL, V170, P2543, DOI 10.1128/jb.170.6.2543-2548.1988; Zhang YM, 2002, J BIOL CHEM, V277, P15558, DOI 10.1074/jbc.M201399200	49	90	108	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44809	44816		10.1074/jbc.M208920200	http://dx.doi.org/10.1074/jbc.M208920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237320	hybrid			2022-12-27	WOS:000179404800030
J	Meyer, C; Notari, L; Becerra, SP				Meyer, C; Notari, L; Becerra, SP			Mapping the type I collagen-binding site on pigment epithelium-derived factor - Implications for its antiangiogenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; FACTOR PEDF; NEUROTROPHIC ACTIVITY; NONINHIBITORY SERPIN; INDUCED RETINOPATHY; SELECTIN BINDING; KINETIC-ANALYSIS; CELL-ADHESION; BOVINE EYES; INHIBITOR	Pigment epithelium-derived factor (PEDF), a neurotrophic and antiangiogenic serpin, is identified in tissues rich in collagen, e.g. cornea, vitreous, bone, and cartilage. We show that recombinant human PEDF formed complexes with collagens from the bovine cornea and vitreous. We have examined the direct binding of PEDF to collagen I and found that interactions were ionic in nature and occurred when PEDF and collagen I were both in solution, when either one was immobilized, or even when collagen I was denatured under reducing conditions. 125 I-PEDF bound to immobilized collagen I in a saturable fashion (K-D = 123 nm). Compared with neurotrophic PEDF-derived peptides, ovalbumin and angiogenic inhibitors, only full-length PEDF competed efficiently with I-125-PEDF for the binding to immobilized collagen I (EC50 = 3 mug/ml). The collagen-binding region was analyzed using controlled proteolysis and chemically modified PEDF. Cleavage of the serpin exposed loop did not prevent binding to collagen 1. Conjugation of lysines with fluorescein increased the collagen binding affinity. However, treatment of PEDF with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide abolished it, implicating the PEDF aspartic and/or glutamic acid residues in its interaction with collagen 1. A negatively charged region on the surface of the PEDF molecule is rich in acidic residues (Glu(41), Glu(42), Glu(43) Asp(44) Asp(64), Asp(256), Asp(258), Glu(290), Glu(291), Glu(296) Asp(300), Glu(304)) available to interact directly with positively charged areas of collagen. This represents the first collagen-binding site described for a serpin, which in PEDF, is distinct from its heparin-binding region, neurotrophic active site, and its serpin exposed loop. The collagen-binding property of PEDF may play a role in surface localization and modulation of its antiangiogenic effects in the eye and bone.	NEI, Retinal Cell & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Becerra, SP (corresponding author), NEI, Retinal Cell & Mol Biol Lab, NIH, Bldg 6,Rm 308,6 Ctr Dr,MSC 2740, Bethesda, MD 20892 USA.			Meyer, Christina/0000-0002-0380-195X	NATIONAL EYE INSTITUTE [Z01EY000306, ZIAEY000306] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alberdi E, 1999, J BIOL CHEM, V274, P31605, DOI 10.1074/jbc.274.44.31605; Alberdi E, 1998, BIOCHEMISTRY-US, V37, P10643, DOI 10.1021/bi9802317; Aymerich MS, 2001, INVEST OPHTH VIS SCI, V42, P3287; Ball EH, 1997, ADV EXP MED BIOL, V425, P239; Becerra SP, 1997, ADV EXP MED BIOL, V425, P223; BECERRA SP, 1993, J BIOL CHEM, V268, P23148; BECERRA SP, 1995, J BIOL CHEM, V270, P25992, DOI 10.1074/jbc.270.43.25992; Bishop PN, 2000, PROG RETIN EYE RES, V19, P323, DOI 10.1016/S1350-9462(99)00016-6; Blacque OE, 2002, J BIOL CHEM, V277, P10783, DOI 10.1074/jbc.M110992200; Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6; Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646; Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263; Crawford SE, 2001, J CELL SCI, V114, P4421; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Di Lullo GA, 2002, J BIOL CHEM, V277, P4223, DOI 10.1074/jbc.M110709200; Hadley JC, 1998, GLYCOCONJUGATE J, V15, P835, DOI 10.1023/A:1006928403140; Holmes JM, 1999, INVEST OPHTH VIS SCI, V40, P804; Houenou LJ, 1999, J COMP NEUROL, V412, P506; Karakousis PC, 2001, MOL VIS, V7, P154; KERN P, 1986, CLIN PHYSIOL BIOCH, V4, P113; Kozaki K, 1998, J BIOL CHEM, V273, P15125, DOI 10.1074/jbc.273.24.15125; LABATROBERT J, 1992, ANN NY ACAD SCI, V673, P16, DOI 10.1111/j.1749-6632.1992.tb27431.x; Lu DW, 2001, J OCUL PHARMACOL TH, V17, P343, DOI 10.1089/108076801753162753; Macdonald JR, 2001, J BIOL CHEM, V276, P25399, DOI 10.1074/jbc.M102471200; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; Ngamkitidechakul C, 2001, INVEST OPHTH VIS SCI, V42, P3135; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; Nishikawa T, 2000, CURR EYE RES, V21, P581, DOI 10.1076/0271-3683(200007)21:1;1-Z;FT581; Ortego J, 1996, INVEST OPHTH VIS SCI, V37, P2759; Perez-Mediavilla LA, 1998, BBA-GENE STRUCT EXPR, V1398, P203, DOI 10.1016/S0167-4781(98)00055-4; REISER KM, 1992, J BIOL CHEM, V267, P24207; Robert L, 2001, PATHOL BIOL, V49, P353, DOI 10.1016/S0369-8114(01)00144-4; Simonovic M, 2001, P NATL ACAD SCI USA, V98, P11131, DOI 10.1073/pnas.211268598; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398; Stratikos E, 1996, PROTEIN SCI, V5, P2575, DOI 10.1002/pro.5560051220; Sweeney SM, 1998, P NATL ACAD SCI USA, V95, P7275, DOI 10.1073/pnas.95.13.7275; Wild MK, 2001, J BIOL CHEM, V276, P31602, DOI 10.1074/jbc.M104844200; Wu YQ, 1996, INVEST OPHTH VIS SCI, V37, P1984; WU YQ, 1995, PROTEIN EXPRES PURIF, V6, P447, DOI 10.1006/prep.1995.1060; Yabe T, 2001, J BIOL CHEM, V276, P43313, DOI 10.1074/jbc.M107831200; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303	42	119	122	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45400	45407		10.1074/jbc.M208339200	http://dx.doi.org/10.1074/jbc.M208339200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237317	hybrid			2022-12-27	WOS:000179404800103
J	Zhu, M; Souillac, PO; Ionescu-Zanetti, C; Carter, SA; Fink, AL				Zhu, M; Souillac, PO; Ionescu-Zanetti, C; Carter, SA; Fink, AL			Surface-catalyzed amyloid fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; IMMUNOGLOBULIN LIGHT-CHAINS; ALPHA-SYNUCLEIN; DEPOSITION DISEASE; PARKINSONS-DISEASE; HEAVY-CHAIN; PEPTIDE; AGGREGATION; MECHANISM; FIBRILLIZATION	Light chain (or AL) amyloidosis is characterized by the pathological deposition of insoluble fibrils of immunoglobulin light chain fragments in various tissues, walls of blood vessels, and basement membranes. In the present investigation, the in vitro assembly of a recombinant amyloidogenic light chain variable domain, SMA, on various surfaces was monitored using atomic force microscopy. SAU formed fibrils on native mica at pH 5.0, conditions under which predominantly amorphous aggregates form in solution. Fibril formation was accelerated significantly on surfaces compared with solution; for example, fibrils grew on surfaces at significantly faster rates and at much lower concentrations than in solution. No fibrils were observed on hydrophobic or positively charged surfaces or at pH >7.0. Two novel types. of fibril growth were observed on the surface: bidirectional linear assembly of oligomeric units, and linear growth from preformed amorphous cores. In addition to catalyzing the rate of fibrillation, the mechanism of fibril formation on the surfaces was significantly different from in solution, but it may be more physiologically relevant because in vivo the deposits are associated with surfaces.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Dept Phys, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, 1156 High St, Santa Cruz, CA 95064 USA.				NIDDK NIH HHS [DK55675] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055675] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blackley HKL, 2000, J MOL BIOL, V298, P833, DOI 10.1006/jmbi.2000.3711; Buxbaum J, 1999, HEMATOL ONCOL CLIN N, V13, P1235, DOI 10.1016/S0889-8588(05)70123-4; BUXBAUM J, 1992, HEMATOL ONCOL CLIN N, V6, P323, DOI 10.1016/S0889-8588(18)30347-2; Ding TT, 1999, METHOD ENZYMOL, V309, P510; Gallo G, 1996, AM J PATHOL, V148, P1397; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Goldsbury C, 1999, J MOL BIOL, V285, P33, DOI 10.1006/jmbi.1998.2299; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; Ionescu-Zanetti C, 1999, P NATL ACAD SCI USA, V96, P13175, DOI 10.1073/pnas.96.23.13175; Jo EJ, 2000, J BIOL CHEM, V275, P34328, DOI 10.1074/jbc.M004345200; Khurana R, 2001, BIOCHEMISTRY-US, V40, P3525, DOI 10.1021/bi001782b; Kim YS, 2001, J BIOL CHEM, V276, P1626, DOI 10.1074/jbc.M007766200; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Koutsos V, 1998, MACROMOLECULES, V31, P116, DOI 10.1021/ma9706182; Koutsos V, 1997, MACROMOLECULES, V30, P4719, DOI 10.1021/ma961625d; Kowalewski T, 1999, P NATL ACAD SCI USA, V96, P3688, DOI 10.1073/pnas.96.7.3688; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Lundberg KM, 1997, CHEM BIOL, V4, P345, DOI 10.1016/S1074-5521(97)90125-3; Mueller Daniel J., 1997, Journal of Structural Biology, V119, P172; MYATT EA, 1994, P NATL ACAD SCI USA, V91, P3034, DOI 10.1073/pnas.91.8.3034; Naiki H, 1999, METHOD ENZYMOL, V309, P305; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Raffen R, 1999, PROTEIN SCI, V8, P509; Sasaki A, 1997, BRAIN RES, V755, P193, DOI 10.1016/S0006-8993(97)00097-8; Solomon A, 1998, P NATL ACAD SCI USA, V95, P9547, DOI 10.1073/pnas.95.16.9547; SOLOMON A, 1991, NEW ENGL J MED, V324, P1845, DOI 10.1056/NEJM199106273242603; Stevens FJ, 1999, IMMUNOL TODAY, V20, P451, DOI 10.1016/S0167-5699(99)01502-9; Stokes MB, 1997, MODERN PATHOL, V10, P1059; Stolz M, 2000, J STRUCT BIOL, V131, P171, DOI 10.1006/jsbi.2000.4301; Tang ZY, 2000, LANGMUIR, V16, P1696, DOI 10.1021/la981491s; van Oss CJ, 2001, COLLOID SURFACE B, V22, P285, DOI 10.1016/S0927-7765(01)00151-5; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Wall J, 1999, BIOCHEMISTRY-US, V38, P14101, DOI 10.1021/bi991131j; Wallace RW, 1996, DRUG DISCOV TODAY, V1, P46, DOI 10.1016/1359-6446(96)89080-5; WILKINSSTEVENS P, 1995, PROTEIN SCI, V4, P421; Yang ZH, 1999, LANGMUIR, V15, P1731, DOI 10.1021/la980839g; Yip CM, 2001, BIOPHYS J, V80, P1359, DOI 10.1016/S0006-3495(01)76109-7	38	223	228	1	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50914	50922		10.1074/jbc.M207225200	http://dx.doi.org/10.1074/jbc.M207225200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12356747	hybrid			2022-12-27	WOS:000180177700094
J	Langley, B; Thomas, M; Bishop, A; Sharma, M; Gilmour, S; Kambadur, R				Langley, B; Thomas, M; Bishop, A; Sharma, M; Gilmour, S; Kambadur, R			Myostatin inhibits myoblast differentiation by down-regulating MyoD expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; CELL-CYCLE WITHDRAWAL; MYOGENIC DIFFERENTIATION; MUSCLE DIFFERENTIATION; FACTOR-BETA; TERMINAL DIFFERENTIATION; SKELETAL-MUSCLE; TRANSCRIPTION FACTORS; GENE-EXPRESSION; KINASE-ACTIVITY	Myostatin, a negative regulator of myogenesis, is shown to function by controlling the proliferation of myoblasts. In this study we show that myostatin is an inhibitor of myoblast differentiation and that this inhibition is mediated through Smad 3. In vitro, increasing concentrations of recombinant mature myostatin reversibly blocked the myogenic differentiation of myoblasts, cultured in low serum media. Western and Northern blot analysis indicated that addition of myostatin to the low serum culture media repressed the levels of MyoD, Myf5, myogenin, and p21 leading to the inhibition of myogenic differentiation. The transient transfection of C2C12 myoblasts with MyoD expressing constructs did not rescue myostatin-inhibited myogenic differentiation. Myostatin signaling specifically induced Smad 3 phosphorylation and increased Smad 3-MyoD association, suggesting that Smad 3 may mediate the myostatin signal by interfering with MyoD activity and expression. Consistent with this, the expression of dominant-negative Smad3 rescued the activity of a MyoD promoter-reporter in C2C12 myoblasts treated with myostatin. Taken together, these results suggest that myostatin inhibits MyoD activity and expression via Smad 3 resulting in the failure of the myoblasts to differentiate into myotubes. Thus we propose that myostatin plays a critical role in myogenic differentiation and that the muscular hyperplasia and hypertrophy seen in animals that lack functional myostatin is because of deregulated proliferation and differentiation of myoblasts.	AgRes, Anim Genom, Hamilton, New Zealand; Univ Auckland, Fac Med & Hlth Sci, Auckland 1, New Zealand	AgResearch - New Zealand; University of Auckland	Kambadur, R (corresponding author), AgRes, Anim Genom, Private Bag 3123,East St, Hamilton, New Zealand.		Langley, Brett C/P-7207-2017	Langley, Brett C/0000-0003-4009-2109; Marshall, Amy/0000-0001-5803-3815				Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; ARNOLD H, 2001, LIFE XY, V1, P1014; Beranger F, 2000, J BIOL CHEM, V275, P16103, DOI 10.1074/jbc.275.21.16103; Berry FB, 2001, J BIOL CHEM, V276, P25057, DOI 10.1074/jbc.M010378200; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Carnac G, 2000, CURR BIOL, V10, P543, DOI 10.1016/S0960-9822(00)00471-1; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; Grobet L, 1998, MAMM GENOME, V9, P210, DOI 10.1007/s003359900727; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Heller H, 2001, J BIOL CHEM, V276, P37307, DOI 10.1074/jbc.M103195200; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Hunter JG, 2001, J BIOL CHEM, V276, P38297; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; Katagiri T, 1997, EXP CELL RES, V230, P342, DOI 10.1006/excr.1996.3432; Kirk S, 2000, J CELL PHYSIOL, V184, P356, DOI 10.1002/1097-4652(200009)184:3<356::AID-JCP10>3.0.CO;2-R; Kitzmann M, 2001, CELL MOL LIFE SCI, V58, P571, DOI 10.1007/PL00000882; Kitzmann M, 1998, J CELL BIOL, V142, P1447, DOI 10.1083/jcb.142.6.1447; Kuroda K, 1999, J BIOL CHEM, V274, P7238, DOI 10.1074/jbc.274.11.7238; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MARTELLI F, 1994, ONCOGENE, V9, P3579; Massague J, 2000, GENE DEV, V14, P627; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; Megeney LA, 1995, BIOCHEM CELL BIOL, V73, P723, DOI 10.1139/o95-080; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Oldham JM, 2001, AM J PHYSIOL-REG I, V280, pR1488, DOI 10.1152/ajpregu.2001.280.5.R1488; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Reynaud EG, 2000, J BIOL CHEM, V275, P18767, DOI 10.1074/jbc.M907412199; Rios R, 2001, BIOCHEM BIOPH RES CO, V280, P561, DOI 10.1006/bbrc.2000.4159; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER MD, 1988, MOL NEUROBIOL, V2, P1, DOI 10.1007/BF02935631; Sharma M, 2001, Exerc Sport Sci Rev, V29, P155, DOI 10.1097/00003677-200110000-00004; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; Yoshida N, 1998, J CELL SCI, V111, P769; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	58	629	701	3	74	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49831	49840		10.1074/jbc.M204291200	http://dx.doi.org/10.1074/jbc.M204291200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12244043	hybrid			2022-12-27	WOS:000180028900097
J	Guo, YS; Cheng, JZ; Jin, GF; Gutkind, JS; Hellmich, MR; Townsend, CM				Guo, YS; Cheng, JZ; Jin, GF; Gutkind, JS; Hellmich, MR; Townsend, CM			Gastrin stimulates cyclooxygenase-2 expression in intestinal epithelial cells through multiple signaling pathways - Evidence for involvement of Erk5 kinase and transactivation of the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; JUN NH2-TERMINAL KINASE; COLON-CANCER-CELLS; TRANSCRIPTION FACTOR; EGF RECEPTOR; CCKB/GASTRIN RECEPTOR; INDEPENDENT PATHWAY; GENE-EXPRESSION; FACTOR-ALPHA; FACTOR-I	Gastrin is a hormone produced by G-cells in the normal gastric antrum. However, colorectal carcinoma cells may aberrantly produce gastrin and exhibit increased expression of cholecystokinin B (CCK-B)/gastrin receptors. Gastrin is trophic for the normal gastric oxyntic mucosa and exerts a growth-promoting action on gastrointestinal malignancy. Thus, gastrin may act as an autocrine/paracrine or endocrine factor in the initiation and progression of colorectal carcinoma. The molecular mechanisms involved have not been elucidated. Hypergastrinemia induced by Helicobacter pylori infection is associated with increased cyclooxygenase-2 (COX-2) expression in gastric and colorectal tissues, suggesting the possibility that gastrin up-regulates COX-2 expression in these tissues; this has not been confirmed. We report here that gastrin significantly increases the expression of COX-2 mRNA and protein, the activity of the COX-2 promoter, and the release of prostaglandin E-2 from a rat intestinal epithelial cell line transfected with the CCK-B receptor. These actions were dependent upon the activation of multiple MAPK signal pathways, including ERK5 kinase; transactivation of the epidermal growth factor receptor; and the increased expression and activities of transcription factors ELK-1, activating transcription factor-2, c-Fos, c-Jun, activator protein-1, and myocyte enhancer factor-2. Thus, our findings identify the signaling pathways coupling the CCK-B receptor with up-regulation of COX-2 expression. This effect may contribute to this hormone-dependent gastrointestinal carcinogenesis, especially in the colon.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Ophthalmol, Galveston, TX 77555 USA; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Guo, YS (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 	NIDDK NIH HHS [P01 DK35608, R01 DK48345] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558, Z01DE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035608, R01DK048345] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akagi K, 1999, BBA-MOL CELL RES, V1452, P243, DOI 10.1016/S0167-4889(99)00137-8; CICCOTOSTO GD, 1995, GASTROENTEROLOGY, V109, P1142, DOI 10.1016/0016-5085(95)90572-3; Coso OA, 1997, J BIOL CHEM, V272, P20691, DOI 10.1074/jbc.272.33.20691; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daulhac L, 1999, J BIOL CHEM, V274, P20657, DOI 10.1074/jbc.274.29.20657; Fukuhara S, 2000, J BIOL CHEM, V275, P21730, DOI 10.1074/jbc.M002410200; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; Guo Y S, 2000, J Hepatobiliary Pancreat Surg, V7, P276, DOI 10.1007/s005340070049; Guo YS, 2001, J BIOL CHEM, V276, P22941, DOI 10.1074/jbc.M101801200; GUO YS, 1990, IN VITRO CELL DEV B, V26, P871; GUO YS, 1993, GASTROENTEROLOGY, V104, P1595, DOI 10.1016/0016-5085(93)90634-O; Guo YS, 1998, J CELL PHYSIOL, V175, P141, DOI 10.1002/(SICI)1097-4652(199805)175:2<141::AID-JCP3>3.0.CO;2-O; GUO YS, 1999, GASTROINTESTINAL END; Hartwich J, 2001, Med Sci Monit, V7, P1171; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hocker M, 1997, AM J PHYSIOL-GASTR L, V272, pG822, DOI 10.1152/ajpgi.1997.272.4.G822; Hocker M, 1997, J BIOL CHEM, V272, P27015, DOI 10.1074/jbc.272.43.27015; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Konturek SJ, 2000, REGUL PEPTIDES, V93, P13, DOI 10.1016/S0167-0115(00)00173-7; Konturek SJ, 2001, PROSTAG OTH LIPID M, V66, P39, DOI 10.1016/S0090-6980(01)00142-3; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Miyazaki Y, 1999, GASTROENTEROLOGY, V116, P78, DOI 10.1016/S0016-5085(99)70231-3; Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; PENNYPACKER KR, 1994, FASEB J, V8, P475, DOI 10.1096/fasebj.8.8.8181665; PODOLSKY DK, 1993, AM J PHYSIOL, V264, P179; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; Schmitz F, 2001, EUR J CLIN INVEST, V31, P812, DOI 10.1046/j.1365-2362.2001.00870.x; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Stepan VM, 1999, AM J PHYSIOL-GASTR L, V276, pG415, DOI 10.1152/ajpgi.1999.276.2.G415; Strakova Z, 1998, AM J PHYSIOL-ENDOC M, V274, pE634, DOI 10.1152/ajpendo.1998.274.4.E634; TODISCO A, 1995, J BIOL CHEM, V270, P28337; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; UPP JR, 1989, CANCER RES, V49, P488; Varro A, 2002, GUT, V50, P827, DOI 10.1136/gut.50.6.827; Watson SA, 2000, CANCER RES, V60, P5902; Watson SA, 1999, EUR J CANCER, V35, P1286, DOI 10.1016/S0959-8049(99)00115-X; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yang TX, 2000, J BIOL CHEM, V275, P23281, DOI 10.1074/jbc.M910237199	50	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48755	48763		10.1074/jbc.M209016200	http://dx.doi.org/10.1074/jbc.M209016200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12239223	hybrid			2022-12-27	WOS:000179789600102
J	Worthington, MT; Pelo, JW; Sachedina, MA; Applegate, JL; Arseneau, KO; Pizarro, TT				Worthington, MT; Pelo, JW; Sachedina, MA; Applegate, JL; Arseneau, KO; Pizarro, TT			RNA binding properties of the AU-rich element-binding recombinant Nup475/TIS11/tristetraprolin protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MESSENGER-RNA; 3'-UNTRANSLATED REGION; POLY(A) TAIL; INTACT-CELLS; IN-VITRO; C-MYC; SEQUENCE; TRISTETRAPROLIN; EXPRESSION	Regulation of messenger RNA stability by AU-rich elements is an important means of regulating genes induced by growth factors and cytokines. Nup475 (also known as tristetraprolin, or TIS11) is the prototype for a family of zinc-binding Cys(3)His motif proteins required for proper regulation of tumor necrosis factor mRNA stability in macrophages. We developed an Escherichia coli expression system to produce soluble Nup475 protein in quantity to study its RNA binding properties. Nup475 protein bound a tumor necrosis factor AU-rich element over a broad range of pH and salt concentrations by RNA gel shift. This binding was inhibited by excess zinc metal, providing a potential mechanism for previous reports of zinc stabilization of AU-rich element (ARE) containing messenger RNAs. Immobilized Nup475 protein was used to select its optimal binding site by RNA SELEX and revealed a strong preference for the extended sequence UUAUUUALTU, rather than a simple AUUUA motif. These findings were confirmed by site-directed mutagenesis of the tumor necrosis factor ARE and RNA gel shifts on c-fos, interferon-gamma, and interferon-beta ARE fragments. A weaker binding activity toward adenine-rich sites, such as a poly(A) tail RNA fragment, can partially disrupt the Nup475-tumor necrosis factor AU-rich element complex.	Univ Virginia, Hlth Sci Ctr, Digest Hlth Ctr Excellence, Charlottesville, VA 22908 USA	University of Virginia	Worthington, MT (corresponding author), Univ Virginia, Hlth Sci Ctr, Digest Hlth Ctr Excellence, MR-4 Bldg,Rm 1036,Lane Rd, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060720, K08DK002501] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60720, DK02501] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe R, 1996, NUCLEIC ACIDS RES, V24, P4895, DOI 10.1093/nar/24.24.4895; AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; Anant S, 2000, MOL CELL BIOL, V20, P1982, DOI 10.1128/MCB.20.6.1982-1992.2000; Andrews LG, 1999, METH MOL B, V118, P233; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; DALE GE, 1994, PROTEIN ENG, V7, P925, DOI 10.1093/protein/7.7.925; Dember LM, 1996, J BIOL CHEM, V271, P2783, DOI 10.1074/jbc.271.5.2783; DRIESSEN C, 1995, IMMUNOLOGY, V84, P272; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; GRAFI G, 1993, MOL CELL BIOL, V13, P3487, DOI 10.1128/MCB.13.6.3487; Johnson BA, 2000, ONCOGENE, V19, P1657, DOI 10.1038/sj.onc.1203474; Johnson BA, 2002, J BIOL CHEM, V277, P18029, DOI 10.1074/jbc.M110465200; Katahira M, 2001, J MOL BIOL, V311, P973, DOI 10.1006/jmbi.2001.4862; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Lippard S. J., 1994, PRINCIPLES BIOINORGA; MA QF, 1991, ONCOGENE, V6, P1277; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Meerarani P, 2000, AM J CLIN NUTR, V71, P81; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; Meisenholder GW, 1996, J BIOL CHEM, V271, P16260, DOI 10.1074/jbc.271.27.16260; MESNER PW, 1995, J NEUROSCI, V15, P7357; MONIA BP, 1989, J BIOL CHEM, V264, P4093; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SAKASHITA E, 1994, NUCLEIC ACIDS RES, V22, P4082, DOI 10.1093/nar/22.20.4082; SEIDMAN CG, 1997, CURRENT PROTOCOLS MO, V1; Setzer DA, 1999, METH MOL B, V118, P115; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1995, J BIOL CHEM, V270, P13341, DOI 10.1074/jbc.270.22.13341; TAYLOR GA, 1995, J CELL PHYSIOL, V162, P378, DOI 10.1002/jcp.1041620310; Wilson GM, 2001, J BIOL CHEM, V276, P8695, DOI 10.1074/jbc.M009848200; Worthington MT, 1996, P NATL ACAD SCI USA, V93, P13754, DOI 10.1073/pnas.93.24.13754; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	40	105	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48558	48564		10.1074/jbc.M206505200	http://dx.doi.org/10.1074/jbc.M206505200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12324455	hybrid			2022-12-27	WOS:000179789600077
J	Baumann, SW; Baur, R; Sigel, E				Baumann, SW; Baur, R; Sigel, E			Forced subunit assembly in alpha(1)beta(2)gamma(2) GABA(A) receptors - Insight into the absolute arrangement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BENZODIAZEPINE BINDING-SITE; AMINOBUTYRIC ACID(A) RECEPTORS; A RECEPTORS; RAT-BRAIN; AGONIST BINDING; GAMMA(2) SUBUNIT; ALPHA-SUBUNIT; BETA-SUBUNIT; STOICHIOMETRY; SUBTYPES	The major isoform of the gamma-aminobutyric acid type A (GABA(A)) receptor is thought to be composed of 2alpha(1), 2beta(2), and 1gamma(2) subunit(s), which surround the ion pore. Definite evidence for the subunit arrangement is lacking. We show here that GABA(A) receptor subunits can be concatenated to a trimer that can be functionally expressed upon combination with a dimer. Many combinations did not result in the functional expression. In contrast, four different combinations of triple subunits with dual subunit constructs, all resulting in the identical pentameric receptor gamma(2)beta(2)alpha(1)beta(2)alpha(1), could be successfully expressed in Xenopus oocytes. We characterized the functional properties of these receptors in respect to agonist, competitive antagonist, and diazepam sensitivity. All properties were similar to those of wild type alpha(1)beta(2)gamma(2) GABA(A) receptors. Thus, together with information on the crystal structure of the homologous acetylcholine-binding protein (Brejc, K., van Dijk, W. J., Klaassen, R. V., Schuurmans, M., van Der Oost, J., Smit, A. B., and Sixma, T. K., (2001) Nature 411, 269-276, we provide evidence for an arrangement gamma(2)beta(2)alpha(1)beta(2)alpha(1), counterclockwise when viewed from the synaptic cleft. Forced subunit assembly will also allow receptors containing different subunit isoforms or mutant subunits to be expressed, each in a desired position. The methods established here should be applicable to the entire ion channel family comprising nicotinic acetylcholine, glycine, and 5HT(3) receptors.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland	University of Bern	Sigel, E (corresponding author), Univ Bern, Dept Pharmacol, Friedbuehlstr 49, CH-3010 Bern, Switzerland.		Sigel, Erwin/F-7736-2015					AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; Amin J, 1997, MOL PHARMACOL, V51, P833, DOI 10.1124/mol.51.5.833; BACKUS KH, 1993, NEUROREPORT, V5, P285, DOI 10.1097/00001756-199312000-00026; Barnard EA, 1998, PHARMACOL REV, V50, P291; Baumann SW, 2001, J BIOL CHEM, V276, P36275, DOI 10.1074/jbc.M105240200; BENKE D, 1994, J BIOL CHEM, V269, P27100; Boileau AJ, 1999, J NEUROSCI, V19, P4847; Boileau AJ, 2002, NEUROPHARMACOLOGY, V43, P695, DOI 10.1016/S0028-3908(02)00036-9; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Buhr A, 1997, MOL PHARMACOL, V52, P676, DOI 10.1124/mol.52.4.676; Buhr A, 1997, P NATL ACAD SCI USA, V94, P8824, DOI 10.1073/pnas.94.16.8824; Buhr A, 1997, J BIOL CHEM, V272, P11799, DOI 10.1074/jbc.272.18.11799; CARUNCHO HJ, 1994, RECEPTOR CHANNEL, V2, P143; Chang YC, 1996, J NEUROSCI, V16, P5415; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; Farrar SJ, 1999, J BIOL CHEM, V274, P10100, DOI 10.1074/jbc.274.15.10100; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; FRITSCHY JM, 1992, P NATL ACAD SCI USA, V89, P6726, DOI 10.1073/pnas.89.15.6726; HARING P, 1985, P NATL ACAD SCI USA, V82, P4837, DOI 10.1073/pnas.82.14.4837; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Khan ZU, 1996, J NEUROCHEM, V66, P685; Klausberger T, 2001, J BIOL CHEM, V276, P16024, DOI 10.1074/jbc.M009508200; Kuhn FJP, 1999, J GEN PHYSIOL, V114, P167, DOI 10.1085/jgp.114.2.167; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Newell JG, 2002, J BIOL CHEM, V277, P21423, DOI 10.1074/jbc.M110312200; Newell JG, 2000, J BIOL CHEM, V275, P14198, DOI 10.1074/jbc.275.19.14198; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; QUIRK K, 1994, MOL PHARMACOL, V45, P1061; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SIGEL E, 1987, J PHYSIOL-LONDON, V386, P73, DOI 10.1113/jphysiol.1987.sp016523; Sigel E, 2000, J NEUROCHEM, V74, P2590, DOI 10.1046/j.1471-4159.2000.0742590.x; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SMITH GB, 1994, J BIOL CHEM, V269, P20380; Somogyi P, 1996, NEUROPHARMACOLOGY, V35, P1425, DOI 10.1016/S0028-3908(96)00086-X; Teissere JA, 2001, J NEUROSCI, V21, P4977, DOI 10.1523/JNEUROSCI.21-14-04977.2001; Tretter V, 1997, J NEUROSCI, V17, P2728; WesthHansen SE, 1997, EUR J PHARMACOL, V329, P253, DOI 10.1016/S0014-2999(97)89186-8; Whiting PJ, 1997, J NEUROSCI, V17, P5027; Whiting PJ, 1999, ANN NY ACAD SCI, V868, P645, DOI 10.1111/j.1749-6632.1999.tb11341.x; WIELAND HA, 1992, J BIOL CHEM, V267, P1426; Wisden W, 1992, Curr Opin Neurobiol, V2, P263, DOI 10.1016/0959-4388(92)90113-Y	47	214	218	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46020	46025		10.1074/jbc.M207663200	http://dx.doi.org/10.1074/jbc.M207663200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324466	hybrid			2022-12-27	WOS:000179529300042
J	Goda, M; Hashimoto, Y; Takase, M; Herai, S; Iwahara, Y; Higashibata, H; Kobayashi, M				Goda, M; Hashimoto, Y; Takase, M; Herai, S; Iwahara, Y; Higashibata, H; Kobayashi, M			Isonitrile hydratase from Pseudomonas putida N19-2 - Cloning, sequencing, gene expression, and identification of its active amino acid residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOCOCCUS-RHODOCHROUS J1; MASS NITRILE HYDRATASE; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; INTRACELLULAR PROTEASE; ANTIMALARIAL ACTIVITY; NATURAL-PRODUCTS; MARINE SPONGES; ISOCYANIDES; PROTEINS	Isonitrile hydratase is a novel enzyme in Pseudomonas putida N19-2 that catalyzes the conversion of isonitriles to N-substituted formamides. Based on N-terminal and internal amino acid sequences, a 535-bp DNA fragment corresponding to a portion of the isonitrile hydratase gene was amplified, which was used as a probe to clone a 6.4-kb DNA fragment containing the whole gene. Sequence analysis of the 6.4-kb fragment revealed that the isonitrile hydratase gene (inhA) was 684 nucleotides long and encoded a protein with a molecular mass of 24,211 Da. Overexpression of inhA in Escherichia coli gave a large amount of soluble isonitrile hydratase exhibiting the same molecular and catalytic properties as the native enzyme from the Pseudomonas strain. The predicted amino acid sequence of inhA showed low similarity to that of an intracellular protease in Pyrococcus horikoshii (PH1704), and an active cysteine residue in the protease was conserved in the isonitrile hydratase at the corresponding position (Cys-101). A mutant enzyme containing Ala instead of Cys-101 did not exhibit isonitrile hydratase activity at all, demonstrating the essential role of this residue in the catalytic function.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan; Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan	University of Tsukuba; Kyoto University	Kobayashi, M (corresponding author), Univ Tsukuba, Inst Appl Biochem, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058572, Japan.			HIGASHIBATA, Hiroki/0000-0001-7416-5316				Abeles RH, 1992, BIOCHEMISTRY-US, P193; ACHENBAC.H, 1972, CHEM BER-RECL, V105, P784, DOI 10.1002/cber.19721050307; ACHENBACH H, 1965, Z NATURFORSCH PT B, VB 20, P137, DOI 10.1515/znb-1965-0209; ANGERHOFER CK, 1992, J NAT PROD, V55, P1787, DOI 10.1021/np50090a014; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRESON BJ, 1975, J AM CHEM SOC, V97, P4763, DOI 10.1021/ja00849a053; CAFIERI F, 1973, TETRAHEDRON, V29, P4259, DOI 10.1016/0040-4020(73)80267-4; CUNNINGHAM ID, 1991, J CHEM SOC PERK T 2, P589, DOI 10.1039/p29910000589; CUNNINGHAM ID, 1988, J CHEM SOC PERK T 2, P1485, DOI 10.1039/p29880001485; Domling A, 2000, CURR OPIN CHEM BIOL, V4, P318, DOI 10.1016/S1367-5931(00)00095-8; Domling A, 2002, CURR OPIN CHEM BIOL, V6, P306, DOI 10.1016/S1367-5931(02)00328-9; Domling A, 2000, ANGEW CHEM INT EDIT, V39, P3168, DOI 10.1002/1521-3773(20000915)39:18<3168::AID-ANIE3168>3.0.CO;2-U; DRENTH W, 1962, RECL TRAV CHIM PAY B, V81, P319; Du XL, 2000, P NATL ACAD SCI USA, V97, P14079, DOI 10.1073/pnas.260503597; EDENBOROUGH MS, 1988, NAT PROD REP, V5, P229, DOI 10.1039/np9880500229; EVANS JR, 1976, J ANTIBIOT, V29, P850, DOI 10.7164/antibiotics.29.850; Fusetani N, 1997, CURR ORG CHEM, V1, P127; Goda M, 2001, J BIOL CHEM, V276, P23480, DOI 10.1074/jbc.M007856200; HAGADONE MR, 1984, J AM CHEM SOC, V106, P2447, DOI 10.1021/ja00320a044; HAGEDORN J, 1957, PHARMAZIE, V12, P567; Halio SB, 1996, J BACTERIOL, V178, P2605, DOI 10.1128/jb.178.9.2605-2612.1996; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; KELLY M, 1967, BIOCHEM J, V102, pC1, DOI 10.1042/bj1020001C; Kobayashi M, 1998, FEBS LETT, V439, P325, DOI 10.1016/S0014-5793(98)01406-9; KOBAYASHI M, 1995, P NATL ACAD SCI USA, V92, P714, DOI 10.1073/pnas.92.3.714; Kobayashi M, 1997, P NATL ACAD SCI USA, V94, P11986, DOI 10.1073/pnas.94.22.11986; KOBAYASHI M, 1993, EUR J BIOCHEM, V217, P327, DOI 10.1111/j.1432-1033.1993.tb18250.x; Kobayashi M, 1999, EUR J BIOCHEM, V261, P1, DOI 10.1046/j.1432-1327.1999.00186.x; KOBAYASHI M, 1993, P NATL ACAD SCI USA, V90, P247, DOI 10.1073/pnas.90.1.247; KOBAYASHI M, 1992, J BIOL CHEM, V267, P20746; Kobayashi M, 1998, NAT BIOTECHNOL, V16, P733, DOI 10.1038/nbt0898-733; KOBAYASHI M, 1992, TRENDS BIOTECHNOL, V10, P402, DOI 10.1016/0167-7799(92)90283-2; KOBAYASHI M, 1994, FEMS MICROBIOL LETT, V120, P217, DOI 10.1016/0378-1097(94)90474-X; Komeda H, 1996, P NATL ACAD SCI USA, V93, P4267, DOI 10.1073/pnas.93.9.4267; Komeda H, 1996, J BIOL CHEM, V271, P15796, DOI 10.1074/jbc.271.26.15796; Komeda H, 1996, P NATL ACAD SCI USA, V93, P10572, DOI 10.1073/pnas.93.20.10572; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mizote T, 1996, MICROBIOL-UK, V142, P2969, DOI 10.1099/13500872-142-10-2969; Mizote T, 1999, MICROBIOL-UK, V145, P495, DOI 10.1099/13500872-145-2-495; NELSON CA, 1971, J BIOL CHEM, V246, P3895; PFEIFER S, 1972, PHARMAZIE, V27, P536; Pogulis R J, 1996, Methods Mol Biol, V57, P167; RUBINSON JF, 1983, BIOCHEMISTRY-US, V22, P6260, DOI 10.1021/bi00295a034; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHEUER PJ, 1992, ACCOUNTS CHEM RES, V25, P433, DOI 10.1021/ar00022a001; Wright AD, 2001, J MED CHEM, V44, P873, DOI 10.1021/jm0010724; Yamada H, 1996, BIOSCI BIOTECH BIOCH, V60, P1391, DOI 10.1271/bbb.60.1391	48	31	33	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45860	45865		10.1074/jbc.M208571200	http://dx.doi.org/10.1074/jbc.M208571200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244065	Green Submitted, hybrid			2022-12-27	WOS:000179529300020
J	Ray, BK; Murphy, R; Ray, P; Ray, A				Ray, BK; Murphy, R; Ray, P; Ray, A			SAF-2, a splice variant of SAF-1, acts as a negative regulator of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-AMYLOID-A; ZINC-FINGER PROTEIN; PRE-MESSENGER-RNA; SEQUENCE-BINDING-FACTOR; GENE-EXPRESSION; MONOCYTE/MACROPHAGE CELLS; ACTIVATING FACTOR; PROMOTER; MAZ; MYC	Serum amyloid A-activating factor-1 (SAF-1), a Cys(2)His(2)-type zinc finger transcription factor, regulates inflammation-induced expression of serum amyloid A protein that is linked to the pathogenesis of reactive amyloidosis, rheumatoid arthritis, and atherosclerosis. Here we report the identification of a novel splice variant, SAF-2, of the SAF family bearing strong sequence similarity to SAF-1. The N-terminal 426 amino acids of both SAF-1 and SAF-2 are identical containing two polyalanine tracts, one proline-rich domain, and six zinc fingers. However, the C terminus of SAF-2 containing two additional zinc fingers is different from SAF-1, which indicates the capability of different biochemical function. We show that SAF-2 interacts more avidly with the SAF-binding element, but its transactivation potential is much lower than SAF-1. Furthermore, co-expression of SAF-2 markedly suppresses SAF-1-regulated promoter function. Finally, we show that the level of SAF-2 protein is reduced during many inflammatory conditions, whereas the SAF-1 protein level remains unchanged. Together, these data suggest that the relative abundance of SAF-2 plays a critical role in the fine tuned regulation of inflammation-responsive genes that are controlled by SAF-1.	Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Ray, BK (corresponding author), Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049205] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK49205] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cote J, 2001, J BIOL CHEM, V276, P8535, DOI 10.1074/jbc.M008924200; Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Hanke J, 1999, TRENDS GENET, V15, P389, DOI 10.1016/S0168-9525(99)01830-2; Her S, 1999, J BIOL CHEM, V274, P8698, DOI 10.1074/jbc.274.13.8698; Hewitt SM, 1996, J BIOL CHEM, V271, P8588, DOI 10.1074/jbc.271.15.8588; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; Kosaki A, 1998, J BIOL CHEM, V273, P10331, DOI 10.1074/jbc.273.17.10331; Ladd AN, 2001, MOL CELL BIOL, V21, P1285, DOI 10.1128/MCB.21.4.1285-1296.2001; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Lou H, 1999, MOL CELL BIOL, V19, P78; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; Parks CL, 1996, J BIOL CHEM, V271, P4417; Ray A, 1999, J BIOL CHEM, V274, P4300, DOI 10.1074/jbc.274.7.4300; Ray A, 1998, MOL CELL BIOL, V18, P7327, DOI 10.1128/MCB.18.12.7327; Ray A, 2002, MOL CELL BIOL, V22, P1027, DOI 10.1128/MCB.22.4.1027-1035.2002; Ray A, 2000, J IMMUNOL, V165, P3411, DOI 10.4049/jimmunol.165.6.3411; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; Ray A, 1996, MOL CELL BIOL, V16, P1584; Ray A, 2000, J BIOL CHEM, V275, P39727, DOI 10.1074/jbc.M007907200; Ray BK, 1997, J BIOL CHEM, V272, P28948, DOI 10.1074/jbc.272.46.28948; Ray BK, 2001, J IMMUNOL, V167, P2343, DOI 10.4049/jimmunol.167.4.2343; Ray BK, 1997, BIOCHEMISTRY-US, V36, P4662, DOI 10.1021/bi9624595; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Shepard J, 2002, MOL CELL BIOL, V22, P221, DOI 10.1128/MCB.22.1.221-230.2002; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; Song J, 1998, J BIOL CHEM, V273, P20603, DOI 10.1074/jbc.273.32.20603; Uchida S, 2000, MOL CELL BIOL, V20, P7319, DOI 10.1128/MCB.20.19.7319-7331.2000; Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432-1327.1999.00657.x; Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X; WANG Z, 1995, RNA, V1, P21	43	12	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46822	46830		10.1074/jbc.M206299200	http://dx.doi.org/10.1074/jbc.M206299200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270922	hybrid			2022-12-27	WOS:000179529300143
J	Rottgers, K; Zufall, N; Guiard, B; Voos, W				Rottgers, K; Zufall, N; Guiard, B; Voos, W			The ClpB homolog Hsp78 is required for the efficient degradation of proteins in the mitochondrial matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; INACTIVATED PROTEINS; REGULATORY SUBUNITS; CHAPERONE SYSTEM; PIM1 PROTEASE; AAA PROTEASE; PROTEOLYSIS	Molecular chaperones perform vital functions in mitochondrial protein import and folding. In yeast mitochondria, two members of the Clp/Hsp100 chaperone family, Hsp78 and Mcx1, have been identified as homologs of the bacterial proteins ClpB and ClpX, respectively. In this report we employed a novel quantitative assay system to assess the role of Hsp78 and Mcx1 in protein degradation within the matrix. Mitochondria were preloaded with large amounts of two purified recombinant reporter proteins exhibiting different folding stabilities. Proteolysis of the imported substrate proteins depended on the mitochondrial level of ATP and was mediated by the matrix protease Pim1/LON. Degradation rates were found to be independent of the folding stability of the reporter proteins. Mitochondria from hsp78Delta cells exhibited a significant defect in the degradation efficiency of both substrates even at low temperature whereas mcx1Delta mitochondria showed wild-type activity. The proteolysis defect in hsp78Delta mitochondria was independent from the aggregation behavior of the substrate proteins. We conclude that Hsp78 is a genuine component of the mitochondrial proteolysis system required for the efficient degradation of substrate proteins in the matrix.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Univ Freiburg, Fak Biol, D-79104 Freiburg, Germany; Univ Paris 06, CNRS, Ctr Genet Mol, F-91190 Gif Sur Yvette, France	University of Freiburg; University of Freiburg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	Voos, W (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str, D-79104 Freiburg, Germany.	wolfgang.voos@biochemie.uni-freiburg.de						Adams A, 1997, METHODS YEAST GENETI; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; BLACKSCHAEFER CL, 1991, BIOCHEM J, V274, P199, DOI 10.1042/bj2740199; Bomer U, 1997, EMBO J, V16, P2205, DOI 10.1093/emboj/16.9.2205; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Halperin T, 2001, PLANT MOL BIOL, V45, P461, DOI 10.1023/A:1010677220323; Kang SG, 2002, J BIOL CHEM, V277, P21095, DOI 10.1074/jbc.M201642200; Konieczny I, 2002, J BIOL CHEM, V277, P18483, DOI 10.1074/jbc.M107580200; Krzewska J, 2001, FEBS LETT, V489, P92, DOI 10.1016/S0014-5793(00)02423-6; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; LEONHARDT SA, 1993, MOL CELL BIOL, V13, P6304, DOI 10.1128/MCB.13.10.6304; Lim JH, 2001, EMBO J, V20, P941, DOI 10.1093/emboj/20.5.941; MOCZKO M, 1995, J MOL BIOL, V254, P538, DOI 10.1006/jmbi.1995.0636; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Rep M, 1996, CURR GENET, V30, P367, DOI 10.1007/s002940050145; Ryan MT, 2001, METHOD CELL BIOL, V65, P189, DOI 10.1016/S0091-679X(01)65012-X; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Savel'ev AS, 1998, J BIOL CHEM, V273, P20596, DOI 10.1074/jbc.273.32.20596; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schmid B, 1996, FEBS LETT, V381, P111, DOI 10.1016/0014-5793(96)00080-4; Schmitt M, 1996, J CELL BIOL, V134, P1375, DOI 10.1083/jcb.134.6.1375; SCHMITT M, 1995, EMBO J, V14, P3434, DOI 10.1002/j.1460-2075.1995.tb07349.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; Tomoyasu T, 2001, MOL MICROBIOL, V40, P397, DOI 10.1046/j.1365-2958.2001.02383.x; van Dijl JM, 1998, P NATL ACAD SCI USA, V95, P10584, DOI 10.1073/pnas.95.18.10584; van Dyck L, 1998, FEBS LETT, V438, P250, DOI 10.1016/S0014-5793(98)01310-6; van Melderen L, 1999, P NATL ACAD SCI USA, V96, P6064, DOI 10.1073/pnas.96.11.6064; VANDYCK L, 1994, J BIOL CHEM, V269, P238; VESTWEBER D, 1988, EMBO J, V7, P1147, DOI 10.1002/j.1460-2075.1988.tb02924.x; von Ahsen O, 2000, J MOL BIOL, V297, P809, DOI 10.1006/jmbi.2000.3574; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; Watanabe YH, 2000, J BIOL CHEM, V275, P12388, DOI 10.1074/jbc.275.17.12388; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x; WOO KM, 1992, J BIOL CHEM, V267, P20429; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	49	52	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45829	45837		10.1074/jbc.M207152200	http://dx.doi.org/10.1074/jbc.M207152200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237310	hybrid			2022-12-27	WOS:000179529300016
J	van der Wel, H; Fisher, SZ; West, CM				van der Wel, H; Fisher, SZ; West, CM			A bifunctional diglycosyltransferase forms the Fuc alpha 1,2Gal,beta 1,3-disaccharide on Skp1 in the cytoplasm of Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPORE COAT; GLYCOSYLTRANSFERASES; GLYCOSYLATION; SYNTHASE; IDENTIFICATION; BIOSYNTHESIS; DISCOIDEUM; RESIDUES; FP21	Skp1 is a subunit of the Skp1 cullin-1 F-box protein (SCF) family of E3 ubiquitin ligases and of other regulatory complexes in the cytoplasm and nucleus. In Dictyostelium, Skp1 is modified by a pentasaccharide with the type I blood group H antigen (Fucalpha1,2Galbeta1,3GlcNAc-) at its core. Addition of the Fuc is catalyzed by FT85, a 768-amino acid protein whose fucosyltransferase activity maps to the C-terminal half of the protein. A strain whose FT85 gene is interrupted by a genetic insertion produces a truncated, GlcNAc-terminated glycan on Skp1, suggesting that FT85 may also have beta-galactosyltransferase activity. In support of this model, highly purified native and recombinant FT85 are each able to galactosylate Skp1 from FT85 mutant cells. Site-directed mutagenesis of predicted key amino acids in the N-terminal region of FT85 abolishes Skp1 beta-galactosyltransferase activity with minimal effects on the fucosyltransferase. In addition, a recombinant form of the N-terminal region exhibits beta-galactosyltransferase but not fucosyltransferase activity. Kinetic analysis of FT85 suggests that its two glycosyltransferase activities normally modify Skp1 processively but can have partial function individually. In conclusion, FT85 is a bifunctional diglycosyltransferase that appears to be designed to efficiently extend the Skp1 glycan in vivo.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	West, CM (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, 1600 SW Archer Rd, Gainesville, FL 32610 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037539] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM37539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARONDES SH, 1987, METHOD CELL BIOL, V28, P387; DeAngelis PL, 2002, GLYCOBIOLOGY, V12, p9R, DOI 10.1093/glycob/12.1.9R; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Garinot-Schneider C, 2000, J BIOL CHEM, V275, P31407, DOI 10.1074/jbc.M004524200; Gentzsch M, 1995, FEBS LETT, V377, P128, DOI 10.1016/0014-5793(95)01324-5; GONZALEZYANES B, 1989, DEV BIOL, V133, P576, DOI 10.1016/0012-1606(89)90060-2; Guan S, 2001, J BACTERIOL, V183, P3318, DOI 10.1128/JB.183.11.3318-3327.2001; Hassan H, 2000, J BIOL CHEM, V275, P38197, DOI 10.1074/jbc.M005783200; Heldermon C, 2001, J BIOL CHEM, V276, P2037, DOI 10.1074/jbc.M002276200; Jorasch P, 2000, EUR J BIOCHEM, V267, P3770, DOI 10.1046/j.1432-1327.2000.01414.x; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Marks DL, 2001, J BIOL CHEM, V276, P26492, DOI 10.1074/jbc.M102612200; Munro S, 2001, FEBS LETT, V498, P223, DOI 10.1016/S0014-5793(01)02488-7; Reiber DC, 1998, ANAL CHEM, V70, P1214, DOI 10.1021/ac971158d; Sassi S, 2001, GLYCOBIOLOGY, V11, P283, DOI 10.1093/glycob/11.4.283; Saxena IM, 2001, PHYTOCHEMISTRY, V57, P1135, DOI 10.1016/S0031-9422(01)00048-6; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; Tarbouriech N, 2001, J MOL BIOL, V314, P655, DOI 10.1006/jmbi.2001.5159; Teng-umnuay P, 1998, J BIOL CHEM, V273, P18242, DOI 10.1074/jbc.273.29.18242; van der Wel H, 2002, J BIOL CHEM, V277, P46328, DOI 10.1074/jbc.M208024200; van der Wel H, 2001, J BIOL CHEM, V276, P33952, DOI 10.1074/jbc.M102555200; West CM, 2002, GLYCOBIOLOGY, V12, p17R, DOI 10.1093/glycob/12.2.17R; West CM, 1996, J BIOL CHEM, V271, P12024, DOI 10.1074/jbc.271.20.12024; West CM, 1997, GENE, V200, P1, DOI 10.1016/S0378-1119(97)00194-7; WEST CM, 2002, IN PRESS CELL MOL LI; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	28	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46527	46534		10.1074/jbc.M208824200	http://dx.doi.org/10.1074/jbc.M208824200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244067	hybrid			2022-12-27	WOS:000179529300107
J	McPherson, LA; Loktev, AV; Weigel, RJ				McPherson, LA; Loktev, AV; Weigel, RJ			Tumor suppressor activity of AP2 alpha mediated through a direct interaction with p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; HUMAN BREAST-CANCER; ESTROGEN-RECEPTOR-ALPHA; DNA-DAMAGE; PROTEIN EXPRESSION; PROGNOSTIC FACTORS; MAMMARY-CARCINOMA; FACTOR FAMILY; CELL-GROWTH; IN-VIVO	The AP2 transcription factor family is a set of developmentally regulated, retinoic acid inducible genes composed of four related factors, AP2alpha, AP2beta, AP2gamma, and AP2delta. AP2 factors orchestrate a variety of cell processes including apoptosis, cell growth, and tissue differentiation during embryogenesis. In studies of primary malignancies, AP2alpha has been shown to function as a tumor suppressor in breast cancer, colon cancer, and malignant melanoma. In cell culture models, overexpression of AP2alpha inhibits cell division and stable colony formation, whereas, a dominant-negative AP2alpha mutant increases invasiveness and tumorigenicity. Here we show that AP2alpha targets the p53 tumor suppressor protein. Studies with chromatin immunoprecipitation demonstrate that AP2alpha is brought to p53 binding sites in p53-regulated promoters. The interaction between AP2alpha and p53 augments p53-mediated transcriptional activation, which results in up-regulation of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). AP2alpha is able to induce G(1) and G(2) cell cycle arrest only in the presence of wild-type p53. Thus, we conclude that the tumor suppressor activity of AP2alpha is mediated through a direct interaction with p53. These results also provide a mechanism to explain patterns of gene expression in cancers where AP2alpha is known to function as a tumor suppressor.	Stanford Univ, Dept Surg, Stanford, CA 94305 USA; Thomas Jefferson Univ, Dept Surg, Philadelphia, PA 19107 USA	Stanford University; Jefferson University	Weigel, RJ (corresponding author), 1025 Walnut St,Suite 605, Philadelphia, PA 19107 USA.			Weigel, Ronald/0000-0002-9249-0793	NCI NIH HHS [R01 CA77350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldi A, 2001, J CELL BIOCHEM, V83, P364, DOI 10.1002/jcb.1235; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Bar-Eli M, 1999, CANCER METAST REV, V18, P377, DOI 10.1023/A:1006377309524; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARBARESCHI M, 1992, AM J CLIN PATHOL, V98, P408, DOI 10.1093/ajcp/98.4.408; BHARGAVA V, 1994, MODERN PATHOL, V7, P361; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; CHARPIN C, 1995, HUM PATHOL, V26, P159, DOI 10.1016/0046-8177(95)90032-2; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; IWAYA K, 1991, JPN J CANCER RES, V82, P835, DOI 10.1111/j.1349-7006.1991.tb02710.x; JAY G, 1981, P NATL ACAD SCI-BIOL, V78, P2932, DOI 10.1073/pnas.78.5.2932; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LiCalsi C, 2000, NUCLEIC ACIDS RES, V28, P1036, DOI 10.1093/nar/28.4.1036; MACGROGAN G, 1995, BREAST CANCER RES TR, V36, P71, DOI 10.1007/BF00690187; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARTINAZZI M, 1993, AM J CLIN PATHOL, V100, P213, DOI 10.1093/ajcp/100.3.213; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; MOSER M, 1995, DEVELOPMENT, V121, P2779; Newman SP, 2000, ONCOGENE, V19, P490, DOI 10.1038/sj.onc.1203416; Nottoli T, 1998, P NATL ACAD SCI USA, V95, P13714, DOI 10.1073/pnas.95.23.13714; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OSTROWSKI JL, 1991, J PATHOL, V164, P75, DOI 10.1002/path.1711640113; Perissi V, 2000, ONCOGENE, V19, P280, DOI 10.1038/sj.onc.1203303; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; POLLER DN, 1992, BRIT J CANCER, V66, P583, DOI 10.1038/bjc.1992.318; Ropponen KM, 2001, J CLIN PATHOL, V54, P533, DOI 10.1136/jcp.54.7.533; Ropponen KM, 1999, BRIT J CANCER, V81, P133, DOI 10.1038/sj.bjc.6690662; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; Schuur ER, 2001, J BIOL CHEM, V276, P15519, DOI 10.1074/jbc.M009001200; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; STENMARKASKMALM M, 1994, EUR J CANCER, V30A, P175, DOI 10.1016/0959-8049(94)90082-5; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; Turner BC, 1998, CANCER RES, V58, P5466; WALDMAN T, 1995, CANCER RES, V55, P5187; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; West-Mays JA, 1999, DEV BIOL, V206, P46, DOI 10.1006/dbio.1998.9132; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200	59	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45028	45033		10.1074/jbc.M208924200	http://dx.doi.org/10.1074/jbc.M208924200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12226108	hybrid			2022-12-27	WOS:000179404800057
J	Zhang, XH; Gan, LX; Pan, HY; Guo, SD; He, XW; Olson, ST; Mesecar, A; Adam, S; Unterman, TG				Zhang, XH; Gan, LX; Pan, HY; Guo, SD; He, XW; Olson, ST; Mesecar, A; Adam, S; Unterman, TG			Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms - Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; PROTEIN-KINASE-B; INSULIN-RESPONSE SEQUENCE; GENE-EXPRESSION; FAMILY MEMBER; PHOSPHOENOLPYRUVATE CARBOXYKINASE; CAENORHABDITIS-ELEGANS; PROMOTER ACTIVITY; FACTOR AFX; DAF-16	FKHR is a member of the FOXO subfamily of Forkhead transcription factors, which are important targets for insulin and growth factor signaling. FKHR contains three predicted protein kinase B phosphorylation sites (Thr-24, Ser-256, and Ser-319) that are conserved in other FOXO proteins. We have reported that phosphorylation of Ser-256 is critical for the ability of insulin and insulin-like growth factors to suppress transactivation by FKHR (Guo, S., Rena, G., Cichy, S., He, X., Cohen, P., and Unterman, T. (1999) J. Biol. Chem. 274, 17184-17192) and for its exclusion from the nucleus (Rena, G., Prescott, A. R., Guo, S., Cohen, P., and Unterman, T. G. (2001) Biochem. J. 354, 605-612). Ser-256 is located in a basic region of the FKHR DNA binding domain where phosphorylation may have direct effects on DNA binding and/or nuclear targeting. Phosphorylation of Ser-256 may also be required for the phosphorylation of Thr-24 and Ser-319. Here, we provide the first direct evidence that basic residues in the FKHR DNA binding domain are critical for DNA binding and that Ser-256 phosphorylation alters binding activity. Ser-256 phosphorylation also is critical for regulating nuclear/cytoplasmic trafficking; however, this effect requires Thr-24/Ser-319 phosphorylation. Transient transfection studies with reporter gene constructs in 293 cells reveal that the phosphorylation of Ser-256 can inhibit the function of FKHR independent of Thr-24/Ser-319 phosphorylation. Studies with GFP(1) fusion proteins indicate that Ser-256 phosphorylation is critical for nuclear exclusion of FKHR. However, this effect is disrupted when Thr-24 and Ser-319 are replaced by alanine, indicating that nuclear exclusion of FKHR also requires Thr-24/Ser-319 phosphorylation. Gel shift and fluorescence anisotropy studies reveal that basic residues at the C-terminal end of the FKHR DBD are important for DNA binding, and the introduction of a negative charge at the site of Ser-256 limits binding activity. Binding is rapid and reversible, providing an opportunity for the phosphorylation of Ser-256 and subsequent phosphorylation of Thr-24 and Ser-319 and nuclear exclusion of FKHR.	VA Chicago Hlth Care Syst, W Side Div, Med Res Unit, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Physiol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Biophys, Chicago, IL 60612 USA; Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA; Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Ctr Pharmaceut Biotechnol, Chicago, IL 60612 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Northwestern University	Unterman, TG (corresponding author), VA Chicago Hlth Care Syst, W Side Div, Med Res Unit, Rm 6229,MP 151,820 S Damien Ave, Chicago, IL 60612 USA.			Mesecar, Andrew/0000-0002-1241-2577; Adam, Stephen/0000-0003-3444-7655	NCI NIH HHS [CA92744-01] Funding Source: Medline; NHLBI NIH HHS [HL-39888] Funding Source: Medline; NIDDK NIH HHS [DK-41430] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA092744] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039888, R37HL039888, R29HL039888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041430, R29DK041430] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam SA, 1999, CURR OPIN CELL BIOL, V11, P402, DOI 10.1016/S0955-0674(99)80056-8; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Biggs WH, 2001, MAMM GENOME, V12, P416, DOI 10.1007/s003350020002; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Deleage G, 2001, COMPUT BIOL MED, V31, P259, DOI 10.1016/S0010-4825(01)00008-7; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GOSWAMI R, 1994, ENDOCRINOLOGY, V134, P2531; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Nakae J, 2001, BIOCHEMISTRY-US, V40, P11768, DOI 10.1021/bi015532m; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; Yang ZY, 2002, J BIOL CHEM, V277, P8068, DOI 10.1074/jbc.M106091200; Yeagley D, 2001, J BIOL CHEM, V276, P33705, DOI 10.1074/jbc.M101215200	43	248	258	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45276	45284		10.1074/jbc.M208063200	http://dx.doi.org/10.1074/jbc.M208063200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228231	hybrid			2022-12-27	WOS:000179404800088
J	Gerbod-Giannone, MC; del Castillo-Olivares, A; Janciauskiene, S; Gil, G; Hylemon, PB				Gerbod-Giannone, MC; del Castillo-Olivares, A; Janciauskiene, S; Gil, G; Hylemon, PB			Suppression of cholesterol 7 alpha-hydroxylase transcription and bile acid synthesis by an alpha(1)-antitrypsin peptide via interaction with alpha(1)-fetoprotein transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME COMPLEX RECEPTOR; ADULT-RAT-HEPATOCYTES; AMYLOID-BETA PEPTIDE; ACUTE-PHASE RESPONSE; HUMAN HEPATOMA-CELLS; STEROL 12-ALPHA-HYDROXYLASE; NUCLEAR RECEPTORS; POTENTIAL ROLE; MESSENGER-RNA; ALPHA-1-ANTITRYPSIN	alpha(1)-Antitrypsin (alpha(1)-AT) is a serum protease inhibitor that is synthesized mainly in the liver, and its rate of synthesis markedly increases in response to inflammation. This increase in alpha(1)-AT synthesis results in an increase in peptides, like its carboxyl-terminal C-36 peptide (C-36), resulting from alpha(1)-AT cleavage by proteases. Atherosclerosis is a form of chronic inflammation, and one of the risk factors is elevated plasma cholesterol levels. Because of the correlation between atherosclerosis, plasma cholesterol content, inflammation, and alpha(1)-AT rate of synthesis, we investigated the effect of the C-36 serpin peptide on hepatic bile acid biosynthesis. We discovered that C-36 is a powerful and specific transcriptional down-regulator of bile acid synthesis in primary rat hepatocytes, through inhibition of the cholesterol 7alpha-hydroxylase/CYP7A1 (7alpha-hydroxylase) promoter. Mice injected with the C-36 peptide also showed a decrease in 7alpha-hydroxylase mRNA. A mutated but very similar peptide did not have any effect on 7alpha-hydroxylase mRNA or its promoter. The sterol 12alpha-hydroxylase/ CYP8B1 (12alpha-hydroxylase) promoter is also down-regulated by the C-36 peptide in HepG2 cells but not by the mutated peptide. The DNA element involved in the C-36-mediated regulation of 7alpha- and 12a-hydroxylase promoters mapped to the alpha(1)-fetoprotein transcription factor (FTF) site in both promoters. The C-36 peptide prevented binding of FTF to its target DNA recognition site by direct interaction with FTF. We hypothesize that the C-36 peptide specifically interacts with FTF and induces a conformational change that results in loss of its DNA binding ability, which results in suppression of 7alpha- and 12alpha-hydroxylase transcription. These results suggest that peptides derived from specific serum proteins may alter hepatic gene expression in a highly specific manner.	Virginia Commonwealth Univ, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Microbiol & Immunol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Univ Hosp, Dept Med, S-20502 Malmo, Sweden	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Lund University; Skane University Hospital	Gil, G (corresponding author), Virginia Commonwealth Univ, Dept Biochem & Mol Biophys, Med Coll Virginia Campus, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038030, R01DK057543] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38030, DK-57543] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bissell D M, 1980, Ann N Y Acad Sci, V349, P85, DOI 10.1111/j.1749-6632.1980.tb29518.x; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CABANA VG, 1989, J LIPID RES, V30, P39; COMMITTEE NRN, 1999, CELL, V97, P161; Crestani M, 1998, J LIPID RES, V39, P2192; del Castill-Olivares A, 2002, J BIOL CHEM, V277, P6750, DOI 10.1074/jbc.M106785200; del Castillo-Olivares A, 2000, J BIOL CHEM, V275, P17793, DOI 10.1074/jbc.M000996200; del Castillo-Olivares A, 2000, NUCLEIC ACIDS RES, V28, P3587; del Castillo-Olivares A, 2001, NUCLEIC ACIDS RES, V29, P4035, DOI 10.1093/nar/29.19.4035; DESROCHERS PE, 1992, J BIOL CHEM, V267, P5005; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINGOLD KR, 1993, J LIPID RES, V34, P2147; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; GALLOWAY MJ, 1985, THROMB RES, V38, P311, DOI 10.1016/0049-3848(85)90131-8; Glass CK, 2000, GENE DEV, V14, P121; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Hardardottir Ingibjorg, 1994, Current Opinion in Lipidology, V5, P207, DOI 10.1097/00041433-199405030-00008; HEUMAN DM, 1989, J LIPID RES, V30, P1161; HOLLANDER W, 1979, ATHEROSCLEROSIS, V34, P391, DOI 10.1016/0021-9150(79)90064-9; HYLEMON PB, 1992, J BIOL CHEM, V267, P16866; HYLEMON PB, 1985, J BIOL CHEM, V260, P1015; JAVITT NB, 1994, FASEB J, V8, P1308, DOI 10.1096/fasebj.8.15.8001744; JOHANSSON J, 1992, FEBS LETT, V299, P146, DOI 10.1016/0014-5793(92)80234-8; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; JOSLIN G, 1993, J BIOL CHEM, V268, P1886; JOSLIN G, 1991, J BIOL CHEM, V266, P21897; JOSLIN G, 1992, J CLIN INVEST, V90, P1150, DOI 10.1172/JCI115934; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; MACKIEWICZ A, 1993, ACUTE PHASE PROTEINS, P3; Memon RA, 2001, J BIOL CHEM, V276, P30118, DOI 10.1074/jbc.M102516200; Miyake JH, 2000, J BIOL CHEM, V275, P21805, DOI 10.1074/jbc.C000275200; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PERLMUTTER DH, 1989, J CLIN INVEST, V84, P138, DOI 10.1172/JCI114133; POLLER W, 1995, J BIOL CHEM, V270, P2841, DOI 10.1074/jbc.270.6.2841; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Rubin H, 1996, NAT MED, V2, P632, DOI 10.1038/nm0696-632; SHAW R, 1979, J BIOL CHEM, V254, P7177; STRAVITZ RT, 1996, AM J PHYSIOL, V271, P293; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Vlahcevic ZR, 2000, GASTROENTEROLOGY, V118, P599, DOI 10.1016/S0016-5085(00)70267-8; Whisstock JC, 2000, J MOL BIOL, V295, P651, DOI 10.1006/jmbi.1999.3375; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200	44	27	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42973	42980		10.1074/jbc.M205089200	http://dx.doi.org/10.1074/jbc.M205089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12223476	hybrid			2022-12-27	WOS:000179081200072
J	Prosise, GL; Wu, JZ; Luecke, H				Prosise, GL; Wu, JZ; Luecke, H			Crystal structure of Tritrichomonas foetus inosine monophosphate dehydrogenase in complex with the inhibitor ribavirin monophosphate reveals a catalysis-dependent ion-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; FETUS INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE; 5'-MONOPHOSPHATE DEHYDROGENASE; ESCHERICHIA-COLI; KINETIC MECHANISM; MYCOPHENOLIC-ACID; PROTEIN; EXPRESSION; PURIFICATION; RESOLUTION	Inosine monophosphate dehydrogenase (IMPDH) catalyzes the rate-limiting step in GMP biosynthesis. The resulting intracellular pool of guanine nucleotides is of great importance to all cells for use in DNA and RNA synthesis, metabolism, and signal transduction. The enzyme binds IMP and the cofactor NAD(+) in random order, IMP is converted to XMP, NAD(+) is reduced to NADH, and finally, NADH and then XMP are released sequentially. XMP is subsequently converted into GMP by GMP synthetase. Drugs that decrease GMP synthesis by inhibiting IMPDH have been shown to have antiproliferative as well as antiviral activity. Several drugs are in use that target the substrate- or cofactor-binding site; however, due to differences between the mammalian and microbial isoforms, most drugs are far less effective against the microbial form of the enzyme than the mammalian form. The high resolution crystal structures of the protozoan parasite Tritrichomonas foetus IMPDH complexed with the inhibitor ribavirin monophosphate as well as monophosphate together with a second inhibitor, mycophenolic acid, are presented here. These structures reveal an active site cation identified previously only in the Chinese hamster IMPDH structure with covalently bound IMP. This cation was not found previously in apo IMPDH, IMPDH in complex with XMP, or covalently bound inhibitor,indicating that the cation-binding site may be catalysis-dependent. A comparison of T. foetus IMPDH with the Chinese hamster and Streptococcus pyogenes structures reveals differences in the active site loop architecture, which contributes to differences in cation binding during the catalytic sequence and the kinetic rates between bacterial, protozoan, and mammalian enzymes. Exploitation of these differences may lead to novel inhibitors, which favor the microbial form of the enzyme.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Ribapharm, Costa Mesa, CA 92626 USA	University of California System; University of California Irvine	Luecke, H (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	hudel@uci.edu	Luecke, Hartmut/F-4712-2012	Luecke, Hartmut/0000-0002-4938-0775	NIGMS NIH HHS [R01-GM56445] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056445] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; BECK JT, 1994, EXP PARASITOL, V78, P101, DOI 10.1006/expr.1994.1010; Bowne SJ, 2002, HUM MOL GENET, V11, P559, DOI 10.1093/hmg/11.5.559; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHIN MS, 1994, MOL BIOCHEM PARASIT, V63, P221, DOI 10.1016/0166-6851(94)90058-2; Colby TD, 1999, P NATL ACAD SCI USA, V96, P3531, DOI 10.1073/pnas.96.7.3531; CRAIG SP, 1991, P NATL ACAD SCI USA, V88, P2500, DOI 10.1073/pnas.88.6.2500; Digits JA, 2000, BIOCHEMISTRY-US, V39, P1771, DOI 10.1021/bi992288e; Digits JA, 1999, BIOCHEMISTRY-US, V38, P2295, DOI 10.1021/bi982305k; Felleisen RSJ, 1999, MICROBES INFECT, V1, P807, DOI 10.1016/S1286-4579(99)80083-5; FRANKLIN TJ, 1969, BIOCHEM J, V113, P515, DOI 10.1042/bj1130515; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAGER PW, 1995, BIOCHEM PHARMACOL, V49, P1323, DOI 10.1016/0006-2952(95)00026-V; HEDSTROM L, 1990, BIOCHEMISTRY-US, V29, P849, DOI 10.1021/bi00456a001; Hubbard S. J., 1993, NACCESS; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kerr KM, 2000, ARCH BIOCHEM BIOPHYS, V375, P131, DOI 10.1006/abbi.1999.1644; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEVINE ND, 1973, PROTOZOAN PARASITES, P89; Markham GD, 1999, BIOCHEMISTRY-US, V38, P4433, DOI 10.1021/bi9829579; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McMillan FM, 2000, BIOCHEMISTRY-US, V39, P4533, DOI 10.1021/bi992645l; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Nimmesgern E, 1999, PROTEIN EXPRES PURIF, V17, P282, DOI 10.1006/prep.1999.1136; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Sintchak M. D., 1999, ANTIVIR RES, V41, pA56; Sintchak MD, 1996, CELL, V85, P921, DOI 10.1016/S0092-8674(00)81275-1; Speer C. A., 1991, Large Animal Veterinarian, V46, P18; STEHLE T, 1991, J MOL BIOL, V221, P1325, DOI 10.1016/0022-2836(91)90936-Z; STREETER DG, 1973, P NATL ACAD SCI USA, V70, P1174, DOI 10.1073/pnas.70.4.1174; VERHAM R, 1987, MOL BIOCHEM PARASIT, V24, P1, DOI 10.1016/0166-6851(87)90110-1; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang W, 1997, BIOCHEMISTRY-US, V36, P8479, DOI 10.1021/bi970226n; Whitby FG, 1997, BIOCHEMISTRY-US, V36, P10666, DOI 10.1021/bi9708850; Whitby FG, 1995, PROTEINS, V23, P598, DOI 10.1002/prot.340230417; YUAN L, 1990, J BIOL CHEM, V265, P13528; YULE A, 1989, PARASITOL TODAY, V5, P373, DOI 10.1016/0169-4758(89)90298-6; Zhang RG, 1999, BIOCHEMISTRY-US, V38, P4691, DOI 10.1021/bi982858v	38	33	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50654	50659		10.1074/jbc.M208330200	http://dx.doi.org/10.1074/jbc.M208330200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12235158	hybrid			2022-12-27	WOS:000180177700061
J	Kitazono, AA; Kron, SJ				Kitazono, AA; Kron, SJ			An essential function of yeast cyclin-dependent kinase Cdc28 maintains chromosome stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE ASSEMBLY CHECKPOINT; CDK-ACTIVATING KINASE; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; PROTEIN-KINASE; BUDDING YEAST; MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURE; GENE CDC28; COMPLEX	Multiple surveillance pathways maintain genomic integrity in yeast during mitosis. Although the cyclin-dependent kinase Cdc28 is a well established regulator of mitotic progression, evidence for a direct role in mitotic surveillance has been lacking. We have now implicated a conserved sequence in the Cdc28 carboxyl terminus in maintaining chromosome stability through mitosis. Six temperature-sensitive mutants were isolated via random mutagenesis of 13 carboxyl-terminal residues. These mutants identify a Cdc28 domain necessary for proper mitotic arrest in the face of kinetochore defects or microtubule inhibitors. These chromosome stability-defective cdc28(CST) mutants inappropriately continue mitosis when the mitotic spindle is disrupted at 23 degreesC, display high rates of spontaneous chromosome loss at 30 degreesC, and suffer catastrophic aneuploidy at 35 degreesC. A dosage suppression screen identified Cak1, a kinase known to phosphorylate and activate Cdc28, as a specific high copy suppressor of cdc28(CST) temperature sensitivity and chromosome instability. Suppression is independent of the kinase activity of Cak1, suggesting that Cak1 may bind to the carboxyl terminus to serve a non-catalytic role in assembly and/or stabilization of active Cdc28 complexes. Significantly, these studies implicate Cdc28 and Cak1 in an essential surveillance function required to maintain genetic stability through mitosis.	Univ Chicago, Ctr Mol Oncol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Kron, SJ (corresponding author), Univ Chicago, Ctr Mol Oncol, 924 E 57th St,Rm R322, Chicago, IL 60637 USA.			Kron, Stephen/0000-0003-1518-2436; Kitazono, Ana/0000-0002-6924-1799	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060443] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM60443] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; Chun KT, 1997, MOL GEN GENET, V256, P365, DOI 10.1007/s004380050580; DEVIN AB, 1990, YEAST, V6, P231, DOI 10.1002/yea.320060308; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gorbsky GJ, 2001, CURR BIOL, V11, pR1001, DOI 10.1016/S0960-9822(01)00609-1; GUTHRIE C, 1991, GUIDE YEAST MOL GENE, V194; HARTWELL LH, 1985, GENETICS, V110, P381; Hoyt MA, 2001, J CELL BIOL, V154, P909, DOI 10.1083/jcb.200108010; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Kitazono AA, 2002, YEAST, V19, P141, DOI 10.1002/yea.806; KOSHLAND D, 1987, METHOD ENZYMOL, V155, P351; KOUPRINA N, 1993, YEAST, V9, P11, DOI 10.1002/yea.320090103; Li XR, 1997, MOL CELL BIOL, V17, P2723, DOI 10.1128/MCB.17.5.2723; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LORINCZ AT, 1986, MOL CELL BIOL, V6, P4099; MACNEILL SA, 1991, MOL GEN GENET, V229, P109, DOI 10.1007/BF00264219; Mendenhall MD, 1998, MICROBIOL MOL BIOL R, V62, P1191, DOI 10.1128/MMBR.62.4.1191-1243.1998; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; Ouspenski II, 1999, NUCLEIC ACIDS RES, V27, P3001, DOI 10.1093/nar/27.15.3001; Pangilinan F, 1996, MOL BIOL CELL, V7, P1195, DOI 10.1091/mbc.7.8.1195; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Russell ID, 1999, J CELL BIOL, V145, P933, DOI 10.1083/jcb.145.5.933; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Skibbens RV, 1998, ANNU REV GENET, V32, P307, DOI 10.1146/annurev.genet.32.1.307; Song HW, 2001, MOL CELL, V7, P615, DOI 10.1016/S1097-2765(01)00208-8; SPENCER F, 1990, GENETICS, V124, P237; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; Straight AF, 1997, METHOD ENZYMOL, V283, P425; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TENNISON CMV, 1998, TECHNICAL TIPS LINE; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; Wagner M, 1997, EMBO J, V16, P1305, DOI 10.1093/emboj/16.6.1305; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Yu YX, 1996, MOL CELL BIOL, V16, P5254	40	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48627	48634		10.1074/jbc.M207247200	http://dx.doi.org/10.1074/jbc.M207247200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12359726	hybrid			2022-12-27	WOS:000179789600086
J	Choi, HK; Park, NY; Kim, DI; Chung, HJ; Ryu, S; Choi, SH				Choi, HK; Park, NY; Kim, DI; Chung, HJ; Ryu, S; Choi, SH			Promoter analysis and regulatory characteristics of vvhBA encoding cytolytic hemolysin of Vibrio vulnificus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RECEPTOR PROTEIN; CYCLIC-AMP; CHOLERA-TOXIN; EXTRACELLULAR CYTOLYSIN; PHENOTYPIC EVALUATION; ELASTOLYTIC PROTEASE; ESCHERICHIA-COLI; ACTIVATOR TOXR; GENE; EXPRESSION	Cytolytic hemolysin, a gene product of vvhA, is a putative virulence factor of the pathogenic bacterium Vibrio vulnificus. We have previously shown that hemolysin production is repressed by adding glucose to culture media and that production can be restored by adding cAMP. In this study, hemolysin activity and the level of vvh transcript were determined to reach a maximum in late exponential phase and were repressed when cells entered stationary phase. Northern blot and primer extension analyses revealed that vvhA is cotranscribed with a second gene, vvhB, located upstream of vvhA. Transcription of the vvhBA operon begins at a single site and is under the direction of a single promoter, P-vvh. A crp null mutation decreased hemolysin production and the level of vvhBA transcript by reducing the activity of P-vvh, indicating that the P-vvh activity is under the positive control of cAMP receptor protein (CRP). A direct interaction between CRP and the regulatory region of the vvhBA operon was demonstrated by gel-mobility shift assays. The CRP binding site, centered at 59.5 bp upstream of the transcription start site, was mapped by deletion analysis of the vvhBA promoter region and confirmed by DNase I protection assays. These results demonstrate that the vvhBA expression is activated by CRP in a growth-dependent manner and that CRP exerts its effects by directly binding to DNA upstream of P-vvh.	Chonnam Natl Univ, Dept Food Sci & Technol, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Mol Biotechnol, Kwangju 500757, South Korea; Chonnam Natl Univ, Inst Biotechnol, Kwangju 500757, South Korea; Seoul Natl Univ, Sch Agr Biotechnol, Dept Food Sci & Technol, Suwon 441744, South Korea	Chonnam National University; Chonnam National University; Chonnam National University; Seoul National University (SNU)	Choi, SH (corresponding author), Chonnam Natl Univ, Dept Food Sci & Technol, Kwangju 500757, South Korea.			Choi, Sang Ho/0000-0003-3865-1039				Bang YB, 1999, J BACTERIOL, V181, P7639, DOI 10.1128/JB.181.24.7639-7642.1999; BLAKE PA, 1980, ANNU REV MICROBIOL, V34, P341, DOI 10.1146/annurev.mi.34.100180.002013; BOTSFORD JL, 1992, MICROBIOL REV, V56, P100, DOI 10.1128/MMBR.56.1.100-122.1992; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CURTISS R, 1987, INFECT IMMUN, V55, P386; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; Gonzalez-Gil G, 1998, EMBO J, V17, P2877, DOI 10.1093/emboj/17.10.2877; GRAY LD, 1985, INFECT IMMUN, V48, P62, DOI 10.1128/IAI.48.1.62-72.1985; HIGGINS DE, 1994, MOL MICROBIOL, V14, P17, DOI 10.1111/j.1365-2958.1994.tb01263.x; Higgins DE, 1996, J BACTERIOL, V178, P1080, DOI 10.1128/jb.178.4.1080-1087.1996; Jeong HS, 2001, J BIOL CHEM, V276, P13875, DOI 10.1074/jbc.M010567200; Jeong KC, 2000, INFECT IMMUN, V68, P5096, DOI 10.1128/IAI.68.9.5096-5106.2000; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Kim SY, 1999, J BIOL CHEM, V274, P25398, DOI 10.1074/jbc.274.36.25398; KLONTZ KC, 1988, ANN INTERN MED, V109, P318, DOI 10.7326/0003-4819-109-4-318; KOTHARY MH, 1987, J GEN MICROBIOL, V133, P1783; KREGER A, 1981, INFECT IMMUN, V33, P583, DOI 10.1128/IAI.33.2.583-590.1981; Lee SE, 2000, J BACTERIOL, V182, P3405, DOI 10.1128/JB.182.12.3405-3415.2000; Linkous DA, 1999, FEMS MICROBIOL LETT, V174, P207, DOI 10.1111/j.1574-6968.1999.tb13570.x; MILLER VL, 1987, CELL, V48, P271, DOI 10.1016/0092-8674(87)90430-2; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Nagai S, 1998, VET MICROBIOL, V60, P227, DOI 10.1016/S0378-1135(98)00144-8; OBYRNE CP, 1994, J BACTERIOL, V176, P905, DOI 10.1128/jb.176.3.905-912.1994; Pfau JD, 1996, MOL MICROBIOL, V20, P213, DOI 10.1111/j.1365-2958.1996.tb02502.x; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SHINODA S, 1985, MICROBIOL IMMUNOL, V29, P583, DOI 10.1111/j.1348-0421.1985.tb00862.x; Skorupski K, 1997, P NATL ACAD SCI USA, V94, P265, DOI 10.1073/pnas.94.1.265; TACKET CO, 1984, J INFECT DIS, V149, P558, DOI 10.1093/infdis/149.4.558; TESTA J, 1984, INFECT IMMUN, V45, P458, DOI 10.1128/IAI.45.2.458-463.1984; WRIGHT AC, 1991, INFECT IMMUN, V59, P192, DOI 10.1128/IAI.59.1.192-197.1991; WRIGHT AC, 1990, INFECT IMMUN, V58, P1769, DOI 10.1128/IAI.58.6.1769-1773.1990; WRIGHT AC, 1985, INFECT IMMUN, V50, P922, DOI 10.1128/IAI.50.3.922-924.1985; YAMAMOTO K, 1990, INFECT IMMUN, V58, P2706, DOI 10.1128/IAI.58.8.2706-2709.1990; YAMANAKA H, 1987, FEMS MICROBIOL LETT, V44, P253	34	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47292	47299		10.1074/jbc.M206893200	http://dx.doi.org/10.1074/jbc.M206893200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356775	hybrid			2022-12-27	WOS:000179663700059
J	Ko, BCB; Lam, AKM; Kapus, A; Fan, LZ; Chung, SK; Chung, SSM				Ko, BCB; Lam, AKM; Kapus, A; Fan, LZ; Chung, SK; Chung, SSM			Fyn and p38 signaling are both required for maximal hypertonic activation of the osmotic response element-binding protein/tonicity-responsive enhancer-binding protein (OREBP/TonEBP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDOSE REDUCTASE GENE; TYROSINE PHOSPHORYLATION; STIMULATES TRANSCRIPTION; INOSITOL COTRANSPORTER; KIDNEY-CELLS; 3T3 CELLS; KINASE; STRESS; SRC; YEAST	When cells are challenged by hyperosmotic stress, one of the crucial adaptive responses is the expression of osmoprotective genes that are responsible for raising the intracellular level of compatible osmolytes such as sorbitol, betaine, and myo-inositol. This is achieved by the activation of the transcription factor called OREBP (also known as TonEBP or NFAT5) that specifically binds to the osmotic response element (ORE) or tonicity-responsive enhancer that enhances the transcription of these genes. Here we show that p38, a subgroup of the mitogen-activated kinases activated by hypertonic stress, and Fyn, a shrinkage-activated tyrosine kinase, are both involved in the hypertonic activation of OREBP/TonEBP. Inhibition of p38 by SB203580 or by the dominant negative p38 mutant partially blocked the hypertonic induction of ORE reporter (reporter gene regulated by ORE). Similarly, hypertonic activation of ORE reporter was partially blocked by pharmacological inhibition of Fyn or by a dominant negative Fyn and was attenuated in Fyn-deficient cells. Importantly, inhibiting p38 in Fyn-deficient cells almost completely abolished the hypertonic induction of ORE reporter activity, indicating that p38 and Fyn are the major signaling pathways for the hypertonic activation of OREBP/TonEBP. Further we show that the transactivation domain of OREBP/TonEBP is the target of p38- and Fyn-mediated hypertonic activation. These results indicate a dual control in regulating the expression of the osmoprotective genes in mammalian cells.	Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Inst Mol Technol Drug Discovery & Synth, Open Lab Chem Biol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; Toronto Gen Hosp, Dept Surg, Toronto, ON M5G 1L7, Canada; Univ Toronto, Toronto, ON M5G 1L7, Canada	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto	Ko, BCB (corresponding author), Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China.		Ko, Chi-bun/ACH-7514-2022	Ko, Ben Chi Bun/0000-0003-2027-5899				Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; Alepuz PM, 2001, MOL CELL, V7, P767, DOI 10.1016/S1097-2765(01)00221-0; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Dahl SC, 2001, AM J PHYSIOL-CELL PH, V280, pC248, DOI 10.1152/ajpcell.2001.280.2.C248; Denkert C, 1998, ARCH BIOCHEM BIOPHYS, V354, P172, DOI 10.1006/abbi.1998.0661; Ferraris JD, 2002, P NATL ACAD SCI USA, V99, P739, DOI 10.1073/pnas.241637298; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Haussinger D, 1999, BIOCHEM BIOPH RES CO, V255, P551, DOI 10.1006/bbrc.1998.9946; Ishino M, 2000, FEBS LETT, V474, P179, DOI 10.1016/S0014-5793(00)01597-0; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; Ko BCB, 2000, BIOCHEM BIOPH RES CO, V270, P52, DOI 10.1006/bbrc.2000.2376; Ko BCB, 1997, J BIOL CHEM, V272, P16431, DOI 10.1074/jbc.272.26.16431; Kultz D, 1997, J BIOL CHEM, V272, P13165, DOI 10.1074/jbc.272.20.13165; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Ohmiya R, 1995, MOL MICROBIOL, V18, P963, DOI 10.1111/j.1365-2958.1995.18050963.x; Pahlman AK, 2001, J BIOL CHEM, V276, P3555, DOI 10.1074/jbc.M007164200; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; Rim JS, 1998, J BIOL CHEM, V273, P20615, DOI 10.1074/jbc.273.32.20615; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; Szaszi K, 1997, J BIOL CHEM, V272, P16670, DOI 10.1074/jbc.272.26.16670; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; UCHIDA S, 1993, J CLIN INVEST, V91, P1604, DOI 10.1172/JCI116367; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; YAMAUCHI A, 1993, AM J PHYSIOL, V264, pF20, DOI 10.1152/ajprenal.1993.264.1.F20; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	37	117	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46085	46092		10.1074/jbc.M208138200	http://dx.doi.org/10.1074/jbc.M208138200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12359721	hybrid			2022-12-27	WOS:000179529300051
J	Lloyd, JA; Forget, AL; Knight, KL				Lloyd, JA; Forget, AL; Knight, KL			Correlation of biochemical properties with the oligomeric state of human Rad52 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS RECOMBINATION; DNA; REPAIR; VISUALIZATION; MEDIATOR; BINDING; COMPLEX; RPA	The human Rad52 protein self-associates to form ring-shaped oligonters, as well as higher order complexes of these rings. We have shown previously that there are two experimentally separable self-association domains in HsRad52, one in the N terminus (residues 1-192) responsible for assembly of individual subunits into rings, and one in the C terminus (residues 218-418) responsible for higher order oligomerization of rings. Earlier studies suggest that the higher order complexes promote DNA end-joining, and others suggest that these complexes are relevant to in vivo Rad52 function. In this study we demonstrate that although inherent binding to single-stranded DNA depends on neither higher order complexes of Rad52 rings nor the ring-shaped oligomers themselves, higher order complexes are important for activities involving simultaneous interaction with more than one DNA molecule. This provides biochemical support for what may be an important in vivo function of Rad52.	Univ Massachusetts, Sch Med, Depb Biochem & Mol Pharmacol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Knight, KL (corresponding author), Univ Massachusetts, Sch Med, Depb Biochem & Mol Pharmacol, Aaron Lazare Med Res Bldg,364 Plantat St, Worcester, MA 01655 USA.	kendall.knight@umassmed.edu			NIGMS NIH HHS [GM44772] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Essers J, 2002, EMBO J, V21, P2030, DOI 10.1093/emboj/21.8.2030; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0027-5107(74)90176-6; Hays SL, 1998, MOL CELL BIOL, V18, P4400, DOI 10.1128/MCB.18.7.4400; Kagawa W, 2002, MOL CELL, V10, P359, DOI 10.1016/S1097-2765(02)00587-7; Kagawa W, 2001, J BIOL CHEM, V276, P35201, DOI 10.1074/jbc.M104938200; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Kito K, 1999, BBA-GENE STRUCT EXPR, V1489, P303, DOI 10.1016/S0167-4781(99)00214-6; Lisby M, 2001, P NATL ACAD SCI USA, V98, P8276, DOI 10.1073/pnas.121006298; Liu YL, 2000, EMBO REP, V1, P85, DOI 10.1093/embo-reports/kvd002; Liu YL, 1999, CURR BIOL, V9, P975, DOI 10.1016/S0960-9822(99)80427-8; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Ranatunga W, 2001, J BIOL CHEM, V276, P15876, DOI 10.1074/jbc.M011747200; Reddy G, 1997, MUTAT RES-FUND MOL M, V377, P53, DOI 10.1016/S0027-5107(97)00057-2; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Song BW, 2000, J BIOL CHEM, V275, P15895, DOI 10.1074/jbc.M910244199; Sonoda E, 2001, P NATL ACAD SCI USA, V98, P8388, DOI 10.1073/pnas.111006398; Stasiak AZ, 2000, CURR BIOL, V10, P337, DOI 10.1016/S0960-9822(00)00385-7; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Van Dyck E, 1998, J MOL BIOL, V284, P1027, DOI 10.1006/jmbi.1998.2203; Van Dyck E, 2001, EMBO REP, V2, P905, DOI 10.1093/embo-reports/kve201; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049	32	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46172	46178		10.1074/jbc.M207262200	http://dx.doi.org/10.1074/jbc.M207262200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12226092	hybrid			2022-12-27	WOS:000179529300063
J	Roudier, N; Ripoche, P; Gane, P; Le Pennec, PY; Daniels, G; Cartron, JP; Bailly, P				Roudier, N; Ripoche, P; Gane, P; Le Pennec, PY; Daniels, G; Cartron, JP; Bailly, P			AQP3 deficiency in humans and the molecular basis of a novel blood group system, GIL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AQUAPORIN WATER CHANNELS; KIDNEY COLLECTING DUCT; ATOMIC-STRUCTURE; GLYCEROL; EXPRESSION; PERMEABILITY; MEMBRANE; CLONING; CHIP; PROTEIN	AQP3 is a water and glycerol channel present on human erythrocytes and in various tissues. By protein and molecular biology analysis, two unrelated probands who developed alloantibodies to the high frequency antigen GIL were found to be AQP3-deficient. The defect is caused by homozygous mutation affecting the 5' donor splice site of intron 5 of the AQP3 gene. This mutation causes the skipping of exon 5 and generates a frameshift and premature stop codon. Functional studies by 90degrees light scattering using a stopped-flow spectrometer revealed the absence of facilitated glycerol transport across red cell membranes from the probands, but the water and urea transports were normal. Expression studies into COS-7 cells followed by flow cytometry analysis showed that only cells transfected with AQP3 cDNA strongly reacted with anti-GIL antibodies. These findings represent the first reported cases of AQP3 deficiency in humans and provide the molecular basis of a new blood group system, GIL, encoded by the AQP3 protein.	Inst Natl Transfus Sanguine, INSERM, U76, F-75015 Paris, France; Bristol Inst Transfus Sci, Bristol BS10 5ND, Avon, England	Institut National de la Sante et de la Recherche Medicale (Inserm)	Cartron, JP (corresponding author), Inst Natl Transfus Sanguine, INSERM, U76, 6 Rue Alexandre Cabanel, F-75015 Paris, France.	cartron@idf.inserm.fr						Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; AGRE P, 1995, TRANSFUS CLIN BIOL, V2, P303, DOI 10.1016/S1246-7820(05)80096-5; CARLSEN A, 1976, ACTA PHYSIOL SCAND, V97, P501, DOI 10.1111/j.1748-1716.1976.tb10290.x; Daniels G L, 1998, Immunohematology, V14, P49; de Baey A, 2000, J EXP MED, V191, P743, DOI 10.1084/jem.191.4.743; DENKER BM, 1988, J BIOL CHEM, V263, P15634; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; Hermand P, 2000, J BIOL CHEM, V275, P26002, DOI 10.1074/jbc.M002823200; Heymann JB, 1999, NEWS PHYSIOL SCI, V14, P187; INASE N, 1995, J BIOL CHEM, V270, P17913, DOI 10.1074/jbc.270.30.17913; ISHIBASHI K, 1995, GENOMICS, V27, P352, DOI 10.1006/geno.1995.1055; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; King LS, 2001, NEW ENGL J MED, V345, P175, DOI 10.1056/NEJM200107193450304; King LS, 2002, P NATL ACAD SCI USA, V99, P1059, DOI 10.1073/pnas.022626499; Kozono D, 2002, J CLIN INVEST, V109, P1395, DOI 10.1172/JCI200215851; LAIZE V, 1995, FEBS LETT, V373, P269, DOI 10.1016/0014-5793(95)01060-R; LIN ECC, 1977, ANNU REV BIOCHEM, V46, P765, DOI 10.1146/annurev.bi.46.070177.004001; LOZANO ME, 1993, TRENDS GENET, V9, P296, DOI 10.1016/0168-9525(93)90237-C; Ma TH, 2002, J BIOL CHEM, V277, P17147, DOI 10.1074/jbc.M200925200; MA TH, 1994, J BIOL CHEM, V269, P21845; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; Mathai JC, 1996, J BIOL CHEM, V271, P1309, DOI 10.1074/jbc.271.3.1309; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; Roudier N, 2002, J BIOL CHEM, V277, P7664, DOI 10.1074/jbc.M105411200; Roudier N, 1998, J BIOL CHEM, V273, P8407, DOI 10.1074/jbc.273.14.8407; SMITH BL, 1994, J CLIN INVEST, V94, P1043, DOI 10.1172/JCI117418; Steck T L, 1974, Methods Enzymol, V31, P172; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13, DOI 10.1152/ajprenal.2000.278.1.F13; Yang BX, 2001, J BIOL CHEM, V276, P624, DOI 10.1074/jbc.M008664200	33	67	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45854	45859		10.1074/jbc.M208999200	http://dx.doi.org/10.1074/jbc.M208999200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12239222	hybrid			2022-12-27	WOS:000179529300019
J	Sandowski, Y; Raver, N; Gussakovsky, EE; Shochat, S; Dym, O; Livnah, O; Rubinstein, M; Krishna, R; Gertler, A				Sandowski, Y; Raver, N; Gussakovsky, EE; Shochat, S; Dym, O; Livnah, O; Rubinstein, M; Krishna, R; Gertler, A			Subcloning, expression, purification, and characterization of recombinant human leptin-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR EXTRACELLULAR DOMAIN; PROTEIN SECONDARY STRUCTURE; HUMAN GROWTH-HORMONE; PROLACTIN RECEPTOR; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MAMMARY-GLAND; OBESE GENE; CHICKEN; BOVINE	A subdomain of the human leptin receptor encoding part of the extracellular domain (amino acids 428 to 635) was subcloned, expressed in a prokaryotic host, and purified to homogeneity, as evidenced by SDS-PAGE, with over 95% monomeric protein. The purified leptin-binding domain (LBD) exhibited the predicted beta structure, was capable of binding human, ovine, and chicken leptins, and formed a stable 1:1 complex with all mammalian leptins. The binding kinetics, assayed by surface plasmon resonance methodology, showed respective k(on) and k(off) values (mean +/- S.E.) of 1.20 +/- 0.23 X 10(-5) mol(-1) ks(-1) and 1.85 +/- 0.30 x 10(-3) s(-1) and a K-d value of 1.54 X 10(-8) m. Similar results were achieved with conventional binding experiments. LBD blocked leptin-induced, but not interieukin-3-induced, proliferation of BAF/3 cells stably transfected with the long form of human leptin receptor. The modeled LBD structure and the known three-dimensional structure of human leptin were used to construct a model of 1:1 LBD-human leptin complex. Two main residues, Phe-500, located in loop L3, and Tyr-441, located in L1, are suggested to contribute to leptin binding.	Hebrew Univ Jerusalem, Inst Biochem Food Sci & Nutr, Fac Agr Food & Environm Qual Sci, IL-76100 Rehovot, Israel; Bar Ilan Univ, Dept Life Sci, IL-52900 Ramat Gan, Israel; Agr Res Org, Volcani Ctr, Inst Hort, IL-50250 Bet Dagan, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Fac Life Sci, IL-91904 Jerusalem, Israel; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Diagnost Syst Labs, Webster, TX 77598 USA	Hebrew University of Jerusalem; Bar Ilan University; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; Hebrew University of Jerusalem; Weizmann Institute of Science	Gertler, A (corresponding author), Hebrew Univ Jerusalem, Inst Biochem Food Sci & Nutr, Fac Agr Food & Environm Qual Sci, IL-76100 Rehovot, Israel.	gertler@agri-huji.ac.il	Gussakovsky, Eugene/W-2706-2019					Almog B, 2001, MOL CELL ENDOCRINOL, V183, P179, DOI 10.1016/S0303-7207(01)00543-3; [Anonymous], 1996, CIRCULAR DICHROISM C; AUTHOR A, 1994, GRAPHPAD PRISM VERSI; Barkan D, 1999, ENDOCRINOLOGY, V140, P1731, DOI 10.1210/en.140.4.1731; Barnes PJ, 2002, ANNU REV PHARMACOL, V42, P81, DOI 10.1146/annurev.pharmtox.42.111901.111143; BAUMGARTNER JW, 1994, J BIOL CHEM, V269, P29094; BIGNON C, 1994, J BIOL CHEM, V269, P3318; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campfield LA, 1998, P NUTR SOC, V57, P429, DOI 10.1079/PNS19980062; Campfield LA, 2000, FRONT HORM RES, V26, P12; Campfield LA, 1996, HORM METAB RES, V28, P619, DOI 10.1055/s-2007-979867; Chehab FF, 2000, TRENDS PHARMACOL SCI, V21, P309, DOI 10.1016/S0165-6147(00)01514-5; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Cohen B, 2001, J BIOL CHEM, V276, P7697, DOI 10.1074/jbc.C000634200; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Devos R, 1997, J BIOL CHEM, V272, P18304, DOI 10.1074/jbc.272.29.18304; DRIDI S, 2002, AM J PHYSIOL-ENDOC M, V279, pE116; Elkins PA, 2000, NAT STRUCT BIOL, V7, P808, DOI 10.1038/79047; Fong TM, 1998, MOL PHARMACOL, V53, P234, DOI 10.1124/mol.53.2.234; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; GERTLER A, 1984, MOL CELL ENDOCRINOL, V34, P51, DOI 10.1016/0303-7207(84)90158-8; Gertler A, 1998, FEBS LETT, V422, P137, DOI 10.1016/S0014-5793(97)01613-X; GOA J, 1953, SCAND J CLIN LAB INV, V5, P218, DOI 10.3109/00365515309094189; Haniu M, 1998, J BIOL CHEM, V273, P28691, DOI 10.1074/jbc.273.44.28691; Houseknecht KL, 1996, DIABETES, V45, P1638, DOI 10.2337/diabetes.45.11.1638; Houseknecht KL, 1998, J ANIM SCI, V76, P1405; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leupen SM, 1997, ENDOCRINOLOGY, V138, P2735, DOI 10.1210/en.138.7.2735; Liu CL, 1997, ENDOCRINOLOGY, V138, P3548, DOI 10.1210/en.138.8.3548; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LOFAS S, 1990, J CHEM SOC CHEM COMM, P1526, DOI 10.1039/c39900001526; Luoh SM, 1997, J MOL ENDOCRINOL, V18, P77, DOI 10.1677/jme.0.0180077; Maamra M, 2001, ENDOCRINOLOGY, V142, P4389, DOI 10.1210/en.142.10.4389; Morrison CD, 2001, J ENDOCRINOL, V168, P317, DOI 10.1677/joe.0.1680317; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Raver N, 1998, PROTEIN EXPRES PURIF, V14, P403, DOI 10.1006/prep.1998.0975; Raver N, 2002, GEN COMP ENDOCR, V126, P52, DOI 10.1006/gcen.2001.7766; Raver N, 2000, PROTEIN EXPRES PURIF, V19, P30, DOI 10.1006/prep.2000.1202; Rock FL, 1996, HORM METAB RES, V28, P748, DOI 10.1055/s-2007-979892; Roh SG, 2001, ENDOCRINOLOGY, V142, P5167, DOI 10.1210/en.142.12.5167; SANDOWSKI Y, 1995, MOL CELL ENDOCRINOL, V115, P1, DOI 10.1016/0303-7207(95)03664-S; Sandowski Y, 2000, GEN COMP ENDOCR, V118, P302, DOI 10.1006/gcen.2000.7465; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Sinha MK, 1996, J CLIN INVEST, V98, P1277, DOI 10.1172/JCI118913; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Spicer LJ, 1998, BIOL REPROD, V58, P207, DOI 10.1095/biolreprod58.1.207; Sporri B, 2001, CYTOKINE GROWTH F R, V12, P27, DOI 10.1016/S1359-6101(00)00020-4; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Taouis M, 2001, DOMEST ANIM ENDOCRIN, V21, P319, DOI 10.1016/S0739-7240(01)00122-9; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TCHELET A, 1995, J ENDOCRINOL, V144, P393, DOI 10.1677/joe.0.1440393; Verploegen SABW, 1997, FEBS LETT, V405, P237, DOI 10.1016/S0014-5793(97)00192-0; Wu ZD, 2002, J CLIN ENDOCR METAB, V87, P2931, DOI 10.1210/jc.87.6.2931; Zhang FM, 1997, NATURE, V387, P206, DOI 10.1038/387206a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	59	50	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46304	46309		10.1074/jbc.M207556200	http://dx.doi.org/10.1074/jbc.M207556200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12226096	hybrid			2022-12-27	WOS:000179529300080
J	Sastry, MSR; Korotkov, K; Brodsky, Y; Baneyx, F				Sastry, MSR; Korotkov, K; Brodsky, Y; Baneyx, F			Hsp31, the Escherichia coli yedU gene product, is a molecular chaperone whose activity is inhibited by ATP at high temperatures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ALPHA-B-CRYSTALLIN; EXPRESSION; SEQUENCE; CLPB; AGGREGATION; NETWORK; K-12; DNAK; IBPB	The Escherichia coli chromosome contains several uncharacterized heat-inducible loci that may encode novel molecular chaperones or proteases. Here we show that the 31-kDa product of the yedU gene is an efficient homodimeric molecular chaperone that is conserved in a number of pathogenic eubacteria and fungi. Heat shock protein (Hsp) 31 relies on temperature-driven conformational changes to expose structured hydrophobic domains that are likely responsible for substrate binding. Complementing the function of refolding, remodeling, and holding chaperones, Hsp 31 preferentially interacts with early unfolding intermediates and rapidly releases them in an active form after transfer to low temperatures. Although Hsp 31 does not appear to exhibit intrinsic ATPase activity, binding of ATP at high temperatures restricts the size or availability of the substrate binding site, thereby modulating chaperone activity. The possible role of ATP in coordinating the function of the cellular complement of molecular chaperones is discussed.	Univ Washington, Dept Chem Engn, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Baneyx, F (corresponding author), Univ Washington, Dept Chem Engn, Box 351750, Seattle, WA 98195 USA.			Korotkov, Konstantin/0000-0002-2182-6843				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CANNON DJ, 1969, BIOCHEM BIOPH RES CO, V35, P403, DOI 10.1016/0006-291X(69)90513-0; Chevalier M, 1998, METHOD ENZYMOL, V290, P384, DOI 10.1016/S0076-6879(98)90033-7; Du XL, 2000, P NATL ACAD SCI USA, V97, P14079, DOI 10.1073/pnas.260503597; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FINDLY RC, 1983, SCIENCE, V219, P1223, DOI 10.1126/science.6828852; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Gross CA, 1996, ESCHERICHIA COLI SAL, P1382; Halio SB, 1996, J BACTERIOL, V178, P2605, DOI 10.1128/jb.178.9.2605-2612.1996; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Korber P, 2000, EMBO J, V19, P741, DOI 10.1093/emboj/19.4.741; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Lund PA, 2001, ADV MICROB PHYSIOL, V44, P93, DOI 10.1016/S0065-2911(01)44012-4; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Muchowski PJ, 1999, J BIOL CHEM, V274, P30190, DOI 10.1074/jbc.274.42.30190; Muchowski PJ, 1998, P NATL ACAD SCI USA, V95, P1004, DOI 10.1073/pnas.95.3.1004; NABERHAUS F, 2002, MICROBIOL MOL BIOL R, V66, P64; Richmond CS, 1999, NUCLEIC ACIDS RES, V27, P3821, DOI 10.1093/nar/27.19.3821; Shearstone JR, 1999, J BIOL CHEM, V274, P9937, DOI 10.1074/jbc.274.15.9937; SINGH M, 1970, J BIOL CHEM, V245, P4636; Smykal P, 2000, PLANT J, V23, P703, DOI 10.1046/j.1365-313x.2000.00837.x; SRERE PA, 1966, J BIOL CHEM, V241, P2157; Thirumalai D, 2001, ANNU REV BIOPH BIOM, V30, P245, DOI 10.1146/annurev.biophys.30.1.245; Thomas JG, 2000, MOL MICROBIOL, V36, P1360, DOI 10.1046/j.1365-2958.2000.01951.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VALLEE BL, 1955, P NATL ACAD SCI USA, V41, P327, DOI 10.1073/pnas.41.6.327; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; YOSHIDA T, 1993, MOL GEN GENET, V237, P113, DOI 10.1007/BF00282791; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	33	69	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46026	46034		10.1074/jbc.M205800200	http://dx.doi.org/10.1074/jbc.M205800200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235139	hybrid			2022-12-27	WOS:000179529300043
J	Song, JJ; Rhee, JG; Suntharalingam, M; Walsh, SA; Spitz, DR; Lee, YJ				Song, JJ; Rhee, JG; Suntharalingam, M; Walsh, SA; Spitz, DR; Lee, YJ			Role of glutaredoxin in metabolic oxidative stress - Glutaredoxin as a sensor of oxidative stress mediated by H2O2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THIOLTRANSFERASE GLUTAREDOXIN; CEREBELLAR GRANULE NEURONS; DOPAMINE-INDUCED APOPTOSIS; KINASE 1 ASK1; NF-KAPPA-B; GLUCOSE DEPRIVATION; INTERACTING PROTEIN; SIGNAL-TRANSDUCTION; CELL-GROWTH; ACTIVATION	Epitope-tagged glutaredoxin (GRX) was utilized to determine the role of GRX in oxidative stress-induced signaling and cytotoxicity in glucose-deprived human cancer cells (MCF-7/ADR and DU-145). GRX-overexpressing cells demonstrated resistance to glucose deprivation-induced cytotoxicity and decreased activation of c-Jun N-terminal kinase (JNK1). Deletion mutants showed the C-terminal portion of apoptosis signal-regulating kinase 1 (ASK1) bound GRX, and glucose deprivation disrupted binding. Treatment with L-buthionine-(S,R)-sulfoximine reduced glutathione content by 99% and prevented glucose deprivation-induced dissociation of GRX from ASK1. A thiol antioxidant, N-acetyl-L-cysteine, or overexpression of an H2O2 scavenger, catalase, inhibited glucose deprivation-induced dissociation of GPX from ASK1. GRX active site cysteine residues (Cys(22) and Cys(25)) were required for dissociation of GPX from ASK1 during glucose deprivation. Kinase assays revealed that SEK1 and JNK1 were regulated in an ASK1-dependent fashion during glucose deprivation. Overexpression of GRX or catalase inhibited activation of ASK1-SEK1-JNK1 signaling during glucose deprivation. These results demonstrate that GRX is a negative regulator of ASK1 and dissociation of GRX from ASK1 activates ASK1-SEK1-JNK1 signaling leading to cytotoxicity during glucose deprivation. These results support the hypothesis that the GRX-ASK1 interaction is redox sensitive and regulated in a glutathione-dependent fashion by H2O2.	Univ Pittsburgh, Hillman Canc Ctr, Dept Surg, Pittsburgh, PA 15232 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15232 USA; Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA; Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Maryland; University of Maryland Baltimore; University of Iowa	Lee, YJ (corresponding author), Univ Pittsburgh, Hillman Canc Ctr, Dept Surg, Rm G-5A,5117 Centre Ave, Pittsburgh, PA 15232 USA.	leeyj@msx.upme.edu		Spitz, Douglas/0000-0002-1254-8765; Song, Jae/0000-0001-8183-9550	NATIONAL CANCER INSTITUTE [P01CA066081] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051469] Funding Source: NIH RePORTER; NCI NIH HHS [CA48000, CA66081] Funding Source: Medline; NHLBI NIH HHS [HL51469] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson ME, 1985, HDB METHODS OXYGEN R, P317; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; Boveris A., 1982, SUPEROXIDE DISMUTASE, VII, P15, DOI DOI 10.1007/978-1-4615-9035-4_5; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; CHRESTENSEN CA, 1995, FEBS LETT, V374, P25, DOI 10.1016/0014-5793(95)01066-N; Ciriolo MR, 1997, J BIOL CHEM, V272, P2700, DOI 10.1074/jbc.272.5.2700; Cohen G, 1997, P NATL ACAD SCI USA, V94, P4890, DOI 10.1073/pnas.94.10.4890; Daily D, 2001, J BIOL CHEM, V276, P21618, DOI 10.1074/jbc.M101400200; Daily D, 2001, J BIOL CHEM, V276, P1335, DOI 10.1074/jbc.M008121200; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; Hoeflich KP, 1999, ONCOGENE, V18, P5814, DOI 10.1038/sj.onc.1202975; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; LAVELLE F, 1973, BIOCHEM BIOPH RES CO, V55, P350, DOI 10.1016/0006-291X(73)91094-2; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Lee YJ, 2001, J CELL SCI, V114, P677; Lee YJ, 2000, FREE RADICAL BIO MED, V28, P575, DOI 10.1016/S0891-5849(99)00267-1; LEHNINGER AL, 1976, BIOCHEMISTRY-US, P456; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NATH KA, 1995, AM J PHYSIOL-CELL PH, V268, pC227, DOI 10.1152/ajpcell.1995.268.1.C227; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; PADILLA CA, 1995, EUR J BIOCHEM, V227, P27, DOI 10.1111/j.1432-1033.1995.tb20356.x; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; POWIS G, 1995, PHARMACOL THERAPEUT, V68, P149, DOI 10.1016/0163-7258(95)02004-7; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Song SH, 2000, FREE RADICAL BIO MED, V29, P61, DOI 10.1016/S0891-5849(00)00326-9; Spitz DR, 2000, ANN NY ACAD SCI, V899, P349, DOI 10.1111/j.1749-6632.2000.tb06199.x; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TUTTLE SW, 1992, INT J RADIAT ONCOL, V22, P671, DOI 10.1016/0360-3016(92)90500-H; Wells W W, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P149; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	52	214	226	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46566	46575		10.1074/jbc.M206826200	http://dx.doi.org/10.1074/jbc.M206826200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244106	hybrid			2022-12-27	WOS:000179529300112
J	Park, GT; Lim, SE; Jang, SI; Morasso, MI				Park, GT; Lim, SE; Jang, SI; Morasso, MI			Suprabasin, a novel epidermal differentiation marker and potential cornified envelope precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSION SUBTRACTIVE HYBRIDIZATION; PROTEIN-KINASE-C; GENE-EXPRESSION; CELL-ENVELOPE; CDNA CLONING; CALCIUM; INVOLUCRIN; COMPLEX; KERATINOCYTES; ENVOPLAKIN	The suprabasin gene is a novel gene expressed in mouse and human differentiating keratinocytes. We identified a partial cDNA encoding suprabasin using a suppression subtractive hybridization method between the proliferative basal and differentiating suprabasal populations of the mouse epidermis. A 3' gene-specific probe hybridized to transcripts of 0.7- and 2.2-kb pairs on Northern blots with specific detection in differentiated keratinocytes of stratified epithelia. The mouse gene was mapped to chromosome 7 by fluorescence in situ hybridization. This region is syntenic to human chromosome band 19q13.1, which contained the only region in the data bases with homology to the mouse suprabasin sequence. During embryonic mouse development, suprabasin mRNA was detected at day 15.5, coinciding with epidermal stratification. Suprabasin was detected in the suprabasal layers of the epithelia in the tongue, stomach, and epidermis. Differentiation of cultured primary epidermal keratinocytes with 0.12 mm Ca2+ or 12-O-tetradecanoylphorbol-13-acetate treatment resulted in the induction of suprabasin. The 2.2-kb cDNA transcript encodes a protein of 72 kDa with a predicted isoelectric point of 6.85. The translated sequence has an amino-terminal domain, a central domain composed of repeats rich in glycine and alanine, and a carboxyl-terminal domain. The alternatively spliced 0.7-kb transcript encodes a smaller protein that shares the NH2- and COOH-terminal regions but lacks the repeat domain region. Cross-linking experiments indicate that suprabasin is a substrate for transglutaminase 2 and 3 activity. Altogether, these results indicate that the suprabasin protein potentially plays a role in the process of epidermal differentiation.	NIAMS, Dev Skin Biol Unit, NIH, Bethesda, MD 20892 USA; NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Morasso, MI (corresponding author), NIAMS, Dev Skin Biol Unit, NIH, Bldg 50,Rm 1525, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041124] Funding Source: NIH RePORTER; NIAMS NIH HHS [Z01 AR041124-06] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aho S, 1998, GENOMICS, V48, P242, DOI 10.1006/geno.1997.5188; Champliaud MF, 1998, J BIOL CHEM, V273, P31547, DOI 10.1074/jbc.273.47.31547; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Diatchenko L, 1999, METHOD ENZYMOL, V303, P349; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Djian P, 2000, J CELL BIOL, V151, P381, DOI 10.1083/jcb.151.2.381; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; Jarnik M, 2002, J INVEST DERMATOL, V118, P102, DOI 10.1046/j.0022-202x.2001.01661.x; Kalinin A, 2001, J CELL SCI, V114, P3069; Koch PJ, 2000, J CELL BIOL, V151, P389, DOI 10.1083/jcb.151.2.389; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LICHTI U, 1988, CANCER RES, V48, P74; Maatta A, 2000, J BIOL CHEM, V275, P19857, DOI 10.1074/jbc.M001028200; Maatta A, 2001, MOL CELL BIOL, V21, P7047, DOI 10.1128/MCB.21.20.7047-7053.2001; MACKEM S, 1991, DEVELOPMENT, V112, P791; Makino T, 2001, J BIOL CHEM, V276, P47445, DOI 10.1074/jbc.M107512200; Marenholz I, 2001, GENOME RES, V11, P341, DOI 10.1101/gr.114801; Marshall D, 2001, P NATL ACAD SCI USA, V98, P13031, DOI 10.1073/pnas.231489198; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; MORASSO MI, 1994, DEV BIOL, V162, P267, DOI 10.1006/dbio.1994.1084; Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; Steinert PM, 1999, J BIOL CHEM, V274, P1657, DOI 10.1074/jbc.274.3.1657; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; VOLZ A, 1993, GENOMICS, V18, P92, DOI 10.1006/geno.1993.1430; Wang A, 2001, GENOMICS, V73, P284, DOI 10.1006/geno.2001.6518; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; Zhao XP, 1997, GENOMICS, V45, P250, DOI 10.1006/geno.1997.4952	34	62	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45195	45202		10.1074/jbc.M205380200	http://dx.doi.org/10.1074/jbc.M205380200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228223	hybrid, Green Accepted			2022-12-27	WOS:000179404800078
J	Richter, K; Reinstein, J; Buchner, J				Richter, K; Reinstein, J; Buchner, J			N-terminal residues regulate the catalytic efficiency of the Hsp90 ATPase cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BINDING; HYDROLYSIS; CHAPERONE; DIMERIZATION; RECEPTOR; MUTL	Hsp90 is an abundant molecular chaperone involved in a variety of cellular processes ranging from signal transduction to viral replication. The function of Hsp90 has been shown to be dependent on its ability to hydrolyze ATP, and in vitro studies suggest that the dimeric nature of Hsp90 is critical for this activity. ATP binding occurs at the N-terminal domains of the Hsp90 dimer, whereas the main dimerization site resides in the very C-terminal domain. ATP hydrolysis is performed in a series of conformational changes. These include the association of the two N-terminal domains, which has been shown to stimulate the hydrolysis reaction. In this study, we set out to identify regions in the N-terminal domain that are important for this interaction. We show that N-terminal deletion variants of Hsp90 are severely impaired in their ability to hydrolyze ATP. However, nucleotide binding of these constructs is similar to that of the wild type protein. Heterodimers of the Hsp90 deletion mutants with wild type protein showed that the first 24 amino acids play a crucial role during the ATPase reaction, because their deletion abolishes the trans-activation between the two N-terminal domains. We propose that the turnover rate of Hsp90 is decisively controlled by intermolecular interactions between the N-terminal domains.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Technical University of Munich; Max Planck Society	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	johannes.buchner@ch.tum.de	Buchner, Johannes/A-2651-2010; Richter, Klaus/A-2673-2010	Richter, Klaus/0000-0002-8952-9642; Buchner, Johannes/0000-0003-1282-7737				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Brino L, 2000, J BIOL CHEM, V275, P9468, DOI 10.1074/jbc.275.13.9468; Maruya M, 1999, J MOL BIOL, V285, P903, DOI 10.1006/jmbi.1998.2349; McLaughlin SH, 2002, J MOL BIOL, V315, P787, DOI 10.1006/jmbi.2001.5245; Morishima Y, 2001, BIOCHEMISTRY-US, V40, P1109, DOI 10.1021/bi002399+; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Owen BAL, 2002, J BIOL CHEM, V277, P7086, DOI 10.1074/jbc.M111450200; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200; Scheibel T, 1997, J BIOL CHEM, V272, P18608, DOI 10.1074/jbc.272.30.18608; SMITH DF, 1992, J BIOL CHEM, V267, P1350; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Weikl T, 2000, J MOL BIOL, V303, P583, DOI 10.1006/jmbi.2000.4157	19	60	60	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44905	44910		10.1074/jbc.M208457200	http://dx.doi.org/10.1074/jbc.M208457200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235160	hybrid			2022-12-27	WOS:000179404800041
J	Thion, L; Laurine, E; Erard, M; Burlet-Schiltz, O; Monsarrat, B; Masson, JM; Saves, I				Thion, L; Laurine, E; Erard, M; Burlet-Schiltz, O; Monsarrat, B; Masson, JM; Saves, I			The two-step cleavage activity of PI-TfuI intein endonuclease demonstrated by matrix-assisted laser desorption ionization time-of-flight mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECORV RESTRICTION-ENDONUCLEASE; CODED HOMING ENDONUCLEASES; ARCHAEA DNA-POLYMERASE; GROUP-I INTRON; INTERVENING SEQUENCES; PYROCOCCUS-FURIOSUS; SCEI ENDONUCLEASE; IDENTIFICATION; BINDING; GENE	PI-TfuI, an intein spliced from the DNA polymerase of Thermococcus fumicolans, is a highly specific endonuclease, whose cleavage efficiency and specificity depend on both the substrate topology and the divalent cation used as cofactor. An open circular intermediate was observed during the cleavage of supercoiled DNA by PI-TfuI, suggesting a two-step cleavage of the DNA. We characterized this nicked intermediate and, through the development of a method of analysis of the cleavage reaction based on matrix-assisted laser desorption ionization time-of-flight mass spectrometry, we demonstrated that the cleavage of DNA by PI-TfuI indeed results from two cleavage events. One step results in the cleavage of the bottom strand, which is independent of the DNA conformation or choice of the metal ion cofactor. A second step, which is slower, leads to the cleavage of the top strand and governs the specific requirements of PI-TfuI concerning the essential cofactor and the DNA topology. These two steps were shown to be independent in optimal conditions of cleavage. These data give support to the existence of two distinct and independent active sites in the endonuclease domain of the archaeal intein.	CNRS, Inst Pharmacol & Biol Struct, IPBS, F-31077 Toulouse, France; Inst Natl Sci Appl, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite de Toulouse; Institut National des Sciences Appliquees de Toulouse	Saves, I (corresponding author), CNRS, Inst Pharmacol & Biol Struct, IPBS, 205 Route de Narbonne, F-31077 Toulouse, France.			Schiltz, Odile/0000-0002-3606-2356				Chiu NHL, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e31; Christ F, 1999, EMBO J, V18, P6908, DOI 10.1093/emboj/18.24.6908; Dalgaard JZ, 1997, NUCLEIC ACIDS RES, V25, P4626, DOI 10.1093/nar/25.22.4626; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Gimble FS, 1996, J MOL BIOL, V263, P163, DOI 10.1006/jmbi.1996.0567; Gimble FS, 1998, J BIOL CHEM, V273, P30524, DOI 10.1074/jbc.273.46.30524; GIMBLE FS, 1995, J BIOL CHEM, V270, P5849, DOI 10.1074/jbc.270.11.5849; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; Gross J, 2001, J AM SOC MASS SPECTR, V12, P180, DOI 10.1016/S1044-0305(00)00209-9; Guhan N, 2002, J BIOL CHEM, V277, P16257, DOI 10.1074/jbc.M112365200; He ZN, 1998, J BIOL CHEM, V273, P4607, DOI 10.1074/jbc.273.8.4607; Heath PJ, 1997, NAT STRUCT BIOL, V4, P468, DOI 10.1038/nsb0697-468; HODGES RA, 1992, NUCLEIC ACIDS RES, V20, P6153, DOI 10.1093/nar/20.23.6153; Jurica NS, 1998, MOL CELL, V2, P469, DOI 10.1016/S1097-2765(00)80146-X; Jurinke C, 1998, GENET ANAL-BIOMOL E, V14, P97, DOI 10.1016/S1050-3862(97)10006-7; Komori K, 1999, NUCLEIC ACIDS RES, V27, P4175, DOI 10.1093/nar/27.21.4175; Komori K, 1999, NUCLEIC ACIDS RES, V27, P4167, DOI 10.1093/nar/27.21.4167; Langley GJ, 1999, RAPID COMMUN MASS SP, V13, P1717, DOI 10.1002/(SICI)1097-0231(19990915)13:17<1717::AID-RCM704>3.0.CO;2-R; MUELLER JE, 1993, NUCLEASES, V2, P111; Nishioka M, 1998, NUCLEIC ACIDS RES, V26, P4409, DOI 10.1093/nar/26.19.4409; Nordhoff E, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.20.e86; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; Saves I, 2000, NUCLEIC ACIDS RES, V28, P4391, DOI 10.1093/nar/28.21.4391; Saves I, 2000, J BIOL CHEM, V275, P2335, DOI 10.1074/jbc.275.4.2335; Saves I, 2002, J CLIN MICROBIOL, V40, P943, DOI 10.1128/JCM.40.3.943-950.2002; Saves I, 2001, NUCLEIC ACIDS RES, V29, P4310, DOI 10.1093/nar/29.21.4310; Schottler S, 2000, BIOCHEMISTRY-US, V39, P15895, DOI 10.1021/bi001775n; Stoerker J, 2000, NAT BIOTECHNOL, V18, P1213, DOI 10.1038/81226; Tolson DA, 1998, NUCLEIC ACIDS RES, V26, P446, DOI 10.1093/nar/26.2.446; TURMEL M, 1995, NUCLEIC ACIDS RES, V23, P2519, DOI 10.1093/nar/23.13.2519; Vipond IB, 1996, BIOCHEMISTRY-US, V35, P1701, DOI 10.1021/bi952391d; Vipond IB, 1996, BIOCHEMISTRY-US, V35, P1712, DOI 10.1021/bi9523926; Wada Y, 1998, J MASS SPECTROM, V33, P187, DOI 10.1002/(SICI)1096-9888(199802)33:2<187::AID-JMS625>3.0.CO;2-A; Wende W, 1996, NUCLEIC ACIDS RES, V24, P4123, DOI 10.1093/nar/24.21.4123	35	2	2	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45442	45450		10.1074/jbc.M203507200	http://dx.doi.org/10.1074/jbc.M203507200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12239210	hybrid			2022-12-27	WOS:000179404800108
J	Horton, MR; Boodoo, S; Powell, JD				Horton, MR; Boodoo, S; Powell, JD			NF-kappa B activation mediates the cross-talk between extracellular matrix and interferon-gamma (IFN-gamma) leading to enhanced monokine induced by IFN-gamma (MIG) expression in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE GENE-EXPRESSION; HYALURONAN FRAGMENTS; MOUSE MACROPHAGES; MURINE MACROPHAGES; INDUCIBLE PROTEIN-10; ALVEOLAR MACROPHAGES; DEPENDENT MECHANISM; T-LYMPHOCYTES; TRANSCRIPTION; BINDING	In intact tissue, the extracellular matrix (ECM) provides support and helps maintain homeostasis but is considered biologically inert. In the setting of inflammation, not only is the ECM the target of inflammation, but its breakdown products modulate the magnitude and quality of an immune response. Fragments of the ECM component hyaluronan (HA) induce macrophage expression of chemokines, cytokines, and growth factors as well greatly enhance IFN-gamma-induced MIG expression. In this report, we demonstrate that the synergistic induction of MIG by HA and IFN-gamma occurs at the level of transcription via NF-kappaB. Using electrophoretic mobility shift assays and reporter assays, we have identified two NF-kappaB sites proximal to the IFN-gamma-responsive element-1 (gammaRE-1) that mediate this effect. Interestingly, our experiments also revealed a critical role for NF-kappaB in mediating IFN-gamma-induced MIG expression independent of HA. These data emphasize the ability of "degraded self" to activate/modify immune responses through the NF-kappaB pathway.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University	Horton, MR (corresponding author), 600 N Wolfe St,Jefferson Bldg B1-170, Baltimore, MD 21287 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003993] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL03993] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amichay D, 1996, J IMMUNOL, V157, P4511; An HZ, 2002, IMMUNOLOGY, V106, P38, DOI 10.1046/j.1365-2567.2002.01401.x; Asensio VC, 1997, J VIROL, V71, P7832, DOI 10.1128/JVI.71.10.7832-7840.1997; BALAZS EA, 1967, ARTHRITIS RHEUM, V10, P357, DOI 10.1002/art.1780100407; BJERMER L, 1989, THORAX, V44, P126, DOI 10.1136/thx.44.2.126; CLARK RAF, 1988, J BIOL CHEM, V263, P12115; Deb A, 2001, J IMMUNOL, V166, P6170, DOI 10.4049/jimmunol.166.10.6170; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GAZZINIELLI RT, 1992, J IMMUNOL, V148, P1752; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; GUYER NB, 1995, J IMMUNOL, V155, P3472; HANCE AJ, 1975, AM REV RESPIR DIS, V112, P657; HIDENORI K, 1996, CELL, V87, P1069; HodgeDufour J, 1997, J IMMUNOL, V159, P2492; Horton MR, 2000, AM J PHYSIOL-LUNG C, V279, pL707, DOI 10.1152/ajplung.2000.279.4.L707; Horton MR, 1999, J IMMUNOL, V162, P4171; Horton MR, 1998, J BIOL CHEM, V273, P35088, DOI 10.1074/jbc.273.52.35088; Horton MR, 1998, J IMMUNOL, V160, P3023; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Jones BW, 2001, J LEUKOCYTE BIOL, V69, P1036; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; LASKIN DL, 1994, AM J RESP CELL MOL, V10, P58, DOI 10.1165/ajrcmb.10.1.8292381; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAURENT TC, 1995, ANN RHEUM DIS, V54, P429, DOI 10.1136/ard.54.5.429; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; LIAO F, 1995, J EXP MED, V182, P1301, DOI 10.1084/jem.182.5.1301; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Luo GY, 2000, MOL ENDOCRINOL, V14, P114, DOI 10.1210/me.14.1.114; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MBAWUIKE IN, 1989, J LEUKOCYTE BIOL, V46, P119, DOI 10.1002/jlb.46.2.119; McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Michalopoulos I, 1999, NUCLEIC ACIDS RES, V27, P503, DOI 10.1093/nar/27.2.503; Narumi S, 1997, J IMMUNOL, V158, P5536; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; Nguyen VT, 2002, J BIOL CHEM, V277, P13796, DOI 10.1074/jbc.M111906200; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; Oertli B, 1998, J IMMUNOL, V161, P3431; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; PICARD V, 1999, PCR CLONING PROTOCOL, V67, P183; Powell JD, 1999, J IMMUNOL, V163, P6631; RENNARD SI, 1981, P NATL ACAD SCI-BIOL, V78, P7147, DOI 10.1073/pnas.78.11.7147; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; Shenkar R, 2001, AM J PHYSIOL-LUNG C, V281, pL418, DOI 10.1152/ajplung.2001.281.2.L418; STRIETER RM, 1995, SHOCK, V4, P155, DOI 10.1097/00024382-199509000-00001; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; VANGURI P, 1990, J BIOL CHEM, V265, P15049; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914	54	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43757	43762		10.1074/jbc.M206007200	http://dx.doi.org/10.1074/jbc.M206007200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226082	hybrid			2022-12-27	WOS:000179272000030
J	Sanchez-Elsner, T; Botella, LM; Velasco, B; Langa, C; Bernabeu, C				Sanchez-Elsner, T; Botella, LM; Velasco, B; Langa, C; Bernabeu, C			Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY HEMORRHAGIC TELANGIECTASIA; LACTATE-DEHYDROGENASE-A; VASCULAR ENDOTHELIAL-CELLS; BINDING-PROTEIN ENDOGLIN; SMOOTH-MUSCLE CELLS; HUMAN SOLID TUMORS; TGF-BETA; INDUCIBLE FACTOR-1; MONOCLONAL-ANTIBODIES; CELLULAR-RESPONSES	Endoglin is a transforming growth factor-beta (TGF-beta) co-receptor expressed mainly on endothelial cells and involved in cardiovascular development, angiogenesis, and vascular remodeling. This is illustrated by the fact that mutations in the endoglin gene give rise to hereditary hemorrhagic telangiectasia type 1, a dominant vascular disease with clinical manifestations that originate by a mechanism of haploinsufficiency. Thus, studies on the regulated expression of endoglin are crucial to devising therapeutic strategies for hereditary hemorrhagic telangiectasia type 1. Endoglin is highly expressed in the neovasculature associated with hypoxia such as ischemic tissues and tumors, but the molecular mechanism of this up-regulation is unknown. Here, we have investigated the possible regulation of endoglin expression by hypoxia. Surface protein, transcript, and promoter activity levels of endoglin were found to be up-regulated by hypoxia, indicating that the regulation takes place at the transcriptional level. A hypoxia-responsive element downstream of the main transcription start site of the endoglin gene was functionally characterized. Whereas hypoxia alone moderately stimulated endoglin transcription, addition of TGF-beta under bypoxic conditions resulted in transcriptional cooperation between both signaling pathways, leading to marked stimulation of endoglin expression. Because basal endoglin transcription is sustained by Sp1, and TGF-beta and hypoxia signaling pathways are mediated by Smad proteins and hypoxia-inducible factor-1 (HIF-1), respectively, the involvement of these transcription factors was analyzed. Functional and co-immunoprecipitation experiments demonstrated the existence of a multiprotein complex (Sp1.Smad3.HIF-1) on the endoglin promoter, mediating the cooperation between the hypoxia and TGF-beta pathways. Within this multiprotein complex, Smad3 appears to function not only as a coactivator factor, but also as an adaptor between HIF-1 and Sp1. We propose that basal endoglin transcription (highly dependent on Sp1) may switch from a constitutive to an inducible state through Sp1 interaction with HIF-1 and Smad transcription factors, induced by hypoxia and TGF-beta, respectively.	CSIC, Ctr Invest Biol, E-28040 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Bernabeu, C (corresponding author), CSIC, Ctr Invest Biol, Ramiro de Maeztu 9, E-28040 Madrid, Spain.	bernabeu.c@cib.csic.es	Botella, Luisa M/L-1392-2014; Bernabeu, Carmelo/P-4662-2019; Bernabeu, Carmelo/L-3226-2014	Bernabeu, Carmelo/0000-0002-1563-6162; Bernabeu, Carmelo/0000-0002-1563-6162; Sanchez-Elsner, Tilman/0000-0003-1915-2410				Adam PJ, 1998, BIOCHEM BIOPH RES CO, V247, P33, DOI 10.1006/bbrc.1998.8734; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Attisano L, 2001, GENOME BIOL, V2; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bodey B, 1998, ANTICANCER RES, V18, P3621; Botella LM, 2001, J BIOL CHEM, V276, P34486, DOI 10.1074/jbc.M011611200; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; Caniggia I, 2000, J CLIN INVEST, V105, P577, DOI 10.1172/JCI8316; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Conley BA, 2000, ATHEROSCLEROSIS, V153, P323, DOI 10.1016/S0021-9150(00)00422-6; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Das P, 1999, GENES CELLS, V4, P123, DOI 10.1046/j.1365-2443.1999.00244.x; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; FALANGA V, 1991, J INVEST DERMATOL, V97, P634, DOI 10.1111/1523-1747.ep12483126; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; FERNANDEZRUIZ E, 1993, CYTOGENET CELL GENET, V64, P204, DOI 10.1159/000133576; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gallione CJ, 1998, HUM MUTAT, V11, P286, DOI 10.1002/(SICI)1098-1004(1998)11:4<286::AID-HUMU6>3.0.CO;2-B; Gleadle JM, 1998, MOL MED TODAY, V4, P122, DOI 10.1016/S1357-4310(97)01198-2; GOUGOS A, 1988, J IMMUNOL, V141, P1925; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Kimura H, 2001, J BIOL CHEM, V276, P2292, DOI 10.1074/jbc.M008398200; KRUPINSKI J, 1994, STROKE, V25, P1794, DOI 10.1161/01.STR.25.9.1794; Kumar S, 1999, CANCER RES, V59, P856; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; LETARTE M, 1997, LEUKOCYTE TYPING, V6, P703; Li CG, 2000, ATHEROSCLEROSIS, V152, P249, DOI 10.1016/S0021-9150(99)00476-1; Li CG, 2001, MICROSC RES TECHNIQ, V52, P437, DOI 10.1002/1097-0029(20010215)52:4<437::AID-JEMT1029>3.0.CO;2-G; Li CG, 2000, FASEB J, V14, P55, DOI 10.1096/fasebj.14.1.55; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; MA X, 2000, ARTERIOSCLER THROMB, P2546; MARCHUK DA, 2001, METABOLIC MOL BASES, V4, P5419; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsuno F, 1999, CLIN CANCER RES, V5, P371; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Miller DW, 1999, INT J CANCER, V81, P568, DOI 10.1002/(SICI)1097-0215(19990517)81:4<568::AID-IJC11>3.3.CO;2-O; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Paquet ME, 2001, HUM MOL GENET, V10, P1347, DOI 10.1093/hmg/10.13.1347; Pece-Barbara N, 1999, HUM MOL GENET, V8, P2171, DOI 10.1093/hmg/8.12.2171; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Pichuantes S, 1997, TISSUE ANTIGENS, V50, P265, DOI 10.1111/j.1399-0039.1997.tb02870.x; Qu R, 1998, CELL TISSUE RES, V292, P333, DOI 10.1007/s004410051064; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; Rius C, 1998, BLOOD, V92, P4677; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Semenza GL, 2000, GENE DEV, V14, P1983; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shovlin CL, 1997, AM J HUM GENET, V61, P68, DOI 10.1086/513906; Shovlin CL, 1999, THORAX, V54, P714, DOI 10.1136/thx.54.8.714; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STJACQUES S, 1994, ENDOCRINOLOGY, V134, P2645, DOI 10.1210/en.134.6.2645; Tabata M, 1999, INT J CANCER, V82, P737, DOI 10.1002/(SICI)1097-0215(19990827)82:5<737::AID-IJC18>3.3.CO;2-#; Takahashi N, 2001, CANCER RES, V61, P7846; Vincent EB, 1998, DEV DYNAM, V213, P237, DOI 10.1002/(SICI)1097-0177(199811)213:3<237::AID-AJA1>3.0.CO;2-M; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Xu Q, 2000, J BIOL CHEM, V275, P24583, DOI 10.1074/jbc.M003894200; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	79	257	270	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43799	43808		10.1074/jbc.M207160200	http://dx.doi.org/10.1074/jbc.M207160200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228247	Green Published, hybrid			2022-12-27	WOS:000179272000036
J	Wiberg, C; Heinegard, D; Wenglen, C; Timpl, R; Morgelin, M				Wiberg, C; Heinegard, D; Wenglen, C; Timpl, R; Morgelin, M			Biglycan organizes collagen VI into hexagonal-like networks resembling tissue structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL PROTEOGLYCAN; BETHLEM MYOPATHY; ARTICULAR-CARTILAGE; COLLOIDAL GOLD; MESSENGER-RNA; CORE PROTEINS; DECORIN; BINDING; EXPRESSION; CHONDROADHERIN	The ability of the leucine-rich repeat (LRR) proteins biglycan, decorin, and chondroadherin to interact with collagen VI and influence its assembly to supramolecular structures was studied by electron microscopy and surface plasmon resonance measurements in the BIA-core 2000 system. Biglyean showed a unique ability to organize collagen VI into extensive hexagonal-like networks over a time period of only a few minutes. Only the intact molecule, substituted with two dermatan sulfate chains, had this capacity. Intact decorin, with one dermatan sulfate chain only, was considerably less efficient, and aggregates of organized collagen VI were found only after several hours. Chondroadherin without glycosaminoglycan substitutions did not induce any ordered collagen VI organization. However, all three related LRR proteins were shown to interact with collagen VI using electron microscopy and surface plasmon resonance. Biglycan and decorin were exclusively found close to the N-terminal parts of the collagen VI tetramers, whereas chondroadherin was shown to bind close to both the N- and C-terminal parts of collagen VI. In the formed hexagonal networks, biglycan was localized to the intra-network junctions of the collagen VI filaments. This was demonstrated by electron microscopy after negative staining of gold-labeled biglyean in aggregation experiments with collagen VI.	Lund Univ, BMC, Dept Cell & Mol Biol, S-22184 Lund, Sweden; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Lund University; Max Planck Society	Morgelin, M (corresponding author), Lund Univ, BMC, Dept Cell & Mol Biol, S-22184 Lund, Sweden.	matthias.morgelin@medkem.lu.se						Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; BASCHONG W, 1990, J ELECTRON MICR TECH, V14, P313, DOI 10.1002/jemt.1060140405; BASCHONG W, 1985, HISTOCHEMISTRY, V83, P409, DOI 10.1007/BF00509201; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; Blaschke UK, 1996, J BIOL CHEM, V271, P30347, DOI 10.1074/jbc.271.48.30347; Bonaldo P, 1998, HUM MOL GENET, V7, P2135, DOI 10.1093/hmg/7.13.2135; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BRUNS RR, 1986, J CELL BIOL, V103, P393, DOI 10.1083/jcb.103.2.393; Burg MA, 1996, J BIOL CHEM, V271, P26110, DOI 10.1074/jbc.271.42.26110; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHU ML, 1987, EUR J BIOCHEM, V168, P309, DOI 10.1111/j.1432-1033.1987.tb13422.x; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; ENGEL J, 1985, ANN NY ACAD SCI, V460, P25, DOI 10.1111/j.1749-6632.1985.tb51154.x; ENGVALL E, 1986, J CELL BIOL, V102, P703, DOI 10.1083/jcb.102.3.703; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEINEGARD D, 1985, BIOCHEM J, V230, P181, DOI 10.1042/bj2300181; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Kielty Cay M., 1993, P103; Krishnan P, 1999, J BIOL CHEM, V274, P10945, DOI 10.1074/jbc.274.16.10945; Kuo HJ, 1997, J BIOL CHEM, V272, P26522, DOI 10.1074/jbc.272.42.26522; Lamande SR, 1999, J BIOL CHEM, V274, P21817, DOI 10.1074/jbc.274.31.21817; Lamande SR, 1998, HUM MOL GENET, V7, P981, DOI 10.1093/hmg/7.6.981; Landgren C, 1998, GENOMICS, V47, P84, DOI 10.1006/geno.1997.5085; LARSSON T, 1991, J BIOL CHEM, V266, P20428; Mansson B, 2001, J BIOL CHEM, V276, P32883, DOI 10.1074/jbc.M101680200; MIOSGE N, 1994, HISTOCHEM J, V26, P939; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; ODERMATT E, 1983, BIOCHEM J, V211, P295, DOI 10.1042/bj2110295; OONO T, 1993, J INVEST DERMATOL, V100, P329, DOI 10.1111/1523-1747.ep12470022; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; POOLE CA, 1988, J CELL SCI, V90, P635; Pullig O, 1999, OSTEOARTHR CARTILAGE, V7, P191, DOI 10.1053/joca.1998.0208; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; Sasaki T, 2000, FASEB J, V14, P761, DOI 10.1096/fasebj.14.5.761; SPISSINGER T, 1995, MATRIX BIOL, V14, P499, DOI 10.1016/0945-053X(95)90007-1; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; TILLET E, 1994, EUR J BIOCHEM, V221, P177, DOI 10.1111/j.1432-1033.1994.tb18727.x; TIMPL R, 1994, EXTRACELLULAR MATRIX, P208; Timpl R., 1987, STRUCTURE FUNCTION C, P105, DOI [10.1016/B978--0--12--481280-2.50008---8, DOI 10.1016/B978--0--12--481280-2.50008---8]; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VONDERMARK H, 1984, EUR J BIOCHEM, V142, P493; Wiberg C, 2001, J BIOL CHEM, V276, P18947, DOI 10.1074/jbc.M100625200	51	134	136	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49120	49126		10.1074/jbc.M206891200	http://dx.doi.org/10.1074/jbc.M206891200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12354766	hybrid			2022-12-27	WOS:000180028900005
J	Hou, ST; Xie, XQ; Baggley, A; Park, DS; Chen, G; Walker, T				Hou, ST; Xie, XQ; Baggley, A; Park, DS; Chen, G; Walker, T			Activation of the Rb/E2F1 pathway by the nonproliferative p38 MAPK during fAs (APO1/CD95)-mediated neuronal apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F1; CYCLIN-DEPENDENT KINASES; SIGNAL-TRANSDUCTION-CASCADES; TRANSIENT FOREBRAIN ISCHEMIA; JUN NH2-TERMINAL KINASE; N-TERMINAL KINASE; PROTEIN-KINASE; CELL-DEATH; CORTICAL-NEURONS; RAT-BRAIN	Aberrant activation of the Rb/E2F1 pathway in cycling cells, in response to mitogenic or nonmitogenic stress signals, leads to apoptosis through hyperphosphorylation of Rb. To test whether in postmitotic neurons the Rb/E2F1 pathway can be activated by the nonmitogenic stress signaling, we examined the role of the p38 stress-activated protein kinase (SAPK) in regulating Rb phosphorylation in response to Fas (CD95/APO1)-mediated apoptosis of cultured cerebellar granule neurons (CGNs). Anti-Fas antibody induced a dramatic and early activation of p38. Activated p38 was correlated with the induction of hyperphosphorylation of both endogenous and exogenous Rb. The p38-selective inhibitor, SB203580, attenuated such an increase in pRb phosphorylation and significantly protected CGNs from Fas-induced apoptosis. The cyclin-dependent kinase-mediated Rb phosphorylation played a lesser role in this neuronal death paradigm, since cyclin-dependent kinase inhibitors, such as olomoucine, roscovitine, and flavopiridol, did not significantly prevent anti-Fas antibody-evoked neuronal apoptosis. Hyperphosphorylation of Rb by p38 SAPK resulted in the release of Rb-bound E2F1. Increased E2F1 modulated neuronal apoptosis, since E2Fl-/- CGNs were significantly less susceptible to Fas-mediated apoptosis in comparison with the wildtype CGNs. Taken together, these studies demonstrate that neuronal Rb/E2F1 is modulated by the nonproliferative p38 SAPK in Fas-mediated neuronal apoptosis.	Natl Res Council Canada, Inst Biol Sci, Expt Stroke Grp, Ottawa, ON K1A 0R6, Canada; Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada	National Research Council Canada; University of Ottawa	Hou, ST (corresponding author), Natl Res Council Canada, Inst Biol Sci, Expt Stroke Grp, 1500 Montreal Rd, Ottawa, ON K1A 0R6, Canada.		Hou, Sheng Tao/AAM-7756-2020; Hou, Sheng Tao/O-3202-2018	Hou, Sheng Tao/0000-0001-9736-342X; Park, David/0000-0002-4490-3784				Adamchak DJ, 2001, SOC SCI J, V38, P1, DOI 10.1016/S0362-3319(00)00107-5; Azuma-Hara N, 1999, EXP CELL RES, V251, P442, DOI 10.1006/excr.1999.4593; Barone FC, 2001, MED RES REV, V21, P129, DOI 10.1002/1098-1128(200103)21:2<129::AID-MED1003>3.0.CO;2-H; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Cheema ZF, 1999, J NEUROSCI, V19, P1754; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Dougherty CJ, 2002, BIOCHEM J, V362, P561, DOI 10.1042/0264-6021:3620561; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Ferguson KL, 2000, J BIOL CHEM, V275, P33593, DOI 10.1074/jbc.M004879200; Gendron TF, 2001, J NEUROCHEM, V78, P316, DOI 10.1046/j.1471-4159.2001.00423.x; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Giovanni A, 1999, J BIOL CHEM, V274, P19011, DOI 10.1074/jbc.274.27.19011; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; Horstmann S, 1998, J NEUROSCI RES, V52, P483, DOI 10.1002/(SICI)1097-4547(19980515)52:4<483::AID-JNR12>3.3.CO;2-Y; Hou ST, 2001, NEUROSCI LETT, V306, P153, DOI 10.1016/S0304-3940(01)01909-7; Hou ST, 2001, J NEUROCHEM, V78, P287, DOI 10.1046/j.1471-4159.2001.00402.x; Hou ST, 2000, J NEUROCHEM, V75, P91, DOI 10.1046/j.1471-4159.2000.0750091.x; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Jin KL, 2002, J NEUROCHEM, V80, P119, DOI 10.1046/j.0022-3042.2001.00678.x; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lamboley C, 2002, J HEPATOL, V36, P385, DOI 10.1016/S0168-8278(01)00284-7; Lauricella M, 2001, FEBS LETT, V499, P191, DOI 10.1016/S0014-5793(01)02553-4; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MacManus JP, 1999, NEUROREPORT, V10, P2711, DOI 10.1097/00001756-199909090-00004; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Mehmet H, 2001, CELL DEATH DIFFER, V8, P659, DOI 10.1038/sj.cdd.4400899; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Nagata S, 1998, INTERNAL MED, V37, P179, DOI 10.2169/internalmedicine.37.179; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Nozaki K, 2001, MOL NEUROBIOL, V23, P1, DOI 10.1385/MN:23:1:01; O'Hare MJ, 2000, J BIOL CHEM, V275, P25358, DOI 10.1074/jbc.M001725200; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rosenbaum DM, 2000, J NEUROSCI RES, V61, P686, DOI 10.1002/1097-4547(20000915)61:6<686::AID-JNR12>3.0.CO;2-7; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shklyaev SS, 2001, THYROID, V11, P629, DOI 10.1089/105072501750362691; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; Takagi Y, 2000, NEUROSCI LETT, V294, P117, DOI 10.1016/S0304-3940(00)01552-4; Tan ZQ, 2001, NEUROREPORT, V12, P1979, DOI 10.1097/00001756-200107030-00040; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tu YH, 1998, J CEREBR BLOOD F MET, V18, P658, DOI 10.1097/00004647-199806000-00008; Verdaguer E, 2002, NEUROREPORT, V13, P413, DOI 10.1097/00001756-200203250-00010; Wang FH, 2002, J CEREBR BLOOD F MET, V22, P171, DOI 10.1097/00004647-200202000-00005; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Waring P, 2001, IMMUNOL CELL BIOL, V79, P264, DOI 10.1046/j.1440-1711.2001.01008.x; Willaime S, 2001, EUR J NEUROSCI, V13, P2037, DOI 10.1046/j.0953-816x.2001.01581.x; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yi FH, 2000, J NEUROIMMUNOL, V109, P211, DOI 10.1016/S0165-5728(00)00288-5; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	65	60	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48764	48770		10.1074/jbc.M206336200	http://dx.doi.org/10.1074/jbc.M206336200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12351630	hybrid			2022-12-27	WOS:000179789600103
J	Sakai, H; Urano, T; Ookata, K; Kim, MH; Hirai, Y; Saito, M; Nojima, Y; Ishikawa, F				Sakai, H; Urano, T; Ookata, K; Kim, MH; Hirai, Y; Saito, M; Nojima, Y; Ishikawa, F			MBD3 and HDAC1, two components of the NuRD complex, are localized at aurora-A-positive centrosomes in M phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; HISTONE DEACETYLASE; PROTEIN-KINASE; CHROMOSOME SEGREGATION; DNA METHYLATION; P53; BINDING; ACETYLTRANSFERASES; PHOSPHORYLATION; ACETYLATION	MBD3, a component of the histone deacetylase NuRD complex, contains the methyl-CpG-binding domain (MBD), yet does not possess appreciable mCpG-specific binding activity. The functional significance of MBD3 in the NuRD complex remains enigmatic, partly because of the limited availability of biochemical approaches, such as immunoprecipitation, to analyze MBD3. In this study, we stably expressed the FIAG-tagged version of MBD3 in HeLa cells. We found that MBD3-FLAG was incorporated into the NuRD complex, and the MBD3-FLAG-containing NuRD complex was efficiently immunoprecipitated by anti-FLAG antibodies. By exploiting this system, we found that MBD3 is phosphorylated in vivo in the late G, and early M phases. Moreover, we found that Aurora-A, a serine/threonine kinase active specifically in the late G(2) and early M phases, phosphorylates MBD3 in vitro, physically associates with MBD3 in vivo, and co-localizes with MBD3 at the centrosomes in the early M phase. Interestingly, HDAC1 is distributed at the centrosomes in a manner similar to MBD3. These results suggest the highly dynamic nature of the temporal and spatial distributions, as well as the biochemical modification, of the NuRD complex in M phase, probably through an interaction with kinases, including Aurora-A. These observations will contribute significantly to the elucidation of the yet-uncharacterized cell cycle-controlled functions of the NuRD complex.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Gunma Univ, Sch Med, Dept Internal Med 3, Maebashi, Gumma 3718511, Japan; Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan	Tokyo Institute of Technology; Gunma University; Nagoya University; Kyoto University	Ishikawa, F (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	fishikaw@lif.kyoto-u.ac.jp	Ishikawa, Fuyuki/AAU-4056-2021	Ishikawa, Fuyuki/0000-0002-5580-2305; Urano, Takeshi/0000-0003-3383-3554				Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Cai R, 2001, BIOCHEM BIOPH RES CO, V283, P445, DOI 10.1006/bbrc.2001.4786; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; Feng Q, 2001, GENE DEV, V15, P827; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Howe L, 2001, GENE DEV, V15, P3144, DOI 10.1101/gad.931401; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Lusser A, 1997, EUR J CELL BIOL, V74, P102; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Ohki I, 1999, EMBO J, V18, P6653, DOI 10.1093/emboj/18.23.6653; Pflum MKH, 2001, J BIOL CHEM, V276, P47733, DOI 10.1074/jbc.M105590200; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; Roghi C, 1998, J CELL SCI, V111, P557; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Shindo M, 1998, BIOCHEM BIOPH RES CO, V244, P285, DOI 10.1006/bbrc.1998.8250; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tanaka T, 1999, CANCER RES, V59, P2041; Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x; Tatsuka M, 1998, CANCER RES, V58, P4811; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wakefield RID, 1999, J MOL BIOL, V291, P1055, DOI 10.1006/jmbi.1999.3023; WEISS G, 1988, FEBS LETT, V238, P205, DOI 10.1016/0014-5793(88)80257-6; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	53	46	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48714	48723		10.1074/jbc.M208461200	http://dx.doi.org/10.1074/jbc.M208461200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12354758	hybrid			2022-12-27	WOS:000179789600097
J	Sheridan, CM; Heist, EK; Beals, CR; Crabtree, GR; Gardner, P				Sheridan, CM; Heist, EK; Beals, CR; Crabtree, GR; Gardner, P			Protein kinase A negatively modulates the nuclear accumulation of NF-ATc1 by priming for subsequent phosphorylation by glycogen synthase kinase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; TRANSCRIPTION FACTOR NFATP; CYCLIN-DEPENDENT KINASES; DNA-BINDING ACTIVITY; NF-AT; CYCLOSPORINE-A; ANTIGEN-RECEPTOR; GENE-EXPRESSION; PHORBOL ESTER; PHOSPHATASE CALCINEURIN	The nuclear localization and transcriptional activity of the NF-ATc family of transcription factors, essential to many developmental, differentiation, and adaptation processes, are determined by the opposing activities of the phosphatase calcineurin, which promotes nuclear accumulation of NF-ATc, and several kinases, which promote cytoplasmic accumulation. Many reports suggest that protein kinase A (PKA) negatively modulates calcineurin-mediated NF-ATc activation. Here we show that overexpression of PKA causes phosphorylation and cytoplasmic accumulation of NF-ATc1 in direct opposition to calcineurin by phosphorylating Ser-245, Ser-269, and Ser-294 in the conserved serine-proline repeat domain, and that mutation of these serines blocks the effect of PKA. Activation of endogenous PKA is similarly able to promote phosphorylation of these sites on NF-ATc1 in two lymphoid cell lines. We further show that a complete block of NF-ATc1 nuclear localization by PKA requires a second kinase activity that can be supplied by glycogen synthase kinase-3 (GSK-3), and that mutation of either the PKA phosphorylation sites or the upstream GSK-3 sites prevents the effect of PKA. Thus, we propose that PKA functions cooperatively as a priming kinase for further phosphorylation by GSK-3 to oppose calcineurin-mediated nuclear accumulation and transcriptional activity of NF-ATc1 and that, through this mechanism, PKA may be an important modulator of many NF-ATc-dependent processes.	Stanford Univ, Program Immunol, Dept Mol Pharmacol, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Dept Pathol & Dev Biol, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University	Gardner, P (corresponding author), Stanford Univ, Program Immunol, Dept Mol Pharmacol, Dept Med, Stanford, CA 94305 USA.	pgardner@stanford.edu			NIAID NIH HHS [5P01AI36535] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI036535] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; ANASTASSIOU ED, 1992, J IMMUNOL, V148, P2845; Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BETZ M, 1991, J IMMUNOL, V146, P108; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; Chow CW, 2000, MOL CELL BIOL, V20, P5227, DOI 10.1128/MCB.20.14.5227-5234.2000; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Chow CW, 2000, MOL CELL BIOL, V20, P702, DOI 10.1128/MCB.20.2.702-712.2000; Chuvpilo S, 1999, J IMMUNOL, V162, P7294; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; DEGROOT RP, 1992, ONCOGENE, V7, P2281; del Arco PG, 2000, J BIOL CHEM, V275, P13872, DOI 10.1074/jbc.275.18.13872; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; HAMA N, 1995, J EXP MED, V181, P1217, DOI 10.1084/jem.181.3.1217; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; Heist EK, 1998, J BIOL CHEM, V273, P19763, DOI 10.1074/jbc.273.31.19763; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Jimenez JL, 2001, J PHARMACOL EXP THER, V299, P753; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Klemm JD, 1997, CURR BIOL, V7, P638, DOI 10.1016/S0960-9822(06)00290-9; LACOUR M, 1994, INT IMMUNOL, V6, P1333, DOI 10.1093/intimm/6.9.1333; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; LEE HJ, 1993, J IMMUNOL, V151, P6135; Li LS, 1999, SCIENCE, V283, P848, DOI 10.1126/science.283.5403.848; Luo C, 1996, MOL CELL BIOL, V16, P3955; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Navarro J, 1998, J VIROL, V72, P4712, DOI 10.1128/JVI.72.6.4712-4720.1998; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; Neilson J, 2001, CURR OPIN IMMUNOL, V13, P346, DOI 10.1016/S0952-7915(00)00225-9; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; NGHIEM P, 1994, NATURE, V371, P347, DOI 10.1038/371347a0; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Paliogianni F, 1996, CELL IMMUNOL, V171, P95, DOI 10.1006/cimm.1996.0178; PALIOGIANNI F, 1993, J EXP MED, V178, P1813, DOI 10.1084/jem.178.5.1813; Paliogianni F, 1996, CELL IMMUNOL, V168, P33, DOI 10.1006/cimm.1996.0046; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Schultz C, 1999, J MED CHEM, V42, P2909, DOI 10.1021/jm9900570; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Stankunas K, 1999, COLD SPRING HARB SYM, V64, P505, DOI 10.1101/sqb.1999.64.505; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; TSURUTA L, 1995, J IMMUNOL, V154, P5255; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; WANG QM, 1994, BIOCHEMISTRY-US, V33, P143, DOI 10.1021/bi00167a018; WATANABE S, 1994, INT IMMUNOL, V6, P523, DOI 10.1093/intimm/6.4.523; Weiss A, 1991, Semin Immunol, V3, P313; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; WOODGETT JR, 2001, SCI STKE; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	100	90	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48664	48676		10.1074/jbc.M207029200	http://dx.doi.org/10.1074/jbc.M207029200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12351631	hybrid			2022-12-27	WOS:000179789600091
J	Ji, HB; Gupta, A; Okamoto, S; Blum, MD; Tan, LJ; Goldring, MB; Lacy, E; Roy, AL; Terhorst, C				Ji, HB; Gupta, A; Okamoto, S; Blum, MD; Tan, LJ; Goldring, MB; Lacy, E; Roy, AL; Terhorst, C			T cell-specific expression of the murine CD3 delta promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V-BETA PROMOTER; TFII-I; BINDING PROTEIN; NATURAL-KILLER; GENE PROMOTER; CD4 ENHANCER; FACTOR YY1; TATA-LESS; ELEMENT; TRANSCRIPTION	T cell-specific expression of human and mouse CD3delta is known to be governed by an enhancer element immediately downstream from the gene. Here we demonstrate by transgenic and in vitro studies that the murine CD3delta (mCD3delta) promoter prefers to be expressed in cells of the T lineage. Deletion analyses of a promoter segment (-401/+48 bp) followed by transient transfections indicate that upstream elements between -149 and -112 bp contribute to full expression of the gene. Furthermore, a core promoter region -37/+29 appears to contribute to a T cell specificity. Using substitution mutant scanning, four positive and one negative regulatory elements were found within the mCD3delta core promoter. The first two positive elements comprise two classical initiator-like sites, which recruit TFII-I, whereas a third contains a functional Ets binding site. Immediately adjacent to the observed transcription start site is a negative element that utilizes the transcription regulator YY1. The last positive regulatory element contains a potentially functional CREB binding site and the minor transcriptional start site. Because NERF-2, Elf-1, and Ets-1 are expressed preferentially in lymphocytes and because, in addition, YY1 represses the promoter activity strongly in non-T cells, we conclude that the combination of these transcription factors contributes to the T cell-specific expression pattern of mouse CD3delta.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Immunol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Rheumatol, Boston, MA 02215 USA; Harvard Inst Med, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Cornell Univ, Weill Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; New England Baptist Hospital; Cornell University; Memorial Sloan Kettering Cancer Center; Tufts University	Ji, HB (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Immunol, RE-206,330 Brookline Ave, Boston, MA 02215 USA.			Lacy, Elizabeth/0000-0001-5457-0728	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017651, R01AI045150, R37AI017651, R21AI017651, R56AI045150] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045378] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-45150, AI-17651] Funding Source: Medline; NIAMS NIH HHS [AR-45378] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Barbeau B, 1999, ONCOGENE, V18, P5535, DOI 10.1038/sj.onc.1202913; Bassuk AG, 1998, MOL MED, V4, P392, DOI 10.1007/BF03401746; Bennett MK, 1999, J BIOL CHEM, V274, P13025, DOI 10.1074/jbc.274.19.13025; BLUM MD, 1993, J EXP MED, V177, P1343, DOI 10.1084/jem.177.5.1343; CHEN CH, 1989, P NATL ACAD SCI USA, V86, P2351, DOI 10.1073/pnas.86.7.2351; Cheriyath V, 2000, J BIOL CHEM, V275, P26300, DOI 10.1074/jbc.M002980200; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; Ellmeier W, 1999, ANNU REV IMMUNOL, V17, P523, DOI 10.1146/annurev.immunol.17.1.523; GALY A, 1995, IMMUNITY, V3, P459, DOI 10.1016/1074-7613(95)90175-2; GEORGOPOULOS K, 1990, EMBO J, V9, P109, DOI 10.1002/j.1460-2075.1990.tb08086.x; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Halle JP, 1997, MOL CELL BIOL, V17, P4220, DOI 10.1128/MCB.17.8.4220; Ikawa T, 1999, J EXP MED, V190, P1617, DOI 10.1084/jem.190.11.1617; LORENZ WW, 1991, P NATL ACAD SCI USA, V88, P4438, DOI 10.1073/pnas.88.10.4438; ManzanoWinkler B, 1996, J BIOL CHEM, V271, P12076, DOI 10.1074/jbc.271.20.12076; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; Montano MA, 1996, P NATL ACAD SCI USA, V93, P12376, DOI 10.1073/pnas.93.22.12376; Rellahan BL, 1998, J IMMUNOL, V160, P2794; Riquet FB, 2001, J BIOL CHEM, V276, P38665, DOI 10.1074/jbc.M009881200; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; SAITO H, 1987, P NATL ACAD SCI USA, V84, P9131, DOI 10.1073/pnas.84.24.9131; Sarafova S, 1999, J BIOL CHEM, V274, P16126, DOI 10.1074/jbc.274.23.16126; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Tung J W, 2001, BMC Mol Biol, V2, P5, DOI 10.1186/1471-2199-2-5; VANDENELSEN P, 1986, P NATL ACAD SCI USA, V83, P2944; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452; Ye JP, 1996, MOL CELL BIOL, V16, P157; Ye JP, 1996, MOL CELL BIOL, V16, P4744; Ye JP, 1999, J BIOL CHEM, V274, P26661, DOI 10.1074/jbc.274.38.26661; Zhou TY, 2001, J BIOL CHEM, V276, P25503, DOI 10.1074/jbc.M102875200	31	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47898	47906		10.1074/jbc.M201025200	http://dx.doi.org/10.1074/jbc.M201025200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12324448	hybrid			2022-12-27	WOS:000179663700137
J	Bouhss, A; Josseaume, N; Severin, A; Tabei, K; Hugonnet, JE; Shlaes, D; Mengin-Lecreulx, D; van Heijenoort, J; Arthur, M				Bouhss, A; Josseaume, N; Severin, A; Tabei, K; Hugonnet, JE; Shlaes, D; Mengin-Lecreulx, D; van Heijenoort, J; Arthur, M			Synthesis of the L-alanyl-L-alanine cross-bridge of Enterococcus faecalis peptidoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM RESISTANCE; BACTERIAL CELL-WALLS; STREPTOCOCCUS-PNEUMONIAE; GLYCOPEPTIDE RESISTANCE; STAPHYLOCOCCUS-AUREUS; IDENTIFICATION; ACTIVATION; GENES	The enzymatic synthesis of the complete L-alanyl(1)-L-alanine, side chain of the peptidoglycan precursors of Enterococcus faecalis was obtained in vitro using purified enzymes. The pathway involved alanyl-tRNA synthetase and two ligases, BppA1 and BppA2, that specifically transfer alanine from Ala-tRNA to the first and second positions of the side chain, respectively. The structure of the UDP-N-acetylmuramoyl-L-Ala-gamma-D-Glu-L-Lys(N-epsilon-L-Ala(1)-L-Ala(2))-D-Ala-D-Ala product of BppA1 and BppA2 was confirmed by mass spectrometry (MS) and MS/MS analyses. The peptidoglycan structure of the wild-type E. faecalis strain JH2-2 was determined by tandem reverse-phase high-pressure liquid chromatography-MS revealing that most muropeptides contained two L-alanyl residues in the cross-bridges and in the free N-terminal ends; Deletion of. the bppAg gene was associated with production of muropeptides containing a single alanyl residue at these positions. The relative abundance of monomers, dimers, trimers, and tetramers in the peptidoglycan of the bppA2 mutant indicated that precursors containing an incomplete side chain were efficiently used by the DD-transpeptidases in the cross-linking reaction. However, the bppA2 deletion impaired expression of intrinsic beta-lactam resistance suggesting that the low affinity penicillin-binding protein 5 did not function optimally with precursors substituted by a single alanine.	Univ Paris 06, INSERM, Unite Format & Rech Broussais Hotel Dieu, Lab Rech Mol Antibiot,E0004, F-75270 Paris 06, France; Univ Paris 11, CNRS, Inst Biochim Biophys Mol & Cellulaire, UMR 8619, F-91405 Orsay, France; Wyeth Ayerst Res, Pearl River, NY 10965 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Pfizer	Arthur, M (corresponding author), Univ Paris 06, INSERM, Unite Format & Rech Broussais Hotel Dieu, Lab Rech Mol Antibiot,E0004, 15 Rue Ecole Med, F-75270 Paris 06, France.		HUGONNET, Jean-Emmanuel/ABC-7914-2021; HUGONNET, Jean-Emmanuel/H-3581-2014; Arthur, Michel/G-3680-2013	HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; Arthur, Michel/0000-0003-1007-636X; MENGIN-LECREULX, Dominique/0000-0003-3205-0275				Arthur M, 1997, J BACTERIOL, V179, P97, DOI 10.1128/jb.179.1.97-106.1997; Arthur M, 1998, MOL MICROBIOL, V30, P819, DOI 10.1046/j.1365-2958.1998.01114.x; ARTHUR M, 1993, ANTIMICROB AGENTS CH, V37, P1563, DOI 10.1128/AAC.37.8.1563; Benson TE, 2002, STRUCTURE, V10, P1107, DOI 10.1016/S0969-2126(02)00807-9; BOUDEWIJN L, 1996, ANTIMICROB AGENTS CH, V40, P863; Bouhss A, 2001, J BACTERIOL, V183, P5122, DOI 10.1128/JB.183.17.5122-5127.2001; Filipe SR, 2000, J BIOL CHEM, V275, P27768; Filipe SR, 2000, P NATL ACAD SCI USA, V97, P4891, DOI 10.1073/pnas.080067697; Hegde SS, 2001, J BIOL CHEM, V276, P6998, DOI 10.1074/jbc.M008591200; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; JACOB AE, 1974, J BACTERIOL, V117, P360, DOI 10.1128/JB.117.2.360-372.1974; Mainardi JL, 2000, J BIOL CHEM, V275, P16490, DOI 10.1074/jbc.M909877199; Mainardi JL, 1998, MICROBIOL-UK, V144, P2679, DOI 10.1099/00221287-144-10-2679; MATSUHAS.M, 1967, J BIOL CHEM, V242, P3191; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; PLAPP R, 1970, J BIOL CHEM, V245, P3667; Rohrer S, 1999, P NATL ACAD SCI USA, V96, P9351, DOI 10.1073/pnas.96.16.9351; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; STAUDENBAUER W, 1972, J BIOL CHEM, V247, P5095; Stranden AM, 1997, J BACTERIOL, V179, P9, DOI 10.1128/jb.179.1.9-16.1997; TRIEUCUOT P, 1990, NUCLEIC ACIDS RES, V18, P3660, DOI 10.1093/nar/18.12.3660; Tschierske M, 1999, FEMS MICROBIOL LETT, V171, P97, DOI 10.1016/S0378-1097(98)00586-2; Weber B, 2000, FEMS MICROBIOL LETT, V188, P81, DOI 10.1016/S0378-1097(00)00214-7	23	61	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45935	45941		10.1074/jbc.M207449200	http://dx.doi.org/10.1074/jbc.M207449200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324463	hybrid			2022-12-27	WOS:000179529300031
J	Bitterman, KJ; Anderson, RM; Cohen, HY; Latorre-Esteves, M; Sinclair, DA				Bitterman, KJ; Anderson, RM; Cohen, HY; Latorre-Esteves, M; Sinclair, DA			Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast Sir2 and human SIRT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; LIFE-SPAN; PROTEIN SIR2; DEACETYLASE ACTIVITY; HISTONE DEACETYLASE; DNA-REPLICATION; GENE FAMILY; NAD; IDENTIFICATION; REPRESSION	The Saccharomyces cerevisiae Sir2 protein is an NAD(+)-dependent histone deacetylase that plays a critical role in transcriptional silencing, genome stability, and longevity. A human homologue of Sir2, SIRT1, regulates the activity of the p53 tumor suppressor and inhibits apoptosis. The Sir2 deacetylation reaction generates two products: O-acetyl-ADP-ribose and nicotinamide, a precursor of nicotinic acid and a form of niacin/vitamin B-3. We show here that nicotinamide strongly inhibits yeast silencing, increases rDNA recombination, and shortens replicative life span to that of a sir2 mutant. Nicotinamide abolishes silencing and leads to an eventual delocalization of Sir2 even in G(1)-arrested cells, demonstrating that silent heterochromatin requires continual Sir2 activity. We show that physiological concentrations of nicotinamide noncompetitively inhibit both Sir2 and SIRT1 in vitro. The degree of inhibition by nicotinamide (IC50 < 50 muM) is equal to or better than the most effective known synthetic inhibitors of this class of proteins. We propose a model whereby nicotinamide inhibits deacetylation by binding to a conserved pocket adjacent to NAD(+), thereby blocking NAD(+) hydrolysis. We discuss the possibility that nicotinamide is a physiologically relevant regulator of Sir2 enzymes.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Sinclair, DA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.	david_Sinclair@hms.harvard.edu	Latorre-Esteves, Magda/GMW-6353-2022	Cohen, Haim Y./0000-0002-6613-8710; Sinclair, David/0000-0002-9936-436X	NIA NIH HHS [AG11972-01] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; Armstrong CM, 2002, MOL BIOL CELL, V13, P1427, DOI 10.1091/mbc.01-10-0482; BARTON AA, 1950, J GEN MICROBIOL, V4, P84, DOI 10.1099/00221287-4-1-84; Bedalov A, 2001, P NATL ACAD SCI USA, V98, P15113, DOI 10.1073/pnas.261574398; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Borra MT, 2002, J BIOL CHEM, V277, P12632, DOI 10.1074/jbc.M111830200; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; Courey AJ, 2001, GENE DEV, V15, P2786; DIETRICH LS, 1971, AM J CLIN NUTR, V24, P800; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; FOSTER JW, 1990, J BACTERIOL, V172, P4187, DOI 10.1128/jb.172.8.4187-4196.1990; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gasser SM, 1998, CIBA F SYMP, V214, P114; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Ghidelli S, 2001, EMBO J, V20, P4522, DOI 10.1093/emboj/20.16.4522; Ghislain M, 2002, YEAST, V19, P215, DOI 10.1002/yea.810; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; HAGINO Y, 1968, J BIOL CHEM, V243, P4980; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Hoppe GJ, 2002, MOL CELL BIOL, V22, P4167, DOI 10.1128/MCB.22.12.4167-4180.2002; HOSHINO J, 1984, BIOCHIM BIOPHYS ACTA, V801, P250, DOI 10.1016/0304-4165(84)90074-6; IJICHI H, 1966, J BIOL CHEM, V241, P3701; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kaanders JHAM, 2002, INT J RADIAT ONCOL, V52, P769, DOI 10.1016/S0360-3016(01)02678-5; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; KENNEDY BK, 1994, J CELL BIOL, V127, P1985, DOI 10.1083/jcb.127.6.1985; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; Kirchmaier AL, 2001, SCIENCE, V291, P646, DOI 10.1126/science.291.5504.646; Knip M, 2000, DIABETOLOGIA, V43, P1337, DOI 10.1007/s001250051536; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Landry J, 2000, BIOCHEM BIOPH RES CO, V278, P685, DOI 10.1006/bbrc.2000.3854; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Li YC, 2001, SCIENCE, V291, P650, DOI 10.1126/science.291.5504.650; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Llorente B, 2000, FEBS LETT, V475, P237, DOI 10.1016/S0014-5793(00)01698-7; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Moazed D, 2001, CURR OPIN CELL BIOL, V13, P232, DOI 10.1016/S0955-0674(00)00202-7; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; Park PU, 1999, MOL CELL BIOL, V19, P3848; RINE J, 1987, GENETICS, V116, P9; Sandmeier JJ, 2002, GENETICS, V160, P877; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; Shou WY, 2001, MOL CELL, V8, P45, DOI 10.1016/S1097-2765(01)00291-X; Sinclair DA, 1998, TRENDS BIOCHEM SCI, V23, P131, DOI 10.1016/S0968-0004(98)01188-8; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Smythe GA, 2002, ANAL BIOCHEM, V301, P21, DOI 10.1006/abio.2001.5490; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Swiecilo A, 2000, ACTA BIOCHIM POL, V47, P355; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wood JG, 2002, TRENDS PHARMACOL SCI, V23, P1, DOI 10.1016/S0165-6147(00)01891-5; Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300	66	776	832	0	70	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45099	45107		10.1074/jbc.M205670200	http://dx.doi.org/10.1074/jbc.M205670200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12297502	hybrid			2022-12-27	WOS:000179404800066
J	Kasahara, H; Hanada, A; Kuzuyama, T; Takagi, M; Kamiya, Y; Yamaguchi, S				Kasahara, H; Hanada, A; Kuzuyama, T; Takagi, M; Kamiya, Y; Yamaguchi, S			Contribution of the mevalonate and methylerythritol phosphate pathways to the biosynthesis of gibberellins in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; ENT-KAURENE BIOSYNTHESIS; ISOPRENOID BIOSYNTHESIS; TERPENOID BIOSYNTHESIS; HIGHER-PLANTS; SYNTHASE-B; ACID; ENZYME; 1-DEOXY-D-XYLULOSE; 4-PHOSPHATE	Gibberellins (GAs) are diterpene plant hormones essential for many developmental processes. Although the GA biosynthesis pathway has been well studied, our knowledge on its early stage is still limited. There are two possible routes for the biosynthesis of isoprenoids leading to GAs, the mevalonate (MVA) pathway in the cytosol and the methylerythritol phosphate (MEP) pathway in plastids. To distinguish these possibilities, metabolites from each isoprenoid pathway were selectively labeled with C-13 in Arabidopsis seedlings. Efficient C-13-labeling was achieved by blocking the endogenous pathway chemically or genetically during the feed of a C-13-labeled precursor specific to the MVA or MEP pathways. Gas chromatography-mass spectrometry analyses demonstrated that both MVA and MEP pathways can contribute to the biosyntheses of GAs and campesterol, a cytosolic sterol, in Arabidopsis seedlings. While GAs are predominantly synthesized through the MEP pathway, the MVA pathway plays a major role in the biosynthesis of campesterol. Consistent with some crossover between the two pathways, phenotypic defects caused by the block of the MVA and MEP pathways were partially rescued by exogenous application of the MEP and MVA precursors, respectively. We also provide evidence to suggest that the MVA pathway still contributes to GA biosynthesis when this pathway is limiting.	RIKEN, Inst Phys & Chem Res, Plant Sci Ctr,Growth Physiol Res Grp, Lab Cellular Growth & Dev, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	RIKEN; University of Tokyo	Yamaguchi, S (corresponding author), RIKEN, Inst Phys & Chem Res, Plant Sci Ctr,Growth Physiol Res Grp, Lab Cellular Growth & Dev, Hirosawa 2-1, Wako, Saitama 3510198, Japan.	shinjiro@postman.riken.go.jp	Takagi, Motoki/C-9052-2009; Kasahara, Hiroyuki/F-6445-2012; Takagi, Motoki/Q-7390-2019; Yamaguchi, Shinjiro/F-9684-2010; Kamiya, Yuji/F-9420-2010	Kasahara, Hiroyuki/0000-0002-4858-0978; Kamiya, Yuji/0000-0003-4415-520X; Kuzuyama, Tomohisa/0000-0002-7221-5858				AACH H, 1995, PLANTA, V197, P333, DOI 10.1007/BF00202655; Adam KP, 1998, PHYTOCHEMISTRY, V48, P953, DOI 10.1016/S0031-9422(97)00992-8; Arigoni D, 1997, P NATL ACAD SCI USA, V94, P10600, DOI 10.1073/pnas.94.20.10600; BAUERLE R, 1990, PLANTA, V181, P229, DOI 10.1007/BF02411543; BLECHSCHMIDT S, 1984, PHYTOCHEMISTRY, V23, P553, DOI 10.1016/S0031-9422(00)80379-9; Choe SW, 1999, PLANT CELL, V11, P207, DOI 10.1105/tpc.11.2.207; Crozier A, 2000, BIOCH MOL BIOL PLANT, P851; Eisenreich W, 1998, CHEM BIOL, V5, pR221, DOI 10.1016/S1074-5521(98)90002-3; Estevez JM, 2000, PLANT PHYSIOL, V124, P95, DOI 10.1104/pp.124.1.95; Estevez JM, 2001, J BIOL CHEM, V276, P22901, DOI 10.1074/jbc.M100854200; Fujioka S, 1997, PLANT CELL, V9, P1951, DOI 10.1105/tpc.9.11.1951; GASKIN P, 1971, PHYTOCHEMISTRY, V10, P1155, DOI 10.1016/S0031-9422(00)89955-0; GASKIN P, 1991, GC MS GIBBERELLINS R, P69; GOAD JL, 1997, ANAL STEROLS, P158; GRAEBE JE, 1972, PLANTA, V102, P261, DOI 10.1007/BF00386896; GRAEBE JE, 1987, ANNU REV PLANT PHYS, V38, P419, DOI 10.1146/annurev.pp.38.060187.002223; GRAY JC, 1987, ADV BOT RES, V14, P25; HANSON JR, 1969, J CHEM SOC C, P981, DOI 10.1039/j39690000981; HEDDEN P, 1981, PHYTOCHEMISTRY, V20, P1011, DOI 10.1016/0031-9422(81)83019-1; Hedden P, 2001, J PLANT GROWTH REGUL, V20, P319, DOI 10.1007/s003440010037; Hirai N, 2000, BIOSCI BIOTECH BIOCH, V64, P1448, DOI 10.1271/bbb.64.1448; KREUZ K, 1984, EUR J BIOCHEM, V141, P531, DOI 10.1111/j.1432-1033.1984.tb08225.x; Kuzuyama T, 2002, BIOSCI BIOTECH BIOCH, V66, P1619, DOI 10.1271/bbb.66.1619; Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P4509, DOI 10.1016/S0040-4039(98)00802-8; Lange BM, 1998, P NATL ACAD SCI USA, V95, P2100, DOI 10.1073/pnas.95.5.2100; Lichtenthaler HK, 1999, ANNU REV PLANT PHYS, V50, P47, DOI 10.1146/annurev.arplant.50.1.47; Mandel MA, 1996, PLANT J, V9, P649, DOI 10.1046/j.1365-313X.1996.9050649.x; Okada K, 2002, PLANTA, V215, P339, DOI 10.1007/s00425-002-0762-0; Piel J, 1998, ANGEW CHEM INT EDIT, V37, P2478, DOI 10.1002/(SICI)1521-3773(19981002)37:18<2478::AID-ANIE2478>3.0.CO;2-Q; RAILTON ID, 1984, PHYTOCHEMISTRY, V23, P1261, DOI 10.1016/S0031-9422(00)80438-0; RAUSCHENBACH P, 1974, MESSUNG RADIOAKTIVEN, P360; Rohdich F, 2002, P NATL ACAD SCI USA, V99, P1158, DOI 10.1073/pnas.032658999; Rohmer M, 1999, NAT PROD REP, V16, P565, DOI 10.1039/a709175c; Rohmer M, 1996, J AM CHEM SOC, V118, P2564, DOI 10.1021/ja9538344; Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788; SAITO T, 1995, PLANT PHYSIOL, V109, P1239, DOI 10.1104/pp.109.4.1239; Schwender J, 2001, PLANTA, V212, P416, DOI 10.1007/s004250000409; SOLER E, 1993, PLANTA, V191, P324, DOI 10.1007/BF00195689; Sponsel VM, 2001, J PLANT GROWTH REGUL, V20, P332, DOI 10.1007/s003440010032; SUN TP, 1994, PLANT CELL, V6, P1509, DOI 10.1105/tpc.6.10.1509; Totte N, 2000, TETRAHEDRON LETT, V41, P6407, DOI 10.1016/S0040-4039(00)01094-7; TREHARNE KJ, 1966, BIOCHEM J, V99, P239, DOI 10.1042/bj0990239; Yamaguchi S, 2000, PLANT CELL PHYSIOL, V41, P251, DOI 10.1093/pcp/41.3.251; Yamaguchi S, 1996, PLANT J, V10, P203, DOI 10.1046/j.1365-313X.1996.10020203.x	45	183	197	5	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45188	45194		10.1074/jbc.M208659200	http://dx.doi.org/10.1074/jbc.M208659200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228237	hybrid			2022-12-27	WOS:000179404800077
J	Koutzamani, E; Loborg, H; Sarg, B; Lindner, HH; Rundquist, I				Koutzamani, E; Loborg, H; Sarg, B; Lindner, HH; Rundquist, I			Linker histone subtype composition and affinity for chromatin in situ in nucleated mature erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE CAPILLARY-ELECTROPHORESIS; VARIANT OVEREXPRESSION; CHICKEN ERYTHROCYTE; H1 DEGREES; XENOPUS; H1-DEGREES; BINDING; PROTEIN; PHOSPHORYLATION; H-1	The replacement linker histones H1(0) and H5 are present in frog and chicken erythrocytes, respectively, and their accumulation coincides with cessation of proliferation and compaction of chromatin. These cells have been analyzed for the affinity of linker histones for chromatin with cytochemical and biochemical methods. Our results show a stronger association between linker histones and chromatin in chicken erythrocyte nuclei than in frog erythrocyte nuclei. Analyses of linker histones from chicken erythrocytes using capillary electrophoresis showed H5 to be the subtype strongest associated with chromatin. The corresponding analyses of frog erythrocyte linker histones using reverse-phase high performance liquid chromatography showed that H1(0) dissociated from chromatin at somewhat higher ionic strength than the three additional subtypes present in frog blood but at lower ionic strength than chicken H5. Which of the two H1(0) variants in frog is expressed in erythrocytes has thus far been unknown. Amino acid sequencing showed that H1(0)-2 is the only H1(0) subtype present in frog erythrocytes and that it is 100% acetylated at its N termini. In conclusion, our results show differences between frog and chicken linker histone affinity for chromatin probably caused by the specific subtype composition present in each cell type. Our data also indicate a lack of correlation between linker histone affinity and chromatin condensation.	Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, SE-58185 Linkoping, Sweden; Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria	Linkoping University; University of Innsbruck	Rundquist, I (corresponding author), Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, SE-58185 Linkoping, Sweden.	ingru@mcb.liu.se	Koutzamani, Elisavet/N-4112-2015	Koutzamani, Elisavet/0000-0003-3059-5191				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BOLUND LA, 1973, EUR J BIOCHEM, V35, P546, DOI 10.1111/j.1432-1033.1973.tb02871.x; Brocard MP, 1997, GENE, V189, P127, DOI 10.1016/S0378-1119(96)00845-1; Brown DT, 1996, NUCLEIC ACIDS RES, V24, P486, DOI 10.1093/nar/24.3.486; CARY PD, 1981, EUR J BIOCHEM, V120, P371, DOI 10.1111/j.1432-1033.1981.tb05714.x; CASSIDY DM, 1978, DEV BIOL, V63, P224, DOI 10.1016/0012-1606(78)90127-6; COLE RD, 1987, INT J PEPT PROT RES, V30, P433; DESTREE OHJ, 1975, BIOCHIM BIOPHYS ACTA, V378, P450, DOI 10.1016/0005-2787(75)90189-6; Dimitrov S, 1996, EMBO J, V15, P5897, DOI 10.1002/j.1460-2075.1996.tb00976.x; Dou YL, 1999, MOL CELL, V4, P641, DOI 10.1016/S1097-2765(00)80215-4; Eufemi M, 2000, MOL BIOL REP, V27, P181, DOI 10.1023/A:1007203513462; Fan YH, 2001, MOL CELL BIOL, V21, P7933, DOI 10.1128/MCB.21.23.7933-7943.2001; GRIGORYEV SA, 1992, EXP CELL RES, V198, P268, DOI 10.1016/0014-4827(92)90379-M; Grigoryev SA, 1999, J BIOL CHEM, V274, P5626, DOI 10.1074/jbc.274.9.5626; Gunjan A, 1999, J BIOL CHEM, V274, P37950, DOI 10.1074/jbc.274.53.37950; HELLIGER W, 1988, BIOCHEM J, V255, P23, DOI 10.1042/bj2550023; HILL CS, 1991, EMBO J, V10, P1939, DOI 10.1002/j.1460-2075.1991.tb07720.x; Horn PJ, 2002, NAT STRUCT BIOL, V9, P263, DOI 10.1038/nsb776; Khochbin S, 2001, GENE, V271, P1, DOI 10.1016/S0378-1119(01)00495-4; KUMAR NM, 1980, NUCLEIC ACIDS RES, V8, P3535, DOI 10.1093/nar/8.16.3535; LINDNER H, 1992, BIOCHEM J, V283, P467, DOI 10.1042/bj2830467; LINDNER H, 1988, J CHROMATOGR, V450, P309, DOI 10.1016/S0021-9673(01)83585-8; LINDNER H, 1992, J CHROMATOGR, V608, P211, DOI 10.1016/0021-9673(92)87126-S; LINDNER H, 1989, J CHROMATOGR, V472, P243, DOI 10.1016/S0021-9673(00)94110-4; LINDNER H, 1993, ELECTROPHORESIS, V14, P480, DOI 10.1002/elps.1150140174; LINDNER H, 1995, ELECTROPHORESIS, V16, P604, DOI 10.1002/elps.1150160197; Loborg H, 1997, CYTOMETRY, V28, P212, DOI 10.1002/(SICI)1097-0320(19970701)28:3<212::AID-CYTO5>3.0.CO;2-F; Loborg H, 2000, CYTOMETRY, V40, P1; MARION C, 1985, BIOCHEMISTRY-US, V24, P6328, DOI 10.1021/bi00344a002; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; NAGARAJA S, 1995, BBA-GENE STRUCT EXPR, V1260, P207, DOI 10.1016/0167-4781(94)00201-D; Parseghian MH, 2001, BIOCHEM CELL BIOL, V79, P289; RISLEY MS, 1981, DEV BIOL, V84, P79, DOI 10.1016/0012-1606(81)90372-9; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; RUTLEDGE RG, 1984, EUR J BIOCHEM, V144, P191, DOI 10.1111/j.1432-1033.1984.tb08448.x; RUTLEDGE RG, 1988, GENE, V70, P117, DOI 10.1016/0378-1119(88)90110-2; Sarg B, 1999, ARCH BIOCHEM BIOPHYS, V372, P333, DOI 10.1006/abbi.1999.1503; SHIMIDZU M, 1987, J BIOCHEM-TOKYO, V102, P351, DOI 10.1093/oxfordjournals.jbchem.a122061; SUN JM, 1990, EMBO J, V9, P1651, DOI 10.1002/j.1460-2075.1990.tb08285.x; SUN JM, 1989, SCIENCE, V245, P68, DOI 10.1126/science.2740916; SUNG MT, 1977, BIOCHEMISTRY-US, V16, P279, DOI 10.1021/bi00621a019; Wagner T E, 1977, Biochemistry, V16, P286; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; Wolffe A., 1998, CHROMATIN STRUCTURE; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; WRIGHT JM, 1987, EUR J BIOCHEM, V168, P281, DOI 10.1111/j.1432-1033.1987.tb13418.x; Zlatanova J, 2000, FASEB J, V14, P1697, DOI 10.1096/fj.99-0869rev; Zlatanova J, 1996, PROG NUCLEIC ACID RE, V52, P217, DOI 10.1016/S0079-6603(08)60968-X; ZLATANOVA J, 1994, FASEB J, V8, P1260, DOI 10.1096/fasebj.8.15.8001738; ZLATANOVA J, 1992, J CELL SCI, V103, P889	50	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44688	44694		10.1074/jbc.M203533200	http://dx.doi.org/10.1074/jbc.M203533200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223471	hybrid			2022-12-27	WOS:000179404800013
J	Berridge, G; Dickinson, G; Parrington, J; Galione, A; Patel, S				Berridge, G; Dickinson, G; Parrington, J; Galione, A; Patel, S			Solubilization of receptors for the novel Ca2+-mobilizing messenger, nicotinic acid adenine dinucleotide phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; INOSITOL TRISPHOSPHATE RECEPTORS; CALCIUM-RELEASE CHANNEL; INDUCED CA2+ RELEASE; NAADP RECEPTORS; BINDING; COORDINATION; PURIFICATION; INHIBITION; CALMODULIN	Nicotinic acid adenine dinucleotide phosphate (NAADP) is a potent Ca2+ mobilizing agent in a variety of broken and intact cell preparations. In sea urchin egg homogenates, NAADP releases Ca2+ independently of inositol trisphosphate or ryanodine receptor activation. Little, however, is known concerning the molecular target for NAADP. Here we report for the first time solubilization of NAADP receptors from sea urchin egg homogenates. Supernatant fractions, prepared following Triton X-100 treatment, bound [P-32]NAADP with similar affinity and selectivity as membrane preparations. Furthermore, the unusual non-dissociating nature of NAADP binding to its receptor was preserved upon solubilization. NAADP receptors could also be released into supernatant fractions upon detergent treatment of membranes prelabeled with [P-32]NAADP. Tagged receptors prepared in this way, were readily resolved by native gel electrophoresis as a single protein target. Gel filtration and sucrose density gradient centrifugation analysis indicates that NAADP receptors are substantially smaller than inositol trisphosphate or ryanodine receptors, providing further biochemical evidence that NAADP activates a novel intracellular Ca2+ release channel.	UCL, Dept Physiol, London WC1E 6BT, England; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of London; University College London; University of Oxford	Patel, S (corresponding author), UCL, Dept Physiol, Gower St, London WC1E 6BT, England.	patel.s@ucl.ac.uk	Dickinson, George/H-6609-2016; Galione, Antony/E-5884-2011; Dickinson, George/D-1461-2009; Patel, Sandip/O-9591-2015	Dickinson, George/0000-0001-7711-0388; Dickinson, George/0000-0001-7711-0388; Galione, Antony/0000-0002-4132-7646; Patel, Sandip/0000-0001-7247-2013				Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Albrieux M, 1998, J BIOL CHEM, V273, P14566, DOI 10.1074/jbc.273.23.14566; Bak J, 2001, CURR BIOL, V11, P987, DOI 10.1016/S0960-9822(01)00269-X; Berg I, 2000, J CELL BIOL, V150, P581, DOI 10.1083/jcb.150.3.581; Berridge G, 2002, BIOCHEM J, V365, P295, DOI 10.1042/BJ20020180; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Billington RA, 2000, BIOCHEM BIOPH RES CO, V276, P112, DOI 10.1006/bbrc.2000.3444; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P7257, DOI 10.1074/jbc.270.13.7257; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Chini EN, 1996, BIOCHEM J, V316, P709, DOI 10.1042/bj3160709; CHINI EN, 1995, J BIOL CHEM, V270, P3216, DOI 10.1074/jbc.270.7.3216; Churchill GC, 2000, J BIOL CHEM, V275, P38687, DOI 10.1074/jbc.M005827200; Churchill GC, 2001, EMBO J, V20, P2666, DOI 10.1093/emboj/20.11.2666; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GALIONE A, 1994, MOL CELL ENDOCRINOL, V98, P125, DOI 10.1016/0303-7207(94)90130-9; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Iino M, 1999, MOL CELL BIOCHEM, V190, P185, DOI 10.1023/A:1006951317052; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 1997, J BIOL CHEM, V272, P20378, DOI 10.1074/jbc.272.33.20378; Lee HC, 2000, J CELL SCI, V113, P4413; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; Patel S, 2000, J BIOL CHEM, V275, P36495, DOI 10.1074/jbc.C000458200; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patel S, 1997, P NATL ACAD SCI USA, V94, P11627, DOI 10.1073/pnas.94.21.11627; Patel S, 2001, TRENDS BIOCHEM SCI, V26, P482, DOI 10.1016/S0968-0004(01)01896-5; Patel S, 2000, BIOCHEM J, V352, P725, DOI 10.1042/0264-6021:3520725; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; Santella L, 2000, J BIOL CHEM, V275, P8301, DOI 10.1074/jbc.275.12.8301; Shi Q., 1998, GEL ELECTROPHORESIS; Sorrentino V, 1995, Adv Pharmacol, V33, P67, DOI 10.1016/S1054-3589(08)60666-3; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; Taylor CW, 1998, BBA-MOL CELL BIOL L, V1436, P19, DOI 10.1016/S0005-2760(98)00122-2; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0	43	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43717	43723		10.1074/jbc.M203224200	http://dx.doi.org/10.1074/jbc.M203224200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223470	hybrid			2022-12-27	WOS:000179272000024
J	Takei, Y; Assenberg, M; Tsujimoto, G; Laskey, R				Takei, Y; Assenberg, M; Tsujimoto, G; Laskey, R			The MCM3 acetylase MCM3AP inhibits initiation, but not elongation, of DNA replication via interaction with MCM3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINICHROMOSOME MAINTENANCE PROTEIN; SACCHAROMYCES-CEREVISIAE; GERMINAL CENTER; NUCLEAR-LOCALIZATION; HELICASE ACTIVITY; BIND CHROMATIN; CELL-CYCLE; S-PHASE; COMPLEX; GANP	Minichromosome maintenance (MCM) proteins are essential components of pre-replication complexes, which limit DNA replication to once per cell cycle. MCM3 acetylating protein, MCM3AP, binds and acetylates MCM3 and inhibits cell cycle progression. In the present study, we examined inhibition of the cell cycle by MCM3AP in a cell-free system. We show here that wild type MCM3AP, but not the acetylase-deficient mutant, inhibits initiation of DNA replication, but not elongation. Both wild type and acetylase-deficient mutant MCM3AP, however, can bind to chromatin through interaction with MCM3. These results indicate that MCM3 acetylase activity of MCM3AP is required to inhibit initiation of DNA replication and that association of MCM3AP to chromatin alone is not sufficient for the inhibition. We also show that interaction between MCM3 and MCM3AP is essential for nuclear localization and chromatin binding of MCM3AP. Furthermore, the chromatin binding of MCM3AP is temporally correlated with that of endogenous MCM3 when cells were released from mitosis. Hence, MCM3AP is a potent natural inhibitor of the initiation of DNA replication whose action is mediated by interaction with MCM3.	Hutchinson MRC Res Ctr, Canc Cell Unit, Med Res Council MRC, Canc Cell Unit, Cambridge CB2 2XZ, England; Univ Cambridge, Dept Zool, Cambridge, England; Childrens Natl Med Ctr, Div Mol Cell Pharmacol, Setagaya Ku, Tokyo 1548509, Japan	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Cambridge	Takei, Y (corresponding author), Hutchinson MRC Res Ctr, Canc Cell Unit, Med Res Council MRC, Canc Cell Unit, Hills Rd, Cambridge CB2 2XZ, England.							Abe E, 2000, GENE, V255, P219, DOI 10.1016/S0378-1119(00)00336-X; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Kimura H, 1996, GENES CELLS, V1, P977, DOI 10.1046/j.1365-2443.1996.840284.x; Krude T, 2000, J BIOL CHEM, V275, P13699, DOI 10.1074/jbc.275.18.13699; Krude T, 1996, J CELL SCI, V109, P309; Krude T, 1999, EXP CELL RES, V247, P148, DOI 10.1006/excr.1998.4342; Kuwahara K, 2000, BLOOD, V95, P2321, DOI 10.1182/blood.V95.7.2321.007k33_2321_2328; Kuwahara K, 2001, P NATL ACAD SCI USA, V98, P10279, DOI 10.1073/pnas.181335698; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Takei Y, 1998, J BIOL CHEM, V273, P22177, DOI 10.1074/jbc.273.35.22177; Takei Y, 2001, EMBO REP, V2, P119, DOI 10.1093/embo-reports/kve026; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Young MR, 1997, MOL BIOL CELL, V8, P1587, DOI 10.1091/mbc.8.8.1587; Young MR, 1997, GENES CELLS, V2, P631, DOI 10.1046/j.1365-2443.1997.1510349.x	21	32	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43121	43125		10.1074/jbc.C200442200	http://dx.doi.org/10.1074/jbc.C200442200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12226073	hybrid			2022-12-27	WOS:000179081200092
J	Chang, JS; Henry, K; Wolf, BL; Geli, M; Lemmon, SK				Chang, JS; Henry, K; Wolf, BL; Geli, M; Lemmon, SK			Protein phosphatase-1 binding to Scd5p is important for regulation of actin organization and endocytosis in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE/THREONINE KINASE PRK1P; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; GLYCOGEN ACCUMULATION; CLATHRIN DEFICIENCY; BUDDING YEAST; TYPE-1; PHOSPHORYLATION; CYTOSKELETON; ENCODES	SCD5, an essential gene, encodes a protein important for endocytosis and actin organization in yeast. Previous two-hybrid screens showed that Scd5p interacts with Glc7p, a yeast Ser/Thr-specific protein phosphatase-1 (PP1) that participates in a variety of cellular processes. PP1 substrate specificity in vivo is regulated by association with different regulatory or targeting subunits, many of which have a consensus PP1-binding site ((V/I)XT, with a basic residue at the -1 or -2 position). Scd5p contains two of these potential PP1-binding motifs: KVDF (amino acids 240-243) and KKVRF (amino acids 272-276). Deletion analysis mapped the PP1-binding domain to a region of Scd5p containing these motifs. Therefore, the consequence of mutating these two potential PP1-binding sites was examined. Although mutation of KVDF had no effect, alteration of KKVRF dramatically reduced Scd5p interaction with Glc7p and resulted in temperature-sensitive growth. Furthermore, this mutation caused defects in fluid phase and receptor-mediated endocytosis and actin organization. Overexpression of GLC7 suppressed the temperature-sensitive growth of the KKVRF mutant and partially rescued the actin organization phenotype. These results provide evidence that Scd5p is a PP1 targeting subunit for regulation of actin organization and endocytosis or that Scd5p is a PP1 substrate, which regulates the function of Scd5p in these processes.	Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany	Case Western Reserve University; Ruprecht Karls University Heidelberg	Lemmon, SK (corresponding author), Case Western Reserve Univ, Dept Mol Biol & Microbiol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	skl@po.ewru.edu	Chang, Ji Suk/N-1957-2017; Geli, Maria Isabel/L-3246-2014	Geli, Maria Isabel/0000-0002-3452-6700; Lemmon, Sandra/0000-0002-8022-130X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM020082, R01GM055796] Funding Source: NIH RePORTER; NIGMS NIH HHS [F31 GM20082, R01 GM55796] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1991, METHOD ENZYMOL, V194, P729; AIYAR A, 1993, BIOTECHNIQUES, V14, P366; Anderson C, 2001, J BACTERIOL, V183, P821, DOI 10.1128/JB.183.3.821-829.2001; Andrews PD, 2000, J CELL SCI, V113, P507; Balguerie A, 1999, J CELL SCI, V112, P2529; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; CANNON JF, 1994, GENETICS, V136, P485; Connor JH, 1998, J BIOL CHEM, V273, P27716, DOI 10.1074/jbc.273.42.27716; Cope MJTV, 1999, J CELL BIOL, V144, P1203, DOI 10.1083/jcb.144.6.1203; Dombek KM, 1999, MOL CELL BIOL, V19, P6029; DULIC V, 1991, METHOD ENZYMOL, V194, P697; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; FENG ZH, 1991, J BIOL CHEM, V266, P23796; Fong NM, 2000, J BIOL CHEM, V275, P35034, DOI 10.1074/jbc.M005541200; FRANCOIS JM, 1992, EMBO J, V11, P87, DOI 10.1002/j.1460-2075.1992.tb05031.x; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; HARDY TA, 1993, J BIOL CHEM, V268, P23799; Henry KR, 2002, MOL BIOL CELL, V13, P2607, DOI 10.1091/mbc.E02-01-0012; HISAMOTO N, 1995, MOL CELL BIOL, V15, P3767; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Huang DQ, 1996, MOL CELL BIOL, V16, P4357; Huang DQ, 1998, MOL CELL BIOL, V18, P3289, DOI 10.1128/MCB.18.6.3289; Huang DQ, 1996, GENETICS, V143, P119; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; James P, 1996, GENETICS, V144, P1425; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; Kaiser C, 1994, METHODS YEAST GENETI, P169; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; MACKELVIE SH, 1995, MOL CELL BIOL, V15, P3777; McAvoy T, 1999, BIOCHEMISTRY-US, V38, P12943, DOI 10.1021/bi991227d; Miller J. H, 1972, EXPT MOL GENETICS; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Nelson KK, 1996, MOL BIOL CELL, V7, P245, DOI 10.1091/mbc.7.2.245; NELSON KK, 1993, MOL CELL BIOL, V13, P521, DOI 10.1128/MCB.13.1.521; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; Oliver CJ, 2002, MOL CELL BIOL, V22, P4690, DOI 10.1128/MCB.22.13.4690-4701.2002; PARK IK, 1994, J BIOL CHEM, V269, P28919; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; ROCKMILL B, 1990, GENETICS, V126, P563; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; Schillace RV, 2001, J BIOL CHEM, V276, P12128, DOI 10.1074/jbc.M010398200; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SIKORSKI RS, 1989, GENETICS, V122, P19; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; STEPP JD, 1995, MOL BIOL CELL, V6, P41, DOI 10.1091/mbc.6.1.41; STONE EM, 1993, CURR BIOL, V3, P13, DOI 10.1016/0960-9822(93)90140-J; STUART JS, 1994, MOL CELL BIOL, V14, P896, DOI 10.1128/MCB.14.2.896; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; Tachikawa H, 2001, J CELL BIOL, V155, P797, DOI 10.1083/jcb.200107008; Tanaka J, 1998, BIOCHEMISTRY-US, V37, P16697, DOI 10.1021/bi980782x; Trinkle-Mulcahy L, 1999, J CELL SCI, V112, P157; Tu JL, 1996, MOL CELL BIOL, V16, P4199; TU JL, 1995, EMBO J, V14, P5939, DOI 10.1002/j.1460-2075.1995.tb00282.x; TUNG HYL, 1995, MOL CELL BIOL, V15, P6064; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Watson HA, 2001, MOL BIOL CELL, V12, P3668, DOI 10.1091/mbc.12.11.3668; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; Wu X, 2001, MOL GENET GENOMICS, V265, P622, DOI 10.1007/s004380100455; Yang S, 1999, MOL BIOL CELL, V10, P2265, DOI 10.1091/mbc.10.7.2265; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; Zeng GH, 2001, MOL BIOL CELL, V12, P3759, DOI 10.1091/mbc.12.12.3759; Zeng GS, 1999, J CELL BIOL, V144, P71, DOI 10.1083/jcb.144.1.71; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	67	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48002	48008		10.1074/jbc.M208471200	http://dx.doi.org/10.1074/jbc.M208471200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12356757	hybrid			2022-12-27	WOS:000179789600006
J	del Pozo, AM; Lacadena, V; Mancheno, JM; Olmo, N; Onaderra, M; Gavilanes, JG				del Pozo, AM; Lacadena, V; Mancheno, JM; Olmo, N; Onaderra, M; Gavilanes, JG			The antifungal protein AFP of Aspergillus giganteus is an oligonucleotide/oligosaccharide binding (OB) fold-containing protein that produces condensation of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD-SHOCK PROTEIN; ESCHERICHIA-COLI; DEOXYRIBONUCLEIC-ACID; ANTITUMOR AGENT; ALPHA-SARCIN; EXPRESSION; CLONING; IDENTIFICATION; REPLICATION; SEQUENCE	The antifungal protein AFP is a small polypeptide of 51 amino acid residues secreted by Aspergillus giganteus. Its potent activity against phytopathogenic fungi converts AFP in a promising tool in plant protection. However, no data have been reported regarding the mode of action of AFP. The three-dimensional structure of this protein, a small and compact beta barrel composed of five highly twisted antiparallel beta strands, displays the characteristic features of the oligonuclootide/oligosaccharide binding (OB fold) structural motif. A comparison of the structures of AFP and OB fold-containing proteins shows this structural similarity despite the absence of any significant sequence similarity. AFP, like most OB fold-containing proteins, binds nucleic acids. The protein promotes charge neutralization and condensation of DNA as demonstrated by electrophoretic mobility shift and ethidium bromide displacement assays. Nucleic acid produces quenching of the protein fluorescence emission. This nucleic acid interacting ability of AFP may be related to the antifungal activity of this small polypeptide.	Univ Complutense Madrid, Dept Bioquim & Biol Mol, Fac Quim, E-28040 Madrid, Spain	Complutense University of Madrid	del Pozo, AM (corresponding author), Univ Complutense Madrid, Dept Bioquim & Biol Mol, Fac Quim, E-28040 Madrid, Spain.	alvaro@bbm1.ucm.es; ppgf@bbm1.ucm.es	LÓPEZ, NIEVES OLMO/K-5266-2014; Gavilanes, Jose G./K-5307-2014; Martinez-del-Pozo, Alvaro/L-8556-2014; Mancheno, Jose/K-4984-2014; OÑADERRA, Mercedes/H-2527-2015	LÓPEZ, NIEVES OLMO/0000-0002-8013-5313; Gavilanes, Jose G./0000-0002-6852-341X; Martinez-del-Pozo, Alvaro/0000-0003-0043-5939; Mancheno, Jose/0000-0001-6943-3291; OÑADERRA, Mercedes/0000-0003-2564-5609				Antson AA, 2000, CURR OPIN STRUC BIOL, V10, P87, DOI 10.1016/S0959-440X(99)00054-8; Bloomfield VA, 1996, CURR OPIN STRUC BIOL, V6, P334, DOI 10.1016/S0959-440X(96)80052-2; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BULSINK H, 1988, EUR J BIOCHEM, V176, P597, DOI 10.1111/j.1432-1033.1988.tb14319.x; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; CAMPOSOLIVAS R, 1995, BIOCHEMISTRY-US, V34, P3009, DOI 10.1021/bi00009a032; CHATTORAJ DK, 1978, J MOL BIOL, V121, P327, DOI 10.1016/0022-2836(78)90367-4; Draper DE, 1999, NUCLEIC ACIDS RES, V27, P381, DOI 10.1093/nar/27.2.381; DURAND M, 1975, BIOCHEMISTRY-US, V14, P563, DOI 10.1021/bi00674a016; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; Golan R, 1999, BIOCHEMISTRY-US, V38, P14069, DOI 10.1021/bi990901o; Gottschalk S, 1996, GENE THER, V3, P448; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; HARD T, 1988, EUR BIOPHYS J BIOPHY, V16, P231, DOI 10.1007/BF00261265; Hase M, 1998, J BIOL CHEM, V273, P28651, DOI 10.1074/jbc.273.44.28651; Jiang WN, 1997, J BIOL CHEM, V272, P196; Kobayashi T, 1997, J BIOL CHEM, V272, P15154, DOI 10.1074/jbc.272.24.15154; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lacadena J, 1995, ARCH BIOCHEM BIOPHYS, V324, P273, DOI 10.1006/abbi.1995.0040; Lee DG, 1999, BIOCHEM BIOPH RES CO, V263, P646, DOI 10.1006/bbrc.1999.1428; Lopez MM, 1999, J BIOL CHEM, V274, P33601, DOI 10.1074/jbc.274.47.33601; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MartinezRuiz A, 1997, BBA-PROTEIN STRUCT M, V1340, P81, DOI 10.1016/S0167-4838(97)00038-1; Marx F, 1995, GENE, V167, P167, DOI 10.1016/0378-1119(95)00701-6; MESSING J, 1983, METHOD ENZYMOL, V101, P20; Meyer V, 2002, MOL GENET GENOMICS, V266, P747, DOI 10.1007/s00438-001-0609-6; MILLER H, 1987, METHOD ENZYMOL, V152, P145; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NAKAYA K, 1990, EUR J BIOCHEM, V193, P31, DOI 10.1111/j.1432-1033.1990.tb19300.x; Oldach KH, 2001, MOL PLANT MICROBE IN, V14, P832, DOI 10.1094/MPMI.2001.14.7.832; OLSON BH, 1965, APPL MICROBIOL, V13, P322, DOI 10.1128/AEM.13.3.322-326.1965; OLSON BH, 1965, APPL MICROBIOL, V13, P314, DOI 10.1128/AEM.13.3.314-321.1965; Sambrook J., 2001, MOL CLONING LAB MANU; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; Vila L, 2001, MOL PLANT MICROBE IN, V14, P1327, DOI 10.1094/MPMI.2001.14.11.1327; WILSON RW, 1979, BIOCHEMISTRY-US, V18, P2192, DOI 10.1021/bi00578a009; WNENDT S, 1994, CURR GENET, V25, P519, DOI 10.1007/BF00351672; WNENDT S, 1990, NUCLEIC ACIDS RES, V18, P3987, DOI 10.1093/nar/18.13.3987	39	31	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46179	46183		10.1074/jbc.M207472200	http://dx.doi.org/10.1074/jbc.M207472200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351633	hybrid			2022-12-27	WOS:000179529300064
J	Hu, AH; Wang, F; Sellers, JR				Hu, AH; Wang, F; Sellers, JR			Mutations in human nonmuscle myosin IIA found in patients with May-Hegglin anomaly and Fechtner syndrome result in impaired enzymatic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; HEAVY-CHAINS; LIGHT-CHAIN; IN-VITRO; STATE; ACTIN; EXPRESSION; FRAGMENTS; PLATELET; COMPLEX	A family of autosomal-dominant diseases including May-Hegglin anomaly, Fechtner syndrome, Sebastian syndrome, Alport syndrome, and Epstein syndrome are commonly characterized by giant platelets and thrombocytopenia. In addition, there may be leukocyte inclusions, deafness, cataracts, and nephritis, depending on the syndrome. Mutations in the human nonmuscle myosin IIA heavy chain gene (WYH9) have been linked to these diseases. Two of the recently described mutations, N93K and R702C, are conserved in smooth and nonmuscle myosins from vertebrates and lie in the head domain of myosin. Interestingly, the two mutations lie within close proximity in the three-dimensional structure of myosin. These two mutations were engineered into a heavy meromyosin-like recombinant fragment of nonmuscle myosin IIA which was expressed in baculovirus along with the appropriate light chains. The R702C mutant displays 25% of the maximal MgATPase activity of wild type heavy meromyosin and moves actin filaments at half the wild type rate. The effects of the N93K mutation are more dramatic. This heavy meromyosin has only 4% of the maximal MgATPase activity of wild type and does not translocate actin filaments in an in vitro motility assay. Biochemical characterization of the mutant is consistent with this mutant being unable to fully adopt the "on" conformation.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Sellers, JR (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10,Rm 8N202, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL001786, ZIAHL001786] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Bobkov AA, 2000, BIOPHYS J, V79, P460, DOI 10.1016/S0006-3495(00)76307-7; Cope MJTV, 1996, STRUCTURE, V4, P969, DOI 10.1016/S0969-2126(96)00103-7; Cuda G, 1997, BIOPHYS J, V72, P1767, DOI 10.1016/S0006-3495(97)78823-4; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Friedman AL, 1998, BIOCHEMISTRY-US, V37, P9679, DOI 10.1021/bi973143f; HARRIS DE, 1994, J MUSCLE RES CELL M, V15, P11, DOI 10.1007/BF00123828; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; Heath KE, 2001, AM J HUM GENET, V69, P1033, DOI 10.1086/324267; Houdusse A, 2000, P NATL ACAD SCI USA, V97, P11238, DOI 10.1073/pnas.200376897; Italiano JE, 1999, J CELL BIOL, V147, P1299, DOI 10.1083/jcb.147.6.1299; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kelley MJ, 2000, NAT GENET, V26, P106, DOI 10.1038/79069; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; Kunishima S, 2001, J HUM GENET, V46, P722, DOI 10.1007/s100380170007; Kunishima S, 2001, BLOOD, V97, P1147, DOI 10.1182/blood.V97.4.1147; Lalwani AK, 2000, AM J HUM GENET, V67, P1121, DOI 10.1016/S0002-9297(07)62942-5; Mhawech P, 2000, AM J CLIN PATHOL, V113, P176, DOI 10.1309/FC4H-LM5V-VCW8-DNJU; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; Sellers J. R., 1999, MYOSINS; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; SELLERS JR, 1983, J BIOL CHEM, V258, P4181; SELLERS JR, 1993, MOTILITY ASSAYS MOTO; Seri M, 2000, NAT GENET, V26, P103; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; Wang F, 2000, BIOCHEMISTRY-US, V39, P5555, DOI 10.1021/bi000133x	30	73	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46512	46517		10.1074/jbc.M208506200	http://dx.doi.org/10.1074/jbc.M208506200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237319	hybrid			2022-12-27	WOS:000179529300105
J	May, MJ; Marienfeld, RB; Ghosh, S				May, MJ; Marienfeld, RB; Ghosh, S			Characterization of the I kappa B-kinase NEMO binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IKK-BETA SUBUNIT; LIVER DEGENERATION; ALPHA-SUBUNIT; MICE LACKING; ACTIVATION; GAMMA; PHOSPHORYLATION; RECRUITMENT; COMPONENT; COMPLEX	Proinflammatory activation of NF-kappaB requires an upstream kinase complex (IkappaB-kinase; IKK) composed of two catalytic subunits (IKKalpha and IKKbeta) and a noncatalytic regulatory component named NEMO (NF-kappaB essential modulator). NEMO interacts with a COOH-terminal sequence within both IKKs termed the NEMO-binding domain (NBD), and a cell-permeable NBD peptide blocks NEMO/lKKbeta interactions and inhibits tumor necrosis factor-alpha-induced NF-kappaB. We report here that a peptide encompassing the NBD not only blocked association of both IKKs with NEMO but also disrupted preformed NEMO/IKK complexes in vitro. Furthermore, peptide blocking and alanine-scanning mutation studies revealed differences between the NBDs of IKKalpha and IKKbeta, and mutational analysis of the IKKbeta NBD identified the physical properties required at each position to maintain association with NEMO. Finally, we demonstrate that loss of NEMO-binding by IKKbeta through deletion of the NBD renders it catalytically active and that potential phosphorylation within the IKKbeta NBD may serve as a signal to down-regulate IKK activity. Our findings therefore provide critical insight into the physical properties of the NBD that will be valuable for the design of drugs aimed at disrupting the IKK complex and also reveal potential regulatory mechanisms controlling the function of the IKK complex.	Yale Univ, Sch Med, Immunobiol Sect, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, Howard Hughes Med Inst, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University	Ghosh, S (corresponding author), Yale Univ, Sch Med, Immunobiol Sect, Howard Hughes Med Inst, 310 Cedar St, New Haven, CT 06520 USA.	sankar.ghosh@yale.edu		May, Michael/0000-0002-2485-3716				Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; D'Acquisto Fulvio, 2002, Mol Interv, V2, P22, DOI 10.1124/mi.2.1.22; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Devin A, 2001, MOL CELL BIOL, V21, P3986, DOI 10.1128/MCB.21.12.3986-3994.2001; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Harhaj EW, 1997, J BIOL CHEM, V272, P5409, DOI 10.1074/jbc.272.9.5409; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Kaisho T, 2001, J EXP MED, V193, P417, DOI 10.1084/jem.193.4.417; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Senftleben U, 2001, IMMUNITY, V14, P217, DOI 10.1016/S1074-7613(01)00104-2; Smahi A, 2000, NATURE, V405, P466; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tchernof A, 2000, DIABETES, V49, P1709, DOI 10.2337/diabetes.49.10.1709; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	42	121	127	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45992	46000		10.1074/jbc.M206494200	http://dx.doi.org/10.1074/jbc.M206494200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244103	hybrid			2022-12-27	WOS:000179529300039
J	Baumann, B; Bohnenstengel, F; Siegmund, D; Wajant, H; Weber, C; Herr, I; Debatin, KM; Proksch, P; Wirth, T				Baumann, B; Bohnenstengel, F; Siegmund, D; Wajant, H; Weber, C; Herr, I; Debatin, KM; Proksch, P; Wirth, T			Rocaglamide derivatives are potent inhibitors of NF-kappa B activation in T-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIINFLAMMATORY SESQUITERPENE LACTONE; PROINFLAMMATORY GENE-EXPRESSION; REL TRANSCRIPTION FACTORS; CANCER-THERAPY; SIGNALING PATHWAY; INDUCED APOPTOSIS; KINASE COMPLEX; TNF; PROTEASOME; CURCUMIN	Crude extracts from different Aglaia species are used as anti-inflammatory remedies in the traditional medicine of several countries from Southeast Asia. Because NF-kappaB transcription factors represent key regulators of genes involved in immune and inflammatory responses, we supposed that the anti-inflammatory effects of Aglaia extracts are mediated by the inhibition of NF-kappaB activity. Purified compounds of Aglaia species, namely 1H-cyclopenta[b]benzofuran lignans of the rocaglamide type as well as one aglain congener were tested for their ability to inhibit NF-kappaB activity. We show that a group of rocaglamides represent highly potent and specific inhibitors of tumor necrosis factor-alpha (TNFalpha) and phorbol 12-myristate 13-acetate (PMA)-induced NF-kappaB-dependent reporter gene activity in Jurkat T cells with IC50 values in the nanomolar range. Some derivatives are less effective, and others are completely inactive. Rocaglamides are able to suppress the PMA-induced expression of NF-kappaB target genes and sensitize leukemic T cells to apoptosis induced by TNFalpha, cisplatin, and gamma-irradiation. The suppression of NF-kappaB activation correlated with the inhibition of induced IkappaBalpha degradation and IkappaBalpha kinase activation. The level of interference was determined and found to be localized upstream of the IkappaB kinase complex but downstream of the TNF receptor-associated protein 2. Our data suggest that rocaglamide derivatives could serve as lead structures in the development of anti-inflammatory and tumoricidal drugs.	Univ Ulm, Dept Chem Phys, D-89081 Ulm, Germany; Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Childrens Hosp, D-89075 Ulm, Germany; Univ Dusseldorf, Inst Pharmaceut Biol, D-40225 Dusseldorf, Germany; Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; German Canc Res Ctr, D-69120 Heidelberg, Germany	Ulm University; Ulm University; Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Heinrich Heine University Dusseldorf; University of Stuttgart; Helmholtz Association; German Cancer Research Center (DKFZ)	Wirth, T (corresponding author), Univ Ulm, Dept Chem Phys, D-89081 Ulm, Germany.	thomas.wirth@medizin.uni-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Proksch, Peter/AAR-4593-2020; Wajant, Harald/A-3020-2017; Wirth, Thomas/X-7172-2019	Debatin, Klaus-Michael/0000-0002-8397-1886; Wajant, Harald/0000-0002-2005-3949; 				Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2002, TRENDS MOL MED, V8, pS49, DOI 10.1016/S1471-4914(02)02315-8; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Baumann B, 1998, J BIOL CHEM, V273, P11448, DOI 10.1074/jbc.273.19.11448; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Bohnenstengel FI, 1999, Z NATURFORSCH C, V54, P55; Bohnenstengel FI, 1999, Z NATURFORSCH C, V54, P1075; Bork PM, 1997, FEBS LETT, V402, P85, DOI 10.1016/S0014-5793(96)01502-5; Brader G, 1998, J NAT PROD, V61, P1482, DOI 10.1021/np9801965; Brennan P, 1998, BIOCHEM PHARMACOL, V55, P965, DOI 10.1016/S0006-2952(97)00535-2; Chaidir, 1999, PHYTOCHEMISTRY, V52, P837, DOI 10.1016/S0031-9422(99)00327-1; Chen F, 1997, BIOCHEM BIOPH RES CO, V231, P99, DOI 10.1006/bbrc.1997.6057; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; Cui BL, 1997, TETRAHEDRON, V53, P17625, DOI 10.1016/S0040-4020(97)10231-9; Daub M, 1998, MOL CELL BIOL, V18, P6698, DOI 10.1128/MCB.18.11.6698; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Denk A, 2000, CYTOKINE GROWTH F R, V11, P303, DOI 10.1016/S1359-6101(00)00009-5; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Flory E, 1998, J VIROL, V72, P2788, DOI 10.1128/JVI.72.4.2788-2794.1998; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Govind S, 1999, ONCOGENE, V18, P6875, DOI 10.1038/sj.onc.1203223; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Han SS, 1999, CLIN IMMUNOL, V93, P152, DOI 10.1006/clim.1999.4769; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hiort J, 1999, J NAT PROD, V62, P1632, DOI 10.1021/np990242g; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Jobin C, 1999, J IMMUNOL, V163, P3474; Kaltschmidt B, 1999, ONCOGENE, V18, P3213, DOI 10.1038/sj.onc.1202657; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Kuprash DV, 1996, J IMMUNOL, V156, P2465; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee JH, 2002, J BIOL CHEM, V277, P18411, DOI 10.1074/jbc.M201368200; Lee SK, 1998, CHEM-BIOL INTERACT, V115, P215, DOI 10.1016/S0009-2797(98)00073-8; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Lyss G, 1997, BIOL CHEM, V378, P951, DOI 10.1515/bchm.1997.378.9.951; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Nugroho BW, 1999, PHYTOCHEMISTRY, V51, P367, DOI 10.1016/S0031-9422(98)00751-1; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Palombella VJ, 1998, P NATL ACAD SCI USA, V95, P15671, DOI 10.1073/pnas.95.26.15671; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443; Rivera-Walsh I, 2000, J BIOL CHEM, V275, P25222, DOI 10.1074/jbc.M000444200; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Siegmund D, 2001, J BIOL CHEM, V276, P43708, DOI 10.1074/jbc.M106421200; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JM, 1999, MOL CELL BIOL, V19, P6195; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; Wu TS, 1997, J NAT PROD, V60, P606, DOI 10.1021/np970163+; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; Zwilling S, 1997, SCIENCE, V277, P221, DOI 10.1126/science.277.5323.221	78	78	83	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44791	44800		10.1074/jbc.M208003200	http://dx.doi.org/10.1074/jbc.M208003200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237314	hybrid			2022-12-27	WOS:000179404800028
J	Cory, GOC; Garg, R; Cramer, R; Ridley, AJ				Cory, GOC; Garg, R; Cramer, R; Ridley, AJ			Phosphorylation of tyrosine enhances the ability of WASp to stimulate actin polymerization and filopodium formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH-SYNDROME; SYNDROME PROTEIN WASP; SRC-FAMILY KINASES; FC-GAMMA-RI; ARP2/3 COMPLEX; N-WASP; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; FUNCTIONAL ASSOCIATION; MEDIATED PHAGOCYTOSIS; RHO GTPASES	Wiskott-Aldrich Syndrome protein (WASp) is a key regulator of the Arp2/3 complex and the actin cytoskeleton in hematopoietic cells. WASp is capable of forming an auto-inhibited conformation, which can be disrupted by binding of Cdc42 and phosphatidylinositol 4,5-bisphosphate, leading to its activation. Stimulation of the collagen receptor on platelets and crosslinking the B-cell receptor induce tyrosine phosphorylation of WASp. Here we show that the Src family kinase Hck induces phosphorylation of WASp-Tyr(291) independently of Cdc42 and that this causes a shift in the mobility of WASp upon SDS-PAGE. A phospho-mimicking mutant, WASp-Y291E, exhibited an enhanced ability to stimulate actin polymerization in a cell-free system and when microinjected into primary macrophages induced extensive filopodium formation with greater efficiency than wild-type WASp or a Y291F mutant. We propose that phosphorylation of Tyr(291) directly regulates WASp function.	Royal Free & Univ Coll Med Sch Branch, Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	Ridley, AJ (corresponding author), Royal Free & Univ Coll Med Sch Branch, Ludwig Inst Canc Res, Courtauld Bldg,91 Riding House St, London W1W 7BS, England.	anne@ludwig.ucl.ac.uk		Cramer, Rainer/0000-0002-8037-2511; Ridley, Anne/0000-0001-8186-5708				Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Allen WE, 1997, J CELL SCI, V110, P707; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Baba Y, 1999, BLOOD, V93, P2003, DOI 10.1182/blood.V93.6.2003.406k13_2003_2012; Banin S, 1999, MOL BIOL REP, V26, P173, DOI 10.1023/A:1006954206151; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Binks M, 1998, EUR J IMMUNOL, V28, P3259; Burns S, 2001, BLOOD, V98, P1142, DOI 10.1182/blood.V98.4.1142; Cannon JL, 2001, IMMUNITY, V15, P249, DOI 10.1016/S1074-7613(01)00178-9; Castellano F, 1999, CURR BIOL, V9, P351, DOI 10.1016/S0960-9822(99)80161-4; Chiaradonna F, 1999, EMBO J, V18, P3013, DOI 10.1093/emboj/18.11.3013; CHO HJ, 1991, BIOCHEMISTRY-US, V30, P6210, DOI 10.1021/bi00239a019; Cory GOC, 1996, J IMMUNOL, V157, P3791; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DURDEN DL, 1995, J IMMUNOL, V154, P4039; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; Fradelizi J, 2001, NAT CELL BIOL, V3, P699, DOI 10.1038/35087009; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; Gallego MD, 1997, BLOOD, V90, P3089, DOI 10.1182/blood.V90.8.3089; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; Gross BS, 1999, BLOOD, V94, P4166, DOI 10.1182/blood.V94.12.4166.424k36_4166_4176; Gruenheid S, 2001, NAT CELL BIOL, V3, P856, DOI 10.1038/ncb0901-856; Guinamard R, 1998, FEBS LETT, V434, P431, DOI 10.1016/S0014-5793(98)01016-3; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Le Clainche C, 2001, J BIOL CHEM, V276, P46689, DOI 10.1074/jbc.C100476200; Leverrier Y, 2001, J IMMUNOL, V166, P4831, DOI 10.4049/jimmunol.166.8.4831; Leverrier Y, 2001, CURR BIOL, V11, P195, DOI 10.1016/S0960-9822(01)00047-1; Linder S, 1999, P NATL ACAD SCI USA, V96, P9648, DOI 10.1073/pnas.96.17.9648; Lorenzi R, 2000, BLOOD, V95, P2943, DOI 10.1182/blood.V95.9.2943.009k17_2943_2946; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; McGavin MKH, 2001, J EXP MED, V194, P1777, DOI 10.1084/jem.194.12.1777; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mizutani K, 2002, CANCER RES, V62, P669; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Scholz G, 2000, J BIOL CHEM, V275, P14615, DOI 10.1074/jbc.275.19.14615; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; Suen PW, 1999, J CELL SCI, V112, P4067; Suzuki T, 2000, J IMMUNOL, V165, P473, DOI 10.4049/jimmunol.165.1.473; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7; Zalevsky J, 2001, J BIOL CHEM, V276, P3468, DOI 10.1074/jbc.M006407200; Zicha D, 1998, BRIT J HAEMATOL, V101, P659, DOI 10.1046/j.1365-2141.1998.00767.x	53	165	171	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45115	45121		10.1074/jbc.M203346200	http://dx.doi.org/10.1074/jbc.M203346200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235133	hybrid			2022-12-27	WOS:000179404800068
J	Hansen, MDH; Ehrlich, JS; Nelson, WJ				Hansen, MDH; Ehrlich, JS; Nelson, WJ			Molecular mechanism for orienting membrane and actin dynamics to nascent cell-cell contacts in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; RAC1 SMALL GTPASES; ANNEXIN-II; ADHESION; CYTOSKELETON; LAMELLIPODIA; RECRUITMENT; ACTIVATION; PROTEIN; BINDING	The small GTPase Rac1 has been implicated in regulation of cell migration and cell-cell adhesion in epithelial cells. Little is known, however, about the spatial and temporal coordination of Rac1 activity required to balance these competing processes. We fractionated endogenous Rac1-containing protein complexes from membranes of Madin-Darby canine kidney cells and identified three major complexes comprising a Rac1(.)PAK (p21-activated kinase) complex, and 11 S and 16 S Rac1 complexes. Significantly, Rac1 shifts from the 11 S to a 16 S particle during initiation of cell-cell adhesion. This shift may reflect a diffusion trapping mechanism by which these Rac1 complexes are localized to cadherin-mediated cell-cell contacts through an interaction with annexin II.	Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	Stanford University	Nelson, WJ (corresponding author), Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA.				NIGMS NIH HHS [R37 GM035527, 5T32GM07365, GM35527, R01 GM035527] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035527, R01GM035527, T32GM007365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; Balch C, 1997, EXP CELL RES, V237, P259, DOI 10.1006/excr.1997.3817; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; Filipenko NR, 2001, J BIOL CHEM, V276, P5310, DOI 10.1074/jbc.M009710200; Ghitescu LD, 2001, DIABETES, V50, P1666, DOI 10.2337/diabetes.50.7.1666; Hansen MDH, 2001, CURR BIOL, V11, P356, DOI 10.1016/S0960-9822(01)00091-4; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Merrifield CJ, 2001, CURR BIOL, V11, P1136, DOI 10.1016/S0960-9822(01)00321-9; Nakagawa M, 2001, J CELL SCI, V114, P1829; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; REGNOUF F, 1991, J NEUROCHEM, V56, P1985, DOI 10.1111/j.1471-4159.1991.tb03457.x; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4	25	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45371	45376		10.1074/jbc.M207747200	http://dx.doi.org/10.1074/jbc.M207747200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244058	hybrid, Green Accepted			2022-12-27	WOS:000179404800100
J	Kim, SY; Sharma, S; Hoskins, JR; Wickner, S				Kim, SY; Sharma, S; Hoskins, JR; Wickner, S			Interaction of the DnaK and DnaJ chaperone system with a native substrate, p1 RepA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONE; ESCHERICHIA-COLI; ATP HYDROLYSIS; BINDING-SPECIFICITY; NUCLEOTIDE EXCHANGE; REPLICATION ORIGIN; INITIATOR PROTEIN; PEPTIDE-BINDING; CLPA CHAPERONE	DnaK, the Hsp70 chaperone of Escherichia coli interacts with protein substrates in an ATP-dependent manner, in conjunction with DnaJ and GrpE co-chaperones, to carry out protein folding, protein remodeling, and assembly and disassembly of multisubunit protein complexes. To understand how DnaJ targets specific proteins for recognition by the DnaK chaperone system, we investigated the interaction of DnaJ and DnaK with a known natural substrate, bacteriophage PI RepA protein. By characterizing RepA deletion derivatives, we found that DnaJ interacts with a region of RepA located between amino acids 180 and 200 of the 286-amino acid protein. A peptide corresponding to amino acids 180195 inhibited the interaction of RepA and DnaJ. Two site-directed RepA mutants with alanine substitutions in this region were about 4-fold less efficiently activated for oriP1 DNA binding by DnaJ and DnaK than wild type RepA. We also identified by deletion analysis a site in RepA, in the region of amino acids 35-49, which interacts with DnaK. An alanine substitution mutant in amino acids 36-39 was constructed and found defective in activation by DnaJ and DnaK. Taken together the results suggest that DnaJ and DnaK interact with separate sites on RepA.	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wickner, S (corresponding author), NCI, Mol Biol Lab, NIH, Bldg 37,Rm 5144,37 Convent Dr,MSC37-4264, Bethesda, MD 20892 USA.							ALFANO C, 1989, J BIOL CHEM, V264, P10699; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Hoskins JR, 2000, J BIOL CHEM, V275, P35361, DOI 10.1074/jbc.M006288200; ISHIAI M, 1994, P NATL ACAD SCI USA, V91, P3839, DOI 10.1073/pnas.91.9.3839; Konieczny I, 2002, J BIOL CHEM, V277, P18483, DOI 10.1074/jbc.M107580200; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Mayer MP, 2000, BIOL CHEM, V381, P877, DOI 10.1515/BC.2000.109; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; Russell R, 1999, BIOCHEMISTRY-US, V38, P4165, DOI 10.1021/bi9824036; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SKOWYRA D, 1993, J BIOL CHEM, V268, P25296; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; TILLY K, 1989, J BACTERIOL, V171, P6025, DOI 10.1128/jb.171.11.6025-6029.1989; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	40	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44778	44783		10.1074/jbc.M206176200	http://dx.doi.org/10.1074/jbc.M206176200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237299	hybrid			2022-12-27	WOS:000179404800026
J	Mochizuki, S; Brassart, B; Hinek, A				Mochizuki, S; Brassart, B; Hinek, A			Signaling pathways transduced through the elastin receptor facilitate proliferation of arterial smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FOCAL ADHESION KINASE; GROWTH-FACTOR RECEPTOR; ELASTIN/LAMININ-BINDING-PROTEIN; EXTRACELLULAR-MATRIX; TYROSINE KINASE; BETA-GALACTOSIDASE; COUPLED RECEPTORS; LAMININ RECEPTOR; ALPHA(V)BETA(3) INTEGRIN	In this report we demonstrate that soluble peptides, elastin degradation products stimulate proliferation of arterial smooth muscle cells. We show that these effects are due to generation of intracellular signals transduced through the cell surface elastin receptor, which consists of peripheral 67-kDa elastin-binding protein (EBP) (spliced variant of beta-galactosidase), immobilized to the transmembrane sialidase and the protective protein. We found that elastin receptor-transduced signaling triggers activation of G proteins, opening Of L-type calcium channels, and a sequential activation of tyrosine kinases: FAK, c-Src, platelet-derived growth factor-receptor kinase and then Ras-Raf-MEK1/2-ERK1/2 phosphorylation cascade. This, in turn, causes an increase in expression of cyclins and cyclin-dependent kinases, and a consequent increase in cellular proliferation. The EBP-transduced signals also induce tyrosine kinase-dependent phosphorylation of beta-tubulin, LC3, microtubule-associated protein 1, and a-actin and troponin-T, which could be linked to reorganization of cytoskeleton. We have also disclosed that induction of these signals can be abolished by anti-EBP antibody or by galactosugars, which cause shedding of EBP from the cell surface. Moreover, elastin-derived peptides did not induce proliferation of EBP-deficient cells derived from patients bearing a nonsense mutation of the P-galactosidase gene or sialidase-deficient cells from patients with congenital sialidosis.	Hosp Sick Children, Cardiovasc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Hinek, A (corresponding author), Hosp Sick Children, Cardiovasc Res Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	alek.hinek@sickkids.ca	Hinek, Aleksander/V-8790-2019					AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARTFELD NS, 1993, J BIOL CHEM, V268, P17270; Bendeck MP, 2000, ARTERIOSCL THROM VAS, V20, P1467, DOI 10.1161/01.ATV.20.6.1467; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; BOUDREAU N, 1991, LAB INVEST, V64, P187; Brassart B, 2001, J BIOL CHEM, V276, P5222, DOI 10.1074/jbc.M003642200; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHIAVEGATO A, 1993, CARDIOSCIENCE, V4, P75; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FAURY G, 1995, J VASC RES, V32, P112, DOI 10.1159/000159084; FLEISCHMANN BK, 1994, P NATL ACAD SCI USA, V91, P11914, DOI 10.1073/pnas.91.25.11914; Fujimoto N, 2000, J INVEST DERMATOL, V115, P633, DOI 10.1046/j.1523-1747.2000.00117.x; FULOP T, 2001, SOC BIOL, V195, P157; GROSSO LE, 1993, BIOCHEMISTRY-US, V32, P13369, DOI 10.1021/bi00211a052; GROSSO LE, 1993, MATRIX, V13, P157, DOI 10.1016/S0934-8832(11)80074-0; Hance KA, 2002, J VASC SURG, V35, P254, DOI 10.1067/mva.2002.120382; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; Hinek A, 2000, AM J PATHOL, V156, P925, DOI 10.1016/S0002-9440(10)64961-9; HINEK A, 1994, CELL ADHES COMMUN, V2, P185, DOI 10.3109/15419069409004436; HINEK A, 1992, EXP CELL RES, V203, P344, DOI 10.1016/0014-4827(92)90008-V; HINEK A, 1991, J CLIN INVEST, V88, P2083, DOI 10.1172/JCI115538; Hinek A, 2000, AM J HUM GENET, V67, P23, DOI 10.1086/302968; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; HINEK A, 1993, J CLIN INVEST, V91, P1198, DOI 10.1172/JCI116280; Hinek A, 1996, BIOL CHEM, V377, P471; HINEK A, 1981, CONNECT TISSUE RES, V8, P181, DOI 10.3109/03008208109152371; Hirata A, 2000, BRIT J PHARMACOL, V131, P1521, DOI 10.1038/sj.bjp.0703730; HORNEBECK W, 1985, EXTRACELLULAR MATRIX, P269; ILLC D, 1995, NATURE, V377, P539; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Ju HS, 1996, CAN J CARDIOL, V12, P1259; JUNG S, 1988, J NEUROPATH EXP NEUR, V57, P429; Kamisato S, 1997, J BIOCHEM-TOKYO, V121, P862; KAMISATO S, 1999, PEPTIDE SCI, V12, P61; Kamoun A, 1995, CELL ADHES COMMUN, V3, P273, DOI 10.3109/15419069509081013; Kenagy RD, 1996, ARTERIOSCL THROM VAS, V16, P1373, DOI 10.1161/01.ATV.16.11.1373; Kimura T, 1997, CIRCULATION, V96, P475; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Li DY, 1998, NATURE, V393, P276, DOI 10.1038/30522; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Lukong KE, 2001, J BIOL CHEM, V276, P46172, DOI 10.1074/jbc.M104547200; Lukong KE, 2001, J BIOL CHEM, V276, P17286, DOI 10.1074/jbc.M100460200; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MACLEOD DC, 1994, J AM COLL CARDIOL, V23, P59, DOI 10.1016/0735-1097(94)90502-9; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MECHAM RP, 1991, J CELL BIOL, V113, P187, DOI 10.1083/jcb.113.1.187; MECHAM RP, 1989, J BIOL CHEM, V264, P16652; MECHAM RP, 1989, BIOCHEMISTRY-US, V28, P3716, DOI 10.1021/bi00435a014; Morelli MAC, 1997, J PEPT RES, V49, P492; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P2591, DOI 10.1073/pnas.050282397; Oak JN, 2001, MOL PHARMACOL, V60, P92, DOI 10.1124/mol.60.1.92; OHO S, 1994, AM J PATHOL, V145, P202; Ozer RS, 2000, MOL BIOL CELL, V11, P3573, DOI 10.1091/mbc.11.10.3573; Papakonstanti EA, 2000, CELL PHYSIOL BIOCHEM, V10, P257, DOI 10.1159/000016366; Peterszegi G, 1996, CR ACAD SCI III-VIE, V319, P799; Privitera S, 1998, J BIOL CHEM, V273, P6319, DOI 10.1074/jbc.273.11.6319; Raines EW, 2000, ANN NY ACAD SCI, V902, P39; RAINES EW, 1993, BRIT HEART J, V69, pS30; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Soga S, 1998, J BIOL CHEM, V273, P822, DOI 10.1074/jbc.273.2.822; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Suto F, 2000, EUR J PHARMACOL, V409, P213, DOI 10.1016/S0014-2999(00)00827-X; SZEWCZYK B, 1988, ANAL BIOCHEM, V168, P48, DOI 10.1016/0003-2697(88)90008-5; Thyberg J, 1996, INT REV CYTOL, V169, P183, DOI 10.1016/S0074-7696(08)61987-7; Urban Z, 2002, AM J HUM GENET, V71, P30, DOI 10.1086/341035; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VARGA Z, 1989, FEBS LETT, V258, P5, DOI 10.1016/0014-5793(89)81602-3; WACHI H, 1995, FEBS LETT, V368, P215, DOI 10.1016/0014-5793(95)00641-L; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WRENN DS, 1988, J BIOL CHEM, V263, P2280; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; ZANELLATO AMC, 1991, CIRC RES, V68, P1349, DOI 10.1161/01.RES.68.5.1349; Zhou B, 1998, CIRC RES, V83, P481, DOI 10.1161/01.RES.83.5.481	86	182	198	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44854	44863		10.1074/jbc.M205630200	http://dx.doi.org/10.1074/jbc.M205630200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244048	hybrid			2022-12-27	WOS:000179404800035
J	Okumoto, S; Schmidt, R; Tegeder, M; Fischer, WN; Rentsch, D; Frommer, WB; Koch, W				Okumoto, S; Schmidt, R; Tegeder, M; Fischer, WN; Rentsch, D; Frommer, WB; Koch, W			High affinity amino acid transporters specifically expressed in xylem parenchyma and developing seeds of Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; PHLOEM TRANSFER; YEAST; PERMEASE; SUCROSE; LEAVES; COMPLEMENTATION; THALIANA; SEQUENCE; NITROGEN	Arabidopsis amino acid transporters (AAPs) show individual temporal and spatial expression patterns. A new amino acid transporter, AAP8 was isolated by reverse transcription-PCR. Growth and transport assays in comparison to AAP1-5 characterize AAP8 and AAP6 as high affinity amino acid transport systems from Arabidopsis. Histochemical promoter-beta-glucuronidase (GUS) studies identified AAP6 expression in xylem parenchyma, cells requiring high affinity transport due to the low amino acid concentration in xylem sap. AAP6 may thus function in uptake of amino acids from xylem. Histochemical analysis of AAP8 revealed stage-dependent expression in siliques and developing seeds. Thus AAP8 is probably responsible for import of organic nitrogen into developing seeds. The only missing transporter of the family AAP7 was nonfunctional in yeast with respect to amino acid transport, and expression was not detectable. Therefore, AAP6 and -8 are the only members of the family able to transport aspartate with physiologically relevant affinity. AAP1, -6 and -8 are the closest AAP paralogs. Although AAP1 and AAP8 originate from a duplicated region on chromosome I, biochemical properties and expression pattern diverged. Overlapping substrate specificities paired with individual properties and expression patterns point to specific functions of each of the AAP genes in nitrogen distribution rather than to mere redundancy.	Zentrum Mol Biol Pflanzen, ZMBP, D-72076 Tubingen, Germany; Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA; Inst Plant Sci, CH-3013 Bern, Switzerland	Eberhard Karls University of Tubingen; Washington State University	Koch, W (corresponding author), Zentrum Mol Biol Pflanzen, ZMBP, Morgenstelle 1, D-72076 Tubingen, Germany.	wolfgang.koch@zmbp.uni-tuebingen.de	Frommer, Wolf B/K-5042-2017; Frommer, Wolf B/A-8256-2008	Frommer, Wolf B/0000-0001-6465-0115; Frommer, Wolf B/0000-0001-6465-0115; Rentsch, Doris/0000-0003-4313-7683				ALLEN RD, 1989, PLANT CELL, V1, P623, DOI 10.1105/tpc.1.6.623; Arabidopsis Genome Initiative, 2000, Nature (London), V408, P796, DOI 10.1038/35048692; Atkins C, 2000, AUST J PLANT PHYSIOL, V27, P531, DOI 10.1071/PP99129; Bechtold N, 1998, METH MOL B, V82, P259; BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; Boorer KJ, 1997, J BIOL CHEM, V272, P13040, DOI 10.1074/jbc.272.20.13040; Boorer KJ, 1996, J BIOL CHEM, V271, P2213, DOI 10.1074/jbc.271.4.2213; Chang HC, 1997, J BIOL CHEM, V272, P30552, DOI 10.1074/jbc.272.48.30552; Chen LS, 2001, PLANT PHYSIOL, V125, P1813, DOI 10.1104/pp.125.4.1813; DeWitt ND, 1996, PLANT PHYSIOL, V112, P833, DOI 10.1104/pp.112.2.833; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; ERICSON ML, 1991, EUR J BIOCHEM, V197, P741, DOI 10.1111/j.1432-1033.1991.tb15966.x; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; Finkelstein RR, 2000, PLANT CELL, V12, P599, DOI 10.1105/tpc.12.4.599; Fischer WN, 1998, TRENDS PLANT SCI, V3, P188, DOI 10.1016/S1360-1385(98)01231-X; Fischer WN, 2002, PLANT J, V29, P717, DOI 10.1046/j.1365-313X.2002.01248.x; FISCHER WN, 1995, J BIOL CHEM, V270, P16315, DOI 10.1074/jbc.270.27.16315; Frommer WB, 1995, P NATL ACAD SCI USA, V92, P12036, DOI 10.1073/pnas.92.26.12036; FROMMER WB, 1993, P NATL ACAD SCI USA, V90, P5944, DOI 10.1073/pnas.90.13.5944; Guilfoyle T, 1998, PLANT PHYSIOL, V118, P341, DOI 10.1104/pp.118.2.341; HARPER JF, 1994, MOL GEN GENET, V244, P572, DOI 10.1007/BF00282747; Hayashi H, 1997, PLANT SOIL, V196, P233, DOI 10.1023/A:1004254124898; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Higo K, 1999, NUCLEIC ACIDS RES, V27, P297, DOI 10.1093/nar/27.1.297; Hirner B, 1998, PLANT J, V14, P535, DOI 10.1046/j.1365-313X.1998.00151.x; HSU LC, 1993, P NATL ACAD SCI USA, V90, P7441, DOI 10.1073/pnas.90.16.7441; JESCHKE WD, 1990, RECENT ADV PHLOEM TR; Kim SY, 1997, PLANT J, V11, P1237, DOI 10.1046/j.1365-313X.1997.11061237.x; KWART M, 1993, PLANT J, V4, P993, DOI 10.1046/j.1365-313X.1993.04060993.x; LAM HM, 1995, PLANT CELL, V7, P887, DOI 10.1105/tpc.7.7.887; LI ZC, 1990, PLANT PHYSIOL, V94, P268, DOI 10.1104/pp.94.1.268; LI ZC, 1991, PLANT PHYSIOL, V96, P1338, DOI 10.1104/pp.96.4.1338; LOHAUS G, 1995, BOT ACTA, V108, P270, DOI 10.1111/j.1438-8677.1995.tb00860.x; Maathuis FJM, 1997, PLANT PHYSIOL, V114, P1141, DOI 10.1104/pp.114.4.1141; MANSFIELD SG, 1991, CAN J BOT, V69, P461, DOI 10.1139/b91-063; Marchant A, 2002, PLANT CELL, V14, P589, DOI 10.1105/tpc.010354; Martin T., 1992, GUS protocols: using the GUS gene as a reporter of gene expression., P23; MCNEIL DL, 1979, PLANT PHYSIOL, V63, P1076, DOI 10.1104/pp.63.6.1076; MINET M, 1992, PLANT J, V2, P417; Miranda M, 2001, PLANT J, V28, P61, DOI 10.1046/j.1365-313X.2001.01129.x; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PATE JS, 1975, PLANTA, V122, P11, DOI 10.1007/BF00385400; PATE JS, 1977, PLANT PHYSIOL, V59, P506, DOI 10.1104/pp.59.3.506; PATRICK JW, 1995, AUST J PLANT PHYSIOL, V22, P681, DOI 10.1071/PP9950681; Rentsch D, 1996, PLANT CELL, V8, P1437, DOI 10.1105/tpc.8.8.1437; RIESMEIER JW, 1993, PLANT CELL, V5, P1591, DOI 10.1105/tpc.5.11.1591; SCHOBERT C, 1990, PLANTA, V181, P85, DOI 10.1007/BF00202328; SOLDAL T, 1978, PHYSIOL PLANTARUM, V43, P181, DOI 10.1111/j.1399-3054.1978.tb02561.x; Swofford D. L., 1998, PAUP PHYLOGENETIC AN; Tegeder M, 2000, PLANT PHYSIOL, V122, P319, DOI 10.1104/pp.122.2.319; VANBEL AJE, 1984, PLANT SCI LETT, V35, P81, DOI 10.1016/0304-4211(84)90162-7; VANBEL AJE, 1979, PLANT SCI LETT, V15, P285, DOI 10.1016/0304-4211(79)90121-4; VANBEL AJE, 1980, PLANT SCI LETT, V19, P101, DOI 10.1016/0304-4211(80)90085-1; Wipf D, 2002, TRENDS BIOCHEM SCI, V27, P139, DOI 10.1016/S0968-0004(01)02054-0; Xiang CB, 1999, PLANT MOL BIOL, V40, P711, DOI 10.1023/A:1006201910593	55	132	151	7	46	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45338	45346		10.1074/jbc.M207730200	http://dx.doi.org/10.1074/jbc.M207730200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244056	hybrid			2022-12-27	WOS:000179404800096
J	Almoguera, C; Rojas, A; Diaz-Martin, J; Prieto-Dapena, P; Carranco, R; Jordano, J				Almoguera, C; Rojas, A; Diaz-Martin, J; Prieto-Dapena, P; Carranco, R; Jordano, J			A seed-specific heat-shock transcription factor involved in developmental regulation during embryogenesis in sunflower	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; ACTIVATION; EXPRESSION; PROMOTER; COMPLEX; THERMOTOLERANCE; ARABIDOPSIS; FAMILY	We report the cloning and functional characterization of the first heat-shock transcription factor that is specifically expressed during embryogenesis in the absence of environmental stress. In sunflower embryos this factor, HaHSFA9, trans-activated promoters with poor consensus heat-shock cis-elements, including that of the seed-specific Hahsp17.6G1 gene. Mutations that improved the heat-shock cis-element consensus at the Hahsp17.7G4 promoter impaired transient activation by HaHSFA9 in sunflower embryos. The same mutations did not affect heat-shock-induced gene expression of this promoter in transgenic tobacco plants but reduced the developmental activation by endogenous heat-shock transcription factors (HSFs) in seeds. Sunflower, and perhaps other plants such as tobacco, differs from the vertebrate animal systems in having at least one specialized HSF with expression and (or) activation patterns strictly restricted to embryos. Our results strongly indicate that HaHSFA9 is a transcription factor critically involved in the developmental activation of Hahsp17.6G1 and in that of similar target genes as Hahsp17.7G4.	CSIC, Inst Recursos Nat & Agrobiol, E-41080 Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS)	Jordano, J (corresponding author), CSIC, Inst Recursos Nat & Agrobiol, Apartado 1052, E-41080 Seville, Spain.	fraga@cica.es	Diaz-Martin, Juan/AAU-1685-2021; Diaz-Martin, Juan/GSI-9230-2022; Rojas, Anabel/E-8768-2014; Almoguera, Concepción/J-7026-2014; Jordano, Juan/J-5829-2012; Prieto-Dapena, Pilar/K-2090-2014; Diaz-Martin, Juan/F-4765-2015; Carranco, Raúl/GXG-1194-2022	Diaz-Martin, Juan/0000-0002-3985-6434; Rojas, Anabel/0000-0003-0733-8277; Almoguera, Concepción/0000-0002-7961-6507; Jordano, Juan/0000-0002-2583-4453; Prieto-Dapena, Pilar/0000-0002-2826-8688; Diaz-Martin, Juan/0000-0002-3985-6434; Carranco, Raúl/0000-0001-9359-9793; DIAZ MARTIN, JUAN JOSE/0000-0003-0962-8403				Almoguera C, 1998, PLANT J, V13, P437, DOI 10.1046/j.1365-313X.1998.00044.x; ALMOGUERA C, 1993, PLANT J, V4, P947, DOI 10.1046/j.1365-313X.1993.04060947.x; Bharti K, 2000, PLANT J, V22, P355, DOI 10.1046/j.1365-313x.2000.00746.x; Boscheinen O, 1997, MOL GEN GENET, V255, P322, DOI 10.1007/s004380050503; Carranco R, 1997, J BIOL CHEM, V272, P27470, DOI 10.1074/jbc.272.43.27470; Carranco R, 1999, PLANT PHYSIOL, V121, P723, DOI 10.1104/pp.121.3.723; Coca MA, 1996, PLANT MOL BIOL, V31, P863, DOI 10.1007/BF00019473; FIORENZA MT, 1995, NUCLEIC ACIDS RES, V23, P467, DOI 10.1093/nar/23.3.467; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; Meijer AH, 2000, PLANT MOL BIOL MANUA, P1; Meisinger C, 1996, MOL BIOTECHNOL, V5, P289, DOI 10.1007/BF02900368; Mishra SK, 2002, GENE DEV, V16, P1555, DOI 10.1101/gad.228802; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Never L, 1996, CELL STRESS CHAPERON, V1, P215, DOI 10.1379/1466-1268(1996)001<0215:THWCAP>2.3.CO;2; Nover L, 2001, CELL STRESS CHAPERON, V6, P177, DOI 10.1379/1466-1268(2001)006<0177:AATHST>2.0.CO;2; Prandl R, 1998, MOL GEN GENET, V258, P269, DOI 10.1007/s004380050731; Rallu M, 1997, P NATL ACAD SCI USA, V94, P2392, DOI 10.1073/pnas.94.6.2392; Rojas A, 2002, PLANT PHYSIOL, V129, P1207, DOI 10.1104/pp.010927; Rojas A, 1999, PLANT J, V20, P601, DOI 10.1046/j.1365-313X.1999.00635.x; Schoffl F, 1998, PLANT PHYSIOL, V117, P1135, DOI 10.1104/pp.117.4.1135; Tanabe M, 1999, J BIOL CHEM, V274, P27845, DOI 10.1074/jbc.274.39.27845; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Yamanouchi U, 2002, P NATL ACAD SCI USA, V99, P7530, DOI 10.1073/pnas.112209199	26	70	84	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43866	43872		10.1074/jbc.M207330200	http://dx.doi.org/10.1074/jbc.M207330200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228226	hybrid, Green Published			2022-12-27	WOS:000179272000045
J	Haddad, LA; Smith, N; Bowser, M; Niida, Y; Murthy, V; Gonzalez-Agosti, C; Ramesh, V				Haddad, LA; Smith, N; Bowser, M; Niida, Y; Murthy, V; Gonzalez-Agosti, C; Ramesh, V			The TSC1 tumor suppressor hamartin interacts with neurofilament-L and possibly functions as a novel integrator of the neuronal cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH CONE MORPHOLOGY; TUBEROUS SCLEROSIS; CELL-GROWTH; EMBRYONIC LETHALITY; GENE-PRODUCTS; COMPLEX; EXPRESSION; MOTILITY; MUTATION; RADIXIN	Tuberous sclerosis complex, an autosomal dominant disease caused by mutations in either TSC1 or TSC2, is characterized by the development of hamartomas in a variety of organs. The proteins encoded by TSC1 and TSC2, hamartin and tuberin, respectively, associate with each other forming a tight complex. Here we show that hamartin binds the neurofilament light chain and it is possible to recover the hamartin-tuberin complex over the neurofilament light chain rod domain spanning amino acids 93-156 by affinity precipitation. Homologous rod domains in other intermediate filaments such as neurofilament medium chain, a-inter-nexin, vimentin, and desmin are not able to bind hamartin. In cultured cortical neurons, hamartin and tuberin co-localize with neurofilament light chain preferentially in the proximal to central growth cone region. Interestingly, in the distal part of the growth cone hamartin overlaps with the ezrin-radixin-moesin family of actin binding proteins, and we have validated the interaction of hamartin with moesin. These results demonstrate that hamartin may anchor neuronal intermediate filaments to the actin cytoskeleton, which may be critical for some of the CNS functions of the hamartin-tuberin complex, and abolishing this through mutations in TSC1 or TSC2 may lead to certain neurological manifestations associated with the disease.	Massachusetts Gen Hosp, Ctr Canc, Mol Neurogenet Unit, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Ramesh, V (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Mol Neurogenet Unit, Bldg 149,13th St,Rm 6222, Charlestown, MA 02129 USA.	ramesh@helix.mgh.harvard.edu	Haddad, Luciana A/D-8002-2012	Haddad, Luciana A/0000-0003-1043-8981	NINDS NIH HHS [NS41917, NS24279] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279, R01NS041917] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Au KS, 1999, AM J HUM GENET, V65, P1790, DOI 10.1086/302648; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; BIRGBAUER E, 1991, J NEUROSCI RES, V30, P232; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Castelo L, 1999, MOL BIOL CELL, V10, P1511, DOI 10.1091/mbc.10.5.1511; Catania MG, 2001, J NEUROSCI RES, V63, P276, DOI 10.1002/1097-4547(20010201)63:3<276::AID-JNR1021>3.0.CO;2-A; CAVINESS VS, 1991, ANN NY ACAD SCI, V615, P187; EKER R, 1981, DIAGN HISTOPATHOL, V4, P99; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Gomez M. R., 1999, TUBEROUS SCLEROSIS C; GonzalezAgosti C, 1996, CELL MOTIL CYTOSKEL, V34, P122, DOI 10.1002/(SICI)1097-0169(1996)34:2<122::AID-CM4>3.0.CO;2-D; GOSLIN K, 1989, J CELL BIOL, V109, P1621, DOI 10.1083/jcb.109.4.1621; Gutmann DH, 2000, ACTA NEUROPATHOL, V99, P223, DOI 10.1007/PL00007431; Henske EP, 1996, AM J HUM GENET, V59, P400; HIROSE T, 1995, ACTA NEUROPATHOL, V90, P387; Hodges AK, 2001, HUM MOL GENET, V10, P2899, DOI 10.1093/hmg/10.25.2899; HUTTENLOCHER PR, 1991, ANN NY ACAD SCI, V615, P140; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; KOBAYASHI T, 1995, NAT GENET, V9, P218, DOI 10.1038/ng0295-218a; Kobayashi T, 1999, CANCER RES, V59, P1206; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Leung CL, 2001, J CELL SCI, V114, P3409; Lin JW, 2000, NAT NEUROSCI, V3, P1282, DOI 10.1038/81814; Murthy V, 2001, ACTA NEUROPATHOL, V101, P202; Murthy V, 2000, AM J PHYSIOL-RENAL, V278, pF737; Nellist M, 2001, HUM MOL GENET, V10, P2889, DOI 10.1093/hmg/10.25.2889; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; Niida Y, 2001, AM J HUM GENET, V69, P493, DOI 10.1086/321972; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Paglini G, 1998, J CELL BIOL, V143, P443, DOI 10.1083/jcb.143.2.443; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413	42	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44180	44186		10.1074/jbc.M207211200	http://dx.doi.org/10.1074/jbc.M207211200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226091	hybrid			2022-12-27	WOS:000179272000084
J	Neal, JW; Clipstone, NA				Neal, JW; Clipstone, NA			Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KEY SIGNALING ENZYME; TRANSCRIPTION FACTORS; CYCLOSPORINE-A; PPAR-GAMMA; MOLECULAR REGULATION; CLONAL EXPANSION; GENE-EXPRESSION; MAP KINASE; IN-VIVO; ADIPOGENESIS	Recent studies have revealed that the calcium-dependent serine/threonine phosphatase calcineurin mediates the effects of intracellular calcium in many different cell types. In this study we investigated the role of calcineurin in the regulation of adipocyte differentiation. We found that the specific calcineurin inhibitors cyclosporin A and FK506 overcame the antiadipogenic effect of calcium ionophore on the differentiation of 3T3-L1 preadipocytes. This finding suggests that calcineurin is responsible for mediating the previously documented Ca2+-dependent inhibition of adipogenesis. We further demonstrate that the expression of a constitutively active calcineurin mutant potently inhibits the ability of 3T3-L1 cells to undergo adipocyte differentiation by preventing expression of the proadipogenic transcription factors peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer-binding protein a (C/EBPalpha). This calcineurin-mediated block in adipocyte differentiation is rescued by ectopic expression of PPARgamma1. Finally, we demonstrate that inhibition of endogenous calcineurin activity with either FK506 or a specific calcineurin inhibitory peptide enhances differentiation of 3T3-L1 cells in response to suboptimal adipogenic stimuli, suggesting that endogenous calcineurin activity normally sets a signaling threshold that antagonizes efficient adipocyte differentiation. Collectively, these data indicate that calcineurin acts as a Ca2+-dependent molecular switch that negatively regulates commitment to adipocyte differentiation by preventing the expression of critical proadipogenic transcription factors.	Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Clipstone, NA (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, 303 E Chicago Ave, Chicago, IL 60611 USA.				NIGMS NIH HHS [R29 GM 55292] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055292] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOULJOUD MS, 1995, TRANSPLANT P, V27, P1121; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; Cowherd RM, 1999, SEMIN CELL DEV BIOL, V10, P3, DOI 10.1006/scdb.1998.0276; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Engelman JA, 1999, J BIOL CHEM, V274, P35630, DOI 10.1074/jbc.274.50.35630; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Fruhbeck G, 2001, AM J PHYSIOL-ENDOC M, V280, pE827, DOI 10.1152/ajpendo.2001.280.6.E827; GAILLARD D, 1989, BIOCHEM J, V257, P389, DOI 10.1042/bj2570389; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Lee MY, 2001, BIOCHEM BIOPH RES CO, V281, P1241, DOI 10.1006/bbrc.2001.4494; Lim HW, 2001, J BIOL CHEM, V276, P15913, DOI 10.1074/jbc.M100452200; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; MATHIEU RL, 1994, EUR J CLIN INVEST, V24, P195, DOI 10.1111/j.1365-2362.1994.tb00988.x; Miller CW, 1996, ENDOCRINOLOGY, V137, P5641, DOI 10.1210/en.137.12.5641; MOR E, 1995, TRANSPLANT P, V27, P1126; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Ntambi JM, 1996, DIFFERENTIATION, V60, P151, DOI 10.1007/s002580050145; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; Shi H, 2000, PHYSIOL GENOMICS, V3, P75, DOI 10.1152/physiolgenomics.2000.3.2.75; Smas CM, 1999, J BIOL CHEM, V274, P12632, DOI 10.1074/jbc.274.18.12632; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VASSAUX G, 1992, J BIOL CHEM, V267, P11092; Visscher TLS, 2001, ANNU REV PUBL HEALTH, V22, P355, DOI 10.1146/annurev.publhealth.22.1.355; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11086, DOI 10.1073/pnas.92.24.11086; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zou YZ, 2001, CIRCULATION, V104, P102, DOI 10.1161/hc2601.090987	51	85	85	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49776	49781		10.1074/jbc.M207913200	http://dx.doi.org/10.1074/jbc.M207913200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12351639	hybrid			2022-12-27	WOS:000180028900090
J	Bezzine, S; Bollinger, JG; Singer, AG; Veatch, SL; Keller, SL; Gelb, MH				Bezzine, S; Bollinger, JG; Singer, AG; Veatch, SL; Keller, SL; Gelb, MH			On the binding preference of human groups IIA and X phospholipases A(2) for membranes with anionic phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR PHYSIOLOGICAL-ROLE; INTERFACIAL BINDING; ARACHIDONIC-ACID; TRYPTOPHAN RESIDUES; CATALYSIS; RELEASE; PHOSPHATIDYLCHOLINE; ACTIVATION; SUBSTRATE; VENOM	Mammals contain 9-10 secreted phospholipases A(2) (sPLA(2)s) that display widely different affinities for membranes, depending on the phospholipid composition. The much higher enzymatic activity of human group X sPLA(2) (hGX) compared with human group IIA sPLA(2) (hGIIA) on phosphatidylcholine (PC)-rich vesicles is due in large part to the higher affinity of the former enzyme for such vesicles; this result also holds when vesicles contain cholesterol and sphingomyelin. The inclusion of anionic phosphatidylserine in PC vesicles dramatically enhances interfacial binding and catalysis of hGILA but not of hGX. This is the result of the large number of lysine and arginine residues scattered over the entire surface of hGIIA, which cause the enzyme to form a supramolecular aggregate with multiple vesicles. Thus, high affinity binding of hGIIA to anionic vesicles is a complex process and cannot be attributed to a few basic residues on its interfacial binding surface, as is also evident from mutagenesis studies. The main reason hGIIA binds poorly to PC-rich vesicles is that it lacks a tryptophan residue on its interfacial binding surface, a residue that contributes to the high affinity binding of hGX to PC-rich vesicles. Results show that the lag in the onset of hydrolysis of PC vesicles by hGIIA is due in part to the poor affinity of this enzyme for these vesicles. Binding affinity of hGIIA, hGX, and their mutants to PC-rich vesicles is well correlated to the ability of these enzymes to act on the PC-rich outer plasma membrane of mammalian cells.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Phys, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.	gelb@chem.washington.edu	Veatch, Sarah L/G-9512-2016	Veatch, Sarah L/0000-0002-9317-2308; gelb, michael/0000-0001-7000-5219; Keller, Sarah/0000-0001-5919-0185	NHLBI NIH HHS [HL36236] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1987, PHOSPHOLIPASES; ARAKISASAKI K, 1995, INVEST OPHTH VIS SCI, V36, P614; Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; Beers SA, 2002, J BIOL CHEM, V277, P1788, DOI 10.1074/jbc.M109777200; Berg OG, 2001, CHEM REV, V101, P2613, DOI 10.1021/cr990139w; Berg OG, 2002, INTERFACIAL ENZYME K; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Buckland AG, 2000, BBA-MOL CELL BIOL L, V1484, P195, DOI 10.1016/S1388-1981(00)00018-4; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; Canaan S, 2002, J BIOL CHEM, V277, P30984, DOI 10.1074/jbc.M203649200; CHANG LS, 1993, BIOCHIM BIOPHYS ACTA, V1202, P216, DOI 10.1016/0167-4838(93)90007-E; Dennis EA, 1983, ENZYMES, P307; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; Enomoto A, 2000, J IMMUNOL, V165, P4007, DOI 10.4049/jimmunol.165.7.4007; Feng JW, 2002, J BIOL CHEM, V277, P19867, DOI 10.1074/jbc.M200938200; Foreman-Wykert AK, 1999, J CLIN INVEST, V103, P715, DOI 10.1172/JCI5468; Gadd ME, 2000, BIOCHEMISTRY-US, V39, P9623, DOI 10.1021/bi000322f; Gesquiere L, 2002, BIOCHEMISTRY-US, V41, P4911, DOI 10.1021/bi015757x; Ghomashchi F, 1998, BIOCHEMISTRY-US, V37, P6697, DOI 10.1021/bi972525i; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P7318, DOI 10.1021/bi00243a037; Han SK, 1997, J BIOL CHEM, V272, P3573, DOI 10.1074/jbc.272.26.16152; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hanasaki K, 2002, J BIOL CHEM, V277, P29116, DOI 10.1074/jbc.M202867200; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Henshaw JB, 1998, BIOCHEMISTRY-US, V37, P10709, DOI 10.1021/bi9728809; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; JAIN MK, 1986, BIOCHIM BIOPHYS ACTA, V860, P475, DOI 10.1016/0005-2736(86)90544-4; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; JAIN MK, 1986, BIOCHIM BIOPHYS ACTA, V860, P462, DOI 10.1016/0005-2736(86)90543-2; Keller SL, 1998, PHYS REV LETT, V81, P5019, DOI 10.1103/PhysRevLett.81.5019; KINKAID AR, 1995, BIOCHEM J, V308, P507, DOI 10.1042/bj3080507; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; Koduri RS, 2002, J BIOL CHEM, V277, P5849, DOI 10.1074/jbc.M109699200; Koumanov K, 1997, BIOCHEM J, V326, P227, DOI 10.1042/bj3260227; Koumanov KS, 1998, BIOCHEM J, V336, P625, DOI 10.1042/bj3360625; Lin Y, 1998, SCIENCE, V279, P1925, DOI 10.1126/science.279.5358.1925; MaoQiang M, 1996, J INVEST DERMATOL, V106, P57, DOI 10.1111/1523-1747.ep12327246; Morioka Y, 2000, ARCH BIOCHEM BIOPHYS, V381, P31, DOI 10.1006/abbi.2000.1977; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Pan YH, 2002, J BIOL CHEM, V277, P29086, DOI 10.1074/jbc.M202531200; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; RAMIREZ F, 1991, PROTEINS, V9, P229, DOI 10.1002/prot.340090402; Richmond BL, 2001, GASTROENTEROLOGY, V120, P1193, DOI 10.1053/gast.2001.23254; Schadow A, 2001, J INVEST DERMATOL, V116, P31, DOI 10.1046/j.1523-1747.2001.00179.x; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; YING HP, 2001, BIOCHEMISTRY-US, V40, P609; Yu BZ, 2000, BIOCHEMISTRY-US, V39, P12312, DOI 10.1021/bi000740k; YU BZ, 1993, BIOCHEMISTRY-US, V32, P6485, DOI 10.1021/bi00076a024; [No title captured]	57	111	111	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48523	48534		10.1074/jbc.M203137200	http://dx.doi.org/10.1074/jbc.M203137200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12244093	hybrid			2022-12-27	WOS:000179789600074
J	Jackson, CJ; Lamb, DC; Marezylo, TH; Warrilow, AGS; Manning, NJ; Lowe, DJ; Kelly, DE; Kelly, SL				Jackson, CJ; Lamb, DC; Marezylo, TH; Warrilow, AGS; Manning, NJ; Lowe, DJ; Kelly, DE; Kelly, SL			A novel sterol 14 alpha-demethylase/ferredoxin fusion protein (MCCYP51FX) from Methylococcus capsulatus represents a new class of the cytochrome P450 superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MYCOBACTERIUM-TUBERCULOSIS; NADPH-P450 REDUCTASE; MONOOXYGENASE; EXPRESSION; CYP51; PURIFICATION; CONSTRUCTION; METHANE; ENZYME	Sterol 14alpha-demethylase encoded by CYP51 is a member of the cytochrome P450 (CYP) superfamily of enzymes and has been shown to have an essential role in sterol biosynthesis in eukaryotes, with orthologues recently being described in some bacteria. Examination of the genome sequence data for the proteobacterium Methylococcus capsulatus, a bacterial species known to produce sterol, revealed the presence of a single CYP with strong homology to CYP51, particularly to a form in Mycobacterium tuberculosis. This M. capsulatus CYP51 protein represents a new class of CYP consisting of the CYP domain naturally fused to a ferredoxin domain at the C terminus via an alanine-rich linker. Expression of the M. capsulatus MCCYP51FX fusion in Escherichia coli yielded a P450, which, when purified to homogeneity, had the predicted molecular mass similar to62 kDa on SDS/PAGE and bound lanosterol as a putative substrate. Sterol 14alpha-demethylase activity was shown (0.24 nmol of lanosterol metabolized per minute per nanomole of MCCYP51FX fusion) by gas chromatography/mass spectrometry with the activity dependent upon the presence of ferredoxin reductase and NADPH. Our unique findings describe a new class of naturally existing cytochrome P450, which will provide pivotal information for CYP structure/function in general.	Univ Wales Aberystwyth, Inst Biol Sci, Wolfson Lab Biodivers P450, Aberystwyth SY23 3DA, Dyfed, Wales; Sheffield Childrens Hosp, Western Bank, Dept Chem Pathol, Sheffield S10 2UH, S Yorkshire, England; John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England	Aberystwyth University; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Kelly, SL (corresponding author), Univ Wales Aberystwyth, Inst Biol Sci, Wolfson Lab Biodivers P450, Aberystwyth SY23 3DA, Dyfed, Wales.			Warrilow, Andrew/0000-0003-0183-8334				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aoyama Y, 1998, J BIOCHEM-TOKYO, V124, P694; Bak S, 1997, PLANT J, V11, P191, DOI 10.1046/j.1365-313X.1997.11020191.x; Bellamine A, 1999, P NATL ACAD SCI USA, V96, P8937, DOI 10.1073/pnas.96.16.8937; BIRD CW, 1971, NATURE, V230, P473, DOI 10.1038/230473a0; BOUVIER P, 1976, BIOCHEM J, V159, P267, DOI 10.1042/bj1590267; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DALTON H, 1976, ARCH MICROBIOL, V109, P147, DOI 10.1007/BF00425127; Deeni YY, 2001, ARCH BIOCHEM BIOPHYS, V396, P16, DOI 10.1006/abbi.2001.2585; DEGTYARENKO KN, 1993, FEBS LETT, V332, P1, DOI 10.1016/0014-5793(93)80470-F; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FISHER CW, 1992, P NATL ACAD SCI USA, V89, P10817, DOI 10.1073/pnas.89.22.10817; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; Gustafsson MCU, 2001, ARCH MICROBIOL, V176, P459, DOI 10.1007/s002030100350; Jefcoate C R, 1978, Methods Enzymol, V52, P258; Lamb DC, 1998, FEBS LETT, V425, P263, DOI 10.1016/S0014-5793(98)00247-6; Lamb DC, 1997, J BIOL CHEM, V272, P5682, DOI 10.1074/jbc.272.9.5682; LEWIS DFV, 2002, GUIDE CYTOCHROMES P4, P51; MURAKAMI H, 1987, DNA-J MOLEC CELL BIO, V6, P189, DOI 10.1089/dna.1987.6.189; Nakayama N, 1996, J BIOCHEM-TOKYO, V119, P435; NARHI LO, 1986, J BIOL CHEM, V261, P7160; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; OMURA T, 1964, J BIOL CHEM, V239, P2379; PETERSON JA, 1976, J BIOL CHEM, V251, P4010; PORTER TD, 1991, J BIOL CHEM, V266, P13469; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; SHET MS, 1993, P NATL ACAD SCI USA, V90, P11748, DOI 10.1073/pnas.90.24.11748; Sibbesen O, 1996, J BIOL CHEM, V271, P22462, DOI 10.1074/jbc.271.37.22462; TURNER SL, 1993, PROTEIN ENG, V6, P101, DOI 10.1093/protein/6.1.101; Venkateswarlu K, 1997, ANTIMICROB AGENTS CH, V41, P776, DOI 10.1128/AAC.41.4.776; YOSHIDA Y, 1984, J BIOL CHEM, V259, P1655; Zhang Y, 1997, J BACTERIOL, V179, P3030, DOI 10.1128/jb.179.9.3030-3035.1997	32	56	59	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46959	46965		10.1074/jbc.M203523200	http://dx.doi.org/10.1074/jbc.M203523200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12235134	hybrid			2022-12-27	WOS:000179663700017
J	Melton, JV; Ewart, GD; Weir, RC; Board, PG; Lee, E; Gage, PW				Melton, JV; Ewart, GD; Weir, RC; Board, PG; Lee, E; Gage, PW			Alphavirus 6K proteins form ion channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEMLIKI-FOREST-VIRUS; SITE-DIRECTED MUTATIONS; ESCHERICHIA-COLI-CELLS; MODIFIES MEMBRANE-PERMEABILITY; SINDBIS-VIRUS; VPU PROTEIN; INDUCIBLE EXPRESSION; M2 PROTEIN; GENE; RELEASE	Ross River virus and Barmah Forest virus are Australian arboviruses of the Alphavirus genus. Features of alphavirus infection include an increased permeability of cells to monovalent cations followed by virion budding. Virally encoded ion channels are thought to have a role in these processes. In this paper, the 6K proteins of Ross River virus and Barmah Forest virus are shown to form cation-selective ion channels in planar lipid bilayers. Using a novel purification method, bacterially expressed 6K proteins were inserted into bilayers with a defined orientation (i.e. N-terminal cis, C-terminal trans). Channel activity was reversibly inhibited by antibodies to the N and C termini of 6K protein added to the cis and trans baths, respectively. Channel conductances varied from 40-800 picosiemens, suggesting that the protein is able to form channels with a range of possible oligomerization states.	Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 2601, Australia; Australian Natl Univ, Biotron Ltd, Canberra, ACT 2601, Australia; Australian Natl Univ, Sch Biochem & Mol Biol, Canberra, ACT 2601, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canberra, ACT 2601, Australia	Australian National University; John Curtin School of Medical Research; Australian National University; Australian National University; Australian National University; John Curtin School of Medical Research	Gage, PW (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, GPO Box 334, Canberra, ACT 2601, Australia.							ALTMANN KH, 1990, BIOPOLYMERS, V30, P107, DOI 10.1002/bip.360300112; BARRY PH, 1991, J MEMBRANE BIOL, V121, P101, DOI 10.1007/BF01870526; BOARD PG, 1983, BRIT J HAEMATOL, V54, P245, DOI 10.1111/j.1365-2141.1983.tb02092.x; CARRASCO L, 1995, ADV VIRUS RES, V45, P61, DOI 10.1016/S0065-3527(08)60058-5; Cordes FS, 2001, BBA-BIOMEMBRANES, V1512, P291, DOI 10.1016/S0005-2736(01)00332-7; Dick M, 1996, VIROLOGY, V220, P204, DOI 10.1006/viro.1996.0301; Ewart GD, 1996, J VIROL, V70, P7108, DOI 10.1128/JVI.70.10.7108-7115.1996; Fischer WB, 2000, BIOPOLYMERS, V53, P529, DOI 10.1002/(SICI)1097-0282(200006)53:7<529::AID-BIP1>3.0.CO;2-6; GAEDIGKNITSCHKO K, 1990, VIROLOGY, V175, P274, DOI 10.1016/0042-6822(90)90209-A; GAEDIGKNITSCHKO K, 1990, VIROLOGY, V175, P282, DOI 10.1016/0042-6822(90)90210-I; GAEDIGKNITSCHKO K, 1991, VIROLOGY, V183, P206, DOI 10.1016/0042-6822(91)90133-V; GAROFF H, 1990, J CELL BIOL, V111, P867, DOI 10.1083/jcb.111.3.867; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; Gonzalez ME, 1998, BIOCHEMISTRY-US, V37, P13710, DOI 10.1021/bi981527f; Gonzalez ME, 2001, VIROLOGY, V279, P201, DOI 10.1006/viro.2000.0708; GUINEA R, 1994, FEBS LETT, V343, P242, DOI 10.1016/0014-5793(94)80564-4; HANKE W, 1998, ION CHANNEL RECONSTI, P141; Hay A.J., 1992, SEMIN VIROL, V3, P21, DOI DOI 10.1016/J.BMC.2015.06.030; Hille B., 1992, IONIC CHANNELS EXCIT, P236; Ivanova L, 1995, VIRUS RES, V39, P165, DOI 10.1016/0168-1702(95)00083-6; IVANOVA L, 1995, VIROLOGY, V206, P1027, DOI 10.1006/viro.1995.1025; IVANOVA L, 1993, J VIROL, V67, P2546, DOI 10.1128/JVI.67.5.2546-2551.1993; KUHN RJ, 1991, VIROLOGY, V182, P430, DOI 10.1016/0042-6822(91)90584-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMA J, 1992, J BIOL CHEM, V267, P15932; LAMA J, 1992, BIOCHEM BIOPH RES CO, V188, P972, DOI 10.1016/0006-291X(92)91327-M; Lee E, 1997, VIROLOGY, V227, P509, DOI 10.1006/viro.1996.8343; LILJESTROM P, 1991, J VIROL, V65, P4107; LILJESTROM P, 1991, J VIROL, V65, P147; LOEWY A, 1995, J VIROL, V69, P469, DOI 10.1128/JVI.69.1.469-475.1995; LU YA, 1991, MOL IMMUNOL, V28, P623; LUSA S, 1991, VIROLOGY, V185, P843, DOI 10.1016/0042-6822(91)90556-Q; MARGOLIS MJ, 1966, CHEM PRINCIPLES CALC, P270; MUNOZ A, 1985, VIROLOGY, V146, P203, DOI 10.1016/0042-6822(85)90004-2; Piller SC, 1996, P NATL ACAD SCI USA, V93, P111, DOI 10.1073/pnas.93.1.111; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; R. New, 1990, LIPOSOMES A PRACTICA, P33; Sakaguchi T, 1996, J CELL BIOL, V133, P733, DOI 10.1083/jcb.133.4.733; Sambrook J., 2002, MOL CLONING LAB MANU; SANZ MA, 1994, J BIOL CHEM, V269, P12106; Sanz MA, 2001, J VIROL, V75, P7778, DOI 10.1128/JVI.75.16.7778-7784.2001; SCHLESINGER MJ, 1993, VIROLOGY, V193, P424, DOI 10.1006/viro.1993.1139; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; STAPLES BR, 1977, J PHYS CHEM REF DATA, V6, P385, DOI 10.1063/1.555551; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Sunstrom NA, 1996, J MEMBRANE BIOL, V150, P127, DOI 10.1007/s002329900037; ULUG ET, 1984, VIROLOGY, V132, P118, DOI 10.1016/0042-6822(84)90096-5; vanKuppeveld FJM, 1997, EMBO J, V16, P3519, DOI 10.1093/emboj/16.12.3519; WELCH WJ, 1980, J VIROL, V33, P230, DOI 10.1128/JVI.33.1.230-237.1980; Yao JS, 1996, J VIROL, V70, P7910, DOI 10.1128/JVI.70.11.7910-7920.1996	50	84	85	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46923	46931		10.1074/jbc.M207847200	http://dx.doi.org/10.1074/jbc.M207847200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12228229	hybrid			2022-12-27	WOS:000179663700013
J	Sbrissa, D; Ikonomov, OC; Deeb, R; Shisheva, A				Sbrissa, D; Ikonomov, OC; Deeb, R; Shisheva, A			Phosphatidylinositol 5-phosphate biosynthesis is linked to PIKfyve and is involved in osmotic response pathway in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; LIPID KINASE; FAB1P; POLYPHOSPHOINOSITIDE; 4,5-BISPHOSPHATE; 3,5-BISPHOSPHATE; ACCUMULATION; TRAFFICKING; ADIPOCYTES; INCREASE	The cellular functions, regulation and enzymology of phosphatidylinositol (PtdIns) 5-P, the newest addition to the family of phosphoinositides (PI), are still elusive. Whereas a kinase that uses PtdIns-5-P as an intracellular substrate has been assigned, a kinase that produces it remained to be identified. Here we report that PIKfyve, the enzyme found to synthesize PtdIns-5-P in vitro and PtdIns-3,5-P-2 in vitro and in vivo, is responsible for PtdIns-5-P production in a cellular context. Evidence is based on examination of two groups of cell types by two independent approaches. First, [P-32]orthophosphate-labeled cells (Sf9, 3T3-L1 fibroblasts, and 3T3-L1 adipocytes) that show a high pressure liquid chromatography (HPLC)-detectable peak of the PtdIns-5-P head group at basal conditions demonstrated a 20-50% increase in radioactive PtdIns-5-P amounts upon expression of PIK-fyve(WT). Second, cell types (HEK293), in which the basal levels of radioactive PtdIns-5-P were undetectable by HPLC head group analysis, demonstrated higher in vitro type II PIP kinase-directed conversion of the endogenous PtdIns-5-P pool into PtdIns-4,5-P-2, when induced to express PIKfyveWT. Conversely, a decrease by 60% in the conversion of PtdIns-5-P to PtdIns-4,5-P-2 was associated with induced expression of the dominant-negative kinase-deficient PIKfyve(K1831E) mutant in HEK293 cells. When 3T3-L1 fibroblasts and 3T3-L1 adipocytes were subjected to osmotic shock, levels of PtdIns-5-P measured by both approaches were found to decrease profoundly upon a hypo-osmotic stimulus. Together, these results identify PIKfyve as an enzyme responsible for PtdIns-5-P biosynthesis and indicate a role for PtdIns-5-P in osmotic response pathways in mammalian cells.	Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA	Wayne State University	Shisheva, A (corresponding author), Wayne State Univ, Sch Med, Dept Physiol, 540 E Canfield, Detroit, MI 48201 USA.	ashishev@med.wayne.edu			NIDDK NIH HHS [DK58058] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058058] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Bonangelino CJ, 2002, J CELL BIOL, V156, P1015, DOI 10.1083/jcb.200201002; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; Chen D, 1999, MOL CELL BIOL, V19, P4684; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; Clarke JH, 2001, BIOCHEM J, V357, P905, DOI 10.1042/0264-6021:3570905; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; DeWald DB, 2001, PLANT PHYSIOL, V126, P759, DOI 10.1104/pp.126.2.759; Dove SK, 2002, CURR BIOL, V12, P885, DOI 10.1016/S0960-9822(02)00891-6; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; EINSPAHR KJ, 1988, J BIOL CHEM, V263, P5775; Fruman DA, 1999, CELL, V97, P817, DOI 10.1016/S0092-8674(00)80792-8; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hughes WE, 2000, BIOCHEM J, V350, P337, DOI 10.1042/0264-6021:3500337; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Ikonomov OC, 2002, ENDOCRINOLOGY, V143, P4742, DOI 10.1210/en.2002-220615; Ikonomov OC, 2002, J BIOL CHEM, V277, P9206, DOI 10.1074/jbc.M108750200; Ikonomov OC, 2001, J BIOL CHEM, V276, P26141, DOI 10.1074/jbc.M101722200; Janez A, 2000, J BIOL CHEM, V275, P26870; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; McEwen RK, 1999, J BIOL CHEM, V274, P33905, DOI 10.1074/jbc.274.48.33905; Meijer HJG, 2001, BIOCHEM J, V360, P491, DOI 10.1042/0264-6021:3600491; Morris JB, 2000, FEBS LETT, V475, P57, DOI 10.1016/S0014-5793(00)01625-2; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; Pical C, 1999, J BIOL CHEM, V274, P38232, DOI 10.1074/jbc.274.53.38232; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; Sbrissa D, 2000, BIOCHEMISTRY-US, V39, P15980, DOI 10.1021/bi001897f; SCHACHT J, 1981, METHOD ENZYMOL, V72, P623; Shisheva A, 2001, CELL BIOL INT, V25, P1201, DOI 10.1006/cbir.2001.0803; Shisheva A, 1999, MOL CELL BIOL, V19, P623; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; Van der Kaay J, 1999, J BIOL CHEM, V274, P35963, DOI 10.1074/jbc.274.50.35963; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; York JD, 2001, ADV ENZYME REGUL, V41, P57, DOI 10.1016/S0065-2571(00)00025-X	39	97	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47276	47284		10.1074/jbc.M207576200	http://dx.doi.org/10.1074/jbc.M207576200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12270933	hybrid			2022-12-27	WOS:000179663700057
J	Shchors, K; Yehiely, F; Kular, RK; Kotlo, KU; Brewer, G; Deiss, LP				Shchors, K; Yehiely, F; Kular, RK; Kotlo, KU; Brewer, G; Deiss, LP			Cell death inhibiting RNA (CDIR) derived from a 3 '-untranslated region binds AUF1 and heat shock protein 27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; DOUBLE-STRANDED-RNA; MESSENGER-RNA; RICH ELEMENT; HNRNP-D; ALPHA-TROPOMYOSIN; GENE-EXPRESSION; STABILITY; KINASE; CLONING	Regulators of programmed cell death were previously identified using a technical knockout genetic screen. Among the elements that inhibited interferon-gamma-induced apoptosis of HeLa cells was a 441-nucleotide fragment derived from the 3'-untranslated region (UTR) of KIAA0425, a gene of unknown function. This fragment was termed cell death inhibiting RNA (CDIR). Deletion and mutation analyses of CDIR were employed to identify the features required for its anti-apoptotic activity. Single nucleotide alterations within either copy of the duplicated U-rich motif found in the CDIR sequence abolished the anti-apoptotic activity of CDIR and altered its in vitro association with a protein complex. Further analysis of the CDIR-binding complex indicated that it contained heat shock protein 27 (Hsp27) and the regulator of mRNA turnover AUF1 (heterogeneous nuclear ribonucleoprotein D). In addition, recombinant AUF1 bound directly to CDIR. Furthermore, expression of another AUF1-binding RNA element, derived from the 3'-UTR of c-myc, inhibited apoptosis. We also demonstrate that the level and the stability of p21(waf1/Cip1/sdi1) mRNA, a target of AUF1 with anti-apoptotic activity, were increased in CDIR-transfected cells. The level of mRNA and protein of Bcl-2, another anti-apoptotic gene, containing an AUF1 binding site in its 3'-UTR was also increased in CDIR-transfected cells. Our data suggest that AUF1 regulates apoptosis by altering mRNA turnover. We propose that CDIR inhibits apoptosis by acting as a competitive inhibitor of AUF1, preventing AUF1 from binding to its targets.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rutgers State University New Brunswick; Rutgers State University Medical Center	Deiss, LP (corresponding author), Univ Illinois, Dept Biol Mol, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.				NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER; NCI NIH HHS [CA52443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; Bhattacharya S, 1999, NUCLEIC ACIDS RES, V27, P1464, DOI 10.1093/nar/27.6.1464; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973; Capaccioli S, 1996, ONCOGENE, V13, P105; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Clemens MJ, 1997, INT J BIOCHEM CELL B, V29, P945, DOI 10.1016/S1357-2725(96)00169-0; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; Davis S, 1996, P NATL ACAD SCI USA, V93, P508, DOI 10.1073/pnas.93.1.508; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Eversole A, 2000, MOL CELL BIOL, V20, P5425, DOI 10.1128/MCB.20.15.5425-5432.2000; Fan HZ, 1996, CANCER RES, V56, P4366; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Goswami PC, 2000, J BIOL CHEM, V275, P38384, DOI 10.1074/jbc.M005298200; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Henics T, 1999, J BIOL CHEM, V274, P17318, DOI 10.1074/jbc.274.24.17318; Hobeika AC, 1999, J INTERF CYTOK RES, V19, P1351, DOI 10.1089/107999099312812; Jiang TJ, 2001, P NATL ACAD SCI USA, V98, P920, DOI 10.1073/pnas.021561498; Jupe ER, 1996, EXP CELL RES, V224, P128, DOI 10.1006/excr.1996.0120; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Kimchi A, 1998, BBA-REV CANCER, V1377, pF13, DOI 10.1016/S0304-419X(98)00002-X; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Lapucci A, 2002, J BIOL CHEM, V277, P16139, DOI 10.1074/jbc.M201377200; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MOGRIDGE J, 1995, GENE DEV, V9, P2831, DOI 10.1101/gad.9.22.2831; NAKAMAKI T, 1995, J CELL PHYSIOL, V165, P484, DOI 10.1002/jcp.1041650306; Powell AJ, 1998, EXP CELL RES, V240, P252, DOI 10.1006/excr.1998.3937; Raca G, 2000, NUCLEIC ACIDS RES, V28, P3943, DOI 10.1093/nar/28.20.3943; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Smedley D, 1999, GENOMICS, V60, P244, DOI 10.1006/geno.1999.5918; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; vanderMaarel SM, 1996, HUM MOL GENET, V5, P887, DOI 10.1093/hmg/5.7.887; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wilkinson MF, 2001, BIOESSAYS, V23, P775, DOI 10.1002/bies.1113; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Wilson GM, 2001, J BIOL CHEM, V276, P44450, DOI 10.1074/jbc.M108521200; Wilson GM, 2001, J BIOL CHEM, V276, P8695, DOI 10.1074/jbc.M009848200; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Xu NH, 2001, MOL CELL BIOL, V21, P6960, DOI 10.1128/MCB.21.20.6960-6971.2001; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zornig M, 2001, BBA-REV CANCER, V1551, pF1, DOI 10.1016/S0304-419X(01)00031-2	53	26	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47061	47072		10.1074/jbc.M202272200	http://dx.doi.org/10.1074/jbc.M202272200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356764	hybrid			2022-12-27	WOS:000179663700031
J	Alberti, S; Demand, J; Esser, C; Emmerich, N; Schild, H; Hohfeld, J				Alberti, S; Demand, J; Esser, C; Emmerich, N; Schild, H; Hohfeld, J			Ubiquitylation of BAG-1 suggests a novel regulatory mechanism during the sorting of chaperone substrates to the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; U-BOX; 26 S; MOLECULAR CHAPERONES; HSC70 CHAPERONE; QUALITY-CONTROL; PROTEIN; SUBUNIT; CHIP; DOMAIN	BAG-1 is a ubiquitin domain protein that links the molecular chaperones Hsc70 and Hsp70 to the proteasome. During proteasomal sorting BAG-1 can cooperate with another co-chaperone, the carboxyl terminus of Hsc70-interacting protein CHIP. CHIP was recently identified as a Hsp70- and Hsp90-associated. ubiquitin ligase that labels chaperone-presented proteins with the degradation marker ubiquitin. Here we show that BAG-1 itself is a substrate of the CHIP ubiquitin ligase in vitro and in vivo. CHIP mediates attachment of ubiquitin moieties to BAG-1 in conjunction with ubiquitin-conjugating enzymes of the LTbc4/5 family. Ubiquitylation of BAG-1 is strongly stimulated when a ternary Hsp70-BAG-1-CHIP complex is formed. Complex formation results in the attachment of an atypical polyubiquitin chain to BAG-1, in which the individual ubiquitin moieties are linked through lysine 11. The noncanonical polyubiquitin chain does not induce the degradation of BAG-1, but it stimulates a degradation-independent association of the co-chaperone with the proteasome. Remarkably, this stimulating activity depends on the simultaneous presentation of the integrated ubiquitin-like domain of BAG-1. Our data thus reveal a cooperative recognition of sorting signals at the proteolytic complex. Attachment of polyubiquitin chains to delivery factors may represent a novel mechanism to regulate protein sorting to the proteasome.	Univ Bonn, Inst Zellbiol & Bonner Forum Biomed, D-53121 Bonn, Germany; Max Planck Inst Biochem, Abt Mol Zellbiol, D-82152 Martinsried, Germany; Univ Tubingen, Inst Zellbiol, Immunol Abt, D-72076 Tubingen, Germany	University of Bonn; Max Planck Society; Eberhard Karls University of Tubingen	Hohfeld, J (corresponding author), Univ Bonn, Inst Zellbiol & Bonner Forum Biomed, Ulrich Haberland Str 61A, D-53121 Bonn, Germany.	hoehfeld@uni-bonn.de	Alberti, Simon/ABB-8277-2021; Alberti, Simon/B-2822-2017	Alberti, Simon/0000-0003-4017-6505				Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Emmerich NPN, 2000, J BIOL CHEM, V275, P21140, DOI 10.1074/jbc.M000740200; Gassler CS, 2001, J BIOL CHEM, V276, P32538, DOI 10.1074/jbc.M105328200; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Luders J, 2000, J BIOL CHEM, V275, P14817, DOI 10.1074/jbc.275.20.14817; Luders J, 1998, BIOL CHEM, V379, P1217, DOI 10.1515/bchm.1998.379.10.1217; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; McClellan AJ, 2001, NAT CELL BIOL, V3, pE51, DOI 10.1038/35055162; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; Sourisseau T, 2001, J CELL SCI, V114, P1409; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Takayama S, 1998, CANCER RES, V58, P3116; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wiederkehr T, 2002, CURR BIOL, V12, pR26, DOI 10.1016/S0960-9822(01)00644-3; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; You JX, 2001, J BIOL CHEM, V276, P19871, DOI 10.1074/jbc.M100034200; You JX, 1999, BIOTECHNIQUES, V27, P950, DOI 10.2144/99275st01; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	45	143	150	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45920	45927		10.1074/jbc.M204196200	http://dx.doi.org/10.1074/jbc.M204196200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12297498	hybrid			2022-12-27	WOS:000179529300029
J	Arnaudeau, S; Frieden, M; Nakamura, K; Castelbou, C; Michalak, M; Demaurex, N				Arnaudeau, S; Frieden, M; Nakamura, K; Castelbou, C; Michalak, M; Demaurex, N			Calreticulin differentially modulates calcium uptake and release in the endoplasmic reticulum and mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; OVEREXPRESSION; INFLUX; ENTRY; APOPTOSIS; OSCILLATIONS; ACTIVATION; DEPLETION; INCREASES; DECREASES	To study the role of calreticulin in Ca2+ homeostasis and apoptosis, we generated cells inducible for full-length or truncated calreticulin and measured Ca2+ signals within the cytosol, the endoplasmic reticulum (ER), and mitochondria with "cameleon" indicators. Induction of calreticulin increased the free Ca2+ concentration within the ER lumen, [Ca2+](ER), from 306 +/- 31 to 595 +/- 53 muM, and doubled the rate of ER refilling. [Ca2+](ER) remained elevated in the presence of thapsigargin, an inhibitor of SERCA-type Ca2+ ATPases. Under these conditions, store-operated Ca2+ influx appeared inhibited but could be reactivated by decreasing [Ca2+](ER) with the low affinity Ca2+ chelator N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine. In contrast, [Ca2+](ER) decreased much faster during stimulation with carbachol. The larger ER release was associated with a larger cytosolic Ca2+ response and, surprisingly, with a shorter mitochondrial Ca2+ response. The reduced mitochondrial signal was not associated with visible morphological alterations of mitochondria or with disruption of the contacts between mitochondria and the ER but correlated with a reduced mitochondrial membrane potential. Altered ER and mitochondrial Ca2+ responses were also observed in cells expressing an N-truncated calreticulin but not in cells overexpressing calnexin, a P-domain containing chaperone, indicating that the effects were mediated by the unique C-domain of calreticulin. In conclusion, calreticulin overexpression increases Ca2+ fluxes across the ER but decreases mitochondrial Ca2+ and membrane potential. The increased Ca2+ turnover between the two organelles might damage mitochondria, accounting for the increased susceptibility of cells expressing high levels of calreticulin to apoptotic stimuli.	Univ Geneva, Med Ctr 1, Dept Physiol, CH-1211 Geneva 4, Switzerland; Univ Alberta, Canadian Inst Hlth Res, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Geneva; Institute for Work & Health; University of Alberta; University of Alberta	Demaurex, N (corresponding author), Univ Geneva, Med Ctr 1, Dept Physiol, CH-1211 Geneva 4, Switzerland.			, Kimitoshi/0000-0003-4903-2428; Demaurex, Nicolas/0000-0002-9933-6772; Frieden, Maud/0000-0001-7135-0874				Arnaudeau S, 2001, J BIOL CHEM, V276, P29430, DOI 10.1074/jbc.M103274200; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Brini M, 2000, EMBO J, V19, P4926, DOI 10.1093/emboj/19.18.4926; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; De Giorgi F, 2000, CELL CALCIUM, V28, P365, DOI 10.1054/ceca.2000.0177; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Fasolato C, 1998, MOL BIOL CELL, V9, P1513, DOI 10.1091/mbc.9.6.1513; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Fraser SA, 2000, J IMMUNOL, V164, P4150, DOI 10.4049/jimmunol.164.8.4150; GERSTEN DM, 1990, BIOCHIM BIOPHYS ACTA, V1096, P20, DOI 10.1016/0925-4439(90)90007-C; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Missiaen L, 2002, J BIOL CHEM, V277, P6898, DOI 10.1074/jbc.M110939200; Missiaen L, 2001, J BIOL CHEM, V276, P39161, DOI 10.1074/jbc.M104044200; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Nakamura K, 2001, J CELL BIOL, V154, P961, DOI 10.1083/jcb.200102073; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Putney JW, 1999, BIOESSAYS, V21, P38; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Wang Z, 1997, P NATL ACAD SCI USA, V94, P12999, DOI 10.1073/pnas.94.24.12999; Waser M, 1997, J CELL BIOL, V138, P547, DOI 10.1083/jcb.138.3.547; Xu W, 2000, J BIOL CHEM, V275, P36676, DOI 10.1074/jbc.M002041200	48	129	150	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46696	46705		10.1074/jbc.M202395200	http://dx.doi.org/10.1074/jbc.M202395200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324449	hybrid, Green Published			2022-12-27	WOS:000179529300128
J	de Keyzer, J; van der Does, C; Driessen, AJM				de Keyzer, J; van der Does, C; Driessen, AJM			Kinetic analysis of the translocation of fluorescent precursor proteins into Escherichia coli membrane vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON MOTIVE FORCE; PLASMA-MEMBRANE; SIGNAL SEQUENCE; SECA PROTEIN; PREPROTEIN TRANSLOCATION; SECRETORY PROTEIN; CATALYTIC CYCLE; BINDING; DOMAIN; PROOMPA	Protein secretion in Escherichia coli is mediated by translocase, a multi-subunit membrane protein complex with SecA as ATP-driven motor protein and the SecYEG complex as translocation pore. A fluorescent assay was developed to facilitate kinetic studies of protein translocation. Single cysteine mutants of proOmpA were site-specific labeled with fluorescent dyes, and the SecA and ATP-dependent translocation into inner membrane vesicles and SecYEG proteoliposomes was monitored by means of protease accessibility and in gel fluorescent imaging. The translocation of fluorescently labeled proOmpA was largely independent on the position and the size of the fluorescent label (up to a size of 13-16 Angstrom). A fluorophore at the +4 position blocked translocation, but inhibition was completely relieved in the PrlA4 mutant. The kinetics of translocation of the fluorescently labeled proOmpA could be directly monitored by means of fluorescence quenching. Inner Membrane vesicles containing wild-type SecYEG were found to translocate proOmpA with a turnover of 4.5 molecules proOmpA/ SecYEG complex/min and an apparent K-m of 180 nm, whereas the PrlA4 mutant showed an almost 10-fold increase in turnover rate and a 3-fold increase of the apparent K-m for proOmpA translocation.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Driessen, AJM (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	a.j.m.driessen@biol.rug.nl	Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104				ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; BASSILANA M, 1992, J BIOL CHEM, V267, P25246; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DRIESSEN AJM, 1992, EMBO J, V11, P847, DOI 10.1002/j.1460-2075.1992.tb05122.x; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; Fekkes P, 1998, MOL MICROBIOL, V29, P1179, DOI 10.1046/j.1365-2958.1998.00997.x; GOODSELL DS, 1991, TRENDS BIOCHEM SCI, V16, P203, DOI 10.1016/0968-0004(91)90083-8; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; Kaufmann A, 1999, BIOCHEMISTRY-US, V38, P9115, DOI 10.1021/bi990539d; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; Nouwen N, 1996, P NATL ACAD SCI USA, V93, P5953, DOI 10.1073/pnas.93.12.5953; Nouwen N, 2001, FEBS LETT, V508, P103, DOI 10.1016/S0014-5793(01)03033-2; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; Uchida K, 1995, J BIOL CHEM, V270, P30862, DOI 10.1074/jbc.270.52.30862; van der Wolk JPW, 1998, EMBO J, V17, P3631, DOI 10.1093/emboj/17.13.3631; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; Veenendaal AKJ, 2001, J BIOL CHEM, V276, P32559, DOI 10.1074/jbc.M103912200	29	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46059	46065		10.1074/jbc.M208449200	http://dx.doi.org/10.1074/jbc.M208449200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12226104	Green Published, hybrid			2022-12-27	WOS:000179529300047
J	Desai, A; Turetsky, D; Vasudevan, K; Buonanno, A				Desai, A; Turetsky, D; Vasudevan, K; Buonanno, A			Analysis of transcriptional regulatory sequences of the N-methyl-D-aspartate receptor 2A subunit gene in cultured cortical neurons and transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTIVE SILENCER FACTOR; HETEROMERIC NMDA RECEPTORS; EXCITATORY AMINO-ACIDS; RNAS ENCODING SUBUNITS; CENTRAL-NERVOUS-SYSTEM; SODIUM-CHANNEL GENE; SPINAL-CORD NEURONS; MESSENGER-RNAS; RAT-BRAIN; DEVELOPMENTAL-CHANGES	The postnatal appearance and up-regulation of the NR2A subunit of the N-methyl-D-aspartate receptor contributes to the functional heterogeneity of the receptor during development. To elucidate the molecular mechanisms that regulate the neural and developmental specific expression of NR2A, an upstream similar to9-kb region of the gene harboring the promoter was isolated and characterized in transgenic mice and transfected cortical neurons. Transgenic mouse lines generated with luciferase reporter constructs driven by either 9 or 1 kb of upstream sequence selectively transcribe the transgene in brain, as compared with other non-neural tissues. Reporter luciferase levels in dissociated cultures made from these mice are over 100-fold greater in neuronal/glial co-cultures than in pure glial cultures. Analysis of NR2A 5'-nested deletions in transfected cultures of cortical neurons and glia indicate that while sequences residing upstream of - 1079 bp augment NR2A neuronal expression, sequences between -486 and -447 bp are sufficient to maintain neuronal preference. An RE1/NRSE element is not necessary for NR2A neuron specificity. Furthermore, comparison of the 5'-deletion constructs in cortical neurons grown for 5, 8, 11, or 14 days in vitro indicate that sequences between -1253 and -1180 bp are necessary for maturational up-regulation of NR2A. Thus, different cis-acting sequences control the regional and temporal expression of NR2A, implicating distinct regulatory pathways.	NICHD, LDN, Mol Neurobiol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Buonanno, A (corresponding author), NICHD, LDN, Mol Neurobiol Sect, NIH, Bldg 49,Rm 5A38,49 Convent Dr, Bethesda, MD 20892 USA.							Ahn S, 2000, ANNU REV PHYSIOL, V62, P803, DOI 10.1146/annurev.physiol.62.1.803; AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; Bai G, 1998, J BIOL CHEM, V273, P1086, DOI 10.1074/jbc.273.2.1086; BAI G, 1993, BIOCHIM BIOPHYS ACTA, V1152, P197, DOI 10.1016/0005-2736(93)90249-Y; Barria A, 2002, NEURON, V35, P345, DOI 10.1016/S0896-6273(02)00776-6; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; Borges K, 2001, J BIOL CHEM, V276, P25929, DOI 10.1074/jbc.M009105200; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Das S, 1998, NATURE, V393, P377, DOI 10.1038/30748; Flint AC, 1997, J NEUROSCI, V17, P2469; Gottmann K, 1997, J NEUROSCI, V17, P2766; Hogan B, 1994, MANIPULATING MOUSE E; Huang F, 1997, J BIOL CHEM, V272, P8618, DOI 10.1074/jbc.272.13.8618; IKEDA K, 1992, FEBS LETT, V313, P34, DOI 10.1016/0014-5793(92)81178-O; Iwasato T, 1997, NEURON, V19, P1201, DOI 10.1016/S0896-6273(00)80412-2; Jones A, 1996, J NEUROCHEM, V67, P907; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; Kutsuwada T, 1996, NEURON, V16, P333, DOI 10.1016/S0896-6273(00)80051-3; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; Li JH, 1998, EUR J NEUROSCI, V10, P1704, DOI 10.1046/j.1460-9568.1998.00169.x; Lonnerberg P, 1996, J BIOL CHEM, V271, P33358, DOI 10.1074/jbc.271.52.33358; Lu HC, 2001, NEURON, V32, P619, DOI 10.1016/S0896-6273(01)00501-3; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Mu WT, 1999, MOL BRAIN RES, V67, P137, DOI 10.1016/S0169-328X(99)00049-2; Myers SJ, 1998, J NEUROSCI, V18, P6723; Myers SJ, 1999, ANNU REV PHARMACOL, V39, P221, DOI 10.1146/annurev.pharmtox.39.1.221; Nishi M, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-23-j0003.2001; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PATHAK BG, 1994, NUCLEIC ACIDS RES, V22, P4748, DOI 10.1093/nar/22.22.4748; PETRALIA RS, 1994, J NEUROSCI, V14, P6102; PorteraCailliau C, 1996, J NEUROCHEM, V66, P692, DOI 10.1046/j.1471-4159.1996.66020692.x; Quinlan EM, 1999, NAT NEUROSCI, V2, P352, DOI 10.1038/7263; RESINK A, 1995, J NEUROCHEM, V64, P558; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Rose K, 1993, IN VITRO BIOL METHOD, P46; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; Sasner M, 1996, J BIOL CHEM, V271, P21316, DOI 10.1074/jbc.271.35.21316; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Stephenson FA, 2001, CURR DRUG TARGETS, V2, P233, DOI 10.2174/1389450013348461; Suchanek B, 1997, BIOL CHEM, V378, P929; SUCHANEK B, 1995, J BIOL CHEM, V270, P41, DOI 10.1074/jbc.270.1.41; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; Takahashi T, 1996, J NEUROSCI, V16, P4376; Thompson CL, 2000, NEUROSCI LETT, V283, P85, DOI 10.1016/S0304-3940(00)00930-7; Tovar KR, 1999, J NEUROSCI, V19, P4180; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; WANG YH, 1995, J NEUROCHEM, V65, P176; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; WICKS IP, 1995, HUM GENE THER, V6, P317, DOI 10.1089/hum.1995.6.3-317; WILLIAMS K, 1993, NEURON, V10, P267, DOI 10.1016/0896-6273(93)90317-K; Wood MW, 1996, J BIOL CHEM, V271, P8115, DOI 10.1074/jbc.271.14.8115; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X; Xia ZG, 1996, J NEUROSCI, V16, P5425; YAMAZAKI M, 1992, FEBS LETT, V300, P39, DOI 10.1016/0014-5793(92)80160-I; ZHONG J, 1995, J NEUROCHEM, V64, P531; ZHONG J, 1994, MOL PHARMACOL, V45, P846	78	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46374	46384		10.1074/jbc.M203032200	http://dx.doi.org/10.1074/jbc.M203032200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12356765	hybrid			2022-12-27	WOS:000179529300088
J	Evguenieva-Hackenberg, E; Schiltz, E; Klug, G				Evguenieva-Hackenberg, E; Schiltz, E; Klug, G			Dehydrogenases from all three domains of life cleave RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-A VIRUS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; RHODOBACTER-CAPSULATUS; BINDING-PROTEIN; RIBOZYME CATALYSIS; ESCHERICHIA-COLI; ROSSMANN FOLD; IDENTIFICATION; RIBONUCLEASE; SEQUENCE	Specific interactions of glyceraldehy-de-3-phosphate dehydrogenase (GAPDH) with RNA have been reported both in vitro and in vivo. We show that eukaryotic and bacterial GAPDH and two proteins from. the hyperthermophilic archaeon Sulfolobus solfataricus, which are annotated as dehydrogenases, cleave RNA producing similar degradation patterns. RNA cleavage is most efficient at 60 degreesC, at MgCl2, concentrations up to 5 mm, and takes place between pyrimidine and adenosine. The RNase active center of the putative aspartate semialdehyde dehydrogenase from S. solfataricus is located within the N-terminal 73 amino acids, which comprise the first mononucleotide-binding site (if the predicted Rossmann fold. Thus, RNA cleavage has to be taken into account in the ongoing discussion of the possible biological function of RNA binding by dehydrogenases.	Univ Giessen, Inst Mikrobiol & Mol Biol, D-35392 Giessen, Germany; Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany	Justus Liebig University Giessen; University of Freiburg	Evguenieva-Hackenberg, E (corresponding author), Univ Giessen, Inst Mikrobiol & Mol Biol, Heinrich Buff Ring 26-32, D-35392 Giessen, Germany.		Evguenieva-Hackenberg, Elena/ABA-8876-2020; Klug, Gabriele/K-5322-2014	Evguenieva-Hackenberg, Elena/0000-0001-7270-3168; Klug, Gabriele/0000-0002-3527-5093				Ausubel FM, 1988, MOL REPROD DEV; Baker ME, 1998, BIOCHEM BIOPH RES CO, V248, P250, DOI 10.1006/bbrc.1998.8951; Conrad C, 1998, NUCLEIC ACIDS RES, V26, P4446, DOI 10.1093/nar/26.19.4446; De BP, 1996, J BIOL CHEM, V271, P24728, DOI 10.1074/jbc.271.40.24728; Evguenieva-Hackenberg E, 2000, J BACTERIOL, V182, P4719, DOI 10.1128/JB.182.17.4719-4729.2000; Griffoni C, 2001, BBA-MOL CELL BIOL L, V1530, P32, DOI 10.1016/S1388-1981(00)00166-9; Heck C, 1996, MOL MICROBIOL, V20, P1165, DOI 10.1111/j.1365-2958.1996.tb02637.x; James CL, 2002, BIOCHEMISTRY-US, V41, P3720, DOI 10.1021/bi015909o; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; LI HL, 1993, NUCLEIC ACIDS RES, V21, P1919, DOI 10.1093/nar/21.8.1919; Lin SS, 2000, VIROLOGY, V271, P46, DOI 10.1006/viro.2000.0302; LIN YZ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P247, DOI 10.1016/0167-4838(90)90212-X; MALHOTRA OP, 1995, EUR J BIOCHEM, V227, P556, DOI 10.1111/j.1432-1033.1995.tb20424.x; MATSUDA T, 1997, NUCL ACIDS S SER, V37, P187; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MORGENEGG G, 1986, J NEUROCHEM, V47, P54; Moussaoui M, 1996, J BIOL CHEM, V271, P4687; Nagy E, 2000, BIOCHEM BIOPH RES CO, V275, P253, DOI 10.1006/bbrc.2000.3246; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; Paris S, 2002, PROTEIN EXPRES PURIF, V24, P99, DOI 10.1006/prep.2001.1538; Petrik J, 1999, J GEN VIROL, V80, P3109, DOI 10.1099/0022-1317-80-12-3109; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; Rauhut R, 1996, NUCLEIC ACIDS RES, V24, P1246, DOI 10.1093/nar/24.7.1246; Schultz DE, 1996, J BIOL CHEM, V271, P14134, DOI 10.1074/jbc.271.24.14134; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; Sioud M, 1996, J MOL BIOL, V257, P775, DOI 10.1006/jmbi.1996.0201; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; THOMAS D, 1989, MOL GEN GENET, V217, P149, DOI 10.1007/BF00330954; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Viola RE, 2001, ACCOUNTS CHEM RES, V34, P339, DOI 10.1021/ar000057q; Yang JJ, 1996, PLANT CELL, V8, P1409, DOI 10.1105/tpc.8.8.1409; Yi MY, 2000, J VIROL, V74, P6459, DOI 10.1128/JVI.74.14.6459-6468.2000; Zang WQ, 1998, VIROLOGY, V248, P46, DOI 10.1006/viro.1998.9255	33	42	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46145	46150		10.1074/jbc.M208717200	http://dx.doi.org/10.1074/jbc.M208717200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12359717	hybrid			2022-12-27	WOS:000179529300059
J	Kalandadze, A; Wu, Y; Robinson, MB				Kalandadze, A; Wu, Y; Robinson, MB			Protein kinase C activation decreases cell surface expression of the GLT-1 subtype of glutamate transporter - Requirement of a carboxyl-terminal domain and partial dependence on serine 486	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; HUMAN DOPAMINE TRANSPORTER; SEROTONIN TRANSPORTERS; PHORBOL ESTER; BRAIN; PHOSPHORYLATION; TRAFFICKING; MODULATION; CLEARANCE; RECEPTOR	Na+-dependent glutamate transporters are required for the clearance of extracellular glutamate and influence both physiological and pathological effects of this excitatory amino acid. In the present study, the effects of a protein kinase C (PKC) activator on the cell surface expression and activity of the GLT-1 subtype of glutamate transporter were examined in two model systems, primary co-cultures of neurons and astrocytes that endogenously express GLT-1 and C6 glioma cells transfected with GLT-1. In both systems, activation of PKC with phorbol ester caused a decrease in GLT-1 cell surface expression. This effect is opposite to the one observed for the EAAC1 subtype of glutamate transporter (Davis, K. E., Straff, D. J., Weinstein, E. A., Bannerman, P. G., Correale, D. M., Rothstein, J. D., and Robinson, M. B. (1998) J. Neurosci. 18, 2475-2485). Several recombinant chimeric proteins between GLT-1 and EAAC1 transporter subtypes were generated to identify domains required for the subtype-specific redistribution of GLT-1. We identified a carboxyl-terminal domain consisting of 43 amino acids (amino acids 475-517) that is required for PKC-induced GLT-1 redistribution. Mutation of a non-conserved serine residue at position 486 partially attenuated but did not completely abolish the PKC-dependent redistribution of GLT-1. Although we observed a phorbol ester-dependent incorporation of P-32 into immunoprecipitable GLT-1, mutation of serine 486 did not reduce this signal. We also found that chimeras containing the first 446 amino acids of GLT-1 were not functional unless amino acids 475-517 of GLT-1 were also present. These non-functional transporters were not as efficiently expressed on the cell surface and migrated to a smaller molecular weight, suggesting that a subtype-specific interaction is required for the formation of functional transporters. These studies demonstrate a novel effect of PKC on GLT-1 activity and define a unique carboxyl-terminal domain as an important determinant in cellular localization and regulation of GLT-1.	Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Robinson, MB (corresponding author), 502N Abramson Pediat Res Bldg,3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	Robinson@pharm.med.upenn.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD026979] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039011, R01NS029868] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26979] Funding Source: Medline; NINDS NIH HHS [NS39011, NS29868] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amara S G, 1998, Adv Pharmacol, V42, P164; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Beckman ML, 2000, NEUROSCIENTIST, V6, P199, DOI 10.1177/107385840000600310; BECKMAN ML, 1999, J NEUROSCI RC, V9, P1; Bergles DE, 1997, NEURON, V19, P1297, DOI 10.1016/S0896-6273(00)80420-1; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; Carrick T., 1999, Society for Neuroscience Abstracts, V25, P426; CASADO M, 1993, J BIOL CHEM, V268, P27313; Chang MY, 2001, J NEUROCHEM, V77, P754, DOI 10.1046/j.1471-4159.2001.00284.x; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Davis KE, 1998, J NEUROSCI, V18, P2475; Dowd LA, 1996, MOL PHARMACOL, V49, P465; FAGG GE, 1983, NEUROSCIENCE, V9, P701, DOI 10.1016/0306-4522(83)90263-4; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; Ganel R, 1998, J NEUROCHEM, V70, P993; Geisler C, 1998, J BIOL CHEM, V273, P21316, DOI 10.1074/jbc.273.33.21316; Gonzalez MI, 2002, MOL PHARMACOL, V62, P901, DOI 10.1124/mol.62.4.901; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Kanai Y, 1995, NEUROREPORT, V6, P2357, DOI 10.1097/00001756-199511270-00020; Karoor V, 1998, J BIOL CHEM, V273, P33035, DOI 10.1074/jbc.273.49.33035; Katagiri H, 2001, EUR J NEUROSCI, V14, P547, DOI 10.1046/j.0953-816x.2001.01664.x; Kazanietz MG, 2000, BIOCHEM PHARMACOL, V60, P1417, DOI 10.1016/S0006-2952(00)00470-6; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Melikian HE, 1999, J NEUROSCI, V19, P7699; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; Nicholson B, 1996, J BIOL CHEM, V271, P12159, DOI 10.1074/jbc.271.21.12159; Oliet SHR, 2001, SCIENCE, V292, P923, DOI 10.1126/science.1059162; Otis TS, 1997, SCIENCE, V277, P1515, DOI 10.1126/science.277.5331.1515; Palos TP, 1996, MOL BRAIN RES, V37, P297, DOI 10.1016/0169-328X(95)00331-L; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Robinson M B, 1997, Adv Pharmacol, V37, P69; Robinson MB, 2002, J NEUROCHEM, V80, P1, DOI 10.1046/j.0022-3042.2001.00698.x; Robinson MB, 1998, NEUROCHEM INT, V33, P479, DOI 10.1016/S0197-0186(98)00055-2; ROBINSON MB, 1993, J NEUROCHEM, V61, P2099, DOI 10.1111/j.1471-4159.1993.tb07447.x; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Sakai N, 1997, J NEUROCHEM, V68, P2618; Sandoval IV, 2000, J BIOL CHEM, V275, P39874, DOI 10.1074/jbc.M006261200; Schlag BD, 1998, MOL PHARMACOL, V53, P355, DOI 10.1124/mol.53.3.355; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; SHIN JY, 1991, J BIOL CHEM, V266, P10658; Sims KD, 1999, CRIT REV NEUROBIOL, V13, P169, DOI 10.1615/CritRevNeurobiol.v13.i2.30; Sims KD, 2000, J BIOL CHEM, V275, P5228, DOI 10.1074/jbc.275.7.5228; Tan J, 1999, J PHARMACOL EXP THER, V289, P1600; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Trotti D, 2001, J BIOL CHEM, V276, P576, DOI 10.1074/jbc.M003779200; Whitworth TL, 2001, J BIOL CHEM, V276, P42932, DOI 10.1074/jbc.M107638200; Xiang B, 2001, J BIOL CHEM, V276, P4709, DOI 10.1074/jbc.M006187200	56	116	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45741	45750		10.1074/jbc.M203771200	http://dx.doi.org/10.1074/jbc.M203771200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324450	hybrid			2022-12-27	WOS:000179529300005
J	Karnak, D; Lee, S; Margolis, B				Karnak, D; Lee, S; Margolis, B			Identification of multiple binding partners for the amino-terminal domain of synapse-associated protein 97	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; TUMOR-SUPPRESSOR PROTEIN; BASOLATERAL MEMBRANE; GLYCOPHORIN-C; COMPLEX; RECEPTOR; MLIN-7; CLONING; SURFACE; SAP97	Multiprotein complexes mediate static and dynamic functions to establish and maintain cell polarity in both epithelial cells and neurons. Membrane-associated guanylate kinase (MAGUK) proteins are thought to be scaffolding molecules in these processes and bind multiple proteins via their obligate postsynaptic density (PSD)95/Disc Large/Zona Occludens-1, Src homology 3, and guanylate kinase-like domains. Subsets of MAGUK proteins have additional protein-protein interaction domains. An additional domain we identified in SAP97 called the MAGUK recruitment (MRE) domain binds the LIN-2,7 amino-terminal (L27N) domain of mLIN-2/CASK, a MAGUK known to bind mLIN-7. Here we show that SAP97 binds two other mLIN-7 binding MAGUK proteins. One of these MAGUK proteins, DLG3, coimmunoprecipitates with SAP97 in lysates from rat brain and transfected Madin-Darby canine kidney cells. This interaction requires the AIRE domain of SAP97 and surprisingly, both the L27N and L27 carboxyl-terminal (L27C) domains of DLG3. We also demonstrate that SAP97 can interact with the MAGUK protein, DLG2, but not the highly related protein, PALS2. The ability of SAP97 to interact with multiple MAGUK proteins is likely to be important for the targeting of specific protein complexes in polarized cells.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Margolis, B (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.		Karnak, Demet/AAP-9959-2020	Karnak, Demet/0000-0001-8463-9802	NIDDK NIH HHS [2-P50-DK39255] Funding Source: Medline; NIGMS NIH HHS [GM08353, 5-T32-GM07544] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008353, T32GM007544] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Caplan MJ, 1997, AM J PHYSIOL-RENAL, V272, pF425, DOI 10.1152/ajprenal.1997.272.4.F425; Chetkovich DM, 2002, J NEUROSCI, V22, P6415; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P317, DOI 10.1016/S0968-0004(00)01599-1; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Harris BZ, 2002, J BIOL CHEM, V277, P34902, DOI 10.1074/jbc.M205856200; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; Makarova O, 2000, BIOTECHNIQUES, V29, P970, DOI 10.2144/00295bm08; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Mok H, 2002, J NEUROSCI, V22, P5253; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Nix SL, 2000, J BIOL CHEM, V275, P41192, DOI 10.1074/jbc.M002078200; Nunomura W, 2000, J BIOL CHEM, V275, P24540, DOI 10.1074/jbc.M002492200; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Straight SW, 2000, AM J PHYSIOL-RENAL, V278, pF464, DOI 10.1152/ajprenal.2000.278.3.F464; Straight SW, 2001, MOL BIOL CELL, V12, P1329, DOI 10.1091/mbc.12.5.1329; Tavalin SJ, 2002, J NEUROSCI, V22, P3044, DOI 10.1523/JNEUROSCI.22-08-03044.2002; Wu HJ, 1998, J CELL SCI, V111, P2365; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73	30	51	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46730	46735		10.1074/jbc.M208781200	http://dx.doi.org/10.1074/jbc.M208781200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351654	hybrid			2022-12-27	WOS:000179529300132
J	Li, MH; Kwok, F; Chang, WR; Lau, CK; Zhang, JP; Lo, SCL; Jiang, T; Liang, DC				Li, MH; Kwok, F; Chang, WR; Lau, CK; Zhang, JP; Lo, SCL; Jiang, T; Liang, DC			Crystal structure of brain pyridoxal kinase, a novel member of the ribokinase superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1.5 ANGSTROM RESOLUTION; ESCHERICHIA-COLI K-12; CATALYTIC ACTIVITY; ADENOSINE KINASE; BINDING-SITE; PROGRAM; IDENTIFICATION; PURIFICATION; MECHANISM; MOBILITY	The three-dimensional structures of brain pyridoxal kinase and its complex with the nucleotide ATP have been elucidated in the dimeric form at 2.1 and 2.6 Angstrom, respectively. Results have shown that pyridoxal kinase, as an enzyme obeying random sequential kinetics in catalysis, does not possess a lid shape structure common to all kinases in the ribokinase superfamily. This finding has been shown to be in line with the condition that pyridoxal kinase binds substrates with variable sizes of chemical groups at position 4 of vitamin B-6 and its derivatives. In addition, the enzyme contains a 12-residue peptide loop in the active site for the prevention of premature hydrolysis of ATP. Conserved amino acid residues Asp(118) and Tyr(127) in the peptide loop could be moved to a position covering the nucleotide after its binding so that its chance to hydrolyze in the aqueous environment of the active site was reduced. With respect to the evolutionary trend of kinase enzymes, the existence of this loop in pyridoxal kinase could be classified as an independent category in the ribokinase superfamily according to the structural feature found and mechanism followed in catalysis.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Hong Kong Polytechnic University	Jiang, T (corresponding author), 15 Datun Rd,Chaoyang Dist, Beijing 100101, Peoples R China.	x-ray@sun5.ibp.ac.cn; dcliang@sun5.ibp.ac.cn	Lau, Terrence/ABB-7900-2021	Lau, Terrence/0000-0002-7505-7306; Lo, Samuel Chun-lap/0000-0003-1134-7299				ARNONE A, 1989, J BIOL CHEM, V264, P4322; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campobasso N, 2000, BIOCHEMISTRY-US, V39, P7868, DOI 10.1021/bi0000061; Cheng G, 2002, STRUCTURE, V10, P225, DOI 10.1016/S0969-2126(02)00708-6; CHURCHICH JE, 1982, J BIOL CHEM, V257, P2136; CHURCHICH JE, 1981, J BIOL CHEM, V256, P780; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; DAKSHINAMURTI K, 1990, ANN NY ACAD SCI, V585, P128, DOI 10.1111/j.1749-6632.1990.tb28049.x; DOMINICI P, 1988, J BIOL CHEM, V263, P14712; Hanna MC, 1997, J BIOL CHEM, V272, P10756; Ito S, 2001, STRUCTURE, V9, P205, DOI 10.1016/S0969-2126(01)00577-9; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KERRY JA, 1986, EUR J BIOCHEM, V158, P581, DOI 10.1111/j.1432-1033.1986.tb09794.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KWOK F, 1979, J BIOL CHEM, V254, P6489; KWOK F, 1987, EUR J BIOCHEM, V168, P577, DOI 10.1111/j.1432-1033.1987.tb13456.x; KWOK F, 1979, EUR J BIOCHEM, V93, P229, DOI 10.1111/j.1432-1033.1979.tb12815.x; KWOK F, 1991, EUR J BIOCHEM, V199, P157, DOI 10.1111/j.1432-1033.1991.tb16104.x; LaineCessac P, 1996, ENZYME PROTEIN, V49, P291, DOI 10.1159/000468639; LaineCessac P, 1997, BIOCHEM PHARMACOL, V54, P863, DOI 10.1016/S0006-2952(97)00252-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li MH, 2002, ACTA CRYSTALLOGR D, V58, P1479, DOI 10.1107/S0907444902011034; Lu GG, 1999, J APPL CRYSTALLOGR, V32, P365, DOI 10.1107/S0021889898015052; Mathews II, 1998, BIOCHEMISTRY-US, V37, P15607, DOI 10.1021/bi9815445; MCCORMICK D, 1961, J BIOL CHEM, V236, P2085; MCCORMICK DB, 1959, P NATL ACAD SCI USA, V45, P1371, DOI 10.1073/pnas.45.9.1371; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; SCHOLZ G, 1989, J BIOL CHEM, V264, P4318; Schumacher MA, 2000, J MOL BIOL, V298, P875, DOI 10.1006/jmbi.2000.3753; SHETTY KT, 1980, EXP NEUROL, V70, P146, DOI 10.1016/0014-4886(80)90012-6; Sigrell JA, 1998, STRUCTURE, V6, P183, DOI 10.1016/S0969-2126(98)00020-3; Sigrell JA, 1999, J MOL BIOL, V290, P1009, DOI 10.1006/jmbi.1999.2938; UBBINK JB, 1990, ANN NY ACAD SCI, V585, P285, DOI 10.1111/j.1749-6632.1990.tb28061.x; WOLKERS WF, 1991, J BIOL CHEM, V266, P20761; Yang Y, 1996, FEMS MICROBIOL LETT, V141, P89, DOI 10.1016/0378-1097(96)00203-0; Yang Y, 1998, J BACTERIOL, V180, P1814, DOI 10.1128/JB.180.7.1814-1821.1998; ZHANG Z, 1991, P NATL ACAD SCI USA, V88, P10407, DOI 10.1073/pnas.88.23.10407	41	68	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46385	46390		10.1074/jbc.M208600200	http://dx.doi.org/10.1074/jbc.M208600200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235162	hybrid			2022-12-27	WOS:000179529300089
J	Pedarzani, P; D'hoedt, D; Doorty, KB; Wadsworth, JDF; Joseph, JS; Jeyaseelan, K; Kini, RM; Gadre, SV; Sapatnekar, SM; Stocker, M; Strong, PN				Pedarzani, P; D'hoedt, D; Doorty, KB; Wadsworth, JDF; Joseph, JS; Jeyaseelan, K; Kini, RM; Gadre, SV; Sapatnekar, SM; Stocker, M; Strong, PN			Tamapin, a venom peptide from the Indian red scorpion (Mesobuthus tamulus) that targets small conductance Ca(2+)-activated K(+) channels and afterhyperpolarization currents in central neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNEL; CHEMICAL-SYNTHESIS; LEIUROTOXIN-I; APAMIN-BINDING; BEE VENOM; PHARMACOLOGICAL CHARACTERIZATION; NEUROTOXIN APAMIN; TITYUS-SERRULATUS; TOXIN; LIGAND	The biophysical properties of small conductance Ca(2+)-activated K(+) (SK) channels are well suited to underlie afterhyperpolarizations (AHPs) shaping the firing patterns of a conspicuous number of central and peripheral neurons. We have identified a. new scorpion toxin (tamapin) that binds to SK channels with high affinity and inhibits SK channel-mediated currents in pyramidal neurons of the hippocampus as well as in cell lines expressing distinct SK channel Subunits. This toxin distinguished between the SK channels underlying the apamin-sensitive I(AHP) and the Ca(2+)-activated K(+) channels mediating the slow I(AHP) (sI(AHP)) in hippocampal neurons. Compared with related scorpion toxins, tamapin displayed a unique, remarkable selectivity for SK2 versus SK1 (similar to1750-fold) and SK3 (similar to70-fold) channels and is the most potent SK2 channel blocker characterized so far (IC(50) for SK2 channels = 24 pm). Tamapin will facilitate the characterization of the subunit composition of native SK channels and help determine their involvement in electrical and biochemical signaling.	Univ London Imperial Coll Sci & Technol, Sch Med, Dept Pediat & Neonatal Med, London W12 0NN, England; UCL, Dept Physiol, London WC1E 6BT, England; UCL, Wellcome Lab Mol Pharmacol, London WC1E 6BT, England; Max Planck Inst Expt Med, D-37075 Gottingen, Germany; Natl Univ Singapore, Singapore 119260, Singapore; Haffkine Inst, Bombay 400012, Maharashtra, India; Sheffield Hallam Univ, Div Biomed Sci, Sheffield S1 1WB, S Yorkshire, England	Imperial College London; University of London; University College London; University of London; University College London; Max Planck Society; National University of Singapore; Sheffield Hallam University	Strong, PN (corresponding author), Univ London Imperial Coll Sci & Technol, Sch Med, Dept Pediat & Neonatal Med, London W12 0NN, England.	p.strong@shu.ac.uk	Kini, Manjunatha/H-8029-2012; Stocker, Martin/C-1844-2008	Wadsworth, Jonathan/0000-0002-4797-2259; Kini, Manjunatha/0000-0002-6100-3251	MRC [MC_U123160655] Funding Source: UKRI; Medical Research Council [MC_U123160655] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AUGUSTE P, 1992, BIOCHEMISTRY-US, V31, P648, DOI 10.1021/bi00118a003; AUGUSTE P, 1990, J BIOL CHEM, V265, P4753; Blanc E, 1997, PROTEINS, V29, P359, DOI 10.1002/(SICI)1097-0134(199711)29:3&lt;359::AID-PROT9&gt;3.0.CO;2-5; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; CASTLE NA, 1986, FEBS LETT, V209, P117, DOI 10.1016/0014-5793(86)81095-X; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHICCHI GG, 1988, J BIOL CHEM, V263, P10192; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; Empson RM, 2001, NEUROSCIENCE, V102, P297, DOI 10.1016/S0306-4522(00)00494-2; Fajloun Z, 2000, EUR J BIOCHEM, V267, P5149, DOI 10.1046/j.1432-1327.2000.01577.x; Fournier C, 2001, BEHAV BRAIN RES, V121, P81, DOI 10.1016/S0166-4328(00)00387-9; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; Garcia ML, 2001, TOXICON, V39, P739, DOI 10.1016/S0041-0101(00)00214-2; Grunnet M, 2001, NEUROPHARMACOLOGY, V40, P879, DOI 10.1016/S0028-3908(01)00028-4; HABERMANN E, 1979, EUR J BIOCHEM, V94, P355, DOI 10.1111/j.1432-1033.1979.tb12901.x; Hille B., 2001, IONIC CHANNELS EXCIT, P814; Hosseini R, 2001, J PHYSIOL-LONDON, V535, P323, DOI 10.1111/j.1469-7793.2001.00323.x; HUGUES M, 1982, J BIOL CHEM, V257, P2762; Ikonen S, 1999, EUR J PHARMACOL, V382, P151, DOI 10.1016/S0014-2999(99)00616-0; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Kharrat R, 1997, FEBS LETT, V406, P284, DOI 10.1016/S0014-5793(97)00285-8; Kharrat R, 1996, EUR J BIOCHEM, V242, P491, DOI 10.1111/j.1432-1033.1996.0491r.x; Khawaled R, 1999, PFLUG ARCH EUR J PHY, V438, P314, DOI 10.1007/s004240050915; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; LATORRE R, 1997, ION CHANNELS CELL TO; Lecomte C, 1999, J PEPT RES, V54, P369, DOI 10.1034/j.1399-3011.1999.00107.x; Legros C, 1996, FEBS LETT, V390, P81, DOI 10.1016/0014-5793(96)00616-3; McIntosh J M, 1999, Methods Enzymol, V294, P605; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; MESSIER C, 1991, BRAIN RES, V551, P322, DOI 10.1016/0006-8993(91)90950-Z; Pedarzani P, 2000, J PHYSIOL-LONDON, V527, P283, DOI 10.1111/j.1469-7793.2000.t01-1-00283.x; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; RomiLebrun R, 1997, EUR J BIOCHEM, V245, P457, DOI 10.1111/j.1432-1033.1997.00457.x; SABATIER JM, 1994, INT J PEPT PROT RES, V43, P486; SABATIER JM, 1993, BIOCHEMISTRY-US, V32, P2763, DOI 10.1021/bi00062a005; Sah P, 2002, PROG NEUROBIOL, V66, P345, DOI 10.1016/S0301-0082(02)00004-7; SANTHANAKRISHNAN BR, 1974, J TROP MED HYG, V77, P133; Seutin V, 1999, TRENDS PHARMACOL SCI, V20, P268, DOI 10.1016/S0165-6147(99)01334-6; Shah M, 2000, BRIT J PHARMACOL, V129, P627, DOI 10.1038/sj.bjp.0703111; Shakkottai VG, 2001, J BIOL CHEM, V276, P43145, DOI 10.1074/jbc.M106981200; Stocker M, 1999, P NATL ACAD SCI USA, V96, P4662, DOI 10.1073/pnas.96.8.4662; Stocker M, 2000, MOL CELL NEUROSCI, V15, P476, DOI 10.1006/mcne.2000.0842; Strobaek D, 2000, BRIT J PHARMACOL, V129, P991, DOI 10.1038/sj.bjp.0703120; Strong PN, 2000, METH TOOLS BIOSCI ME, P127; Strong PN, 2001, ARCH BIOCHEM BIOPHYS, V385, P138, DOI 10.1006/abbi.2000.2135; Terstappen GC, 2001, NEUROPHARMACOLOGY, V40, P772, DOI 10.1016/S0028-3908(01)00007-7; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X; Uchitel OD, 1997, TOXICON, V35, P1161, DOI 10.1016/S0041-0101(96)00210-3; WADSWORTH JDF, 1994, J BIOL CHEM, V269, P18053; Wolfart J, 2001, J NEUROSCI, V21, P3443, DOI 10.1523/JNEUROSCI.21-10-03443.2001; ZERROUK H, 1993, FEBS LETT, V320, P189, DOI 10.1016/0014-5793(93)80583-G; Zerrouk H, 1996, INT J PEPT PROT RES, V48, P514	55	72	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46101	46109		10.1074/JBC.m206465200	http://dx.doi.org/10.1074/JBC.m206465200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12239213	hybrid			2022-12-27	WOS:000179529300053
J	Xia, Z; Sniderman, AD; Cianflone, K				Xia, Z; Sniderman, AD; Cianflone, K			Acylation-stimulating protein (ASP) deficiency induces obesity resistance and increased energy expenditure in ob/ob mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; FATTY-ACID; LIPOPROTEIN-LIPASE; FOOD-INTAKE; DENSITY-LIPOPROTEIN; METABOLIC-RATE; LEPTIN; HYPERTRIGLYCERIDEMIA; GLUCOSE; MUSCLE	Acylation-stimulating protein (ASP) acts as a paracrine signal to increase triglyceride synthesis in adipocytes. ASP administration results in more rapid postprandial lipid clearance. In mice, C3 (the precursor to ASP) knockout results in ASP deficiency and leads to reduced body fat and leptin levels. The protective potential of ASP deficiency against obesity and involvement of the leptin pathway were examined in ob/ob C3(-/-) double knockout mice (2KO). Compared with age-matched ob/ob mice, 2KO mice had delayed postprandial triglyceride and fatty acid clearance; associated with decreased body weight (4-17 weeks age: male: -13.7%, female: -20.6%, p < 0.0001) and HOMA (homeostasis model assessment) index (-37.7%), suggesting increased insulin sensitivity. By contrast, food intake in 2KO mice was +9.1% higher over ob/ob mice (p < 0.001, 2KO 5.1 +/- 0.2 g/day, ob/ob 4.5 +/- 0.2 g/day, wild type 2.6 +/- 0.1 g/day). The hyperphagia/leanness was balanced by a 28.5% increase in energy expenditure (oxygen consumption: 2KO, 131 +/- 8.9 ml/h; ob/ob, 102 +/- 4.5 ml/h; p < 0.01; wild type, 144 8.9 ml/h). These results suggest that the ASP regulation of energy storage may influence energy expenditure and dynamic metabolic balance.	McGill Univ, Ctr Hlth, Mike Rosenbloom Lab Cardiovasc Res, Montreal, PQ H3A 1A1, Canada	McGill University	Cianflone, K (corresponding author), Royal Victoria Hosp, 687 Pine Ave W,H7-30, Montreal, PQ H3A 1A1, Canada.	katherine.cianflone@mcgill.ca						Argyropoulos G, 2002, J APPL PHYSIOL, V92, P2187, DOI 10.1152/japplphysiol.00994.2001; BALDO A, 1995, J LIPID RES, V36, P1415; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; Breslow MJ, 1999, AM J PHYSIOL-ENDOC M, V276, pE443, DOI 10.1152/ajpendo.1999.276.3.E443; Charlesworth JA, 1998, INT J OBESITY, V22, P1096, DOI 10.1038/sj.ijo.0800733; CIANFLONE K, 1995, INT J OBESITY, V19, P604; CIANFLONE K, 1995, EUR J CLIN INVEST, V25, P817, DOI 10.1111/j.1365-2362.1995.tb01690.x; CIANFLONE K, 1994, BIOCHEMISTRY-US, V33, P9489, DOI 10.1021/bi00198a014; Cianflone K, 1997, J ENDOCRINOL, V155, P203, DOI 10.1677/joe.0.1550203; Cianflone K, 1999, SEMIN CELL DEV BIOL, V10, P31, DOI 10.1006/scdb.1998.0272; Circolo A, 1999, IMMUNOPHARMACOLOGY, V42, P135, DOI 10.1016/S0162-3109(99)00021-1; Commins SP, 1999, ENDOCRINOLOGY, V140, P292, DOI 10.1210/en.140.1.292; FUHBECK G, 1997, BIOCH BIOPHYS REV CO, V240, P590; GERMINARIO R, 1993, METABOLISM, V42, P574, DOI 10.1016/0026-0495(93)90215-A; Goudriaan JR, 2001, ARTERIOSCL THROM VAS, V21, P1488, DOI 10.1161/hq0901.095147; HAMMOND VA, 1987, METABOLISM, V36, P308, DOI 10.1016/0026-0495(87)90199-5; Havel PJ, 1999, AM J CLIN NUTR, V70, P305; Havel PJ, 1999, DIABETES, V48, P334, DOI 10.2337/diabetes.48.2.334; HUGLI TE, 1990, CURR TOP MICROBIOL, V153, P181; Hwa JJ, 1997, AM J PHYSIOL-REG I, V272, pR1204, DOI 10.1152/ajpregu.1997.272.4.R1204; Kalant D., 1995, Clinical and Investigative Medicine, V18, pB10; MAEDA N, 1994, J BIOL CHEM, V269, P23610; Marti A, 1998, BIOCHEM BIOPH RES CO, V246, P859, DOI 10.1006/bbrc.1998.8539; Maslowska M, 1999, EUR J CLIN INVEST, V29, P679, DOI 10.1046/j.1365-2362.1999.00514.x; Maslowska M, 1997, J LIPID RES, V38, P1; MATTACKS CA, 1988, INT J OBESITY, V12, P585; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Mistry AM, 1997, J NUTR, V127, P2065; MIYOSHI H, 1988, J CLIN INVEST, V81, P1545, DOI 10.1172/JCI113487; Mueller WM, 1998, ENDOCRINOLOGY, V139, P551, DOI 10.1210/en.139.2.551; Muller G, 1997, J BIOL CHEM, V272, P10585, DOI 10.1074/jbc.272.16.10585; Murray I, 1999, J BIOL CHEM, V274, P36219, DOI 10.1074/jbc.274.51.36219; Murray I, 1997, J LIPID RES, V38, P2492; Murray I, 2000, ENDOCRINOLOGY, V141, P1041, DOI 10.1210/en.141.3.1041; Namae M, 1998, LAB ANIM SCI, V48, P103; Newsholme E A, 1976, Biochem Soc Symp, P61; Newsholme E A, 1978, Biochem Soc Symp, P183; NEWSHOLME EA, 1980, NEW ENGL J MED, V302, P400, DOI 10.1056/NEJM198002143020711; Niskanen L, 1997, INT J OBESITY, V21, P309, DOI 10.1038/sj.ijo.0800406; Ohinata K, 2002, PEPTIDES, V23, P127, DOI 10.1016/S0196-9781(01)00588-5; Reidy SP, 2002, AM J PHYSIOL-ENDOC M, V282, pE312, DOI 10.1152/ajpendo.00037.2001; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; Saleh J, 1998, J LIPID RES, V39, P884; Saleh J, 2001, INT J OBESITY, V25, P705, DOI 10.1038/sj.ijo.0801613; Scantlebury T, 1998, J BIOL CHEM, V273, P20903, DOI 10.1074/jbc.273.33.20903; Scarpace PJ, 1997, AM J PHYSIOL-ENDOC M, V273, pE226, DOI 10.1152/ajpendo.1997.273.1.E226; SCHUPF N, 1983, J NEUROIMMUNOL, V5, P305, DOI 10.1016/0165-5728(83)90051-6; SHIMADA M, 1993, J BIOL CHEM, V268, P17924; TAGLIAFERRO AR, 1990, INT J OBESITY, V14, P957; TAO YZ, 1997, BIOCHIM BIOPHYS ACTA, V1344, P211; Van Hermelen V, 1999, J BIOL CHEM, V274, P18243, DOI 10.1074/jbc.274.26.18243; Weinstock PH, 1995, J CLIN INVEST, V96, P2555, DOI 10.1172/JCI118319; Wetsel RA, 1999, J BIOL CHEM, V274, P19429, DOI 10.1074/jbc.274.27.19429; Yagyu H, 2002, J BIOL CHEM, V277, P10037, DOI 10.1074/jbc.M109966200; YASRUEL Z, 1991, LIPIDS, V26, P495, DOI 10.1007/BF02536592; YASUSHI I, 1990, SCIENCE, V249, P790; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	57	87	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45874	45879		10.1074/jbc.M207281200	http://dx.doi.org/10.1074/jbc.M207281200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244109	hybrid			2022-12-27	WOS:000179529300022
J	Mercier, JF; Salahpour, A; Angers, S; Breit, A; Bouvier, M				Mercier, JF; Salahpour, A; Angers, S; Breit, A; Bouvier, M			Quantitative assessment of beta(1)- and beta(2)-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAILING HUMAN HEARTS; HORMONE RECEPTOR; TRANSFER BRET; DIMERIZATION; PROTEIN; OLIGOMERIZATION; IDENTIFICATION; SUBTYPES; DOPAMINE; FAILURE	Quantitative bioluminescence resonance energy transfer (BRET) analysis was applied to the study of beta(1)- and beta(2)-adrenergic receptor homo- and heterodimerization. To assess the relative affinity between each of the protomers, BRET saturation experiments were carried out in HEK-293T cells. beta(1)- and beta(2)-adrenergic receptors were found to have similar propensity to engage in homo- and heterotropic interactions suggesting that, at equivalent expression levels of the two receptor subtypes, an equal proportion of homo- and heterodimers would form. Analysis of the data also revealed that, at equimolar expression levels of energy donor and acceptor, more than 80% of the receptor molecules exist as dimers and that this high incidence of receptor dimerization is insensitive to receptor density for expression levels varying between 1.4 and 26.9 pmol of receptor/mg of membrane protein. Taken together, these results indicate that most of the receptors expressed in cells exist as constitutive dimers and that, at least in undifferentiated fibroblasts, the proportion of homo- and heterodimers between the closely related beta(1)- and beta(2)-adrenergic receptors is determined by their relative levels of expression.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Grp Rech Syst Nerveux Autonome, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Bouvier, M (corresponding author), Univ Montreal, Dept Biochim, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.		Angers, Stephane/E-1432-2014; Bouvier, Michel/H-2758-2014	Angers, Stephane/0000-0001-7241-9044; Bouvier, Michel/0000-0003-1128-0100				Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Ayoub MA, 2002, J BIOL CHEM, V277, P21522, DOI 10.1074/jbc.M200729200; Boivin V, 2001, KIDNEY INT, V59, P515, DOI 10.1046/j.1523-1755.2001.059002515.x; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; BRISTOW MR, 1993, J AM COLL CARDIOL, V22, pA61, DOI 10.1016/0735-1097(93)90465-D; BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; Brodde OE, 1999, PHARMACOL REV, V51, P651; BRODDE OE, 1983, CIRC RES, V53, P752, DOI 10.1161/01.RES.53.6.752; Brodde OE, 1998, J CARDIOVASC PHARM, V31, P585, DOI 10.1097/00005344-199804000-00018; Brodie J, 2001, WATER SCI TECHNOL, V43, P203, DOI 10.2166/wst.2001.0540; Cheng ZJ, 2001, J BIOL CHEM, V276, P48040, DOI 10.1074/jbc.M105668200; Ciruela F, 1995, J NEUROSCI RES, V42, P818, DOI 10.1002/jnr.490420610; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; DELMONTE F, 1993, CIRCULATION, V88, P854, DOI 10.1161/01.CIR.88.3.854; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GARZON J, 1995, MOL PHARMACOL, V47, P738; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; Laurent CE, 2001, AM J PHYSIOL-REG I, V280, pR355, DOI 10.1152/ajpregu.2001.280.2.R355; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; NGUYEN CT, 1995, BIOMED J, V2, P34; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Petrecca K, 1998, J ANAT, V192, P517, DOI 10.1046/j.1469-7580.1998.19240517.x; Ramsay D, 2002, BIOCHEM J, V365, P429, DOI 10.1042/BJ20020251; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Roess DA, 2000, ENDOCRINOLOGY, V141, P4518, DOI 10.1210/en.141.12.4518; SANO M, 1993, LIFE SCI, V52, P1063, DOI 10.1016/0024-3205(93)90199-D; STEINFATH M, 1992, BRIT J PHARMACOL, V105, P463, DOI 10.1111/j.1476-5381.1992.tb14276.x; VEATCH W, 1977, J MOL BIOL, V113, P89, DOI 10.1016/0022-2836(77)90042-0; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Vila-Coro AJ, 2000, P NATL ACAD SCI USA, V97, P3388, DOI 10.1073/pnas.050457797; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	44	401	415	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44925	44931		10.1074/jbc.M205767200	http://dx.doi.org/10.1074/jbc.M205767200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244098	hybrid			2022-12-27	WOS:000179404800044
J	Thuault, S; Gangloff, YG; Kirchner, J; Sanders, S; Werten, S; Romier, C; Weil, PA; Davidson, I				Thuault, S; Gangloff, YG; Kirchner, J; Sanders, S; Werten, S; Romier, C; Weil, PA; Davidson, I			Functional analysis of the TFIID-specific yeast TAF4 (yTAF(II)48) reveals an unexpected organization of its histone-fold domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; TAF(II)-CONTAINING COMPLEX; NUCLEOSOME ACETYLATION; TRANSCRIPTION; GENE; COMPONENTS; IDENTIFICATION; ACTIVATION; MULTIPLE; SUBUNITS	Yeast TFIID comprises the TATA binding protein and 14 TBP-associated factors (TAF(II)s), nine of which contain histone-fold domains (HFDs). The C-terminal region of the TFIID-specific yTAF4 (yTAF(II)48) containing the HFD shares strong sequence similarity with Drosophila (d)TAF4 (dTAF(II)110) and human TAF4 (hTAF(II)135). A structure/function analysis of yTAF4 demonstrates that the HFD, a short conserved C-terminal domain (CCTD), and the region separating them are all required for yTAF4 function. Temperature-sensitive mutations in the yTAF4 HFD alpha2 helix or the CCTD can be suppressed upon overexpression of yTAF12 (yTAF(II)68). Moreover, coexpression in Escherichia coli indicates direct yTAF4-yTAF12 heterodimerization optimally requires both the yTAF4 HFD and CCTD. The x-ray crystal structure of the orthologous hTAF4-hTAF12 histone-like heterodimer indicates that the alpha3 region within the predicted TAF4 HFD is unstructured and does not correspond to the bona fide alpha3 helix. Our functional and biochemical analysis of yTAF4, rather provides strong evidence that the HFD alpha3 helix of the TAF4 family lies within the CCTD. These results reveal an unexpected and novel HFD organization in which the alpha3 helix is separated from the alpha2 helix by an extended loop containing a conserved functional domain.	Univ Louis Pasteur Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Vanderbilt University	Davidson, I (corresponding author), Univ Louis Pasteur Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, Boite Postale 163, F-67404 Illkirch Graffenstaden, France.	irwin@titus.u-strasbg.fr	Werten, Sebastiaan/AAU-9011-2021; GANGLOFF, Yann-Gaël/I-2161-2014	Werten, Sebastiaan/0000-0003-2244-9688; GANGLOFF, Yann-Gaël/0000-0001-9031-1184; Romier, Christophe/0000-0002-3680-935X; Davidson, Irwin/0000-0001-5533-1171; THUAULT, Sylvie/0000-0003-0133-3803	NIGMS NIH HHS [GM52461] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM052461, R01GM052461] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Asahara H, 2001, MOL CELL BIOL, V21, P7892, DOI 10.1128/MCB.21.23.7892-7900.2001; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Chen Z, 2000, MOL CELL BIOL, V20, P5064, DOI 10.1128/MCB.20.14.5064-5076.2000; Durso RJ, 2001, MOL CELL BIOL, V21, P7331, DOI 10.1128/MCB.21.21.7331-7344.2001; Fribourg S, 2001, J MOL BIOL, V306, P363, DOI 10.1006/jmbi.2000.4376; Gangloff YG, 2000, MOL CELL BIOL, V20, P340, DOI 10.1128/MCB.20.1.340-351.2000; Gangloff YG, 2001, TRENDS BIOCHEM SCI, V26, P250, DOI 10.1016/S0968-0004(00)01741-2; Gangloff YG, 2001, MOL CELL BIOL, V21, P1841, DOI 10.1128/MCB.21.5.1841-1853.2001; Gangloff YG, 2001, MOL CELL BIOL, V21, P5109, DOI 10.1128/MCB.21.15.5109-5121.2001; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; Guermah M, 2001, MOL CELL BIOL, V21, P6882, DOI 10.1128/MCB.21.20.6882-6894.2001; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Hernandez-Hernandez A, 2001, MOL CELL BIOL, V21, P614, DOI 10.1128/MCB.21.2.614-623.2001; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; Kirchner J, 2001, MOL CELL BIOL, V21, P6668, DOI 10.1128/MCB.21.19.6668-6680.2001; Kirschner DB, 2002, MOL CELL BIOL, V22, P3178, DOI 10.1128/MCB.22.9.3178-3193.2002; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; Leurent C, 2002, EMBO J, V21, P3424, DOI 10.1093/emboj/cdf342; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Mazzarelli JM, 1997, J VIROL, V71, P7978, DOI 10.1128/JVI.71.10.7978-7983.1997; Metzger D, 1999, EMBO J, V18, P4823, DOI 10.1093/emboj/18.17.4823; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; PERLETTI L, 2001, BMC MOL BIOL, V2; Reese JC, 2000, J BIOL CHEM, V275, P17391, DOI 10.1074/jbc.M001635200; Sanders SL, 2000, J BIOL CHEM, V275, P13895, DOI 10.1074/jbc.275.18.13895; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; Saurin AJ, 2001, NATURE, V412, P655, DOI 10.1038/35088096; Schroeder SC, 1998, NUCLEIC ACIDS RES, V26, P4186, DOI 10.1093/nar/26.18.4186; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; Selleck W, 2002, NAT STRUCT BIOL, V9, P231; Selleck W, 2001, NAT STRUCT BIOL, V8, P695, DOI 10.1038/90408; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; Soldatov A, 1999, MOL CELL BIOL, V19, P3769; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Wassarman DA, 2000, P NATL ACAD SCI USA, V97, P1154, DOI 10.1073/pnas.97.3.1154; Werten S, 2002, J BIOL CHEM, V277, P45502, DOI 10.1074/jbc.M206587200; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Zhou JM, 1998, P NATL ACAD SCI USA, V95, P13483, DOI 10.1073/pnas.95.23.13483	48	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45510	45517		10.1074/jbc.M206556200	http://dx.doi.org/10.1074/jbc.M206556200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237303	Green Published, hybrid			2022-12-27	WOS:000179404800116
J	Weir, AP; Burton, EA; Harrod, G; Davies, KE				Weir, AP; Burton, EA; Harrod, G; Davies, KE			A- and B-utrophin have different expression patterns and are differentially up-regulated in mdx muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-RELATED PROTEIN; DUCHENNE MUSCULAR-DYSTROPHY; ENDOTHELIAL-CELLS; SKELETAL-MUSCLE; ACTIN-BINDING; MONOCLONAL-ANTIBODIES; BETA-DYSTROBREVIN; DEFICIENT MICE; MOUSE; COMPLEXES	Duchenne muscular dystrophy (DMD) is a fatal childhood disease caused by mutations that abolish the expression of dystrophin in muscle. Utrophin is a paralogue of dystrophin and can functionally replace it in skeletal muscle. A method to induce utrophin up-regulation in muscle should therefore be therapeutically useful in DMD. We have previously shown that there are two full-length utrophin mRNA species: A and B. Here we describe the generation and characterization of antibodies specific to A- and B-utrophin. We show that both mRNA isoforms are translated into full-length proteins, which have very different expression patterns. B-utrophin is expressed in vascular endothelial cells; A-utrophin is expressed at the neuromuscular junction, choroid plexus, pia mater, and renal glomerulus. We have analyzed the expression of A- and B-utrophin protein and RNA in dystrophin-deficient tissues. We conclude that (i) the previously described expression patterns of utrophin represent a composite of A- and B-utrophin, (ii) A- but not B-utrophin is up-regulated in dystrophin-deficient striated muscle, and (iii) this up-regulation occurs post-transcriptionally with an additional transcriptional component in skeletal muscle. These results have important implications for understanding the biology of utrophin and are crucial for future studies aiming to effect its therapeutic up-regulation in DMD patients.	Univ Oxford, MRC, Funct Genet Unit, Dept Human Anat & Genet, Oxford OX1 3QX, England	University of Oxford	Davies, KE (corresponding author), Univ Oxford, MRC, Funct Genet Unit, Dept Human Anat & Genet, S Parks Rd, Oxford OX1 3QX, England.		Burton, Edward/AAO-9677-2021; Burton, Edward/ABB-1324-2021	Burton, Edward/0000-0002-8072-4636				Blake DJ, 1998, P NATL ACAD SCI USA, V95, P241, DOI 10.1073/pnas.95.1.241; Blake DJ, 1999, J CELL BIOL, V147, P645, DOI 10.1083/jcb.147.3.645; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Burton EA, 1999, P NATL ACAD SCI USA, V96, P14025, DOI 10.1073/pnas.96.24.14025; Deconinck AE, 1997, J CELL BIOL, V136, P883, DOI 10.1083/jcb.136.4.883; Ferrari G, 2001, NATURE, V411, P1014, DOI 10.1038/35082631; Grady RM, 1997, J CELL BIOL, V136, P871, DOI 10.1083/jcb.136.4.871; Gramolini AO, 1999, J NEUROPATH EXP NEUR, V58, P235, DOI 10.1097/00005072-199903000-00003; Gramolini AO, 1999, P NATL ACAD SCI USA, V96, P3223, DOI 10.1073/pnas.96.6.3223; HELLIWELL TR, 1992, NEUROMUSCULAR DISORD, V2, P177, DOI 10.1016/0960-8966(92)90004-P; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; KARPATI G, 1993, J NEUROPATH EXP NEUR, V52, P119, DOI 10.1097/00005072-199303000-00004; KHURANA TS, 1992, J CELL BIOL, V119, P357, DOI 10.1083/jcb.119.2.357; Knuesel I, 2000, J COMP NEUROL, V422, P594, DOI 10.1002/1096-9861(20000710)422:4<594::AID-CNE8>3.0.CO;2-Q; KUNKEL LM, 1985, P NATL ACAD SCI USA, V82, P4778, DOI 10.1073/pnas.82.14.4778; Loh NY, 2001, MOL CELL BIOL, V21, P7442, DOI 10.1128/MCB.21.21.7442-7448.2001; Loh NY, 2000, J CELL SCI, V113, P2715; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; Lumeng C, 1999, NAT NEUROSCI, V2, P611, DOI 10.1038/10165; MATSUMURA K, 1993, FEBS LETT, V326, P289, DOI 10.1016/0014-5793(93)81810-M; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; Moores CA, 2000, CELL MOTIL CYTOSKEL, V46, P116, DOI 10.1002/1097-0169(200006)46:2<116::AID-CM4>3.0.CO;2-L; Morris GE, 1999, BIOCHEM J, V337, P119, DOI 10.1042/0264-6021:3370119; Nguyen T M, 1991, J Cell Biol, V115, P1695, DOI 10.1083/jcb.115.6.1695; Partridge T, 2000, NEUROL SCI, V21, pS939; Perkins KJ, 2001, NUCLEIC ACIDS RES, V29, P4843, DOI 10.1093/nar/29.23.4843; PONS F, 1994, CIRCULATION, V90, P369, DOI 10.1161/01.CIR.90.1.369; Raats CJI, 2000, AM J PATHOL, V156, P1749, DOI 10.1016/S0002-9440(10)65046-8; Roberts RG, 1998, HUM MOL GENET, V7, P589, DOI 10.1093/hmg/7.4.589; Sewry CA, 2001, HISTOCHEM J, V33, P9, DOI 10.1023/A:1017531627935; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; TINSLEY JM, 1993, NEUROMUSCULAR DISORD, V3, P537, DOI 10.1016/0960-8966(93)90111-V; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; Ueda H, 2000, NEUROSCI LETT, V283, P121, DOI 10.1016/S0304-3940(00)00925-3; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Wang B, 2000, P NATL ACAD SCI USA, V97, P13714, DOI 10.1073/pnas.240335297; WINDER SJ, 1995, J CELL SCI, V108, P63; Zaccaria ML, 2001, NEUROSCIENCE, V104, P311, DOI 10.1016/S0306-4522(01)00092-6	42	96	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45285	45290		10.1074/jbc.M205177200	http://dx.doi.org/10.1074/jbc.M205177200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235137	hybrid			2022-12-27	WOS:000179404800089
J	Yukitake, H; Furusawa, M; Taira, T; Iguchi-Ariga, SMM; Ariga, H				Yukitake, H; Furusawa, M; Taira, T; Iguchi-Ariga, SMM; Ariga, H			AAT-1, a novel testis-specific AMY-1-binding protein, forms a quaternary complex with AMY-1, a-kinase anchor protein 84, and a regulatory subunit of cAMP-dependent protein kinase and is phosphorylated by its kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SPERM CAPACITATION; TYROSINE PHOSPHORYLATION; MOUSE SPERMATOZOA; BINDING-PROTEIN; ASSOCIATION; EXPRESSION; S-AKAP84; AKAP149	AMY-1 has been identified by us as a c-Myc-binding protein and was found to stimulate c-Myc transcription activity. AMY-1 was also found to be associated with protein kinase A anchor protein 84/149 (S-AKAP84/AKAP149) in the mitochondria in somatic cells and sperm, suggesting that it plays a role in spermatogenesis. To determine the molecular function of AMY-1, a two-hybrid screening of cDNAs encoding AMY-1-binding proteins was carried out with AMY-1 as a bait using a human testis cDNA library, and a clone encoding a novel protein, AAT-1, was obtained. Three isoforms of AAT-1, AAT-1alpha, -beta, and -gamma, were found to be derived from an alternative splicing of the transcripts of the aat-1 gene, which was mapped at human chromosome 3q13-3q21. AAT-1 was found to be specifically expressed in the testis during the course of spermatogenesis and also to be present in the spermatid and mature sperm, as was AMY-1. AAT-1alpha was found to bind to and be colocalized in mitochondria with AMY-1 in human HeLa and mouse GC-1 cells. Furthermore, AAT-1alpha was found to bind to the N-terminal half of S-AKAP84/AKAP149 in a quaternary complex with AMY-1 and a regulatory subunit (RII) of cAMP-dependent kinase (PKA), in which AAT-1alpha was associated with RII via S-AKAP84/AKAP149, in rat testis and HeLa cells. It was then found that AAT-1alpha weakly stimulated a phosphorylation activity of PKA and also that AAT-1 itself was phosphorylated by PKA in vivo and in vitro. These results suggest that both AAT-1 and AMY-1 play roles in spermatogenesis.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Hokkaido University; Japan Science & Technology Agency (JST)	Ariga, H (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.	hiro@pharm.hokudai.ac.jp	Ariga, Hiroyoshi/B-5895-2013; Ariga, Sanae/H-9647-2013	Ariga, Hiroyoshi/0000-0001-7384-2143; 				AITKEN RJ, 1995, J CELL SCI, V108, P2017; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P456; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; FLORKE S, 1983, DIFFERENTIATION, V24, P250, DOI 10.1111/j.1432-0436.1983.tb01328.x; Fujimoto M, 2001, GENES CELLS, V6, P1067, DOI 10.1046/j.1365-2443.2001.00488.x; Furusawa M, 2000, INT J ONCOL, V16, P339; Furusawa M, 2001, J BIOL CHEM, V276, P36647, DOI 10.1074/jbc.M103885200; Gadella BM, 2000, DEVELOPMENT, V127, P2407; GalantinoHomer HL, 1997, BIOL REPROD, V56, P707, DOI 10.1095/biolreprod56.3.707; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Haigermoser C, 1996, NUCLEIC ACIDS RES, V24, P3846, DOI 10.1093/nar/24.19.3846; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Leclerc P, 1997, FREE RADICAL BIO MED, V22, P643, DOI 10.1016/S0891-5849(96)00379-6; Leclerc P, 1996, BIOL REPROD, V55, P684, DOI 10.1095/biolreprod55.3.684; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; MALI P, 1989, REPROD FERT DEVELOP, V1, P369, DOI 10.1071/RD9890369; NAZ RK, 1991, J CELL SCI, V99, P157; Ono T, 2000, J BIOL CHEM, V275, P31145, DOI 10.1074/jbc.M003031200; Reinton N, 2000, DEV BIOL, V223, P194, DOI 10.1006/dbio.2000.9725; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Schillace RV, 1999, CURR BIOL, V9, P321, DOI 10.1016/S0960-9822(99)80141-9; SORRENTINO V, 1991, ONCOGENE, V6, P149; Steen RL, 2000, J CELL BIOL, V150, P1251, DOI 10.1083/jcb.150.6.1251; Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365-2443.1998.00206.x; Trendelenburg G, 1996, BIOCHEM BIOPH RES CO, V225, P313, DOI 10.1006/bbrc.1996.1172; VISCONTI PE, 1995, DEVELOPMENT, V121, P1139; VISCONTI PE, 1995, DEVELOPMENT, V121, P1129; Yukitake H, 2002, BBA-GENE STRUCT EXPR, V1577, P126, DOI 10.1016/S0167-4781(02)00411-6	30	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45480	45492		10.1074/jbc.M206201200	http://dx.doi.org/10.1074/jbc.M206201200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223483	hybrid			2022-12-27	WOS:000179404800113
J	Kang, HY; Huang, KE; Chang, SY; Ma, WL; Lin, WJ; Chang, C				Kang, HY; Huang, KE; Chang, SY; Ma, WL; Lin, WJ; Chang, C			Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; PROSTATE-CANCER CELLS; TGF-BETA RECEPTOR; TRANSCRIPTIONAL ACTIVATION; DU145 CELLS; DPC4 SMAD4; CROSS-TALK; COACTIVATOR; PROTEIN; INHIBITION	Smad proteins have been demonstrated to be key components in the transforming growth factor 13 signaling cascade. Here we demonstrate that Smad4, together with Smad3, can interact with the androgen receptor (AR) in the DNA-binding and ligand-binding domains, which may result in the modulation of 5alpha-dihydrotestosterone-induced AR transactivation. Interestingly, in the prostate PC3 and LNCaP cells, addition of Smad3 can enhance AR transactivation, and co-transfection of Smad3 and Smad4 can then repress AR transactivation in various androgen response element-promoter reporter assays as well as Northern blot and reverse transcription-PCR quantitation assays with prostate-specific antigen mRNA expression. In contrast, in the SW480-C7 cell, lacking endogenous functional Smad4, the influence of Smad3 on AR transactivation is dependent on the various androgen response element-promoters. The influence of Smad3/Smad4 on the AR transactivation may involve the acetylation since the treatment of trichostatin A or sodium butyrate can reverse Smad3/Smad4-repressed AR transactivation and Smad3/Smad4 complex can also decrease the acetylation level of AR. Together, these results suggest that the interactions between AR, Smad3, and Smad4 may result in the differential regulation of the AR transactivation, which further strengthens their roles in the prostate cancer progression.	Chang Gung Univ, Mem Hosp, Ctr Menopause & Reprod Med Res, Kaohsiung 833, Taiwan; Univ Rochester, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, George Whipple Lab Canc Res, Dept Radiat Oncol, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA	Chang Gung University; University of Rochester; University of Rochester; University of Rochester; University of Rochester	Huang, KE (corresponding author), Chang Gung Univ, Mem Hosp, Ctr Menopause & Reprod Med Res, Kaohsiung 833, Taiwan.		Kang, Hong-Yo/W-9031-2019; Lin, Wen-Jye/D-1028-2016	Kang, Hong-Yo/0000-0003-0626-5037; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060905] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60905] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brodin G, 1999, CANCER RES, V59, P2731; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Dai JL, 1999, P NATL ACAD SCI USA, V96, P1427, DOI 10.1073/pnas.96.4.1427; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hayes SA, 2001, CANCER RES, V61, P2112; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Kang HY, 2001, P NATL ACAD SCI USA, V98, P3018, DOI 10.1073/pnas.061305498; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lee DK, 2000, J BIOL CHEM, V275, P9308, DOI 10.1074/jbc.275.13.9308; Leong GM, 2001, J BIOL CHEM, V276, P18243, DOI 10.1074/jbc.M010815200; Liberati NT, 2001, J BIOL CHEM, V276, P22595, DOI 10.1074/jbc.M010778200; List HJ, 1999, EXP CELL RES, V252, P471, DOI 10.1006/excr.1999.4638; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Schutte M, 1996, CANCER RES, V56, P2527; Sharma M, 2001, MOL ENDOCRINOL, V15, P1918, DOI 10.1210/me.15.11.1918; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; Subramaniam N, 2001, J BIOL CHEM, V276, P15741, DOI 10.1074/jbc.M011033200; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wotton D, 2001, CELL GROWTH DIFFER, V12, P457; Wotton D, 2001, CURR TOP MICROBIOL, V254, P145; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	45	86	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43749	43756		10.1074/jbc.M205603200	http://dx.doi.org/10.1074/jbc.M205603200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226080	hybrid			2022-12-27	WOS:000179272000029
J	Pai, TG; Ohkimoto, K; Sakakibara, Y; Suiko, M; Sugahara, T; Liu, MC				Pai, TG; Ohkimoto, K; Sakakibara, Y; Suiko, M; Sugahara, T; Liu, MC			Manganese stimulation and stereospecificity of the dopa (3,4-dihydroxyphenylalanine)/tyrosine-sulfating activity of human monoamine-form phenol sulfotransferase - Kinetic studies of the mechanism using wild-type and mutant enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEREOSELECTIVE SULFATE CONJUGATION; HUMAN HEPATOMA-CELLS; AMINO-ACID OXIDASE; SUBSTRATE-SPECIFICITY; D-ASPARTATE; MOLECULAR-BIOLOGY; D-ALANINE; BRAIN; PROTEINS; TYROSINE	Kinetic studies were performed to dissect the mechanism underlying the remarkable Mn2+ stimulation of the Dopa/tyrosine-sulfating activity of the human monoamine (M)-form phenol sulfotransferase (PST). The activities and the stimulation by Mn2+ are highly stereospecific for the D-form enantiomers of tyrosine and Dopa. Analysis of the kinetic results strongly suggests that tyrosine-Mn2+ and tyrosine-Mn2+-tyrosine complexes are obligatory substrates, whereas Dopa-Mn2+ complexes may be better substrates than Dopa alone. This activation of the Dopa/tyrosine-sulfating activity of M-form PST by Mn2+ via complex formation between Mn2+ and the substrate is the first reported case of a regulatory mechanism in this important class of enzymes. Our previous studies using point-mutated M-form PSTs established that the Mn2+ (in the substrate-Mn2+ complex) exerts its stimulatory effect by binding predominantly to the Asp-86 residue at the active site. We present here further studies using dopamine as substrate to bolster this conclusion. The possible physiological implications of this rather unusual specificity for the D-amino acid and its derivatives and the stimulation by Mn2+ are discussed in the context of protective and detoxification mechanisms that may operate in neurodegenerative processes in the brain. The, Mn2+ stimulation of the activity of M-form PST toward D-enantiomers of Dopa/tyrosine may have implications for other substrates (including chiral drugs) and for the other cytosolic sulfotransferases that are involved in the regulation of endogenous metabolites as well as in detoxification.	Univ Texas Hlth Ctr, Biomed Res Ctr, Tyler, TX 75708 USA		Liu, MC (corresponding author), Univ Texas Hlth Ctr, Biomed Res Ctr, 11937 US Highway 271, Tyler, TX 75708 USA.			Sugahara, Takuya/0000-0002-0335-8273				BARBEAU A, 1984, NEUROTOXICOLOGY, V5, P13; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER PR, 1983, J NEUROCHEM, V41, P630, DOI 10.1111/j.1471-4159.1983.tb04788.x; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; CORELL J, 1999, NEUROEPIDEMIOLOGY, V18, P303; COTZIAS GC, 1976, MED CLIN N AM, V60, P729, DOI 10.1016/S0025-7125(16)31856-9; Coughtrie MWH, 1998, CHEM-BIOL INTERACT, V109, P3, DOI 10.1016/S0009-2797(97)00117-8; Dajani R, 1999, J BIOL CHEM, V274, P37862, DOI 10.1074/jbc.274.53.37862; DANIELLO A, 1993, J BIOL CHEM, V268, P26941; Duffel MW, 1997, COMPREHENSIVE TOXICO, V3, P365; Falany CN, 1997, FASEB J, V11, P206, DOI 10.1096/fasebj.11.4.9068609; FERNANDO PHP, 1993, BIOSCI BIOTECH BIOCH, V5, P1974; FISHER GH, 1991, BRAIN RES BULL, V26, P983, DOI 10.1016/0361-9230(91)90266-M; GAVIN CE, 1992, TOXICOL APPL PHARM, V115, P1, DOI 10.1016/0041-008X(92)90360-5; GERGELY A, 1971, ACTA CHIM HUNG, V68, P285; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; HEROUX JA, 1988, MOL PHARMACOL, V34, P194; Keller JN, 1998, J NEUROSCI, V18, P687; Klaassen CD., 1996, CASARETT DOULLS TOXI; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin ES, 2000, BIOCHEM BIOPH RES CO, V271, P818, DOI 10.1006/bbrc.2000.2722; LIPMANN F, 1958, SCIENCE, V128, P575, DOI 10.1126/science.128.3324.575; LIU MC, 1984, P NATL ACAD SCI-BIOL, V81, P3695, DOI 10.1073/pnas.81.12.3695; Liu MC, 2000, J BIOL CHEM, V275, P13460, DOI 10.1074/jbc.275.18.13460; LONDON WP, 1969, BIOCHEMISTRY-US, V8, P1767, DOI 10.1021/bi00832a061; LUTHRA M, 1994, J BIOL CHEM, V269, P22678; MAN EH, 1987, J NEUROCHEM, V48, P510, DOI 10.1111/j.1471-4159.1987.tb04122.x; MARTELL AE, 1974, CRITICAL STABILTIY C, V1; MATSUI M, 1994, INT J BIOCHEM, V26, P1237; Mulder G.J., 1990, CONJUGATION REACTION, P107; PERSOLA GR, 1993, CHIRALITY, V5, P602; Rubin GL, 1996, XENOBIOTICA, V26, P1113, DOI 10.3109/00498259609050256; Sakakibara Y, 1998, J BIOL CHEM, V273, P6242, DOI 10.1074/jbc.273.11.6242; Sakakibara Y, 1997, BBA-MOL CELL RES, V1355, P102, DOI 10.1016/S0167-4889(96)00166-8; Segel I.H., 1975, ENZYME KINETICS; SEKURA RD, 1979, ANAL BIOCHEM, V95, P82, DOI 10.1016/0003-2697(79)90188-X; SINGH R, 1991, J ORG CHEM, V56, P2332, DOI 10.1021/jo00007a018; Stegman LD, 1998, HUM GENE THER, V9, P185, DOI 10.1089/hum.1998.9.2-185; Suiko M, 1998, J BIOCHEM-TOKYO, V124, P707, DOI 10.1093/oxfordjournals.jbchem.a022170; Suiko M, 1996, BIOCHEM J, V314, P151, DOI 10.1042/bj3140151; ULTER MF, 1976, MED CLIN N AM, V60, P713; WALLE T, 1992, DRUG METAB DISPOS, V20, P333; WALLE UK, 1993, BRIT J CLIN PHARMACO, V35, P413, DOI 10.1111/j.1365-2125.1993.tb04159.x; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; Wilson AA, 1997, XENOBIOTICA, V27, P1147, DOI 10.1080/004982597239903; Yanagisawa K, 1998, BIOSCI BIOTECH BIOCH, V62, P1037, DOI 10.1271/bbb.62.1037	46	8	9	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43813	43820		10.1074/jbc.M200785200	http://dx.doi.org/10.1074/jbc.M200785200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228221	hybrid			2022-12-27	WOS:000179272000038
J	Richter, S; Lamppa, GK				Richter, S; Lamppa, GK			Determinants for removal and degradation of transit peptides of chloroplast precursor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMAL PROCESSING PEPTIDASE; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE; TUMOR NECROSIS FACTOR; SUBCELLULAR-LOCALIZATION; PEA-CHLOROPLASTS; STRUCTURAL BASIS; GENE-EXPRESSION; THYLAKOID LUMEN; IMPORT; SEQUENCE	The stromal processing peptidase (SPP) cleaves a large diversity of chloroplast precursor proteins, removing an N-terminal transit peptide. We predicted previously that this key step of the import pathway is mediated by features of the transit peptide that determine precursor binding and cleavage followed by transit peptide conversion to a degradable substrate. Here we performed competition experiments using synthesized oligopeptides of the transit peptide of ferredoxin precursor to investigate the mechanism of these processes. We found that binding and processing of ferredoxin precursor depend on specific interactions of SPP with the region consisting of the C-terminal 12 residues of the transit peptide. Analysis of four other precursors suggests that processing depends on the same region, although their transit peptides are highly divergent in primary sequence and length. Upon processing, SPP terminates its interaction with the transit peptide by a second cleavage, converting it to a subfragment form. From the competition experiments we deduce that SPP releases a subfragment consisting of the transit peptide without its original C terminus. Interestingly, examination of the ATP-dependent metallopeptidase activity responsible for degradation of transit peptide subfragments suggests that it may recognize other unrelated peptides and, hence, act separately from SPP as a novel stromal oligopeptidase.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago	Lamppa, GK (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 920 E 58Th St, Chicago, IL 60637 USA.							ABAD MS, 1989, PLANT PHYSIOL, V90, P117, DOI 10.1104/pp.90.1.117; Adam Z, 2000, BIOCHIMIE, V82, P647, DOI 10.1016/S0300-9084(00)00612-X; Adam Z, 2001, PLANT PHYSIOL, V125, P1912, DOI 10.1104/pp.125.4.1912; ARCHER EK, 1993, PLANT MOL BIOL, V23, P1105, DOI 10.1007/BF00042345; ARSDELL JN, 1985, SCIENCE, V228, P149; BASSHAM DC, 1994, J BIOL CHEM, V269, P16062; Bauer J, 2001, CELL MOL LIFE SCI, V58, P420, DOI 10.1007/PL00000867; BEERS EP, 1992, J BIOL CHEM, V267, P15432; Bruce BD, 2001, BBA-MOL CELL RES, V1541, P2, DOI 10.1016/S0167-4889(01)00149-5; BUSHNELL TP, 1993, PLANT PHYSIOL, V103, P585, DOI 10.1104/pp.103.2.585; Chen K, 2000, BIOCHEM SOC T, V28, P485, DOI 10.1042/0300-5127:0280485; CLARK SE, 1991, J CELL BIOL, V114, P681, DOI 10.1083/jcb.114.4.681; Claros MG, 1997, CURR OPIN STRUC BIOL, V7, P394, DOI 10.1016/S0959-440X(97)80057-7; Desimone M, 1998, PLANTA, V205, P459, DOI 10.1007/s004250050344; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Halperin T, 1996, PLANT MOL BIOL, V30, P925, DOI 10.1007/BF00020804; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KUEHN MJ, 1993, SCIENCE, V262, P1234, DOI 10.1126/science.7901913; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPPA GK, 1985, MOL CELL BIOL, V5, P1370, DOI 10.1128/MCB.5.6.1370; LEVY M, 1995, PLANT MOL BIOL, V29, P53, DOI 10.1007/BF00019118; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; MUSGROVE JE, 1989, PLANT PHYSIOL, V90, P1616, DOI 10.1104/pp.90.4.1616; OBLONG JE, 1992, EMBO J, V11, P4401, DOI 10.1002/j.1460-2075.1992.tb05540.x; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PILON M, 1992, J BIOL CHEM, V267, P19907; PILON M, 1995, J BIOL CHEM, V270, P3882, DOI 10.1074/jbc.270.8.3882; Rensink WA, 2000, J BIOL CHEM, V275, P10265, DOI 10.1074/jbc.275.14.10265; Richter S, 1999, J CELL BIOL, V147, P33, DOI 10.1083/jcb.147.1.33; Richter S, 1998, P NATL ACAD SCI USA, V95, P7463, DOI 10.1073/pnas.95.13.7463; Sarath G., 1989, PROTEOLYTIC ENZYMES, P25; SCHIGGER H, 1987, ANAL BIOCHEM, V166, P368; SHANKLIN J, 1995, PLANT CELL, V7, P1713, DOI 10.1105/tpc.7.10.1713; SMEEKENS S, 1985, NUCLEIC ACIDS RES, V13, P3179, DOI 10.1093/nar/13.9.3179; Sokolenko A, 1997, PLANT PHYSIOL, V115, P827, DOI 10.1104/pp.115.2.827; Soto GE, 1998, EMBO J, V17, P6155, DOI 10.1093/emboj/17.21.6155; TAME JRH, 1994, SCIENCE, V264, P1578, DOI 10.1126/science.8202710; Taylor AB, 2001, STRUCTURE, V9, P615, DOI 10.1016/S0969-2126(01)00621-9; The Arabidopsis Genome Initiative, 2000, NATURE, V408, P796; VANDERVERE PS, 1995, P NATL ACAD SCI USA, V92, P7177, DOI 10.1073/pnas.92.16.7177; VANTHOF R, 1995, J BIOL CHEM, V270, P22368, DOI 10.1074/jbc.270.38.22368; VANTHOF R, 1993, J BIOL CHEM, V268, P4037; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; Vothknecht UC, 2000, BIOL CHEM, V381, P887, DOI 10.1515/BC.2000.110; Wan JX, 1998, PLANT J, V15, P459, DOI 10.1046/j.1365-313X.1998.00224.x; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; WERNEKE JM, 1988, P NATL ACAD SCI USA, V85, P787, DOI 10.1073/pnas.85.3.787; Wienk HLJ, 1999, FEBS LETT, V453, P318, DOI 10.1016/S0014-5793(99)00653-5	51	50	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43888	43894		10.1074/jbc.M206020200	http://dx.doi.org/10.1074/jbc.M206020200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12235143	hybrid			2022-12-27	WOS:000179272000048
J	Willcocks, JP; Mulquiney, PJ; Ellory, JC; Veech, RL; Radda, GK; Clarke, K				Willcocks, JP; Mulquiney, PJ; Ellory, JC; Veech, RL; Radda, GK; Clarke, K			Simultaneous determination of low free Mg2+ and pH in human sickle cells using P-31 NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; INTRACELLULAR FREE MAGNESIUM; ANEMIA RED-CELLS; ADENOSINE 5'-TRIPHOSPHATE; DISSOCIATION-CONSTANT; STABILITY-CONSTANTS; POTASSIUM-TRANSPORT; HUMAN-ERYTHROCYTES; IONIZED MAGNESIUM; KINETIC-MODEL	The concentrations of free magnesium, [Mg2+](free), [H+], and [ATP] are important in the dehydration of red blood cells from patients with sickle cell anemia, but they are not easily measured. Consequently, we have developed a rapid, noninvasive NMR spectroscopic method using the phosphorus chemical shifts of ATP and 2,3-diphosphoglycerate (DPG) to determine [Mg2+](free) and pH(i) simultaneously in fully oxygenated whole blood. The method employs theoretical equations expressing the observed chemical shift as a function of pH, K+, and [Mg2+](free), over a pH range of 5.75-8.5 and [Mg2+](free) range 0-5 mm. The equations were adjusted to allow for the binding of hemoglobin to ATP and DPG, which required knowledge of the intracellular concentrations of ATP, DPG, K+, and hemoglobin. Normal oxygenated whole blood (n = 33) had a pH(i) of 7.20. +/- 0.02, a [Mg2+](free) of 0.41 +/- 0.03 mM and [DPG] of 7.69 +/- 0.47 mm. Under the same conditions, whole sickle blood (n = 9) had normal [ATP] but significantly lower pH(i) (7.10 +/- 0.03) and [Mg2+](free) (0.32 +/- 0.05 mM) than normal red cells, whereas [DPG] (10.8 +/- 1.2 mm) was significantly higher. Because total magnesium was normal in sickle cells, the lower [Mg2+](free) could be attributed to increased [DPG] and therefore greater magnesium binding capacity of sickle cells.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Oxford, Dept Physiol, Oxford OX1 3QU, England; NIAAA, Rockville, MD 20852 USA	University of Oxford; University of Oxford; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Clarke, K (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	Kieran.Clarke@bioch.ox.ac.uk			British Heart Foundation [PS/02/002/14893] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000099] Funding Source: NIH RePORTER	British Heart Foundation(British Heart Foundation); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ACHILLES W, 1972, ACTA BIOL MED GER, V29, P531; ALTURA BM, 1995, ALCOHOL, V12, P131, DOI 10.1016/0741-8329(94)00072-7; BERGER H, 1973, EUR J BIOCHEM, V38, P553, DOI 10.1111/j.1432-1033.1973.tb03090.x; BRUGNARA C, 1989, ANN NY ACAD SCI, V565, P96, DOI 10.1111/j.1749-6632.1989.tb24155.x; Clarke K, 1996, J BIOL CHEM, V271, P21142, DOI 10.1074/jbc.271.35.21142; CORASH LM, 1974, J LAB CLIN MED, V84, P147; De Franceschi L, 2000, BRIT J HAEMATOL, V108, P284; DeFranceschi L, 1997, J CLIN INVEST, V100, P1847, DOI 10.1172/JCI119713; Duley L, 2002, LANCET, V359, P1877, DOI 10.1016/s0140-6736(02)08778-0; ELLORY JC, 1983, J PHYSIOL-LONDON, V340, P1; FLATMAN P, 1977, NATURE, V267, P360, DOI 10.1038/267360a0; FLATMAN PW, 1988, J PHYSIOL-LONDON, V397, P471, DOI 10.1113/jphysiol.1988.sp017013; FLATMAN PW, 1980, J PHYSIOL-LONDON, V300, P19, DOI 10.1113/jphysiol.1980.sp013148; GARFINKEL L, 1984, BIOCHEMISTRY-US, V23, P3547, DOI 10.1021/bi00310a025; GERBER G, 1974, EUR J BIOCHEM, V45, P39, DOI 10.1111/j.1432-1033.1974.tb03527.x; GEVEN WB, 1991, CLIN CHEM, V37, P2076; GOLDBERG RN, 1991, BIOPHYS CHEM, V40, P241, DOI 10.1016/0301-4622(91)80024-L; GOLDING EM, 1995, MAGNET RESON MED, V33, P467, DOI 10.1002/mrm.1910330403; GUPTA RK, 1983, BIOCHEM BIOPH RES CO, V117, P210, DOI 10.1016/0006-291X(83)91562-0; GUPTA RK, 1983, PHYSIOL CHEM PHYS, V15, P265; GUPTA RK, 1978, J BIOL CHEM, V253, P6165; GUPTA RK, 1980, J BIOL CHEM, V255, P3987; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; Jaeger BR, 2001, THER APHER, V5, P252, DOI 10.1046/j.1526-0968.2001.00350.x; KAPERONIS AA, 1979, BRIT J HAEMATOL, V43, P391, DOI 10.1111/j.1365-2141.1979.tb03766.x; LAM YF, 1979, BLOOD, V54, P196; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; LONDON RE, 1991, ANNU REV PHYSIOL, V53, P241, DOI 10.1146/annurev.physiol.53.1.241; MARJANOVIC M, 1993, J PHYSIOL-LONDON, V470, P559, DOI 10.1113/jphysiol.1993.sp019875; MOON RB, 1973, J BIOL CHEM, V248, P7276; MOSHER TJ, 1992, MAGNET RESON MED, V24, P163, DOI 10.1002/mrm.1910240117; Mulquiney PJ, 1997, NMR BIOMED, V10, P129, DOI 10.1002/(SICI)1099-1492(199705)10:3<129::AID-NBM459>3.0.CO;2-2; Mulquiney PJ, 1997, EUR J BIOCHEM, V245, P71, DOI 10.1111/j.1432-1033.1997.00071.x; NOGUCHI CT, 1981, BLOOD, V58, P1057; NOGUCHI CT, 1983, J CLIN INVEST, V72, P846, DOI 10.1172/JCI111055; ORTIZ OE, 1986, BLOOD, V67, P710; ORTIZ OE, 1990, J PHYSIOL-LONDON, V427, P211, DOI 10.1113/jphysiol.1990.sp018168; OUWERKERK R, 1989, BIOCHIM BIOPHYS ACTA, V1010, P294, DOI 10.1016/0167-4889(89)90052-9; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; Raftos JE, 1999, EUR J BIOCHEM, V263, P635, DOI 10.1046/j.1432-1327.1999.00506.x; RAMIREZ F, 1980, BIOCHIM BIOPHYS ACTA, V589, P21, DOI 10.1016/0005-2728(80)90129-2; RESNICK LM, 1990, AM J HYPERTENS, V3, P373, DOI 10.1093/ajh/3.5.373; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; ROBERTS JKM, 1981, BIOCHEMISTRY-US, V20, P5389, DOI 10.1021/bi00522a006; SCARPA A, 1982, TECH CELL PHYSL, V127, P1; STEPHENSON EW, 1977, J GEN PHYSIOL, V69, P1, DOI 10.1085/jgp.69.1.1; TEHRANI AY, 1982, BLOOD CELLS, V8, P245; VASAVADA KV, 1984, J INORG BIOCHEM, V21, P323, DOI 10.1016/0162-0134(84)85054-0; VEECH RL, 1994, ALCOHOL CLIN EXP RES, V18, P1040, DOI 10.1111/j.1530-0277.1994.tb00081.x; WERNER A, 1985, BIOMED BIOCHIM ACTA, V44, P185; Willcocks JP, 2000, BIOPHYS J, V78, p449A; Willcocks JP, 1999, BIOPHYS J, V76, pA233; WILLIAMS GD, 1993, ANAL BIOCHEM, V214, P458, DOI 10.1006/abio.1993.1523; Zhang WQ, 1997, ANAL BIOCHEM, V251, P246, DOI 10.1006/abio.1997.2238	54	24	26	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49911	49920		10.1074/jbc.M207551200	http://dx.doi.org/10.1074/jbc.M207551200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12297506	hybrid			2022-12-27	WOS:000180028900106
J	Patikoglou, GA; Koelle, MR				Patikoglou, GA; Koelle, MR			An N-terminal region of Caenorhabditis elegans RGS proteins EGL-10 and EAT-16 directs inhibition of G alpha(o) versus G alpha(q) signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; HETEROTRIMERIC G-PROTEINS; C-ELEGANS; MAMMALIAN-CELLS; REGULATORS; DOMAIN; GAIP; G(Q)ALPHA; PATHWAYS; BEHAVIOR	Regulator of G protein signaling (RGS) proteins contain an RGS domain that inhibits Galpha signaling by activating Galpha GTPase activity. Certain RGS proteins also contain a Ggamma-like (GGL) domain and a poorly characterized but conserved N-terminal region. We assessed the functions of these subregions in the Caenorhabditis elegans RGS proteins EGL-10 and EAT-16, which selectively inhibit GOA-1 (Galpha(o)) and EGL-30 (Galpha(q)), respectively. Using transgenes in C. elegans, we expressed EGL-10, EAT-16, their subregions, or EGL-10/EAT-16 chimeras. The chimeras showed that the GGL/RGS region of either protein can act on either GOA-1 or EGL-30 and that a key factor determining Ga target selectivity is the manner in which the N-terminal and GGL/RGS regions are linked. We also found that coexpressing N-terminal and GGL/RGS fragments of EGL-10 gave full EGL-10 activity, whereas either fragment alone gave little activity. Biochemical analysis showed that coexpressing the two fragments caused both to increase in abundance and also caused the GGL/RGS fragment to move to the membrane, where the N-terminal fragment is localized. By coimmunoprecipitation, we found that the N-terminal fragment complexes with the C-terminal fragment and its associated Gbeta subunit, GPB-2. We conclude that the N-terminal region directs inhibition of Galpha signaling by forming a complex with the GGL/RGS region and affecting its stability, membrane localization, and Galpha target specificity.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Koelle, MR (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St,SHM C-E30, New Haven, CT 06520 USA.							Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Brundage L, 1996, NEURON, V16, P999, DOI 10.1016/S0896-6273(00)80123-3; Chase DL, 2001, CURR BIOL, V11, P222, DOI 10.1016/S0960-9822(01)00071-9; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Diverse-Pierluissi MA, 1999, J BIOL CHEM, V274, P14490, DOI 10.1074/jbc.274.20.14490; Dong MQ, 2000, GENE DEV, V14, P2003; Hajdu-Cronin YM, 1999, GENE DEV, V13, P1780, DOI 10.1101/gad.13.14.1780; He W, 2000, J BIOL CHEM, V275, P37093, DOI 10.1074/jbc.M006982200; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Hoffman GA, 2000, J BIOL CHEM, V275, P37533, DOI 10.1074/jbc.M005751200; Hu G, 2002, P NATL ACAD SCI USA, V99, P9755, DOI 10.1073/pnas.152094799; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Ingi T, 1998, J NEUROSCI, V18, P7178; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Lishko PV, 2002, J BIOL CHEM, V277, P24376, DOI 10.1074/jbc.M203237200; Mello C, 1995, METHOD CELL BIOL, V48, P451; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; Skiba NP, 2001, J BIOL CHEM, V276, P37365, DOI 10.1074/jbc.M106431200; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4	28	35	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47004	47013		10.1074/jbc.M208186200	http://dx.doi.org/10.1074/jbc.M208186200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354761	hybrid			2022-12-27	WOS:000179663700024
J	Schwenger, GTF; Kok, CC; Arthaningtyas, E; Thomas, MA; Sanderson, CJ; Mordvinov, VA				Schwenger, GTF; Kok, CC; Arthaningtyas, E; Thomas, MA; Sanderson, CJ; Mordvinov, VA			Specific activation of human interleukin-5 depends on de novo synthesis of an AP-1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-3; CIS-REGULATORY ELEMENTS; NUCLEAR FACTOR; T-CELLS; GENE-EXPRESSION; TH2-SPECIFIC EXPRESSION; PROTEIN-KINASE; CYCLIC-AMP; TH2 CELLS; PROMOTER	It is clear from the biology of eosinophilia that a specific regulatory mechanism must exist. Because interleukin-5 (IL5) is the key regulatory cytokine, it follows that a gene-specific control of IL5 expression must exist that differs even from closely related cytokines such as IL4. Two features of IL5 induction make it unique compared with other cytokines; first, induction by cyclic adenosine monophosphate (cAMP), which inhibits other T-cell-derived cytokines, and second, sensitivity to protein synthesis inhibitors, which have no effect on other cytokines. This study has utilized the activation of different transcription factors by different stimuli in a human T-cell line to study the role of conserved lymphokine element 0 (CLE0) in the specific induction of IL5. In unstimulated cells the ubiquitous Oct-1 binds to CLE0. Stimulation induces de novo synthesis of the AP-1 members JunD and Fra-2, which bind to CLE0. The amount of IL5 produced correlates with the production of the AP-1 complex, suggesting a key role in IL5 expression. The formation of the AP-1 complex is essential, but the rate-limiting step is the synthesis of AP-1, especially Fra-2. This provides an explanation for the sensitivity of IL5 to protein synthesis inhibitors and a mechanism for the specific induction of IL5 compared with other cytokines.	Western Australian Inst Med Res, Mol Immunol Grp, Perth, WA 6000, Australia; Curtin Univ Technol, Sch Biomed Sci, Perth, WA 6000, Australia; Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Free Univ Brussels, Fac Med, Expt Immunol Lab, B-1070 Brussels, Belgium	University of Western Australia; Curtin University; University of Lausanne; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Schwenger, GTF (corresponding author), Western Australian Inst Med Res, Mol Immunol Grp, Level 5,MRF Bldg,Rear 50 Murray St, Perth, WA 6000, Australia.	gretchen@cyllene.uwa.edu.au	Mordvinov, Viatcheslav A/S-8277-2017	Mordvinov, Viatcheslav A/0000-0002-6173-0774				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; BOHJANEN PR, 1990, P NATL ACAD SCI USA, V87, P5283, DOI 10.1073/pnas.87.14.5283; Chen CH, 2000, J IMMUNOL, V165, P5597, DOI 10.4049/jimmunol.165.10.5597; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; Coombe DR, 1998, J IMMUNOL METHODS, V215, P145, DOI 10.1016/S0022-1759(98)00081-7; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; De Boer ML, 1999, INT J BIOCHEM CELL B, V31, P1221, DOI 10.1016/S1357-2725(99)00069-2; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DENHERTOG J, 1992, NUCLEIC ACIDS RES, V20, P125, DOI 10.1093/nar/20.1.125; DERIGS HG, 1990, LEUKEMIA, V4, P471; Ferber IA, 1999, CLIN IMMUNOL, V91, P134, DOI 10.1006/clim.1999.4718; GRUARTGOUILLEUX V, 1995, EUR J IMMUNOL, V25, P1431, DOI 10.1002/eji.1830250544; GRUDA MC, 1994, ONCOGENE, V9, P2537; JAIN JN, 1993, J IMMUNOL, V151, P837; JENKINS F, 1995, J IMMUNOL, V155, P1240; Karlen S, 1996, BLOOD, V88, P211; KARLEN S, 1993, J VIROL, V67, P4296, DOI 10.1128/JVI.67.7.4296-4306.1993; KARLEN S, 1997, INT REV IMMUNOL, V16, P227; KEES UR, 1994, J IMMUNOL METHODS, V168, P1, DOI 10.1016/0022-1759(94)90202-X; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; LEE HJ, 1993, J IMMUNOL, V151, P6135; Lee HJ, 1998, J IMMUNOL, V160, P2343; Leung DYM, 1998, MOL GENET METAB, V63, P157, DOI 10.1006/mgme.1998.2682; Li-Weber M, 1998, J IMMUNOL, V161, P1380; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; Mordvinov VA, 1999, J IMMUNOL METHODS, V228, P163, DOI 10.1016/S0022-1759(99)00088-5; NAORA H, 1995, EXP HEMATOL, V23, P597; NAORA H, 1994, BLOOD, V83, P3620; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; Ranganath S, 1998, J IMMUNOL, V161, P3822; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; SANDERSON CJ, 1988, IMMUNOL REV, V102, P29, DOI 10.1111/j.1600-065X.1988.tb00740.x; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Sanderson CJ, 1999, LUNG BIOL HEALTH DIS, V125, P267; Schandene L, 1996, J CLIN INVEST, V97, P309, DOI 10.1172/JCI118417; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwenger GTF, 2001, J BIOL CHEM, V276, P48502, DOI 10.1074/jbc.M107836200; Short JD, 2002, J BIOL CHEM, V277, P32697, DOI 10.1074/jbc.M204553200; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; STRANICK KS, 1995, J BIOL CHEM, V270, P20575, DOI 10.1074/jbc.270.35.20575; Thomas MA, 1999, EUR J BIOCHEM, V265, P300, DOI 10.1046/j.1432-1327.1999.00732.x; THOMAS RS, 1995, ONCOGENE, V11, P2135; TOMINAGA A, 1988, J IMMUNOL, V140, P1175; VANSTRAATEN JFM, 1994, CYTOKINE, V6, P229, DOI 10.1016/1043-4666(94)90017-5; WARREN DJ, 1985, IMMUNOLOGY, V54, P615; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; Yazgan O, 2002, J BIOL CHEM, V277, P29710, DOI 10.1074/jbc.M204552200; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	52	18	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47022	47027		10.1074/jbc.M207414200	http://dx.doi.org/10.1074/jbc.M207414200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354764	hybrid			2022-12-27	WOS:000179663700026
J	Yan, G; Lennarz, WJ				Yan, G; Lennarz, WJ			Studies on the function of oligosaccharyl transferase subunits - Stt3p is directly involved in the glycosylation process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE OLIGOSACCHARYLTRANSFERASE; ASPARAGINE-LINKED GLYCOSYLATION; AMINO-ACID-SEQUENCE; ACTIVITY IN-VIVO; YEAST OLIGOSACCHARYLTRANSFERASE; ENDOPLASMIC-RETICULUM; PROTEIN COMPLEX; GLYCOPROTEIN-BIOSYNTHESIS; N-GLYCOSYLATION; 50-KDA SUBUNIT	In the yeast, Saccharomyces cerevisiae, oligosaccharyl transferase (OT) is composed of nine different transmembrane proteins. Using a glycosylatable peptide containing a photoprobe, we previously found that only one essential subunit, Ost1p, was specifically labeled by the photoprobe and recently have shown that it does not contain the recognition domain for the glycosylatable sequence Asn-Xaa-Thr/Ser. In this study we utilized additional glycosylatable peptides containing two photoreactive groups and found that these were linked to Stt3p and Ost3p. Stt3p is the most conserved subunit in the OT complex, and therefore 21 block mutants in the lumenal region were prepared. Of the 14 lethal mutant proteins only two, as well as one temperature-sensitive mutant protein, were incorporated into the OT complex. However, using microsomes prepared from these three strains, the labeling of Ost1p was markedly decreased upon photoactivation with the Asn-Bpa-Thr photoprobe. Based on the block mutants single amino acid mutations were prepared and analyzed. From all of these results, we conclude that the sequence from residues 516 to 520, WWDYG in Stt3p, plays a central role in glycosylatable peptide recognition and/or the catalytic glycosylation process.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lennarz, WJ (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	wlennarz@notes.ce.sunysb.edu			NIGMS NIH HHS [GM33185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033185, R37GM033185] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; Baldwin RL, 2002, SCIENCE, V295, P1657, DOI 10.1126/science.1069893; BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; BREUER W, 1995, EUR J BIOCHEM, V228, P689, DOI 10.1111/j.1432-1033.1995.0689m.x; Chi JH, 1996, J BIOL CHEM, V271, P3132, DOI 10.1074/jbc.271.6.3132; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; EVANS PA, 1991, PROTEINS, V9, P248, DOI 10.1002/prot.340090404; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; IMPERIALI B, 1991, BIOCHEMISTRY-US, V30, P4374, DOI 10.1021/bi00232a002; IMPERIALI B, 1992, J AM CHEM SOC, V114, P7944, DOI 10.1021/ja00046a069; Imperiali B, 1995, BIOORGAN MED CHEM, V3, P1565, DOI 10.1016/0968-0896(95)00142-5; IMPERIALI B, 1992, J AM CHEM SOC, V114, P7942, DOI 10.1021/ja00046a068; Karaoglu D, 1997, J BIOL CHEM, V272, P32513, DOI 10.1074/jbc.272.51.32513; KARAOGLU D, 1995, J CELL BIOL, V130, P567, DOI 10.1083/jcb.130.3.567; Kelleher DJ, 1997, P NATL ACAD SCI USA, V94, P4994, DOI 10.1073/pnas.94.10.4994; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KELLEHER DJ, 1994, J BIOL CHEM, V269, P12908; Kim H, 2000, P NATL ACAD SCI USA, V97, P1516, DOI 10.1073/pnas.040556797; Klein-Seetharaman J, 2002, SCIENCE, V295, P1719, DOI 10.1126/science.1067680; Knauer R, 1999, BBA-GEN SUBJECTS, V1426, P259, DOI 10.1016/S0304-4165(98)00128-7; KNAUER R, 1994, FEBS LETT, V344, P83, DOI 10.1016/0014-5793(94)00356-4; Knauer R, 1999, J BIOL CHEM, V274, P17249, DOI 10.1074/jbc.274.24.17249; KUMAR V, 1994, J BIOL CHEM, V269, P13451; KUMAR V, 1995, ARCH BIOCHEM BIOPHYS, V320, P217, DOI 10.1016/0003-9861(95)90003-9; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; NILSSON I, 1993, J BIOL CHEM, V268, P5798; PATHAK R, 1995, BIOCHEMISTRY-US, V34, P4179, DOI 10.1021/bi00013a005; PATHAK R, 1995, FEBS LETT, V362, P229, DOI 10.1016/0014-5793(95)00253-6; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; Reiss G, 1997, EMBO J, V16, P1164, DOI 10.1093/emboj/16.6.1164; ROOS J, 1994, P NATL ACAD SCI USA, V91, P1485, DOI 10.1073/pnas.91.4.1485; SILBERSTEIN S, 1995, J CELL BIOL, V131, P371, DOI 10.1083/jcb.131.2.371; SILBERSTEIN S, 1995, J CELL BIOL, V128, P525, DOI 10.1083/jcb.128.4.525; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; Spirig U, 1997, MOL GEN GENET, V256, P628, DOI 10.1007/s004380050611; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; WELPLY JK, 1986, ARCH BIOCHEM BIOPHYS, V246, P808, DOI 10.1016/0003-9861(86)90337-1; WELPLY JK, 1985, J BIOL CHEM, V260, P6459; Yan Q, 1999, J BIOL CHEM, V274, P5021, DOI 10.1074/jbc.274.8.5021; Yan Q, 1999, BIOCHEM BIOPH RES CO, V266, P684, DOI 10.1006/bbrc.1999.1886; YOSHIDA S, 1992, MOL GEN GENET, V231, P337, DOI 10.1007/BF00292700; YOSHIDA S, 1995, GENE, V164, P167, DOI 10.1016/0378-1119(95)00431-5; ZUFFEREY R, 1995, EMBO J, V14, P4949, DOI 10.1002/j.1460-2075.1995.tb00178.x	47	126	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47692	47700		10.1074/jbc.M208136200	http://dx.doi.org/10.1074/jbc.M208136200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359722	hybrid			2022-12-27	WOS:000179663700111
J	Berdiev, BK; Xia, JZ; Jovov, B; Markert, JM; Mapstone, TB; Gillespie, GY; Fuller, CM; Bubien, JK; Benos, DJ				Berdiev, BK; Xia, JZ; Jovov, B; Markert, JM; Mapstone, TB; Gillespie, GY; Fuller, CM; Bubien, JK; Benos, DJ			Protein kinase C isoform antagonism controls BNaC2 (ASIC1) function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; PLANAR LIPID BILAYERS; SENSING ION CHANNELS; GLIOBLASTOMA CELL-LINES; CARDIAC CA2+ CHANNELS; GATED CATION CHANNELS; EPSILON-PKC ISOZYME; MOLECULAR-CLONING; SODIUM-CHANNEL; SENSORY NEURONS	We explored the involvement of protein kinase C (PKC) and its isoforms in the regulation of BNaC2. Reverse transcriptase PCR evaluation of PKC isoform expression at the level of mRNA revealed the presence of alpha and epsilon/epsilon' in all glioma cell lines analyzed; most, but not all cell lines expressed delta and zeta. No messages were found for the betaI and betaII isotypes of PKC in the tumor cells. Normal astrocytes expressed beta but not gamma. The essential features of these results were confirmed at the protein level by Western analysis. This disproportionate pattern of PKC isoform expression in glioma cell lines was further echoed in the functional effects of these PKC isoforms on BNaC2 activity in bilayers. PKC holoenzyme or the combination of PKCbetaI and PKCbetaII isoforms inhibited BNaC2. Neither PKCepsilon nor PKCzeta or their combination had any effect on BNaC2 activity in bilayers. The inhibitory effect of the PKCbetaI and PKCbetaII mixture on BNaC2 activity was abolished by a 5-fold excess of a PKCepsilon and PKCzeta combination. PKC holoenzymes, PKCbetaI, PKCbetaII, PKCdelta, PKCepsilon, and PKCzeta phosphorylated BNaC2 in vitro. In patch clamp experiments,the combination of PKCbetaI and PKCbetaII inhibited the basally activated inward Na+ conductance. The variable expression of the PKC isotypes and their functional antagonism in regulating BNaC2 activity support the idea that the participation of multiple PKC isotypes contributes to the overall activity of BNaC2.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; Emory Univ, Dept Neurosurg, Atlanta, GA 30322 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Emory University	Benos, DJ (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, 1918 Univ Blvd,MCLM 704, Birmingham, AL 35294 USA.	benos@physiology.uab.edu	Fuller, Cathy/B-4046-2011	Gillespie, George/0000-0001-6436-9542	NCI NIH HHS [CA71933] Funding Source: Medline; NIDDK NIH HHS [DK37206] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA071933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037206, R56DK037206] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akopian AN, 2000, NEUROREPORT, V11, P2217, DOI 10.1097/00001756-200007140-00031; Anzai N, 2002, J BIOL CHEM, V277, P16655, DOI 10.1074/jbc.M201087200; Awayda MS, 2000, J GEN PHYSIOL, V115, P559, DOI 10.1085/jgp.115.5.559; AWAYDA MS, 1995, AM J PHYSIOL-CELL PH, V268, pC1450, DOI 10.1152/ajpcell.1995.268.6.C1450; Awayda MS, 1996, J GEN PHYSIOL, V108, P49, DOI 10.1085/jgp.108.1.49; Babinski K, 1999, J NEUROCHEM, V72, P51, DOI 10.1046/j.1471-4159.1999.0720051.x; Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; Berdiev BK, 2001, J BIOL CHEM, V276, P38755, DOI 10.1074/jbc.M107266200; Biagini G, 2001, NEUROBIOL DIS, V8, P45, DOI 10.1006/nbdi.2000.0331; Bianchi L, 2002, NEURON, V34, P337, DOI 10.1016/S0896-6273(02)00687-6; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Bubien JK, 1999, AM J PHYSIOL-CELL PH, V276, pC1405, DOI 10.1152/ajpcell.1999.276.6.C1405; Caterina MJ, 1999, CURR OPIN NEUROBIOL, V9, P525, DOI 10.1016/S0959-4388(99)00009-4; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Cho KK, 1999, INT J DEV NEUROSCI, V17, P447, DOI 10.1016/S0736-5748(99)00054-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIVAN MM, 1987, J MEMBRANE BIOL, V97, P193, DOI 10.1007/BF01869222; Corey DP, 1996, SCIENCE, V273, P323, DOI 10.1126/science.273.5273.323; de Weille JR, 1998, FEBS LETT, V433, P257, DOI 10.1016/S0014-5793(98)00916-8; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Donson AM, 2000, J NEURO-ONCOL, V47, P109, DOI 10.1023/A:1006406208376; Duggan A, 2002, J BIOL CHEM, V277, P5203, DOI 10.1074/jbc.M104748200; Els WJ, 1998, AM J PHYSIOL-CELL PH, V275, pC120; Garcia-Anoveros J, 2001, J NEUROSCI, V21, P2678, DOI 10.1523/JNEUROSCI.21-08-02678.2001; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Grunder S, 2000, NEUROREPORT, V11, P1607; Gunthorpe NJ, 2001, PFLUG ARCH EUR J PHY, V442, P668; Hruska-Hageman AM, 2002, BIOCHEM J, V361, P443, DOI 10.1042/0264-6021:3610443; Hu KL, 2000, AM J PHYSIOL-HEART C, V279, pH2658, DOI 10.1152/ajpheart.2000.279.6.H2658; Ishibashi K, 1998, BIOCHEM BIOPH RES CO, V245, P589, DOI 10.1006/bbrc.1998.8483; ISMAILOV II, 1995, KIDNEY INT, V48, P1167, DOI 10.1038/ki.1995.400; Ismailov II, 1997, J PHYSIOL-LONDON, V504, P287, DOI 10.1111/j.1469-7793.1997.287be.x; Johnson MB, 2001, J CEREBR BLOOD F MET, V21, P734, DOI 10.1097/00004647-200106000-00011; Jovov B, 1999, J BIOL CHEM, V274, P37845, DOI 10.1074/jbc.274.53.37845; Korchak HM, 2001, AM J PHYSIOL-CELL PH, V281, pC514, DOI 10.1152/ajpcell.2001.281.2.C514; Kress M, 1999, TRENDS PHARMACOL SCI, V20, P112, DOI 10.1016/S0165-6147(99)01294-8; KRISHTAL OA, 1981, NEUROSCI LETT, V24, P243, DOI 10.1016/0304-3940(81)90164-6; KRISHTAL OA, 1980, NEUROSCIENCE, V5, P2325, DOI 10.1016/0306-4522(80)90149-9; LING BN, 1989, AM J PHYSIOL, V256, pF1094, DOI 10.1152/ajprenal.1989.256.6.F1094; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Lo CF, 1999, ANN NY ACAD SCI, V868, P431, DOI 10.1111/j.1749-6632.1999.tb11307.x; Mandil R, 2001, CANCER RES, V61, P4612; McCleskey EW, 1999, ANNU REV PHYSIOL, V61, P835, DOI 10.1146/annurev.physiol.61.1.835; MOHRMANN M, 1987, AM J PHYSIOL, V253, pF372, DOI 10.1152/ajprenal.1987.253.2.F372; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; OH YS, 1993, AM J PHYSIOL, V265, pC85, DOI 10.1152/ajpcell.1993.265.1.C85; Park MJ, 2000, NEUROSCI LETT, V290, P201, DOI 10.1016/S0304-3940(00)01358-6; PEREZ G, 1994, BIOPHYS J, V66, P1022, DOI 10.1016/S0006-3495(94)80883-5; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Reeh P W, 2001, Curr Opin Pharmacol, V1, P45, DOI 10.1016/S1471-4892(01)00014-5; REVAN S, 1991, J PHYSL, V433, P145; ROUCH AJ, 1993, AM J PHYSIOL, V265, pF569, DOI 10.1152/ajprenal.1993.265.4.F569; Sharif TR, 2001, INT J MOL MED, V7, P373; Sharif TR, 1999, INT J ONCOL, V15, P237; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Song JC, 2001, AM J PHYSIOL-CELL PH, V281, pC649, DOI 10.1152/ajpcell.2001.281.2.C649; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; Stockando JD, 2000, J BIOL CHEM, V275, P25760, DOI 10.1074/jbc.M003615200; Ugawa S, 2001, NEUROREPORT, V12, P2865, DOI 10.1097/00001756-200109170-00022; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; WANG WH, 1992, ANNU REV PHYSIOL, V54, P81; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wood JN, 1997, ANNU REV PHYSIOL, V59, P457, DOI 10.1146/annurev.physiol.59.1.457; Xiao GQ, 2001, AM J PHYSIOL-CELL PH, V281, pC1477, DOI 10.1152/ajpcell.2001.281.5.C1477; XIAO HG, 1994, J NEUROSURG, V81, P734, DOI 10.3171/jns.1994.81.5.0734; YANASE M, 1986, AM J PHYSIOL, V250, pC517, DOI 10.1152/ajpcell.1986.250.3.C517; YANG J, 1993, NEURON, V10, P127, DOI 10.1016/0896-6273(93)90305-B; Yiangou YG, 2001, EUR J GASTROEN HEPAT, V13, P891, DOI 10.1097/00042737-200108000-00003; Zhang ZH, 1997, CIRC RES, V80, P720, DOI 10.1161/01.RES.80.5.720	75	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45734	45740		10.1074/jbc.M208995200	http://dx.doi.org/10.1074/jbc.M208995200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244121	hybrid			2022-12-27	WOS:000179529300004
J	Holnthoner, W; Pillinger, M; Groger, M; Wolff, K; Ashton, AW; Albanese, C; Neumeister, P; Pestell, RG; Petzelbauer, P				Holnthoner, W; Pillinger, M; Groger, M; Wolff, K; Ashton, AW; Albanese, C; Neumeister, P; Pestell, RG; Petzelbauer, P			Fibroblast growth factor-2 induces Lef/Tcf-dependent transcription in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; ADENOMATOUS POLYPOSIS-COLI; CYCLIN D1 GENE; BETA-CATENIN; SIGNALING PATHWAY; NEGATIVE REGULATOR; KINASE 3; PROTEIN; WNT; TARGET	Lef/Tcf proteins belong to a family of architectural transcription factors that control developmental processes and play an important role in oncogenesis. Classical activators of Lef/Tcf-dependent transcription comprise the Wnt family of proteins, which translocate beta-catenin into the nucleus and allow the formation of transactivation-competent Lef/Tcf-beta-catenin complexes. Here we show that in human endothelial cells fibroblast growth factor-2 (FGF-2) reduces GSK-3 activity and augments nuclear levels of beta-catenin. FGF-2 induced Lef/Tcf-dependent transcription of a cyclin D1-luciferase construct. Gel shift assays revealed binding of Tcf-4 as the only Lef/Tcf family member and of P-catenin to the Lef/Tcf site in the cyclin D1 promoter. Cotransfection with a dominant negative Tcf-4 construct inhibited the FGF-2-induced cyclin D1 promoter activity. Overexpression of an uninhibitable GSK-3beta mutant resulted in partial inhibition of FGF-2-mediated cyclin D1 induction. The importance for cyclin D1 in FGF-2-induced angiogenesis in vivo is shown in cyclin D1(-/-) mice, where FGF-2-induced new vessel formation was significantly reduced compared with FGF-2-induced angiogenesis in cyclin D1(+/+) mice. In conclusion, FGF-2 is a novel modulator of Lef/Tcf-beta-catenin signaling in endothelial cells, suggesting that angiogenic properties of FGF-2 are at least in part mediated by Lef/Tcf-beta-catenin activation.	Univ Vienna, Sch Med, Dept Dermatol, Div Gen Dermatol, A-1090 Vienna, Austria; Albert Einstein Comprehens Canc Ctr, Div Hormone Dependent Tumor Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA	University of Vienna; Yeshiva University; Yeshiva University; Albert Einstein College of Medicine	Petzelbauer, P (corresponding author), Univ Vienna, Sch Med, Dept Dermatol, Div Gen Dermatol, Waehringer Guertel 18-2, A-1090 Vienna, Austria.	Peter.Petzelbauer@AKH-Wien.ac.at	petzelbauer, peter/GLU-3941-2022	Holnthoner, Wolfgang/0000-0001-6425-9028; Petzelbauer, Peter/0000-0001-7080-5259	NATIONAL CANCER INSTITUTE [R01CA075503, R01CA070896, R01CA086072] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA75503, R01CA86072, R01CA70896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen RH, 2000, J BIOL CHEM, V275, P17894, DOI 10.1074/jbc.M905336199; Christian SL, 2002, J IMMUNOL, V169, P758, DOI 10.4049/jimmunol.169.2.758; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; El-Hariry I, 2001, BRIT J CANCER, V84, P1656, DOI 10.1054/bjoc.2001.1813; El-Hariry I, 2001, INT J CANCER, V94, P652, DOI 10.1002/ijc.1515; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Grimson MJ, 2000, NATURE, V408, P727, DOI 10.1038/35047099; Halama T, 2001, J INVEST DERMATOL, V116, P110, DOI 10.1046/j.1523-1747.2001.00176.x; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hashimoto M, 2002, J BIOL CHEM, V277, P32985, DOI 10.1074/jbc.M202803200; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Hobmayer B, 2000, NATURE, V407, P186, DOI 10.1038/35025063; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korswagen HC, 2000, NATURE, V406, P527, DOI 10.1038/35020099; Lamberti C, 2001, J BIOL CHEM, V276, P42276, DOI 10.1074/jbc.M104227200; Malinda KM, 2001, METH MOLEC MED, V46, P47, DOI 10.1385/1-59259-143-4:047; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Mayo LD, 2001, J BIOL CHEM, V276, P25184, DOI 10.1074/jbc.M102932200; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Murakami T, 2001, BIOCHEM BIOPH RES CO, V288, P8, DOI 10.1006/bbrc.2001.5719; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; PETZELBAUER P, 1993, J IMMUNOL, V151, P5062; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Ryves WJ, 1998, ANAL BIOCHEM, V264, P124, DOI 10.1006/abio.1998.2832; Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169; Shih IM, 2000, CANCER RES, V60, P1671; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thorpe CJ, 2000, TRENDS CELL BIOL, V10, P10, DOI 10.1016/S0962-8924(99)01672-4; Torres MA, 1999, MOL CELL BIOL, V19, P1427; van der Heyden MAG, 1998, J CELL SCI, V111, P1741; Venkiteswaran K, 2002, AM J PHYSIOL-CELL PH, V283, pC811, DOI 10.1152/ajpcell.00417.2001; Wang XH, 2002, CIRC RES, V90, P340, DOI 10.1161/hh0302.104466; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; Wright M, 1999, BIOCHEM BIOPH RES CO, V263, P384, DOI 10.1006/bbrc.1999.1344; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681	56	111	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45847	45853		10.1074/jbc.M209354200	http://dx.doi.org/10.1074/jbc.M209354200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235165	hybrid			2022-12-27	WOS:000179529300018
J	Teyssier, C; Chen, DG; Stallcup, MR				Teyssier, C; Chen, DG; Stallcup, MR			Requirement for multiple domains of the protein arginine methyltransferase CARM1 in its transcriptional coactivator function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR FUNCTION; STEROID-RECEPTORS; ZINC-FINGER; DNA-BINDING; ACTIVATION; ACETYLATION; ESTROGEN; FAMILY; YEAST; ACETYLTRANSFERASE	The p160 coactivator complex plays a critical role in transcriptional activation by nuclear receptors and possibly other classes of DNA-binding transcriptional activators. The complex contains at least one of three p160 coactivators (SRC-1, GRIP1/TIF2, or pCIP/RAC3/ACTR/ AIB1/TRAM1), a histone acetyltransferase such as CBP or p300, and the histone methyltransferase CARM1 (coactivator-associated arginine methyltransferase 1). Methylation of histone H3 and possibly other proteins in the transcription initiation complex by CARM1 occurs along with acetylation of histones and other proteins by CBP and p300 to help remodel chromatin structure and recruit RNA polymerase II. Here we show that other domains of CARM1 are required for the coactivator function of CARM1 in addition to the methyltransferase activity. The methyltransferase GRIP1, binding, and homo-oligomerization activities all reside in the central region of CARM1, which is highly conserved among the entire protein arginine methyltransferase family. In addition to this conserved domain, the unique N- and C-terminal regions of CARM1 were also required for enhancement of transcriptional activation by nuclear receptors. While the N-terminal region has no known activity at present, the C-terminal part of CARM1 contains an autonomous activation domain, suggesting that it interacts with other proteins that help to mediate CARM1 coactivator function.	Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301,2011 Zonal Ave, Los Angeles, CA 90089 USA.		Teyssier, Catherine/AAC-2395-2020	Teyssier, Catherine/0000-0003-4937-6503				Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; Frankel A, 2000, J BIOL CHEM, V275, P32974, DOI 10.1074/jbc.M006445200; Glass CK, 2000, GENE DEV, V14, P121; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Goodman RH, 2000, GENE DEV, V14, P1553; GREEN S, 1988, EMBO J, V7, P3037, DOI 10.1002/j.1460-2075.1988.tb03168.x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; LEE HW, 1977, BIOCHEMISTRY-US, V16, P78, DOI 10.1021/bi00620a013; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Liu Z, 2001, P NATL ACAD SCI USA, V98, P12426, DOI 10.1073/pnas.231474798; Ma H, 1999, MOL CELL BIOL, V19, P6164; Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McBride AE, 2000, J BIOL CHEM, V275, P3128, DOI 10.1074/jbc.275.5.3128; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Rho J, 2001, J BIOL CHEM, V276, P11393, DOI 10.1074/jbc.M008660200; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Weiss VH, 2000, NAT STRUCT BIOL, V7, P1165; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Zhang X, 2000, EMBO J, V19, P3509, DOI 10.1093/emboj/19.14.3509	39	80	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46066	46072		10.1074/jbc.M207623200	http://dx.doi.org/10.1074/jbc.M207623200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351636	hybrid			2022-12-27	WOS:000179529300048
J	Yang, J; Wu, J; Jiang, H; Mortensen, R; Austin, S; Manning, DR; Woulfe, D; Brass, LF				Yang, J; Wu, J; Jiang, H; Mortensen, R; Austin, S; Manning, DR; Woulfe, D; Brass, LF			Signaling through G(i) family members in platelets - Redundancy and specificity in the regulation of adenylyl cyclase and other effectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GLYCOPROTEIN-IB-BETA; CYCLIC-NUCLEOTIDES; INTACT PLATELETS; AGGREGATION; PROSTACYCLIN; CALCIUM; CELLS; PHOSPHORYLATION; IDENTIFICATION	Platelet responses at sites of vascular injury are regulated by intracellular cAMP levels, which rise rapidly when prostacyclin (PGI(2)) is released from endothelial cells. Platelet agonists such as ADP and epinephrine suppress PGI(2)-stimulated cAMP formation by activating receptors coupled to G(i) family members, four of which are present in platelets. To address questions about the specificity of receptor:G protein coupling, the regulation of cAMP formation in vivo and the contribution of G(i)-mediated pathways that do not involve adenylyl cyclase, we studied platelets from mice that lacked the a subunits of one or more of the three most abundantly expressed G(i) family members and compared the results with platelets from mice that lacked the PGI(2) receptor, IP. As reported previously, loss of G(i2alpha) or G(zalpha) inhibited aggregation in response to ADP and epinephrine, respectively, producing defects that could not be reversed by adding an adenylyl cyclase inhibitor. Platelets that lacked both G(i2alpha) and G(zalpha) showed impaired responses to both agonists, but the impairment was no greater than in the individual knockouts. Loss of G(i3alpha) had no effect either alone or in combination with G(zalpha) Loss of either G(zalpha) or G(i2alpha) impaired the ability of ADP and epinephrine to inhibit PGI(2)-stimulated adenylyl cyclase activity and caused a 40%-50% rise in basal cAMP levels, whereas loss of G(i3alpha) did not. Conversely, deletion of IP abolished responses to PGI(2) and caused cAMP levels to fall by 30%, effects that did not translate into enhanced responsiveness to agonists ex vivo. From these results we conclude that 1) cAMP levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and IP, but not G(i3); 2) platelet epinephrine (alpha(2A)-adrenergic) and ADP (P2Y12) receptors display strong preferences among Gi family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3). Finally, the failure of ADP and epinephrine to inhibit basal, as opposed to PGI(2)-stimulated, cAMP formation highlights the need during platelet activation for G(i) signaling pathways that involve effectors other than adenylyl cyclase.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Michigan, Dept Physiol & Med Endocrine, Ann Arbor, MI 48109 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Michigan System; University of Michigan	Brass, LF (corresponding author), Univ Penn, Dept Med, Rm 913 BRB-II,421 Curie Blvd, Philadelphia, PA 19104 USA.				NHLBI NIH HHS [HL-45181, HL-54500] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045181, P50HL054500] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Austin SC, 2001, ARTERIOSCL THROM VAS, V21, P709; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Brass S, 2001, NATURE, V409, P145, DOI 10.1038/35051688; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Daniel JL, 1999, THROMB HAEMOSTASIS, V82, P1322; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; FISCHER TH, 1989, BIOCHEM BIOPH RES CO, V159, P644, DOI 10.1016/0006-291X(89)90043-0; FOX JEB, 1987, J BIOL CHEM, V262, P12627; GAGNON AW, 1991, BLOOD, V78, P1247; Gorman R R, 1978, Adv Cyclic Nucleotide Res, V9, P597; HALLAM TJ, 1985, BIOCHEM J, V232, P373, DOI 10.1042/bj2320373; Haslam RJ, 1999, THROMB HAEMOSTASIS, V82, P412; HATHAWAY DR, 1979, P NATL ACAD SCI USA, V76, P1653, DOI 10.1073/pnas.76.4.1653; HIRSCH E, 2001, FASEB J, V15, P307; Jain M, 2001, AM J PHYSIOL-HEART C, V280, pH569, DOI 10.1152/ajpheart.2001.280.2.H569; Jantzen HM, 2001, J CLIN INVEST, V108, P477; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; KASERGLANZMANN R, 1977, BIOCHIM BIOPHYS ACTA, V466, P429, DOI 10.1016/0005-2736(77)90336-4; KASERGLANZMANN R, 1979, BIOCHIM BIOPHYS ACTA, V558, P34; Keularts IMLW, 2000, J BIOL CHEM, V275, P1763, DOI 10.1074/jbc.275.3.1763; Kim S, 2002, BLOOD, V99, P3629, DOI 10.1182/blood.V99.10.3629; Manganello JM, 1999, J BIOL CHEM, V274, P28003, DOI 10.1074/jbc.274.39.28003; MILLER OV, 1976, J CYCLIC NUCL PROT, V2, P79; MILLS DCB, 1971, BIOCHEM J, V121, P185, DOI 10.1042/bj1210185; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Nagata K, 2000, CIRC RES, V87, P903, DOI 10.1161/01.RES.87.10.903; Ryningen A, 1998, BBA-LIPID LIPID MET, V1394, P235, DOI 10.1016/S0005-2760(98)00106-4; Schwarz UR, 2001, BIOCHEM PHARMACOL, V62, P1153, DOI 10.1016/S0006-2952(01)00760-2; WALLACH D, 1978, J BIOL CHEM, V253, P4739; WARDELL MR, 1989, J BIOL CHEM, V264, P15656; WATSON SP, 1984, J BIOL CHEM, V259, P3199; WEKSLER BB, 1977, P NATL ACAD SCI USA, V74, P3922, DOI 10.1073/pnas.74.9.3922; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220; WILLIAMS AG, 1990, BLOOD, V76, P721; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597; ZAHAVI M, 1984, THROMB HAEMOSTASIS, V52, P205	38	111	113	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46035	46042		10.1074/jbc.M208519200	http://dx.doi.org/10.1074/jbc.M208519200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12297509	hybrid			2022-12-27	WOS:000179529300044
J	Mokros, T; Rehm, A; Droese, J; Oppermann, M; Lipp, M; Hopken, UE				Mokros, T; Rehm, A; Droese, J; Oppermann, M; Lipp, M; Hopken, UE			Surface expression and endocytosis of the human cytomegalovirus-encoded chemokine receptor US28 is regulated by agonist-independent phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; C-TERMINAL TAIL; KINASE-C; CELLS; CCR5; DESENSITIZATION; INTERNALIZATION; IDENTIFICATION; INFECTION; DOMAIN	Human cytomegalovirus encodes the G protein-coupled chemokine receptor homologue US28 that binds several CC chemokines and sequesters extracellular chemokines from the environment of infected cells. Mechanistically, it has been shown that US28 undergoes rapid constitutive receptor endocytosis and recycling. Monoclonal antibodies were raised that allowed the characterization of a ligand-independent phosphorylation and low surface expression of the US28 receptor in transiently transfected HEK293A cells. Phosphoamino acid analysis defined C-terminal serine and threonine residues as phospho-acceptor sites for constitutive receptor phosphorylation. Coexpression of G protein-coupled receptor kinase-2 and US28 enhanced ligand-independent receptor phosphorylation. C-terminal serine to alanine mutagenesis of US28 resulted in a decreased phosphorylation rate that correlated with enhanced surface expression. Maximal surface expression was detected when all C-terminal serines were substituted. Exchange of all C-terminal serines also significantly reduced receptor endocytosis. Thus, constitutive US28 phosphorylation regulates receptor endocytosis and receptor surface display and may thereby provide a pathogenic mechanism for a potential decoy function of the virally encoded receptor.	Max Delbruck Ctr Mol Med, Dept Tumorgenet & Immunogenet, D-13092 Berlin, Germany; Dept Hematol Oncol & Tumorimmunol, D-13092 Berlin, Germany; Univ Klinikum Charite, Dept Hematol Oncol & Tumorimmunol, Robert Rossle Klin, D-13125 Berlin, Germany; Univ Gottingen, Dept Immunol, D-37075 Gottingen, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Gottingen	Hopken, UE (corresponding author), Max Delbruck Ctr Mol Med, Dept Tumorgenet & Immunogenet, Robert Rossle Str 10, D-13092 Berlin, Germany.		Lipp, Martin/G-2235-2010	Lipp, Martin/0000-0002-0087-2672				Aragay AM, 1998, FEBS LETT, V430, P37, DOI 10.1016/S0014-5793(98)00495-5; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Billstrom MA, 1999, AM J RESP CELL MOL, V21, P163, DOI 10.1165/ajrcmb.21.2.3673; Billstrom MA, 1998, J VIROL, V72, P5535, DOI 10.1128/JVI.72.7.5535-5544.1998; Bodaghi B, 1998, J EXP MED, V188, P855, DOI 10.1084/jem.188.5.855; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fraile-Ramos A, 2001, MOL BIOL CELL, V12, P1737, DOI 10.1091/mbc.12.6.1737; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GAO JL, 1994, J BIOL CHEM, V269, P28539; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; KUHN DE, 1995, BIOCHEM BIOPH RES CO, V211, P325, DOI 10.1006/bbrc.1995.1814; Leurs R, 1998, TRENDS BIOCHEM SCI, V23, P418, DOI 10.1016/S0968-0004(98)01287-0; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; Rosenkilde MM, 2001, ONCOGENE, V20, P1582, DOI 10.1038/sj.onc.1204191; Smit MJ, 2002, J VIROL, V76, P1744, DOI 10.1128/JVI.76.4.1744-1752.2002; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; Venkatesan S, 2001, J BIOL CHEM, V276, P40133, DOI 10.1074/jbc.M105722200; Waldhoer M, 2002, J VIROL, V76, P8161, DOI 10.1128/JVI.76.16.8161-8168.2002; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105	28	60	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45122	45128		10.1074/jbc.M208214200	http://dx.doi.org/10.1074/jbc.M208214200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244063	hybrid			2022-12-27	WOS:000179404800069
J	Shan, Q; Haddrill, JL; Lynch, JW				Shan, Q; Haddrill, JL; Lynch, JW			Comparative surface accessibility of a pore-lining threonine residue (T6 ') in the glycine and GABA(A) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; M2 SEGMENT; ALPHA-SUBUNIT; ION CHANNELS; OPEN STATE; PROTEIN; IDENTIFICATION; MUTATIONS; LOCATION; REGION	The substituted cysteine accessibility method was used to probe the surface exposure of a pore-lining threonine residue (T6') common to both the glycine receptor (GlyR) and gamma-aminobutyric acid, type A receptor (GABAAR) chloride channels. This residue lies close to the channel activation gate, the ionic selectivity filter, and the main pore blocker binding site. Despite their high amino acid sequence homologies and common role in conducting chloride ions, recent studies have suggested that the GlyRs and GABA(A)Rs have divergent open state pore structures at the 6' position. When both the human alpha1(T6'C) homomeric GlyR and the rat alpha1(T6'C)beta1(T6'C) heteromeric GABA(A)R were expressed in human embryonic kidney 293 cells, their 6' residue surface accessibilities differed significantly in the closed state. However, when a soluble cysteine-modifying compound was applied in the presence of saturating agonist concentrations, both receptors were locked into the open state. This action was not induced by oxidizing agents in either receptor. These results provide evidence for a conserved pore opening mechanism in anion-selective members of the ligand-gated ion channel family. The results also indicate that the GABA(A)R pore structure at the 6' level may vary between different expression systems.	Univ Queensland, Sch Biomed Sci, Dept Physiol & Pharmacol, Brisbane, Qld 4072, Australia	University of Queensland	Lynch, JW (corresponding author), Univ Queensland, Sch Biomed Sci, Dept Physiol & Pharmacol, Brisbane, Qld 4072, Australia.		Lynch, Joseph/C-8636-2009					AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; Arias HR, 1998, BBA-REV BIOMEMBRANES, V1376, P173, DOI 10.1016/S0304-4157(98)00004-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COHEN BN, 1992, J GEN PHYSIOL, V99, P545, DOI 10.1085/jgp.99.4.545; Gisselmann G, 2002, NAT NEUROSCI, V5, P11, DOI 10.1038/nn787; Harvey RJ, 1999, J PHYSIOL-LONDON, V520, P53, DOI 10.1111/j.1469-7793.1999.00053.x; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; JONES MV, 1995, NEURON, V15, P181, DOI 10.1016/0896-6273(95)90075-6; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Krasowski MD, 1999, CELL MOL LIFE SCI, V55, P1278, DOI 10.1007/s000180050371; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lynch JW, 2001, J NEUROSCI, V21, P2589, DOI 10.1523/JNEUROSCI.21-08-02589.2001; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; Panicker S, 2002, J NEUROSCI, V22, P1629, DOI 10.1523/JNEUROSCI.22-05-01629.2002; Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717; Reeves DC, 2001, J BIOL CHEM, V276, P42035, DOI 10.1074/jbc.M106066200; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Shan Q, 2001, J NEUROCHEM, V76, P1109, DOI 10.1046/j.1471-4159.2001.00124.x; SWEET RM, 1983, J MOL BIOL, V171, P479, DOI 10.1016/0022-2836(83)90041-4; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; VILLARROEL A, 1992, P ROY SOC B-BIOL SCI, V249, P317, DOI 10.1098/rspb.1992.0121; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; Wilson GG, 2001, P NATL ACAD SCI USA, V98, P1241, DOI 10.1073/pnas.031567798; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; Zhang H, 1998, BIOCHEMISTRY-US, V37, P7952, DOI 10.1021/bi980143m	30	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44845	44853		10.1074/jbc.M208647200	http://dx.doi.org/10.1074/jbc.M208647200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12239220	hybrid			2022-12-27	WOS:000179404800034
J	Yasuda, K; Hirayoshi, K; Hirata, H; Kubota, H; Hosokawa, N; Nagata, K				Yasuda, K; Hirayoshi, K; Hirata, H; Kubota, H; Hosokawa, N; Nagata, K			The Kruppel-like factor Zf9 and proteins in the Sp1 family regulate the expression of HSP47, a collagen-specific molecular chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; BINDING STRESS PROTEIN; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTORS; II COLLAGEN; GENE-TRANSCRIPTION; 3 FINGERS; PROMOTER; MOUSE; PROCOLLAGEN	In several cells and tissues the synthesis of HSP47, a collagen-specific molecular chaperone in the endoplasmic reticulum, is closely correlated with the synthesis of collagen. We previously reported that the Sp1 binding site at -210 bp in the promoter region and the first and second introns are required for the tissue-specific expression of HSP47 in transgenic mice (Hirata, H., Yamamura, I., Yasuda, K., Kobayashi, A., Tada, N., Suzuki, M., Hirayoshi, K., Hosokawa, N., and Nagata, K. (1999) J. Biol Chem. 274, 35703-35710). Here, we analyze how these introns influence the transcriptional regulation of the hsp47 gene in BALB/c 3T3 cells, which produce high levels of HSP47. In vitro promoter analysis using a luciferase reporter and gel mobility shift analysis revealed that two cis-acting elements in the first and second introns, BS5-B and EP7-D, respectively, are required for the activation of hsp47 in BALB/c 3T3 cells. Several members of the Kruppel-like factor (KLF) family of proteins were identified as BS5-B-binding proteins by yeast one-hybrid analysis using these elements as baits. One of these proteins, KLF-6/Zf9, binds to the BS5-B element and activates expression of the reporter construct when transfected into cells. Chromatin immunoprecipitation assay analysis revealed that the endogenous KLF-6/Zf9 binds the BS5-B elements that contain the CACCC motif, which is a consensus recognition sequence for other proteins in the KLF family. We also showed that BS5-B and EP7-D are bound by two members of the Sp1 family, Sp2 and Sp3. These results suggest that at least three sequences are required for the constitutive expression of hsp47 in BALB/c 3T3 cells: the -210 bp Sp1 binding site, the BS5-B element in the first intron, and the EP7-D element in the second intron. We suggest that KLF proteins regulate the transcription of hsp47 by binding the BS5-B element in cooperation with Sp2 and/or Sp3.	Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Sakyo Ku, Kyoto 6068397, Japan; Kyoto Univ, Dept Ultrastruct Res, Inst Frontier Med Sci, Kyoto 6068397, Japan; Kyoto Univ, Inst Virus Res, Kyoto 6065807, Japan	Kyoto University; Kyoto University; Kyoto University	Nagata, K (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Sakyo Ku, Kyoto 6068397, Japan.			Hirata, Hiromi/0000-0002-3769-7441				Asada S, 1999, CELL STRUCT FUNCT, V24, P187, DOI 10.1247/csf.24.187; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Bishop CE, 2000, NAT GENET, V26, P490, DOI 10.1038/82652; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Grant SFA, 1996, NAT GENET, V14, P203, DOI 10.1038/ng1096-203; Higaki Y, 2002, NUCLEIC ACIDS RES, V30, P2270, DOI 10.1093/nar/30.11.2270; Hirata H, 1999, J BIOL CHEM, V274, P35703, DOI 10.1074/jbc.274.50.35703; HIRAYOSHI K, 1991, MOL CELL BIOL, V11, P4036, DOI 10.1128/MCB.11.8.4036; HOSOKAWA N, 1993, GENE, V126, P187, DOI 10.1016/0378-1119(93)90366-B; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Koide T, 2002, J BIOL CHEM, V277, P6178, DOI 10.1074/jbc.M106497200; Krebsbach PH, 1996, J BIOL CHEM, V271, P4298, DOI 10.1074/jbc.271.8.4298; Kubota H, 2000, J BIOL CHEM, V275, P28641, DOI 10.1074/jbc.M005009200; Kuroda K, 1998, J INVEST DERMATOL, V111, P1023, DOI 10.1046/j.1523-1747.1998.00437.x; MASUDA H, 1994, J CLIN INVEST, V94, P2481, DOI 10.1172/JCI117617; Masuda H, 1998, CELL STRESS CHAPERON, V3, P256, DOI 10.1379/1466-1268(1998)003<0256:EALOCB>2.3.CO;2; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; Murakami S, 2001, ATHEROSCLEROSIS, V157, P361, DOI 10.1016/S0021-9150(00)00743-7; Nagai N, 2000, J CELL BIOL, V150, P1499, DOI 10.1083/jcb.150.6.1499; NAGATA K, 1988, J BIOL CHEM, V263, P8344; Naitoh M, 2001, BIOCHEM BIOPH RES CO, V280, P1316, DOI 10.1006/bbrc.2001.4257; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; Okano J, 2000, FEBS LETT, V473, P95, DOI 10.1016/S0014-5793(00)01468-X; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; SAVAGNER P, 1995, DNA CELL BIOL, V14, P501, DOI 10.1089/dna.1995.14.501; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Sunamoto M, 1998, INT J EXP PATHOL, V79, P133, DOI 10.1046/j.1365-2613.1998.00061.x; Sunamoto M, 1998, LAB INVEST, V78, P967; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Vergeer WP, 2000, ARCH BIOCHEM BIOPHYS, V377, P69, DOI 10.1006/abbi.2000.1760; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917; Zhao JL, 2000, J BIOL CHEM, V275, P8903, DOI 10.1074/jbc.275.12.8903	45	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44613	44622		10.1074/jbc.M208558200	http://dx.doi.org/10.1074/jbc.M208558200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235161	hybrid			2022-12-27	WOS:000179404800005
J	Chang, SC; Miller, AL; Feng, YC; Wente, SR; Majerus, PW				Chang, SC; Miller, AL; Feng, YC; Wente, SR; Majerus, PW			The human homolog of the rat inositol phosphate multikinase is an inositol 1,3,4,6-tetrakisphosphate 5-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,4,5-TRISPHOSPHATE 3-KINASE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; MOLECULAR-CLONING; YEAST; CELLS; 1,3,4,5,6-PENTAKISPHOSPHATE; 1,3,4-TRISPHOSPHATE; TRISPHOSPHATE; EXPRESSION; KINASE	We have demonstrated that the human homolog of the rat inositol phosphate multikinase is an inositol 1,3,4,6-tetrakisphosphate 5-kinase (InSP4 5-kinase). The cDNA of the human gene contained a putative open reading frame of 1251 bp encoding 416 amino acids with 83.6% identity compared with the rat protein. The substrate specificity of the recombinant human protein demonstrated preference for Ins(1,3,4,6)P-4 with a catalytic efficiency (V-max/K-m) 43-fold greater than that of Ins(1,3,4,5)P-4 and 2-fold greater than that of Ins(1,4,5)P-3. The apparent V-max was 114 nmol of Ins(1,3,4,5,6)P-5 formed/min/mg of protein, and the apparent K-m was 0.3 mum Ins(1,3,4,6)P-4. The functional homolog in yeast is Ipk2p, and ipk2-null yeast strains do not synthesize Ins(1,3,4,5,6)P-5 or InSP6. Synthesis of these compounds was restored by transformation with wild-type yeast IPK2 but not with human InSP4 5-kinase. Thus the human gene does not complement for the loss of the yeast gene because yeast cells do not contain the substrate Ins(1,3,4,6)P-4, and the reaction of the human protein with Ins(1,3,4,5)P-4 is insufficient to effect rescue or synthesis of InSP5 and InsP,. Therefore the major activity of human InSP4 5-kinase is phosphorylation at the D-5 position, and the pathways for synthesis of Ins(1,3,4,5,6)P-5 in yeast versus humans are different.	Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Majerus, PW (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Hematol, 660 S Euclid Ave,Campus Box 8125, St Louis, MO 63110 USA.	phil@im.wustl.edu			NHLBI NIH HHS [R01-HL55672, R01-HL16634] Funding Source: Medline; PHS HHS [H107088] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016634, R01HL055672] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bertsch U, 2000, J BIOL CHEM, V275, P1557, DOI 10.1074/jbc.275.3.1557; CHANDA VB, 1997, CURRENT PROTOCOLS MO; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; COMMUNI D, 1995, CELL SIGNAL, V7, P643, DOI 10.1016/0898-6568(95)00035-N; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; DUBOIS E, 1987, MOL GEN GENET, V207, P142, DOI 10.1007/BF00331501; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HUGHES PJ, 1989, J BIOL CHEM, V264, P19871; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Ives EB, 2000, J BIOL CHEM, V275, P36575, DOI 10.1074/jbc.M007586200; LIN A, 1993, ARCH BIOCHEM BIOPHYS, V303, P412, DOI 10.1006/abbi.1993.1303; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; Nalaskowski MM, 2002, BIOCHEM J, V366, P549, DOI 10.1042/BJ20020327; Norris FA, 1998, P NATL ACAD SCI USA, V95, P14057, DOI 10.1073/pnas.95.24.14057; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; OLIVER KG, 1992, J BIOL CHEM, V267, P21528; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2001, J BIOL CHEM, V276, P39179, DOI 10.1074/jbc.M106842200; Saiardi A, 2001, P NATL ACAD SCI USA, V98, P2306, DOI 10.1073/pnas.041614598; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHEARS SB, 1989, J BIOL CHEM, V264, P19879; Sherman F, 1986, LAB COURSE MANUAL ME; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Spencer J.F.T., 1989, YEAST GENETICS MANUA; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; TAKAZAWA K, 1990, BIOCHEM J, V268, P213, DOI 10.1042/bj2680213; TAKAZAWA K, 1991, BIOCHEM J, V278, P883, DOI 10.1042/bj2780883; THOMAS S, 1994, BBA-MOL CELL RES, V1220, P219, DOI 10.1016/0167-4889(94)90139-2; Verbsky JW, 2002, J BIOL CHEM, V277, P31857, DOI 10.1074/jbc.M205682200; Wilson MP, 1996, J BIOL CHEM, V271, P11904, DOI 10.1074/jbc.271.20.11904; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; York JD, 2001, ADV ENZYME REGUL, V41, P57, DOI 10.1016/S0065-2571(00)00025-X; Zhang XL, 1998, J BIOL CHEM, V273, P1574, DOI 10.1074/jbc.273.3.1574; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	39	60	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43836	43843		10.1074/jbc.M206134200	http://dx.doi.org/10.1074/jbc.M206134200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223481	hybrid			2022-12-27	WOS:000179272000041
J	Buechler, C; Bared, SM; Aslanidis, C; Ritter, M; Drobnik, W; Schmitz, G				Buechler, C; Bared, SM; Aslanidis, C; Ritter, M; Drobnik, W; Schmitz, G			Molecular and functional interaction of the ATP-binding cassette transporter A1 with Fas-associated death domain protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANGIER-DISEASE; TRANSBILAYER REDISTRIBUTION; CHOLESTEROL EFFLUX; T-CELLS; FIBROBLASTS; ABCA1; PHOSPHATIDYLSERINE; MUTATIONS; GROWTH; MUTANT	ATP-binding cassette transporter A1 (ABCA1) is a major regulator of cellular cholesterol and phospholipid homeostasis. Its function has not been fully characterized and may depend on the association with additional proteins. To identify ABCA1-interacting proteins a human liver yeast two-hybrid library was screened with the 144 C-terminal amino acids of ABCA1. Fas-associated death domain protein (FADD) was identified to bind to ABCA1, and this interaction was confirmed by pull-down assays and co-immunoprecipitations. Recombinant expression of a dominant negative form of FADD or the C terminus of ABCA1 in the human hepatoma cell line HepG2 markedly reduced the transfer of phospholipids to apoA-I. This indicates that the binding of additional proteins, one of them being full-length FADD, is required for ABCA1 function. The association of FADD with ABCA1 provides an unexpected link between high density lipoprotein metabolism and an adaptor molecule mainly described in death receptor signal transduction.	Univ Regensburg, Inst Clin Chem & Lab Med, D-93053 Regensburg, Germany	University of Regensburg	Schmitz, G (corresponding author), Univ Regensburg, Inst Clin Chem & Lab Med, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	gerd.schmitz@klinik.uni-regensburg.de	Buechler, Christa/AAH-3004-2020	Schmitz, Gerd/0000-0002-1325-1007				Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Buechler C, 2002, BIOCHEM BIOPH RES CO, V293, P759, DOI 10.1016/S0006-291X(02)00303-0; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Diederich W, 2001, ATHEROSCLEROSIS, V159, P313, DOI 10.1016/S0021-9150(01)00518-4; Drobnik W, 1999, ARTERIOSCL THROM VAS, V19, P28, DOI 10.1161/01.ATV.19.1.28; Drobnik W, 2002, TRAFFIC, V3, P268, DOI 10.1034/j.1600-0854.2002.030404.x; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hirano K, 2000, FEBS LETT, V484, P275, DOI 10.1016/S0014-5793(00)02171-2; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Hueber AO, 2000, J BIOL CHEM, V275, P10453, DOI 10.1074/jbc.275.14.10453; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kunzelmann-Marche C, 2001, J BIOL CHEM, V276, P5134, DOI 10.1074/jbc.M007924200; Newton K, 2001, CURR BIOL, V11, P273, DOI 10.1016/S0960-9822(01)00067-7; Oram JF, 1999, J LIPID RES, V40, P1769; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schmitz G, 1999, PATHOBIOLOGY, V67, P236, DOI 10.1159/000028100; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Szakacs G, 2001, BIOCHEM BIOPH RES CO, V288, P1258, DOI 10.1006/bbrc.2001.5905; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tsukamoto K, 2001, BIOCHEM BIOPH RES CO, V287, P757, DOI 10.1006/bbrc.2001.5575; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Zha XH, 2001, J BIOL CHEM, V276, P39476, DOI 10.1074/jbc.M105067200	23	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41307	41310		10.1074/jbc.C200436200	http://dx.doi.org/10.1074/jbc.C200436200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12235128	hybrid			2022-12-27	WOS:000178985300004
J	Zhang, HB; Howard, EM; Roepe, PD				Zhang, HB; Howard, EM; Roepe, PD			Analysis of the antimalarial drug resistance protein Pfcrt expressed in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITE PLASMODIUM-FALCIPARUM; DIGESTIVE VACUOLAR PH; CODON USAGE PATTERNS; HUMAN MDR-1 PROTEIN; SACCHAROMYCES-CEREVISIAE; HETEROLOGOUS EXPRESSION; ESCHERICHIA-COLI; MALARIA PARASITE; PICHIA-PASTORIS; DIHYDROFOLATE-REDUCTASE	Mutations in the novel membrane protein Pfcrt were recently found to be essential for chloroquine resistance (CQR) in Plasmodium falciparum, the parasite responsible for most lethal human malaria (Fidock, D. A., Nomura, T., Talley, A. K., Cooper, R. A., Dzekunov, S. M., Ferdig, M. T., Ursos, L. M., Sidhu, A. B., Naude, B., Deitsch, K. W., Su, X. Z., Wootton, J. C., Roepe, P. D., and Wellems, T. E. (2000) Mol. Cell 6, 861-871). Pfcrt is localized to the digestive vacuolar membrane of the intraerythrocytic parasite and may function as a transporter. Study of this putative transport function would be greatly assisted by overexpression in yeast followed by characterization of membrane vesicles. Unfortunately, the very high AT content of malarial genes precludes efficient heterologous expression. Thus, we back-translated Pfcrt to design idealized genes with preferred yeast codons, no long poly(A) sequences, and minimal stem-loop structure. We synthesized a designed gene with a two-step PCR method, fused this to N- and C-terminal sequences to aid membrane insertion and purification, and now report efficient expression of wild type and mutant Pfcrt proteins in the plasma membrane of Saccharomyces cerevisiae and Pichia pastoris yeast. To our knowledge, this is the first successful expression of a full-length malarial parasite integral membrane protein in yeast. Purified membranes and inside-out plasma membrane vesicle preparations were used to analyze wild type versus CQR-conferring mutant Pfcrt function, which may include effects on H+ transport (Dzekunov, S., Ursos, L. M. B., and Roepe, P. D. (2000) Mol. Biochem. Parasitol. 110, 107-124), and to perfect a rapid purification of biotinylated Pfcrt. These data expand on the role of Pfcrt in conferring CQR and define a productive route for analysis of important P. falciparum transport proteins and membrane associated vaccine candidates.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Chem, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Program Tumor Biol, Washington, DC 20007 USA	Georgetown University; Georgetown University; Georgetown University	Roepe, PD (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Chem, 37th & O St, Washington, DC 20007 USA.	roepep@georgetown.edu			NIAID NIH HHS [AI 45957] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045957] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersen B, 1998, PROTEIN EXPRES PURIF, V13, P111, DOI 10.1006/prep.1998.0862; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; Bray PG, 1999, J CELL BIOL, V145, P363, DOI 10.1083/jcb.145.2.363; Carter NS, 2001, TRENDS PARASITOL, V17, P142, DOI 10.1016/S1471-4922(00)01806-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Doring F, 1998, MOL MEMBR BIOL, V15, P79, DOI 10.3109/09687689809027522; Duvel K, 1999, NUCLEIC ACIDS RES, V27, P4751, DOI 10.1093/nar/27.24.4751; Dzekunov SM, 2000, MOL BIOCHEM PARASIT, V110, P107, DOI 10.1016/S0166-6851(00)00261-9; EVANS GL, 1995, J BIOENERG BIOMEMBR, V27, P43, DOI 10.1007/BF02110330; Ferreira T, 2001, J BIOL CHEM, V276, P29613, DOI 10.1074/jbc.R100022200; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; Fritz F, 1999, BIOCHEMISTRY-US, V38, P4214, DOI 10.1021/bi981929n; Gardner MJ, 1999, CURR OPIN GENET DEV, V9, P704, DOI 10.1016/S0959-437X(99)00032-5; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; Graber JH, 1999, NUCLEIC ACIDS RES, V27, P888, DOI 10.1093/nar/27.3.888; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; Guo ZJ, 1996, TRENDS BIOCHEM SCI, V21, P477, DOI 10.1016/S0968-0004(96)10057-8; Gupta SS, 2000, FEBS LETT, V481, P77, DOI 10.1016/S0014-5793(00)01977-3; KARCZ SR, 1994, MOL BIOCHEM PARASIT, V65, P123, DOI 10.1016/0166-6851(94)90121-X; Kiser GL, 2001, ARCH BIOCHEM BIOPHYS, V390, P195, DOI 10.1006/abbi.2001.2385; KUCHLER K, 1992, P NATL ACAD SCI USA, V89, P2302, DOI 10.1073/pnas.89.6.2302; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; MARTINEY JA, 1995, J BIOL CHEM, V270, P22393, DOI 10.1074/jbc.270.38.22393; McIntosh MT, 2001, MOL BIOCHEM PARASIT, V114, P183, DOI 10.1016/S0166-6851(01)00251-1; MENENDEZ A, 1995, ANAL BIOCHEM, V230, P308, DOI 10.1006/abio.1995.1479; Milek RLB, 2000, VACCINE, V18, P1402, DOI 10.1016/S0264-410X(99)00392-8; Musto H, 1999, J MOL EVOL, V49, P27, DOI 10.1007/PL00006531; MUSTO H, 1995, GENE, V152, P127, DOI 10.1016/0378-1119(94)00708-Z; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; Pan WQ, 1999, NUCLEIC ACIDS RES, V27, P1094, DOI 10.1093/nar/27.4.1094; Prapunwattana P, 1996, MOL BIOCHEM PARASIT, V83, P93, DOI 10.1016/S0166-6851(96)02756-9; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; ROMANOS MA, 1992, YEAST, V8, P423, DOI 10.1002/yea.320080602; Santai CT, 1999, BIOCHEMISTRY-US, V38, P4227, DOI 10.1021/bi981930m; SAUL A, 1988, MOL BIOCHEM PARASIT, V27, P35, DOI 10.1016/0166-6851(88)90022-9; SHARP PM, 1988, NUCLEIC ACIDS RES, V16, P8207, DOI 10.1093/nar/16.17.8207; SIRAWARAPORN W, 1990, BIOCHEMISTRY-US, V29, P10779, DOI 10.1021/bi00500a009; STEMMER WPC, 1995, GENE, V164, P49, DOI 10.1016/0378-1119(95)00511-4; Ursos LMB, 2002, MED RES REV, V22, P465, DOI 10.1002/med.10016; Ursos LMB, 2000, MOL BIOCHEM PARASIT, V110, P125, DOI 10.1016/S0166-6851(00)00262-0; van Helden J, 2000, NUCLEIC ACIDS RES, V28, P1000; Wang HC, 2001, MOL BIOL EVOL, V18, P792, DOI 10.1093/oxfordjournals.molbev.a003861; WEBER JL, 1987, GENE, V52, P103, DOI 10.1016/0378-1119(87)90399-4; Weiss HM, 1998, BIOCHEM J, V330, P1137, DOI 10.1042/bj3301137; Withers-Martinez C, 1999, PROTEIN ENG, V12, P1113, DOI 10.1093/protein/12.12.1113; Woodrow CJ, 2000, P NATL ACAD SCI USA, V97, P9931, DOI 10.1073/pnas.170153097; Yelin R, 2001, BBA-BIOMEMBRANES, V1510, P426, DOI 10.1016/S0005-2736(00)00374-6	49	130	132	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49767	49775		10.1074/jbc.M204005200	http://dx.doi.org/10.1074/jbc.M204005200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12351620	hybrid			2022-12-27	WOS:000180028900089
J	Beinker, P; Schlee, S; Groemping, Y; Seidel, R; Reinstein, J				Beinker, P; Schlee, S; Groemping, Y; Seidel, R; Reinstein, J			The N terminus of C1pB from Thermus thermophilus is not essential for the chaperone activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLECULAR CHAPERONES; TRANSFER-RNA; PROTEIN; CLPB; DNAK; DOMAINS; BINDING; SYSTEM; ATPASE	ClpB from Thermus thermophilus belongs to the Clp/Hsp100 protein family and reactivates protein aggregates in cooperation with the DnaK chaperone system. The mechanism of protein reactivation and interaction with the DnaK system remains unclear. ClpB possesses two nucleotide binding domains, which are essential for function and show a complex allosteric behavior. The role of the N-terminal domain that precedes the first nucleotide binding domain is largely unknown. We purified and characterized an N-terminal shortened ClpB variant (ClpBDeltaN; amino acids 140-854), which remained active in refolding assays with three different substrate proteins. In addition the N-terminal truncation did not significantly change the nucleotide binding affinities, the nucleotide-dependent oligomerization, and the allosteric behavior of the protein. In contrast casein binding and stimulation of the ATPase activity by kappa-casein were affected. These results suggest that the N-terminal domain is not essential for the chaperone function, does not influence the binding of nucleotides, and is not involved in the formation of intermolecular contacts. It contributes to the casein binding site of ClpB, but other substrate proteins do not necessarily interact with the N terminus. This indicates a substantial difference in the binding mode of kappa-casein that is often used as model substrate for ClpB and other possibly more suitable substrate proteins.	Max Planck Inst Mol Physiol, Phys Biochem Abt, D-44227 Dortmund, Germany	Max Planck Society	Reinstein, J (corresponding author), Max Planck Inst Mol Physiol, Phys Biochem Abt, Otto Hahn Str 11, D-44227 Dortmund, Germany.	joachim.reinstein@mpi-dortmund.mpg.de						Barnett ME, 2000, J BIOL CHEM, V275, P37565, DOI 10.1074/jbc.M005211200; Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; BERGMEYER HU, 1962, METHODEN ENZYMATI ED, P573; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; Clarke AK, 2000, J BACTERIOL, V182, P7092, DOI 10.1128/JB.182.24.7092-7096.2000; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; EHRESMAN.B, 1973, ANAL BIOCHEM, V54, P454, DOI 10.1016/0003-2697(73)90374-6; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Groemping Y, 2001, J MOL BIOL, V305, P1173, DOI 10.1006/jmbi.2000.4373; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Klostermeier D, 1999, J MOL BIOL, V287, P511, DOI 10.1006/jmbi.1999.2636; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Liu ZH, 2002, J MOL BIOL, V321, P111, DOI 10.1016/S0022-2836(02)00591-0; Lo JH, 2001, PROTEIN SCI, V10, P551, DOI 10.1110/ps.41401; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Neuwald AF, 1999, GENOME RES, V9, P27; PARK SK, 1993, J BIOL CHEM, V268, P20170; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7440, DOI 10.1021/bi00484a013; Schlee S, 2001, J MOL BIOL, V306, P889, DOI 10.1006/jmbi.2001.4455; SEOL JH, 1994, J BIOL CHEM, V269, P29468; Singh SK, 2001, J BIOL CHEM, V276, P29420, DOI 10.1074/jbc.M103489200; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; Tek V, 2002, PROTEIN SCI, V11, P1192, DOI 10.1110/ps.4860102; Thrall SH, 1996, BIOCHEMISTRY-US, V35, P4609, DOI 10.1021/bi9526387; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; WOO KM, 1992, J BIOL CHEM, V267, P20429; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	33	69	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47160	47166		10.1074/jbc.M207853200	http://dx.doi.org/10.1074/jbc.M207853200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351638	hybrid			2022-12-27	WOS:000179663700042
J	Chung, KT; Shen, Y; Hendershot, LM				Chung, KT; Shen, Y; Hendershot, LM			BAP, a mammalian BiP-associated protein, is a nucleotide exchange factor that regulates the ATPase activity of BiP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HSP70 CHAPERONE ACTIVITY; IMMUNOGLOBULIN HEAVY-CHAIN; ENDOPLASMIC-RETICULUM; DNAJ HOMOLOG; ER STRESS; IN-VIVO; MOLECULAR CHAPERONES; NEGATIVE REGULATOR; SECRETORY PATHWAY; BINDING-PROTEIN	We identified a mammalian BiP-associated protein, BAP, using a yeast two-hybrid screen that shared low homology with yeast Sls1p/Sil1p and mammalian HspBP1, both of which regulate the ATPase activity of their Hsp70 partner. BAP encoded an similar to54-kDa protein with an N-terminal endoplasmic reticulum (ER) targeting sequence, two sites of N-linked glycosylation, and a C-terminal ER retention sequence. Immunofluorescence staining demonstrated that BAP co-localized with GRP94 in the endoplasmic reticulum. BAP was ubiquitously expressed but showed the highest levels of expression in secretory organ tissues, a pattern similar to that observed with BiP. BAP binding was affected by the conformation of the ATPase domain of BiP based on in vivo binding studies with BiP mutants. BAP stimulated the ATPase activity of BiP when added alone or together with the ER DnaJ protein, ERdj4, by promoting the release of ADP from BiP. Together, these data demonstrate that BAP serves as a nucleotide exchange factor for BiP and provide insights into the mechanisms that control protein folding in the mammalian ER.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Hendershot, LM (corresponding author), Dept Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38105 USA.	linda.hendershot@stjude.org	Hendershot, Linda/N-8124-2018	Hendershot, Linda/0000-0002-5473-0274	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054068] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NIGMS NIH HHS [GM54068] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai C, 1996, METHOD ENZYMOL, V273, P331; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bies C, 1999, BIOL CHEM, V380, P1175, DOI 10.1515/BC.1999.149; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; BOORSTEIN WR, 1994, J MOL EVOL, V38, P1; Brewer JW, 1997, EMBO J, V16, P7207, DOI 10.1093/emboj/16.23.7207; BRIGHTMAN SE, 1995, GENE, V153, P249, DOI 10.1016/0378-1119(94)00741-A; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Chevalier M, 2000, J BIOL CHEM, V275, P19620, DOI 10.1074/jbc.M001333200; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Gassler CS, 2001, J BIOL CHEM, V276, P32538, DOI 10.1074/jbc.M105328200; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Kabani M, 2000, MOL CELL BIOL, V20, P6923, DOI 10.1128/MCB.20.18.6923-6934.2000; Kabani M, 2002, MOL CELL BIOL, V22, P4677, DOI 10.1128/MCB.22.13.4677-4689.2002; Lee YK, 1999, MOL BIOL CELL, V10, P2209, DOI 10.1091/mbc.10.7.2209; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Miao BJ, 1997, J MOL BIOL, V265, P541, DOI 10.1006/jmbi.1996.0762; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Nollen EAA, 2000, MOL CELL BIOL, V20, P1083, DOI 10.1128/MCB.20.3.1083-1088.2000; Nollen EAA, 2001, J BIOL CHEM, V276, P4677, DOI 10.1074/jbc.M009745200; Raynes DA, 1998, J BIOL CHEM, V273, P32883, DOI 10.1074/jbc.273.49.32883; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shen Y, 2002, J BIOL CHEM, V277, P15947, DOI 10.1074/jbc.M112214200; Skowronek MH, 1999, BIOL CHEM, V380, P1133, DOI 10.1515/BC.1999.142; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Tyson JR, 2000, EMBO J, V19, P6440, DOI 10.1093/emboj/19.23.6440; Vanhove M, 2001, IMMUNITY, V15, P105, DOI 10.1016/S1074-7613(01)00163-7; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; Yu M, 2000, J BIOL CHEM, V275, P24984, DOI 10.1074/jbc.M000739200	40	140	143	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47557	47563		10.1074/jbc.M208377200	http://dx.doi.org/10.1074/jbc.M208377200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356756	hybrid			2022-12-27	WOS:000179663700094
J	Francis, SH; Bessay, EP; Kotera, J; Grimes, KA; Liu, L; Thompson, WJ; Corbin, JD				Francis, SH; Bessay, EP; Kotera, J; Grimes, KA; Liu, L; Thompson, WJ; Corbin, JD			Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; PROTEIN; SITES; PDE5	Substrate binding to the phosphodiesterase-5 (PDE5) catalytic site increases cGMP binding to the regulatory domain (R domain). The latter promotes PDE5 phosphorylation by cyclic nucleotide-dependent protein kinases, which activates catalysis, enhances allosteric cGMP binding, and causes PDE5A1 to apparently elongate. A human PDE5A1 R domain fragment (Val(46)-Glu(539)) containing the phosphorylation site (Ser(102)) and allosteric cGMP-binding sites was studied. The rate, cGMP dependence, and stoichiometry of phosphorylation of the PDE5 R domain by the catalytic subunit of cAMP-dependent protein kinase are comparable with that of the holoenzyme. Migration in native polyacrylamide gels suggests that either cGMP binding or phosphorylation produces distinct conformers of the R domain. Phosphorylation of the R domain increases affinity for cGMP similar to10-fold (K-D values 97.8+/-17 and 10.0+/-0.5 nM for unphospho- and phospho-R domains, respectively). [3 H]cGMP dissociates from the phospho-R domain with a single rate (t(1/2)=339+/-30 min) compared with the biphasic pattern of the unphospho-R domain (t(1/2)=39.0+/-4.8 and 265+/-28 min, for the fast and slow components, respectively). Thus, cGMP-directed regulation of PDE5 phosphorylation and the resulting increase in cGMP binding affinity occur largely within the R domain. Conformational change(s) elicited by phosphorylation of the R domain within the PDE5 holoenzyme may also cause or participate in stimulating catalysis.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Univ S Alabama, Sch Med, Dept Pharmacol, Mobile, AL 36688 USA; Cell Pathways Inc, Horsham, PA 19044 USA	Vanderbilt University; University of South Alabama	Francis, SH (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.	sharron.francis@mcmail.vanderbilt.edu			NHLBI NIH HHS [HL46494] Funding Source: Medline; NIDDK NIH HHS [DK40029, DK58277] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029, R01DK058277] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; BEAVO JA, 1971, J BIOL CHEM, V246, P3841; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; Charbonneau H., 1990, CYCLIC NUCLEOTIDE PH, P267; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; FLOCKHART DA, 1984, BRAIN RECEPTOR MET A, P209; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; FRANCIS SH, 1980, J BIOL CHEM, V255, P620; Francis SH, 1998, METHODS, V14, P81, DOI 10.1006/meth.1997.0567; Johnson LN, 1997, ADV SEC MESS PHOSPH, V31, P11; Liu L, 2002, CELL SIGNAL, V14, P45, DOI 10.1016/S0898-6568(01)00216-9; Loughney K, 1998, GENE, V216, P139, DOI 10.1016/S0378-1119(98)00303-5; Manganiello V.C., 1990, CYCLIC NUCLEOTIDE PH, P61; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Mullershausen F, 2001, J CELL BIOL, V155, P271, DOI 10.1083/jcb.200107001; Rybalkin SD, 2002, J BIOL CHEM, V277, P3310, DOI 10.1074/jbc.M106562200; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; STROOP SD, 1991, J BIOL CHEM, V266, P23802; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; Turko IV, 1998, BIOCHEM J, V329, P505; Weber G, 1975, Adv Protein Chem, V29, P1, DOI 10.1016/S0065-3233(08)60410-6; WYATT TA, 1998, AM J PHYSIOL, V274, P448; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619	26	68	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47581	47587		10.1074/jbc.M206088200	http://dx.doi.org/10.1074/jbc.M206088200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359732	hybrid			2022-12-27	WOS:000179663700097
J	Ozcan, S				Ozcan, S			Two different signals regulate repression and induction of gene expression by glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; HEXOSE TRANSPORTERS; BUDDING YEAST; SENSORS; DEREPRESSION; MECHANISMS; MUTANTS; CELLS	In addition to being the universal carbon and energy source, glucose also regulates gene expression in many organisms. In the yeast Saccharomyces cerevisiae glucose regulates gene expression via two different pathways known as the glucose repression and glucose induction pathways. The signal for glucose induction of hexose transporter (HX7) genes is generated via two glucose-transporter like molecules, Snf3 and Rgt2. A strain lacking both sensors is unable to induce RXT gene expression and is defective in glucose uptake. The snf3 rgt2 double mutant is also defective in glucose repression of transcription, raising the possibility that Snf3 and Rgt2 are also involved in generating the glucose repression signal. In this report, I show that induction and repression of gene expression by glucose in yeast is regulated by two independent signals. While the signal for induction of HXT gene expression is generated by Snf3 and Rgt2 glucose receptors, the repression signal requires the uptake and metabolism of glucose. In addition, the glucose induction of the HXT genes is required for repression of gene expression by glucose. Therefore the glucose repression defect of the snt3 rgt2 strain is indirect and is due to the lack of glucose uptake in this double mutant.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Chandler Med Ctr, Lexington, KY 40536 USA	University of Kentucky	Ozcan, S (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Chandler Med Ctr, 800 Rose St,MN 608, Lexington, KY 40536 USA.							Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CARLSON M, 1981, GENETICS, V98, P25; CIRIACY M, 1977, MOL GEN GENET, V154, P213, DOI 10.1007/BF00330840; Foufelle F, 1998, Curr Opin Clin Nutr Metab Care, V1, P323, DOI 10.1097/00075197-199807000-00002; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; Lafuente MJ, 2000, MOL MICROBIOL, V35, P161, DOI 10.1046/j.1365-2958.2000.01688.x; Meijer MMC, 1998, J BIOL CHEM, V273, P24102, DOI 10.1074/jbc.273.37.24102; Ozcan S, 1998, EMBO J, V17, P2566, DOI 10.1093/emboj/17.9.2566; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; OZCAN S, 1995, MOL CELL BIOL, V15, P1564; Ozcan S, 1996, P NATL ACAD SCI USA, V93, P12428, DOI 10.1073/pnas.93.22.12428; Reifenberger E, 1997, EUR J BIOCHEM, V245, P324, DOI 10.1111/j.1432-1033.1997.00324.x; Schmidt MC, 1999, MOL CELL BIOL, V19, P4561; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; Ye L, 1999, J BACTERIOL, V181, P4673, DOI 10.1128/JB.181.15.4673-4675.1999; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; ZIMMERMANN FK, 1977, MOL GEN GENET, V151, P95, DOI 10.1007/BF00446918	22	29	29	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46993	46997		10.1074/jbc.M208726200	http://dx.doi.org/10.1074/jbc.M208726200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351652	hybrid			2022-12-27	WOS:000179663700022
J	Ramanathan, MP; Curley, E; Su, M; Chambers, JA; Weiner, DB				Ramanathan, MP; Curley, E; Su, M; Chambers, JA; Weiner, DB			Carboxyl terminus of hVIP/mov34 is critical for HIV-1-Vpr interaction and glucocorticoid-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CELL-CYCLE ARREST; VPR PROTEIN; LIVING CELLS; DNA-REPAIR; IN-VITRO; RECEPTOR; TRANSCRIPTION; REPLICATION; EXPRESSION	Human immunodeficiency virus, type 1 (HIV-1) vpr is a highly conserved gene among lentiviruses. The diverse functions of Vpr support interactions of this HIV accessory protein with host cell partners of important pathways. hVIP/mov34 (human Vpr Interacting Protein) is one of these identified Vpr ligands. hVIP is a 34-kDa member of the eIF3 family that is vital for early embryonic development in transgenic mice and important in cell cycle regulation. Its interaction with Vpr, however, is not yet clearly defined. Therefore, we constructed a panel of deletion mutants of this cytoplasmic cellular ligand to map the protein domain that mediates its interaction with Vpr. We observed that the carboxyl-terminal region of hVIP is critical for its interaction with Vpr. In the absence of Vpr or HIV infection, full-length hVIP is expressed in the cytoplasm. The cytoplasmic localization pattern of full-length hVIP protein, however, is shifted to a clear nuclear localization pattern in cells expressing both hVIP and Vpr. In contrast, Vpr did not alter the localization pattern of hVIP mutants, which have their carboxyl-terminal domain deleted. The movement of hVIP supported prior work that suggested that Vpr triggers activation of the GR receptor complex. In fact, we also observed that dexamethasone moves hVIP into the nucleus and that glucocorticoid antagonists inhibit this effect. Interestingly, the expression of an hVIP carboxyl-terminal mutant, which is not responsive to Vpr, is also not responsive to dexamethasone. These data illustrate that the carboxyl-terminal domain of hVIP is critical for mediating hVIP-Vpr interaction as well as for its glucocorticoid response. These results support the view that hVIP is a member of the complex array of nucleocytoplasmic shuttling proteins that are regulated by HIV infection and glucocorticoids.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Weiner, DB (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 422 Curie Blvd,505 Stellar Chance Labs, Philadelphia, PA 19104 USA.		Weiner, David B/H-8579-2014					Agostini I, 1996, J MOL BIOL, V261, P599, DOI 10.1006/jmbi.1996.0485; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; Ayyavoo V, 2002, INT IMMUNOL, V14, P13, DOI 10.1093/intimm/14.1.13; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957; DODERA D, 1989, J VIROL, V63, P3205; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Gragerov A, 1998, VIROLOGY, V245, P323, DOI 10.1006/viro.1998.9138; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; LAVALLEE C, 1994, J VIROL, V68, P1926; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LEVY DN, 1995, J VIROL, V69, P1243, DOI 10.1128/JVI.69.2.1243-1252.1995; LU YL, 1995, J VIROL, V69, P6873, DOI 10.1128/JVI.69.11.6873-6879.1995; Mahalingam S, 1998, P NATL ACAD SCI USA, V95, P3419, DOI 10.1073/pnas.95.7.3419; Mahalingam S, 1997, DNA CELL BIOL, V16, P137, DOI 10.1089/dna.1997.16.137; Mahalingam S, 1997, J VIROL, V71, P6339, DOI 10.1128/JVI.71.9.6339-6347.1997; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Planelles V, 1996, J VIROL, V70, P2516, DOI 10.1128/JVI.70.4.2516-2524.1996; Rafaeli Y, 1995, P NATL ACAD SCI USA, V92, P3621; Ramanathan MP, 2001, DNA CELL BIOL, V20, P101, DOI 10.1089/104454901750070300; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; Sawaya BE, 2000, J BIOL CHEM, V275, P35209, DOI 10.1074/jbc.M005197200; Sherman MP, 2001, J VIROL, V75, P1522, DOI 10.1128/JVI.75.3.1522-1532.2001; Sherman MP, 2000, J VIROL, V74, P8159, DOI 10.1128/JVI.74.17.8159-8165.2000; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Stark LA, 1998, J VIROL, V72, P3037, DOI 10.1128/JVI.72.4.3037-3044.1998; Stewart SA, 1999, P NATL ACAD SCI USA, V96, P12039, DOI 10.1073/pnas.96.21.12039; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Stivahtis GL, 1997, J VIROL, V71, P4331, DOI 10.1128/JVI.71.6.4331-4338.1997; Vanitharani R, 2001, VIROLOGY, V289, P334, DOI 10.1006/viro.2001.1153; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; WithersWard ES, 1997, J VIROL, V71, P9732, DOI 10.1128/JVI.71.12.9732-9742.1997; YUAN XF, 1990, J VIROL, V64, P5688	46	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47854	47860		10.1074/jbc.M203905200	http://dx.doi.org/10.1074/jbc.M203905200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12237292	hybrid			2022-12-27	WOS:000179663700131
J	Terao, Y; Kawabata, S; Nakata, M; Nakagawa, I; Hamada, S				Terao, Y; Kawabata, S; Nakata, M; Nakagawa, I; Hamada, S			Molecular characterization of a novel fibronectin-binding protein of Streptococcus pyogenes strains isolated from toxic shock-like syndrome patients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCUS; STAPHYLOCOCCUS-AUREUS; GENOME SEQUENCE; SURFACE PROTEIN; CYSTEINE PROTEASE; SEROTYPE M3; GENE; IDENTIFICATION; ACTIVATION; MULTIPLE	Group A Streptococcus pyogenes has surface-located fibronectin (Fn)-binding proteins known to be a major virulence factor, which adheres to and invades host cells. We present a novel Fn-binding protein of group A streptococcus serotype M3 and M18 strains isolated from patients with toxic shock-like syndrome (TSLS). By searching the whole genome sequence of an M3 strain from a TSLS patient, an open reading frame was found among the putative surface proteins. It possessed an LPXTG motif and Fn-binding repeat domains in the C-terminal region and was designated as FbaB (Fn-binding protein of group A streptococci type B). The fbaB gene was found in all M3 and M18 strains examined, although not in other M serotypes. Furthermore, FbaB protein was expressed on the cell surface of TSLS strains but not on non-TSLS ones. Enzyme-linked immunosorbent assay and ligand blotting revealed that recombinant FbaB exhibits a strong Fn-binding ability. An FbaB-deficient mutant strain showed 6-fold lower adhesion and invasion efficiencies to HEp-2 cells than the wild type. Moreover, mortality was decreased in mice infected with the mutant strain in comparison to the wild type. These data suggest that FbaB is etiologically involved in the development of invasive streptococcal diseases.	Osaka Univ, Dept Oral & Mol Microbiol, Grad Sch Dent, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi, Saitama 3320012, Japan	Osaka University; Japan Science & Technology Agency (JST)	Kawabata, S (corresponding author), Osaka Univ, Dept Oral & Mol Microbiol, Grad Sch Dent, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan.	kawabata@dent.osaka-u.ac.jp		Nakata, Masanobu/0000-0003-1686-5415; Terao, Yutaka/0000-0002-4450-5583				Beckmann C, 2002, INFECT IMMUN, V70, P2869, DOI 10.1128/IAI.70.6.2869-2876.2002; Beres SB, 2002, P NATL ACAD SCI USA, V99, P10078, DOI 10.1073/pnas.152298499; CAPARON MG, 1991, METHOD ENZYMOL, V204, P556; Courtney HS, 1999, MOL MICROBIOL, V32, P89, DOI 10.1046/j.1365-2958.1999.01328.x; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Eichenbaum Z, 1996, INFECT IMMUN, V64, P1956, DOI 10.1128/IAI.64.6.1956-1960.1996; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; Fogg GC, 1997, J BACTERIOL, V179, P6172, DOI 10.1128/jb.179.19.6172-6180.1997; FRITHZ E, 1989, MOL MICROBIOL, V3, P1111, DOI 10.1111/j.1365-2958.1989.tb00261.x; Gilot P, 1999, INFECT IMMUN, V67, P6698; HAMADA S, 1991, INFECT IMMUN, V59, P4161, DOI 10.1128/IAI.59.11.4161-4167.1991; HAUSER AR, 1991, J CLIN MICROBIOL, V29, P1562, DOI 10.1128/JCM.29.8.1562-1567.1991; HUANG TT, 1989, MOL MICROBIOL, V3, P197, DOI 10.1111/j.1365-2958.1989.tb01808.x; Inagaki Y, 2000, J INFECT DIS, V181, P975, DOI 10.1086/315299; Jaffe J, 1996, MOL MICROBIOL, V21, P373, DOI 10.1046/j.1365-2958.1996.6331356.x; Kingsley RA, 2002, MOL MICROBIOL, V43, P895, DOI 10.1046/j.1365-2958.2002.02805.x; KREIKEMEYER B, 1995, MOL MICROBIOL, V17, P137, DOI 10.1111/j.1365-2958.1995.mmi_17010137.x; Massey RC, 2001, CELL MICROBIOL, V3, P839, DOI 10.1046/j.1462-5822.2001.00157.x; MCGAVIN MJ, 1993, J BIOL CHEM, V268, P23946; McIver KS, 2002, MOL MICROBIOL, V43, P1591, DOI 10.1046/j.1365-2958.2002.02849.x; MCIVER KS, 1995, J BACTERIOL, V177, P6619, DOI 10.1128/jb.177.22.6619-6624.1995; Murakami J, 2002, EPIDEMIOL INFECT, V128, P397, DOI 10.1017/S0950268802006854; Nakagawa I, 2001, CELL MICROBIOL, V3, P395, DOI 10.1046/j.1462-5822.2001.00122.x; NATANSON S, 1995, J INFECT DIS, V171, P871, DOI 10.1093/infdis/171.4.871; Ozeri V, 2001, MOL MICROBIOL, V41, P561, DOI 10.1046/j.1365-2958.2001.02535.x; Ozeri V, 1998, MOL MICROBIOL, V30, P625, DOI 10.1046/j.1365-2958.1998.01097.x; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Podbielski A, 1999, MOL MICROBIOL, V31, P1051, DOI 10.1046/j.1365-2958.1999.01241.x; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; Raeder R, 1998, RES MICROBIOL, V149, P539, DOI 10.1016/S0923-2508(99)80001-1; Rasmussen M, 2000, INFECT IMMUN, V68, P6370, DOI 10.1128/IAI.68.11.6370-6377.2000; Rasmussen M, 1999, J BIOL CHEM, V274, P15336, DOI 10.1074/jbc.274.22.15336; Rocha CL, 1999, INFECT IMMUN, V67, P2720, DOI 10.1128/IAI.67.6.2720-2728.1999; RUSSELL RRB, 1992, J BIOL CHEM, V267, P4631; Sambrook J., 2001, MOL CLONING LAB MANU; SCHMIDT KH, 1993, FEMS IMMUNOL MED MIC, V7, P135; SELA S, 1993, MOL MICROBIOL, V10, P1049, DOI 10.1111/j.1365-2958.1993.tb00975.x; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; Smoot JC, 2002, P NATL ACAD SCI USA, V99, P4668, DOI 10.1073/pnas.062526099; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; Stockbauer KE, 1999, P NATL ACAD SCI USA, V96, P242, DOI 10.1073/pnas.96.1.242; TALAY SR, 1994, MOL MICROBIOL, V13, P531, DOI 10.1111/j.1365-2958.1994.tb00448.x; TALKINGTON DF, 1993, INFECT IMMUN, V61, P3369, DOI 10.1128/IAI.61.8.3369-3374.1993; TAO L, 1992, GENE, V120, P105, DOI 10.1016/0378-1119(92)90016-I; Terao Y, 2001, MOL MICROBIOL, V42, P75, DOI 10.1046/j.1365-2958.2001.02579.x; Terao Y, 2002, INFECT IMMUN, V70, P993; THERN A, 1995, J IMMUNOL, V154, P375; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Whatmore AM, 2001, MICROBIOL-UK, V147, P419, DOI 10.1099/00221287-147-2-419	50	88	88	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47428	47435		10.1074/jbc.M209133200	http://dx.doi.org/10.1074/jbc.M209133200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359713	hybrid			2022-12-27	WOS:000179663700078
J	Watanabe, H; Vriens, J; Suh, SH; Benham, CD; Droogmans, G; Nilius, B				Watanabe, H; Vriens, J; Suh, SH; Benham, CD; Droogmans, G; Nilius, B			Heat-evoked activation of TRPV4 channels in a HEK293 cell expression system and in native mouse aorta endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSAICIN-RECEPTOR; CATION CHANNEL; SENSORY NEURONS; NOXIOUS HEAT; ION-CHANNEL; CURRENTS; MECHANISMS; PROTEIN; AGONIST; OTRPC4	We have compared activation by heat of TRPV4 channels, heterogeneously expressed in HEK293 cells, and endogenous channels in mouse aorta endothelium (MAEC). Increasing the temperature above 25degreesC activated currents and increased [Ca2+](i) in HEK293 cells transfected with TRPV4 and in MAEC. When compared with activation of TRPV4 currents by the selective ligand 4alphaPDD (alpha-phorbol 12,13-didecanoate), heat-activated currents in both systems showed the typical biophysical properties of currents through TRPV4, including their single channel conductance. Deletion of the three N-terminal ankyrin binding domains of TRPV4 abolished current activation cells by heat in HEK293. In inside-out patches, TRPV4 could not be activated by heat but still responded to the ligand 4alphaPDD. In MAEC, the same channel is activated under identical conditions as in the HEK expression system. Our data indicate that TRPV4 is a functional temperature-sensing channel in native endothelium, that is likely involved in temperature-dependent Ca2+ signaling. The failure to activate TRPV4 channels by heat in inside-out patches, which responded to 4alphaPDD, may indicate that heat activation depends on the presence of an endogenous ligand, which is missing in inside-out patches.	Katholieke Univ Leuven, Fysiol Lab, Dept Physiol, B-3000 Louvain, Belgium; GlaxoSmithKline, Neurol CEDD, Harlow CM19 5AW, Essex, England	KU Leuven; GlaxoSmithKline	Nilius, B (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Dept Physiol, Campus Gasthuisberg ,Herestr 49, B-3000 Louvain, Belgium.		Vriens, Joris/G-9966-2018	Vriens, Joris/0000-0002-2502-0409				Basavappa S, 1998, J NEUROPHYSIOL, V79, P1441, DOI 10.1152/jn.1998.79.3.1441; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Colbert HA, 1997, J NEUROSCI, V17, P8259; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Guler AD, 2002, J NEUROSCI, V22, P6408; Gunthorpe MJ, 2002, TRENDS PHARMACOL SCI, V23, P183, DOI 10.1016/S0165-6147(02)01999-5; Hoffmann EK, 2000, CELL PHYSIOL BIOCHEM, V10, P273, DOI 10.1159/000016356; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Minson CT, 2001, J APPL PHYSIOL, V91, P1619, DOI 10.1152/jappl.2001.91.4.1619; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Nilius B, 2001, PFLUG ARCH EUR J PHY, V443, P227, DOI 10.1007/s004240100676; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Schumacher MA, 2000, J BIOL CHEM, V275, P2756, DOI 10.1074/jbc.275.4.2756; Schwarz S, 2000, J PHYSIOL-LONDON, V528, P539, DOI 10.1111/j.1469-7793.2000.00539.x; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Suh SH, 1999, PFLUG ARCH EUR J PHY, V438, P612, DOI 10.1007/s004240051084; Szallasi A, 1999, PHARMACOL REV, V51, P159; Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Viana F, 2002, NAT NEUROSCI, V5, P254, DOI 10.1038/nn809; Voets T, 2002, J BIOL CHEM, V277, P33704, DOI 10.1074/jbc.M204828200; Vyklicky L, 1999, J PHYSIOL-LONDON, V517, P181, DOI 10.1111/j.1469-7793.1999.0181z.x; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Wei L, 2001, BMC Physiol, V1, P3, DOI 10.1186/1472-6793-1-3; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882	36	474	508	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47044	47051		10.1074/jbc.M208277200	http://dx.doi.org/10.1074/jbc.M208277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354759	Green Submitted, hybrid			2022-12-27	WOS:000179663700029
J	West, JM; Tsuruta, H; Kantrowitz, ER				West, JM; Tsuruta, H; Kantrowitz, ER			Stabilization of the R allosteric structure of Escherichia coli aspartate transcarbamoylase by disulfide bond formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTROPIC INTERACTIONS; HOMOTROPIC COOPERATIVITY; QUATERNARY STRUCTURE; KINETIC MECHANISM; CATALYTIC CHAIN; DOMAIN CLOSURE; TRANSITION; CARBAMOYLTRANSFERASE; MODEL; CONSEQUENCES	Here we report the first use of disulfide bond formation to stabilize the R allosteric structure of Escherichia coli aspartate transcarbamoylase. In the R allosteric state, residues in the 240s loop from two catalytic chains of different subunits are close together, whereas in the T allosteric state they are far apart. By substitution of Ala-241 in the 240s loop of the catalytic chain with cysteine, a disulfide bond was formed between two catalytic chains of different subunits. The cross-linked enzyme did not exhibit cooperativity for aspartate. The maximal velocity was increased, and the concentration of aspartate required to obtain one-half the maximal velocity, [Asp](0.5), was reduced substantially. Furthermore, the allosteric effectors ATP and CTP did not alter the activity of the cross-linked enzyme. When the disulfide bonds were reduced by the addition of 1,4-dithio-DL-threitol the resulting enzyme had kinetic parameters very similar to those observed for the wild-type enzyme and regained the ability to be activated by ATP and inhibited by CTP. Small-angle x-ray scattering was used to verify that the cross-linked enzyme was structurally locked in the R state and that this enzyme after reduction with 1,4-dithio-DL-threitol could undergo an allosteric transition similar to that of the wild-type enzyme. The complete abolition of homotropic and heterotropic regulation from stabilizing the 240s loop in its closed position in the R state, which forms the catalytically competent active site, demonstrates the significance that the quaternary structural change and closure of the 240s loop has in the functional mechanism of aspartate transcarbamoylase.	Boston Coll, Merkert Chem Ctr, Dept Chem, Chestnut Hill, MA 02467 USA; Stanford Linear Accelerator Ctr, Stanford Synchrotron Radiat Lab, Menlo Pk, CA 94025 USA	Boston College; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Kantrowitz, ER (corresponding author), Boston Coll, Merkert Chem Ctr, Dept Chem, Chestnut Hill, MA 02467 USA.				NCRR NIH HHS [P41RR01209] Funding Source: Medline; NIGMS NIH HHS [GM26237] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026237] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER DP, 1993, BIOCHEMISTRY-US, V32, P10150, DOI 10.1021/bi00089a034; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN WWC, 1981, CAN J BIOCHEM CELL B, V59, P461, DOI 10.1139/o81-064; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P680; ENNS CA, 1979, J BIOL CHEM, V254, P6180; ENNS CA, 1978, J BIOL CHEM, V253, P2511; FETLER L, 1995, BIOCHEMISTRY-US, V34, P15654, DOI 10.1021/bi00048a008; GERHART JC, 1968, BIOCHEMISTRY-US, V7, P538, DOI 10.1021/bi00842a600; GERHART JC, 1967, J BIOL CHEM, V242, P2886; GERHART JC, 1962, J BIOL CHEM, V237, P891; HOWLETT GJ, 1977, BIOCHEMISTRY-US, V16, P5091, DOI 10.1021/bi00642a023; HSUANYU Y, 1989, BIOCHIM BIOPHYS ACTA, V995, P54, DOI 10.1016/0167-4838(89)90232-X; HSUANYU Y, 1987, ARCH BIOCHEM BIOPHYS, V259, P316, DOI 10.1016/0003-9861(87)90498-X; Jin L, 1999, PROTEINS, V37, P729, DOI 10.1002/(SICI)1097-0134(19991201)37:4<729::AID-PROT21>3.0.CO;2-F; KANTROWITZ ER, 1988, SCIENCE, V241, P669, DOI 10.1126/science.3041592; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BH, 1995, J BIOL CHEM, V270, P15620, DOI 10.1074/jbc.270.26.15620; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOODY MF, 1979, J MOL BIOL, V133, P517, DOI 10.1016/0022-2836(79)90405-4; NEWTON CJ, 1990, BIOCHEMISTRY-US, V29, P1444, DOI 10.1021/bi00458a015; NEWTON CJ, 1990, P NATL ACAD SCI USA, V87, P2309, DOI 10.1073/pnas.87.6.2309; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; PASTRALANDIS SC, 1978, J BIOL CHEM, V253, P4624; PERBAL B, 1972, J MOL BIOL, V70, P511, DOI 10.1016/0022-2836(72)90556-6; Sakash JB, 2000, J BIOL CHEM, V275, P752, DOI 10.1074/jbc.275.2.752; SCHACHMAN HK, 1988, J BIOL CHEM, V263, P18583; SILVER RS, 1983, J MOL BIOL, V168, P729, DOI 10.1016/S0022-2836(83)80072-2; STEVENS RC, 1990, BIOCHEMISTRY-US, V29, P7691, DOI 10.1021/bi00485a019; TAUC P, 1994, PROTEIN SCI, V3, P1998, DOI 10.1002/pro.5560031112; TAUC P, 1982, J MOL BIOL, V155, P155, DOI 10.1016/0022-2836(82)90442-9; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WILD JR, 1989, P NATL ACAD SCI USA, V86, P46, DOI 10.1073/pnas.86.1.46; XU W, 1988, BIOCHEMISTRY-US, V27, P5507, DOI 10.1021/bi00415a018	40	8	8	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47300	47304		10.1074/jbc.M209913200	http://dx.doi.org/10.1074/jbc.M209913200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359710	hybrid			2022-12-27	WOS:000179663700060
J	Aiello, DP; Fu, LW; Miseta, A; Bedwell, DM				Aiello, DP; Fu, LW; Miseta, A; Bedwell, DM			Intracellular glucose 1-phosphate and glucose 6-phosphate levels modulate Ca2+ homeostasis in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN COUPLED RECEPTOR; YEAST SECRETORY PATHWAY; TRANSCRIPTION FACTOR; H+/CA2+ EXCHANGE; GENE-EXPRESSION; CALCIUM INFLUX; CA-2+ INFLUX; LACKING PMR1; PUMP PMR1; PHOSPHOGLUCOMUTASE	The enzyme phosphoglucomutase plays a key role in cellular metabolism by virtue of its ability to interconvert Glc-1-P and Glc-6-P. It was recently shown that a yeast strain lacking the major isoform of phosphoglucomutase (pgm2Delta) accumulates a high level of Glc-1-P and exhibits several phenotypes related to altered Ca2+ homeostasis when D-galactose is utilized as the carbon source (Fu, L., Miseta, A., Hunton, D., Marchase, R. B., and Bedwell, D. M. (2000) J. Biol. Chem 275, 5431-5440). These phenotypes include increased Ca2+ uptake and accumulation and sensitivity to high environmental Ca2+ levels. In the present study, we overproduced the enzyme UDP-Glc pyrophosphorylase to test whether the overproduction of a downstream metabolite produced from Glc-1-P can also mediate changes in Ca2+ homeostasis. We found that overproduction of UDP-Glc did not cause any alterations in Ca2+ uptake or accumulation. We also examined whether Glc-6-P can influence cellular Ca2+ homeostasis. A yeast strain lacking the beta-subunit of phosphofructokinase (ptk2Delta) accumulates a high level of Glc-6-P (Huang, D., Wilson, W. A., and Roach, P. J. (1997) J. BioL Chem. 272, 22495-22501). We found that this increase in Glc-6-P led to a 1.5-2-fold increase in total cellular Ca2+. We also found that the pgm2Delta/pfk2Delta strain, which accumulated high levels of both Glc-6-P and Glc-1-P, no longer exhibited the Ca2+-related phenotypes associated with high Glc-1-P levels in the pgm2Delta mutant. These results provide strong evidence that cellular Ca2+ homeostasis is coupled to the relative levels of Glc-6-P and Glc-1-P in yeast.	Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Univ Pecs, Sch Med, Dept Clin Chem, H-7624 Pecs, Hungary	University of Alabama System; University of Alabama Birmingham; University of Pecs	Bedwell, DM (corresponding author), Univ Alabama, Dept Microbiol, BBRB 432,Box 8,1530 3rd Ave S, Birmingham, AL 35294 USA.			Bedwell, David/0000-0002-6605-818X; Fu, Karl/0000-0001-5386-9429; Miseta, Attila/0000-0002-7984-3347				Adams Alison, 1997, P99; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; ARVANITIDIS A, 1994, J BIOL CHEM, V269, P8911; BENEDETTI A, 1988, J BIOL CHEM, V263, P3466; BENEDETTI A, 1985, BIOCHIM BIOPHYS ACTA, V816, P267, DOI 10.1016/0005-2736(85)90494-8; BERGER W, 1984, HUM NEUROBIOL, V3, P163; BERGMEYER HU, 1985, METHOD ENZYMAT AN, V7, P524; Bonilla M, 2002, EMBO J, V21, P2343, DOI 10.1093/emboj/21.10.2343; Chen PY, 1998, DIABETES, V47, P874, DOI 10.2337/diabetes.47.6.874; Colombo S, 1998, EMBO J, V17, P3326, DOI 10.1093/emboj/17.12.3326; Coons DM, 1997, YEAST, V13, P9, DOI 10.1002/(SICI)1097-0061(199701)13:1<9::AID-YEA51>3.0.CO;2-U; Cronin SR, 2002, J CELL BIOL, V157, P1017, DOI 10.1083/jcb.200203052; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; DARAN JM, 1995, EUR J BIOCHEM, V233, P520, DOI 10.1111/j.1432-1033.1995.520_2.x; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; DEY NB, 1994, J BIOL CHEM, V269, P27143; Dlugai S, 2001, FEBS LETT, V505, P389, DOI 10.1016/S0014-5793(01)02854-X; DUNN T, 1994, J BIOL CHEM, V269, P7273; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; EILAM Y, 1990, J GEN MICROBIOL, V136, P2537, DOI 10.1099/00221287-136-12-2537; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; Fu LW, 2000, J BIOL CHEM, V275, P5431, DOI 10.1074/jbc.275.8.5431; FU LW, 1995, J BACTERIOL, V177, P3087, DOI 10.1128/jb.177.11.3087-3094.1995; FULCERI R, 1990, BIOCHIM BIOPHYS ACTA, V1022, P129, DOI 10.1016/0005-2736(90)90409-H; Gerin I, 2002, FEBS LETT, V517, P257, DOI 10.1016/S0014-5793(02)02640-6; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; Halachmi D, 1996, FEBS LETT, V392, P194, DOI 10.1016/0014-5793(96)00799-5; Huang DQ, 1997, J BIOL CHEM, V272, P22495, DOI 10.1074/jbc.272.36.22495; IIDA H, 1990, J BIOL CHEM, V265, P13391; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kraakman L, 1999, MOL MICROBIOL, V32, P1002, DOI 10.1046/j.1365-2958.1999.01413.x; Lafuente MJ, 2000, MOL MICROBIOL, V35, P161, DOI 10.1046/j.1365-2958.2000.01688.x; Lin BC, 2000, HUM GENET, V107, P526, DOI 10.1007/s004390000404; Lin BC, 1998, J BIOL CHEM, V273, P31656, DOI 10.1074/jbc.273.48.31656; Locke EG, 2000, MOL CELL BIOL, V20, P6686, DOI 10.1128/MCB.20.18.6686-6694.2000; LU M, 1994, J BACTERIOL, V176, P5847, DOI 10.1128/JB.176.18.5847-5851.1994; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARCHASE RB, 1993, J BIOL CHEM, V268, P8341; Marchi V, 1999, FEBS LETT, V454, P181, DOI 10.1016/S0014-5793(99)00803-0; MARSHALLCARLSON L, 1990, MOL CELL BIOL, V10, P1105, DOI 10.1128/MCB.10.3.1105; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Miseta A, 1999, J BIOL CHEM, V274, P5939, DOI 10.1074/jbc.274.9.5939; Miseta A, 1999, FEBS LETT, V451, P132, DOI 10.1016/S0014-5793(99)00519-0; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; OH D, 1990, MOL CELL BIOL, V10, P1415, DOI 10.1128/MCB.10.4.1415; Ozcan S, 1998, EMBO J, V17, P2566, DOI 10.1093/emboj/17.9.2566; Palmer CP, 2001, P NATL ACAD SCI USA, V98, P7801, DOI 10.1073/pnas.141036198; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Putney James W. Jr, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P143; Rolland F, 2000, MOL MICROBIOL, V38, P348, DOI 10.1046/j.1365-2958.2000.02125.x; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Schmidt MC, 1999, MOL CELL BIOL, V19, P4561; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; Strayle J, 1999, EMBO J, V18, P4733, DOI 10.1093/emboj/18.17.4733; Suzuki C, 1999, MOL MICROBIOL, V32, P813, DOI 10.1046/j.1365-2958.1999.01400.x; Tisi R, 2002, FEBS LETT, V520, P133, DOI 10.1016/S0014-5793(02)02806-5; Yoshimoto H, 2002, J BIOL CHEM, V277, P31079, DOI 10.1074/jbc.M202718200	60	31	32	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45751	45758		10.1074/jbc.M208748200	http://dx.doi.org/10.1074/jbc.M208748200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351653	hybrid			2022-12-27	WOS:000179529300006
J	Bellemare, DR; Shaner, L; Morano, KA; Beaudoin, J; Langlois, J; Labbe, S				Bellemare, DR; Shaner, L; Morano, KA; Beaudoin, J; Langlois, J; Labbe, S			Ctr6, a vacuolar membrane copper transporter in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; METAL-ION TRANSPORT; SACCHAROMYCES-CEREVISIAE; IRON UPTAKE; FISSION YEAST; MOLECULAR CHARACTERIZATION; METALLOCHAPERONE COX17; SUPEROXIDE-DISMUTASE; MUTATIONAL ANALYSIS; FERRIC REDUCTASE	Aerobic organisms possess efficient systems for the transport of copper. This involves transporters that mediate the passage of copper across biological membranes to reach essential intracellular copper-requiring enzymes. In this report, we identify a new copper transporter in Schizosaccharomyces pombe, encoded by the ctr6(+) gene. The transcription of ctr6(+) is induced under copper-limiting conditions. This regulation is mediated by the cis-acting promoter element CuSE (copper-signaling element) through the copper-sensing transcription factor Cuf1. An S. pombe strain bearing a disrupted ctr6Delta allele displays a strong reduction of copper,zinc superoxide dismutase activity. When the ctr6+ gene is overexpressed from the thiamine-inducible nmt1(+) promoter, the cells are unable to grow on medium containing exogenous copper. Surprisingly, this copper-sensitive growth phenotype is not due to an increase of copper uptake at the cell surface. Instead, copper delivery across the plasma membrane is reduced. Consistently, this results in repressing ctr4(+) gene expression. By using a functional ctr6(+) epitope-tagged allele expressed under the control of its own promoter, we localize the Ctr6 protein on the membrane of vacuoles. Furthermore, we demonstrate that Ctr6 is an integral membrane protein that can trimerize. Moreover, we show that Ctr6 harbors a putative copper-binding Met-X-His-Cys-X-Met-X-Met motif in the amino terminus, which is essential for its function. Our findings suggest that under conditions in which copper is scarce, Ctr6 is required as a means to mobilize stored copper from the vacuole to the cytosol.	Univ Sherbrooke, Dept Biochim, Fac Med, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Dept Med Nucl & Radiobiol, Fac Med, Sherbrooke, PQ J1H 5N4, Canada; CHU Sherbrooke, Sherbrooke PET Ctr, Sherbrooke, PQ J1H 5N4, Canada; Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	University of Sherbrooke; University of Sherbrooke; University of Sherbrooke; University of Texas System	Labbe, S (corresponding author), Univ Sherbrooke, Dept Biochim, Fac Med, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	Simon.Labbe@USherbrooke.ca		Morano, Kevin/0000-0002-5992-0253; Labbe, Simon/0000-0002-4947-523X				ALFA C, 1993, EXPT FISSION YEASTS; Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; Beaudoin J, 2001, J BIOL CHEM, V276, P15472, DOI 10.1074/jbc.M011256200; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Beers J, 2002, J BIOL CHEM, V277, P22185, DOI 10.1074/jbc.M202545200; Bellemare DR, 2001, GENE, V273, P191, DOI 10.1016/S0378-1119(01)00591-1; Bezanilla M, 1997, MOL BIOL CELL, V8, P2693, DOI 10.1091/mbc.8.12.2693; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; COTTAREL G, 1993, CURR GENET, V23, P547, DOI 10.1007/BF00312650; Crapo J D, 1978, Methods Enzymol, V53, P382; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; Dancis A, 1998, J PEDIATR-US, V132, pS24, DOI 10.1016/S0022-3476(98)70524-4; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; Eide DJ, 2000, ADV MICROB PHYSIOL, V43, P1, DOI 10.1016/S0065-2911(00)43001-8; EIDE DJ, 1993, MOL GEN GENET, V241, P447, DOI 10.1007/BF00284699; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Forsburg SL, 1997, GENE, V191, P191, DOI 10.1016/S0378-1119(97)00058-9; Forsburg SL, 2000, NAT GENET, V25, P263, DOI 10.1038/77015; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; Gaits F, 1999, MOL BIOL CELL, V10, P2647, DOI 10.1091/mbc.10.8.2647; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; KAMPFENKEL K, 1995, J BIOL CHEM, V270, P28479, DOI 10.1074/jbc.270.47.28479; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; KNIGHT SAB, 1994, MOL CELL BIOL, V14, P7792, DOI 10.1128/MCB.14.12.7792; Koch KA, 1996, MOL CELL BIOL, V16, P724; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Labbe S, 1999, TRENDS MICROBIOL, V7, P500, DOI 10.1016/S0966-842X(99)01638-8; Labbe Simon, 2002, P571; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; McNabb DS, 1997, BIOTECHNIQUES, V22, P1134, DOI 10.2144/97226rr01; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Pasion SG, 1999, MOL BIOL CELL, V10, P4043, DOI 10.1091/mbc.10.12.4043; Pelletier B, 2002, J BIOL CHEM, V277, P22950, DOI 10.1074/jbc.M202682200; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; PREDKI PF, 1992, J BIOL CHEM, V267, P5842; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rentzsch A, 1999, CURR GENET, V35, P103, DOI 10.1007/s002940050438; Szczypka MS, 1997, YEAST, V13, P1423, DOI 10.1002/(SICI)1097-0061(199712)13:15<1423::AID-YEA190>3.3.CO;2-3; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; Veenhoff LM, 2002, TRENDS BIOCHEM SCI, V27, P242, DOI 10.1016/S0968-0004(02)02077-7; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhou H, 2001, J BIOL CHEM, V276, P20529, DOI 10.1074/jbc.M102004200	72	67	71	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46676	46686		10.1074/jbc.M206444200	http://dx.doi.org/10.1074/jbc.M206444200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244050	hybrid			2022-12-27	WOS:000179529300126
J	Garrel, G; Lozach, A; Bachir, LK; Laverriere, JN; Counis, R				Garrel, G; Lozach, A; Bachir, LK; Laverriere, JN; Counis, R			Pituitary adenylate cyclase-activating polypeptide stimulates nitric-oxide synthase type I expression and potentiates the cGMP response to gonadotropin-releasing hormone of rat pituitary gonadotrophs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; NEURONAL NADPH DIAPHORASE; LUTEINIZING-HORMONE; GROWTH-HORMONE; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; RECEPTOR GENE; CYCLIC-AMP; NATRIURETIC PEPTIDE; ALPHA-T3-1 CELLS	Nitric-oxide synthase type I (NOS I) is expressed primarily in gonadotrophs and in folliculo-stellate cells of the anterior pituitary. In gonadotrophs, the expression and the activity of NOS I are stimulated by gonadotropin-releasing hormone (GnRH) under both experimental and physiological conditions. In the present study, we show that pituitary adenylate cyclase-activating polypeptide (PACAP) is twice as potent as GnRH at increasing NOS I levels in cultured rat anterior pituitary cells. The action of PACAP is detectable after 4-6 h and maximal at 24 h, this effect is mimicked by 8-bromo-cAMP and cholera toxin and suppressed by H89 suggesting a mediation through the cAMP pathway. Surprisingly, NADPH diaphorase staining revealed that these changes occurred in gonadotrophs exclusively although PACAP and cAMP, in contrast to GnRH, have the potential to target several types of pituitary cells including folliculo-stellate cells. There was no measurable alteration in NOS I mRNA levels after cAMP or PACAP induction. PACAP also stimulated cGMP synthesis, which was maximal within 15 min and independent of cAMP, however, only part resulted from NOS I/soluble guanylate cyclase activation implying that in contrast to GnRH, PACAP has a dual mechanism in cGMP production. Interestingly, induction of NOS I by PACAP markedly enhanced the capacity of gonadotrophs to produce cGMP in response to GnRH. The fact that PACAP may act on gonadotrophs to alter NOS I levels, generate cGMP, and potentiate the cGMP response to GnRH, suggests that cGMP could play important cellular functions.	Univ Paris 06, CNRS, UMR 7079, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Counis, R (corresponding author), Univ Paris 06, CNRS, UMR 7079, Case 256, F-75252 Paris 05, France.	Raymond.Counis@snv.jussieu.fr	Laverriere, Jean-Noel/L-3286-2017; GARREL, Ghislaine/L-2654-2017	Laverriere, Jean-Noel/0000-0003-0442-1358; GARREL, Ghislaine/0000-0001-8547-1191				Alarid ET, 1996, DEVELOPMENT, V122, P3319; Andric SA, 2001, J BIOL CHEM, V276, P844, DOI 10.1074/jbc.M004406200; Bachir LK, 2001, ENDOCRINOLOGY, V142, P4631, DOI 10.1210/en.142.11.4631; Belsham DD, 1996, EMBO J, V15, P538, DOI 10.1002/j.1460-2075.1996.tb00386.x; BHAT GK, 1995, NEUROENDOCRINOLOGY, V62, P187, DOI 10.1159/000127004; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CECCATELLI S, 1993, P NATL ACAD SCI USA, V90, P11292, DOI 10.1073/pnas.90.23.11292; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Choi EJ, 2000, MOL BRAIN RES, V80, P35, DOI 10.1016/S0169-328X(00)00116-9; COUNIS R, 1991, TRENDS ENDOCRIN MET, V2, P181, DOI 10.1016/1043-2760(91)90016-G; COUNIS R, 1999, ENCY REPROD, V2, P507; CULLER MD, 1991, ENDOCRINOLOGY, V129, P2260, DOI 10.1210/endo-129-4-2260; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; DUHAU L, 1991, J IMMUNOASSAY, V12, P233, DOI 10.1080/01971529108055069; DUVILANSKI BH, 1995, P NATL ACAD SCI USA, V92, P170, DOI 10.1073/pnas.92.1.170; Evans JJ, 1999, ENDOCR REV, V20, P46, DOI 10.1210/er.20.1.46; Fowkes RC, 2000, J ENDOCRINOL, V166, P195, DOI 10.1677/joe.0.1660195; Fowkes RC, 2000, TRENDS ENDOCRIN MET, V11, P333, DOI 10.1016/S1043-2760(00)00288-5; FOWKES RC, 2002, 84 ANN M END SOC SAN, P332; FRANDSEN EK, 1976, LIFE SCI, V18, P529, DOI 10.1016/0024-3205(76)90331-3; Garrel G, 1998, ENDOCRINOLOGY, V139, P2163, DOI 10.1210/en.139.4.2163; GARREL G, 1995, NEUROENDOCRINOLOGY, V62, P514, DOI 10.1159/000127042; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; Gobbetti A, 1999, BIOL REPROD, V60, P1217, DOI 10.1095/biolreprod60.5.1217; Grandclement B, 1995, J NEUROENDOCRINOL, V7, P939, DOI 10.1111/j.1365-2826.1995.tb00739.x; GUPTA RK, 1979, CLIN CHEM, V25, P752; Harmar AJ, 1998, PHARMACOL REV, V50, P265; HART GR, 1992, J ENDOCRINOL, V134, P33, DOI 10.1677/joe.0.1340033; HARTT DJ, 1995, BIOCHEM BIOPH RES CO, V214, P918, DOI 10.1006/bbrc.1995.2374; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KATO M, 1992, ENDOCRINOLOGY, V131, P2133, DOI 10.1210/en.131.5.2133; KAWAKAMI M, 1980, ENDOCRINOLOGY, V106, P626, DOI 10.1210/endo-106-2-626; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Kostic TS, 2001, MOL ENDOCRINOL, V15, P1010, DOI 10.1210/me.15.6.1010; Koves K, 1996, ANN NY ACAD SCI, V805, P648; LERRANT Y, 1995, ENDOCRINOLOGY, V136, P2803, DOI 10.1210/en.136.7.2803; LLOYD RV, 1995, AM J PATHOL, V146, P86; Lozach A, 1998, MOL CELL ENDOCRINOL, V143, P43, DOI 10.1016/S0303-7207(98)00135-X; MATTERI RL, 1987, DOMEST ANIM ENDOCRIN, V4, P157, DOI 10.1016/0739-7240(87)90011-7; MCARDLE CA, 1994, ENDOCRINOLOGY, V134, P2599, DOI 10.1210/en.134.6.2599; McArdle CA, 1996, TRENDS ENDOCRIN MET, V7, P168, DOI 10.1016/1043-2760(96)00051-3; Mitchell P, 2001, CURR OPIN CELL BIOL, V13, P320, DOI 10.1016/S0955-0674(00)00214-3; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Murthy KS, 1998, AM J PHYSIOL-CELL PH, V275, pC1409, DOI 10.1152/ajpcell.1998.275.6.C1409; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; NAOR Z, 1980, ENDOCRINOLOGY, V107, P1438, DOI 10.1210/endo-107-5-1438; NAOR Z, 1980, J BIOL CHEM, V255, P342; Pincas H, 2001, MOL ENDOCRINOL, V15, P319, DOI 10.1210/me.15.2.319; Pincas H, 2001, J BIOL CHEM, V276, P23562, DOI 10.1074/jbc.M100563200; Pinilla L, 1999, HORM RES, V51, P242, DOI 10.1159/000023378; Pinilla L, 1999, J ENDOCRINOL INVEST, V22, P340, DOI 10.1007/BF03343571; Prevot V, 2000, BRAIN RES REV, V34, P27, DOI 10.1016/S0165-0173(00)00035-7; Qian X, 1999, ENDOCRINE, V11, P123, DOI 10.1385/ENDO:11:2:123; Rawlings SR, 1996, ENDOCR REV, V17, P4, DOI 10.1210/er.17.1.4; SCHOMERUS E, 1994, ENDOCRINOLOGY, V134, P315, DOI 10.1210/en.134.1.315; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; SPENGLER D, 1992, MOL ENDOCRINOL, V6, P1931, DOI 10.1210/me.6.11.1931; STEINER AL, 1972, J BIOL CHEM, V247, P1106; TATSUNO I, 1991, ENDOCRINOLOGY, V129, P1797, DOI 10.1210/endo-129-4-1797; Thomas P, 1996, ENDOCRINOLOGY, V137, P2979, DOI 10.1210/en.137.7.2979; TSUJII T, 1994, ENDOCRINOLOGY, V135, P826, DOI 10.1210/en.135.3.826; TSUJII T, 1995, LIFE SCI, V56, P1103, DOI 10.1016/0024-3205(95)00047-A; TSUJII T, 1995, MOL CELL ENDOCRINOL, V113, P123, DOI 10.1016/0303-7207(95)03613-C; Vankelecom H, 1997, MOL CELL ENDOCRINOL, V129, P157, DOI 10.1016/S0303-7207(97)04054-9; Vaudry D, 2000, PHARMACOL REV, V52, P269; Wang Y, 1999, CRIT REV NEUROBIOL, V13, P21, DOI 10.1615/CritRevNeurobiol.v13.i1.20; Wang Y, 1999, P NATL ACAD SCI USA, V96, P12150, DOI 10.1073/pnas.96.21.12150; Yamada K, 1997, NEUROENDOCRINOLOGY, V65, P147, DOI 10.1159/000127175; Yu WH, 1997, ENDOCRINOLOGY, V138, P5055, DOI 10.1210/en.138.11.5055; ZWILLER J, 1981, BIOCHEM BIOPH RES CO, V101, P1381, DOI 10.1016/0006-291X(81)91600-4	72	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46391	46401		10.1074/jbc.M203763200	http://dx.doi.org/10.1074/jbc.M203763200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244042	hybrid			2022-12-27	WOS:000179529300090
J	Petris, MJ; Voskoboinik, I; Cater, M; Smith, K; Kim, BE; Llanos, RM; Strausak, D; Camakaris, J; Mercer, JFB				Petris, MJ; Voskoboinik, I; Cater, M; Smith, K; Kim, BE; Llanos, RM; Strausak, D; Camakaris, J; Mercer, JFB			Copper-regulated trafficking of the Menkes disease copper ATPase is associated with formation of a phosphorylated catalytic intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; INTRACELLULAR-LOCALIZATION; DEPENDENT TRAFFICKING; FUNCTIONAL EXPRESSION; PLASMA-MEMBRANE; BIOCHEMICAL-CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; MURINE HOMOLOG; BINDING SITES; PROTEIN	The Menkes protein (MNK; ATP7A) is a copper-transporting P-type ATPase that is defective in the copper deficiency disorder, Menkes disease. MINK is localized in the trans-Golgi network and transports copper to enzymes synthesized within secretory compartments. However, in cells exposed to excessive copper, MNK traffics to the plasma membrane where it functions in copper efflux. A conserved feature of all P-type ATPases is the formation of an acyl-phosphate intermediate, which occurs as part of the catalytic cycle during cation transport. In this study we investigated the effect of mutations within conserved catalytic regions of MNK on intracellular localization and trafficking from the trans-Golgi network (TGN). Our findings suggest that mutations that block formation of the phosphorylated catalytic intermediate also prevent copper-induced relocalization of MNK from the TGN. Furthermore, mutations in the phosphatase domain, which resulted in hyperphosphorylation. of MNK, caused constitutive trafficking from the TGN to the plasma membrane. A similar effect on trafficking was observed with a phosphatase mutation in the closely related copper ATPase, ATP7B, affected in Wilson disease. These findings suggest that the copper-induced trafficking of the Menkes and Wilson disease copper ATPases is associated with the phosphorylated intermediate that is formed during the catalysis of these pumps. Our findings describe a novel mechanism for regulating the subcellular location of a transport protein involving the recognition of intermediate conformations during catalysis.	Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA; Univ Melbourne, Dept Genet, Melbourne, Vic 3010, Australia; Deakin Univ, Ctr Cellular & Mol Biol, Melbourne, Vic 3125, Australia	University of Missouri System; University of Missouri Columbia; University of Melbourne; Deakin University	Petris, MJ (corresponding author), Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA.		Mercer, Julian/R-8583-2019	Voskoboinik, Ilia/0000-0002-6410-009X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059893] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59893] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ambrosini L, 1999, HUM MOL GENET, V8, P1547, DOI 10.1093/hmg/8.8.1547; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Bissig KD, 2001, BIOCHEM J, V357, P217, DOI 10.1042/0264-6021:3570217; CAMAKARIS J, 1995, HUM MOL GENET, V4, P2117, DOI 10.1093/hmg/4.11.2117; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Danks D. M, 1995, METABOLIC BASIS INHE, VI, P2211; Forbes JR, 1998, AM J HUM GENET, V63, P1663, DOI 10.1086/302163; Forbes JR, 2000, HUM MOL GENET, V9, P1927, DOI 10.1093/hmg/9.13.1927; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Goodyer ID, 1999, HUM MOL GENET, V8, P1473, DOI 10.1093/hmg/8.8.1473; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Kaler SG, 1996, NAT GENET, V13, P21, DOI 10.1038/ng0596-21; La Fontaine S, 1998, J BIOL CHEM, V273, P31375; La Fontaine S, 2001, HUM MOL GENET, V10, P361, DOI 10.1093/hmg/10.4.361; La Fontaine S, 1999, HUM MOL GENET, V8, P1069, DOI 10.1093/hmg/8.6.1069; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ogawa A, 1999, J HUM GENET, V44, P206, DOI 10.1007/s100380050144; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; PAYNTER JA, 1994, FEBS LETT, V351, P186, DOI 10.1016/0014-5793(94)00868-X; Petris MJ, 1999, HUM MOL GENET, V8, P2107, DOI 10.1093/hmg/8.11.2107; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 2000, HUM MOL GENET, V9, P2845, DOI 10.1093/hmg/9.19.2845; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG639, DOI 10.1152/ajpgi.1999.276.3.G639; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Terada K, 1998, J BIOL CHEM, V273, P1815, DOI 10.1074/jbc.273.3.1815; Tsivkovskii R, 2002, J BIOL CHEM, V277, P976, DOI 10.1074/jbc.M109368200; Tumer Z, 1999, ADV EXP MED BIOL, V448, P83; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; Yoshimizu T, 1998, BIOSCI BIOTECH BIOCH, V62, P1258, DOI 10.1271/bbb.62.1258	37	100	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46736	46742		10.1074/jbc.M208864200	http://dx.doi.org/10.1074/jbc.M208864200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12228238	hybrid, Green Submitted			2022-12-27	WOS:000179529300133
J	Ito, J; Nagayasu, Y; Ueno, S; Yokoyama, S				Ito, J; Nagayasu, Y; Ueno, S; Yokoyama, S			Apolipoprotein-mediated cellular lipid release requires replenishment of sphingomyelin in a phosphatidylcholine-specific phospholipase C-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HIGH-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; BINDING CASSETTE TRANSPORTER-1; TANGIER-DISEASE; CHOLESTEROL EFFLUX; MEMBRANE; INHIBITION; MUTATIONS; BREAKDOWN	When sphingomyelin is digested by sphingomyelinase in the plasma membrane of rat astrocytes, productions of sphingomyelin, diacylglycerol, and phosphatidylcholine are stimulated. D609, an inhibitor of phosphatidylcholine-specific phospholipase C, suppressed these effects. Similarly, when apolipoprotein A-I removed cellular cholesterol, phosphatidylcholine, and sphingomyelin to generate high density lipoprotein, cholesterol synthesis from acetate subsequently increased, and sphingomyelin synthesis from acetate and serine also increased. D609 inhibited these effects again. D609 also inhibited the cholesterol removal by apoA-I not only from the astrocytes but also from BALB/3T3 and RAW264 cells. D609 decreased cholesterol synthesis, although D609 did not directly inhibit hydroxymethylglutaryl-CoA reductase. ApoA-I-stimulated translocation of newly synthesized cholesterol to cytosol was also decreased by D609. A diacylglycerol analog increased the apoA-I-mediated cholesterol release, whereas ceramide did not influence it. We concluded that removal of cellular sphingomyelin by apolipoproteins is replenished by transfer of phosphorylcholine from phosphatidylcholine to ceramide, and this reaction may limit the removal of cholesterol by apoA-I. This reaction also produces diacylglycerol that potentially triggers subsequent cellular signal cascades and regulates intracellular cholesterol trafficking.	Nagoya City Univ, Grad Sch Med Sci, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Yokoyama, S (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Mizuho Ku, Kawasumi 1,Mizuho Cho, Nagoya, Aichi 4678601, Japan.							Amtmann E, 1996, DRUG EXP CLIN RES, V22, P287; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arakawa R, 2000, J LIPID RES, V41, P1952; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHEN H, 1993, J LIPID RES, V34, P2159; DUSSERRE E, 1994, BIOCHEM MED METAB B, V52, P45, DOI 10.1006/bmmb.1994.1032; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Francis GA, 1996, BIOCHEMISTRY-US, V35, P15188, DOI 10.1021/bi9618169; GUPTA AK, 1991, J LIPID RES, V32, P125; Ito J, 1999, J NEUROCHEM, V72, P2362, DOI 10.1046/j.1471-4159.1999.0722362.x; Ito J, 2000, J LIPID RES, V41, P894; Ito J, 2002, J BIOL CHEM, V277, P7929, DOI 10.1074/jbc.M103878200; KANEKO I, 1978, EUR J BIOCHEM, V87, P313; KATO T, 1984, BRAIN RES, V301, P83, DOI 10.1016/0006-8993(84)90405-0; LI QQ, 1993, BIOCHEMISTRY-US, V32, P4597, DOI 10.1021/bi00068a016; Li QQ, 1997, BIOCHEMISTRY-US, V36, P12045, DOI 10.1021/bi970079t; LI QQ, 1995, J BIOL CHEM, V270, P26216, DOI 10.1074/jbc.270.44.26216; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; LUNDKATZ S, 1988, BIOCHEMISTRY-US, V27, P3416, DOI 10.1021/bi00409a044; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MULLERDECKER K, 1989, BIOCHEM BIOPH RES CO, V162, P198, DOI 10.1016/0006-291X(89)91981-5; NAZIH H, 1994, ARTERIOSCLER THROMB, V14, P1321, DOI 10.1161/01.ATV.14.8.1321; NISHIKAWA O, 1986, J BIOCHEM, V99, P295, DOI 10.1093/oxfordjournals.jbchem.a135473; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SAUER G, 1984, P NATL ACAD SCI-BIOL, V81, P3263, DOI 10.1073/pnas.81.11.3263; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; Tomimoto S, 2001, ARTERIOSCL THROM VAS, V21, P394, DOI 10.1161/01.ATV.21.3.394; Ueno S, 2002, BBA-MOL CELL RES, V1589, P261, DOI 10.1016/S0167-4889(02)00181-7; VANBLITTERSWIJK WJ, 1987, BIOCHEMISTRY-US, V26, P1746, DOI 10.1021/bi00380a038; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; WU YQ, 1992, ENDOCRINOLOGY, V131, P2935, DOI 10.1210/en.131.6.2935; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9	36	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44709	44714		10.1074/jbc.M208379200	http://dx.doi.org/10.1074/jbc.M208379200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228236	hybrid			2022-12-27	WOS:000179404800016
J	Latif, R; Graves, P; Davies, TF				Latif, R; Graves, P; Davies, TF			Ligand-dependent inhibition of oligomerization at the human thyrotropin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; DELTA-OPIOID RECEPTOR; PROTEIN-COUPLED RECEPTORS; LUTEINIZING-HORMONE RECEPTORS; TSH RECEPTOR; TRANSFER MICROSCOPY; LIVING CELLS; EXTRACELLULAR DOMAIN; FLUORESCENT PROTEIN; PLASMA-MEMBRANE	Recently, several studies have reported oligomerization of G protein-coupled receptors, although the functional implications of this phenomenon are still unclear. Using fluorescence resonance energy transfer (FRET) and coimmunoprecipitation (COIP), we previously reported that the human thyrotropin (TSH) receptor tagged with green fluorescent protein (TSHRGFP) and expressed in a heterologous system was present as oligomeric complexes on the cell surface. Here, we have extended this biophysical and biochemical approach to study the regulation of such oligomeric complexes. Co-expression of TSHRGFP and TSHRMyc constructs in Chinese hamster ovary cells resulted in FRET-positive cells. The specificity of the FRET signal was verified by the absence of energy transfer in individually transfected TSHRGFP and TSHRMyc:Cy3 cells cultured together and also by acceptor photobleaching. Occupation of the receptor molecule by the ligand (TSH) resulted in a dose-dependent decrease in the FRET index from 20% in the absence of TSH to <1% with 10(3) microunits/ml of TSH. Such reduction in oligomeric forms was also confirmed by coimmunoprecipitation. Exposure of TSHRGFP/Myc cells to forskolin or cytochalasin D caused no change in the FRET index, confirming that the decrease in the oligomeric complexes was a receptor-dependent phenomenon and free of energy or microtuble requirements. The TSH-induced decrease in TSHR oligomers was found to be secondary to dissociation of the TSHR complexes as evidenced by an increase in fluorescent intensity of photobleached spots of GFP fluorescence with 10(3) microunits/ml of TSH. These data indicated that the less active conformation of the TSHR was comprised of receptor complexes and that such complexes were dissociated on the binding of ligand. Such observations support the concept of a constitutively active TSHR dimer or monomer that is naturally inhibited by the formation of higher order complexes. Inhibition of these oligomeric forms by ligand binding returns the TSHR to an activated state.	Mt Sinai Sch Med, Dept Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Latif, R (corresponding author), Mt Sinai Sch Med, Dept Med, Div Endocrinol Diabet & Bone Dis, Box 1055,1 Gustave L Levy Pl, New York, NY 10029 USA.	rauf.latif@mssm.edu	Latif, Rauf/ABH-4394-2020; latif, rauf/AAR-1634-2020	Latif, Rauf/0000-0002-4226-3728; 	NCRR NIH HHS [1S10RR9145-01] Funding Source: Medline; NIDDK NIH HHS [DK52464, DK35764, DK45011] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR009145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052464, R01DK045011, R01DK035764] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Chan FKM, 2001, CYTOMETRY, V44, P361, DOI 10.1002/1097-0320(20010801)44:4<361::AID-CYTO1128>3.0.CO;2-3; Cheng ZJ, 2001, J BIOL CHEM, V276, P48040, DOI 10.1074/jbc.M105668200; Clegg Robert M, 2002, J Biotechnol, V82, P177; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Davies T, 2002, J CLIN INVEST, V110, P161, DOI 10.1172/JCI200216234; Day RN, 2001, METHODS, V25, P4, DOI 10.1006/meth.2001.1211; Devi LA, 2000, TRENDS PHARMACOL SCI, V21, P324, DOI 10.1016/S0165-6147(00)01519-4; Devi LA, 2000, NEUROPSYCHOPHARMACOL, V23, pS3, DOI 10.1016/S0893-133X(00)00154-8; Duprez L, 1997, FEBS LETT, V409, P469, DOI 10.1016/S0014-5793(97)00532-2; Elmhurst JL, 2000, MOL BRAIN RES, V80, P63, DOI 10.1016/S0169-328X(00)00120-0; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; Gomes I, 2001, J MOL MED, V79, P226, DOI 10.1007/s001090100219; Graves PN, 1996, ENDOCRINOLOGY, V137, P3915, DOI 10.1210/en.137.9.3915; GRAVES PN, 1995, ENDOCRINOLOGY, V136, P521, DOI 10.1210/en.136.2.521; Graves PN, 2000, ENDOCRIN METAB CLIN, V29, P267, DOI 10.1016/S0889-8529(05)70131-6; Grosse R, 1997, MOL ENDOCRINOL, V11, P1305, DOI 10.1210/me.11.9.1305; Guo J, 2000, MOL PHARMACOL, V58, P1050, DOI 10.1124/mol.58.5.1050; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Horvat RD, 2001, MOL ENDOCRINOL, V15, P534, DOI 10.1210/me.15.4.534; Horvat RD, 2001, MOL ENDOCRINOL, V15, P695, DOI 10.1210/me.15.5.695; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Latif R, 2001, J BIOL CHEM, V276, P45217, DOI 10.1074/jbc.M103727200; Latif R, 2000, THYROID, V10, P407, DOI 10.1089/thy.2000.10.407; Lee SP, 2000, NEUROPSYCHOPHARMACOL, V23, pS32, DOI 10.1016/S0893-133X(00)00155-X; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; MISRAHI M, 1994, EUR J BIOCHEM, V222, P711, DOI 10.1111/j.1432-1033.1994.tb18916.x; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Periasamy A, 2001, J BIOMED OPT, V6, P287, DOI 10.1117/1.1383063; Rapoport B, 1998, ENDOCR REV, V19, P673, DOI 10.1210/er.19.6.673; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Roess DA, 2000, ENDOCRINOLOGY, V141, P4518, DOI 10.1210/en.141.12.4518; Salahpour A, 2000, TRENDS ENDOCRIN MET, V11, P163, DOI 10.1016/S1043-2760(00)00260-5; Sanders J, 1997, BAILLIERE CLIN ENDOC, V11, P451, DOI 10.1016/S0950-351X(97)80693-3; SMITH BR, 1988, ENDOCR REV, V9, P106, DOI 10.1210/edrv-9-1-106; Szkudlinski MW, 2002, PHYSIOL REV, V82, P473, DOI 10.1152/physrev.00031.2001; Trapaidze N, 2000, DNA CELL BIOL, V19, P195, DOI 10.1089/104454900314465; Trapaidze N, 2000, DNA CELL BIOL, V19, P93, DOI 10.1089/104454900314609; Trapaidze N, 2000, MOL BRAIN RES, V76, P220, DOI 10.1016/S0169-328X(00)00002-4; Truong K, 2001, CURR OPIN STRUC BIOL, V11, P573, DOI 10.1016/S0959-440X(00)00249-9; Vassart G, 1996, ANN ENDOCRINOL-PARIS, V57, P50; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; Vlaeminck-Guillem V, 2002, MOL ENDOCRINOL, V16, P736, DOI 10.1210/me.16.4.736; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Wurch T, 2001, FEBS LETT, V507, P109, DOI 10.1016/S0014-5793(01)02969-6; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487	56	91	93	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45059	45067		10.1074/jbc.M206693200	http://dx.doi.org/10.1074/jbc.M206693200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223484	hybrid			2022-12-27	WOS:000179404800061
J	Le Rouzic, E; Mousnier, A; Rustum, C; Stutz, F; Hallberg, E; Dargemont, C; Benichou, S				Le Rouzic, E; Mousnier, A; Rustum, C; Stutz, F; Hallberg, E; Dargemont, C; Benichou, S			Docking of HIV-1 Vpr to the nuclear envelope is mediated by the interaction with the nucleoporin hCG1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REGULATORY PROTEIN VPR; CELL-CYCLE ARREST; MESSENGER-RNA EXPORT; PORE COMPLEX; PREINTEGRATION COMPLEXES; MACROPHAGE INFECTION; MAMMALIAN-CELLS; TERMINAL DOMAIN; GAG PRECURSOR	The HIV-1 genome contains several genes coding for auxiliary proteins, including the small Vpr protein. Vpr affects the integrity of the nuclear envelope and participates in the nuclear translocation of the preintegration complex containing the viral DNA. Here, we show by photobleaching experiments performed on living cells expressing a Vpr-green fluorescent protein fusion that the protein shuttles between the nucleus and the cytoplasm, but a significant fraction is concentrated at the nuclear envelope, supporting the hypothesis that Vpr interacts with components of the nuclear pore complex. An interaction between HIV-1 Vpr and the human nucleoporin CG1 (hCG1) was revealed in the yeast two-hybrid system, and then confirmed both in vitro and in transfected cells. This interaction does not involve the FG repeat domain of hCG1 but rather the N-terminal region of the protein. Using a nuclear import assay based on digitonin-permeabilized cells, we demonstrate that hCG1 participates in the docking of Vpr at the nuclear envelope. This association of Vpr with a component of the nuclear pore complex may contribute to the disruption of the nuclear envelope and to the nuclear import of the viral DNA.	Univ Paris 05, U567, Inst Cochin, Dept Infect Dis,INSERM, F-75014 Paris, France; Univ Paris 06, CNRS, UMR 7592, Inst Jacques Monod, Paris, France; Univ Paris 07, Paris, France; Sodertorns Hogskola, S-14189 Huddinge, Sweden; Inst Microbiol, Lausanne, Switzerland; Stockholm Univ, Dept Neurochem & Neurotoxicol, S-10691 Stockholm, Sweden	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Sodertorn University; Stockholm University	Benichou, S (corresponding author), Univ Paris 05, U567, Inst Cochin, Dept Infect Dis,INSERM, Batiment Gustave Roussy,27 Rue Faubourg St Jacque, F-75014 Paris, France.		Stutz, Françoise C/N-4329-2017	Mousnier, Aurelie/0000-0002-7317-1009; Benichou, Serge/0000-0003-3602-3530; Hallberg, Einar/0000-0003-2092-457X				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Allen TD, 2000, J CELL SCI, V113, P1651; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Bachand F, 1999, J BIOL CHEM, V274, P9083, DOI 10.1074/jbc.274.13.9083; Belgareh N, 1999, PROTOPLASMA, V209, P133, DOI 10.1007/BF01453442; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; BUKRINSKY MI, 1999, FRONT BIOSCI, V4, P772; BUSS F, 1994, J CELL SCI, V107, P631; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; CRONSHAW JM, 2002, J CELL BIOL, V26, P315; Cullen BR, 2001, NAT MED, V7, P20, DOI 10.1038/83295; de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957; de Rocquigny H, 1997, J BIOL CHEM, V272, P30753, DOI 10.1074/jbc.272.49.30753; Depienne C, 2000, EXP CELL RES, V260, P387, DOI 10.1006/excr.2000.5016; Depienne C, 2001, J BIOL CHEM, V276, P18102, DOI 10.1074/jbc.M009029200; DIMARZIO P, 1995, J VIROL, V69, P7909, DOI 10.1128/JVI.69.12.7909-7916.1995; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; Farjot G, 1999, J BIOL CHEM, V274, P17309, DOI 10.1074/jbc.274.24.17309; Fouchier RAM, 1999, ADV VIRUS RES, V52, P275, DOI 10.1016/S0065-3527(08)60302-4; Fouchier RAM, 1998, J VIROL, V72, P6004, DOI 10.1128/JVI.72.7.6004-6013.1998; FREED EO, 1995, J VIROL, V69, P3949, DOI 10.1128/JVI.69.6.3949-3954.1995; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gruenbaum Y, 2000, J STRUCT BIOL, V129, P313, DOI 10.1006/jsbi.2000.4216; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; Kamata M, 2000, J VIROL, V74, P7179, DOI 10.1128/JVI.74.15.7179-7186.2000; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; MAHALINGAM S, 1995, VIROLOGY, V212, P331, DOI 10.1006/viro.1995.1490; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; Ossareh-Nazari B, 2001, TRAFFIC, V2, P684, DOI 10.1034/j.1600-0854.2001.21002.x; Popov S, 1998, J BIOL CHEM, V273, P13347, DOI 10.1074/jbc.273.21.13347; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Saavedra CA, 1997, GENE DEV, V11, P2845, DOI 10.1101/gad.11.21.2845; Schuler W, 1999, J MOL BIOL, V285, P2105, DOI 10.1006/jmbi.1998.2381; Segura-Totten M, 2001, SCIENCE, V294, P1016, DOI 10.1126/science.1066729; Selig L, 1999, J VIROL, V73, P592, DOI 10.1128/JVI.73.1.592-600.1999; Selig L, 1997, J VIROL, V71, P4842, DOI 10.1128/JVI.71.6.4842-4846.1997; Sherman MP, 2001, J VIROL, V75, P1522, DOI 10.1128/JVI.75.3.1522-1532.2001; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Strahm Y, 1999, EMBO J, V18, P5761, DOI 10.1093/emboj/18.20.5761; Stutz F, 1996, MOL CELL BIOL, V16, P7144; Vasu SK, 2001, CURR OPIN CELL BIOL, V13, P363, DOI 10.1016/S0955-0674(00)00221-0; Vigouroux C, 2001, J CELL SCI, V114, P4459; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; Wecker K, 1999, EUR J BIOCHEM, V266, P359, DOI 10.1046/j.1432-1327.1999.00858.x; Wiegand HL, 2002, MOL CELL BIOL, V22, P245, DOI 10.1128/MCB.22.1.245-256.2002; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zhou Y, 1998, VIROLOGY, V242, P414, DOI 10.1006/viro.1998.9028	59	94	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45091	45098		10.1074/jbc.M207439200	http://dx.doi.org/10.1074/jbc.M207439200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228227	hybrid			2022-12-27	WOS:000179404800065
J	Sarkar, SN; Pal, S; Sen, GC				Sarkar, SN; Pal, S; Sen, GC			Crisscross enzymatic reaction between the two molecules in the active dimeric P69 form of the 2 '-5 ' oligodenylate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-BETA; 2'-5'-OLIGOADENYLATE SYNTHETASE; 100-KDA FORMS; HUMAN-CELLS; INTERFERON; ISOZYME; MUTANTS; FAMILY; SITES; BINDING	2'-5' oligoadenylate (2-5 (A)) synthetases are major components of the antiviral pathways induced by interferons. In the presence of double-stranded RNA, they polymerize ATP to form 2-5 (A) oligomers that, in turn, activate the latent ribonuclease RNase L, causing mRNA degradation. These enzymes, unlike other nucleotidyl transferases, catalyze 2'-5', not 3'-5', phosphodiester bond formation between substrates bound to the acceptor and donor sites. Moreover, unlike other members of this extended family, the P69 isozyme of 2-5 (A) synthetase functions as a homodimer. Here, we report that the need for P69 dimerization is because of a crisscross enzyme reaction joining two substrate molecules bound to two opposite subunits. Consequently, although homodimers of mutants in the previously identified acceptor site, the donor site, or the catalytic site were inactive, selective heterodimers of the mutants were active because of subunit complementation. The catalytic site had to be present in the same subunit that contained the acceptor site, whereas the donor site had to be provided by the other subunit. These results allowed us to design a mutant protein that acted as a dominant-negative inhibitor of wt P69 but not of another isozyme of 2-5 (A) synthetase.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol NC20, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Sen, GC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol NC20, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Sarkar, Saumendra N/B-5038-2011	Sarkar, Saumendra N/0000-0002-2850-6121	NATIONAL CANCER INSTITUTE [R01CA068782, P01CA062220] Funding Source: NIH RePORTER; NCI NIH HHS [CA68782, CA62220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; Ghosh A, 2000, VIROLOGY, V266, P319, DOI 10.1006/viro.1999.0085; Ghosh A, 2001, J BIOL CHEM, V276, P25447, DOI 10.1074/jbc.M100496200; GRIBAUDO G, 1991, J VIROL, V65, P1748, DOI 10.1128/JVI.65.4.1748-1757.1991; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; HOVANESSIAN AG, 1988, J BIOL CHEM, V263, P4945; Justesen J, 2000, CELL MOL LIFE SCI, V57, P1593, DOI 10.1007/PL00000644; Lau FW, 1999, BIOCHEMISTRY-US, V38, P5521, DOI 10.1021/bi982763t; MARIE I, 1990, J BIOL CHEM, V265, P18601; Rebouillat D, 1999, J BIOL CHEM, V274, P1557, DOI 10.1074/jbc.274.3.1557; Rebouillat D, 1999, J INTERF CYTOK RES, V19, P295, DOI 10.1089/107999099313992; Sarkar SN, 2002, J BIOL CHEM, V277, P24321, DOI 10.1074/jbc.M110202200; Sarkar SN, 1999, J BIOL CHEM, V274, P25535, DOI 10.1074/jbc.274.36.25535; Sarkar SN, 1999, J BIOL CHEM, V274, P1848, DOI 10.1074/jbc.274.3.1848; Sarkar SN, 1998, METHODS, V15, P233, DOI 10.1006/meth.1998.0627; Saxl RL, 2001, BIOCHEMISTRY-US, V40, P5275, DOI 10.1021/bi002925x; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TOBIAS KE, 1993, BIOCHEMISTRY-US, V32, P5842, DOI 10.1021/bi00073a017; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P31, DOI 10.1073/pnas.84.1.31	21	8	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44760	44764		10.1074/jbc.M207126200	http://dx.doi.org/10.1074/jbc.M207126200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223486	hybrid			2022-12-27	WOS:000179404800023
J	Schreiner, SJ; Schiavone, AP; Smithgall, TE				Schreiner, SJ; Schiavone, AP; Smithgall, TE			Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; DNA-BINDING ACTIVITY; C-SRC; V-SRC; CRYSTAL-STRUCTURE; GROWTH-FACTOR; 3-DIMENSIONAL STRUCTURE; MYELOID CELLS; HUMAN CANCER; IN-VIVO	STAT3 is a member of a family of transcription factors with Src homology 2 (SH2) domains that are activated by tyrosine phosphorylation in response to a wide variety of cytokines and growth factors. In this study, we investigated the mechanism of STAT3 activation by the Src family of nonreceptor tyrosine kinases, which have been linked to STAT activation in both normal and transformed cell types. Using Sf-9 insect cells, we demonstrate direct STAT3 tyrosine phosphorylation and stimulation of DNA binding activity by five members of the Src kinase family (Src, Hck, Lyn, Fyn, and Fgr). We also observed stable STAT3-Src family kinase complex formation in this system. Recombinant Src family kinase SH3 domains were sufficient for interaction with STAT3, suggesting a mechanistic basis for the Src kinase-STAT3 interaction. To test the contribution of Src family kinase SH3 domains to the recruitment and activation of STAT3 in vivo, we used Rat-2 fibroblasts expressing activated mutants of the myeloid Src family member Hck. Transformation of fibroblasts by an activated Hck mutant lacking the negative regulatory tail tyrosine residue (Hck-YF) induced strong DNA binding activity of endogenous STAT3. Inactivation of Hck SH3 function by Ala replacement of a conserved Trp residue (W93A mutant) completely abolished STAT3 activation by Hck-YF and reduced transforming activity by 50% without affecting Hck kinase activity. Finally, overexpression of STAT3 in Rat-2 cells transiently stimulated Hck and c-Src kinase activity in the absence of extracellular signals, an effect that was dependent upon a putative SH3 binding motif in STAT3. These results support a model in which Src family kinases recruit STAT3 through an SH3-dependent mechanism, resulting in transient kinase activation and STAT3 phosphorylation.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Smithgall, TE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	tsmithga@pitt.edu			NCI NIH HHS [CA81398] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081398] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Briggs SD, 1999, J BIOL CHEM, V274, P26579, DOI 10.1074/jbc.274.37.26579; Briggs SD, 2000, BIOCHEMISTRY-US, V39, P489, DOI 10.1021/bi992504j; Briggs SD, 2001, J BIOL CHEM, V276, P25605, DOI 10.1074/jbc.M103244200; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; Denny MF, 1999, J BIOL CHEM, V274, P5146, DOI 10.1074/jbc.274.8.5146; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Hassaine G, 2001, J BIOL CHEM, V276, P16885, DOI 10.1074/jbc.M009076200; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Lund TC, 1999, CELL SIGNAL, V11, P789, DOI 10.1016/S0898-6568(99)00045-5; Lund TC, 1997, J VIROL, V71, P6677, DOI 10.1128/JVI.71.9.6677-6682.1997; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pellicena P, 2002, FRONT BIOSCI-LANDMRK, V7, pD256, DOI 10.2741/pellicen; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; Peters KL, 1999, CELL SIGNAL, V11, P507, DOI 10.1016/S0898-6568(99)00021-2; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; REYNOLDS PJ, 1992, ONCOGENE, V7, P1949; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Skorski T, 1998, BLOOD, V91, P406, DOI 10.1182/blood.V91.2.406.406_406_418; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; Susa M, 2000, TRENDS PHARMACOL SCI, V21, P489, DOI 10.1016/S0165-6147(00)01567-4; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VEILLETTE A, 1992, ONCOGENE, V7, P971; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200	63	134	135	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45680	45687		10.1074/jbc.M204255200	http://dx.doi.org/10.1074/jbc.M204255200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244095	hybrid			2022-12-27	WOS:000179404800135
J	Zhang, WJ; Yatskievych, TA; Cao, X; Antin, PB				Zhang, WJ; Yatskievych, TA; Cao, X; Antin, PB			Regulation of Hex gene expression by a Smads-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEINS; GROWTH-FACTOR-BETA; HOMEOBOX GENE; DNA-BINDING; LIVER DEVELOPMENT; INDUCTION; HEART; SPECIFICATION; TRANSCRIPTION; ELEMENTS	The homeobox gene Hex is expressed in multiple cell types during embryogenesis and is required for liver and monocyte development. Hex is expressed in the foregut region of late gastrula avian and mammalian embryos in a pattern that overlaps with expression of bone morphogenetic proteins (BMPs). Here we investigate the relationship between BMP signaling and Hex gene expression. We find that Hex expression in avian anterior lateral endoderm is regulated by autocrine BMP signaling. Characterization of the mouse Hex gene promoter identified a 71-nucleotide BMP-responsive element (BRE) that is required for up-regulation of Hex by an activated BMP signaling pathway. The Hex BRE binds Smad4 and Smad1-Smad4 complexes in vitro, and in transfection assays, it is responsive to Smad1 and Smad4 but not to Smad2 and Smad4 or Smad3 and Smad4. The BRE contains two copies of a GCCGnCGC-like motif that in Drosophila is the binding site for Mad and Madea followed by two CAGAG boxes that are similar to sequences required for transforming growth factor-beta/activin responsiveness of several vertebrate genes. Mutation of the GC elements, but not the two CAGAG boxes, abolishes Smads responsiveness in the intact Hex promoter, whereas mutations in both the GC elements and CAGAG boxes show that they act cooperatively to confer Smads responsiveness to the Hex promoter. The Hex BRE can confer Smads responsiveness to a heterologous promoter, and in this context, both the GC-rich elements and the CAGAG boxes are required for Smads-dependent promoter activity. An element almost identical to the Hex BRE is present within the BMP-responsive Nkx2-5 gene promoter, suggesting that the Hex BRE represents a common response element for genes regulated by BMP signaling in the foregut region of the embryo.	Univ Arizona, Dept Cell Biol & Anat, Tucson, AZ 85724 USA; Univ Alabama Birmingham, Sch Med, Dept Pathol, Birmingham, AL 35294 USA	University of Arizona; University of Alabama System; University of Alabama Birmingham	Antin, PB (corresponding author), Univ Arizona, Dept Cell Biol & Anat, Tucson, AZ 85724 USA.	pba@u.arizona.edu		Antin, Parker/0000-0001-9066-7412	NHLBI NIH HHS [HL54133] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054133] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andree B, 1998, MECH DEVELOP, V70, P119, DOI 10.1016/S0925-4773(97)00186-X; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Barron M, 2000, DEV DYNAM, V218, P383, DOI 10.1002/(SICI)1097-0177(200006)218:2<383::AID-DVDY11>3.0.CO;2-P; BODMER R, 1993, DEVELOPMENT, V118, P719; Bogue CW, 2000, DEV DYNAM, V219, P84, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1028>3.0.CO;2-5; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P5661, DOI 10.1093/nar/20.21.5661; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Henningfeld KA, 2000, J BIOL CHEM, V275, P21827, DOI 10.1074/jbc.M000978200; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Jiang SW, 1996, NUCLEIC ACIDS RES, V24, P3278, DOI 10.1093/nar/24.16.3278; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; Keng VW, 2000, BIOCHEM BIOPH RES CO, V276, P1155, DOI 10.1006/bbrc.2000.3548; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Ladd AN, 1998, DEV BIOL, V204, P407, DOI 10.1006/dbio.1998.9094; LEDOUARIN N, 1964, J EMBRYOL EXP MORPH, V12, P651; LEDOUARIN NM, 1975, MED BIOL, V53, P427; Liberatore CM, 2002, DEV BIOL, V244, P243, DOI 10.1006/dbio.2002.0604; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Lough J, 2000, DEV DYNAM, V217, P327, DOI 10.1002/(SICI)1097-0177(200004)217:4<327::AID-DVDY1>3.3.CO;2-B; Lough J, 1996, DEV BIOL, V178, P198, DOI 10.1006/dbio.1996.0211; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Myint Z, 1999, J BIOCHEM-TOKYO, V125, P795, DOI 10.1093/oxfordjournals.jbchem.a022351; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P320; Newman CS, 1997, MECH DEVELOP, V66, P83, DOI 10.1016/S0925-4773(97)00092-0; Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4; Rodriguez TA, 2001, DEV BIOL, V234, P304, DOI 10.1006/dbio.2001.0265; Rossi JM, 2001, GENE DEV, V15, P1998, DOI 10.1101/gad.904601; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schlange T, 2000, MECH DEVELOP, V91, P259, DOI 10.1016/S0925-4773(99)00311-1; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; SCHULTHEISS TM, 1999, HEART DEV, P52; Searcy RD, 1998, DEVELOPMENT, V125, P4461; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YQ, 2000, DEV BIOL, V224, P226, DOI 10.1006/dbio.2000.9802; Thomas PQ, 1998, DEVELOPMENT, V125, P85; Walters MJ, 2001, MECH DEVELOP, V100, P263, DOI 10.1016/S0925-4773(00)00535-9; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yatskievych TA, 1999, MECH DEVELOP, V80, P107, DOI 10.1016/S0925-4773(98)00204-4; Zaret KS, 2000, MECH DEVELOP, V92, P83, DOI 10.1016/S0925-4773(99)00326-3; Zaret KS, 1996, ANNU REV PHYSIOL, V58, P231, DOI 10.1146/annurev.physiol.58.1.231; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3; Zhu XL, 1996, DEV DYNAM, V207, P429, DOI 10.1002/(SICI)1097-0177(199612)207:4<429::AID-AJA7>3.0.CO;2-J	57	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45435	45441		10.1074/jbc.M208056200	http://dx.doi.org/10.1074/jbc.M208056200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12270938	hybrid			2022-12-27	WOS:000179404800107
J	Yang, YY; Chen, Q; Zhang, JT				Yang, YY; Chen, Q; Zhang, JT			Structural and functional consequences of mutating cysteine residues in the amino terminus of human multidrug resistance-associated protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; DRUG-BINDING DOMAIN; ABC TRANSPORTER SUPERFAMILY; MEMBRANE TOPOLOGY; LEUKOTRIENE C-4; CONFORMATIONAL-CHANGES; SUBSTRATE-SPECIFICITY; SCANNING MUTAGENESIS; NUCLEOTIDE-BINDING; CROSS-LINKING	Multidrug resistance-associated protein 1 (MRP1) is a member of the ATP-binding cassette membrane transport superfamily and is responsible for multidrug resistance in cancer cells. Currently, there are nine known human MRPs. Distinct from many other members of the ATP-binding cassette superfamily, human MRP1 and four other MRPs have an additional membrane-spanning domain (MSD) with a putative extracellular amino terminus. The functional significance of this additional MSD (MSD1) is currently unknown. To understand the role of MSD1 in human MRP1 structure and function, we studied the amino-terminal 33 amino acids. We found that the amino terminus of human MRP1 has two cysteine residues (Cys(7) and Cys(32)) that are conserved among the five human MRPs that have MSD1. Mutation analyses of the two cysteines in human MRP1 revealed that the Cys(7) residue is critical for the MRP1-mediated drug resistance and leukotriene C-4 transport activity. On the other hand, mutation of Cys(32) reduced only moderately the MRP1 function. The effect of Cys(7) mutation on MRP1 activity appears to be due to the 5-7-fold decrease in the maximal transport rate V-max. We also found that mutation of Cys(7) changed the amino-terminal conformation of MRP1. This conformational change is likely responsible for the decrease in V-max of LTC4 transport mediated by the mutant MRP1. Based on these studies, we conclude that the amino terminus of human MRP1 is important and that the Cys(7) residue plays a critical role in maintaining the proper structure and function of human MRP1.	Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Ctr Canc, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr Walther Canc Inst, Ctr Canc, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Zhang, JT (corresponding author), Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Ctr Canc, 1044 W Walnut St,R4-166, Indianapolis, IN 46202 USA.		Zhang, Jian-Ting/L-8334-2015		NCI NIH HHS [CA64539] Funding Source: Medline; NIGMS NIH HHS [GM59475] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064539, R29CA064539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059475] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 2000, J CELL SCI, V113, P4451; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; Belinsky MG, 1998, J NATL CANCER I, V90, P1735, DOI 10.1093/jnci/90.22.1735; Bera TK, 2001, MOL MED, V7, P509, DOI 10.1007/BF03401856; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; Buchler M, 1996, J BIOL CHEM, V271, P15091; Chen Q, 2002, BIOCHEMISTRY-US, V41, P9052, DOI 10.1021/bi025634s; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Daoud R, 2001, J BIOL CHEM, V276, P12324, DOI 10.1074/jbc.M009782200; Daoud R, 2000, BIOCHEMISTRY-US, V39, P6094, DOI 10.1021/bi9922188; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1996, CANCER RES, V56, P3307; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Hopper E, 2001, CANCER LETT, V162, P181, DOI 10.1016/S0304-3835(00)00646-7; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; Lee K, 1998, CANCER RES, V58, P2741; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Longhurst TJ, 1996, BRIT J CANCER, V74, P1331, DOI 10.1038/bjc.1996.545; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; Manciu L, 2001, FEBS LETT, V493, P31, DOI 10.1016/S0014-5793(01)02270-0; Mechetner EB, 1997, P NATL ACAD SCI USA, V94, P12908, DOI 10.1073/pnas.94.24.12908; Prechtl S, 2000, J IMMUNOL, V164, P754, DOI 10.4049/jimmunol.164.2.754; Qian YM, 2001, J BIOL CHEM, V276, P38636, DOI 10.1074/jbc.M107025200; Stride BD, 1999, J BIOL CHEM, V274, P22877, DOI 10.1074/jbc.274.32.22877; Stride BD, 1997, MOL PHARMACOL, V52, P344, DOI 10.1124/mol.52.3.344; Theodoulou FL, 2000, BBA-BIOMEMBRANES, V1465, P79, DOI 10.1199/tab.0153; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897; Zhang DW, 2001, J BIOL CHEM, V276, P34966, DOI 10.1074/jbc.M105063200; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200; Zhang JT, 2000, BIOCHEM J, V348, P597, DOI 10.1042/0264-6021:3480597; Zhang M, 1996, BIOCHEMISTRY-US, V35, P9728, DOI 10.1021/bi960400s; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	44	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44268	44277		10.1074/jbc.M207003200	http://dx.doi.org/10.1074/jbc.M207003200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12235150	hybrid			2022-12-27	WOS:000179272000096
J	Bencsath, KP; Podgorski, MS; Pagala, VR; Slaughter, CA; Schulman, BA				Bencsath, KP; Podgorski, MS; Pagala, VR; Slaughter, CA; Schulman, BA			Identification of a multifunctional binding site on Ubc9p required for Smt3p conjugation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PROTEIN MODIFICATION; ACTIVATING ENZYME; SUMO CONJUGATION; UBIQUITIN; COMPLEX; PATHWAY; INSIGHTS; SYSTEM; NEDD8	Ubiquitin-like proteins (ub-lps) are conjugated by a conserved enzymatic pathway, involving ATP-dependent activation at the C terminus by an activating enzyme (E1) and formation of a thiolester intermediate with a conjugating enzyme (E2) prior to ligation to the target. Ubc9, the E2 for SUMO, synthesizes polymeric chains in the presence of its El and MgATP. To better understand conjugation of ub-lps, we have performed mutational analysis of Saccharomyces cerevisiae Ubc9p, which conjugates the SUMO family member Smt3p. We have identified Ubc9p surfaces involved in thiolester bond and Smt3p-Smt3p chain formation. The residues involved in thiolester bond formation map to a surface we show is the E1 binding site, and E2s for other ub-lps are likely to bind to their E1s at a homologous site. We also find that this same surface binds Smt3p. A mutation that impairs binding to El but not Smt3p impairs thiolester bond formation, suggesting that it is the El interaction at this site that is crucial. Interestingly, other E2s and their relatives also use this same surface for binding to ubiquitin, E3s, and other proteins, revealing this to be a multipurpose binding site and suggesting that the entire E1-E2-E3 pathway has coevolved for a given ub-1p.	St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Genet Tumor Cell Biol, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Schulman, BA (corresponding author), St Jude Childrens Res Hosp, Dept Biol Struct, 332 N Lauderdale,MS 311, Memphis, TN 38105 USA.	Brenda.schulman@stjude.org			NATIONAL CANCER INSTITUTE [R25CA023944, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [2 P30 CA 21765-24-25, R25 CA023944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; COOK WJ, 1992, J BIOL CHEM, V267, P15116; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Giraud MF, 1998, ACTA CRYSTALLOGR D, V54, P891, DOI 10.1107/S0907444998002480; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; GOSINK MM, 1995, P NATL ACAD SCI USA, V92, P9117, DOI 10.1073/pnas.92.20.9117; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1988, J BIOL CHEM, V263, P13268; Hamilton KS, 2001, STRUCTURE, V9, P897, DOI 10.1016/S0969-2126(01)00657-8; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Lin YQ, 2002, J BIOL CHEM, V277, P21913, DOI 10.1074/jbc.M109398200; Liu Q, 1999, J BIOL CHEM, V274, P16979, DOI 10.1074/jbc.274.24.16979; McKenna S, 2001, J BIOL CHEM, V276, P40120, DOI 10.1074/jbc.M102858200; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Miura T, 1999, J MOL BIOL, V290, P213, DOI 10.1006/jmbi.1999.2859; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PITLUK ZW, 1995, MOL CELL BIOL, V15, P1210; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SULLIVAN ML, 1991, J BIOL CHEM, V266, P23878; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	59	105	108	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47938	47945		10.1074/jbc.M207442200	http://dx.doi.org/10.1074/jbc.M207442200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354763	hybrid			2022-12-27	WOS:000179663700141
J	Lents, NH; Keenan, SM; Bellone, C; Baldassare, JJ				Lents, NH; Keenan, SM; Bellone, C; Baldassare, JJ			Stimulation of the Raf/MEK/ERK cascade is necessary and sufficient for activation and Thr-160 phosphorylation of a nuclear-targeted CDK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; S-PHASE ENTRY; PROTEIN-KINASE; RETINOBLASTOMA PROTEIN; SUBSTRATE-SPECIFICITY; ECTOPIC EXPRESSION; CELL-PROLIFERATION; RESTRICTION POINT; G(1) PROGRESSION; IN-VITRO	The activity of cyclin-dependent kinase 2 is required for G(1)-S-phase progression of the eukaryotic cell cycle. In this study, we examine the activation of CDK2-cyclin E by constructing a CDK2 that is constitutively targeted to the nucleus. Activation of CDK2 requires the removal of two inhibitory phosphates (Thr-14 and Tyr-15) and the addition of one activating phosphate (Thr-160) by a nuclear localized CDK-activating kinase, which is thought to be constitutively active. Surprisingly, nuclear localized CDK2-NLS and CDK2-NLS(A14,F15), which lacks the inhibitory phosphorylation sites, require serum to become active, despite complexing with expressed cyclin E. We show that inhibition of mitogen-mediated ERK activation by treatment with U0126, a selective MEK inhibitor, or expression of dominant-negative ERK markedly reduces the phosphorylation of Thr-160 and enzymatic activity of both CDK2-NLS constructs. Consistent with a role for ERK in Thr-160 phosphorylation, expression of constitutively active Raf-1 induces Thr-160 phosphorylation of CDK2-NLS in serum-arrested cells, an effect that is blocked by treatment with U0126. Taken together, these data show a new role for ERK in G1 cell cycle progression: In addition to its role in stimulating cyclin D1 expression and nuclear translocation of CDK2, ERK regulates Thr-160 phosphorylation of CDK2-cyclin E.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University	Baldassare, JJ (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA.	baldasjj@slu.edu						BATES S, 1994, ONCOGENE, V9, P71; Blanchard DA, 2000, ONCOGENE, V19, P4184, DOI 10.1038/sj.onc.1203761; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; Chiariello M, 2000, BIOCHEM J, V349, P869, DOI 10.1042/bj3490869; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; DENT P, 1995, MOL CELL BIOL, V15, P4125; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Dietrich C, 1997, EXP CELL RES, V232, P72, DOI 10.1006/excr.1997.3507; DOU QP, 1993, CANCER RES, V53, P1493; Dubravka D, 2000, CELL RES, V10, P1, DOI 10.1038/sj.cr.7290031; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Goel R, 2002, J BIOL CHEM, V277, P18640, DOI 10.1074/jbc.M108995200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harper JW, 1998, GENE DEV, V12, P285, DOI 10.1101/gad.12.3.285; HARPER JW, 1993, CELL, V75, P805; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kaldis P, 2000, EUR J BIOCHEM, V267, P4213, DOI 10.1046/j.1432-1327.2000.01455.x; KATO J, 1993, GENE DEV, V7, P331; Keenan SM, 2001, J BIOL CHEM, V276, P22404, DOI 10.1074/jbc.M100409200; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Larochelle S, 1998, GENE DEV, V12, P370, DOI 10.1101/gad.12.3.370; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Martinez AM, 1997, EMBO J, V16, P343, DOI 10.1093/emboj/16.2.343; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Nagahara H, 1999, P NATL ACAD SCI USA, V96, P14961, DOI 10.1073/pnas.96.26.14961; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAM SW, 1994, ONCOGENE, V9, P2663; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAKRAKLIDES V, 2002, J BIOL CHEM; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Winey M, 1999, CURR BIOL, V9, pR449, DOI 10.1016/S0960-9822(99)80279-6; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456	57	66	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47469	47475		10.1074/jbc.M207425200	http://dx.doi.org/10.1074/jbc.M207425200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359725	hybrid			2022-12-27	WOS:000179663700083
J	Miyazaki, K; Kawamoto, T; Tanimoto, K; Nishiyama, M; Honda, H; Kato, Y				Miyazaki, K; Kawamoto, T; Tanimoto, K; Nishiyama, M; Honda, H; Kato, Y			Identification of functional hypoxia response elements in the promoter region of the DEC1 and DEC2 genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR 1-ALPHA; UBIQUITIN-PROTEASOME PATHWAY; HUMAN ERYTHROPOIETIN GENE; TUMOR-SUPPRESSOR PROTEIN; LACTATE-DEHYDROGENASE-A; LOOP-HELIX PROTEIN; TRANSCRIPTION FACTOR; FACTOR-I; CHONDROGENIC DIFFERENTIATION; REPRESSES TRANSCRIPTION	Adaptation to hypoxia is a crucial process both physiologically (i.e. in chondrocytes) and pathologically (i.e. in tumor cells). Previous studies have shown that DEC1, a basic helix-loop-helix transcription factor, is induced by hypoxia in glioma cells (Ivanova, A. V., Ivanov, S. V., Danilkovitch-Miagkova, A., and Lerman, M. I. (2001) J. Biol. Chem. 276,15306-15315). In the present study, we found that hypoxia or CoCl2 enhanced the mRNA expression of DEC2, as well as DEC1, within 24 h in chondrogenic ATDC5, 293T, and HeLa cells. In luciferase assays, the regions between -524 and -401 in the DEC1 promoter, and between -863 and -258 in the DEC2 promoter, were responsible for the hypoxia- or hypoxia-inducible factor-1alpha (HIF-1alpha)-induced transcription. In these regions, we identified functional hypoxia response elements (HREs) that bound to HIF-1alpha and HIF-1beta. In addition to an HIF-1 binding site consensus sequence, the DEC1 HRE had cAMP response element-like and CACAG sequences, which were also involved in the transcription activation in response to HIF-1alpha. Although the DEC2 HRE did not have a cAMP response element-like or CACAG sequence, it showed a higher affinity for HIF-1 than did the DEC1 HRE. Because DEC1 and DEC2 are directly inducible by HIF-1, these transcription factors may be crucial for the adaptation to hypoxia.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Dent & Med Biochem, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Dept Dev Biol, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Dept Translat Canc Res, Div Clin & Expt Oncol, Res Inst Radiat Biol & Med,Minami Ku, Hiroshima 7348553, Japan	Hiroshima University; Hiroshima University; Hiroshima University	Kato, Y (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Dent & Med Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.		, 河本健/D-7938-2015; Keiji, Tanimoto/U-1839-2019	, 河本健/0000-0003-3337-1775; Keiji, Tanimoto/0000-0003-4912-4197				Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; Fujimoto K, 2001, BIOCHEM BIOPH RES CO, V280, P164, DOI 10.1006/bbrc.2000.4133; Garriga-Canut M, 2001, J BIOL CHEM, V276, P14821, DOI 10.1074/jbc.M011619200; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Lee SG, 2001, FEBS LETT, V507, P259, DOI 10.1016/S0014-5793(01)02989-1; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; Mazure NM, 2002, CANCER RES, V62, P1158; Mukhopadhyay CK, 2000, J BIOL CHEM, V275, P21048, DOI 10.1074/jbc.M000636200; Nakamasu K, 1999, BBA-GENE STRUCT EXPR, V1447, P258, DOI 10.1016/S0167-4781(99)00173-6; Oikawa M, 2001, BIOCHEM BIOPH RES CO, V289, P39, DOI 10.1006/bbrc.2001.5927; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Schipani E, 2001, GENE DEV, V15, P2865; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Teramoto M, 2001, J BIOCHEM-TOKYO, V129, P391, DOI 10.1093/oxfordjournals.jbchem.a002869; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zawel L, 2002, P NATL ACAD SCI USA, V99, P2848, DOI 10.1073/pnas.261714999	40	175	179	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47014	47021		10.1074/jbc.M204938200	http://dx.doi.org/10.1074/jbc.M204938200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354771	hybrid			2022-12-27	WOS:000179663700025
J	Young, SH; Wu, SV; Rozengurt, E				Young, SH; Wu, SV; Rozengurt, E			Ca2+-stimulated Ca2+ oscillations produced by the Ca2+-sensing receptor require negative feedback by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; ACTIVATION; STIMULATION; BRADYKININ; MECHANISM; FREQUENCY; BOMBESIN	We examined the role of protein kinase C (PKC) in the mechanism and regulation of intracellular Ca2+ concentration ([Ca2+](i)) oscillations elicited by an increase in the extracellular concentration of Ca2+ ([Ca2+](e)) in human embryonic kidney 293 cells expressing the Ca2+ sensing receptor (CaR). Exposure to the PKC inhibitors bisindolylmaleimide I (GF I) or Ro-31-8220 converted oscillatory responses to transient, non-oscillatory responses, significantly reducing the percentage of cells that showed [Ca2+](i) oscillations but without decreasing the overall response to increase in [Ca2+](e). Exposure to 100 nm phorbol 12,13-dibutyrate, a direct activator of PKC, eliminated [Ca2+](i) oscillations. Addition of phorbol 12,13-dibutyrate at lower concentrations (3 and 10 nm) did not eliminate the oscillations but greatly reduced their frequency in a dose-dependent manner. Co-expression of CaR with constitutively active mutants of PKC (either epsilon or beta(1) isoforms) also reduced [Ca2+](i) oscillation frequency. Expression of a mutant CaR in which the major PKC phosphorylation site is altered by substitution of alanine for threonine (T888A) eliminated oscillatory behavior, producing [Ca2+](i) responses almost identical to those produced by the wild type CaR exposed to PKC inhibitors. These results support a model in which phosphorylation of the CaR at the inhibitory threonine 888 by PKC provides the negative feedback needed to cause [Ca2+](i) oscillations mediated by this receptor.	Univ Calif Los Angeles, David Geffen Sch Med,Dept Med, Unit Signal Transduct & Gastrointestinal Canc, CURE Digest Dis Res Ctr,Div Digest Dis, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med,Dept Med, Unit Signal Transduct & Gastrointestinal Canc, CURE Digest Dis Res Ctr,Div Digest Dis, Rm 11-124,Warren Hall,900 Vet Ave, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu			NATIONAL CANCER INSTITUTE [P50CA090388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017294, R01DK056930, R01DK017294] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA90388] Funding Source: Medline; NIDDK NIH HHS [DK 55003, DK 56930, DK 17294] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai M, 1998, J BIOL CHEM, V273, P21267, DOI 10.1074/jbc.273.33.21267; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; Breitwieser GE, 2001, AM J PHYSIOL-CELL PH, V280, pC1412, DOI 10.1152/ajpcell.2001.280.6.C1412; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Buchan AMJ, 2001, GASTROENTEROLOGY, V120, P1128, DOI 10.1053/gast.2001.23246; Cheng I, 1997, GASTROENTEROLOGY, V112, pA1139; Codazzi F, 2001, CURR BIOL, V11, P1089, DOI 10.1016/S0960-9822(01)00326-8; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; Dale LB, 2001, J BIOL CHEM, V276, P35900, DOI 10.1074/jbc.M103847200; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hendy GN, 2000, HUM MUTAT, V16, P281, DOI 10.1002/1098-1004(200010)16:4<281::AID-HUMU1>3.0.CO;2-A; HO C, 1995, NAT GENET, V11, P389, DOI 10.1038/ng1295-389; Hu QH, 1999, J BIOL CHEM, V274, P33995, DOI 10.1074/jbc.274.48.33995; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Luo D, 2001, J BIOL CHEM, V276, P5613, DOI 10.1074/jbc.M007524200; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oda Y, 2000, J BIOL CHEM, V275, P1183, DOI 10.1074/jbc.275.2.1183; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Riccardi D, 1998, AM J PHYSIOL-RENAL, V274, pF611, DOI 10.1152/ajprenal.1998.274.3.F611; Schaefer M, 2001, FASEB J, V15, P1634, DOI 10.1096/fj.00-0824fje; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Soderling TR, 2001, J BIOL CHEM, V276, P3719, DOI 10.1074/jbc.R000013200; Taylor CW, 2001, CURR BIOL, V11, pR352, DOI 10.1016/S0960-9822(01)00192-0; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; Usachev YM, 2002, NEURON, V33, P113, DOI 10.1016/S0896-6273(01)00557-8; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; Young SH, 2002, AM J PHYSIOL-CELL PH, V282, pC1414, DOI 10.1152/ajpcell.00432.2001; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; Yue CP, 2000, J BIOL CHEM, V275, P30220, DOI 10.1074/jbc.M004276200; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	41	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46871	46876		10.1074/jbc.M207083200	http://dx.doi.org/10.1074/jbc.M207083200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356761	hybrid			2022-12-27	WOS:000179663700007
J	Hall, DB; Struhl, K				Hall, DB; Struhl, K			The VP16 activation domain interacts with multiple transcriptional components as determined by protein-protein cross-linking in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA BOX-BINDING; HISTONE ACETYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; SWI/SNF COMPLEX; SAGA COMPLEX; FACTOR TFIIB; RECRUITMENT; PROMOTER; DISTINCT; COACTIVATOR	Transcriptional activator proteins recruit the RNA polymerase II machinery and chromatin-modifying activities to promoters. Biochemical experiments indicate that activator proteins can associate with a large number of proteins, and many such proteins have been proposed to be direct targets of activators. However, there is great uncertainty about which biochemical interactions are physiologically relevant. Here, we develop a formaldehyde-based cross-linking procedure to identify protein-protein interactions that occur under physiological conditions. We show that the VP16 activation domain directly interacts with TATA-binding protein (TBP), TFIIB, and the SAGA histone acetylase complex in vivo.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Struhl, K (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	kevin@hms.harvard.edu		Hall, Daniel B/0000-0002-5085-8334				BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Chou S, 1997, MOL CELL BIOL, V17, P6794, DOI 10.1128/MCB.17.12.6794; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; Drysdale CM, 1998, MOL CELL BIOL, V18, P1711, DOI 10.1128/MCB.18.3.1711; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORI R, 1995, P NATL ACAD SCI USA, V92, P6047, DOI 10.1073/pnas.92.13.6047; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; Katan-Khaykovich Y, 2002, GENE DEV, V16, P743, DOI 10.1101/gad.967302; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; Kotani T, 2000, P NATL ACAD SCI USA, V97, P7178, DOI 10.1073/pnas.120074297; Kuo MH, 2000, MOL CELL, V6, P1309, DOI 10.1016/S1097-2765(00)00129-5; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Melcher K, 2000, J MOL BIOL, V301, P1097, DOI 10.1006/jmbi.2000.4034; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Neely KE, 2002, MOL CELL BIOL, V22, P1615, DOI 10.1128/MCB.22.6.1615-1625.2002; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; Papamichos-Chronakis M, 2002, MOL CELL, V9, P1297, DOI 10.1016/S1097-2765(02)00545-2; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Roberts SM, 1997, GENETICS, V147, P451; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sanders SL, 2002, MOL CELL BIOL, V22, P6000, DOI 10.1128/MCB.22.16.6000-6013.2002; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Shen F, 1996, J BIOL CHEM, V271, P4827; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; TANSEY WP, 1995, P NATL ACAD SCI USA, V92, P10550, DOI 10.1073/pnas.92.23.10550; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; Yudkovsky N, 1999, GENE DEV, V13, P2369, DOI 10.1101/gad.13.18.2369	67	99	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46043	46050		10.1074/jbc.M208911200	http://dx.doi.org/10.1074/jbc.M208911200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12297514	hybrid			2022-12-27	WOS:000179529300045
J	Leivonen, SK; Chantry, A; Hakkinen, L; Han, JH; Kahari, VM				Leivonen, SK; Chantry, A; Hakkinen, L; Han, JH; Kahari, VM			Smad3 mediates transforming growth factor-beta-induced collagenase-3 (matrix metalloproteinase-13) expression in human gingival fibroblasts - Evidence for cross-talk between Smad3 and p38 signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DEPENDENT TRANSCRIPTIONAL ACTIVATION; GENE COL7A1 PROMOTER; TGF-BETA; FUNCTIONAL-CHARACTERIZATION; DERMAL FIBROBLASTS; INHIBITOR-1 GENE; BINDING-ELEMENT; JUN FAMILY; CELLS	Transforming growth factor-beta (TGF-beta) is a potent inducer of collagenase-3 (NIMP-13) gene expression in human gingival fibroblasts, and this requires activation of the p38 mitogen-activated protein kinase pathway. Here, we have constructed recombinant adenoviruses harboring genes for hemagglutinin-tagged Smad2, Smad3, and Smad4 and used these in dissecting the role of Smads, the signaling mediators of TGF-beta, in regulation of endogenous MMP-13 gene expression in human gingival fibroblasts. Adenoviral expression of Smad3, but not Smad2, augmented the TGF-beta-elicited induction of MMP-13 expression. In addition, adenoviral gene delivery of dominant negative Smad3 blocked the TGF-beta-induced MMP-13 expression in gingival fibroblasts. Co-expression of Smad3 with constitutively active MKK3b and MKK6b, the upstream activators of p38, resulted in nuclear translocation of Smad3 in the absence of TGF-beta and in induction of MMP-13 expression. The induction of MMP-13 expression by Smad3 and constitutively active mutants of MKK3b or MKK6b was blocked by specific p38 inhibitor SB203580 and by the dominant negative form of p38alpha. These results show that TGF-beta-induced expression of human MMP-13 gene in gingival fibroblasts is dependent on the activation of two distinct signaling pathways (i.e. Smad3 and p38alpha). In addition, these findings provide evidence for a novel type of crosstalk between Smad and p38 mitogen-activated protein kinase signaling cascades, which involves activation of Smad3 by p38alpha.	Univ Turku, Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, Ctr Biotechnol, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Univ Turku, Dept Dermatol, FIN-20520 Turku, Finland; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of Turku; Abo Akademi University; University of Turku; University of Turku; University of East Anglia; University of British Columbia; Scripps Research Institute	Kahari, VM (corresponding author), Univ Turku, Ctr Biotechnol, Tykistokatu 6 B, FIN-20520 Turku, Finland.	veli-matti.kahari@utu.fi	Kahari, Veli-Matti/T-4925-2019; Leivonen, Suvi-Katri/AAK-3096-2021; Hakkinen, Lari/B-2228-2016; Han, J/G-4671-2010; Kähäri, Veli-Matti/E-5144-2011	Kahari, Veli-Matti/0000-0003-2421-9368; Kähäri, Veli-Matti/0000-0003-2421-9368				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Ala-Aho R, 2002, INT J CANCER, V97, P283, DOI 10.1002/ijc.1619; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; BOUKAMP P, 1990, CANCER RES, V50, P2840; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dooley S, 2001, FEBS LETT, V502, P4, DOI 10.1016/S0014-5793(01)02656-4; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Jaakkola P, 2000, GENE THER, V7, P1640, DOI 10.1038/sj.gt.3301293; Jin G, 1997, J BIOL CHEM, V272, P26620, DOI 10.1074/jbc.272.42.26620; Johansson N, 2000, J CELL SCI, V113, P227; Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Johansson N, 1997, CELL GROWTH DIFFER, V8, P243; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; MAKELA JK, 1988, NUCLEIC ACIDS RES, V16, P349, DOI 10.1093/nar/16.1.349; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; Nagarajan RP, 1999, J BIOL CHEM, V274, P31229, DOI 10.1074/jbc.274.44.31229; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Pendas AM, 1997, GENOMICS, V40, P222, DOI 10.1006/geno.1996.4554; Piek E, 1999, INT J CANCER, V80, P756, DOI 10.1002/(SICI)1097-0215(19990301)80:5<756::AID-IJC21>3.0.CO;2-N; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Ravanti L, 2001, FASEB J, V15, P1098, DOI 10.1096/fj.00-0588fje; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Sato M, 2002, J INVEST DERMATOL, V118, P704, DOI 10.1046/j.1523-1747.2002.01719.x; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; StahleBackdahl M, 1997, LAB INVEST, V76, P717; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Tardif G, 2001, J RHEUMATOL, V28, P1631; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Werner F, 2000, J BIOL CHEM, V275, P36653, DOI 10.1074/jbc.M004536200; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; Wong C, 1999, MOL CELL BIOL, V19, P1821; Yuan WH, 2001, J BIOL CHEM, V276, P38502, DOI 10.1074/jbc.M107081200; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	59	94	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46338	46346		10.1074/jbc.M206535200	http://dx.doi.org/10.1074/jbc.M206535200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270924	hybrid			2022-12-27	WOS:000179529300084
J	Phadtare, S; Tyagi, S; Inouye, M; Severinov, K				Phadtare, S; Tyagi, S; Inouye, M; Severinov, K			Three amino acids in Escherichia coli CspE surface-exposed aromatic patch are critical for nucleic acid melting activity leading to transcription antitermination and cold acclimation of cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUTION NMR STRUCTURE; SHOCK PROTEIN CSPA; RNA; BINDING; FAMILY; DOMAIN; CONDENSATION; SUBUNIT; DNA	Cold-shock proteins of the CspA family of Escherichia coli help the cells to acclimate to low temperature conditions through an unknown mechanism. In vitro, these proteins bind to single-stranded nucleic acids and destabilize nucleic acid secondary structures. An unusual surface-exposed patch of 6 evolutionarily conserved aromatic amino acids is thought to be involved in RNA binding by the cold-shock proteins. Here we investigated the functional role of the aromatic patch in E. coli CspE by substituting individual aromatic residues with positively charged Arg residues. These substitutions do not affect the RNA binding activity of the CspE mutants. We show that substitutions of three centrally located aromatic patch amino acid residues, Phe(17), Phe(30), and His(32), abolish the ability of the mutant CspE to acclimatize cells to cold, antiterminate transcription and melt nucleic acids but have no effect on RNA binding. On the other hand, peripherally located Trp(10), Phe(19), and Phe(33) can be substituted with Arg without loss of any of the in vivo and in vitro CspE functions tested. The results thus indicate that these aromatic patch residues have clearly distinct functional roles and further extend the correlation between the essential function of CspA homologues in cold acclimation and their ability to antiterminate transcription.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Publ Hlth Res Inst, Newark, NJ 07103 USA; Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick	Severinov, K (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.		Severinov, Konstantin/C-8545-2016	Tyagi, Sanjay/0000-0001-7303-5827	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059295, R37GM019043, R01GM019043] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 59295, GM 19043] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae WH, 2000, P NATL ACAD SCI USA, V97, P7784, DOI 10.1073/pnas.97.14.7784; CHATTERJEE S, 1993, J BIOCHEM, V114, P663, DOI 10.1093/oxfordjournals.jbchem.a124234; Feng WQ, 1998, BIOCHEMISTRY-US, V37, P10881, DOI 10.1021/bi980269j; Feng Y, 2001, J BIOL CHEM, V276, P31651, DOI 10.1074/jbc.M102855200; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; Hanna MM, 1998, J MOL BIOL, V282, P227, DOI 10.1006/jmbi.1998.2005; Hillier BJ, 1998, FOLD DES, V3, P87, DOI 10.1016/S1359-0278(98)00014-5; Hu KH, 1996, GENETICS, V143, P1521; Jiang WN, 1997, J BIOL CHEM, V272, P196; JONES PG, 1987, J BACTERIOL, V169, P2092, DOI 10.1128/jb.169.5.2092-2095.1987; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; NEWKIRK K, 1994, P NATL ACAD SCI USA, V91, P5114, DOI 10.1073/pnas.91.11.5114; Phadtare S, 1999, CURR OPIN MICROBIOL, V2, P175, DOI 10.1016/S1369-5274(99)80031-9; Phadtare S, 2000, BACTERIAL STRESS RESPONSES, P33; Phadtare S, 1999, MOL MICROBIOL, V33, P1004, DOI 10.1046/j.1365-2958.1999.01541.x; Phadtare S, 2002, J BIOL CHEM, V277, P7239, DOI 10.1074/jbc.M111496200; Phadtare S, 2001, J BACTERIOL, V183, P1205, DOI 10.1128/JB.183.4.1205-1214.2001; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SCHRODER K, 1995, MOL MICROBIOL, V16, P699, DOI 10.1111/j.1365-2958.1995.tb02431.x; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; Vu DM, 2001, PROTEIN SCI, V10, P2028, DOI 10.1110/ps.16201; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Xia B, 2001, MOL MICROBIOL, V40, P179, DOI 10.1046/j.1365-2958.2001.02372.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zakharova N, 1998, J BIOL CHEM, V273, P24912, DOI 10.1074/jbc.273.38.24912	26	60	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46706	46711		10.1074/jbc.M208118200	http://dx.doi.org/10.1074/jbc.M208118200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324471	hybrid			2022-12-27	WOS:000179529300129
J	St-Pierre, B; Flock, G; Zacksenhaus, E; Egan, SE				St-Pierre, B; Flock, G; Zacksenhaus, E; Egan, SE			Stra13 homodimers repress transcription through class B E-box elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; BETA-CASEIN GENE; TUMOR-SUPPRESSOR; DNA-BINDING; ENHANCER; IDENTIFICATION; EXPRESSION; DROSOPHILA; ACTIVATION; HYPOXIA	A mammalian basic helix-loop-helix protein known variably as Stra13, Sharp2, and Dec1 has been implicated in cell activation, proliferation, and differentiation. Indeed, Stra13 null mice develop age-induced antoimmunity as a result of impaired T-lymphocyte activation, leading ultimately to the accumulation of autoreactive T-cells and B-cells. Stra13 is expressed in embryonic as well as adult tissues derived from neuroectoderm, mesoderm, and endoderm and has been associated with response to hypoxia, suggesting a complex role for this protein and the highly related Sharp1/Dec2 protein in homeostatic regulation. Whereas Stra13 is known to regulate many important cellular functions and is known to cross-regulate biological responses to other basic helix-loop-helix containing transcription factors, including c-Myc and USF, it is unclear if this protein binds directly to DNA. Indeed, the basic domain of Stra13 contains a proline residue at an unprecedented position. Herein, we have determined that Stra13 binds with high affinity to CACGTG class B E-box elements as a homodimer with preference for elements preceded by T and/or followed by A residues. In addition, transient transfection experiments reveal that Stra13 represses transcription when bound to these and related sites. Our data suggest that Stra13 regulates cellular functions through antagonism of E-box activator proteins and also through active repression from E-box elements.	Toronto Gen Res Inst, Univ Hlth Network, Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada; Hosp Sick Children, Program Canc Res, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Univ Toronto, Toronto Gen Res Inst, Univ Hlth Network, Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Lab Med, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Pathobiol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Egan, SE (corresponding author), Toronto Gen Res Inst, Univ Hlth Network, Div Cell & Mol Biol, 67 Coll St, Toronto, ON M5G 2M1, Canada.		Zacksenhaus, Eldad/AAD-3584-2020					BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Dear TN, 1997, ONCOGENE, V14, P891, DOI 10.1038/sj.onc.1200912; Dhar M, 2001, ONCOGENE, V20, P4750, DOI 10.1038/sj.onc.1204637; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Jennings BH, 1999, MOL CELL BIOL, V19, P4600; Krylov D, 1997, P NATL ACAD SCI USA, V94, P12274, DOI 10.1073/pnas.94.23.12274; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; OELLERS N, 1994, MOL GEN GENET, V244, P465, DOI 10.1007/BF00583897; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Shen M, 2001, EUR J CELL BIOL, V80, P329, DOI 10.1078/0171-9335-00167; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; Teramoto M, 2001, J BIOCHEM-TOKYO, V129, P391, DOI 10.1093/oxfordjournals.jbchem.a002869; TIETZE K, 1992, P NATL ACAD SCI USA, V89, P6152, DOI 10.1073/pnas.89.13.6152; Wartmann M, 1996, J BIOL CHEM, V271, P31863, DOI 10.1074/jbc.271.50.31863; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yoon DY, 2001, BIOCHEM BIOPH RES CO, V288, P882, DOI 10.1006/bbrc.2001.5867; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zawel L, 2002, P NATL ACAD SCI USA, V99, P2848, DOI 10.1073/pnas.261714999	24	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46544	46551		10.1074/jbc.M111652200	http://dx.doi.org/10.1074/jbc.M111652200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12297495	hybrid			2022-12-27	WOS:000179529300109
J	Xue, T; Li, RA				Xue, T; Li, RA			An external determinant in the S5-P linker of the pacemaker (HCN) channel identified by sulfhydryl modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE MUTAGENESIS; CYCLIC-NUCLEOTIDE; POTASSIUM CHANNEL; LINING RESIDUES; SODIUM-CHANNELS; SLOW INACTIVATION; CHARGED RESIDUES; MOLECULAR-BASIS; ALPHA-SUBUNIT; ION CHANNELS	Hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels underlie spontaneous rhythmic activities in the heart and brain. Sulfhydryl miodification of ion channels is a proven approach for studying their structure-function relationships; here we! examined the effects of the hydrophilic sulfhydryl-modifying agents methanethiosulfonate ethylammonium (MTSEA(+)) and methanethiosulfonate ethylsulfonate (MTSES-) on wildtype (WT) and engineered HCN1 channels. External application of MTSEA(+) to WT channels irreversibly reduced whole-cell currents (I-MTSEA/I-Control = 42 +/- 2%), slowed activation and deactivation kinetics (similar to7- and similar to3-fold at -140 and -20 mV, respectively), and produced hyperpolarizing shifts of steady-state activation (V-1/2(MTSEA) = -125.8 +/- 9.0 mV versus V-1/2(Control) = -76.4 +/- 1.6 mV). Sequence inspection revealed the presence of five endogenous cysteines in the transmembrane domains of HCN1: three are putatively close to the extracellular milieu (Cys(303), cys(318), and Cys(347) in the S5, S5-P, and P segments, respectively), whereas the remaining two are likely to be cytoplasmic or buried. To identify the molecular constituent(s) responsible for the effects of MTSEA(+), we mutated the three "external" cysteines individually to serine. C303S did not yield measurable currents. Whereas C347S channels remained sensitive to MTSEA(+), C318S was not modified (I-MTSEA/I-Control = 101 +/- 2%, V-1/2(MTSEA) = -78.4 +/- 1.1 mV, and V-1/2(Control) = -79.8 +/- 2.3 mV). Likewise, WT (but not C318S) channels were sensitive to MTSES-. Despite their opposite charges, MTSES- produced changes directionally similar to those effected by MTSEA+ (I-MTSES/I-Control = 22 +/- 1.6% and V-1/2(MTSES) = -145.9 +/- 4.9 mV). We conclude that S5-P CyS318 of HCN1 is externally accessible and that the external pore vestibule and activation gating of HCN channels are allosterically coupled.	Johns Hopkins Univ, Inst Mol Cardiobiol, Sch Med, Baltimore, MD 21205 USA	Johns Hopkins University	Li, RA (corresponding author), Johns Hopkins Univ, Inst Mol Cardiobiol, Sch Med, 720 Rutland Ave,Ross 844, Baltimore, MD 21205 USA.		Xue, Tian/G-9009-2018		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052768] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-52768] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; AZENE E, 2002, IN PRESS CIRCULATION; Balser JR, 1996, J PHYSIOL-LONDON, V494, P431, DOI 10.1113/jphysiol.1996.sp021503; Benitah JP, 1996, P NATL ACAD SCI USA, V93, P7392, DOI 10.1073/pnas.93.14.7392; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; Chiamvimonvat N, 1996, J PHYSIOL-LONDON, V491, P51, DOI 10.1113/jphysiol.1996.sp021195; Clapham DE, 1998, NEURON, V21, P5, DOI 10.1016/S0896-6273(00)80508-5; Creighton T. E, 1997, PROTEINS STRUCTURES; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dun W, 1999, PFLUG ARCH EUR J PHY, V439, P141, DOI 10.1007/s004240051138; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; HENRIKSON CA, 2002, IN PRESS CIRCULATION; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Horn R, 1998, METHOD ENZYMOL, V293, P145; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kaupp UB, 2001, ANNU REV PHYSIOL, V63, P235, DOI 10.1146/annurev.physiol.63.1.235; Li RA, 2000, J GEN PHYSIOL, V115, P81, DOI 10.1085/jgp.115.1.81; Li RA, 2001, CIRCULATION, V104, P309; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 1999, CELL PHYSIOL BIOCHEM, V9, P179, DOI 10.1159/000016315; Marten I, 1998, BIOPHYS J, V74, P2953, DOI 10.1016/S0006-3495(98)78002-6; Pardo-Lopez L, 2002, J BIOL CHEM, V277, P16403, DOI 10.1074/jbc.M200460200; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; Santoro B, 1999, ANN NY ACAD SCI, V868, P741, DOI 10.1111/j.1749-6632.1999.tb11353.x; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Sun ZP, 1996, NEURON, V16, P141, DOI 10.1016/S0896-6273(00)80031-8; Townsend C, 1997, J GEN PHYSIOL, V110, P23, DOI 10.1085/jgp.110.1.23; Tsushima RG, 1997, J GEN PHYSIOL, V109, P463, DOI 10.1085/jgp.109.4.463; Tsushima RG, 1997, J GEN PHYSIOL, V110, P59, DOI 10.1085/jgp.110.1.59; Ulens C, 2001, J BIOL CHEM, V276, P6069, DOI 10.1074/jbc.C000738200; Xue T, 2002, CIRC RES, V90, P1267, DOI 10.1161/01.RES.0000024390.97889.C6; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	37	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46233	46242		10.1074/jbc.M204915200	http://dx.doi.org/10.1074/jbc.M204915200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351622	hybrid			2022-12-27	WOS:000179529300071
J	Avvakumov, GV; Grishkovskaya, I; Muller, YA; Hammond, GL				Avvakumov, GV; Grishkovskaya, I; Muller, YA; Hammond, GL			Crystal structure of human sex hormone-binding globulin in complex with 2-methoxyestradiol reveals the molecular basis for high affinity interactions with C-2 derivatives of estradiol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEM; CRYSTALLOGRAPHY; TRANSPORT; PROGRAM; CANCER; PLASMA; DOMAIN; SITE	In a crystal structure of the amino-terminal laminin G-like domain of human sex hormone-binding globulin (SHBG), the biologically active estrogen metabolite, 2-methoxyestradiol (2-MeOE2), binds in the same orientation as estradiol. The high affinity of SHBG for 2-MeOE2 relies primarily on hydrogen bonding between the hydroxyl at C-3 of 2-MeOE2 and Asp(65) and an interaction between the methoxy group at C-2 and the amido group of Asn(82). Accommodation of the 2-MeOE2 methoxy group causes an outward displacement of residues Ser(128)-Pro(130), which appears to disorder and displace the loop region (Leu(131)-His(136)) that covers the steroid-binding site. This could influence the binding kinetics of 2-MeOE2 and/or facilitate ligand-dependent interactions between SHBG and other proteins. Occupancy of a zinc-binding site reduces the affinity of SHBG for 2-MeOE2 and estradiol in the same way. The higher affinity of SHBG for estradiol derivatives with a halogen atom at C-2 is due to either enhanced hydrogen bonding between the hydroxyl at C-3 and Asp(65) (2-fluoroestradiol) or accommodation of the functional group at C-2 (2-bromoestradiol), rather than an interaction with Asn(82). By contrast, the low affinity of SHBG for 2-hydroxyestradiol can be attributed to intra-molecular hydrogen bonding between the hydroxyls in the aromatic steroid ring A, which generates a steric clash with the amido group of Asn(82). Understanding how C-2 derivatives of estradiol interact with SHBG could facilitate the design of biologically active synthetic estrogens.	Univ Western Ontario, Dept Obstet & Gynecol, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 4L6, Canada; Univ Western Ontario, Canadian Inst Hlth, Res Grp Fetal & Neonatal Hlth & Dev, London, ON N6A 4L6, Canada; Max Delbruck Ctr Mol Med, Forsch Grp Kristallog, D-13092 Berlin, Germany; Univ Sussex, Sch Biol Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Sussex	Hammond, GL (corresponding author), London Reg Canc Ctr, Canc Res Labs, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.		Muller, Yves A/R-5397-2016	Muller, Yves A/0000-0003-0519-8928; Hammond, Geoffrey/0000-0002-4639-7336				Avvakumov GV, 2000, J BIOL CHEM, V275, P25920, DOI 10.1074/jbc.M004484200; AVVAKUMOV GV, 1986, BIOCHIM BIOPHYS ACTA, V881, P489, DOI 10.1016/0304-4165(86)90043-7; Avvakumov GV, 2001, J BIOL CHEM, V276, P34453, DOI 10.1074/jbc.M106274200; BOCCHINFUSO WP, 1991, MOL ENDOCRINOL, V5, P1723, DOI 10.1210/mend-5-11-1723; Brueggemeier RW, 2001, J STEROID BIOCHEM, V78, P145, DOI 10.1016/S0960-0760(01)00090-5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P3964, DOI 10.1073/pnas.91.9.3964; Dawling S, 2001, CANCER RES, V61, P6716; DUNN JF, 1981, J CLIN ENDOCR METAB, V53, P58, DOI 10.1210/jcem-53-1-58; FERNLUND P, 1990, J STEROID BIOCHEM, V36, P75, DOI 10.1016/0022-4731(90)90115-9; Fletcher DA, 1996, J CHEM INF COMP SCI, V36, P746, DOI 10.1021/ci960015+; Grishkovskaya I, 2000, EMBO J, V19, P504, DOI 10.1093/emboj/19.4.504; Grishkovskaya I, 2002, J BIOL CHEM, V277, P32086, DOI 10.1074/jbc.M203999200; Grishkovskaya I, 2002, J MOL BIOL, V318, P621, DOI 10.1016/S0022-2836(02)00169-9; Grishkovskaya I, 1999, ACTA CRYSTALLOGR D, V55, P2053, DOI 10.1107/S0907444999012883; HAMMOND GL, 1983, CLIN CHIM ACTA, V132, P101, DOI 10.1016/0009-8981(83)90237-1; Hammond GL, 1995, TRENDS ENDOCRIN MET, V6, P298, DOI 10.1016/1043-2760(95)00162-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAULING L, 1960, NATURE CHEM BOND, P494; PORTO CS, 1991, ENDOCRINOLOGY, V129, P436, DOI 10.1210/endo-129-1-436; Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478; ROSNER W, 1991, J STEROID BIOCHEM, V40, P813, DOI 10.1016/0960-0760(91)90307-Q; Rudenko G, 2001, TRENDS BIOCHEM SCI, V26, P363, DOI 10.1016/S0968-0004(01)01832-1; Seimbille Y, 2002, STEROIDS, V67, P765, DOI 10.1016/S0039-128X(02)00025-9; VERBIST JJ, 1972, ACTA CRYSTALL B-STRU, VB 28, P3006, DOI 10.1107/S0567740872007368; WESTPHAL U, 1986, STEROID PROTEIN INTE, V2, P198; WUNDERLICH H, 1971, ACTA CRYSTALL B-STRU, VB 27, P1684, DOI 10.1107/S0567740871004618	32	28	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45219	45225		10.1074/jbc.M207762200	http://dx.doi.org/10.1074/jbc.M207762200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228253	hybrid			2022-12-27	WOS:000179404800081
J	Mao, XR; Moerman, AM; Barger, SW				Mao, XR; Moerman, AM; Barger, SW			Neuronal kappa B-binding factors consist of Sp1-related proteins - Functional implications for autoregulation of N-methyl-D-aspartate receptor-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; TRANSCRIPTION FACTOR; GLUTAMATE NEUROTOXICITY; REPRESS TRANSCRIPTION; SUBUNIT GENE; CELL-DEATH; IN-VITRO; ACTIVATION; SP1; APOPTOSIS	Neurons contain a protein factor capable of binding DNA elements normally bound by the transcription factor NF-kappaB. However, several lines of evidence suggest that this neuronal kappaB-binding factor (NKBF) is not bona fide NF-kappaB. We have identified NkappaBF from cultures of neocortical neurons as a complex containing proteins related to Sp1. This complex was bound by antibodies to Sp1, Sp3, and Sp4 and was competed from binding to an NF-kappaB element by an oligonucleotide, containing an Sp1-binding site. This Sp1 oligonucleotide detected an abundant factor in neuronal nuclei that migrated in electrophoretic mobility shift assays at a position consistent with NKBF. Expression of transfected Sp1 stimulated transcription in a manner dependent upon a kappaB cis-element. Similar to our previous reports for NKBF (Mao, X., Moerman, A. M., Lucas, M. M., and Barger, S. W. (1999) J. Neurochem. 73, 1851-1858 and Moerman, A. M., Mao, X., Lucas, M. M., and Barger, S. W. (1999) Mol. Brain Res. 67, 303-315), the activity of the Sp1-related factor was reduced by activation of ionotropic glutamate receptors, consistent with proteolytic degradation of all three Sp1-related factors. Expression of the N-methyl-D-aspartate receptor-1 (NR1) subunit of glutamate receptors correlated with the activity of the Sp1-related factor, specifically through an Sp1 element in the NR1 promoter. These data provide the first evidence that Sp1 or related family members are responsible for kappaB-binding activity and are involved in a negative feedback for NR1 in central nervous system neurons.	Univ Arkansas Med Sci, Dept Anat & Neurobiol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA; Ctr Geriatr Res Educ & Clin, Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Barger, SW (corresponding author), Reynolds Ctr Aging, 629 S Elm St,807, Little Rock, AR 72205 USA.			Moerman-Herzog, Andrea/0000-0002-5969-8939; Barger, Steven/0000-0001-6049-6480	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG012411] Funding Source: NIH RePORTER; NIA NIH HHS [2P01AG12411-04A1003] Funding Source: Medline; NINDS NIH HHS [F32 NS09630] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMMENDOLA R, 1992, J BIOL CHEM, V267, P17944; AMMENDOLA R, 1994, EUR J BIOCHEM, V225, P483, DOI 10.1111/j.1432-1033.1994.t01-1-00483.x; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; Bai G, 1997, J BIOL CHEM, V272, P5936, DOI 10.1074/jbc.272.9.5936; Bai G, 1998, J BIOL CHEM, V273, P1086, DOI 10.1074/jbc.273.2.1086; BAI G, 1995, J BIOL CHEM, V270, P7737, DOI 10.1074/jbc.270.13.7737; Behl C, 2000, J NEURAL TRANSM, V107, P393, DOI 10.1007/s007020070082; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1987, J NEUROSCI, V7, P369; CONDORELLI DF, 1994, NEUROCHEM RES, V19, P489, DOI 10.1007/BF00967329; CORRADIN SB, 1993, GLIA, V7, P255, DOI 10.1002/glia.440070309; Follesa P, 1996, J NEUROSCI, V16, P2172; Grilli M, 1996, J BIOL CHEM, V271, P15002, DOI 10.1074/jbc.271.25.15002; GUERRINI L, 1995, P NATL ACAD SCI USA, V92, P9077, DOI 10.1073/pnas.92.20.9077; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Li YK, 2000, J NEUROSCI, V20, P149, DOI 10.1523/JNEUROSCI.20-01-00149.2000; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Mao XR, 1999, J NEUROCHEM, V73, P1851; Mao XR, 1998, NEUROREPORT, V9, P759, DOI 10.1097/00001756-199803090-00036; Moerman AM, 1999, MOL BRAIN RES, V67, P303, DOI 10.1016/S0169-328X(99)00091-1; Qin ZH, 2000, MOL BRAIN RES, V80, P111, DOI 10.1016/S0169-328X(00)00147-9; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reynolds IJ, 1999, ANN NY ACAD SCI, V893, P33, DOI 10.1111/j.1749-6632.1999.tb07816.x; Rickers A, 1999, EUR J BIOCHEM, V261, P269, DOI 10.1046/j.1432-1327.1999.00273.x; SAKAI T, 1995, J BIOCHEM-TOKYO, V118, P621, DOI 10.1093/oxfordjournals.jbchem.a124955; Schinder AF, 1996, J NEUROSCI, V16, P6125; SONNENBERG JL, 1989, J NEUROSCI RES, V24, P72, DOI 10.1002/jnr.490240111; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Supp DM, 1996, DEV BIOL, V176, P284, DOI 10.1006/dbio.1996.0134; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; SZEKELY AM, 1990, MOL PHARMACOL, V38, P624; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yabe T, 2001, J BIOL CHEM, V276, P43313, DOI 10.1074/jbc.M107831200	44	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44911	44919		10.1074/jbc.M204292200	http://dx.doi.org/10.1074/jbc.M204292200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244044	hybrid			2022-12-27	WOS:000179404800042
J	Sakurada, K; Kato, H; Nagumo, H; Hiraoka, H; Furuya, K; Ikuhara, T; Yamakita, Y; Fukunaga, K; Miyamoto, E; Matsumura, F; Matsuo, YI; Naito, Y; Sasaki, Y				Sakurada, K; Kato, H; Nagumo, H; Hiraoka, H; Furuya, K; Ikuhara, T; Yamakita, Y; Fukunaga, K; Miyamoto, E; Matsumura, F; Matsuo, YI; Naito, Y; Sasaki, Y			Synapsin I is phosphorylated at Ser(603) by p21-activated kinases (PAKs) in vitro and in PC12 cells stimulated with bradykinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; LONG-TERM POTENTIATION; GTP-BINDING-PROTEIN; NEUROTRANSMITTER RELEASE; SYNAPTIC VESICLES; FOCAL COMPLEXES; F-ACTIN; RHO; CALCIUM; GTPASES	The function of synapsin I is regulated by phosphorylation of the molecule at multiple sites; among them, the Ser(603) residue (site 3) is considered to be a pivotal site targeted by Ca2+/calmodulin-dependent kinase II (CaMKII). Although phosphorylation of the Ser(603) residue responds to several kinds of stimuli, it is unlikely that many or all of the stimuli activate the CaMKII-involved pathway. Among the several stimulants tested in PC12 cells, bradykinin evoked the phosphorylation of Ser(603) without inducing the autophosphorylation of CaMKII, which was determined using phosphorylation site-specific antibodies against phospho-Ser(603)-synapsin I (pS(603)-Syn I-Ab) and phospho-Thr(286/287)-CaMKII. The bradykinin-evoked phosphorylation of Ser(603) was not suppressed by the CaAMI inhibitor KN62, whereas high KCl-evoked phosphorylation was accompanied by CaMKII autophosphorylation and inhibited by KN62. Thus, we attempted to identify Ser(603) kinase(s) besides CaMKII. We consequently detected four and three fractions with Ca2+/calmodulin-independent Ser(603) kinase activity on the DEAE column chromatography of bovine brain homogenate and PC12 cell lysate, respectively, two of which were purified and identified by amino acid sequence of proteolytic fragments as p21-activated kinase (PAK) 1 and PAK3. The immunoprecipitants from bovine brain homogenate with anti-PAK1 and PAK3 antibodies incorporated P-32 into synapsin I in a Cdc42/GTPgammaS-dependent manner, and its phosphorylation site was confirmed as Ser(603) using pS(603)-Syn I-Ab. Additionally, recombinant GST-PAK2 could phosphorylate the Ser(603) residue in the presence of Cdc42/GTPgammaS. Finally, we confirmed by immunocytochemical analysis that the transfection of constitutively active rat alphaPAK (PAK1) in PC12 cells evokes the phosphorylation of Ser(603) even in the resting mutant cells and enhances it in the bradykinin-stimulated cells, whereas that of dominant-negative aPAK quenches the phosphorylation. These results raise the possibility that Ser(603) on synapsin I is alternatively phosphorylated by PAKs, not only by CaMKII, in neuronal cells in response to some stimulants.	Asahi Chem Ind Co Ltd, Frontier 21 Project, Life Sci Res Inst, Fuji, Shizuoka 4168501, Japan; Kitasato Univ, Sch Pharmaceut Sci, Dept Pharmacol, Minato Ku, Tokyo 1088641, Japan; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA; Kumamoto Univ, Sch Med, Dept Pharmacol, Kumamoto 8608501, Japan	Kitasato University; Rutgers State University New Brunswick; Kumamoto University	Sasaki, Y (corresponding author), Asahi Chem Ind Co Ltd, Frontier 21 Project, Life Sci Res Inst, 2-1 Samejima, Fuji, Shizuoka 4168501, Japan.		Yamakita, Yoshihiko/A-3003-2016; Fukunaga, Kohji/AAI-8811-2021	Ikeda-Matsuo, Yuri/0000-0001-9269-9119; Matsumura, Fumio/0000-0002-8204-153X; Fukunaga, Kohji/0000-0001-8526-2824				APPELL KC, 1989, BIOCHEM J, V263, P11, DOI 10.1042/bj2630011; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BENFENATI F, 1992, NEURON, V8, P377, DOI 10.1016/0896-6273(92)90303-U; BROWNING MD, 1992, SYNAPSE, V10, P62, DOI 10.1002/syn.890100109; CECCALDI PE, 1995, J CELL BIOL, V128, P905, DOI 10.1083/jcb.128.5.905; Chin D, 1997, J BIOL CHEM, V272, P31235, DOI 10.1074/jbc.272.50.31235; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; CHUANG TH, 1994, BIOCHEM J, V303, P761, DOI 10.1042/bj3030761; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Foster DB, 2000, J BIOL CHEM, V275, P1959, DOI 10.1074/jbc.275.3.1959; FUKUNAGA K, 1982, J NEUROCHEM, V39, P1607, DOI 10.1111/j.1471-4159.1982.tb07994.x; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; Gasman S, 1997, J BIOL CHEM, V272, P20564, DOI 10.1074/jbc.272.33.20564; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Hilfiker S, 1999, PHILOS T ROY SOC B, V354, P269, DOI 10.1098/rstb.1999.0378; Hosaka M, 1999, NEURON, V24, P377, DOI 10.1016/S0896-6273(00)80851-X; Iwata SI, 1996, J PHARMACOL EXP THER, V278, P1428; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323, DOI 10.1038/73888; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; King AJ, 2001, FEBS LETT, V497, P6, DOI 10.1016/S0014-5793(01)02425-5; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Liu J, 1999, J NEUROSCI, V19, P8292; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; Meriane M, 2000, J BIOL CHEM, V275, P33046, DOI 10.1074/jbc.M001566200; Nagumo H, 2000, AM J PHYSIOL-CELL PH, V278, pC57, DOI 10.1152/ajpcell.2000.278.1.C57; Nakamura K, 1998, J NEUROCHEM, V71, P646; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ohtakara K, 2000, BIOCHEM BIOPH RES CO, V272, P712, DOI 10.1006/bbrc.2000.2854; PARFITT KD, 1991, P NATL ACAD SCI USA, V88, P2361, DOI 10.1073/pnas.88.6.2361; Sakurada K, 1998, AM J PHYSIOL-CELL PH, V274, pC1563, DOI 10.1152/ajpcell.1998.274.6.C1563; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; SHIONO S, 1993, BIOCHEM BIOPH RES CO, V193, P667, DOI 10.1006/bbrc.1993.1676; Tabuchi H, 2000, ENDOCRINOLOGY, V141, P2350, DOI 10.1210/en.141.7.2350; Turner KM, 1999, TRENDS NEUROSCI, V22, P459, DOI 10.1016/S0166-2236(99)01436-8; WilkBlaszczak MA, 1997, J NEUROSCI, V17, P4094; YAMAGATA Y, 1995, NEUROSCIENCE, V64, P1, DOI 10.1016/0306-4522(94)00492-N; Yokota S, 2001, J NEUROCHEM, V77, P618, DOI 10.1046/j.1471-4159.2001.00270.x; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	46	25	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45473	45479		10.1074/jbc.M206673200	http://dx.doi.org/10.1074/jbc.M206673200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237306	hybrid			2022-12-27	WOS:000179404800112
J	Tomita, M; Reinhold, MI; Molkentin, JD; Naski, MC				Tomita, M; Reinhold, MI; Molkentin, JD; Naski, MC			Calcineurin and NFAT4 induce chondrogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA-SUPERFAMILY; TRANSCRIPTION FACTOR; NF-ATC; CUBITUS-INTERRUPTUS; LIMB CHONDROGENESIS; NUCLEAR FACTOR; CHICK LIMB; PROTEIN; MOUSE; DIFFERENTIATION	Nuclear factor of activated T-cells (NFAT) and calcineurin are essential regulators of immune cell and mesenchymal cell differentiation. Here we show that elevated intracellular calcium induces chondrogenesis through a calcineurin/NFAT signaling axis that activates bone morphogenetic protein (BMP) expression. The calcium ionophore, ionomycin, induced chondrogenesis through activation of calcineurin. The calcineurin substrate, NFAT4, also induced chondrogenesis and chondrocyte gene expression. Significantly, the BMP antagonist, noggin, or dominant negative BMP receptors blocked the effects of elevated intracellular calcium on chondrogenesis. This suggested that calcineurin/NFAT4 activates BMP expression. Consistent with this, BMP2 gene expression was increased by ionomycin and suppressed by the calcineurin inhibitor, cyclosporine A. Furthermore, activated NFAT4 induced BMP2 gene expression. These results have important implications for the effects of NFATs during development and adaptive responses.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA; Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA	University of Texas System; University of Texas Health San Antonio; Cincinnati Children's Hospital Medical Center	Naski, MC (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.			Molkentin, Jeffery/0000-0002-3558-6529	NIAMS NIH HHS [AR47070] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047070] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Aza-Blanc P, 2000, DEVELOPMENT, V127, P4293; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; Duprez D, 1996, MECH DEVELOP, V57, P145, DOI 10.1016/0925-4773(96)00540-0; EdwallArvidsson C, 1996, ANAT EMBRYOL, V193, P453; FENG JQ, 1995, J BIOL CHEM, V270, P28364, DOI 10.1074/jbc.270.47.28364; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Galvin KM, 2000, NAT GENET, V24, P171, DOI 10.1038/72835; Ghosh-Choudhury N, 2001, BIOCHEM BIOPH RES CO, V286, P101, DOI 10.1006/bbrc.2001.5351; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Helvering LM, 2000, GENE, V256, P123, DOI 10.1016/S0378-1119(00)00364-4; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Kawai S, 2001, BONE, V29, P54, DOI 10.1016/S8756-3282(01)00470-7; Kawakami Y, 1996, DEVELOPMENT, V122, P3557; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; Pizette S, 2000, DEV BIOL, V219, P237, DOI 10.1006/dbio.2000.9610; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Stevenson AS, 2001, J BIOL CHEM, V276, P15018, DOI 10.1074/jbc.M011684200; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; WIDELITZ RB, 1993, J CELL PHYSIOL, V156, P399, DOI 10.1002/jcp.1041560224; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191	42	83	86	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42214	42218		10.1074/jbc.C200504200	http://dx.doi.org/10.1074/jbc.C200504200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12239209	hybrid			2022-12-27	WOS:000178985300115
J	Rogers, MA; Langbein, L; Winter, H; Ehmann, C; Praetzel, S; Schweizer, J				Rogers, MA; Langbein, L; Winter, H; Ehmann, C; Praetzel, S; Schweizer, J			Characterization of a first domain of human high glycine-tyrosine and high sulfur keratin-associated protein (KAP) genes on chromosome 21q22.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TYPE-I; CYSTEINE-RICH PROTEINS; HUMAN HAIR KERATINS; DIFFERENTIAL EXPRESSION; MESSENGER-RNA; CDNA CLONES; SHEEP WOOL; FOLLICLE; FAMILY; ORGANIZATION	Analysis of the EBI/GeneBank(TM) data base using non-human hair keratin-associated protein (KAP) cDNA sequences as a query resulted in the identification of a first domain of high glycine-tyrosine and high sulfur KAP genes located on human chromosome 21q22.1. This domain, present on the DNA accession numbers AP001078 and AP001709, was similar to535 kb in size and contained 17 high glycine-tyrosine and 7 high sulfur KAP genes, as well as 9 KAP pseudogenes. Based on amino acid sequence comparisons of the encoded proteins, the KAP genes could be divided into seven high glycine-tyrosine gene families (KAP6-KAP8, and KAP19-KAP22) and four high sulfur gene families (KAP11, KAP13, KAP15, and KAP23). The high glycine-tyrosine genes described here appear to represent the complete set of this type of KAP genes present in the human genome. Both systematic cDNA isolation studies from an arrayed scalp cDNA library and in situ hybridization expression studies of all of the KAP genes identified in the 21q22.1 region revealed varying degrees and regions of expression of 11 members of the high tyrosine-glycine genes and 6 members of the high sulfur KAP genes in the hair forming compartment.	German Canc Res Ctr, Sect Normal & Neoplast Epidermal Differentiat B05, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Cell Biol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Rogers, MA (corresponding author), German Canc Res Ctr, Sect Normal & Neoplast Epidermal Differentiat B05, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Rogers, Michael A./J-9803-2012	Rogers, Michael A./0000-0002-3728-2107				Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333; Aoki N, 1997, J BIOL CHEM, V272, P30512, DOI 10.1074/jbc.272.48.30512; Aoki N, 1998, J INVEST DERMATOL, V111, P804, DOI 10.1046/j.1523-1747.1998.00387.x; Cole SE, 1998, GENOMICS, V54, P437, DOI 10.1006/geno.1998.5590; DOPHEIDE TA, 1973, EUR J BIOCHEM, V34, P120, DOI 10.1111/j.1432-1033.1973.tb02737.x; FRATINI A, 1993, J BIOL CHEM, V268, P4511; FRATINI A, 1994, J INVEST DERMATOL, V102, P178, DOI 10.1111/1523-1747.ep12371759; FRENKEL MJ, 1989, GENOMICS, V4, P182, DOI 10.1016/0888-7543(89)90298-X; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Gillespie J.M., 1983, BIOCH PHYSL SKIN, P475; Gillespie J.M., 1991, PHYSL BIOCH MOL BIOL, P625; GILLESPIE JM, 1972, COMP BIOCHEM PHYSIOL, V41, P723, DOI 10.1016/0305-0491(72)90085-5; Gillespie JM, 1990, CELLULAR MOL BIOL IN, P95; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HUH N, 1994, J INVEST DERMATOL, V102, P716, DOI 10.1111/1523-1747.ep12375385; JENKINS BJ, 1994, J INVEST DERMATOL, V103, P310, DOI 10.1111/1523-1747.ep12394770; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; KUCZEK E, 1985, EUR J BIOCHEM, V146, P89, DOI 10.1111/j.1432-1033.1985.tb08623.x; KUCZEK ES, 1987, EUR J BIOCHEM, V166, P79, DOI 10.1111/j.1432-1033.1987.tb13486.x; Kuhn F, 1999, MECH DEVELOP, V86, P193, DOI 10.1016/S0925-4773(99)00115-X; LANGBEIN L, 1993, DIFFERENTIATION, V55, P57, DOI 10.1111/j.1432-0436.1993.tb00033.x; Langbein L, 1999, J BIOL CHEM, V274, P19874, DOI 10.1074/jbc.274.28.19874; Langbein L, 2001, J BIOL CHEM, V276, P35123, DOI 10.1074/jbc.M103305200; MACKINNON PJ, 1991, MAMM GENOME, V1, P53, DOI 10.1007/BF00350846; MACKINNON PJ, 1990, J CELL BIOL, V111, P2587, DOI 10.1083/jcb.111.6.2587; MARSHALL RC, 1980, P 6 INT WOOL TEXT RE, P147; MCNAB AR, 1990, P NATL ACAD SCI USA, V87, P6848, DOI 10.1073/pnas.87.17.6848; Miklos GLG, 2001, PROTEOMICS, V1, P169, DOI 10.1002/1615-9861(200102)1:2<169::AID-PROT169>3.0.CO;2-C; Mitsui S, 1998, GENE, V208, P123, DOI 10.1016/S0378-1119(97)00607-0; Perez C, 1999, GENE, V227, P137, DOI 10.1016/S0378-1119(98)00616-7; Powell B C, 1997, EXS, V78, P59; POWELL BC, 1983, NUCLEIC ACIDS RES, V11, P5327, DOI 10.1093/nar/11.16.5327; POWELL BC, 1995, DIFFERENTIATION, V58, P227, DOI 10.1046/j.1432-0436.1995.5830227.x; Reymond A, 2002, GENOMICS, V79, P824, DOI 10.1006/geno.2002.6781; ROGERS GE, 1993, J INVEST DERMATOL, V101, pS50, DOI 10.1111/1523-1747.ep12362626; Rogers MA, 1998, J BIOL CHEM, V273, P26683, DOI 10.1074/jbc.273.41.26683; Rogers MA, 1997, DIFFERENTIATION, V61, P187, DOI 10.1046/j.1432-0436.1997.6130187.x; Rogers MA, 2001, J BIOL CHEM, V276, P19440, DOI 10.1074/jbc.M100657200; Rogers MA, 2000, J INVEST DERMATOL, V114, P464, DOI 10.1046/j.1523-1747.2000.00910.x; Shimomura Y, 2002, J INVEST DERMATOL, V118, P226, DOI 10.1046/j.0022-202x.2001.01653.x; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; SWART LS, 1973, BIOCHEM J, V133, P641, DOI 10.1042/bj1330641; SWART LS, 1976, P 5 INT WOOL TEXT RE, P254; Takaishi M, 1998, J INVEST DERMATOL, V111, P128, DOI 10.1046/j.1523-1747.1998.00241.x; Tkatchenko AV, 2001, DEVELOPMENT, V128, P1547; Winter H, 2001, HUM GENET, V108, P37, DOI 10.1007/s004390000439; ZHUMABAEVA BD, 1992, MOL BIOL+, V26, P550	50	84	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48993	49002		10.1074/jbc.M206422200	http://dx.doi.org/10.1074/jbc.M206422200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12359730	hybrid			2022-12-27	WOS:000179789600132
J	Rousset, R; Wharton, DA; Zimmermann, G; Scott, MP				Rousset, R; Wharton, DA; Zimmermann, G; Scott, MP			Zinc-dependent interaction between dishevelled and the Drosophila Wnt antagonist naked cuticle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING; SIGNALING PATHWAY; BETA-CATENIN; PROTEIN; DOMAIN; PDZ; MEMBRANE; KINASE; TRANSCRIPTION; MOTIFS	During Drosophila development, the naked cuticle (nkd) gene attenuates wingless/Wnt signaling through a negative feedback loop mechanism. Fly and vertebrate Nkd proteins contain a putative calcium-binding EF-hand motif, the EFX domain, that interacts with the basic/PDZ region of the Wnt signal transducer, dishevelled (Dsh). Here we show that Dsh binding by Drosophila Nkd in vitro is mediated by the EFX domain as well as an adjacent C-terminal sequence. In vivo data suggest that both of these regions contribute to the ability of Nkd to antagonize Wnt signaling. Mutations in the Nkd EF-hand designed to eliminate potential ion binding affected Nkd-Dsh interactions in the yeast two-hybrid assay but not in the glutathione S-transferase pull-down assay. Addition of the chelating agent EDTA abolished the in vitro Nkd-Dsh interaction. Surprisingly zinc, but not calcium, was able to restore Nkd-Dsh binding, suggesting a zinc-mediated interaction. Calcium 45- and zinc 65-blotting experiments show that Nkd is a zinc-binding metalloprotein. The results further clarify how Nkd may antagonize Wnt signaling via interaction with Dsh, and identify a novel zinc-binding domain in Drosophila Nkd that collaborates with the conserved EFX domain to bind Dsh.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University	Scott, MP (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Dev Biol, Stanford, CA 94305 USA.	scott@pmgm2.stanford.edu	Rousset, Raphael/E-5908-2017	Rousset, Raphael/0000-0002-4999-403X	Howard Hughes Medical Institute Funding Source: Medline; NICHD NIH HHS [K08 HD 01164-06] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD001164] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Andersson M, 1997, PROTEIN SCI, V6, P1139, DOI 10.1002/pro.5560060602; Bray S, 2000, CURR BIOL, V10, pR155, DOI 10.1016/S0960-9822(00)00330-4; Brodersen DE, 1999, BIOCHEMISTRY-US, V38, P1695, DOI 10.1021/bi982483d; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CELIS JE, 1990, FEBS LETT, V262, P159, DOI 10.1016/0014-5793(90)80179-M; Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; Gribenko AV, 1998, J MOL BIOL, V283, P679, DOI 10.1006/jmbi.1998.2116; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hino SI, 2001, MOL CELL BIOL, V21, P330, DOI 10.1128/MCB.21.1.330-342.2001; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; James P, 1996, GENETICS, V144, P1425; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Maekawa K, 1999, BIOCHEM J, V337, P179, DOI 10.1042/0264-6021:3370179; Maret W, 2000, J NUTR, V130, p1455S, DOI 10.1093/jn/130.5.1455S; Maret W, 1997, P NATL ACAD SCI USA, V94, P2233, DOI 10.1073/pnas.94.6.2233; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MAZEN A, 1988, ANAL BIOCHEM, V172, P39, DOI 10.1016/0003-2697(88)90408-3; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Park M, 2002, NAT CELL BIOL, V4, P20, DOI 10.1038/ncb716; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Polakis P, 2000, GENE DEV, V14, P1837; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; Rousset R, 2001, GENE DEV, V15, P658, DOI 10.1101/gad.869201; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; SCHIFF LA, 1988, P NATL ACAD SCI USA, V85, P4195, DOI 10.1073/pnas.85.12.4195; Schofield RMS, 1997, J EXP BIOL, V200, P3235; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Strovel ET, 2000, J BIOL CHEM, V275, P2399, DOI 10.1074/jbc.275.4.2399; Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; VALLEE BL, 1984, ADV ENZYMOL RAMB, V56, P283; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wei Y, 1999, BIOCHEMISTRY-US, V38, P14534, DOI 10.1021/bi9911233; Wharton KA, 2001, DEV BIOL, V234, P93, DOI 10.1006/dbio.2001.0238; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507; Yan D, 2001, P NATL ACAD SCI USA, V98, P3802, DOI 10.1073/pnas.071041898; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Zeng WL, 2000, NATURE, V403, P789, DOI 10.1038/35001615	56	26	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					49019	49026		10.1074/jbc.M203246200	http://dx.doi.org/10.1074/jbc.M203246200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12354775	hybrid			2022-12-27	WOS:000179789600135
J	van der Kleij, D; Latz, E; Brouwers, JFHM; Kruize, YCM; Schmitz, M; Kurt-Jones, EA; Espevik, T; de Jong, EC; Kapsenberg, ML; Golenbock, DT; Tielens, AGM; Yazdanbakhsh, M				van der Kleij, D; Latz, E; Brouwers, JFHM; Kruize, YCM; Schmitz, M; Kurt-Jones, EA; Espevik, T; de Jong, EC; Kapsenberg, ML; Golenbock, DT; Tielens, AGM; Yazdanbakhsh, M			A novel host-parasite lipid cross-talk - Schistosomal lyso-phosphatidylserine activates Toll-like receptor 2 and affects immune polarization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DENDRITIC CELLS; BACTERIAL LIPOPROTEINS; TEGUMENTAL MEMBRANES; T-CELLS; TLR2; LIPOPOLYSACCHARIDE; RECOGNITION; MATURATION; MANSONI; MICE	Schistosome infections are characterized by prominent T cell hyporesponsiveness during the chronic stage of infection. We found that schistosome-specific phosphatidylserine (PS) activated TLR2 and affected dendritic cells such that mature dendritic cells gained the ability to induce the development of IL-10-producing regulatory T cells. Using mass spectrometry, schistosomal lysophosphatidylserine (lyso-PS) was identified as the TLR2-activating molecule. This activity appears to be a unique property of schistosomal lyso-PS, containing specific acyl chains, because neither a synthetic lyso-PS (16:0) nor PS isolated from the mammalian host activates TLR2. Taken together, these findings provide evidence for a novel host-parasite interaction that may be central to long term survival of the parasite and limited host pathology with implications beyond parasitology.	Leiden Univ, Med Ctr, Dept Parasitol, NL-2300 RC Leiden, Netherlands; Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, NL-3508 TD Utrecht, Netherlands; Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis, Worcester, MA 01655 USA; Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, N-7489 Trondheim, Norway; Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1100 DD Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Dermatol, NL-1100 DD Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Utrecht University; University of Massachusetts System; University of Massachusetts Worcester; Norwegian University of Science & Technology (NTNU); University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Yazdanbakhsh, M (corresponding author), Leiden Univ, Med Ctr, Dept Parasitol, Postbus 2600, NL-2300 RC Leiden, Netherlands.		Brouwers, Jos F/AAH-1444-2019; Yazdanbakhsh, Maria/AAI-3996-2020; Latz, Eicke/H-3951-2014	Brouwers, Jos F/0000-0003-2924-3279; Yazdanbakhsh, Maria/0000-0002-7666-1441; Latz, Eicke/0000-0003-1488-5666; Tielens, Aloysius/0000-0002-5485-1105				Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; ALLAN D, 1987, MOL BIOCHEM PARASIT, V23, P123, DOI 10.1016/0166-6851(87)90147-2; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brouwers JFHM, 1999, PARASITOLOGY, V119, P287, DOI 10.1017/S0031182099004679; Brouwers JFHM, 1998, MOL BIOCHEM PARASIT, V96, P49, DOI 10.1016/S0166-6851(98)00103-0; Brouwers JFHM, 1998, J LIPID RES, V39, P344; Cella M, 1999, J EXP MED, V189, P821, DOI 10.1084/jem.189.5.821; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; de Jong EC, 2002, J IMMUNOL, V168, P1704, DOI 10.4049/jimmunol.168.4.1704; Flo TH, 2000, J IMMUNOL, V164, P2064, DOI 10.4049/jimmunol.164.4.2064; Grogan JL, 1996, EUR J IMMUNOL, V26, P1365, DOI 10.1002/eji.1830260628; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hertz CJ, 2001, J IMMUNOL, V166, P2444, DOI 10.4049/jimmunol.166.4.2444; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Jacinto R, 2002, J IMMUNOL, V168, P6136, DOI 10.4049/jimmunol.168.12.6136; Jankovic D, 2002, IMMUNITY, V16, P429, DOI 10.1016/S1074-7613(02)00278-9; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; King CL, 1996, J IMMUNOL, V156, P4715; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Le LQ, 2001, IMMUNITY, V14, P561, DOI 10.1016/S1074-7613(01)00145-5; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; Means TK, 1999, J IMMUNOL, V163, P6748; Michelsen KS, 2001, J BIOL CHEM, V276, P25680, DOI 10.1074/jbc.M011615200; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Noss EH, 2001, J IMMUNOL, V167, P910, DOI 10.4049/jimmunol.167.2.910; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Re F, 2001, J BIOL CHEM, V276, P37692, DOI 10.1074/jbc.M105927200; ROUSER G, 1969, METHOD ENZYMOL, V14, P272; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Sewell DL, 2002, IMMUNOL LETT, V82, P101, DOI 10.1016/S0165-2478(02)00025-1; Sharif S, 2001, NAT MED, V7, P1057, DOI 10.1038/nm0901-1057; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; van der Kleij D, 1999, INFECT IMMUN, V67, P5946, DOI 10.1128/IAI.67.11.5946-5950.1999; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Walterscheid JP, 2002, J EXP MED, V195, P171, DOI 10.1084/jem.20011450; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Yazdanbakhsh M, 2001, TRENDS IMMUNOL, V22, P372, DOI 10.1016/S1471-4906(01)01958-5; Zhang GL, 2001, J CLIN INVEST, V107, P13, DOI 10.1172/JCI11837	48	479	494	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48122	48129		10.1074/jbc.M206941200	http://dx.doi.org/10.1074/jbc.M206941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12359728	hybrid, Green Published			2022-12-27	WOS:000179789600021
J	Hase, H; Kanno, Y; Kojima, H; Morimoto, C; Okumura, K; Kobata, T				Hase, H; Kanno, Y; Kojima, H; Morimoto, C; Okumura, K; Kobata, T			CD27 and CD40 inhibit p53-independent mitochondrial pathways in apoptosis of B cells induced by B cell receptor ligation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; BCL-X; MEDIATED APOPTOSIS; LYMPHOMA-CELLS; P53; LYMPHOCYTES; EXPRESSION; PROTEINS; MEMBER; FAMILY	B cells in the germinal center are known to undergo apoptosis after B cell receptor (BCR) ligation, a process relevant to immunological tolerance. Human CD27 is a B cell co-stimulatory molecule. The aim of this study was to compare the effects of CD27 and CD40 signals on BCR-mediated apoptosis of B cells. BCR ligation activated mitochondrial apoptotic pathways including down-regulation of Bcl-X-L, dissipation of mitochondrial transmembrane potential, release of cytochrome c, and activation of caspase-9. Each of these effects was significantly inhibited by CD27 and CD40. Bik expression was weakly but significantly down-regulated by CD27 but up-regulated by CD40. BCR ligation resulted in p53 activation including its phosphorylation at Ser(15), nuclear translocation, and target gene p53AIP1 induction. CD27 and CD40 clearly suppressed these processes. Analyses that used dominant-negative p53 variants revealed a low but still substantial level of BCR-mediated apoptosis and intact mitochondria-mediated apoptotic pathway. These pathways were further inhibited by CD27 and CD40, although the cells showed no p53 phosphorylation or p53AIP1 expression. Our results suggested that, at the mitochondrial level, CD27 and CD40 co-stimulatory signals regulated the p53-amplified apoptotic pathway in B cells through the inhibition of p53-independent apoptotic pathway primarily induced by BCR ligation.	Dokkyo Univ, Sch Med, Inst Med Sci, Div Immunol, Mibu, Tochigi 3210293, Japan; Univ Tokyo, Inst Med Sci, Div Clin Immunol, Adv Clin Res Ctr, Tokyo 1088639, Japan; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan	Dokkyo Medical University; University of Tokyo; Juntendo University	Kobata, T (corresponding author), Dokkyo Univ, Sch Med, Inst Med Sci, Div Immunol, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan.	tkobata@dokkyomed.ac.jp						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Agematsu K, 2000, IMMUNOL TODAY, V21, P204, DOI 10.1016/S0167-5699(00)01605-4; Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; An SK, 1996, FEBS LETT, V386, P115, DOI 10.1016/0014-5793(96)00427-9; Berard R, 1999, J IMMUNOL, V163, P4655; Bouchon A, 2000, EUR J IMMUNOL, V30, P69, DOI 10.1002/1521-4141(200001)30:1<69::AID-IMMU69>3.0.CO;2-#; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; Craxton A, 1999, ADV IMMUNOL, V73, P79, DOI 10.1016/S0065-2776(08)60786-5; Doi T, 1999, INT IMMUNOL, V11, P933, DOI 10.1093/intimm/11.6.933; Fang W, 1998, IMMUNITY, V9, P35, DOI 10.1016/S1074-7613(00)80586-5; Ghia P, 1998, BLOOD, V91, P244, DOI 10.1182/blood.V91.1.244.244_244_251; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOODNOW CC, 1995, ADV IMMUNOL, V59, P279, DOI 10.1016/S0065-2776(08)60633-1; GRAVESTEIN LA, 1995, INT IMMUNOL, V7, P551, DOI 10.1093/intimm/7.4.551; Hagiyama H, 1999, ONCOGENE, V18, P4091, DOI 10.1038/sj.onc.1202772; Hendriks J, 2000, NAT IMMUNOL, V1, P433, DOI 10.1038/80877; Jacquot S, 1997, J IMMUNOL, V159, P2652; Jiang AM, 2001, J IMMUNOL, V166, P6025, DOI 10.4049/jimmunol.166.10.6025; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; KOBATA T, 1995, P NATL ACAD SCI USA, V92, P11249, DOI 10.1073/pnas.92.24.11249; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; Kruse N, 1997, J IMMUNOL METHODS, V210, P195, DOI 10.1016/S0022-1759(97)00188-9; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lens SMA, 1998, J IMMUNOL, V160, P6083; Morimoto S, 2000, J IMMUNOL, V164, P4097, DOI 10.4049/jimmunol.164.8.4097; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oshima H, 1998, INT IMMUNOL, V10, P517, DOI 10.1093/intimm/10.4.517; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; Shick L, 1997, CELL GROWTH DIFFER, V8, P121; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Suzuki T, 2001, J IMMUNOL, V166, P5567, DOI 10.4049/jimmunol.166.9.5567; Tangye SG, 1998, J EXP MED, V188, P1691, DOI 10.1084/jem.188.9.1691; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOUDSEN KH, 2000, CELL, V103, P691; WANG ZH, 1995, J IMMUNOL, V155, P3722; Wu M, 1998, J EXP MED, V187, P1671, DOI 10.1084/jem.187.10.1671; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	40	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46950	46958		10.1074/jbc.M209050200	http://dx.doi.org/10.1074/jbc.M209050200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12324477	hybrid			2022-12-27	WOS:000179663700016
J	Holst, B; Elling, CE; Schwartz, TW				Holst, B; Elling, CE; Schwartz, TW			Metal ion-mediated agonism and agonist enhancement in melanocortin MC1 and MC4 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TACHYKININ NK-1 RECEPTOR; TRANSMEMBRANE DOMAIN-III; ALLOSTERIC INTERACTIONS; CONFORMATIONAL-CHANGES; MOLECULAR-BASIS; MORBID-OBESITY; LIGAND-BINDING; NK1 RECEPTOR; ZINC-SITE; ALPHA-MSH	An endogenous metal-ion site in the melanocortin MC1 and MC4 receptors was characterized mainly in transiently transfected COS-7 cells. ZnCl2 alone stimulated signaling through the Gs pathway with a potency of 11 and 13 muM and an efficacy of 50 and 20% of that of alpha-melanocortin stimulating hormone (alpha-MSH) in the MC1 and MC4 receptors, respectively. In the presence of peptide agonist, Zn(II) acted as an enhancer on both receptors, because it shifted the dose-response curves to the left: most pronounced was a 6-fold increase in alpha-MSH potency on the MC1 receptor. The effect of the metal ion appeared to be additive, because the maximal cAMP response for alpha-MSH in the presence of Zn(II) was 60% above the maximal response for the peptide alone. The affinity of Zn(II) could be increased through binding of the metal ion in complex with small hydrophobic chelators. The binding affinities and profiles were similar for a number of the 2,2'-bipyridine and 1,10-phenanthroline analogs in complex with Zn(II) in the MC1 and MC4 receptors. However, the potencies and efficacies of the metal-ion complexes were very different in the two receptors, and close to full agonism was obtained in the MC1 receptor. Metal ion-chelator complexes having antagonistic properties were also found. An initial attempt to map the metal-ion binding site in the MC1 receptor indicated that Cys(271) in extracellular loop 3 and possibly Asp(119) at the extracellular end of TM-III, which are both conserved among all MC receptors, are parts of the site. It is concluded that the function of the MCI and MC4 receptors can be positively modulated by metal ions acting both as partial agonists and as potentiators for other agonists, including the endogenous peptide ligand alpha-MSH at Zn(II) concentrations that could be physiological. Furthermore, the metal ion-chelator complexes may serve as leads in the development of novel melanocortin receptor modulators.	Univ Copenhagen, Panum Inst, Inst Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark; 7TM Pharma AS, DK-2100 Copenhagen, Denmark	University of Copenhagen	Holst, B (corresponding author), Univ Copenhagen, Panum Inst, Inst Pharmacol, Mol Pharmacol Lab, Blegdamsvej 3, DK-2200 Copenhagen, Denmark.		Solano, Francisco/G-5001-2013	Solano, Francisco/0000-0001-9612-761X; Schwartz, Thue W./0000-0002-0261-6904; Holst, Birgitte/0000-0001-7432-097X				ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Barsh GS, 2000, NATURE, V404, P644, DOI 10.1038/35007519; Beattie JH, 1998, P NATL ACAD SCI USA, V95, P358, DOI 10.1073/pnas.95.1.358; Chen AS, 2000, NAT GENET, V26, P97, DOI 10.1038/79254; Cowley MA, 1999, NEURON, V24, P155, DOI 10.1016/S0896-6273(00)80829-6; Dinulescu DM, 2000, J BIOL CHEM, V275, P6695, DOI 10.1074/jbc.275.10.6695; Elling CE, 1999, P NATL ACAD SCI USA, V96, P12322, DOI 10.1073/pnas.96.22.12322; Elling CE, 2000, BIOCHEMISTRY-US, V39, P667, DOI 10.1021/bi991777b; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; Elling CE, 1996, EMBO J, V15, P6213, DOI 10.1002/j.1460-2075.1996.tb01011.x; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Farooqi IS, 2000, J CLIN INVEST, V106, P271, DOI 10.1172/JCI9397; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; GETHER U, 1995, J BIOL CHEM, V270, P28268; GETHER U, 1993, J BIOL CHEM, V268, P7893; Hadley ME, 1999, ANN NY ACAD SCI, V885, P1; He L, 2001, NAT GENET, V27, P40, DOI 10.1038/83741; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; Holst B, 2000, MOL PHARMACOL, V58, P263, DOI 10.1124/mol.58.2.263; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Huang EP, 1997, P NATL ACAD SCI USA, V94, P13386, DOI 10.1073/pnas.94.25.13386; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Kenakin TP., 1993, PHARM ANAL DRUG RECE, V2; Lazareno S, 2000, MOL PHARMACOL, V58, P194, DOI 10.1124/mol.58.1.194; Leppik RA, 2000, MOL PHARMACOL, V57, P436, DOI 10.1124/mol.57.3.436; Loland CJ, 2002, P NATL ACAD SCI USA, V99, P1683, DOI 10.1073/pnas.032386299; Luger TA, 2000, ANN NY ACAD SCI, V917, P232; Marks DL, 2001, RECENT PROG HORM RES, V56, P359, DOI 10.1210/rp.56.1.359; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; PEREZCASTEJON C, 1994, HISTOL HISTOPATHOL, V9, P259; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; Rink L, 2001, BIOMETALS, V14, P367, DOI 10.1023/A:1012986225203; Robinson SW, 2000, ANNU REV GENET, V34, P687, DOI 10.1146/annurev.genet.34.1.687; Rosenkilde MM, 1998, FEBS LETT, V439, P35, DOI 10.1016/S0014-5793(98)01331-3; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SMART TG, 1994, PROG NEUROBIOL, V42, P393, DOI 10.1016/0301-0082(94)90082-5; STE ML, 2000, P NATL ACAD SCI USA, V97, P12339; STRADER CD, 1991, J BIOL CHEM, V266, P5; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; Swaminath G, 2002, MOL PHARMACOL, V61, P65, DOI 10.1124/mol.61.1.65; Thirstrup K, 1996, J BIOL CHEM, V271, P7875, DOI 10.1074/jbc.271.14.7875; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Van der Ploeg LHT, 2002, P NATL ACAD SCI USA, V99, P11381, DOI 10.1073/pnas.172378699; Vandenberg RJ, 1998, MOL PHARMACOL, V54, P189, DOI 10.1124/mol.54.1.189; Wessells H, 1998, J UROLOGY, V160, P389, DOI 10.1016/S0022-5347(01)62903-3; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; Wikberg JES, 1999, EUR J PHARMACOL, V375, P295, DOI 10.1016/S0014-2999(99)00298-8; Yang Y, 2000, BIOCHEMISTRY-US, V39, P14900, DOI 10.1021/bi001684q; Yang YK, 1997, J BIOL CHEM, V272, P23000, DOI 10.1074/jbc.272.37.23000	56	82	84	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47662	47670		10.1074/jbc.M202103200	http://dx.doi.org/10.1074/jbc.M202103200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12244039	hybrid			2022-12-27	WOS:000179663700107
J	Peng, K; Shu, Q; Liu, ZH; Liang, SP				Peng, K; Shu, Q; Liu, ZH; Liang, SP			Function and solution structure of huwentoxin-IV, a potent neuronal tetrodotoxin (TTX)-sensitive sodium channel antagonist from Chinese bird spider Selenocosmia huwena	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MU-CONOTOXIN GIIIA; DISULFIDE BRIDGES; NA+-CHANNELS; CYSTINE KNOT; ASSIGNMENT; BINDING; PEPTIDE; TOXINS; LOOP; DETERMINANTS	We have isolated a highly potent neurotoxin from the venom of the Chinese bird spider, Selenocosmia huwena. This 4.1-kDa toxin, which has been named huwentoxin-IV, contains 35 residues with three disulfide bridges: Cys-2-Cys-17, Cys-9-Cys-24, and Cys-16-Cys-31, assigned by a chemical strategy including partial reduction of the toxin and sequence analysis of the modified intermediates. It specifically inhibits the neuronal tetrodotoxin-sensitive (TTX-S) voltage-gated sodium channel with the IC50 value of 30 nM in adult rat dorsal root ganglion neurons, while having no significant effect on the tetrodotoxin-resistant (TTX-R) voltage-gated sodium channel. This toxin seems to be a site I toxin affecting the sodium channel through a mechanism quite similar to that of TTX: it suppresses the peak sodium current without altering the activation or inactivation kinetics. The three-dimensional structure of huwentoxin-IV has been determined by two-dimensional H-1 NMR combined with distant geometry and simulated annealing calculation by using 527 nuclear Overhauser effect constraints and 14 dihedral constraints. The resulting structure is composed of a double-stranded antiparallel beta-sheet (Leu-22-Ser-25 and Trp-30-Tyr-33) and four turns (Glu-4-Lys-7, Pro-11-Asp-14, Lys-18-Lys-21 and Arg-26-Arg-29) and belongs to the inhibitor cystine knot structural family. After comparison with other toxins purified from the same species, we are convinced that the positively charged residues of loop IV (residues 25-29), especially residue Arg-26, must be crucial to its binding to the neuronal tetrodotoxin-sensitive voltage-gated sodium channel.	Hunan Normal Univ, Coll Life Sci, Changsha 410081, Peoples R China	Hunan Normal University	Liang, SP (corresponding author), Hunan Normal Univ, Coll Life Sci, Changsha 410081, Peoples R China.	liangsp@public.cs.hn.cn						Boccaccio A, 1999, BIOPHYS J, V77, P229, DOI 10.1016/S0006-3495(99)76884-0; BRUNGER AT, 1992, XPLOR MANUAL VERSION; Chahine M, 1998, BIOPHYS J, V75, P236, DOI 10.1016/S0006-3495(98)77510-1; Cummins TR, 1997, J NEUROSCI, V17, P3503; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; GRAY WR, 1993, PROTEIN SCI, V2, P1749, DOI 10.1002/pro.5560021018; Hilber K, 2001, J BIOL CHEM, V276, P27831, DOI 10.1074/jbc.M101933200; Hill JM, 1997, STRUCTURE, V5, P571, DOI 10.1016/S0969-2126(97)00212-8; Hill JM, 1996, BIOCHEMISTRY-US, V35, P8824, DOI 10.1021/bi960073o; Hu ZH, 1997, J PHYSIOL-LONDON, V501, P67, DOI 10.1111/j.1469-7793.1997.067bo.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li RA, 2001, J BIOL CHEM, V276, P11072, DOI 10.1074/jbc.M010862200; Li RK, 2000, J BIOL CHEM, V275, P27551; Meir A, 1999, PHYSIOL REV, V79, P1019, DOI 10.1152/physrev.1999.79.3.1019; NARAHASHI T, 1964, J GEN PHYSIOL, V47, P965, DOI 10.1085/jgp.47.5.965; NARAHASHI T, 1960, AM J PHYSIOL, V198, P934, DOI 10.1152/ajplegacy.1960.198.5.934; Nicholson GM, 1996, TOXICON, V34, P1443, DOI 10.1016/S0041-0101(96)00089-X; NICHOLSON GM, 1994, PFLUG ARCH EUR J PHY, V428, P400, DOI 10.1007/BF00724524; Nicholson GM, 1998, PFLUG ARCH EUR J PHY, V436, P117, DOI 10.1007/s004240050612; Norton RS, 1998, TOXICON, V36, P1573, DOI 10.1016/S0041-0101(98)00149-4; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; Peng K, 2001, TOXICON, V39, P491, DOI 10.1016/S0041-0101(00)00150-1; Penzotti JL, 1998, BIOPHYS J, V75, P2647, DOI 10.1016/S0006-3495(98)77710-0; Porreca F, 1999, P NATL ACAD SCI USA, V96, P7640, DOI 10.1073/pnas.96.14.7640; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; ROY ML, 1992, J NEUROSCI, V12, P2104; Sampo B, 2000, P NATL ACAD SCI USA, V97, P3666, DOI 10.1073/pnas.97.7.3666; SATO K, 1991, J BIOL CHEM, V266, P16989; Shon KJ, 1998, J NEUROSCI, V18, P4473; Shu Q, 1999, J PEPT RES, V53, P486, DOI 10.1034/j.1399-3011.1999.00039.x; Strachan LC, 1999, J PHARMACOL EXP THER, V288, P379; Waxman SG, 1999, PAIN, pS133, DOI 10.1016/S0304-3959(99)00147-5; Waxman SG, 1999, P NATL ACAD SCI USA, V96, P7635, DOI 10.1073/pnas.96.14.7635; Wu J, 1997, PROTEIN SCI, V6, P391; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YANAGAWA Y, 1988, BIOCHEMISTRY-US, V27, P6256, DOI 10.1021/bi00417a009; ZHANG DG, 1993, J PROTEIN CHEM, V12, P735, DOI 10.1007/BF01024931	39	129	145	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47564	47571		10.1074/jbc.M204063200	http://dx.doi.org/10.1074/jbc.M204063200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12228241	hybrid			2022-12-27	WOS:000179663700095
J	Itoh, A; Schilmiller, AL; McCaig, BC; Howe, GA				Itoh, A; Schilmiller, AL; McCaig, BC; Howe, GA			Identification of a jasmonate-regulated allene oxide synthase that metabolizes 9-hydroperoxides of linoleic and linolenic acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVINYL ETHER SYNTHASE; MOLECULAR-CLONING; FATTY-ACIDS; HYDROPEROXIDE ISOMERASE; SUBSTRATE-SPECIFICITY; GENETIC-ANALYSIS; CORN GERM; LIPOXYGENASE; BIOSYNTHESIS; DEFENSE	Allene oxide synthase (AOS) is a cytochrome P-450 (CYP74A) that catalyzes the first step in the conversion of 13-hydroperoxy linolenic acid to jasmonic acid and related signaling molecules in plants. Here, we report the molecular cloning and characterization of a novel AOS-encoding cDNA (LeAOS3) from Lycopersicon esculentum whose predicted amino acid sequence classifies it as a member of the CYP74C subfamily of enzymes that was hitherto not known to include AOSs. Recombinant LeAOS3 expressed in Escherichia coli showed spectral characteristics of a P-450. The enzyme transformed 9-and 13-hydroperoxides of linoleic and linolenic acid to alpha-ketol, gamma-ketol, and cyclopentenone compounds that arise from spontaneous hydrolysis of Unstable allene oxides, indicating that the enzyme is an AOS. Kinetic assays demonstrated that LeAOS3 was approximate to10-fold morel active against 9-hydroperoxides than the corresponding 13-isomers. LeAOS3 transcripts accumulated in roots, but were undetectable in aerial parts of mature plants. In contrast to wild-type plants, LeAOS3 expression was undetectable in roots of a tomato mutaint that is defective in jasmonic acid signaling. These findings suggest that LeAOS3 plays a role in the metabolism of 9-lipoxygenase-derived hydroperoxides in roots, and that this branch of oxylipin biosynthesis is regulated by the jasmonate signaling cascade.	Michigan State Univ, US DOE, Plant Res Lab, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University; United States Department of Energy (DOE); Michigan State University	Howe, GA (corresponding author), Michigan State Univ, US DOE, Plant Res Lab, E Lansing, MI 48824 USA.	howeg@msu.edu	Howe, Gregg A/N-1887-2014	Howe, Gregg A/0000-0002-9218-979X; Schilmiller, Anthony/0000-0001-7069-7120				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRASH AR, 1988, P NATL ACAD SCI USA, V85, P3382, DOI 10.1073/pnas.85.10.3382; Caldelari D, 1998, PHYTOCHEMISTRY, V47, P599, DOI 10.1016/S0031-9422(97)00443-3; Chapple C, 1998, ANNU REV PLANT PHYS, V49, P311, DOI 10.1146/annurev.arplant.49.1.311; ESHED Y, 1994, EUPHYTICA, V79, P175, DOI 10.1007/BF00022516; FENG P, 1979, LIPIDS, V14, P710, DOI 10.1007/BF02533895; Feussner I, 2002, ANNU REV PLANT BIOL, V53, P275, DOI 10.1146/annurev.arplant.53.100301.135248; Froehlich JE, 2001, PLANT PHYSIOL, V125, P306, DOI 10.1104/pp.125.1.306; GARDNER HW, 1970, J LIPID RES, V11, P311; GARDNER HW, 1975, LIPIDS, V10, P602, DOI 10.1007/BF02532724; GEMZELLDANIELSSON K, 1994, HUM REPROD, V9, P1626, DOI 10.1093/oxfordjournals.humrep.a138763; Gobel C, 2001, J BIOL CHEM, V276, P6267, DOI 10.1074/jbc.M008606200; GRECHKIN AN, 1994, BBA-LIPID LIPID MET, V1213, P199, DOI 10.1016/0005-2760(94)90027-2; Grechkin AN, 2000, BIOCHEM J, V352, P501, DOI 10.1042/0264-6021:3520501; Hamberg M, 2000, LIPIDS, V35, P353, DOI 10.1007/s11745-000-532-z; HAMBERG M, 1988, BIOCHEM BIOPH RES CO, V156, P543, DOI 10.1016/S0006-291X(88)80876-3; HAMBERG M, 1990, ARCH BIOCHEM BIOPHYS, V276, P518, DOI 10.1016/0003-9861(90)90753-L; HAMBERG M, 1987, BIOCHIM BIOPHYS ACTA, V920, P76, DOI 10.1016/0005-2760(87)90313-4; HAMBERG M, 1988, ADV PROSTAGLANDIN TH, V19, P64; HECKER M, 1989, J BIOL CHEM, V264, P141; Howe GA, 2000, PLANT PHYSIOL, V123, P711, DOI 10.1104/pp.123.2.711; Howe GA, 2002, CURR OPIN PLANT BIOL, V5, P230, DOI 10.1016/S1369-5266(02)00250-9; Itoh A, 2001, J BIOL CHEM, V276, P3620, DOI 10.1074/jbc.M008964200; Kolomiets MV, 2001, PLANT CELL, V13, P613, DOI 10.1105/tpc.13.3.613; LAU SMC, 1993, BIOCHEMISTRY-US, V32, P1945, DOI 10.1021/bi00059a010; Laudert D, 1998, PLANT J, V15, P675, DOI 10.1046/j.1365-313x.1998.00245.x; Li L, 2002, P NATL ACAD SCI USA, V99, P6416, DOI 10.1073/pnas.072072599; Li L, 2001, PLANT PHYSIOL, V127, P1414, DOI 10.1104/pp.010705; MASUI H, 1989, PHYTOCHEMISTRY, V28, P2613, DOI 10.1016/S0031-9422(00)98051-8; Matsui K, 2000, FEBS LETT, V481, P183, DOI 10.1016/S0014-5793(00)01997-9; Maucher H, 2000, PLANT J, V21, P199, DOI 10.1046/j.1365-313x.2000.00669.x; Paquette SM, 2000, DNA CELL BIOL, V19, P307, DOI 10.1089/10445490050021221; Quackenbush J, 2000, NUCLEIC ACIDS RES, V28, P141, DOI 10.1093/nar/28.1.141; Rance I, 1998, P NATL ACAD SCI USA, V95, P6554, DOI 10.1073/pnas.95.11.6554; Rusterucci C, 1999, J BIOL CHEM, V274, P36446, DOI 10.1074/jbc.274.51.36446; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sivasankar S, 2000, PLANT PHYSIOL, V122, P1335, DOI 10.1104/pp.122.4.1335; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; Staswick PE, 1998, PLANT J, V15, P747, DOI 10.1046/j.1365-313X.1998.00265.x; Stintzi A, 2001, P NATL ACAD SCI USA, V98, P12837, DOI 10.1073/pnas.211311098; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006; Stumpe M, 2001, FEBS LETT, V507, P371, DOI 10.1016/S0014-5793(01)03019-8; SWOFORD DL, 2000, PAUP ASTERISK PHYLOG; TANKSLEY SD, 1992, GENETICS, V132, P1141; Tijet N, 2001, ARCH BIOCHEM BIOPHYS, V386, P281, DOI 10.1006/abbi.2000.2218; Turner JG, 2002, PLANT CELL, V14, pS153, DOI 10.1105/tpc.000679; VICK BA, 1991, LIPIDS, V26, P315, DOI 10.1007/BF02537143; VICK BA, 1979, PLANT PHYSIOL, V63, P490, DOI 10.1104/pp.63.3.490; VICK BA, 1984, PLANT PHYSIOL, V75, P458, DOI 10.1104/pp.75.2.458; VICK BA, 1983, BIOCHEM BIOPH RES CO, V111, P470, DOI 10.1016/0006-291X(83)90330-3; Vijayan P, 1998, P NATL ACAD SCI USA, V95, P7209, DOI 10.1073/pnas.95.12.7209; Weber H, 1999, PLANT CELL, V11, P485, DOI 10.1105/tpc.11.3.485; Yokoyama M, 2000, PLANT CELL PHYSIOL, V41, P110, DOI 10.1093/pcp/41.1.110; Ziegler J, 2001, PHYTOCHEMISTRY, V58, P729, DOI 10.1016/S0031-9422(01)00284-9; ZIMMERMAN DC, 1970, PLANT PHYSIOL, V46, P445, DOI 10.1104/pp.46.3.445	57	75	83	1	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46051	46058		10.1074/jbc.M207234200	http://dx.doi.org/10.1074/jbc.M207234200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351632	hybrid			2022-12-27	WOS:000179529300046
J	Gerasimovskaya, EV; Ahmad, S; White, CW; Jones, PL; Carpenter, TC; Stenmark, KR				Gerasimovskaya, EV; Ahmad, S; White, CW; Jones, PL; Carpenter, TC; Stenmark, KR			Extracellular ATP is an autocrine/paracrine regulator of hypoxia-induced adventitial fibroblast growth - Signaling through extracellular signal-regulated kinase-1/2 and the Egr-1 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-CELL PROLIFERATION; ACTIVATED PROTEIN-KINASE; PULMONARY-ARTERY; INDUCED RELEASE; P2X RECEPTORS; UP-REGULATION; SHEAR-STRESS; IN-VITRO; NUCLEOTIDES; EXPRESSION	Important autocrine/paracrine functions for the adenine nucleotides have been proposed in several tissues. We addressed the possibility that extracellular ATP would modulate/mediate hypoxia-induced adventitial fibroblast growth. Acute hypoxia (3% O-2, 10-60 min) increased extracellular ATP concentrations in adventitial fibroblasts and in lung microvascular endothelial cells, and chronic hypoxia (3% O-2, 14-30 days) markedly attenuated the rate of extracellular ATP hydrolysis by ecto-nucleotidase(s). Exogenous ATP stimulated [H-3]thymidine incorporation in fibroblasts as did UTP, ADPbeta, 2-methylthioadenosine triphosphate, adenosine 5'-(alpha,beta-methylene)triphosphate, and benzoylbenzoyl-ATP (2'-3'-O-(4-benzoylbenzoyl)-ATP), indicating that both P2Y and P2X purinoceptors can mediate mitogenic responses. Suramin (100 muM), Cibacron blue 3GA (100 pm), and pyridoxalphosphate-6-azophenyl-2',-4'-disulfonic acid (100 muM) as well as apyrase (5 units/ml) attenuated hypoxia- and ATP-induced and DNA synthesis, indicating activation and a functional role of purinoceptors under hypoxic conditions. ATP-induced DNA synthesis was augmented by hypoxia in an additive fashion, whereas ATP and hypoxia synergistically increased growth factor-induced DNA synthesis, again suggesting that ATP and hypoxia utilize similar signaling pathways to induce proliferation. Indeed, we found that ATP (100 pm) and hypoxia (3% 02) induced expression and activation of Egr-1 transcription factor, and both stimuli acted, in part, through a Galpha(i)/ERK1/2-dependent signaling pathway. Suramin, Cibacron blue 3GA, and apyrase attenuated hypoxia-induced ERK1/2 activation and Egr-1 expression. We conclude that hypoxia induces ATP release from endothelial cells and fibroblasts and that the activation of P2 purinoceptors is involved in the regulation of DNA synthesis by fibroblasts under hypoxic conditions.	Univ Colorado, Hlth Sci Ctr, Dev Lung Biol Res Lab, Dept Pediat, Denver, CO 80262 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health	Gerasimovskaya, EV (corresponding author), Univ Colorado, Hlth Sci Ctr, Dev Lung Biol Res Lab, Dept Pediat, Res Bridge,B131,4200 E 9th Ave, Denver, CO 80262 USA.	Evgenia.Gerasimovskaya@UCHSC.edu	ahmad, shama/GNH-1803-2022; stenmark, kurt/AFI-6776-2022; Carpenter, Todd/A-7503-2011; stenmark, kurt/AAH-3124-2022	ahmad, shama/0000-0003-1049-5054; Carpenter, Todd/0000-0002-9855-0021; Jones, Peter Lloyd/0000-0003-1445-4081	NHLBI NIH HHS [HL 56481, HL 14985] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbracchio MP, 1998, JPN J PHARMACOL, V78, P113, DOI 10.1254/jjp.78.113; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Belknap JK, 1997, AM J RESP CELL MOL, V16, P366, DOI 10.1165/ajrcmb.16.4.9115746; BODIN P, 1995, EXPERIENTIA, V51, P256, DOI 10.1007/BF01931108; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; BROWN HA, 1991, MOL PHARMACOL, V40, P648; Burnstock G, 2002, ARTERIOSCL THROM VAS, V22, P364, DOI 10.1161/hq0302.105360; Chung TW, 1997, J BIOL CHEM, V272, P3064, DOI 10.1074/jbc.272.5.3064; Communi D, 2000, CELL SIGNAL, V12, P351, DOI 10.1016/S0898-6568(00)00083-8; DAS M, 1995, AM J PHYSIOL-LUNG C, V269, pL660, DOI 10.1152/ajplung.1995.269.5.L660; Das M, 2001, J BIOL CHEM, V276, P15631, DOI 10.1074/jbc.M010690200; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Davidson JD, 2001, WOUND REPAIR REGEN, V9, P175, DOI 10.1046/j.1524-475x.2001.00175.x; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Di Virgilio F, 2002, BRIT J PHARMACOL, V135, P831, DOI 10.1038/sj.bjp.0704524; Dowd FJ, 1999, ARCH ORAL BIOL, V44, P1055, DOI 10.1016/S0003-9969(99)00100-4; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Dubyak GR, 2002, AM J PHYSIOL-CELL PH, V282, pC242, DOI 10.1152/ajpcell.00522.2001; Erlinge D, 1998, GEN PHARMACOL-VASC S, V31, P1, DOI 10.1016/S0306-3623(97)00420-5; Ferguson DR, 1997, J PHYSIOL-LONDON, V505, P503, DOI 10.1111/j.1469-7793.1997.503bb.x; FILTZ TM, 1994, MOL PHARMACOL, V46, P8; FORRESTER T, 1977, J PHYSIOL-LONDON, V268, P371, DOI 10.1113/jphysiol.1977.sp011862; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Graff RD, 2000, ARTHRITIS RHEUM-US, V43, P1571, DOI 10.1002/1529-0131(200007)43:7<1571::AID-ANR22>3.3.CO;2-C; GRIERSON JP, 1995, J BIOL CHEM, V270, P4451, DOI 10.1074/jbc.270.9.4451; Hamada K, 1998, J BIOL CHEM, V273, P6334, DOI 10.1074/jbc.273.11.6334; Harden TK, 1997, TRENDS PHARMACOL SCI, V18, P43, DOI 10.1016/S0165-6147(97)89795-7; Hofer G, 1996, J BIOL CHEM, V271, P28306, DOI 10.1074/jbc.271.45.28306; Homolya L, 2000, J CELL BIOL, V150, P1349, DOI 10.1083/jcb.150.6.1349; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; KATSURAGI T, 1991, J PHARMACOL EXP THER, V259, P513; KENNEDY C, 1995, TRENDS PHARMACOL SCI, V16, P168, DOI 10.1016/S0165-6147(00)89010-0; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Khachigian LM, 1997, ARTERIOSCL THROM VAS, V17, P2280, DOI 10.1161/01.ATV.17.10.2280; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; Khakh BS, 2001, PHARMACOL REV, V53, P107; KINANE TB, 1994, J BIOL CHEM, V269, P27503; Koyama T, 2001, J PHYSIOL-LONDON, V532, P759, DOI 10.1111/j.1469-7793.2001.0759e.x; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Lo LW, 2001, J CELL PHYSIOL, V188, P304, DOI 10.1002/jcp.1124; MITCHELL CH, 2001, J PHYSL, V334, P193; Moser TL, 2001, P NATL ACAD SCI USA, V98, P6656, DOI 10.1073/pnas.131067798; Nakamura E, 2000, AM J PHYSIOL-CELL PH, V279, pC510, DOI 10.1152/ajpcell.2000.279.2.C510; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; NUPENKO EV, 1991, BIOCHIM BIOPHYS ACTA, V1091, P213, DOI 10.1016/0167-4889(91)90064-5; Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735; PEARSON JD, 1979, NATURE, V281, P384, DOI 10.1038/281384a0; Pirotton S, 1996, J AUTON PHARMACOL, V16, P353, DOI 10.1111/j.1474-8673.1996.tb00052.x; Ralevic V, 1998, PHARMACOL REV, V50, P413; Robson SC, 1997, J EXP MED, V185, P153, DOI 10.1084/jem.185.1.153; Santiago FS, 1999, AM J PATHOL, V155, P897, DOI 10.1016/S0002-9440(10)65189-9; SchulzeLohoff E, 1996, J AUTON PHARMACOL, V16, P381, DOI 10.1111/j.1474-8673.1996.tb00058.x; Schwiebert LM, 2002, AM J PHYSIOL-CELL PH, V282, pC289, DOI 10.1152/ajpcell.01387.2000; SEDAA KO, 1990, J PHARMACOL EXP THER, V252, P1060; Solini A, 1999, J CELL SCI, V112, P297; Stenmark KR, 1997, ANNU REV PHYSIOL, V59, P89, DOI 10.1146/annurev.physiol.59.1.89; TORRY DJ, 1994, J CLIN INVEST, V93, P1525, DOI 10.1172/JCI117131; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Welsh DJ, 1998, AM J RESP CRIT CARE, V158, P1757, DOI 10.1164/ajrccm.158.6.9706054; WESTFALL DP, 1990, ANN NY ACAD SCI, V603, P300; Wilden PA, 1998, AM J PHYSIOL-HEART C, V275, pH1209, DOI 10.1152/ajpheart.1998.275.4.H1209; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; YANG SM, 1994, CIRC RES, V74, P401, DOI 10.1161/01.RES.74.3.401; Yu SM, 1996, MOL PHARMACOL, V50, P1000; ZHANG M, 2000, J PHYSL, V15, P143	66	106	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44638	44650		10.1074/jbc.M203012200	http://dx.doi.org/10.1074/jbc.M203012200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244041	hybrid			2022-12-27	WOS:000179404800008
J	Kozak, KR; Crews, BC; Morrow, JD; Wang, LH; Ma, YH; Weinander, R; Jakobsson, PJ; Marnett, LJ				Kozak, KR; Crews, BC; Morrow, JD; Wang, LH; Ma, YH; Weinander, R; Jakobsson, PJ; Marnett, LJ			Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HUMAN-PLATELETS; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; CYCLOOXYGENASE-2 COX-2; ARACHIDONIC-ACID; COLON-CANCER; ACTIVE-SITE; D SYNTHASE; PURIFICATION; BIOSYNTHESIS	Cyclooxygenase-2 (COX-2) action on the endocannabinoids, 2-arachidonylglycerol (2-AG) and anandamide (AEA), generates prostaglandin glycerol esters (PG-G) and ethanolamides (PG-EA), respectively. The diversity of PG-Gs and PG-EAs that can be formed enzymatically following COX-2 oxygenation of endocannabinoids was examined in cellular and subcellular systems. In cellular systems, glycerol esters and ethanolamides of PGE(2), PGD(2), and PGF(2alpha) were major products of the endocannabinoid-derived COX-2 products, PGH(2)-G and PGH(2)-EA. The sequential action of purified COX-2 and thromboxane synthase on AEA and 2-AG provided thromboxane A(2) ethanolamide and glycerol ester, respectively. Similarly, bovine prostacyclin synthase catalyzed the isomerization of the intermediate endoperoxides, PGH(2)-G and PGH(2)-EA, to the corresponding prostacyclin derivatives. Quantification of the efficiency of prostaglandin and thromboxane synthase-directed endoperoxide isomerization demonstrated that PGE, PGD, and PGI synthases catalyze the isomerization of PGH(2)-G at rates approaching those observed with PGH(2). In contrast, thromboxane synthase was far more efficient at catalyzing PGH(2) isomerization than at catalyzing the isomerization of PGH(2)-G. These results define the in vitro diversity of endocannabinoid-derived prostanoids and will permit focused investigations into their production and potential biological actions in vivo.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Ctr Mol Toxicol, Nashville, TN 37232 USA; Univ Houston, Dept Internal Med, Div Hematol, Houston, TX 77030 USA; Aventis Pharmaceut, Resp RA Dis Grp, Bridgewater, NJ 08807 USA; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Houston System; University of Houston; Sanofi-Aventis; Karolinska Institutet	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.		Jakobsson, Per-Johan/ABC-5594-2021		NATIONAL CANCER INSTITUTE [P01CA077839, P01CA068484, R01CA089450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, T32GM007347, P50GM015431] Funding Source: NIH RePORTER; NCI NIH HHS [CA68484, CA77839, CA89450] Funding Source: Medline; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NIGMS NIH HHS [GM15431, GM07347] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735; CHO MJ, 1978, PROSTAGLANDINS, V15, P943, DOI 10.1016/0090-6980(78)90037-0; CHRISTHAZELHOF E, 1979, BIOCHIM BIOPHYS ACTA, V572, P43, DOI 10.1016/0005-2760(79)90198-X; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DEWITT DL, 1983, J BIOL CHEM, V258, P3285; DICZFALUSY U, 1979, FEBS LETT, V105, P291, DOI 10.1016/0014-5793(79)80632-8; DICZFALUSY U, 1980, BIOCHEM BIOPH RES CO, V94, P1417, DOI 10.1016/0006-291X(80)90577-X; Ek M, 2001, NATURE, V410, P430, DOI 10.1038/35068632; ENSOR CM, 1994, BBA-PROTEIN STRUCT M, V1208, P151, DOI 10.1016/0167-4838(94)90172-4; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HAMMARSTROM S, 1980, J BIOL CHEM, V255, P518; HAMMARSTROM S, 1977, P NATL ACAD SCI USA, V74, P3691, DOI 10.1073/pnas.74.9.3691; HAMMARSTROM S, 1982, ARCH BIOCHEM BIOPHYS, V214, P431, DOI 10.1016/0003-9861(82)90047-9; HAURAND M, 1985, J BIOL CHEM, V260, P5059; HECKER M, 1987, ARCH BIOCHEM BIOPHYS, V254, P124, DOI 10.1016/0003-9861(87)90088-9; HECKER M, 1989, J BIOL CHEM, V264, P141; Hsu PY, 1999, J BIOL CHEM, V274, P762, DOI 10.1074/jbc.274.2.762; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kalgutkar AS, 2000, P NATL ACAD SCI USA, V97, P925, DOI 10.1073/pnas.97.2.925; Kalgutkar AS, 1998, J MED CHEM, V41, P4800, DOI 10.1021/jm980303s; Kanaoka Y, 2000, EUR J BIOCHEM, V267, P3315, DOI 10.1046/j.1432-1327.2000.01362.x; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; Kozak KR, 2000, J BIOL CHEM, V275, P33744, DOI 10.1074/jbc.M007088200; Kozak KR, 2002, J BIOL CHEM, V277, P23278, DOI 10.1074/jbc.M201084200; Kozak KR, 2001, J BIOL CHEM, V276, P36993, DOI 10.1074/jbc.M105854200; KUNGCHAO DTY, 1980, BIOCHIM BIOPHYS ACTA, V614, P1, DOI 10.1016/0005-2744(80)90161-8; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; MARNETT LJ, 1977, BIOCHEMISTRY-US, V16, P4303, DOI 10.1021/bi00638a027; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; MONCADA S, 1977, LANCET, V1, P18; OHNO H, 1978, J BIOCHEM-TOKYO, V84, P1485, DOI 10.1093/oxfordjournals.jbchem.a132272; PATRIGNANI P, 1982, J CLIN INVEST, V69, P1366, DOI 10.1172/JCI110576; Rao CV, 1997, CANCER RES, V57, P3717; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; SALMON JA, 1982, METHOD ENZYMOL, V86, P477; SHIMIZU T, 1979, J BIOL CHEM, V254, P5222; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Sugiura T, 2002, PROSTAG LEUKOTR ESS, V66, P173, DOI 10.1054/plef.2001.0356; THALERDAO H, 1976, ADV PROSTAG THROMB R, V1, P177; Ueno N, 2001, J BIOL CHEM, V276, P34918, DOI 10.1074/jbc.M100429200; Wang LH, 1996, J BIOL CHEM, V271, P19970, DOI 10.1074/jbc.271.33.19970; WATANABE K, 1985, J BIOL CHEM, V260, P7035; WHITTAKER N, 1977, Tetrahedron Letters, V32, P2805; Yu M, 1997, J BIOL CHEM, V272, P21181, DOI 10.1074/jbc.272.34.21181	47	291	295	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44877	44885		10.1074/jbc.M206788200	http://dx.doi.org/10.1074/jbc.M206788200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244105	hybrid			2022-12-27	WOS:000179404800038
J	McCudden, CR; James, KA; Hasilo, C; Wagner, GF				McCudden, CR; James, KA; Hasilo, C; Wagner, GF			Characterization of mammalian stanniocalcin receptors - Mitochondrial targeting of ligand and receptor for regulation of cellular metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; OVARIAN STANNIOCALCIN; MESSENGER-RNA; RAT-KIDNEY; HORMONE; CLONING; LOCALIZATION; CELLS; IDENTIFICATION; PROTEIN	The polypeptide hormone stanniocalcin (STC) is widely expressed in mammalian tissues. STC acts locally in kidney and gut to modulate calcium and phosphate excretion, and its overexpression in mice results in high serum phosphate, dwarfism, and increased metabolic rate. STC has also been linked to cancer, pregnancy, lactation, angiogenesis, organogenesis, cerebral ischemia, and hypertonic stress. In this report we have characterized the STC receptor and the functional targeting of ligand and receptor to mitochondria. For receptor binding analysis, a stanniocalcin-alkaline phosphatase fusion protein was engineered. Subsequent binding assays using the fusion protein indicated that kidney and liver contained the highest number of binding sites with affinities of 0.8 and 0.25 nm, respectively. Intriguingly, purified mitochondria from both tissues yielded similar high affinity binding sites. Fractionation analysis revealed that the majority of binding sites were localized to the inner mitochondrial membrane. In further studies, we characterized the time course of STC-alkaline phosphatase fusion protein sequestration by intact mitochondria. In situ ligand binding also revealed discrete, displaceable, binding to plasma membranes and mitochondria of nephron cells and liver hepatocytes. The existence of mitochondrial receptors prompted a similar search for the ligand. Immunogold electron microscopy revealed that STC was preferentially concentrated in the mitochondria of all nephron segments targeted by STC. Subcellular fractionation revealed that >90% of cellular STC immunoreactivity was mitochondrial, confined to the inner matrix, and similar in size to recombinant STC (50 kDa). In functional studies, recombinant STC had concentration-dependent stimulatory effects on electron transfer by sub-mitochondrial particles. Collectively the evidence implies a role for STC in cell metabolism.	Univ Western Ontario, Fac Med & Dent, Dept Physiol, London, ON N6A 5C1, Canada; Univ Western Ontario, Fac Sci, Dept Biol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Wagner, GF (corresponding author), Univ Western Ontario, Fac Med & Dent, Dept Physiol, London, ON N6A 5C1, Canada.	graham.wagner@fmd.uwo.ca		McCudden, Christopher/0000-0002-4172-4641				Amemiya Y, 2002, MOL CELL ENDOCRINOL, V188, P141, DOI 10.1016/S0303-7207(01)00741-9; BERGERON JJM, 1978, J BIOL CHEM, V253, P4058; Cadenas E, 2000, FREE RADICAL RES, V33, P747, DOI 10.1080/10715760000301271; CHANG ACM, 1995, MOL CELL ENDOCRINOL, V112, P241, DOI 10.1016/0303-7207(95)03601-3; Chang ACM, 1996, MOL CELL ENDOCRINOL, V124, P185, DOI 10.1016/S0303-7207(96)03929-9; Chen WJ, 2001, J EXP MED, V194, P439, DOI 10.1084/jem.194.4.439; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; Clausmeyer S, 1999, CIRC RES, V84, P337, DOI 10.1161/01.RES.84.3.337; De Niu P, 2000, MOL CELL ENDOCRINOL, V162, P131, DOI 10.1016/S0303-7207(00)00199-4; De Niu P, 1998, MOL CELL ENDOCRINOL, V137, P155, DOI 10.1016/S0303-7207(97)00243-8; Deol HK, 2000, ENDOCRINOLOGY, V141, P3412, DOI 10.1210/en.141.9.3412; DUNAIF AE, 1982, ENDOCRINOLOGY, V110, P1465, DOI 10.1210/endo-110-5-1465; Filvaroff EH, 2002, ENDOCRINOLOGY, V143, P3681, DOI 10.1210/en.2001-211424; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Flanagan JG, 2000, METHOD ENZYMOL, V327, P198, DOI 10.1016/S0076-6879(00)27277-7; Fujiwara Y, 2000, INT J ONCOL, V16, P799; Graham J M, 1993, Methods Mol Biol, V19, P19; Haddad M, 1996, ENDOCRINOLOGY, V137, P2113, DOI 10.1210/en.137.5.2113; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Kahn J, 2000, AM J PATHOL, V156, P1887, DOI 10.1016/S0002-9440(10)65062-6; Kriz W, 1992, KIDNEY PHYSL PATHOPH, P707; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; LU MQ, 1994, AM J PHYSIOL-REG I, V267, pR1356, DOI 10.1152/ajpregu.1994.267.5.R1356; Madsen KL, 1998, AM J PHYSIOL-GASTR L, V274, pG96, DOI 10.1152/ajpgi.1998.274.1.G96; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; McCudden CR, 2001, BIOL REPROD, V65, P763, DOI 10.1095/biolreprod65.3.763; McCudden CR, 2001, J ENDOCRINOL, V171, P33, DOI 10.1677/joe.0.1710033; Miura W, 2000, APMIS, V108, P367, DOI 10.1034/j.1600-0463.2000.d01-70.x; MORRE JD, 1971, METHOD ENZYMOL, P648; Nelson AE, 1996, MOL CELL ENDOCRINOL, V124, P17, DOI 10.1016/S0303-7207(96)03928-7; Olsen HS, 1996, P NATL ACAD SCI USA, V93, P1792, DOI 10.1073/pnas.93.5.1792; RAO CV, 1973, BIOCHIM BIOPHYS ACTA, V313, P372, DOI 10.1016/0304-4165(73)90037-8; REINHART PH, 1982, BIOCHEM J, V204, P731, DOI 10.1042/bj2040731; Sheikh-Hamad D, 2000, AM J PHYSIOL-RENAL, V278, pF417, DOI 10.1152/ajprenal.2000.278.3.F417; Stasko SE, 2001, MOL CELL ENDOCRINOL, V174, P145, DOI 10.1016/S0303-7207(00)00394-4; Stasko SE, 2001, DEV DYNAM, V220, P49, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1086>3.0.CO;2-5; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Varghese R, 1998, ENDOCRINOLOGY, V139, P4714, DOI 10.1210/en.139.11.4714; Varghese R, 2002, ENDOCRINOLOGY, V143, P868, DOI 10.1210/en.143.3.868; Wagner GF, 1997, J BONE MINER RES, V12, P165, DOI 10.1359/jbmr.1997.12.2.165; Wagner Graham F., 1994, P273; Wong CKC, 1998, J ENDOCRINOL, V158, P183, DOI 10.1677/joe.0.1580183; Wong CKC, 2002, J ENDOCRINOL, V173, P199, DOI 10.1677/joe.0.1730199; Wrutniak-Cabello C, 2001, J MOL ENDOCRINOL, V26, P67, DOI 10.1677/jme.0.0260067; Zhang JL, 1998, PROTEIN EXPRES PURIF, V12, P390, DOI 10.1006/prep.1997.0857; Zhang KZ, 2000, P NATL ACAD SCI USA, V97, P3637, DOI 10.1073/pnas.070045897	47	102	107	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45249	45258		10.1074/jbc.M205954200	http://dx.doi.org/10.1074/jbc.M205954200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223480	hybrid			2022-12-27	WOS:000179404800085
J	Omote, H; Al-Shawi, MK				Omote, H; Al-Shawi, MK			A novel electron paramagnetic resonance approach to determine the mechanism of drug transport by P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; PLASMA-MEMBRANE; CYTOPLASMIC LEAFLET; ATPASE ACTIVITY; BINDING; PROTEIN; CELLS; HOECHST-33342; EFFLUX; SITES	ATP-driven pumping of a variety of drugs out of cells by the human P-glycoprotein poses a serious problem to medical therapy. High level heterologous expression of human P-glycoprotein, in the yeast Saccharomyces cerevisiae, has facilitated biophysical studies in purified proteoliposome preparations. Membrane permeability of transported drugs and consequent lack of an experimentally defined drug position have made resolution of the transport mechanism difficult by classical techniques. To overcome these obstacles we devised a novel EPR spin-labeled verapamil for use as a transport substrate. Spin-labeled verapamil was an excellent transport substrate with apparent turnover number, K-m and K-i values of 5.8 s(-1), 4 mum, and 210 muM, respectively, at pH 7.4 and 37 degreesC. The apparent affinities were similar to10-fold higher than for unlabeled verapamil. Spin-labeled verapamil stimulated ATPase activity similar to5-fold, was relatively hydrophilic, and had a very low flip-flop rate, making it an ideal transport substrate. The K-m for MgATP activation of transport was 0.8 mm. By measuring the mobility of spin-labeled verapamil during transport experiments, we were able to resolve the location of the drug in proteoliposome suspensions. Steady state gradients of spin-labeled verapamil within the range of K-i/K-m ratios were observed.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	University of Virginia	Al-Shawi, MK (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, POB 800736, Charlottesville, VA 22908 USA.		OMOTE, Hiroshi/B-1635-2011		NIGMS NIH HHS [GM52502] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052502] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AlShawi MK, 1997, J BIOL CHEM, V272, P2300; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; ANDREE HAM, 1994, ANAL BIOCHEM, V222, P465, DOI 10.1006/abio.1994.1518; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; Eytan GD, 1996, J BIOL CHEM, V271, P12897, DOI 10.1074/jbc.271.22.12897; Figler RA, 2000, ARCH BIOCHEM BIOPHYS, V376, P34, DOI 10.1006/abbi.2000.1712; FLEWELLING RF, 1986, BIOPHYS J, V49, P531, DOI 10.1016/S0006-3495(86)83663-3; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, DOI [10.1007/978-1-4757-3061-6, 10.1007/978-1-4757-3061-6_6, DOI 10.1007/978-1-4757-3061-6_6]; Regev R, 1999, EUR J BIOCHEM, V259, P18, DOI 10.1046/j.1432-1327.1999.00037.x; Romsicki Y, 1999, BIOCHEMISTRY-US, V38, P6887, DOI 10.1021/bi990064q; Seelig A, 2000, EUR J PHARM SCI, V12, P31, DOI 10.1016/S0928-0987(00)00177-9; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Shapiro AB, 1997, EUR J BIOCHEM, V250, P130, DOI 10.1111/j.1432-1033.1997.00130.x; Shapiro AB, 1998, EUR J BIOCHEM, V254, P181, DOI 10.1046/j.1432-1327.1998.2540181.x; Shapiro AB, 1997, EUR J BIOCHEM, V250, P115, DOI 10.1111/j.1432-1033.1997.00115.x; Shapiro AB, 1997, EUR J BIOCHEM, V250, P122, DOI 10.1111/j.1432-1033.1997.00122.x; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; Victor KG, 2001, BIOPHYS J, V81, P2241, DOI 10.1016/S0006-3495(01)75871-7; White SH, 2001, J BIOL CHEM, V276, P32395, DOI 10.1074/jbc.R100008200; YUSA K, 1989, CANCER RES, V49, P5002; ZAMORA JM, 1988, MOL PHARMACOL, V33, P454	27	65	67	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45688	45694		10.1074/jbc.M206479200	http://dx.doi.org/10.1074/jbc.M206479200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244102	hybrid			2022-12-27	WOS:000179404800136
J	Song, L; De Sarno, P; Jope, RS				Song, L; De Sarno, P; Jope, RS			Central role of glycogen synthase kinase-3 beta in endoplasmic reticulum stress-induced caspase-3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PEPTIDE; PROTEIN-KINASE-B; SH-SY5Y NEUROBLASTOMA-CELLS; GROWTH-FACTOR WITHDRAWAL; HIPPOCAMPAL-NEURONS; SIGNALING PATHWAY; SUBCELLULAR-DISTRIBUTION; NUCLEAR ACCUMULATION; MUTANT PRESENILIN-1; CALCIUM HOMEOSTASIS	Stress of the endoplasmic reticulum (ER), which is associated with many neurodegenerative conditions, can lead to the elimination of affected cells by apoptosis through only partially understood mechanisms. Thapsigargin, which causes ER stress by inhibiting the ER Ca2+-ATPase, was found to not only activate the apoptosis effector caspase-3 but also to cause a large and prolonged increase in the activity of glycogen synthase kinase-3beta (GSK3beta). Activation of GSK3beta was obligatory for thapsigargin-induced activation of caspase-3, because inhibition of GSK3beta by expression of dominant-negative GSK3beta or by the GSK3beta inhibitor lithium blocked caspase-3 activation. Thapsigargin treatment activated GSK3beta by inducing dephosphorylation of phospho-Ser-9 of GSK3beta, a phosphorylation that normally maintains GSK3beta inactivated. Caspase-3 activation induced by thapsigargin was blocked by increasing the phosphorylation of Ser-9-GSK3beta with insulin-like growth factor-1 or with the phosphatase inhibitors okadaic acid and calyculin A, but the calcineurin inhibitors FK506 and cyclosporin A were ineffective. Insulin-like growth factor-1, okadaic acid, calyculin A, and lithium also protected cells from two other inducers of ER stress, tunicamycin and brefeldin A. Thus, ER stress activates GSK3beta through dephosphorylation of phospho-Ser-9, a prerequisite for caspase-3 activation, and this process is amenable to pharmacological intervention.	Univ Alabama, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Jope, RS (corresponding author), Univ Alabama, Dept Psychiat, Sparks Ctr 1057, Birmingham, AL 35294 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038752, R56MH038752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037768] Funding Source: NIH RePORTER; NIMH NIH HHS [MH38752] Funding Source: Medline; NINDS NIH HHS [NS37768] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alvarez G, 1999, FEBS LETT, V453, P260, DOI 10.1016/S0014-5793(99)00685-7; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Asai A, 1999, J BIOL CHEM, V274, P34450, DOI 10.1074/jbc.274.48.34450; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Carmichael J, 2002, J BIOL CHEM, V277, P33791, DOI 10.1074/jbc.m204861200; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; Crowder RJ, 2000, J BIOL CHEM, V275, P34266, DOI 10.1074/jbc.M006160200; Culbert AA, 2001, FEBS LETT, V507, P288, DOI 10.1016/S0014-5793(01)02990-8; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Elyaman W, 2002, EUR J NEUROSCI, V15, P651, DOI 10.1046/j.1460-9568.2002.01899.x; Ferkey DM, 2000, DEV BIOL, V225, P471, DOI 10.1006/dbio.2000.9816; FURUYA Y, 1994, CANCER RES, V54, P6167; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; Guo Q, 1998, P NATL ACAD SCI USA, V95, P3227, DOI 10.1073/pnas.95.6.3227; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Guo Q, 1997, J NEUROSCI, V17, P4212; Guo Q, 1999, J NEUROCHEM, V72, P1019, DOI 10.1046/j.1471-4159.1999.0721019.x; Hall JL, 2001, DIABETES, V50, P1171, DOI 10.2337/diabetes.50.5.1171; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Hetman M, 2000, J NEUROSCI, V20, P2567; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Imahori K, 1997, J BIOCHEM, V121, P179; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; Johnson Gail V. W., 1998, Alzheimer's Disease Review, V3, P125; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; King TD, 2001, BRAIN RES, V919, P106, DOI 10.1016/S0006-8993(01)03005-0; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kurihara S, 2000, ENDOCR J, V47, P739, DOI 10.1507/endocrj.47.739; LAM LK, 1994, J BIOL CHEM, V91, P6569; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Lotem J, 1999, P NATL ACAD SCI USA, V96, P12016, DOI 10.1073/pnas.96.21.12016; Maggirwar SB, 1999, J NEUROCHEM, V73, P578, DOI 10.1046/j.1471-4159.1999.0730578.x; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; McGinnis KM, 1998, J BIOL CHEM, V273, P19993, DOI 10.1074/jbc.273.32.19993; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Mora A, 2002, CELL SIGNAL, V14, P557, DOI 10.1016/S0898-6568(01)00282-0; Mora A, 2001, J NEUROCHEM, V78, P199, DOI 10.1046/j.1471-4159.2001.00410.x; Mukerjee N, 2000, ARCH BIOCHEM BIOPHYS, V379, P337, DOI 10.1006/abbi.2000.1889; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nath R, 1997, BIOCHEM MOL BIOL INT, V43, P197; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; Nonaka S, 1998, P NATL ACAD SCI USA, V95, P2642, DOI 10.1073/pnas.95.5.2642; Nonaka S, 1998, NEUROREPORT, V9, P2081, DOI 10.1097/00001756-199806220-00031; Pap M, 2002, MOL CELL BIOL, V22, P578, DOI 10.1128/MCB.22.2.578-586.2002; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Paschen W, 1999, J CEREBR BLOOD F MET, V19, P1, DOI 10.1097/00004647-199901000-00001; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Pei JJ, 1997, J NEUROPATH EXP NEUR, V56, P70, DOI 10.1097/00005072-199701000-00007; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Sato N, 2001, J BIOL CHEM, V276, P2108, DOI 10.1074/jbc.M006886200; Schneider I, 2001, J BIOL CHEM, V276, P11539, DOI 10.1074/jbc.M010977200; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shiurba RA, 1996, BRAIN RES, V737, P119, DOI 10.1016/0006-8993(96)00717-2; Somervaille TCP, 2001, BLOOD, V98, P1374, DOI 10.1182/blood.V98.5.1374; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TAKASHIMA A, 1995, NEUROSCI LETT, V198, P83, DOI 10.1016/0304-3940(95)11964-X; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Tong HY, 2002, CIRC RES, V90, P377, DOI 10.1161/01.RES.0000012567.95445.55; Tong N, 2001, EUR J NEUROSCI, V13, P1913, DOI 10.1046/j.0953-816x.2001.01572.x; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Wei H, 2001, NEUROSCIENCE, V106, P603, DOI 10.1016/S0306-4522(01)00311-6; Wei HF, 2000, EUR J PHARMACOL, V392, P117, DOI 10.1016/S0014-2999(00)00127-8; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Yamaguchi H, 1996, ACTA NEUROPATHOL, V92, P232, DOI 10.1007/s004010050513; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	87	246	264	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44701	44708		10.1074/jbc.M206047200	http://dx.doi.org/10.1074/jbc.M206047200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228224	hybrid			2022-12-27	WOS:000179404800015
J	Xiang, XQ; Zang, MW; Waelde, CA; Wen, R; Luo, ZJ				Xiang, XQ; Zang, MW; Waelde, CA; Wen, R; Luo, ZJ			Phosphorylation of (SSYY341)-S-338 regulates specific interaction between Raf-1 and MEK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NEGATIVE REGULATION; CATALYTIC DOMAIN; ACTIVATES RAF-1; B-RAF; AKT; PATHWAY; GROWTH; CELLS; DIFFERENTIATION	The present study characterizes the interaction between the Raf-1 kinase domain and MEK1 and examines whether the magnitude of their interaction correlates to the ability of Raf to phosphorylate MEK1. Here we show that the minimal domain required for the Raf kinase activity starts from tryptophan 342. Maximal binding of the Raf kinase domain to MEK1 and its kinase activity are achieved upon phosphorylation of the region (SSYY341)-S-338 in response to 4beta-12-O-tetradecanoylphorbol-13-acetate (TPA), or mutation of Y340Y341 to aspartic acids. Conversely, the TPA-stimulated MEK binding and kinase activity are diminished when this region is deleted or Ser(338) and Ser(339) are mutated to alanines. We also show that the integrity of the Raf ATP-binding site is necessary for the interaction between Raf-1 and MEK1. Furthermore, two MEK-binding sites are identified; the first is localized between amino acids 325 and 349, and the second is within the region between amino acids 350 and 648. Separately, the binding of each site to MEK1 is weak, but in a cis context, they give rise to a much stronger association, which can be further stimulated by TPA. Finally, we find that tryptophan 342, which is conserved among the Raf family and other protein kinases, is essential for the Ser(338) phosphorylation of the full-length Raf and its binding to MEK1. Taken together, our results indicate that the phosphorylation of Ser(338) and Tyr(341) on Raf exerts an important effect on reconfiguring the two MEK-binding sites. As a result, these two sites coordinate to form a high affinity MEK-binding epitope, leading to a marked increase in Raf kinase activity.	Boston Univ, Sch Med, Diabet & Metab Res Unit, Endocrinol Sect,Evans Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Univ Penn, Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA	Boston University; Boston University; University of Pennsylvania	Luo, ZJ (corresponding author), Boston Univ, Sch Med, Diabet & Metab Res Unit, Endocrinol Sect,Evans Dept Med, 650 Albany St,Rm 820, Boston, MA 02118 USA.		Luo, Zhijun/AAE-9302-2019	Luo, Zhijun/0000-0001-8105-5289; Zang, Mengwei/0000-0002-2502-2586; Luo, Zhijun/0000-0003-3509-4046	NIGMS NIH HHS [GM 57959] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057959] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Guan KL, 2000, J BIOL CHEM, V275, P27354; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; King AJ, 2001, FEBS LETT, V497, P6, DOI 10.1016/S0014-5793(01)02425-5; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Light Y, 2002, MOL CELL BIOL, V22, P4984, DOI 10.1128/MCB.22.14.4984-4996.2002; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; McPherson RA, 2000, ONCOGENE, V19, P3616, DOI 10.1038/sj.onc.1203678; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; Yip-Schneider MT, 2000, BIOCHEM J, V351, P151, DOI 10.1042/0264-6021:3510151; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200; Zang MW, 2001, J BIOL CHEM, V276, P25157, DOI 10.1074/jbc.M100152200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	37	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44996	45003		10.1074/jbc.M203953200	http://dx.doi.org/10.1074/jbc.M203953200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244094	hybrid			2022-12-27	WOS:000179404800053
J	Cheng, F; Mani, K; van den Born, J; Ding, K; Belting, M; Fransson, LA				Cheng, F; Mani, K; van den Born, J; Ding, K; Belting, M; Fransson, LA			Nitric oxide-dependent processing of heparan sulfate in recycling S-nitrosylated glypican-1 takes place in caveolin-1-containing endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-UNSUBSTITUTED GLUCOSAMINE; HUMAN LUNG FIBROBLASTS; NUCLEAR-LOCALIZATION; ENDOTHELIAL-CELLS; MONOCLONAL-ANTIBODY; SKIN FIBROBLASTS; PLASMA-MEMBRANE; CORE PROTEIN; BREFELDIN-A; PROTEOGLYCANS	We have previously demonstrated intracellular degradation of the heparan sulfate side chains in recycling glypican-1 by heparanase and by deaminative cleavage at N-unsubstituted glucosamine with nitric oxide derived from intrinsic nitrosothiols (see Ding, K., Mani, K., Cheng, F., Belting, M. and Fransson, L.-A (2002) J. Biol. Chem. 277, 33353- 33360). To determine where and in what order events take place, we have visualized, by using confocal laser-scanning immunofluorescence microscopy, glypican-1 variants in unperturbed cells or arrested at various stages of processing. In unperturbed proliferating cells, glypican-1 was partly S-nitrosylated. Intracellular glypican-1 was enriched in endosomes, colocalized significantly with GM-1 ganglioside, caveolin-1, and Rab9-positive endosomes, and carried side chains rich in N-unsubstituted glucosamine residues. However, such residues were scarce in cell surface glypican-1. Brefeldin A-arrested glypican-1, which was non-S-nitrosylated and carried side chains rich in N-unsubstituted glucosamines, colocalized extensively with caveolin-1 but not with Rab9. Suramin, which inhibits heparanase, induced the appearance of S-nitrosylated glypican-1 in caveolin-l-rich compartments. Inhibition of deaminative cleavage did not prevent heparanase from generating heparan sulfate oligosaccharides that colocalized strongly with caveolin-1. Growth-quiescent cells displayed extensive NO-dependent deaminative cleavage of heparan sulfate-generating anhydromannose-terminating fragments that were partly associated with acidic vesicles. Proliferating cells generated such fragments during polyamine uptake. We conclude that recycling glypican-1 that is associated with caveolin-1-containing endosomes undergoes sequential N-desulfation/N-deacetylation, heparanase cleavage, S-nitrosylation, NO release, and deaminative cleavage of its side chains in conjunction with polyamine uptake.	Lund Univ, Dept Cell & Mol Biol, SE-22184 Lund, Sweden; Free Univ Amsterdam, Dept Cell Biol, NL-1081 BT Amsterdam, Netherlands	Lund University; Vrije Universiteit Amsterdam	Fransson, LA (corresponding author), Lund Univ, Dept Cell & Mol Biol, BMC C13, SE-22184 Lund, Sweden.	lars-ake.fransson@medkem.lu.se		Mani, Katrin/0000-0002-1821-0634; Belting, Mattias/0000-0003-1585-5434				Barbero P, 2002, J CELL BIOL, V156, P511, DOI 10.1083/jcb.200109030; Belting M, 2002, P NATL ACAD SCI USA, V99, P371, DOI 10.1073/pnas.012346499; Belting M, 1999, J BIOL CHEM, V274, P19375, DOI 10.1074/jbc.274.27.19375; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brown J, 2000, LAB INVEST, V80, P37, DOI 10.1038/labinvest.3780006; Chatterjee S, 2001, CELL MOL LIFE SCI, V58, P1969, DOI 10.1007/PL00000831; Chen RL, 2001, J BIOL CHEM, V276, P7507, DOI 10.1074/jbc.M008283200; Cheng F, 2001, J CELL BIOCHEM, V83, P597, DOI 10.1002/jcb.1254; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DEBOECK H, 1987, BIOCHEM J, V247, P765, DOI 10.1042/bj2470765; Ding K, 2002, J BIOL CHEM, V277, P33353, DOI 10.1074/jbc.M203383200; Ding K, 2001, J BIOL CHEM, V276, P46779, DOI 10.1074/jbc.M105419200; Ding K, 2001, J BIOL CHEM, V276, P3885, DOI 10.1074/jbc.M005238200; Dirks WG, 1999, IN VITRO CELL DEV-AN, V35, P558; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fansson LA, 2000, MATRIX BIOL, V19, P367, DOI 10.1016/S0945-053X(00)00083-4; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; Filmus J, 2001, GLYCOBIOLOGY, V11, p19R, DOI 10.1093/glycob/11.3.19R; Fivaz M, 2002, EMBO J, V21, P3989, DOI 10.1093/emboj/cdf398; FRANSSON L, 1995, GLYCOBIOLOGY, V5, P407, DOI 10.1093/glycob/5.4.407; FRANSSON LA, 1983, J BIOL CHEM, V258, P4342; FRANSSON LA, 1982, CARBOHYD RES, V110, P127, DOI 10.1016/0008-6215(82)85031-3; Gagliardi ART, 1998, CANCER LETT, V125, P97, DOI 10.1016/S0304-3835(97)00496-5; Giraldez AJ, 2002, DEV CELL, V2, P667, DOI 10.1016/S1534-5807(02)00180-6; Goldshmidt O, 2001, J BIOL CHEM, V276, P29178, DOI 10.1074/jbc.M102462200; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Huang SS, 1997, FEBS LETT, V416, P297, DOI 10.1016/S0014-5793(97)01213-1; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Kobayashi T, 2002, J BIOL CHEM, V277, P32157, DOI 10.1074/jbc.M202838200; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; Leteux C, 2001, J BIOL CHEM, V276, P12539, DOI 10.1074/jbc.M010291200; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; Mani K, 2000, GLYCOBIOLOGY, V10, P577, DOI 10.1093/glycob/10.6.577; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; Murakami M, 2000, BBA-MOL CELL BIOL L, V1488, P159, DOI 10.1016/S1388-1981(00)00118-9; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; PEJLER G, 1988, J BIOL CHEM, V263, P5197; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Razani B, 2001, J BIOL CHEM, V276, P38121; Richardson TP, 2001, J CELL SCI, V114, P1613; Schlegel A, 2001, CYTOKINE GROWTH F R, V12, P41, DOI 10.1016/S1359-6101(00)00022-8; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Spillmann D, 2001, BIOCHIMIE, V83, P811, DOI 10.1016/S0300-9084(01)01290-1; Stubauer G, 1999, J BIOL CHEM, V274, P28128, DOI 10.1074/jbc.274.40.28128; Tammi R, 2001, J BIOL CHEM, V276, P35111, DOI 10.1074/jbc.M103481200; TANABE H, 1999, TISSUE CULT RES COMM, V18, P329, DOI DOI 10.11418/JTCA1981.18.4_329; THORENS B, 1993, J CELL BIOL, V123, P1687, DOI 10.1083/jcb.123.6.1687; Tumova S, 1999, BIOCHEM J, V337, P471, DOI 10.1042/0264-6021:3370471; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; WERMUTH B, 1982, METHOD ENZYMOL, V89, P181	60	64	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44431	44439		10.1074/jbc.M205241200	http://dx.doi.org/10.1074/jbc.M205241200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226079	hybrid			2022-12-27	WOS:000179272000114
J	Rui, HL; Fan, E; Zhou, HM; Xu, Z; Zhang, Y; Lin, SC				Rui, HL; Fan, E; Zhou, HM; Xu, Z; Zhang, Y; Lin, SC			SUMO-1 modification of the C-terminal KVEKVD of axin is required for JNK activation but has no effect on Wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; KAPPA-B-ALPHA; F-BOX PROTEIN; BETA-CATENIN; NEGATIVE REGULATOR; FUNCTIONAL INTERACTION; KINASE ACTIVATION; BINDING PROTEIN; NUCLEAR-BODIES; PATHWAY	Axin is a multifunctional protein, regulating Wnt signaling and the c-Jun N-terminal/stress-activated protein kinase (JNK/SAPK) pathway as well as tumorigenesis. In the present study, we found that Axin interacts with three SUMO-1 (small ubiquitin-related modifier) conjugating enzymes 3 (E3), PIAS1, PIASxbeta, and PIASy. The extreme C-terminal six amino acid residues of Axin are critical for the Axin/E3 interaction as deletion of the six residues (AxinDeltaC6) completely abolished the ability of Axin to interact with E3 enzymes. AxinDeltaC6 also failed to activate JNK although it was intact in both its interaction with MEKK1 and homodimerization. Consistent with the presence of a doublet of the KV(E/D) sumoylation consensus motif at the C-terminal end (KVEKVD), we found that Axin is heavily sumoylated. Deletion of the C-terminal six amino acids drastically reduced sumoylation, indicating that the C-terminal six amino acids stretch is the main sumoylation site for Axin. Sumoylation-defective mutants failed to activate JNK but effectively destabilized beta-catenin and attenuated LEF1 transcriptional activity. In addition, we show that dominant negative Axin mutants blocked PIAS-mediated JNK activation, in accordance with the requirement of sumoylation for Axin-mediated JNK activation. Taken together, we demonstrate that sumoylation plays a role for Axin to function in the JNK pathway.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Tsing Hua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China	Hong Kong University of Science & Technology; Tsinghua University	Lin, SC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China.		Lin, SC/G-4666-2010; Xu, Zhen/P-3029-2014; Rui, Hongliang/GNM-9930-2022	Xu, Zhen/0000-0002-2190-3861; Rui, Hongliang/0000-0002-7584-9610; Zhang, Yi/0000-0003-2785-1780				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kadoya T, 2000, J BIOL CHEM, V275, P37030, DOI 10.1074/jbc.M005984200; Kadoya T, 2002, MOL CELL BIOL, V22, P3803, DOI 10.1128/MCB.22.11.3803-3819.2002; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, J BIOL CHEM, V276, P36624, DOI 10.1074/jbc.M101085200; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Neo SY, 2000, BIOCHEM BIOPH RES CO, V272, P144, DOI 10.1006/bbrc.2000.2751; Nishida T, 2001, J BIOL CHEM, V276, P39060, DOI 10.1074/jbc.M103955200; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Polakis P, 2000, GENE DEV, V14, P1837; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang Y, 1999, J BIOL CHEM, V274, P2851, DOI 10.1074/jbc.274.5.2851; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zhang Y, 2002, J BIOL CHEM, V277, P17706, DOI 10.1074/jbc.M111982200; Zhang Y, 2001, J BIOL CHEM, V276, P32152, DOI 10.1074/jbc.M104451200; Zhang Y, 2000, J BIOL CHEM, V275, P25008, DOI 10.1074/jbc.M002491200	50	71	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42981	42986		10.1074/jbc.M208099200	http://dx.doi.org/10.1074/jbc.M208099200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12223491	hybrid			2022-12-27	WOS:000179081200073
J	Stevenson-Paulik, J; Odom, AR; York, JD				Stevenson-Paulik, J; Odom, AR; York, JD			Molecular and biochemical characterization of two plant inositol polyphosphate 6-/3-/5-kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMATURE SOYBEAN SEEDS; MESSENGER-RNA EXPORT; 1,3,4,5,6-PENTAKISPHOSPHATE 2-KINASE; 1,3,4-TRISPHOSPHATE 5/6-KINASE; 1,4,5-TRISPHOSPHATE 3-KINASE; SACCHAROMYCES-CEREVISIAE; HEXAKISPHOSPHATE KINASE; MULTIKINASE; IDENTIFICATION; TRISPHOSPHATE	Despite the high deposition of inositol hexakisphosphate (IP6), also known as phytate or phytin, in certain plant tissues little is known at the molecular level about the pathway(s) involved in its production. In budding yeast, IP6 synthesis occurs through the sequential phosphorylation of I(1,4,5)P, by two gene products, Ipk2 and Ipk1, a IP3/IP4 dual-specificity 6-/3-kinase and an inositol 1,3,4,5,6-pentakisphosphate 2-kinase, respectively. Here we report the identification and characterization of two inositol polyphosphate kinases from Arabidopsis thaliana, designated AtIpk2alpha and AtIpk2beta that are encoded by distinct genes on chromosome 5 and that are ubiquitously expressed in mature tissue. The primary structures of AtIpk2alpha and AtIpk2beta are 70% identical to each other and 12-18% identical to Ipk2s from yeast and mammals. Similar to yeast Ipk2, purified recombinant AtIpk2alpha and AtIpk2beta have 6-/3-kinase activities that sequentially phosphorylate 1(1,4,5)P-3 to generate I(1,3,4,5,6)P-5 predominantly via an 1(1,4,5,6)P-4 intermediate. While 1(1,3,4,5)P-4 is a substrate for the plant Ipk2s, it does not appear to be a detectable product of the IP3 reaction. Additionally, we report that the plant and yeast Ipk2 have a novel 5-kinase activity toward I(1,3,4,6)P-4 and I(1,2,3,4,6)P-5, which would allow these proteins to participate in at least two proposed pathways in the synthesis of IP6. Heterologous expression of either plant isoform in an ipk2 mutant yeast strain restores IP4 and IP5 production in vivo and rescues its temperature-sensitive growth defects. Collectively our results provide a molecular basis for the synthesis of higher inositol polyphosphates in plants through multiple routes and indicate that the 6-/3-/5-kinase activities found in plant extracts may be encoded by the IPK2 gene class.	Duke Univ, Dept Pharmacol, Howard Hughes Med Inst, Med Ctr, Durham, NC 27710 USA; Duke Univ, Dept Canc Biol, Howard Hughes Med Inst, Med Ctr, Durham, NC 27710 USA; Duke Univ, Dept Biochem, Howard Hughes Med Inst, Med Ctr, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	York, JD (corresponding author), Duke Univ, Dept Pharmacol, Howard Hughes Med Inst, Med Ctr, Durham, NC 27710 USA.	yorkj@duke.edu	John, Audrey Odom/AAF-1300-2019	John, Audrey Odom/0000-0001-8395-8537	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-55672] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berdy SE, 2001, PLANT PHYSIOL, V126, P801, DOI 10.1104/pp.126.2.801; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Brearley CA, 1996, BIOCHEM J, V314, P227, DOI 10.1042/bj3140227; CHATTAWAY JA, 1992, PLANTA, V187, P542, DOI 10.1007/BF00199975; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; COMMUNI D, 1995, CELL SIGNAL, V7, P643, DOI 10.1016/0898-6568(95)00035-N; Dubois E, 2002, J BIOL CHEM, V277, P23755, DOI 10.1074/jbc.M202206200; Ho MWY, 2002, CURR BIOL, V12, P477, DOI 10.1016/S0960-9822(02)00713-3; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Ives EB, 2000, J BIOL CHEM, V275, P36575, DOI 10.1074/jbc.M007586200; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Loewus FA, 2000, PLANT SCI, V150, P1, DOI 10.1016/S0168-9452(99)00150-8; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; Nalaskowski MM, 2002, BIOCHEM J, V366, P549, DOI 10.1042/BJ20020327; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Phillippy BQ, 1998, PLANT PHYSIOL, V116, P291, DOI 10.1104/pp.116.1.291; PHILLIPPY BQ, 1994, J BIOL CHEM, V269, P28393; RABOY V, 1990, PLANT BIOL, V9, P55; Raboy V, 1996, Subcell Biochem, V26, P257; Raboy V, 2001, TRENDS PLANT SCI, V6, P458, DOI 10.1016/S1360-1385(01)02104-5; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Saiardi A, 2001, P NATL ACAD SCI USA, V98, P2306, DOI 10.1073/pnas.041614598; Schell MJ, 1999, FEBS LETT, V461, P169, DOI 10.1016/S0014-5793(99)01462-3; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; STEPHENS LR, 1990, NATURE, V346, P580, DOI 10.1038/346580a0; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; Togashi S, 1997, BIOCHEM J, V326, P221, DOI 10.1042/bj3260221; Verbsky JW, 2002, J BIOL CHEM, V277, P31857, DOI 10.1074/jbc.M205682200; Wilson MP, 1996, J BIOL CHEM, V271, P11904, DOI 10.1074/jbc.271.20.11904; Wilson MP, 1997, BIOCHEM BIOPH RES CO, V232, P678, DOI 10.1006/bbrc.1997.6355; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; Zhang T, 2001, FEBS LETT, V494, P208, DOI 10.1016/S0014-5793(01)02351-1	35	100	115	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42711	42718		10.1074/jbc.M209112200	http://dx.doi.org/10.1074/jbc.M209112200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12226109	hybrid			2022-12-27	WOS:000179081200038
J	Touz, MC; Gottig, N; Nash, TE; Lujan, HD				Touz, MC; Gottig, N; Nash, TE; Lujan, HD			Identification and characterization of a novel secretory granule calcium-binding protein from the early branching eukaryote Giardia lamblia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYST WALL PROTEIN; ENDOPLASMIC-RETICULUM; PRIMITIVE EUKARYOTE; INTRACELLULAR CALCIUM; MOLECULAR CHAPERONES; ANTIGENIC VARIATION; VESICLE FORMATION; CELLS; TRANSPORT; GOLGI	Giardia lamblia is a flagellate protozoan that infects humans and other mammals and the most frequently isolated intestinal parasite worldwide. Giardia trophozoites undergo essential biological changes to survive outside the intestine of their host by differentiating into infective cysts. Cyst formation, or encystation, is considered one of the most primitive adaptive responses developed by eukaryotes early in evolution and crucial for the transmission of the parasite among susceptible hosts. During this process, proteins that will assemble into the extracellular cyst wall (CWP1 and CWP2) are transported to the cell surface within encystation-specific secretory vesicles (ESVs) by a developmentally regulated secretory pathway. Cyst wall proteins (CWPs) are maintained as a dense material inside the ESVs, but after exocytosis, they form the fibrillar matrix of the cyst wall. Little is known about the molecular mechanisms involved in granule biogenesis and discharge in Giardia, as well as the assembly of the extracellular wall. In this work, we provide evidences that a novel 54-kDa protein that exclusively localizes to the ESVs is induced during encystation similar to CWPs, proteolytically processed during granule maturation, and able to bind calcium in vitro. The gene encoding this molecule predicts a novel protein (called gGSP for (G) under bar. lamblia (G) under bar ranule-(s) under bar pecific (P) under bar rotein) without homology to any other protein reported in public databases. Nevertheless, it possesses characteristics of calcium-sequestering molecules of higher eukaryotes. Inhibition of gGSP expression abolishes cyst wall formation, suggesting that this secretory granule protein regulates Ca2+-dependent degranulation of ESVs during cyst wall formation.	Univ Nacl Cordoba, Catedra Bioquim & Biol Mol, Fac Ciencias Med, RA-5000 Cordoba, Argentina; NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA	National University of Cordoba; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lujan, HD (corresponding author), Univ Nacl Cordoba, Catedra Bioquim & Biol Mol, Fac Ciencias Med, Pabellon Argentina 2 Piso, RA-5000 Cordoba, Argentina.			TOUZ, MARIA/0000-0002-6769-6896	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000161, ZIAAI000161] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adam RD, 2000, INT J PARASITOL, V30, P475, DOI 10.1016/S0020-7519(99)00191-5; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERER R, 1977, J ULTRA MOL STRUCT R, V60, P21, DOI 10.1016/S0022-5320(77)80037-3; Arvan Peter, 1992, Trends in Cell Biology, V2, P327; BILINSKI M, 1981, J CELL BIOL, V88, P179, DOI 10.1083/jcb.88.1.179; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOUCHER SEM, 1990, INFECT IMMUN, V58, P3516, DOI 10.1128/IAI.58.11.3516-3522.1990; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; Carruthers Vern B., 1999, Parasitology International, V48, P1; Chilcoat ND, 1996, J CELL BIOL, V135, P1775, DOI 10.1083/jcb.135.6.1775; Coppens I, 1999, EUR J CELL BIOL, V78, P463, DOI 10.1016/S0171-9335(99)80073-9; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; DIERKS T, 1993, PHILOS T ROY SOC B, V339, P335, DOI 10.1098/rstb.1993.0032; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; Elmendorf HG, 2001, MOL BIOCHEM PARASIT, V113, P157, DOI 10.1016/S0166-6851(01)00211-0; FAUBERT G, 1991, EXP PARASITOL, V72, P345, DOI 10.1016/0014-4894(91)90080-G; FEELY DE, 1990, HUMAN PARASITIC DIS; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Gerasimenko OV, 1996, PFLUG ARCH EUR J PHY, V432, P1055, DOI 10.1007/s004240050234; GERDES HH, 1989, J BIOL CHEM, V264, P12009; Gillin FD, 1996, ANNU REV MICROBIOL, V50, P679, DOI 10.1146/annurev.micro.50.1.679; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; Knodler LA, 1999, J BIOL CHEM, V274, P29805, DOI 10.1074/jbc.274.42.29805; KRAUSE KH, 1990, BIOCHEM J, V270, P545, DOI 10.1042/bj2700545; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; Liang JO, 1997, J BIOL CHEM, V272, P4141, DOI 10.1074/jbc.272.7.4141; Lujan HD, 1996, BIOL CELL, V86, P11, DOI 10.1016/0248-4900(96)89519-0; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; LUJAN HD, 1995, J BIOL CHEM, V270, P4612, DOI 10.1074/jbc.270.9.4612; Lujan HD, 1997, MICROBIOL MOL BIOL R, V61, P294; LUJAN HD, 1997, PARASITOL TODAY, V14, P446; LUJAN HD, 1996, P NATL ACAD SCI USA, V93, P7627; MacGowan GA, 2001, J BIOMED OPT, V6, P23, DOI 10.1117/1.1316091; McArthur AG, 2001, MOL BIOL EVOL, V18, P1455, DOI 10.1093/oxfordjournals.molbev.a003931; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Meng TC, 1996, MOL BIOCHEM PARASIT, V79, P103, DOI 10.1016/0166-6851(96)02636-9; MOWATT MR, 1995, MOL MICROBIOL, V15, P955, DOI 10.1111/j.1365-2958.1995.tb02364.x; NASH TE, 1989, EXP PARASITOL, V68, P238, DOI 10.1016/0014-4894(89)90104-5; NASH TE, 1993, P NATL ACAD SCI USA, V90, P5489, DOI 10.1073/pnas.90.12.5489; NASH TE, 1988, J IMMUNOL, V141, P636; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Orci L, 1998, P NATL ACAD SCI USA, V95, P2279, DOI 10.1073/pnas.95.5.2279; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Pelham HRB, 2000, CELL, V102, P713, DOI 10.1016/S0092-8674(00)00060-X; Petersen OH, 2001, TRENDS NEUROSCI, V24, P271, DOI 10.1016/S0166-2236(00)01787-2; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Sambrook J., 2002, MOL CLONING LAB MANU; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Shin DW, 2000, FEBS LETT, V486, P178, DOI 10.1016/S0014-5793(00)02246-8; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Soltys BJ, 1996, J CELL SCI, V109, P1909; Stroh A, 1999, EUR J CELL BIOL, V78, P151, DOI 10.1016/S0171-9335(99)80094-6; Touz MC, 2002, J BIOL CHEM, V277, P8474, DOI 10.1074/jbc.M110250200; Verbsky JW, 1998, MOL BIOL CELL, V9, P497, DOI 10.1091/mbc.9.2.497; YOO SH, 1990, J BIOL CHEM, V265, P13446; Yuasa K, 2000, PLANT PHYSIOL, V124, P1069, DOI 10.1104/pp.124.3.1069	61	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50557	50563		10.1074/jbc.M202558200	http://dx.doi.org/10.1074/jbc.M202558200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12354777	hybrid			2022-12-27	WOS:000180177700049
J	Diaz, AR; Mansilla, MC; Vila, AJ; de Mendoza, D				Diaz, AR; Mansilla, MC; Vila, AJ; de Mendoza, D			Membrane topology of the acyl-lipid desaturase from Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEAROYL-COA DESATURASE; ALKALINE-PHOSPHATASE; ALKANE HYDROXYLASE; HISTIDINE-RESIDUES; PROTEIN; GENE; EXPRESSION; SEQUENCE; ENCODES; CARRIER	The Bacillus subtilis acyl-lipid desaturase (Delta5-Des) is an iron-dependent integral membrane protein, able to selectively introduce double bonds into long chain fatty acids. Structural information on membrane-bound desaturases is still limited, and the present topological information is restricted to hydropathy plots or sequence comparison with the evolutionary related alkane hydroxylase. The topology of Delta5-Des was determined experimentally in Escherichia coli using a set of nine different fusions of N-terminal fragments of Delta5-Des with the reporter alkaline phosphatase (Delta5-Des-PhoA). The alkaline phosphatase activities of cells expressing the Delta5-Des-PhoA fusions, combined with site-directed mutagenesis of His residues identified in most desaturases, suggest that a tripartite motif of His essential for catalysis is located on the cytoplasmic phase of the membrane. These data, together with surface Lys biotinylation experiments, support a model for Delta5-Des as a polytopic membrane protein with six transmembrane- and one membrane-associated domain, which likely represents a substrate-binding motif. This study provides the first experimental evidence for the topology of a plasma membrane fatty acid desaturase. On the basis of our results and the presently available hydrophobicity profile of many acyl-lipid desaturases, we propose that these enzymes contain a new transmembrane domain that might play a critical role in the desaturation of fatty acids esterified in glycerolipids.	Univ Nacl Rosario, Inst Biol Mol & Celular Rosario, RA-2000 Rosario, Argentina; Univ Nacl Rosario, Dept Microbiol, RA-2000 Rosario, Argentina; Univ Nacl Rosario, Dept Quim Biol, Area Biofis, Fac Ciencias Bioquim & Farmaceut, RA-2000 Rosario, Argentina	National University of Rosario; National University of Rosario; National University of Rosario	de Mendoza, D (corresponding author), Univ Nacl Rosario, Inst Biol Mol & Celular Rosario, Suipacha 531,S2002LRK, RA-2000 Rosario, Argentina.	diegonet@citynet.net.ar	Mansilla, María/R-8500-2019	Mansilla, María/0000-0002-1444-8661; Vila, Alejandro/0000-0002-7978-3233				Aguilar PS, 1998, J BACTERIOL, V180, P2194, DOI 10.1128/JB.180.8.2194-2200.1998; Aguilar PS, 2001, EMBO J, V20, P1681, DOI 10.1093/emboj/20.7.1681; AVELANGEMACHEREL MH, 1995, FEBS LETT, V361, P111, DOI 10.1016/0014-5793(95)00163-4; BOYD D, 1993, J BACTERIOL, V175, P553, DOI 10.1128/JB.175.2.553-556.1993; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Cho HP, 1999, J BIOL CHEM, V274, P471, DOI 10.1074/jbc.274.1.471; Cho HP, 1999, J BIOL CHEM, V274, P37335, DOI 10.1074/jbc.274.52.37335; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; de Mendoza D., 2001, BACILLUS SUBTILIS IT, P43; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; GRAU R, 1993, MOL MICROBIOL, V8, P535, DOI 10.1111/j.1365-2958.1993.tb01598.x; Green DH, 2000, J BACTERIOL, V182, P278, DOI 10.1128/JB.182.2.278-285.2000; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lindqvist Y, 1996, EMBO J, V15, P4081, DOI 10.1002/j.1460-2075.1996.tb00783.x; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Mitaku S, 1999, PROTEIN ENG, V12, P953, DOI 10.1093/protein/12.11.953; MURATA N, 1995, BIOCHEM J, V308, P1; Mustardy L, 1996, P NATL ACAD SCI USA, V93, P10524, DOI 10.1073/pnas.93.19.10524; OHLROGGE J, 1995, PLANT CELL, V7, P957, DOI 10.1105/tpc.7.7.957; OKAYASU T, 1981, ARCH BIOCHEM BIOPHYS, V206, P21, DOI 10.1016/0003-9861(81)90061-8; PUGH EL, 1977, J BIOL CHEM, V252, P68; PUGH EL, 1979, LIPIDS, V14, P159, DOI 10.1007/BF02533867; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; THIEDE MA, 1986, J BIOL CHEM, V261, P3230; Tocher DR, 1998, PROG LIPID RES, V37, P73, DOI 10.1016/S0163-7827(98)00005-8; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; VANBEILEN JB, 1992, J BIOL CHEM, V267, P9194; vanGeest M, 1996, J BIOL CHEM, V271, P25582, DOI 10.1074/jbc.271.41.25582; Zhu QS, 1999, J BIOL CHEM, V274, P27898, DOI 10.1074/jbc.274.39.27898	32	55	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48099	48106		10.1074/jbc.M208960200	http://dx.doi.org/10.1074/jbc.M208960200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12324476	hybrid			2022-12-27	WOS:000179789600018
J	van Rooij, E; Doevendans, PA; de Theije, CC; Babiker, FA; Molkentin, JD; De Windt, LJ				van Rooij, E; Doevendans, PA; de Theije, CC; Babiker, FA; Molkentin, JD; De Windt, LJ			Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; JUN NH2-TERMINAL KINASE; CARDIAC-HYPERTROPHY; NF-ATC; HEART-FAILURE; MUSCLE-CELLS; IN-VIVO; TARGETED INHIBITION; SIGNALING PATHWAYS; NEGATIVE REGULATOR	The calcium-activated phosphatase calcineurin has been implicated as a critical intracellular signal transducer of cardiomyocyte hypertrophy. Although previous data suggested the nuclear factor of activated T-cells (NFAT) as its sole transcriptional effector, the absolute requirement of NFAT as a mediator of calcineurin signaling has not been examined in the heart. We therefore investigated the expression and activation profile of NFAT genes in the heart. Four members (NFATc1-c4) are expressed in cardiomyocytes, elicit nuclear translocation upon calcineurin activation, and are able to drive transactivation of cardiac promoter luciferase constructs. To define the necessary function of NFAT factors as hypertrophic transducers, a dominant negative NFAT construct was created, encompassing part of the N-terminal region of NFATc4 containing a conserved calcineurin-binding motif. Cotransfection of this construct dose-dependently abrogated promoter activation, irrespective of the NFAT isoform used, whereas a control construct with the calcineurin-binding motif mutated displayed no such effects. Adenoviral gene transfer of dominant negative NFAT rendered cardiomyocytes resistant toward all aspects of calcineurin or agonist-induced cardiomyocyte hypertrophy, whereas adenoviral gene transfer of the control construct had no discernable effect on these parameters. These results indicate that multiple NFAT isoforms are expressed in cardiomyocytes where they function as necessary transducers of calcineurin in facilitating cardiomyocyte hypertrophy.	Univ Hosp, Dept Cardiol, Inst Cardiovasc Res, NL-6202 AZ Maastricht, Netherlands; Interuniv Cardiol Inst Netherlands, NL-3501 DG Utrecht, Netherlands; Childrens Hosp, Med Ctr, Dept Pediat, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA	Maastricht University; Interuniversity Cardiology Institute of the Netherlands; Utrecht University; Cincinnati Children's Hospital Medical Center	De Windt, LJ (corresponding author), Univ Hosp, Dept Cardiol, Inst Cardiovasc Res, P Debeyelaan 25,POB 5800, NL-6202 AZ Maastricht, Netherlands.		de Windt, Leon/AAO-6395-2020	de Windt, Leon/0000-0002-7793-2856; Molkentin, Jeffery/0000-0002-3558-6529	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL060562, T32HL007382, R01HL060562] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07382, HL60562] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; Bueno OF, 2002, CARDIOVASC RES, V53, P806, DOI 10.1016/S0008-6363(01)00493-X; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Chow CW, 1999, MOL CELL BIOL, V19, P2300; Chuvpilo S, 1999, J IMMUNOL, V162, P7294; Cleland JGF, 2001, EUR HEART J, V22, P623, DOI 10.1053/euhj.2000.2493; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; De Windt LJ, 2001, P NATL ACAD SCI USA, V98, P3322, DOI 10.1073/pnas.031371998; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; DeWindt LJ, 1997, J MOL CELL CARDIOL, V29, P2095, DOI 10.1006/jmcc.1997.0444; Friday BB, 2001, J CELL SCI, V114, P303; Garcia-Cozar FJ, 1998, J BIOL CHEM, V273, P23877, DOI 10.1074/jbc.273.37.23877; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Hardt SE, 2002, CIRC RES, V90, P1055, DOI 10.1161/01.RES.0000018952.70505.F1; Hautala N, 2002, PFLUG ARCH EUR J PHY, V443, P362, DOI 10.1007/s004240100699; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Horsley V, 2001, J CELL BIOL, V153, P329, DOI 10.1083/jcb.153.2.329; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Imamura R, 1998, J IMMUNOL, V161, P3455; Kakita T, 2001, CIRC RES, V88, P1239, DOI 10.1161/hh1201.091794; Kegley KM, 2001, DEV BIOL, V232, P115, DOI 10.1006/dbio.2001.0179; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; Lim HW, 2000, CIRCULATION, V101, P2431, DOI 10.1161/01.CIR.101.20.2431; Lorell BH, 2000, CIRCULATION, V102, P470; Luo C, 1996, J EXP MED, V184, P141, DOI 10.1084/jem.184.1.141; Marttila M, 2001, ENDOCRINOLOGY, V142, P4693, DOI 10.1210/en.142.11.4693; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 2000, CIRC RES, V87, P731, DOI 10.1161/01.RES.87.9.731; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Park S, 2000, P NATL ACAD SCI USA, V97, P7130, DOI 10.1073/pnas.97.13.7130; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Schaap FG, 1999, CIRC RES, V85, P329, DOI 10.1161/01.RES.85.4.329; Stevenson AS, 2001, J BIOL CHEM, V276, P15018, DOI 10.1074/jbc.M011684200; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Suzuki E, 2002, CIRC RES, V90, P1004, DOI 10.1161/01.RES.0000017629.70769.CC; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; WILKINSON BJ, MOL CELL BIOL, V22, P7603; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2; Zou YZ, 2001, CIRCULATION, V104, P97, DOI 10.1161/01.CIR.104.1.97	61	96	100	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48617	48626		10.1074/jbc.M206532200	http://dx.doi.org/10.1074/jbc.M206532200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12226086	hybrid			2022-12-27	WOS:000179789600085
J	Crisp, RJ; Knauer, MF; Knauer, DJ				Crisp, RJ; Knauer, MF; Knauer, DJ			Protease nexin 1 is a potent urinary plasminogen activator inhibitor in the presence of collagen type IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; UROKINASE RECEPTOR; IN-VITRO; THROMBIN; BINDING; HEPARIN; SPECIFICITY; COMPLEXES; CELLS; BRAIN	Protease nexin 1 (PN1) in solution forms inhibitory complexes with thrombin or urokinase, which have opposing effects on the blood coagulation cascade. An initial report provided data supporting the idea that PN1 target protease specificity is under the influence of collagen type IV (1). Although collagen type IV demonstrated no effect on the association rate between PN1 and thrombin, the study reported that the association rate between PN1 and urokinase was allosterically reduced 10-fold. This has led to the generally accepted idea that the primary role of PN1 in the brain is to act as a rapid thrombin inhibition and clearance mechanism during trauma and loss of vascular integrity. In studies to identify the structural determinants of PN1 that mediate the allosteric interaction with collagen type IV, we found that protease specificity was only affected after transient exposure of PN1 to acidic conditions that mimic the elution protocol from a monoclonal antibody column. Because PN1 used in previous studies was purified over a monoclonal antibody column, we propose that the allosteric regulation of PN1 target protease specificity by collagen type IV is a result of the purification protocol. We provide both biochemical and kinetic data to support this conclusion. This finding is significant because it implies that PN1 may play a much larger role in the modeling and remodeling of brain tissues during development and is not simply an extravasated thrombin clearance mechanism as previously suggested.	Univ Calif Irvine, Dept Cellular & Dev Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Knauer, DJ (corresponding author), Univ Calif Irvine, Dept Cellular & Dev Biol, Irvine, CA 92697 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007311, R01GM034001] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM07311-27, GM34001-12] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; Cunningham DD, 1997, ADV EXP MED BIOL, V425, P67; DONOVAN FM, 1994, J BIOL CHEM, V269, P17199; Donovan FM, 1998, J BIOL CHEM, V273, P12746, DOI 10.1074/jbc.273.21.12746; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; FARRELL DH, 1988, J CELL PHYSIOL, V134, P179, DOI 10.1002/jcp.1041340203; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; GUENTHER J, 1985, EMBO J, V4, P1963, DOI 10.1002/j.1460-2075.1985.tb03878.x; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Knauer DJ, 2000, J BIOL CHEM, V275, P37340, DOI 10.1074/jbc.M003909200; KNAUER DJ, 1983, J CELL PHYSIOL, V117, P385, DOI 10.1002/jcp.1041170314; Knauer MF, 1999, J BIOL CHEM, V274, P275, DOI 10.1074/jbc.274.1.275; Knauer MF, 1997, J BIOL CHEM, V272, P12261, DOI 10.1074/jbc.272.19.12261; Knauer MF, 1997, J BIOL CHEM, V272, P29039, DOI 10.1074/jbc.272.46.29039; Kridel SJ, 1996, J BIOL CHEM, V271, P20935, DOI 10.1074/jbc.271.34.20935; KUHN K, 1994, MATRIX BIOL, V14, P439; MANSUY IM, 1993, DEVELOPMENT, V119, P1119; OKADA SS, 1995, EXP CELL RES, V217, P180, DOI 10.1006/excr.1995.1077; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; REINHARD E, 1994, J NEUROSCI RES, V37, P256, DOI 10.1002/jnr.490370211; ROSENBERG RD, 1977, SEMIN HEMATOL, V14, P427; ROSENBLATT DE, 1987, BRAIN RES, V415, P40, DOI 10.1016/0006-8993(87)90267-8; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; SOMMER J, 1987, BIOCHEMISTRY-US, V26, P6407, DOI 10.1021/bi00394a016; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; VANNOSTRAND WE, 1988, BIOCHEMISTRY-US, V27, P2176, DOI 10.1021/bi00406a054; VerdiereSahuque M, 1996, EXP CELL RES, V222, P70, DOI 10.1006/excr.1996.0009; WAGNER SL, 1989, J BIOL CHEM, V264, P611; Wagner SN, 1996, HISTOCHEM CELL BIOL, V105, P53, DOI 10.1007/BF01450878	32	8	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47285	47291		10.1074/jbc.M204813200	http://dx.doi.org/10.1074/jbc.M204813200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356769	hybrid			2022-12-27	WOS:000179663700058
J	Roti, ECR; Myers, CD; Ayers, RA; Boatman, DE; Delfosse, SA; Chan, EKL; Ackerman, MJ; January, CT; Robertson, GA				Roti, ECR; Myers, CD; Ayers, RA; Boatman, DE; Delfosse, SA; Chan, EKL; Ackerman, MJ; January, CT; Robertson, GA			Interaction with GM130 during HERG ion channel trafficking - Disruption by type 2 congenital long QT syndrome mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFECTIVE PROTEIN TRAFFICKING; INHERITED CARDIAC-ARRHYTHMIA; AMINO-TERMINAL DOMAIN; GOLGI MATRIX PROTEIN; POTASSIUM CHANNEL; K+-CHANNEL; ENDOPLASMIC-RETICULUM; KINASE-C; MUTANT; GENE	Many mutations in the Human Ether-a-go-go-Related Gene (HERG) cause type 2 congenital long QT syndrome (LQT2) by disrupting trafficking of the HERG-encoded potassium channel. Beyond observations that some mutations trap channels in the endoplasmic reticulum, little is known about how trafficking fails. Even less is known about what checkpoints are encountered in normal trafficking. To identify protein partners encountered as HERG channels are transported among subcellular compartments, we screened a human heart library with the C terminus of HERG using yeast two-hybrid technology. Among the proteins isolated was GM130, a Golgi-associated protein involved in vesicular transport. The interaction mapped to two non-contiguous regions of HERG and to a region just upstream of the GRASP-65 interaction domain of GM130. GM130 did not interact with the N or C terminus of either KvLQT1 or Shaker channels. LQT2-causing mutations in the HERG C terminus selectively disrupted interactions with GM130 but not Tara, another HERG-interacting protein. Native GM130 and stably expressed HERG were co-immunoprecipitated from HEK-293 cells using GM130 antibodies. In rat cardiac myocytes and HEK-293 cells, confocal immunocytochemistry showed co-localization of GM130 and HERG to the Golgi apparatus. Overexpression of GM130 suppressed HERG current amplitude in Xenopus oocytes, as if by providing an excess of substrate at the Golgi checkpoint. These findings indicate that GM130 plays a previously undefined role in cargo transport. We propose that the cytoplasmic C terminus of HERG participates in the tethering or possibly targeting of HERG-containing vesicles within the Golgi via its interaction with GM130.	Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; The Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pediat, Div Pediat Cardiol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol, Rochester, MN 55905 USA; Univ Wisconsin, Dept Med, Sect Cardiovasc Med, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; Scripps Research Institute; Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Wisconsin System; University of Wisconsin Madison	Robertson, GA (corresponding author), Univ Wisconsin, Dept Physiol, 1300 Univ Ave, Madison, WI 53706 USA.		Chan, Edward K. L./B-5671-2009	Chan, Edward K. L./0000-0003-3938-9503; Robertson, Gail/0000-0003-4694-5790	NHLBI NIH HHS [R01-HL55973, R01-HL60723, R01-HL68868] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055973, R01HL060723, R01HL068868] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ackerman MJ, 1998, MAYO CLIN PROC, V73, P250, DOI 10.4065/73.3.250; Alvarez C, 2001, J BIOL CHEM, V276, P2693, DOI 10.1074/jbc.M007957200; Aydar E, 2001, J PHYSIOL-LONDON, V534, P1, DOI 10.1111/j.1469-7793.2001.t01-3-00001.x; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Barr FA, 1998, EMBO J, V17, P3258, DOI 10.1093/emboj/17.12.3258; Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; Berthet M, 1999, CIRCULATION, V99, P1464, DOI 10.1161/01.CIR.99.11.1464; Chen J, 1999, J BIOL CHEM, V274, P10113, DOI 10.1074/jbc.274.15.10113; Choukroun GJ, 2000, J CLIN INVEST, V106, P983, DOI 10.1172/JCI8914; Corse E, 2002, J VIROL, V76, P1273, DOI 10.1128/JVI.76.3.1273-1284.2002; Cui J, 2000, CURR BIOL, V10, P671, DOI 10.1016/S0960-9822(00)00516-9; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Eystathioy T, 2000, J AUTOIMMUN, V14, P179, DOI 10.1006/jaut.1999.0359; FAWCETT DW, 1969, J CELL BIOL, V42, P1, DOI 10.1083/jcb.42.1.1; Ficker E, 2000, AM J PHYSIOL-HEART C, V279, pH1748, DOI 10.1152/ajpheart.2000.279.4.H1748; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; Furutani M, 1999, CIRCULATION, V99, P2290, DOI 10.1161/01.CIR.99.17.2290; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; He JQ, 2000, J PHYSIOL-LONDON, V524, P807, DOI 10.1111/j.1469-7793.2000.00807.x; Jakymiw A, 2000, J BIOL CHEM, V275, P4137, DOI 10.1074/jbc.275.6.4137; James P, 1996, GENETICS, V144, P1425; Keating MT, 1996, CURR OPIN GENET DEV, V6, P326, DOI 10.1016/S0959-437X(96)80010-4; Kiehn J, 2000, TRENDS CARDIOVAS MED, V10, P205, DOI 10.1016/S1050-1738(00)00071-2; Laitinen P, 2000, Hum Mutat, V15, P580, DOI 10.1002/1098-1004(200006)15:6<580::AID-HUMU16>3.3.CO;2-S; Lambert G, 2001, J BIOL CHEM, V276, P20340, DOI 10.1074/jbc.M011209200; Lees-Miller JP, 2000, CIRC RES, V86, P507, DOI 10.1161/01.RES.86.5.507; Marra P, 2001, NAT CELL BIOL, V3, P1101, DOI 10.1038/ncb1201-1101; MCNUTT NS, 1969, J CELL BIOL, V42, P46, DOI 10.1083/jcb.42.1.46; Moyer BD, 2001, TRAFFIC, V2, P268, DOI 10.1034/j.1600-0854.2001.1o007.x; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; Perez JL, 2001, J NEUROSCI, V21, P5417, DOI 10.1523/JNEUROSCI.21-15-05417.2001; Robertson GA, 2000, CIRC RES, V86, P492, DOI 10.1161/01.RES.86.5.492; RODEN DM, 1995, J CARDIOVASC ELECTR, V6, P1023, DOI 10.1111/j.1540-8167.1995.tb00379.x; Sanguinetti MC, 1997, NEUROPHARMACOLOGY, V36, P755, DOI 10.1016/S0028-3908(97)00029-4; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1991, AM J PHYSIOL, V260, pH393, DOI 10.1152/ajpheart.1991.260.2.H393; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; SARASTE J, 1991, J CELL SCI, V100, P415; Satler CA, 1996, AM J MED GENET, V65, P27, DOI 10.1002/(SICI)1096-8628(19961002)65:1<27::AID-AJMG4>3.3.CO;2-J; Seemann J, 2000, MOL BIOL CELL, V11, P635, DOI 10.1091/mbc.11.2.635; Seipel K, 2001, J CELL SCI, V114, P389; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Wang JL, 1998, J GEN PHYSIOL, V112, P637, DOI 10.1085/jgp.112.5.637; Wang JL, 2000, J GEN PHYSIOL, V115, P749, DOI 10.1085/jgp.115.6.749; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	51	57	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47779	47785		10.1074/jbc.M206638200	http://dx.doi.org/10.1074/jbc.M206638200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12270925	hybrid			2022-12-27	WOS:000179663700122
J	Smith, DE; Ketchem, RR; Moore, H; Anderson, Z; Renshaw, BR; Friend, DJ; Sims, JE				Smith, DE; Ketchem, RR; Moore, H; Anderson, Z; Renshaw, BR; Friend, DJ; Sims, JE			A single amino acid difference between human and monkey interleukin (IL)-1 beta dictates effective binding to soluble type II IL-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CRYSTAL-STRUCTURE; DECOY RECEPTOR; PROTEIN; IDENTIFICATION; ANTAGONIST; SEQUENCE; SITES; GENES	Soluble type II interleukin (IL)-1 receptor (sIL1R-II) binds human IL-1beta with high affinity and neutralizes its activity. Recombinant sIL1R-II is considered a potentially useful anti-IL-1 therapeutic, and preclinical studies have been undertaken with this molecule in primates. To better understand the cytokine-receptor interactions occurring in this nonhuman context, monkey IL-1 and IL1R-II were cloned, and their binding abilities were examined in vitro. IL-1beta from cynomolgus monkey was capable of binding and activating the human type I IL-1 receptor. However, unlike human IL-1beta, it was unable to effectively bind and become neutralized by sIL1R-II. Human and cynomolgus IL-1beta proteins are 96% identical, differing by only six amino acids. Structural and mutational analysis revealed that the unique sIL1R-II binding ability of human IL-1beta is due to a single amino acid difference compared with monkey IL-1beta.	Amgen Corp, Seattle, WA 98101 USA		Smith, DE (corresponding author), Amgen Corp, 51 Univ St, Seattle, WA 98101 USA.		Ketchem, Randal R/K-2258-2017; Ketchem, Randal/AAB-4372-2020	Ketchem, Randal R/0000-0002-7821-2682; Ketchem, Randal/0000-0002-7821-2682; Sims, John/0000-0002-5667-9185				Attur MG, 2002, J IMMUNOL, V168, P2001, DOI 10.4049/jimmunol.168.4.2001; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bessis N, 2000, EUR J IMMUNOL, V30, P867, DOI 10.1002/1521-4141(200003)30:3<867::AID-IMMU867>3.0.CO;2-M; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508, DOI 10.1002/jlb.67.4.508; CAMACHO NP, 1993, BIOCHEMISTRY-US, V32, P8749, DOI 10.1021/bi00085a005; COLOTTA F, 1994, IMMUNOL TODAY, V15, P562, DOI 10.1016/0167-5699(94)90217-8; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; EVANS RJ, 1995, J BIOL CHEM, V270, P11477, DOI 10.1074/jbc.270.19.11477; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GRUTTER MG, 1994, PROTEIN ENG, V7, P663, DOI 10.1093/protein/7.5.663; Itoh S, 1999, J IMMUNOL, V162, P7434; Liu CL, 1996, J BIOL CHEM, V271, P20965, DOI 10.1074/jbc.271.34.20965; Mantovani A, 2001, TRENDS IMMUNOL, V22, P328, DOI 10.1016/S1471-4906(01)01941-X; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Morris AE, 1997, ANIMAL CELL TECHNOLOGY, P529; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; Schreuder H, 1997, NATURE, V386, P194, DOI 10.1038/386194a0; SHAANAN B, 1992, SCIENCE, V257, P961, DOI 10.1126/science.1502561; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; Totsuka K, 1998, INT ARCH ALLERGY IMM, V116, P40, DOI 10.1159/000023923; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103; Vigers GPA, 1997, NATURE, V386, P190, DOI 10.1038/386190a0; VILLINGER F, 1995, J IMMUNOL, V155, P3946	25	7	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47619	47625		10.1074/jbc.M206636200	http://dx.doi.org/10.1074/jbc.M206636200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356774	hybrid			2022-12-27	WOS:000179663700102
J	Anjos, S; Nguyen, A; Ounissi-Benkalha, H; Tessier, MC; Polychronakos, C				Anjos, S; Nguyen, A; Ounissi-Benkalha, H; Tessier, MC; Polychronakos, C			A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTLA-4 GENE POLYMORPHISM; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; DIABETES-MELLITUS IDDM; GRAVES-DISEASE; ENDOPLASMIC-RETICULUM; CHROMOSOME 2Q33; HASHIMOTOS-THYROIDITIS; CONFERS SUSCEPTIBILITY; NEGATIVE REGULATOR; ADDISONS-DISEASE	A common T17A polymorphism. in the signal peptide of the cytotoxic T-lymphocyte antigen 4 (CTLA-4), a T-cell receptor that negatively regulates immune responses, is associated with risk for autoimmune disease. Because the polymorphism is absent from the mature protein, we hypothesized that its biological effect must involve early stages of protein processing, prior to signal peptide cleavage. Constructs representing the two alleles were compared by in vitro translation, in the presence of endoplasmic reticulum. membranes. We studied glycosylation by endoglycosidase H digestion and glycosylation mutant constructs, cleavage of peptide with inhibitors, and membrane integration by ultracentrifugation and proteinase K sensitivity. A major cleaved and glycosylated product was seen for both alleles of the protein but a band representing incomplete glycosyIation was markedly more abundant in the predisposing Ala allele (32.7 +/- 1.0 versus 10.6% +/- 1.2 for Thr, p < 10(-9)). In addition, differential intracellular/surface partitioning was studied with co-transfection of the alleles fused to distinct fluorescent proteins in COS-1 cells. By quantitative confocal microscopy we found a higher ratio of cell surface/total CTLAThr(17) versus CTLAAla(17) (p = 0.01). Our findings corroborate observations, in other proteins, that the signal peptide can determine the efficiency of post-translational modifications other than cleavage and suggest inefficient processing of the autoimmunity predisposing Ala allele as the explanation for the genetic effect.	McGill Univ, Ctr Hlth, Endocrine Genet Lab, Dept Pediat,Div Pediat Endocrinol, Montreal, PQ H3H 1P3, Canada; McGill Univ, Lady Davis Inst Med Res, Montreal, PQ H3H 1P3, Canada	McGill University; Lady Davis Institute; McGill University	Polychronakos, C (corresponding author), McGill Univ, Ctr Hlth, Endocrine Genet Lab, Dept Pediat,Div Pediat Endocrinol, 2300 Tupper, Montreal, PQ H3H 1P3, Canada.		Polychronakos, Constantin/B-8151-2008	Polychronakos, Constantin/0000-0002-7624-6635				Awata T, 1998, DIABETES, V47, P128, DOI 10.2337/diab.47.1.128; Bachmann MF, 1999, J IMMUNOL, V163, P1128; Barbesino G, 1998, J CLIN ENDOCR METAB, V83, P1580, DOI 10.1210/jc.83.5.1580; Barrat FJ, 1999, P NATL ACAD SCI USA, V96, P8645, DOI 10.1073/pnas.96.15.8645; Beuret N, 1999, J BIOL CHEM, V274, P18965, DOI 10.1074/jbc.274.27.18965; Chambers CA, 1997, IMMUNITY, V7, P885, DOI 10.1016/S1074-7613(00)80406-9; Chen XM, 2001, J BIOL CHEM, V276, P2411, DOI 10.1074/jbc.M007723200; DELEAGE G, 1987, ANAL BIOCHEM, V163, P292, DOI 10.1016/0003-2697(87)90226-0; Djilali-Saiah I, 1998, GUT, V43, P187, DOI 10.1136/gut.43.2.187; Donner H, 1997, J CLIN ENDOCR METAB, V82, P4130, DOI 10.1210/jc.82.12.4130; Donner H, 1997, J CLIN ENDOCR METAB, V82, P143, DOI 10.1210/jc.82.1.143; Dubuisson J, 2000, J BIOL CHEM, V275, P30605, DOI 10.1074/jbc.M004326200; Eagar TN, 2002, EUR J IMMUNOL, V32, P972, DOI 10.1002/1521-4141(200204)32:4<972::AID-IMMU972>3.0.CO;2-M; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Giscombe R, 2002, J RHEUMATOL, V29, P950; Heward JM, 1999, J CLIN ENDOCR METAB, V84, P2398, DOI 10.1210/jc.84.7.2398; Holopainen PM, 2001, J IMMUNOL, V167, P2457, DOI 10.4049/jimmunol.167.5.2457; Holst B, 1996, EMBO J, V15, P3538, DOI 10.1002/j.1460-2075.1996.tb00723.x; Hurwitz AA, 1997, J NEUROIMMUNOL, V73, P57, DOI 10.1016/S0165-5728(96)00168-3; ITO M, 1993, J CLIN INVEST, V91, P2565, DOI 10.1172/JCI116494; Karandikar NJ, 2000, J NEUROIMMUNOL, V109, P173, DOI 10.1016/S0165-5728(00)00322-2; Karandikar NJ, 1996, J EXP MED, V184, P783, DOI 10.1084/jem.184.2.783; KARAPLIS AC, 1995, J BIOL CHEM, V270, P1629, DOI 10.1074/jbc.270.4.1629; Karplus K, 1998, BIOINFORMATICS, V14, P846, DOI 10.1093/bioinformatics/14.10.846; KASTURI L, 1995, J BIOL CHEM, V270, P14756, DOI 10.1074/jbc.270.24.14756; Kemp EH, 1998, CLIN ENDOCRINOL, V49, P609; King AL, 2002, J MED GENET, V39, P51, DOI 10.1136/jmg.39.1.51; Kotsa K, 1997, CLIN ENDOCRINOL, V46, P551, DOI 10.1046/j.1365-2265.1997.1710996.x; Kouki T, 2000, J IMMUNOL, V165, P6606, DOI 10.4049/jimmunol.165.11.6606; Kouki T, 2002, J ENDOCRINOL INVEST, V25, P208, DOI 10.1007/BF03343992; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee KM, 1998, SCIENCE, V282, P2263, DOI 10.1126/science.282.5397.2263; LEUNG HT, 1995, J BIOL CHEM, V270, P25107, DOI 10.1074/jbc.270.42.25107; Li Y, 1996, P NATL ACAD SCI USA, V93, P9606, DOI 10.1073/pnas.93.18.9606; Linsley PS, 1996, IMMUNITY, V4, P535, DOI 10.1016/S1074-7613(00)80480-X; Luhder F, 1998, J EXP MED, V187, P427, DOI 10.1084/jem.187.3.427; Marron MP, 2000, DIABETES, V49, P492, DOI 10.2337/diabetes.49.3.492; Marron MP, 1997, HUM MOL GENET, V6, P1275, DOI 10.1093/hmg/6.8.1275; Matoba S, 1998, J BIOL CHEM, V273, P18841, DOI 10.1074/jbc.273.30.18841; Maurer M, 2002, IMMUNOGENETICS, V54, P1, DOI 10.1007/s00251-002-0429-9; Metzler WJ, 1997, NAT STRUCT BIOL, V4, P527, DOI 10.1038/nsb0797-527; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nistico L, 1996, HUM MOL GENET, V5, P1075, DOI 10.1093/hmg/5.7.1075; Nithiyananthan R, 2002, THYROID, V12, P3, DOI 10.1089/105072502753451896; Perez VL, 1997, IMMUNITY, V6, P411, DOI 10.1016/S1074-7613(00)80284-8; Perrin PJ, 1996, J IMMUNOL, V157, P1333; RACCHI M, 1993, J BIOL CHEM, V268, P5735; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Todd JA, 1996, HUM MOL GENET, V5, P1443, DOI 10.1093/hmg/5.Supplement_1.1443; Tomer Y, 2001, J CLIN ENDOCR METAB, V86, P1687, DOI 10.1210/jc.86.4.1687; Vaidya B, 1999, HUM MOL GENET, V8, P1195, DOI 10.1093/hmg/8.7.1195; Vaidya B, 2002, RHEUMATOLOGY, V41, P180, DOI 10.1093/rheumatology/41.2.180; VanDerAuwera BJ, 1997, CLIN EXP IMMUNOL, V110, P98, DOI 10.1111/j.1365-2249.1997.t01-1-512-ce1410.x; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Walunas TL, 1998, J IMMUNOL, V160, P3855; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Yanagawa T, 1997, THYROID, V7, P843, DOI 10.1089/thy.1997.7.843; YANAGAWA T, 1995, J CLIN ENDOCR METAB, V80, P41, DOI 10.1210/jc.80.1.41	62	222	230	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46478	46486		10.1074/jbc.M206894200	http://dx.doi.org/10.1074/jbc.M206894200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244107	hybrid			2022-12-27	WOS:000179529300101
J	Anthony, LC; Burgess, RR				Anthony, LC; Burgess, RR			Conformational flexibility in or sigma(70) region 2 during transcription initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; DNA-BINDING; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; DISULFIDE BOND; OPEN COMPLEX; CORE; PROMOTER; SUBUNIT; SITE	Prokaryotic RNA polymerase holoenzyme is composed of core subunits (alpha(2)betabeta'omega) plus a sigma factor that confers promoter specificity allowing for regulation of gene expression. Holoenzyme is known to undergo several conformational changes during the multiple steps of transcription initiation. However, the effects of these changes on the functions of specific regions have not been well characterized. In this work, we addressed the role of possible conformational change in region 2 of Escherichia coli sigma(70) by engineering disulfide bonds that "lock" region 2.1 with region 2.2 and region 2.2 with region 2.3. When these mutant holoenzymes were characterized for gross defects in multiple-round transcription, we found that insertion of either disulfide bond did not result in a fundamental block, indicating that the disulfide-containing holoenzymes are active. However, both disulfide-containing holoenzymes exhibited defects in formation and stability of the open complex. Our results suggest that conformational flexibility within sigma(70) region 2 facilitates open complex formation and transcription initiation.	Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Burgess, RR (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	burgess@oncology.wisc.edu		Burgess, Richard/0000-0001-9545-3165	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028575] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28575] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOUYAL M, 1987, J MOL BIOL, V195, P795, DOI 10.1016/0022-2836(87)90485-2; Anthony LC, 2002, J BACTERIOL, V184, P2634, DOI 10.1128/JB.184.10.2634-2641.2002; Arthur TM, 2000, J BIOL CHEM, V275, P23113, DOI 10.1074/jbc.M002040200; Arthur TM, 1998, J BIOL CHEM, V273, P31381, DOI 10.1074/jbc.273.47.31381; Barker MM, 2001, J MOL BIOL, V305, P673, DOI 10.1006/jmbi.2000.4327; Bowers CW, 1999, EMBO J, V18, P709, DOI 10.1093/emboj/18.3.709; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; Buc H, 1997, CURR BIOL, V7, pR97, DOI 10.1016/S0960-9822(06)00047-9; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; Burgess RR, 2001, CURR OPIN MICROBIOL, V4, P126, DOI 10.1016/S1369-5274(00)00177-6; Callaci S, 1999, MOL CELL, V3, P229, DOI 10.1016/S1097-2765(00)80313-5; Callaci S, 1998, J BIOL CHEM, V273, P32995, DOI 10.1074/jbc.273.49.32995; Callaci S, 1998, BIOCHEMISTRY-US, V37, P3312, DOI 10.1021/bi972041m; Craig ML, 1998, J MOL BIOL, V283, P741, DOI 10.1006/jmbi.1998.2129; Darst SA, 1998, J STRUCT BIOL, V124, P115, DOI 10.1006/jsbi.1998.4057; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; Dombkowski AA, 2000, PROTEIN ENG, V13, P679, DOI 10.1093/protein/13.10.679; DOMBROSKI AJ, 1993, CELL MOL BIOL RES, V39, P311; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Gruber TM, 2001, MOL CELL, V8, P21, DOI 10.1016/S1097-2765(01)00292-1; HARRIS SJ, 1995, BIOCHEMISTRY-US, V34, P8752, DOI 10.1021/bi00027a026; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Ko DC, 1998, GENE DEV, V12, P3276, DOI 10.1101/gad.12.20.3276; KOVACIC RT, 1987, J BIOL CHEM, V262, P13654; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; METZGER W, 1993, J MOL BIOL, V232, P35, DOI 10.1006/jmbi.1993.1368; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Owens JT, 1998, P NATL ACAD SCI USA, V95, P6021, DOI 10.1073/pnas.95.11.6021; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; Ring BZ, 1996, CELL, V86, P485, DOI 10.1016/S0092-8674(00)80121-X; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; Ross W, 1998, J BACTERIOL, V180, P5375, DOI 10.1128/JB.180.20.5375-5383.1998; Saecker RM, 2002, J MOL BIOL, V319, P649, DOI 10.1016/S0022-2836(02)00293-0; SAUER RT, 1986, BIOCHEMISTRY-US, V25, P5992, DOI 10.1021/bi00368a024; SHANER SL, 1982, BIOCHEMISTRY-US, V21, P5539, DOI 10.1021/bi00265a025; Sharp MM, 1999, GENE DEV, V13, P3015, DOI 10.1101/gad.13.22.3015; STEARMAN RS, 1988, BIOCHEMISTRY-US, V27, P7571, DOI 10.1021/bi00419a059; Storch MM, 1999, BIOCHEMISTRY-US, V38, P5054, DOI 10.1021/bi982158q; THOMPSON NE, 1992, BIOCHEMISTRY-US, V31, P7003, DOI 10.1021/bi00145a019; Tiebel B, 1998, EMBO J, V17, P5112, DOI 10.1093/emboj/17.17.5112; TRAVERS AA, 1969, NATURE, V222, P537, DOI 10.1038/222537a0; TRAYERS AA, 1969, NATURE, V223, P1107; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	47	11	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46433	46441		10.1074/jbc.M208205200	http://dx.doi.org/10.1074/jbc.M208205200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12359719	hybrid			2022-12-27	WOS:000179529300095
J	Harder, J; Schroder, JM				Harder, J; Schroder, JM			RNase 7, a novel innate immune defense antimicrobial protein of healthy human skin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL CATIONIC PROTEIN; BETA-DEFENSIN; HUMAN BETA-DEFENSIN-1; PEPTIDE ANTIBIOTICS; INDUCIBLE PEPTIDE; EXPRESSION; RIBONUCLEASE; KERATINOCYTES; FAMILY; HBD-1	We analyzed healthy human skin for the presence of endogenous antimicrobial proteins that might explain the unusually high resistance of human skin against infections. A novel 14.5-kDa antimicrobial ribonuclease, termed RNase 7, was isolated from skin-derived stratum corneum. RNase 7 exhibited potent ribonuclease activity and thus may contribute to the well known ribonuclease activity of human skin. RNase 7 revealed broad spectrum antimicrobial activity against many pathogenic microorganisms and remarkably potent activity (lethal dose of 90% < 30 nm) against a vancomycin-resistant Enterococcus faecium. Molecular cloning from skinderived primary keratinocytes and purification of RNase 7 from supernatants of cultured primary keratinocytes indicate that keratinocytes represent the major cellular source in skin and that RNase 7 is secreted. RNase 7 mRNA expression was detected in various epithelial tissues including skin, respiratory tract, genitourinary tract, and at a low level, in the gut. In addition to a constitutive expression, RNase 7 mRNA was induced in cultured primary keratinocytes by interleukin-1beta, interferon-gamma, and bacterial challenge. This is the first report demonstrating RNases as a novel class of epithelial inducible antimicrobial proteins, which may play an important role in the innate immune defense system of human epithelia.	Univ Hosp Kiel, Dept Dermatol, Clin Res Unit, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital	Schroder, JM (corresponding author), Univ Hosp Kiel, Dept Dermatol, Clin Res Unit, Schittenhelmstr 7, D-24105 Kiel, Germany.	jschroeder@dermatology.uni-kiel.de	Harder, Jürgen/B-3162-2010; Schroeder, Jens M/B-3994-2009	Harder, Jurgen/0000-0002-4075-4603				BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Boman HG, 1998, SCAND J IMMUNOL, V48, P15; Domachowske JB, 1998, J INFECT DIS, V177, P1458, DOI 10.1086/515322; Domachowske JB, 1998, NUCLEIC ACIDS RES, V26, P3358, DOI 10.1093/nar/26.14.3358; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Fulton C, 1997, LANCET, V350, P1750, DOI 10.1016/S0140-6736(05)63574-X; Garcia JRC, 2001, FASEB J, V15, P1819, DOI 10.1096/fj.00-0865fje; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Harder J, 2000, AM J RESP CELL MOL, V22, P714, DOI 10.1165/ajrcmb.22.6.4023; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Krisanaprakornkit S, 1998, INFECT IMMUN, V66, P4222; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; LEHRER RI, 1989, J IMMUNOL, V142, P4428; Liu AY, 2002, J INVEST DERMATOL, V118, P275, DOI 10.1046/j.0022-202x.2001.01651.x; Noso N, 1996, J IMMUNOL, V156, P1946; O'Neil DA, 1999, J IMMUNOL, V163, P6718; ROSENBERG HF, 1995, J BIOL CHEM, V270, P7876, DOI 10.1074/jbc.270.14.7876; Rosenberg HF, 1998, CELL MOL LIFE SCI, V54, P795, DOI 10.1007/s000180050208; ROSENBERG HF, 1995, J BIOL CHEM, V270, P30234; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schittek B, 2001, NAT IMMUNOL, V2, P1133, DOI 10.1038/ni732; Schroder JM, 1999, BIOCHEM PHARMACOL, V57, P121, DOI 10.1016/S0006-2952(98)00226-3; SCHRODER JM, 1992, J INVEST DERMATOL, V98, P241, DOI 10.1111/1523-1747.ep12556058; Schroder JM, 1999, INT J BIOCHEM CELL B, V31, P645, DOI 10.1016/S1357-2725(99)00013-8; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Wiedow O, 1998, BIOCHEM BIOPH RES CO, V248, P904, DOI 10.1006/bbrc.1998.9069; Zhang JZ, 2002, NUCLEIC ACIDS RES, V30, P1169, DOI 10.1093/nar/30.5.1169	31	312	348	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46779	46784		10.1074/jbc.M207587200	http://dx.doi.org/10.1074/jbc.M207587200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244054	hybrid			2022-12-27	WOS:000179529300138
J	Kiianitsa, K; Solinger, JA; Heyer, WD				Kiianitsa, K; Solinger, JA; Heyer, WD			Rad54 protein exerts diverse modes of ATPase activity on duplex DNA partially and fully covered with Rad51 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; ESCHERICHIA-COLI RECA; YEAST SWI/SNF COMPLEX; SACCHAROMYCES-CEREVISIAE; NUCLEOPROTEIN FILAMENT; FUNCTIONAL INTERACTIONS; RECOMBINATIONAL REPAIR; MEIOTIC RECOMBINATION; BINDING PROPERTIES; DEPENDENT ATPASE	Rad54 protein is a Snf2-like ATPase with a specialized function in the recombinational repair of DNA damage. Rad54 is thought to stimulate the search of homology via formation of a specific complex with the presynaptic Rad51 filament on single-stranded DNA. Herein, we address the interaction of Rad54 with Rad51 filaments on double-stranded (ds) DNA, an intermediate in DNA strand exchange with unclear functional significance. We show that Saccharomyces cerevisiae Rad54 exerts distinct modes of ATPase activity on partially and fully saturated filaments of Rad51 protein on dsDNA. The highest ATPase activity is observed on dsDNA containing short patches of yeast Rad51 filaments resulting in a 6-fold increase compared with protein-firee DNA. This enhanced ATPase mode of yeast Rad54 can also be elicited by partial filaments of human Rad51 protein but to a lesser extent. In contrast, the interaction of Rad54 protein with duplex DNA fully covered with Rad51 is entirely species-specific. When yeast Rad51 fully covers dsDNA, Rad54 protein hydrolyzes ATP in a reduced mode at 60-80% of its rate on protein-free DNA. Instead, saturated filaments with human Rad51 fail to support the yeast Rad54 ATPase. We suggest that the interaction of Rad54 with dsDNA-Rad51 complexes is of functional importance in homologous recombination.	Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Ctr Genet & Dev, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Heyer, WD (corresponding author), Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA.				NIGMS NIH HHS [R01-GM58015] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058015] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bazett-Jones DP, 1999, MOL CELL BIOL, V19, P1470; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Boyer LA, 2000, J BIOL CHEM, V275, P18864, DOI 10.1074/jbc.M002810200; Chanet R, 1996, MOL CELL BIOL, V16, P4782; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; Clever B, 1999, YEAST, V15, P721, DOI 10.1002/(SICI)1097-0061(19990630)15:9<721::AID-YEA414>3.0.CO;2-W; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; DONOVAN JW, 1994, GENE DEV, V8, P2552, DOI 10.1101/gad.8.21.2552; Egelman EH, 2001, J MOL BIOL, V309, P539, DOI 10.1006/jmbi.2001.4686; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; Gavin I, 2001, MOL CELL, V7, P97, DOI 10.1016/S1097-2765(01)00158-7; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; Kiianitsa K, 1997, P NATL ACAD SCI USA, V94, P7837, DOI 10.1073/pnas.94.15.7837; KODADEK T, 1988, BIOCHEMISTRY-US, V27, P3210, DOI 10.1021/bi00409a013; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; Krejci L, 2001, MOL CELL BIOL, V21, P966, DOI 10.1128/MCB.21.3.966-976.2001; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; McIlwraith MJ, 2000, J MOL BIOL, V304, P151, DOI 10.1006/jmbi.2000.4180; Namsaraev EA, 1998, J BIOL CHEM, V273, P6177, DOI 10.1074/jbc.273.11.6177; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OGAWA T, 1995, ADV BIOPHYS, V31, P93, DOI 10.1016/0065-227X(95)99385-3; PALLADINO F, 1992, GENETICS, V132, P23; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; SCHILD D, 1995, GENETICS, V140, P115; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Shinohara M, 2000, P NATL ACAD SCI USA, V97, P10814, DOI 10.1073/pnas.97.20.10814; Solinger JA, 2001, P NATL ACAD SCI USA, V98, P8447, DOI 10.1073/pnas.121009898; Solinger JA, 2001, J MOL BIOL, V307, P1207, DOI 10.1006/jmbi.2001.4555; Song BW, 2000, J BIOL CHEM, V275, P15895, DOI 10.1074/jbc.M910244199; Stasiak A, 1988, GENETIC RECOMBINATIO, P265; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Zaitseva EM, 1999, J BIOL CHEM, V274, P2907, DOI 10.1074/jbc.274.5.2907	58	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46205	46215		10.1074/jbc.M207967200	http://dx.doi.org/10.1074/jbc.M207967200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12359723	hybrid			2022-12-27	WOS:000179529300068
J	Long, DJ; Iskander, K; Gaikwad, A; Arin, M; Roop, DR; Knox, R; Barrios, R; Jaiswal, AK				Long, DJ; Iskander, K; Gaikwad, A; Arin, M; Roop, DR; Knox, R; Barrios, R; Jaiswal, AK			Disruption of dihydronicotinamide riboside : quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DT-DIAPHORASE; INCREASED SUSCEPTIBILITY; CANCER-CHEMOTHERAPY; MITOMYCIN-C; MOUSE SKIN; GENE; CARCINOGENESIS; BIOACTIVATION; POLYMORPHISM; NAD(P)H	Dilrydronicotinamide riboside (NRH):quinone oxidoreductase 2 (NQO2) is a flavoenzyme that catalyzes the reductive metabolism of quinones. To examine the in vivo role of NQO2, NQO2-null. (NQO2-/-) mice were generated using targeted gene disruption. Mice lacking NQO2 gene expression showed no detectable developmental abnormalities and were indistingruishable from wild-type (NQO2+/+) mice. However, NQO2-null mice exhibited myeloid hyperplasia of the bone marrow and increased neutrophils, basophils, eosinophils, and platelets in the peripheral blood. Decreased apoptosis of bone marrow cells and circulating granulocytes contributed to myeloid hyperplasia and hyperactivity of bone marrow in NQO2-null mice. The hematological changes in NQO2-/- mice were specifically associated with loss of the NQO2 gene because histological analysis of various tissues including spleen, thymus, blood cultures, and urine analysis demonstrated no sign of infection. NQO2-null mice also demonstrated decreased toxicity when exposed to menadione or menadione with NRH. These results establish a role for NQO2 in protection against myelogenous hyperplasia and in metabolic activation of menadione, leading to hepatic toxicity. The NQO2-null mice are a model for NQO2 deficiency in humans and can be used to determine the role of this enzyme in sensitivities to toxicity and carcinogenesis.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Enact Pharma PLC, Salisbury SP4 0JQ, Wilts, England	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007943] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES07943] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Begleiter A, 1997, ONCOL RES, V9, P371; Boyer MJ, 1997, ONCOL RES, V9, P391; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen S, 2000, FREE RADICAL BIO MED, V29, P276, DOI 10.1016/S0891-5849(00)00308-7; CHESIS PL, 1984, P NATL ACAD SCI-BIOL, V81, P1696, DOI 10.1073/pnas.81.6.1696; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEFLORA S, 1985, CANCER RES, V45, P3188; Dinkova-Kostova LT, 2000, FREE RADICAL BIO MED, V29, P231, DOI 10.1016/S0891-5849(00)00300-2; Foster CE, 1999, BIOCHEMISTRY-US, V38, P9881, DOI 10.1021/bi990799v; Gaikwad A, 2001, J BIOL CHEM, V276, P22559, DOI 10.1074/jbc.M101053200; Jaiswal AK, 1999, PHARMACOGENETICS, V9, P413, DOI 10.1097/00008571-199906000-00020; JAISWAL AK, 1990, BIOCHEMISTRY-US, V29, P1899, DOI 10.1021/bi00459a034; Joseph P, 1996, INT J CANCER, V65, P263; Knox RJ, 2000, CANCER RES, V60, P4179; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Larson RA, 1999, BLOOD, V94, P803, DOI 10.1182/blood.V94.2.803.414k44_803_807; LIND C, 1985, ARCH BIOCHEM BIOPHYS, V280, P226; Long DJ, 2000, CANCER RES, V60, P5913; Long DJ, 2000, GENE, V252, P107, DOI 10.1016/S0378-1119(00)00221-3; Long DJ, 2001, JNCI-J NATL CANCER I, V93, P1166, DOI 10.1093/jnci/93.15.1166; Moran JL, 1999, P NATL ACAD SCI USA, V96, P8150, DOI 10.1073/pnas.96.14.8150; OBRIEN PJ, 1991, CHEM-BIOL INTERACT, V80, P1, DOI 10.1016/0009-2797(91)90029-7; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Rauth AM, 1997, ONCOL RES, V9, P339; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; ROSS D, 1994, ONCOL RES, V6, P493; Ross D, 2000, CHEM-BIOL INTERACT, V129, P77, DOI 10.1016/S0009-2797(00)00199-X; Rothman N, 1997, CANCER RES, V57, P2839; SARTORELLI AC, 1994, ONCOL RES, V6, P501; SARVANKUMAR D, 2000, CURR TOP CELL REGUL, V36, P201; SHAW PM, 1991, EUR J BIOCHEM, V195, P171, DOI 10.1111/j.1432-1033.1991.tb15691.x; Smith MT, 1999, P NATL ACAD SCI USA, V96, P7624, DOI 10.1073/pnas.96.14.7624; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WORKMAN P, 1993, CANCER METAST REV, V12, P73, DOI 10.1007/BF00689802; WORKMAN P, 1994, ONCOL RES, V6, P461; Wu KB, 1997, ARCH BIOCHEM BIOPHYS, V347, P221, DOI 10.1006/abbi.1997.0344; Zhao QJ, 1997, P NATL ACAD SCI USA, V94, P1669, DOI 10.1073/pnas.94.5.1669	38	95	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46131	46139		10.1074/jbc.M208675200	http://dx.doi.org/10.1074/jbc.M208675200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351651	hybrid			2022-12-27	WOS:000179529300057
J	MacLeod, KJ; Husain, RD; Gage, DA; Ahn, K				MacLeod, KJ; Husain, RD; Gage, DA; Ahn, K			Constitutive phosphorylation of human endothelin-converting enzyme-1 isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR COMPARTMENT; MOLECULAR-CLONING; SUBCELLULAR LOCALIZATIONS; PROTEIN; CELLS; ECE-1; KINASE; METALLOPROTEASE; EXPRESSION; MEMBRANE	To investigate the phosphorylation of human endothelin-converting enzyme-1 (hECE-1) and identify potential residues involved, both in vivo and in vitro phosphorylation labeling assays of hECE-1 isoforms were performed in combination with site-directed mutagenesis and mass spectrometric analyses. Initial studies found that endogenous hECE-1 was constitutively phosphorylated in a primary endothelial cell line. The four known isoforms of hECE-1 expressed in this cell line (1a, 1b, 1c, and 1d) were then cloned by reverse transcription-PCR to determine which isoform(s) may be phosphorylated. The isoforms differ only in the first portion of their short aminoterminal cytoplasmic domains whereas their transmembrane domains and ectodomains of the proteins are identical. Isoforms 1b, 1c, and 1d but not 1a, were constitutively phosphorylated in vivo when expressed in Chinese hamster ovary cells and casein kinase I readily phosphorylated the immunopurified isoforms in vitro. Site-directed mutagenesis established that two conserved serine residues, Ser(18) and Ser(20), (numbering based on isoform 1c) form at least one phosphorylation site in these three isoforms. Mutant forms of 1b, 1c, and 1d were constructed in which a single alanine was introduced at either serine residue and a double mutant for each isoform was constructed as well in which both serines were replaced with alanine. Phosphorylation of the single mutants was greatly reduced and was nearly abolished in the double mutants in both in vivo and in vitro labeling assays. Analysis by MALDI-MS of (32)p-labeled proteolytic peptides derived from wild type 1c and the lc mutants supported both Ser(18) and Ser(20) as phosphorylated residues. These data demonstrate the first finding that hECE-1 is constitutively phosphorylated within its cytoplasmic domain in an isoform-specific manner.	Pfizer Global Res & Dev, Dept CNS Mol Sci, Ann Arbor Labs, Ann Arbor, MI 48105 USA; Pfizer Global Res & Dev, Dept Discovery Technol, Ann Arbor Labs, Ann Arbor, MI 48105 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Pfizer; Pfizer; Michigan State University	MacLeod, KJ (corresponding author), Pfizer Global Res & Dev, Dept CNS Mol Sci, Ann Arbor Labs, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.							[Anonymous], 1995, Nat Genet, V11, P130; Azarani A, 1998, BIOCHEM J, V333, P439, DOI 10.1042/bj3330439; Barnes K, 1998, HYPERTENSION, V31, P3, DOI 10.1161/01.HYP.31.1.3; Barnes K, 1996, J CELL SCI, V109, P919; Cailler F, 1999, BIOCHEM J, V341, P119, DOI 10.1042/0264-6021:3410119; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; Fahnoe DC, 2000, J CARDIOVASC PHARM, V36, pS22, DOI 10.1097/00005344-200036051-00009; Ganju RK, 1996, BLOOD, V88, P4159; Hoang MV, 1997, BIOCHEM J, V327, P23, DOI 10.1042/bj3270023; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Johnson GD, 1999, J BIOL CHEM, V274, P4053, DOI 10.1074/jbc.274.7.4053; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; MacLeod KJ, 2001, J BIOL CHEM, V276, P30608, DOI 10.1074/jbc.M103928200; MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7; NISHIKORI K, 1991, NEUROCHEM INT, V18, P535, DOI 10.1016/0197-0186(91)90152-4; OHNAKA K, 1993, J BIOL CHEM, V268, P26759; Orzechowski HD, 1997, J MOL MED-JMM, V75, P512, DOI 10.1007/s001090050136; Orzechowski HD, 2001, MOL PHARMACOL, V60, P1332, DOI 10.1124/mol.60.6.1332; Pulgar V, 1999, EUR J BIOCHEM, V260, P520, DOI 10.1046/j.1432-1327.1999.00195.x; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Russell FD, 1999, BRIT J PHARMACOL, V126, P391, DOI 10.1038/sj.bjp.0702315; Russell FD, 1998, CIRC RES, V83, P314, DOI 10.1161/01.RES.83.3.314; Schweizer A, 1997, BIOCHEM J, V328, P871, DOI 10.1042/bj3280871; SHIMADA K, 1994, J BIOL CHEM, V269, P18275; TAKAHASHI M, 1993, J BIOL CHEM, V268, P21394; Tullai JW, 2000, J BIOL CHEM, V275, P36514, DOI 10.1074/jbc.M001843200; Valdenaire O, 1999, EUR J BIOCHEM, V264, P341, DOI 10.1046/j.1432-1327.1999.00602.x; VALDENAIRE O, 1995, J BIOL CHEM, V270, P29794; Valdenaire O, 1999, J CELL SCI, V112, P3115; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1	30	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46355	46363		10.1074/jbc.M207972200	http://dx.doi.org/10.1074/jbc.M207972200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244060	hybrid			2022-12-27	WOS:000179529300086
J	Shen, MR; Chou, CY; Hsu, KF; Ellory, JC				Shen, MR; Chou, CY; Hsu, KF; Ellory, JC			Osmotic shrinkage of human cervical cancer cells induces an extracellular Cl--dependent nonselective cation channel, which requires p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLECTING DUCT CELLS; ACTIVATED PROTEIN-KINASES; ENDOTHELIAL-CELLS; VOLUME REGULATION; HYPERTONICITY; CONDUCTANCE; MECHANISMS; EXPRESSION; PATHWAYS; STRESS	This study is to integrate a functional role of nonselective cation (NSC) channels into a model of volume regulation on osmotic shrinkage for human cervical cancer cells. Application of a hypertonic solution (400 mosm kg(-1)) induced cell shrinkage, which was accompanied by a 7-fold increase of inward currents at -80 mV from -4.1 +/- 0.4 pA pF(-1) to -29 +/- 1.1 pA pF(-1) (n = 36,p < 0.001). There is a good correlation of channel activity and cell volume changes. Replacement of bath Na+ by K+, Cs+, Li+, or Rb+ did not affect the stimulated inward current significantly, but replacement by Ca2+, Ba2+, or the impermeable cation N-methyl-D-glucamine abolished the inward current; this demonstrates that the shrinkage-induced currents discriminate poorly between monovalent cations but are not carried by divalent cations. Replacement of extracellular Cl- by gluconate abolished the shrinkage-induced currents in a concentration-dependent manner without changing the reversal potential. Gadolinium (Gd3+) inhibited the stimulated current, whereas bumetanide and amiloride had no inhibitory effect. Cell shrinkage triggered mitogen-activated protein (MAP) kinase cascades leading to the activation of MAP/extracellular signal-regulated kinase 1/2 (ERK1/2) kinase (MEK1/2), and p38 kinase. Interference with p38 MAPK by either the specific inhibitor (SB202190), or a dominant-negative mutant profoundly suppressed the activation of the shrinkage-induced NSC channels. In contrast, the regulatory mechanism of shrinkage-induced NSC channels was independent of the volume-responsive MEK1/2 signaling pathway. More importantly, the cell volume response to hypertonicity was inhibited significantly in p38 dominant-negative mutant or by SB202190. Therefore, p38 MAPK is critically involved in the activation of a shrinkage-induced NSC channel, which plays an important role in the volume regulation of human cervical cancer cells.	Natl Cheng Kung Univ, Coll Med, Dept Obstet & Gynecol, Tainan 704, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 704, Taiwan; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	National Cheng Kung University; National Cheng Kung University; University of Oxford	Shen, MR (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan.		Hsu, Keng-Fu/C-1441-2009					Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; Bohmer C, 2001, FEBS LETT, V494, P125, DOI 10.1016/S0014-5793(01)02303-1; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHAN HC, 1992, SCIENCE, V257, P669, DOI 10.1126/science.1379742; Chang MY, 1999, EXP CELL RES, V248, P589, DOI 10.1006/excr.1999.4436; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Fisher AB, 2001, AM J PHYSIOL-LUNG C, V281, pL529, DOI 10.1152/ajplung.2001.281.3.L529; GRAY MA, 1990, BIOCHIM BIOPHYS ACTA, V1029, P33, DOI 10.1016/0005-2736(90)90433-O; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAN JH, 1995, BBA-MOL CELL RES, V1265, P224, DOI 10.1016/0167-4889(95)00002-A; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; Ji HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1182; Junger WG, 1998, J CLIN INVEST, V101, P2768, DOI 10.1172/JCI1354; KAWAHARA K, 1991, AM J PHYSIOL, V260, pF27, DOI 10.1152/ajprenal.1991.260.1.F27; Koch JP, 2000, J MEMBRANE BIOL, V177, P231, DOI 10.1007/s002320010006; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lepple-Wienhues A, 1998, J CELL BIOL, V141, P281, DOI 10.1083/jcb.141.1.281; MCCARTY NA, 1992, PHYSIOL REV, V72, P1037, DOI 10.1152/physrev.1992.72.4.1037; Muraki K, 2001, J PHYSIOL-LONDON, V537, P431, DOI 10.1111/j.1469-7793.2001.00431.x; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Nelson DJ, 1996, AM J PHYSIOL-CELL PH, V270, pC179, DOI 10.1152/ajpcell.1996.270.1.C179; Niggel J, 2000, J MEMBRANE BIOL, V174, P121, DOI 10.1007/s002320001037; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; OKADA Y, 1997, AM J PHYSIOL, V273, P755; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Reifarth FW, 1999, BBA-BIOMEMBRANES, V1417, P63, DOI 10.1016/S0005-2736(98)00257-0; Roger F, 1999, J BIOL CHEM, V274, P34103, DOI 10.1074/jbc.274.48.34103; ROSS PE, 1995, J GEN PHYSIOL, V106, P415, DOI 10.1085/jgp.106.3.415; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; Shen MR, 2002, J BIOL CHEM, V277, P15592, DOI 10.1074/jbc.M111043200; Shen MR, 2002, PFLUG ARCH EUR J PHY, V444, P276, DOI 10.1007/s00424-002-0811-3; Shen MR, 2001, J PHYSIOL-LONDON, V537, P347, DOI 10.1111/j.1469-7793.2001.00347.x; Shen MR, 2000, J PHYSIOL-LONDON, V529, P385, DOI 10.1111/j.1469-7793.2000.00385.x; Urbach V, 1999, J MEMBRANE BIOL, V168, P29, DOI 10.1007/s002329900495; VOLK T, 1995, P NATL ACAD SCI USA, V92, P8478, DOI 10.1073/pnas.92.18.8478; Yang TX, 2000, J BIOL CHEM, V275, P23281, DOI 10.1074/jbc.M910237199	38	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45776	45784		10.1074/jbc.M207993200	http://dx.doi.org/10.1074/jbc.M207993200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12226098	hybrid			2022-12-27	WOS:000179529300010
J	Terry-Lorenzo, RT; Elliot, E; Weiser, DC; Prickett, TD; Brautigan, DL; Shenolikar, S				Terry-Lorenzo, RT; Elliot, E; Weiser, DC; Prickett, TD; Brautigan, DL; Shenolikar, S			Neurabins recruit protein phosphatase-1 and inhibitor-2 to the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE MYOSIN PHOSPHATASE; FILAMENT-BINDING PROTEIN; RABBIT SKELETAL-MUSCLE; RAT-LIVER NUCLEI; CATALYTIC SUBUNIT; SMOOTH-MUSCLE; SERINE/THREONINE PHOSPHATASES; PHOSPHORYLASE-PHOSPHATASE; REGULATORY SUBUNIT; TARGETING SUBUNIT	Inhibitor-2 (I-2) bound protein phosphatase-1 (PP1) and several PP1-binding proteins from rat brain extracts, including the actin-binding proteins, neurabin I and neurabin II. Neurabins from rat brain lysates were sedimented by I-2 and its structural homologue, I-4. The central domain of both neurabins bound PP1 and I-2, and mutation of a conserved PP1-binding motif abolished neurabin binding to both proteins. Microcystin-LR, a PP1 inhibitor, also attenuated I-2 binding to neurabins. Immunoprecipitation of neurabin I established its association with PP1 and I-2 in HEK293T cells and suggested that PP1 mediated I-2 binding to neurabins. The C terminus of I-2, although not required for PP1 binding, facilitated PP1 recruitment by neurabins, which also targeted I-2 to polymerized F-actin. Mutations that attenuated PP1 binding to I-2 and neurabin I suggested distinct and overlapping sites for these two proteins on the PP1 catalytic subunit. Immunocytochemistry in epithelial cells and cultured hippocampal neurons showed that endogenous neurabin II and I-2 colocalized at actin-rich structures, consistent with the ability of neurabins to target the PP1(.)I-2 complex to actin cytoskeleton and regulate cell morphology.	Duke Univ, Ctr Med, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA	Duke University; University of Virginia	Shenolikar, S (corresponding author), Duke Univ, Ctr Med, Dept Pharmacol & Canc Biol, LSRC C315,Res Dr, Durham, NC 27710 USA.				NIGMS NIH HHS [GM56362] Funding Source: Medline; NINDS NIH HHS [NS41063] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041063] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adler HT, 1999, MOL CELL BIOL, V19, P7050; Agarwal-Mawal A, 2001, J BIOL CHEM, V276, P23712, DOI 10.1074/jbc.M010002200; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Baker SH, 1997, GENETICS, V145, P615; BALLOU LM, 1983, BIOCHEMISTRY-US, V22, P3393, DOI 10.1021/bi00283a014; Brady MJ, 1997, J BIOL CHEM, V272, P20198, DOI 10.1074/jbc.272.32.20198; Cohen PTW, 2002, J CELL SCI, V115, P241; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; Connor JH, 1998, J BIOL CHEM, V273, P27716, DOI 10.1074/jbc.273.42.27716; Connor JH, 2000, J BIOL CHEM, V275, P18670, DOI 10.1074/jbc.M909312199; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; Damer CK, 1998, J BIOL CHEM, V273, P24396, DOI 10.1074/jbc.273.38.24396; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; Dinischiotu A, 1997, FEBS LETT, V402, P141, DOI 10.1016/S0014-5793(96)01514-1; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Eto M, 1999, BIOCHEMISTRY-US, V38, P16952, DOI 10.1021/bi992030o; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Goslin K., 1998, CULTURING NERVE CELL, P339; GRUPPUSO PA, 1985, J BIOL CHEM, V260, P4288; Hata Y, 1999, CELL MOL LIFE SCI, V56, P461, DOI 10.1007/s000180050445; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; HIRAGA A, 1986, EUR J BIOCHEM, V161, P763, DOI 10.1111/j.1432-1033.1986.tb10505.x; Hirano K, 1997, J BIOL CHEM, V272, P3683, DOI 10.1074/jbc.272.6.3683; Hsieh-Wilson LC, 1999, BIOCHEMISTRY-US, V38, P4365, DOI 10.1021/bi982900m; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Koyama M, 2000, FEBS LETT, V475, P197, DOI 10.1016/S0014-5793(00)01654-9; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; Li L, 1998, J PHYSIOL-LONDON, V508, P871, DOI 10.1111/j.1469-7793.1998.871bp.x; Liu J, 2000, BIOCHEM J, V346, P77, DOI 10.1042/0264-6021:3460077; McAvoy T, 1999, BIOCHEMISTRY-US, V38, P12943, DOI 10.1021/bi991227d; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; Oliver CJ, 2002, MOL CELL BIOL, V22, P4690, DOI 10.1128/MCB.22.13.4690-4701.2002; PLATT T, 1972, EXPT MOL GENETICS, P352; Ramaswamy NT, 1998, GENETICS, V149, P57; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Senba S, 1999, J BIOCHEM-TOKYO, V125, P354, DOI 10.1093/oxfordjournals.jbchem.a022294; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Shirato H, 2000, BIOCHEMISTRY-US, V39, P13848, DOI 10.1021/bi001326n; Stephens DJ, 2000, BIOCHEM J, V345, P185, DOI 10.1042/0264-6021:3450185; Strack S, 1999, J COMP NEUROL, V413, P373; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P27716, DOI 10.1074/jbc.M203365200; Terry-Lorenzo RT, 2000, J BIOL CHEM, V275, P2439, DOI 10.1074/jbc.275.4.2439; WANG QM, 1995, J BIOL CHEM, V270, P18352, DOI 10.1074/jbc.270.31.18352; Watanabe T, 2001, P NATL ACAD SCI USA, V98, P3080, DOI 10.1073/pnas.051003898; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Winder DG, 2001, NAT REV NEUROSCI, V2, P461, DOI 10.1038/35081514; Wu J, 1996, BIOCHEMISTRY-US, V35, P13858, DOI 10.1021/bi961669e; Wu XL, 2001, BIOCHEMISTRY-US, V40, P7410, DOI 10.1021/bi002796k; Yang J, 2000, J BIOL CHEM, V275, P22635, DOI 10.1074/jbc.M003082200	57	61	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46535	46543		10.1074/jbc.M206960200	http://dx.doi.org/10.1074/jbc.M206960200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270929	hybrid			2022-12-27	WOS:000179529300108
J	Apetri, AC; Surewicz, WK				Apetri, AC; Surewicz, WK			Kinetic intermediate in the folding of human prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMODYNAMIC STABILITY; AGGREGATION; CONVERSION; TRANSITION; MECHANISM; DISEASES; DOMAIN; STATE; ACID; PRP	Transmissible spongiform encephalopathies are associated with the conversion of cellular prion protein, PrPC, into a misfolded oligomeric form, PrPSc. Here we have examined the kinetics of folding and unfolding reactions for the recombinant human prion protein C-terminal fragment 90-231 at pH 4.8 and 7.0. The stopped-flow data provide clear evidence for the population of an intermediate on the refolding pathway of the prion protein as indicated by a pronounced curvature in chevron plots and the presence of significant burst phase amplitude in the refolding kinetics. In addition to its role in the normal prion protein folding, this intermediate likely represents a crucial monomeric precursor of the pathogenic PrPSc isoform.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Surewicz, WK (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038604] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38604] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Caughey B, 2000, NAT MED, V6, P751, DOI 10.1038/77476; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Ferguson N, 1999, J MOL BIOL, V286, P1597, DOI 10.1006/jmbi.1998.2548; Fersht A., 1999, STRUCTURE MECH PROTE; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; Hosszu LLP, 1999, NAT STRUCT BIOL, V6, P740, DOI 10.1038/11507; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Kelly JW, 1997, STRUCTURE, V5, P595, DOI 10.1016/S0969-2126(97)00215-3; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; Krantz BA, 2000, BIOCHEMISTRY-US, V39, P11696, DOI 10.1021/bi000792+; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; MICHOLSON EM, 2002, J MOL BIOL, V316, P807; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Morillas M, 2001, BIOCHEMISTRY-US, V40, P6982, DOI 10.1021/bi010232q; Otzen DE, 1999, BIOCHEMISTRY-US, V38, P6499, DOI 10.1021/bi982819j; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; RICK R, 1996, NATURE, V382, P180; Roder H, 1997, CURR OPIN STRUC BIOL, V7, P15, DOI 10.1016/S0959-440X(97)80004-8; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Silow M, 1997, P NATL ACAD SCI USA, V94, P6084, DOI 10.1073/pnas.94.12.6084; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; Wildegger G, 1999, NAT STRUCT BIOL, V6, P550, DOI 10.1038/9323; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145	31	80	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44589	44592		10.1074/jbc.C200507200	http://dx.doi.org/10.1074/jbc.C200507200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12356762				2022-12-27	WOS:000179404800001
J	Jung, J; Lee, SY; Hwang, SW; Cho, H; Shin, J; Kang, YS; Kim, S; Oh, L				Jung, J; Lee, SY; Hwang, SW; Cho, H; Shin, J; Kang, YS; Kim, S; Oh, L			Agonist recognition sites in the cytosolic tails of vanilloid receptor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; NONSELECTIVE CATION CHANNEL; ACTIVATED ION-CHANNEL; CAPSAICIN-RECEPTOR; PAIN PATHWAY; BINDING; DOMAIN; HEAT; ACID; HYPERALGESIA	Vanilloid receptor 1 (VR1), a ligand-gated ion channel activated by vanilloids, acid, and heat, is a molecular detector that integrates multiple modes of pain. Although the function and the biophysical properties of the channel are now known, the regions of VR1 that recognize ligands are largely unknown. By the stepwise deletion of VR1 and by chimera construction using its capsaicin-insensitive homologue, VRL1, we localized key amino acids, Arg-114 and Glu-761, in the N- and C-cytosolic tails, respectively, that determine ligand binding. Point mutations of the two key residues resulted in a loss of sensitivity to capsaicin and a concomitant loss of specific binding to [H-3]resiniferatoxin, a potent vanilloid. Furthermore, changes in the charges of the two amino acids blocked capsaicin-sensitive currents and ligand binding without affecting current responses to heat. Thus, these two regions in the cytoplasmic tails of VR1 provide structural elements for its hydrophilic interaction with vanilloids and might constitute a long-suspected binding pocket.	Seoul Natl Univ, Coll Pharm, Sensory Res Ctr, Creat Res Initiat,Kwanak Gu, Seoul 151742, South Korea; Seoul Natl Univ, Coll Pharm, Ctr Aminoacyl tRNA Synthetase Network, Creat Res Initiat,Kwanak Gu, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Oh, L (corresponding author), Seoul Natl Univ, Coll Pharm, Sensory Res Ctr, Creat Res Initiat,Kwanak Gu, Shinlim 9 Dong, Seoul 151742, South Korea.		Kim, Sunghoon/AAE-8314-2020	Hwang, Sun Wook/0000-0001-8460-7480				Acs G, 1996, MOL BRAIN RES, V35, P173, DOI 10.1016/0169-328X(95)00204-6; BEVAN S, 1990, TRENDS PHARMACOL SCI, V11, P330; BEVAN S, 1992, BRIT J PHARMACOL, V107, P544, DOI 10.1111/j.1476-5381.1992.tb12781.x; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Gunthorpe NJ, 2001, PFLUG ARCH EUR J PHY, V442, P668; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Jung J, 1999, J NEUROSCI, V19, P529; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Kuzhikandathil EV, 2001, J NEUROSCI, V21, P8697, DOI 10.1523/JNEUROSCI.21-22-08697.2001; LAMOTTE RH, 1978, J NEUROPHYSIOL, V41, P509, DOI 10.1152/jn.1978.41.2.509; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; MEYER RA, 1981, SCIENCE, V213, P1527, DOI 10.1126/science.7280675; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Oh U, 1996, J NEUROSCI, V16, P1659; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Schumacher MA, 2000, J BIOL CHEM, V275, P2756, DOI 10.1074/jbc.275.4.2756; Shin J, 2002, P NATL ACAD SCI USA, V99, P10150, DOI 10.1073/pnas.152002699; Shin JS, 2001, NEUROSCI LETT, V299, P135, DOI 10.1016/S0304-3940(00)01777-8; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; SZALLASI A, 1992, J PHARMACOL EXP THER, V262, P883; Szallasi A, 1999, MOL PHARMACOL, V56, P581, DOI 10.1124/mol.56.3.581; SZALLASI A, 1990, BRAIN RES, V524, P106, DOI 10.1016/0006-8993(90)90498-Z; Szallasi A, 1999, PHARMACOL REV, V51, P159; SZOLCSANYI J, 1975, ARZNEIMITTEL-FORSCH, V25, P1877; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; WALPOLE CSJ, 1993, J MED CHEM, V36, P2373, DOI 10.1021/jm00068a015; WALPOLE CSJ, 1993, CAPSAICIN STUDY PAIN; Welch JM, 2000, P NATL ACAD SCI USA, V97, P13889, DOI 10.1073/pnas.230146497; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	41	133	141	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44448	44454		10.1074/jbc.M207103200	http://dx.doi.org/10.1074/jbc.M207103200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228246	hybrid			2022-12-27	WOS:000179272000116
J	Zhang, YB; Wu, XH; Guo, DY; Rechkoblit, O; Taylor, JS; Geacintov, NE; Wang, ZG				Zhang, YB; Wu, XH; Guo, DY; Rechkoblit, O; Taylor, JS; Geacintov, NE; Wang, ZG			Lesion bypass activities of human DNA polymerase mu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; TRANSLESION SYNTHESIS; MAMMALIAN-CELLS; SYNTHESIS PAST; THYMINE DIMER; UV-LIGHT; MUTAGENESIS; ADDUCTS	DNA polymerase mu (Polmu) is a newly discovered member of the polymerase X family with unknown cellular function. The understanding of Polmu function should be facilitated by an understanding of its biochemical activities. By using purified human Polmu for biochemical analyses, we discovered the lesion bypass activities of this polymerase in response to several types of damage. When it encountered a template 8-oxoguanine, abasic site, or 1,N-6-ethenoadenine, purified human Polmu efficiently bypassed the lesion. Even bulky DNA adducts such as N-2-acetylaminofluorene-adducted guanine, (+)-and (-)-trans-anti-benzo[a]pyrene-N-2-dG were unable to block the polymerase activity of human Polmu. Bypass of these simple base damage and bulky adducts was predominantly achieved by human Polmu through a deletion mechanism. The Polmu specificity of nueleotide incorporation indicates that the deletion resulted from primer realignment before translesion synthesis. Purified human Polmu also effectively bypassed a template cis-syn TT dimer. However, this bypass was achieved in a mainly error-free manner with AA incorporation opposite the TT dimer. These results provide new insights into the biochemistry of human Polmu and show that efficient translesion synthesis activity is not strictly confined to the Y family polymerases.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; NYU, Dept Chem, New York, NY 10003 USA; Washington Univ, Dept Chem, St Louis, MO 63130 USA	University of Kentucky; New York University; Washington University (WUSTL)	Wang, ZG (corresponding author), Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA.		Zhang, Yanbin/F-2998-2011; Taylor, John-Stephen/AAA-3218-2020	Zhang, Yanbin/0000-0002-7263-5510; Taylor, John-Stephen/0000-0002-8615-7257; Rechkoblit, Olga/0000-0003-4270-7242	NATIONAL CANCER INSTITUTE [R01CA040463, R01CA020851, R37CA040463, R01CA092528] Funding Source: NIH RePORTER; NCI NIH HHS [CA92528, CA40463, CA20851] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; BENTOLILA LA, 1995, EMBO J, V14, P4221, DOI 10.1002/j.1460-2075.1995.tb00096.x; CHANG LMS, 1986, CRC CR REV BIOCH MOL, V21, P27, DOI 10.3109/10409238609113608; Cleaver JE, 2000, J DERMATOL SCI, V23, P1, DOI 10.1016/S0923-1811(99)00088-2; COSMAN M, 1990, CARCINOGENESIS, V11, P1667, DOI 10.1093/carcin/11.9.1667; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; Duvauchelle JB, 2002, NUCLEIC ACIDS RES, V30, P2061, DOI 10.1093/nar/30.9.2061; Friedberg EC, 2001, CELL, V107, P9, DOI 10.1016/S0092-8674(01)00509-8; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; GEACINTOV NE, 1991, CARCINOGENESIS, V12, P2099, DOI 10.1093/carcin/12.11.2099; GENTIL A, 1992, J MOL BIOL, V227, P981, DOI 10.1016/0022-2836(92)90513-J; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Guo DY, 2001, NUCLEIC ACIDS RES, V29, P2875, DOI 10.1093/nar/29.13.2875; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LARIMER FW, 1989, J BACTERIOL, V171, P230, DOI 10.1128/jb.171.1.230-237.1989; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; Levine RL, 2000, CANCER RES, V60, P4098; Livneh Z, 2001, J BIOL CHEM, V276, P25639, DOI 10.1074/jbc.R100019200; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; McGregor WG, 1999, MOL CELL BIOL, V19, P147; Moriya M, 1996, BIOCHEMISTRY-US, V35, P16646, DOI 10.1021/bi9608875; Nelson JR, 2000, MOL MICROBIOL, V37, P549, DOI 10.1046/j.1365-2958.2000.01997.x; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Rajpal DK, 2000, MUTAT RES-DNA REPAIR, V461, P133, DOI 10.1016/S0921-8777(00)00047-1; Rechkoblit O, 1999, BIOCHEMISTRY-US, V38, P11834, DOI 10.1021/bi990614k; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Shibutani S, 1998, BIOCHEMISTRY-US, V37, P12034, DOI 10.1021/bi981059+; SMITH CA, 1993, J BIOL CHEM, V268, P11143; Wang Z, 2001, Mol Interv, V1, P269; Wang ZG, 2001, MUTAT RES-DNA REPAIR, V486, P59, DOI 10.1016/S0921-8777(01)00089-1; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4717, DOI 10.1093/nar/28.23.4717; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000; Zhang YB, 2002, DNA REPAIR, V1, P559, DOI 10.1016/S1568-7864(02)00055-1; Zhang YB, 2001, MOL CELL BIOL, V21, P7995, DOI 10.1128/MCB.21.23.7995-8006.2001; Zhang YB, 2001, NUCLEIC ACIDS RES, V29, P928, DOI 10.1093/nar/29.4.928	42	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44582	44587		10.1074/jbc.M207297200	http://dx.doi.org/10.1074/jbc.M207297200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228225	hybrid			2022-12-27	WOS:000179272000131
J	Bera, AK; Chatav, M; Akabas, MH				Bera, AK; Chatav, M; Akabas, MH			GABA(A) receptor M2-M3 loop secondary structure and changes in accessibility during channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING SEGMENT; NICOTINIC ACETYLCHOLINE-RECEPTOR; TRANSMEMBRANE ALPHA-HELICES; GATED CHLORIDE CHANNEL; ION CHANNELS; M2 SEGMENT; GLYCINE RECEPTORS; LINING RESIDUES; LIGAND-BINDING; A RECEPTORS	The gamma-aminobutyric acid type A (GABA(A)) receptor M2-M3 loop structure and its role in gating were investigated using the substituted cysteine accessibility method. Residues from alpha(1)Arg-273 to alpha(1)Ile-289 were mutated to cysteine, one at a time. MTSET' or MTSES(-)reacted with all mutants from alpha(1)R273C to alpha(1)Y281C, except alpha(1)P277C, in the absence and presence of GABA. The MTSET' closed-state reaction rate was >1000 liters/ mol-s at alpha(1)N274C, alpha(1)S275C, alpha(1)K278C, and alpha(1)Y281C and was <300 liters/mol-s at alpha(1)R273C, alpha(1)L276C, alpha(1)V279C, alpha(1)A280C, and alpha(1)A284C. These two groups of residues lie on opposite sides of an alpha-helix. The fast reacting group lies on a continuation of the M2 segment channel-lining helix face. This suggests that the M2 segment alpha-helix extends about two helical turns beyond alpha(1)N274 (20'), aligned with the extracellular ring of charge. At alpha(1)S275C, alpha(1)V279C, alpha(1)A280C, and alpha(1)A284C the reaction rate was faster in the presence of GABA. The reagents had no functional effect on the mutants from alA282C to alpha(1)I289C, except alpha(1)A284C. Access may be sterically hindered possibly by close interaction with the extracellular domain. We suggest that the M2 segment alpha-helix extends beyond the predicted extracellular end of the M2 segment and that gating induces a conformational change in and/or around the N-terminal half of the M2-M3 loop. Implications for coupling ligand-evoked conformational changes in the extracellular domain to channel gating in the membrane-spanning domain are discussed.	Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Akabas, MH (corresponding author), Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Bera, Amal Kanti/0000-0003-0362-5578; Akabas, Myles/0000-0001-8781-7846	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM063266, P01GM061925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030808] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61925, GM63266] Funding Source: Medline; NINDS NIH HHS [NS30808] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Boileau AJ, 1999, J NEUROSCI, V19, P10213; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; BROWN KA, 1993, P NATL ACAD SCI USA, V90, P11753, DOI 10.1073/pnas.90.24.11753; CamposCaro A, 1996, P NATL ACAD SCI USA, V93, P6118, DOI 10.1073/pnas.93.12.6118; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; Davies M, 2001, J NEUROCHEM, V79, P55, DOI 10.1046/j.1471-4159.2001.00527.x; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; Fu DY, 1996, BIOCHEMISTRY-US, V35, P11278, DOI 10.1021/bi960928x; Grosman C, 2000, J GEN PHYSIOL, V116, P327, DOI 10.1085/jgp.116.3.327; Horenstein J, 1998, MOL PHARMACOL, V53, P870; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KIENKER P, 1994, BIOPHYS J, V66, P325, DOI 10.1016/S0006-3495(94)80781-7; Klausberger T, 2000, J BIOL CHEM, V275, P8921, DOI 10.1074/jbc.275.12.8921; Krasowski MD, 1999, CELL MOL LIFE SCI, V55, P1278, DOI 10.1007/s000180050371; Le Novere N, 1999, BIOPHYS J, V76, P2329, DOI 10.1016/S0006-3495(99)77390-X; Le Novere N, 1999, NUCLEIC ACIDS RES, V27, P340, DOI 10.1093/nar/27.1.340; Lewis TM, 1998, J PHYSIOL-LONDON, V507, P25, DOI 10.1111/j.1469-7793.1998.025bu.x; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Lynch JW, 1997, EMBO J, V16, P110, DOI 10.1093/emboj/16.1.110; Lynch JW, 2001, J NEUROSCI, V21, P2589, DOI 10.1523/JNEUROSCI.21-08-02589.2001; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; Nilsson I, 1998, J MOL BIOL, V284, P1185, DOI 10.1006/jmbi.1998.2219; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; O'Shea SM, 2000, J BIOL CHEM, V275, P22764, DOI 10.1074/jbc.M001299200; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; Ranganathan R, 2000, NATURE, V408, P470, DOI 10.1038/35044083; Reeves DC, 2001, J BIOL CHEM, V276, P42035, DOI 10.1074/jbc.M106066200; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Rovira JC, 1999, PFLUG ARCH EUR J PHY, V439, P86, DOI 10.1007/s004240051131; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; Sieghart W, 1999, NEUROCHEM INT, V34, P379, DOI 10.1016/S0197-0186(99)00045-5; Sigel E, 1999, J NEUROCHEM, V73, P1758, DOI 10.1046/j.1471-4159.1999.731758.x; Taylor PM, 2000, J NEUROSCI, V20, P1297; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; Vassilatis DK, 1997, J MOL EVOL, V44, P501, DOI 10.1007/PL00006174; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; Wang CT, 1999, BIOPHYS J, V77, P691, DOI 10.1016/S0006-3495(99)76924-9; Williams DB, 2000, MOL PHARMACOL, V58, P1129, DOI 10.1124/mol.58.5.1129; Williams DB, 1999, BIOPHYS J, V77, P2563, DOI 10.1016/S0006-3495(99)77091-8; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Zhang H, 1998, BIOCHEMISTRY-US, V37, P7952, DOI 10.1021/bi980143m	53	82	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43002	43010		10.1074/jbc.M206321200	http://dx.doi.org/10.1074/jbc.M206321200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12226083	hybrid			2022-12-27	WOS:000179081200076
